Serotonin O
receptor O
2A O
( O
HTR2A O
) O
gene O
polymorphism O
predicts O
treatment O
response O
to O
venlafaxine B
XR I
in O
generalized O
anxiety O
disorder O
. O

We O
tested O
the O
hypothesis O
that O
the O
genetic O
polymorphism O
rs7997012 O
in O
the O
HTR2A O
gene O
predicts O
treatment O
outcome O
in O
GAD O
patients O
treated O
with O
venlafaxine B
XR I
. O

Treatment O
response O
was O
assessed O
in O
156 O
patients O
that O
participated O
in O
a O
6 O
- O
month O
open O
- O
label O
clinical O
trial O
of O
venlafaxine B
XR I
for O
GAD O
. O

The O
data O
indicates O
that O
fetal O
exposure O
to O
dioxins B
and O
furans B
( O
PCDD B
/ O
Fs O
) O
, O
polychlorinated O
biphenyls O
( O
PCBs O
) O
, O
p O
, O
p O
' O
- O
DDE O
, O
and O
methylmercury O
depends O
on O
the O
mother O
' O
s O
parity O
, O
and O
age O
. O

The O
fish O
ingredient O
N3 B
- I
docosahexaenoic I
acid I
22 O
: O
6 O
n O
- O
3 O
( O
DHA O
) O
stimulates O
brain O
development O
. O

Twelve O
FVCs O
were O
identified O
in O
the O
pink O
- O
yellow O
cultivar O
, O
with O
linalool O
as O
the O
major O
compound O
; O
30 O
FVCs O
were O
identified O
in O
the O
yellow O
cultivar O
, O
with O
linalool O
and O
terpineol B
as O
the O
two O
major O
compounds O
. O

Ten O
compounds O
have O
been O
identified O
, O
in O
which O
3 B
- I
methylthio I
- I
1 I
- I
propene I
was O
the O
most O
significant O
component O
. O

Diclavatol B
and O
tetronic B
acids I
from O
Penicillium O
griseoroseum O
. O

In O
our O
continuous O
studies O
on O
the O
chemistry O
of O
the O
endophytic O
fungus O
Penicillium O
griseoroseum O
, O
an O
endophyte O
isolated O
from O
fruits O
of O
Coffea O
arabica O
, O
we O
isolated O
clavatol B
, O
a O
dimethylated B
tetraketide I
, O
and O
its O
dimer O
which O
appears O
to O
be O
a O
novel O
natural O
compound O
. O

The O
studies O
also O
resulted O
in O
the O
identification O
of O
two O
known O
tetronic B
acids I
, O
viridicatic B
acid I
and O
terrestric B
acid I
, O
found O
in O
ethyl O
acetate O
and O
n O
- O
butanol O
extracts O
. O

Two O
other O
tetronic B
acids I
congeners O
were O
identified O
through O
HPLC O
/ O
MS O
/ O
MS O
studies O
, O
based O
on O
fragmentation O
pattern O
of O
ions O
produced O
from O
ionised O
tetronic B
acids I
, O
and O
UV O
light O
absorptions O
. O

A O
total O
of O
18 O
substances O
were O
identified O
, O
consisting O
of O
a O
complex O
mixture O
of O
sesquiterpenes O
( O
83 O
. O
52 O
% O
) O
, O
monoterpenes B
( O
5 O
. O
46 O
% O
) O
and O
triterpenes O
( O
4 O
. O
56 O
% O
) O
. O

The O
main O
components O
in O
the O
oil O
were O
beta B
- I
caryophyllene I
( O
56 O
. O
87 O
% O
) O
, O
alpha O
- O
cadinol O
( O
12 O
. O
52 O
% O
) O
, O
8S B
, I
13 I
- I
cedran I
- I
diol I
( O
5 O
. O
41 O
% O
) O
, O
alpha O
- O
terpineol O
( O
3 O
. O
99 O
% O
) O
, O
beta B
- I
eudesmol I
( O
2 O
. O
54 O
% O
) O
, O
caryophyllene B
oxide I
( O
2 O
. O
51 O
% O
) O
and O
ethyl B
iso I
- I
allocholate I
( O
2 O
. O
03 O
% O
) O
along O
with O
beta B
- I
cubebene I
, O
gamma B
- I
cadinene I
, O
cubenol B
, O
1 O
, O
8 O
- O

cineol O
, O
o B
- I
cymene I
, O
curcumenol B
, O
spathulenol B
, O
friedeline B
and O
beta O
- O
sitosterol O
as O
minor O
constituents O
. O

The O
present O
work O
was O
undertaken O
to O
evaluate O
the O
protective O
effect O
of O
an O
aqueous O
extract O
of O
green O
tea O
( O
GT O
, O
Camellia O
sinensis O
) O
leaves O
against O
arsenic O
( O
NaAsO2 B
) O
- O
induced O
biochemical O
toxicity O
and O
lipid O
peroxidation O
production O
in O
experimental O
rats O
. O

Determination O
of O
aflatoxin B
M1 I
in O
milk O
by O
high O
- O
performance O
liquid O
chromatography O
in O
Mashhad O
( O
north O
east O
of O
Iran O
) O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
aflatoxin B
M1 I
( O
AFM1 B
) O
contamination O
in O
milk O
samples O
in O
Mashhad O
in O
Iran O
. O

The O
occurrence O
and O
concentration O
range O
of O
AFM1 B
in O
the O
samples O
were O
investigated O
by O
high O
- O
performance O
liquid O
chromatography O
method O
. O

AFM1 B
was O
found O
in O
100 O
% O
of O
the O
examined O
milk O
samples O
by O
average O
concentration O
of O
16 O
. O
16 O
ng O
/ O
L O
and O
the O
contamination O
level O
ranging O
between O
2 O
and O
64 O
ng O
/ O
L O
. O

The O
concentration O
of O
AFM1 B
in O
all O
the O
samples O
was O
lower O
than O
the O
Iranian O
national O
standard O
and O
Food O
and O
Drug O
Administration O
limit O
( O
500 O
ng O
/ O
L O
) O
, O
and O
only O
in O
one O
( O
1 O
. O
6 O
% O
) O
of O
the O
samples O
, O
the O
concentration O
of O
AFM1 B
was O
greater O
than O
the O
maximum O
tolerance O
limit O
( O
50 O
ng O
/ O
L O
) O
accepted O
by O
European O
Union O
and O
Codex O
Alimentarius O
Commission O
. O

Statistical O
evaluation O
showed O
no O
significant O
difference O
between O
the O
mean O
concentrations O
of O
AFM1 B
in O
milk O
samples O
taken O
from O
different O
regions O
( O
p O
> O
0 O
. O
05 O
) O
. O

CNS O
distribution O
of O
metabotropic O
glutamate O
2 O
and O
3 O
receptors O
: O
transgenic O
mice O
and O
[ B
( I
3 I
) I
H I
] I
LY459477 I
autoradiography O
. O

A O
selective O
and O
structurally O
novel O
mGlu O
( O
2 O
/ O
3 O
) O
receptor O
agonist O
, O
2 B
- I
amino I
- I
4 I
- I
fluorobicyclo I
[ I
3 I
. I
1 I
. I
0 I
] I
hexane I
- I
2 I
, I
6 I
- I
dicarboxylic I
acid I
( O
LY459477 B
) O
was O
tritiated O
and O
the O
distribution O
of O
mGlu O
( O
2 O
) O
and O
mGlu O
( O
3 O
) O
receptors O
was O
studied O
in O
transgenic O
mice O
lacking O
either O
mGlu O
( O
2 O
) O
, O
mGlu O
( O
3 O
) O
or O
both O
receptors O
. O

LY459477 B
is O
an O
agonist O
with O
1 O
- O
2 O
nM O
potency O
for O
rodent O
and O
human O
mGlu O
( O
2 O
) O
and O
mGlu O
( O
3 O
) O
receptors O
. O

The O
functional O
selectivity O
of O
LY459477 B
was O
demonstrated O
by O
over O
640 O
- O
fold O
selectivity O
and O
the O
displacement O
binding O
selectivity O
was O
greater O
than O
320 O
- O
fold O
for O
all O
glutamate O
receptors O
except O
mGlu O
( O
6 O
) O
( O
~ O
230 O
- O
fold O
) O
. O

Like O
atypical O
antipsychotic O
drugs O
, O
LY459477 B
reversed O
in O
vitro O
electrophysiological O
effects O
of O
a O
serotonergic O
hallucinogen O
and O
behavioral O
effects O
of O
phencyclidine O
or O
amphetamine O
. O

There O
was O
virtually O
no O
binding O
of O
[ B
( I
3 I
) I
H I
] I
LY459477 I
to O
any O
brain O
region O
in O
mice O
with O
a O
deletion O
of O
both O
mGlu O
( O
2 O
) O
and O
mGlu O
( O
3 O
) O
receptors O
. O

These O
findings O
suggest O
[ B
( I
3 I
) I
H I
] I
LY459477 I
should O
be O
a O
useful O
tool O
to O
further O
define O
the O
role O
of O
mGlu O
( O
2 O
) O
and O
mGlu O
( O
3 O
) O
receptors O
throughout O
the O
brain O
with O
respect O
to O
major O
neuropsychiatric O
syndromes O
. O

The O
formulation O
factors O
for O
such O
patches O
, O
including O
eudragit B
RL I
100 I
and O
eudragit B
RS I
100 I
as O
matrix O
forming O
polymers O
, O
olive O
oil O
, O
groundnut O
oil O
and O
jojoba O
oil O
in O
different O
concentrations O
as O
enhancers O
and O
amount O
of O
drug O
loaded O
were O
investigated O
. O

Among O
the O
tested O
preparations O
, O
formulations O
with O
20 O
% O
risperidone O
, O
3 O
: O
2 O
ERL B
100 I
and O
ERS B
100 I
as O
polymers O
, O
mixture O
of O
olive O
oil O
and O
jojoba O
oil O
as O
enhancer O
, O
exhibited O
greatest O
cumulative O
amount O
of O
drug O
permeated O
( O
1 O
. O
87 O
+ O
/ O
- O
0 O
. O
09 O
mg O
/ O
cm O
( O
2 O
) O
) O
in O
72 O
h O
, O
so O
batch O
ROJ O
was O
concluded O
as O
optimized O
formulation O
and O
assessed O
for O
pharmacokinetic O
, O
pharmacodynamic O
and O
skin O
irritation O
potential O
. O

Trans B
- I
3 I
( I
10 I
) I
- I
caren I
- I
4 I
- I
ol I
( O
22 O
. O
3 O
% O
) O
, O
artemisia O
ketone O
( O
18 O
. O
6 O
% O
) O
, O
1 B
, I
8 I
- I
cineole I
( O
14 O
. O
9 O
% O
) O
, O
delta B
- I
selinene I
( O
13 O
. O
0 O
% O
) O
and O
alpha O
- O
pinene O
( O
8 O
. O
2 O
% O
) O
were O
the O
major O
compounds O
. O

Oxygenated O
monoterpenes B
were O
the O
main O
compounds O
with O
51 O
. O
6 O
% O
followed O
by O
sesquiterpene B
hydrocarbons I
( O
13 O
. O
3 O
% O
) O
, O
monoterpene B
hydrocarbons I
( O
9 O
. O
9 O
% O
) O
and O
other O
compounds O
( O
8 O
. O
3 O
% O
) O
. O

This O
coincided O
with O
significantly O
elevated O
oxidative O
damage O
evidenced O
by O
a O
marked O
reduction O
in O
glutathione O
redox O
status O
( O
ratio O
of O
reduced O
GSH O
/ O
oxidized B
GSSG I
) O
and O
an O
increase O
in O
lipid O
peroxidation O
( O
TBARS O
levels O
) O
. O

Simultaneous O
determination O
of O
glucoraphanin B
and O
sulforaphane O
in O
Brassica O
oleracea O
seeds O
by O
high O
- O
performance O
liquid O
chromatography O
with O
evaporative O
light O
- O
scattering O
detector O
. O

In O
this O
article O
, O
a O
novel O
and O
efficient O
analysis O
method O
is O
described O
to O
simultaneously O
and O
quantitatively O
determine O
glucoraphanin B
and O
its O
major O
degradation O
product O
sulforaphane O
by O
reversed O
- O
phase O
high O
- O
performance O
liquid O
chromatography O
( O
HPLC O
) O
coupled O
with O
an O
evaporative O
light O
- O
scattering O
detector O
( O
ELSD O
) O
. O

The O
HPLC O
- O
ELSD O
method O
was O
successfully O
used O
to O
assess O
the O
contents O
of O
glucoraphanin B
and O
sulforaphane O
in O
varieties O
of O
Brassica O
oleracea O
seeds O
. O

The O
developed O
analytical O
method O
not O
only O
avoids O
the O
underestimation O
of O
total O
glucoraphanin B
content O
, O
but O
also O
provides O
a O
reduction O
in O
analysis O
time O
and O
good O
efficiency O
and O
sensitivity O
compared O
to O
with O
conventional O
HPLC O
methods O
. O

Serratin B
a O
new O
metabolite O
obtained O
from O
Serratia O
marcescens O
, O
a O
bacterium O
isolated O
from O
the O
microflora O
associated O
with O
banana O
plantations O
. O

When O
cultures O
of O
Serratia O
marcescens O
, O
an O
enterobacteria O
isolated O
from O
the O
microflora O
associated O
with O
banana O
plantations O
incubated O
at O
27 O
degrees O
C O
in O
a O
yeast O
- O
calcium O
carbonate O
- O
dextrose B
solid O
medium O
( O
10 O
g O
of O
yeast O
extract O
, O
20 O
g O
dextrose B
, O
15 O
g O
bacteriological O
agar O
, O
20 O
g O
calcium O
carbonate O
and O
1000 O
mL O
distilled O
water O
) O
were O
extracted O
with O
chloroform O
and O
purified O
by O
column O
chromatography O
, O
we O
obtained O
a O
new O
colourless O
bacterial O
metabolite O
which O
according O
to O
spectroscopic O
data O
proved O
to O
be O
serratin B
. O

In O
particular O
, O
we O
have O
isolated O
and O
identified O
harpagide B
, O
7 B
- I
beta I
- I
hydroxy I
- I
harpagide I
, O
ajugol B
, O
5 B
- I
allosyloxy I
- I
aucubin I
, O
verbascoside O
and O
, O
for O
the O
first O
time O
in O
this O
genus O
, O
arbutin O
. O

Pharmacokinetic O
and O
pharmacodynamic O
evaluation O
of O
floating O
microspheres O
of O
metformin B
hydrochloride I
. O

Metformin B
hydrochloride I
( O
MH O
) O
, O
a O
biguanide O
antidiabetic O
, O
is O
the O
drug O
of O
choice O
in O
obese O
patients O
. O

Unexpectedly O
, O
both O
the O
mGluR O
( O
5 O
) O
specific O
agonist O
, O
CHPG B
, O
and O
the O
group O
II O
mGluR O
( O
mGlu O
( O
2 O
/ O
3 O
) O
) O
agonist O
, O
LY379268 O
( O
LY O
) O
, O
induced O
a O
TTX O
- O
insensitive O
outward O
current O
/ O
hyperpolarization O
. O

Both O
outward O
currents O
were O
significantly O
reduced O
by O
the O
mGluR O
antagonist O
MCPG B
and O
the O
CHPG B
- O
induced O
current O
was O
blocked O
by O
the O
specific O
mGluR O
( O
5 O
) O
antagonist O
MTEP O
. O

Concurrent O
Ca O
( O
2 O
+ O
) O
imaging O
revealed O
that O
while O
CHPG B
actions O
did O
include O
release O
of O
Ca O
( O
2 O
+ O
) O
from O
CPA O
/ O
thapsigargin O
- O
sensitive O
intracellular O
stores O
, O
actions O
of O
LY O
did O
not O
. O

Both O
CHPG B
- O
and O
LY O
- O
induced O
outward O
currents O
were O
mediated O
by O
a O
TEA O
- O
sensitive O
potassium O
conductance O
. O

The O
large O
- O
conductance O
, O
Ca O
( O
2 O
+ O
) O
- O
dependent O
potassium O
( O
BK O
) O
channel O
blocker O
, O
iberiotoxin O
, O
attenuated O
CHPG B
actions O
. O

Consistent O
with O
actions O
on O
the O
BK O
conductance O
, O
CHPG B
enhanced O
the O
amplitude O
of O
the O
fast O
component O
of O
the O
after O
hyperpolarizing O
potential O
, O
concurrent O
with O
a O
reduction O
in O
the O
firing O
rate O
. O

We O
have O
examined O
the O
effectiveness O
of O
two O
novel O
Chk1 O
selective O
inhibitors O
, O
AR323 B
and O
AR678 B
, O
in O
a O
panel O
of O
melanoma O
cell O
lines O
and O
normal O
cell O
types O
. O

Ten O
known O
compounds O
including O
two O
steroids O
( O
1 O
- O
2 O
) O
, O
six O
bibenzyls B
( O
3 O
, O
5 O
- O
9 O
) O
, O
a O
flavonoid O
( O
10 O
) O
, O
and O
a O
terpenoid O
( O
4 O
) O
were O
isolated O
from O
these O
calluses O
. O

The O
allelopathic O
effect O
of O
the O
six O
bibenzyls B
was O
assessed O
in O
Arabidopsis O
thaliana O
. O

Results O
revealed O
that O
bibenzyls B
could O
inhibit O
seedling O
growth O
in O
a O
dose O
- O
dependent O
manner O
. O

Firstly O
, O
sustained O
release O
ketoprofen O
fine O
granules O
were O
developed O
by O
spray O
drying O
the O
aqueous O
dispersions O
composed O
of O
Eudragit B
RS I
- I
30D I
, O
Starch O
1500 O
and O
PEG B
6000 I
. O

Subsequently O
, O
the O
obtained O
granules O
were O
directly O
compressed O
into O
KODSRTs O
after O
mixing O
with O
lactose O
, O
mannitol O
and O
a O
superdisintegrant O
, O
crosslinked O
polyvinylpyrrolidone O
( O
PVPP B
) O
. O

Besides O
, O
the O
disintegration O
time O
of O
KODSRTs O
depended O
on O
the O
percentage O
of O
PVPP B
in O
tablets O
. O

Recent O
observations O
suggest O
that O
transformed O
cells O
have O
a O
derangement O
in O
the O
cyclic B
adenosine I
monophosphate I
/ O
cAMP O
- O
dependent O
protein O
kinase O
( O
cAMP O
/ O
PKA O
) O
pathway O
, O
which O
is O
known O
to O
regulate O
several O
mitochondrial O
functions O
. O

A O
new O
chromone O
, O
5 B
, I
7 I
- I
dihydroxy I
- I
2 I
- I
( I
hydroxymethyl I
) I
- I
6 I
, I
8 I
- I
dimethyl I
- I
chromen I
- I
4 I
- I
one I
, O
named O
melachromone B
, O
together O
with O
12 O
known O
compounds O
, O
including O
chromones B
, O
anthraquinone O
, O
flavonoids O
, O
flavonoid B
glycosides I
, O
benzene O
derivatives O
, O
ellagic B
acids I
and O
terpenes O
, O
were O
isolated O
from O
the O
leaves O
of O
Melaleuca O
cajuputi O
Powell O
. O

Two O
new O
oleanane O
triterpenoid O
saponins O
, O
xanthohuskisides B
A O
( O
1 O
) O
and O
B O
( O
2 O
) O
, O
were O
isolated O
from O
the O
husks O
of O
Xanthoceras O
sorbifolia O
. O

( O
1 O
) O
and O
3 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
( I
1 I
- I
- I
> I
6 I
) I
- I
[ I
beta I
- I
D I
- I
glucopyranosyl I
( I
1 I
- I
- I
> I
2 I
) I
] I
- I
beta I
- I
D I
- I
glucopyranosyl I
, I
28 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
( I
1 I
- I
- I
> I
6 I
) I
- I
beta I
- I
D I
- I
glucopyranosyl I
16 I
- I
deoxybarringtogenol I
C I
( O
2 O
) O
, O
respectively O
, O
based O
on O
the O
analysis O
on O
their O
spectral O
data O
including O
NMR O
and O
HR O
- O
ESI O
- O
MS O
. O

Effects O
of O
sinensetin B
on O
lipid O
metabolism O
in O
mature O
3T3 O
- O
L1 O
adipocytes O
. O

Sinensetin B
is O
a O
rare O
polymethoxylated B
flavone I
found O
in O
certain O
citrus O
fruits O
. O

In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
sinensetin B
on O
lipid O
metabolism O
in O
mature O
3T3 O
- O
L1 O
adipocytes O
. O

Sinensetin B
decreased O
the O
expression O
of O
sterol O
regulatory O
element O
- O
binding O
protein O
1c O
( O
SREBP1c O
) O
, O
suggesting O
its O
antiadipogeneic O
property O
via O
downreguation O
of O
SREBP1c O
. O

Also O
, O
sinensetin B
increased O
the O
phosphorylation O
of O
protein O
kinase O
A O
and O
hormone O
- O
sensitive O
lipase O
, O
indicating O
its O
lipolytic O
property O
via O
a O
cAMP O
- O
mediated O
signaling O
pathway O
. O

Moreover O
, O
sinensetin B
inhibited O
insulin O
- O
stimulated O
glucose O
uptake O
by O
decreasing O
the O
phosphorylation O
of O
insulin O
receptor O
substrate O
and O
Akt O
. O

Furthermore O
, O
sinensetin B
increased O
the O
phosphorylation O
of O
AMP O
- O
activated O
protein O
kinase O
( O
AMPK O
) O
and O
acetyl O
- O
CoA O
carboxylase O
. O

It O
also O
upregulated O
mRNA O
expression O
of O
carnitine O
palmitoyltransferase O
- O
1a O
, O
suggesting O
that O
sinensetin B
enhances O
fatty O
acid O
beta O
- O
oxidation O
through O
the O
AMPK O
pathway O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
sinensetin B
may O
have O
potential O
as O
a O
natural O
agent O
for O
prevention O
/ O
improvement O
of O
obesity O
. O

New O
immunosuppressive O
cyclomyrsinol B
diterpenes I
from O
Euphorbia O
kopetdaghi O
Prokh O
. O

Aceton B
: O
chloroform O
( O
1 O
: O
2 O
) O
extracts O
of O
the O
aerial O
parts O
of O
Euphorbia O
kopetdaghi O
Prokh O
. O

( O
Euphorbiaceae O
) O
were O
investigated O
for O
its O
diterpenoids O
and O
afforded O
three O
new O
five O
- O
membered O
ring O
, O
pentacyclic B
myrisinane I
polyester I
comprised O
of O
3 B
, I
5 I
, I
10 I
- I
O I
- I
triacetyl I
- I
8 I
- I
O I
- I
isobutanoyl I
- I
14 I
- I
O I
- I
benzoylcyclomyrsinol I
( O
1 O
) O
, O
3 B
, I
5 I
, I
10 I
, I
14 I
- I
O I
- I
tetraacetyl I
- I
8 I
- I
O I
- I
( I
2 I
' I
- I
methyl I
butanoyl I
) I
- I
cyclomyrsinol I
( O
2 O
) O
and O
3 O
, O

The O
structures O
were O
elucidated O
based O
on O
( B
13 I
) I
C I
- O
and O
( O
1 O
) O
H O
- O
NMR O
as O
well O
as O
2D O
- O
NMR O
, O
IR O
and O
different O
MS O
spectra O
and O
the O
immunomodulation O
activity O
for O
compound O
1 O
was O
evaluated O
through O
lymphocyte O
proliferation O
assay O
, O
IL O
- O
2 O
assay O
, O
oxidative O
burst O
of O
phagocytic O
leukocytes O
and O
through O
their O
cytotoxicity O
on O
two O
cell O
lines O
. O

Monoterpene O
( O
25 O
. O
2 O
- O
84 O
. O
9 O
% O
) O
and O
sesquiterpene B
hydrocarbons I
( O
12 O
. O
2 O
- O
46 O
. O
8 O
% O
) O
were O
the O
principal O
subclasses O
of O
compounds O
, O
with O
alpha O
- O
pinene O
( O
15 O
- O
65 O
. O
4 O
% O
) O
, O
germacrene B
D I
( O
5 O
. O
9 O
- O
30 O
. O
5 O
% O
) O
, O
delta B
- I
3 I
- I
carene I
( O
2 O
- O
16 O
. O
6 O
% O
) O
and O
gamma B
- I
cadinene I
( O
1 O
. O
3 O
- O
9 O
. O
8 O
% O
) O
as O
the O
main O
constituents O
. O

These O
oils O
were O
differentiated O
by O
the O
content O
of O
the O
major O
constituents O
( O
alpha O
- O
pinene O
, O
germacrene B
D I
, O
delta B
- I
3 I
- I
carene I
and O
gamma B
- I
cadinene I
) O
, O
geographical O
location O
and O
climatic O
characteristics O
. O

In O
this O
review O
, O
we O
highlight O
how O
PP2A O
holoenzyme O
biogenesis O
and O
enzymatic O
activity O
are O
controlled O
by O
a O
sophisticatedly O
coordinated O
network O
of O
five O
PP2A O
modulators O
, O
consisting O
of O
alpha O
4 O
, O
phosphatase O
2A O
phosphatase O
activator O
( O
PTPA O
) O
, O
leucine B
carboxyl I
methyl I
transferase O
1 O
( O
LCMT1 O
) O
, O
PP2A O
methyl O
esterase O
1 O
( O
PME O
- O
1 O
) O
and O
, O
potentially O
, O
target O
of O
rapamycin O
signaling O
pathway O
regulator O
- O
like O
1 O
( O
TIPRL1 O
) O
, O
which O
serve O
to O
prevent O

In O
addition O
, O
a O
significant O
elevation O
of O
serum O
albumin O
( O
ALBU O
) O
, O
alkaline O
phosphatase O
( O
ALP O
) O
, O
alanine O
transaminase O
( O
ALT O
) O
, O
aspartate O
transaminase O
( O
AST O
) O
and O
total O
protein O
as O
well O
as O
a O
decline O
in O
creatinine O
, O
total O
cholesterol O
, O
urea B
nitrogen I
and O
glucose O
levels O
with O
MKA O
also O
ameliorated O
the O
hepatic O
and O
renal O
functions O
in O
normal O
ageing O
process O
. O

The O
present O
study O
investigated O
the O
effects O
of O
the O
aqueous O
extract O
from O
Bixa O
orellana O
seeds O
( O
AEBO O
) O
in O
mice O
with O
hyperlipidemia O
induced O
by O
tyloxapol B
, O
fructose O
and O
ethanol O
. O

In O
hyperlipidemia O
induced O
by O
Triton B
WR1339 I
, O
400 O
and O
800 O
mg O
/ O
kg O
AEBO O
reduced O
triglycerides O
( O
TG O
) O
serum O
levels O
at O
24 O
h O
and O
48 O
h O
. O

In O
conclusion O
, O
the O
aqueous O
extract O
of O
the O
seeds O
of O
Bixa O
orellana O
was O
capable O
of O
reversing O
the O
hypertriglyceridemia O
induced O
by O
Triton B
, O
fructose O
and O
ethanol O
, O
demonstrating O
a O
hypolipidemic O
effect O
. O

Sarmentosamide B
, O
a O
novel O
hexadienamide B
from O
Thai O
soil O
actinomycetes O
. O

A O
new O
hexadienamide O
derivative O
named O
sarmentosamide B
( O
1 O
) O
was O
identified O
from O
the O
culture O
of O
Streptomyces O
sp O
. O

Among O
them O
, O
gamma B
- I
sitosterol I
was O
found O
to O
be O
the O
major O
constituent O
. O

Isolation O
of O
a O
p B
- I
hydroxyphenyl I
anhydride I
from O
the O
leaves O
of O
Diphysa O
carthagenensisw O
. O

Diphysidione B
( O
1 O
) O
, O
a O
new O
p B
- I
hydroxyphenyl I
anhydride I
, O
and O
vitexin B
( O
2 O
) O
were O
isolated O
from O
the O
leaves O
of O
Diphysa O
carthagenensis O
. O

The O
structure O
of O
the O
new O
metabolite O
was O
characterised O
as O
4 B
- I
( I
4 I
- I
hydroxy I
- I
phenyl I
) I
- I
3H I
- I
pyran I
- I
2 I
, I
6 I
- I
dione I
using O
1D O
and O
2D O
NMR O
spectroscopy O
. O

A O
new O
abietane B
diterpenoid I
from O
Salvia O
xanthocheila O
Boiss O
. O

From O
the O
chloroform O
extract O
of O
aerial O
part O
of O
Salvia O
xanthocheila O
Boiss O
. O
one O
new O
abietane B
diterpenoid I
, O
xantoquinone B
( O
5 B
alpha I
, I
6 I
alpha I
- I
dimethoxy I
- I
7 I
, I
11 I
, I
14 I
- I
trioxoabieta I
- I
8 I
, I
12 I
- I
diene I
) O
and O
one O
known O
oleanene B
triterpenoid I
namely O
1 B
beta I
, I
3 I
beta I
- I
dihydroxy I
- I
12 I
- I
oleanene I
were O
isolated O
. O

Two O
lupeol O
- O
type O
pentacyclic B
triterpenoids I
characterised O
as O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
beta I
- I
ol I
- I
27 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
A I
) O
and O
lup B
- I
12 I
, I
20 I
( I
29 I
) I
- I
dien I
- I
3 I
beta I
- I
ol I
- I
26 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
B I
) O
and O
lanst B
- I
5 I
, I
24 I
- I
dien I
- I
3 I
beta I
- I
yl I
acetate I
( O
moruslanosteryl B
acetate I
) O
along O
with O
the O
known O
triterpenoidal O

phytoconstituents O
alpha B
- I
amyrin I
acetate I
, O
beta B
- I
amyrin I
- I
beta I
- I
D I
- I
glucopyranoside I
and O
betulinic O
acid O
have O
been O
isolated O
from O
the O
stem O
bark O
of O
Morus O
alba O
L O
. O

Synergy O
between O
L B
- I
DOPA I
and O
a O
novel O
positive O
allosteric O
modulator O
of O
metabotropic O
glutamate O
receptor O
4 O
: O
implications O
for O
Parkinson O
' O
s O
disease O
treatment O
and O
dyskinesia O
. O

For O
this O
reason O
, O
group O
III O
mGlu O
receptors O
, O
in O
particular O
mGlu4 O
, O
have O
been O
considered O
as O
key O
strategic O
targets O
for O
non O
- O
dopaminergic O
pharmacological O
treatments O
aimed O
at O
modulating O
these O
synapses O
, O
without O
producing O
the O
well O
known O
side O
- O
effects O
of O
l B
- I
DOPA I
, O
in O
particular O
the O
highly O
disabling O
l B
- I
DOPA I
- O
induced O
dyskinesia O
( O
LID O
) O
. O

Herein O
we O
add O
physiological O
and O
functional O
support O
to O
this O
hypothesis O
using O
Lu B
AF21934 I
, O
a O
novel O
selective O
and O
brain O
- O
penetrant O
mGlu4 O
receptor O
positive O
allosteric O
modulator O
( O
PAM O
) O
tool O
compound O
. O

By O
in O
vitro O
electrophysiological O
recordings O
we O
demonstrate O
that O
Lu B
AF21934 I
inhibits O
corticostriatal O
synaptic O
transmission O
and O
enhances O
the O
effect O
of O
the O
orthosteric O
mGlu4 O
receptor O
- O
preferred O
agonist O
LSP1 B
- I
2111 I
. O

In O
na O
i O
ve O
rats O
, O
Lu B
AF21934 I
dose O
- O
dependently O
( O
10 O
and O
30 O
mg O
/ O
kg O
) O
alleviated O
haloperidol O
- O
induced O
catalepsy O
. O

In O
hemiparkinsonian O
rats O
( O
unilateral O
6 O
- O
hydroxydopamine O
lesion O
of O
the O
substantia O
nigra O
pars O
compacta O
) O
, O
Lu B
AF21934 I
alone O
did O
not O
affect O
akinesia O
at O
the O
doses O
tested O
( O
10 O
and O
30 O
mg O
/ O
kg O
) O
. O

However O
, O
when O
Lu B
AF21934 I
was O
combined O
with O
sub O
- O
threshold O
doses O
of O
l B
- I
DOPA I
( O
1 O
and O
5 O
mg O
/ O
kg O
) O
, O
it O
acted O
synergistically O
in O
alleviating O
akinesia O
in O
a O
dose O
- O
dependent O
manner O
and O
, O
notably O
, O
also O
reduced O
the O
incidence O
of O
LID O
but O
not O
its O
severity O
. O

Interestingly O
, O
these O
effects O
occurred O
at O
Lu B
AF21934 I
brain O
free O
concentrations O
that O
showed O
functional O
activity O
in O
in O
vitro O
screens O
( O
calcium O
flux O
and O
electrophysiology O
assays O
) O
. O

These O
results O
support O
the O
potential O
for O
antiparkinsonian O
clinical O
use O
of O
a O
combined O
treatment O
consisting O
in O
l B
- I
DOPA I
and O
a O
mGlu4 O
receptor O
PAM O
to O
reduce O
efficacious O
l B
- I
DOPA I
doses O
( O
generally O
known O
as O
l B
- I
DOPA I
sparing O
) O
, O
while O
maintaining O
the O
same O
benefit O
on O
PD O
motor O
troubles O
, O
and O
at O
the O
same O
time O
minimizing O
the O
development O
of O
LID O
. O

A O
new O
pentacyclic B
triterpenoid I
and O
three O
new O
derivatives O
based O
on O
the O
taraxer B
- I
14 I
- I
ene I
skeleton O
with O
a O
C O
- O
28 O
attached O
a O
carboxylic O
acid O
group O
have O
been O
isolated O
from O
the O
stem O
bark O
of O
Hypodaphnis O
zenkeri O
, O
together O
with O
six O
known O
compounds O
. O

The O
new O
product O
was O
identified O
as O
2 B
alpha I
, I
3 I
alpha I
- I
dihydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
1 O
) O
. O

Its O
derivatives O
, O
2 B
alpha I
, I
3 I
alpha I
- I
diacetyltaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
2 O
) O
, O
2 B
alpha I
, I
3 I
alpha I
- I
di I
- I
O I
- I
carbonyl I
- I
2 I
alpha I
, I
3 I
alpha I
- I
dihydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
3 O
) O
and O
2 B
alpha I
, I
3 I
alpha I
- I
dipropionyltaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
4 O
) O
were O
obtained O
by O
semisynthesis O
. O

The O
known O
compounds O
were O
identified O
as O
3 B
beta I
- I
hydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
or O
aleuritolic B
acid I
( O
5 O
) O
( O
McPhail O
, O
A O
. O
T O
. O
, O
McPhail O
, O
D O
. O
R O
. O
, O
Wani O
, O
M O
. O
C O
. O
, O
Wall O
, O
M O
. O
E O
. O
& O
A O
. O
W O
. O
, O
Nicholas O
, O
A O
. O
W O
. O
( O
1989 O
) O
. O
Identity O
of O
maprounic B
acid I
with O
aleuritolic B
acid I
. O
Revision O
of O
the O
structure O
of O
maprounic B
acid I
: O
X O
- O
ray O
crystal O
structure O
of O
p O
- O
bromobenzyl O

acetylmaprounate O
. O
Journal O
Natural O
Products O
, O
52 O
, O
212 O
) O
, O
3 B
alpha I
- I
hydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
or O
isoaleuritolic B
acid I
( O
6 O
) O
, O
3 B
alpha I
- I
acetyltaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
acetate I
or O
aleuritolic B
acid I
acetate I
( O
7 O
) O
( O
Chaudhuri O
, O
S O
. O
K O
. O
, O
Fullas O
, O
F O
. O
, O
Brown O
, O
D O
. O
M O
. O
, O
Wani O
, O
M O
. O
C O
. O
, O
Wall O
, O
M O
. O
E O
. O
, O
Cai O
, O
L O
. O
, O
. O
. O
. O

Kinghorn O
, O
A O
. O
D O
. O
( O
1995 O
) O
. O
Isolation O
and O
structural O
elucidation O
of O
pentacyclic O
triterpenoids O
from O
Maprounea O
africana O
. O
Journal O
of O
Natural O
Products O
, O
58 O
, O
1 O
- O
9 O
) O
, O
3 B
- I
oxo I
- I
taraxer I
- I
14 I
- I
ene I
or O
taraxerone B
( O
8 O
) O
beta O
- O
sitosterol O
( O
9 O
) O
and O
stigmasterol O
( O
10 O
) O
( O
Kamboj O
& O
Saluja O
, O
2011 O
) O
, O
together O
with O
fatty O
acids O
. O

A O
new O
acylated B
flavonoid I
, O
3 B
- I
O I
- I
rhamnocitrin I
- I
6 I
- I
O I
- I
benzoyl I
- I
beta I
- I
D I
- I
glucopyranoside I
( O
1 O
) O
, O
together O
with O
five O
known O
flavonoids O
, O
rhamnocitrin B
( O
2 O
) O
, O
pratensein B
( O
3 O
) O
, O
( B
3R I
) I
- I
7 I
, I
3 I
' I
- I
dihydroxy I
- I
2 I
' I
, I
4 I
' I
- I
dimethoxyisoflavan I
( O
4 O
) O
, O
( O
3R O
) O
- O
7 O
, O
2 O
' O
- O
dihydroxy O
- O
3 O
' O
, O
4 O
' O
- O

dimethoxyisoflavan O
( O
5 O
) O
and O
isoliquiritigenin B
( O
6 O
) O
, O
was O
isolated O
from O
Oxytropis O
ochrocephala O
Bunge O
. O

Continuous O
infusion O
of O
20 B
- I
hydroxyecdysone I
increased O
mass O
of O
triceps O
brachii O
in O
C57BL O
/ O
6 O
mice O
. O

Phytoecdysteroids B
have O
been O
attributed O
with O
numerous O
pharmacological O
properties O
in O
animals O
, O
including O
increasing O
muscle O
mass O
, O
and O
20 B
- I
hydroxyecdysone I
( O
20E O
) O
is O
one O
of O
the O
most O
abundant O
phytoecdysteroids B
produced O
by O
plants O
. O

Griseofulvin B
and O
Naproxen O
were O
milled O
in O
both O
recirculation O
mode O
and O
multi O
- O
pass O
continuous O
mode O
to O
study O
the O
breakage O
dynamics O
and O
to O
determine O
the O
effects O
of O
suspension O
flow O
rate O
. O

In O
this O
study O
, O
we O
fabricated O
microneedles O
from O
a O
biocompatible O
polymer O
, O
namely O
, O
poly B
( I
ethylene I
glycol I
) I
diacrylate I
. O

Various O
polymers O
were O
evaluated O
as O
stabilizing O
agents O
among O
which O
polyvinylpyrrolidone O
17PF O
and O
amino B
methacrylate I
copolymer O
exhibited O
a O
significant O
inhibitory O
effect O
on O
fenofibrate O
recrystallization O
in O
the O
hot O
- O
melt O
extrudates O
. O

This O
LTD O
was O
concentration O
dependent O
and O
was O
blocked O
by O
the O
group O
II O
mGlu O
receptor O
antagonist O
, O
LY341495 B
. O

To O
investigate O
further O
the O
role O
of O
mGlu3 O
receptors O
, O
we O
used O
LY395756 B
( O
an O
mGlu2 O
agonist O
and O
mGlu3 O
antagonist O
) O
, O
which O
acts O
as O
a O
pure O
mGlu3 O
receptor O
antagonist O
in O
this O
rat O
strain O
. O

To O
address O
whether O
mGlu2 O
activation O
alone O
is O
also O
sufficient O
to O
induce O
LTD O
at O
this O
synapse O
we O
used O
LY541850 O
( O
the O
active O
enantiomer O
of O
LY395756 B
) O
in O
wild O
- O
type O
mice O
. O

Effect O
of O
water O
extracts O
from O
edible O
myrtaceae O
plants O
on O
uptake O
of O
2 B
- I
( I
n I
- I
( I
7 I
- I
nitrobenz I
- I
2 I
- I
oxa I
- I
1 I
, I
3 I
- I
diazol I
- I
4 I
- I
yl I
) I
amino I
) I
- I
2 I
- I
deoxyglucose I
in O
TNF O
- O
alpha O
- O
treated O
FL83B O
mouse O
hepatocytes O
. O

The O
fluorescent O
dye O
2 B
- I
( I
n I
- I
( I
7 I
- I
nitrobenz I
- I
2 I
- I
oxa I
- I
1 I
, I
3 I
- I
diazol I
- I
4 I
- I
yl I
) I
amino I
) I
- I
2 I
- I
deoxyglucose I
was O
used O
to O
estimate O
the O
uptake O
ability O
of O
the O
cells O
. O

Two O
new O
C O
- O
15 O
enolic B
acyl I
phragmalin I
- O
type O
limonoids B
from O
Chukrasia O
tabularis O
var O
. O
velutina O
. O

Two O
new O
C O
- O
15 O
enolic B
acyl I
phragmalin I
- O
type O
limonoid B
orthoesters I
, O
chukvelutilide B
G I
( O
1 O
) O
and O
chukrasine B
F I
( O
2 O
) O
, O
were O
isolated O
from O
the O
stem O
barks O
of O
Chukrasia O
tabularis O
var O
. O
velutina O
. O

A O
new O
xanthone B
from O
the O
bark O
of O
Calophyllum O
thorelii O
. O

A O
new O
xanthone B
, O
calothorexanthone B
, O
together O
with O
five O
known O
compounds O
, O
garbogiol B
, O
1 B
, I
4 I
, I
8 I
- I
trihydroxyxanthone I
, O
delta B
- I
tocotrienol I
, O
1 B
, I
7 I
- I
dihydroxyxanthone I
and O
globuxanthone B
, O
was O
isolated O
from O
a O
petroleum O
ether O
extract O
of O
the O
bark O
of O
Calophyllum O
thorelii O
. O

Preparation O
and O
cyclodextrin O
assisted O
dissolution O
rate O
enhancement O
of O
itraconazolium B
dinitrate I
salt O
. O

The O
poor O
solubility O
of O
itraconazole O
( O
ITR B
) O
results O
in O
its O
variable O
oral O
absorption O
and O
bioavailability O
and O
has O
also O
proven O
to O
be O
a O
major O
setback O
in O
developing O
an O
efficient O
oral O
delivery O
system O
. O

To O
improve O
its O
solubility O
and O
dissolution O
profile O
, O
itraconazolium B
dinitrate I
salt O
( O
ITRDNT B
) O
was O
prepared O
and O
characterized O
using O
various O
spectral O
and O
thermal O
techniques O
. O

Broth O
microdilution O
assay O
demonstrated O
antifungal O
efficacy O
of O
ITRDNT B
similar O
to O
ITR B
against O
four O
different O
fungal O
strains O
namely O
, O
Asparagillus O
fumigatus O
, O
Microsporum O
canis O
, O
Microsporum O
gypsum O
and O
Trichophyton O
rubrum O
. O

The O
salt O
exhibited O
better O
solubility O
profile O
than O
ITR B
in O
water O
and O
a O
number O
of O
pharmaceutical O
solvents O
. O

Dissolution O
studies O
revealed O
the O
total O
amount O
of O
drug O
released O
from O
ITRDNT B
in O
3 O
h O
was O
four O
times O
greater O
than O
that O
of O
ITR B
. O

To O
further O
improve O
dissolution O
characteristics O
, O
the O
physical O
mixtures O
of O
ITR B
and O
ITRDNT B
with O
two O
cyclodextrins O
, O
beta O
- O
cyclodextrin O
( O
beta O
- O
CD O
) O
and O
HP B
- I
beta I
- I
cyclodextrin I
( O
HP O
- O
beta O
- O
CD O
) O
were O
prepared O
and O
their O
molar O
ratios O
were O
optimized O
. O

It O
was O
observed O
that O
about O
75 O
% O
of O
drug O
was O
released O
in O
30 O
min O
from O
1 O
: O
3 O
molar O
ratio O
of O
ITRDNT B
and O
HP O
- O
beta O
- O
CD O
physical O
mixture O
, O
which O
was O
distinctly O
higher O
than O
ITR B
commercial O
capsules O
( O
70 O
% O
) O
. O

Owing O
to O
its O
facile O
and O
economical O
preparation O
and O
substantially O
better O
in O
vitro O
release O
profile O
, O
the O
ITRDNT B
and O
its O
CD O
physical O
mixtures O
could O
be O
better O
and O
cost O
effective O
alternatives O
to O
ITR B
and O
commercial O
ITR B
capsules O
. O

Mouse O
hippocampal O
synaptosomes O
were O
preloaded O
with O
[ B
( I
3 I
) I
H I
] I
D I
- I
gamma I
- I
aminobutyric I
acid I
( O
[ O
( O
3 O
) O
H O
] O
GABA O
) O
and O
then O
exposed O
in O
superfusion O
to O
12 O
mM O
KCl O
. O

The O
K O
( O
+ O
) O
- O
evoked O
[ O
( O
3 O
) O
H O
] O
GABA O
release O
was O
inhibited O
by O
the O
mGlu7 O
allosteric O
agonist O
N B
, I
N I
' I
- I
dibenzyhydryl I
- I
ethane I
- I
1 I
, I
2 I
- I
diamine I
dihydrochloride I
( O
AMN082 O
, O
0 O
. O
001 O
- O
10 O
mu O
M O
) O
, O
as O
well O
as O
by O
the O
group O
III O
mGlu O
receptor O
agonist O
l B
- I
( I
+ I
) I
- I
2 I
- I
amino I
- I
4 I
- I
phosphonobutyric I
acid I
[ O
( O
l O
) O
- O
AP4 O
, O
0 O
. O
01 O
- O
1 O
mM O
] O
. O

AMN082 O
and O
( O
l O
) O
- O
AP4 O
- O
induced O
effects O
were O
recovered O
by O
the O
mGlu7 O
negative O
allosteric O
modulator O
( O
NAM O
) O
6 B
- I
( I
4 I
- I
methoxyphenyl I
) I
- I
5 I
- I
methyl I
- I
3 I
- I
( I
4 I
- I
pyridinyl I
) I
- I
isoxazolo I
[ I
4 I
, I
5 I
- I
c I
] I
pyridin I
- I
4 I
( I
5H I
) I
- I
one I
hydrochloride I
( O
MMPIP B
) O
. O

AMN082 O
also O
inhibited O
in O
a O
MMPIP B
- O
sensitive O
manner O
the O
K O
( O
+ O
) O
- O
evoked O
release O
of O
endogenous O
GABA O
. O

AMN082 O
and O
the O
adenylyl O
cyclase O
( O
AC O
) O
inhibitor O
MDL B
- I
12 I
, I
330A I
reduced O
[ O
( O
3 O
) O
H O
] O
GABA O
exocytosis O
in O
a O
8 B
- I
Br I
- I
cAMP I
- O
sensitive O
. O

AMN082 O
- O
inhibitory O
effect O
was O
additive O
to O
that O
caused O
by O
( O
- O
) O
baclofen O
, O
but O
insensitive O
to O
the O
GABA O
( O
B O
) O
antagonist O
3 B
- I
[ I
[ I
( I
3 I
, I
4 I
- I
Dichlorophenyl I
) I
methyl I
] I
amino I
] I
propyl I
] I
diethoxymethyl I
) I
phosphinic I
acid I
( O
CGP52432 B
) O
. O

Conversely O
, O
( O
- O
) O
baclofen O
- O
induced O
inhibition O
of O
GABA O
exocytosis O
was O
insensitive O
to O
MMPIP B
. O

A O
new O
method O
for O
preparing O
pentacyclic B
triterpene I
rich O
Centella O
asiatica O
extracts O
. O

This O
study O
evaluated O
microwave O
- O
assisted O
extraction O
( O
MAE O
) O
for O
four O
pentacyclic B
triterpenes I
as O
well O
as O
developed O
a O
method O
for O
preparing O
a O
pentacyclic B
triterpenene I
rich O
extract O
from O
Centella O
asiatica O
. O

MAE O
was O
capable O
of O
increasing O
the O
yield O
of O
the O
pentacyclic B
triterpenes I
up O
to O
twice O
that O
produced O
by O
the O
heat O
reflux O
method O
, O
and O
it O
was O
also O
much O
less O
time O
consuming O
. O

Here O
, O
we O
provide O
a O
simple O
method O
for O
the O
preparation O
of O
the O
pentacyclic B
triterpene I
rich O
C O
. O
asiatica O
extracts O
, O
which O
contained O
not O
less O
than O
65 O
% O
w O
/ O
w O
total O
pentacyclic B
triterpenes I
. O

Sm O
. O
: O
alpha O
- O
pinene O
, O
p B
- I
cymene I
, O
1 B
, I
8 I
- I
cineole I
, O
and O
limonene O
. O

In O
a O
comparison O
of O
the O
components O
of O
the O
mixed O
inhalation O
, O
the O
ratio O
of O
alpha O
- O
pinene O
increased O
to O
about O
three O
times O
that O
of O
1 B
, I
8 I
- I
cineole I
. O

Total O
lipids O
were O
extracted O
using O
a O
solvent O
mixture O
of O
methanol O
/ O
chloroform O
( O
2 O
/ O
1 O
, O
v O
/ O
v O
) O
and O
further O
derivatised O
to O
FA B
methyl I
esters I
( O
FAME B
) O
. O

The O
analyses O
of O
FAME B
samples O
were O
performed O
by O
gas O
chromatography O
coupled O
to O
a O
flame O
ionisation O
detector O
. O

The O
most O
abundant O
saturated O
FA O
were O
palmitic O
( O
C16 B
: I
0 I
) O
and O
myristic B
( O
C14 B
: I
0 I
) O
, O
while O
oleic O
( O
C18 B
: I
1 I
n O
- O
9 O
) O
was O
the O
dominant O
monounsaturated B
acid I
. O

All O
seaweeds O
contained O
linoleic B
FA I
( O
C18 B
: I
2 I
n O
- O
6 O
) O
. O

The O
alpha B
- I
linolenic I
( O
C18 B
: I
3 I
n O
- O
3 O
) O
and O
eicosapentaenoic O
( O
20 O
: O
5 O
n O
- O
3 O
) O
acids O
were O
present O
only O
in O
Porphyra O
sp O
. O

The O
stable O
inclusion O
complex O
of O
puerarin O
and O
2 B
- I
hydroxypropyl I
- I
beta I
- I
cyclodextrin I
( O
HPCD B
) O
was O
prepared O
by O
a O
ball O
mill O
under O
the O
following O
conditions O
: O
equimolar O
ratio O
of O
puerarin O
to O
HPCD B
; O
rotational O
speed O
of O
250 O
rpm O
; O
milling O
time O
of O
90 O
min O
; O
steel O
balls O
of O
22 O
mm O
diameter O
. O

The O
optimal O
formulation O
of O
SMEDDS O
obtained O
was O
comprised O
of O
60 O
% O
Cremophor O
( O
( O
R O
) O
) O
EL O
, O
30 O
% O
Transcutol B
( O
( O
R O
) O
) O
HP O
and O
10 O
% O
Capryol B
( O
TM O
) O
90 O
. O

Improvement O
of O
liver O
function O
in O
humans O
using O
a O
mixture O
of O
schisandra O
fruit O
extract O
and O
sesamin B
. O

The O
study O
was O
focused O
on O
the O
potential O
effects O
of O
a O
mixture O
of O
Schisandra O
fruit O
extract O
and O
sesamin B
( O
hereinafter O
called O
' O
SCH B
' O
) O
in O
the O
subjects O
with O
borderline O
high O
levels O
( O
40 O
- O
60 O
U O
/ O
L O
) O
of O
alanine O
aminotransferase O
( O
ALT O
) O
or O
aspartate O
aminotransferase O
( O
AST O
) O
. O

Twenty O
subjects O
taking O
SCH B
( O
four O
tablets O
per O
day O
) O
and O
20 O
subjects O
taking O
a O
placebo O
( O
four O
tablets O
per O
day O
) O
were O
studied O
. O

The O
effects O
of O
SCH B
on O
ALT O
, O
AST O
, O
total O
bilirubin O
, O
direct O
bilirubin O
, O
free O
radical O
levels O
, O
total O
antioxidant O
status O
, O
glutathione O
peroxidase O
, O
glutathione O
reductase O
, O
and O
the O
lag O
time O
for O
low O
- O
density O
lipoprotein O
oxidation O
were O
determined O
. O

Intervention O
of O
SCH B
clearly O
reduced O
the O
levels O
of O
ALT O
and O
AST O
, O
but O
it O
made O
no O
change O
in O
the O
total O
bilirubin O
and O
direct O
bilirubin O
. O

Intake O
of O
SCH B
also O
greatly O
increased O
the O
antioxidant O
capacity O
and O
decreased O
the O
values O
of O
thiobarbituric O
acid O
reactive O
substances O
, O
total O
free O
radicals O
, O
and O
superoxide O
anion O
radicals O
in O
the O
plasma O
. O

SCH B
proved O
to O
have O
the O
effects O
of O
antioxidation O
and O
improving O
liver O
function O
. O

We O
have O
previously O
shown O
that O
the O
inhibitor O
of O
pyruvate O
dehydrogenase O
kinase O
( O
PDK O
) O
dichloroacetate B
( O
DCA B
) O
activates O
glucose O
oxidation O
and O
induces O
apoptosis O
in O
cancer O
cells O
in O
vitro O
and O
in O
vivo O
. O

We O
hypothesized O
that O
DCA B
will O
also O
reverse O
the O
' O
pseudohypoxic O
' O
mitochondrial O
signals O
that O
lead O
to O
HIF1 O
alpha O
activation O
in O
cancer O
, O
even O
in O
the O
absence O
of O
hypoxia O
and O
inhibit O
cancer O
angiogenesis O
. O

Using O
pharmacologic O
and O
molecular O
approaches O
that O
suppress O
the O
prolyl O
- O
hydroxylase O
( O
PHD O
) O
- O
mediated O
inhibition O
of O
HIF1 O
alpha O
, O
we O
show O
that O
DCA B
inhibits O
HIF1 O
alpha O
by O
both O
a O
PHD O
- O
dependent O
mechanism O
( O
that O
involves O
a O
DCA B
- O
induced O
increase O
in O
the O
production O
of O
mitochondria O
- O
derived O
alpha O
- O
ketoglutarate O
) O
and O
a O
PHD O
- O
independent O
mechanism O
, O
involving O
activation O
of O
p53 O
via O
mitochondrial O
- O
derived O
H O
( O
2 O
) O
O O
( O
2 O
) O
, O
as O
well O
as O
activation O
of O
GSK3 O
beta O
. O

Single O
non O
- O
ionic O
surfactant O
based O
self O
- O
nanoemulsifying O
drug O
delivery O
system O
( O
SNEDDS O
) O
was O
formulated O
and O
characterised O
for O
poor O
water O
soluble O
drug O
, O
Atorvastatin B
calcium I
. O

Capmul O
MCM O
oil O
showing O
highest O
solubility O
for O
Atorvastatin B
calcium I
was O
selected O
as O
oil O
phase O
. O

Self O
- O
nanoemulsifying O
capacity O
of O
Cremophor O
RH O
40 O
, O
Cremophor O
EL O
, O
Tween B
20 I
, O
Tween B
60 I
, O
Tween O
80 O
and O
Labrasol O
were O
tested O
for O
the O
selected O
oil O
. O

Capmul O
MCM O
was O
found O
to O
be O
better O
nanoemulsified O
in O
decreasing O
order O
of O
Cremophor O
RH O
40 O
> O
Cremophor O
EL O
> O
Tween B
20 I
> O
Tween B
60 I
> O
Tween O
80 O
. O

SNEDDS O
formulated O
with O
Tween B
20 I
surfactant O
showed O
enhanced O
dissolution O
with O
t85 O
% O
and O
DE O
values O
at O
10 O
min O
and O
78 O
. O
70 O
, O
respectively O
. O

Tween B
20 I
based O
SNEDDS O
enhanced O
permeation O
of O
the O
drug O
as O
compared O
with O
pure O
drug O
across O
cell O
lines O
. O

It O
can O
be O
concluded O
that O
SNEDDS O
can O
be O
formulated O
by O
using O
single O
non O
- O
ionic O
surfactant O
system O
for O
enhance O
dissolution O
and O
absorption O
of O
poorly O
soluble O
drug O
, O
Atorvastatin B
calcium I
. O

Astaxanthin O
( O
C40H52O4 B
) O
is O
an O
important O
natural O
pigment O
that O
has O
considerable O
promising O
applications O
in O
human O
health O
. O

Silibinin B
triggers O
apoptosis O
and O
cell O
- O
cycle O
arrest O
of O
SGC7901 O
cells O
. O

Silibinin B
, O
a O
flavonoid O
compound O
, O
has O
shown O
to O
be O
of O
chemopreventive O
potential O
against O
many O
cancers O
. O

Here O
, O
we O
assessed O
the O
activity O
of O
Silibinin B
on O
apoptosis O
and O
cell O
- O
cycle O
arrest O
in O
human O
gastric O
cells O
culture O
system O
using O
SGC O
- O
7901 O
as O
the O
model O
. O

Silibinin B
treatment O
could O
inhibit O
the O
cell O
growth O
and O
cause O
a O
prominent O
G2 O
phase O
arrest O
and O
apoptosis O
in O
dose O
- O
and O
time O
- O
dependent O
manner O
. O

In O
mechanistic O
studies O
, O
Silibinin B
decreased O
the O
protein O
level O
of O
p34cdc2 O
, O
which O
might O
be O
the O
possible O
molecular O
mechanism O
of O
Silibinin B
efficacy O
on O
the O
growth O
inhibition O
in O
SGC O
- O
7901 O
cells O
. O

In O
addition O
, O
Silibinin B
caused O
an O
increase O
in O
p53 O
and O
p21 O
protein O
level O
as O
well O
as O
mRNA O
levels O
. O

Interestingly O
, O
Silibinin B
- O
induced O
apoptosis O
in O
SGC O
- O
7901 O
cells O
was O
independent O
of O
caspases O
activation O
. O

These O
results O
indicated O
that O
Silibinin B
is O
a O
cell O
- O
cycle O
regulator O
and O
apoptosis O
inducer O
in O
human O
gastric O
carcinoma O
SGC O
- O
7901 O
cells O
and O
might O
be O
used O
as O
a O
candidate O
chemopreventive O
agent O
for O
gastric O
carcinoma O
prevention O
and O
intervention O
. O

Two O
new O
alkaloid B
galactosides I
from O
the O
kernel O
of O
Prinsepia O
uniflora O
. O

Two O
new O
alkaloid B
galactosides I
have O
been O
isolated O
from O
the O
kernel O
of O
Prinsepia O
uniflora O
. O

Their O
structures O
were O
elucidated O
as O
5 B
- I
[ I
( I
alpha I
- I
D I
- I
galactopyranosyloxy I
) I
methyl I
] I
- I
1H I
- I
pyrrole I
- I
2 I
- I
carbaldehyde I
( O
1 O
) O
and O
6 B
- I
[ I
( I
alpha I
- I
D I
- I
galactopyranosyloxy I
) I
methyl I
] I
- I
3 I
- I
pyridinol I
( O
2 O
) O
by O
various O
spectroscopic O
means O
including O
HR O
- O
ESI O
- O
MS O
, O
IR O
, O
1D O
and O
2D O
NMR O
. O

The O
determined O
structures O
were O
characterized O
with O
a O
unit O
of O
galactose O
which O
is O
rarely O
seen O
in O
the O
previously O
isolated O
pyrrole O
and O
pyridinol B
compounds O
. O

Here O
we O
review O
the O
effects O
of O
newly O
- O
designed O
group O
- O
III O
orthosteric O
agonists O
on O
neuroprotection O
, O
neurorestoration O
and O
reduction O
of O
l B
- I
DOPA I
induced O
dyskinesia O
in O
animal O
models O
of O
PD O
. O

Solid O
lipid O
nanoparticles O
and O
nanosuspension O
of O
adefovir B
dipivoxil I
for O
bioavailability O
improvement O
: O
formulation O
, O
characterization O
, O
pharmacokinetic O
and O
biodistribution O
studies O
. O

The O
present O
study O
was O
aimed O
at O
developing O
colloidal O
formulations O
like O
solid O
lipid O
nanoparticles O
( O
SLN O
) O
and O
nanosuspension O
( O
NS O
) O
for O
improving O
bioavailability O
of O
adefovir B
dipivoxil I
( O
AD O
) O
, O
a O
nucleoside O
reverse O
transcriptase O
inhibitor O
which O
displays O
poor O
oral O
bioavailability O
. O

The O
relative O
bioavailability O
for O
adefovir B
NS O
and O
SLN O
were O
52 O
. O
46 O
% O
and O
78 O
. O
23 O
% O
respectively O
compared O
to O
34 O
. O
34 O
% O
bioavailability O
obtained O
after O
administration O
of O
adefovir B
micro O
suspension O
( O
AMS O
) O
, O
indicating O
suitability O
of O
both O
nanoparticulate O
formulations O
for O
improving O
bioavailability O
. O

A O
new O
bromobenzyl B
methyl I
sulphoxide I
from O
marine O
red O
alga O
Symphyocladia O
latiuscula O
. O

A O
new O
bromophenol B
, O
2 B
, I
3 I
, I
6 I
- I
tribromo I
- I
4 I
, I
5 I
- I
dihydroxybenzyl I
methyl I
sulphoxide I
, O
was O
isolated O
from O
the O
EtOH O
extract O
of O
the O
marine O
alga O
Symphyocladia O
latiuscula O
. O

This O
new O
bromophenol B
showed O
moderate O
antifungal O
activity O
against O
Candida O
albicans O
with O
MIC O
value O
of O
37 O
. O
5 O
micro O
g O
mL O
( O
- O
1 O
) O
. O

Aromadendrine B
, O
a O
new O
component O
of O
the O
flavonoid O
pattern O
of O
Olea O
europaea O
L O
. O
and O
its O
anti O
- O
inflammatory O
activity O
. O

In O
the O
medium O
polar O
fraction O
, O
we O
isolated O
the O
two O
hydroxy B
- I
phenyl I
- I
ethyl I
alcohols I
( O
hydroxyl B
- I
tyrosol I
and O
tyrosol O
) O
that O
are O
the O
main O
component O
of O
olives O
. O

In O
addition O
, O
we O
isolated O
a O
flavonoidic B
compound O
, O
aromadendrine B
, O
a O
dihydroflavonol B
yet O
known O
but O
quite O
rare O
in O
nature O
. O

It O
is O
the O
first O
time O
that O
aromadendrine B
is O
isolated O
in O
O O
. O
europaea O
and O
we O
studied O
the O
aromadendrine B
biological O
activity O
. O

In O
particular O
, O
the O
ability O
of O
aromadendrine B
to O
reduce O
the O
inflammation O
induced O
in O
normal O
keratinocytes O
using O
an O
in O
vitro O
cell O
model O
was O
evaluated O
. O

The O
results O
of O
the O
present O
research O
indicate O
aromadendrine B
as O
a O
novel O
component O
in O
O O
. O
europaea O
with O
effective O
activity O
against O
skin O
inflammation O
. O

A O
modern O
approach O
for O
controlled O
transdermal O
delivery O
of O
diflunisal B
: O
optimization O
and O
in O
vivo O
evaluation O
. O

The O
purpose O
of O
the O
present O
work O
was O
to O
elaborate O
an O
optimized O
transdermal O
therapeutic O
system O
for O
diflunisal B
. O

Composition O
of O
microemulsion O
( O
ME O
) O
systems O
consisting O
of O
butyl B
lactate I
, O
Brij B
( O
( O
R O
) O
) O
97 O
, O
Transcutol B
( O
( O
R O
) O
) O
and O
water O
was O
optimized O
using O
augmented O
simplex O
lattice O
mixture O
design O
. O

The O
independent O
variables O
selected O
were O
the O
percentages O
of O
butyl B
lactate I
, O
surfactant O
mixture O
and O
water O
. O

The O
optimized O
ME O
formulation O
was O
converted O
into O
gel O
using O
Carbomer B
( O
( O
R O
) O
) O
934 O
. O

The O
microemulsion O
based O
gel O
( O
MBG O
) O
showed O
better O
spreadability O
and O
5 O
. O
07 O
- O
fold O
increase O
in O
the O
transdermal O
flux O
than O
Carbomer B
( O
( O
R O
) O
) O
934 O
gel O
. O

The O
developed O
MBG O
proved O
its O
in O
vivo O
efficiency O
for O
transdermal O
delivery O
of O
diflunisal B
. O

Feroniellides B
C I
- I
E I
, O
new O
apotirucallane B
triterpenoids I
from O
the O
stem O
bark O
of O
Feroniella O
lucida O
. O

Bioassay O
- O
directed O
isolation O
of O
Feroniella O
lucida O
stem O
bark O
yielded O
three O
new O
apotirucallane B
triterpenoids I
named O
feroniellides B
C I
- I
E I
. O

Of O
triterpenoids O
examined O
, O
feroniellides B
D I
and I
E I
revealed O
anticancer O
activity O
against O
KB O
and O
HeLa O
cells O
with O
IC50 O
values O
in O
range O
of O
3 O
. O
4 O
- O
14 O
. O
2 O
micro O
g O
mL O
( O
- O
1 O
) O
, O
which O
are O
significantly O
more O
potent O
than O
feroniellides B
A I
- I
C I
( O
IC50 O
25 O
. O
5 O
- O
60 O
. O
0 O
micro O
g O
mL O
( O
- O
1 O
) O
) O
. O

The O
present O
investigation O
suggests O
that O
an O
isovalerate B
moiety O
in O
feroniellides B
D I
and I
E I
is O
possibly O
associated O
with O
exerting O
cytotoxicity O
against O
cancer O
cells O
. O

Garcinielliptone B
FC I
( O
GFC B
) O
, O
a O
natural O
prenylated B
benzophenone I
, O
was O
extracted O
from O
Platonia O
insignis O
Mart O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
cytotoxic O
and O
leishmanicidal O
effects O
of O
GFC B
using O
in O
vitro O
models O
. O

The O
experimental O
data O
demonstrated O
that O
the O
polyisoprenylated B
benzophenone I
GFC I
possesses O
cytotoxic O
and O
leishmanicidal O
activities O
. O

A O
new O
acylated B
flavone I
glycoside I
with O
antioxidant O
and O
radical O
scavenging O
activities O
from O
Teucrium O
polium O
leaves O
. O

On O
the O
basis O
of O
the O
comparable O
bioactivity O
of O
luteolin O
- O
based O
compounds O
, O
the O
presence O
of O
an O
ortho B
- I
dihydroxy I
substitution O
in O
the O
flavone O
B O
- O
ring O
is O
supposed O
to O
be O
the O
structural O
feature O
responsible O
for O
the O
antioxidant O
activity O
. O

The O
main O
components O
in O
the O
oil O
were O
butylated O
hydroxytoluene O
( O
BHT O
) O
( O
34 O
. O
17 O
% O
) O
, O
phytol B
( O
12 O
. O
66 O
% O
) O
, O
alpha B
- I
caryophyllene I
( O
11 O
. O
84 O
% O
) O
, O
delta B
- I
elemene I
( O
10 O
. O
65 O
% O
) O
, O
beta B
- I
caryophyllene I
( O
7 O
. O
82 O
% O
) O
, O
gamma B
- I
elemene I
( O
4 O
. O
24 O
% O
) O
and O
germacrene B
D I
( O
2 O
. O
82 O
% O
) O
. O

A O
new O
caryolane B
sesquiterpene I
from O
Heteropappus O
altaicus O
( O
Willd O
. O
) O
Novopokr O
. O

A O
new O
caryolane B
sesquiterpene I
, O
1 B
beta I
- I
methoxycaryol I
- I
9 I
- I
one I
( O
1 O
) O
, O
along O
with O
eight O
known O
compounds O
( O
2 O
- O
9 O
) O
, O
was O
isolated O
from O
the O
whole O
plant O
of O
Heteropappus O
altaicus O
. O

An O
antileishmanial O
prenyloxy B
- I
naphthoquinone I
from O
roots O
of O
Plumbago O
zeylanica O
. O

This O
study O
discloses O
strong O
in O
vitro O
antileishmanial O
activity O
of O
2 B
- I
methyl I
- I
5 I
- I
( I
3 I
' I
- I
methyl I
- I
but I
- I
2 I
' I
- I
enyloxy I
) I
- I
[ I
1 I
, I
4 I
] I
naphthoquinone I
( O
1 O
) O
, O
a O
prenyloxy B
- I
naphthoquinone I
isolated O
and O
characterised O
from O
roots O
of O
the O
plant O
Plumbago O
zeylanica O
( O
family O
- O
Plumbaginaceae O
) O
. O

The O
observed O
EC50 O
for O
the O
compound O
1 O
against O
promastigote O
and O
amastigote O
forms O
of O
L O
. O
donovani O
was O
significantly O
( O
p O
< O
0 O
. O
001 O
) O
lower O
than O
miltefosine B
, O
a O
reference O
drug O
. O

Isolation O
and O
structure O
determination O
of O
new O
siderophore O
tsukubachelin B
B I
from O
Streptomyces O
sp O
. O

The O
new O
siderophore O
tsukubachelin B
B I
( O
1 O
) O
was O
isolated O
from O
the O
iron O
- O
deficient O
culture O
medium O
of O
the O
newly O
isolated O
strain O
Streptomyces O
sp O
. O

The O
chemical O
structure O
of O
tsukubachelin B
B I
( O
1 O
) O
was O
established O
via O
interpretation O
of O
2D O
nuclear O
magnetic O
resonance O
and O
electrospray O
ionization O
- O
mass O
spectroscopic O
data O
. O

The O
structure O
of O
tsukubachelin B
B I
( O
1 O
) O
comprises O
6 O
mol O
of O
amino O
acids O
, O
including O
2 O
mol O
of O
serine O
and O
1 O
mol O
each O
of O
ornithine O
, O
N B
- I
alpha I
- I
methyl I
- I
N I
- I
delta I
- I
hydroxy I
- I
N I
- I
delta I
- I
formylornithine I
, O
N B
- I
alpha I
- I
methyl I
- I
N I
- I
delta I
- I
hydroxyornithine I
, O
and O
cyclic B
N I
- I
hydroxyornithine I
. O

Anti O
- O
diabetic O
Activity O
of O
Swertiamarin O
is O
due O
to O
an O
Active O
Metabolite O
, O
Gentianine B
, O
that O
Upregulates O
PPAR O
- O
gamma O
Gene O
Expression O
in O
3T3 O
- O
L1 O
cells O
. O

Gentianine B
is O
an O
active O
metabolite O
of O
swertiamarin O
that O
possesses O
a O
pharmacophoric O
moiety O
. O

The O
aim O
of O
this O
study O
was O
to O
explore O
the O
possibility O
whether O
the O
anti O
- O
diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine B
. O

On O
the O
other O
hand O
, O
treatment O
with O
gentianine B
significantly O
increased O
adipogenesis O
, O
which O
was O
associated O
with O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
PPAR O
- O
gamma O
, O
GLUT O
- O
4 O
and O
adiponectin O
. O

These O
findings O
suggest O
, O
for O
the O
first O
time O
, O
that O
the O
anti O
- O
diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine B
, O
an O
active O
metabolite O
of O
swertiamarin O
. O

Chronic O
treatment O
with O
selective O
I2 O
- O
imidazoline B
receptor O
ligands O
decreases O
the O
content O
of O
pro O
- O
apoptotic O
markers O
in O
rat O
brain O
. O

Selective O
I O
( O
2 O
) O
- O
imidazoline B
receptor O
ligands O
induce O
neuroprotection O
through O
various O
molecular O
mechanisms O
including O
blockade O
of O
N O
- O
methyl O
- O
D O
- O
aspartate O
( O
NMDA O
) O
receptors O
. O

To O
investigate O
new O
neuroprotective O
mechanisms O
associated O
with O
I O
( O
2 O
) O
- O
imidazoline B
receptors O
, O
the O
effects O
of O
selective O
( O
2 B
- I
styryl I
- I
2 I
- I
imidazoline I
( O
LSL B
61122 I
) O
, O
2 B
- I
( I
2 I
- I
benzofuranyl I
) I
- I
2 I
- I
imidazoline I
( O
2 B
- I
BFI I
) O
, O
2 B
- I
( I
4 I
, I
5 I
- I
dihydroimidazol I
- I
2 I
- I
yl I
) I
quinoline I
hydrochloride I
( O
BU B
- I
224 I
) O
) O
and O
non O
- O
selective O
( O
idazoxan B
) O
I O
( O
2 O
) O
- O
drugs O
on O

The O
acute O
treatment O
with O
LSL B
61122 I
( O
10 O
mg O
/ O
kg O
) O
reduced O
the O
content O
of O
mitochondrial O
( O
pro O
- O
apoptotic O
) O
Bax O
( O
- O
33 O
% O
) O
and O
cytochrome O
c O
( O
- O
31 O
% O
) O
, O
which O
was O
prevented O
by O
idazoxan B
, O
an O
I O
( O
2 O
) O
- O
receptor O
antagonist O
. O

The O
sustained O
stimulation O
of O
I O
( O
2 O
) O
- O
imidazoline B
receptors O
with O
selective O
drugs O
( O
10 O
mg O
/ O
kg O
, O
every O
12 O
h O
for O
seven O
days O
) O
was O
associated O
with O
down O
- O
regulation O
of O
key O
components O
of O
the O
extrinsic O
( O
Fas O
receptor O
: O
- O
20 O
% O
; O
Fas O
associated O
protein O
with O
death O
domain O
( O
FADD O
) O
adaptor O
: O
- O
47 O
- O
54 O
% O
) O
and O
/ O
or O
intrinsic O
( O
Bax O
: O
- O
20 O
- O
23 O
% O
; O
cytochrome O
c O
: O
- O
22 O
- O
28 O
% O
) O
apoptotic O
signalling O
and O
/ O
or O
up O
- O
regulation O
of O
survival O
anti O
- O
apoptotic O
factors O
( O
p O
- O

Ser194 B
FADD O
/ O
FADD O
ratio O
: O
+ O
1 O
. O
6 O
- O
2 O
. O
5 O
- O
fold O
; O
and O
/ O
or O
Bcl O
- O
2 O
/ O
Bax O
ratio O
: O
+ O
1 O
. O
5 O
- O
fold O
) O
, O
which O
in O
the O
long O
- O
term O
could O
dampen O
cell O
death O
in O
the O
brain O
. O

Similar O
chronic O
treatments O
with O
LSL B
60101 I
( O
the O
imidazole O
analogue O
of O
2 B
- I
BFI I
) O
and O
idazoxan B
( O
a O
mixed O
I O
( O
2 O
) O
/ O
alpha O
( O
2 O
) O
- O
ligand O
) O
did O
not O
induce O
significant O
alterations O
of O
pro O
- O
or O
anti O
- O
apoptotic O
proteins O
. O

The O
disclosed O
anti O
- O
apoptotic O
mechanisms O
of O
selective O
I O
( O
2 O
) O
- O
imidazoline B
drugs O
may O
work O
in O
concert O
with O
other O
molecular O
mechanisms O
of O
neuroprotection O
( O
e O
. O
g O
. O
blockade O
of O
NMDA O
receptors O
) O
that O
are O
engaged O
by O
I O
( O
2 O
) O
- O
ligands O
. O

A O
new O
furolactone B
- O
type O
lignan O
from O
Lycium O
chinense O
. O

The O
phytochemical O
investigation O
of O
extracts O
from O
the O
root O
barks O
of O
Lycium O
chinense O
yielded O
a O
new O
furolactone O
- O
type O
lignan O
, O
lyciumin B
( O
1 O
) O
. O

With O
a O
trace O
fear O
conditioning O
paradigm O
, O
administration O
of O
the O
5HT2AR O
agonist O
TCB B
- I
2 I
( O
1 O
. O
0 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
before O
the O
extinction O
test O
facilitated O
the O
acquisition O
of O
extinction O
of O
fear O
memory O
as O
compared O
to O
vehicle O
treatment O
. O

In O
contrast O
, O
administration O
of O
the O
5HT2AR O
antagonist O
MDL B
11 I
, I
939 I
( O
0 O
. O
5 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
delayed O
the O
acquisition O
of O
extinction O
of O
fear O
memory O
. O

Further O
, O
the O
post O
- O
conditioning O
administration O
of O
TCB B
- I
2 I
enhanced O
contextual O
and O
cued O
fear O
memory O
, O
possibly O
by O
facilitating O
the O
consolidation O
of O
fear O
memory O
. O

Administration O
of O
TCB B
- I
2 I
also O
facilitated O
the O
acquisition O
of O
extinction O
of O
fear O
memory O
in O
delay O
fear O
conditioned O
mice O
. O

Finally O
, O
administration O
of O
TCB B
- I
2 I
right O
after O
training O
in O
an O
object O
recognition O
task O
enhanced O
the O
consolidation O
of O
object O
memory O
. O

Rescue O
of O
this O
impaired O
extinction O
consolidation O
/ O
retrieval O
was O
achieved O
with O
d B
- I
cycloserine I
( O
N B
- I
methly I
- I
d I
- I
aspartate I
partial O
agonist O
) O
or O
MS B
- I
275 I
( O
histone O
deacetylase O
( O
HDAC O
) O
inhibitor O
) O
, O
applied O
after O
extinction O
training O
. O

Rescue O
of O
both O
impaired O
extinction O
acquisition O
and O
deficient O
extinction O
consolidation O
/ O
retrieval O
was O
achieved O
with O
prior O
extinction O
training O
administration O
of O
valproic O
acid O
( O
a O
GABAergic O
enhancer O
and O
HDAC O
inhibitor O
) O
or O
AMN082 O
[ O
metabotropic O
glutamate O
receptor O
7 O
( O
mGlu7 O
) O
agonist O
] O
, O
while O
MS B
- I
275 I
or O
PEPA B
( O
AMPA O
receptor O
potentiator O
) O
failed O
to O
affect O
extinction O
acquisition O
in O
S1 O
mice O
. O

The O
optimized O
preparation O
of O
Poly B
- I
( I
lactide I
- I
co I
- I
glycolic I
acid I
) I
( O
PLGA O
) O
nanospheres O
containing O
ubiquinone O
( O
UQ O
) O
for O
cosmetic O
products O
was O
pursued O
. O

Here O
, O
we O
used O
two O
compounds O
, O
Compound O
44 O
[ O
6 B
, I
6 I
- I
dimethyl I
- I
3 I
- I
( I
3 I
- I
hydroxypropyl I
) I
thio I
- I
1 I
- I
( I
thiazol I
- I
2 I
- I
yl I
) I
- I
6 I
, I
7 I
- I
dihydro I
- I
2 I
- I
benzothiophen I
- I
4 I
( I
5H I
) I
- I
one I
] O
and O
Compound O
6 O
[ O
methyl B
3 I
, I
5 I
- I
diphenylpyridazine I
- I
4 I
- I
carboxylate I
] O
, O
with O
functional O
activity O
as O
potentiators O
of O
gamma O
- O
aminobutyric O
acid O
at O
GABA O
( O
A O
) O
alpha O
5 O
receptors O
, O
to O

Geraniol O
, O
alpha B
- I
cedrene I
and O
p B
- I
cymene I
were O
determined O
as O
the O
main O
components O
. O

Geraniol O
was O
detected O
as O
a O
major O
component O
in O
C O
. O
cilicica O
( O
14 O
. O
64 O
% O
) O
, O
and O
alpha B
- I
cedrene I
was O
detected O
as O
a O
major O
component O
with O
26 O
. O
03 O
% O
for O
C O
. O
lycica O
, O
16 O
. O
93 O
% O
for O
C O
. O
scoparia O
, O
13 O
. O
01 O
% O
for O
C O
. O
davisiana O
and O
10 O
. O
94 O
% O
for O
C O
. O
paphlagonica O
. O

Cephalaria O
scoparia O
, O
C O
. O
davisiana O
and O
C O
. O
gazipashensis O
have O
considerable O
amount O
of O
p B
- I
cymene I
as O
12 O
. O
86 O
% O
, O
12 O
. O
70 O
% O
and O
11 O
. O
16 O
% O
, O
respectively O
. O

Auraptene B
and O
its O
Effects O
on O
the O
Re O
- O
emergence O
of O
Colon O
Cancer O
Stem O
Cells O
. O

Recent O
studies O
indicate O
that O
auraptene B
( O
7 B
- I
geranyloxycoumarin I
, O
AUR B
) O
, O
a O
geranyloxycoumarin B
extracted O
from O
fruits O
of O
edible O
plants O
belonging O
to O
the O
Rutaceae O
family O
, O
may O
represent O
a O
novel O
lead O
compound O
for O
dietary O
colon O
cancer O
chemoprevention O
in O
rodents O
. O

As O
a O
continuation O
of O
studies O
aimed O
to O
better O
depict O
the O
pharmacological O
effects O
and O
mechanism O
of O
action O
of O
the O
title O
natural O
compound O
, O
the O
current O
investigation O
was O
undertaken O
to O
determine O
whether O
AUR B
would O
be O
able O
to O
prevent O
the O
growth O
and O
sphere O
( O
surrogate O
tumors O
) O
formation O
of O
FOLFOX O
- O
resistant O
colon O
cancer O
cells O
that O
are O
highly O
enriched O
in O
cancer O
stem O
cells O
( O
CSCs O
) O
. O

Our O
results O
demonstrate O
that O
AUR B
at O
a O
concentration O
of O
10 O
mu O
M O
was O
able O
to O
inhibit O
the O
growth O
and O
formation O
of O
colonospheres O
of O
FOLFOX O
- O
resistant O
colon O
cancer O
HT O
- O
29 O
cells O
in O
vitro O
. O

The O
corresponding O
parental O
cells O
were O
also O
similarly O
affected O
by O
AUR B
at O
the O
same O
concentration O
level O
. O

These O
findings O
suggest O
that O
AUR B
could O
prevent O
the O
re O
- O
emergence O
of O
CSCs O
. O

The O
free O
- O
radical O
scavenging O
activity O
of O
the O
extracts O
was O
also O
determined O
by O
the O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picryhydrazyl I
( O
DPPH O
) O
assay O
. O

Perturbing O
peptide O
cation O
- O
radical O
electronic O
states O
by O
thioxoamide B
groups O
: O
formation O
, O
dissociations O
, O
and O
energetics O
of O
thioxopeptide O
cation O
- O
radicals O
. O

Thioxodipeptides B
Gly B
- I
thio I
- I
Lys I
( O
GtK B
) O
, O
Ala B
- I
thio I
- I
Lys I
( O
AtK B
) O
, O
and O
Ala B
- I
thio I
- I
Arg I
( O
AtR O
) O
in O
which O
the O
amide O
group O
has O
been O
modified O
to O
a O
thioxoamide B
were O
made O
into O
dications O
by O
electrospray O
ionization O
and O
converted O
to O
cation O
- O
radicals O
, O
( O
GtK B
+ O
2H O
) O
( O
+ O
* O
) O
, O
( O
AtK B
+ O
2H O
) O
( O
+ O
* O
) O
, O
and O
( O
AtR O
+ O
2H O
) O
( O
+ O
* O
) O
, O
by O
electron O
transfer O

dissociation O
( O
ETD O
) O
tandem O
mass O
spectrometry O
using O
fluoranthene B
anion I
- I
radical I
as O
an O
electron O
donor O
. O

The O
ground O
electronic O
states O
of O
several O
( O
GtK B
+ O
2H O
) O
( O
+ O
* O
) O
, O
( O
AtK B
+ O
2H O
) O
( O
+ O
* O
) O
, O
and O
( O
AtR O
+ O
2H O
) O
( O
+ O
* O
) O
conformers O
were O
explored O
by O
extensive O
ab O
initio O
and O
density O
functional O
theory O
calculations O
of O
the O
potential O
energy O
surface O
. O

In O
silico O
electron O
transfer O
to O
the O
precursor O
dications O
, O
( O
GtK B
+ O
2H O
) O
( O
2 O
+ O
) O
, O
( O
AtK B
+ O
2H O
) O
( O
2 O
+ O
) O
, O
and O
( O
AtR O
+ O
2H O
) O
( O
2 O
+ O
) O
, O
formed O
zwitterionic O
intermediates O
containing O
thioenol B
anion I
- I
radical I
and O
ammonium B
cation I
groups O
that O
were O
local O
energy O
minima O
on O
the O
potential O
energy O
surface O
of O
the O
ground O
electronic O
state O
. O

The O
zwitterions O
underwent O
facile O
isomerization O
by O
N O
- O
terminal O
ammonium B
proton O
migration O
to O
the O
thioenol B
anion I
- I
radical I
group O
forming O
aminothioketyl B
intermediates O
. O

Combined O
potential O
energy O
mapping O
and O
RRKM O
calculations O
of O
dissociation O
rate O
constants O
identified O
N B
- I
C I
( I
alpha I
) I
bond O
cleavages O
as O
the O
most O
favorable O
dissociation O
pathways O
, O
in O
a O
stark O
contrast O
to O
the O
experimental O
results O
. O

For O
( O
GtK B
+ O
2H O
) O
( O
+ O
* O
) O
, O
these O
excited O
states O
were O
characterized O
by O
time O
- O
dependent O
density O
functional O
theory O
as O
A O
- O
C O
states O
that O
had O
large O
components O
of O
Rydberg O
- O
like O
3s O
molecular O
orbitals O
at O
the O
N O
- O
terminal O
and O
lysine O
ammonium B
groups O
that O
are O
conducive O
to O
hydrogen O
atom O
loss O
. O

In O
this O
multicenter O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
randomized O
, O
four O
way O
cross O
- O
over O
proof O
- O
of O
- O
mechanism O
study O
, O
we O
tested O
the O
effect O
of O
the O
positive O
allosteric O
alpha O
7 O
nicotinic O
acetylcholine O
receptor O
( O
nAChR O
) O
modulator O
JNJ B
- I
39393406 I
in O
a O
key O
translational O
assay O
( O
sensory O
P50 O
gating O
) O
in O
39 O
regularly O
smoking O
male O
patients O
with O
schizophrenia O
. O

All O
patients O
were O
clinically O
stable O
and O
JNJ B
- I
39393406 I
was O
administered O
as O
an O
adjunct O
treatment O
to O
antipsychotics O
. O

No O
indication O
was O
found O
that O
JNJ B
- I
39393406 I
has O
the O
potential O
to O
reverse O
basic O
deficits O
of O
information O
processing O
in O
schizophrenia O
( O
sensory O
P50 O
gating O
) O
or O
has O
a O
significant O
effect O
on O
other O
tested O
electrophysiological O
markers O
( O
MMN O
, O
P300 O
and O
quantitative O
resting O
EEG O
) O
. O

Effects O
of O
collisional O
and O
vibrational O
velocity O
on O
proton O
and O
deuteron B
transfer O
in O
the O
reaction O
of O
HOD B
+ I
with O
CO O
. O

Reaction O
of O
HOD B
( I
+ I
) I
with O
CO O
was O
studied O
over O
the O
collision O
energy O
( O
E O
( O
col O
) O
) O
range O
between O
0 O
. O
18 O
and O
2 O
. O
87 O
eV O
, O
for O
HOD B
( I
+ I
) I
in O
its O
ground O
state O
and O
with O
one O
quantum O
in O
each O
of O
its O
vibrational O
modes O
: O
( O
001 O
) O
- O
- O
predominantly O
OH O
stretch O
; O
( O
010 O
) O
- O
- O
bend O
, O
and O
( O
100 O
) O
- O
- O
predominately O
OD O
stretch O
. O

The O
dominant O
reactions O
are O
near O
- O
thermoneutral O
proton O
and O
deuteron B
transfer O
, O
generating O
HCO O
( O
+ O
) O
and O
DCO B
( I
+ I
) I
product O
ions O
by O
a O
predominantly O
direct O
mechanism O
. O

The O
HCO O
( O
+ O
) O
and O
DCO B
( I
+ I
) I
channels O
occur O
with O
a O
combined O
efficiency O
of O
76 O
% O
for O
ground O
state O
HOD B
( I
+ I
) I
at O
our O
lowest O
E O
( O
col O
) O
, O
increasing O
to O
94 O
% O
for O
E O
( O
col O
) O
around O
0 O
. O
33 O
eV O
, O
then O
falling O
at O
high O
E O
( O
col O
) O
to O
~ O
40 O
% O
. O

The O
HCO O
( O
+ O
) O
and O
DCO B
( I
+ I
) I
channels O
have O
a O
complicated O
dependence O
on O
the O
HOD B
( I
+ I
) I
vibrational O
state O
. O

There O
is O
no O
coupling O
of O
energy O
initially O
in O
any O
HOD B
( I
+ I
) I
vibrational O
mode O
to O
recoil O
velocity O
of O
either O
of O
the O
product O
ions O
, O
even O
at O
low O
E O
( O
col O
) O
where O
vibrational O
excitation O
doubles O
or O
triples O
the O
energy O
available O
to O
products O
. O

HOCO O
( O
+ O
) O
+ O
D O
and O
DOCO B
( I
+ I
) I
+ O
H O
products O
are O
also O
observed O
, O
but O
as O
minor O
channels O
despite O
being O
barrierless O
and O
exoergic O
. O

Density O
functional O
theory O
study O
on O
the O
reaction O
mechanism O
of O
synthesizing O
1 B
, I
3 I
- I
dimethyl I
- I
2 I
- I
imidazolidinone I
by O
urea O
method O
. O

We O
report O
a O
first O
- O
principles O
density O
functional O
theory O
investigation O
on O
tailoring O
the O
fundamental O
reaction O
mechanism O
of O
synthesizing O
1 B
, I
3 I
- I
dimethyl I
- I
2 I
- I
imidazolidinone I
( O
DMI B
) O
through O
the O
urea O
method O
with O
water O
serving O
as O
both O
solvent O
and O
catalyst O
. O

One O
- O
NH O
group O
of O
dimethylethylenediam B
( O
DMEDA B
) O
first O
attacks O
the O
carbon O
atom O
of O
urea O
, O
eliminating O
one O
- O
NH3 O
group O
and O
forming O
an O
intermediate O
state O
CH3NHC2H4N B
( I
CH3 I
) I
CONH2 I
( O
IMI O
) O
. O

IMI O
subsequently O
undergoes O
the O
cyclization O
process O
through O
a O
secondary B
ammonia I
removal O
via O
similar O
manner O
. O

Due O
to O
the O
spatial O
configuration O
, O
the O
direct O
proton O
migration O
from O
the O
N O
atoms O
of O
ethylenediamine B
to O
urea O
is O
difficult O
to O
occur O
. O

The O
current O
computational O
understanding O
on O
the O
prototypical O
reaction O
to O
DMI B
can O
be O
extended O
to O
guide O
developing O
more O
efficient O
routes O
to O
synthesize O
imidazolidinone O
derivatives O
through O
the O
urea O
method O
. O

Certain O
benztropine B
analogs O
act O
as O
highly O
selective O
DA O
reuptake O
inhibitors O
while O
lacking O
the O
reinforcing O
actions O
, O
and O
thus O
abuse O
potential O
, O
of O
psychostimulants O
. O

To O
assess O
the O
potential O
use O
of O
these O
compounds O
in O
the O
treatment O
of O
ADHD O
, O
we O
examined O
the O
effects O
of O
a O
well O
- O
characterized O
benztropine B
analog O
, O
AHN B
2 I
- I
005 I
, O
on O
performance O
of O
rats O
in O
a O
PFC O
- O
dependent O
delayed O
- O
alternation O
task O
of O
spatial O
working O
memory O
. O

Similar O
to O
that O
seen O
with O
all O
drugs O
currently O
approved O
for O
ADHD O
, O
AHN B
2 I
- I
005 I
dose O
- O
dependently O
improved O
performance O
in O
this O
task O
. O

Despite O
the O
selectivity O
of O
this O
compound O
for O
the O
DA O
transporter O
, O
additional O
microdialysis O
studies O
demonstrated O
that O
a O
cognition O
- O
enhancing O
dose O
of O
AHN B
2 I
- I
005 I
that O
lacked O
locomotor O
activating O
effects O
increased O
extracellular O
levels O
of O
both O
DA O
and O
NE O
in O
the O
PFC O
. O

AHN B
2 I
- I
005 I
produced O
a O
larger O
increase O
in O
extracellular O
DA O
in O
the O
nucleus O
accumbens O
, O
although O
the O
magnitude O
of O
this O
was O
well O
below O
that O
seen O
with O
motor O
activating O
doses O
of O
psychostimulants O
. O

Collectively O
, O
these O
observations O
suggest O
that O
benztropine B
analogs O
may O
be O
efficacious O
in O
the O
treatment O
of O
ADHD O
or O
other O
disorders O
associated O
with O
PFC O
dysfunction O
. O

These O
studies O
provide O
a O
strong O
rationale O
for O
future O
research O
focused O
on O
the O
neural O
mechanisms O
contributing O
to O
the O
cognition O
- O
enhancing O
actions O
and O
the O
potential O
clinical O
utility O
of O
AHN B
2 I
- I
005 I
and O
related O
compounds O
. O

In O
nanocrystals O
with O
thick O
shells O
, O
we O
furthermore O
observe O
a O
wurtzite O
to O
NiAs B
transformation O
, O
which O
does O
not O
occur O
in O
the O
pure O
bulk O
materials O
. O

This O
nicotine O
effect O
was O
blocked O
by O
pretreatment O
with O
the O
non O
- O
specific O
nicotinic O
acetylcholine O
( O
nACh O
) O
receptor O
antagonist O
mecamylamine O
, O
or O
the O
5 O
- O
HT1A O
antagonist O
WAY100635 B
. O

The O
ameliorating O
action O
of O
nicotine O
on O
PPI O
deficits O
in O
DAT O
KO O
mice O
was O
blocked O
by O
mecamylamine O
, O
the O
alpha O
7 O
nACh O
receptor O
antagonist O
methyllycaconitine O
or O
WAY100635 B
, O
while O
the O
alpha O
4 O
beta O
2 O
nACh O
receptor O
antagonist O
dihydro B
- I
beta I
- I
erythroidinehydrobro I
( O
DH O
beta O
E O
) O
produced O
only O
a O
non O
- O
significant O
trend O
toward O
attenuation O
of O
nicotine O
effects O
. O

This O
amelioration O
was O
antagonized O
by O
pretreatment O
with O
WAY100635 B
. O

Two O
new O
cassane B
- O
type O
diterpenes O
, O
Caesalpinolide B
F I
( O
1 O
) O
and O
Caesalpinolide B
G I
( O
2 O
) O
were O
isolated O
from O
Caesalpinia O
minax O
Hance O
. O

Disposition O
of O
diiosononyl B
phthalate I
and O
its O
effects O
on O
sexual O
development O
of O
the O
male O
fetus O
following O
repeated O
dosing O
in O
pregnant O
rats O
. O

Pregnant O
Sprague O
- O
Dawley O
rats O
received O
50 O
, O
250 O
, O
and O
500 O
mg O
/ O
kg O
/ O
day O
diisononyl B
phthalate I
( O
DiNP O
) O
from O
GD O
12 O
to O
19 O
via O
corn O
oil O
gavage O
to O
study O
the O
dose O
response O
for O
effects O
on O
fetal O
male O
rat O
sexual O
development O
as O
well O
as O
metabolite O
disposition O
in O
the O
dam O
and O
fetus O
. O

Monoisononyl B
phthalate I
( O
MiNP B
) O
, O
mono B
( I
carboxy I
- I
isooctyl I
) I
phthalate I
( O
MCiOP B
) O
, O
mono B
( I
hydroxyl I
- I
isononyl I
) I
phthalate I
( O
MHiNP B
) O
, O
mono B
( I
oxo I
- I
isononyl I
) I
phthalate I
( O
MOiNP B
) O
, O
and O
monoisononyl B
phthalate I
glucuronide I
( O
MiNP B
- I
G I
) O
were O
found O
in O
all O
measured O
tissues O
. O

MCiOP B
was O
the O
major O
metabolite O
, O
followed O
in O
decreasing O
order O
by O
MiNP B
, O
MHiNP B
, O
MOiNP B
, O
and O
MiNP B
- I
G I
. O

Quantitative O
prediction O
of O
CYP2B6 O
induction O
by O
estradiol O
during O
pregnancy O
: O
potential O
explanation O
for O
increased O
methadone B
clearance O
during O
pregnancy O
. O

When O
the O
E O
( O
max O
) O
and O
EC O
( O
50 O
) O
values O
were O
compared O
with O
those O
for O
carbamazepine O
and O
rifampin B
, O
estradiol O
was O
found O
to O
be O
as O
potent O
an O
inducer O
of O
CYP2B6 O
as O
rifampin B
and O
carbamazepine O
. O

This O
could O
in O
part O
explain O
the O
observed O
increase O
in O
methadone B
clearance O
during O
pregnancy O
. O

Although O
DHEAS B
has O
a O
good O
sensitivity O
in O
the O
detection O
of O
adrenal O
origin O
of O
hyperandrogenism O
( O
and O
hence O
a O
good O
negative O
predictive O
value O
) O
it O
is O
not O
specific O
( O
specificity O
ranging O
from O
85 O
to O
98 O
% O
) O
. O

Pharmacokinetic O
characterization O
of O
the O
novel O
TAZ O
modulator O
TM B
- I
25659 I
using O
a O
multicompartment O
kinetic O
model O
in O
rats O
and O
a O
possibility O
of O
its O
drug O
- O
drug O
interactions O
in O
humans O
. O

This O
study O
evaluated O
the O
pharmacokinetics O
of O
the O
novel O
TAZ O
modulator O
TM B
- I
25659 I
in O
rats O
following O
intravenous O
and O
oral O
administration O
at O
dose O
ranges O
of O
0 O
. O
5 O
- O
5 O
mg O
/ O
kg O
and O
2 O
- O
10 O
mg O
/ O
kg O
, O
respectively O
. O

Recovery O
of O
TM B
- I
25659 I
was O
43 O
. O
6 O
% O
in O
bile O
and O
< O
1 O
% O
in O
urine O
. O

TM B
- I
25659 I
was O
stable O
in O
plasma O
. O

TM B
- I
25659 I
showed O
high O
permeation O
of O
Caco O
- O
2 O
cells O
and O
did O
not O
appear O
to O
inhibit O
CYP450 O
. O

TM B
- I
25659 I
was O
metabolized O
in O
phase O
I O
and O
II O
steps O
in O
rat O
liver O
microsomes O
. O

In O
conclusion O
, O
the O
pharmacokinetics O
of O
TM B
- I
25659 I
was O
characterized O
for O
intravenous O
and O
oral O
administration O
at O
doses O
of O
0 O
. O
5 O
- O
5 O
and O
2 O
- O
10 O
mg O
/ O
kg O
, O
respectively O
. O

TM B
- I
25659 I
was O
eliminated O
primarily O
by O
hepatic O
metabolism O
and O
urinary O
excretion O
. O

Density O
functional O
studies O
illustrate O
that O
noncovalent O
functionalization O
of O
isoniazid O
( O
INH B
) O
is O
preferred O
over O
covalent O
attachment O
, O
exhibiting O
low O
adsorption O
energy O
values O
, O
HOMO O
- O
LUMO O
gap O
and O
comparison O
of O
quantum O
molecular O
descriptors O
performed O
in O
( O
5 O
, O
5 O
) O
and O
( O
9 O
, O
0 O
) O
SWNT O
systems O
. O

Substitution O
doping O
of O
boron O
facilitates O
the O
adsorption O
of O
INH B
onto O
the O
otherwise O
inert O
nanotube O
. O

The O
charge O
transfer O
is O
significant O
in O
covalent O
functionalization O
of O
INH B
via O
the O
B O
- O
dopant O
atom O
, O
whereas O
in O
noncovalent O
functionalization O
a O
small O
amount O
of O
charge O
transfer O
is O
noted O
. O

Solvation O
studies O
demonstrate O
the O
dissolution O
of O
INH B
in O
B O
- O
doped O
( O
5 O
, O
5 O
) O
and O
( O
9 O
, O
0 O
) O
SWNTs O
to O
be O
higher O
compared O
to O
pristine O
nanotube O
- O
INH B
complexes O
. O

In O
this O
study O
, O
we O
investigated O
the O
protection O
by O
chrysin O
, O
apigenin O
, O
and O
luteolin O
against O
tert O
- O
butyl O
hydroperoxide O
( O
tBHP B
) O
- O
induced O
oxidative O
stress O
and O
the O
possible O
mechanisms O
involved O
in O
rat O
primary O
hepatocytes O
. O

Chrysin O
, O
apigenin O
, O
and O
luteolin O
dose O
- O
dependently O
up O
- O
regulated O
the O
protein O
expression O
of O
heme O
oxygenase O
1 O
( O
HO O
- O
1 O
) O
and O
glutamate O
cysteine O
ligase O
( O
GCL O
) O
catalytic O
( O
GCLC O
) O
and O
modifier O
subunit O
( O
GCLM O
) O
and O
increased O
the O
intracellular O
glutathione O
( O
GSH O
) O
content O
and O
the O
ratio O
of O
GSH O
to O
oxidized B
GSH I
. O

Cellular O
reactive O
oxygen O
species O
production O
induced O
by O
tBHP B
was O
attenuated O
by O
pretreatment O
with O
chrysin O
, O
apigenin O
, O
and O
luteolin O
( O
P O
< O
. O
05 O
) O
, O
and O
this O
protection O
was O
reversed O
by O
the O
GCL O
inhibitor O
l B
- I
buthionine I
- I
S I
- I
sulfoximine I
and O
the O
HO O
- O
1 O
inhibitor O
zinc O
protoporphyrin O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
chrysin O
, O
apigenin O
, O
and O
luteolin O
inhibit O
tBHP B
- O
induced O
oxidative O
stress O
by O
up O
- O
regulating O
HO O
- O
1 O
, O
GCLC O
, O
and O
GCLM O
gene O
transcription O
via O
the O
ERK2 O
/ O
Nrf2 O
/ O
ARE O
signaling O
pathways O
in O
rat O
primary O
hepatocytes O
. O

Alteration O
in O
plasma O
protein O
binding O
properties O
of O
propranolol O
and O
flurbiprofen B
during O
development O
of O
adjuvant O
- O
induced O
arthritis O
in O
rats O
. O

We O
choose O
propranolol O
( O
PL O
) O
and O
flurbiprofen B
( O
FP O
) O
as O
model O
basic O
and O
acidic O
drugs O
, O
respectively O
, O
and O
investigated O
the O
effect O
of O
AA O
induction O
on O
their O
plasma O
protein O
binding O
at O
each O
developing O
stage O
of O
inflammation O
. O

The O
optimal O
chromatographic O
conditions O
were O
achieved O
on O
a O
C18 O
column O
with O
gradient O
elution O
using O
acetonitrile O
and O
1 O
mmol O
. O
L O
( O
- O
1 O
) O
KH2PO4 B
buffer O
solution O
at O
203 O
nm O
. O

A O
large O
proportion O
of O
the O
population O
carries O
restorative O
dental O
fillings O
containing O
either O
classic O
Hg O
- O
based O
amalgams B
and O
/ O
or O
the O
more O
frequently O
used O
methacrylates B
. O

The O
results O
obtained O
show O
that O
both O
amalgams B
and O
resin O
- O
based O
composite O
fillings O
can O
induce O
genotoxic O
damage O
in O
human O
oral O
mucosa O
cells O
, O
as O
convincingly O
and O
dose O
- O
dependently O
inferred O
from O
the O
results O
of O
the O
MN O
test O
and O
, O
more O
marginally O
, O
from O
comet O
assay O
data O
. O

Thus O
, O
we O
provide O
unequivocal O
evidence O
for O
the O
genotoxicity O
of O
both O
amalgams B
and O
resin O
- O
based O
dental O
fillings O
in O
humans O
not O
only O
by O
testing O
circulating O
lymphocytes O
but O
also O
by O
analyzing O
oral O
mucosa O
cells O
. O

Anti O
- O
inflammatory O
and O
antioxidant O
activity O
of O
thymoquinone B
in O
a O
rat O
model O
of O
acute O
bacterial O
prostatitis O
. O

The O
aim O
of O
this O
study O
was O
to O
detect O
whether O
thymoquinone B
( O
TQ O
) O
could O
ameliorate O
oxidative O
damage O
and O
the O
proliferative O
response O
induced O
by O
Escherichia O
coli O
( O
E O
. O
coli O
) O
in O
rats O
. O

Anti O
- O
inflammatory O
trends O
of O
1 B
, I
3 I
- I
diphenyl I
- I
2 I
- I
propen I
- I
1 I
- I
one I
derivatives O
. O

Chalcones O
( O
1 B
, I
3 I
- I
Diphenyl I
- I
2 I
- I
propen I
- I
1 I
- I
one I
) O
are O
constituted O
by O
a O
three O
carbon O
alpha O
, O
beta O
- O
unsaturated O
carbonyl O
system O
. O

Silent O
information O
regulator O
2 O
( O
Sir2 O
) O
enzymes O
or O
sirtuins O
are O
a O
family O
of O
evolutionarily O
conserved O
intracellular O
protein O
deacetylases O
that O
can O
catalyze O
the O
acetyl O
group O
removal O
from O
the O
specific O
N B
epsilon I
- I
acetyl I
- I
lysine I
( O
AcK O
) O
side O
chains O
on O
a O
variety O
of O
proteins O
from O
all O
kingdoms O
of O
life O
. O

Specifically O
, O
the O
sirtuin O
- O
catalyzed O
AcK O
side O
chain O
deacetylation O
is O
not O
merely O
an O
amide O
hydrolysis O
reaction O
, O
instead O
is O
coupled O
to O
the O
nicotinamide O
cleavage O
from O
beta B
- I
nicotinamide I
adenine I
dinucleotide I
( O
beta B
- I
NAD I
+ O
or O
NAD O
+ O
) O
with O
the O
generation O
of O
three O
enzymatic O
products O
, O
i O
. O
e O
. O
the O
deacetylated O
protein O
species O
, O
nicotinamide O
, O
and O
2 B
' I
- I
O I
- I
acetyl I
- I
ADP I
- I
ribose I
( O
2 B
' I
- I
O I
- I
AADPR I
) O
. O

Thiazolidinediones O
( O
TZDs B
) O
affect O
osteoblast O
viability O
and O
biomarkers O
independently O
of O
the O
TZD O
effects O
on O
aromatase O
. O

Thiazolidinediones O
( O
TZDs B
) O
are O
insulin O
sensitizers O
used O
for O
treatment O
of O
diabetes O
. O

We O
have O
previously O
reported O
that O
TZDs B
reduce O
estrogen O
synthesis O
by O
inhibiting O
aromatase O
activity O
in O
human O
granulosa O
cells O
( O
HGC O
) O
. O

Multiple O
clinical O
trials O
demonstrated O
that O
TZDs B
increase O
the O
risk O
of O
fractures O
in O
postmenopausal O
women O
with O
type O
2 O
diabetes O
. O

TZDs B
inhibited O
estradiol O
production O
by O
up O
to O
84 O
% O
in O
HGC O
/ O
mouse O
osteoblast O
co O
- O
cultures O
. O

TZDs B
induced O
mouse O
osteoblast O
death O
and O
increased O
oleic O
acid O
uptake O
. O

TZDs B
also O
inhibited O
alkaline O
phosphatase O
activity O
( O
58 O
- O
75 O
% O
, O
p O
< O
0 O
. O
046 O
) O
and O
osteocalcin O
production O
( O
52 O
- O
75 O
% O
, O
p O
< O
0 O
. O
031 O
) O
. O

New O
alloferon B
analogues O
: O
synthesis O
and O
antiviral O
properties O
. O

We O
have O
extended O
our O
study O
on O
structure O
/ O
activity O
relationship O
studies O
of O
insect O
peptide O
alloferon B
( O
H B
- I
His I
- I
Gly I
- I
Val I
- I
Ser I
- I
Gly I
- I
His I
- I
Gly I
- I
Gln I
- I
His I
- I
Gly I
- I
Val I
- I
His I
- I
Gly I
- I
OH I
) O
by O
evaluating O
the O
antiviral O
effects O
of O
new O
alloferon B
analogues O
. O

We O
synthesized O
18 O
alloferon B
analogues O
: O
12 O
peptides O
with O
sequences O
shortened O
from O
N O
- O
or O
C O
- O
terminus O
and O
6 O
N O
- O
terminally O
modified O
analogues O
H O
- O
X O
( O
1 O
) O
- O
Gly B
- I
Val I
- I
Ser I
- I
Gly I
- I
His I
- I
Gly I
- I
Gln I
- I
His I
- I
Gly I
- I
Val I
- I
His I
- I
Gly I
- I
OH I
, O
where O
X O
( O
1 O
) O
= O
Phe O
( O
13 O
) O
, O
Tyr O
( O
14 O
) O
, O
Trp O
( O
15 O
) O
, O
Phg O
( O
16 O
) O
, O
Phe B
( I
p I
- I
Cl I
) I
( O
17 O
) O
, O
and O
Phe B
( I
p I
- I
OMe I
) I
( O
18 O
) O

Our O
results O
indicate O
that O
the O
compound O
[ B
3 I
- I
13 I
] I
- I
alloferon I
( O
1 O
) O
exhibits O
the O
strongest O
antiviral O
activity O
( O
IC O
( O
50 O
) O
= O
38 O
mu O
M O
) O
among O
the O
analyzed O
compound O
. O

The O
chemicals O
used O
for O
the O
synthesis O
of O
various O
shaped O
ZnO O
are O
Zn O
salt O
, O
sodium O
hydroxide O
and O
ammonia B
solution I
without O
other O
structure O
directing O
agent O
or O
surfactant O
needed O
. O

Psychostimulants O
such O
as O
mixed O
amphetamine O
salts O
( O
MAS O
, O
brand O
name O
Adderall B
) O
are O
widely O
used O
for O
cognitive O
enhancement O
by O
healthy O
young O
people O
, O
yet O
laboratory O
research O
on O
effectiveness O
has O
yielded O
variable O
results O
. O

An O
application O
to O
propylene B
oxide I
. O

In O
this O
article O
we O
report O
calculations O
of O
the O
activation O
free O
energy O
for O
a O
chemical O
reaction O
between O
propylene B
oxide I
and O
DNA O
, O
in O
particular O
with O
the O
guanine O
at O
the O
N7 O
position O
. O

The O
role O
of O
long O
chain O
omega B
- I
3 I
polyunsaturated I
fatty I
acids I
in O
reducing O
lipid O
peroxidation O
among O
elderly O
patients O
with O
mild O
cognitive O
impairment O
: O
a O
case O
- O
control O
study O
. O

The O
present O
work O
explores O
the O
effect O
of O
dietary O
omega B
- I
3 I
polyunsaturated I
fatty I
acids I
( O
PUFAs O
) O
intake O
on O
lipid O
peroxidation O
among O
mild O
cognitive O
impairment O
( O
MCI O
) O
patients O
. O

Previous O
in O
vitro O
studies O
have O
revealed O
that O
BP B
phenols I
are O
excreted O
as O
Phase O
II O
metabolites O
including O
glucuronides O
and O
sulfates O
. O

The O
ultimate O
carcinogenic O
Phase O
I O
BP O
metabolite O
anti O
- O
BP B
- I
7 I
, I
8 I
- I
dihydrodiol I
- I
9 I
, I
10 I
- I
epoxide I
( O
BPDE B
) O
can O
be O
detoxified O
by O
glutathione O
conjugate O
formation O
catalyzed O
by O
glutathione O
S O
- O
transferases O
. O

In O
the O
present O
study O
, O
differentiated O
human O
intestinal O
Caco O
- O
2 O
cells O
were O
used O
as O
a O
model O
for O
the O
human O
small O
intestine O
to O
investigate O
the O
detoxification O
of O
BPDE B
and O
excretion O
of O
stereoisomeric O
glutathione O
conjugates O
in O
the O
presence O
of O
an O
inhibitor O
of O
the O
glutathione O
- O
cleaving O
enzyme O
gamma O
- O
glutamyl O
transpeptidase O
at O
the O
cell O
surface O
. O

The O
results O
indicate O
that O
the O
glutathione O
conjugates O
of O
BPDE B
are O
formed O
and O
excreted O
mainly O
to O
the O
apical O
and O
to O
a O
minor O
extent O
to O
the O
basolateral O
side O
of O
polarized O
Caco O
- O
2 O
monolayers O
. O

Inhibition O
studies O
revealed O
that O
the O
multidrug O
resistance O
- O
associated O
proteins O
( O
ABCCs O
) O
are O
involved O
in O
the O
transport O
of O
BPDE B
glutathione I
conjugates O
. O

Stable O
ABCC1 O
, O
ABCC2 O
and O
ABCC3 O
knockdown O
cell O
lines O
were O
generated O
, O
thus O
making O
it O
possible O
to O
demonstrate O
that O
ABCC1 O
mediates O
the O
basolateral O
and O
ABCC2 O
the O
apical O
excretion O
of O
BPDE B
glutathione I
conjugates O
. O

In O
conclusion O
, O
the O
ultimate O
carcinogen O
BPDE B
is O
detoxified O
via O
glutathione O
conjugation O
and O
subsequently O
excreted O
by O
Caco O
- O
2 O
cells O
in O
both O
apical O
and O
basolateral O
directions O
. O

Oleuropein B
supplementation O
increases O
urinary O
noradrenaline O
and O
testicular O
testosterone O
levels O
and O
decreases O
plasma O
corticosterone O
level O
in O
rats O
fed O
high O
- O
protein O
diet O
. O

The O
effects O
of O
oleuropein B
, O
a O
phenolic O
compound O
in O
extra O
virgin O
olive O
oil O
, O
on O
protein O
metabolism O
were O
investigated O
by O
measuring O
testicular O
testosterone O
and O
plasma O
corticosterone O
levels O
in O
rats O
fed O
diets O
with O
different O
protein O
levels O
. O

In O
Experiment O
1 O
, O
rats O
were O
fed O
experimental O
diets O
with O
different O
protein O
levels O
( O
40 O
, O
25 O
and O
10 O
g O
/ O
100 O
g O
casein O
) O
with O
or O
without O
0 O
. O
1 O
g O
/ O
100 O
g O
oleuropein B
. O

After O
28 O
days O
of O
feeding O
, O
the O
testosterone O
level O
in O
the O
testis O
was O
significantly O
higher O
and O
the O
plasma O
corticosterone O
level O
was O
significantly O
lower O
in O
rats O
fed O
the O
40 O
% O
casein O
diet O
with O
oleuropein B
than O
in O
those O
fed O
the O
same O
diet O
without O
oleuropein B
. O

The O
urinary O
noradrenaline O
level O
, O
nitrogen O
balance O
and O
hepatic O
arginase O
activity O
were O
significantly O
higher O
in O
rats O
fed O
the O
40 O
% O
casein O
diet O
with O
oleuropein B
supplementation O
than O
in O
those O
fed O
the O
40 O
% O
casein O
diet O
without O
oleuropein B
supplementation O
. O

In O
Experiment O
2 O
, O
the O
effects O
of O
oleuropein B
aglycone O
( O
a O
major O
phenolic O
compound O
in O
extra O
virgin O
olive O
oil O
and O
the O
absorbed O
form O
of O
oleuropein B
ingested O
in O
the O
gastrointestinal O
tracts O
) O
on O
the O
secretion O
of O
luteinizing O
hormone O
( O
LH O
) O
from O
the O
pituitary O
gland O
, O
which O
regulates O
testosterone O
production O
in O
the O
testis O
, O
were O
investigated O
in O
anesthetized O
rats O
. O

Plasma O
LH O
level O
increased O
dose O
dependently O
after O
the O
administration O
of O
oleuropein B
aglycone O
( O
P O
< O
. O
001 O
, O
r O
= O
0 O
. O
691 O
) O
. O

These O
findings O
suggest O
that O
dietary O
supplementation O
with O
0 O
. O
1 O
g O
/ O
100 O
g O
oleuropein B
alters O
the O
levels O
of O
hormones O
associated O
with O
protein O
anabolism O
by O
increasing O
urinary O
noradrenaline O
and O
testicular O
testosterone O
levels O
and O
decreasing O
plasma O
corticosterone O
level O
in O
rats O
fed O
a O
high O
- O
protein O
diet O
. O

Materials O
and O
methods O
: O
Three O
modified O
- O
release O
formulations O
of O
aminophylline B
consisted O
of O
Carbopol O
( O
R O
) O
971P O
/ O
HPMC O
K4M O
( O
F O
- O
I O
) O
, O
and O
HPMC O
K100M O
( O
F O
- O
II O
) O
or O
HPMC O
K4M O
( O
F O
- O
III O
) O
were O
used O
. O

Commercial O
products O
were O
Aminofilin B
retard O
350 O
mg O
tablets O
, O
Srbolek O
, O
Serbia O
( O
R O
- O
I O
) O
and O
Phyllocontin B
( O
( O
R O
) O
) O
350 O
, O
tablets O
Purdue O
Frederic O
, O
Canada O
( O
R O
- O
II O
) O
. O

Impact O
of O
lead O
and O
mercuric B
ions O
on O
the O
interleukin O
- O
2 O
- O
dependent O
proliferation O
and O
survival O
of O
T O
cells O
. O

The O
objective O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
mercuric B
( O
Hg O
( O
2 O
+ O
) O
) O
and O
lead O
( O
Pb O
( O
2 O
+ O
) O
) O
ions O
on O
T O
cells O
. O

In O
contrast O
, O
HgCl B
( I
2 I
) I
caused O
a O
concentration O
- O
dependent O
decline O
of O
viable O
leukocytes O
and O
especially O
of O
activated O
T O
cells O
. O

Additionally O
, O
Hg O
( O
2 O
+ O
) O
induced O
reactive O
oxygen O
species O
( O
ROS O
) O
generation O
accompanied O
by O
the O
loss O
of O
mitochondrial O
transmembrane O
potential O
, O
measured O
by O
Dihydrorhodamine B
and O
Rhodamine B
- I
123 I
, O
respectively O
. O

The O
anticholinesterase O
( O
antiChE O
) O
organophosphorus O
( O
OP O
) O
and O
methylcarbamate B
( O
MC O
) O
insecticides O
have O
been O
used O
very O
effectively O
as O
contact O
and O
systemic O
plant O
protectants O
for O
seven O
decades O
. O

Disposition O
and O
metabolism O
of O
[ B
( I
1 I
) I
4 I
C I
] I
PTZ601 I
in O
healthy O
volunteers O
. O

1 O
. O
Six O
healthy O
male O
subjects O
were O
given O
a O
single O
dose O
of O
500 O
mg O
of O
[ B
14C I
] I
PTZ601 I
( O
mean O
radioactivity O
79 O
. O
2 O
mu O
Ci O
) O
by O
intravenous O
( O
IV O
) O
infusion O
over O
1 O
h O
, O
and O
observed O
for O
5 O
days O
post O
- O
dose O
during O
which O
pharmacokinetic O
( O
PK O
) O
samples O
were O
collected O
. O

Plasma O
PTZ601 B
concentrations O
and O
metabolite O
identification O
were O
determined O
using O
LC O
- O
MS O
/ O
MS O
; O
PK O
parameters O
were O
estimated O
by O
non O
- O
compartmental O
analysis O
. O

2 O
. O
The O
disposition O
of O
PTZ601 B
was O
best O
described O
by O
a O
fast O
absorption O
, O
followed O
by O
a O
biphasic O
elimination O
phase O
. O

Peak O
PTZ601 B
plasma O
concentrations O
were O
reached O
within O
0 O
. O
5 O
- O
1 O
h O
. O

4 O
. O
The O
majority O
of O
the O
drug O
was O
excreted O
in O
urine O
as O
multiple O
open O
ring O
metabolites O
: O
M17 O
. O
3 O
( O
oxidative O
ring O
- O
opened O
product O
) O
and O
M22 O
. O
2 O
( O
di B
- I
cysteine I
conjugate O
of O
17 O
. O
3 O
) O
; O
unchanged O
PTZ601 B
in O
urine O
contributed O
to O
15 O
% O
of O
radioactivity O
. O

5 O
. O
PTZ601 B
was O
well O
tolerated O
. O

In O
particular O
, O
we O
demonstrate O
that O
upon O
stress O
- O
induced O
phosphorylation O
of O
p53 O
on O
Ser46 B
by O
homeodomain O
interacting O
protein O
kinase O
2 O
, O
Pin1 O
stimulates O
its O
mitochondrial O
trafficking O
signal O
, O
that O
is O
, O
monoubiquitination O
. O

Chemical O
functionalization O
of O
a O
single O
- O
walled O
carbon O
nanotube O
( O
CNT O
) O
with O
different O
carboxylic O
derivatives O
including O
- O
COOX B
( O
X O
= O
H O
, O
CH3 O
, O
CH2NH2 B
, O
CH3Ph B
, O
CH2NO2 B
, O
and O
CH2CN B
) O
has O
been O
theoretically O
investigated O
in O
terms O
of O
geometric O
, O
energetic O
, O
and O
electronic O
properties O
. O

The O
results O
reveal O
that O
the O
reaction O
energy O
is O
increased O
by O
increasing O
the O
electron O
withdrawing O
character O
of O
the O
functional O
groups O
so O
that O
the O
relative O
magnitude O
order O
is O
- O
CH2NO2 B
> O
- O
CH2CN B
> O
- O
H O
> O
- O
CH2Ph B
> O
- O
CH3 O
> O
- O
CH2NH2 B
. O

LUMO O
, O
HOMO O
, O
and O
Fermi O
level O
of O
the O
CNT O
are O
shifted O
to O
lower O
energies O
especially O
in O
the O
case O
of O
- O
CH2NO2 B
and O
- O
CH2CN B
functional O
groups O
. O

Ultrasound O
promoted O
one O
- O
pot O
synthesis O
of O
2 B
- I
amino I
- I
4 I
, I
8 I
- I
dihydropyrano I
[ I
3 I
, I
2 I
- I
b I
] I
pyran I
- I
3 I
- I
carbonitrile I
scaffolds O
in O
aqueous O
media O
: O
a O
complementary O
' O
green O
chemistry O
' O
tool O
to O
organic O
synthesis O
. O

A O
green O
and O
simple O
approach O
to O
assembling O
of O
2 B
- I
amino I
- I
4 I
, I
8 I
- I
dihydropyrano I
[ I
3 I
, I
2 I
- I
b I
] I
pyran I
- I
3 I
- I
carbonitrile I
scaffolds O
via O
three O
- O
component O
reaction O
of O
kojic O
acid O
, O
malononitrile O
, O
and O
aromatic O
aldehydes O
in O
aqueous O
media O
under O
ultrasound O
irradiation O
is O
described O
. O

Cell O
transplantation O
approaches O
to O
retinal B
ganglion O
cell O
neuroprotection O
in O
glaucoma O
. O

Glaucoma O
is O
a O
complex O
neurodegenerative O
disease O
that O
involves O
interactions O
among O
multiple O
signaling O
pathways O
, O
ultimately O
leading O
to O
progressive O
retinal B
ganglion O
cell O
( O
RGC O
) O
death O
. O

These O
animal O
models O
are O
based O
on O
chemical O
interventions O
( O
e O
. O
g O
. O
pentylenetetrazol O
, O
kainic B
acid I
, O
pilocarpine O
) O
, O
electrical O
stimulations O
( O
e O
. O
g O
. O
kindling O
, O
electroshock O
) O
, O
and O
genetic O
/ O
selective O
breeding O
paradigms O
( O
e O
. O
g O
. O
genetically O
epilepsy O
- O
prone O
rats O
( O
GEPRs O
) O
, O
genetic O
absence O
epilepsy O
rat O
from O
Strasbourg O
( O
GAERS O
) O
, O
WAG O
/ O
Rij O
rats O
, O
swim O
lo O
- O
active O
rats O
( O
SwLo O
) O
) O
. O

The O
specificities O
of O
these O
mAbs O
were O
evaluated O
by O
frontal O
affinity O
chromatography O
using O
142 O
kinds O
of O
2 B
- I
aminopyridine I
( O
PA O
) O
- O
derivatized O
oligosaccharides O
. O

Diethyldithiocarbama B
induces O
apoptosis O
in O
neuroblastoma O
cells O
by O
raising O
the O
intracellular O
copper O
level O
, O
triggering O
cytochrome O
c O
release O
and O
caspase O
activation O
. O

Dithiocarbamates B
are O
nitrogen O
- O
and O
sulfur O
- O
containing O
compounds O
commonly O
used O
in O
pharmacology O
, O
medicine O
and O
agriculture O
. O

The O
molecular O
effects O
of O
dithiocarbamates B
on O
neuronal O
cell O
systems O
are O
not O
fully O
understood O
, O
especially O
in O
terms O
of O
their O
ability O
to O
accumulate O
copper O
ions O
inside O
the O
cell O
. O

In O
this O
work O
, O
the O
molecular O
effects O
of O
N B
, I
N I
- I
diethyldithiocarbama I
( O
DEDTC B
) O
were O
studied O
in O
human O
SH O
- O
SY5Y O
neuroblastoma O
cells O
to O
determine O
the O
role O
of O
copper O
in O
the O
DEDTC B
toxicity O
and O
the O
pathway O
trigged O
in O
cell O
by O
the O
complex O
Cu B
- I
DEDTC I
. O

From O
concentration O
- O
dependent O
studies O
, O
we O
found O
that O
5 O
mu O
M O
of O
this O
compound O
induced O
a O
drastic O
decrease O
in O
viable O
cells O
with O
a O
concomitant O
accumulation O
in O
intracellular O
copper O
resulted O
from O
complexation O
with O
DEDTC B
, O
measured O
by O
atomic O
absorption O
spectroscopy O
. O

The O
mechanism O
of O
DEDTC B
- O
induced O
apoptosis O
in O
neuronal O
model O
cells O
is O
thought O
to O
occur O
through O
the O
death O
receptor O
signaling O
triggered O
by O
DEDTC B
- I
copper I
complex O
in O
low O
concentration O
that O
is O
associated O
with O
the O
activation O
of O
caspase O
8 O
. O

This O
pathway O
is O
induced O
by O
the O
cytotoxic O
effects O
that O
occur O
when O
DEDTC B
forms O
a O
complex O
with O
the O
copper O
ions O
present O
in O
the O
culture O
medium O
and O
transports O
them O
into O
the O
cell O
, O
suggesting O
that O
the O
DEDTC B
by O
itself O
was O
not O
able O
to O
cause O
cell O
death O
and O
the O
major O
effect O
is O
from O
its O
copper O
- O
complex O
in O
neuroblastoma O
cells O
. O

The O
present O
study O
suggests O
a O
role O
for O
the O
influence O
of O
copper O
by O
low O
concentrations O
of O
DEDTC B
in O
the O
extracellular O
media O
, O
the O
absorption O
and O
accumulation O
of O
copper O
in O
the O
cell O
and O
apoptotic O
events O
, O
induced O
by O
the O
cytotoxic O
effects O
that O
occur O
when O
DEDTC B
forms O
a O
complex O
with O
the O
copper O
ions O
. O

Pregnant O
ApoE O
( O
- O
/ O
- O
) O
mice O
were O
given O
drinking O
water O
containing O
85 O
mg O
/ O
l O
NaAsO B
( I
2 I
) I
( O
49 O
ppm O
arsenic O
) O
from O
gestation O
day O
( O
GD O
) O
8 O
to O
18 O
. O

Toxicity O
profile O
of O
small O
- O
molecule O
IAP O
antagonist O
GDC B
- I
0152 I
is O
linked O
to O
TNF O
- O
alpha O
pharmacology O
. O

GDC B
- I
0152 I
is O
a O
small O
- O
molecule O
drug O
that O
triggers O
tumor O
cell O
apoptosis O
by O
selectively O
antagonizing O
IAPs O
. O

GDC B
- I
0152 I
induces O
NF O
- O
kappa O
B O
transcriptional O
activity O
leading O
to O
expression O
of O
several O
chemokines O
and O
cytokines O
, O
of O
which O
tumor O
necrosis O
factor O
alpha O
( O
TNF O
- O
alpha O
) O
is O
the O
most O
important O
for O
single O
- O
agent O
tumor O
activity O
. O

The O
toxicity O
profile O
of O
GDC B
- I
0152 I
in O
dogs O
and O
rats O
was O
characterized O
after O
iv O
dose O
administration O
once O
every O
2 O
weeks O
for O
four O
doses O
. O

Furthermore O
, O
elevations O
in O
blood O
neutrophil O
count O
, O
serum O
monocyte O
chemoattractant O
protein O
- O
1 O
, O
and O
other O
markers O
of O
inflammation O
corresponded O
to O
GDC B
- I
0152 I
exposure O
and O
toxicity O
and O
thus O
may O
have O
utility O
as O
safety O
biomarkers O
. O

The O
increased O
detrusor O
contractions O
by O
1 O
- O
h O
acrolein O
treatment O
were O
significantly O
reversed O
by O
the O
PKC O
inhibitor O
RO32 B
- I
0432 I
, O
and O
the O
decreased O
detrusor O
contractions O
by O
24 O
- O
h O
acrolein O
treatment O
were O
significantly O
reversed O
by O
the O
iNOS O
inhibitor O
and O
IL O
- O
6 O
- O
neutralizing O
antibody O
. O

A O
novel O
reproductive O
peptide O
, O
phoenixin B
. O

Release O
from O
the O
gland O
of O
the O
reproductive O
hormones O
luteinising O
hormone O
and O
follicle O
- O
stimulating O
hormone O
is O
regulated O
primarily O
by O
hypothalamically O
- O
derived O
gonadotrophin B
- I
releasing I
hormone I
( O
GnRH B
) O
, O
although O
other O
releasing O
factors O
( O
RF O
) O
have O
been O
postulated O
to O
exist O
. O

Using O
a O
bioinformatic O
approach O
, O
we O
have O
identified O
a O
novel O
peptide O
, O
phoenixin B
, O
that O
regulates O
pituitary O
gonadotrophin O
secretion O
by O
modulating O
the O
expression O
of O
the O
GnRH B
receptor O
, O
an O
action O
with O
physiologically O
relevant O
consequences O
. O

Compromise O
of O
phoenixin B
in O
vivo O
using O
small O
interfering O
RNA O
resulted O
in O
the O
delayed O
appearance O
of O
oestrus O
and O
a O
reduction O
in O
GnRH B
receptor O
expression O
in O
the O
pituitary O
. O

Phoenixin B
may O
represent O
a O
new O
class O
of O
hypothalamically O
- O
derived O
pituitary O
priming O
factors O
that O
sensitise O
the O
pituitary O
to O
the O
action O
of O
other O
RFs O
, O
rather O
than O
directly O
stimulating O
the O
fusion O
of O
secretary O
vesicles O
to O
pituitary O
membranes O
. O

Robust O
and O
aligned O
carbon O
nanotube O
/ O
titania B
core O
/ O
shell O
films O
for O
flexible O
TCO O
- O
free O
photoelectrodes O
. O

Adult O
ovariectomised O
rats O
were O
divided O
into O
six O
groups O
and O
injected O
either O
with O
vehicle O
or O
a O
single O
dose O
of O
oestradiol O
, O
a O
selective O
ER O
alpha O
agonist O
- O
PPT O
[ O
4 B
, I
4 I
' I
, I
4 I
' I
' I
- I
( I
4 I
- I
propyl I
- I
[ I
1H I
] I
- I
pyrazole I
- I
1 I
, I
3 I
, I
5 I
- I
triyl I
) I
trisphenol I
] O
, O
a O
selective O
ER O
beta O
agonist O
- O
DPN O
[ O
2 O
, O
3 O
- O
bis O
( O
4 O
- O
hydroxyphenyl O
) O
- O
propionitrile O
] O
, O
a O
selective O
ER O
alpha O
antagonist O
- O
MPP O
[ O
1 O
, O

3 O
- O
bis O
( O
4 O
- O
hydroxyphenyl O
) O
- O
4 O
- O
methyl O
- O
5 O
- O
[ O
4 O
- O
( O
2 O
- O
piperidinylethoxy O
) O
phenol O
] O
- O
1H B
- I
pyrazole I
dihydrochloride I
] O
or O
a O
selective O
ER O
beta O
antagonist O
- O
PHTPP B
( O
4 B
- I
[ I
2 I
- I
phenyl I
- I
5 I
, I
7 I
- I
bis I
( I
trifluoromethyl I
) I
pyrazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidin I
- I
3 I
- I
yl I
] I
phenol I
) O
. O

In O
the O
present O
studies O
, O
dose O
- O
response O
curves O
for O
d O
- O
amphetamine O
( O
AMPH B
) O
- O
induced O
hyperlocomotion O
were O
similar O
in O
standard O
B6 O
mice O
and O
in O
the O
BTBR O
mouse O
model O
of O
autism O
. O

AMPH B
produced O
significant O
, O
robust O
reductions O
in O
the O
high O
level O
of O
repetitive O
self O
- O
grooming O
that O
characterizes O
BTBR O
, O
and O
also O
reduced O
the O
low O
baseline O
grooming O
in O
B6 O
, O
indicating O
that O
AMPH B
- O
induced O
hyperlocomotion O
competes O
with O
time O
spent O
engaged O
in O
self O
- O
grooming O
. O

We O
then O
tested O
AMPH B
in O
B6 O
and O
BTBR O
on O
the O
3 O
- O
chambered O
social O
approach O
task O
. O

This O
finding O
replicated O
across O
multiple O
cohorts O
treated O
with O
AMPH B
and O
saline O
vehicle O
. O

In O
- O
depth O
analysis O
revealed O
that O
AMPH B
increased O
the O
number O
and O
decreased O
the O
duration O
of O
sniffing O
bouts O
in O
BTBR O
, O
suggesting O
BTBR O
treated O
with O
AMPH B
mostly O
engaged O
in O
brief O
sniffs O
rather O
than O
true O
social O
interactions O
with O
the O
novel O
mouse O
during O
the O
social O
approach O
task O
. O

Rats O
received O
five O
consecutive O
daily O
iv O
injections O
of O
saline O
or O
gadodiamide B
( O
2 O
. O
5 O
mmol O
/ O
kg O
/ O
day O
) O
. O

Secondly O
, O
the O
safety O
profile O
and O
in O
vivo O
propensity O
to O
dissociate O
of O
all O
categories O
of O
marketed O
GCs O
( O
gadoterate B
, O
gadobutrol B
, O
gadobenate B
, O
gadopentetate B
, O
and O
gadodiamide B
) O
were O
compared O
in O
rats O
receiving O
adenine O
- O
enriched O
diet O
for O
16 O
days O
. O

Gadodiamide B
- O
induced O
high O
mortality O
and O
skin O
lesions O
( O
dermal O
fibrosis O
, O
calcification O
, O
and O
inflammation O
) O
were O
related O
to O
adenine O
diet O
duration O
. O

Unlike O
macrocyclic O
GCs O
, O
gadodiamide B
, O
gadopentetate B
, O
and O
gadobenate B
gradually O
increased O
the O
r O
( O
1 O
) O
relaxivity O
value O
, O
consistent O
with O
in O
vivo O
dissociation O
and O
release O
of O
soluble O
Gd O
( O
or O
, O
in O
the O
case O
of O
gadobenate B
, O
the O
consequence O
of O
protein O
binding O
) O
. O

Gadodiamide B
- O
induced O
cutaneous O
and O
systemic O
toxicity O
depended O
on O
baseline O
renal O
function O
. O

We O
demonstrate O
in O
vivo O
dissociation O
of O
linear O
GCs O
, O
gadodiamide B
, O
and O
gadopentetate B
, O
whereas O
macrocyclic O
agents O
remained O
stable O
over O
the O
study O
period O
. O

Potent O
organophosphorous B
( O
OP O
) O
agents O
, O
such O
as O
VX O
, O
are O
hazardous O
by O
absorption O
through O
the O
skin O
and O
are O
resistant O
to O
conventional O
pharmacological O
antidotal O
treatments O
. O

Plasma O
concentrations O
of O
intramuscularly O
- O
administered O
atropine B
, O
diazepam O
and O
HI O
- O
6 O
reached O
a O
peak O
within O
15min O
and O
were O
eliminated O
rapidly O
within O
4h O
. O

Ultrasound O
- O
assisted O
coating O
of O
silk O
yarn O
with O
sphere O
- O
like O
Mn3O4 B
nanoparticles O
. O

The O
growth O
of O
sphere O
- O
like O
trimanganese B
tetraoxide I
( O
Mn B
( I
3 I
) I
O I
( I
4 I
) I
) O
nanoparticles O
on O
silk O
fiber O
was O
achieved O
by O
sequential O
dipping O
in O
an O
alternating O
bath O
of O
potassium B
hydroxide I
and O
manganese B
( I
II I
) I
nitrate I
under O
ultrasound O
irradiation O
. O

In O
BCPAP O
and O
TPC1 O
cells O
also O
significant O
increase O
of O
radio B
- I
iodine I
uptake O
was O
induced O
. O

In O
previous O
studies O
, O
we O
have O
characterized O
three O
new O
synthesized O
guanidine O
and O
2 B
- I
aminoimidazoline I
aromatic O
derivatives O
( O
8b O
, O
17b O
and O
20b O
) O
as O
alpha O
2 O
- O
adrenoceptor O
antagonists O
that O
are O
able O
to O
increase O
extracellular O
concentration O
of O
noradrenaline O
in O
rat O
brain O
. O

Di B
2 I
- I
ethyl I
hexyl I
phthalate I
affects O
differentiation O
and O
matrix O
mineralization O
of O
rat O
calvarial O
osteoblasts O
- O
- O
in O
vitro O
. O

Di B
- I
2 I
- I
ethyl I
hexyl I
phthalate I
( O
DEHP O
) O
, O
an O
industrial O
plasticizer O
and O
a O
ubiquitous O
environmental O
contaminant O
, O
is O
an O
established O
endocrine O
disruptor O
( O
ED O
) O
. O

Ultraviolet O
B O
activated O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
affects O
the O
level O
of O
fibroblast O
growth O
factor O
- O
23 O
in O
human O
. O

Several O
studies O
suggest O
that O
dietary O
phosphate O
, O
serum O
phosphate O
and O
1 O
, O
25 O
- O
dihydroxyvitamin O
D O
[ O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
] O
are O
candidate O
regulators O
of O
FGF O
- O
23 O
. O

Twenty B
five I
- I
hydroxyvitamin I
D I
[ O
25 B
( I
OH I
) I
D I
] O
increased O
by O
115 O
% O
( O
19 O
. O
8 O
ng O
/ O
mL O
to O
40 O
. O
5 O
ng O
/ O
mL O
, O
p O
< O
0 O
. O
001 O
) O
after O
4 O
weeks O
of O
UVB O
exposure O
. O

While O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
increased O
by O
75 O
% O
( O
49 O
. O
9 O
pg O
/ O
mL O
to O
64 O
. O
4 O
pg O
/ O
mL O
, O
p O
< O
0 O
. O
001 O
) O
then O
both O
level O
decreased O
after O
4 O
weeks O
of O
withdrawal O
. O

UVB O
exposure O
effectively O
increased O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
with O
delayed O
stimulatory O
effect O
on O
FGF O
- O
23 O
. O

This O
result O
could O
support O
the O
regulatory O
loop O
of O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
and O
FGF O
- O
23 O
in O
human O
, O
FGF O
- O
23 O
regulation O
by O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
. O

A O
recent O
study O
suggested O
that O
the O
purinergic O
receptor O
antagonist O
A438079 B
protects O
against O
APAP O
- O
induced O
liver O
injury O
by O
preventing O
the O
activation O
of O
the O
Nalp3 O
inflammasome O
in O
Kupffer O
cells O
and O
thereby O
preventing O
inflammatory O
injury O
. O

To O
test O
the O
hypothesis O
that O
A438079 B
actually O
affects O
the O
intracellular O
signaling O
events O
in O
hepatocytes O
, O
C57Bl O
/ O
6 O
mice O
were O
treated O
with O
APAP O
( O
300 O
mg O
/ O
kg O
) O
and O
A438079 B
( O
80 O
mg O
/ O
kg O
) O
or O
saline O
and O
GSH O
depletion O
, O
protein O
adduct O
formation O
, O
c O
- O
jun O
- O
N O
- O
terminal O
kinase O
( O
JNK O
) O
activation O
, O
oxidant O
stress O
, O
and O
liver O
cell O
necrosis O
were O
determined O
between O
0 O
and O
6 O
h O
after O
APAP O
administration O
. O

A438079 B
significantly O
attenuated O
GSH O
depletion O
, O
which O
resulted O
in O
a O
50 O
% O
reduction O
of O
total O
liver O
and O
mitochondrial O
protein O
adducts O
and O
substantial O
reduction O
of O
JNK O
activation O
, O
mitochondrial O
P O
- O
JNK O
translocation O
, O
oxidant O
stress O
, O
and O
liver O
injury O
. O

A438079 B
did O
not O
directly O
affect O
JNK O
activation O
induced O
by O
tert O
- O
butyl O
hydroperoxide O
and O
GSH O
depletion O
. O

However O
, O
A438079 B
dose O
- O
dependently O
inhibited O
hepatic O
P450 O
enzyme O
activity O
. O

Thus O
, O
the O
protective O
effect O
of O
A438079 B
against O
APAP O
hepatotoxicity O
in O
vivo O
can O
be O
explained O
by O
its O
effect O
on O
metabolic O
activation O
and O
cell O
death O
pathways O
in O
hepatocytes O
without O
involvement O
of O
the O
Nalp3 O
inflammasome O
. O

Withaferin B
A I
- O
stimulated O
Ca2 O
+ O
entry O
, O
ceramide B
formation O
and O
suicidal O
death O
of O
erythrocytes O
. O

Withaferin B
A I
, O
a O
triterpenoid O
component O
from O
Withania O
somnifera O
, O
counteracts O
malignancy O
, O
an O
effect O
attributed O
to O
stimulation O
of O
apoptosis O
. O

Withaferin B
A I
is O
partially O
effective O
through O
induction O
of O
oxidative O
stress O
, O
altered O
gene O
expression O
and O
mitochondrial O
depolarization O
. O

Triggers O
of O
eryptosis O
include O
increase O
of O
cytosolic O
Ca O
( O
2 O
+ O
) O
- O
activity O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
following O
activation O
of O
oxidant O
- O
sensitive O
Ca O
( O
2 O
+ O
) O
- O
permeable O
cation O
channels O
, O
ceramide B
formation O
and O
/ O
or O
ATP O
- O
depletion O
. O

The O
present O
study O
explored O
, O
whether O
withaferin B
A I
triggers O
eryptosis O
. O

To O
this O
end O
, O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
was O
estimated O
from O
Fluo3 B
- O
fluorescence O
, O
cell O
volume O
from O
forward O
scatter O
, O
phosphatidylserine O
exposure O
from O
annexin O
- O
V O
- O
binding O
, O
hemolysis O
from O
hemoglobin O
release O
, O
oxidative O
stress O
from O
DCFDA B
- O
fluorescence O
and O
ceramide B
abundance O
utilizing O
antibodies O
. O

A O
48 O
h O
exposure O
to O
withaferin B
A I
significantly O
decreased O
forward O
scatter O
( O
at O
> O
= O
10 O
mu O
M O
withaferin B
concentration O
) O
and O
increased O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
( O
> O
= O
5 O
mu O
M O
) O
, O
ROS O
- O
formation O
( O
> O
= O
10 O
mu O
M O
) O
ceramide B
- O
formation O
( O
> O
= O
10 O
mu O
M O
) O
as O
well O
as O
annexin O
- O
V O
- O
binding O
( O
> O
= O
5 O
mu O
M O
) O
. O

Withaferin B
A I
treatment O
was O
followed O
by O
slight O
but O
significant O
increase O
of O
hemolysis O
. O

Extracellular O
Ca O
( O
2 O
+ O
) O
removal O
, O
amiloride O
, O
and O
the O
antioxidant O
N O
- O
acetyl O
- O
l O
- O
cysteine O
significantly O
blunted O
withaferin B
A I
- O
triggered O
annexin O
- O
V O
- O
binding O
. O

The O
present O
observations O
reveal O
that O
withaferin B
A I
triggers O
suicidal O
erythrocyte O
death O
despite O
the O
absence O
of O
gene O
expression O
and O
key O
elements O
of O
apoptosis O
such O
as O
mitochondria O
. O

Aryl B
methylcarbamates I
: O
Potency O
and O
selectivity O
towards O
wild O
- O
type O
and O
carbamate O
- O
insensitive O
( O
G119S O
) O
Anopheles O
gambiae O
acetylcholinesterase O
, O
and O
toxicity O
to O
G3 O
strain O
An O
. O
gambiae O
. O

Valproic O
acid O
but O
not O
D B
- I
cycloserine I
facilitates O
sleep O
- O
dependent O
offline O
learning O
of O
extinction O
and O
habituation O
of O
conditioned O
fear O
in O
humans O
. O

The O
effectiveness O
of O
D B
- I
cycloserine I
( O
DCS B
) O
, O
an O
N B
- I
methyl I
- I
D I
- I
aspartate I
glutamate I
receptor O
partial O
agonist O
, O
and O
valproic O
acid O
( O
VPA O
) O
, O
a O
histone O
deacetylase O
inhibitor O
, O
in O
facilitating O
the O
extinction O
of O
fear O
- O
conditioned O
memory O
has O
been O
explored O
in O
humans O
and O
animals O
. O

Here O
, O
we O
confirmed O
whether O
DCS B
( O
100 O
mg O
) O
and O
VPA O
( O
400 O
mg O
) O
act O
in O
off O
- O
line O
learning O
processes O
during O
sleep O
or O
waking O
, O
for O
further O
clinical O
application O
to O
anxiety O
disorders O
and O
posttraumatic O
stress O
disorder O
( O
PTSD O
) O
. O

Newly O
acquired O
conditioned O
fear O
was O
also O
eliminated O
or O
habituated O
by O
DCS B
and O
VPA O
administration O
, O
in O
line O
with O
previous O
findings O
. O

Furthermore O
, O
VPA O
facilitated O
the O
off O
- O
line O
learning O
process O
of O
conditioned O
fear O
extinction O
and O
habituation O
during O
sleep O
, O
while O
DCS B
facilitated O
this O
process O
during O
waking O
. O

These O
novel O
findings O
suggest O
that O
DCS B
and O
VPA O
might O
enhance O
exposure O
- O
based O
cognitive O
therapy O
for O
anxiety O
disorders O
and O
PTSD O
by O
reducing O
the O
vulnerability O
to O
reinstatement O
and O
preventing O
relapses O
of O
fear O
- O
conditioned O
responses O
, O
and O
provide O
evidence O
for O
a O
peculiarity O
of O
the O
sleep O
- O
dependent O
off O
- O
line O
learning O
process O
for O
conditioned O
fear O
extinction O
. O

Induction O
of O
apoptosis O
in O
human O
ovarian O
cancer O
cells O
by O
new O
anticancer O
compounds O
, O
epothilone B
A I
and I
B I
. O

Epothilones B
are O
a O
new O
group O
of O
compounds O
with O
action O
mechanisms O
similar O
to O
taxanes O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
effects O
of O
epothilone B
A I
( O
Epo B
A I
) O
and O
epothilone B
B I
( O
Epo B
B I
) O
on O
ovarian O
cancer O
cell O
line O
SKOV O
- O
3 O
with O
those O
of O
paclitaxel O
( O
PTX O
) O
, O
a O
classic O
taxane O
. O

The O
production O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
and O
changes O
in O
mitochondrial O
membrane O
potential O
( O
Delta O
Psi O
m O
) O
in O
cells O
exposed O
to O
Epo B
A I
, O
Epo B
B I
and O
PTX O
were O
studied O
using O
specific O
fluorescence O
probes O
, O
DCFH B
( I
2 I
) I
- I
DA I
( O
2 B
' I
, I
7 I
' I
- I
dichlorodihydrofluor I
diacetate I
) O
and O
JC B
- I
1 I
( O
5 B
, I
5 I
' I
, I
6 I
, I
6 I
' I
- I
tetrachloro I
- I
1 I
, I
1 I
' I
, I
3 I
, I
3 I
' I
- I
tetraethylbenzimidaz I
) O
. O

The O
results O
obtained O
demonstrated O
that O
the O
antiproliferative O
capacity O
of O
Epo B
A I
and O
Epo B
B I
in O
SKOV O
- O
3 O
cell O
line O
( O
measured O
as O
IC O
( O
50 O
) O
after O
72 O
h O
continuous O
treatment O
) O
was O
six O
and O
five O
times O
greater O
than O
that O
of O
PTX O
' O
s O
respectively O
. O

Epothilones B
induced O
timecourse O
- O
dependent O
apoptosis O
and O
necrosis O
. O

Apoptotic O
and O
necrotic O
events O
were O
partially O
blocked O
by O
NAC O
, O
indicating O
ROS O
played O
a O
substantial O
role O
in O
epothilone B
- O
induced O
apoptosis O
. O

Cell O
death O
was O
also O
associated O
with O
a O
decrease O
in O
mitochondrial O
membrane O
potential O
, O
which O
was O
more O
pronounced O
after O
treatment O
with O
epothilones B
as O
compared O
to O
paclitaxel O
. O

Enhanced O
oral O
bioavailability O
of O
isradipine B
via O
proniosomal O
systems O
. O

The O
objective O
of O
the O
present O
research O
was O
to O
develop O
a O
proniosomal O
formulation O
of O
isradipine B
and O
to O
evaluate O
the O
influence O
of O
proniosomal O
systems O
on O
the O
oral O
bioavailability O
of O
the O
drug O
in O
albino O
Wistar O
rats O
. O

Proniosomes O
were O
prepared O
by O
film O
deposition O
on O
carrier O
' O
s O
method O
using O
various O
molar O
ratios O
of O
nonionic O
surfactants O
such O
as O
span20 B
, O
span40 B
, O
span60 B
, O
and O
span80 B
with O
cholesterol O
as O
membrane O
stabilizing O
agent O
and O
dicetylphosphate B
as O
a O
charge O
inducer O
. O

The O
prepared O
proniosomes O
have O
shown O
higher O
dissolution O
of O
isradipine B
compared O
with O
pure O
drug O
powder O
. O

The O
optimum O
formulation O
of O
SMEDDS O
was O
a O
system O
consisting O
of O
ethyl B
oleate I
, O
tween O
80 O
, O
and O
propylene O
glycol O
with O
a O
mean O
droplet O
size O
of O
39 O
. O
42 O
nm O
. O

The O
" O
Met O
- O
turn O
" O
structure O
contains O
a O
conserved O
Met O
residue O
that O
forms O
a O
hydrophobic O
basement O
for O
the O
three O
zinc O
- O
binding O
histidines B
in O
the O
consensus O
sequence O
. O

Wogonoside B
induces O
autophagy O
in O
MDA O
- O
MB O
- O
231 O
cells O
by O
regulating O
MAPK O
- O
mTOR O
pathway O
. O

Previous O
studies O
have O
demonstrated O
that O
wogonoside B
, O
a O
bioactive O
flavonoid O
extracted O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Gerogi O
, O
has O
anti O
- O
inflammatory O
and O
anti O
- O
angiogenic O
activities O
. O

In O
this O
study O
, O
we O
evaluated O
wogonoside B
- O
induced O
autophagy O
on O
human O
breast O
MDA O
- O
MB O
- O
231 O
cells O
. O

We O
report O
that O
wogonoside B
triggered O
the O
formation O
of O
microtubule O
- O
associated O
protein O
- O
light O
chain O
3 O
( O
MAP O
- O
LC3 O
) O
positive O
autophagosomes O
and O
the O
accumulation O
of O
acidic O
vesicular O
and O
autolysosomes O
in O
MDA O
- O
MB O
- O
231 O
cells O
. O

In O
addition O
, O
cells O
treated O
by O
wogonoside B
developed O
autophagosome O
- O
like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O

The O
results O
showed O
that O
wogonoside B
promotes O
the O
expression O
of O
LC3 O
- O
II O
and O
Beclin O
- O
1 O
. O

Furthermore O
, O
wogonoside B
inhibited O
cell O
growth O
of O
MDA O
- O
MB O
- O
231 O
cells O
in O
a O
concentration O
- O
and O
time O
- O
dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside B
- O
induced O
autophagy O
. O

Wogonoside B
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
( O
mTOR O
) O
and O
p70 O
- O
S6 O
kinase O
( O
p70S6K O
) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal O
- O
regulated O
kinase O
( O
ERK1 O
/ O
2 O
) O
and O
p38 O
involved O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
signaling O
pathway O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside B
partially O
inhibits O
MDA O
- O
MB O
- O
231 O
cell O
growth O
by O
inducing O
autophagy O
through O
the O
MAPK O
- O
mTOR O
pathway O
and O
may O
be O
a O
promising O
anti O
- O
tumor O
agent O
. O

Neurosurgical O
intervention O
was O
performed O
in O
almost O
all O
cases O
, O
and O
post O
- O
surgical O
treatment O
comprised O
radioiodine B
, O
external O
beam O
radiotherapy O
, O
and O
radiosurgery O
. O

An O
early O
diagnosis O
appears O
important O
, O
and O
a O
comprehensive O
strategy O
for O
treatment O
( O
neurosurgery O
, O
radioiodine B
, O
external O
radiotherapy O
, O
and O
radiosurgery O
) O
appears O
advisable O
. O

This O
study O
introduces O
GS967 B
( O
6 B
- I
[ I
4 I
- I
( I
trifluoromethoxy I
) I
phenyl I
] I
- I
3 I
- I
( I
trifluoromethyl I
) I
- I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
4 I
, I
3 I
- I
a I
] I
pyridine I
) O
, O
a O
potent O
and O
selective O
inhibitor O
of O
late O
I O
( O
Na O
) O
, O
and O
demonstrates O
its O
effectiveness O
to O
suppress O
ventricular O
arrhythmias O
. O

The O
effects O
of O
GS967 B
on O
rabbit O
ventricular O
myocyte O
ion O
channel O
currents O
and O
action O
potentials O
were O
determined O
. O

Anti O
- O
arrhythmic O
actions O
of O
GS967 B
were O
characterized O
in O
ex O
vivo O
and O
in O
vivo O
rabbit O
models O
of O
reduced O
repolarization O
reserve O
and O
ischemia O
. O

GS967 B
inhibited O
Anemonia O
sulcata O
toxin O
II O
( O
ATX O
- O
II O
) O
- O
induced O
late O
I O
( O
Na O
) O
in O
ventricular O
myocytes O
and O
isolated O
hearts O
with O
IC O
( O
50 O
) O
values O
of O
0 O
. O
13 O
and O
0 O
. O
21 O
micro O
M O
, O
respectively O
. O

Reduction O
of O
peak O
I O
( O
Na O
) O
by O
GS967 B
was O
minimal O
at O
a O
holding O
potential O
of O
- O
120 O
mV O
but O
increased O
at O
- O
80 O
mV O
. O

GS967 B
did O
not O
prolong O
action O
potential O
duration O
or O
the O
QRS O
interval O
. O

GS967 B
prevented O
and O
reversed O
proarrhythmic O
effects O
( O
afterdepolarizations O
and O
torsades O
de O
pointes O
) O
of O
the O
late O
I O
( O
Na O
) O
enhancer O
ATX O
- O
II O
and O
the O
I O
( O
Kr B
) O
inhibitor O
E B
- I
4031 I
in O
isolated O
ventricular O
myocytes O
and O
hearts O
. O

GS967 B
significantly O
attenuated O
the O
proarrhythmic O
effects O
of O
methoxamine B
+ O
clofilium B
and O
suppressed O
ischemia O
- O
induced O
arrhythmias O
. O

GS967 B
was O
more O
potent O
and O
effective O
to O
reduce O
late O
I O
( O
Na O
) O
and O
arrhythmias O
than O
either O
flecainide B
or O
ranolazine B
. O

Results O
of O
all O
studies O
and O
assays O
of O
binding O
and O
activity O
of O
GS967 B
at O
numerous O
receptors O
, O
transporters O
, O
and O
enzymes O
indicated O
that O
GS967 B
selectively O
inhibited O
late O
I O
( O
Na O
) O
. O

In O
summary O
, O
GS967 B
selectively O
suppressed O
late O
I O
( O
Na O
) O
and O
prevented O
and O
/ O
or O
reduced O
the O
incidence O
of O
experimentally O
induced O
arrhythmias O
in O
rabbit O
myocytes O
and O
hearts O
. O

The O
cationic O
polymer O
polyethylenimine O
( O
PEI O
) O
or O
the O
cationic O
lipid O
oleylamine O
( O
OAM B
) O
were O
added O
to O
monoolein B
( O
MO O
) O
- O
based O
systems O
in O
different O
concentrations O
, O
and O
after O
dispersion O
in O
aqueous O
medium O
, O
liquid O
crystalline O
phase O
nanodispersions O
were O
obtained O
and O
characterized O
by O
their O
physicochemical O
properties O
. O

Then O
, O
in O
vitro O
penetration O
studies O
using O
diffusion O
cell O
and O
pig O
ear O
skin O
were O
carried O
out O
to O
evaluate O
the O
effect O
of O
the O
nanodispersions O
on O
the O
skin O
penetration O
of O
siRNA O
; O
based O
on O
these O
results O
, O
the O
nanodispersions O
containing O
MO O
/ O
OA O
/ O
PEI O
/ O
aqueous O
phase O
( O
8 O
: O
2 O
: O
5 O
: O
85 O
, O
w O
/ O
w O
/ O
w O
/ O
w O
) O
and O
MO O
/ O
OA O
/ O
OAM B
/ O
aqueous O
phase O
( O
8 O
: O
2 O
: O
2 O
: O
88 O
, O
w O
/ O
w O
/ O
w O
/ O
w O
) O
were O
selected O
. O

These O
systems O
were O
investigated O
in O
vivo O
for O
skin O
penetration O
, O
skin O
irritation O
, O
and O
the O
ability O
to O
knockdown O
glyceraldehyde B
3 I
- I
phosphate I
dehydrogenase O
( O
GAPDH O
) O
protein O
levels O
in O
animal O
models O
. O

Ten O
microlitres O
aliquots O
of O
peripheral O
venous O
human O
blood O
were O
incubated O
with O
tarragon O
extract O
, O
saline O
, O
or O
the O
mutagen O
sodium B
dichromate I
. O

Cell O
suspensions O
dispersed O
in O
low O
- O
melting O
agarose O
were O
electrophoresed O
in O
ethidium B
bromide I
. O

These O
outcomes O
are O
possibly O
due O
to O
the O
presence O
in O
tarragon O
of O
methylchavicol B
and O
other O
genotoxic O
compounds O
. O

The O
effect O
of O
concurrent O
administration O
of O
elacridar B
on O
regional O
tumor O
distribution O
of O
erlotinib O
was O
evaluated O
. O

Inhibition O
of O
P O
- O
gp O
and O
Bcrp O
by O
the O
dual O
inhibitor O
elacridar B
dramatically O
increased O
erlotinib O
delivery O
to O
the O
tumor O
core O
, O
rim O
, O
and O
normal O
brain O
. O

Gallic O
acid O
and O
p B
- I
cumaric I
acid I
were O
identified O
for O
Ayval O
i O
k O
and O
Domat O
at O
each O
period O
of O
ripening O
, O
respectively O
. O

In O
addition O
, O
gallic O
acid O
, O
p B
- I
cumaric I
acid I
, O
sinapinic B
and I
apigenin I
acids I
were O
detected O
in O
Gemlik O
olive O
fruit O
. O

Hydroxytyrosol O
, O
rutin O
, O
oleoropein B
, O
luteolin O
, O
tyrosol O
, O
vanilic B
acid I
and O
gallic O
acid O
in O
Ayval O
i O
k O
olive O
fruit O
in O
all O
ripening O
periods O
were O
determined O
. O

The O
tyrasol B
contents O
varied O
between O
0 O
. O
18 O
to O
1 O
. O
57mg O
/ O
kg O
. O

In O
contrast O
, O
oils O
had O
the O
lowest O
syringic B
, I
p I
- I
cumaric I
, I
chlorogenic I
and I
ferulic I
acids I
. O

Volatile O
compounds O
identified O
by O
GC O
- O
MS O
analysis O
showed O
that O
the O
content O
of O
the O
important O
meaty O
flavour O
compounds O
( O
such O
as O
2 B
- I
methyl I
- I
3 I
- I
furanthiol I
, O
bis B
( I
2 I
- I
methyl I
- I
3 I
- I
furyl I
) I
disulfide I
) O
of O
MSPC O
were O
dramatically O
higher O
than O
that O
of O
MRPs O
from O
uncross O
- O
linking O
peptides O
. O

Like O
diazepam O
( O
a O
GABA O
( O
A O
) O
- O
benzodiazepine O
( O
BZD B
) O
receptor O
agonist O
) O
, O
the O
hypnotic O
effects O
of O
GRPE O
, O
GOPE O
, O
and O
their O
EA O
fractions O
were O
fully O
inhibited O
by O
flumazenil O
( O
a O
GABA O
( O
A O
) O
- O
BZD B
receptor O
antagonist O
) O
. O

The O
formation O
of O
supramolecular O
inclusion O
complexes O
between O
rutin O
and O
four O
cyclodextrins O
, O
namely O
beta O
- O
cyclodextrin O
( O
beta O
- O
CD O
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
alpha I
- I
cyclodextrin I
( O
HP B
- I
alpha I
- I
CD I
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
beta I
- I
cyclodextrin I
( O
HP O
- O
beta O
- O
CD O
) O
and O
( B
2 I
- I
hydroxypropyl I
) I
- I
gamma I
- I
cyclodextrin I
( O
HP O
- O
gamma O
- O

CD O
) O
, O
and O
the O
effects O
of O
the O
complexation O
on O
the O
stability O
and O
antioxidant O
activity O
of O
rutin B
were O
investigated O
. O

Results O
from O
phase O
- O
solubility O
studies O
showed O
that O
rutin O
formed O
1 O
: O
1 O
stoichiometric O
inclusion O
complexes O
with O
HP B
- I
alpha I
- I
CD I
, O
beta O
- O
CD O
, O
HP O
- O
beta O
- O
CD O
and O
HP B
- I
gamma I
- I
CD I
; O
the O
complexes O
formed O
with O
HP B
- I
gamma I
- I
CD I
and O
HP O
- O
beta O
- O
CD O
had O
the O
greatest O
stability O
constants O
, O
followed O
by O
beta O
- O
CD O
and O
HP B
- I
alpha I
- I
CD I
. O

Direct O
- O
acting O
CB1 O
agonists O
, O
including O
Delta O
( O
9 O
) O
- O
tetrahydrocannabinol O
, O
WIN B
55 I
, I
212 I
[ O
R B
- I
( I
1 I
) I
- I
[ I
2 I
, I
3 I
- I
dihydro I
- I
5 I
- I
methyl I
- I
3 I
- I
[ I
( I
morpholinyl I
) I
methyl I
] I
pyrrolo I
[ I
1 I
, I
2 I
, I
3 I
- I
de I
] I
- I
1 I
, I
4 I
- I
benzoxazinyl I
] I
- I
( I
1 I
- I
naphthalenyl I
) I
methanone I
mesylate I
] O
, O
AM2389 B
[ O
9 O
beta O
- O
hydroxy O
- O
3 O
- O
( O
1 O
- O
hexyl O

- O
cyclobut O
- O
1 O
- O
yl O
) O
- O
hexahydrocannabinol O
] O
, O
and O
AM4054 B
[ O
9 B
beta I
- I
( I
hydroxymethyl I
) I
- I
3 I
- I
( I
1 I
- I
adamantyl I
) I
- I
hexahydrocannabinol I
] O
, O
produced O
dose O
- O
dependent O
increases O
in O
diuresis O
and O
decreases O
in O
colonic O
temperature O
, O
with O
slightly O
lower O
ED O
( O
50 O
) O
values O
for O
diuresis O
than O
for O
hypothermia O
. O

The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26 O
- O
32 O
g O
/ O
kg O
urine O
; O
comparable O
effects O
were O
obtained O
with O
10 O
mg O
/ O
kg O
furosemide O
and O
3 O
. O
0 O
mg O
/ O
kg O
trans B
- I
( I
- I
) I
- I
3 I
, I
4 I
- I
dichloro I
- I
N I
- I
methyl I
- I
N I
- I
[ I
2 I
- I
( I
1 I
- I
pyrrolidinyl I
) I
cyclohexyl I
] I
benzeneacetamide I
( O
U50 O
- O
488 O
) O
. O

Methanandamide B
( O
10 O
. O
0 O
mg O
/ O
kg O
) O
had O
lesser O
effect O
than O
other O
CB O
agonists O
, O
and O
the O
CB2 O
agonist O
AM1241 B
[ O
1 B
- I
( I
methylpiperidin I
- I
2 I
- I
ylmethyl I
) I
- I
3 I
- I
( I
2 I
- I
iodo I
- I
5 I
- I
nitrobenzoyl I
) I
indole I
] O
, O
the O
anandamide O
transport O
inhibitor O
AM404 B
, O
and O
the O
CB O
antagonist O
rimonabant O
did O
not O
have O
diuretic O
effects O
. O

In O
further O
studies O
, O
the O
diuretic O
effects O
of O
the O
CB1 O
agonist O
AM4054 O
were O
similar O
in O
male O
and O
female O
rats O
, O
displayed O
a O
relatively O
rapid O
onset O
to O
action O
, O
and O
were O
dose O
- O
dependently O
antagonized O
by O
30 O
minutes O
pretreatment O
with O
rimonabant O
, O
but O
not O
by O
the O
vanilloid B
receptor O
type O
I O
antagonist O
capsazepine O
, O
nor O
were O
the O
effects O
of O
WIN B
55 I
, I
212 I
antagonized O
by O
the O
CB2 O
antagonist O
AM630 B
[ O
( O
6 O
- O
iodo O
- O
2 O
- O
methyl O
- O
1 O
- O
[ O
2 O
- O
( O
4 O
- O
morpholinyl O
) O
ethyl O
] O
- O

Role O
of O
carbonyl B
reducing O
enzymes O
in O
the O
phase O
I O
biotransformation O
of O
the O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
nabumetone B
in O
vitro O
. O

Nabumetone B
is O
a O
clinically O
used O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
, O
its O
biotransformation O
includes O
major O
active O
metabolite O
6 B
- I
methoxy I
- I
2 I
- I
naphtylacetic I
acid I
and O
another O
three O
phase O
I O
as O
well O
as O
corresponding O
phase O
II O
metabolites O
which O
are O
regarded O
as O
inactive O
. O

One O
important O
biotransformation O
pathway O
is O
carbonyl O
reduction O
, O
which O
leads O
to O
the O
phase O
I O
metabolite O
, O
reduced O
nabumetone B
. O

The O
aim O
of O
this O
study O
is O
the O
determination O
of O
the O
role O
of O
a O
particular O
human O
liver O
subcellular O
fraction O
in O
the O
nabumetone B
reduction O
and O
the O
identification O
of O
participating O
carbonyl O
reducing O
enzymes O
along O
with O
their O
stereospecificities O
. O

Both O
subcellular O
fractions O
take O
part O
in O
the O
carbonyl O
reduction O
of O
nabumetone B
and O
the O
reduction O
is O
at O
least O
in O
vitro O
the O
main O
biotransformation O
pathway O
. O

The O
activities O
of O
eight O
cytosolic O
carbonyl O
reducing O
enzymes O
- O
- O
CBR1 O
, O
CBR3 O
, O
AKR1B1 O
, O
AKR1B10 O
, O
AKR1C1 O
- O
4 O
- O
- O
toward O
nabumetone B
were O
tested O
. O

Except O
for O
CBR3 O
, O
all O
tested O
reductases O
transform O
nabumetone B
to O
its O
reduced O
metabolite O
. O

The O
stereospecificity O
of O
the O
majority O
of O
the O
tested O
enzymes O
is O
shifted O
to O
the O
production O
of O
an O
( O
+ O
) O
- O
enantiomer O
of O
reduced O
nabumetone B
; O
only O
AKR1C1 O
and O
AKR1C4 O
produce O
predominantly O
an O
( O
- O
) O
- O
enantiomer O
. O

This O
project O
provides O
for O
the O
first O
time O
evidence O
that O
seven O
specific O
carbonyl O
reducing O
enzymes O
participate O
in O
nabumetone B
metabolism O
. O

Transport O
of O
gemifloxacin B
, O
a O
4th O
generation O
quinolone O
antibiotic O
, O
in O
the O
Caco O
- O
2 O
and O
engineered O
MDCKII O
cells O
, O
and O
potential O
involvement O
of O
efflux O
transporters O
in O
the O
intestinal O
absorption O
of O
the O
drug O
. O

The O
oral O
( O
po O
) O
bioavailability O
of O
gemifloxacin B
mesylate I
in O
rats O
and O
its O
possible O
association O
with O
efflux O
transporters O
was O
investigated O
. O

The O
apparent O
permeabilities O
( O
Papp O
) O
of O
gemifloxacin B
across O
the O
Caco O
- O
2 O
cell O
monolayer O
were O
1 O
. O
20 O
+ O
/ O
- O
0 O
. O
09 O
x O
10 O
( O
- O
5 O
) O
cm O
/ O
s O
for O
apical O
to O
basal O
( O
absorptive O
) O
transport O
, O
and O
2 O
. O
13 O
+ O
/ O
- O
0 O
. O
6 O
x O
10 O
( O
- O
5 O
) O
cm O
/ O
s O
for O
basal O
to O
apical O
( O
secretory O
) O
transport O
for O
a O
5 O
- O
500 O
mu O
M O
concentration O
range O
, O
suggesting O
the O
involvement O
of O
a O
carrier O
- O
mediated O
efflux O
in O
the O
secretory O
transport O
. O

Efflux O
transporters O
appeared O
to O
significantly O
limit O
the O
bioavailability O
of O
gemifloxacin B
in O
rats O
, O
suggesting O
their O
possible O
contribution O
to O
the O
low O
bioavailability O
of O
the O
drug O
in O
the O
human O
( O
70 O
% O
) O
. O

A O
phase O
I O
, O
open O
- O
label O
, O
single O
- O
dose O
, O
mass O
balance O
study O
of O
14C B
- I
labeled I
abiraterone I
acetate I
in O
healthy O
male O
subjects O
. O

1 O
. O
Metabolic O
disposition O
of O
( B
14 I
) I
C I
- I
abiraterone I
acetate I
( O
AA O
) O
, O
a O
prodrug O
of O
abiraterone B
was O
assessed O
in O
a O
phase O
I O
, O
open O
- O
label O
, O
single O
- O
dose O
( O
1000 O
mg O
, O
approximately O
100 O
mu O
Ci O
) O
study O
in O
healthy O
males O
( O
18 O
- O
55 O
years O
, O
N O
= O
8 O
) O
. O

Blood O
, O
urine O
, O
and O
faecal O
samples O
were O
obtained O
at O
specified O
timepoints O
for O
determination O
of O
abiraterone B
concentrations O
in O
the O
plasma O
, O
total O
radioactivity O
( O
TR O
) O
, O
and O
the O
metabolite O
profile O
. O

The O
mean O
maximum O
plasma O
concentration O
( O
Cmax O
) O
of O
abiraterone B
was O
10 O
. O
4 O
ng O
/ O
mL O
, O
mean O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
( O
AUC O
) O
from O
0 O
to O
the O
last O
measurable O
plasma O
concentration O
( O
AUC0 O
- O
last O
) O
was O
74 O
. O
8 O
ng O
. O
h O
/ O
mL O
. O

The O
exposures O
for O
TR O
in O
plasma O
( O
Cmax O
= O
3429 O
ng O
. O
eq O
/ O
mL O
; O
AUC0 O
- O
last O
= O
26 O
, O
683 O
ng O
eq O
. O
h O
/ O
mL O
) O
and O
whole O
blood O
( O
Cmax O
= O
1836 O
ng O
. O
eq O
/ O
mL O
; O
AUC0 O
- O
last O
= O
12 O
, O
162 O
ng O
. O
eq O
. O
h O
/ O
mL O
) O
were O
> O
300 O
- O
fold O
higher O
than O
abiraterone B
exposure O
in O
plasma O
. O

3 O
. O
Main O
circulating O
metabolites O
were O
abiraterone B
sulfate I
and O
N B
- I
oxide I
abiraterone I
sulfate I
. O

The O
main O
metabolite O
excreted O
in O
urine O
was O
N B
- I
oxide I
abiraterone I
sulfate I
( O
4 O
. O
22 O
% O
of O
TR O
) O
. O

Major O
components O
of O
TR O
in O
faeces O
were O
unchanged O
AA O
( O
55 O
. O
3 O
% O
of O
TR O
) O
and O
abiraterone B
( O
22 O
. O
3 O
% O
of O
TR O
) O
. O

Here O
the O
effect O
of O
reducing O
cortical O
GABA O
synthesis O
with O
l B
- I
allylglycine I
( O
LAG B
) O
on O
attention O
was O
tested O
using O
three O
different O
versions O
of O
the O
5 O
- O
choice O
serial O
reaction O
time O
task O
( O
5CSRTT O
) O
. O

Intra O
- O
cortical O
LAG B
( O
10 O
mu O
g O
/ O
0 O
. O
5 O
mu O
l O
/ O
side O
) O
infusions O
increased O
Fos O
expression O
and O
resulted O
in O
hyperactivity O
in O
the O
open O
field O
. O

Intra O
- O
cortical O
LAG B
infusions O
did O
not O
affect O
attention O
in O
any O
version O
of O
the O
5CSRTT O
. O

Cytisine B
confers O
neuronal O
protection O
against O
excitotoxic O
injury O
by O
down O
- O
regulating O
GluN2B O
- O
containing O
NMDA O
receptors O
. O

Cytisine B
( O
CYT B
) O
, O
one O
of O
the O
principal O
bioactive O
components O
derived O
from O
the O
seeds O
of O
Cytisus O
laborinum O
L O
, O
has O
been O
widely O
used O
for O
central O
nervous O
system O
( O
CNS O
) O
diseases O
treatment O
. O

The O
present O
study O
investigated O
the O
protective O
effect O
of O
CYT B
on O
cultured O
cortical O
neural O
injury O
induced O
by O
N O
- O
methyl O
- O
d O
- O
aspartate O
( O
NMDA O
) O
. O

Our O
data O
showed O
that O
CYT B
conferred O
protective O
effect O
against O
loss O
of O
cellular O
viability O
induced O
by O
brief O
exposure O
to O
200 O
mu O
M O
NMDA O
in O
a O
concentration O
- O
dependent O
manner O
. O

CYT B
significantly O
inhibited O
the O
neuronal O
apoptosis O
induced O
by O
NMDA O
exposure O
by O
reversing O
intracellular O
Ca O
( O
2 O
+ O
) O
overload O
and O
balancing O
Bcl O
- O
2 O
and O
Bax O
expression O
levels O
. O

Furthermore O
, O
CYT B
significantly O
reversed O
the O
up O
- O
regulation O
of O
GluN2B O
- O
containing O
NMDA O
receptors O
by O
exposure O
to O
NMDA O
, O
but O
it O
did O
not O
affect O
the O
level O
of O
GluN2A O
- O
containing O
NMDA O
receptors O
. O

These O
findings O
suggest O
that O
CYT B
protects O
cortical O
neurons O
, O
at O
least O
partially O
, O
by O
inhibiting O
the O
level O
of O
GluN2B O
- O
containing O
NMDA O
receptors O
and O
regulating O
Bcl O
- O
2 O
family O
. O

In O
this O
study O
, O
we O
performed O
live O
imaging O
analyses O
of O
Neuro O
- O
2a O
cells O
expressing O
SCAT3 O
, O
a O
caspase O
- O
3 O
cleavage O
peptide O
sequence O
linking O
two O
fluorescent O
proteins O
; O
enhanced O
cyan O
fluorescence O
protein O
( O
ECFP O
) O
and O
Venus O
, O
to O
determine O
whether O
sodium O
arsenite O
( O
NaAsO B
( I
2 I
) I
; O
0 O
, O
1 O
, O
5 O
, O
or O
10 O
mu O
M O
) O
affects O
both O
neurite O
outgrowth O
and O
/ O
or O
induces O
apoptosis O
with O
the O
same O
doses O
and O
in O
the O
same O
cell O
cultures O
. O

We O
observed O
that O
the O
area O
ratio O
of O
neurite O
to O
cell O
body O
in O
SCAT3 O
- O
expressing O
cells O
was O
significantly O
reduced O
by O
5 O
and O
10 O
mu O
M O
NaAsO B
( I
2 I
) I
, O
but O
not O
by O
1 O
mu O
M O
, O
although O
the O
emission O
ratio O
of O
ECFP O
to O
Venus O
, O
an O
endpoint O
of O
caspase O
- O
3 O
activity O
, O
was O
not O
changed O
. O

However O
, O
cytological O
assay O
using O
apoptotic O
and O
necrotic O
markers O
resulted O
in O
that O
apoptosis O
, O
but O
not O
necrosis O
, O
was O
significantly O
induced O
in O
Neuro O
- O
2a O
cells O
when O
NaAsO B
( I
2 I
) I
exposure O
continued O
after O
the O
significant O
effects O
of O
NaAsO B
( I
2 I
) I
on O
neurite O
outgrowth O
were O
found O
by O
live O
imaging O
. O

These O
results O
suggested O
that O
neurite O
outgrowth O
was O
suppressed O
by O
NaAsO B
( I
2 I
) I
prior O
to O
NaAsO B
( I
2 I
) I
- O
induced O
apoptosis O
. O

Next O
, O
we O
examined O
the O
effects O
of O
NaAsO B
( I
2 I
) I
on O
cytoskeletal O
gene O
expression O
in O
Neuro O
- O
2a O
cells O
. O

NaAsO B
( I
2 I
) I
increased O
the O
mRNA O
levels O
of O
the O
light O
and O
medium O
subunits O
of O
neurofilament O
and O
decreased O
the O
mRNA O
levels O
of O
tau O
and O
tubulin O
in O
a O
dose O
- O
dependent O
manner O
; O
no O
significant O
effect O
was O
found O
in O
the O
mRNA O
levels O
of O
the O
heavy O
subunit O
of O
neurofilament O
, O
microtubule O
- O
associated O
protein O
2 O
, O
or O
actin O
. O

The O
changes O
in O
cytoskeletal O
gene O
expression O
are O
likely O
responsible O
for O
the O
inhibitory O
effects O
of O
NaAsO B
( I
2 I
) I
on O
neurite O
outgrowth O
. O

Metabolism O
of O
triethylenetetramine B
and O
1 B
, I
12 I
- I
diamino I
- I
3 I
, I
6 I
, I
9 I
- I
triazadodecane I
by O
the O
spermidine O
/ O
spermine O
- O
N O
( O
1 O
) O
- O
acetyltransferase O
and O
thialysine O
acetyltransferase O
. O

Triethylenetetramine B
( O
TETA B
; O
Syprine B
; O
Merck O
Rahway O
, O
NJ O
) O
, O
a O
drug O
for O
Wilson O
' O
s O
disease O
, O
is O
a O
copper O
chelator O
and O
a O
charge O
- O
deficient O
analog O
of O
polyamine O
spermidine O
. O

We O
recently O
showed O
that O
TETA B
is O
metabolized O
in O
vitro O
by O
polyamine O
catabolic O
enzyme O
spermidine O
/ O
spermine O
- O
N O
( O
1 O
) O
- O
acetyltransferase O
( O
SSAT1 O
) O
and O
by O
thialysine O
acetyltransferase O
( O
SSAT2 O
) O
to O
its O
monoacetylated O
derivative O
( O
MAT O
) O
. O

The O
acetylation O
of O
TETA B
is O
increased O
in O
SSAT1 O
- O
overexpressing O
mice O
compared O
with O
wild O
- O
type O
mice O
. O

However O
, O
SSAT1 O
- O
deficient O
mice O
metabolize O
TETA B
at O
the O
same O
rate O
as O
the O
wild O
- O
type O
mice O
, O
indicating O
the O
existence O
of O
another O
N O
- O
acetylase O
respons O
2ible O
for O
its O
metabolism O
in O
mice O
. O

Here O
, O
we O
show O
that O
siRNA O
- O
mediated O
knockdown O
of O
SSAT2 O
in O
HEPG2 O
cells O
and O
in O
primary O
hepatocytes O
from O
the O
SSAT1 O
- O
deficient O
or O
wild O
- O
type O
mice O
reduced O
the O
metabolism O
of O
TETA B
to O
MAT O
. O

By O
contrast O
, O
1 B
, I
12 I
- I
diamino I
- I
3 I
, I
6 I
, I
9 I
- I
triazadodecane I
( O
SpmTrien B
) O
, O
a O
charge O
- O
deficient O
spermine O
analog O
, O
was O
an O
extremely O
poor O
substrate O
of O
human O
recombinant O
SSAT2 O
and O
was O
metabolized O
by O
SSAT1 O
in O
HEPG2 O
cells O
and O
in O
wild O
- O
type O
primary O
hepatocytes O
. O

Thus O
, O
despite O
the O
similar O
structures O
of O
TETA B
and O
SpmTrien B
, O
SSAT2 O
is O
the O
main O
acetylator O
of O
TETA B
, O
whereas O
SpmTrien B
is O
primarily O
acetylated O
by O
SSAT1 O
. O

rSULT2A1 O
catalyzes O
the O
sulfation O
of O
hydroxysteroids B
and O
xenobiotic O
alcoholic O
compounds O
. O

Natural O
products O
as O
sources O
of O
new O
fungicides O
( O
I O
) O
: O
synthesis O
and O
antifungal O
activity O
of O
acetophenone B
derivatives O
against O
phytopathogenic O
fungi O
. O

Several O
series O
of O
45 O
acetophenone B
derivatives O
bearing O
various O
alkyl O
or O
benzyl O
substituents O
were O
conveniently O
synthesized O
and O
their O
structures O
characterized O
by O
( O
1 O
) O
H O
and O
( O
13 O
) O
C O
NMR O
spectroscopy O
, O
HRMS O
and O
single O
- O
crystal O
X O
- O
ray O
analysis O
. O

Of O
them O
, O
12 O
derivatives O
( O
e O
. O
g O
. O
, O
3a O
- O
c O
, O
4c O
and O
4e O
) O
exhibited O
more O
potent O
antifungal O
effects O
on O
some O
phytopathogens O
than O
a O
commercial O
fungicide O
hymexazol B
as O
positive O
control O
. O

The O
preliminary O
structure O
- O
activity O
relationship O
( O
SAR O
) O
studies O
of O
a O
series O
of O
acetophenones B
are O
also O
discussed O
. O

Here O
we O
report O
novel O
ASK1 O
inhibitor O
scaffold O
, O
namely O
5 B
- I
( I
5 I
- I
Phenyl I
- I
furan I
- I
2 I
- I
ylmethylene I
) I
- I
2 I
- I
thioxo I
- I
thiazolidin I
- I
4 I
- I
one I
, O
that O
has O
been O
identified O
using O
virtual O
screening O
and O
biochemical O
tests O
. O

It O
was O
revealed O
that O
the O
most O
active O
compounds O
4 B
- I
( I
( I
5Z I
) I
- I
5 I
- I
{ I
[ I
5 I
- I
( I
4 I
- I
bromophenyl I
) I
- I
2 I
- I
furyl I
] I
methylene I
} I
- I
4 I
- I
oxo I
- I
2 I
- I
thioxo I
- I
1 I
, I
3 I
- I
thiazolidin I
- I
3 I
- I
yl I
) I
butanoic I
acid I
and O
6 O
- O
( O
( O
5Z O
) O
- O
5 O
- O
{ O
[ O
5 O
- O
( O
4 O
- O
bromophenyl O
) O
- O
2 O
- O
furyl O
] O
methylene O
} O
- O
4 O
- O
oxo O
- O
2 O
- O
thioxo O
- O
1 O
, O
3 O
- O

Structure O
- O
activity O
relationships O
of O
33 O
derivatives O
of O
5 B
- I
( I
5 I
- I
Phenyl I
- I
furan I
- I
2 I
- I
ylmethylene I
) I
- I
2 I
- I
thioxo I
- I
thiazolidin I
- I
4 I
- I
one I
have O
been O
studied O
and O
binding O
mode O
of O
this O
chemical O
class O
has O
been O
predicted O
. O

Differential O
cell O
- O
protective O
function O
of O
two O
resveratrol O
( B
trans I
- I
3 I
, I
5 I
, I
4 I
' I
- I
trihydroxystilbene I
) I
glucosides I
against O
oxidative O
stress O
. O

Resveratrol O
( O
trans O
- O
3 O
, O
5 O
, O
4 O
' O
- O
trihydroxystilbene O
; O
RSV B
) O
, O
a O
natural O
polyphenol O
, O
exerts O
a O
beneficial O
effect O
on O
health O
and O
diseases O
. O

RSV B
targets O
and O
activates O
the O
NAD O
( O
+ O
) O
- O
dependent O
protein O
deacetylase O
SIRT1 O
; O
in O
turn O
, O
SIRT1 O
induces O
an O
intracellular O
antioxidative O
mechanism O
by O
inducing O
mitochondrial O
superoxide O
dismutase O
( O
SOD2 O
) O
. O

In O
this O
study O
, O
we O
compared O
the O
effects O
of O
RSV B
and O
two O
glycosyl B
RSVs I
, O
resveratrol B
- I
3 I
- I
O I
- I
beta I
- I
d I
- I
glucoside I
( O
3G B
- I
RSV I
; O
polydatin B
/ O
piceid B
) O
and O
resveratrol B
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucoside I
( O
4 B
' I
G I
- I
RSV I
) O
, O
at O
the O
cellular O
level O
. O

In O
oxygen O
radical O
absorbance O
capacity O
and O
2 O
, O
2 O
- O
diphenyl O
- O
1 O
- O
picrylhydrazyl O
radical O
scavenging O
assays O
, O
the O
antioxidant O
activity O
of O
3G B
- I
RSV I
was O
comparable O
to O
that O
of O
RSV B
, O
whereas O
the O
radical O
- O
scavenging O
efficiency O
of O
4 B
' I
G I
- I
RSV I
was O
less O
than O
50 O
% O
of O
that O
of O
RSV B
. O

However O
, O
4 B
' I
G I
- I
RSV I
, O
but O
not O
3G B
- I
RSV I
, O
induced O
SIRT1 O
- O
dependent O
histone O
H3 O
deacetylation O
and O
SOD2 O
expression O
in O
mouse O
C2C12 O
skeletal O
myoblasts O
; O
as O
with O
RSV B
, O
SIRT1 O
knockdown O
blunted O
these O
effects O
. O

RSV B
and O
4 B
' I
G I
- I
RSV I
, O
but O
not O
3G B
- I
RSV I
, O
mitigated O
oxidative O
stress O
- O
induced O
cell O
death O
in O
C2C12 O
cells O
and O
primary O
neonatal O
rat O
cardiomyocytes O
. O

RSV B
and O
4 B
' I
G I
- I
RSV I
inhibited O
C2C12 O
cell O
proliferation O
, O
but O
3G B
- I
RSV I
did O
not O
. O

RSV B
was O
found O
in O
both O
the O
intracellular O
and O
extracellular O
fractions O
of O
C2C12 O
cells O
that O
had O
been O
incubated O
with O
4 B
' I
G I
- I
RSV I
, O
indicating O
that O
4 B
' I
G I
- I
RSV I
was O
extracellularly O
deglycosylated O
to O
RSV B
, O
which O
was O
then O
taken O
up O
by O
the O
cells O
. O

C2C12 O
cells O
did O
not O
deglycosylate O
3G B
- I
RSV I
. O

Our O
results O
point O
to O
4 B
' I
G I
- I
RSV I
as O
a O
useful O
RSV B
prodrug O
with O
high O
water O
solubility O
. O

Metabolism O
and O
disposition O
of O
vilanterol B
, O
a O
long O
- O
acting O
beta O
( O
2 O
) O
- O
adrenoceptor O
agonist O
for O
inhalation O
use O
in O
humans O
. O

The O
metabolism O
and O
disposition O
of O
vilanterol B
, O
a O
novel O
long O
- O
acting O
beta O
( O
2 O
) O
- O
adrenoceptor O
agonist O
( O
LABA O
) O
for O
inhalation O
use O
, O
was O
investigated O
after O
oral O
administration O
in O
humans O
. O

Single O
oral O
administrations O
of O
up O
to O
500 O
mu O
g O
of O
vilanterol B
were O
shown O
to O
be O
safe O
and O
well O
tolerated O
in O
two O
clinical O
studies O
in O
healthy O
men O
. O

In O
a O
human O
radiolabel O
study O
, O
six O
healthy O
men O
received O
a O
single O
oral O
dose O
of O
200 O
mu O
g O
of O
[ B
( I
14 I
) I
C I
] I
vilanterol I
( O
74 O
kBq O
) O
. O

Plasma O
, O
urine O
, O
and O
feces O
were O
collected O
up O
to O
168 O
hours O
after O
the O
dose O
and O
were O
analyzed O
for O
vilanterol B
, O
metabolites O
, O
and O
radioactivity O
. O

Vilanterol B
represented O
a O
very O
small O
percentage O
( O
< O
0 O
. O
5 O
% O
) O
of O
the O
total O
drug O
- O
related O
material O
in O
plasma O
, O
indicative O
of O
extensive O
first O
- O
pass O
metabolism O
. O

The O
therapeutic O
dose O
level O
for O
vilanterol B
is O
25 O
mu O
g O
by O
the O
inhalation O
route O
. O

In O
addition O
to O
providing O
an O
assessment O
of O
the O
disposition O
of O
vilanterol B
in O
human O
, O
this O
work O
highlights O
a O
number O
of O
complexities O
associated O
with O
determining O
human O
absorption O
, O
distribution O
, O
metabolism O
, O
and O
excretion O
( O
ADME O
) O
for O
inhaled O
molecules O
- O
- O
mainly O
related O
to O
the O
low O
chemical O
doses O
and O
complications O
associated O
with O
the O
inhalation O
route O
of O
administration O
. O

First O
, O
we O
identified O
suitable O
condition O
of O
UV O
- O
irradiation O
( O
3 O
. O
5 O
J O
/ O
cm O
( O
2 O
) O
) O
by O
investigating O
the O
effect O
of O
UVA O
irradiation O
on O
intracellular O
IL O
- O
18 O
on O
untreated O
or O
chloropromazine B
( O
a O
representative O
phototoxic O
compound O
) O
- O
treated O
NCTC2544 O
cells O
. O

Then O
, O
the O
effect O
of O
UVA O
- O
irradiation O
over O
NCTC2544 O
cells O
treated O
with O
increasing O
concentrations O
of O
15 O
compounds O
including O
photoallergens O
( O
benzophenone O
, O
4 B
- I
ter I
- I
butyl I
- I
4 I
- I
methoxy I
- I
dibenzoylmethane I
, I
2 I
- I
ethylexyl I
- I
p I
- I
methoxycinnamate I
, O
ketoprofen O
, O
6 B
- I
methylcumarin I
) O
; O
photoirritant O
and O
photoallergen O
( O
4 B
- I
aminobenzoic I
acid I
, O
chlorpromazine O
, O
promethazine B
) O
; O
photoirritants O
( O
acridine O
, O

ibuprofen O
, O
8 O
- O
methoxypsoralen O
, O
retinoic O
acid O
) O
; O
and O
negative O
compounds O
( O
lactic O
acid O
, O
SDS O
and O
p B
- I
phenilendiamine I
) O
was O
investigated O
. O

Differing O
effects O
of O
PTH O
1 O
- O
34 O
, O
PTH O
1 O
- O
84 O
, O
and O
zoledronic B
acid I
on O
bone O
microarchitecture O
and O
estimated O
strength O
in O
postmenopausal O
women O
with O
osteoporosis O
: O
an O
18 O
- O
month O
open O
- O
labeled O
observational O
study O
using O
HR O
- O
pQCT O
. O

A O
group O
of O
postmenopausal O
osteoporotic O
women O
receiving O
zoledronic B
acid I
( O
5 O
mg O
infusion O
once O
yearly O
, O
n O
= O
33 O
) O
was O
also O
included O
. O

Zoledronic B
acid I
did O
not O
impact O
cortical O
porosity O
at O
either O
site O
but O
increased O
cortical O
thickness O
( O
3 O
. O
0 O
+ O
/ O
- O
3 O
. O
5 O
% O
, O
p O
< O
0 O
. O
01 O
) O
, O
total O
( O
2 O
. O
7 O
+ O
/ O
- O
2 O
. O
5 O
% O
, O
p O
< O
0 O
. O
001 O
) O
and O
cortical O
density O
( O
1 O
. O
5 O
+ O
/ O
- O
2 O
. O
0 O
% O
, O
p O
< O
0 O
. O
01 O
) O
in O
tibia O
as O
well O
as O
trabecular O
volume O
fraction O
in O
radius O
( O
2 O
. O
5 O
+ O
/ O
- O
5 O
. O
1 O
% O
, O
p O
< O
0 O
. O
05 O
) O
and O
tibia O
( O
2 O
. O
2 O

FE O
estimated O
bone O
strength O
was O
preserved O
, O
but O
not O
increased O
, O
with O
PTH O
1 O
- O
34 O
and O
zoledronic B
acid I
at O
both O
sites O
, O
whereas O
it O
decreased O
with O
PTH O
1 O
- O
84 O
in O
radius O
( O
- O
2 O
. O
8 O
+ O
/ O
- O
5 O
. O
8 O
% O
, O
p O
< O
0 O
. O
05 O
) O
and O
tibia O
( O
- O
3 O
. O
9 O
+ O
/ O
- O
4 O
. O
8 O
% O
, O
p O
< O
0 O
. O
001 O
) O
. O

Conclusively O
, O
divergent O
treatment O
- O
specific O
effects O
in O
cortical O
and O
trabecular O
bone O
were O
observed O
with O
anabolic O
and O
zoledronic B
acid I
therapy O
. O

Interspecies O
variation O
in O
the O
metabolism O
of O
zoniporide B
by O
aldehyde O
oxidase O
. O

2 O
. O
Current O
studies O
explored O
in O
vitro O
metabolism O
of O
zoniporide B
in O
various O
animal O
species O
and O
humans O
using O
S9 O
fractions O
. O

4 O
. O
All O
animals O
except O
the O
dog O
and O
cat O
converted O
zoniporide B
to O
2 B
- I
oxozoniporide I
( O
M1 O
) O
. O

5 O
. O
Michael O
- O
Menten O
kinetic O
studies O
were O
conducted O
in O
species O
that O
turned O
over O
zoniporide B
to O
M1 O
. O

6 O
. O
Marked O
differences O
in O
KM O
, O
Vmax O
and O
Clint O
were O
observed O
in O
the O
oxidation O
of O
zoniporide B
. O

7 O
. O
Although O
the O
KM O
and O
Vmax O
of O
zoniporide B
oxidation O
in O
male O
and O
female O
human O
S9 O
was O
similar O
, O
some O
gender O
difference O
was O
observed O
in O
animals O
especially O
, O
in O
Vmax O
. O

8 O
. O
The O
domestic O
animals O
also O
showed O
marked O
species O
differences O
in O
the O
AO O
activity O
and O
affinity O
toward O
zoniporide B
. O

Complex O
yet O
appealing O
rutile O
TiO O
( O
2 O
) O
flower O
films O
are O
, O
for O
the O
first O
time O
, O
directly O
hydrothermally O
grown O
on O
a O
transparent O
conducting O
fluorine B
- I
doped I
tin I
oxide I
( O
FTO O
) O
substrate O
. O

We O
demonstrate O
that O
treatment O
with O
a O
highly O
- O
selective O
novel O
MC4R O
agonist O
( O
BIM B
- I
22493 I
or O
RM B
- I
493 I
) O
resulted O
in O
transient O
decreases O
in O
food O
intake O
( O
35 O
% O
) O
, O
with O
persistent O
weight O
loss O
over O
8 O
weeks O
of O
treatment O
( O
13 O
. O
5 O
% O
) O
in O
a O
diet O
- O
induced O
obese O
nonhuman O
primate O
model O
. O

Importantly O
, O
we O
observed O
no O
increases O
in O
blood O
pressure O
or O
heart O
rate O
with O
BIM B
- I
22493 I
treatment O
. O

In O
contrast O
, O
treatment O
with O
LY2112688 B
, O
an O
MC4R O
agonist O
previously O
shown O
to O
increase O
blood O
pressure O
and O
heart O
rate O
in O
humans O
, O
caused O
increases O
in O
blood O
pressure O
and O
heart O
rate O
, O
while O
modestly O
decreasing O
food O
intake O
. O

Magnesium B
sulfate I
treatment O
against O
sarin O
poisoning O
: O
dissociation O
between O
overt O
convulsions O
and O
recorded O
cortical O
seizure O
activity O
. O

Magnesium B
sulfate I
( O
MGS B
) O
is O
used O
to O
suppress O
eclamptic O
seizures O
in O
pregnant O
women O
with O
hypertension O
and O
was O
shown O
to O
block O
kainate O
- O
induced O
convulsions O
. O

Magnesium B
sulfate I
was O
evaluated O
herein O
as O
an O
anticonvulsant O
against O
sarin O
poisoning O
and O
its O
efficacy O
was O
compared O
with O
the O
potent O
anticonvulsants O
midazolam O
( O
MDZ O
) O
and O
caramiphen O
( O
CRM B
) O
. O

Rats O
were O
exposed O
to O
a O
convulsant O
dose O
of O
sarin O
( O
96 O
mu O
g O
/ O
kg O
, O
im O
) O
and O
1 O
min O
later O
treated O
with O
the O
oxime O
TMB4 B
and O
atropine B
to O
increase O
survival O
. O

Five O
minutes O
after O
initiation O
of O
convulsions O
, O
MGS B
, O
CRM B
, O
or O
MDZ O
were O
administered O
. O

However O
, O
radio O
- O
telemetric O
electro O
- O
corticography O
( O
ECoG O
) O
monitoring O
demonstrated O
sustained O
seizure O
activity O
in O
MGS B
- O
injected O
animals O
while O
this O
activity O
was O
completely O
blocked O
by O
MDZ O
and O
CRM B
. O

Additionally O
, O
histopathological O
analyses O
of O
MGS B
- O
treated O
group O
showed O
typical O
sarin O
- O
induced O
brain O
injury O
excluding O
the O
hippocampus O
that O
was O
partially O
protected O
. O

Our O
results O
clearly O
show O
that O
MGS B
demonstrated O
misleading O
features O
as O
an O
anticonvulsant O
against O
sarin O
- O
induced O
seizures O
. O

Cu O
- O
dependent O
tyrosinase O
activity O
was O
also O
markedly O
reduced O
in O
both O
types O
of O
CLDN O
knockdown O
cells O
when O
incubated O
with O
the O
substrate O
l B
- I
DOPA I
. O

INO B
- I
8875 I
, O
a O
highly O
selective O
A1 O
adenosine O
receptor O
agonist O
: O
evaluation O
of O
chronotropic O
, O
dromotropic O
, O
and O
hemodynamic O
effects O
in O
rats O
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
evaluate O
the O
cardiovascular O
profile O
of O
INO B
- I
8875 I
, O
a O
highly O
selective O
A O
( O
1 O
) O
R O
agonist O
, O
and O
to O
compare O
its O
properties O
with O
N B
- I
[ I
3 I
( I
R I
) I
- I
tetrahydrofuranyl I
] I
- I
6 I
- I
aminopurine I
riboside I
( O
CVT B
- I
510 I
) O
, O
which O
has O
already O
been O
shown O
to O
induce O
negative O
dromotropic O
effects O
with O
minimal O
cardiovascular O
side O
effects O
in O
animals O
and O
in O
clinical O
studies O
. O

Dose O
- O
response O
experiments O
in O
the O
isolated O
hearts O
of O
rats O
were O
used O
to O
evaluate O
the O
functional O
selectivity O
of O
INO B
- I
8875 I
for O
the O
slowing O
of O
A O
- O
V O
- O
nodal O
conduction O
. O

Ventilated O
adult O
rats O
were O
used O
to O
study O
the O
effects O
of O
INO B
- I
8875 I
, O
in O
vivo O
, O
on O
arterial O
blood O
pressure O
as O
well O
as O
on O
supraventricular O
electrophysiology O
. O

Ex O
vivo O
, O
INO B
- I
8875 I
( O
100 O
nM O
to O
3 O
mu O
M O
) O
progressively O
prolonged O
A O
- O
V O
- O
nodal O
conduction O
without O
reducing O
left O
ventricular O
function O
or O
coronary O
resistance O
. O

In O
vivo O
, O
INO B
- I
8875 I
up O
to O
a O
dose O
of O
50 O
mu O
g O
/ O
kg O
did O
not O
reduce O
the O
carotid O
arterial O
blood O
pressure O
( O
n O
= O
4 O
) O
. O

INO B
- I
8875 I
( O
1 O
- O
50 O
mu O
g O
/ O
kg O
) O
and O
CVT B
- I
510 I
( O
20 O
and O
50 O
mu O
g O
/ O
kg O
) O
both O
induced O
a O
dose O
- O
dependent O
decrease O
in O
heart O
rate O
and O
atrial O
refractoriness O
, O
as O
well O
as O
slowing O
of O
A O
- O
V O
- O
nodal O
conduction O
. O

However O
, O
compared O
with O
CVT B
- I
510 I
, O
the O
activity O
of O
INO B
- I
8875 I
was O
more O
pronounced O
in O
A O
- O
V O
- O
nodal O
function O
. O

INO B
- I
8875 I
exhibited O
a O
greater O
duration O
of O
action O
, O
lasting O
up O
to O
2 O
. O
5 O
hours O
post O
dosing O
, O
whereas O
the O
effects O
of O
CVT B
- I
510 I
dissipated O
over O
1 O
hour O
. O

INO B
- I
8875 I
demonstrates O
functional O
properties O
of O
a O
highly O
selective O
A O
( O
1 O
) O
R O
agonist O
. O

INO B
- I
8875 I
exhibits O
an O
increased O
dromotropic O
effect O
and O
greater O
duration O
of O
action O
compared O
with O
CVT B
- I
510 I
. O

Resistance O
of O
mosquitoes O
to O
organochlorines B
, O
organophosphates O
, O
carbamates O
and O
pyrethroids O
led O
to O
a O
regain O
of O
interest O
for O
the O
use O
of O
neonicotinoid O
insecticides O
in O
vector O
control O
. O

Suppressive O
effect O
of O
accumulated O
aluminum B
trichloride I
on O
the O
hepatic O
microsomal O
cytochrome O
P450 O
enzyme O
system O
in O
rats O
. O

Thus O
, O
the O
aim O
of O
this O
study O
is O
to O
investigate O
the O
effects O
of O
aluminum B
trichloride I
( O
AlCl B
( I
3 I
) I
) O
on O
CYPS O
in O
rats O
. O

Forty O
male O
Wistar O
rats O
( O
5weeks O
old O
) O
weighing O
110 O
- O
120g O
were O
randomly O
allocated O
and O
orally O
exposed O
to O
0 O
, O
64 O
. O
18 O
, O
128 O
. O
36 O
and O
256 O
. O
72mg O
/ O
kg O
body O
weight O
( O
BW O
) O
AlCl B
( I
3 I
) I
in O
drinking O
water O
for O
120days O
. O

The O
body O
weight O
( O
BW O
) O
of O
rats O
, O
hepatosomatic O
index O
( O
HSI O
) O
, O
hepatic O
Al O
content O
, O
the O
concentrations O
of O
cytochrome O
P450 O
( O
CYP450 O
) O
, O
cytochrome O
B5 O
( O
B5 O
) O
, O
microsomal O
protein O
and O
the O
activities O
of O
NADPH O
- O
cytochrome O
c O
reductase O
( O
CR O
) O
, O
aminopyrin B
N O
- O
demethylase O
( O
AND O
) O
, O
erythromycin O
N O
- O
demethylase O
( O
ERND O
) O
and O
aniline O
- O
4 O
- O
hydeoxylase O
( O
AH O
) O
were O
assessed O

The O
results O
revealed O
that O
exposure O
to O
AlCl B
( I
3 I
) I
inhibited O
the O
microsomal O
CYP450 O
dependent O
enzyme O
system O
of O
liver O
. O

Our O
findings O
suggest O
that O
long O
term O
daily O
exposure O
of O
AlCl B
( I
3 I
) I
exerts O
the O
suppressive O
effects O
and O
thus O
may O
cause O
dysfunction O
of O
hepatic O
CYP450 O
dependent O
enzyme O
system O
of O
rat O
. O

These O
biochemical O
variations O
include O
the O
degree O
and O
positioning O
of O
d B
- I
alanyl I
and O
glycosyl O
substitution O
in O
lipoteichoic O
acids O
, O
and O
acetylation O
of O
peptidoglycan O
. O

Owing O
to O
their O
unique O
physical O
and O
chemical O
properties O
, O
graphene O
and O
its O
derivatives O
such O
as O
graphene O
oxide O
( O
GO O
) O
, O
reduced B
graphene I
oxide I
( O
RGO B
) O
and O
GO O
- O
nanocomposites O
have O
attracted O
tremendous O
interest O
in O
many O
different O
fields O
including O
biomedicine O
in O
recent O
years O
. O

In O
the O
present O
study O
, O
ESB O
values O
are O
reported O
for O
34 O
polycyclic B
aromatic I
hydrocarbon I
, O
32 O
other O
organic O
contaminants O
, O
and O
seven O
metals O
( O
cadmium O
, O
chromium O
, O
copper O
, O
nickel O
, O
lead O
, O
silver O
, O
zinc O
) O
. O

Exposures O
to O
1 B
, I
3 I
- I
dimethylamylamine I
- O
containing O
products O
reported O
to O
Texas O
poison O
centers O
. O

1 B
, I
3 I
- I
Dimethylamylamine I
( O
DMAA B
) O
is O
an O
ingredient O
in O
a O
number O
of O
weight O
loss O
and O
exercise O
performance O
enhancing O
products O
. O

However O
, O
information O
on O
the O
safety O
of O
DMAA B
- O
containing O
products O
is O
limited O
. O

Exposures O
to O
DMAA B
- O
containing O
products O
reported O
to O
Texas O
poison O
centers O
during O
2010 O
- O
2011 O
were O
identified O
and O
selected O
factors O
were O
examined O
. O

The O
most O
common O
treatments O
were O
dilution O
( O
41 O
. O
1 O
% O
) O
, O
food O
( O
19 O
. O
6 O
% O
) O
, O
and O
activated O
charcoal B
( O
14 O
. O
3 O
% O
) O
. O

It O
should O
be O
noted O
that O
the O
adverse O
clinical O
effects O
may O
be O
due O
to O
other O
ingredients O
in O
the O
DMAA B
- O
containing O
products O
, O
such O
as O
caffeine O
. O

The O
present O
evaluation O
concerns O
the O
concentrations O
of O
the O
blended O
phosphates O
( O
also O
known O
as O
polyphosphates O
, O
condensed O
complex O
phosphates O
, O
polyphosphate O
glassy O
balls O
, O
and O
pyrophosphates B
) O
intended O
to O
aid O
regulatory O
agencies O
in O
decisions O
to O
avoid O
contact O
with O
affected O
water O
. O

Ingested O
polyphosphates O
are O
degraded O
by O
phosphatase O
enzymes O
to O
monophosphates B
, O
substances O
that O
are O
over O
- O
the O
- O
counter O
bowel O
purgatives O
. O

High O
oral O
doses O
of O
the O
monophosphates B
can O
induce O
transient O
hyperphosphatemia O
in O
older O
and O
susceptible O
young O
people O
, O
which O
can O
lead O
to O
acute O
phosphate O
nephropathy O
. O

Based O
on O
the O
acute O
diarrhea O
after O
the O
ingestion O
of O
a O
single O
oral O
dose O
of O
monobasic O
( O
NaH2PO B
( I
4 I
) I
) O
and O
dibasic O
( O
Na2HPO B
( I
4 I
) I
) O
monophosphates B
in O
adults O
, O
a O
do O
not O
consume O
concentration O
of O
600 O
mg O
PO B
( I
4 I
) I
/ O
L O
can O
be O
derived O
. O

Based O
on O
mild O
local O
irritation O
after O
topical O
application O
of O
1 O
. O
0 O
% O
sodium B
metaphosphate I
[ O
( B
NaPO I
( I
3 I
) I
) I
6 I
* I
H2O I
] O
to O
intact O
skin O
of O
sensitive O
volunteers O
, O
a O
do O
not O
use O
concentration O
of O
8 O
, O
000 O
mg O
PO4 B
/ O
L O
can O
be O
assigned O
. O

Given O
the O
lack O
of O
eye O
irritation O
in O
rabbits O
after O
direct O
instillation O
of O
0 O
. O
2 O
% O
( B
NaPO I
( I
3 I
) I
) I
6 I
* I
H2O I
, O
an O
acute O
ocular O
contact O
limit O
of O
50 O
mg O
PO4 B
/ O
L O
serves O
as O
the O
overall O
do O
not O
use O
level O
. O

Platinum O
complexes O
such O
as O
cisplatin O
and O
caboplatin B
are O
widely O
used O
in O
cancer O
chemotherapy O
. O

Most O
studies O
were O
carried O
out O
with O
naturally O
occurring O
heterocyclic O
compounds O
such O
as O
plant O
polyphenols O
: O
flavonoids O
, O
xanthones O
, O
coumarins O
, O
and O
ellagitannins B
, O
or O
plant O
derived O
products O
( O
juices O
, O
extracts O
, O
supplements O
) O
rich O
in O
bioactive O
heterocyclic O
compounds O
. O

FoxA1 O
corrupts O
the O
antiandrogenic O
effect O
of O
bicalutamide O
but O
only O
weakly O
attenuates O
the O
effect O
of O
MDV3100 B
( O
Enzalutamide O
( O
TM O
) O
) O
. O

Here O
we O
compare O
the O
antiandrogenic O
capacity O
of O
BIC O
to O
a O
new O
antiandrogen O
, O
MDV3100 B
( O
MDV O
) O
or O
Enzalutamide O
( O
TM O
) O
. O

While O
bacterial O
infections O
are O
now O
successfully O
treated O
with O
repeated O
inhalation O
of O
antibiotics O
such O
as O
tobramycine B
, O
57 O
% O
of O
CF O
patients O
are O
colonized O
by O
Aspergillus O
species O
. O

While O
current O
standard O
of O
treatment O
of O
ABPA O
in O
CF O
patients O
is O
to O
suppress O
the O
allergy O
related O
symptoms O
by O
administration O
of O
glucocorticoids O
, O
itraconazole O
( O
ITRA B
) O
, O
administered O
orally O
at O
high O
doses O
, O
can O
alleviate O
the O
symptoms O
of O
ABPA O
. O

However O
, O
no O
inhalable O
formulation O
of O
ITRA B
is O
available O
to O
enable O
local O
treatment O
of O
aspergillosis O
. O

The O
aim O
of O
this O
study O
was O
to O
describe O
an O
aqueous O
nanosuspension O
of O
ITRA B
and O
to O
characterize O
the O
pharmacokinetics O
after O
single O
dose O
inhalation O
. O

Using O
wet O
- O
milling O
with O
organic O
milling O
beads O
, O
a O
stable O
nanosuspension O
with O
particle O
size O
in O
the O
range O
of O
200nm O
and O
an O
ITRA B
concentration O
of O
20 O
% O
( O
v O
/ O
w O
) O
could O
be O
obtained O
, O
using O
polysorbate B
80 I
at O
a O
concentration O
of O
14 O
% O
relative O
to O
ITRA B
. O

The O
data O
indicate O
that O
ITRA B
nanosuspension O
represents O
an O
interesting O
formulation O
for O
inhaled O
administration O
in O
CF O
patients O
suffering O
from O
ABPA O
. O

Adenosine O
levels O
and O
receptor O
- O
mediated O
effects O
of O
adenosine O
are O
regulated O
by O
intracellular O
ATP O
consumption O
, O
cellular O
release O
of O
ATP O
, O
metabolism O
of O
extracellular O
ATP O
( O
and O
other O
adenine B
nucleotides I
) O
, O
adenosine O
influx O
, O
adenosine O
efflux O
and O
adenosine O
metabolism O
. O

The O
toxicity O
of O
the O
N B
- I
hydroxy I
and O
6 B
- I
hydroxy I
metabolites O
of O
3 B
, I
4 I
- I
dichloropropionanili I
does O
not O
depend O
on O
calcium O
release O
- O
activated O
calcium O
channel O
inhibition O
. O

( O
Kiely O
, O
T O
. O
, O
Donaldson O
, O
D O
. O
, O
and O
Grube O
, O
A O
. O
[ O
2004 O
] O
. O
Pesticide O
Industry O
Sales O
and O
Usage O
. O
2000 O
and O
2001 O
Market O
Estimates O
. O
Available O
at O
: O
http O
: O
/ O
/ O
www O
. O
epa O
. O
gov O
/ O
pesticides O
/ O
pestsales O
/ O
01pestsales O
/ O
market O
_ O
estimates2001 O
. O
pdf O
. O
Accessed O
October O
25 O
, O
2012 O
. O
) O
Propanil B
( O
3 B
, I
4 I
- I
dichloropropionanili I
[ O
DCPA B
] O
) O
is O
a O
commonly O
used O
herbicide O
in O
the O
United O
States O
, O
with O
2 O
- O
4 O
million O

The O
immunomodulatory O
effects O
of O
DCPA B
have O
been O
well O
documented O
, O
but O
limited O
data O
are O
available O
on O
the O
effects O
of O
its O
metabolites O
. O

( O
Salazar O
, O
K O
. O
D O
. O
, O
Ustyugova O
, O
I O
. O
V O
. O
, O
Brundage O
, O
K O
. O
M O
. O
, O
Barnett O
, O
J O
. O
B O
. O
, O
and O
Schafer O
, O
R O
. O
[ O
2008 O
] O
. O
A O
review O
of O
the O
immunotoxicity O
of O
the O
pesticide O
3 B
, I
4 I
- I
dichloropropionanali I
. O
J O
. O
Toxicol O
. O
Environ O
. O
Health O
B O
Crit O
. O
Rev O
. O
11 O
, O
630 O
- O
645 O
. O
) O
In O
mammals O
, O
hepatic O
enzymes O
metabolize O
DCPA B
, O
resulting O
in O
the O
production O
of O
3 O
, O
4 O
- O

dichloroaniline O
( O
DCA B
) O
. O

Further O
biotransformation O
of O
DCA B
leads O
to O
the O
production O
of O
6 B
- I
hydroxy I
- I
3 I
, I
4 I
- I
dichloroaniline I
( O
6OH B
- I
DCA I
) O
and O
N B
- I
hydroxy I
- I
3 I
, I
4 I
- I
dichloroaniline I
( O
NOH B
- I
DCA I
) O
. O

We O
report O
, O
for O
the O
first O
time O
, O
the O
immunotoxic O
effects O
of O
DCPA B
metabolites O
on O
T O
- O
cell O
function O
. O

Human O
Jurkat O
T O
cells O
were O
exposed O
to O
varying O
concentrations O
of O
DCPA B
or O
its O
metabolites O
and O
assayed O
for O
effects O
on O
T O
- O
cell O
function O
. O

In O
addition O
, O
fluorine O
analogs O
of O
DCPA B
and O
DCA B
were O
investigated O
to O
determine O
the O
relative O
role O
of O
chlorine O
substituents O
on O
T O
- O
cell O
immunotoxicity O
. O

Here O
we O
report O
that O
exposure O
of O
Jurkat O
T O
cells O
to O
DCPA B
and O
DCA B
alters O
IL O
- O
2 O
secretion O
, O
nuclear O
factor O
of O
activated O
T O
cells O
( O
NFAT O
) O
activity O
, O
and O
calcium O
influx O
. O

However O
, O
exposure O
to O
6OH B
- I
DCA I
and O
NOH B
- I
DCA I
reduces O
IL O
- O
2 O
secretion O
and O
NFAT O
activity O
but O
has O
no O
effect O
on O
calcium O
flux O
. O

When O
both O
chlorines B
in O
DCPA B
and O
DCA B
were O
substituted O
with O
fluorines B
all O
effects O
were O
abrogated O
. O

Our O
data O
indicate O
that O
metabolites O
of O
DCPA B
have O
differential O
effects O
on O
T O
- O
cell O
function O
and O
the O
presence O
of O
chlorines B
plays O
an O
important O
role O
in O
eliciting O
these O
effects O
. O

Metabolism O
and O
quantification O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
, O
a O
new O
TSPO O
positron O
emission O
tomography O
radioligand O
. O

[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
[ O
N B
, I
N I
- I
diethyl I
- I
2 I
- I
( I
2 I
- I
( I
4 I
- I
( I
2 I
[ I
( I
18 I
) I
F I
] I
- I
fluoroethoxy I
) I
phenyl I
) I
5 I
, I
7dimethylpyrazolo I
[ I
1 I
, I
5a I
] I
pyrimidin I
- I
3 I
- I
yl I
) I
acetamide I
] O
is O
a O
new O
radioligand O
currently O
used O
for O
imaging O
the O
18 O
- O
kDa O
translocator O
protein O
in O
animal O
models O
of O
neuroinflammation O
and O
recently O
in O
humans O
. O

The O
biodistribution O
by O
positron O
emission O
tomography O
( O
PET O
) O
in O
baboons O
and O
the O
in O
vitro O
and O
in O
vivo O
metabolism O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
were O
investigated O
in O
rats O
, O
baboons O
, O
and O
humans O
. O

The O
liver O
was O
a O
major O
route O
of O
elimination O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
, O
and O
urine O
was O
a O
route O
of O
excretion O
for O
radiometabolites O
. O

Rat O
microsomal O
incubations O
and O
analyses O
by O
liquid O
chromatography O
- O
mass O
spectrometry O
( O
LC O
- O
MS O
) O
identified O
seven O
metabolites O
, O
characterized O
as O
O B
- I
deethyl I
, O
hydroxyl O
, O
and O
N B
- I
deethyl I
derivatives O
of O
nonradioactive O
DPA B
- I
714 I
, O
two O
of O
them O
having O
the O
same O
retention O
times O
than O
those O
detected O
in O
rat O
and O
baboon O
plasma O
. O

O O
- O
deethylation O
led O
to O
a O
nonradioactive O
compound O
and O
[ B
( I
18 I
) I
F I
] I
fluoroacetic I
acid I
. O

Finally O
an O
easy O
, O
rapid O
, O
and O
accurate O
method O
- O
- O
indispensable O
for O
PET O
quantitative O
clinical O
studies O
- O
- O
for O
quantifying O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
by O
solid O
- O
phase O
extraction O
was O
developed O
. O

In O
vivo O
, O
an O
extensive O
metabolism O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
was O
observed O
in O
rats O
and O
baboons O
, O
identified O
as O
[ B
( I
18 I
) I
F I
] I
deethyl I
, O
[ B
( I
18 I
) I
F I
] I
hydroxyl I
, O
and O
[ B
( I
18 I
) I
F I
] I
carboxylic I
acid I
derivatives O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
. O

Here O
, O
we O
show O
that O
a O
kinase O
- O
inducible O
bimolecular O
switch O
comprising O
a O
kinase O
- O
specific O
substrate O
and O
a O
phosphoamino B
acid I
binding O
domain O
can O
be O
used O
for O
acute O
regulation O
of O
cellular O
events O
. O

As O
a O
proof O
of O
concept O
, O
we O
employed O
a O
Protein O
Kinase O
A O
( O
PKA O
) O
- O
dependent O
switch O
and O
coupled O
it O
to O
a O
lipid O
phosphatase O
to O
manipulate O
the O
level O
of O
phosphatidylinositol O
4 O
, O
5 O
- O
bisphosphate O
( O
PI B
( I
4 I
, I
5 I
) I
P I
( I
2 I
) I
) O
in O
living O
cells O
. O

PKA O
activation O
results O
in O
rapid O
degradation O
of O
PI B
( I
4 I
, I
5 I
) I
P I
( I
2 I
) I
. O

Conversely O
, O
when O
PKA O
is O
inhibited O
, O
dephosphorylation O
of O
the O
switch O
leads O
to O
the O
replenishment O
of O
PI B
( I
4 I
, I
5 I
) I
P I
( I
2 I
) I
. O

The O
present O
work O
first O
describes O
the O
synthesis O
and O
characterization O
of O
five O
new O
O B
- I
2 I
, I
O I
- I
3 I
permethylated I
O I
- I
6 I
alkylthio I
- I
and I
perfluoroalkyl I
- I
propanethio I
- I
amphiphilic I
beta I
- I
cyclodextrins I
. O

Fingolimod O
( O
FTY720 B
) O
, O
a O
novel O
drug O
approved O
for O
the O
treatment O
of O
relapsing O
- O
remitting O
multiple O
sclerosis O
, O
activates O
different O
sphingosine O
- O
1 O
- O
phosphate O
receptor O
( O
S1PR O
) O
subtypes O
. O

However O
, O
recent O
evidence O
suggests O
that O
the O
action O
of O
FTY720 B
involves O
S1PRs O
expressed O
by O
cells O
resident O
in O
the O
CNS O
, O
including O
neurons O
. O

Here O
, O
we O
examined O
the O
effect O
of O
FTY720 B
, O
its O
active O
metabolite O
, O
FTY720 B
- I
P I
, O
and O
sphingosine O
- O
1 O
- O
phosphate O
( O
S1P O
) O
on O
neuronal O
viability O
using O
a O
classical O
in O
vitro O
model O
of O
excitotoxic O
neuronal O
death O
. O

FTY720 B
, O
FTY720 B
- I
P I
, O
and O
S1P O
were O
all O
neuroprotective O
when O
applied O
18 O
- O
20 O
h O
prior O
to O
the O
NMDA O
pulse O
. O

Neuroprotection O
was O
attenuated O
by O
pertussis O
toxin O
, O
and O
inhibited O
by O
the O
selective O
type O
- O
1 O
S1PR O
( O
S1P1R O
) O
antagonist O
, O
W146 B
, O
and O
by O
inhibitors O
of O
the O
mitogen O
associated O
protein O
kinase O
( O
MAPK O
) O
and O
the O
phosphatidylinositol O
- O
3 O
- O
kinase O
( O
PtdIns O
- O
3 O
- O
K O
) O
pathways O
. O

Both O
FTY720 B
and O
FTY720 B
- I
P I
retained O
their O
protective O
activity O
in O
pure O
cultures O
of O
mouse O
or O
rat O
cortical O
neurons O
. O

These O
data O
offer O
the O
first O
direct O
demonstration O
that O
FTY720 B
and O
its O
active O
metabolite O
protect O
neurons O
against O
excitotoxic O
death O
. O

An O
anticancer O
drug O
, O
doxorubicin B
hydrochloride I
( O
Dox O
) O
, O
has O
been O
loaded O
into O
MSNs O
and O
HA O
- O
MSNs O
as O
drug O
delivery O
vehicles O
. O

Intestinal O
porcine O
epithelial O
cells O
derived O
from O
the O
jejunum O
of O
piglets O
were O
exposed O
to O
DON O
and O
a O
mycotoxin O
binder O
( O
efficacy O
testing O
) O
or O
exposed O
to O
tylosin B
and O
a O
mycotoxin O
binder O
( O
drug O
interaction O
testing O
) O
. O

Active O
carbon O
and O
bentonite B
were O
used O
in O
the O
efficacy O
and O
drug O
interaction O
trials O
, O
respectively O
, O
to O
validate O
the O
developed O
model O
. O

The O
evaluated O
parameters O
were O
passage O
of O
DON O
and O
tylosin B
through O
the O
epithelial O
monolayer O
, O
the O
integrity O
of O
the O
monolayer O
by O
measurements O
of O
the O
trans O
- O
epithelial O
electrical O
resistance O
and O
the O
viability O
of O
the O
monolayer O
using O
the O
neutral O
red O
assay O
. O

In O
our O
drug O
interaction O
model O
, O
the O
interaction O
between O
tylosin B
and O
mycotoxin O
binders O
was O
investigated O
as O
some O
authors O
suggest O
binding O
of O
macrolide O
antibiotics O
to O
bentonite B
clays O
. O

Indeed O
, O
a O
bentonite B
clay O
showed O
decreased O
passage O
of O
tylosin B
through O
the O
epithelial O
monolayer O
, O
indicating O
binding O
of O
tylosin B
by O
bentonite B
. O

This O
indicates O
that O
the O
combined O
use O
of O
bentonite B
and O
tylosin B
in O
the O
feed O
could O
lead O
to O
therapy O
failure O
. O

The O
modified O
gluco O
- O
mannan O
binder O
did O
not O
alter O
the O
passage O
of O
tylosin B
significantly O
, O
indicating O
safe O
combined O
use O
. O

The O
peak O
GH O
responses O
were O
significantly O
lower O
with O
the O
ARG B
test O
( O
median O
4 O
. O
43 O
mu O
g O
/ O
L O
) O
( O
p O
< O
0 O
. O
0001 O
) O
than O
with O
the O
ITT O
( O
median O
9 O
. O
38 O
mu O
g O
/ O
L O
) O
, O
and O
the O
peak O
GH O
responses O
with O
the O
GHRP O
- O
2 O
test O
( O
median O
28 O
. O
88 O
mu O
g O
/ O
L O
) O
were O
higher O
( O
p O
< O
0 O
. O
0001 O
) O
. O

However O
, O
among O
the O
AGHD O
patients O
, O
there O
was O
no O
significant O
difference O
between O
the O
peak O
GH O
responses O
to O
the O
ARG B
test O
and O
the O
ITT O
. O

The O
sensitivities O
and O
specificities O
of O
the O
ARG B
/ O
GHRP O
- O
2 O
tests O
compared O
to O
the O
ITT O
for O
the O
diagnosis O
of O
severe O
AGHD O
( O
peak O
GH O
responses O
to O
ITT O
< O
= O
1 O
. O
8 O
mu O
g O
/ O
L O
) O
were O
93 O
. O
8 O
% O
/ O
81 O
. O
3 O
% O
and O
85 O
. O
5 O
% O
/ O
94 O
. O
5 O
% O
, O
respectively O
. O

Improved O
preparation O
of O
methyl B
bis I
( I
2 I
, I
2 I
, I
2 I
- I
trifluoroethoxy I
) I
- I
bromophosphonoacetat I
for O
the O
stereoselective O
synthesis O
of O
( B
E I
) I
- I
alpha I
- I
bromoacrylates I
. O

We O
have O
established O
an O
efficient O
method O
for O
preparing O
methyl B
bis I
( I
2 I
, I
2 I
, I
2 I
- I
trifluoroethoxy I
) I
bromophosphonoacetat I
, O
which O
we O
developed O
for O
the O
stereoselective O
synthesis O
of O
( B
E I
) I
- I
alpha I
- I
bromoacrylates I
. O

This O
improved O
method O
enables O
the O
reagent O
to O
be O
prepared O
reproducibly O
in O
one O
step O
from O
methyl B
bis I
( I
2 I
, I
2 I
, I
2 I
- I
trifluoroethoxy I
) I
phosphonoacetate I
. O

Toxic O
effects O
of O
microcystin B
- I
LR I
on O
the O
reproductive O
system O
of O
male O
Rana O
nigromaculata O
in O
vitro O
. O

This O
study O
aims O
to O
demonstrate O
that O
microcystin B
- I
LR I
( O
MC B
- I
LR I
) O
has O
toxic O
effects O
on O
the O
reproductive O
system O
of O
male O
Rana O
nigromaculata O
in O
vitro O
. O

Results O
show O
that O
exposure O
to O
1 O
nmol O
/ O
L O
to O
100 O
nmol O
/ O
L O
of O
MC B
- I
LR I
decreased O
sperm O
motility O
and O
number O
of O
sperm O
cells O
and O
increased O
the O
sperm O
abnormality O
rate O
, O
whose O
values O
were O
significantly O
different O
from O
those O
of O
the O
control O
( O
P O
< O
0 O
. O
01 O
) O
. O

Moreover O
, O
the O
same O
dosage O
of O
MC B
- I
LR I
increased O
reactive O
oxygen O
species O
production O
and O
malondialdehyde O
content O
. O

The O
results O
demonstrate O
for O
the O
first O
time O
that O
MC B
- I
LR I
could O
induce O
toxicity O
in O
the O
male O
reproductive O
system O
of O
R O
. O
nigromaculata O
. O

The O
findings O
in O
this O
research O
will O
provide O
more O
insights O
into O
the O
relationships O
between O
aquatic O
microcystins B
and O
amphibians O
. O

Ultrasound O
- O
promoted O
coating O
of O
silk O
yarn O
with O
different O
morphology O
of O
magnesium B
hydroxide I
nanostructures O
. O

The O
growth O
of O
magnesium B
hydroxide I
nanostructures O
on O
silk O
yarn O
was O
achieved O
by O
sequential O
dipping O
steps O
in O
alternating O
bath O
of O
magnesium B
nitrate I
and O
potassium B
hydroxide I
under O
ultrasound O
irradiation O
. O

The O
effects O
of O
ultrasound O
irradiation O
, O
concentration O
, O
pH O
and O
sequential O
dipping O
steps O
on O
growth O
of O
the O
Mg B
( I
OH I
) I
( I
2 I
) I
nanostructures O
have O
been O
studied O
. O

The O
exposure O
of O
highly O
toxic O
aconitine O
does O
not O
significantly O
impact O
the O
activity O
and O
expression O
of O
cytochrome O
P450 O
3A O
in O
rats O
determined O
by O
a O
novel O
ultra O
performance O
liquid O
chromatography O
- O
tandem O
mass O
spectrometric O
method O
of O
a O
specific O
probe O
buspirone B
. O

Our O
study O
aims O
to O
explore O
the O
potent O
effects O
of O
AC O
, O
as O
a O
marker O
component O
of O
Aconitum O
, O
on O
CYP3A O
using O
the O
probe O
buspirone B
in O
rats O
. O

The O
effects O
of O
oral O
AC O
on O
pharmacokinetics O
of O
buspirone B
were O
evaluated O
. O

CYP3A O
activity O
and O
protein O
levels O
in O
rat O
liver O
microsomes O
pretreated O
with O
oral O
AC O
were O
also O
measured O
using O
in O
vitro O
buspirone B
metabolism O
and O
Western O
blot O
. O

Buspirone B
and O
its O
major O
metabolites O
1 B
- I
( I
2 I
- I
pyrimidinyl I
) I
piperazine I
and O
6 B
' I
- I
hydroxybuspirone I
were O
determined O
using O
a O
newly O
validated O
UPLC O
- O
MS O
/ O
MS O
method O
. O

Single O
dose O
and O
7 O
- O
day O
AC O
administration O
at O
0 O
. O
125mg O
/ O
kg O
had O
no O
effect O
on O
CYP3A O
activity O
since O
no O
change O
in O
the O
formation O
of O
1 B
- I
( I
2 I
- I
pyrimidinyl I
) I
piperazine I
and O
6 B
' I
- I
hydroxybuspirone I
. O

Low O
volatile O
organophosphorous B
nerve O
agents O
such O
as O
VX O
, O
will O
most O
likely O
enter O
the O
body O
via O
the O
skin O
. O

The O
pharmacokinetics O
of O
drugs O
such O
as O
oximes O
, O
atropine B
and O
diazepam O
, O
are O
not O
aligned O
with O
the O
variable O
and O
persistent O
toxicokinetics O
of O
the O
agent O
. O

Because O
of O
the O
effectiveness O
of O
continuous O
treatment O
, O
it O
was O
investigated O
to O
what O
extent O
a O
subchronic O
pretreatment O
with O
carbamate O
( O
pyridostigmine B
or O
physostigmine O
combined O
with O
either O
procyclidine O
or O
scopolamine O
) O
would O
protect O
against O
percutaneous O
VX O
exposure O
. O

To O
evaluate O
the O
window O
of O
opportunity O
for O
decontamination O
, O
the O
fielded O
skin O
decontaminant O
Reactive O
Skin O
Decontaminant O
Lotion O
( O
RSDL O
) O
was O
tested O
at O
different O
times O
in O
hairless O
guinea O
pigs O
percutaneously O
challenged O
with O
4 O
x O
LD50 O
VX O
in O
IPA B
. O

Furthermore O
, O
antibodies O
to O
DNA O
show O
localized O
binding O
to O
these O
microstructures O
, O
which O
also O
react O
positively O
with O
DNA O
intercalating O
stains O
propidium O
iodide O
( O
PI O
) O
and O
4 B
' I
, I
6 I
' I
- I
diamidino I
- I
2 I
- I
phenylindole I
dihydrochloride I
( O
DAPI O
) O
. O

Telmisartan O
( O
TLM B
) O
, O
a O
poorly O
water O
- O
soluble O
angiotensin O
II O
receptor O
antagonist O
in O
crystalline O
form O
, O
was O
transformed O
into O
the O
amorphous O
state O
by O
the O
melt O
quench O
technique O
, O
as O
well O
as O
a O
cryogenic O
grinding O
method O
, O
in O
order O
to O
improve O
its O
physiochemical O
properties O
. O

The O
chemical O
stability O
of O
TLM B
, O
that O
is O
, O
the O
tendency O
of O
the O
material O
to O
resist O
change O
or O
decomposition O
due O
to O
internal O
reaction O
, O
or O
due O
to O
the O
effects O
of O
air O
, O
heat O
, O
light O
, O
pressure O
, O
etc O
. O
, O
during O
formation O
of O
the O
amorphous O
phase O
was O
assessed O
by O
monitoring O
high O
performance O
liquid O
chromatography O
. O

In O
the O
next O
stage O
, O
the O
solubility O
of O
TLM B
in O
0 O
. O
1M O
HCl O
, O
phosphate O
buffer O
, O
pH O
= O
6 O
. O
8 O
, O
and O
water O
( O
25 O
degrees O
C O
and O
37 O
degrees O
C O
) O
was O
determined O
. O

Both O
amorphous O
forms O
of O
TLM B
( O
vitrified O
and O
cryogrinded O
) O
had O
a O
higher O
solubility O
( O
mu O
g O
/ O
ml O
) O
than O
their O
crystalline O
counterpart O
. O

An O
important O
and O
interesting O
problem O
of O
the O
study O
was O
to O
evaluate O
how O
the O
tableting O
process O
was O
affected O
by O
the O
choice O
of O
either O
a O
crystalline O
or O
an O
amorphous O
form O
of O
TLM B
. O

Eight O
different O
tablet O
formulations O
were O
evaluated O
using O
both O
the O
crystalline O
and O
the O
amorphous O
form O
of O
TLM B
. O

The O
aim O
of O
the O
present O
study O
was O
to O
assess O
whether O
lactational O
exposure O
to O
polychlorinated B
biphenyl I
- I
153 I
( O
PCB B
- I
153 I
) O
, O
dichlorodiphenyldich O
( O
DDE O
) O
, O
or O
hexachlorobenzene B
( O
HCB B
) O
as O
estimated O
with O
a O
physiologically O
based O
pharmacokinetic O
( O
PBPK O
) O
model O
, O
is O
associated O
with O
decrements O
in O
mental O
and O
psychomotor O
development O
scores O
of O
the O
Bayley O
Scales O
of O
Infant O
Development O
( O
BSID O
) O
test O
in O
children O
aged O
around O
14 O
- O
months O
of O
a O
subsample O
( O
N O
= O

Although O
in O
the O
present O
study O
population O
PCB B
- I
153 I
, O
DDE O
and O
HCB B
exposure O
increased O
within O
the O
first O
months O
of O
postnatal O
life O
, O
no O
associations O
were O
found O
between O
different O
periods O
of O
postnatal O
exposure O
to O
these O
compounds O
and O
mental O
or O
psychomotor O
scores O
. O

Increasing O
prenatal O
PCB B
- I
153 I
concentrations O
were O
associated O
with O
worse O
mental O
and O
psychomotor O
scores O
, O
although O
significance O
was O
only O
reached O
for O
psychomotor O
development O
( O
beta O
[ O
95 O
% O
CI O
] O
= O
- O
1 O
. O
36 O
[ O
- O
2 O
. O
61 O
, O
- O
0 O
. O
11 O
] O
) O
. O

Results O
of O
the O
present O
study O
suggest O
that O
, O
although O
breastfeeding O
increases O
children O
' O
s O
blood O
persistent O
organic O
pollutants O
( O
POPs O
) O
levels O
during O
postnatal O
life O
, O
deleterious O
effects O
of O
PCB B
- I
153 I
on O
neuropsychological O
development O
are O
mainly O
attributable O
to O
prenatal O
exposure O
. O

Upregulated O
interleukin O
( O
IL O
) O
- O
1 O
beta O
maturation O
, O
IL O
- O
18 O
secretion O
, O
and O
caspase O
- O
1 O
cleavage O
were O
observed O
in O
MDMs O
from O
type O
2 O
diabetic O
patients O
after O
stimulation O
with O
various O
danger O
molecules O
( O
ATP O
, O
high O
- O
mobility O
group O
protein O
B1 O
, O
free O
fatty O
acids O
, O
islet O
amyloid O
polypeptide O
, O
and O
monosodium B
uric I
acid I
crystals O
) O
. O

Due O
to O
the O
substantial O
degradation O
of O
DDT O
to O
dichlorodiphenyldich O
( O
DDD B
) O
in O
sediment O
, O
sediment O
toxicity O
to O
C O
. O
dilutus O
increased O
, O
while O
it O
decreased O
for O
H O
. O
azteca O
with O
extended O
aging O
times O
. O

A O
toxic O
unit O
- O
based O
fiber O
LC50 O
value O
represented O
the O
DDT O
mixture O
( O
DDT O
and O
DDD B
) O
toxicity O
for O
both O
species O
. O

Effects O
of O
DMSA B
- O
coated O
Fe3O4 O
nanoparticles O
on O
the O
transcription O
of O
genes O
related O
to O
iron O
and O
osmosis O
homeostasis O
. O

In O
this O
article O
, O
we O
checked O
the O
effect O
of O
2 B
, I
3 I
- I
dimercaptosuccinic I
acid I
- O
coated O
Fe O
( O
3 O
) O
O O
( O
4 O
) O
nanoparticles O
on O
gene O
expression O
of O
mouse O
macrophage O
RAW264 O
. O
7 O
cells O
and O
found O
that O
the O
transcription O
of O
several O
important O
genes O
related O
to O
intracellular O
iron O
homeostasis O
were O
significantly O
changed O
. O

Then O
, O
we O
designed O
and O
validated O
a O
method O
based O
on O
centrifugation O
for O
assaying O
intracellular O
irons B
in O
ion O
and O
nanoparticle O
state O
. O

Cholesteryl B
ester I
( O
CE O
) O
- O
rich O
LDs O
normally O
accumulate O
in O
steroidogenic O
cells O
and O
their O
mobilization O
is O
the O
preferred O
initial O
source O
of O
cholesterol O
for O
steroidogenesis O
. O

Selenium O
and O
Hg O
were O
provided O
as O
L B
- I
selenomethionine I
( O
SeMet O
) O
and O
methylmercury O
( O
MeHg O
) O
, O
respectively O
. O

Enhanced O
charge O
carrier O
mobility O
in O
two O
- O
dimensional O
high O
dielectric O
molybdenum B
oxide I
. O

We O
demonstrate O
that O
the O
energy O
bandgap O
of O
layered O
, O
high O
- O
dielectric O
alpha B
- I
MoO I
( I
3 I
) I
can O
be O
reduced O
to O
values O
viable O
for O
the O
fabrication O
of O
2D O
electronic O
devices O
. O

As O
a O
result O
, O
devices O
with O
alpha B
- I
MoO I
( I
3 I
) I
of O
~ O
11 O
nm O
thickness O
and O
carrier O
mobilities O
larger O
than O
1100 O
cm O
( O
2 O
) O
V O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
are O
obtained O
. O

Combination O
lopinavir B
and O
ritonavir O
alter O
exogenous O
and O
endogenous O
bile O
acid O
disposition O
in O
sandwich O
- O
cultured O
rat O
hepatocytes O
. O

Antiretroviral O
protease O
inhibitors O
lopinavir B
( O
LPV B
) O
and O
ritonavir O
( O
RTV B
) O
are O
reported O
BSEP O
inhibitors O
. O

However O
, O
the O
consequences O
of O
LPV B
and O
RTV B
, O
alone O
and O
combined O
( O
LPV B
/ O
r O
) O
, O
on O
hepatocyte O
viability O
, O
bile O
acid O
transport O
, O
and O
endogenous O
bile O
acid O
disposition O
in O
rat O
hepatocytes O
have O
not O
been O
examined O
. O

The O
effect O
of O
LPV B
, O
RTV B
, O
and O
LPV B
/ O
r O
on O
cellular O
viability O
and O
the O
disposition O
of O
[ B
( I
3 I
) I
H I
] I
taurocholic I
acid I
( O
TCA B
) O
and O
[ B
( I
14 I
) I
C I
] I
chenodeoxycholic I
acid I
( O
CDCA B
) O
was O
determined O
in O
sandwich O
- O
cultured O
rat O
hepatocytes O
( O
SCRH O
) O
and O
suspended O
rat O
hepatocytes O
. O

Lactate O
dehydrogenase O
and O
ATP O
assays O
revealed O
a O
concentration O
- O
dependent O
effect O
of O
LPV B
and O
RTV B
on O
cellular O
viability O
. O

LPV B
( O
5 O
micro O
M O
) O
, O
alone O
and O
combined O
with O
5 O
micro O
M O
RTV B
, O
significantly O
decreased O
[ B
( I
3 I
) I
H I
] I
TCA I
accumulation O
in O
cells O
+ O
bile O
of O
SCRHs O
compared O
with O
control O
. O

LPV B
/ O
r O
significantly O
increased O
[ B
( I
3 I
) I
H I
] I
TCA I
cellular O
accumulation O
( O
7 O
. O
7 O
+ O
/ O
- O
0 O
. O
1 O
pmol O
/ O
mg O
of O
protein O
) O
compared O
with O
vehicle O
and O
5 O
micro O
M O
LPV B
alone O
( O
5 O
. O
1 O
+ O
/ O
- O
0 O
. O
7 O
and O
5 O
. O
0 O
+ O
/ O
- O
0 O
. O
5 O
pmol O
/ O
mg O
of O
protein O
) O
. O

The O
[ B
( I
3 I
) I
H I
] I
TCA I
biliary O
clearance O
was O
reduced O
significantly O
by O
LPV B
and O
RTV B
and O
further O
reduced O
by O
LPV B
/ O
r O
. O

LPV B
and O
RTV B
did O
not O
affect O
the O
initial O
uptake O
rates O
of O
[ B
( I
3 I
) I
H I
] I
TCA I
or O
[ B
( I
14 I
) I
C I
] I
CDCA I
in O
suspended O
rat O
hepatocytes O
. O

LPV B
( O
50 O
micro O
M O
) O
, O
RTV B
( O
5 O
micro O
M O
) O
, O
and O
LPV B
/ O
r O
( O
5 O
and O
50 O
micro O
M O
/ O
5 O
micro O
M O
) O
significantly O
decreased O
the O
accumulation O
of O
total O
measured O
endogenous O
bile O
acids O
( O
TCA B
, O
glycocholic B
acid I
, O
taurochenodeoxycholi B
acid I
, O
glycochenodeoxycholi B
acid I
, O
and O
alpha B
/ I
beta I
- I
tauromuricholic I
acid I
) O
in O
SCRH O
. O

The O
theoretical O
calculation O
successfully O
predicted O
the O
experimental O
observation O
that O
the O
monomodal O
- O
poly B
( I
dimethyl I
siloxane I
) I
( O
PDMS O
) O
- O
brush O
- O
grafted O
TiO O
( O
2 O
) O
nanoparticles O
can O
only O
be O
well O
dispersed O
within O
a O
small O
molecular O
weight O
silicone O
matrix O
. O

The O
complete O
and O
reversible O
charge O
- O
selective O
sequestration O
of O
fluorophores O
by O
a O
weak O
polyelectrolyte O
brush O
, O
poly B
( I
2 I
- I
( I
dimethylamino I
) I
ethylmethacrylate I
) I
( O
PDMAEMA O
) O
was O
demonstrated O
using O
fluorescence O
correlation O
spectroscopy O
( O
FCS O
) O
. O

Blood O
pressure O
was O
increased O
in O
rats O
exposed O
to O
IH O
, O
and O
treatment O
with O
the O
PDK O
- O
1 O
inhibitor O
OSU B
- I
03012 I
[ O
2 B
- I
amino I
- I
N I
- I
{ I
4 I
- I
[ I
5 I
- I
( I
2 I
- I
phenanthrenyl I
) I
- I
3 I
- I
( I
trifluoromethyl I
) I
- I
1H I
- I
pyrazol I
- I
1 I
- I
yl I
] I
- I
phenyl I
} I
- I
acetamide I
] O
( O
33 O
mg O
/ O
day O
) O
lowered O
blood O
pressure O
in O
IH O
but O
not O
sham O
group O
rats O
. O

The O
majority O
of O
protein O
sulfhydryl O
depletion O
was O
due O
to O
reversible O
oxidation O
since O
the O
global O
- O
and O
lobule O
- O
specific O
effects O
were O
essentially O
reversed O
when O
the O
samples O
were O
reduced O
with O
tris B
( I
2 I
- I
carboxyethy I
) I
phosphine I
before O
maleimide O
labeling O
. O

The O
potency O
at O
P2Y O
( O
12 O
) O
was O
2 B
- I
( I
methylthio I
) I
- I
ADP I
> O
2 B
- I
( I
methylthio I
) I
- I
ATP I
> O
ADP O
> O
ATP O
. O

N B
- I
Methyl I
- I
anthraniloyl I
modification O
at O
the O
3 B
' I
- I
OH I
of O
the O
2 B
' I
- I
deoxyribose I
leads O
to O
ligands O
( O
mant O
- O
deoxy O
- O
ATP O
[ O
dATP O
] O
, O
mant O
- O
deoxy O
- O
ADP O
) O
with O
inverse O
agonist O
activity O
. O

Over O
12 O
months O
, O
we O
followed O
- O
up O
75 O
schizophrenia O
patients O
who O
were O
classified O
into O
two O
groups O
according O
to O
antipsychotic O
treatment O
: O
clozapine O
or O
olanzapine O
( O
group O
I O
) O
versus O
aripiprazole B
or O
amisulpride O
( O
group O
II O
) O
. O

Following O
CdCl B
2 I
treatment O
, O
ICAM2 O
was O
found O
to O
be O
upregulated O
during O
restructuring O
of O
the O
seminiferous O
epithelium O
, O
with O
round O
spermatids O
becoming O
increasingly O
immunoreactive O
for O
ICAM2 O
by O
6 O
- O
16 O
h O
. O

Interestingly O
, O
there O
was O
a O
loss O
in O
the O
binding O
of O
ICAM2 O
to O
actin O
during O
CdCl B
2 I
- O
induced O
germ O
cell O
loss O
, O
suggesting O
that O
a O
loss O
of O
ICAM2 O
- O
actin O
interactions O
might O
have O
facilitated O
junction O
restructuring O
. O

Using O
this O
assay O
, O
we O
reveal O
that O
the O
delta O
- O
opioid O
receptor O
agonist O
ADL5859 B
, O
which O
is O
currently O
in O
clinical O
trials O
, O
has O
a O
10 O
- O
fold O
higher O
potency O
against O
delta O
- O
opioid O
receptor O
homomers O
than O
delta O
/ O
mu O
- O
opioid O
receptor O
heteromers O
( O
pEC O
( O
50 O
) O
= O
6 O
. O
7 O
+ O
/ O
- O
0 O
. O
1 O
versus O
5 O
. O
8 O
+ O
/ O
- O
0 O
. O
2 O
) O
. O

Two O
new O
dimeric O
anthraquinone O
derivatives O
, O
bulgareone B
A I
( O
1 O
) O
and O
bulgareone B
B I
( O
2 O
) O
, O
were O
isolated O
from O
the O
fruit O
bodies O
of O
Bulgaria O
inquinans O
. O

Consumption O
of O
seafood O
containing O
the O
phytoplankton O
- O
derived O
toxin O
domoic O
acid O
( O
DOM B
) O
causes O
neurotoxicity O
in O
humans O
and O
in O
animals O
. O

It O
has O
been O
reported O
that O
DOM B
- O
induced O
symptoms O
may O
be O
more O
severe O
in O
men O
than O
women O
, O
but O
to O
date O
the O
effect O
of O
sex O
on O
DOM B
- O
induced O
effects O
in O
adults O
is O
not O
known O
. O

We O
investigated O
sex O
differences O
in O
DOM B
- O
induced O
effects O
in O
adult O
rats O
. O

Since O
low O
level O
exposure O
is O
of O
greatest O
relevance O
to O
human O
health O
( O
due O
to O
DOM B
regulatory O
limit O
) O
, O
we O
examined O
the O
effects O
of O
low O
level O
exposure O
. O

Adult O
male O
and O
female O
Sprague O
Dawley O
rats O
were O
administered O
a O
single O
intraperitoneal O
injection O
of O
DOM B
( O
0 O
, O
1 O
. O
0 O
, O
1 O
. O
8 O
mg O
/ O
kg O
) O
. O

DOM B
increased O
locomotor O
and O
grooming O
activity O
, O
compared O
to O
vehicle O
group O
. O

DOM B
exposure O
also O
significantly O
increased O
stereotypic O
behaviours O
and O
decreased O
phosphorylated B
cAMP I
response O
element O
- O
binding O
protein O
immunoreactivity O
( O
pCREB O
- O
IR O
) O
. O

There O
was O
no O
effect O
of O
sex O
on O
the O
magnitude O
of O
the O
behavioural O
responses O
, O
but O
the O
onset O
of O
DOM B
- O
induced O
locomotor O
activity O
and O
ear O
scratches O
was O
quicker O
in O
females O
than O
in O
males O
. O

Mixed O
effect O
modelling O
revealed O
the O
predicted O
peak O
in O
locomotor O
activity O
in O
response O
to O
DOM B
was O
also O
quicker O
in O
females O
than O
in O
males O
. O

Severe O
toxicity O
was O
evident O
in O
2 O
/ O
7 O
male O
rats O
and O
0 O
/ O
8 O
female O
rats O
dosed O
with O
1 O
. O
8 O
mg O
/ O
kg O
DOM B
. O

These O
data O
suggest O
that O
males O
exposed O
to O
low O
level O
DOM B
may O
be O
more O
susceptible O
to O
severe O
neurotoxicity O
, O
whereas O
females O
are O
affected O
more O
quickly O
. O

Understanding O
sex O
differences O
in O
DOM B
- O
induced O
neurotoxicity O
may O
contribute O
to O
future O
protective O
strategies O
and O
treatments O
. O

Toxicokinetic O
study O
and O
absolute O
oral O
bioavailability O
of O
deoxynivalenol O
, O
T B
- I
2 I
toxin I
and O
zearalenone O
in O
broiler O
chickens O
. O

Little O
information O
is O
available O
on O
the O
absolute O
oral O
bioavailability O
and O
the O
toxicokinetic O
parameters O
of O
deoxynivalenol O
, O
T B
- I
2 I
and O
zearalenone O
in O
broilers O
. O

For O
deoxynivalenol O
a O
bolus O
of O
0 O
. O
75mg O
/ O
kg O
BW O
was O
administered O
, O
for O
T B
- I
2 I
toxin I
0 O
. O
02mg O
/ O
kg O
BW O
and O
for O
zearalenone O
0 O
. O
3mg O
/ O
kg O
BW O
. O

For O
zearalenone O
and O
T B
- I
2 I
no O
plasma O
levels O
above O
the O
limit O
of O
quantification O
were O
observed O
after O
an O
oral O
bolus O
. O

Volumes O
of O
distribution O
were O
recorded O
, O
i O
. O
e O
. O
4 O
. O
99 O
, O
0 O
. O
14 O
and O
22 O
. O
26L O
/ O
kg O
for O
deoxynivalenol O
, O
T B
- I
2 I
toxin I
and O
zearalenone O
, O
respectively O
. O

Total O
body O
clearance O
was O
0 O
. O
12 O
, O
0 O
. O
03 O
and O
0 O
. O
48L O
/ O
minkg O
for O
deoxynivalenol O
, O
T B
- I
2 I
toxin I
and O
zearalenone O
, O
respectively O
. O

After O
IV O
administration O
, O
T B
- I
2 I
toxin I
had O
the O
shortest O
elimination O
half O
- O
life O
( O
3 O
. O
9min O
) O
, O
followed O
by O
deoxynivalenol O
( O
27 O
. O
9min O
) O
and O
zearalenone O
( O
31 O
. O
8min O
) O
. O

The O
primary O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
Ortanique O
peel O
polymethoxylated O
flavones O
extract O
( O
PMF B
( O
ort O
) O
) O
on O
organ O
function O
parameters O
in O
the O
serum O
of O
hypercholesterolemic O
and O
normal O
rats O
. O

Thirty O
Sprague O
- O
Dawley O
rats O
were O
fed O
high O
cholesterol O
diets O
supplemented O
with O
1 O
. O
5 O
% O
PMF B
( O
ort O
) O
and O
niacin O
respectively O
for O
49days O
. O

Hypercholesterolemic O
rats O
fed O
PMF B
( O
ort O
) O
had O
significant O
reductions O
in O
the O
activities O
of O
aspartate O
aminotransferase O
and O
alkaline O
phosphatase O
( O
69 O
. O
12 O
+ O
/ O
- O
3 O
. O
34 O
and O
87 O
. O
22 O
+ O
/ O
- O
8 O
. O
42U O
/ O
L O
respectively O
) O
compared O
to O
the O
untreated O
hypercholesterolemic O
group O
( O
118 O
. O
61 O
+ O
/ O
- O
4 O
. O
85 O
and O
132 O
. O
62 O
+ O
/ O
- O
10 O
. O
62U O
/ O
L O
respectively O
, O
p O
< O
0 O
. O
05 O
) O
. O

Supplementation O
of O
the O
diet O
with O
niacin B
or O
PMF B
( O
ort O
) O
resulted O
in O
no O
significant O
differences O
in O
the O
serum O
levels O
of O
creatinine O
or O
urea O
in O
any O
of O
the O
groups O
. O

Supplementation O
of O
the O
diets O
of O
hypercholesterolemic O
rats O
with O
PMF B
( O
ort O
) O
resulted O
in O
significant O
reductions O
in O
the O
activities O
of O
serum O
creatine O
kinase O
and O
lactate O
dehydrogenase O
( O
119 O
. O
3 O
+ O
/ O
- O
25 O
. O
3 O
; O
222 O
. O
5 O
+ O
/ O
- O
50 O
. O
3U O
/ O
L O
, O
p O
< O
0 O
. O
05 O
) O
respectively O
relative O
to O
the O
untreated O
hypercholesterolemic O
group O
( O
257 O
. O
2 O
+ O
/ O
- O
48 O
. O
3 O
; O
648 O
. O
8 O
+ O
/ O
- O
103U O
/ O
L O
, O
p O
< O
0 O
. O
05 O
) O
. O

The O
results O
would O
suggest O
that O
PMF B
( O
ort O
) O
modulates O
hypercholesterolemia O
- O
associated O
organ O
injury O
in O
rats O
. O

PMF B
( O
ort O
) O
could O
therefore O
be O
a O
suitable O
candidate O
for O
prophylactic O
and O
therapeutic O
treatment O
of O
hypercholesterolemia O
- O
associated O
organ O
injury O
. O

Importantly O
, O
cells O
with O
downregulated O
expression O
of O
P O
- O
gp O
gradually O
lost O
their O
ability O
to O
decrease O
the O
intracellular O
level O
of O
nilotinib O
although O
they O
still O
significantly O
decreased O
the O
intracellular O
level O
of O
daunorubicin B
( O
DNR B
) O
. O

Accordingly O
, O
cells O
with O
the O
reduced O
expression O
of O
P O
- O
gp O
concomitantly O
failed O
to O
provide O
resistance O
to O
nilotinib O
, O
however O
, O
they O
exhibited O
a O
significant O
resistance O
to O
DNR B
. O

Reversal O
of O
the O
deleterious O
effects O
of O
chronic O
dietary O
HFCS B
- I
55 I
intake O
by O
PPAR O
- O
delta O
agonism O
correlates O
with O
impaired O
NLRP3 O
inflammasome O
activation O
. O

Although O
high B
- I
fructose I
corn I
syrup I
( O
HFCS B
- I
55 I
) O
is O
the O
major O
sweetener O
in O
foods O
and O
soft O
- O
drinks O
, O
its O
potential O
role O
in O
the O
pathophysiology O
of O
diabetes O
and O
obesity O
( O
" O
diabesity O
" O
) O
remains O
unclear O
. O

This O
study O
was O
designed O
to O
evaluate O
( O
i O
) O
the O
metabolic O
and O
renal O
consequences O
of O
HFCS B
- I
55 I
administration O
( O
15 O
% O
wt O
/ O
vol O
in O
drinking O
water O
) O
for O
30 O
weeks O
on O
male O
C57Bl6 O
/ O
J O
mice O
and O
( O
ii O
) O
the O
effects O
of O
the O
selective O
PPAR O
- O
delta O
agonist O
GW0742 B
( O
1 O
mg O
/ O
kg O
/ O
day O
for O
16 O
weeks O
) O
in O
this O
condition O
. O

HFCS B
- I
55 I
caused O
( O
i O
) O
hyperlipidemia O
, O
( O
ii O
) O
insulin O
resistance O
, O
and O
( O
iii O
) O
renal O
injury O
/ O
inflammation O
. O

In O
the O
liver O
, O
HFCS B
- I
55 I
enhanced O
the O
expression O
of O
fructokinase O
resulting O
in O
hyperuricemia O
and O
caused O
abnormalities O
in O
known O
insulin O
- O
driven O
signaling O
events O
. O

In O
the O
kidney O
, O
HFCS B
- I
55 I
enhanced O
the O
expression O
of O
the O
NLRP3 O
( O
nucleotide O
- O
binding O
domain O
and O
leucine O
- O
rich O
- O
repeat O
- O
protein O
3 O
) O
inflammasome O
complex O
, O
resulting O
in O
caspase O
- O
1 O
activation O
and O
interleukin O
- O
1 O
beta O
production O
. O

All O
of O
the O
above O
effects O
of O
HFCS B
- I
55 I
were O
attenuated O
by O
the O
specific O
PPAR O
- O
delta O
agonist O
GW0742 B
. O

Thus O
, O
we O
demonstrate O
for O
the O
first O
time O
that O
the O
specific O
PPAR O
- O
delta O
agonist O
GW0742 B
attenuates O
the O
metabolic O
abnormalities O
and O
the O
renal O
dysfunction O
/ O
inflammation O
caused O
by O
chronic O
HFCS B
- I
55 I
exposure O
by O
preventing O
upregulation O
of O
fructokinase O
( O
liver O
) O
and O
activation O
of O
the O
NLRP3 O
inflammasome O
( O
kidney O
) O
. O

Hydrogen O
sulfide O
, O
H2S B
, O
is O
a O
colorless O
gas O
with O
a O
strong O
odor O
that O
until O
recently O
was O
only O
considered O
to O
be O
a O
toxic O
environmental O
pollutant O
with O
little O
or O
no O
physiological O
significance O
. O

However O
, O
the O
past O
few O
years O
have O
demonstrated O
its O
role O
in O
many O
biological O
systems O
and O
it O
is O
becoming O
increasingly O
clear O
that O
H2S B
is O
likely O
to O
join O
nitric O
oxide O
( O
NO O
) O
and O
carbon O
monoxide O
( O
CO O
) O
as O
a O
major O
player O
in O
mammalian O
biology O
. O

In O
this O
review O
, O
we O
have O
provided O
an O
overview O
of O
the O
chemistry O
and O
biology O
of O
H2S B
and O
have O
summarized O
the O
chemistry O
and O
biological O
activity O
of O
some O
natural O
and O
synthetic O
H2S B
- O
donating O
compounds O
. O

The O
naturally O
occurring O
compounds O
discussed O
include O
, O
garlic O
, O
sulforaphane O
, O
erucin B
, O
and O
iberin B
. O

The O
synthetic O
H2S B
donors O
reviewed O
include O
, O
GYY4137 B
; O
cysteine O
analogs O
; O
S B
- I
propyl I
cysteine I
, O
S B
- I
allyl I
cysteine I
, O
S B
- I
propargyl I
cysteine I
, O
and O
N O
- O
acetyl O
cysteine O
. O

Dithiolethione B
and O
its O
NSAID O
and O
other O
chimeras O
such O
as O
, O
L B
- I
DOPA I
, O
sildenafil O
, O
aspirin O
, O
diclofenac O
, O
naproxen O
, O
ibuprofen O
, O
indomethacin O
, O
and O
mesalamine B
have O
also O
been O
reviewed O
in O
detail O
. O

The O
newly O
reported O
NOSH B
- I
aspirin I
that O
releases O
both O
NO O
and O
H2S B
has O
also O
been O
discussed O
. O

Synthesis O
and O
chiral O
recognition O
of O
nickel B
( I
II I
) I
macrocyclic O
complex O
with O
( B
R I
) I
- I
naphthylethyleneamin I
pendant O
groups O
and O
its O
self O
- O
assembled O
framework O
. O

A O
novel O
nickel B
( I
II I
) I
hexaaza I
macrocyclic O
complex O
, O
[ B
Ni I
( I
L I
( I
R I
, I
R I
) I
) I
] I
( I
ClO I
( I
4 I
) I
) I
( I
2 I
) I
( O
1 O
) O
, O
containing O
chiral O
pendant O
groups O
was O
synthesized O
by O
an O
efficient O
one O
- O
pot O
template O
condensation O
and O
characterized O
( O
L O
( O
R O
, O
R O
) O
= O
1 B
, I
8 I
- I
di I
( I
( I
R I
) I
- I
alpha I
- I
methylnaphthyl I
) I
- I
1 I
, I
3 I
, I
6 I
, I
8 I
, I
10 I
, I
13 I
- I
hexaazacyclotetradec I
) O
. O

The O
complex O
was O
found O
to O
have O
a O
square O
- O
planar O
coordination O
environment O
for O
the O
nickel B
( I
II I
) I
ion O
. O

Open O
framework O
[ B
Ni I
( I
L I
( I
R I
, I
R I
) I
) I
] I
( I
3 I
) I
[ I
C I
( I
6 I
) I
H I
( I
3 I
) I
( I
COO I
) I
( I
3 I
) I
] I
( I
2 I
) I
( O
2 O
) O
was O
constructed O
from O
the O
self O
- O
assembly O
of O
compound O
1 O
with O
deprotonated O
1 B
, I
3 I
, I
5 I
- I
benzenetricarboxylic I
acid I
, O
BTC B
( I
3 I
- I
) I
. O

Chiral O
discrimination O
of O
rac B
- I
1 I
, I
1 I
' I
- I
bi I
- I
2 I
- I
naphthol I
and O
rac B
- I
2 I
, I
2 I
, I
2 I
- I
trifluoro I
- I
1 I
- I
( I
9 I
- I
anthryl I
) I
ethanol I
was O
performed O
to O
determine O
the O
chiral O
recognition O
ability O
of O
the O
chiral O
complex O
( O
1 O
) O
and O
its O
self O
- O
assembled O
framework O
( O
2 O
) O
. O

Binaphthol B
showed O
a O
good O
chiral O
discrimination O
on O
the O
framework O
( O
2 O
) O
. O

Room O
- O
temperature O
electron O
spin O
amplifier O
based O
on O
Ga B
( I
In I
) I
NAs I
alloys O
. O

An O
efficient O
, O
defect O
- O
enabled O
spin O
amplifier O
based O
on O
a O
non O
- O
magnetic O
semiconductor O
, O
Ga B
( I
In I
) I
NAs I
, O
is O
proposed O
and O
demonstrated O
, O
with O
a O
large O
spin O
gain O
( O
up O
to O
2700 O
% O
at O
zero O
field O
) O
for O
conduction O
electrons O
and O
a O
high O
cut O
- O
off O
frequency O
of O
up O
to O
1 O
GHz O
. O

Ethyl O
acetate O
( O
ethyl B
ethanoate I
) O
was O
crystallized O
in O
situ O
and O
the O
crystal O
structure O
was O
determined O
. O

Consequently O
, O
the O
relative O
effects O
of O
pulsed O
( O
2 O
and O
4 O
d O
) O
and O
continuous O
exposures O
of O
the O
duckweed O
Lemna O
minor O
to O
isoproturon B
, O
metsulfuron B
- I
methyl I
, O
and O
pentachlorophenol B
over O
a O
period O
of O
42 O
d O
were O
explored O
in O
the O
present O
study O
. O

At O
the O
highest O
test O
concentrations O
, O
exposure O
of O
L O
. O
minor O
to O
pulses O
of O
metsulfuron B
- I
methyl I
resulted O
in O
effects O
on O
growth O
similar O
to O
those O
of O
an O
equivalent O
continuous O
exposure O
. O

For O
isoproturon B
, O
pulsed O
exposures O
had O
a O
lower O
impact O
than O
a O
corresponding O
continuous O
exposure O
, O
whereas O
the O
effect O
of O
pentachlorophenol B
delivered O
in O
pulses O
was O
greater O
. O

Reversal O
of O
efflux O
mediated O
antifungal O
resistance O
underlies O
synergistic O
activity O
of O
two O
monoterpenes B
with O
fluconazole O
. O

Thymol O
( O
THY B
) O
and O
carvacrol O
( O
CARV B
) O
, O
the O
principal O
chemical O
components O
of O
thyme O
oil O
have O
long O
been O
known O
for O
their O
wide O
use O
in O
medicine O
due O
to O
antimicrobial O
and O
disinfectant O
properties O
. O

This O
study O
, O
however O
, O
draws O
attention O
to O
a O
possible O
synergistic O
antifungal O
effect O
of O
these O
monoterpenes B
with O
azole O
antimycotic O
- O
fluconazole O
. O

To O
put O
forward O
this O
approach O
, O
we O
investigated O
the O
combination O
effects O
of O
these O
monoterpenes B
and O
FLC B
against O
38 O
clinically O
obtained O
FLC B
- O
sensitive O
, O
and O
eleven O
FLC B
- O
resistant O
Candida O
isolates O
. O

Synergism O
was O
observed O
with O
combinations O
of O
THY B
- O
FLC B
and O
CARV B
- O
FLC B
evaluated O
by O
checkerboard O
microdilution O
method O
and O
nature O
of O
the O
interactions O
was O
calculated O
by O
FICI O
. O

The O
drug O
efflux O
activity O
was O
determined O
using O
two O
dyes O
, O
Rhodamine6G B
( O
R6G B
) O
and O
fluorescent O
Hoechst O
33342 O
. O

However O
, O
a O
significantly O
higher O
efflux O
was O
recorded O
in O
FLC B
- O
resistant O
isolates O
when O
glucose O
was O
added O
. O

Both O
monoterpenes B
inhibited O
efflux O
by O
70 O
- O
90 O
% O
, O
showing O
their O
high O
potency O
to O
block O
drug O
transporter O
pumps O
. O

Significant O
differences O
, O
in O
the O
expression O
levels O
of O
CDR1 O
and O
MDR1 O
, O
induced O
by O
monoterpenes B
revealed O
reversal O
of O
FLC B
- O
resistance O
. O

The O
selectively O
fungicidal O
characteristics O
and O
ability O
to O
restore O
FLC B
susceptibility O
in O
resistant O
isolates O
signify O
a O
promising O
candidature O
of O
THY B
and O
CARV B
as O
antifungal O
agents O
in O
combinational O
treatments O
for O
candidiasis O
. O

Experimental O
exposure O
of O
red O
- O
legged O
partridges O
( O
Alectoris O
rufa O
) O
to O
seeds O
coated O
with O
imidacloprid O
, O
thiram B
and O
difenoconazole B
. O

One O
year O
- O
old O
partridges O
( O
n O
= O
42 O
pairs O
) O
were O
fed O
for O
10 O
days O
in O
spring O
( O
prior O
to O
breeding O
) O
with O
wheat O
treated O
with O
difenoconazole B
( O
fungicide O
) O
, O
thiram B
( O
fungicide O
) O
or O
imidacloprid O
( O
insecticide O
) O
, O
using O
two O
doses O
for O
each O
pesticide O
( O
the O
one O
recommended O
, O
and O
its O
double O
to O
represent O
potential O
cases O
of O
abuse O
of O
pesticides O
) O
. O

Thiram B
and O
imidacloprid O
at O
high O
exposure O
doses O
produced O
mortalities O
of O
41 O
. O
6 O
and O
58 O
. O
3 O
% O
, O
respectively O
. O

The O
first O
death O
was O
observed O
at O
day O
3 O
for O
imidacloprid O
and O
at O
day O
7 O
for O
thiram B
. O

The O
high O
exposure O
doses O
of O
imidacloprid O
and O
thiram B
also O
produced O
a O
decrease O
in O
cellular O
immune O
response O
measured O
by O
the O
phytohemagglutinin O
test O
in O
males O
. O

Bearing O
in O
mind O
the O
limitation O
of O
the O
small O
number O
of O
surviving O
pairs O
in O
some O
treatments O
, O
we O
found O
that O
the O
three O
pesticides O
reduced O
the O
size O
of O
eggs O
and O
imidacloprid O
and O
difenoconazole B
also O
reduced O
the O
fertilization O
rate O
. O

In O
addition O
, O
both O
thiram B
and O
imidacloprid O
reduced O
chick O
survival O
. O

In O
other O
groups O
, O
each O
atrium O
was O
incubated O
with O
selective O
adenosine O
A O
( O
1 O
) O
antagonist O
( O
8 B
- I
cyclopentyl I
- I
1 I
, I
3 I
- I
dipropylxanthine I
( O
DPCPX B
) O
, O
10 O
( O
- O
4 O
) O
M O
) O
or O
selective O
adenosine O
A O
( O
2a O
) O
receptor O
antagonist O
( O
8 B
- I
( I
3 I
- I
chlorostyryl I
) I
caffeine I
, O
10 O
( O
- O
5 O
) O
M O
) O
before O
amitriptyline O
administration O
. O

DPCPX B
significantly O
decreased O
the O
50 O
- O
mu O
M O
amitriptyline O
- O
induced O
APD O
( O
50 O
) O
and O
APD O
( O
80 O
) O
prolongation O
( O
p O
< O
0 O
. O
001 O
) O
. O

DPCPX B
significantly O
prevented O
the O
effects O
of O
amitriptyline O
( O
1 O
mu O
M O
and O
50 O
mu O
M O
) O
on O
maximum O
rise O
slope O
of O
AP O
( O
p O
< O
0 O
. O
05 O
) O
. O

DPCPX B
significantly O
prevented O
the O
amitriptyline O
- O
induced O
( O
50 O
mu O
M O
) O
reduction O
in O
maximum O
decay O
slope O
of O
AP O
( O
p O
< O
0 O
. O
001 O
) O
. O

Spectral O
analysis O
of O
thioacetamide B
- O
induced O
electroencephalograp O
changes O
in O
rats O
. O

Thioacetamide B
( O
TAA B
) O
is O
widely O
used O
as O
a O
model O
of O
hepatic O
encephalopathy O
( O
HE O
) O
. O

The O
aim O
of O
our O
study O
was O
to O
investigate O
the O
effects O
of O
TAA B
on O
electroencephalograp O
( O
EEG O
) O
changes O
in O
rats O
and O
to O
compare O
them O
with O
human O
HE O
. O

Male O
Wistar O
rats O
were O
divided O
into O
groups O
: O
( O
1 O
) O
saline O
- O
treated O
group O
and O
( O
2 O
) O
TAA B
- O
treated O
groups O
: O
TAA B
( O
300 O
) O
( O
300 O
mg O
/ O
kg O
) O
, O
TAA B
( O
600 O
) O
( O
600 O
mg O
/ O
kg O
) O
, O
and O
TAA B
( O
900 O
) O
( O
900 O
mg O
/ O
kg O
) O
. O

Daily O
dose O
of O
TAA B
( O
300 O
mg O
/ O
kg O
) O
was O
administered O
intraperitoneally O
once O
( O
TAA B
( O
300 O
) O
) O
, O
twice O
( O
TAA B
( O
600 O
) O
) O
, O
or O
thrice O
( O
TAA B
( O
900 O
) O
) O
in O
subsequent O
days O
. O

EEG O
changes O
were O
recorded O
about O
24 O
h O
after O
the O
last O
dose O
of O
TAA B
. O

Absolute O
and O
relative O
power O
density O
in O
alpha O
bands O
were O
significantly O
higher O
in O
TAA B
( O
300 O
) O
versus O
control O
group O
. O

In O
TAA B
( O
300 O
) O
, O
absolute O
beta O
power O
density O
was O
higher O
and O
relative O
beta O
power O
density O
was O
lower O
versus O
control O
group O
. O

Absolute O
alpha O
, O
theta O
, O
delta O
, O
and O
relative O
theta O
power O
were O
significantly O
lower O
, O
while O
relative O
power O
in O
delta O
band O
was O
significantly O
higher O
in O
TAA B
( O
900 O
) O
versus O
control O
group O
( O
p O
< O
0 O
. O
01 O
) O
. O

In O
conclusion O
, O
decrease O
in O
EEG O
voltage O
with O
an O
increase O
in O
delta O
relative O
power O
, O
which O
correspond O
to O
the O
EEG O
manifestations O
of O
severe O
HE O
in O
humans O
, O
was O
observed O
in O
TAA B
( O
900 O
) O
group O
. O

Electrical O
activity O
in O
TAA B
( O
300 O
) O
group O
correlates O
with O
mild O
HE O
in O
humans O
. O

Cisplatin O
( O
Cisp B
) O
is O
one O
of O
the O
most O
effective O
chemotherapeutic O
drugs O
. O

However O
, O
the O
dose O
of O
Cisp B
is O
greatly O
limited O
by O
its O
toxicity O
. O

The O
purpose O
of O
this O
study O
was O
to O
explore O
the O
protective O
effect O
of O
rhEPO O
against O
Cisp B
- O
induced O
renal O
and O
liver O
dysfunctions O
. O

Adult O
male O
Wistar O
rats O
were O
divided O
into O
six O
groups O
of O
six O
each O
: O
control O
, O
rhEPO O
- O
alone O
group O
, O
Cisp B
- O
alone O
group O
and O
rhEPO O
+ O
Cisp B
group O
( O
pretreatment O
, O
cotreatment O
and O
posttreatment O
conditions O
) O
. O

Our O
results O
showed O
that O
Cisp B
- O
induced O
a O
marked O
renal O
and O
liver O
failure O
characterized O
by O
a O
significant O
decrease O
in O
body O
weight O
, O
organ O
weight O
and O
organ O
ratio O
and O
a O
significant O
increase O
in O
creatinine O
, O
blood O
urea O
nitrogen O
, O
alanine O
aminotransferase O
, O
aspartate O
aminotransferase O
, O
G O
- O
glutamyl O
transferase O
, O
alkaline O
phosphatase O
, O
bilirubin O
conjugated O
and O
bilirubin O
total O
levels O
in O
serum O
. O

Histological O
examination O
showed O
that O
Cisp B
caused O
kidney O
alterations O
. O

rhEPO O
treatments O
restored O
body O
weight O
, O
organ O
weight O
and O
organ O
ratio O
as O
well O
as O
serum O
biochemical O
parameters O
changed O
due O
to O
Cisp B
exposure O
. O

In O
the O
present O
study O
, O
we O
explored O
the O
effect O
of O
nicotine O
treatment O
using O
different O
routes O
of O
administration O
in O
the O
dextran O
sodium B
sulfate I
( O
DSS O
) O
colitis O
mouse O
model O
. O

The O
extract O
inhibited O
elevation O
of O
the O
intracellular O
Ca O
( O
2 O
+ O
) O
concentration O
caused O
by O
stimulation O
by O
antigen O
, O
while O
not O
suppressing O
degranulation O
induced O
by O
a O
calcium O
ionophore O
A23187 B
. O

The O
most O
abundant O
anthraquinones O
in O
the O
investigated O
extracts O
were O
chrysophanol B
in O
R O
. O
alaternus O
( O
3 O
. O
14 O
mg O
/ O
g O
) O
, O
emodin O
in O
R O
. O
pumila O
( O
0 O
. O
339 O
mg O
/ O
g O
) O
, O
and O
physcion B
in O
R O
. O
fallax O
( O
2 O
. O
70 O
mg O
/ O
g O
) O
and O
R O
. O
intermedia O
( O
0 O
. O
285 O
mg O
/ O
g O
) O
. O

Syzygium O
aqueum O
leaf O
extract O
and O
its O
bioactive O
compounds O
enhances O
pre O
- O
adipocyte O
differentiation O
and O
2 B
- I
NBDG I
uptake O
in O
3T3 O
- O
L1 O
cells O
. O

The O
insulin O
- O
like O
and O
/ O
or O
insulin O
- O
sensitising O
effects O
of O
Syzygium O
aqueum O
leaf O
extract O
and O
its O
six O
bioactive O
compounds O
; O
4 B
- I
hydroxybenzaldehyde I
, O
myricetin B
- I
3 I
- I
O I
- I
rhamnoside I
, O
europetin B
- I
3 I
- I
O I
- I
rhamnoside I
, O
phloretin O
, O
myrigalone B
- I
G I
and O
myrigalone B
- I
B I
were O
investigated O
in O
3T3 O
- O
L1 O
adipocytes O
. O

Clearly O
, O
the O
compounds O
myricetin B
- I
3 I
- I
O I
- I
rhamnoside I
and O
europetin B
- I
3 I
- I
O I
- I
rhamnoside I
showed O
insulin O
- O
like O
and O
insulin O
- O
sensitising O
effects O
on O
adipocytes O
from O
a O
concentration O
of O
0 O
. O
08 O
mu O
M O
. O

These O
compounds O
were O
far O
better O
than O
rosiglitazone O
and O
the O
other O
isolated O
compounds O
in O
enhancing O
adipogenesis O
, O
stimulating O
2 B
- I
NBDG I
uptake O
and O
increasing O
adiponectin O
secretion O
at O
all O
the O
concentrations O
tested O
. O

Phillyrin B
attenuates O
high O
glucose O
- O
induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
through O
the O
activation O
of O
LKB1 O
/ O
AMP O
- O
activated O
protein O
kinase O
- O
dependent O
signalling O
. O

Phillyrin B
, O
an O
active O
constituent O
found O
in O
many O
medicinal O
plants O
and O
certain O
functional O
foods O
, O
has O
anti O
- O
obesity O
activity O
in O
vivo O
. O

The O
aim O
of O
our O
study O
was O
to O
provide O
new O
data O
on O
the O
molecular O
mechanism O
( O
s O
) O
underlying O
the O
role O
of O
phillyrin B
in O
the O
prevention O
of O
high O
glucose O
- O
induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
. O

We O
found O
that O
phillyrin B
suppressed O
high O
glucose O
- O
induced O
lipid O
accumulation O
in O
HepG2 O
cells O
. O

Phillyrin B
strongly O
inhibited O
high O
glucose O
- O
induced O
fatty O
acid O
synthase O
( O
FAS O
) O
expression O
by O
modulating O
sterol O
regulatory O
element O
- O
binding O
protein O
- O
1c O
( O
SREBP O
- O
1c O
) O
activation O
. O

Moreover O
, O
use O
of O
the O
pharmacological O
AMP O
- O
activated O
protein O
kinase O
( O
AMPK O
) O
inhibitor O
compound B
C I
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP O
- O
1c O
expression O
in O
phillyrin B
- O
treated O
cells O
. O

Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
( O
LKB1 O
) O
phosphorylation O
is O
required O
for O
the O
phillyrin B
- O
enhanced O
activation O
of O
AMPK O
in O
HepG2 O
hepatocytes O
. O

These O
results O
indicate O
that O
phillyrin B
prevents O
lipid O
accumulation O
in O
HepG2 O
cells O
by O
blocking O
the O
expression O
of O
SREBP O
- O
1c O
and O
FAS O
through O
LKB1 O
/ O
AMPK O
activation O
, O
suggesting O
that O
phillyrin B
is O
a O
novel O
AMPK O
activator O
with O
a O
role O
in O
the O
prevention O
and O
treatment O
of O
obesity O
. O

The O
whole O
fruit O
also O
contained O
higher O
levels O
of O
terpene B
alcohols I
. O

Foliage O
of O
Coriandrum O
sativum O
is O
a O
rich O
source O
of O
natural O
folates O
amenable O
for O
enhancement O
through O
salicylic O
acid O
- O
mediated O
elicitation O
, O
thereby O
holding O
a O
great O
promise O
for O
natural O
- O
mode O
alleviation O
of O
this O
vitamin B
( I
B I
( I
9 I
) I
) I
deficiency O
. O

In O
the O
present O
study O
we O
report O
salicylic O
acid O
- O
mediated O
differential O
elicitation O
of O
different O
forms O
of O
folates O
- O
5 B
- I
methyltetrahydrofola I
, O
5 B
- I
formyltetrahydrofola I
and O
10 B
- I
formyltetrahydrofola I
- O
their O
stabilities O
during O
microwave O
- O
drying O
and O
bioaccessibilities O
from O
fresh O
and O
dried O
foliage O
. O

Serum O
levels O
of O
eicosanoids B
were O
compared O
in O
individuals O
before O
and O
after O
intake O
of O
different O
breakfasts O
. O

Univariate O
descriptive O
analysis O
was O
used O
to O
characterise O
the O
cohort O
selected O
for O
this O
study O
and O
multivariate O
analysis O
to O
reveal O
statistical O
differences O
of O
normalised O
eicosanoids B
concentrations O
( O
determined O
by O
solid O
- O
phase O
extraction O
coupled O
to O
LC O
- O
MS O
/ O
MS O
) O
depending O
on O
the O
edible O
oil O
used O
for O
breakfast O
preparation O
. O

The O
results O
showed O
that O
the O
intake O
of O
breakfast O
prepared O
with O
pure O
sunflower O
oil O
subjected O
to O
deep O
frying O
causes O
an O
effect O
over O
the O
eicosanoids B
profile O
that O
enables O
discrimination O
versus O
the O
rest O
of O
individuals O
. O

The O
effect O
was O
a O
significant O
increase O
in O
the O
concentration O
of O
hydroxyoctadecadieno B
acid I
( O
HODE B
) O
metabolites O
, O
indicative O
markers O
of O
the O
intake O
of O
fried O
oils O
. O

The O
concentration O
of O
HODE B
metabolites O
was O
lower O
when O
the O
oil O
contained O
either O
natural O
antioxidants O
from O
olive O
- O
oil O
pomace O
or O
a O
synthetic O
autooxidation O
inhibitor O
as O
dimethylsiloxane B
. O

Twenty O
- O
three O
compounds O
, O
including O
various O
phenolic O
glycosides O
, O
a O
new O
dimeric O
phenylpropanoid B
glucoside I
, O
saponins O
, O
and O
fatty O
acids O
were O
identified O
online O
, O
or O
after O
targeted O
isolation O
. O

Neferine B
induces O
reactive O
oxygen O
species O
mediated O
intrinsic O
pathway O
of O
apoptosis O
in O
HepG2 O
cells O
. O

Neferine B
, O
an O
alkaloid O
from O
N O
. O
nucifera O
was O
found O
to O
exert O
cytotoxicity O
on O
liver O
cancer O
cells O
HepG2 O
in O
a O
dose O
- O
dependent O
manner O
. O

The O
reactive O
oxygen O
species O
level O
has O
been O
increased O
upon O
neferine B
treatment O
with O
concomitant O
decrease O
in O
reduced O
glutathione O
. O

Our O
data O
further O
indicate O
reduction O
of O
Delta O
psi O
M O
and O
increased O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
during O
apoptosis O
induction O
by O
neferine B
with O
increased O
expression O
of O
apoptotic O
proteins O
such O
as O
Bax O
, O
Bad O
, O
cleaved O
forms O
of O
caspase O
3 O
, O
caspase O
9 O
and O
PARP O
, O
with O
the O
downregulation O
of O
anti O
- O
apoptotic O
protein O
Bcl2 O
in O
HepG2 O
cells O
. O

In O
addition O
, O
expression O
levels O
of O
TNF O
- O
alpha O
, O
p38 O
and O
ERK1 O
/ O
2 O
MAP O
kinases O
were O
increased O
upon O
neferine B
treatment O
. O

These O
results O
imply O
that O
mitochondrial O
- O
mediated O
ROS O
generation O
induced O
by O
neferine B
leads O
to O
caspase O
- O
dependent O
apoptosis O
in O
HepG2 O
cells O
. O

The O
effect O
of O
the O
main O
gangliosides O
( O
GM O
( O
1 O
) O
, O
GM O
( O
3 O
) O
, O
GD O
( O
3 O
) O
) O
and O
free O
sialic O
acid O
( O
Neu5Ac B
) O
upon O
the O
adhesion O
of O
pathogenic O
bacteria O
implicated O
in O
infant O
diarrhoea O
is O
assessed O
in O
vitro O
using O
the O
Caco O
- O
2 O
cell O
line O
. O

Results O
show O
that O
GM O
( O
3 O
) O
, O
GD O
( O
3 O
) O
, O
GM O
( O
1 O
) O
and O
Neu5Ac B
at O
the O
assayed O
concentrations O
are O
able O
to O
interfere O
with O
the O
adhesion O
of O
several O
pathogenic O
bacteria O
involved O
in O
neonatal O
diseases O
- O
the O
greatest O
effect O
corresponding O
to O
Neu5Ac B
, O
followed O
by O
GD O
( O
3 O
) O
, O
GM O
( O
1 O
) O
and O
GM O
( O
3 O
) O
. O

A O
simple O
GC O
- O
MS O
method O
for O
the O
screening O
of O
betulinic B
, I
corosolic I
, I
maslinic I
, I
oleanolic I
and I
ursolic I
acid I
contents O
in O
commercial O
botanicals O
used O
as O
food O
supplement O
ingredients O
. O

The O
occurrence O
of O
triterpene B
pentacyclic I
acids I
in O
plants O
is O
extensive O
, O
but O
little O
is O
known O
about O
their O
availability O
in O
commercial O
extracts O
. O

A O
simple O
GC O
- O
MS O
method O
for O
the O
simultaneous O
determination O
of O
betulinic B
, I
corosolic I
, I
maslinic I
, I
oleanolic I
and I
ursolic I
acids I
was O
developed O
and O
applied O
to O
38 O
different O
commercial O
plant O
extracts O
sold O
as O
ingredients O
for O
dietary O
supplements O
. O

Remarkable O
quantities O
of O
corosolic B
acid I
were O
found O
in O
dried O
extracts O
from O
aerial O
parts O
of O
Lagerstroemia O
speciosa O
and O
Ortosiphon O
stamineus O
( O
14233 O
and O
1132 O
mg O
/ O
kg O
, O
respectively O
) O
, O
while O
oleanolic O
acid O
was O
abundant O
in O
O O
. O
stamineus O
and O
Crataegus O
monogyna O
flowers O
( O
2774 O
and O
2339 O
mg O
/ O
kg O
) O
; O
ursolic B
was O
identified O
in O
O O
. O
stamineus O
, O
C O
. O
monogyna O
, O
L O
. O
speciosa O
and O
Arctostaphylos O
uva O
- O
ursi O
leaves O
( O
7773 O
, O
4165 O

Only O
L O
. O
speciosa O
was O
rich O
in O
maslinic B
acid I
( O
4958 O
mg O
/ O
kg O
) O
, O
while O
minor O
amounts O
of O
betulinic O
acid O
( O
257 O
and O
80 O
mg O
/ O
kg O
) O
were O
detected O
in O
L O
. O
speciosa O
and O
C O
. O
monogyna O
extracts O
. O

Lower O
quantities O
of O
triterpenic B
acids I
were O
identified O
in O
dried O
extracts O
of O
Harpagophyton O
procumbens O
root O
, O
propolis O
, O
Punica O
granatum O
root O
, O
Styrax O
benzoin O
, O
Vaccinium O
myrtillus O
fruits O
and O
Vitis O
vinifera O
seeds O
. O

Decoctions O
and O
fluid O
extracts O
lacked O
or O
contained O
very O
low O
amounts O
of O
triterpenic B
acids I
. O

Investigation O
on O
the O
phase O
behaviour O
of O
a O
biopolymer O
mixture O
has O
been O
performed O
using O
7 O
. O
5 O
% O
( O
w O
/ O
w O
) O
gelatin O
and O
1 O
. O
5 O
% O
( O
w O
/ O
w O
) O
agarose O
in O
the O
presence O
of O
variable O
amounts O
of O
polydextrose B
as O
the O
co O
- O
solute O
from O
low O
to O
high O
levels O
of O
total O
solids O
. O

Systematic O
increase O
in O
the O
concentration O
of O
polydextrose B
prevents O
the O
formation O
of O
a O
stable O
agarose O
network O
, O
with O
the O
polysaccharide O
chains O
dispersing O
in O
the O
high O
solids O
environment O
. O

This O
approach O
allowed O
the O
identification O
of O
four O
endocrine O
compounds O
( O
tetrahydroaldosteron B
- I
3 I
- I
glucuronide I
, O
cortolone B
- I
3 I
- I
glucuronide I
, O
testosterone B
- I
glucuronide I
and O
17 O
- O
hydroxyprogesterone O
) O
, O
which O
belonged O
to O
the O
steroid O
biosynthesis O
pathway O
as O
significant O
metabolites O
upregulated O
by O
citrus O
juice O
intake O
. O

Identification O
of O
flavonoids O
and O
flavonoid B
rhamnosides I
from O
Rhododendron O
mucronulatum O
for O
. O
albiflorum O
and O
their O
inhibitory O
activities O
against O
aldose O
reductase O
. O

A O
chromatography O
of O
the O
active O
EtOAc O
fraction O
of O
RMAF O
led O
to O
the O
isolation O
of O
six O
flavonoids O
, O
which O
were O
identified O
by O
spectroscopic O
analysis O
as O
kaempferol O
( O
1 O
) O
, O
afzelin B
( O
2 O
) O
, O
quercetin O
( O
3 O
) O
, O
quercitrin B
( O
4 O
) O
, O
myricetin O
( O
5 O
) O
and O
myricitrin B
( O
6 O
) O
. O

HPLC O
/ O
UV O
analysis O
revealed O
that O
the O
major O
flavonoids O
of O
RMAF O
and O
RMF O
are O
quercitrin B
( O
4 O
) O
and O
myricitrin B
( O
6 O
) O
. O

CSEE O
exhibited O
a O
significant O
concentration O
- O
dependent O
decrease O
in O
the O
intracellular O
accumulation O
of O
trigycerides B
in O
3T3 O
- O
L1 O
adipocytes O
. O

The O
results O
showed O
that O
ECPC O
and O
ECPA O
contain O
four O
common O
chemical O
markers O
such O
as O
berberine O
, O
but O
palmatine O
and O
jatrorrhizin B
were O
not O
found O
in O
CPC O
in O
contrast O
to O
the O
presence O
in O
CPA O
. O

Our O
laboratories O
have O
synthesized O
and O
have O
initiated O
testing O
of O
novel O
phenoxyalkyl B
pyridinium I
oximes I
( O
patent O
pending O
) O
that O
are O
more O
lipophilic O
than O
currently O
approved O
oximes O
. O

This O
is O
a O
preliminary O
report O
on O
these O
novel O
oximes O
which O
have O
been O
tested O
in O
vitro O
in O
rat O
brain O
homogenates O
with O
highly O
relevant O
surrogates O
for O
sarin O
( O
phthalimidyl B
isopropyl I
methylphosphonate I
; O
PIMP B
) O
and O
VX O
( O
nitrophenyl B
ethyl I
methylphosphonate I
; O
NEMP B
) O
. O

An O
in O
vivo O
testing O
paradigm O
was O
developed O
in O
which O
the O
novel O
oxime O
was O
administered O
at O
the O
time O
of O
maximal O
brain O
AChE O
inhibition O
( O
about O
80 O
% O
) O
( O
1h O
) O
elicited O
by O
nitrophenyl B
isopropyl I
methylphosphonate I
( O
NIMP B
; O
sarin O
surrogate O
) O
. O

The O
initial O
studies O
of O
these O
oximes O
in O
vivo O
with O
the O
sarin O
surrogate O
NIMP B
have O
indicated O
reactivation O
of O
up O
to O
about O
25 O
% O
at O
30min O
after O
oxime O
administration O
and O
substantial O
attenuation O
of O
seizure O
behavior O
from O
some O
of O
the O
oximes O
. O

Heterologous O
expression O
of O
rCtr1 O
in O
HEK293 O
cells O
( O
HEK O
/ O
rCtr1 O
cells O
) O
increased O
the O
uptake O
and O
cytotoxicity O
of O
copper O
, O
oxaliplatin B
, O
cisplatin O
and O
carboplatin B
, O
in O
comparison O
to O
isogenic O
vector O
- O
transfected O
control O
cells O
. O

Cultured O
rat O
DRG O
neurons O
accumulated O
platinum O
during O
their O
exposure O
to O
oxaliplatin B
and O
were O
sensitive O
to O
oxaliplatin B
cytotoxicity O
. O

The O
accumulation O
of O
platinum O
by O
both O
cultured O
rat O
DRG O
neurons O
and O
HEK O
/ O
rCtr1 O
cells O
, O
during O
oxaliplatin B
exposure O
, O
was O
saturable O
and O
temperature O
dependent O
, O
but O
was O
inhibited O
by O
copper O
only O
in O
HEK O
/ O
rCtr1 O
cells O
. O

DRG O
neurons O
display O
substantial O
capacity O
for O
accumulating O
copper O
via O
a O
transport O
process O
mediated O
by O
rCtr1 O
, O
but O
appear O
able O
to O
resist O
copper O
toxicity O
and O
use O
alternative O
mechanisms O
to O
take O
up O
oxaliplatin B
. O

Cysteine O
concentrations O
in O
TAMR O
- O
MCF O
- O
7 O
cells O
and O
medium O
conditioned O
by O
cell O
culture O
for O
42h O
were O
markedly O
decreased O
, O
while O
GSH O
, O
hypotaurine B
, O
and O
taurine O
concentrations O
in O
the O
medium O
were O
increased O
. O

The O
addition O
of O
propargylglycine B
, O
a O
specific O
cystathionine O
gamma O
- O
lyase O
inhibitor O
, O
and O
buthionine O
sulfoximine O
, O
a O
specific O
gamma O
- O
glutamylcysteine O
ligase O
inhibitor O
, O
to O
TAMR O
- O
MCF O
- O
7 O
cells O
, O
but O
not O
to O
MCF O
- O
7 O
cells O
, O
resulted O
in O
cytotoxicity O
after O
sulfur O
amino O
acid O
deprivation O
. O

The O
distance O
between O
delta O
nitrogen O
of O
His438 B
to O
epsilon O
oxygen O
of O
Glu325 B
and O
epsilon O
nitrogen O
of O
His438 B
to O
gamma O
oxygen O
of O
Ser198 B
were O
highly O
altered O
in O
L307P O
mutant O
than O
the O
wild O
and O
other O
three O
variants O
throughout O
the O
simulation O
. O

Absolute O
quantitation O
of O
stevioside B
and O
rebaudioside B
A I
in O
commercial O
standards O
by O
quantitative O
NMR O
. O

The O
extract O
prepared O
from O
the O
leaves O
of O
Stevia O
rebaudiana O
BERTONI O
( O
Asteraceae O
) O
contains O
sweet O
steviol B
glycosides I
, O
mainly O
stevioside B
and O
rebaudioside B
A I
. O

They O
contain O
various O
types O
of O
steviol B
glycosides I
, O
and O
their O
main O
components O
are O
stevioside B
and O
rebaudioside B
A I
. O

The O
content O
of O
each O
steviol B
glycoside I
is O
quantified O
by O
comparing O
the O
ratios O
of O
the O
molecular O
weights O
and O
the O
chromatographic O
peak O
areas O
of O
the O
samples O
to O
those O
of O
stevioside B
or O
rebaudioside B
A I
standards O
of O
the O
Food O
and O
Agriculture O
Organization O
of O
the O
United O
Nations O
( O
FAO O
) O
/ O
World O
Health O
Organization O
( O
WHO O
) O
Joint O
Expert O
Committee O
on O
Food O
Additives O
( O
JECFA O
) O
and O
other O
specifications O
. O

However O
, O
various O
commercial O
standard O
reagents O
of O
stevioside B
and O
rebaudioside B
A I
are O
available O
. O

Therefore O
, O
the O
measured O
values O
of O
stevioside B
and O
rebaudioside B
A I
contained O
in O
a O
sample O
vary O
according O
to O
the O
standard O
used O
for O
the O
quantification O
. O

In O
this O
study O
, O
we O
utilized O
an O
accurate O
method O
, O
quantitative O
NMR O
( O
qNMR O
) O
, O
for O
determining O
the O
contents O
of O
stevioside B
and O
rebaudioside B
A I
in O
standards O
, O
with O
traceability O
to O
the O
International O
System O
of O
Units O
( O
SI O
units O
) O
. O

2 B
- I
Amino I
- I
4 I
- I
arylthiazole I
compounds O
as O
TRPA1 O
antagonists O
( O
WO O
2012085662 O
) O
: O
a O
patent O
evaluation O
. O

The O
patent O
claims O
2 B
- I
amino I
- I
4 I
- I
arylthiazole I
derivative O
compounds O
as O
inhibitors O
of O
the O
TRPA1 O
( O
transient O
receptor O
potential O
ankyrin O
, O
member O
1 O
) O
receptor O
. O

Structures O
of O
the O
isolated O
compounds O
were O
elucidated O
as O
sclareol B
, O
beta O
- O
sitosterol O
, O
salvigenin B
, O
oleanolic O
acid O
and O
ursolic O
acid O
. O

Their O
anticholinesterase O
activity O
was O
carried O
out O
by O
the O
Ellman O
assay O
against O
both O
enzymes O
, O
acetylcholinesterase O
( O
AChE O
) O
and O
butyrylcholinesteras O
, O
and O
diterpene O
sclareol B
exhibited O
fairly O
good O
activity O
against O
both O
the O
enzymes O
while O
the O
two O
triterpenoids O
oleanolic B
and I
ursolic I
acids I
exhibited O
selective O
activity O
against O
AChE O
. O

Decreased O
expression O
of O
the O
Nei O
- O
like O
glycosylases O
Neil1 O
and O
Neil2 O
that O
preferentially O
excise O
ring O
- O
opened O
purines O
and O
5 B
- I
hydroxyuracil I
, O
respectively O
, O
did O
not O
alter O
the O
above O
parameters O
of O
allergic O
immune O
responses O
to O
RWPE O
. O

The O
key O
technologies O
of O
this O
device O
involve O
controlling O
the O
O O
( O
2 O
) O
content O
and O
the O
temperature O
of O
SO B
( I
2 I
) I
as O
well O
as O
the O
quantification O
of O
sulfur O
in O
SF O
. O

This O
device O
can O
reduce O
the O
possibility O
of O
reaction O
between O
bioactive O
compounds O
and O
sulfur O
/ O
sulfurous B
acid I
, O
as O
well O
as O
control O
the O
limitation O
of O
SO B
( I
2 I
) I
residues O
. O

Nerium O
oleander O
derived O
cardiac O
glycoside O
oleandrin B
is O
a O
novel O
inhibitor O
of O
HIV O
infectivity O
. O

Oleandrin B
, O
the O
principle O
cardiac O
glycoside O
( O
CG O
) O
in O
Anvirzel O
( O
TM O
) O
has O
been O
shown O
to O
exhibit O
anti O
- O
cancer O
properties O
but O
its O
efficacy O
against O
HIV O
is O
unknown O
. O

Relative O
to O
untreated O
cultures O
, O
virus O
in O
cultures O
treated O
with O
oleandrin B
had O
significantly O
reduced O
expression O
of O
the O
envelope O
protein O
gp120 O
, O
the O
sole O
determinant O
of O
virus O
infectivity O
, O
suggesting O
a O
novel O
mechanism O
underlying O
the O
impaired O
infectivity O
. O

These O
results O
support O
the O
potential O
utility O
of O
the O
Nerium O
oleander O
aqueous O
extract O
, O
containing O
the O
CG O
oleandrin B
as O
a O
novel O
candidate O
anti O
- O
HIV O
therapeutic O
. O

As O
revealed O
by O
glucose O
oxidase O
( O
GOD O
) O
and O
radioimmunoassay O
( O
RIA O
) O
, O
both O
dimethyldiguanide B
( O
DC O
, O
0 O
. O
6gkg O
( O
- O
1 O
) O
d O
( O
- O
1 O
) O
) O
and O
CPS O
( O
0 O
. O
3 O
, O
0 O
. O
6 O
, O
1 O
. O
2gkg O
( O
- O
1 O
) O
d O
( O
- O
1 O
) O
) O
treatments O
significantly O
resulted O
in O
down O
- O
regulation O
of O
blood O
glucose O
and O
insulin O
levels O
in O
serum O
, O
while O
the O
levels O
of O
oxidative O
stress O
markers O
were O
markedly O
lowered O
through O
ELISA O
assay O
. O

Nine O
new O
steroidal O
glycosides O
, O
named O
as O
stauntosides B
C I
- I
K I
( O
2 O
, O
5 O
, O
7 O
- O
10 O
, O
13 O
, O
14 O
, O
and O
16 O
) O
, O
along O
with O
seven O
known O
compounds O
( O
1 O
, O
3 O
, O
4 O
, O
6 O
, O
11 O
, O
12 O
, O
and O
15 O
) O
were O
isolated O
from O
the O
95 O
% O
ethanol O
extract O
of O
the O
roots O
of O
Cynanchum O
stauntonii O
. O

Unambiguous O
structure O
elucidation O
of O
heterocyclic O
products O
from O
condensation O
- O
cyclisation O
reactions O
of O
enaminones B
by O
2D O
INADEQUATE O
and O
15N B
NMR O
. O

The O
reaction O
of O
enaminones B
with O
3 B
- I
amino I
- I
2 I
- I
cyanopent I
- I
2 I
- I
enedinitrile I
can O
lead O
to O
an O
array O
of O
12 O
possible O
products O
, O
depending O
on O
the O
reaction O
pathway O
and O
tautomerization O
. O

Efficacy O
of O
the O
levonorgestrel B
intrauterine O
system O
( O
LNG B
- O
IUS O
) O
in O
the O
prevention O
of O
the O
atypical O
endometrial O
hyperplasia O
and O
endometrial O
cancer O
: O
retrospective O
data O
from O
selected O
obese O
menopausal O
symptomatic O
women O
. O

The O
aim O
of O
this O
retrospective O
study O
was O
to O
evaluate O
the O
efficacy O
of O
levonorgestrel B
intrauterine O
system O
- O
releasing O
( O
LNG B
- O
IUS O
) O
insertion O
in O
preventing O
atypical O
endometrial O
hyperplasia O
( O
AH O
) O
and O
endometrial O
cancer O
( O
EC O
) O
in O
symptomatic O
postmenopausal O
overweight O
/ O
obese O
women O
. O

A O
total O
of O
34 O
overweight O
/ O
obese O
postmenopausal O
women O
, O
presenting O
abnormal O
uterine O
bleeding O
( O
AUB O
) O
and O
endometrial O
hyperplasia O
( O
EH O
) O
, O
and O
who O
were O
submitted O
to O
LNG B
- O
IUS O
insertion O
, O
were O
identified O
from O
registry O
data O
. O

Endometrial O
histology O
at O
LNG B
- O
IUS O
insertion O
showed O
simple O
EH O
in O
20 O
cases O
( O
58 O
. O
8 O
% O
) O
, O
complex O
EH O
in O
14 O
cases O
( O
41 O
. O
2 O
% O
) O
. O

LNG B
- O
IUS O
represents O
an O
effective O
treatment O
option O
to O
manage O
postmenopausal O
obese O
women O
affected O
by O
AUB O
and O
EH O
. O

We O
also O
tested O
the O
effects O
of O
the O
alpha O
( O
2 O
) O
- O
adreoceptor O
antagonist O
, O
idazoxan B
and O
novel O
antidepressant O
, O
agomelatine O
, O
which O
both O
increase O
cortical O
noradrenaline O
concentrations O
through O
non O
- O
reuptake O
mechanisms O
. O

Neither O
idazoxan B
nor O
agomelatine O
significantly O
reduced O
premature O
responding O
, O
suggesting O
a O
lack O
of O
efficacy O
at O
the O
doses O
tested O
. O

We O
investigated O
the O
effects O
of O
Cd O
and O
17 O
- O
alpha O
- O
ethinylestradiol O
( O
EE B
2 I
) O
on O
AhR O
- O
associated O
gene O
expression O
after O
oral O
exposure O
of O
ovariectomized O
female O
Wistar O
rats O
, O
and O
metallothionein O
( O
Mt1a O
) O
expression O
as O
a O
typical O
metal O
- O
response O
marker O
. O

Mt1a O
in O
the O
small O
intestine O
was O
strongly O
induced O
by O
co O
- O
treatment O
with O
CdCl B
2 I
at O
2 O
mg O
/ O
kg O
b O
. O
wt O
( O
Cd O
2 O
) O
and O
0 O
. O
1 O
mg O
/ O
kg O
b O
. O
wt O
EE2 O
than O
by O
the O
single O
compound O
( O
3 O
- O
day O
gavage O
) O
. O

Interestingly O
, O
the O
EE B
2 I
- O
induced O
down O
- O
regulation O
of O
Cyp1a1 O
, O
Gsta2 O
, O
and O
Nqo1 O
mRNA O
was O
antagonized O
by O
Cd O
2 O
in O
vivo O
and O
in O
colon O
cancer O
cell O
lines O
( O
HT O
- O
29 O
and O
CaCo O
- O
2 O
, O
treated O
5 O
days O
with O
Cd O
1 O
micro O
M O
and O
/ O
or O
E O
2 O
0 O
. O
01 O
micro O
M O
) O
with O
low O
or O
no O
ER O
- O
beta O
expression O
. O

Dose O
dependency O
was O
studied O
after O
Cd O
exposure O
with O
drinking O
water O
( O
5 O
and O
50 O
ppm O
CdCl B
2 I
equivalent O
to O
0 O
. O
4 O
and O
4 O
mg O
/ O
kg O
b O
. O
wt O
; O
Cd O
0 O
. O
4 O
, O
Cd O
4 O
) O
for O
28 O
days O
and O
EE B
2 I
as O
reference O
. O

Intestinal O
Mt1a O
expression O
was O
dose O
dependently O
induced O
, O
while O
AhR O
target O
genes O
were O
down O
- O
regulated O
by O
Cd O
0 O
. O
4 O
similar O
to O
EE B
2 I
and O
more O
pronounced O
than O
by O
Cd O
4 O
. O

How O
is O
( B
68 I
) I
Ga I
labeling O
of O
macrocyclic O
chelators O
influenced O
by O
metal O
ion O
contaminants O
in O
( B
68 I
) I
Ge I
/ O
( B
68 I
) I
Ga I
generator O
eluates O
? O

To O
assess O
the O
influence O
of O
Zn O
( O
2 O
+ O
) O
, O
Cu O
( O
2 O
+ O
) O
, O
Fe O
( O
3 O
+ O
) O
, O
Al O
( O
3 O
+ O
) O
, O
Ti O
( O
IV O
) O
, O
and O
Sn B
( I
IV I
) I
on O
incorporation O
of O
( B
68 I
) I
Ga I
( I
3 I
+ I
) I
into O
pendant O
- O
arm O
macrocyclic O
chelators O
, O
the O
( B
68 I
) I
Ga I
labeling O
of O
1 B
, I
4 I
, I
7 I
- I
triazacyclononane I
- I
1 I
, I
4 I
, I
7 I
- I
triacetic I
acid I
( O
NOTA B
) O
, O
1 O
, O
4 O
, O
7 O
, O
10 O
- O
tetraazacyclododecan O
- O

1 O
, O
4 O
, O
7 O
, O
10 O
- O
tetraacetic O
acid O
( O
DOTA B
) O
, O
1 B
, I
4 I
, I
7 I
- I
triazacyclononane I
- I
1 I
, I
4 I
, I
7 I
- I
tris I
[ I
methyl I
( I
2 I
- I
carboxyethyl I
) I
phosphinic I
acid I
] I
) I
( O
TRAP B
) O
, O
and O
1 O
, O
4 O
, O
7 O
- O
triazacyclononane O
- O
1 O
- O
[ O
methyl O
( O
2 O
- O
carboxyethyl O
) O
phosphinic O
acid O
] O
- O
4 O
, O
7 O
- O
bis O
[ O
methyl O
( O
2 O
- O
hydroxymethyl O
) O
phosphinic O

acid O
] O
( O
NOPO B
) O
, O
as O
well O
as O
their O
peptide O
conjugates O
, O
was O
investigated O
in O
the O
presence O
of O
varying O
concentrations O
of O
these O
metal O
ions O
. O

The O
( B
68 I
) I
Ga I
labeling O
yield O
for O
carboxylate O
- O
type O
chelators O
NOTA B
and O
DOTA O
is O
decreased O
at O
lower O
metal O
ion O
contaminant O
concentrations O
compared O
with O
phosphinate B
- O
type O
chelators O
TRAP B
and O
NOPO B
. O

The O
latter O
are O
able O
to O
rapidly O
exchange O
coordinated O
Zn O
( O
II O
) O
with O
( B
68 I
) I
Ga I
( I
3 I
+ I
) I
, O
as O
confirmed O
by O
mass O
spectrometry O
and O
( O
31 O
) O
P O
NMR O
spectroscopy O
. O

( B
68 I
) I
Ga I
labeling O
of O
Zn O
( O
II O
) O
complexes O
of O
TRAP B
and O
NOPO B
proceeds O
as O
efficient O
as O
labeling O
of O
neat O
NOTA B
; O
this O
applies O
also O
to O
the O
corresponding O
peptide O
conjugates O
of O
these O
chelators O
. O

This O
behavior O
results O
in O
substantially O
improved O
selectivity O
for O
Ga B
( I
3 I
+ I
) I
and O
, O
therefore O
, O
in O
more O
robust O
and O
reliable O
( B
68 I
) I
Ga I
labeling O
procedures O
. O

In O
addition O
, O
none O
of O
the O
investigated O
chelators O
binds O
( B
68 I
) I
Ge I
, O
rendering O
post O
- O
labeling O
purification O
protocols O
, O
for O
example O
, O
solid O
- O
phase O
extraction O
, O
a O
reliable O
means O
of O
removal O
of O
( B
68 I
) I
Ge I
contamination O
from O
( B
68 I
) I
Ga I
radiopharmaceuticals O
. O

Mice O
were O
intraperitioneally O
injected O
with O
selenite B
once O
daily O
for O
five O
days O
at O
a O
dose O
of O
3 O
mg O
Se O
/ O
kg O
, O
which O
fully O
suppressed O
animal O
growth O
but O
did O
not O
cause O
death O
. O

Surprisingly O
the O
co O
- O
administration O
of O
the O
selenite B
and O
nontoxic O
doses O
of O
EGCG O
( O
10 O
, O
20 O
and O
40 O
mg O
/ O
kg O
, O
intraperitioneally O
) O
resulted O
in O
the O
mortality O
of O
treated O
mice O
in O
a O
dose O
and O
time O
- O
dependent O
manner O
( O
33 O
. O
3 O
% O
, O
100 O
% O
and O
100 O
% O
, O
respectively O
) O
. O

EGCG O
- O
selenite B
induced O
lethality O
did O
not O
result O
from O
enhanced O
selenium O
accumulation O
but O
appeared O
to O
involve O
the O
suppression O
of O
a O
selenite B
- O
induced O
adaptive O
response O
as O
evidenced O
by O
hepatic O
glutathione O
S O
- O
transferase O
activity O
. O

Saxitoxin O
( O
STX B
) O
is O
a O
low O
molecular O
weight O
neurotoxin O
mainly O
produced O
by O
certain O
marine O
dinoflagellates O
that O
, O
along O
with O
its O
family O
of O
similarly O
related O
paralytic O
shellfish O
toxins O
, O
may O
cause O
the O
potentially O
fatal O
intoxication O
known O
as O
paralytic O
shellfish O
poisoning O
. O

Here O
we O
report O
the O
discovery O
of O
a O
DNA O
aptamer O
that O
targets O
STX B
. O

Concentration O
- O
dependent O
and O
selective O
binding O
of O
the O
aptamer O
to O
STX B
was O
determined O
using O
a O
surface O
plasmon O
resonance O
sensor O
. O

Not O
only O
does O
this O
work O
represent O
the O
first O
reported O
aptamer O
to O
STX B
, O
but O
also O
the O
first O
aptamer O
to O
any O
marine O
biotoxin O
. O

The O
selected O
STX B
aptamer O
sequence O
is O
provided O
here O
, O
making O
it O
available O
to O
any O
investigator O
for O
use O
in O
assay O
development O
for O
the O
detection O
of O
STX B
. O

Nanomedicine O
for O
the O
treatment O
of O
retinal B
and O
optic O
nerve O
diseases O
. O

In O
this O
chapter O
, O
we O
review O
ophthalmic O
applications O
of O
nanotechnology O
in O
the O
following O
areas O
: O
drug O
and O
trophic O
factor O
therapy O
for O
glaucoma O
, O
retinal O
degenerative O
, O
and O
retinal O
vascular O
disease O
; O
gene O
therapy O
for O
retinal B
degenerative O
disease O
; O
regenerative O
medicine O
, O
including O
optogenetics O
and O
optic O
nerve O
regeneration O
; O
and O
diagnostics O
( O
minimally O
invasive O
IOP O
monitoring O
) O
. O

The O
3D O
- O
structure O
of O
HmTx O
consists O
of O
three O
conserved O
alpha O
- O
helices O
: O
h1 O
( O
Lys24 B
- O
His34 B
) O
, O
h2 O
( O
Cys59 B
- O
Asp71 B
) O
, O
and O
h3 O
( O
Ala80 B
- O
Phe89 B
) O
. O

The O
beta O
- O
sheet O
consisted O
of O
a O
single O
stranded O
anti O
- O
parallel O
beta O
- O
sheet O
( O
b1 O
. O
1 O
at O
Glu43 B
- O
Lys45 B
and O
b1 O
. O
2 O
at O
Lys48 O
- O
Asn50 B
) O
that O
was O
highly O
similar O
to O
the O
conserved O
sequences O
( O
- O
CGXG O
- O
, O
- O
CCXXHDXC O
- O
and O
CXCEXXXXXC O
- O
) O
of O
Apis O
mellifera O
( O
bee O
) O
phospholipases O
. O

Rev1 O
is O
a O
dCMP B
transferase O
, O
but O
additionally O
plays O
non O
- O
catalytic O
functions O
in O
translesion O
synthesis O
. O

Supporting O
functional O
significance O
of O
this O
interaction O
, O
both O
the O
Rev1 O
pathway O
and O
Rad5 O
are O
required O
for O
translesion O
synthesis O
and O
mutagenesis O
of O
1 B
, I
N I
( I
6 I
) I
- I
ethenoadenine I
. O

Furthermore O
, O
disrupting O
the O
Rev1 O
- O
Rad5 O
interaction O
by O
mutating O
Rev1 O
did O
not O
affect O
its O
dCMP B
transferase O
, O
but O
led O
to O
inactivation O
of O
the O
Rev1 O
non O
- O
catalytic O
function O
in O
translesion O
synthesis O
of O
UV O
- O
induced O
DNA O
damage O
. O

Furthermore O
, O
TNF O
- O
alpha O
- O
induced O
CXCL8 O
secretion O
was O
( O
i O
) O
inhibited O
by O
the O
MR O
antagonist O
tiotropium O
and O
the O
M3R O
antagonist O
4 B
- I
DAMP I
and O
( O
ii O
) O
enhanced O
by O
the O
M1 O
/ O
M3R O
agonist O
pilocarpine O
and O
the O
cholinesterase O
inhibitor O
physostigmine O
. O

Using O
an O
embryo O
- O
larval O
bioassay O
, O
embryos O
were O
either O
treated O
with O
1000 O
pptr O
( O
parts O
- O
per O
- O
trillion O
, O
pg O
/ O
mL O
) O
17 B
alpha I
- I
ethynylestradiol I
( O
EE2 O
) O
alone O
from O
6h O
post O
fertilization O
( O
hpf O
) O
to O
4 O
days O
post O
fertilization O
( O
dpf O
) O
, O
or O
pre O
- O
treated O
with O
dioxin O
( O
4 O
- O
5 O
hpf O
) O
prior O
to O
EE2 O
. O

Pre O
- O
treatment O
with O
400 O
pptr O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo O
- O
p O
- O
dioxin O
( O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
TCDD I
) O
or O
1 B
, I
2 I
, I
3 I
, I
7 I
, I
8 I
- I
pentachlorodibenzo I
- I
p I
- I
dioxin I
inhibited O
the O
EE2 O
induction O
of O
vtg1 O
, O
vtg2 O
and O
vtg3 O
by O
> O
95 O
% O
( O
p O
< O
= O
0 O
. O
05 O
) O
. O

In O
comparison O
, O
a O
splice O
- O
blocking O
AHR2 O
morpholino O
used O
to O
down O
- O
regulate O
ahr2 O
expression O
significantly O
reduced O
the O
inhibition O
of O
vtg1 O
, O
vtg2 O
and O
vtg3 O
by O
400 O
pptr O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
TCDD I
( O
20 O
. O
7 O
- O
27 O
. O
4 O
% O
rescue O
) O
. O

These O
studies O
demonstrate O
that O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
TCDD I
directly O
inhibits O
the O
vitellogenin O
pathway O
in O
vivo O
through O
activation O
of O
the O
AHR2 O
. O

Effects O
of O
octylphenol B
and O
bisphenol O
A O
on O
the O
expression O
of O
calcium O
transport O
genes O
in O
the O
mouse O
duodenum O
and O
kidney O
during O
pregnancy O
. O

Octylphenol B
( O
OP O
) O
is O
the O
degradative O
product O
of O
alkylphenol B
ethoxylates I
that O
are O
widely O
used O
to O
produce O
rubber O
, O
pesticides O
, O
and O
paints O
. O

From O
6 O
. O
5 O
to O
16 O
. O
5 O
day O
post O
coitus O
( O
dpc O
) O
, O
pregnant O
mice O
were O
given O
oral O
doses O
of O
17 B
alpha I
- I
ethynylestradiol I
( O
EE O
, O
0 O
. O
2mg O
/ O
kg O
/ O
day O
) O
, O
BPA O
( O
5 O
or O
50mg O
/ O
kg O
/ O
day O
) O
, O
or O
OP O
( O
3 O
, O
12 O
, O
or O
48 O
mg O
/ O
kg O
/ O
day O
) O
dissolved O
in O
corn O
oil O
. O

The O
interactions O
of O
these O
liposomes O
with O
two O
local O
anesthetics O
, O
tetracaine B
and O
lidocaine O
, O
and O
one O
general O
anesthetic O
, O
propofol O
, O
were O
studied O
. O

The O
effect O
of O
cholesterol O
was O
investigated O
by O
comparing O
anesthetic O
interactions O
with O
POPC O
/ O
SM O
liposomes O
and O
POPC O
/ O
SM O
/ O
CHOL B
liposomes O
. O

Tetracaine B
interacts O
more O
with O
raftlike O
domains O
, O
lidocaine O
induces O
stronger O
modifications O
on O
POPC O
/ O
SM O
liposomes O
and O
the O
results O
for O
propofol O
are O
not O
fully O
conclusive O
but O
it O
seems O
to O
be O
the O
least O
prone O
to O
lipid O
interactions O
. O

O2 O
- O
independent O
formation O
of O
the O
inactive O
states O
of O
NiFe B
hydrogenase O
. O

We O
studied O
the O
mechanism O
of O
aerobic O
inactivation O
of O
Desulfovibrio O
fructosovorans O
nickel B
- I
iron I
( O
NiFe B
) O
hydrogenase O
by O
quantitatively O
examining O
the O
results O
of O
electrochemistry O
, O
EPR O
and O
FTIR O
experiments O
. O

Our O
findings O
offer O
new O
ways O
toward O
the O
understanding O
of O
O O
( O
2 O
) O
inactivation O
and O
O O
( O
2 O
) O
tolerance O
in O
NiFe B
hydrogenases O
. O

In O
addition O
, O
Kupffer O
cells O
were O
responsive O
to O
inflammatory O
stimuli O
such O
as O
LPS O
demonstrating O
the O
possibility O
to O
detect O
inflammation O
- O
mediated O
toxicity O
as O
exemplified O
by O
the O
drug O
trovafloxacin B
. O

Alachlor B
, O
which O
has O
demonstrated O
thyroid O
effects O
in O
mammals O
, O
may O
be O
largely O
responsible O
for O
the O
observed O
effects O
. O

In O
vitro O
exposure O
of O
precision O
- O
cut O
lung O
slices O
to O
2 B
- I
( I
4 I
- I
amino I
- I
3 I
- I
methylphenyl I
) I
- I
5 I
- I
fluorobenzothiazole I
lysylamide I
dihydrochloride I
( O
NSC B
710305 I
, O
Phortress B
) O
increases O
inflammatory O
cytokine O
content O
and O
tissue O
damage O
. O

The O
anticancer O
drug O
( O
2 B
- I
[ I
4 I
- I
amino I
- I
3 I
- I
methylphenyl I
] I
- I
5 I
- I
fluorobenzothiazole I
lysylamide I
dihydrochloride I
) O
( O
NSC B
710305 I
, O
Phortress B
) O
is O
a O
metabolically O
activated O
prodrug O
that O
causes O
DNA O
adduct O
formation O
and O
subsequent O
toxicity O
. O

An O
ex O
vivo O
precision O
- O
cut O
lung O
slice O
( O
PCLS O
) O
model O
was O
used O
to O
search O
for O
concentration O
dependent O
effects O
of O
NSC B
710305 I
( O
10 O
, O
25 O
, O
50 O
, O
and O
100 O
micro O
M O
) O
on O
cytokine O
content O
, O
protein O
content O
, O
and O
immuno O
/ O
histological O
endpoints O
. O

Preparation O
and O
culture O
of O
PCLS O
caused O
an O
initial O
spike O
in O
proinflammatory O
cytokine O
expression O
and O
therefore O
treatment O
with O
NSC B
710305 I
was O
delayed O
until O
48 O
h O
after O
initiating O
the O
slice O
cultures O
to O
avoid O
confounding O
the O
response O
to O
slicing O
with O
any O
drug O
response O
. O

PCLSs O
were O
evaluated O
after O
24 O
, O
48 O
, O
and O
72 O
h O
exposures O
to O
NSC B
710305 I
. O

NSC B
710305 I
caused O
a O
concentration O
- O
dependent O
cytokine O
response O
, O
and O
only O
the O
toxicity O
caused O
by O
a O
72 O
- O
h O
exposure O
to O
25 O
micro O
M O
reversed O
during O
the O
24 O
- O
h O
recovery O
period O
. O

In O
conclusion O
, O
the O
concentration O
- O
and O
time O
- O
dependent O
inflammatory O
response O
of O
PCLS O
to O
NSC B
710305 I
preceded O
relevant O
tissue O
damage O
by O
a O
few O
days O
. O

The O
no O
- O
observable O
adverse O
effect O
level O
( O
NOAEL O
) O
for O
24 O
, O
48 O
, O
and O
72 O
h O
exposures O
was O
established O
as O
10 O
micro O
M O
NSC B
710305 I
. O

We O
demonstrate O
its O
suitability O
as O
a O
transfection O
agent O
by O
delivering O
miR O
- O
126 O
to O
human O
vascular O
endothial O
cells O
( O
HUVECs O
) O
via O
polyarginine B
- O
and O
RGD O
- O
modified O
bowties O
and O
evaluating O
the O
downstream O
effects O
on O
proliferation O
and O
tube O
formation O
. O

Mesalamine B
modulates O
intercellular O
adhesion O
through O
inhibition O
of O
p O
- O
21 O
activated O
kinase O
- O
1 O
. O

Mesalamine B
( O
5 B
- I
ASA I
) O
is O
widely O
used O
for O
the O
treatment O
of O
ulcerative O
colitis O
, O
a O
remitting O
condition O
characterized O
by O
chronic O
inflammation O
of O
the O
colon O
. O

Knowledge O
about O
the O
molecular O
and O
cellular O
targets O
of O
5 B
- I
ASA I
is O
limited O
and O
a O
clear O
understanding O
of O
its O
activity O
in O
intestinal O
homeostasis O
and O
interference O
with O
neoplastic O
progression O
is O
lacking O
. O

We O
sought O
to O
identify O
molecular O
pathways O
interfered O
by O
5 B
- I
ASA I
, O
using O
CRC O
cell O
lines O
with O
different O
genetic O
background O
. O

Microarray O
was O
performed O
for O
gene O
expression O
profile O
of O
5 B
- I
ASA I
- O
treated O
and O
untreated O
cells O
( O
HCT116 O
and O
HT29 O
) O
. O

Filtering O
and O
analysis O
of O
data O
identified O
three O
oncogenic O
pathways O
interfered O
by O
5 B
- I
ASA I
: O
MAPK O
/ O
ERK O
pathway O
, O
cell O
adhesion O
and O
beta O
- O
catenin O
/ O
Wnt O
signaling O
. O

PAK1 O
emerged O
as O
a O
consensus O
target O
of O
5 B
- I
ASA I
, O
orchestrating O
these O
pathways O
. O

We O
further O
investigated O
the O
effect O
of O
5 B
- I
ASA I
on O
cell O
adhesion O
. O

5 B
- I
ASA I
increased O
cell O
adhesion O
which O
was O
measured O
by O
cell O
adhesion O
assay O
and O
transcellular O
- O
resistance O
measurement O
. O

Moreover O
, O
5 B
- I
ASA I
treatment O
restored O
membranous O
expression O
of O
adhesion O
molecules O
E O
- O
cadherin O
and O
beta O
- O
catenin O
. O

PAK1 O
expression O
was O
elevated O
in O
APC O
( O
min O
) O
polyps O
and O
5 B
- I
ASA I
treatment O
reduced O
its O
expression O
. O

Our O
data O
demonstrates O
novel O
pharmacological O
mechanism O
of O
mesalamine B
in O
modulation O
of O
cell O
adhesion O
and O
role O
of O
PAK1 O
in O
APC O
( O
min O
) O
polyposis O
. O

We O
propose O
that O
inhibition O
of O
PAK1 O
expression O
by O
5 B
- I
ASA I
can O
impede O
with O
neoplastic O
progression O
in O
colorectal O
carcinogenesis O
. O

The O
mechanism O
of O
PAK1 O
inhibition O
and O
induction O
of O
membranous O
translocation O
of O
adhesion O
proteins O
by O
5 B
- I
ASA I
might O
be O
independent O
of O
its O
known O
anti O
- O
inflammatory O
action O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
potential O
effects O
of O
puerarin O
( O
PR O
) O
, O
an O
effective O
isoflavonoid B
compound O
purified O
from O
Pueraria O
lobata O
, O
in O
treating O
hepatic O
fibrosis O
( O
HF O
) O
rats O
induced O
by O
carbon O
tetrachloride O
( O
CCl O
( O
4 O
) O
, O
2 O
mL O
kg O
( O
- O
1 O
) O
d O
( O
- O
1 O
) O
) O
. O

Phytochemical O
analysis O
revealed O
the O
presence O
of O
sweroside O
, O
swertiamarin O
and O
gentiopicrin B
in O
high O
concentrations O
in O
both O
extracts O
. O

PBMCs O
, O
isolated O
from O
blood O
samples O
of O
four O
male O
and O
four O
female O
healthy O
individuals O
, O
were O
exposed O
in O
vitro O
for O
18h O
to O
either O
a O
dioxin O
- O
like O
polychlorinated O
biphenyl O
( O
PCB126 O
, O
1 O
mu O
M O
) O
, O
a O
non O
- O
dioxin O
- O
like O
polychlorinated O
biphenyl O
( O
PCB153 B
, O
10 O
mu O
M O
) O
, O
a O
brominated O
flame O
retardant O
( O
BDE47 B
, O
10 O
mu O
M O
) O
, O
a O
perfluorinated B
alkyl I
acid I
( O
PFOA O
, O
10 O
mu O
M O
) O
or O

bisphenol B
( O
BPA O
, O
10 O
mu O
M O
) O
. O

Hierarchical O
cluster O
analysis O
created O
three O
groups O
and O
clustered O
: O
( O
1 O
) O
PCB126 O
- O
exposed O
samples O
, O
( O
2 O
) O
PCB153 B
and O
BDE47 B
, O
( O
3 O
) O
PFOA O
and O
BPA O
. O

BDE47 B
and O
PCB153 B
are O
known O
to O
disrupt O
thyroid O
metabolism O
and O
exposure O
influenced O
the O
expression O
of O
the O
nuclear O
receptors O
PPAR O
gamma O
and O
ESR2 O
, O
respectively O
. O

In O
Ca O
( O
2 O
+ O
) O
- O
free O
medium O
, O
treatment O
with O
the O
endoplasmic O
reticulum O
Ca O
( O
2 O
+ O
) O
pump O
inhibitor O
thapsigargin O
( O
TG O
) O
or O
2 B
, I
5 I
- I
di I
- I
tert I
- I
butylhydroquinone I
( O
BHQ B
) O
inhibited O
carvacrol O
- O
induced O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
rise O
. O

Conversely O
, O
incubation O
with O
carvacrol O
inhibited O
TG O
or O
BHQ B
- O
induced O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
rise O
. O

Inhibition O
of O
phospholipase O
C O
( O
PLC O
) O
with O
U73122 B
abolished O
carvacrol O
- O
induced O
[ O
Ca O
( O
2 O
+ O
) O
] O
( O
i O
) O
rise O
. O

Carvacrol O
decreased O
cell O
viability O
, O
which O
was O
not O
reversed O
when O
cytosolic O
Ca O
( O
2 O
+ O
) O
was O
chelated O
with O
BAPTA O
- O
AM O
( O
1 B
, I
2 I
- I
bis I
( I
2 I
- I
aminophenoxy I
) I
ethane I
- I
N I
, I
N I
, I
N I
' I
, I
N I
' I
- I
tetraacetic I
acid I
- I
acetoxymethyl I
ester I
) O
. O

The O
2 O
, O
2 O
' O
, O
4 O
, O
4 O
' O
- O
tetrabromodiphenyl O
ether O
hydroxylated O
metabolites O
5 B
- I
OH I
- I
BDE I
- I
47 I
and O
6 B
- I
OH I
- I
BDE I
- I
47 I
stimulate O
estradiol O
secretion O
in O
the O
ovary O
by O
activating O
aromatase O
expression O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
assess O
the O
effect O
of O
two O
hydroxylated B
BDE I
- I
47 I
metabolites O
, O
5 B
- I
OH I
- I
BDE I
- I
47 I
and O
6 B
- I
OH I
- I
BDE I
- I
47 I
, O
on O
steroidogenesis O
in O
the O
ovary O
. O

Direct O
assessment O
of O
aromatase O
activity O
by O
dibenzylfluorescein B
assay O
and O
indirect O
assessment O
of O
aromatase O
activity O
by O
measurement O
of O
the O
conversion O
of O
testosterone O
to O
estradiol O
confirmed O
that O
5 B
- I
OH I
- I
BDE I
- I
47 I
and O
6 B
- I
OH I
- I
BDE I
- I
47 I
stimulate O
aromatase O
activity O
. O

The O
aromatase O
inhibitor O
CGS B
16949A I
abolished O
this O
stimulatory O
activity O
and O
reduced O
estradiol O
levels O
in O
the O
control O
and O
treatment O
groups O
. O

Enhanced O
bile O
acid O
synthesis O
in O
these O
animals O
was O
also O
confirmed O
by O
a O
2 O
- O
fold O
increase O
in O
plasma O
marker O
7 B
alpha I
- I
hydroxy I
- I
4 I
- I
cholesten I
- I
3 I
- I
one I
. O

The O
major O
bacterial O
fermentation O
products O
are O
acetate O
, O
propionate B
and O
butyrate B
; O
and O
the O
production O
of O
these O
tends O
to O
lower O
the O
colonic O
pH O
. O

These O
weak O
acids O
influence O
the O
microbial O
composition O
and O
directly O
affect O
host O
health O
, O
with O
butyrate B
the O
preferred O
energy O
source O
for O
the O
colonocytes O
. O

Anti O
- O
proliferative O
effect O
of O
( B
19Z I
) I
- I
halichondramide I
, O
a O
novel O
marine O
macrolide O
isolated O
from O
the O
sponge O
Chondrosia O
corticata O
, O
is O
associated O
with O
G2 O
/ O
M O
cell O
cycle O
arrest O
and O
suppression O
of O
mTOR O
signaling O
in O
human O
lung O
cancer O
cells O
. O

Five O
oxazole B
- O
containing O
macrolides O
isolated O
from O
the O
marine O
sponge O
Chondrosia O
corticata O
were O
evaluated O
for O
their O
anti O
- O
proliferative O
activity O
in O
a O
panel O
of O
human O
solid O
cancer O
cell O
lines O
. O

( B
19Z I
) I
- I
Halichondramide I
( O
( B
19Z I
) I
- I
HCA I
) O
, O
a O
novel O
trisoxazole B
- O
containing O
macrolide O
, O
exhibited O
the O
highest O
potency O
among O
the O
macrolides O
, O
with O
IC50 O
values O
in O
the O
submicro O
- O
molar O
ranges O
. O

Prompted O
by O
the O
high O
potency O
of O
growth O
inhibition O
of O
cancer O
cells O
, O
we O
investigated O
the O
mechanism O
of O
action O
of O
the O
anti O
- O
proliferative O
activity O
of O
( B
19Z I
) I
- I
HCA I
in O
human O
A549 O
lung O
cancer O
cells O
. O

( B
19Z I
) I
- I
HCA I
induced O
cell O
cycle O
arrest O
in O
the O
G2 O
/ O
M O
phase O
, O
and O
this O
event O
was O
highly O
correlated O
with O
the O
expression O
of O
checkpoint O
proteins O
, O
including O
the O
up O
- O
regulation O
of O
p53 O
and O
GADD45 O
alpha O
and O
the O
down O
- O
regulation O
of O
cyclin O
B1 O
, O
cyclin O
A O
, O
CDC2 O
, O
and O
CDC25C O
. O

In O
addition O
, O
the O
growth O
inhibition O
by O
( B
19Z I
) I
- I
HCA I
was O
associated O
with O
the O
suppression O
of O
mTOR O
and O
its O
downstream O
effector O
molecules O
4EBP1 O
and O
p70S6K O
. O

The O
modulation O
of O
mTOR O
signaling O
by O
( B
19Z I
) I
- I
HCA I
was O
found O
to O
be O
mediated O
by O
the O
regulation O
of O
upstream O
proteins O
, O
including O
the O
down O
- O
regulation O
of O
Akt O
and O
p38 O
MAPK O
and O
the O
up O
- O
regulation O
of O
AMPK O
. O

These O
data O
suggest O
the O
potential O
of O
( B
19Z I
) I
- I
HCA I
to O
serve O
as O
a O
candidate O
for O
cancer O
chemotherapeutic O
agents O
derived O
from O
marine O
organisms O
by O
virtue O
of O
arresting O
the O
cell O
cycle O
in O
the O
G2 O
/ O
M O
phase O
and O
the O
modulation O
of O
mTOR O
/ O
AMPK O
signaling O
pathways O
. O

Using O
a O
range O
of O
in O
vitro O
acetylphenylhydrazin B
incubations O
, O
we O
validated O
a O
field O
- O
adapted O
technique O
against O
laboratory O
wet O
- O
mounts O
and O
verified O
the O
stability O
of O
this O
technique O
for O
one O
month O
following O
preparation O
. O

The O
polycyclic B
aromatic I
hydrocarbon I
( O
PAH O
) O
benzo O
[ O
a O
] O
pyrene O
( O
BP O
) O
is O
metabolized O
into O
a O
complex O
pattern O
of O
BP O
derivatives O
, O
among O
which O
the O
ultimate O
carcinogen O
( B
+ I
) I
- I
anti I
- I
BP I
- I
7 I
, I
8 I
- I
diol I
- I
9 I
, I
10 I
- I
epoxide I
( O
BPDE B
) O
is O
formed O
to O
certain O
extents O
. O

Cultured O
primary O
keratinocytes O
revealed O
a O
level O
of O
genotoxicity O
comparable O
with O
that O
of O
direct O
exposure O
to O
50 O
- O
100 O
nM O
of O
BPDE B
. O

Design O
, O
synthesis O
and O
anticancer O
activity O
of O
N B
( I
3 I
) I
, I
N I
( I
11 I
) I
- I
bis I
( I
2 I
- I
hydroxyethyl I
) I
- I
14 I
- I
aryl I
- I
14H I
- I
dibenzo I
[ I
a I
, I
j I
] I
xanthenes I
- I
3 I
, I
11 I
- I
dicarboxamide I
. O

A O
series O
of O
novel O
N B
( I
3 I
) I
, I
N I
( I
11 I
) I
- I
bis I
( I
2 I
- I
hydroxyethyl I
) I
- I
14 I
- I
aryl I
- I
14H I
- I
dibenzo I
[ I
a I
, I
j I
] I
xanthenes I
- I
3 I
, I
11 I
- I
dicarboxamide I
, O
three O
N B
( I
3 I
) I
, I
N I
( I
11 I
) I
- I
bis I
( I
2 I
- I
hydroxyethyl I
) I
- I
14 I
- I
aryl I
- I
14H I
- I
dibenzo I
[ I
a I
, I
j I
] I
xanthene I
- I
3 I
, I
11 I
- I
dimethanamine I
derivatives O
and O
their O
intermediates O
14 O
- O
aryl O
- O
14H O
- O
dibenzo O
[ O

a O
, O
j O
] O
xanthenes O
- O
3 O
, O
11 O
- O
dicarboxylic O
acid O
, O
were O
synthesized O
, O
and O
the O
structures O
of O
which O
were O
characterized O
by O
( B
1 I
) I
H I
- O
NMR O
, O
( O
13 O
) O
C O
- O
NMR O
, O
high O
resolution O
( O
HR O
) O
- O
MS O
, O
and O
IR O
spectra O
. O

In O
a O
previous O
work O
we O
showed O
that O
a O
new O
class O
of O
compounds O
derived O
from O
XR9576 B
( O
tariquidar O
) O
selectively O
inhibits O
BCRP O
. O

CAPs O
off O
to O
the O
S B
- I
S I
bond O
: O
Application O
of O
a O
strategy O
involving O
the O
introduction O
of O
intramolecular O
disulfide O
bonds O
to O
amphipathic O
cationic O
antimicrobial O
peptides O
( O
CAPs O
) O
led O
to O
decreased O
alpha O
- O
helicity O
and O
hydrophobicity O
. O

According O
to O
the O
fluid O
mosaic O
model O
proposed O
by O
Singer O
and O
Nicholson O
, O
the O
glycerophospholipid B
bilayer O
is O
a O
two O
- O
dimensional O
fluid O
construct O
that O
allows O
the O
lateral O
movement O
of O
membrane O
components O
. O

A O
number O
of O
integral O
membrane O
G O
protein O
- O
coupled O
receptors O
( O
GPCRs O
) O
share O
common O
structural O
features O
( O
including O
palmytoilated B
aminoacid I
residues O
and O
consensus O
sequences O
specific O
for O
interaction O
with O
cholesterol O
) O
that O
allow O
them O
to O
interact O
with O
lipid O
rafts O
, O
membrane O
cholesterol O
- O
rich O
microdomains O
able O
to O
regulate O
GPCR O
signalling O
and O
functions O
. O

TCDD O
increased O
the O
expression O
of O
40 O
% O
of O
the O
genes O
of O
the O
epidermal O
differentiation O
complex O
found O
on O
chromosome O
1q21 O
and O
75 O
% O
of O
the O
genes O
required O
for O
de O
novo O
ceramide B
biosynthesis O
. O

Delta O
( O
9 O
) O
- O
tetrahydrocannabinol O
( O
Delta B
( I
9 I
) I
- I
THC I
) O
has O
potent O
immune O
modulatory O
properties O
and O
can O
impair O
pathogen O
- O
induced O
immune O
defenses O
, O
which O
in O
part O
have O
been O
attributed O
to O
ligation O
of O
the O
cannabinoid O
receptors O
1 O
( O
CB O
( O
1 O
) O
) O
and O
2 O
( O
CB O
( O
2 O
) O
) O
. O

This O
study O
focused O
on O
the O
modulation O
of O
the O
inflammatory O
immune O
response O
to O
influenza O
by O
Delta B
( I
9 I
) I
- I
THC I
and O
the O
role O
of O
CB O
( O
1 O
) O
and O
/ O
or O
CB O
( O
2 O
) O
as O
receptor O
targets O
for O
Delta B
( I
9 I
) I
- I
THC I
. O

C57Bl O
/ O
6 O
( O
wild O
type O
) O
and O
CB O
( O
1 O
) O
( O
- O
/ O
- O
) O
CB O
( O
2 O
) O
( O
- O
/ O
- O
) O
mice O
were O
administered O
Delta B
( I
9 I
) I
- I
THC I
( O
75 O
mg O
/ O
kg O
) O
surrounding O
the O
intranasal O
instillation O
of O
A O
/ O
PR O
/ O
8 O
/ O
34 O
influenza O
virus O
. O

Three O
days O
post O
infection O
( O
dpi O
) O
, O
Delta B
( I
9 I
) I
- I
THC I
broadly O
decreased O
expression O
levels O
of O
mRNA O
induced O
by O
the O
innate O
immune O
response O
to O
influenza O
, O
suppressed O
the O
percentage O
of O
interferon O
- O
gamma O
( O
IFN O
- O
gamma O
) O
- O
producing O
CD4 O
( O
+ O
) O
and O
interleukin O
- O
17 O
- O
producing O
NK1 O
. O
1 O
( O
+ O
) O
cells O
, O
and O
reduced O
the O
influx O
of O
antigen O
- O
presenting O
cells O
( O
APC O
) O
, O
including O
inflammatory O
myeloid O
cells O
and O
monocytes O
/ O
macrophages O
, O
into O
the O
lung O
in O
a O
CB O
( O
1 O
) O
- O
and O
/ O
or O
CB O
( O
2 O
) O
- O
dependent O
manner O
. O

Delta B
( I
9 I
) I
- I
THC I
had O
little O
effect O
on O
the O
expression O
of O
CD86 O
, O
major O
histocompatibility O
complex O
I O
( O
MHC O
I O
) O
, O
and O
MHC O
II O
by O
APC O
isolated O
from O
the O
lung O
. O

In O
vitro O
studies O
demonstrated O
that O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
maturation O
was O
suppressed O
by O
Delta B
( I
9 I
) I
- I
THC I
in O
bone O
marrow O
- O
derived O
DC O
( O
bmDC O
) O
. O

Furthermore O
, O
antigen O
- O
specific O
IFN O
- O
gamma O
production O
by O
CD8 O
( O
+ O
) O
T O
cells O
after O
coculture O
was O
reduced O
by O
Delta B
( I
9 I
) I
- I
THC I
treatment O
of O
bmDC O
in O
a O
CB O
( O
1 O
) O
- O
and O
/ O
or O
CB O
( O
2 O
) O
- O
dependent O
manner O
. O

Collectively O
, O
these O
studies O
suggest O
that O
Delta B
( I
9 I
) I
- I
THC I
potently O
suppresses O
myeloid O
cell O
immune O
function O
, O
in O
a O
manner O
involving O
CB O
( O
1 O
) O
and O
/ O
or O
CB O
( O
2 O
) O
, O
thereby O
impairing O
immune O
responses O
to O
influenza O
infection O
. O

Development O
of O
solid O
lipid O
nanoparticles O
( O
SLNs O
) O
of O
lopinavir B
using O
hot O
self O
nano O
- O
emulsification O
( O
SNE O
) O
technique O
. O

Solid O
lipid O
nanoparticles O
( O
SLNs O
) O
of O
poor O
orally O
bioavailable O
drug O
lopinavir B
were O
prepared O
using O
hot O
self O
nano O
- O
emulsification O
( O
SNE O
) O
technique O
. O

Higher O
oral O
bioavailability O
was O
found O
for O
lopinavir B
loaded O
SLNs O
in O
comparison O
to O
bulk O
lopinavir B
due O
to O
higher O
lymphatic O
drug O
transport O
( O
p O
< O
0 O
. O
05 O
) O
. O

Using O
coumarin B
- I
6 I
as O
a O
model O
drug O
and O
fluorescent O
marker O
, O
we O
show O
that O
liposome O
surface O
modification O
by O
PLL O
dramatically O
increased O
delivery O
to O
mouse O
retina O
segments O
after O
eye O
drop O
administration O
. O

In O
this O
study O
, O
we O
investigated O
enhancers O
with O
amino O
acids O
( O
proline O
, O
sarcosine O
, O
alanine O
, O
beta B
- I
alanine I
, O
and O
glycine O
) O
attached O
to O
hydrophobic O
chain O
( O
s O
) O
via O
a O
biodegradable O
ester O
link O
. O

The O
proline O
derivative O
l B
- I
Pro2 I
reached O
enhancement O
ratios O
of O
up O
to O
40 O
at O
1 O
% O
concentration O
, O
which O
is O
higher O
than O
that O
of O
the O
well O
- O
established O
and O
standard O
enhancers O
Azone B
, O
DDAIP B
, O
DDAK B
, O
and O
Transkarbam B
12 I
. O

l B
- I
Pro2 I
acted O
synergistically O
with O
propylene O
glycol O
. O

Infrared O
studies O
revealed O
that O
l B
- I
Pro2 I
forms O
a O
separate O
liquid O
ordered O
phase O
in O
the O
stratum O
corneum O
lipids O
and O
has O
no O
significant O
effect O
on O
proteins O
. O

l B
- I
Pro2 I
action O
was O
at O
least O
partially O
reversible O
as O
measured O
by O
skin O
electrical O
impedance O
. O

Furthermore O
, O
l B
- I
Pro2 I
was O
rapidly O
decomposed O
in O
plasma O
. O

In O
vivo O
transdermal O
absorption O
studies O
in O
rats O
confirmed O
the O
enhancing O
activity O
of O
l B
- I
Pro2 I
and O
suggested O
its O
negligible O
skin O
toxicity O
and O
minimal O
effect O
on O
transepidermal O
water O
loss O
. O

These O
properties O
make O
l B
- I
Pro2 I
a O
promising O
candidate O
for O
potential O
clinical O
use O
. O

The O
onset O
of O
antineutrophil O
cytoplasmic O
antibody O
- O
associated O
vasculitis O
immediately O
after O
methimazole O
was O
switched O
to O
propylthiouracil B
in O
a O
woman O
with O
Graves O
' O
disease O
who O
wished O
to O
become O
pregnant O
. O

Propylthiouracil B
( O
PTU O
) O
is O
recommended O
as O
a O
first O
- O
line O
antithyroid O
drug O
( O
ATD O
) O
during O
first O
trimester O
organogenesis O
in O
pregnancy O
because O
recent O
evidence O
suggests O
that O
methimazole O
( O
MMI B
) O
may O
be O
associated O
with O
congenital O
anomalies O
. O

However O
, O
PTU O
more O
commonly O
causes O
myeloperoxidase O
( O
MPO O
) O
- O
antineutrophil O
cytoplasmic O
antibody O
( O
ANCA O
) O
- O
associated O
vasculitis O
, O
which O
usually O
occurs O
during O
prolonged O
treatment O
, O
compared O
with O
MMI B
. O

This O
case O
indicated O
that O
MPO O
- O
ANCA O
vasculitis O
occurred O
within O
several O
weeks O
after O
the O
initiation O
of O
PTU O
and O
that O
this O
side O
effect O
could O
be O
caused O
by O
the O
change O
from O
MMI B
to O
PTU O
. O

Two O
alginate O
- O
mAb1 O
sustained O
release O
formulations O
were O
developed O
by O
an O
internal O
gelation O
technique O
using O
CaCO O
( O
3 O
) O
and O
CaHPO B
( I
4 I
) I
as O
calcium O
sources O
for O
physical O
cross O
- O
linking O
. O

CaHPO B
( I
4 I
) I
led O
to O
a O
lower O
pH O
and O
stronger O
alginate O
- O
mAb1 O
interactions O
. O

The O
CaHPO B
( I
4 I
) I
cross O
- O
linked O
alginate O
released O
mAb1 O
over O
a O
period O
of O
10 O
- O
15 O
days O
. O

Several O
brain O
metabolites O
can O
be O
measured O
by O
the O
means O
of O
( O
1 O
) O
H O
MRS O
: O
N B
- I
acetylaspartate I
( O
NAA B
) O
, O
choline O
containing O
compounds O
( O
Cho O
) O
, O
myo O
- O
inositol O
( O
mI O
) O
and O
glutamate O
( O
Glu O
) O
, O
glutamine O
( O
Gln O
) O
and O
GABA O
( O
together O
as O
Glx O
complex O
or O
separately O
) O
. O

Most O
of O
them O
addressed O
the O
effects O
of O
antipsychotics O
in O
schizophrenia O
and O
mainly O
focusing O
on O
NAA B
alterations O
. O

Follow O
up O
studies O
indicated O
antipsychotic O
drugs O
may O
act O
by O
increasing O
NAA B
levels O
in O
selected O
brain O
areas O
( O
the O
frontal O
lobe O
and O
thalamus O
) O
, O
especially O
during O
the O
short O
- O
time O
observation O
. O

The O
above O
results O
were O
reviewed O
according O
to O
the O
most O
recent O
theories O
in O
the O
field O
accounting O
for O
the O
impact O
of O
antipsychotics O
( B
1 I
) I
HMRS I
measures O
. O

Effects O
of O
molecular O
weight O
on O
permeability O
and O
microstructure O
of O
mixed O
ethyl B
- I
hydroxypropyl I
- O
cellulose O
films O
. O

Precursors O
of O
bioactive O
peptides O
as O
dermaseptins O
, O
phylloseptins O
, O
tryptophyllins O
, O
and O
bradykinin B
- O
like O
peptideswere O
also O
found O
in O
this O
library O
. O

The O
aldehyde O
dehydrogenase O
( O
ALDH O
) O
superfamily O
is O
composed O
of O
nicotinamide O
adenine O
dinucleotide O
( O
phosphate O
) O
( O
NAD B
( I
P I
) I
( I
+ I
) I
) O
- O
dependent O
enzymes O
that O
catalyze O
the O
oxidation O
of O
aldehydes O
to O
their O
corresponding O
carboxylic O
acids O
. O

Rats O
were O
dosed O
orally O
for O
7 O
days O
to O
determine O
( O
1 O
) O
if O
HDN O
( O
induced O
by O
2 O
- O
propanol O
or O
D B
- I
limonene I
) O
altered O
the O
newer O
renal O
biomarkers O
and O
not O
BUN O
or O
creatinine O
, O
( O
2 O
) O
if O
renal O
biomarkers O
could O
distinguish O
between O
HDN O
and O
oxidative O
stress O
- O
induced O
kidney O
injury O
( O
induced O
by O
potassium B
bromate I
) O
, O
( O
3 O
) O
sensitivity O
of O
HDN O
- O
induced O
renal O
biomarker O
changes O
relative O
to O
D B
- I
limonene I
dose O
, O
and O
( O
4 O
) O
reversibility O
of O
HDN O
and O
renal O
biomarkers O
, O
using O

vehicle O
or O
300 O
mg O
/ O
kg O
/ O
day O
D B
- I
limonene I
with O
7 O
days O
of O
dosing O
and O
necropsies O
scheduled O
over O
the O
period O
of O
Days O
8 O
- O
85 O
. O

HDN O
- O
induced O
renal O
biomarker O
changes O
in O
male O
rats O
were O
potentially O
compound O
specific O
: O
( O
1 O
) O
2 O
- O
propanol O
induced O
mild O
HDN O
without O
increased O
renal O
biomarkers O
, O
( O
2 O
) O
potassium B
bromate I
induced O
moderate O
HDN O
with O
increased O
clusterin O
, O
and O
( O
3 O
) O
D B
- I
limonene I
induced O
marked O
HDN O
with O
increased O
alpha O
GST O
, O
mu O
GST O
and O
albumin O
. O

Administration O
of O
potassium B
bromate I
did O
not O
result O
in O
oxidative O
stress O
- O
induced O
kidney O
injury O
, O
based O
on O
histopathology O
and O
renal O
biomarkers O
creatinine O
and O
BUN O
. O

The O
compound O
D B
- I
limonene I
induced O
a O
dose O
dependent O
increase O
in O
HDN O
severity O
and O
renal O
biomarker O
changes O
without O
altering O
BUN O
, O
creatinine O
or O
NAG O
: O
( O
1 O
) O
minimal O
induction O
of O
HDN O
and O
no O
altered O
biomarkers O
at O
10 O
mg O
/ O
kg O
/ O
day O
, O
( O
2 O
) O
mild O
induction O
of O
HDN O
with O
increased O
alpha O
GST O
and O
mu O
GST O
at O
50 O
mg O
/ O
kg O
/ O
day O
and O
( O
3 O
) O
marked O
induction O
of O
HDN O
with O
increased O
alpha O
GST O
, O
mu O
GST O
and O
albumin O
at O
300 O
mg O
/ O
kg O
/ O
day O
. O

HDN O
induced O
by O
D B
- I
limonene I
was O
reversible O
, O
but O
with O
a O
variable O
renal O
biomarker O
pattern O
over O
time O
: O
Day O
8 O
there O
was O
increased O
alpha O
GST O
, O
mu O
GST O
and O
albumin O
; O
on O
Day O
15 O
increased O
clusterin O
, O
albumin O
and O
Kim O
- O
1 O
. O

This O
single O
nucleotide O
transition O
, O
predicted O
to O
change O
phenyalanine B
646 O
to O
serine O
( O
F646S O
) O
, O
also O
maps O
to O
the O
SH2 O
domain O
. O

The O
authors O
examined O
the O
toxicity O
of O
two O
fire O
retardant O
products O
, O
PHOS B
- I
CHEK I
259F I
and I
LC I
- I
95A I
, O
to O
salmon O
undergoing O
parr O
- O
smolt O
transformation O
. O

Concentrations O
of O
the O
products O
that O
caused O
50 O
% O
mortality O
were O
140 O
. O
5 O
and O
339 O
. O
8 O
mg O
/ O
L O
for O
259F B
and O
LC B
- I
95A I
, O
respectively O
, O
and O
could O
occur O
during O
accidental O
drops O
into O
aquatic O
habitats O
. O

Un O
- O
ionized O
ammonia O
levels O
, O
from O
259F B
, O
were O
sufficient O
to O
cause O
acute O
mortality O
; O
but O
additional O
factors O
, O
indicated O
by O
increased O
phagosome O
prevalence O
in O
the O
gills O
, O
might O
have O
contributed O
to O
mortality O
during O
LC B
- I
95A I
exposure O
. O

Field O
- O
effect O
transistors O
are O
fabricated O
from O
thin O
films O
of O
Ag B
- I
doped I
PbSe I
nanocrystals O
to O
analyze O
the O
influence O
of O
electronically O
active O
impurities O
on O
electrical O
transport O
in O
this O
important O
material O
for O
nanocrystal O
applications O
. O

Pre O
- O
training O
peripheral O
injections O
of O
methyllycaconitine O
( O
MLA O
) O
or O
dihydro B
- I
beta I
- I
erythroidine I
( O
DH O
beta O
E O
) O
, O
which O
are O
specific O
alpha O
7 O
and O
alpha O
4 O
beta O
2 O
nicotinic O
receptor O
antagonists O
, O
respectively O
, O
dose O
- O
dependently O
impaired O
retention O
latencies O
in O
an O
inhibitory O
avoidance O
task O
when O
tested O
7 O
- O
days O
but O
not O
1 O
h O
after O
training O
. O

Enantioselective O
synthesis O
of O
derivatives O
and O
structure O
- O
activity O
relationship O
study O
in O
the O
development O
of O
NA255 B
as O
a O
novel O
host O
- O
targeting O
anti O
- O
HCV O
agent O
. O

Previously O
we O
reported O
the O
identification O
of O
NA255 B
from O
our O
natural O
products O
library O
using O
a O
HCV O
sub O
- O
genomic O
replicon O
cell O
culture O
system O
. O

Herein O
, O
we O
report O
how O
the O
absolute O
stereochemistry O
of O
NA255 B
was O
determined O
and O
an O
enantioselective O
synthetic O
method O
for O
NA255 B
derivatives O
was O
developed O
. O

The O
structure O
- O
activity O
relationship O
of O
the O
NA255 B
derivatives O
and O
rat O
pharmacokinetic O
profiles O
of O
the O
representative O
compounds O
are O
disclosed O
. O

Catalpol B
inhibits O
LPS O
plus O
IFN O
- O
gamma O
- O
induced O
inflammatory O
response O
in O
astrocytes O
primary O
cultures O
. O

Our O
previous O
studies O
described O
the O
neuroprotective O
effects O
of O
catalpol B
in O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
inflammatory O
models O
, O
in O
which O
catalpol B
was O
shown O
to O
prevent O
mesencephalic O
neuron O
death O
and O
ameliorate O
cognitive O
ability O
animals O
. O

To O
further O
investigate O
the O
protective O
effect O
and O
underlying O
mechanism O
of O
catalpol B
, O
astrocytes O
were O
pretreated O
with O
low O
( O
0 O
. O
1mM O
) O
and O
high O
dose O
( O
0 O
. O
5mM O
) O
catalpol B
for O
1h O
prior O
to O
LPS O
plus O
interferon O
- O
gamma O
stimulation O
. O

Biochemical O
analyses O
showed O
that O
NO O
and O
ROS O
production O
and O
iNOS O
activity O
were O
significantly O
reduced O
by O
catalpol B
. O

Data O
at O
transcriptional O
level O
also O
demonstrated O
that O
catalpol B
potently O
attenuated O
gene O
expressions O
involved O
in O
inflammation O
, O
such O
as O
iNOS O
, O
COX O
- O
2 O
and O
TLR4 O
. O

In O
addition O
, O
our O
exploration O
further O
revealed O
that O
the O
suppressive O
action O
of O
catalpol B
on O
inflammation O
was O
mediated O
via O
inhibiting O
nuclear O
factor O
- O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
activation O
. O

Collectively O
, O
these O
results O
suggest O
that O
catalpol B
can O
exert O
inhibitory O
effects O
on O
the O
inflammatory O
reaction O
in O
astrocytes O
and O
that O
inactivation O
of O
NF O
- O
kappa O
B O
could O
be O
the O
major O
determinant O
for O
its O
anti O
- O
inflammatory O
mechanism O
. O

Therefore O
, O
catalpol B
may O
potentially O
be O
a O
highly O
effective O
therapeutic O
agent O
in O
treating O
neurodegenerative O
diseases O
associated O
with O
inflammation O
. O

3 O
- O
Nitropropionic O
acid O
( O
3 B
- I
NP I
) O
, O
a O
mitochondrial O
toxin O
, O
has O
been O
reported O
to O
induce O
an O
acute O
cochlear O
damage O
. O

This O
study O
aimed O
to O
observe O
the O
protective O
effect O
of O
KRG O
in O
an O
ototoxic O
animal O
model O
using O
3 B
- I
NP I
intratympanic O
injection O
. O

BALB O
/ O
c O
mice O
were O
classified O
into O
5 O
groups O
( O
n O
= O
15 O
) O
and O
dose O
- O
dependent O
toxic O
effects O
after O
intratympanic O
injection O
with O
3 B
- I
NP I
( O
300 O
- O
5000 O
mM O
) O
on O
the O
left O
ear O
were O
investigated O
to O
determine O
the O
appropriate O
toxicity O
level O
of O
3 B
- I
NP I
. O

For O
observation O
of O
the O
protective O
effects O
of O
KRG O
, O
23 O
mice O
were O
grouped O
into O
3 B
- I
NP I
( O
500 O
mM O
, O
n O
= O
12 O
) O
and O
KRG O
+ O
3 B
- I
NP I
groups O
( O
300 O
mg O
/ O
kg O
KRG O
for O
7 O
days O
before O
500 O
mM O
3 B
- I
NP I
administration O
, O
n O
= O
11 O
) O
. O

The O
ABR O
thresholds O
in O
the O
800 O
- O
5000 O
mM O
groups O
exceeded O
the O
maximum O
recording O
limit O
at O
16 O
and O
32 O
kHz O
1 O
day O
after O
3 B
- I
NP I
administration O
. O

The O
ABR O
threshold O
in O
the O
500 O
mM O
3 B
- I
NP I
+ O
KRG O
group O
was O
significantly O
lower O
than O
that O
in O
the O
500 O
mM O
3 B
- I
NP I
group O
from O
post O
1 O
week O
to O
1 O
month O
. O

The O
mean O
type O
II O
fibrocyte O
counts O
significantly O
differed O
between O
the O
control O
and O
3 B
- I
NP I
groups O
and O
between O
the O
3 B
- I
NP I
and O
3 B
- I
NP I
+ O
KRG O
groups O
. O

Spiral O
ganglion O
cell O
degeneration O
in O
the O
3 B
- I
NP I
group O
was O
more O
severe O
than O
that O
in O
the O
3 B
- I
NP I
+ O
KRG O
group O
. O

KRG O
administration O
ameliorated O
the O
deterioration O
of O
hearing O
by O
3 B
- I
NP I
. O

Reproductive O
and O
developmental O
toxicity O
screening O
test O
of O
3 B
- I
cyanopyridine I
in O
rats O
. O

Crl O
: O
CD O
( O
SD O
) O
rats O
were O
given O
3 B
- I
cyanopyridine I
by O
gavage O
at O
0 O
, O
5 O
, O
30 O
or O
180 O
mg O
/ O
kg O
/ O
day O
. O

Three O
- O
month O
subchronic O
intramuscular O
toxicity O
study O
of O
rotigotine B
- O
loaded O
microspheres O
in O
Cynomolgus O
monkeys O
. O

Rotigotine B
is O
a O
non O
- O
ergoline B
D O
( O
3 O
) O
/ O
D O
( O
2 O
) O
/ O
D O
( O
1 O
) O
dopamine O
receptor O
agonist O
for O
treating O
PD O
. O

As O
a O
new O
treatment O
option O
for O
CDS O
, O
rotigotine B
- O
loaded O
microspheres O
( O
RoMS O
) O
, O
long O
- O
acting O
sustained O
- O
release O
microspheres O
with O
poly O
( O
lactide O
- O
co O
- O
glycolide O
) O
as O
drug O
carrier O
, O
are O
now O
being O
evaluated O
in O
clinical O
trial O
. O

The O
major O
toxicological O
effects O
were O
associated O
with O
dopamine O
agonist O
- O
related O
pharmacodynamic O
properties O
of O
rotigotine B
( O
e O
. O
g O
. O
, O
hyperactivity O
and O
stereotype O
, O
decreased O
serum O
prolactin O
level O
) O
and O
foreign O
body O
removal O
reaction O
induced O
by O
poly O
( O
lactide O
- O
co O
- O
glycolide O
) O
and O
carboxymethycellulos O
sodium O
( O
e O
. O
g O
. O
, O
increased O
mononuclear O
cells O
and O
neutrophils O
, O
thymus O
atrophy O
and O
vacuolar O
degeneration O
of O
adrenal O
cortex O
, O
foreign O
body O
granuloma O
with O
foam O
cells O
accumulation O
at O

Sodium B
dodecyl I
benzene I
sulfonate I
( O
SDBS B
) O
and O
cetyl B
trimethyl I
ammonium I
chloride I
( O
CTAC B
) O
are O
two O
kinds O
of O
surfactants O
widely O
applied O
in O
various O
industries O
. O

Dunaliella O
bardawil O
was O
employed O
in O
the O
present O
research O
to O
test O
the O
toxic O
effects O
of O
SDBS B
, O
CTAC B
, O
and O
their O
mixture O
on O
cell O
growth O
, O
cellular O
morphology O
, O
beta O
- O
carotene O
accumulation O
, O
and O
enzymatic O
activities O
of O
superoxide O
dismutase O
( O
SOD O
) O
and O
catalase O
( O
CAT O
) O
. O

The O
results O
showed O
that O
SDBS B
at O
200 O
, O
550 O
, O
900 O
, O
1 O
, O
350 O
, O
1 O
, O
800 O
, O
and O
2 O
, O
400 O
mg O
/ O
L O
and O
CTAC B
at O
0 O
. O
4 O
, O
0 O
. O
7 O
, O
1 O
. O
0 O
, O
1 O
. O
3 O
, O
2 O
. O
8 O
, O
and O
3 O
. O
5 O
mg O
/ O
L O
inhibited O
algal O
growth O
and O
beta O
- O
carotene O
accumulation O
, O
both O
of O
which O
declined O
and O
then O
increased O
. O

In O
particular O
, O
CTAC B
( O
median O
inhibitory O
concentration O
at O
10 O
days O
[ O
IC50 O
] O
( O
10 O
d O
) O
= O
2 O
. O
8 O
+ O
/ O
- O
1 O
. O
49 O
mg O
/ O
L O
) O
was O
more O
hazardous O
than O
SDBS B
( O
IC50 O
( O
10 O
d O
) O
= O
2 O
, O
044 O
+ O
/ O
- O
637 O
. O
3 O
mg O
/ O
L O
) O
. O

The O
additive O
index O
( O
AI O
) O
calculated O
from O
carotene O
content O
data O
was O
( O
- O
4 O
. O
10 O
, O
- O
1 O
. O
67 O
) O
< O
0 O
, O
indicating O
an O
antagonistic O
effect O
between O
SDBS B
and O
CTAC B
. O

Algae O
cultivated O
at O
level O
6 O
of O
the O
binary O
system O
showed O
hormesis O
due O
to O
the O
mitigated O
toxicity O
; O
SDBS B
at O
2 O
, O
400 O
mg O
/ O
L O
, O
CTAC O
at O
3 O
. O
5 O
mg O
/ O
L O
, O
and O
combined O
surfactants O
at O
level O
6 O
exerted O
lethal O
effects O
on O
D O
. O
bardawil O
. O

Both O
SOD O
and O
CAT O
activities O
showed O
similar O
associations O
with O
varied O
concentrations O
of O
surfactants O
: O
SOD O
was O
significantly O
promoted O
by O
550 O
to O
1 O
, O
800 O
mg O
/ O
L O
SDBS B
, O
0 O
. O
7 O
to O
1 O
. O
3 O
mg O
/ O
L O
CTAC B
, O
and O
mixtures O
at O
levels O
2 O
to O
4 O
; O
CAT O
was O
clearly O
promoted O
by O
900 O
mg O
/ O
L O
SDBS B
, O
0 O
. O
4 O
to O
1 O
. O
3 O
mg O
/ O
L O
CTAC B
, O
and O
mixtures O
at O
levels O
2 O
to O
4 O
. O

Using O
a O
newly O
developed O
strategy O
whose O
key O
step O
is O
the O
regioselective O
propargylation O
of O
hydroxyxanthone B
substrates O
, O
99 O
structurally O
diverse O
Garcinia O
natural O
- O
product O
- O
like O
xanthones O
based O
on O
gambogic B
acid I
were O
designed O
and O
synthesized O
and O
their O
in O
vitro O
antitumor O
activity O
was O
evaluated O
. O

The O
antitumor O
activity O
of O
compound O
112 O
, O
administered O
po O
, O
showed O
more O
potent O
in O
vivo O
oral O
antitumor O
activity O
than O
gambogic B
acid I
. O

Absorption O
, O
metabolism O
and O
excretion O
of O
darexaban B
( O
YM150 B
) O
, O
a O
new O
direct O
factor O
Xa O
inhibitor O
in O
humans O
. O

1 O
. O
The O
absorption O
, O
metabolism O
and O
excretion O
of O
darexaban B
( O
YM150 B
) O
, O
a O
novel O
oral O
direct O
factor O
Xa O
inhibitor O
, O
were O
investigated O
after O
a O
single O
oral O
administration O
of O
[ B
( I
14 I
) I
C I
] I
darexaban I
maleate I
at O
a O
dose O
of O
60 O
mg O
in O
healthy O
male O
human O
subjects O
. O

2 O
. O
[ B
( I
14 I
) I
C I
] I
Darexaban I
was O
rapidly O
absorbed O
, O
with O
both O
blood O
and O
plasma O
concentrations O
peaking O
at O
approximately O
0 O
. O
75 O
h O
post O
- O
dose O
. O

Plasma O
concentrations O
of O
darexaban B
glucuronide I
( O
M1 O
) O
, O
the O
pharmacological O
activity O
of O
which O
is O
equipotent O
to O
darexaban B
in O
vitro O
, O
also O
peaked O
at O
approximately O
0 O
. O
75 O
h O
. O

The O
N B
- I
oxides I
of O
M1 O
, O
a O
mixture O
of O
two O
diastereomers O
designated O
as O
M2 O
and O
M3 O
, O
were O
also O
present O
in O
plasma O
and O
urine O
, O
accounting O
for O
up O
to O
13 O
. O
2 O
% O
of O
radioactivity O
in O
plasma O
. O

In O
faeces O
, O
darexaban B
was O
the O
major O
drug O
- O
related O
component O
, O
and O
N B
- I
demethyl I
darexaban I
( O
M5 O
) O
was O
detected O
as O
a O
minor O
metabolite O
. O

5 O
. O
These O
findings O
suggested O
that O
, O
following O
oral O
administration O
of O
darexaban B
in O
humans O
, O
M1 O
is O
quickly O
formed O
during O
first O
- O
pass O
metabolism O
via O
UDP O
- O
glucuronosyltransfer O
, O
exerting O
its O
pharmacological O
activity O
in O
blood O
before O
being O
excreted O
into O
urine O
and O
faeces O
. O

Fabrication O
of O
3 O
- O
dimensional O
cellular O
constructs O
via O
microstereolithograp O
using O
a O
simple O
, O
three O
- O
component O
, O
poly B
( I
ethylene I
glycol I
) I
acrylate I
- O
based O
system O
. O

8 B
, I
8 I
- I
dialkyldihydroberber I
with O
potent O
antiprotozoal O
activity O
. O

Semisynthetic O
8 B
, I
8 I
- I
dialkyldihydroberber I
( O
8 B
, I
8 I
- I
DDBs I
) O
were O
found O
to O
possess O
mid O
- O
to O
low O
- O
nanomolar O
potency O
against O
Plasmodium O
falciparum O
blood O
- O
stage O
parasites O
, O
Leishmania O
donovani O
intracellular O
amastigotes O
, O
and O
Trypanosoma O
brucei O
brucei O
bloodstream O
forms O
. O

For O
example O
, O
8 B
, I
8 I
- I
diethyldihydroberber I
chloride I
( O
5b O
) O
exhibited O
in O
vitro O
IC50 O
values O
of O
77 O
, O
100 O
, O
and O
5 O
. O
3 O
nM O
against O
these O
three O
parasites O
, O
respectively O
. O

In O
turn O
, O
two O
8 B
, I
8 I
- I
dialkylcanadines I
, O
obtained O
by O
reduction O
of O
the O
corresponding O
8 B
, I
8 I
- I
DDBs I
, O
were O
much O
less O
potent O
against O
these O
parasites O
in O
vitro O
. O

While O
the O
natural O
product O
berberine O
is O
a O
weak O
DNA O
binder O
, O
the O
8 B
, I
8 I
- I
DDBs I
displayed O
no O
affinity O
for O
DNA O
, O
as O
assessed O
by O
changes O
in O
the O
melting O
temperature O
of O
poly B
( I
dA I
. I
dT I
) I
DNA O
. O

Selected O
8 B
, I
8 I
- I
DDBs I
showed O
efficacy O
in O
mouse O
models O
of O
visceral O
leishmaniasis O
and O
African O
trypanosomiasis O
, O
with O
8 B
, I
8 I
- I
dimethyldihydroberbe I
chloride I
( O
5a O
) O
reducing O
liver O
parasitemia O
by O
46 O
% O
in O
L O
. O
donovani O
- O
infected O
BALB O
/ O
c O
mice O
when O
given O
at O
an O
intraperitoneal O
dose O
of O
10 O
mg O
/ O
kg O
/ O
day O
for O
five O
days O
. O

Benzodiazepines O
( O
BZDs B
) O
are O
first O
- O
line O
therapy O
for O
treatment O
of O
status O
epilepticus O
( O
SE O
) O
. O

However O
, O
BZD B
treatment O
is O
negatively O
affected O
by O
seizure O
duration O
due O
to O
decreases O
in O
BZD B
- O
sensitive O
GABA O
( O
A O
) O
receptors O
during O
prolonged O
SE O
. O

Stiripentol O
( O
STP B
) O
is O
an O
anticonvulsant O
that O
is O
used O
as O
add O
- O
on O
treatment O
for O
Dravet O
Syndrome O
. O

Recent O
studies O
have O
shown O
that O
STP B
is O
a O
positive O
allosteric O
modulator O
of O
the O
GABA O
( O
A O
) O
receptor O
. O

The O
subunit O
selectivity O
of O
STP B
at O
this O
receptor O
suggests O
that O
it O
would O
be O
anticonvulsant O
in O
both O
brief O
as O
well O
as O
prolonged O
SE O
. O

We O
tested O
this O
possibility O
by O
comparing O
the O
ability O
of O
STP B
and O
diazepam O
( O
DZP B
) O
, O
a O
commonly O
used O
BZD B
, O
to O
terminate O
behavioral O
convulsions O
in O
a O
rodent O
model O
of O
pharmacoresistant O
SE O
. O

We O
found O
that O
STP B
was O
anticonvulsant O
in O
this O
model O
and O
remained O
effective O
during O
prolonged O
SE O
, O
unlike O
DZP B
which O
exhibited O
a O
14 O
fold O
increase O
in O
its O
ED O
( O
50 O
) O
. O

Whole O
cell O
recording O
from O
hippocampal O
slices O
from O
these O
animals O
revealed O
that O
STP B
potentiated O
GABAergic O
IPSCs O
, O
as O
well O
as O
tonic O
GABAergic O
current O
by O
acting O
at O
a O
site O
on O
the O
GABA O
( O
A O
) O
receptor O
separate O
from O
the O
BDZ B
binding O
site O
. O

Potentiation O
of O
GABAergic O
currents O
by O
STP B
remained O
intact O
during O
prolonged O
SE O
, O
while O
potentiation O
by O
DZP B
was O
lost O
. O

Both O
IPSC O
potentiation O
and O
anticonvulsant O
activity O
of O
STP B
were O
greater O
in O
younger O
animals O
than O
in O
adults O
. O

These O
findings O
suggest O
that O
at O
doses O
that O
yield O
therapeutically O
relevant O
concentrations O
, O
STP B
is O
anticonvulsant O
by O
potentiating O
GABAergic O
inhibition O
and O
that O
the O
subunit O
selectivity O
profile O
of O
STP B
enables O
it O
to O
remain O
effective O
despite O
GABA O
( O
A O
) O
receptor O
subunit O
changes O
during O
prolonged O
SE O
. O

Further O
, O
5 O
- O
HT1A O
autoreceptor O
desensitization O
was O
evidenced O
by O
electrophysiological O
studies O
, O
GTP B
- I
gamma I
- I
S I
coupling O
to O
5 O
- O
HT1A O
autoreceptor O
and O
a O
lower O
hypothermic O
response O
to O
5 O
- O
HT1A O
activation O
. O

Metabolism O
and O
pharmacokinetics O
of O
3 B
- I
n I
- I
butylphthalide I
( O
NBP B
) O
in O
humans O
: O
the O
role O
of O
cytochrome O
P450s O
and O
alcohol O
dehydrogenase O
in O
biotransformation O
. O

3 B
- I
n I
- I
Butylphthalide I
( O
NBP B
) O
is O
a O
cardiovascular O
drug O
currently O
used O
for O
the O
treatment O
of O
cerebral O
ischemia O
. O

The O
present O
study O
aims O
to O
investigate O
the O
metabolism O
, O
pharmacokinetics O
, O
and O
excretion O
of O
NBP B
in O
humans O
and O
identify O
the O
enzymes O
responsible O
for O
the O
formation O
of O
major O
metabolites O
. O

NBP B
underwent O
extensive O
metabolism O
after O
an O
oral O
administration O
of O
200 O
mg O
NBP B
and O
23 O
metabolites O
were O
identified O
in O
human O
plasma O
and O
urine O
. O

Principal O
metabolic O
pathways O
included O
hydroxylation O
on O
alkyl O
side O
chain O
, O
particularly O
at O
3 B
- I
, I
omega I
- I
1 I
- I
, I
and I
omega I
- I
carbons I
, O
and O
further O
oxidation O
and O
conjugation O
. O

Approximately O
81 O
. O
6 O
% O
of O
the O
dose O
was O
recovered O
in O
urine O
, O
mainly O
as O
NBP B
- I
11 I
- I
oic I
acid I
( O
M5 O
- O
2 O
) O
and O
glucuronide O
conjugates O
of O
M5 O
- O
2 O
and O
mono O
- O
hydroxylated O
products O
. O

10 B
- I
Keto I
- I
NBP I
( O
M2 O
) O
, O
3 B
- I
hydroxy I
- I
NBP I
( O
M3 O
- O
1 O
) O
, O
10 B
- I
hydroxy I
- I
NBP I
( O
M3 O
- O
2 O
) O
, O
and O
M5 O
- O
2 O
were O
the O
major O
circulating O
metabolites O
, O
wherein O
the O
areas O
under O
the O
curve O
values O
were O
1 O
. O
6 O
- O
, O
2 O
. O
9 O
- O
, O
10 O
. O
3 O
- O
, O
and O
4 O
. O
1 O
- O
fold O
higher O
than O
that O
of O
NBP B
. O

In O
vitro O
phenotyping O
studies O
demonstrated O
that O
multiple O
cytochrome O
P450 O
( O
P450 O
) O
isoforms O
, O
especially O
CYP3A4 O
, O
2E1 O
, O
and O
1A2 O
, O
were O
involved O
in O
the O
formation O
of O
M3 O
- O
1 O
, O
M3 O
- O
2 O
, O
and O
11 B
- I
hydroxy I
- I
NBP I
. O

Using O
M3 O
- O
2 O
and O
11 B
- I
hydroxy I
- I
NBP I
as O
substrates O
, O
human O
subcellular O
fractions O
experiments O
revealed O
that O
P450 O
, O
alcohol O
dehydrogenase O
, O
and O
aldehyde O
dehydrogenase O
catalyzed O
the O
generation O
of O
M2 O
and O
M5 O
- O
2 O
. O

Formation O
of O
M5 O
- O
2 O
was O
much O
faster O
than O
that O
of O
M2 O
, O
and O
M5 O
- O
2 O
can O
undergo O
beta O
- O
oxidation O
to O
yield O
phthalide B
- I
3 I
- I
acetic I
acid I
in O
rat O
liver O
homogenate O
. O

Overall O
, O
our O
study O
demonstrated O
that O
NBP B
was O
well O
absorbed O
and O
extensively O
metabolized O
by O
multiple O
enzymes O
to O
various O
metabolites O
prior O
to O
urinary O
excretion O
. O

Pharmacokinetics O
, O
metabolism O
, O
and O
excretion O
of O
the O
antidiabetic O
agent O
ertugliflozin B
( O
PF B
- I
04971729 I
) O
in O
healthy O
male O
subjects O
. O

The O
disposition O
of O
ertugliflozin B
( O
PF B
- I
04971729 I
) O
, O
an O
orally O
active O
selective O
inhibitor O
of O
the O
sodium O
- O
dependent O
glucose O
cotransporter O
2 O
, O
was O
studied O
after O
a O
single O
25 O
- O
mg O
oral O
dose O
of O
[ B
( I
14 I
) I
C I
] I
- I
ertugliflozin I
to O
healthy O
human O
subjects O
. O

The O
absorption O
of O
ertugliflozin B
in O
humans O
was O
rapid O
with O
a O
T O
( O
max O
) O
at O
~ O
1 O
. O
0 O
hour O
. O

Of O
the O
total O
radioactivity O
excreted O
in O
feces O
and O
urine O
, O
unchanged O
ertugliflozin B
collectively O
accounted O
for O
~ O
35 O
. O
3 O
% O
of O
the O
dose O
, O
suggestive O
of O
moderate O
metabolic O
elimination O
in O
humans O
. O

The O
structure O
of O
M4a O
and O
M4c O
were O
confirmed O
to O
be O
ertugliflozin B
- I
4 I
- I
O I
- I
beta I
- I
and I
- I
3 I
- I
O I
- I
beta I
- I
glucuronide I
, O
respectively O
, O
via O
comparison O
of O
the O
HPLC O
retention O
time O
and O
mass O
spectra O
with O
authentic O
standards O
. O

A O
minor O
metabolic O
fate O
involved O
oxidation O
by O
cytochrome O
P450 O
to O
yield O
monohydroxylated O
metabolites O
M1 O
and O
M3 O
and O
des B
- I
ethyl I
ertugliflozin I
( O
M2 O
) O
, O
which O
accounted O
for O
~ O
5 O
. O
2 O
% O
of O
the O
dose O
in O
excreta O
. O

In O
plasma O
, O
unchanged O
ertugliflozin B
and O
the O
corresponding O
4 O
- O
O O
- O
beta O
- O
( O
M4a O
) O
and O
3 O
- O
O O
- O
beta O
- O
( O
M4c O
) O
glucuronides O
were O
the O
principal O
components O
, O
which O
accounted O
for O
49 O
. O
9 O
, O
12 O
. O
2 O
, O
and O
24 O
. O
1 O
% O
of O
the O
circulating O
radioactivity O
. O

Although O
aspirin O
and O
thienopyridines B
have O
proved O
their O
efficacy O
in O
the O
prevention O
of O
arterial O
thrombotic O
events O
, O
limited O
efficacy O
, O
increased O
risk O
of O
bleeding O
, O
significant O
inter O
- O
individual O
variability O
in O
the O
response O
and O
extended O
duration O
of O
action O
that O
cannot O
be O
reversed O
if O
the O
need O
for O
haemostasis O
or O
emergency O
surgery O
arises O
represent O
major O
limitations O
of O
these O
drugs O
. O

Although O
ad O
hoc O
studies O
on O
their O
efficacy O
in O
the O
stroke O
prevention O
are O
currently O
lacking O
, O
newer O
antiplatelet O
agents O
( O
mainly O
ticagrelor B
and O
prasugrel B
) O
do O
not O
provide O
a O
significant O
better O
protection O
over O
and O
above O
aspirin O
and O
/ O
or O
clopidogrel O
in O
the O
prevention O
of O
atherothrombotic O
stroke O
. O

In O
addition O
, O
a O
significantly O
increased O
bleeding O
risk O
has O
been O
reported O
in O
subjects O
receiving O
these O
new O
thienopyridines B
. O

Spo0A O
reactivates O
the O
accDA O
operon O
that O
encodes O
the O
carboxylase O
component O
of O
the O
acetyl O
- O
CoA O
carboxylase O
enzyme O
, O
which O
catalyses O
the O
first O
and O
rate O
- O
limiting O
step O
in O
de O
novo O
lipid O
biosynthesis O
, O
malonyl B
- I
CoA I
formation O
. O

Name O
your O
splice O
: O
FR901464 O
analogues O
and O
herboxidiene B
inhibit O
constitutive O
splicing O
, O
most O
likely O
by O
inhibiting O
spliceosomal O
subunit O
SF3b O
. O

A O
parallel O
comparison O
of O
these O
compounds O
in O
a O
cell O
- O
based O
assay O
system O
showed O
meayamycin B
B I
as O
the O
most O
potent O
splicing O
inhibitor O
among O
these O
small O
molecules O
. O

Contaminant O
- O
mobilizing O
capability O
of O
fullerene O
nanoparticles O
( O
nC60 B
) O
: O
Effect O
of O
solvent O
- O
exchange O
process O
in O
nC60 B
formation O
. O

Fullerene O
nanoparticles O
( O
nC B
( I
60 I
) I
) O
in O
aqueous O
environments O
can O
significantly O
enhance O
the O
transport O
of O
hydrophobic O
organic O
contaminants O
by O
serving O
as O
a O
contaminant O
carrier O
. O

In O
the O
present O
study O
, O
the O
authors O
examine O
the O
effect O
of O
the O
solvent O
- O
exchange O
process O
on O
nC B
( I
60 I
) I
aggregate O
formation O
and O
, O
subsequently O
, O
on O
nC B
( I
60 I
) I
' O
s O
contaminant O
- O
mobilizing O
capability O
. O

A O
series O
of O
nC B
( I
60 I
) I
samples O
were O
prepared O
using O
a O
modified O
toluene O
- O
water O
solvent O
- O
exchange O
method O
through O
the O
inclusion O
of O
a O
secondary O
organic O
solvent O
in O
the O
phase O
transfer O
of O
molecular O
C O
( O
60 O
) O
in O
toluene O
to O
nC B
( I
60 I
) I
in O
water O
. O

The O
involvement O
of O
a O
secondary O
solvent O
in O
the O
phase O
transfer O
process O
had O
only O
small O
effects O
on O
the O
particle O
size O
and O
distribution O
, O
zeta O
potential O
, O
and O
mobility O
of O
the O
nC B
( I
60 I
) I
products O
but O
significantly O
influenced O
the O
capability O
of O
nC B
( I
60 I
) I
to O
enhance O
the O
transport O
of O
2 B
, I
2 I
' I
, I
5 I
, I
5 I
' I
- I
polychlorinated I
biphenyl I
( O
PCB O
) O
in O
a O
saturated O
sandy O
soil O
column O
, O
regardless O
of O
whether O
the O
secondary O
solvent O
was O
water O
- O
miscible O
or O
non O
- O
water O
- O
miscible O
. O

The O
two O
groups O
of O
secondary O
solvents O
appear O
to O
affect O
the O
aggregation O
properties O
of O
nC B
( I
60 I
) I
in O
water O
via O
different O
mechanisms O
. O

In O
general O
, O
nC B
( I
60 I
) I
products O
made O
with O
a O
secondary O
water O
- O
miscible O
solvent O
have O
stronger O
capabilities O
to O
enhance O
PCB O
transport O
. O

Taken O
together O
, O
the O
results O
indicate O
that O
according O
to O
formation O
conditions O
and O
solvent O
constituents O
, O
nC B
( I
60 I
) I
will O
vary O
significantly O
in O
its O
interactions O
with O
organic O
contaminants O
, O
specifically O
as O
related O
to O
adsorption O
or O
desorption O
as O
well O
as O
transport O
in O
porous O
media O
. O

Histopathological O
effects O
of O
waterborne O
copper O
nanoparticles O
and O
copper B
sulphate I
on O
the O
organs O
of O
rainbow O
trout O
( O
Oncorhynchus O
mykiss O
) O
. O

This O
study O
aimed O
to O
describe O
the O
pathologies O
in O
gill O
, O
gut O
, O
liver O
, O
kidney O
, O
brain O
and O
muscle O
of O
juvenile O
rainbow O
trout O
, O
Oncorhynchus O
mykiss O
, O
exposed O
in O
triplicate O
to O
either O
a O
control O
( O
no O
added O
Cu O
) O
, O
20 O
or O
100 O
mu O
g O
l O
( O
- O
1 O
) O
of O
either O
dissolved O
Cu O
( O
as O
CuSO B
( I
4 I
) I
) O
or O
Cu O
- O
NPs O
( O
mean O
primary O
particle O
size O
of O
87 O
+ O
/ O
- O
27 O
nm O
) O
in O
a O
semi O
- O
static O
waterborne O
exposure O
regime O
. O

All O
treatments O
caused O
organ O
injuries O
, O
and O
the O
kinds O
of O
pathologies O
observed O
with O
Cu O
- O
NPs O
were O
broadly O
of O
the O
same O
type O
as O
CuSO B
( I
4 I
) I
including O
: O
hyperplasia O
, O
aneurisms O
, O
and O
necrosis O
in O
the O
secondary O
lamellae O
of O
the O
gills O
; O
swelling O
of O
goblet O
cells O
, O
necrosis O
in O
the O
mucosa O
layer O
and O
vacuole O
formation O
in O
the O
gut O
; O
hepatitis O
- O
like O
injury O
and O
cells O
with O
pyknotic O
nuclei O
in O
the O
liver O
; O
damage O
to O
the O
epithelium O
of O
some O
renal O
tubules O
and O
increased O
Bowman O
' O
s O
space O
in O
the O
kidney O
. O

Overall O
the O
data O
showed O
that O
pathology O
from O
CuSO B
( I
4 I
) I
and O
Cu O
- O
NPs O
were O
of O
similar O
types O
, O
but O
there O
were O
some O
material O
- O
type O
effects O
in O
the O
severity O
or O
incidence O
of O
injuries O
with O
Cu O
- O
NPs O
causing O
more O
injury O
in O
the O
intestine O
, O
liver O
and O
brain O
than O
the O
equivalent O
concentration O
of O
CuSO B
( I
4 I
) I
by O
the O
end O
of O
the O
experiment O
, O
but O
in O
the O
gill O
and O
muscle O
CuSO B
( I
4 I
) I
caused O
more O
pathology O
. O

Pharmacological O
and O
behavioral O
characterization O
of O
the O
novel O
CRF O
( O
1 O
) O
antagonist O
BMS B
- I
763534 I
. O

BMS B
- I
763534 I
is O
a O
potent O
( O
CRF O
( O
1 O
) O
IC O
( O
50 O
) O
= O
0 O
. O
4 O
nM O
) O
and O
selective O
( O
> O
1000 O
- O
fold O
selectivity O
vs O
. O
all O
other O
sites O
tested O
) O
CRF O
( O
1 O
) O
receptor O
antagonist O
( O
pA2 O
= O
9 O
. O
47 O
vs O
. O
CRF O
( O
1 O
) O
- O
mediated O
cAMP O
production O
in O
Y79 O
cells O
) O
. O

BMS B
- I
763534 I
accelerated O
the O
dissociation O
of O
( O
125 O
) O
I O
- O
o O
- O
CRF O
from O
rat O
frontal O
cortex O
membrane O
CRF O
( O
1 O
) O
receptors O
consistent O
with O
a O
negative O
allosteric O
modulation O
of O
CRF O
binding O
. O

BMS B
- I
763534 I
produced O
dose O
- O
dependent O
increases O
in O
CRF O
( O
1 O
) O
receptor O
occupancy O
and O
anxiolytic O
efficacy O
; O
lowest O
effective O
anxiolytic O
dose O
= O
0 O
. O
56 O
mg O
/ O
kg O
, O
PO O
, O
which O
was O
associated O
with O
71 O
+ O
/ O
- O
5 O
% O
CRF O
( O
1 O
) O
receptor O
occupancy O
of O
frontoparietal O
CRF O
( O
1 O
) O
receptors O
. O

Sedative O
/ O
ataxic O
effects O
of O
BMS B
- I
763534 I
were O
only O
observed O
at O
high O
dose O
multiples O
( O
54 O
- O
179 O
x O
) O
relative O
to O
the O
lowest O
dose O
required O
for O
anxiolytic O
efficacy O
. O

At O
doses O
of O
5 O
- O
to O
18 O
- O
fold O
higher O
than O
the O
lowest O
efficacious O
dose O
in O
the O
anxiety O
assay O
, O
BMS B
- I
763534 I
shared O
subjective O
effects O
with O
the O
benzodiazepine O
chlordiazepoxide O
. O

Interestingly O
BMS B
- I
790318 I
, O
the O
O O
- O
demethylated O
metabolite O
of O
BMS B
- I
763534 I
, O
showed O
weak O
affinity O
for O
the O
TBOB B
site O
of O
the O
GABA O
( O
A O
) O
receptor O
( O
67 O
% O
inhibition O
at O
10 O
mu O
M O
) O
and O
augmented O
GABA O
evoked O
currents O
( O
EC O
( O
50 O
) O
= O
1 O
. O
6 O
mu O
M O
) O
. O

Thus O
, O
the O
unanticipated O
signal O
in O
the O
drug O
discrimination O
assay O
may O
have O
resulted O
from O
an O
interaction O
of O
the O
metabolite O
BMS B
- I
790318 I
with O
the O
TBOB B
site O
on O
the O
GABA O
( O
A O
) O
channel O
where O
it O
appears O
to O
behave O
as O
an O
allosteric O
potentiator O
of O
GABA O
evoked O
currents O
. O

The O
transport O
abilities O
were O
examined O
and O
the O
cellular O
accumulation O
of O
rhodamine B
- I
123 I
( O
R B
- I
123 I
) O
was O
also O
measured O
. O

In O
Caco O
- O
2 O
cells O
, O
emodin O
elevated O
the O
accumulation O
of O
R B
- I
123 I
and O
decreased O
the O
efflux O
ratio O
of O
R B
- I
123 I
, O
which O
indicates O
the O
inhibition O
of O
P O
- O
gp O
function O
. O

The O
reaction O
mechanism O
of O
CO O
oxidation O
on O
the O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
110 O
) O
and O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
111 O
) O
surfaces O
is O
investigated O
by O
means O
of O
spin O
- O
polarized O
density O
functional O
theory O
( O
DFT O
) O
within O
the O
GGA O
+ O
U O
framework O
. O

( O
2 O
) O
( O
a O
) O
+ O
CO B
( O
g O
) O
- O
- O
> O
CO O
( O
2 O
) O
( O
g O
) O
+ O
O O
( O
a O
) O
] O
on O
( O
110 O
) O
- O
A O
/ O
( O
111 O
) O
- O
A O
; O
4 O
) O
CO O
oxidation O
is O
a O
structure O
- O
sensitive O
reaction O
, O
and O
the O
activation O
energy O
of O
CO O
oxidation O
follows O
the O
order O
of O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
111 O
) O
- O
A O
( O
0 O
. O
78 O
eV O
) O
> O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
111 O
) O
- O
B O
( O
0 O
. O
68 O
eV O
) O
> O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
110 O
) O
- O
A O
( O
0 O
. O
51 O
eV O
) O
> O
Co O

( O
3 O
) O
O O
( O
4 O
) O
( O
110 O
) O
- O
B O
( O
0 O
. O
41 O
eV O
) O
, O
that O
is O
, O
the O
( O
110 O
) O
surface O
shows O
higher O
reactivity O
for O
CO B
oxidation O
than O
the O
( O
111 O
) O
surface O
; O
5 O
) O
in O
addition O
to O
the O
O O
( O
2f O
) O
, O
it O
was O
also O
found O
that O
Co B
( I
3 I
+ I
) I
is O
more O
active O
than O
Co O
( O
2 O
+ O
) O
, O
so O
both O
O O
( O
2f O
) O
and O
Co B
( I
3 I
+ I
) I
control O
the O
catalytic O
activity O
of O
CO O
oxidation O
on O
Co B
( I
3 I
) I
O I
( I
4 I
) I
, O
as O
opposed O
to O
a O
previous O
DFT O
study O
which O
concluded O
that O
either O
Co B
( I
3 I
+ I
) I
or O
O O
( O

Ginkgo O
biloba O
extract O
attenuates O
hippocampal O
neuronal O
loss O
and O
cognitive O
dysfunction O
resulting O
from O
trimethyltin B
in O
mice O
. O

The O
present O
study O
was O
an O
attempt O
to O
investigate O
the O
neuromodulatory O
potential O
of O
Ginkgo O
biloba O
extract O
( O
GBE O
) O
against O
hippocamapal O
structural O
and O
functional O
damages O
induced O
by O
trimethyltin B
( O
TMT B
) O
a O
potent O
neurotoxicant O
. O

Male O
Balb O
/ O
C O
mice O
were O
administered O
with O
Ginkgo O
biloba O
extract O
for O
14 O
days O
at O
a O
dose O
of O
70 O
mg O
/ O
kg O
body O
weight O
interperitoneally O
and O
on O
11 O
- O
day O
of O
treatment O
animals O
were O
exposed O
to O
Trimethyltin B
( O
2 O
. O
5 O
mg O
/ O
kg O
b O
. O
w O
) O
single O
intraperitoneal O
injection O
. O

The O
co O
- O
administered O
of O
TMT B
with O
GBE O
showed O
marked O
improvement O
in O
memory O
and O
aggressive O
behavior O
. O

The O
conjunctive O
treatment O
also O
showed O
significant O
decrease O
in O
oxidative O
stress O
as O
assessed O
by O
MDA O
levels O
and O
the O
antioxidant O
enzymes O
( O
GSH O
, O
GSSH B
, O
GPX O
, O
total O
glutathione O
, O
Catalase O
and O
Superoxide O
dismutase O
) O
which O
were O
depressed O
by O
TMT B
treatment O
was O
significantly O
improved O
by O
GBE O
. O

Correspondingly O
, O
induction O
of O
Bcl O
- O
2 O
mitochondrial O
apoptotic O
pathway O
by O
trimethyltin B
was O
down O
regulated O
by O
Ginkgo O
biloba O
treatment O
. O

Therefore O
, O
it O
is O
suggested O
that O
prophylactic O
treatment O
of O
Ginkgo O
biloba O
extract O
protects O
against O
the O
trimethyltin B
induced O
neurodegenration O
by O
multiple O
mechanism O
involved O
in O
its O
antioxidant O
effects O
and O
may O
be O
useful O
in O
developing O
therapies O
against O
neurodegenration O
. O

Etazolate B
, O
an O
alpha O
- O
secretase O
activator O
, O
reduces O
neuroinflammation O
and O
offers O
persistent O
neuroprotection O
following O
traumatic O
brain O
injury O
in O
mice O
. O

Hence O
, O
the O
aim O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
etazolate B
, O
an O
alpha O
- O
secretase O
activator O
, O
on O
acute O
and O
belated O
post O
- O
TBI O
consequences O
. O

The O
mouse O
model O
of O
TBI O
by O
mechanical O
percussion O
was O
used O
and O
injured O
mice O
received O
either O
the O
vehicle O
or O
etazolate B
at O
the O
dose O
of O
1 O
, O
3 O
or O
10 O
mg O
/ O
kg O
at O
2 O
h O
post O
- O
TBI O
. O

A O
single O
administration O
of O
etazolate B
exerted O
a O
dose O
- O
dependent O
anti O
- O
inflammatory O
and O
anti O
- O
oe O
dematous O
effect O
accompanied O
by O
lasting O
memory O
improvement O
, O
reduction O
of O
locomotor O
hyperactivity O
and O
olfactory O
bulb O
tissue O
protection O
, O
with O
a O
therapeutic O
window O
of O
at O
least O
2 O
h O
. O

The O
main O
physiological O
actions O
of O
the O
biologically O
most O
active O
metabolite O
of O
vitamin O
D O
, O
1 O
alpha O
, O
25 O
- O
dihydroxyvitamin O
D O
( O
3 O
) O
( O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
( I
3 I
) I
) O
, O
are O
calcium O
and O
phosphorus O
uptake O
and O
transport O
and O
thereby O
controlling O
bone O
formation O
. O

Other O
emergent O
areas O
of O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
( I
3 I
) I
action O
are O
in O
the O
control O
of O
immune O
functions O
, O
cellular O
growth O
and O
differentiation O
. O

All O
genomic O
actions O
of O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
( I
3 I
) I
are O
mediated O
by O
the O
transcription O
factor O
vitamin O
D O
receptor O
( O
VDR O
) O
that O
has O
been O
the O
subject O
of O
intense O
study O
since O
the O
1980 O
' O
s O
. O

Thus O
, O
some O
deviations O
of O
the O
experimental O
points O
with O
respect O
the O
H O
- O
H O
profiles O
can O
be O
attributed O
to O
specific O
interactions O
between O
the O
buffering O
electrolyte O
and O
the O
drug O
due O
to O
the O
hydrotrophic O
character O
of O
citric B
and I
lactic I
acids I
. O

In O
other O
cases O
, O
the O
observed O
deviations O
are O
independent O
of O
the O
buffers O
used O
since O
they O
are O
caused O
by O
the O
formation O
of O
new O
species O
such O
as O
drug O
aggregates O
( O
cefadroxil B
) O
or O
the O
precipitation O
of O
a O
salt O
from O
a O
cationic O
species O
of O
the O
analyzed O
compound O
( O
quetiapine O
) O
. O

Garlic O
- O
derived O
diallyl B
disulfide I
modulates O
peroxisome O
proliferator O
activated O
receptor O
gamma O
co O
- O
activator O
1 O
alpha O
in O
neuroblastoma O
cells O
. O

In O
the O
present O
report O
we O
show O
that O
, O
in O
SH O
- O
SY5Y O
neuroblastoma O
cells O
, O
garlic O
- O
derived O
diallyl B
disulfide I
( O
DADS O
) O
is O
able O
to O
increase O
PGC1 O
alpha O
expression O
in O
a O
ROS O
- O
dependent O
manner O
and O
to O
induce O
mitochondrial O
biogenesis O
at O
early O
stage O
of O
treatment O
that O
precede O
cell O
cycle O
arrest O
and O
apoptosis O
outcome O
. O

The O
preparation O
of O
core O
- O
shell O
polymeric O
nanoparticles O
simultaneously O
loaded O
with O
docetaxel O
( O
DTXL B
) O
and O
doxorubicin O
( O
DOX O
) O
is O
reported O
herein O
. O

The O
self O
- O
assembly O
of O
the O
aliphatic O
biodegradable O
copolyester O
PBS O
/ O
PBDL B
( O
poly B
( I
butylene I
succinate I
- I
co I
- I
butylene I
dilinoleate I
) I
) O
and O
HPMA O
- O
based O
copolymers O
( O
N O
- O
( O
2 O
- O
hydroxypropyl O
) O
methacrylamide O
- O
based O
copolymers O
) O
hydrophobically O
modified O
by O
the O
incorporation O
of O
cholesterol O
led O
to O
the O
formation O
of O
narrow O
- O
size O
- O
distributed O
( O
PDI O
< O
0 O
. O
10 O
) O
sub O
- O
200 O
- O
nm O
polymeric O
nanoparticles O
suitable O
for O
passive O
tumor O
- O

The O
PHPMA B
provided O
to O
the O
self O
- O
assembled O
nanoparticle O
stability O
against O
aggregation O
as O
evaluated O
in O
vitro O
. O

The O
highly O
hydrophobic O
drug O
docetaxel O
( O
DTXL B
) O
was O
physically O
entrapped O
within O
the O
PBS O
/ O
PBDL B
copolyester O
core O
and O
the O
hydrophilic O
drug O
doxorubicin B
hydrochloride I
( O
DOX B
. I
HCl I
) O
was O
chemically O
conjugated O
to O
the O
reactive O
PHPMA B
copolymer O
shell O
via O
hydrazone O
bonding O
that O
allowed O
its O
pH O
- O
sensitive O
release O
. O

This O
strategy O
enabled O
the O
combination O
chemotherapy O
by O
the O
simultaneous O
DOX O
and O
DTXL B
drug O
delivery O
. O

The O
use O
of O
nanoparticles O
simultaneously O
loaded O
with O
DTXL B
and O
DOX O
provided O
a O
more O
efficient O
suppression O
of O
tumor O
- O
cell O
growth O
in O
mice O
bearing O
EL O
- O
4 O
T O
cell O
lymphoma O
when O
compared O
to O
the O
effect O
of O
nanoparticles O
loaded O
with O
either O
DTXL B
or O
DOX O
separately O
. O

Retraction O
note O
to O
: O
The O
effect O
of O
lead B
acetate I
toxicity O
on O
experimental O
male O
albino O
rat O
. O

The O
currently O
available O
hydrocortisone O
or O
cortisone B
acetate I
preparations O
do O
not O
allow O
an O
accurate O
reproduction O
of O
the O
physiological O
secretion O
pattern O
of O
cortisol O
. O

One O
new O
compound O
named O
amauroamoienin B
( O
1 O
) O
, O
together O
with O
thirteen O
known O
compounds O
( O
2 O
- O
14 O
) O
, O
was O
isolated O
from O
the O
EtOAc O
extract O
of O
Amauroderma O
amoiensis O
. O

Three O
- O
dimensional O
hierarchical O
GeSe2 B
nanostructures O
for O
high O
performance O
flexible O
all O
- O
solid O
- O
state O
supercapacitors O
. O

Highly O
flexible O
stacked O
and O
in O
- O
plane O
all O
- O
solid O
- O
state O
supercapacitors O
are O
fabricated O
on O
3D O
hierarchical O
GeSe2 B
nanostructures O
with O
high O
performance O
, O
and O
, O
when O
configured O
as O
a O
self O
- O
powered O
photodetector O
nanosystem O
, O
can O
be O
used O
to O
power O
CdSe O
nanowire O
photodetectors O
. O

Intergrowth O
of O
two O
partially O
miscible O
phases O
of O
BiFeO B
( I
3 I
) I
and O
BiMnO B
( I
3 I
) I
gives O
a O
new O
class O
of O
room O
- O
temperature O
multiferroic O
phase O
, O
Bi B
( I
3 I
) I
Fe I
( I
2 I
) I
Mn I
( I
2 I
) I
O I
( I
10 I
+ I
delta I
) I
, O
which O
has O
a O
unique O
supercell O
( O
SC O
) O
structure O
. O

These O
results O
open O
up O
a O
new O
avenue O
for O
exploring O
room O
- O
temperature O
single O
- O
phase O
multiferroic O
thin O
films O
by O
controlling O
the O
phase O
mixing O
of O
two O
perovskite O
BiRO B
( I
3 I
) I
( O
R O
= O
Cr O
, O
Mn O
, O
Fe O
, O
Co O
, O
Ni O
) O
materials O
. O

Benzothiazole O
and O
benzimidazole O
containing O
phthalimide O
derivatives O
( O
NK037 B
, O
NK041 B
, O
NK042 B
, O
NK0139A B
and O
NK0148 B
) O
have O
been O
synthesized O
and O
their O
anti O
- O
angiogenic O
activity O
was O
evaluated O
using O
ex O
vivo O
egg O
yolk O
angiogenesis O
model O
. O

NK037 B
, O
NK041 B
and O
NK042 B
were O
equally O
potent O
in O
blocking O
egg O
yolk O
angiogenesis O
and O
the O
anti O
- O
angiogenesis O
effect O
was O
higher O
than O
NKTA B
suggesting O
the O
efficacy O
of O
these O
three O
derivatives O
in O
blocking O
angiogenesis O
when O
compare O
to O
control O
. O

Other O
two O
derivatives O
NK0139A B
and O
NK0148 B
showed O
effect O
less O
than O
NKTA B
and O
stronger O
than O
control O
in O
ex O
vivo O
angiogenesis O
. O

Neurodegeneration O
was O
related O
with O
decreased O
[ B
( I
3 I
) I
H I
] I
glutamate I
uptake O
and O
decreased O
Akt O
immunoreactivity O
, O
however O
phospho O
- O
GSK O
- O
3 O
- O
beta O
( O
Ser9 B
) O
was O
not O
altered O
in O
( O
PhTe O
) O
( O
2 O
) O
injected O
rat O
. O

Recent O
studies O
proposed O
a O
functional O
coupling O
between O
17 O
beta O
- O
hydroxysteroid O
dehydrogenase O
3 O
( O
17 O
beta O
- O
HSD3 O
) O
- O
dependent O
testosterone O
formation O
and O
11 O
beta O
- O
hydroxysteroid O
dehydrogenase O
1 O
( O
11 O
beta O
- O
HSD1 O
) O
- O
mediated O
interconversion O
of O
glucocorticoids O
through O
competition O
for O
the O
luminal O
pyridine B
nucleotide I
pool O
. O

To O
test O
this O
hypothesis O
, O
we O
used O
human O
embryonic O
kidney O
- O
293 O
cells O
transfected O
with O
17 O
beta O
- O
HSD3 O
and O
/ O
or O
11 O
beta O
- O
HSD1 O
, O
in O
the O
absence O
or O
presence O
of O
hexose B
- I
6 I
- I
phosphate I
dehydrogenase O
that O
generates O
reduced O
nicotinamide O
adenine O
dinucleotide O
phosphate O
( O
NADPH O
) O
in O
the O
endoplasmic O
reticulum O
and O
determined O
enzyme O
activities O
. O

17 O
beta O
- O
HSD3 O
- O
dependent O
reduction O
of O
Delta B
4 I
- I
androstene I
- I
3 I
, I
17 I
- I
dione I
was O
affected O
by O
neither O
coexpression O
with O
11 O
beta O
- O
HSD1 O
nor O
overexpression O
or O
knockdown O
of O
hexose B
- I
6 I
- I
phosphate I
dehydrogenase O
. O

Upon O
selective O
permeabilization O
of O
the O
plasma O
membrane O
by O
digitonin B
, O
17 O
beta O
- O
HSD3 O
but O
not O
11 O
beta O
- O
HSD1 O
was O
detected O
by O
antibodies O
against O
C O
- O
terminal O
epitope O
tags O
, O
suggesting O
a O
cytoplasmic O
orientation O
of O
17 O
beta O
- O
HSD3 O
. O

One O
pot O
synthesis O
and O
biological O
activity O
evaluation O
of O
novel O
Schiff O
bases O
derived O
from O
2 B
- I
hydrazinyl I
- I
1 I
, I
3 I
, I
4 I
- I
thiadiazole I
. O

Considering O
the O
structural O
features O
of O
a O
group O
of O
known O
potent O
inhibitors O
of O
human O
platelet O
aggregation O
containing O
hydrazone O
structural O
backbone O
, O
a O
series O
of O
novel O
hydrazone O
derivatives O
of O
2 B
- I
hydrazinyl I
- I
1 I
, I
3 I
, I
4 I
- I
thiadiazole I
were O
synthesized O
using O
a O
one O
- O
pot O
process O
and O
tested O
for O
their O
inhibitory O
activity O
against O
platelet O
aggregation O
induced O
by O
arachidonic O
acid O
and O
ADP O
. O

Electronic O
transition O
moments O
of O
6 B
- I
methyl I
isoxanthopterin I
- O
- O
a O
fluorescent O
analogue O
of O
the O
nucleic O
acid O
base O
guanine O
. O

We O
studied O
the O
orientations O
and O
magnitudes O
of O
the O
electric O
dipole O
transition O
moments O
( O
EDTMs O
) O
of O
6 B
- I
methyl I
isoxanthopterin I
( O
6 B
- I
MI I
) O
, O
a O
fluorescent O
analogue O
of O
guanine O
that O
has O
been O
particularly O
useful O
in O
biological O
studies O
. O

Our O
results O
indicate O
that O
the O
two O
experimentally O
observed O
lowest O
- O
energy O
transitions O
, O
which O
occur O
at O
29 O
, O
687 O
cm O
( O
- O
1 O
) O
( O
337 O
nm O
) O
and O
34 O
, O
596 O
cm O
( O
- O
1 O
) O
( O
289 O
nm O
) O
, O
are O
each O
polarized O
within O
the O
plane O
of O
the O
6 B
- I
MI I
base O
. O

Based O
on O
these O
results O
, O
we O
constructed O
an O
exciton O
model O
to O
describe O
the O
absorption O
spectra O
of O
a O
6 B
- I
MI I
dinucleotide O
- O
substituted O
double O
- O
stranded O
DNA O
construct O
. O

The O
orientations O
and O
intensities O
of O
the O
low O
- O
energy O
electronic O
transitions O
of O
6 B
- I
MI I
reported O
here O
should O
be O
useful O
for O
studying O
local O
conformations O
of O
DNA O
and O
RNA O
in O
biologically O
important O
complexes O
. O

Initially O
, O
this O
study O
confirmed O
that O
co O
- O
administration O
of O
A317491 B
( O
60 O
mu O
g O
/ O
paw O
) O
, O
a O
selective O
P2X3 O
receptor O
antagonist O
, O
or O
pre O
- O
treatment O
with O
dexamethasone O
( O
1 O
mg O
/ O
mL O
/ O
kg O
) O
prevents O
the O
mechanical O
hyperalgesia O
induced O
by O
carrageenan O
( O
300 O
mu O
g O
/ O
paw O
) O
in O
the O
rat O
' O
s O
hind O
paw O
. O

Sub O
- O
threshold O
doses O
of O
PGE O
( O
2 O
) O
( O
4 O
ng O
/ O
paw O
) O
or O
dopamine O
( O
0 O
. O
4 O
mu O
g O
/ O
paw O
) O
, O
that O
do O
not O
induce O
hyperalgesia O
by O
themselves O
, O
when O
injected O
just O
following O
alpha B
beta I
meATP I
or O
carrageenan O
in O
rats O
treated O
with O
dexamethasone O
induced O
hyperalgesia O
, O
which O
is O
prevented O
by O
A317491 B
or O
treatment O
with O
periganglionar O
( O
DRG O
- O
L5 O
) O
injections O
of O
ODN O
- O
antisense O
, O
against O
P2X3 O
receptor O
. O

Furthermore O
, O
because O
PKC O
epsilon O
translocation O
induces O
an O
increase O
of O
neuronal O
susceptibility O
to O
inflammatory O
mediators O
, O
this O
study O
demonstrates O
that O
alpha B
beta I
meATP I
in O
peripheral O
tissue O
increases O
the O
expression O
of O
PKC O
epsilon O
in O
cell O
membranes O
of O
DRG O
- O
L5 O
, O
and O
in O
contrast O
, O
the O
administration O
of O
PKC O
epsilon O
translocation O
inhibitor O
( O
1 O
mu O
g O
/ O
paw O
) O
in O
peripheral O
tissue O
45 O
min O
before O
alpha B
beta I
meATP I
, O
prevented O
the O
hyperalgesia O
induced O
by O
sub O
- O
threshold O
dose O
of O
PGE O
( O
2 O
) O
( O
4 O
ng O
/ O
paw O
) O
. O

Furthermore O
, O
it O
consists O
of O
fatty B
acid I
alkyl I
esters I
( O
FAAS B
) O
which O
have O
a O
great O
influence O
on O
biodiesel O
fuel O
properties O
and O
in O
the O
storage O
lifetime O
of O
biodiesel O
itself O
. O

This O
method O
uses O
condutimetric O
monitoring O
and O
induces O
the O
degradation O
of O
FAAS B
by O
heating O
the O
sample O
at O
a O
constant O
temperature O
. O

In O
this O
research O
, O
we O
aimed O
at O
developing O
a O
fast O
and O
simple O
alternative O
method O
to O
determine O
the O
induction O
time O
( O
IT O
) O
based O
on O
the O
FAAS B
ultrasonic O
- O
accelerated O
oxidation O
. O

The O
UV O
- O
Vis O
spectrometry O
was O
used O
to O
monitor O
the O
FAAS B
sonodegradation O
by O
measuring O
the O
absorbance O
at O
270nm O
every O
2 O
. O

Quantification O
of O
silanol O
sites O
for O
the O
most O
common O
mesoporous O
ordered O
silicas O
and O
organosilicas B
: O
total O
versus O
accessible O
silanols B
. O

IR O
and O
NMR O
spectroscopy O
were O
used O
to O
determine O
the O
silanol O
content O
in O
the O
most O
common O
mesoporous O
ordered O
silicas O
: O
MCM O
- O
41 O
, O
MCM B
- I
48 I
, O
SBA O
- O
15 O
and O
SBA B
- I
16 I
. O

In O
addition O
, O
a O
spray O
dried O
MCM O
- O
41 O
and O
an O
ethene B
bridged O
PMO B
are O
investigated O
. O

The O
results O
are O
compared O
with O
a O
commercial O
chromatographic O
silica O
( O
Nucleosil B
) O
. O

The O
complete O
distribution O
of O
surface O
and O
bulk O
silanols B
, O
and O
of O
isolated O
, O
geminal B
and I
vicinal I
silanols I
for O
all O
these O
materials O
is O
presented O
. O

All O
mesoporous O
ordered O
silicas O
, O
and O
especially O
the O
thick O
walled O
SBA O
- O
type O
materials O
and O
the O
PMO B
contain O
a O
surprisingly O
high O
amount O
of O
total O
silanol O
sites O
, O
albeit O
that O
up O
to O
90 O
% O
of O
these O
silanols B
are O
buried O
inside O
the O
walls O
and O
are O
not O
reachable O
for O
small O
silanes O
. O

Effect O
of O
structural O
defects O
and O
chemical O
functionalisation O
on O
the O
intrinsic O
mechanical O
properties O
of O
graphene B
. O

Also O
, O
the O
presence O
of O
structural O
defects O
in O
the O
system O
will O
stiffen O
the O
system O
upon O
low O
strain O
, O
but O
reduces O
the O
elastic O
limit O
from O
more O
than O
20 O
% O
strain O
for O
pristine B
graphene I
to O
less O
than O
10 O
% O
strain O
when O
defects O
are O
present O
. O

Mechanism O
of O
the O
antiproliferative O
activity O
of O
some O
naphthalene B
diimide I
G O
- O
quadruplex O
ligands O
. O

We O
report O
here O
on O
investigations O
into O
the O
mechanism O
of O
action O
of O
tetra O
- O
substituted O
naphthalene B
diimide I
ligands O
on O
the O
basis O
of O
cell O
biologic O
data O
together O
with O
a O
National O
Cancer O
Institute O
COMPARE O
study O
. O

Mangiferin B
- O
a O
bioactive O
xanthonoid B
, O
not O
only O
from O
mango O
and O
not O
just O
antioxidant O
. O

Mangiferin B
is O
a O
plant O
natural O
polyphenol O
of O
C B
- I
glycosylxanthone I
structure O
and O
various O
pharmacological O
activities O
. O

Mangiferin B
is O
also O
present O
in O
some O
medicinal O
herbs O
, O
influencing O
their O
therapeutic O
and O
preventive O
properties O
, O
and O
in O
honeybush O
( O
Cyclopia O
sp O
. O
) O
, O
a O
popular O
South O
African O
herbal O
tea O
. O

Mangiferin B
dissolves O
well O
in O
water O
, O
so O
it O
can O
be O
easily O
extracted O
into O
infusions O
and O
decoctions O
. O

In O
the O
mangiferin B
molecule O
, O
four O
aromatic B
hydroxyl I
groups O
determine O
its O
strong O
antiradical O
and O
antioxidant O
properties O
. O

Mangiferin B
is O
also O
an O
efficient O
iron O
chelator O
, O
therefore O
preventing O
the O
generation O
of O
hydroxyl O
radical O
in O
Fenton O
- O
type O
reactions O
. O

Numerous O
published O
in O
vitro O
and O
in O
vivo O
pharmacological O
studies O
, O
demonstrated O
many O
other O
activities O
of O
mangiferin B
: O
analgesic O
, O
antidiabetic O
, O
antisclerotic O
, O
atimicrobial O
and O
antiviral O
, O
cardio O
- O
, O
hepato O
- O
, O
and O
neuroprotective O
, O
antiinflammatory O
, O
antiallergic O
, O
MAO O
inhibiting O
and O
memory O
improving O
, O
as O
well O
as O
radioprotective O
against O
X O
- O
ray O
, O
gamma O
, O
and O
UV O
radiation O
. O

Supramolecular O
hydrogels O
with O
reverse O
thermal O
gelation O
properties O
from O
( B
oligo I
) I
tyrosine I
containing O
block O
copolymers O
. O

Novel O
block O
copolymers O
comprising O
poly O
( O
ethylene O
glycol O
) O
( O
PEG O
) O
and O
an O
oligo B
( I
tyrosine I
) I
block O
were O
synthesized O
in O
different O
compositions O
by O
N B
- I
carboxyanhydride I
( O
NCA B
) O
polymerization O
. O

It O
was O
shown O
that O
PEG2000 B
- I
Tyr I
( I
6 I
) I
undergoes O
thermoresponsive O
hydrogelation O
at O
a O
low O
concentration O
range O
of O
0 O
. O
25 O
- O
3 O
. O
0 O
wt O
% O
within O
a O
temperature O
range O
of O
25 O
- O
50 O
degrees O
C O
. O

2 B
, I
5 I
- I
Dihydroxy I
- I
4 I
- I
methoxybenzophenone I
: O
a O
novel O
major O
in O
vitro O
metabolite O
of O
benzophenone B
- I
3 I
formed O
by O
rat O
and O
human O
liver O
microsomes O
. O

1 O
. O
When O
benzophenone B
- I
3 I
( O
2 B
- I
hydroxy I
- I
4 I
- I
methoxybenzophenone I
; O
BP B
- I
3 I
) O
was O
incubated O
with O
liver O
microsomes O
of O
untreated O
rats O
in O
the O
presence O
of O
NADPH O
, O
the O
5 O
- O
hydroxylated O
metabolite O
, O
2 B
, I
5 I
- I
dihydroxy I
- I
4 I
- I
methoxybenzophenone I
( O
5 B
- I
OH I
- I
BP I
- I
3 I
) O
, O
was O
formed O
as O
a O
major O
novel O
metabolite O
of O
BP B
- I
3 I
. O

The O
4 O
- O
desmethylated O
metabolite O
, O
2 O
, O
4 O
- O
dihydroxybenzophenon O
( O
2 B
, I
4 I
- I
diOH I
- I
BP I
) O
, O
previously O
reported O
as O
the O
major O
in O
vivo O
metabolite O
of O
BP B
- I
3 I
, O
was O
also O
detected O
. O

However O
, O
the O
amount O
of O
5 B
- I
OH I
- I
BP I
- I
3 I
formed O
in O
vitro O
was O
about O
the O
same O
as O
that O
of O
2 B
, I
4 I
- I
diOH I
- I
BP I
. O

2 O
. O
The O
oxidase O
activity O
affording O
5 B
- I
OH I
- I
BP I
- I
3 I
was O
inhibited O
by O
SKF B
525 I
- I
A I
and O
ketoconazole O
, O
and O
partly O
by O
quinidine O
and O
sulfaphenazole B
. O

The O
oxidase O
activity O
affording O
2 B
, I
4 I
- I
diOH I
- I
BP I
was O
inhibited O
by O
SKF B
525 I
- I
A I
, O
ketoconazole O
and O
alpha B
- I
naphthoflavone I
, O
and O
partly O
by O
sulfaphenazole B
. O

3 O
. O
The O
oxidase O
activity O
affording O
5 B
- I
OH I
- I
BP I
- I
3 I
was O
enhanced O
in O
liver O
microsomes O
of O
dexamethasone O
- O
, O
phenobarbital O
- O
and O
3 O
- O
methylcholanthrene O
- O
treated O
rats O
. O

The O
activity O
affording O
2 B
, I
4 I
- I
diOH I
- I
BP I
was O
enhanced O
in O
liver O
microsomes O
of O
3 O
- O
methylcholanthrene O
- O
and O
phenobarbital O
- O
treated O
rats O
. O

4 O
. O
When O
examined O
recombinant O
rat O
cytochrome O
P450 O
isoforms O
catalyzing O
the O
metabolism O
of O
BP B
- I
3 I
, O
5 O
- O
hydroxylation O
was O
catalyzed O
by O
P450 O
3A2 O
, O
1A1 O
, O
2B1 O
, O
2C6 O
and O
2D1 O
, O
while O
4 O
- O
desmethylation O
was O
catalyzed O
by O
P450 O
2C6 O
and O
1A1 O
. O

Green O
asymmetric O
synthesis O
: O
beta B
- I
amino I
alcohol I
- O
catalyzed O
direct O
asymmetric O
aldol B
reactions O
in O
aqueous O
micelles O
. O

The O
ability O
of O
chiral B
beta I
- I
amino I
alcohols I
to O
catalyze O
the O
direct O
asymmetric O
aldol B
reaction O
was O
evaluated O
for O
the O
first O
time O
in O
aqueous O
micellar O
media O
. O

A O
family O
of O
cheap O
and O
easily O
accessible O
beta B
- I
amino I
alcohols I
, O
obtained O
in O
one O
step O
from O
naturally O
occurring O
amino O
acids O
, O
was O
shown O
to O
successfully O
catalyze O
the O
asymmetric O
aldol B
reaction O
between O
a O
series O
of O
ketones O
and O
aromatic O
aldehydes O
. O

These O
aldol B
reactions O
furnished O
the O
corresponding O
beta B
- I
hydroxy I
ketones I
with O
up O
to O
93 O
% O
isolated O
yield O
and O
89 O
% O
ee O
. O

( B
S I
) I
- I
2 I
- I
phenylglycinol I
and O
Triton B
X I
- I
100 I
proved O
to O
be O
the O
best O
organocatalyst O
and O
surfactant O
, O
respectively O
. O

We O
observed O
that O
when O
ATDC5 O
cells O
were O
cultured O
on O
functional O
peptide O
nanofibers O
, O
they O
rapidly O
aggregated O
in O
insulin O
- O
free O
medium O
and O
formed O
cartilage O
- O
like O
nodules O
and O
deposited O
sulfated O
glycosaminoglycans O
shown O
by O
Safranin B
- I
O I
staining O
. O

The O
performance O
of O
these O
modified O
electrodes O
was O
evaluated O
and O
compared O
to O
bare O
GCE O
by O
cyclic O
voltammetry O
experiments O
and O
by O
flow O
injection O
analysis O
( O
FIA O
) O
with O
amperometric O
detection O
monitoring O
the O
response O
of O
gallic B
, I
caffeic I
, I
ferulic I
and I
p I
- I
coumaric I
acids I
in O
0 O
. O
050 O
M O
acetate O
buffer O
pH O
4 O
. O
5 O
containing O
100 O
mM O
NaCl O
. O

Amongst O
the O
4 O
cationic O
peptides O
, O
the O
peptide O
sequence O
ALPMHIR O
, O
identified O
as O
lactokinin B
and O
known O
to O
exert O
an O
important O
antihypertensive O
effect O
, O
was O
recovered O
with O
an O
estimated O
66 O
% O
migration O
rate O
. O

The O
presence O
of O
D B
- I
fagomine I
in O
the O
human O
diet O
from O
buckwheat O
- O
based O
foodstuffs O
. O

Buckwheat O
( O
Fagopyrum O
esculentum O
Moench O
) O
groats O
contain O
the O
iminosugar O
D B
- I
fagomine I
as O
a O
minor O
component O
that O
might O
contribute O
to O
the O
alleged O
health O
benefits O
of O
this O
pseudo O
- O
cereal O
. O

This O
study O
presents O
analysis O
of O
D B
- I
fagomine I
in O
buckwheat O
- O
based O
foodstuffs O
by O
liquid O
chromatography O
coupled O
to O
mass O
spectrometry O
and O
an O
estimation O
of O
its O
presence O
in O
the O
human O
diet O
based O
on O
a O
published O
population O
- O
based O
cross O
- O
sectional O
nutrition O
survey O
. O

D B
- I
fagomine I
is O
present O
in O
common O
buckwheat O
- O
based O
foodstuffs O
in O
amounts O
ranging O
from O
1 O
to O
25 O
mg O
/ O
kg O
or O
mg O
/ O
L O
, O
it O
is O
stable O
during O
boiling O
, O
baking O
, O
frying O
and O
fermentation O
, O
and O
it O
is O
biosynthesised O
upon O
sprouting O
. O

The O
estimated O
total O
intake O
of O
D B
- I
fagomine I
resulting O
from O
a O
diet O
that O
includes O
such O
foodstuffs O
would O
be O
between O
3 O
and O
17 O
mg O
per O
day O
( O
mean O
for O
both O
genders O
; O
range O
from O
P5 O
to O
P95 O
) O
. O

A O
diet O
rich O
in O
buckwheat O
products O
would O
provide O
a O
daily O
amount O
of O
D B
- I
fagomine I
that O
may O
in O
part O
explain O
the O
beneficial O
properties O
traditionally O
attributed O
to O
buckwheat O
consumption O
. O

A O
new O
QSAR O
model O
, O
for O
angiotensin B
I I
- O
converting O
enzyme O
inhibitory O
oligopeptides O
. O

A O
new O
quantitative O
structure O
activity O
relationship O
( O
QSAR O
) O
model O
is O
established O
for O
oligopeptides O
that O
inhibit O
angiotensin B
I I
- O
converting O
enzyme O
( O
ACE O
) O
. O

However O
, O
in O
the O
C O
- O
4 O
position O
, O
the O
model O
indicates O
a O
clear O
preference O
for O
bulky O
hydrophobic O
amino O
acids O
and O
for O
sulphur B
- O
containing O
amino O
acids O
. O

In O
addition O
, O
the O
phenolic O
content O
of O
the O
tea O
products O
was O
determined O
using O
the O
Folin B
- I
Ciocalteu I
phenol I
reagent O
. O

The O
AA O
% O
of O
the O
tea O
products O
was O
determined O
using O
a O
2 B
, I
2 I
' I
- I
diphenyl I
picrylhydrazyl I
( O
DPPH O
) O
radical O
assay O
method O
. O

Cyanidin B
- I
3 I
- I
O I
- I
glucoside I
was O
the O
anthocyanin O
most O
highly O
correlated O
with O
AA O
% O
( O
r O
= O
0 O
. O
843 O
( O
* O
* O
) O
, O
p O
< O
= O
0 O
. O
01 O
in O
unaerated O
tea O
) O
. O

A O
simple O
multiresidue O
analytical O
method O
is O
developed O
for O
the O
simultaneous O
determination O
of O
carbendazim B
( O
CB O
) O
, O
thiabendazole B
( O
TB O
) O
, O
and O
6 B
- I
benzyl I
aminopurine I
( O
6 B
- I
BA I
) O
in O
bean O
sprouts O
. O

Except O
for O
6 B
- I
BA I
, O
the O
rest O
of O
the O
analytes O
had O
values O
lower O
than O
their O
LOQs O
. O

In O
sum O
, O
carbendazim B
, O
thiabendazole B
, O
and O
6 B
- I
BA I
were O
extracted O
in O
a O
single O
step O
, O
and O
no O
steps O
for O
clean O
- O
up O
or O
concentration O
of O
the O
extracts O
were O
needed O
. O

The O
results O
showed O
that O
the O
molecular O
weight O
of O
CPP O
was O
900 O
kDa O
, O
and O
it O
contained O
64 O
. O
8 O
% O
total O
sugar O
, O
23 O
. O
5 O
% O
uronic B
acid I
, O
9 O
. O
26 O
% O
protein O
, O
and O
six O
kinds O
of O
monosaccharides O
, O
including O
glucose O
, O
rhamnose B
, O
arabinose O
, O
xylose O
, O
mannose O
and O
galactose O
, O
with O
molar O
percentages O
of O
32 O
. O
7 O
% O
, O
9 O
. O
33 O
% O
, O
30 O
. O
6 O
% O
, O
3 O
. O
48 O
% O
, O
10 O
. O
4 O
% O
, O
and O
13 O
. O
5 O
% O
, O
respectively O
. O

In O
the O
present O
study O
, O
we O
investigated O
whether O
acute O
exposure O
to O
organophosphate O
( O
OP O
) O
chlorpyrifos O
( O
CPF B
) O
is O
related O
to O
long O
- O
term O
lack O
of O
inhibitory O
control O
; O
we O
also O
examined O
the O
possible O
neurochemical O
basis O
of O
this O
association O
. O

Lister O
Hooded O
rats O
were O
exposed O
to O
an O
acute O
dose O
of O
CPF B
( O
250 O
mg O
/ O
kg O
) O
. O

We O
manipulated O
the O
baseline O
conditions O
of O
this O
task O
and O
also O
systemically O
pre O
- O
administered O
d O
- O
amphetamine O
, O
quinpirole O
, O
dizocilpine B
( O
MK O
- O
801 O
) O
or O
ketanserin B
. O

On O
the O
5 O
- O
CSRT O
task O
, O
CPF B
- O
exposed O
rats O
showed O
elevated O
perseverative O
responses O
that O
persisted O
across O
manipulation O
of O
baseline O
conditions O
of O
the O
task O
and O
under O
most O
of O
the O
pharmacological O
challenges O
tested O
. O

Only O
D O
- O
amphetamine O
induced O
a O
dose O
- O
dependent O
amelioration O
of O
the O
increased O
perseverative O
responses O
in O
the O
CPF B
group O
. O

The O
CPF B
group O
also O
exhibited O
increased O
levels O
of O
dopamine O
metabolism O
in O
the O
hippocampus O
and O
decreased O
levels O
of O
gamma O
- O
aminobutyric O
acid O
( O
GABA O
) O
and O
glutamate O
in O
the O
striatum O
compared O
to O
the O
vehicle O
group O
. O

These O
findings O
suggest O
that O
CPF B
induced O
a O
long O
- O
term O
compulsivity O
that O
was O
apparent O
in O
the O
5 O
- O
CSRT O
task O
and O
associated O
with O
changes O
in O
monoaminergic O
and O
amino O
acid O
brain O
systems O
of O
inhibitory O
control O
function O
. O

Synthesis O
and O
antiplasmodial O
evaluation O
of O
novel O
( B
4 I
- I
aminobutyloxy I
) I
quinolines I
. O

A O
variety O
of O
5 B
- I
, I
6 I
- I
and I
8 I
- I
( I
4 I
- I
aminobutyloxy I
) I
quinolines I
as O
novel O
oxygen O
analogues O
of O
known O
4 B
- I
and I
8 I
- I
( I
4 I
- I
aminobutylamino I
) I
quinoline I
antimalarial O
drugs O
was O
generated O
from O
hydroxyquinolines B
through O
a O
three O
- O
step O
approach O
with O
a O
rhodium B
- O
catalyzed O
hydroformylation O
as O
the O
key O
step O
. O

To O
better O
understand O
AhR O
- O
driven O
pathways O
, O
we O
analyzed O
the O
transcriptional O
program O
in O
response O
to O
coplanar O
PCB B
126 I
in O
contact O
- O
inhibited O
rat O
liver O
progenitor O
WB O
- O
F344 O
cells O
using O
high O
- O
density O
microarrays O
. O

Water O
- O
soluble O
star O
- O
like O
poly O
( O
vinyl O
alcohol O
) O
/ O
C O
( O
60 O
) O
and O
poly B
{ I
[ I
poly I
( I
ethylene I
glycol I
) I
acrylate I
] I
- I
co I
- I
( I
vinyl I
acetate I
) I
} I
/ O
C O
( O
60 O
) O
nanohybrids O
are O
prepared O
by O
grafting O
macroradicals O
onto O
C O
( O
60 O
) O
and O
are O
assessed O
as O
photosensitizers O
for O
photodynamic O
therapy O
. O

The O
advantages O
of O
both O
nanohybrids O
are O
encountered O
in O
a O
third O
one O
, O
poly B
[ I
( I
N I
- I
vinylpyrrolidone I
) I
- I
co I
- I
( I
vinyl I
acetate I
) I
] I
/ O
C O
( O
60 O
) O
, O
which O
has O
linear O
grafts O
without O
hydroxyl O
groups O
, O
and O
shows O
a O
better O
photodynamic O
activity O
. O

Initial O
uptake O
rate O
and O
steady O
- O
state O
cell O
- O
to O
- O
medium O
ratio O
of O
[ B
( I
3 I
) I
H I
] I
MTX I
were O
correlated O
with O
both O
RFC1 O
expression O
level O
and O
MTX O
sensitivity O
. O

In O
the O
present O
studies O
, O
the O
effects O
of O
CB O
( O
1 O
) O
agonists O
[ O
( B
6aR I
, I
10aR I
) I
- I
3 I
- I
( I
1 I
- I
adamantyl I
) I
- I
6 I
, I
6 I
, I
9 I
- I
trimethyl I
- I
6a I
, I
7 I
, I
10 I
, I
10a I
- I
tetrahydrobenzo I
[ I
c I
] I
chromen I
- I
1 I
- I
ol I
( O
AM411 B
) O
, O
9 B
beta I
- I
( I
hydroxymethyl I
) I
- I
3 I
- I
( I
1 I
- I
adamantyl I
) I
- I
hexahydrocannabinol I
( O
AM4054 O
) O
, O
R O
- O
( O
+ O
) O
- O
[ O
2 O

, O
3 O
- O
dihydro O
- O
5 O
- O
methyl O
- O
3 O
- O
[ O
( O
morpholinyl O
) O
methyl O
] O
pyrrolo O
[ O
1 O
, O
2 O
, O
3 O
- O
de O
] O
- O
1 O
, O
4 O
- O
benzoxazinyl O
] O
- O
( O
1 O
- O
naphthalenyl O
) O
methanone O
mesylate O
( O
WIN55 B
, I
212 I
. I
2 I
) O
, O
Delta O
( O
9 O
) O
- O
tetrahydrocannabinol O
( O
Delta B
( I
9 I
) I
- I
THC I
) O
, O
( O
R O
) O
- O
( O
+ O
) O
- O
arachidonyl O
- O
1 O
' O
- O
hydroxy O
- O
2 O
' O
- O

propylamide O
( O
methanandamide O
) O
] O
, O
CB O
( O
1 O
) O
antagonists O
[ O
5 B
- I
( I
4 I
- I
chlorophenyl I
) I
- I
1 I
- I
( I
2 I
, I
4 I
- I
dichloro I
- I
phenyl I
) I
- I
4 I
- I
methyl I
- I
N I
- I
( I
piperidin I
- I
1 I
- I
yl I
) I
- I
1H I
- I
pyrazole I
- I
3 I
- I
carboxamide I
( O
SR141716A O
) O
, O
5 O
- O
( O
4 O
- O
alkylphenyl O
) O
- O
1 O
- O
( O
2 O
, O
4 O
- O
dichlorophenyl O
) O
- O
4 O
- O
methyl O
- O
N O
- O
( O

piperidin O
- O
1 O
- O
yl O
) O
- O
1H O
- O
pyrazole O
- O
3 O
- O
carboxamide O
( O
AM4113 B
) O
] O
, O
and O
dopamine O
( O
DA O
) O
- O
related O
[ O
methamphetamine O
, O
( B
+ I
/ I
- I
) I
- I
6 I
- I
chloro I
- I
7 I
, I
8 I
- I
dihydroxy I
- I
3 I
- I
allyl I
- I
1 I
- I
phenyl I
- I
2 I
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
3 I
- I
benzazepine I
hydrobromide I
( O
SKF82958 B
) O
, O
( O
R O
) O
- O
( O
+ O
) O
- O
7 O

- O
chloro O
- O
8 O
- O
hydroxy O
- O
3 O
- O
methyl O
- O
1 O
- O
phenyl O
- O
2 O
, O
3 O
, O
4 O
, O
5 O
- O
tetrahydro O
- O
1H O
- O
3 O
- O
benzazepine O
hydrochloride O
( O
SCH23390 B
) O
, O
( B
6aR I
) I
- I
5 I
, I
6 I
, I
6a I
, I
7 I
- I
tetrahydro I
- I
6 I
- I
propyl I
- I
4H I
- I
dibenzo I
[ I
de I
, I
g I
] I
quinoline I
- I
10 I
, I
11 I
- I
diol I
( O
R B
- I
( I
- I
) I
- I
NPA I
) O
, O
haloperidol O
] O
and O

opioid O
( O
morphine O
, O
naltrexone B
) O
drugs O
on O
scheduled O
- O
controlled O
responding O
under O
a O
30 O
- O
response O
fixed O
ratio O
schedule O
of O
stimulus O
- O
shock O
termination O
in O
squirrel O
monkeys O
were O
compared O
before O
and O
during O
chronic O
treatment O
with O
the O
long O
- O
acting O
CB O
( O
1 O
) O
agonist O
AM411 B
( O
1 O
. O
0 O
mg O
/ O
kg O
per O
day O
, O
i O
. O
m O
. O
) O
. O

Prechronic O
treatment O
with O
all O
drugs O
except O
naltrexone B
( O
1 O
- O
10 O
mg O
/ O
kg O
) O
produced O
dose O
- O
related O
decreases O
in O
responses O
rates O
. O

Dose O
- O
response O
re O
- O
determinations O
during O
chronic O
treatment O
revealed O
the O
following O
: O
1 O
) O
> O
250 O
- O
fold O
( O
AM411 B
, O
methanandamide B
) O
and O
> O
45 O
- O
fold O
( O
AM4054 O
, O
WIN55 O
, O
212 O
. O
2 O
, O
Delta B
( I
9 I
) I
- I
THC I
) O
rightward O
shifts O
in O
the O
ED O
( O
50 O
) O
values O
for O
CB O
( O
1 O
) O
agonists O
; O
2 O
) O
> O
100 O
- O
fold O
and O
> O
20 O
- O
fold O
leftward O
shifts O
in O
the O
ED O
( O
50 O
) O
values O
for O
SR141716A O
and O
AM4113 O
, O
respectively O
; O
and O
3 O
) O
approximately O
4 O
. O
8 O
- O
fold O
and O
10 O
- O

fold O
rightward O
shifts O
in O
the O
ED O
( O
50 O
) O
values O
for O
methamphetamine O
and O
the O
DA O
D O
( O
2 O
) O
agonist O
R B
- I
( I
- I
) I
- I
NPA I
, O
respectively O
. O

Finally O
, O
the O
development O
of O
cross O
- O
tolerance O
to O
methamphetamine O
and O
R B
- I
( I
- I
) I
- I
NPA I
bolsters O
previous O
evidence O
of O
interplay O
between O
CB O
( O
1 O
) O
and O
DA O
D O
( O
2 O
) O
signaling O
mechanisms O
. O

We O
explore O
the O
transport O
of O
electrons O
between O
electrodes O
that O
encase O
a O
two O
- O
dimensional O
array O
of O
metallic O
quantum O
dots O
linked O
by O
molecular O
bridges O
( O
such O
as O
alpha O
, O
omega O
alkaline O
dithiols B
) O
. O

The O
content O
of O
eight O
biogenic O
amines O
( O
putrescine O
, O
cadaverine B
, O
spermidine O
, O
spermine O
, O
histamine O
, O
tyramine O
, O
tryptamine O
and O
phenylethylamine B
) O
were O
determined O
. O

Putrescine O
, O
cadaverine B
and O
tyramine O
showed O
very O
good O
correspondence O
with O
the O
level O
of O
applied O
pressure O
and O
organoleptic O
properties O
. O

Tryptamine O
, O
phenylethylamine B
and O
histamine O
( O
with O
the O
single O
exception O
of O
a O
sample O
stored O
for O
70 O
days O
) O
were O
not O
detected O
in O
pressure O
- O
treated O
samples O
kept O
at O
3 O
. O
5 O
degrees O
C O
. O

Glycosides O
of O
( B
Z I
) I
- I
3 I
- I
hexen I
- I
1 I
- I
ol I
and O
hexanol B
( O
green O
- O
note O
volatiles O
) O
were O
present O
in O
considerable O
amounts O
. O

GC O
- O
olfactometry O
analysis O
of O
the O
hydrolysates O
of O
ripe O
' O
Hayward O
' O
and O
' O
Hort16A O
' O
revealed O
the O
presence O
of O
2 B
- I
phenylethanol I
, O
beta B
- I
damascenone I
, O
vanillin O
and O
2 B
, I
5 I
- I
dimethyl I
- I
4 I
- I
hydroxy I
- I
3 I
( I
2H I
) I
- I
furanone I
( O
DMHF B
) O
. O

This O
is O
the O
first O
report O
of O
DMHF B
in O
' O
Hayward O
' O
kiwifruit O
. O

Proximate O
composition O
, O
fatty O
acid O
profile O
, O
cholesterol O
, O
alpha B
- I
tocoferol I
content O
and O
essential O
( O
K O
, O
Na O
, O
Cl O
, O
S O
, O
Mg O
, O
Ca O
, O
Zn O
, O
Cu O
, O
Fe O
, O
Mn O
, O
and O
Se O
) O
and O
contaminant O
element O
( O
Hg O
/ O
MeHg O
, O
Cd O
, O
Pb O
, O
and O
As O
) O
levels O
in O
silver O
scabbardfish O
( O
Lepidopus O
caudatus O
) O
, O
hake O
( O
Merluccius O
merluccius O
) O
, O
and O
ray O
( O
Raja O
spp O
. O
) O
were O
investigated O
. O

The O
toxins O
were O
extracted O
with O
acetonitrile O
/ O
water O
( O
90 O
: O
10 O
, O
v O
/ O
v O
) O
containing O
0 O
. O
1 O
% O
formic O
acid O
and O
cleaned O
by O
HLB O
and O
GCB B
sorbents O
. O

The O
limit O
of O
detection O
( O
LOD O
) O
was O
below O
the O
recommended O
regulatory O
limit O
of O
170 O
mu O
gSTX B
( O
equ O
. O
) O
/ O
kg O
and O
the O
proposed O
method O
fully O
meets O
the O
needs O
of O
daily O
monitoring O
. O

The O
discovery O
and O
structure O
- O
activity O
relationships O
of O
4 B
- I
azaindole I
cores O
. O

A O
series O
of O
4 B
- I
azaindole I
oxoacetic I
acid I
piperazine I
benzamides I
was O
synthesized O
and O
evaluated O
in O
an O
effort O
to O
identify O
an O
oral O
HIV O
- O
1 O
attachment O
inhibitor O
with O
the O
potential O
to O
improve O
upon O
the O
pre O
- O
clinical O
profile O
of O
BMS B
- I
378806 I
( O
7 O
) O
, O
an O
initial O
clinical O
compound O
. O

Modifications O
at O
the O
7 O
- O
position O
of O
the O
4 B
- I
azaindole I
core O
modulated O
potency O
significantly O
and O
SAR O
showed O
that O
certain O
compounds O
with O
a O
5 O
- O
membered O
ring O
heteroaryl O
group O
at O
that O
position O
were O
the O
most O
potent O
. O

( B
- I
) I
- I
6 I
- I
( I
7 I
- I
Methoxy I
- I
2 I
- I
( I
trifluoromethyl I
) I
pyrazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyridin I
- I
4 I
- I
yl I
) I
- I
5 I
- I
methyl I
- I
4 I
, I
5 I
- I
dihydropyridazin I
- I
3 I
( I
2H I
) I
- I
one I
( O
KCA B
- I
1490 I
) O
exhibits O
moderate O
dual O
PDE3 O
/ O
4 O
- O
inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory O
/ O
anti O
- O
inflammatory O
agent O
. O

N O
- O
alkylation O
of O
the O
pyridazinone B
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 O
inhibition O
. O

Addition O
of O
a O
6 B
- I
aryl I
- I
4 I
, I
5 I
- I
dihydropyridazin I
- I
3 I
( I
2H I
) I
- I
one I
extension O
to O
the O
N O
- O
alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4 O
- O
inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O

Both O
dihydropyridazinone B
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4 B
, I
4 I
- I
dimethylpyrazolone I
subunits O
and O
the O
core O
pyrazolopyridine B
by O
isosteric O
bicyclic O
heteroaromatics O
. O

The O
effect O
of O
the O
phytoestrogen O
, O
quercetin O
( O
QT O
) O
on O
the O
reproductive O
toxicity O
of O
atrazine O
( O
ATZ B
) O
was O
explored O
in O
interstitial O
Leydig O
cells O
( O
ILCs O
) O
. O

by O
real O
- O
time O
- O
PCR O
after O
cultured O
cells O
were O
treated O
in O
vitro O
with O
ATZ B
( O
232 O
mu O
M O
) O
and O
QT O
( O
50 O
mu O
M O
) O
. O

The O
mRNA O
expression O
of O
tested O
genes O
increased O
with O
ATZ B
treatment O
and O
was O
normalized O
by O
quercetin O
except O
AR O
and O
ER O
- O
alpha O
expression O
. O

Furthermore O
, O
the O
expressions O
of O
tested O
genes O
were O
unaffected O
by O
cyclic O
- O
AMP O
at O
6h O
when O
the O
stimulatory O
effects O
of O
ATZ B
on O
tested O
genes O
were O
sustained O
. O

These O
findings O
suggest O
that O
ATZ B
may O
stimulate O
the O
expression O
of O
tested O
steroidogenesis O
genes O
in O
ILCs O
via O
a O
mechanism O
independent O
of O
cyclic O
- O
AMP O
which O
was O
partially O
antagonize O
by O
QT O
. O

Thiazole O
- O
Zn O
is O
a O
newly O
Chinese O
- O
created O
systemic O
fungicide O
, O
and O
belongs O
to O
the O
sort O
of O
thiadiazole B
compounds O
, O
some O
of O
which O
have O
been O
found O
to O
be O
thyroid O
disrupters O
. O

Next O
, O
we O
examined O
expression O
of O
genes O
encoding O
five O
progesterone O
metabolizing O
enzymes O
: O
the O
3 B
- I
keto I
and I
20 I
- I
ketosteroid I
reductases O
( O
AKR1C1 O
- O
AKR1C3 O
) O
and O
5 O
alpha O
- O
reductases O
( O
SRD5A1 O
and O
SRD5A2 O
) O
; O
and O
the O
opposing O
20 B
alpha I
- I
hydroxysteroid I
dehydrogenase O
( O
HSD17B2 O
) O
. O

The O
self O
- O
assembling O
co O
- O
polymer O
stearoyl B
- I
PEG I
- I
poly I
- I
sulfadimethoxine I
methacrylate I
( O
stearoyl B
- I
PEG I
- I
polySDM I
) O
was O
prepared O
to O
obtain O
micelles O
with O
responsive O
behaviour O
in O
the O
physiopathologic O
pH O
range O
. O

Stearoyl B
- I
PEG I
- I
polySDM I
was O
synthesised O
using O
a O
multi O
- O
step O
procedure O
that O
includes O
pH O
- O
sensitive O
sulfadimethoxine B
methacrylate I
polymerisation O
by O
AGET O
- O
ATRP O
at O
the O
amino O
terminal O
side O
of O
stearoyl B
- I
PEG I
- I
NH2 I
. O

Chemical O
analysis O
showed O
that O
the O
stearoyl B
- I
PEG I
- I
polySDM I
co O
- O
polymer O
contained O
a O
mean O
of O
seven O
methacryloyl B
sulfadimethoxines I
per O
molecule O
. O

Potentiometric O
and O
turbidimetric O
analyses O
showed O
that O
stearoyl B
- I
PEG I
- I
polySDM I
has O
an O
apparent O
pKa O
of O
7 O
. O
2 O
and O
a O
cloud O
point O
at O
pH O
7 O
. O
0 O
. O

Cell O
- O
culture O
studies O
showed O
that O
the O
material O
was O
more O
biocompatible O
with O
respect O
to O
the O
control O
Brij B
- I
700 I
( O
R O
) O
. O

Fluorescence O
spectroscopic O
and O
cytofluorimetric O
studies O
showed O
that O
the O
incubation O
of O
MCF O
- O
7 O
tumour O
cells O
with O
fluorescein O
- O
labelled O
stearoyl B
- I
PEG I
- I
polySDM I
at O
pH O
6 O
. O
5 O
resulted O
in O
massive O
time O
- O
dependent O
cell O
association O
, O
while O
the O
incubation O
at O
pH O
7 O
. O
4 O
showed O
significantly O
lower O
cell O
interaction O
. O

Confocal O
microscopy O
confirmed O
that O
at O
pH O
6 O
. O
5 O
, O
the O
micelles O
are O
taken O
up O
by O
cells O
and O
that O
the O
fluorescein O
- O
labelled O
stearoyl B
- I
PEG I
- I
polySDM I
is O
distributed O
into O
the O
cytosol O
. O

At O
pH O
6 O
. O
5 O
, O
paclitaxel O
- O
loaded O
stearoyl B
- I
PEG I
- I
polySDM I
micelles O
had O
a O
higher O
cytotoxic O
effect O
than O
the O
micelles O
incubated O
at O
pH O
7 O
. O
4 O
. O

Evidences O
for O
the O
regulation O
of O
GnRH O
and O
GTH O
expression O
by O
GnIH B
in O
the O
goldfish O
, O
Carassius O
auratus O
. O

Gonadotrophin B
- I
inhibitory I
hormone I
( O
GnIH B
) O
plays O
an O
important O
role O
in O
regulating O
of O
reproduction O
in O
teleosts O
. O

In O
the O
hypothalamus O
, O
GnIHRs O
were O
found O
in O
the O
NPP O
, O
NPO O
and O
NLT O
, O
whereas O
sGnRH O
neurons O
were O
reported O
to O
be O
located O
, O
and O
potentially O
regulated O
by O
GnIH B
. O

In O
the O
pituitary O
, O
only O
two O
GnIHRs O
were O
observed O
and O
they O
were O
localized O
to O
the O
PI O
instead O
of O
the O
adenohypophysis O
where O
GtH O
- O
expressing O
cells O
are O
localized O
, O
suggesting O
indirect O
regulation O
of O
GtH O
by O
GnIH B
. O

In O
vivo O
, O
intraperitoneal O
( O
i O
. O
p O
. O
) O
injections O
of O
synthetic O
goldfish O
GnIH B
- O
II O
peptide O
and O
GnIH B
- O
III O
peptide O
significantly O
decreased O
sGnRH O
and O
FSH O
beta O
mRNA O
levels O
. O

Only O
GnIH B
- O
II O
decreased O
LH O
beta O
mRNA O
levels O
significantly O
. O

In O
vitro O
, O
both O
GnIH B
- O
II O
and O
GnIH B
- O
III O
showed O
no O
effect O
on O
GtH O
synthesis O
, O
but O
an O
inhibition O
of O
GnRH O
- O
stimulated O
LH O
beta O
and O
FSH O
beta O
synthesis O
was O
observed O
when O
GnIH B
- O
III O
was O
applied O
to O
primary O
pituitary O
cells O
in O
culture O
. O

Thus O
, O
GnIH B
could O
contribute O
to O
the O
regulation O
of O
gonadotropin O
in O
the O
brain O
and O
pituitary O
in O
teleosts O
. O

Aggression O
- O
and O
sex O
- O
induced O
neural O
activity O
across O
vasotocin B
populations O
in O
the O
brown O
anole O
. O

Activity O
within O
the O
social O
behavior O
neural O
network O
is O
modulated O
by O
the O
neuropeptide O
arginine B
vasotocin I
( O
AVT B
) O
and O
its O
mammalian O
homologue O
arginine O
vasopressin O
( O
AVP B
) O
. O

However O
, O
central O
AVT B
/ O
AVP B
release O
causes O
different O
behavioral O
effects O
across O
species O
and O
social O
environments O
. O

These O
differences O
may O
be O
due O
to O
the O
activation O
of O
different O
neuronal O
AVT B
/ O
AVP B
populations O
or O
to O
similar O
activity O
patterns O
causing O
different O
behavioral O
outputs O
. O

We O
examined O
neural O
activity O
( O
assessed O
as O
Fos O
induction O
) O
within O
AVT B
neurons O
in O
male O
brown O
anole O
lizards O
( O
Anolis O
sagrei O
) O
participating O
in O
aggressive O
or O
sexual O
encounters O
. O

In O
accordance O
with O
findings O
in O
other O
species O
, O
AVT B
neurons O
in O
the O
anole O
paraventricular O
nucleus O
( O
PVN O
) O
were O
activated O
during O
aggressive O
encounters O
; O
but O
unlike O
in O
other O
species O
, O
a O
positive O
correlation O
was O
found O
between O
aggression O
levels O
and O
activation O
. O

Activation O
of O
AVT B
neurons O
within O
the O
supraoptic O
nucleus O
( O
SON O
) O
occurred O
nonspecifically O
with O
participation O
in O
either O
aggressive O
or O
sexual O
encounters O
. O

Activation O
of O
AVT B
neurons O
in O
the O
preoptic O
area O
( O
POA O
) O
and O
bed O
nucleus O
of O
the O
stria O
terminalis O
( O
BNST O
) O
was O
associated O
with O
engagement O
in O
sexual O
behaviors O
. O

However O
, O
aggressive O
encounters O
also O
increased O
activation O
of O
AVT B
neurons O
in O
the O
BNST O
, O
which O
is O
incongruous O
with O
findings O
in O
other O
species O
. O

Thus O
, O
some O
species O
differences O
involve O
the O
encoding O
of O
social O
stimuli O
as O
different O
neural O
activation O
patterns O
within O
the O
AVT B
/ O
AVP B
network O
, O
whereas O
other O
behavioral O
differences O
arise O
downstream O
of O
this O
system O
. O

Fenamiphos B
is O
recalcitrant O
to O
the O
hydrolysis O
by O
alloforms O
PON1 O
Q192R O
of O
human O
serum O
. O

Fenamiphos B
( O
ethyl B
4 I
- I
methylthio I
- I
m I
- I
tolyl I
isopropylphosphorami I
) O
is O
a O
racemic O
organophosphorus O
nematicide O
widely O
used O
in O
agriculture O
around O
the O
world O
. O

In O
this O
work O
, O
the O
separation O
of O
the O
enantiomers O
of O
fenamiphos B
by O
HPLC O
using O
the O
column O
CHIRALCEL O
OJ O
and O
a O
mobile O
phase O
of O
hexane O
/ O
ethanol O
( O
99 O
/ O
1 O
) O
is O
presented O
. O

The O
method O
resulted O
linear O
response O
in O
a O
range O
concentration O
between O
50 O
and O
800 O
mu O
M O
with O
a O
detection O
and O
quantification O
limit O
between O
0 O
. O
6 O
and O
2 O
mu O
M O
for O
the O
( B
+ I
) I
- I
fenamiphos I
, O
and O
between O
0 O
. O
7 O
and O
2 O
. O
3 O
mu O
M O
for O
the O
( B
- I
) I
- I
fenamiphos I
. O

The O
levels O
of O
the O
Ca O
( O
2 O
+ O
) O
- O
dependent O
hydrolysis O
( O
residual O
concentration O
[ O
mu O
M O
] O
) O
quantified O
during O
30min O
of O
reaction O
were O
only O
just O
4 O
- O
14 O
% O
for O
both O
fenamiphos B
enantiomers O
with O
the O
three O
alloforms O
of O
PON1 O
Q192R O
of O
the O
two O
groups O
of O
serum O
studied O
. O

Antimutagenic O
evaluation O
of O
vitamins B
B1 I
, I
B6 I
and I
B12 I
in O
vitro O
and O
in O
vivo O
, O
with O
the O
Ames O
test O
. O

The O
aim O
of O
this O
work O
is O
to O
evaluate O
vitamins O
B O
antimutagenic O
effect O
against O
alkylatings O
methyl B
- I
N I
- I
nitro I
- I
N I
- I
nitrosoguanidine I
( O
MNNG B
) O
, O
ethyl B
- I
N I
- I
nitro I
- I
N I
' I
- I
nitrosoguanidine I
( O
ENNG B
) O
, O
frameshift O
mutagens O
2 B
- I
aminoanthracene I
( O
2AA B
) O
and O
2 B
- I
acetyl I
- I
amino I
- I
fluorene I
( O
2AF B
) O
and O
ROS O
- O
generating O
antibiotics O
norfloxacin O
( O
NOR O
) O
and O
nalidixic B
acid I
( O
NLX B
) O
, O
using O

In O
vivo O
antimutagenesis O
studies O
were O
performed O
against O
urinary O
mutagens O
induced O
by O
NOR O
( O
70 O
mg O
/ O
kg O
) O
or O
NLX B
( O
100 O
mg O
/ O
kg O
) O
in O
CD1 O
mice O
. O

Vitamin B
B1 I
was O
antimutagenic O
against O
alkylatings O
MNNG B
( O
P O
< O
0 O
. O
05 O
) O
or O
ENNG B
( O
P O
< O
0 O
. O
001 O
) O
. O

All O
of O
them O
reduced O
mutagenesis O
of O
NOR O
or O
NLX B
( O
P O
< O
0 O
. O
001 O
) O
. O

In O
vivo O
studies O
showed O
that O
vitamins B
B1 I
and I
B6 I
( O
10 O
or O
100 O
mg O
/ O
kg O
) O
reduced O
urinary O
mutagens O
from O
NOR O
( O
P O
< O
0 O
. O
001 O
) O
or O
NLX B
( O
P O
< O
0 O
. O
02 O
) O
either O
free O
or O
beta O
- O
glucoronidase O
- O
conjugates O
. O

Vitamin O
B12 O
( O
4 O
mg O
/ O
kg O
) O
reduced O
urinary O
mutagens O
of O
NOR O
or O
NLX B
( O
P O
< O
0 O
. O
02 O
) O
. O

Vitamins O
B O
inhibited O
DNA O
mutations O
induced O
by O
ROS O
generated O
by O
NLX B
or O
NOR O
, O
both O
in O
vitro O
and O
in O
vivo O
. O

Vitamin B
B1is I
antimutagenic O
against O
mutations O
induced O
by O
the O
alkylating O
MNNG B
or O
ENNG B
. O

The O
effect O
of O
body O
- O
weight O
loading O
onto O
the O
articular O
cartilage O
on O
the O
occurrence O
of O
chondrotoxicity O
was O
investigated O
in O
male O
juvenile O
Sprague O
- O
Dawley O
rats O
given O
ofloxacin B
( O
OFLX B
) O
orally O
once O
at O
900 O
mg O
/ O
kg O
. O

Just O
after O
dosing O
of O
OFLX B
, O
hindlimb O
unloading O
was O
performed O
for O
0 O
, O
2 O
, O
4 O
, O
or O
8 O
h O
by O
a O
tail O
- O
suspension O
method O
. O

Our O
results O
clearly O
indicate O
that O
body O
- O
weight O
loading O
onto O
the O
cartilage O
is O
necessary O
to O
induce O
cartilage O
lesions O
and O
gene O
expression O
of O
Tnfrsf12a O
, O
Ptgs2 O
, O
Plaur O
, O
and O
Mmp3 O
in O
juvenile O
rats O
treated O
with O
OFLX B
. O

An O
increase O
of O
endogenous O
jasmonic B
acid I
concentration O
was O
observed O
only O
in O
K O
. O
obovata O
, O
both O
at O
Day O
1 O
and O
at O
Day O
49 O
, O
which O
suggests O
that O
this O
hormone O
plays O
an O
important O
role O
in O
metal O
tolerance O
under O
short O
- O
term O
and O
long O
- O
term O
metal O
treatment O
. O

Two O
- O
dimensional O
( O
2D O
) O
atomic O
crystals O
, O
such O
as O
graphene O
and O
transition B
- I
metal I
dichalcogenides I
, O
have O
emerged O
as O
a O
new O
class O
of O
materials O
with O
remarkable O
physical O
properties O
. O

A O
rechargeable O
room O
- O
temperature O
sodium B
superoxide I
( O
NaO2 B
) O
battery O
. O

Much O
work O
has O
been O
focused O
on O
aprotic O
Li B
- I
O I
( I
2 I
) I
cells O
( O
mostly O
with O
carbonate O
- O
based O
electrolytes O
and O
Li B
( I
2 I
) I
O I
( I
2 I
) I
as O
a O
potential O
discharge O
product O
) O
, O
where O
large O
overpotentials O
are O
observed O
and O
a O
complex O
cell O
chemistry O
is O
found O
. O

In O
fact O
, O
recent O
studies O
evidence O
that O
Li B
- I
O I
( I
2 I
) I
cells O
suffer O
from O
irreversible O
electrolyte O
decomposition O
during O
cycling O
. O

Here O
we O
report O
on O
a O
Na B
- I
O I
( I
2 I
) I
cell O
reversibly O
discharging O
/ O
charging O
at O
very O
low O
overpotentials O
( O
< O
200 O
mV O
) O
and O
current O
densities O
as O
high O
as O
0 O
. O
2 O
mA O
cm O
( O
- O
2 O
) O
using O
a O
pure O
carbon O
cathode O
without O
an O
added O
catalyst O
. O

Crystalline O
sodium B
superoxide I
( O
NaO B
( I
2 I
) I
) O
forms O
in O
a O
one O
- O
electron O
transfer O
step O
as O
a O
solid O
discharge O
product O
. O

The O
best O
inhibitor O
, O
Cbz O
- O
AVLQ O
- O
CN B
with O
an O
N O
- O
terminal O
carbobenzyloxy B
group O
, O
was O
~ O
10x O
more O
potent O
than O
the O
other O
inhibitors O
tested O
. O

Crystal O
structures O
of O
the O
enzyme O
- O
inhibitor O
complexes O
showed O
that O
the O
nitrile O
warhead O
inhibits O
3CL O
( O
pro O
) O
by O
forming O
a O
covalent O
bond O
with O
the O
catalytic O
Cys145 B
residue O
, O
while O
the O
AVLQ O
peptide O
forms O
a O
number O
of O
favourable O
interactions O
with O
the O
S1 O
- O
S4 O
substrate O
- O
binding O
pockets O
. O

We O
have O
further O
showed O
that O
the O
peptidomimetic O
inhibitor O
, O
Cbz O
- O
AVLQ O
- O
CN B
, O
has O
broad O
- O
spectrum O
inhibition O
against O
3CL O
( O
pro O
) O
from O
human O
coronavirus O
strains O
229E O
, O
NL63 O
, O
OC43 O
, O
HKU1 O
, O
and O
infectious O
bronchitis O
virus O
, O
with O
IC O
( O
50 O
) O
values O
ranging O
from O
1 O
. O
3 O
to O
3 O
. O
7 O
mu O
M O
, O
but O
no O
detectable O
inhibition O
against O
caspase O
- O
3 O
. O

Synthesis O
and O
antibacterial O
and O
antifungal O
evaluation O
of O
some O
chalcone O
based O
sulfones B
and O
bisulfones B
. O

Two O
series O
of O
chalcone O
based O
sulfone O
and O
bisulfone B
derivatives O
were O
synthesized O
using O
chalcone O
, O
thiophenol O
and O
sodium O
metal O
at O
room O
temperature O
, O
followed O
by O
oxidation O
of O
chalcone B
sulfides I
with O
m B
- I
CPBA I
at O
0 O
degrees O
C O
in O
a O
novel O
method O
. O

Both O
sulfones B
and O
bisulfones B
were O
evaluated O
for O
their O
antimicrobial O
activities O
against O
Aspergillus O
niger O
and O
Candida O
albicans O
( O
yeast O
) O
, O
Bacillus O
subtilis O
and O
Staphylococcus O
aureus O
( O
Gram O
( O
+ O
) O
bacteria O
) O
and O
Pseudomonas O
aeruginosa O
and O
Salmonella O
typhimurium O
( O
Gram O
( O
- O
) O
bacteria O
) O
strains O
. O

Amphotericin O
- O
B O
and O
Nystatin B
. O

Compound O
1c O
has O
shown O
slightly O
better O
antibacterial O
activity O
against O
B O
. O
subtilis O
and O
compounds O
5c O
, O
6c O
and O
7c O
have O
shown O
excellent O
antibacterial O
activity O
against O
S O
. O
typhimurium O
in O
compare O
to O
reference O
drugs O
Ampicillin O
and O
Kanamycin B
. O

Identification O
of O
novel O
chromenone B
derivatives O
as O
interleukin O
- O
5 O
inhibitors O
. O

A O
series O
of O
( B
E I
) I
- I
5 I
- I
alkoxy I
- I
3 I
- I
( I
3 I
- I
phenyl I
- I
3 I
- I
oxoprop I
- I
1 I
- I
enyl I
) I
- I
4H I
- I
chromen I
- I
4 I
- I
ones I
( O
4 O
) O
and O
( B
E I
) I
- I
5 I
- I
alkoxy I
- I
3 I
- I
( I
3 I
- I
hydroxy I
- I
3 I
- I
phenylprop I
- I
1 I
- I
enyl I
) I
- I
4H I
- I
chromen I
- I
4 I
- I
ones I
( O
5 O
) O
were O
synthesized O
and O
evaluated O
for O
their O
IL O
- O
5 O
inhibitory O
activity O
. O

Propenone B
analogs O
4 O
possess O
some O
of O
the O
structurally O
important O
characteristics O
of O
isoflavone O
2 O
and O
chalcone O
3 O
previously O
known O
as O
potent O
IL O
- O
5 O
inhibitor O
. O

This O
enhanced O
activity O
of O
5 O
compared O
to O
4 O
could O
be O
due O
to O
the O
effective O
location O
of O
hydroxyl O
group O
of O
allylic B
alcohol I
moiety O
of O
5 O
in O
the O
3D O
structure O
. O

The O
electron O
withdrawing O
substituents O
at O
position O
4 O
of O
phenyl O
ring O
of O
5 O
enhances O
the O
activity O
possibly O
due O
to O
an O
increase O
in O
the O
strength O
of O
hydrogen O
bonding O
property O
of O
hydroxyl O
group O
of O
allylic B
alcohol I
moiety O
. O

Synthesis O
, O
antibacterial O
activity O
and O
docking O
of O
14 B
- I
membered I
9 I
- I
O I
- I
( I
3 I
- I
arylalkyl I
) I
oxime I
11 I
, I
12 I
- I
cyclic I
carbonate I
ketolides I
. O

A O
series O
of O
9 B
- I
O I
- I
( I
3 I
- I
aryl I
- I
2 I
- I
propargyl I
) I
oxime I
ketolides I
8 O
was O
synthesized O
and O
evaluated O
for O
in O
vitro O
antibacterial O
activity O
. O

Especially O
, O
8i O
( O
Ar O
= O
4 B
- I
isoquinolyl I
) O
possessed O
an O
MIC O
of O
0 O
. O
064 O
mu O
g O
/ O
mL O
against O
constitutively O
MLS O
( O
B O
) O
- O
resistant O
Streptococcus O
pneumoniae O
, O
and O
MICs O
of O
0 O
. O
032 O
- O
0 O
. O
064 O
mu O
g O
/ O
mL O
against O
methicillin O
- O
resistant O
Staphylococcus O
aureus O
and O
methicillin O
- O
resistant O
Staphylococcus O
hominis O
. O

The O
analog O
10 O
with O
a O
propyl O
linker O
was O
less O
effective O
than O
both O
the O
corresponding O
8 O
and O
9 O
containing O
propynyl B
and O
propenyl B
linkers O
. O

Hybrid O
furoxanyl B
N I
- I
acylhydrazone I
derivatives O
as O
hits O
for O
the O
development O
of O
neglected O
diseases O
drug O
candidates O
. O

N B
- I
Acylhydrazone I
moiety O
is O
a O
repeated O
functional O
group O
present O
in O
several O
prototypes O
and O
drug O
candidates O
for O
these O
neglected O
diseases O
. O

On O
the O
other O
hand O
, O
furoxan B
system O
has O
been O
studied O
as O
pharmacophore O
for O
Leishmaniosis O
and O
Chagas O
diseases O
. O

Here O
we O
report O
on O
the O
design O
and O
preparation O
of O
forty O
hybrid O
furoxanyl B
N I
- I
acylhydrazones I
and O
on O
their O
activity O
on O
Mycobacterium O
tuberculosis O
, O
H37Rv O
and O
MDR O
strains O
, O
Trypanosoma O
cruzi O
, O
and O
Leishmania O
amazonensis O
. O

Hybrid O
compound O
N B
' I
- I
( I
4 I
- I
phenyl I
- I
3 I
- I
furoxanylmethylidene I
) I
isoniazide I
9 O
showed O
the O
best O
antibacterial O
profile O
with O
MIC O
value O
4 O
. O
5 O
lesser O
than O
the O
value O
for O
the O
reference O
isoniazid O
against O
MDR O
strain O
. O

Furoxanyl B
N I
- I
acylhydrazone I
( B
E I
) I
- I
2 I
- I
methyl I
- I
N I
' I
- I
( I
4 I
- I
phenyl I
- I
3 I
- I
furoxanylmethylidene I
) I
- I
4H I
- I
imidazo I
[ I
1 I
, I
2 I
- I
a I
] I
pyridine I
- I
3 I
- I
carbohydrazide I
15 O
was O
ten O
- O
fold O
more O
potent O
against O
T O
. O
cruzi O
Amastigotes O
than O
the O
standard O
drug O
nifurtimox O
. O

On O
the O
other O
hand O
, O
derivatives O
( B
E I
) I
- I
N I
' I
- I
( I
5 I
- I
benzofuroxanylmethyl I
) I
benzo I
[ I
d I
] I
[ I
1 I
, I
3 I
] I
dioxole I
- I
5 I
- I
carbohydrazide I
25 O
and O
( B
E I
) I
- I
N I
' I
- I
( I
4 I
- I
hydroxy I
- I
3 I
- I
methoxyphenylmethyli I
) I
- I
3 I
- I
methylfuroxan I
- I
4 I
- I
carbohydrazide I
37 O
emerged O
as O
leads O
for O
the O
development O
of O
new O
leishmanicidal O
agents O
. O

The O
protein O
amide O
( B
1 I
) I
H I
( I
N I
) I
chemical O
shift O
temperature O
coefficient O
reflects O
thermal O
expansion O
of O
the O
N O
- O
H O
. O
. O
. O
O O
= O
C O
hydrogen O
bond O
. O

The O
protein O
amide O
( B
1 I
) I
H I
( I
N I
) I
chemical O
shift O
temperature O
coefficient O
can O
be O
determined O
with O
high O
accuracy O
by O
recording O
spectra O
at O
different O
temperatures O
, O
but O
the O
physical O
mechanism O
responsible O
for O
this O
temperature O
dependence O
is O
not O
well O
understood O
. O

Parallel O
tempering O
molecular O
dynamics O
simulation O
suggests O
that O
the O
hydrogen O
bond O
distance O
variation O
at O
different O
temperatures O
/ O
replicas O
is O
largely O
responsible O
for O
the O
( B
1 I
) I
H I
( I
N I
) I
chemical O
shift O
temperature O
dependence O
, O
from O
which O
an O
empirical O
equation O
is O
proposed O
to O
predict O
the O
hydrogen O
bond O
thermal O
expansion O
coefficient O
, O
revealing O
responses O
of O
individual O
hydrogen O
bonds O
to O
temperature O
changes O
. O

Synthesis O
, O
characterization O
and O
pharmacodynamics O
of O
vitamin B
- I
B I
( I
12 I
) I
- O
conjugated O
glucagon O
- O
like O
peptide O
- O
1 O
. O

A O
new O
vitamin B
B I
( I
12 I
) I
- O
GLP O
- O
1 O
conjugate O
is O
investigated O
and O
shown O
to O
have O
insulinotropic O
properties O
similar O
to O
the O
unmodified O
peptide O
. O

These O
results O
are O
critical O
to O
the O
exploitation O
of O
the O
vitamin B
B I
( I
12 I
) I
oral O
uptake O
pathway O
for O
peptide O
delivery O
. O

Effects O
of O
single O
or O
repeated O
silymarin O
administration O
on O
pharmacokinetics O
of O
risperidone O
and O
its O
major O
metabolite O
, O
9 B
- I
hydroxyrisperidone I
in O
rats O
. O

2 O
. O
The O
objective O
of O
this O
article O
is O
to O
examine O
the O
effects O
of O
single O
and O
repeated O
administrations O
of O
silymarin O
on O
pharmacokinetics O
of O
a O
P O
- O
gp O
substrate O
, O
risperidone O
, O
and O
its O
major O
metabolite O
, O
9 B
- I
hydroxyrisperidone I
, O
in O
rats O
. O

3 O
. O
To O
determine O
the O
plasma O
levels O
of O
risperidone O
and O
9 B
- I
hydroxyrisperidone I
in O
rats O
, O
a O
HPLC O
method O
was O
developed O
using O
a O
liquid O
- O
liquid O
acid O
back O
extraction O
. O

When O
risperidone O
( O
6 O
mg O
/ O
kg O
) O
was O
co O
- O
administered O
with O
silymarin O
( O
40 O
mg O
/ O
kg O
) O
to O
rats O
orally O
, O
the O
C O
( O
max O
) O
of O
9 B
- I
hydroxyrisperidone I
was O
significantly O
increased O
to1 O
. O
3 O
- O
fold O
( O
p O
< O
0 O
. O
05 O
) O
, O
while O
the O
other O
pharmacokinetic O
parameters O
did O
not O
show O
any O
significant O
differences O
. O

Expanding O
the O
experiment O
where O
rats O
were O
repeatedly O
administered O
with O
silymarin O
for O
5 O
days O
prior O
to O
giving O
risperidone O
, O
the O
C O
( O
max O
) O
of O
risperidone O
and O
9 B
- I
hydroxyrisperidone I
were O
significantly O
increased O
to O
2 O
. O
4 O
- O
fold O
( O
p O
< O
0 O
. O
001 O
) O
and O
1 O
. O
7 O
- O
fold O
( O
p O
< O
0 O
. O
001 O
) O
, O
respectively O
, O
and O
the O
AUC O
( O
0 O
- O
t O
) O
, O
as O
well O
to O
1 O
. O
7 O
- O
fold O
( O
p O
< O
0 O
. O
05 O
) O
and O
2 O
. O
1 O
- O
fold O
( O
p O
< O
0 O
. O
01 O
) O
, O
respectively O
. O

4 O
. O
The O
repeated O
exposures O
of O
silymarin O
, O
compared O
to O
single O
administration O
of O
silymarin O
, O
increased O
oral O
bioavailability O
and O
affected O
the O
pharmacokinetics O
of O
risperidone O
and O
9 B
- I
hydroxyrisperidone I
, O
by O
inhibiting O
P O
- O
gp O
. O

A O
new O
perfluoropolyether B
- O
based O
hydrophobic O
and O
chemically O
resistant O
photoresist O
structured O
by O
two O
- O
photon O
polymerization O
. O

Two O
- O
photon O
polymerization O
technology O
has O
been O
used O
to O
fabricate O
submicrometer O
three O
- O
dimensional O
( O
3D O
) O
structures O
using O
a O
new O
polyfunctional O
perfluoropolyether B
- O
based O
resist O
, O
which O
is O
a O
polymer O
intrinsically O
hydrophobic O
and O
chemically O
resistant O
. O

On O
the O
basis O
of O
a O
vertically O
aligned O
ultralong O
Pb B
( I
Zr I
( I
0 I
. I
52 I
) I
Ti I
( I
0 I
. I
48 I
) I
) I
O I
( I
3 I
) I
( O
PZT B
) O
nanowire O
array O
fabricated O
using O
electrospinning O
nanofibers O
, O
we O
developed O
a O
new O
type O
of O
integrated O
nanogenerator O
( O
NG O
) O
with O
ultrahigh O
output O
voltage O
of O
209 O
V O
and O
current O
density O
of O
23 O
. O
5 O
mu O
A O
/ O
cm O
( O
2 O
) O
, O
which O
are O
3 O
. O
6 O
times O
and O
2 O
. O
9 O
times O
of O
the O
previous O
record O
values O
, O
respectively O
. O

Three O
PEMs O
are O
considered O
: O
Nafion O
, O
sulfonated B
polystyrene I
( O
sPS O
) O
that O
forms O
the O
hydrophilic O
subphase O
of O
segregated O
sPS O
- O
polyolefin B
block O
copolymers O
, O
and O
random O
sPS O
- O
polyethylene O
copolymer O
. O

We O
found O
that O
sarin O
concentrates O
at O
the O
interface O
between O
the O
hydrophilic O
and O
hydrophobic O
subphases O
of O
hydrated B
Nafion I
acting O
as O
a O
surfactant O
. O

In O
hydrated B
sPS I
, O
where O
the O
scale O
of O
water O
- O
polymer O
segregation O
is O
much O
smaller O
( O
1 O
- O
2 O
nm O
) O
, O
sarin O
also O
interacts O
favorably O
with O
hydrophobic O
and O
hydrophilic O
components O
. O

As O
a O
result O
, O
Fe O
( O
3 O
) O
O O
( O
4 O
) O
@ O
Ag O
/ O
SiO O
( O
2 O
) O
/ O
Au O
microspheres O
have O
the O
best O
enhancement O
effect O
in O
the O
Raman O
active O
research O
by O
using O
Rhodamine O
- O
b O
( O
RdB B
) O
as O
a O
probe O
molecule O
. O

The O
enhancement O
factor O
is O
estimated O
to O
be O
2 O
. O
2 O
x O
10 O
( O
4 O
) O
for O
RdB B
from O
the O
long O
- O
range O
plasmon O
transfer O
of O
Ag O
to O
Au O
, O
corresponding O
to O
an O
attenuation O
of O
the O
enhancement O
by O
a O
factor O
of O
only O
0 O
. O
672 O
x O
10 O
( O
4 O
) O
compared O
to O
RdB B
adsorbed O
directly O
on O
the O
Fe O
( O
3 O
) O
O O
( O
4 O
) O
@ O
Ag O
microspheres O
. O

RdB B
can O
be O
detected O
down O
to O
10 O
( O
- O
9 O
) O
M O
even O
without O
the O
resonance O
SERS O
effect O
. O

Highly O
solvatochromic O
fluorescent O
naphthalimides B
: O
design O
, O
synthesis O
, O
photophysical O
properties O
and O
fluorescence O
switch O
- O
on O
sensing O
of O
ct O
- O
DNA O
. O

The O
synthesized O
naphthalimides B
containing O
propargyl B
ends O
showed O
highly O
solvatochromic O
intramolecular O
charge O
transfer O
( O
ICT O
) O
feature O
as O
was O
revealed O
from O
the O
UV O
- O
visible O
, O
fluorescence O
photophysical O
properties O
of O
these O
fluorophores O
and O
DFT O
/ O
TDDFT O
calculation O
. O

Fluorescence O
life O
times O
for O
the O
imide B
fluorophores O
were O
also O
measured O
in O
different O
solvents O
. O

The O
propargyl B
linker O
containing O
naphthalimides B
can O
further O
be O
exploited O
for O
the O
synthesis O
of O
labeled O
biomolecular O
building O
blocks O
. O

Design O
, O
synthesis O
and O
bioevalution O
of O
novel O
benzamides B
derivatives O
as O
HDAC O
inhibitors O
. O

A O
series O
of O
novel O
benzamides B
derivatives O
was O
designed O
and O
synthesized O
as O
HDAC O
inhibitors O
. O

A O
systematic O
study O
of O
the O
degradation O
of O
dimethyl B
phthalate I
using O
a O
high O
- O
frequency O
ultrasonic O
process O
. O

A O
comprehensive O
study O
of O
the O
sonochemical O
degradation O
of O
dimethyl B
phthalate I
( O
DMP O
) O
was O
carried O
out O
using O
high O
- O
frequency O
ultrasonic O
processes O
. O

Among O
the O
principle O
reaction O
intermediates O
identified O
, O
tri O
- O
and O
tetra O
- O
hydroxylated O
derivatives O
of O
DMP O
, O
as O
well O
as O
hydroxylated B
monomethyl I
phthalates I
and O
hydroxylated B
phthalic I
acid I
were O
reported O
for O
the O
first O
time O
in O
this O
study O
. O

Also O
, O
it O
is O
found O
that O
as O
temperature O
increases O
to O
42 O
degrees O
C O
then O
the O
total O
dihydroxybenzoic O
acid O
( O
Total O
DHBA B
) O
produced O
is O
virtually O
identical O
for O
382kHz O
and O
862kHz O
, O
though O
582kHz O
is O
substantially O
lower O
, O
when O
the O
power O
levels O
are O
set O
at O
approximately O
9W O
for O
all O
systems O
. O

The O
first O
step O
was O
the O
selection O
of O
a O
suitable O
dataset O
of O
heterocyclic O
compounds O
that O
include O
chromones B
, O
coumarins O
, O
chalcones O
, O
thiazolylhydrazones B
, O
etc O
. O

Triterpene B
saponins I
from O
Clethra O
barbinervis O
and O
their O
hyaluronidase O
inhibitory O
activities O
. O

From O
the O
active O
fractions O
, O
seven O
new O
triterpene B
saponins I
( O
1 O
- O
4 O
, O
6 O
- O
8 O
) O
and O
a O
new O
lignan B
glycoside I
( O
14 O
) O
were O
isolated O
together O
with O
14 O
known O
compounds O
( O
5 O
, O
9 O
- O
13 O
, O
15 O
- O
22 O
) O
. O

Enantiospecific O
total O
synthesis O
of O
( B
- I
) I
- I
bengamide I
E I
. O

Total O
synthesis O
of O
the O
polyhydroxy B
caprolactam I
amide I
natural O
product O
, O
bengamide B
E I
, O
is O
accomplished O
starting O
from O
tartaric O
acid O
. O

Key O
reactions O
in O
the O
synthesis O
include O
desymmetrization O
of O
the O
bis B
( I
dimethylamide I
) I
unit O
of O
tartaric O
acid O
, O
Zn B
( I
BH I
( I
4 I
) I
) I
( I
2 I
) I
- O
mediated O
anti O
- O
selective O
reduction O
, O
and O
a O
Horner O
- O
Wadsworth O
- O
Emmons O
olefination O
. O

In O
this O
work O
, O
we O
used O
dual O
whole O
cell O
patch O
clamp O
recording O
to O
examine O
the O
functional O
effects O
of O
mutations O
at O
the O
Arg B
( O
75 O
) O
position O
. O

The O
chemical O
breath O
of O
modulators O
includes O
natural O
products O
such O
as O
fusicoccin B
A I
and O
derivatives O
but O
also O
compounds O
identified O
via O
high O
- O
throughput O
and O
in O
silico O
screening O
, O
which O
has O
yielded O
a O
toolbox O
of O
useful O
inhibitors O
and O
stabilizers O
for O
this O
interesting O
class O
of O
adapter O
proteins O
. O

The O
stabilization O
of O
oil O
- O
water O
interfaces O
by O
the O
modified O
ferritin O
was O
investigated O
by O
dynamic O
surface O
tension O
measurements O
and O
compared O
to O
the O
individual O
components O
of O
the O
bionanoparticle O
conjugate O
, O
namely O
, O
unmodified O
ferritin O
and O
pure O
PNIMAAm B
of O
similar O
molecular O
weight O
. O

This O
smart O
fluid O
is O
an O
aqueous O
solution O
of O
cationic O
surfactant O
oleyl B
bis I
( I
2 I
- I
hydroxyethyl I
) I
methyl I
ammonium I
chloride I
( O
OHAC B
, O
3 O
. O
4 O
mM O
) O
and O
the O
sodium O
salt O
of O
4 B
- I
phenylazo I
benzoic I
acid I
( O
ACA B
, O
2 O
mM O
) O
. O

Initially O
, O
ACA B
is O
in O
a O
trans O
configuration O
and O
the O
OHAC B
/ O
ACA B
solution O
is O
viscoelastic O
and O
exhibits O
DR O
( O
of O
up O
to O
80 O
% O
relative O
to O
pure O
water O
) O
. O

Upon O
UV O
irradiation O
, O
trans B
- I
ACA I
is O
converted O
to O
cis B
- I
ACA I
, O
and O
in O
turn O
, O
the O
solution O
is O
converted O
to O
its O
EHT O
mode O
( O
i O
. O
e O
. O
, O
it O
loses O
its O
viscoelasticity O
and O
DR O
) O
but O
it O
now O
has O
a O
heat O
- O
transfer O
capability O
comparable O
to O
that O
of O
water O
. O

In O
the O
DR O
mode O
, O
the O
OHAC B
/ O
trans B
- I
ACA I
molecules O
assemble O
into O
long O
threadlike O
micelles O
that O
impart O
viscoelasticity O
and O
DR O
capability O
to O
the O
fluid O
. O

Conversely O
, O
in O
the O
EHT O
mode O
the O
mixture O
of O
OHAC B
and O
cis B
- I
ACA I
forms O
much O
shorter O
cylindrical O
micelles O
that O
contribute O
to O
negligible O
viscoelasticity O
and O
effective O
heat O
transfer O
. O

These O
nanostructural O
changes O
are O
confirmed O
by O
cryo O
- O
transmission O
electron O
microscopy O
( O
cryo O
- O
TEM O
) O
, O
and O
the O
photoisomerization O
of O
trans B
- I
ACA I
and O
cis B
- I
ACA I
is O
verified O
by O
( O
1 O
) O
H O
NMR O
. O

However O
, O
only O
one O
of O
them O
, O
CX B
- I
4945 I
, O
has O
recently O
completed O
Phase O
I O
clinical O
trial O
as O
potential O
anticancer O
drug O
. O

In O
the O
last O
two O
decades O
, O
there O
have O
been O
numerous O
empirical O
approaches O
to O
improve O
the O
biotechnological O
production O
of O
taxanes O
, O
leading O
to O
the O
conclusion O
that O
treatment O
of O
Taxus O
sp O
. O
cells O
with O
methyl B
jasmonate I
or O
other O
elicitors O
is O
the O
most O
effective O
strategy O
. O

The O
pentacyclic B
triterpenoids I
in O
herbal O
medicines O
and O
their O
pharmacological O
activities O
in O
diabetes O
and O
diabetic O
complications O
. O

Pentacyclic B
triterpenoids I
including O
the O
oleanane O
, O
ursane B
and O
lupane B
groups O
are O
widely O
distributed O
in O
many O
medicinal O
plants O
, O
such O
as O
Glycyrrhiza O
species O
, O
Gymnema O
species O
, O
Centella O
asiatica O
, O
Camellia O
sinensis O
, O
Crataegus O
species O
and O
Olea O
europaea O
, O
which O
are O
commonly O
used O
in O
traditional O
medicine O
for O
the O
treatment O
of O
diabetes O
and O
diabetic O
complications O
. O

A O
large O
number O
of O
bioactive O
pentacyclic B
triterpenoids I
, O
such O
as O
oleanolic O
acid O
, O
glycyrrhizin O
, O
glycyrrhetinic O
acid O
, O
ursolic O
acid O
, O
betulin B
, O
betulinic O
acid O
and O
lupeol O
have O
shown O
multiple O
biological O
activities O
with O
apparent O
effects O
on O
glucose O
absorption O
, O
glucose O
uptake O
, O
insulin O
secretion O
, O
diabetic O
vascular O
dysfunction O
, O
retinopathy O
and O
nephropathy O
. O

The O
versatility O
of O
the O
pentacyclic B
triterpenes I
provides O
a O
promising O
approach O
for O
diabetes O
management O
. O

For O
example O
, O
resveratrol O
and O
thymoquinone B
are O
hitherto O
known O
compounds O
to O
possess O
proapoptotic O
effects O
on O
platelets O
. O

In O
contrast O
, O
cinnamtannin B
B1 I
and O
crocin O
exhibit O
antiapoptotic O
effects O
. O

Synthesis O
and O
HIV O
- O
1 O
inhibitory O
activities O
of O
dicaffeoyl B
and I
digalloyl I
esters I
of O
quinic O
acid O
derivatives O
. O

Twenty O
analogues O
of O
the O
anti O
- O
HIV O
- O
1 O
integrase O
( O
IN O
) O
inhibitors O
dicaffeoylquinic O
acids O
( O
DCQAs B
) O
were O
prepared O
. O

Acetylated O
or O
benzylated O
and O
/ O
or O
with O
cyclohexylidene B
group O
compounds O
exhibited O
no O
inhibition O
of O
integration O
in O
biochemical O
assays O
or O
viral O
replication O
in O
HIV O
- O
infected O
cells O
, O
with O
the O
exception O
of O
16 O
and O
36 O
. O

Compounds O
19 O
, O
31 O
, O
and O
38 O
, O
all O
digalloyls B
, O
exhibited O
the O
most O
robust O
inhibitory O
performance O
in O
biochemical O
assays O
as O
well O
as O
in O
cell O
culture O
and O
less O
toxicity O
than O
other O
molecules O
in O
the O
current O
study O
. O

The O
high O
- O
efficacy O
agonist O
R B
( I
- I
) I
- I
norpropylapomorphine I
[ O
( B
- I
) I
- I
NPA I
] O
, O
low O
- O
efficacy O
agonist O
aripiprazole B
( O
ARI B
) O
, O
and O
antagonist O
eticlopride B
( O
ETIC B
) O
were O
administered O
acutely O
to O
monkeys O
self O
- O
administering O
cocaine O
under O
a O
food O
- O
cocaine O
choice O
procedure O
in O
which O
a O
cocaine O
self O
- O
administration O
dose O
- O
effect O
curve O
was O
determined O
daily O
. O

The O
effects O
of O
5 O
- O
day O
treatment O
with O
ARI O
and O
( B
- I
) I
- I
NPA I
were O
characterized O
under O
conditions O
in O
which O
monkeys O
did O
( O
ARI B
) O
or O
did O
not O
[ O
ARI B
and O
( B
- I
) I
- I
NPA I
] O
self O
- O
administer O
cocaine O
during O
treatment O
. O

When O
administered O
acutely O
, O
ARI B
and O
ETIC B
increased O
the O
choice O
of O
low O
cocaine O
doses O
, O
and O
only O
( B
- I
) I
- I
NPA I
decreased O
the O
choice O
of O
higher O
cocaine O
doses O
and O
cocaine O
intake O
; O
effects O
were O
similar O
across O
social O
ranks O
. O

When O
administered O
repeatedly O
while O
self O
administration O
occurred O
only O
on O
days O
1 O
and O
5 O
of O
treatment O
, O
ARI B
, O
but O
not O
( B
- I
) I
- I
NPA I
, O
decreased O
cocaine O
choice O
in O
dominant O
monkeys O
, O
whereas O
( B
- I
) I
- I
NPA I
, O
but O
not O
ARI B
, O
did O
so O
in O
subordinates O
. O

When O
dominant O
monkeys O
self O
- O
administered O
cocaine O
on O
all O
five O
days O
of O
ARI B
treatment O
, O
however O
, O
these O
effects O
were O
not O
observed O
. O

We O
studied O
the O
in O
vitro O
antioxidant O
and O
in O
vivo O
hepatoprotective O
activities O
of O
a O
70 O
% O
ethanolic O
extract O
of O
L O
. O
obtusiloba O
( O
LOE O
) O
containing O
62 O
. O
9 O
% O
quercitrin B
and O
22 O
. O
0 O
% O
afzelin B
. O

LOE O
prevented O
tert O
- O
butyl O
hydroperoxide O
( O
t B
- I
BHP I
) O
- O
induced O
oxidative O
damage O
in O
HepG2 O
cells O
. O

Along O
with O
its O
high O
antioxidant O
potency O
in O
vitro O
, O
our O
animal O
study O
confirmed O
that O
pretreatment O
with O
LOE O
( O
500 O
or O
2000 O
mg O
/ O
kg O
) O
for O
7 O
days O
prior O
to O
a O
single O
dose O
of O
t B
- I
BHP I
( O
i O
. O
p O
. O
: O
0 O
. O
5 O
mmol O
/ O
kg O
) O
significantly O
lowered O
the O
serum O
levels O
of O
alanine O
and O
aspartate O
aminotransferases O
. O

The O
histopathological O
examinations O
of O
rat O
livers O
showed O
that O
LOE O
significantly O
reduced O
the O
incidence O
of O
liver O
lesions O
induced O
by O
t B
- I
BHP I
. O

We O
further O
showed O
that O
central O
administration O
of O
an O
ER O
alpha O
agonist O
, O
propyl B
pyrazole I
triol I
, O
acutely O
increases O
physical O
interaction O
between O
SRC1 O
and O
ER O
alpha O
in O
the O
hypothalamus O
. O

We O
found O
ADP O
- O
ribosylating O
activity O
for O
the O
SCO5461 O
protein O
product O
through O
its O
co O
- O
incubation O
with O
guanosine O
and O
NAD O
( O
+ O
) O
, O
which O
resulted O
in O
the O
formation O
of O
N B
( I
2 I
) I
- I
( I
ADP I
- I
ribos I
- I
1 I
- I
yl I
) I
- I
guanosine I
( O
( B
ar2 I
) I
Guo I
) O
, O
with O
a O
K O
( O
m O
) O
value O
of O
110 O
mu O
M O
. O

SCO5461 O
was O
further O
found O
to O
ADP O
- O
ribosylate O
deoxyguanosine B
, O
GMP B
, O
dGMP B
, O
GTP O
, O
dGTP B
, O
and O
cyclic B
GMP I
with O
k O
( O
cat O
) O
values O
of O
150 O
- O
370 O
s O
( O
- O
1 O
) O
. O

This O
is O
the O
first O
report O
of O
the O
ADP O
- O
ribosylation O
of O
guanosine O
and O
guanine B
mononucleotides I
among O
the O
family O
members O
of O
various O
ADP O
- O
ribosylating O
enzymes O
. O

Theoretical O
study O
of O
the O
reaction O
of O
CH2XO B
( O
X O
= O
F O
, O
Cl O
, O
Br O
) O
radicals O
with O
the O
NO O
radical O
. O

In O
this O
paper O
, O
we O
focus O
on O
the O
multiple O
- O
channel O
reactions O
of O
CH B
( I
2 I
) I
XO I
( O
X O
= O
F O
, O
Cl O
, O
Br O
) O
radicals O
with O
the O
NO O
radical O
by O
means O
of O
direct O
dynamic O
methods O
. O

Adsorption O
of O
phenanthrene O
, O
2 O
- O
naphthol O
, O
and O
1 B
- I
naphthylamine I
to O
colloidal O
oxidized O
multiwalled O
carbon O
nanotubes O
: O
effects O
of O
humic O
acid O
and O
surfactant O
modification O
. O

In O
the O
present O
study O
, O
the O
authors O
examined O
the O
adsorption O
of O
phenanthrene O
, O
2 O
- O
naphthol O
, O
and O
1 B
- I
naphthylamine I
to O
three O
colloidal O
CNTs O
, O
including O
a O
stable O
suspension O
of O
oxidized O
multiwalled O
carbon O
nanotubes O
( O
O O
- O
MWNT O
) O
, O
a O
humic O
acid O
( O
HA O
) O
- O
modified O
colloidal O
O O
- O
MWNT O
, O
and O
a O
sodium O
dodecyl O
sulfate O
( O
SDS O
) O
- O
modified O
colloidal O
O O
- O
MWNT O
. O

Previous O
studies O
have O
shown O
inexplicable O
declines O
in O
breeding O
waterbirds O
within O
western O
New O
York O
/ O
New O
Jersey O
Harbor O
between O
1996 O
and O
2002 O
and O
elevated O
polychlorinated B
dibenzo I
- I
p I
- I
dioxins I
and O
polychlorinated O
biphenyls O
( O
PCBs O
) O
in O
double O
- O
crested O
cormorant O
( O
Phalacrocorax O
auritus O
) O
eggs O
. O

Strong O
negative O
correlations O
( O
r O
= O
- O
0 O
. O
95 O
to O
- O
0 O
. O
98 O
) O
between O
the O
PHA O
response O
and O
dioxins B
and O
PCBs O
in O
gull O
livers O
was O
strong O
evidence O
suggesting O
that O
these O
chemicals O
contribute O
significantly O
to O
immunosuppression O
in O
New O
York O
Harbor O
waterbirds O
. O

Reduced B
graphene I
oxide I
nanoribbon O
networks O
: O
a O
novel O
approach O
towards O
scalable O
fabrication O
of O
transparent O
conductive O
films O
. O

An O
innovative O
approach O
is O
developed O
for O
the O
high O
- O
throughput O
, O
large O
- O
area O
, O
and O
low O
- O
cost O
fabrication O
of O
reduced B
graphene I
oxide I
( O
RGO B
) O
nanoribbon O
networks O
by O
using O
electrospun O
polymer O
- O
based O
nanowires O
as O
the O
etching O
mask O
. O

Combined O
with O
their O
tunable O
, O
controllable O
structures O
and O
transmittance O
/ O
conductivity O
properties O
, O
the O
as O
- O
fabricated O
RGO B
nanoribbon O
networks O
exhibit O
potential O
as O
transparent O
conductive O
film O
electrodes O
, O
for O
example O
, O
in O
electrochromic O
devices O
. O

Specifically O
, O
we O
evaluated O
the O
actions O
of O
E O
( O
2 O
) O
on O
the O
mitochondrial O
permeability O
transition O
pore O
( O
MPTP O
) O
by O
the O
calcein O
- O
acetoxymethylester B
/ O
cobalt O
method O
using O
fluorescence O
microscopy O
and O
flow O
cytometry O
. O

Preparation O
of O
functionalized O
alkynyl B
magnetic O
microspheres O
for O
the O
selective O
enrichment O
of O
cell O
glycoproteins O
based O
on O
click O
chemistry O
. O

Functionalized O
alkynyl B
polyvinyl I
alcohol I
magnetic O
microspheres O
( O
PVA O
MMs O
) O
were O
developed O
for O
the O
specific O
enrichment O
of O
sialic O
acid O
- O
rich O
glycoproteins O
by O
click O
chemistry O
. O

The O
functionalized O
alkynyl B
PVA I
MMs O
showed O
a O
high O
specificity O
and O
strong O
binding O
capability O
for O
glycoproteins O
through O
a O
[ O
3 O
+ O
2 O
] O
cycloaddition O
reaction O
. O

The O
results O
indicated O
that O
the O
functionalized O
alkynyl B
PVA I
MMs O
could O
be O
applied O
to O
the O
enrichment O
of O
cell O
glycoproteins O
, O
and O
the O
merits O
of O
the O
MMs O
suggested O
an O
attractive O
and O
potential O
way O
to O
facilitate O
glycoprotein O
research O
. O

Optical O
pumping O
of O
a O
single O
electron O
spin O
bound O
to O
a O
fluorine O
donor O
in O
a O
ZnSe B
nanostructure O
. O

Here O
we O
demonstrate O
optical O
pumping O
of O
a O
single O
electron O
within O
a O
semiconductor O
nanostructure O
comprised O
of O
a O
single O
fluorine O
donor O
located O
within O
a O
ZnSe B
/ O
ZnMgSe B
quantum O
well O
. O

Ameliorative O
effect O
of O
aspalathin B
from O
rooibos O
( O
Aspalathus O
linearis O
) O
on O
acute O
oxidative O
stress O
in O
Caenorhabditis O
elegans O
. O

Rooibos O
is O
rich O
in O
antioxidant O
polyphenols O
, O
with O
the O
dihydrochalcone B
, O
aspalathin B
, O
as O
a O
major O
active O
ingredient O
. O

Furthermore O
, O
green O
rooibos O
was O
a O
more O
potent O
antioxidant O
than O
red O
rooibos O
, O
probably O
due O
to O
its O
substantially O
higher O
aspalathin B
content O
. O

In O
addition O
, O
rooibos O
decreased O
acute O
oxidative O
damage O
caused O
by O
the O
superoxide O
anion O
radical O
generator O
, O
juglone O
, O
with O
aspalathin B
playing O
a O
major O
role O
in O
improving O
the O
survival O
rate O
of O
C O
. O
elegans O
. O

Quantitative O
real O
- O
time O
PCR O
results O
demonstrated O
that O
aspalathin B
targets O
stress O
and O
ageing O
related O
genes O
, O
reducing O
the O
endogenous O
intracellular O
level O
of O
ROS O
. O

Synthesis O
, O
antimalarial O
activity O
and O
cytotoxic O
potential O
of O
new O
monocarbonyl B
analogues O
of O
curcumin O
. O

A O
series O
of O
novel O
monocarbonyl B
analogues O
of O
curcumin O
have O
been O
designed O
, O
synthesized O
and O
tested O
for O
their O
activity O
against O
Molt4 O
, O
HeLa O
, O
PC3 O
, O
DU145 O
and O
KB O
cancer O
cell O
lines O
. O

Inhibitory O
effects O
of O
metachromins B
L I
- I
Q I
and O
its O
related O
analogs O
against O
receptor O
tyrosine O
kinases O
EGFR O
and O
HER2 O
. O

Metachromins B
are O
a O
series O
of O
sesquiterpenoid B
quinones I
isolated O
from O
Okinawan O
marine O
sponges O
. O

Inhibitory O
effects O
of O
metachromins B
L I
- I
Q I
( O
1 O
- O
6 O
) O
, O
sesquiterpenoid B
quinones I
with O
an O
amino O
acid O
residue O
, O
and O
their O
related O
analogs O
( O
7 O
- O
18 O
) O
prepared O
from O
metachromins B
A O
( O
19 O
) O
and O
C O
( O
20 O
) O
against O
receptor O
tyrosine O
kinases O
EGFR O
and O
HER2 O
were O
investigated O
. O

Two O
analogs O
11 O
and O
12 O
showed O
relatively O
stronger O
inhibitory O
activity O
against O
EGFR O
, O
while O
metachromins B
L I
- I
Q I
( O
1 O
- O
6 O
) O
and O
seven O
analogs O
( O
8 O
, O
10 O
, O
11 O
, O
and O
15 O
- O
18 O
) O
showed O
inhibitory O
activities O
against O
HER2 O
. O

4 B
- I
tert I
- I
Octylphenol I
stimulates O
the O
expression O
of O
cathepsins O
in O
human O
breast O
cancer O
cells O
and O
xenografted O
breast O
tumors O
of O
a O
mouse O
model O
via O
an O
estrogen O
receptor O
- O
mediated O
signaling O
pathway O
. O

In O
this O
study O
, O
we O
examined O
the O
effect O
( O
s O
) O
of O
4 B
- I
tert I
- I
octylphenol I
( O
OP O
) O
, O
a O
potent O
EDC O
, O
on O
the O
expression O
of O
cathepsins O
B O
and O
D O
in O
human O
MCF O
- O
7 O
breast O
cancer O
cells O
and O
a O
xenograft O
mouse O
model O
. O

Antiviral O
activity O
of O
( B
+ I
) I
- I
sattabacin I
against O
varicella O
zoster O
. O

The O
first O
report O
of O
the O
antiviral O
activity O
of O
( B
+ I
) I
- I
sattabacin I
against O
varicella O
- O
zoster O
virus O
( O
VZV O
) O
is O
described O
. O

Our O
results O
show O
that O
( B
+ I
) I
- I
sattabacin I
potently O
inhibits O
the O
growth O
of O
VZV O
at O
concentrations O
in O
the O
range O
of O
other O
drugs O
commonly O
prescribed O
for O
VZV O
infection O
. O

Experiments O
detailing O
the O
synthesis O
of O
( B
+ I
) I
- I
sattabacin I
, O
quantification O
of O
cytotoxicity O
and O
gene O
expression O
data O
in O
human O
fibroblast O
cells O
are O
also O
presented O
. O

Gene O
expression O
data O
was O
obtained O
through O
microarray O
analysis O
from O
human O
fibroblast O
cells O
exposed O
to O
sattabacin B
in O
order O
to O
identify O
a O
possible O
mechanism O
by O
which O
( B
+ I
) I
- I
sattabacin I
inhibits O
VZV O
replication O
. O

3 B
- I
Hydroxykynurenine I
: O
an O
intriguing O
molecule O
exerting O
dual O
actions O
in O
the O
Central O
Nervous O
System O
. O

Kynurenine B
pathway O
is O
gaining O
attention O
due O
to O
the O
many O
metabolic O
processes O
in O
which O
it O
has O
been O
involved O
. O

3 B
- I
Hydroxykynurenine I
has O
been O
largely O
described O
as O
one O
of O
these O
toxic O
metabolites O
capable O
of O
inducing O
oxidative O
damage O
and O
cell O
death O
; O
consequently O
, O
this O
metabolite O
has O
been O
hypothesized O
to O
play O
a O
pivotal O
role O
in O
different O
neurological O
and O
psychiatric O
disorders O
. O

Supporting O
evidence O
has O
shown O
altered O
3 B
- I
hydroxykynurenine I
levels O
in O
samples O
of O
patients O
from O
several O
disorders O
. O

Through O
this O
collected O
evidence O
, O
we O
provide O
an O
integrative O
hypothesis O
on O
how O
3 B
- I
hydroxykynurenine I
is O
exerting O
its O
dual O
actions O
in O
the O
Central O
Nervous O
System O
and O
what O
will O
be O
the O
course O
of O
investigations O
in O
this O
field O
for O
the O
next O
years O
. O

3 B
- I
( I
1H I
- I
indol I
- I
3 I
- I
yl I
) I
- I
2 I
- I
[ I
3 I
- I
( I
4 I
- I
nitrophenyl I
) I
ureido I
] I
propanamide I
enantiomers O
with O
human O
formyl B
- O
peptide O
receptor O
agonist O
activity O
: O
molecular O
modeling O
of O
chiral O
recognition O
by O
FPR2 O
. O

N B
- I
formyl I
peptide O
receptors O
( O
FPRs O
) O
are O
G O
protein O
- O
coupled O
receptors O
( O
GPCRs O
) O
that O
play O
critical O
roles O
in O
inflammatory O
reactions O
, O
and O
FPR O
- O
specific O
interactions O
can O
possibly O
be O
used O
to O
facilitate O
the O
resolution O
of O
pathological O
inflammatory O
reactions O
. O

Here O
, O
we O
investigated O
the O
structure O
- O
activity O
relationship O
of O
24 O
chiral O
ureidopropanamides B
, O
including O
previously O
reported O
compounds O
PD168368 B
/ O
PD176252 B
and O
their O
close O
analogs O
, O
and O
used O
molecular O
modeling O
to O
define O
chiral O
recognition O
by O
FPR2 O
. O

Unlike O
previously O
reported O
6 B
- I
methyl I
- I
2 I
, I
4 I
- I
disubstituted I
pyridazin I
- I
3 I
( I
2H I
) I
- I
ones I
, O
whose O
R O
- O
forms O
preferentially O
activated O
FPR1 O
/ O
FPR2 O
, O
we O
found O
that O
four O
S O
- O
enantiomers O
in O
the O
seven O
ureidopropanamide B
pairs O
tested O
preferentially O
activated O
intracellular O
Ca O
( O
2 O
+ O
) O
flux O
in O
FPR2 O
- O
transfected O
cells O
, O
while O
the O
R O
- O
counterpart O
was O
more O
active O
in O
two O
enantiomer O
pairs O
. O

Esters O
of O
phthalic B
acid I
are O
chemical O
agents O
used O
to O
improve O
the O
plasticity O
of O
industrial O
polymers O
. O

This O
study O
investigated O
cytotoxicity O
, O
endocrine O
disruption O
, O
effects O
mediated O
via O
AhR O
, O
lipid O
peroxidation O
and O
effects O
on O
expression O
of O
enzymes O
of O
xenobiotic O
metabolism O
caused O
by O
di B
- I
( I
2 I
- I
ethy I
hexyl I
) I
phthalate I
( O
DEHP O
) O
, O
diethyl B
phthalate I
( O
DEP B
) O
, O
dibutyl O
phthalate O
( O
DBP B
) O
and O
benzyl B
butyl I
phthalate I
( O
BBP B
) O
in O
developing O
fish O
embryos O
. O

Oxidative O
stress O
was O
identified O
as O
the O
critical O
mechanism O
of O
toxicity O
( O
CMTA O
) O
in O
the O
case O
of O
DEHP O
and O
DEP B
, O
while O
the O
efficient O
removal O
of O
DBP B
and O
BBP B
by O
phase O
1 O
enzymes O
resulted O
in O
lesser O
toxicity O
. O

DEHP O
and O
DEP B
did O
not O
mimic O
estradiol O
( O
E O
( O
2 O
) O
) O
in O
transactivation O
studies O
, O
but O
at O
concentrations O
of O
10mg O
/ O
L O
synthesis O
of O
sex O
steroid O
hormones O
was O
affected O
. O

The O
order O
of O
potency O
of O
the O
4 O
phthalates O
studied O
was O
; O
DEHP O
> O
DEP B
> O
BBP B
> O
DBP B
. O

Also O
, O
the O
DOX O
modulatory O
effect O
on O
choline O
uptake O
transport O
system O
was O
assessed O
by O
measuring O
the O
uptake O
of O
[ B
( I
3 I
) I
H I
] I
- I
choline I
. O

Capreomycin B
supergenerics O
for O
pulmonary O
tuberculosis O
treatment O
: O
preparation O
, O
in O
vitro O
, O
and O
in O
vivo O
characterization O
. O

The O
aim O
of O
this O
study O
was O
to O
develop O
a O
simple O
and O
scalable O
method O
to O
produce O
capreomycin B
inhalable O
powders O
to O
use O
as O
supergeneric O
. O

Capreomycin B
and O
three O
different O
hydrophobic O
counterions O
, O
namely O
oleate B
, O
linoleate B
, O
and O
linolenate B
, O
were O
combined O
in O
solution O
to O
obtain O
hydrophobic O
ion O
- O
pairs O
that O
were O
successively O
spray O
- O
dried O
. O

In O
the O
case O
of O
capreomycin B
oleate I
, O
both O
instruments O
, O
mini O
and O
nano O
spray O
- O
dryer O
, O
were O
suitable O
to O
maintain O
a O
high O
ion O
- O
paired O
content O
, O
while O
for O
capreomycin B
linoleate I
and I
linolenate I
, O
mini O
spray O
- O
dryer O
was O
the O
most O
appropriate O
instrument O
. O

Capreomycin B
oleate I
and I
linoleate I
showed O
the O
same O
efficacy O
of O
capreomycin B
sulfate I
against O
M O
. O
tuberculosis O
, O
while O
capreomycin B
linolenate I
showed O
a O
reduced O
efficacy O
, O
even O
though O
strain O
growth O
was O
inhibited O
at O
10 O
( O
- O
4 O
) O
mycobacterial O
inoculum O
. O

In O
vivo O
acute O
toxicity O
studies O
evidenced O
the O
lowest O
toxic O
potential O
for O
capreomycin B
oleate I
when O
compared O
to O
the O
single O
components O
or O
the O
other O
two O
salts O
. O

Overall O
, O
capreomycin B
oleate I
seems O
to O
possess O
the O
most O
promising O
characteristics O
to O
be O
used O
as O
supergenerics O
in O
pulmonary O
tuberculosis O
treatment O
. O

Total O
content O
of O
phenol O
in O
extracts O
was O
determined O
as O
pyrocatechol B
equivalent O
. O

The O
most O
active O
was O
also O
physodic B
acid I
. O

The O
mixed O
micelles O
with O
lower O
than O
0 O
. O
2mM O
sodium O
deoxycholate O
( O
SDC B
) O
had O
no O
significant O
effects O
on O
cell O
viability O
and O
proliferation O
. O

When O
the O
level O
of O
SDC B
was O
higher O
than O
0 O
. O
4mM O
and O
the O
lecithin O
/ O
SDC B
ratio O
was O
lower O
than O
2 O
: O
1 O
, O
the O
mixed O
micelles O
caused O
significant O
changes O
in O
cell O
viability O
and O
proliferation O
. O

Specifically O
, O
the O
tight O
junctions O
were O
transiently O
opened O
rather O
than O
damaged O
by O
the O
mixed O
micelles O
with O
SDC B
of O
between O
0 O
. O
2 O
and O
0 O
. O
6mM O
. O

Six O
biodegradable O
polymers O
have O
been O
investigated O
as O
drug O
carriers O
using O
molecular O
simulations O
: O
l B
- I
polylactide I
, O
d B
- I
polylactide I
, O
chitosan O
, O
polyglycolic B
acid I
, O
polyethylene O
glycol O
and O
cellulose O
. O

Because O
GK O
contains O
polyacetylenes B
and O
because O
other O
polyacetylenes B
have O
been O
found O
to O
exhibit O
anti O
- O
inflammatory O
and O
anti O
- O
cancer O
activities O
, O
we O
hypothesized O
that O
the O
polyacetylene O
gymnasterkoreayne B
B I
( O
GKB B
) O
, O
known O
to O
increase O
hepatic O
detoxification O
enzymes O
, O
may O
also O
exert O
anti O
- O
inflammatory O
and O
anti O
- O
cancer O
activities O
. O

We O
fed O
male O
C57BL O
/ O
6 O
mice O
purified O
AIN93G O
diets O
containing O
no O
additions O
, O
GKB B
or O
the O
GKB B
- O
rich O
fraction O
of O
an O
ethanol O
extract O
( O
GE O
) O
from O
GK O
to O
determine O
if O
these O
diets O
would O
slow O
or O
prevent O
either O
inflammation O
or O
inflammation O
- O
enhanced O
colon O
cancer O
, O
using O
the O
dextran O
sulfate O
sodium O
/ O
azoxymethane B
mouse O
model O
. O

The O
GKB B
( O
500 O
mu O
mol O
/ O
kg O
diet O
daily O
) O
showed O
some O
anti O
- O
inflammatory O
activity O
, O
but O
GE O
, O
containing O
an O
equal O
dose O
of O
GKB B
, O
protected O
strongly O
against O
both O
inflammation O
and O
colon O
cancer O
, O
decreasing O
adenocarcinomas O
by O
90 O
% O
. O

Benzylparaben O
( O
BzP B
) O
, O
a O
type O
of O
parabens O
being O
used O
as O
a O
preservative O
agent O
in O
cosmetics O
, O
food O
, O
and O
pharmaceutical O
products O
, O
may O
be O
ingested O
by O
humans O
. O

In O
this O
study O
, O
we O
performed O
an O
immature O
uterotrophic O
assay O
using O
Sprague O
Dawley O
( O
SD O
) O
rats O
by O
intragastric O
administration O
to O
determine O
the O
estrogenic O
effects O
of O
BzP B
and O
found O
significant O
increases O
in O
uterine O
weight O
with O
doses O
of O
0 O
. O
16 O
mg O
/ O
kg O
body O
weight O
and O
higher O
( O
P O
< O
0 O
. O
05 O
) O
. O

The O
in O
vivo O
estrogenicity O
of O
BzP B
was O
supported O
by O
in O
vitro O
results O
from O
the O
human O
estrogen O
receptor O
alpha O
( O
hER O
alpha O
) O
- O
coactivator O
recruiting O
assay O
and O
in O
silico O
molecular O
docking O
analysis O
performed O
in O
this O
study O
. O

The O
in O
vitro O
estrogenic O
activity O
of O
BzP B
can O
be O
observed O
at O
concentrations O
of O
1 O
. O
0 O
x O
10 O
( O
- O
8 O
) O
M O
and O
higher O
. O

Molecular O
docking O
analysis O
showed O
that O
BzP B
fits O
well O
into O
the O
agonist O
pocket O
of O
hER O
alpha O
. O

The O
lowest O
observed O
effect O
dose O
( O
LOED O
) O
( O
0 O
. O
16 O
mg O
/ O
kg O
/ O
day O
) O
of O
BzP B
is O
much O
lower O
than O
the O
documented O
LOEDs O
of O
other O
parabens O
. O

Actual O
risk O
may O
exist O
for O
people O
who O
consume O
a O
diet O
high O
in O
BzP B
or O
use O
BzP B
- O
laden O
cosmetics O
. O

MAPK O
signaling O
pathways O
regulate O
mitochondrial O
- O
mediated O
apoptosis O
induced O
by O
isoorientin B
in O
human O
hepatoblastoma O
cancer O
cells O
. O

Isoorientin B
( O
ISO O
) O
( O
CAS O
RN O
: O
4261 B
- I
42 I
- I
1 I
) O
is O
a O
flavonoid O
compound O
that O
can O
be O
extracted O
from O
several O
plant O
species O
, O
such O
as O
Phyllostachys O
pubescens O
, O
Patrinia O
, O
and O
Drosophyllum O
lusitanicum O
. O

Hepatic O
metabolism O
of O
sulfur B
amino I
acids I
in O
db O
/ O
db O
mice O
. O

To O
determine O
the O
effect O
of O
type O
- O
2 O
diabetes O
and O
obesity O
on O
the O
hepatic O
metabolism O
of O
sulfur B
amino I
acids I
, O
hepatic O
sulfur B
amino I
acid I
metabolism O
was O
determined O
in O
db O
/ O
db O
mice O
. O

The O
decrease O
in O
hepatic O
methionine O
was O
reflected O
by O
decreased O
sulfur O
- O
containing O
methionine O
metabolites O
, O
including O
S O
- O
adenosylmethionine O
, O
homocysteine O
, O
cysteine O
, O
and O
hypotaurine B
in O
liver O
and O
plasma O
. O

The O
decreased O
hepatic O
hypotaurine B
may O
be O
attributable O
to O
the O
downregulation O
of O
cysteine O
dioxygenase O
. O

Antithrombotic O
and O
profibrinolytic O
activities O
of O
isorhamnetin B
- I
3 I
- I
O I
- I
galactoside I
and O
hyperoside O
. O

The O
potential O
anticoagulant O
activities O
of O
two O
single O
compounds O
, O
isorhamnetin B
- I
3 I
- I
O I
- I
galactoside I
( O
IMG B
) O
and O
hyperoside O
, O
from O
Oenanthe O
javanica O
, O
were O
tested O
. O

Treatment O
with O
IMG B
and O
hyperoside O
resulted O
in O
significantly O
prolonged O
aPTT O
and O
PT O
and O
inhibition O
of O
the O
activities O
of O
thrombin O
and O
FXa O
, O
and O
IMG B
or O
hyperoside O
inhibited O
production O
of O
thrombin O
and O
FXa O
in O
HUVECs O
. O

In O
addition O
, O
treatment O
with O
IMG B
and O
hyperoside O
resulted O
in O
inhibition O
of O
TNF O
- O
alpha O
- O
induced O
production O
of O
PAI O
- O
1 O
, O
and O
treatment O
with O
IMG B
resulted O
in O
significant O
reduction O
of O
the O
PAI O
- O
1 O
to O
t O
- O
PA O
ratio O
. O

The O
anticoagulant O
and O
profibrinolytic O
effects O
of O
IMG B
were O
greater O
than O
those O
of O
hyperoside O
, O
indicating O
positive O
regulation O
of O
its O
anticoagulant O
function O
by O
the O
methoxy O
group O
of O
IMG B
. O

IMG B
and O
hyperoside O
possess O
antithrombotic O
activities O
and O
offer O
bases O
for O
development O
of O
a O
novel O
anticoagulant O
. O

Silent O
information O
regulator O
2 O
( O
Sir2 O
) O
enzymes O
or O
sirtuins O
are O
a O
family O
of O
NAD O
( O
+ O
) O
- O
dependent O
protein O
N B
( I
epsilon I
) I
- I
acetyl I
- I
lysine I
( O
AcK B
) O
deacetylases O
. O

2 B
- I
Phenoxy I
- I
nicotinamides I
are O
potent O
agonists O
at O
the O
bile O
acid O
receptor O
GPBAR1 O
( O
TGR5 O
) O
. O

Potency O
with O
potential O
: O
2 B
- I
Phenoxy I
- I
nicotinamides I
were O
identified O
as O
potent O
agonists O
at O
the O
GPBAR1 O
receptor O
, O
a O
target O
in O
the O
treatment O
of O
obesity O
, O
type O
2 O
diabetes O
and O
metabolic O
syndrome O
. O

Instead O
, O
expression O
levels O
of O
o O
- O
series O
gangliosides O
involving O
GM1 O
- O
b O
and O
GD1 O
- O
alpha O
increased O
dramatically O
, O
whereas O
a O
- O
/ O
b O
- O
series O
gangliosides B
were O
predominantly O
detected O
in O
wild O
- O
type O
( O
WT O
) O
cells O
. O

At O
present O
, O
triorganotin B
, O
such O
as O
tributyltin O
, O
have O
been O
demonstrated O
to O
produce O
imposex O
, O
and O
mammalian O
reproductive O
and O
metabolic O
toxicity O
. O

For O
most O
mammals O
, O
triorganotin B
exposure O
predominantly O
occurs O
through O
the O
ingestion O
, O
and O
this O
compound O
can O
cross O
the O
placenta O
. O

Oxidative O
modification O
of O
neurofilament O
- O
L O
and O
neuronal O
cell O
death O
induced O
by O
the O
catechol O
neurotoxin O
, O
tetrahydropapaveroli B
. O

Tetrahydropapaveroli B
( O
THP B
) O
, O
which O
is O
an O
endogenous O
neurotoxin O
, O
has O
been O
suspected O
to O
be O
associated O
with O
dopaminergic O
neurotoxicity O
of O
l B
- I
DOPA I
. O

In O
this O
study O
, O
we O
examined O
oxidative O
modification O
of O
neurofilament O
- O
L O
( O
NF O
- O
L O
) O
and O
neuronal O
cell O
death O
induced O
by O
THP B
. O

When O
disassembled O
NF O
- O
L O
was O
incubated O
with O
THP B
, O
protein O
aggregation O
was O
increased O
in O
a O
time O
- O
and O
THP B
dose O
- O
dependent O
manner O
. O

The O
formation O
of O
carbonyl O
compounds O
and O
dityrosine B
were O
observed O
in O
the O
THP B
- O
mediated O
NF O
- O
L O
aggregates O
. O

Radical O
scavengers O
reduced O
THP B
- O
mediated O
NF O
- O
L O
modification O
. O

These O
results O
suggest O
that O
the O
modification O
of O
NF O
- O
L O
by O
THP B
may O
be O
due O
to O
oxidative O
damage O
resulting O
from O
the O
generation O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
. O

When O
THP B
exposed O
NF O
- O
L O
was O
subjected O
to O
amino O
acid O
analysis O
, O
glutamate O
, O
proline O
and O
lysine O
residues O
were O
found O
to O
be O
particularly O
sensitive O
. O

We O
also O
investigated O
the O
effects O
of O
copper O
ions O
on O
THP B
- O
mediated O
NF O
- O
L O
modification O
. O

At O
a O
low O
concentration O
of O
THP B
, O
copper O
ions O
enhanced O
the O
modification O
of O
NF O
- O
L O
. O

Treatment O
of O
C6 O
astrocyte O
cells O
with O
THP B
led O
to O
a O
concentration O
- O
dependent O
reduction O
in O
cell O
viability O
. O

When O
these O
cells O
were O
treated O
with O
100 O
mu O
M O
THP B
, O
the O
levels O
of O
ROS O
increased O
3 O
. O
5 O
- O
fold O
compared O
with O
control O
cells O
. O

Furthermore O
, O
treatment O
of O
cells O
with O
THP B
increased O
NF O
- O
L O
aggregate O
formation O
, O
suggesting O
the O
involvement O
of O
NF O
- O
L O
modification O
in O
THP B
- O
induced O
cell O
damage O
. O

Synthesis O
and O
antibacterial O
evaluation O
of O
novel O
11 B
, I
4 I
' I
' I
- I
disubstituted I
azithromycin I
analogs O
with O
greatly O
improved O
activity O
against O
erythromycin O
- O
resistant O
bacteria O
. O

A O
series O
of O
novel O
11 B
, I
4 I
' I
' I
- I
disubstituted I
azithromycin I
analogs O
were O
synthesized O
and O
evaluated O
for O
their O
antibacterial O
activity O
. O

All O
the O
11 O
, O
4 O
' O
' O
- O
disubstituted O
analogs O
exhibited O
excellent O
activity O
( O
0 O
. O
03 O
- O
0 O
. O
12 O
mu O
g O
/ O
ml O
) O
against O
erythromycin O
- O
susceptible O
Streptococcus O
pneumoniae O
, O
and O
significantly O
improved O
activity O
against O
three O
phenotypes O
of O
erythromycin O
- O
resistant O
S O
. O
pneumoniae O
compared O
with O
erythromycin B
A I
, O
clarithromycin O
or O
azithromycin O
. O

It O
is O
noteworthy O
that O
the O
most O
active O
compounds O
described O
above O
possess O
the O
same O
terminal O
3 B
, I
5 I
- I
dinitrophenyl I
groups O
on O
their O
C O
- O
4 O
' O
' O
bisamide B
side O
chains O
. O

Neutral O
and O
charged O
phosphine B
/ I
scorpionate I
copper I
( I
I I
) I
complexes I
: O
effects O
of O
ligand O
assembly O
on O
their O
antiproliferative O
activity O
. O

Ligand O
- O
exchange O
reactions O
of O
copper O
( O
I O
) O
precursors O
( O
[ B
Cu I
( I
CH I
( I
3 I
) I
CN I
) I
( I
4 I
) I
] I
BF I
( I
4 I
) I
, O
CuCl B
) O
with O
a O
panel O
of O
bis B
( I
azolyl I
) I
borates I
or O
poly B
( I
pyrazolyl I
) I
methanes I
and O
a O
tertiary B
monodentate I
phosphine I
( O
PTA B
= O
1 B
, I
3 I
, I
5 I
- I
triaza I
- I
7 I
- I
phosphaadamantane I
, O
PCN B
= O
tris B
( I
cyanoethyl I
) I
phosphine I
) O
produced O
two O
series O
of O
heteroleptic O
, O

' O
2 O
+ O
1 O
+ O
1 O
' O
- O
type O
complexes O
include O
a O
N O
, O
N O
- O
bidentate O
chelate O
and O
two O
monodentate O
phosphines O
( O
1 O
- O
8 O
) O
and O
' O
3 O
+ O
1 O
' O
- O
type O
complexes O
comprise O
a O
N O
, O
N O
, O
O O
- O
or O
N O
, O
N O
, O
N O
- O
tridentate O
chelate O
and O
one O
monodentate O
phosphine B
( O
9 O
- O
12 O
) O
. O

Conversely O
, O
' O
2 O
+ O
1 O
+ O
1 O
' O
complexes O
exhibit O
increased O
propensity O
to O
dissociation O
as O
shown O
by O
ESI O
- O
MS O
measurements O
and O
X O
- O
ray O
structure O
determination O
at O
low O
temperature O
( O
150 O
K O
) O
of O
the O
polymeric O
complex O
{ B
[ I
H I
( I
2 I
) I
B I
( I
tz I
( I
NO2 I
) I
) I
( I
2 I
) I
] I
Cu I
[ I
PCN I
] I
} I
( I
n I
) I
6b O
. O

In O
this O
complex O
, O
either O
the O
bis B
( I
triazolyl I
) I
borate I
and O
the O
PCN B
ligands O
act O
as O
bidentate O
, O
with O
PCN B
being O
also O
the O
mu O
( O
2 O
) O
- O
bridiging O
linker O
between O
adjacent O
monomers O
. O

Compound O
6b O
is O
the O
first O
reported O
example O
of O
a O
polymeric O
PCN B
compound O
with O
a O
tetra O
- O
coordinate O
metal O
centre O
. O

We O
identified O
one O
compound O
, O
E235 B
( B
N I
- I
( I
1 I
- I
benzyl I
- I
piperidin I
- I
4 I
- I
yl I
) I
- I
2 I
- I
( I
4 I
- I
fluoro I
- I
phenyl I
) I
- I
benzo I
[ I
d I
] I
imidazo I
[ I
2 I
, I
1 I
- I
b I
] I
thiazole I
- I
7 I
- I
carboxamide I
) I
, O
that O
activated O
the O
ISR O
and O
dose O
- O
dependently O
increased O
levels O
of O
ATF4 O
in O
transformed O
cells O
. O

A O
dose O
- O
dependent O
decrease O
in O
viability O
was O
observed O
in O
several O
mouse O
and O
human O
tumor O
cell O
lines O
, O
and O
knockdown O
of O
ATF4 O
significantly O
increased O
the O
antiproliferative O
effects O
of O
E235 B
. O

Interestingly O
, O
low O
mu O
M O
doses O
of O
E235 B
induced O
senescence O
in O
many O
cell O
types O
, O
including O
HT1080 O
human O
fibrosarcoma O
and O
B16F10 O
mouse O
melanoma O
cells O
. O

E235 B
- O
mediated O
induction O
of O
senescence O
was O
not O
dependent O
on O
p21 O
or O
p53 O
; O
however O
, O
p21 O
conferred O
protection O
against O
the O
growth O
inhibitory O
effects O
of O
E235 B
. O

Treatment O
with O
E235 B
resulted O
in O
an O
increase O
in O
cells O
arrested O
at O
the O
G2 O
/ O
M O
phase O
with O
a O
concurrent O
decrease O
in O
S O
- O
phase O
cells O
. O

E235 B
also O
activated O
DNA O
damage O
response O
signaling O
, O
resulting O
in O
increased O
levels O
of O
Ser15 B
- O
phosphorylated O
p53 O
, O
gamma O
- O
H2AX O
, O
and O
phosphorylated O
checkpoint O
kinase O
2 O
( O
Chk2 O
) O
, O
although O
E235 B
does O
not O
appear O
to O
cause O
physical O
DNA O
damage O
. O

Together O
, O
these O
results O
suggest O
that O
modulation O
of O
the O
ISR O
pathway O
with O
the O
small O
molecule O
E235 B
could O
be O
a O
promising O
antitumor O
strategy O
. O

CBMs O
that O
bind O
beta O
- O
glucan O
chains O
often O
display O
broad O
specificity O
recognizing O
beta O
1 O
, O
4 O
- O
glucans O
( O
cellulose O
) O
, O
beta O
1 O
, O
3 O
- O
beta O
1 O
, O
4 O
- O
mixed O
linked O
glucans O
and O
xyloglucan O
, O
a O
beta O
1 O
, O
4 O
- O
glucan O
decorated O
with O
alpha B
1 I
, I
6 I
- I
xylose I
residues O
, O
by O
targeting O
structures O
common O
to O
the O
three O
polysaccharides O
. O

The O
bovine O
ATP O
- O
binding O
cassette O
transporter O
ABCG2 O
Tyr581Ser O
single O
- O
nucleotide O
polymorphism O
increases O
milk O
secretion O
of O
the O
fluoroquinolone O
danofloxacin B
. O

Our O
purpose O
was O
to O
study O
the O
in O
vivo O
effect O
of O
this O
polymorphism O
on O
the O
secretion O
of O
danofloxacin B
, O
a O
widely O
used O
veterinary O
antibiotic O
, O
into O
milk O
. O

Danofloxacin B
( O
1 O
. O
25 O
mg O
/ O
kg O
) O
was O
administered O
to O
six O
Y O
/ O
Y O
581 O
homozygous O
and O
six O
Y O
/ O
S O
581 O
heterozygous O
lactating O
cows O
, O
and O
plasma O
and O
milk O
samples O
were O
collected O
and O
analyzed O
by O
high O
- O
performance O
liquid O
chromatography O
. O

No O
differences O
were O
found O
in O
the O
pharmacokinetic O
parameters O
of O
danofloxacin B
in O
plasma O
between O
the O
two O
groups O
of O
animals O
. O

In O
contrast O
, O
Y O
/ O
S O
heterozygous O
cows O
showed O
a O
2 O
- O
fold O
increase O
in O
danofloxacin B
levels O
in O
milk O
. O

Synthesis O
of O
polystyrene O
/ O
polysilsesquioxane B
core O
/ O
shell O
composite O
particles O
via O
emulsion O
polymerization O
in O
the O
existence O
of O
poly B
( I
gamma I
- I
methacryloxypropyl I
trimethoxysilane I
) I
sol O
. O

Here O
, O
we O
synthesized O
the O
polystyrene O
/ O
polysilsesquioxane B
( O
PS O
/ O
PSQ B
) O
core O
/ O
shell O
latex O
particles O
via O
emulsion O
polymerization O
, O
which O
behave O
as O
an O
amusing O
morphology O
. O

First O
, O
the O
nanosized O
PSQ B
particles O
were O
prepared O
by O
the O
hydrolysis O
- O
condensation O
reaction O
of O
gamma B
- I
methacryloxypropyl I
trimethoxysilane I
( O
MPTS B
) O
in O
ethanol O
medium O
. O

Subsequently O
, O
the O
as O
- O
obtained O
methacryloxypropylen B
functionalized O
PSQ B
( O
PMPTS B
) O
sol O
was O
directly O
added O
into O
the O
emulsion O
system O
of O
styrene O
( O
St O
) O
monomer O
, O
and O
PS O
/ O
PSQ B
composite O
particles O
with O
core O
/ O
shell O
structure O
were O
obtained O
through O
emulsion O
polymerization O
. O

We O
found O
that O
the O
structure O
of O
the O
composite O
particles O
can O
be O
affected O
by O
the O
synthesis O
parameters O
such O
as O
reaction O
time O
, O
content O
of O
PMPTS B
added O
in O
the O
reaction O
, O
amount O
of O
coemulsifier O
, O
and O
the O
pH O
value O
of O
emulsion O
system O
, O
which O
were O
systemically O
explored O
by O
transmission O
electron O
microscopy O
( O
TEM O
) O
, O
scanning O
electron O
microscope O
( O
SEM O
) O
, O
Fourier O
transform O
infrared O
( O
FTIR O
) O
spectroscopy O
, O
dynamic O
light O
scattering O
( O
DLS O
) O
, O
and O
thermogravimetric O
analysis O
( O
TGA O
) O
in O
this O
work O
. O

These O
results O
indicate O
that O
the O
PMPTS B
particles O
in O
the O
size O
of O
about O
5 O
nm O
could O
first O
absorb O
onto O
the O
surface O
of O
PS O
latex O
particles O
so O
as O
to O
assemble O
in O
a O
strawberry O
- O
like O
morphology O
. O

The O
further O
coalescence O
among O
the O
PMPTS B
particles O
would O
result O
in O
a O
continuous O
PMPTS B
shell O
around O
the O
PS O
core O
. O

Moreover O
, O
the O
hollow O
PSQ B
capsules O
were O
prepared O
after O
extraction O
of O
the O
PS O
core O
by O
organic O
solvent O
, O
further O
confirming O
the O
core O
/ O
shell O
structure O
of O
the O
as O
- O
synthesized O
PS O
/ O
PMPTS B
particles O
. O

Meanwhile O
, O
we O
also O
explored O
the O
application O
of O
the O
PS O
/ O
PSQ B
core O
/ O
shell O
particles O
as O
a O
new O
kind O
of O
Pickering O
emulsifier O
in O
the O
emulsion O
polymerization O
of O
St O
, O
and O
composite O
particles O
with O
complex O
patchy O
morphologies O
have O
been O
obtained O
finally O
under O
different O
ratios O
of O
styrene O
monomer O
to O
PS O
/ O
PMPTS B
colloidal O
emulsifier O
. O

Discovery O
of O
4 B
- I
phenyl I
- I
2 I
- I
phenylaminopyridine I
based O
TNIK O
inhibitors O
. O

A O
series O
of O
compounds O
based O
on O
a O
4 B
- I
phenyl I
- I
2 I
- I
phenylaminopyridine I
scaffold O
that O
are O
potent O
and O
selective O
inhibitors O
of O
Traf2 O
- O
and O
Nck O
- O
interacting O
kinase O
( O
TNIK O
) O
activity O
are O
described O
. O

New O
amide B
alkaloids I
from O
Piper O
longum O
. O

By O
analyses O
of O
the O
MS O
, O
IR O
, O
UV O
, O
1D O
and O
2D O
NMR O
data O
, O
the O
two O
new O
compounds O
were O
identified O
as O
3 B
beta I
, I
4 I
alpha I
- I
dihydroxy I
- I
1 I
- I
( I
3 I
- I
phenylpropanoyl I
) I
- I
piperidine I
- I
2 I
- I
one I
( O
1 O
) O
and O
( B
2E I
, I
4E I
, I
14Z I
) I
- I
6 I
- I
hydroxyl I
- I
N I
- I
isobutyleicosa I
- I
2 I
, I
4 I
, I
14 I
- I
trienamide I
( O
2 O
) O
. O

Event O
based O
analysis O
of O
chlorothalonil B
concentrations O
following O
application O
to O
managed O
turf O
. O

Chlorothalonil B
concentrations O
exceeding O
acute O
toxicity O
levels O
for O
certain O
organisms O
have O
been O
measured O
in O
surface O
water O
discharge O
events O
from O
managed O
turf O
watersheds O
. O

Chlorothalonil B
concentrations O
were O
measured O
from O
discharge O
waters O
draining O
a O
managed O
turf O
watershed O
in O
Duluth O
, O
Minnesota O
, O
USA O
, O
between O
2003 O
and O
2009 O
. O

The O
median O
chlorothalonil B
concentration O
was O
0 O
. O
58 O
micro O
g O
/ O
L O
. O

A O
conflict O
exists O
between O
the O
transportability O
of O
chlorothalonil B
as O
suggested O
by O
its O
chemical O
properties O
and O
the O
data O
collected O
in O
the O
present O
study O
. O

With O
respect O
to O
course O
- O
wide O
golf O
course O
application O
, O
avoiding O
application O
until O
after O
the O
major O
autumn O
rainfall O
period O
but O
before O
the O
first O
snow O
coverage O
is O
recommended O
to O
reduce O
occurrence O
of O
chlorothalonil B
concentrations O
that O
exceed O
toxic O
levels O
associated O
with O
acute O
and O
chronic O
levels O
of O
concern O
. O

Design O
and O
synthesis O
of O
diazatricyclodecane B
agonists O
of O
the O
G O
- O
protein O
- O
coupled O
receptor O
119 O
. O

A O
series O
of O
GPR119 O
agonists O
based O
on O
a O
2 B
, I
6 I
- I
diazatricyclo I
[ I
3 I
. I
3 I
. I
1 I
. I
1 I
~ I
3 I
, I
7 I
~ I
] I
decane I
ring O
system O
is O
described O
. O

Also O
provided O
is O
a O
detailed O
account O
of O
the O
development O
of O
a O
multigram O
scale O
synthesis O
of O
the O
diazatricyclic B
ring O
system O
, O
which O
was O
achieved O
using O
a O
Hofmann O
- O
L O
o O
ffler O
- O
Freytag O
reaction O
as O
the O
key O
step O
. O

The O
basis O
for O
the O
use O
of O
this O
complex O
framework O
lies O
in O
an O
attempt O
to O
constrain O
one O
end O
of O
the O
molecule O
in O
the O
" O
agonist O
conformation O
" O
as O
was O
previously O
described O
for O
3 B
- I
oxa I
- I
7 I
- I
aza I
- I
bicyclo I
[ I
3 I
. I
3 I
. I
1 I
] I
nonanes I
. O

Optimization O
of O
carbamate O
analogues O
of O
the O
diazatricylic B
compounds O
led O
to O
the O
identification O
of O
32i O
as O
a O
potent O
agonist O
of O
the O
GPR119 O
receptor O
with O
low O
unbound O
human O
liver O
microsomal O
clearance O
. O

Here O
we O
report O
the O
functionalization O
of O
monodisperse O
iron O
oxide O
nanoparticles O
( O
NPs O
) O
with O
commercially O
available O
functional O
acids O
containing O
multiple O
double O
bonds O
such O
as O
linolenic B
( I
LLA I
) I
and I
linoleic I
( I
LEA I
) I
acids I
or O
pyridine O
moieties O
such O
as O
6 B
- I
methylpyridine I
- I
2 I
- I
carboxylic I
acid I
, O
isonicotinic B
acid I
, O
3 B
- I
hydroxypicolinic I
acid I
, O
and O
6 B
- I
( I
1 I
- I
piperidinyl I
) I
pyridine I
- I
3 I
- I
carboxlic I
acid I
( O
PPCA B
) O
. O

We O
determined O
that O
both O
LLA B
and O
LEA B
stabilize O
magnetic O
iron O
oxide O
NPs O
, O
allowing O
the O
formation O
of O
pi O
- O
complexes O
with O
bis B
( I
acetonitrile I
) I
dichloropalladium I
( I
II I
) I
in O
the O
NP O
shells O
. O

In O
the O
case O
of O
pyridine O
- O
containing O
ligands O
, O
only O
PPCA B
with O
two O
N O
- O
containing O
rings O
is O
able O
to O
provide O
NP O
stabilization O
and O
functionalization O
whereas O
other O
pyridine O
- O
containing O
acids O
did O
now O
allow O
sufficient O
steric O
stabilization O
. O

The O
interaction O
of O
PPCA B
- O
based O
particles O
with O
Pd B
acetate I
also O
leads O
to O
aggregation O
because O
of O
interparticle O
interactions O
, O
but O
the O
aggregates O
that O
are O
formed O
are O
much O
smaller O
. O

Nevertheless O
, O
the O
catalytic O
properties O
in O
the O
selective O
hydrogenation O
of O
dimethylethynylcarbi B
( O
DMEC B
) O
to O
dimethylvinylcarbino B
were O
the O
best O
for O
the O
catalyst O
based O
on O
LLA B
, O
demonstrating O
that O
the O
NP O
aggregates O
in O
all O
cases O
are O
penetrable O
for O
DMEC B
. O

While O
AT1R O
signaling O
suppresses O
the O
influence O
of O
corticotropin O
on O
the O
generation O
of O
cyclic B
adenosine I
monophosphate I
, O
the O
expression O
of O
the O
AT1R O
and O
its O
associated O
enzyme O
activities O
are O
under O
the O
control O
of O
glucocorticoids O
. O

The O
most O
potent O
of O
these O
compounds O
is O
ethyl B
2 I
- I
( I
N I
- I
( I
( I
4 I
- I
iodo I
- I
6 I
- I
methoxypyrimidin I
- I
2 I
- I
yl I
) I
carbamoyl I
) I
sulfamoyl I
) I
benzoate I
( O
10c O
) O
, O
which O
has O
a O
K O
( O
i O
) O
value O
of O
3 O
. O
8 O
nM O
for O
C O
. O
albicans O
AHAS O
and O
an O
MIC O
9 O
0 O
of O
0 O
. O
7 O
mu O
g O
/ O
mL O
for O
this O
fungus O
in O
cell O
- O
based O
assays O
. O

Isoliquiritigenin B
showed O
strong O
inhibitory O
effects O
towards O
multiple O
UDP O
- O
glucuronosyltransfer O
( O
UGT O
) O
isoform O
- O
catalyzed O
4 B
- I
methylumbelliferone I
( O
4 B
- I
MU I
) O
glucuronidation O
. O

Isoliquiritigenin B
, O
a O
herbal O
ingredient O
with O
chalcone O
structure O
, O
has O
been O
speculated O
to O
be O
able O
to O
inhibit O
one O
of O
the O
most O
drug O
- O
metabolizing O
enzymes O
( O
DMEs O
) O
UDP O
- O
glucuronosyltransfer O
( O
UGT O
) O
. O

Therefore O
, O
the O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
inhibition O
of O
isoliquiritigenin B
towards O
important O
UGT O
isoforms O
in O
the O
liver O
and O
intestine O
, O
including O
UGT1A1 O
, O
1A3 O
, O
1A6 O
, O
1A7 O
, O
1A8 O
, O
1A9 O
and O
1A10 O
. O

The O
recombinant O
UGT O
- O
catalyzed O
4 B
- I
methylumbelliferone I
( O
4 B
- I
MU I
) O
glucuronidation O
was O
used O
as O
probe O
reactions O
. O

The O
results O
showed O
that O
100 O
mu O
M O
of O
isoliquiritigenin B
inhibited O
the O
activity O
of O
UGT1A1 O
, O
UGT1A3 O
, O
UGT1A6 O
, O
UGT1A7 O
, O
UGT1A8 O
, O
UGT1A9 O
, O
and O
UGT1A10 O
by O
95 O
. O
2 O
% O
, O
76 O
. O
1 O
% O
, O
78 O
. O
9 O
% O
, O
87 O
. O
2 O
% O
, O
67 O
. O
2 O
% O
, O
94 O
. O
8 O
% O
, O
and O
91 O
. O
7 O
% O
, O
respectively O
. O

The O
data O
fitting O
using O
Dixon O
plot O
and O
Lineweaver O
- O
Burk O
plot O
showed O
that O
the O
inhibition O
of O
UGT1A1 O
, O
UGT1A9 O
and O
UGT1A10 O
by O
isoliquiritigenin B
was O
all O
best O
fit O
to O
the O
competitive O
inhibition O
, O
and O
the O
second O
plot O
using O
the O
slopes O
from O
the O
Lineweaver O
- O
Burk O
plot O
versus O
isoliquiritigenin B
concentrations O
was O
used O
to O
calculate O
the O
inhibition O
kinetic O
parameter O
( O
K O
( O
i O
) O
) O
to O
be O
0 O
. O
7 O
mu O
M O
, O
0 O
. O
3 O
mu O
M O
, O
and O
18 O
. O
3 O
mu O
M O
for O

All O
these O
results O
indicated O
the O
risk O
of O
clinical O
application O
of O
isoliquiritigenin B
on O
the O
drug O
- O
drug O
interaction O
and O
other O
possible O
diseases O
induced O
by O
the O
inhibition O
of O
isoliquiritigenin B
towards O
these O
UGT O
isoforms O
. O

However O
, O
a O
third O
one O
was O
discovered O
by O
the O
crystal O
structure O
of O
a O
bifunctional O
enzyme O
4 B
- I
hydroxy I
- I
2 I
- I
ketovalerate I
aldolase O
/ O
acylating O
acetaldehyde O
dehydrogenase O
( O
DmpFG O
) O
from O
Pseudomonas O
sp O
. O
strain O
CF600 O
( O
Manjasetty O
et O
al O
. O
, O
Proc O
. O
Natl O
. O
Acad O
. O
Sci O
. O
USA O
100 O
( O
2003 O
) O
6992 O
- O
6997 O
) O
. O

In O
this O
study O
, O
we O
undertook O
the O
characterization O
of O
the O
catalytic O
and O
structural O
properties O
of O
MhpEF O
from O
Escherichia O
coli O
, O
an O
ortholog O
of O
DmpFG O
in O
which O
MhpF O
converts O
acetaldehyde O
, O
produced O
by O
the O
cleavage O
of O
4 B
- I
hydroxy I
- I
2 I
- I
ketovalerate I
by O
MhpE O
, O
into O
acetyl O
- O
CoA O
. O

Directional O
scrolling O
of O
SiGe B
/ O
Si O
/ O
Cr O
nanoribbon O
on O
Si O
( O
111 O
) O
surfaces O
controlled O
by O
two O
- O
fold O
rotational O
symmetry O
underetching O
. O

The O
controllable O
fabrication O
of O
self O
- O
scrolling O
SiGe B
/ O
Si O
/ O
Cr O
helical O
nanoribbons O
on O
Si O
( O
111 O
) O
substrates O
is O
investigated O
. O

The O
chirality O
of O
the O
SiGe B
/ O
Si O
/ O
Cr O
helices O
with O
isotropic O
Young O
' O
s O
moduli O
is O
governed O
by O
the O
anisotropic O
underetching O
in O
the O
initial O
stage O
, O
which O
can O
be O
precisely O
judged O
, O
as O
the O
orientation O
of O
the O
ribbon O
is O
predesigned O
. O

Modulation O
of O
multidrug O
resistance O
in O
cancer O
cells O
by O
chelidonine B
and O
Chelidonium O
majus O
alkaloids O
. O

This O
study O
demonstrates O
that O
chelidonine B
and O
an O
alkaloid O
extract O
from O
Chelidonium O
majus O
, O
which O
contains O
protoberberine B
and I
benzo I
[ I
c I
] I
phenanthridine I
alkaloids I
, O
has O
the O
ability O
to O
overcome O
MDR O
of O
different O
cancer O
cell O
lines O
through O
interaction O
with O
ABC O
- O
transporters O
, O
CYP3A4 O
and O
GST O
, O
by O
induction O
of O
apoptosis O
, O
and O
cytotoxic O
effects O
. O

Chelidonine B
and O
the O
alkaloid O
extract O
inhibited O
P O
- O
gp O
/ O
MDR1 O
activity O
in O
a O
concentration O
- O
dependent O
manner O
in O
Caco O
- O
2 O
and O
CEM O
/ O
ADR5000 O
and O
reversed O
their O
doxorubicin O
resistance O
. O

In O
addition O
, O
chelidonine B
and O
the O
alkaloid O
extract O
inhibited O
the O
activity O
of O
the O
drug O
modifying O
enzymes O
CYP3A4 O
and O
GST O
in O
a O
dose O
- O
dependent O
manner O
. O

The O
alkaloids O
induced O
apoptosis O
in O
MDR O
cells O
which O
was O
accompanied O
by O
an O
activation O
of O
caspase O
- O
3 O
, O
- O
8 O
, O
- O
6 O
/ O
9 O
, O
and O
phosphatidyl B
serine I
( O
PS O
) O
exposure O
. O

cDNA O
arrays O
were O
applied O
to O
identify O
differentially O
expressed O
genes O
after O
treatment O
with O
chelidonine B
and O
the O
alkaloid O
extract O
. O

Treatment O
of O
Caco O
- O
2 O
cells O
with O
50 O
mu O
g O
/ O
ml O
alkaloid O
extract O
and O
50 O
mu O
M O
chelidonine B
for O
up O
to O
48 O
h O
resulted O
in O
a O
significant O
decrease O
in O
mRNA O
levels O
of O
P O
- O
gp O
/ O
MDR1 O
, O
MRP1 O
, O
BCRP O
, O
CYP3A4 O
, O
GST O
, O
and O
hPXR O
and O
in O
a O
significant O
increase O
in O
caspase O
- O
3 O
and O
caspase O
- O
8 O
mRNA O
. O

Thus O
, O
chelidonine B
is O
a O
promising O
model O
compound O
for O
overcoming O
MDR O
and O
for O
enhancing O
cytotoxicity O
of O
chemotherapeutics O
, O
especially O
against O
leukaemia O
cells O
. O

Higher O
tolerance O
to O
As B
( I
3 I
+ I
) I
[ O
maximum O
tolerable O
concentration O
( O
MTC O
) O
: O
> O
= O
10 O
mM O
] O
, O
As O
( O
5 O
+ O
) O
( O
MTC O
: O
> O
= O
100 O
mM O
) O
and O
other O
heavy O
metals O
like O
Cu O
( O
2 O
+ O
) O
, O
Cr B
( I
2 I
+ I
) I
, O
Ni O
( O
2 O
+ O
) O
etc O
. O

Although O
no O
direct O
correlation O
among O
taxonomic O
identity O
of O
bacterial O
strains O
and O
their O
metabolic O
abilities O
as O
mentioned O
above O
was O
apparent O
, O
several O
isolates O
affiliated O
to O
genera O
Ochrobactrum O
, O
Achromobacter O
and O
unclassified O
Rhizobiaceae O
members O
were O
found O
to O
be O
highly O
resistant O
to O
As B
( I
3 I
+ I
) I
and O
As O
( O
5 O
+ O
) O
and O
positive O
for O
all O
the O
test O
properties O
. O

Based O
on O
the O
results O
we O
propose O
that O
under O
the O
prevailing O
low O
nutrient O
condition O
inhabitant O
bacteria O
capable O
of O
using O
inorganic O
electron O
donors O
play O
a O
synergistic O
role O
wherein O
siderophores O
and O
phosphatase O
activities O
facilitate O
the O
release O
of O
sediment O
bound O
As O
( O
5 O
+ O
) O
, O
which O
is O
subsequently O
reduced O
by O
arsenate O
reductase O
resulting O
into O
the O
mobilization O
of O
As B
( I
3 I
+ I
) I
in O
groundwater O
. O

Caught O
in O
the O
act O
: O
The O
FRET O
- O
Capture O
approach O
exploits O
a O
bound O
solvatochromic O
fluorophore O
, O
4 B
- I
N I
, I
N I
- I
dimethylamino I
- I
1 I
, I
8 I
- I
naphthalimide I
, O
as O
a O
FRET O
donor O
in O
both O
inter O
- O
and O
intramolecular O
energy O
transfer O
. O

3 B
, I
14 I
- I
Bis I
( I
p I
- I
nitrophenyl I
) I
- I
17 I
, I
17 I
- I
dipentyltetrabenzo I
[ I
a I
, I
c I
, I
g I
, I
i I
] I
- I
fluorene I
: O
a O
new O
fluorophore O
displaying O
both O
remarkable O
solvatochromism O
and O
crystalline O
- O
induced O
emission O
. O

A O
series O
of O
17 B
, I
17 I
- I
dialkyl I
- I
3 I
, I
14 I
- I
diaryltetrabenzofluo I
were O
efficiently O
prepared O
by O
using O
Suzuki O
- O
Miyaura O
cross O
- O
coupling O
reactions O
of O
the O
corresponding O
3 B
, I
14 I
- I
dibromo I
derivatives O
. O

In O
addition O
, O
the O
fluorescence O
wavelength O
of O
the O
bis B
( I
p I
- I
nitrophenyl I
) I
derivative O
is O
remarkably O
solvent O
- O
dependent O
in O
a O
manner O
that O
correlates O
with O
the O
solvent O
polarity O
parameter O
E O
( O
T O
) O
( O
30 O
) O
. O

Controlled O
Synthesis O
of O
Double O
- O
Wall O
a O
- O
FePO4 B
Nanotubes O
and O
their O
LIB O
Cathode O
Properties O
. O

Double O
- O
wall O
amorphous O
FePO4 B
nanotubes O
are O
prepared O
by O
an O
oil O
- O
phase O
chemical O
route O
. O

The O
double O
- O
wall O
FePO4 B
nanotubes O
show O
interesting O
cathode O
performance O
in O
Li O
ion O
batteries O
. O

Using O
a O
rapid O
, O
high O
- O
throughput O
polymerization O
and O
screening O
platform O
with O
a O
comprehensive O
library O
of O
66 O
monomer O
- O
grafted O
membrane O
surfaces O
, O
the O
optimal O
substrate O
, O
N B
- I
[ I
3 I
- I
( I
dimethylamino I
) I
propyl I
] I
methacrylamide I
( O
DMAPMA B
) O
has O
been O
identified O
to O
support O
strong O
attachment O
, O
high O
expansion O
capacity O
, O
and O
long O
- O
term O
self O
- O
renewal O
of O
ES O
cells O
( O
up O
to O
7 O
passages O
) O
. O

A O
multiscale O
investigation O
was O
carried O
out O
to O
study O
the O
dark O
and O
light O
- O
enhanced O
bactericidal O
mechanisms O
of O
poly B
( I
phenylene I
ethynylene I
) I
( O
PPE B
) O
- O
based O
cationic O
conjugated O
polyelectrolytes O
( O
CPEs O
) O
and O
oligo B
- I
phenylene I
ethynylenes I
( O
OPEs B
) O
. O

Measurements O
of O
dark O
membrane O
perturbation O
activity O
of O
the O
CPEs O
and O
OPEs B
using O
model O
lipid O
membranes O
support O
a O
carpet O
or O
detergent O
- O
like O
mechanism O
by O
which O
the O
antimicrobial O
compounds O
induce O
membrane O
collapse O
and O
phase O
transitions O
. O

Under O
UV O
- O
irradiation O
, O
E O
. O
coli O
bacteria O
exposed O
to O
CPEs O
and O
OPEs B
showed O
covalent O
modifications O
and O
damages O
to O
both O
cellular O
protein O
and O
plasmid O
DNA O
, O
likely O
through O
oxidative O
pathways O
mediated O
by O
singlet O
oxygen O
and O
subsequent O
reactive O
oxygen O
species O
sensitized O
by O
the O
CPE O
and O
OPE O
compounds O
. O

We O
study O
the O
growth O
and O
misfit O
stress O
relaxation O
mechanism O
by O
cutting O
through O
the O
center O
of O
the O
InGaAs B
/ O
GaAs O
nanopillars O
using O
focused O
ion O
beam O
and O
inspecting O
with O
high O
- O
resolution O
transmission O
electron O
microscopy O
. O

Furthermore O
, O
InGaAs B
was O
found O
to O
be O
in O
direct O
contact O
with O
silicon O
, O
in O
agreement O
with O
the O
observed O
crystal O
orientation O
alignment O
and O
good O
electrical O
conduction O
across O
the O
interface O
. O

This O
is O
in O
sharp O
contrast O
to O
many O
III O
- O
V O
nanowires O
on O
silicon O
which O
are O
observed O
to O
stem O
from O
thin O
SiN B
( I
x I
) I
, O
SiO O
( O
2 O
) O
, O
or O
SiO O
( O
2 O
) O
/ O
Si O
openings O
. O

In O
addition O
, O
GaAs O
was O
found O
to O
grow O
perfectly O
as O
a O
shell O
layer O
on O
In B
( I
0 I
. I
2 I
) I
Ga I
( I
0 I
. I
8 I
) I
As I
with O
an O
extraordinary O
thickness O
, O
which O
is O
15 O
times O
greater O
than O
the O
theoretical O
thin O
- O
film O
critical O
thickness O
for O
a O
1 O
. O
5 O
% O
lattice O
mismatch O
. O

A O
comparative O
study O
of O
the O
rotational O
dynamics O
of O
PF6 O
( O
- O
) O
anions O
in O
the O
crystals O
and O
liquid O
states O
of O
1 B
- I
butyl I
- I
3 I
- I
methylimidazolium I
hexafluorophosphate I
: O
results O
from O
31P O
NMR O
spectroscopy O
. O

The O
rotational O
dynamics O
of O
the O
hexafluorophosphate B
anion O
( O
PF B
( I
6 I
) I
( I
- I
) I
) O
in O
the O
crystalline O
and O
liquid O
states O
of O
the O
archetypal O
room O
temperature O
ionic O
liquid O
( O
RTIL O
) O
1 B
- I
butyl I
- I
3 I
- I
methylimidazolium I
hexafluorophosphate I
( O
[ B
C I
( I
4 I
) I
mim I
] I
PF I
( I
6 I
) I
) O
are O
investigated O
using O
( O
31 O
) O
P O
NMR O
spectroscopy O
line O
shape O
analyses O
and O
spin O
- O
lattice O
relaxation O
time O
measurements O
. O

The O
PF B
( I
6 I
) I
( I
- I
) I
anion O
performs O
isotropic O
rotation O
in O
all O
three O
polymorphic O
crystals O
phases O
alpha O
, O
beta O
, O
and O
gamma O
as O
well O
as O
in O
the O
liquid O
state O
with O
a O
characteristic O
time O
scale O
that O
ranges O
from O
a O
few O
ps O
to O
a O
few O
hundred O
ps O
over O
a O
temperature O
range O
of O
180 O
- O
280 O
K O
. O

The O
rotational O
correlation O
time O
tau O
( O
c O
) O
for O
PF B
( I
6 I
) I
( I
- I
) I
rotation O
follows O
the O
sequence O
gamma O
- O
phase O
< O
alpha O
- O
phase O
= O
~ O
liquid O
< O
beta O
- O
phase O
. O

On O
the O
other O
hand O
, O
in O
the O
liquid O
state O
, O
all O
local O
motions O
in O
the O
cation O
as O
well O
as O
its O
global O
rotational O
reorientation O
are O
characterized O
by O
time O
scales O
that O
are O
slower O
compared O
to O
that O
for O
the O
PF B
( I
6 I
) I
( I
- I
) I
anion O
rotation O
. O

The O
time O
scale O
tau O
( O
c O
) O
and O
the O
activation O
energy O
of O
PF B
( I
6 I
) I
( I
- I
) I
rotation O
in O
this O
RTIL O
are O
found O
to O
be O
comparable O
with O
those O
observed O
in O
ordinary O
alkali O
and O
ammonium B
salts I
despite O
the O
large O
counterion O
size O
and O
low O
melting O
point O
of O
the O
former O
. O

The O
high O
sphericity O
of O
the O
PF B
( I
6 I
) I
( I
- I
) I
ion O
is O
hypothesized O
to O
play O
an O
important O
role O
in O
the O
decoupling O
of O
its O
rotational O
dynamics O
that O
appear O
to O
be O
practically O
independent O
of O
the O
averaged O
cation O
- O
anion O
interaction O
. O

Large O
polystyrene O
particles O
stabilized O
by O
poly O
( O
acrylic O
acid O
) O
( O
PAA O
) O
( O
L O
- O
PS B
( I
PAA I
) I
) O
( O
as O
the O
core O
) O
and O
small O
polystyrene O
particles O
stabilized O
by O
poly B
( I
vinyl I
pyrrolidone I
) I
( O
PVP O
) O
( O
S O
- O
PS B
( I
PVP I
) I
) O
( O
as O
the O
corona O
) O
were O
successfully O
used O
to O
prepare O
raspberry O
- O
like O
particles O
by O
a O
heterocoagulation O
technique O
utilizing O
the O
hydrogen O
bonding O
interaction O
between O
PAA O
and O
PVP O
. O

The O
coverage O
of O
L O
- O
PS B
( I
PAA I
) I
by O
S O
- O
PS B
( I
PVP I
) I
could O
be O
controlled O
by O
adding O
PVP O
homopolymer O
to O
the O
L O
- O
PS B
( I
PAA I
) I
dispersion O
and O
by O
changing O
the O
molecular O
weight O
of O
the O
stabilizers O
. O

Moreover O
, O
the O
heterocoagulation O
of O
large O
poly O
( O
methyl O
methacrylate O
) O
particles O
stabilized O
by O
PAA O
( O
L O
- O
PMMA B
( I
PAA I
) I
) O
and O
S O
- O
PS B
( I
PVP I
) I
particles O
was O
also O
accomplished O
, O
resulting O
in O
the O
formation O
of O
L O
- O
PMMA B
( I
PAA I
) I
- O
core O
/ O
S O
- O
PS B
( I
PVP I
) I
- O
corona O
raspberry O
- O
like O
composite O
particles O
. O

Generation O
of O
B B
- I
doped I
graphene I
nanoplatelets O
using O
a O
solution O
process O
and O
their O
supercapacitor O
applications O
. O

This O
is O
the O
first O
report O
on O
the O
production O
of O
B B
- I
doped I
graphene I
nanoplatelets O
from O
a O
solution O
process O
and O
on O
the O
use O
of O
B B
- I
doped I
graphene I
materials O
in O
supercapacitors O
. O

A O
new O
gemini O
surfactant O
with O
a O
long O
and O
rigid O
spacer O
, O
O B
, I
O I
' I
- I
bis I
( I
sodium I
2 I
- I
dodecylcarboxylate I
) I
- I
p I
- I
dibenzenediol I
( O
referred O
to O
as O
C B
( I
12 I
) I
phi I
( I
2 I
) I
C I
( I
12 I
) I
) O
, O
has O
been O
synthesized O
. O

The O
homologue O
O B
, I
O I
' I
- I
bis I
( I
sodium I
2 I
- I
dodecylcarboxylate I
) I
- I
p I
- I
benzenediol I
( O
C B
( I
12 I
) I
phi I
C I
( I
12 I
) I
) O
whose O
spacer O
only O
contains O
a O
single O
phenyl O
group O
was O
also O
examined O
for O
comparison O
. O

Dynamic O
light O
scattering O
( O
DLS O
) O
revealed O
the O
unexpected O
existence O
of O
large O
aggregates O
in O
the O
solution O
of O
C B
( I
12 I
) I
phi I
( I
2 I
) I
C I
( I
12 I
) I
. O

However O
, O
C B
( I
12 I
) I
phi I
C I
( I
12 I
) I
showed O
rather O
normal O
aggregation O
behavior O
. O

Both O
the O
results O
of O
intrinsic O
viscosity O
and O
light O
scattering O
demonstrated O
a O
loose O
structure O
for O
the O
large O
aggregates O
of O
C B
( I
12 I
) I
phi I
( I
2 I
) I
C I
( I
12 I
) I
. O

This O
behavior O
was O
attributed O
to O
an O
extending O
configuration O
of O
C B
( I
12 I
) I
phi I
( I
2 I
) I
C I
( I
12 I
) I
with O
the O
two O
alkyl O
tails O
stretching O
toward O
the O
solution O
due O
to O
the O
rigidity O
of O
the O
long O
spacer O
. O

The O
cationic O
polymer O
nanobrush O
was O
synthesized O
on O
a O
gold O
substrate O
by O
AIBN B
photoinitiated O
polymerization O
, O
using O
a O
70 O
: O
30 O
ratio O
of O
2 B
- I
aminoethyl I
methacrylate I
hydrochloride I
( O
AEMA B
) O
: O
N O
- O
isopropylacrylamide O
( O
NIPAAM B
) O
. O

The O
brush O
- O
adsorbed O
biomolecules O
were O
recovered O
by O
treating O
the O
nanobrush O
with O
ammonium B
hydroxide I
, O
which O
effectively O
collapsed O
the O
brush O
, O
thereby O
releasing O
the O
trapped O
compounds O
for O
MALDI O
MS O
analysis O
. O

A O
dimeric O
form O
of O
N B
- I
methoxycarbonyl I
- I
2 I
- I
amino I
- I
1 I
, I
8 I
- I
naphthyridine I
bound O
to O
the O
A O
- O
A O
mismatch O
in O
the O
CAG O
/ O
CAG O
base O
triad O
in O
dsRNA O
. O

A O
dimeric O
form O
of O
N B
- I
methoxycarbonyl I
- I
2 I
- I
amino I
- I
1 I
, I
8 I
- I
naphthyridine I
( O
MCND B
) O
connected O
at O
the O
C2 O
position O
with O
a O
three O
- O
atom O
linker O
was O
examined O
for O
the O
binding O
to O
mismatches O
in O
double O
stranded O
RNA O
. O

Despite O
the O
fully O
complementary O
hydrogen O
bonding O
groups O
to O
guanine O
, O
MCND B
did O
not O
bind O
to O
guanine O
- O
guanine O
mismatch O
but O
did O
to O
adenine O
- O
adenine O
mismatch O
. O

The O
A O
- O
A O
mismatch O
in O
the O
GAC O
/ O
GAC O
sequence O
was O
a O
poor O
substrate O
for O
the O
MCND B
binding O
. O

A O
monomeric O
derivative O
of O
MCND B
and O
another O
derivative O
lacking O
a O
methylcarbamate B
group O
showed O
negligilble O
binding O
to O
the O
A O
- O
A O
mismatch O
and O
the O
sequence O
selectivity O
. O

Naphthyridinone B
( O
NTD B
) O
integrase O
inhibitors O
: O
N1 O
protio O
and O
methyl O
combination O
substituent O
effects O
with O
C3 O
amide O
groups O
. O

Substituent O
effects O
of O
a O
series O
of O
N1 O
protio O
and O
methyl B
naphthyridinone I
HIV O
- O
1 O
integrase O
strand O
- O
transfer O
inhibitors O
has O
been O
explored O
. O

The O
impact O
of O
substitution O
on O
ligand O
efficiency O
was O
considered O
and O
several O
compounds O
were O
advanced O
into O
in O
vivo O
pharmacokinetic O
studies O
ultimately O
leading O
to O
the O
clinical O
candidate O
GSK364735 B
. O

It O
is O
a O
commonly O
used O
chemotherapeutic O
agent O
binding O
mono O
- O
or O
bifunctionally O
to O
guanines B
in O
DNA O
. O

A O
thirteen O
week O
feeding O
study O
was O
conducted O
by O
feeding O
young O
adult O
male O
and O
female O
Sprague O
Dawley O
[ O
Crl O
: O
CD O
( O
R O
) O
( O
SD O
) O
] O
rats O
diets O
containing O
grain O
from O
genetically O
modified O
( O
GM O
) O
DP O
- O
O O
O O
4114 O
- O
3 O
maize O
that O
was O
either O
untreated O
( O
4114 O
) O
or O
treated O
in O
the O
field O
with O
glufosinate B
ammonium I
( O
4114GLU O
) O
. O

Non O
- O
ionic O
Gd O
- O
based O
MRI O
contrast O
agents O
are O
optimal O
for O
encapsulation O
into O
phosphatidyldiglycer B
- O
based O
thermosensitive O
liposomes O
. O

Here O
the O
feasibility O
of O
6 O
clinically O
approved O
CAs O
( O
Gd B
- I
DTPA I
, O
Gd B
- I
BOPTA I
, O
Gd B
- I
DOTA I
, O
Gd B
- I
BT I
- I
DO3A I
, O
Gd B
- I
DTPA I
- I
BMA I
, O
and O
Gd B
- I
HP I
- I
DO3A I
) O
for O
formulation O
into O
TSL O
was O
investigated O
. O

CAs O
were O
passively O
encapsulated O
with O
323 O
mOs O
kg O
( O
- O
1 O
) O
into O
1 O
, O
2 O
- O
dipalmitoyl O
- O
sn O
- O
glycero O
- O
3 O
- O
phosphocholine O
/ O
1 B
, I
2 I
- I
distearoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
/ O
1 B
, I
2 I
- I
dipalmitoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphodiglycerol I
50 O
/ O
20 O
/ O
30 O
( O
mol O
/ O
mol O
) O
TSL O
( O
DPPG B
( I
2 I
) I
- O
TSL O
) O

Wogonin B
inhibits O
H2O2 O
- O
induced O
vascular O
permeability O
through O
suppressing O
the O
phosphorylation O
of O
caveolin O
- O
1 O
. O

Wogonin B
, O
a O
naturally O
occurring O
monoflavonoid B
extracted O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Georgi O
, O
has O
been O
reported O
for O
its O
anti O
- O
oxidant O
activity O
. O

However O
, O
it O
is O
still O
unclear O
whether O
wogonin B
can O
inhibit O
oxidant O
- O
induced O
vascular O
permeability O
. O

In O
this O
study O
, O
we O
evaluated O
the O
effects O
of O
wogonin B
on O
H2O2 O
- O
induced O
vascular O
permeability O
in O
human O
umbilical O
vein O
endothelial O
cells O
( O
HUVECs O
) O
. O

We O
found O
that O
wogonin B
can O
suppress O
the O
H2O2 O
- O
stimulated O
actin O
remodeling O
and O
albumin O
uptake O
of O
HUVECs O
, O
as O
well O
as O
transendothelial O
cell O
migration O
of O
the O
human O
breast O
carcinoma O
cell O
MDA O
- O
MB O
- O
231 O
. O

The O
mechanism O
revealed O
that O
wogonin B
inhibited O
H2O2 O
- O
induced O
phosphorylation O
of O
caveolin O
- O
1 O
( O
cav O
- O
1 O
) O
associating O
with O
the O
suppression O
of O
stabilization O
of O
VE O
- O
cadherin O
and O
beta O
- O
catenin O
. O

Moreover O
, O
wogonin B
repressed O
anisomycin O
- O
induced O
phosphorylation O
of O
p38 O
, O
cav O
- O
1 O
and O
vascular O
permeability O
. O

These O
results O
suggested O
that O
wogonin B
could O
inhibit O
H2O2 O
- O
induced O
vascular O
permeability O
by O
downregulating O
the O
phosphorylation O
of O
cav O
- O
1 O
, O
and O
that O
it O
might O
have O
a O
therapeutic O
potential O
for O
the O
diseases O
associated O
with O
the O
development O
of O
both O
oxidant O
and O
vascular O
permeability O
. O

While O
studying O
possible O
mechanisms O
involved O
in O
this O
inhibition O
, O
we O
observed O
that O
pre O
- O
treatment O
with O
dexamethasone O
, O
zileuton O
or O
Boc2 B
( O
a O
selective O
antagonist O
of O
formyl B
peptide O
receptors O
) O
, O
but O
not O
with O
indomethacin O
, O
canceled O
out O
the O
inhibitory O
effect O
of O
Cdt O
venom O
on O
the O
edema O
induced O
by O
BCG O
. O

Evaluation O
of O
genotoxicity O
in O
leukocytes O
and O
testis O
following O
intra O
- O
vasal O
contraception O
with O
RISUG O
and O
its O
reversal O
by O
DMSO O
and O
NaHCO3 B
in O
Wistar O
albino O
rats O
. O

Animals O
were O
allotted O
into O
groups O
of O
sham O
operated O
control O
, O
vas O
occlusion O
with O
RISUG O
( O
5 O
- O
7 O
mu O
l O
) O
for O
360 O
days O
and O
reversal O
by O
DMSO O
( O
250 O
- O
500 O
mu O
l O
) O
and O
5 O
% O
NaHCO3 B
( O
500 O
mu O
l O
) O
. O

Influence O
of O
developmental O
lead O
exposure O
on O
expression O
of O
DNA O
methyltransferases O
and O
methyl B
cytosine I
- O
binding O
proteins O
in O
hippocampus O
. O

Since O
DNA O
methylation O
is O
regulated O
by O
DNA O
methyltransferases O
and O
methyl B
cytosine I
- O
binding O
proteins O
, O
this O
study O
assessed O
the O
extent O
to O
which O
developmental O
Pb O
exposure O
might O
affect O
expression O
of O
these O
proteins O
in O
the O
hippocampus O
. O

Long O
Evans O
dams O
were O
fed O
chow O
with O
or O
without O
added O
Pb B
acetate I
( O
0 O
, O
150 O
, O
375 O
, O
750 O
ppm O
) O
prior O
to O
breeding O
and O
remained O
on O
the O
same O
diet O
through O
weaning O
( O
perinatal O
exposure O
group O
) O
. O

New O
formulation O
approaches O
to O
improve O
solubility O
and O
drug O
release O
from O
fixed O
dose O
combinations O
: O
Case O
examples O
pioglitazone O
/ O
glimepiride B
and O
ezetimibe B
/ O
simvastatin O
. O

The O
first O
FDC O
contained O
a O
weak O
acid O
( O
glimepiride B
) O
and O
a O
weak O
base O
( O
pioglitazone O
) O
, O
while O
the O
second O
FDC O
contained O
two O
compounds O
( O
simvastatin O
and O
ezetimibe B
) O
that O
are O
essentially O
non O
- O
ionised O
over O
the O
physiological O
pH O
range O
. O

The O
in O
vitro O
performance O
of O
the O
different O
formulation O
approaches O
, O
as O
gauged O
by O
solubility O
and O
dissolution O
experiments O
, O
was O
compared O
with O
that O
of O
the O
marketed O
products O
containing O
the O
respective O
fixed O
dose O
combinations O
, O
Tandemact B
( O
R O
) O
30mg O
/ O
4mg O
tablets O
and O
Inegy B
( O
R O
) O
10mg O
/ O
40mg O
tablets O
. O

For O
example O
, O
in O
pH O
conditions O
of O
the O
fasted O
small O
intestine O
after O
a O
test O
duration O
of O
240min O
, O
we O
observed O
100 O
% O
dissolution O
of O
both O
drugs O
from O
the O
ternary O
pioglitazone O
/ O
glimepiride B
( O
30mg O
/ O
4mg O
) O
complex O
formulation O
, O
whereas O
from O
the O
marketed O
formulation O
less O
than O
5 O
% O
pioglitazone O
, O
and O
only O
25 O
% O
glimepiride B
dissolved O
. O

Using O
the O
same O
conditions O
, O
60 O
% O
ezetimibe B
and O
85 O
% O
simvastatin O
dissolved O
from O
the O
ternary O
ezetimibe B
/ O
simvastatin O
( O
10mg O
/ O
40mg O
) O
complex O
formulation O
, O
whereas O
with O
less O
than O
5 O
% O
ezetimibe B
and O
10 O
% O
simvastatin O
dissolved O
after O
240min O
, O
the O
marketed O
FDC O
formulation O
showed O
poor O
dissolution O
. O

We O
investigated O
the O
relationship O
between O
muscular O
bioaccumulation O
levels O
of O
metals O
( O
Hg O
, O
Cd O
, O
Pb O
, O
Cu O
, O
Zn O
, O
Ni O
, O
Cr O
, O
As O
and O
Se O
) O
, O
PCBs O
and O
organochlorine O
pesticides O
( O
DDTs B
) O
, O
the O
health O
status O
( O
condition O
factor O
and O
lipid O
reserves O
) O
and O
the O
associated O
transcriptional O
response O
in O
liver O
and O
gill O
tissues O
for O
genes O
involved O
in O
metal O
detoxification O
( O
metallothionein O
, O
MT O
) O
and O
oxidative O
metabolism O
( O
cytochrome O
P4501A O
, O
CYP1A O
) O
of O
xenobiotic O
compounds O
. O

A O
comparative O
VCD O
study O
of O
methyl B
mandelate I
in O
methanol O
, O
dimethyl O
sulfoxide O
, O
and O
chloroform O
: O
explicit O
and O
implicit O
solvation O
models O
. O

Vibrational O
absorption O
( O
VA O
) O
and O
vibrational O
circular O
dichroism O
( O
VCD O
) O
spectra O
of O
methyl B
mandelate I
, O
a O
prototype O
chiral O
molecule O
, O
in O
a O
series O
of O
organic O
solvents O
, O
namely O
methanol O
( O
MeOH B
- I
d I
( I
4 I
) I
) O
, O
dimethyl O
sulfoxide O
( O
DMSO O
- O
d O
( O
6 O
) O
) O
, O
and O
chloroform O
( O
CDCl B
( I
3 I
) I
) O
, O
have O
been O
measured O
in O
the O
finger O
print O
region O
from O
1800 O
to O
1150 O
cm O
( O
- O
1 O
) O
. O

Initial O
geometry O
searches O
have O
been O
carried O
out O
at O
the O
B3LYP O
/ O
6 O
- O
31G O
( O
d O
) O
level O
for O
the O
methyl B
mandelate I
monomer O
and O
its O
explicit O
1 O
: O
1 O
and O
1 O
: O
2 O
solute O
- O
solvent O
hydrogen O
- O
bonded O
complexes O
. O

ORD O
spectra O
of O
methyl B
mandelate I
in O
the O
aforementioned O
solvents O
at O
different O
concentrations O
under O
5 O
excitation O
wavelengths O
have O
also O
been O
measured O
. O

Association O
of O
Shiga O
toxin O
glycosphingolipid B
receptors O
with O
membrane O
microdomains O
of O
toxin O
- O
sensitive O
lymphoid O
and O
myeloid O
cells O
. O

Glycosphingolipids B
( O
GSLs O
) O
of O
the O
globo O
- O
series O
constitute O
specific O
receptors O
for O
Shiga O
toxins O
( O
Stxs O
) O
released O
by O
certain O
types O
of O
pathogenic O
Escherichia O
coli O
strains O
. O

Enhancement O
of O
the O
water O
solubility O
of O
flavone B
glycosides I
by O
disruption O
of O
molecular O
planarity O
of O
the O
aglycone O
moiety O
. O

We O
applied O
this O
strategy O
to O
some O
natural O
flavone B
glycosides I
, O
especially O
diosmin B
, O
a O
highly O
insoluble O
citroflavonoid B
prescribed O
as O
an O
oral O
phlebotropic O
drug O
. O

Disruption O
of O
planarity O
at O
the O
aglycone O
moiety O
by O
3 O
- O
bromination O
or O
chlorination O
afforded O
3 B
- I
bromo I
- I
and I
3 I
- I
chlorodiosmin I
, O
displaying O
a O
dramatic O
solubility O
increase O
compared O
with O
the O
parent O
compound O
. O

Interplay O
between O
structure O
and O
relaxations O
in O
perfluorosulfonic B
acid I
proton O
conducting O
membranes O
. O

The O
spectral O
changes O
evident O
in O
the O
vibrational O
spectra O
of O
the O
3M O
membranes O
can O
be O
associated O
with O
two O
major O
phenomena O
: O
( O
1 O
) O
dissociation O
of O
the O
proton O
from O
the O
sulfonic O
acid O
groups O
even O
in O
the O
presence O
of O
small O
amounts O
of O
water O
; O
and O
( O
2 O
) O
changes O
in O
the O
conformation O
or O
the O
degree O
of O
crystallinity O
of O
the O
poly B
( I
tetrafluoroethylene I
) I
hydrophobic O
domains O
both O
as O
a O
function O
of O
EW O
and O
membrane O
water O
content O
. O

Here O
, O
for O
the O
first O
time O
, O
we O
show O
that O
with O
addition O
of O
a O
biological O
buffer O
, O
4 B
- I
( I
2 I
- I
hydroxyethyl I
) I
piperazine I
- I
1 I
- I
ethanesulfonic I
acid I
( O
HEPES B
) O
, O
into O
aqueous O
solutions O
of O
tetrahydrofuran O
( O
THF O
) O
, O
1 B
, I
3 I
- I
dioxolane I
, I
1 I
, I
4 I
- I
dioxane I
, I
1 I
- I
propanol I
, O
2 O
- O
propanol O
, O
tert B
- I
butanol I
, O
acetonitrile O
, O
or O
acetone O
, O
the O
organic O
solvent O
can O
be O
excluded O
from O
water O
to O
form O
a O
new O
liquid O
phase O
. O

In O
order O
to O
understand O
why O
and O
how O
a O
zwitterion O
solute O
( O
HEPES B
) O
induced O
phase O
separation O
of O
the O
investigated O
systems O
, O
molecular O
dynamics O
( O
MD O
) O
simulation O
studies O
are O
performed O
for O
HEPES B
+ O
water O
+ O
THF O
system O
. O

The O
reliability O
of O
the O
simulation O
results O
of O
HEPES B
in O
pure O
water O
and O
beyond O
the O
phase O
separation O
mixtures O
was O
justified O
by O
comparing O
the O
densities O
obtained O
from O
MD O
with O
the O
experimental O
values O
. O

The O
simulation O
results O
of O
HEPES B
in O
pure O
THF O
and O
in O
a O
composition O
inside O
the O
phase O
separation O
region O
were O
justified O
qualitatively O
. O

Interestingly O
, O
all O
HEPES B
molecules O
entirely O
aggregated O
in O
pure O
THF O
. O

This O
reveals O
that O
HEPES B
is O
insoluble O
in O
pure O
THF O
, O
which O
is O
consistent O
with O
the O
experimental O
results O
. O

Mechanisms O
limiting O
distribution O
of O
the O
threonine O
- O
protein O
kinase O
B O
- O
RaF O
( O
V600E O
) O
inhibitor O
dabrafenib B
to O
the O
brain O
: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases O
. O

Clinical O
trials O
with O
dabrafenib B
have O
shown O
encouraging O
results O
; O
however O
, O
the O
central O
nervous O
system O
distribution O
of O
dabrafenib B
remains O
unknown O
. O

Thus O
, O
the O
objective O
of O
the O
current O
study O
was O
to O
evaluate O
the O
brain O
distribution O
of O
dabrafenib B
in O
mice O
, O
and O
to O
see O
whether O
active O
efflux O
by O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
and O
breast O
cancer O
resistance O
protein O
( O
BCRP O
) O
restricts O
its O
delivery O
across O
the O
blood O
- O
brain O
barrier O
( O
BBB O
) O
. O

In O
vitro O
accumulation O
studies O
conducted O
in O
Madin O
- O
Darby O
canine O
kidney O
II O
cells O
indicate O
that O
dabrafenib B
is O
an O
avid O
substrate O
for O
both O
P O
- O
gp O
and O
BCRP O
. O

In O
vivo O
, O
the O
ratio O
of O
area O
under O
the O
concentration O
- O
time O
curve O
( O
AUC O
) O
( O
brain O
) O
to O
AUC O
( O
plasma O
) O
( O
K O
( O
p O
) O
) O
of O
dabrafenib B
after O
an O
i O
. O
v O
. O
dose O
( O
2 O
. O
5 O
mg O
/ O
kg O
) O
was O
0 O
. O
023 O
, O
which O
increased O
by O
18 O
- O
fold O
in O
Mdr1 O
a O
/ O
b O
( O
- O
/ O
- O
) O
Bcrp1 O
( O
- O
/ O
- O
) O
mice O
to O
0 O
. O
42 O
. O

Dabrafenib B
plasma O
exposure O
was O
~ O
2 O
- O
fold O
greater O
in O
Mdr1 O
a O
/ O
b O
( O
- O
/ O
- O
) O
Bcrp1 O
( O
- O
/ O
- O
) O
mice O
as O
compared O
with O
wild O
- O
type O
with O
an O
oral O
dose O
( O
25 O
mg O
/ O
kg O
) O
; O
however O
, O
the O
brain O
distribution O
was O
increased O
by O
~ O
10 O
- O
fold O
with O
a O
resulting O
K O
( O
p O
) O
of O
0 O
. O
25 O
. O

Further O
, O
compared O
with O
vemurafenib O
, O
another O
BRAF O
( O
V600E O
) O
inhibitor O
, O
dabrafenib B
showed O
greater O
brain O
penetration O
with O
a O
similar O
dose O
. O

In O
conclusion O
, O
the O
dabrafenib B
brain O
distribution O
is O
limited O
in O
an O
intact O
BBB O
model O
, O
and O
the O
data O
presented O
herein O
may O
have O
clinical O
implications O
in O
the O
prevention O
and O
treatment O
of O
melanoma O
brain O
metastases O
. O

We O
begin O
by O
capturing O
RISC O
using O
a O
complementary O
2 B
' I
- I
O I
- I
methyl I
oligonucleotide O
tethered O
to O
beads O
. O

Percutaneous O
transdermal O
absorption O
of O
esculetin O
( O
6 B
, I
7 I
- I
dihydroxycoumarin I
) O
, O
an O
oxidative O
damage O
inhibitor O
, O
was O
evaluated O
by O
means O
of O
in O
vitro O
permeation O
studies O
in O
which O
vertical O
Franz O
- O
type O
diffusion O
cells O
and O
pig O
ear O
skin O
were O
employed O
. O

Pretreatment O
of O
porcine O
skin O
was O
performed O
with O
ethanol O
( O
control O
vehicle O
) O
, O
decenoic B
acid I
, O
oleic O
acid O
, O
R B
- I
( I
+ I
) I
- I
limonene I
, O
and O
laurocapram B
( O
Azone B
( O
R O
) O
) O
( O
5 O
% O
in O
ethanol O
, O
w O
/ O
w O
, O
respectively O
) O
. O

Pretreatment O
of O
skin O
with O
oleic O
acid O
or O
laurocapram B
led O
to O
statistically O
significant O
differences O
in O
the O
transdermal O
flux O
of O
esculetin O
with O
respect O
to O
controls O
. O

Of O
the O
two O
enhancers O
, O
laurocapram B
showed O
the O
greatest O
capacity O
to O
enhance O
the O
flux O
of O
esculetin O
across O
pig O
skin O
. O

Design O
and O
exploration O
of O
novel O
boronic B
acid I
inhibitors O
reveals O
important O
interactions O
with O
a O
clavulanic B
acid I
- O
resistant O
sulfhydryl O
- O
variable O
( O
SHV O
) O
beta O
- O
lactamase O
. O

The O
K234R O
substitution O
in O
the O
SHV O
beta O
- O
lactamase O
, O
from O
Klebsiella O
pneumoniae O
, O
results O
in O
resistance O
to O
ampicillin O
/ O
clavulanate B
. O

After O
site O
- O
saturation O
mutagenesis O
of O
Lys O
- O
234 O
in O
SHV O
, O
microbiological O
and O
biochemical O
characterization O
of O
the O
resulting O
beta O
- O
lactamases O
revealed O
that O
only O
- O
Arg B
conferred O
resistance O
to O
ampicillin O
/ O
clavulanate B
. O

X O
- O
ray O
crystallography O
revealed O
two O
conformations O
of O
Arg B
- O
234 O
and O
Ser O
- O
130 O
in O
SHV O
K234R O
. O

The O
movement O
of O
Ser O
- O
130 O
is O
the O
principal O
cause O
of O
the O
observed O
clavulanate B
resistance O
. O

A O
panel O
of O
boronic B
acid I
inhibitors O
was O
designed O
and O
tested O
against O
SHV O
- O
1 O
and O
SHV O
K234R O
. O

An O
integral O
asymmetric O
membrane O
was O
fabricated O
in O
a O
fast O
and O
one O
- O
step O
process O
by O
combining O
the O
self O
- O
assembly O
of O
an O
amphiphilic O
block O
copolymer O
( O
PS B
- I
b I
- I
P4VP I
) O
with O
nonsolvent O
- O
induced O
phase O
separation O
. O

Superconductivity O
in O
the O
cuprate O
YBa B
( I
2 I
) I
Cu I
( I
3 I
) I
O I
( I
7 I
) I
( O
YBCO B
) O
persists O
up O
to O
huge O
magnetic O
fields O
( O
B O
) O
up O
to O
several O
tens O
of O
Teslas O
, O
and O
sensitive O
direct O
current O
( O
dc O
) O
superconducting O
quantum O
interference O
devices O
( O
SQUIDs O
) O
can O
be O
realized O
in O
epitaxially O
grown O
YBCO B
films O
by O
using O
grain O
boundary O
Josephson O
junctions O
( O
GBJs O
) O
. O

Here O
we O
present O
the O
realization O
of O
high O
- O
quality O
YBCO B
nanoSQUIDs O
, O
patterned O
by O
focused O
ion O
beam O
milling O
. O

Role O
of O
pharmacogenetics O
in O
busulfan B
/ O
cyclophosphamide O
conditioning O
therapy O
prior O
to O
hematopoietic O
stem O
cell O
transplantation O
. O

Busulfan B
( O
Bu O
) O
and O
cyclophosphamide O
( O
Cy O
) O
are O
the O
most O
commonly O
used O
alkylators O
in O
high O
- O
dose O
pretransplant O
conditioning O
for O
HSCT O
; O
a O
treatment O
that O
is O
correlated O
with O
drug O
- O
related O
toxicity O
and O
relapse O
. O

Moreover O
, O
glutathione O
- O
S O
- O
transferase O
isoenzymes O
have O
been O
associated O
with O
cellular O
outward O
transport O
of O
various O
alkylating O
agents O
, O
including O
Cy O
metabolites O
, O
melphalan B
, O
Bu O
and O
chlorambucil B
. O

Carbon O
monoxide O
- O
releasing O
molecules O
( O
CO O
- O
RMs O
) O
are O
a O
class O
of O
organometallo B
carbonyl I
complexes O
capable O
of O
delivering O
controlled O
quantities O
of O
CO O
gas O
to O
cells O
and O
tissues O
thus O
exerting O
a O
broad O
spectrum O
of O
pharmacological O
effects O
. O

Here O
we O
report O
on O
the O
chemical O
synthesis O
, O
CO O
releasing O
properties O
, O
cytotoxicity O
profile O
and O
pharmacological O
activities O
of O
four O
novel O
structurally O
related O
iron B
- I
allyl I
carbonyls I
. O

The O
major O
difference O
among O
the O
new O
CO O
- O
RMs O
tested O
was O
that O
three O
compounds O
( O
CORM B
- I
307 I
, O
CORM B
- I
308 I
and O
CORM B
- I
314 I
) O
were O
soluble O
in O
dimethylsulfoxide O
( O
DMSO O
) O
, O
whereas O
a O
fourth O
one O
( O
CORM B
- I
319 I
) O
was O
rendered O
water O
- O
soluble O
by O
reacting O
the O
iron B
- I
carbonyl I
with O
hydrogen B
tetrafluoroborate I
. O

More O
specifically O
, O
iron B
carbonyls I
soluble O
in O
DMSO O
released O
CO O
with O
a O
fast O
kinetic O
and O
displayed O
a O
marked O
cytotoxic O
effect O
in O
smooth O
muscle O
cells O
and O
RAW O
247 O
. O
6 O
macrophages O
despite O
exerting O
a O
rapid O
and O
pronounced O
vasorelaxation O
ex O
vivo O
. O

In O
contrast O
, O
CORM B
- I
319 I
that O
is O
soluble O
in O
water O
and O
liberated O
CO O
with O
a O
slower O
rate O
, O
preserved O
smooth O
muscle O
cell O
viability O
, O
relaxed O
aortic O
tissue O
and O
exerted O
a O
significant O
anti O
- O
inflammatory O
effect O
in O
macrophages O
challenged O
with O
endotoxin O
. O

These O
data O
suggest O
that O
iron B
carbonyls I
can O
be O
used O
as O
scaffolds O
for O
the O
design O
and O
synthesis O
of O
pharmacologically O
active O
CO O
- O
RMs O
and O
indicate O
that O
increasing O
water O
solubility O
and O
controlling O
the O
rate O
of O
CO O
release O
are O
important O
parameters O
for O
limiting O
their O
potential O
toxic O
effects O
. O

The O
use O
of O
a O
tissue O
- O
selective O
estrogen O
complex O
( O
TSEC O
) O
has O
been O
proposed O
as O
a O
novel O
menopausal O
hormone O
therapy O
strategy O
to O
eliminate O
the O
requirement O
for O
a O
progestogen B
. O

Combination O
of O
bazedoxifene O
( O
BZA B
) O
with O
conjugated O
estrogens O
( O
CEs O
) O
, O
the O
first O
TSEC O
, O
has O
shown O
beneficial O
effects O
. O

Both O
CE O
and O
E O
( O
2 O
) O
alone O
increased O
DNA O
synthesis O
and O
reduced O
apoptosis O
with O
activation O
of O
MAPK O
, O
Akt O
, O
and O
p70S6K O
and O
up O
- O
regulation O
of O
antiapoptotic O
factors O
survivin O
, O
Bcl O
- O
2 O
, O
and O
X O
- O
linked O
inhibitor O
of O
apoptosis O
protein O
, O
These O
effects O
could O
be O
completely O
blocked O
by O
BZA B
. O

BZA B
effectively O
blocked O
each O
of O
these O
effects O
and O
showed O
no O
estrogen O
agonistic O
effects O
when O
used O
alone O
. O

Our O
results O
indicate O
that O
the O
stimulatory O
effects O
of O
E O
( O
2 O
) O
or O
CE O
on O
breast O
cancer O
cells O
could O
be O
completely O
abrogated O
by O
BZA B
. O

These O
studies O
imply O
that O
the O
CE O
/ O
BZA B
, O
TSEC O
, O
exerts O
antiestrogenic O
effects O
on O
breast O
cancer O
cells O
and O
might O
block O
the O
growth O
of O
occult O
breast O
neoplasms O
in O
postmenopausal O
women O
, O
resulting O
in O
an O
overall O
reduction O
in O
tumor O
incidence O
. O

Synthesis O
and O
characterization O
of O
self O
- O
bridged O
silver B
vanadium I
oxide I
/ O
CNTs O
composite O
and O
its O
enhanced O
lithium O
storage O
performance O
. O

We O
designed O
a O
function O
- O
oriented O
hybrid O
material O
consisting O
of O
silver B
vanadium I
oxide I
( O
beta O
- O
AgVO B
( I
3 I
) I
) O
nanowires O
modified O
with O
uniform O
Ag O
nanoparticles O
and O
multi O
- O
walled O
carbon O
nanotubes O
( O
CNTs O
) O
as O
a O
high O
- O
performance O
cathode O
material O
for O
LIBs O
. O

The O
Ag O
nanoparticles O
which O
precipitated O
automatically O
in O
the O
synthetic O
process O
act O
as O
a O
bridge O
between O
the O
beta O
- O
AgVO B
( I
3 I
) I
nanowires O
and O
CNTs O
, O
creating O
a O
self O
- O
bridged O
network O
structure O
. O

The O
Ag O
particles O
at O
the O
junction O
of O
the O
nanowires O
and O
CNTs O
facilitate O
electron O
transport O
from O
the O
CNTs O
to O
the O
nanowires O
, O
and O
thereby O
improve O
the O
electrical O
conductivity O
of O
the O
beta O
- O
AgVO B
( I
3 I
) I
nanowires O
and O
the O
composite O
. O

The O
improved O
performance O
of O
the O
composite O
arises O
from O
its O
unique O
nanosized O
beta O
- O
AgVO B
( I
3 I
) I
nanowires O
with O
short O
diffusion O
pathway O
for O
lithium O
ions O
, O
efficient O
electron O
collection O
and O
transfer O
in O
the O
presence O
of O
Ag O
nanoparticles O
, O
together O
with O
excellent O
electrical O
conductivity O
of O
CNTs O
. O

The O
photophysics O
of O
7 B
- I
( I
N I
, I
N I
' I
- I
diethylamino I
) I
coumarin I
- I
3 I
- I
carboxylic I
acid I
in O
water O
/ O
AOT O
/ O
isooctane O
reverse O
micelles O
: O
an O
excitation O
wavelength O
dependent O
study O
. O

In O
this O
manuscript O
we O
have O
studied O
the O
photophysics O
of O
7 B
- I
( I
N I
, I
N I
' I
- I
diethylamino I
) I
coumarin I
- I
3 I
- I
carboxylic I
acid I
( O
7 B
- I
DCCA I
) O
in O
water O
/ O
AOT O
/ O
isooctane O
reverse O
micelles O
. O

We O
have O
studied O
the O
spectral O
behaviour O
of O
7 B
- I
DCCA I
inside O
the O
water O
/ O
AOT O
/ O
isooctane O
reverse O
micelles O
with O
variation O
of O
excitation O
wavelength O
. O

We O
have O
observed O
the O
excitation O
wavelength O
dependent O
dynamics O
of O
7 B
- I
DCCA I
in O
the O
reverse O
micelles O
. O

The O
fluorescence O
quantum O
yield O
, O
decay O
time O
, O
solvent O
relaxation O
time O
and O
rotational O
relaxation O
time O
of O
7 B
- I
DCCA I
in O
reverse O
micelles O
vary O
with O
the O
excitation O
wavelength O
. O

A O
two O
step O
and O
wobbling O
- O
in O
- O
cone O
model O
was O
used O
to O
interpret O
the O
rotational O
relaxation O
dynamics O
of O
7 B
- I
DCCA I
in O
reverse O
micelles O
. O

Effect O
of O
guanidinylation O
on O
the O
properties O
of O
poly B
( I
2 I
- I
aminoethylmethacryla I
) I
- O
based O
antibacterial O
materials O
. O

The O
effect O
of O
converting O
ammonium B
into O
guanidine O
moieties O
, O
compared O
to O
other O
factors O
such O
as O
molecular O
weight O
or O
hydrophobicity O
, O
on O
the O
antibacterial O
activity O
is O
investigated O
for O
homo O
- O
and O
copolymers O
of O
2 B
- I
aminoethylmethacryla I
in O
solution O
or O
coatings O
. O

Optical O
activity O
of O
achiral O
ligand O
SCH3 B
adsorbed O
on O
achiral O
Ag55 B
clusters O
: O
relationship O
between O
adsorption O
site O
and O
circular O
dichroism O
. O

The O
electronic O
circular O
dichroism O
( O
CD O
) O
spectra O
of O
a O
methyl B
- I
thiol I
adsorbed O
at O
different O
sites O
on O
an O
icosahedral O
silver O
nanoparticle O
is O
studied O
by O
using O
time O
- O
perturbed O
density O
functional O
theory O
. O

Despite O
that O
separately O
molecule O
and O
nanoparticle O
are O
achiral O
and O
consequently O
optically O
inactive O
, O
the O
Ag B
( I
55 I
) I
- I
SCH I
( I
3 I
) I
compound O
emerges O
with O
a O
new O
symmetry O
, O
which O
may O
be O
chiral O
or O
not O
depending O
on O
the O
adsorption O
site O
and O
orientation O
of O
the O
molecule O
. O

Chiral O
compounds O
have O
characteristic O
CD O
spectra O
in O
the O
UV O
- O
visible O
region O
, O
where O
Ag B
( I
55 I
) I
shows O
optical O
absorption O
but O
SCH B
( I
3 I
) I
does O
not O
; O
revealing O
that O
highly O
degenerated O
molecular O
- O
like O
electronic O
states O
of O
Ag B
( I
55 I
) I
are O
modified O
by O
the O
presence O
of O
the O
molecule O
inducing O
optical O
activity O
. O

For O
instance O
, O
crystals O
grown O
at O
the O
interface O
of O
a O
0 O
. O
01 O
% O
diglycerol B
monolaurate I
( O
C B
( I
12 I
) I
G I
( I
2 I
) I
) O
nonionic O
surfactant O
in O
butanol O
with O
benzene O
lead O
to O
the O
formation O
of O
flower O
- O
shaped O
microcrystals O
of O
average O
sizes O
in O
the O
range O
of O
10 O
- O
35 O
mu O
m O
. O

Mixtures O
of O
flower O
- O
shaped O
C O
( O
60 O
) O
crystals O
and O
free O
- O
standing O
C O
( O
60 O
) O
nanotubes O
are O
found O
in O
the O
0 O
. O
1 O
% O
C B
( I
12 I
) I
G I
( I
2 I
) I
/ O
butanol O
system O
. O

However O
, O
clusters O
or O
giant O
aggregates O
of O
nanowhiskers O
lacking O
any O
specific O
shape O
are O
observed O
in O
the O
1 O
% O
C B
( I
12 I
) I
G I
( I
2 I
) I
/ O
butanol O
system O
although O
these O
crystals O
exhibit O
hexagonal O
close O
- O
packed O
structures O
. O

Flower O
- O
shaped O
C O
( O
60 O
) O
microcrystals O
are O
also O
observed O
with O
anionic O
surfactants O
cetyltrimethylammoni B
bromide I
( O
CTAB O
) O
and O
cetyltrimethylammoni B
chloride I
( O
CTAC B
) O
. O

C O
( O
60 O
) O
flowers O
obtained O
from O
0 O
. O
01 O
% O
CTAB O
and O
0 O
. O
01 O
% O
CTAC B
also O
exhibit O
hexagonal O
structures O
with O
cell O
dimensions O
of O
a O
= O
2 O
. O
329 O
nm O
and O
c O
= O
1 O
. O
273 O
nm O
, O
a O
= O
2 O
. O
459 O
nm O
and O
c O
= O
0 O
. O
938 O
nm O
, O
respectively O
. O

Evaluation O
of O
drug O
interactions O
of O
GSK1292263 B
( O
a O
GPR119 O
agonist O
) O
with O
statins O
: O
from O
in O
vitro O
data O
to O
clinical O
study O
design O
. O

1 O
. O
This O
work O
investigated O
the O
drug O
interaction O
potential O
of O
GSK1292263 B
, O
a O
novel O
GPR119 O
agonist O
, O
with O
the O
HMG O
- O
coA O
reductase O
inhibitors O
simvastatin O
and O
rosuvastatin O
. O

2 O
. O
In O
vitro O
experiments O
assessed O
the O
inhibition O
of O
transporters O
and O
CYP O
enzymes O
by O
GSK1292263 B
, O
and O
a O
clinical O
drug O
interaction O
study O
investigated O
the O
effect O
of O
GSK1292263 B
( O
300 O
mg O
BID O
) O
on O
the O
pharmacokinetic O
profile O
of O
simvastatin O
( O
40 O
mg O
single O
dose O
) O
and O
rosuvastatin O
( O
10 O
mg O
single O
dose O
) O
. O

3 O
. O
In O
vitro O
, O
GSK1292263 B
demonstrated O
little O
/ O
weak O
inhibition O
( O
IC50 O
values O
> O
30 O
mu O
M O
) O
towards O
CYPs O
( O
CYP1A2 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
3A4 O
) O
, O
Pgp O
, O
OATP1B3 O
, O
or O
OCT2 O
. O

However O
, O
GSK1292263 B
inhibited O
BCRP O
and O
OATP1B1 O
, O
which O
are O
transporters O
involved O
in O
statin O
disposition O
. O

4 O
. O
In O
the O
clinical O
study O
, O
small O
increases O
in O
the O
AUC O
( O
0 O
- O
inf O
) O
of O
simvastatin O
[ O
mean O
ratio O
( O
90 O
% O
CI O
) O
of O
1 O
. O
34 O
( O
1 O
. O
22 O
, O
1 O
. O
48 O
) O
] O
and O
rosuvastatin O
[ O
mean O
ratio O
( O
90 O
% O
CI O
) O
of O
1 O
. O
39 O
( O
1 O
. O
30 O
, O
1 O
. O
49 O
) O
] O
were O
observed O
when O
co O
- O
administered O
with O
GSK1292263 B
, O
which O
is O
consistent O
with O
an O
inhibitory O
effect O
on O
intestinal O
BCRP O
and O
CYP3A4 O
. O

In O
contrast O
, O
GSK1292263 B
did O
not O
inhibit O
OATP1B1 O
based O
on O
the O
lack O
of O
changes O
in O
simvastatin O
acid O
exposure O
[ O
mean O
AUC O
( O
0 O
- O
inf O
) O
ratio O
( O
90 O
% O
CI O
) O
of O
1 O
. O
05 O
( O
0 O
. O
91 O
, O
1 O
. O
21 O
) O
] O
. O

5 O
. O
GSK1292263 B
has O
a O
weak O
drug O
interaction O
with O
simvastatin O
and O
rosuvastain B
. O

This O
study O
provides O
a O
mechanistic O
understanding O
of O
the O
in O
vivo O
inhibition O
of O
transporters O
and O
enzymes O
by O
GSK1292263 B
. O

Iridium B
- O
catalyzed O
enantioselective O
allylic O
vinylation O
. O

The O
first O
example O
of O
Ir O
- O
catalyzed O
asymmetric O
substitution O
reaction O
with O
vinyl B
trifluoroborates I
is O
described O
. O

The O
direct O
reaction O
between O
branched O
, O
racemic O
allylic B
alcohols I
and O
potassium B
alkenyltrifluorobora I
proceeded O
with O
high O
site O
selectivity O
and O
excellent O
enantioselectivity O
( O
up O
to O
99 O
% O
) O
mediated O
by O
an O
Ir B
- I
( I
P I
, I
olefin I
) I
complex O
. O

This O
method O
allows O
rapid O
access O
to O
various O
1 B
, I
4 I
- I
dienes I
or O
trienes B
including O
the O
biologically O
active O
natural O
products O
( B
- I
) I
- I
nyasol I
and O
( B
- I
) I
- I
hinokiresinol I
. O

ADX71743 B
, O
a O
potent O
and O
selective O
negative O
allosteric O
modulator O
of O
metabotropic O
glutamate O
receptor O
7 O
: O
in O
vitro O
and O
in O
vivo O
characterization O
. O

Here O
we O
characterized O
a O
potent O
and O
selective O
mGlu O
( O
7 O
) O
negative O
allosteric O
modulator O
( O
NAM O
) O
( B
+ I
) I
- I
6 I
- I
( I
2 I
, I
4 I
- I
dimethylphenyl I
) I
- I
2 I
- I
ethyl I
- I
6 I
, I
7 I
- I
dihydrobenzo I
[ I
d I
] I
oxazol I
- I
4 I
( I
5H I
) I
- I
one I
( O
ADX71743 B
) O
. O

In O
vitro O
, O
Schild O
plot O
analysis O
and O
reversibility O
tests O
at O
the O
target O
confirmed O
the O
NAM O
properties O
of O
the O
compound O
and O
attenuation O
of O
L B
- I
( I
+ I
) I
- I
2 I
- I
amino I
- I
4 I
- I
phosphonobutyric I
acid I
- O
induced O
synaptic O
depression O
confirmed O
activity O
at O
the O
native O
receptor O
. O

The O
pharmacokinetic O
analysis O
of O
ADX71743 B
in O
mice O
and O
rats O
revealed O
that O
it O
is O
bioavailable O
after O
s O
. O
c O
. O
administration O
and O
is O
brain O
penetrant O
( O
cerebrospinal O
fluid O
concentration O
/ O
total O
plasma O
concentration O
ratio O
at O
C O
( O
max O
) O
= O
5 O
. O
3 O
% O
) O
. O

In O
vivo O
, O
ADX71743 B
( O
50 O
, O
100 O
, O
150 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
caused O
no O
impairment O
of O
locomotor O
activity O
in O
rats O
and O
mice O
or O
activity O
on O
rotarod O
in O
mice O
. O

ADX71743 B
had O
an O
anxiolytic O
- O
like O
profile O
in O
the O
marble O
burying O
and O
elevated O
plus O
maze O
tests O
, O
dose O
- O
dependently O
reducing O
the O
number O
of O
buried O
marbles O
and O
increasing O
open O
arm O
exploration O
, O
respectively O
. O

Whereas O
ADX71743 B
caused O
a O
small O
reduction O
in O
amphetamine O
- O
induced O
hyperactivity O
in O
mice O
, O
it O
was O
inactive O
in O
the O
mouse O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
- O
induced O
head O
twitch O
and O
the O
rat O
conditioned O
avoidance O
response O
tests O
. O

These O
data O
suggest O
that O
ADX71743 B
is O
a O
suitable O
compound O
to O
help O
unravel O
the O
physiologic O
role O
of O
mGlu O
( O
7 O
) O
and O
to O
better O
understand O
its O
implication O
in O
central O
nervous O
system O
diseases O
. O

Our O
in O
vivo O
tests O
using O
ADX71743 B
, O
reported O
here O
, O
suggest O
that O
pharmacological O
inhibition O
of O
mGlu O
( O
7 O
) O
is O
a O
valid O
approach O
for O
developing O
novel O
pharmacotherapies O
to O
treat O
anxiety O
disorders O
, O
but O
may O
not O
be O
suitable O
for O
treatment O
of O
depression O
or O
psychosis O
. O

Synthesis O
of O
substituted O
6 B
- I
amino I
- I
4 I
- I
( I
2 I
, I
4 I
- I
dimethoxyphenyl I
) I
- I
[ I
1 I
, I
2 I
] I
dithiolo I
[ I
4 I
, I
3 I
- I
b I
] I
pyrrol I
- I
5 I
- I
ones I
and O
their O
raising O
leukocyte O
count O
activities O
. O

The O
design O
and O
synthesis O
of O
a O
series O
of O
substituted O
6 B
- I
amino I
- I
4 I
- I
( I
2 I
, I
4 I
- I
dimethoxyphenyl I
) I
- I
[ I
1 I
, I
2 I
] I
dithiolo I
[ I
4 I
, I
3 I
- I
b I
] I
pyrrol I
- I
5 I
- I
ones I
are O
described O
. O

( B
4 I
, I
4 I
' I
) I
- I
Bipyridine I
in O
vacuo O
and O
in O
solvents O
: O
a O
quantum O
chemical O
study O
of O
a O
prototypical O
floppy O
molecule O
from O
a O
molecular O
transport O
perspective O
. O

We O
report O
results O
of O
quantum O
chemical O
calculations O
for O
the O
neutral O
and O
anionic O
species O
of O
( B
4 I
, I
4 I
' I
) I
- I
bipyridine I
( O
44BPY B
) O
, O
a O
prototypical O
molecule O
with O
a O
floppy O
degree O
of O
freedom O
, O
placed O
in O
vacuo O
and O
in O
solvents O
. O

Special O
attention O
is O
paid O
to O
the O
floppy O
strongly O
anharmonic O
degree O
of O
freedom O
of O
44BPY B
, O
which O
is O
related O
to O
the O
most O
salient O
structural O
feature O
, O
namely O
the O
twist O
angle O
theta O
between O
the O
two O
pyridine O
rings O
. O

5 B
- I
cholesten I
- I
3 I
beta I
, I
25 I
- I
diol I
3 I
- I
sulfate I
decreases O
lipid O
accumulation O
in O
diet O
- O
induced O
nonalcoholic O
fatty O
liver O
disease O
mouse O
model O
. O

We O
previously O
reported O
that O
a O
cholesterol O
metabolite O
, O
5 B
- I
cholesten I
- I
3 I
beta I
, I
25 I
- I
diol I
3 I
- I
sulfate I
( O
25HC3S B
) O
, O
inhibits O
the O
LXR O
alpha O
signaling O
and O
reduces O
lipogenesis O
by O
decreasing O
SREBP O
- O
1c O
expression O
in O
primary O
hepatocytes O
. O

The O
present O
study O
aims O
to O
investigate O
the O
effects O
of O
25HC3S B
on O
lipid O
homeostasis O
in O
diet O
- O
induced O
NAFLD O
mouse O
models O
. O

The O
effects O
of O
25HC3S B
on O
lipid O
homeostasis O
, O
inflammatory O
responses O
, O
and O
insulin O
sensitivity O
were O
evaluated O
after O
acute O
treatments O
or O
long O
- O
term O
treatments O
. O

Acute O
treatments O
with O
25HC3S B
decreased O
serum O
lipid O
levels O
, O
and O
long O
- O
term O
treatments O
decreased O
hepatic O
lipid O
accumulation O
in O
the O
NAFLD O
mice O
. O

Gene O
expression O
analysis O
showed O
that O
25HC3S B
significantly O
suppressed O
the O
SREBP O
- O
1c O
signaling O
pathway O
that O
was O
associated O
with O
the O
suppression O
of O
the O
key O
enzymes O
involved O
in O
lipogenesis O
: O
fatty O
acid O
synthase O
, O
acetyl O
- O
CoA O
carboxylase O
1 O
, O
and O
glycerol B
- I
3 I
- I
phosphate I
acyltransferase O
. O

In O
addition O
, O
25HC3S B
significantly O
reduced O
HFD O
- O
induced O
hepatic O
inflammation O
as O
evidenced O
by O
decreasing O
tumor O
necrosis O
factor O
and O
interleukin O
1 O
alpha O
/ O
beta O
mRNA O
levels O
. O

A O
glucose O
tolerance O
test O
and O
insulin O
tolerance O
test O
showed O
that O
25HC3S B
administration O
improved O
HFD O
- O
induced O
insulin O
resistance O
. O

The O
present O
results O
indicate O
that O
25HC3S B
as O
a O
potent O
endogenous O
regulator O
decreases O
lipogenesis O
, O
and O
oxysterol O
sulfation O
can O
be O
a O
key O
protective O
regulatory O
pathway O
against O
lipid O
accumulation O
and O
lipid O
- O
induced O
inflammation O
in O
vivo O
. O

Oxygen O
tracer O
diffusion O
along O
interfaces O
of O
strained O
Y2O3 O
/ O
YSZ B
multilayers O
. O

In O
recent O
studies O
an O
enhancement O
of O
the O
ionic O
conductivity O
was O
indeed O
observed O
in O
micro O
- O
/ O
nanoscaled O
Y B
( I
2 I
) I
O I
( I
3 I
) I
- O
stabilised O
ZrO O
( O
2 O
) O
( O
YSZ B
) O
composites O
and O
hetero O
multilayers O
of O
thin O
films O
. O

In O
order O
to O
obtain O
independent O
information O
on O
the O
role O
of O
heterophase O
boundaries O
for O
fast O
transport O
in O
strained O
solid O
electrolytes O
, O
systematic O
measurements O
of O
the O
( B
18 I
) I
O I
- O
tracer O
diffusion O
coefficient O
in O
nanoscaled O
YSZ B
/ O
Y B
( I
2 I
) I
O I
( I
3 I
) I
multilayers O
were O
performed O
. O

To O
separate O
interface O
and O
bulk O
transport O
from O
the O
total O
oxygen O
diffusivity O
of O
the O
multilayer O
system O
, O
the O
( O
average O
) O
thickness O
of O
the O
YSZ B
- O
layers O
in O
the O
multilayers O
was O
varied O
from O
45 O
nm O
to O
12 O
nm O
. O

Upon O
decreasing O
the O
thickness O
of O
the O
YSZ B
layers O
, O
respectively O
increasing O
the O
density O
of O
parallel O
interfaces O
, O
the O
total O
diffusion O
coefficient O
of O
the O
multilayer O
system O
is O
increased O
by O
a O
factor O
of O
2 O
compared O
to O
bulk O
YSZ B
. O

Here O
, O
iron O
L O
- O
edge O
X O
- O
ray O
absorption O
spectroscopy O
, O
interpreted O
using O
a O
valence O
bond O
configuration O
interaction O
multiplet O
model O
, O
is O
applied O
to O
directly O
probe O
the O
electronic O
structure O
of O
the O
iron O
in O
the O
biomimetic O
Fe O
- O
O O
( O
2 O
) O
heme O
complex O
[ B
Fe I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
O I
( I
2 I
) I
] I
( O
pfp B
( O
" O
picket B
fence I
porphyrin I
" O
) O
= O
meso B
- I
tetra I
( I
alpha I
, I
alpha I
, I
alpha I
, I
alpha I
- I
o I
- I
pivalamidophenyl I
) I
porphyrin I
or O
TpivPP B
) O
. O

The O
L O
- O
edge O
spectrum O
of O
[ B
Fe I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
O I
( I
2 I
) I
] I
is O
further O
compared O
to O
those O
of O
[ B
Fe I
( I
II I
) I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
( I
2 I
) I
] I
, O
[ B
Fe I
( I
II I
) I
( I
pfp I
) I
] I
, O
and O
[ B
Fe I
( I
III I
) I
( I
tpp I
) I
( I
ImH I
) I
( I
2 I
) I
] I
Cl I
( O
tpp O
= O
meso B
- I
tetraphenylporphyrin I
) O
which O
have O
Fe O
( O
II O
) O
S O
= O
0 O
, O
Fe O
( O
II O
) O
S O
= O
1 O
, O
and O
Fe O
( O
III O
) O
S O

These O
serve O
as O
references O
for O
the O
three O
possible O
contributions O
to O
the O
ground O
state O
of O
oxy B
- I
pfp I
. O

The O
Fe O
- O
O O
( O
2 O
) O
pfp B
site O
is O
experimentally O
determined O
to O
have O
both O
significant O
sigma O
- O
donation O
and O
a O
strong O
pi O
- O
interaction O
of O
the O
O O
( O
2 O
) O
with O
the O
iron O
, O
with O
the O
latter O
having O
implications O
with O
respect O
to O
the O
spin O
polarization O
of O
the O
ground O
state O
. O

The O
surface O
of O
graphene O
oxide O
is O
first O
sensitized O
by O
Sn B
( I
2 I
+ I
) I
ions O
, O
and O
subsequently O
, O
Pd O
or O
Pt O
nanoparticles O
are O
deposited O
on O
the O
surface O
of O
graphene O
oxide O
. O

Finally O
, O
graphene O
oxide O
was O
reduced O
to O
graphene O
by O
further O
adding O
NaBH B
( I
4 I
) I
. O

Compared O
to O
other O
carbon O
- O
( O
e O
. O
g O
. O
, O
Vulcan B
XC I
- I
72R I
) O
supported O
Pd O
and O
Pt O
, O
the O
resultant O
graphene O
- O
Pd O
and O
Pt O
composites O
exhibit O
better O
electrocatalytic O
activity O
and O
long O
- O
term O
stability O
toward O
alcohol O
electrooxidation O
. O

The O
C O
- O
H O
bonds O
of O
precise O
location O
of O
inert O
polymer O
surfaces O
were O
readily O
transferred O
to O
bromoalkyl B
initiator O
, O
followed O
by O
ATRP O
of O
2 O
- O
( O
dimethylamino O
) O
ethyl O
methacrylate O
( O
DMAEMA O
) O
and O
glycidyl B
methacrylate I
( O
GMA B
) O
, O
respectively O
, O
to O
produce O
the O
resultant O
patterned O
BOPP O
- O
g O
- O
P B
( I
DMAEMA I
) I
and O
BOPP O
- O
g O
- O
P B
( I
GMA I
) I
films O
. O

The O
epoxy O
groups O
of O
the O
P B
( I
GMA I
) I
microdomains O
can O
be O
aminated O
for O
covalently O
coupling O
IgG O
, O
while O
the O
P B
( I
DMAEMA I
) I
microdomains O
were O
used O
for O
immobilizing O
IgG O
via O
electronic O
interactions O
. O

Several O
inhibitors O
of O
Lp O
- O
PLA O
( O
2 O
) O
have O
been O
described O
, O
including O
darapladib B
, O
which O
is O
currently O
in O
phase O
3 O
clinical O
development O
for O
the O
treatment O
of O
atherosclerosis O
. O

The O
selectivity O
that O
darapladib B
and O
other O
Lp O
- O
PLA O
( O
2 O
) O
inhibitors O
display O
across O
the O
larger O
serine O
hydrolase O
family O
has O
not O
, O
however O
, O
been O
reported O
. O

We O
show O
that O
both O
darapladib B
and O
a O
novel O
class O
of O
structurally O
distinct O
carbamate O
inhibitors O
inactivate O
Lp O
- O
PLA O
( O
2 O
) O
in O
mouse O
tissues O
and O
human O
cell O
lines O
with O
high O
selectivity O
. O

Identification O
of O
benzofuran O
central O
cores O
for O
the O
inhibition O
of O
leukotriene B
A I
( I
4 I
) I
hydrolase O
. O

Leukotrienes B
( O
LT O
' O
s O
) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O

Leukotriene B
A I
( I
4 I
) I
hydrolase O
( O
LTA O
( O
4 O
) O
H O
) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA B
( I
4 I
) I
to O
LTB B
( I
4 I
) I
. O

LTB B
( I
4 I
) I
is O
a O
known O
pro O
- O
inflammatory O
mediator O
. O

The O
benzofuran O
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB B
( I
4 I
) I
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O

Disruption O
of O
the O
cell O
- O
cycle O
boxes O
also O
affected O
growth O
in O
a O
DNA O
polymerase O
- O
defective O
strain O
background O
where O
mismatch O
repair O
is O
essential O
, O
particularly O
in O
the O
presence O
of O
the O
DNA O
damaging O
agent O
methyl B
methane I
sulfonate I
( O
MMS O
) O
. O

3 B
, I
4 I
- I
Methylenedioxy I
- I
methamphetamine I
induces O
in O
vivo O
regional O
up O
- O
regulation O
of O
central O
nicotinic O
receptors O
in O
rats O
and O
potentiates O
the O
regulatory O
effects O
of O
nicotine O
on O
these O
receptors O
. O

Recent O
work O
has O
demonstrated O
that O
the O
recreational O
drug O
3 B
, I
4 I
- I
methylenedioxy I
- I
methamphetamine I
( O
MDMA O
) O
has O
affinity O
for O
nAChR O
and O
also O
induces O
up O
- O
regulation O
of O
nAChR O
in O
PC O
12 O
cells O
. O

In O
the O
prefrontal O
cortex O
, O
NIC O
and O
MDMA O
each O
induced O
significant O
increases O
in O
[ B
( I
3 I
) I
H I
] I
epibatidine I
binding O
( O
29 O
. O
5 O
and O
34 O
. O
6 O
% O
, O
respectively O
) O
with O
respect O
to O
saline O
- O
treated O
rats O
, O
and O
these O
increases O
were O
significantly O
potentiated O
( O
up O
to O
72 O
. O
1 O
% O
) O
when O
the O
two O
drugs O
were O
associated O
. O

Also O
in O
this O
area O
, O
[ B
( I
3 I
) I
H I
] I
methyllycaconitine I
binding O
was O
increased O
a O
42 O
. O
1 O
% O
with O
NIC O
+ O
MDMA O
but O
not O
when O
they O
were O
given O
alone O
. O

The O
olfactory O
GSTs O
conjugated O
prototypical O
GST O
substrates O
, O
but O
only O
OlfGST O
rho O
catalyzed O
the O
demethylation O
of O
the O
pesticide O
methyl B
parathion I
. O

OlfGST O
pi O
and O
rho O
exhibited O
thiol O
oxidoreductase O
activity O
toward O
2 B
- I
hydroxyethyl I
disulfide I
( O
2 B
- I
HEDS I
) O
and O
conjugated O
4 O
- O
hydroxynonenal O
( O
HNE B
) O
, O
a O
toxic O
aldehyde O
with O
neurodegenerative O
properties O
. O

The O
kinetic O
parameters O
for O
OlfGST O
pi O
conjugation O
of O
HNE B
were O
K O
( O
M O
) O
= O
0 O
. O
16 O
+ O
/ O
- O
0 O
. O
06mM O
and O
V O
( O
max O
) O
= O
0 O
. O
5 O
+ O
/ O
- O
0 O
. O
1 O
mu O
molmin O
- O
( O
1 O
) O
mg O
- O
( O
1 O
) O
, O
whereas O
OlfGST O
rho O
was O
more O
efficient O
at O
catalyzing O
HNE B
conjugation O
( O
K O
( O
M O
) O
= O
0 O
. O
022 O
+ O
/ O
- O
0 O
. O
008 O
mM O
and O
V O
( O
max O
) O
= O
0 O
. O
47 O
+ O
/ O
- O
0 O
. O
05 O
mu O
molmin O
- O
( O
1 O

Salsolinol B
induced O
apoptotic O
changes O
in O
neural O
stem O
cells O
: O
amelioration O
by O
neurotrophin O
support O
. O

Salsolinol B
( O
SAL B
) O
, O
a O
catechol B
isoquinoline I
has O
invited O
considerable O
attention O
due O
to O
its O
structural O
similarity O
with O
dopaminergic O
neurotoxin O
1 O
- O
methyl O
- O
4 O
- O
phenyl O
- O
1 O
, O
2 O
, O
3 O
, O
6 O
- O
tetrahydropyridine O
( O
MPTP O
) O
. O

SAL B
is O
also O
present O
in O
alcohol O
beverages O
and O
certain O
food O
materials O
and O
can O
get O
access O
to O
brain O
especially O
in O
conditions O
of O
immature O
or O
impaired O
BBB O
. O

Besides O
this O
, O
the O
effect O
of O
SAL B
on O
neural O
stem O
cells O
( O
NSCs O
) O
which O
are O
potential O
candidates O
for O
adult O
neurogenesis O
and O
transplantation O
mediated O
rejuvenating O
attempts O
for O
Parkinson O
' O
s O
disease O
( O
PD O
) O
brain O
has O
not O
been O
known O
so O
far O
. O

In O
this O
study O
we O
explored O
the O
toxicity O
of O
SAL B
toward O
NSCs O
focusing O
on O
apoptosis O
and O
status O
of O
PI3K O
survival O
signaling O
. O

NSCs O
cultured O
from O
embryonic O
day O
11 O
rat O
fetal O
brain O
including O
those O
differentiated O
to O
TH O
( O
+ O
ve O
) O
colonies O
, O
when O
challenged O
with O
SAL B
( O
1 O
- O
100 O
mu O
M O
) O
, O
elicited O
a O
concentration O
and O
time O
dependent O
cell O
death O
/ O
loss O
of O
mitochondrial O
viability O
. O

10 O
mu O
M O
SAL B
on O
which O
significant O
mitochondrial O
impairment O
initiated O
was O
further O
used O
to O
study O
mechanism O
of O
toxicity O
. O

Sal B
toxicity O
coincided O
with O
reduced O
pAkt O
level O
and O
its O
downstream O
effectors O
: O
pCREB O
, O
pGSK O
- O
3 O
beta O
, O
Bcl O
- O
2 O
and O
neurotrophins O
GDNF O
, O
BDNF O
suggesting O
repressed O
PI3K O
/ O
Akt O
signaling O
. O

Multiple O
neurotrophic O
factor O
support O
in O
the O
form O
of O
Olfactory O
Ensheathing O
Cell O
' O
s O
Conditioned O
Media O
( O
OEC O
CM O
) O
potentially O
protected O
NSCs O
against O
SAL B
through O
activating O
PI3K O
/ O
Akt O
pathway O
. O

We O
inferred O
that O
SAL B
exerts O
substantial O
toxicity O
toward O
NSCs O
. O

The O
outcome O
of O
these O
tests O
grouped O
the O
tested O
compounds O
in O
three O
categories O
following O
their O
detoxification O
effect O
( O
benzo O
( O
a O
) O
pyrene O
, O
valproic O
acid O
) O
, O
their O
bio O
- O
activation O
effect O
( O
aflatoxin O
B1 O
) O
and O
their O
specific O
effect O
on O
inhibition O
of O
cell O
proliferation O
( O
cycloheximide O
, O
sodium B
lauryl I
sulphate I
, O
atropine B
sulphate I
monohydrate I
, O
acetylsalicylic O
acid O
) O
. O

The O
results O
from O
a O
subchronic O
feeding O
study O
conducted O
in O
Sprague O
- O
Dawley O
rats O
fed O
with O
diets O
containing O
grain O
from O
4114 O
( O
OECD O
unique O
identifier O
: O
DP O
- O
O O
O O
4114 O
- O
3 O
) O
maize O
that O
was O
untreated O
( O
4114 O
) O
or O
sprayed O
in O
field O
with O
glufosinate B
ammonium I
( O
4114GLU O
) O
in O
a O
design O
similar O
to O
previous O
studies O
are O
reported O
. O

The O
test O
material O
, O
4114 O
maize O
, O
is O
a O
hybrid O
maize O
produced O
by O
transformation O
with O
a O
DNA O
construct O
encoding O
4 O
different O
transgenic O
proteins O
for O
resistance O
to O
lepidopteran O
pests O
, O
coleopteran O
pests O
, O
and O
tolerance O
to O
the O
herbicidal O
active O
ingredient O
glufosinate B
ammonium I
. O

Olive O
oil O
oleuropein B
has O
anti O
- O
breast O
cancer O
properties O
with O
higher O
efficiency O
on O
ER O
- O
negative O
cells O
. O

In O
the O
present O
report O
we O
have O
shown O
that O
oleuropein B
, O
a O
pharmacologically O
safe O
natural O
product O
of O
olive O
leaf O
, O
has O
potent O
anti O
- O
breast O
cancer O
properties O
. O

Indeed O
, O
oleuropein B
exhibits O
specific O
cytotoxicity O
against O
breast O
cancer O
cells O
, O
with O
higher O
effect O
on O
the O
basal O
- O
like O
MDA O
- O
MB O
- O
231 O
cells O
than O
on O
the O
luminal O
MCF O
- O
7 O
cells O
. O

Moreover O
, O
oleuropein B
inhibits O
cell O
proliferation O
by O
delaying O
the O
cell O
cycle O
at O
S O
phase O
and O
up O
- O
regulated O
the O
cyclin O
- O
dependent O
inhibitor O
p21 O
. O

Furthermore O
, O
oleuropein B
inhibited O
the O
anti O
- O
apoptosis O
and O
pro O
- O
proliferation O
protein O
NF O
- O
kappa O
B O
and O
its O
main O
oncogenic O
target O
cyclin O
D1 O
. O

This O
inhibition O
could O
explain O
the O
great O
effect O
of O
oleuropein B
on O
cell O
proliferation O
and O
cell O
death O
of O
breast O
cancer O
cells O
. O

Therefore O
, O
oleuropein B
warrants O
further O
investigations O
to O
prove O
its O
utility O
in O
preventing O
/ O
treating O
breast O
cancer O
, O
especially O
the O
less O
- O
responsive O
basal O
- O
like O
type O
. O

Monotropein B
isolated O
from O
the O
roots O
of O
Morinda O
officinalis O
ameliorates O
proinflammatory O
mediators O
in O
RAW O
264 O
. O
7 O
macrophages O
and O
dextran O
sulfate O
sodium O
( O
DSS O
) O
- O
induced O
colitis O
via O
NF O
- O
kappa O
B O
inactivation O
. O

We O
previously O
demonstrated O
that O
monotropein B
isolated O
from O
the O
roots O
of O
Morinda O
officinalis O
( O
Rubiaceae O
) O
has O
anti O
- O
inflammatory O
effects O
in O
vivo O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
molecular O
mechanisms O
underlying O
the O
anti O
- O
inflammatory O
effects O
of O
monotropein B
in O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
RAW O
264 O
. O
7 O
macrophages O
and O
dextran O
sulfate O
sodium O
( O
DSS O
) O
- O
induced O
colitis O
mouse O
model O
. O

Monotropein B
was O
found O
to O
inhibit O
the O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
( O
iNOS O
) O
, O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
, O
and O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1 O
beta O
) O
mRNA O
in O
LPS O
- O
induced O
RAW O
264 O
. O
7 O
macrophages O
. O

Treatment O
with O
monotropein B
decreased O
the O
DNA O
binding O
activity O
of O
nuclear O
factor O
- O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
. O

Consistent O
with O
these O
findings O
, O
monotropein B
also O
suppressed O
phosphorylation O
and O
degradation O
of O
inhibitory O
kappa O
B O
- O
alpha O
( O
I O
kappa O
B O
- O
alpha O
) O
, O
and O
consequently O
the O
translocations O
of O
NF O
- O
kappa O
B O
. O

In O
the O
DSS O
- O
induced O
colitis O
model O
, O
monotropein B
reduced O
disease O
activity O
index O
( O
DAI O
) O
, O
myeloperoxidase O
( O
MPO O
) O
activity O
, O
and O
inflammation O
- O
related O
protein O
expressions O
by O
suppressing O
NF O
- O
kappa O
B O
activation O
in O
colon O
mucosa O
. O

Taken O
together O
, O
these O
findings O
suggest O
that O
the O
anti O
- O
inflammatory O
effects O
of O
monotropein B
are O
mainly O
related O
to O
the O
inhibition O
of O
the O
expressions O
of O
inflammatory O
mediators O
via O
NF O
- O
kappa O
B O
inactivation O
, O
and O
support O
its O
possible O
therapeutic O
role O
in O
colitis O
. O

Synthesis O
, O
crystal O
structure O
and O
antidiabetic O
activity O
of O
substituted O
( B
E I
) I
- I
3 I
- I
( I
Benzo I
[ I
d I
] I
thiazol I
- I
2 I
- I
ylamino I
) I
phenylprop I
- I
2 I
- I
en I
- I
1 I
- I
one I
. O

A O
novel O
series O
of O
substituted O
( B
E I
) I
- I
3 I
- I
( I
Benzo I
[ I
d I
] I
thiazol I
- I
2 I
- I
ylamino I
) I
phenylprop I
- I
2 I
- I
en I
- I
1 I
- I
onewere I
synthesized O
starting O
from O
2 B
- I
aminobenzothiazole I
and O
1 B
- I
aryl I
- I
3 I
, I
3 I
- I
bis I
- I
( I
methylsulfanyl I
) I
- I
2 I
- I
propen I
- I
1 I
- I
onesin I
the O
presence O
of O
a O
catalytic O
amount O
of O
sodium B
hydride I
in O
THF O
. O

These O
compounds O
were O
evaluated O
for O
their O
antidiabetic O
activity O
, O
and O
most O
of O
the O
derivatives O
of O
( B
E I
) I
- I
3 I
- I
( I
Benzo I
[ I
d I
] I
thiazol I
- I
2 I
- I
ylamino I
) I
phenylprop I
- I
2 I
- I
en I
- I
1 I
- I
one I
displayed O
significant O
antidiabetic O
activity O
. O

C B
( I
22 I
) I
- I
steroidal I
lactone I
glycosides I
from O
stems O
and O
leaves O
of O
Paris O
polyphylla O
var O
. O
yunnanensis O
. O

Further O
phytochemical O
investigation O
on O
the O
stems O
and O
leaves O
of O
Paris O
polyphylla O
var O
. O
yunnanensis O
has O
led O
to O
the O
isolation O
of O
three O
C B
( I
22 I
) I
- I
steroidal I
lactone I
glycosides I
. O

Two O
of O
these O
are O
new O
compounds O
, O
designated O
as O
chonglouoside B
SL I
- I
7 I
( O
1 O
) O
and O
chonglouoside B
SL I
- I
8 I
( O
2 O
) O
. O

This O
is O
the O
first O
report O
of O
C B
( I
22 I
) I
- I
steroidal I
lactone I
glycosides I
isolated O
from O
the O
Paris O
genus O
. O

l B
- I
Glutamate I
( O
30 O
mu O
M O
) O
- O
induced O
inward O
currents O
were O
recorded O
via O
the O
two O
- O
electrode O
voltage O
clamp O
method O
. O

The O
electrochemical O
reduction O
of O
benzoic O
acid O
in O
the O
presence O
and O
absence O
of O
hydrogen O
( O
H O
( O
2 O
) O
) O
has O
been O
investigated O
using O
a O
10 O
mu O
m O
diameter O
platinum O
microelectrode O
in O
four O
different O
room O
temperature O
ionic O
liquids O
( O
RTILs O
) O
, O
namely O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
NTf I
( I
2 I
) I
] I
, O
[ B
C I
( I
4 I
) I
mpyrr I
] I
[ I
NTf I
( I
2 I
) I
] I
, O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
OTf I
] I
and O
[ O
C O
( O
4 O
) O
mim O
] O
[ O
BF O
( O
4 O
) O
] O
, O
versus O
Ag O
/ O
Ag O
( O

In O
all O
cases O
, O
reductive O
voltammetry O
is O
observed O
, O
and O
is O
suggested O
to O
occur O
via O
a O
CE O
mechanism O
in O
which O
dissociation O
of O
benzoic B
acid I
is O
followed O
by O
electron O
transfer O
to O
H O
( O
+ O
) O
ultimately O
forming O
adsorbed O
hydrogen O
. O

Furthermore O
, O
the O
adsorbed O
H O
atoms O
, O
formed O
from O
the O
reduction O
of O
benzoic O
acid O
, O
could O
be O
used O
to O
achieve O
the O
rapid O
hydrogenolysis O
of O
the O
organic O
compound O
( O
bis B
( I
benzyloxycarbonyl I
) I
- I
l I
- I
lysine I
) O
on O
the O
timescale O
of O
the O
voltammetric O
technique O
under O
moderate O
conditions O
( O
25 O
degrees O
C O
) O
. O

Probing O
the O
structural O
, O
electronic O
and O
magnetic O
properties O
of O
multicenter O
Fe B
2 I
S I
2 I
0 O
/ O
- O
, O
Fe B
3 I
S I
4 I
0 O
/ O
- O
and O
Fe B
4 I
S I
4 I
0 O
/ O
- O
clusters O
. O

The O
structural O
, O
electronic O
and O
magnetic O
properties O
of O
neutral O
and O
anion O
Fe2S2 B
, O
Fe3S4 B
and O
Fe4S4 B
have O
been O
investigated O
with O
the O
aid O
of O
previous O
photoelectron O
spectroscopy O
and O
density O
functional O
theory O
calculations O
. O

The O
optimized O
structures O
show O
that O
the O
ground O
state O
structures O
of O
Fe2S2 B
( O
0 O
/ O
- O
) O
, O
Fe3S4 B
( O
0 O
/ O
- O
) O
and O
Fe4S4 B
( O
0 O
/ O
- O
) O
favor O
high O
spin O
state O
and O
are O
similar O
to O
their O
structures O
in O
proteins O
. O

The O
response O
of O
soil O
organism O
communities O
to O
the O
application O
of O
the O
insecticide O
lindane B
in O
terrestrial O
model O
ecosystems O
. O

Therefore O
, O
a O
higher O
- O
tier O
experiment O
suitable O
to O
assess O
the O
risk O
for O
soil O
organisms O
was O
conducted O
to O
further O
develop O
the O
TME O
( O
terrestrial O
model O
ecosystems O
) O
methodology O
in O
a O
dose O
- O
response O
design O
with O
the O
persistent O
insecticidal O
model O
compound O
lindane B
( O
gamma B
- I
HCH I
) O
. O

The O
effects O
of O
lindane B
on O
soil O
communities O
such O
as O
collembolans O
, O
oribatid O
mites O
, O
nematodes O
, O
soil O
fungi O
and O
plant O
biomass O
were O
determined O
in O
42 O
TME O
. O

Lindane B
was O
applied O
in O
five O
concentrations O
between O
0 O
. O
032 O
mg O
active O
ingredients O
( O
ai O
) O
/ O
kg O
dry O
soil O
and O
3 O
. O
2 O
mg O
ai O
/ O
kg O
dry O
weight O
soil O
, O
six O
- O
fold O
replicated O
each O
. O

Significance O
of O
peptide O
transporter O
1 O
in O
the O
intestinal O
permeability O
of O
valacyclovir B
in O
wild O
- O
type O
and O
PepT1 O
knockout O
mice O
. O

The O
purpose O
of O
this O
study O
was O
to O
quantitatively O
determine O
the O
contribution O
of O
PepT1 O
[ O
peptide O
transporter O
1 O
( O
SLC15A1 O
) O
] O
to O
the O
intestinal O
permeability O
of O
valacyclovir B
, O
an O
ester O
prodrug O
of O
the O
antiviral O
drug O
acyclovir O
. O

In O
situ O
single O
- O
pass O
intestinal O
perfusions O
were O
employed O
( O
pH O
6 O
. O
5 O
x O
90 O
minutes O
) O
to O
assess O
the O
effective O
permeability O
( O
P O
( O
eff O
) O
) O
of O
100 O
mu O
M O
[ B
( I
3 I
) I
H I
] I
valacyclovir I
in O
wild O
- O
type O
and O
PepT1 O
knockout O
mice O
. O

Acyclovir O
pharmacokinetics O
was O
also O
evaluated O
after O
oral O
administration O
of O
25 O
nmol O
/ O
g O
valacyclovir B
. O

In O
wild O
- O
type O
mice O
, O
jejunal O
uptake O
of O
valacyclovir B
was O
best O
described O
by O
both O
saturable O
( O
K O
( O
m O
) O
= O
10 O
. O
2 O
mM O
) O
and O
nonsaturable O
components O
where O
the O
saturable O
pathway O
accounted O
for O
82 O
% O
of O
total O
transport O
. O

Valacyclovir B
P O
( O
eff O
) O
was O
2 O
. O
4 O
x O
10 O
( O
- O
4 O
) O
cm O
/ O
s O
in O
duodenum O
, O
1 O
. O
7 O
x O
10 O
( O
- O
4 O
) O
cm O
/ O
s O
in O
jejunum O
, O
2 O
. O
1 O
x O
10 O
( O
- O
4 O
) O
cm O
/ O
s O
in O
ileum O
, O
and O
0 O
. O
27 O
x O
10 O
( O
- O
4 O
) O
cm O
/ O
s O
in O
colon O
. O

Valacyclovir B
P O
( O
eff O
) O
was O
similar O
in O
the O
colon O
of O
both O
genotypes O
. O

There O
were O
no O
differences O
in O
valacyclovir B
P O
( O
eff O
) O
between O
any O
of O
the O
intestinal O
segments O
of O
PepT1 O
knockout O
mice O
. O

Valacyclovir B
P O
( O
eff O
) O
was O
significantly O
reduced O
by O
the O
dipeptide O
glycylsarcosine B
and O
the O
aminocephalosporin B
cefadroxil I
, O
but O
not O
by O
the O
amino O
acids O
l B
- I
valine I
or O
l B
- I
histidine I
, O
the O
organic O
acid O
p B
- I
aminohippurate I
, O
or O
the O
organic O
base O
tetraethylammonium O
( O
all O
at O
25 O
mM O
) O
. O

PepT1 O
ablation O
resulted O
in O
3 O
- O
to O
5 O
- O
fold O
reductions O
in O
the O
in O
vivo O
rate O
and O
extent O
of O
valacyclovir B
absorption O
. O

Our O
findings O
conclusively O
demonstrate O
, O
using O
in O
situ O
and O
in O
vivo O
validations O
in O
genetically O
modified O
mice O
, O
that O
PepT1 O
has O
a O
major O
influence O
in O
improving O
the O
oral O
absorption O
of O
valacyclovir B
. O

Mammalian O
frataxin O
controls O
sulfur O
production O
and O
iron O
entry O
during O
de O
novo O
Fe4S4 B
cluster O
assembly O
. O

Iron B
- I
sulfur I
( O
Fe B
- I
S I
) O
cluster O
- O
containing O
proteins O
are O
essential O
components O
of O
cells O
. O

In O
eukaryotes O
, O
Fe B
- I
S I
clusters O
are O
synthesized O
by O
the O
mitochondrial O
iron B
- I
sulfur I
cluster O
( O
ISC O
) O
machinery O
and O
the O
cytosolic O
iron B
- I
sulfur I
assembly O
( O
CIA O
) O
system O
. O

In O
the O
mammalian O
ISC O
machinery O
, O
preassembly O
of O
the O
Fe B
- I
S I
cluster O
on O
the O
scaffold O
protein O
( O
ISCU O
) O
involves O
a O
cysteine O
desulfurase O
complex O
( O
NFS1 O
/ O
ISD11 O
) O
and O
frataxin O
( O
FXN O
) O
, O
the O
protein O
deficient O
in O
Friedreich O
' O
s O
ataxia O
. O

Furthermore O
, O
we O
show O
for O
the O
first O
time O
that O
in O
the O
presence O
of O
iron O
and O
L B
- I
cysteine I
, O
an O
[ O
Fe B
( I
4 I
) I
S I
( I
4 I
) I
] O
cluster O
is O
formed O
within O
the O
quaternary O
complex O
that O
can O
be O
transferred O
to O
mammalian O
aconitase O
( O
mACO2 O
) O
to O
generate O
an O
active O
enzyme O
. O

In O
the O
absence O
of O
FXN O
, O
although O
the O
ternary O
complex O
can O
assemble O
an O
Fe B
- I
S I
cluster O
, O
the O
cluster O
is O
inefficiently O
transferred O
to O
ACO2 O
. O

Taken O
together O
, O
these O
data O
help O
to O
unravel O
further O
the O
Fe B
- I
S I
cluster O
assembly O
process O
and O
the O
molecular O
basis O
of O
Friedreich O
' O
s O
ataxia O
. O

This O
decrease O
was O
, O
therefore O
, O
correlated O
with O
starch O
concentration O
, O
and O
the O
composition O
and O
stability O
of O
the O
potassium B
triiodide I
solution O
were O
optimised O
. O

Concentration O
of O
the O
extract O
by O
microfiltration O
led O
to O
epoxy O
- O
furanoxy B
rearrangement O
of O
violaxanthin B
and O
antheraxanthin B
. O

Myricetin O
and O
myricitrin B
are O
naturally O
occurring O
flavonoids O
have O
been O
suggested O
to O
play O
a O
role O
in O
inhibition O
of O
proliferation O
and O
transformation O
of O
carcinogenic O
cell O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
clarify O
the O
molecular O
mechanisms O
of O
apoptosis O
cell O
on O
the O
prostate O
cancer O
induced O
by O
myricetin O
, O
myricitrin B
, O
quercetin O
and O
quercitrin B
. O

The O
MTT O
assay O
confirmed O
that O
myricetin O
had O
the O
strongest O
inhibitory O
effect O
on O
human O
prostate O
cancer O
cell O
line O
PC O
- O
3 O
, O
myricitrin B
was O
second O
, O
and O
quercitrin B
was O
the O
weakest O
. O

A O
noticeable O
synergistic O
effect O
was O
observed O
with O
the O
inhibition O
of O
cell O
proliferation O
when O
myricetin O
was O
used O
in O
combination O
with O
myricitrin B
. O

The O
acridine B
orange I
analysis O
and O
annexin O
V O
- O
FITC O
/ O
PI O
double O
- O
staining O
results O
confirmed O
that O
myricetin O
and O
myricitrin B
were O
effective O
in O
inducing O
PC O
- O
3 O
cell O
apoptosis O
. O

The O
results O
showed O
that O
myricetin O
was O
more O
effective O
than O
myricitrin B
in O
inducing O
cell O
apoptosis O
. O

A O
synergistic O
effect O
was O
observed O
on O
the O
apoptosis O
rate O
when O
myricetin O
was O
used O
in O
combination O
with O
myricitrin B
. O

A O
gas O
chromatographic O
method O
for O
the O
determination O
of O
endocrine O
disruptor O
pesticides O
( O
Chlorpyrifos O
, O
Penconazole B
, O
Procymidone O
, O
Iprodione O
, O
Bromopropylate B
and O
Lambda O
- O
Cyhalothrin O
) O
in O
wine O
samples O
is O
described O
. O

Four O
different O
separation O
techniques O
were O
tested O
and O
the O
method O
employing O
florosil B
column O
after O
a O
LLE O
procedure O
was O
applied O
for O
wine O
samples O
with O
satisfactory O
recovery O
ratios O
( O
72 O
- O
97 O
% O
) O
. O

The O
pesticides O
were O
extracted O
from O
the O
sample O
by O
cyclohexane O
- O
ethyl O
acetate O
mixture O
( O
1 O
: O
1 O
v O
/ O
v O
) O
and O
cleaned O
up O
by O
florosil B
column O
. O

After O
baking O
, O
mycelium O
- O
supplemented O
bread O
still O
contained O
substantial O
amounts O
of O
gamma O
- O
aminobutyric O
acid O
and O
ergothioneine B
( O
0 O
. O
23 O
- O
0 O
. O
86 O
and O
0 O
. O
79 O
- O
2 O
. O
10 O
mg O
/ O
g O
dry O
matter O
, O
respectively O
) O
. O

Hepatoprotective O
effect O
of O
2 B
, I
3 I
- I
dehydrosilybin I
on O
carbon O
tetrachloride O
- O
induced O
liver O
injury O
in O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
protective O
effect O
of O
2 B
, I
3 I
- I
dehydrosilybin I
( O
DHS B
) O
against O
carbon O
tetrachloride O
( O
CCl O
( O
4 O
) O
) O
- O
induced O
liver O
injury O
in O
rats O
. O

Administration O
of O
DHS B
significantly O
attenuated O
the O
levels O
of O
serum O
aspartate O
aminotransferase O
, O
alanine O
aminotransferase O
, O
and O
liver O
lipid O
peroxidation O
in O
CCl O
( O
4 O
) O
- O
treated O
rats O
. O

Moreover O
, O
we O
showed O
that O
DHS B
prevented O
DNA O
damage O
and O
decreased O
the O
protein O
levels O
of O
gamma O
- O
H2AX O
, O
which O
is O
a O
specific O
DNA O
damage O
marker O
, O
in O
CCl O
( O
4 O
) O
- O
treated O
rat O
livers O
. O

Furthermore O
, O
we O
found O
that O
DHS B
significantly O
inhibited O
the O
production O
of O
serum O
nitric O
oxide O
as O
well O
as O
the O
levels O
of O
serum O
IL O
- O
6 O
, O
IFN O
- O
gamma O
, O
and O
TNF O
- O
alpha O
in O
CCl O
( O
4 O
) O
- O
treated O
rats O
. O

Additionally O
, O
DHS B
significantly O
suppressed O
iNOS O
expression O
on O
the O
protein O
levels O
in O
CCl O
( O
4 O
) O
- O
treated O
rat O
livers O
. O

Collectively O
, O
the O
present O
study O
suggests O
that O
DHS B
protects O
the O
liver O
from O
CCl O
( O
4 O
) O
- O
induced O
hepatic O
damage O
via O
antioxidant O
and O
anti O
- O
inflammatory O
mechanisms O
. O

The O
method O
explores O
the O
ABTS O
radical O
( O
2 B
, I
2 I
' I
- I
azinobis I
( I
3 I
- I
ethylbenzothiazoline I
- I
6 I
- I
sulphonic I
acid I
) I
) O
assay O
as O
a O
redox O
probe O
and O
it O
relays O
on O
measuring O
catalytic O
voltammetric O
currents O
. O

The O
electrocatalysis O
comprises O
redox O
regeneration O
of O
the O
electrochemically O
created O
ABTS O
( O
+ O
) O
radical O
either O
by O
Trolox O
( O
6 B
- I
hydroxy I
- I
2 I
, I
5 I
, I
7 I
, I
8 I
- I
tetramethychroman I
- I
2 I
- I
carboxylic I
acid I
) O
or O
by O
antioxidants O
present O
in O
studied O
oils O
. O

We O
have O
isolated O
the O
bacterial O
strain O
SY8519 O
, O
which O
has O
been O
shown O
to O
metabolize O
daidzein O
to O
O B
- I
desmethylangolensin I
and O
to O
produce O
2 B
- I
( I
4 I
- I
hydroxyphenyl I
) I
propionic I
acid I
from O
genistein O
. O

According O
to O
chiral O
HPLC O
analysis O
, O
the O
2 B
- I
( I
4 I
- I
hydroxyphenyl I
) I
propionic I
acid I
obtained O
from O
the O
bacterium O
was O
optically O
active O
. O

To O
determine O
the O
absolute O
stereochemistry O
of O
the O
microbial O
product O
, O
we O
prepared O
( B
S I
) I
- I
2 I
- I
( I
4 I
- I
hydroxyphenyl I
) I
propionic I
acid I
from O
( B
S I
) I
- I
2 I
- I
phenylpropionic I
and O
concluded O
that O
the O
microbial O
product O
had O
an O
R O
- O
configuration O
by O
chiral O
HPLC O
analysis O
. O

We O
also O
applied O
the O
metabolite O
to O
mouse O
adipocytes O
and O
found O
that O
2 B
- I
HPPA I
was O
less O
effective O
at O
reducing O
leptin O
secretion O
than O
the O
parent O
compound O
genistein O
. O

Our O
results O
suggested O
that O
' O
O B
- I
desmethylangolensin I
- O
production O
' O
attenuates O
the O
effect O
of O
soy O
isoflavonoids O
by O
reducing O
not O
only O
the O
activity O
of O
daidzein O
but O
also O
that O
of O
genistein O
. O

Flowers O
were O
hand O
- O
pollinated O
and O
the O
resulting O
fruits O
were O
analysed O
at O
different O
developmental O
stages O
using O
an O
HPLC O
- O
DAD O
method O
validated O
for O
the O
quantification O
of O
glucovanillin B
and O
seven O
other O
compounds O
. O

LC O
- O
ESI O
- O
MS O
studies O
corroborated O
the O
identities O
of O
four O
glucosides O
and O
seven O
aglycones O
, O
among O
them O
vanillin O
( O
5 O
. O
7 O
/ O
100 O
g O
) O
, O
4 B
- I
hydroxybenzyl I
alcohol I
( O
3 O
. O
6 O
/ O
100 O
g O
) O
, O
and O
anisyl B
alcohol I
( O
7 O
. O
1 O
/ O
100 O
g O
) O
were O
found O
in O
high O
concentrations O
. O

Development O
of O
sample O
preparation O
method O
for O
isoliquiritigenin B
, O
liquiritin B
, O
and O
glycyrrhizic B
acid I
analysis O
in O
licorice O
by O
ionic O
liquids O
- O
ultrasound O
based O
extraction O
and O
high O
- O
performance O
liquid O
chromatography O
detection O
. O

An O
ionic O
liquid O
- O
based O
ultrasonic O
- O
assisted O
extraction O
( O
ILUAE O
) O
method O
had O
been O
used O
for O
the O
effective O
extraction O
of O
isoliquiritigenin B
( O
IQ O
) O
, O
liquiritin B
( O
LQ O
) O
and O
glycyrrhizic B
acid I
( O
GA O
) O
from O
licorice O
. O

The O
ionic O
liquids O
with O
different O
cations O
and O
anions O
were O
investigated O
in O
this O
work O
and O
0 O
. O
5 O
M O
1 B
- I
butyl I
- I
3 I
- I
methylimidazolium I
bromide I
solution O
was O
selected O
as O
solvent O
. O

The O
comparative O
formation O
of O
the O
heterocyclic O
aromatic O
amine O
2 O
- O
amino O
- O
1 O
- O
methyl O
- O
6 O
- O
phenylimidazo O
[ O
4 O
, O
5 O
- O
b O
] O
pyridine O
( O
PhIP O
) O
in O
both O
creatinine O
/ O
phenylalanine O
( O
CRN B
/ O
Phe O
) O
and O
creatinine O
/ O
phenylalanine O
/ O
4 O
- O
oxo O
- O
2 O
- O
nonenal O
( O
CRN B
/ O
Phe O
/ O
ON O
) O
systems O
was O
studied O
to O
analyse O
the O
ability O
of O
lipid O
- O
derived O
reactive O
carbonyls O
to O
promote O
PhIP O
formation O
. O

Although O
PhIP O
was O
produced O
to O
some O
extent O
in O
the O
CRN B
/ O
Phe O
system O
, O
the O
presence O
of O
the O
oxidized O
lipid O
increased O
considerably O
the O
amount O
of O
PhIP O
produced O
. O

On O
the O
other O
hand O
, O
the O
addition O
of O
the O
lipid O
did O
not O
seem O
to O
produce O
PhIP O
by O
an O
alternative O
mechanism O
because O
PhIP O
was O
formed O
analogously O
in O
both O
CRN B
/ O
Phe O
and O
CRN B
/ O
Phe O
/ O
ON O
systems O
as O
a O
function O
of O
pH O
, O
creatinine O
concentration O
, O
phenylalanine O
concentration O
, O
time O
, O
temperature O
, O
oxygen O
concentration O
in O
the O
reaction O
atmosphere O
, O
and O
the O
addition O
of O
different O
amounts O
of O
ammonia O
. O

All O
these O
results O
suggest O
that O
the O
ability O
of O
lipid O
oxidation O
products O
to O
produce O
PhIP O
is O
related O
to O
their O
capacity O
to O
induce O
the O
Strecker O
degradation O
of O
phenylalanine O
to O
phenylacetaldehyde B
. O

The O
headspace O
volatile O
compounds O
were O
collected O
after O
irradiation O
using O
a O
single O
drop O
of O
n B
- I
heptadecan I
. O

E O
- O
beta O
- O
ocimene O
( O
53 O
. O
81 O
% O
) O
, O
R O
- O
D O
- O
decalactone O
( O
12 O
. O
75 O
% O
) O
, O
alpha O
- O
pinene O
( O
6 O
. O
43 O
% O
) O
, O
n B
- I
heptanol I
( O
6 O
. O
27 O
% O
) O
, O
beta B
- I
phellanderne I
( O
2 O
. O
70 O
% O
) O
and O
linalool O
( O
1 O
. O
89 O
% O
) O
were O
the O
major O
constituents O
. O

CMs O
rapidly O
accumulated O
9 B
, I
10 I
- I
epoxy I
- I
18 I
- I
hydroxyoctadecanoic I
acid I
at O
a O
very O
early O
stage O
of O
leaf O
development O
. O

UPLC O
and O
HPLC O
of O
caffeoyl B
esters I
in O
wild O
and O
cultivated O
Arctium O
lappa O
L O
. O

Analytical O
methods O
including O
ultra O
- O
performance O
liquid O
chromatography O
( O
UPLC O
) O
and O
high O
- O
performance O
liquid O
chromatography O
( O
HPLC O
) O
with O
photodiode O
array O
( O
PDA O
) O
detector O
were O
developed O
for O
the O
analysis O
of O
caffeoylquinic B
acid I
derivatives O
in O
seeds O
, O
leaves O
and O
roots O
of O
Arctium O
lappa O
L O
. O

Subsequently O
the O
methods O
were O
applied O
for O
the O
identification O
and O
quantification O
of O
chlorogenic O
acid O
( O
5 B
- I
CQA I
) O
and O
1 O
, O
5 O
- O
dicaffeoylquinic O
acid O
( O
1 B
, I
5 I
- I
DCQA I
) O
as O
main O
compounds O
in O
samples O
. O

The O
total O
phenolic O
content O
of O
samples O
ranged O
from O
3 O
. O
93 O
to O
14 O
. O
13 O
g O
of O
5 B
- I
CQA I
equivalent O
/ O
100g O
dry O
weight O
( O
DW O
) O
. O

There O
was O
a O
significant O
variability O
from O
89 O
to O
571 O
mg O
/ O
100g O
for O
5 B
- I
CQA I
and O
48 O
to O
486 O
mg O
/ O
100g O
for O
1 B
, I
5 I
- I
DCQA I
in O
dry O
material O
. O

The O
use O
of O
diethylaminoethyl B
microspin O
column O
to O
isolate O
spiked O
lunasin O
in O
human O
plasma O
showed O
that O
most O
lunasin O
( O
37 O
. O
8 O
- O
46 O
. O
5 O
% O
) O
bound O
to O
the O
column O
eluted O
with O
Tris B
- I
HCl I
buffer O
, O
pH O
7 O
. O
5 O
with O
a O
yield O
up O
to O
76 O
. O
6 O
% O
. O

The O
chromatographic O
and O
spectral O
data O
revealed O
the O
presence O
of O
several O
simple O
phenolic O
acids O
, O
derivatives O
of O
both O
caffeic B
and I
benzoic I
acids I
, O
and O
flavonoids O
in O
the O
produced O
extracts O
. O

Purification O
, O
antioxidant O
activity O
and O
protein O
- O
precipitating O
capacity O
of O
punicalin B
from O
pomegranate O
husk O
. O

Punicalin B
is O
a O
kind O
of O
ellagitannin O
, O
existing O
in O
pomegranate O
husk O
, O
and O
has O
shown O
remarkable O
biological O
activities O
. O

A O
rapid O
and O
large O
- O
scale O
separation O
method O
of O
punicalin B
from O
pomegranate O
husk O
was O
established O
, O
using O
medium O
pressure O
liquid O
chromatography O
( O
MPLC O
) O
. O

Under O
this O
condition O
, O
339 O
mg O
of O
95 O
. O
9 O
% O
punicalin B
could O
be O
obtained O
in O
40 O
min O
. O

Afterwards O
, O
the O
antioxidant O
and O
protein O
- O
precipitating O
capacities O
of O
the O
purified O
punicalin B
, O
together O
with O
punicalagin B
, O
were O
evaluated O
. O

Results O
showed O
that O
punicalin B
had O
strong O
antioxidant O
activity O
, O
and O
it O
exhibited O
a O
low O
affinity O
for O
protein O
. O

This O
suggested O
that O
the O
antioxidant O
of O
punicalin B
would O
not O
be O
greatly O
masked O
by O
tannin B
- O
protein O
precipitation O
in O
application O
, O
and O
hence O
confirmed O
punicalin B
to O
be O
a O
promising O
antioxidant O
. O

Highly O
selective O
separation O
of O
arsenite O
species O
[ O
As O
( O
III O
) O
] O
was O
achieved O
by O
chelation O
with O
sodium B
diethyldithiocarbama I
( O
DDTC B
) O
followed O
by O
dispersion O
with O
40 O
mg O
of O
1 B
- I
octyl I
- I
3 I
- I
methylimidazolium I
hexafluorophosphate I
( O
[ B
C I
( I
8 I
) I
mim I
] I
[ I
PF I
( I
6 I
) I
] I
) O
IL O
. O

Thus O
, O
determination O
of O
total O
arsenic O
was O
performed O
by O
previous O
degradation O
of O
organo B
- I
arsenic I
species O
, O
followed O
by O
a O
reduction O
. O

By O
the O
methods O
of O
the O
computer O
simulation O
of O
the O
copigmentation O
process O
we O
determined O
the O
sites O
responsible O
for O
the O
stabilization O
of O
a O
cyanidin B
quinoidal I
base I
- O
baicalin O
complex O
. O

Glucose O
, O
fructose O
and O
sucrose O
increase O
the O
solubility O
of O
protein O
- O
tannin B
complexes O
and O
at O
high O
concentration O
, O
glucose O
and O
sucrose O
interfere O
with O
bisulphite B
bleaching O
of O
wine O
pigments O
. O

Wines O
were O
modified O
with O
increasing O
sugar O
concentrations O
and O
decreasing O
tannin B
concentrations O
and O
analysed O
by O
a O
combination O
of O
protein O
precipitation O
and O
bisulphite B
bleaching O
. O

Increasing O
sugar O
concentration O
decreased O
the O
precipitation O
of O
tannin B
and O
protein O
- O
precipitable O
polymeric O
pigments O
( O
PPP O
) O
. O

The O
use O
of O
a O
hydrogen O
bond O
disruptor O
( O
urea O
) O
to O
reduce O
protein O
- O
tannin B
and O
protein O
- O
pigment O
complex O
formation O
showed O
that O
the O
effect O
of O
sugar O
concentration O
occurred O
by O
increasing O
the O
solubility O
of O
the O
tannin B
- O
protein O
complex O
, O
not O
by O
interfering O
with O
protein O
- O
tannin B
complex O
formation O
. O

There O
was O
also O
an O
increase O
in O
total O
polymeric O
pigments O
at O
each O
tannin B
concentration O
with O
increasing O
glucose O
and O
sucrose O
concentration O
, O
indicating O
that O
sugar O
concentration O
might O
also O
affect O
bisulphite B
bleaching O
of O
wine O
pigments O
. O

While O
a O
significant O
effect O
of O
sugar O
concentration O
on O
tannin B
- O
protein O
complex O
solubility O
was O
observed O
, O
these O
effects O
were O
greatest O
at O
sugar O
concentrations O
far O
in O
excess O
of O
normal O
wine O
making O
conditions O
. O

Under O
normal O
wine O
making O
conditions O
, O
sugar O
concentration O
will O
have O
a O
negligible O
effect O
on O
protein O
- O
precipitable O
tannin B
, O
PPP O
and O
nPPP O
concentrations O
. O

Ribose O
induced O
the O
highest O
degree O
of O
modification O
resulting O
in O
76 O
% O
of O
BLG O
modified O
and O
an O
average O
of O
three O
anhydroribose B
units O
attached O
. O

Influence O
of O
processing O
on O
the O
volatile O
profile O
of O
strawberry O
spreads O
made O
with O
isomaltulose B
. O

A O
new O
strawberry O
spread O
formulated O
with O
fructose O
and O
isomaltulose B
( O
replacing O
sucrose O
partially O
or O
totally O
) O
and O
a O
high O
percentage O
of O
fruit O
was O
developed O
in O
line O
with O
the O
new O
trend O
of O
healthier O
products O
. O

The O
ripeness O
of O
the O
raw O
strawberries O
influences O
the O
concentrations O
of O
some O
of O
the O
compounds O
in O
the O
spreads O
, O
such O
as O
isobutyl B
acetate I
, O
butyl B
butyrate I
, O
3 B
- I
hexen I
- I
1 I
- I
yl I
acetate I
or O
propan B
- I
2 I
- I
ol I
. O

Most O
of O
the O
esters O
and O
alcohols O
decreased O
whereas O
13 O
new O
compounds O
appear O
, O
mostly O
furans B
( O
furfural O
, O
2 B
- I
acetylfurane I
, O
5 B
- I
methyl I
furfural I
, O
mesifurane B
) O
and O
aldehydes O
( O
octanal O
, O
nonanal B
, O
decanal B
and O
benzaldeyhde B
) O
. O

In O
general O
, O
the O
spreads O
formulated O
with O
sucrose O
- O
isomaltulose B
that O
contained O
higher O
levels O
of O
pectin O
and O
citric O
acid O
gave O
better O
results O
in O
the O
preservation O
of O
the O
original O
aromatic O
compounds O
in O
raw O
strawberries O
. O

Optimization O
of O
ABTS B
radical I
cation I
assay O
specifically O
for O
determination O
of O
antioxidant O
capacity O
of O
intracellular O
extracts O
of O
microalgae O
and O
cyanobacteria O
. O

GC O
/ O
MS O
analysis O
showed O
that O
aldehydes O
, O
alcohols O
, O
and O
pyrazines B
were O
the O
main O
volatile O
components O
of O
almonds O
. O

Aliphatic O
aldehydes O
such O
as O
hexanal B
, O
( B
E I
) I
- I
2 I
- I
octenal I
, O
and O
nonanal B
were O
produced O
as O
off O
- O
odours O
during O
storage O
. O

We O
postulate O
that O
hexanal B
and O
nonanal B
might O
be O
better O
indicators O
of O
the O
shelf O
life O
of O
roasted O
almonds O
than O
the O
current O
standard O
, O
peroxide O
value O
. O

Synthesis O
of O
new O
triazole B
acetamides I
with O
inotropic O
effects O
. O

A O
series O
of O
new O
triazole B
acetamides I
5a O
- O
w O
were O
synthesized O
and O
evaluated O
for O
their O
positive O
inotropic O
activity O
of O
left O
atrium O
stroke O
volume O
on O
isolated O
rabbit O
- O
heart O
preparations O
. O

The O
majority O
of O
the O
derivatives O
presented O
favorable O
in O
vitro O
activity O
compared O
with O
the O
reference O
drug O
, O
milrinone B
. O

Among O
them O
triazole B
acetamide I
5a O
was O
identified O
as O
the O
most O
potent O
with O
20 O
. O
29 O
+ O
/ O
- O
0 O
. O
18 O
% O
increased O
stroke O
volume O
( O
milrinone B
: O
2 O
. O
46 O
+ O
/ O
- O
0 O
. O
07 O
% O
) O
at O
a O
concentration O
of O
3 O
x O
10 O
( O
- O
5 O
) O
M O
. O

Novel O
limonene O
and O
citral O
based O
2 B
, I
5 I
- I
disubstituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
: O
a O
natural O
product O
coupled O
approach O
to O
semicarbazones B
for O
antiepileptic O
activity O
. O

Two O
novel O
series O
of O
N B
( I
4 I
) I
- I
( I
5 I
- I
( I
2 I
/ I
3 I
/ I
4 I
- I
substituted I
- I
phenyl I
) I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazol I
- I
2 I
- I
yl I
) I
- I
N I
( I
1 I
) I
- I
( I
2 I
- I
methyl I
- I
5 I
- I
( I
prop I
- I
1 I
- I
en I
- I
2 I
- I
yl I
) I
cyclohex I
- I
2 I
- I
enylidene I
) I
semicarbazide I
and O
N O
( O
4 O
) O
- O
( O
5 O
- O
( O
2 O
/ O
3 O
/ O
4 O
- O
substituted O
- O
phenyl O
) O
- O
1 O
, O
3 O
, O
4 O
- O
oxadiazol O
- O
2 O
- O

The O
anticonvulsant O
activities O
of O
the O
compounds O
were O
investigated O
using O
maximal O
electroshock O
seizure O
( O
MES O
) O
, O
subcutaneous O
pentylenetrtrazole B
( O
scPTZ O
) O
and O
subcutaneous O
strychnine O
( O
scSTY O
) O
models O
. O

Lead O
optimization O
of O
isocytosine B
- O
derived O
xanthine O
oxidase O
inhibitors O
. O

We O
report O
our O
attempts O
at O
improving O
the O
oral O
efficacy O
of O
low O
- O
nanomolar O
inhibitors O
of O
xanthine O
oxidase O
from O
isocytosine B
series O
through O
chemical O
modifications O
. O

Discovery O
and O
preliminary O
structure O
- O
activity O
relationship O
analysis O
of O
1 B
, I
14 I
- I
sperminediphenylacet I
as O
potent O
and O
selective O
antimalarial O
lead O
compounds O
. O

Screening O
of O
synthesized O
and O
isolated O
marine O
natural O
products O
for O
in O
vitro O
activity O
against O
four O
parasitic O
protozoa O
has O
identified O
the O
ascidian O
metabolite O
1 B
, I
14 I
- I
sperminedihomovanill I
( O
orthidine B
F I
, O
1 O
) O
as O
being O
a O
non O
- O
toxic O
, O
moderate O
growth O
inhibitor O
of O
Plasmodium O
falciparum O
( O
IC O
( O
50 O
) O
0 O
. O
89 O
mu O
M O
) O
. O

One O
analogue O
, O
1 B
, I
14 I
- I
spermine I
- I
di I
- I
( I
2 I
- I
hydroxyphenylacetami I
) I
( O
3 O
) O
, O
exhibited O
two O
orders O
of O
magnitude O
increased O
anti O
- O
P O
. O

The O
ease O
of O
synthesis O
of O
phenylacetamido B
- I
polyamines I
, O
coupled O
with O
potent O
nM O
levels O
of O
activity O
towards O
dual O
drug O
resistant O
strains O
of O
P O
. O
falciparum O
makes O
this O
compound O
class O
of O
interest O
in O
the O
development O
of O
new O
antimalarial O
therapeutics O
. O

Lead O
optimization O
of O
a O
dihydropyrrolopyrimi B
inhibitor O
against O
phosphoinositide O
3 O
- O
kinase O
( O
PI3K O
) O
to O
improve O
the O
phenol B
glucuronic I
acid I
conjugation O
. O

Based O
on O
structure O
- O
activity O
relationship O
( O
SAR O
) O
information O
and O
a O
FlexSIS O
docking O
simulation O
score O
, O
aminopyrimidine B
was O
identified O
as O
a O
bioisostere O
of O
phenol O
. O

An O
X O
- O
ray O
structure O
study O
revealed O
a O
hydrogen O
bonding O
pattern O
of O
aminopyrimidine B
derivatives O
. O

Finally O
, O
aminopyrimidine B
derivatives O
33 O
showed O
strong O
tumor O
growth O
inhibition O
against O
a O
KPL O
- O
4 O
breast O
cancer O
xenograft O
model O
in O
vivo O
. O

High O
- O
throughput O
screening O
resulted O
in O
discovery O
of O
a O
hit O
compound O
( O
ST B
- I
37 I
) O
possessing O
a O
benzimidazole O
core O
which O
led O
to O
a O
potent O
compound O
series O
. O

Herein O
, O
we O
report O
SAR O
studies O
which O
involved O
structural O
modifications O
to O
the O
phenyl O
rings O
and O
methylamino B
linker O
portion O
attached O
to O
the O
benzimidazole O
core O
. O

Ultimately O
, O
lead O
compound O
ST B
- I
193 I
was O
identified O
and O
later O
found O
to O
be O
efficacious O
in O
a O
lethal O
LASV O
guinea O
pig O
model O
showing O
superior O
protection O
compared O
to O
ribavirin O
treatment O
. O

Tri B
- I
and I
diorganotin I
( I
IV I
) I
complexes O
of O
biologically O
important O
orotic B
acid I
: O
synthesis O
, O
spectroscopic O
studies O
, O
in O
vitro O
anti O
- O
cancer O
, O
DNA O
fragmentation O
, O
enzyme O
assays O
and O
in O
vivo O
anti O
- O
inflammatory O
activities O
. O

Tri B
- I
and I
diorganotin I
( I
IV I
) I
orotates I
of O
general O
formula O
, O
R B
( I
n I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
( I
m I
) I
[ O
n O
= O
3 O
/ O
2 O
, O
m O
= O
1 O
/ O
2 O
, O
R O
= O
Me O
, O
n B
- I
Bu I
, O
n B
- I
Oct I
and O
Ph O
; O
H B
( I
2 I
) I
Or I
( I
- I
) I
= O
monoanion O
of O
orotic B
acid I
( O
H B
( I
3 I
) I
Or I
) O
] O
( O
n B
- I
Bu I
( I
2 I
) I
Sn I
( I
HOr I
) I
as O
an O
exception O
) O
have O
been O
synthesized O
. O

On O
the O
basis O
of O
various O
spectroscopic O
studies O
it O
is O
revealed O
that O
R B
( I
3 I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
and O
R B
( I
2 I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
( I
2 I
) I
exhibit O
distorted O
trigonal O
- O
bipyramidal O
and O
distorted O
octahedral O
geometry O
, O
respectively O
, O
and O
n B
- I
Bu I
( I
2 I
) I
Sn I
( I
HOr I
) I
shows O
both O
five O
and O
six O
coordination O
geometry O
around O
tin O
. O

In O
vitro O
anti O
- O
cancer O
screening O
against O
MCF O
- O
7 O
( O
mammary O
) O
, O
HEK O
- O
293 O
( O
kidney O
) O
, O
PC O
- O
3 O
( O
prostate O
) O
, O
HCT O
- O
15 O
( O
colon O
) O
and O
HepG O
- O
2 O
( O
liver O
) O
cancer O
cell O
lines O
suggest O
that O
the O
n B
- I
Oct I
( I
2 I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
( I
2 I
) I
is O
the O
most O
active O
complex O
among O
all O
of O
the O
studied O
complexes O
. O

Determination O
of O
bioactive O
, O
free O
isothiocyanates O
from O
a O
glucosinolate B
- O
containing O
phytotherapeutic O
agent O
: O
a O
pilot O
study O
with O
in O
vitro O
models O
and O
human O
intervention O
. O

Isothiocyanates O
( O
ITCs B
) O
derived O
from O
plants O
of O
the O
order O
Brassicales O
are O
known O
for O
their O
antibacterial O
, O
anti O
- O
inflammatory O
or O
anticarcinogenic O
potential O
. O

Although O
only O
the O
free O
ITCs B
exert O
bioactivity O
, O
quantification O
in O
vivo O
is O
almost O
exclusively O
performed O
on O
total O
ITC B
/ O
metabolite O
content O
. O

We O
therefore O
investigated O
in O
a O
pilot O
study O
the O
amount O
of O
free O
ITC B
at O
different O
steps O
critical O
for O
therapeutic O
efficacy O
. O

A O
sensitive O
and O
specific O
GC O
- O
MS O
/ O
MS O
method O
for O
the O
simultaneous O
quantification O
of O
individual O
free O
ITC B
after O
solid O
- O
phase O
extraction O
( O
SPE O
) O
was O
developed O
. O

We O
show O
here O
that O
release O
of O
biologically O
active O
ITC B
from O
plants O
occurs O
at O
not O
only O
alkaline O
but O
also O
acidic O
pH O
. O

This O
was O
also O
observed O
in O
the O
urine O
of O
human O
volunteers O
, O
where O
- O
in O
correlation O
with O
the O
pH O
value O
- O
a O
mean O
of O
0 O
. O
16 O
to O
1 O
. O
03 O
mu O
mol O
ITC B
was O
detected O
after O
oral O
application O
of O
a O
phytotherapeutic O
agent O
containing O
30 O
. O
4 O
mu O
mol O
of O
the O
initial O
pro O
- O
drugs O
. O

The O
amounts O
of O
free O
ITC B
being O
necessary O
for O
bioactivity O
in O
vitro O
were O
found O
to O
be O
indeed O
achieved O
in O
vivo O
. O

These O
data O
might O
be O
helpful O
to O
better O
understand O
the O
beneficial O
effects O
of O
ITC B
observed O
in O
vivo O
. O

Cytotoxicity O
and O
structure O
activity O
relationships O
of O
phytosterol B
from O
Phyllanthus O
emblica O
. O

Fourteen O
sterols O
( O
1 O
- O
14 O
) O
, O
including O
two O
new O
sterols O
, O
trihydroxysitosterol B
( O
2 O
) O
and O
5 B
alpha I
, I
6 I
beta I
, I
7 I
alpha I
- I
7 I
alpha I
- I
acetoxysitosterol I
( O
3 O
) O
, O
were O
isolated O
from O
the O
branches O
and O
leaves O
of O
Phyllanthus O
emblica O
L O
. O

Within O
the O
series O
of O
phytosterol B
derivatives O
tested O
, O
compound O
15 O
was O
the O
most O
active O
, O
displaying O
potent O
cytotoxicity O
against O
HL O
- O
60 O
with O
IC O
( O
50 O
) O
of O
5 O
. O
10 O
mu O
mol O
/ O
L O
, O
and O
most O
of O
the O
active O
compounds O
showed O
selective O
cytotoxicity O
against O
tumor O
and O
non O
- O
tumor O
cell O
lines O
, O
especially O
compound O
10 O
with O
a O
safety O
index O
of O
4 O
. O
42 O
. O

Both O
suramin O
and O
doxorubicin O
are O
potent O
( O
low O
- O
micro O
M O
) O
DNA O
- O
and O
nucleotide B
triphosphate I
- O
competitive O
priming O
inhibitors O
that O
interact O
with O
more O
than O
one O
site O
on O
Mtb O
DnaG O
. O

Development O
of O
hypoxia O
- O
inducible O
factor O
( O
HIF O
) O
- O
1 O
alpha O
inhibitors O
: O
effect O
of O
ortho B
- I
carborane I
substituents O
on O
HIF O
transcriptional O
activity O
under O
hypoxia O
. O

A O
series O
of O
substituted O
ortho B
- I
carboranylphenoxyace I
were O
synthesized O
and O
evaluated O
for O
their O
ability O
to O
inhibit O
hypoxia O
- O
induced O
HIF O
- O
1 O
transcriptional O
activity O
using O
a O
cell O
- O
based O
reporter O
assay O
in O
HeLa O
cells O
expressing O
the O
HRE O
- O
dependent O
firefly O
luciferase O
reporter O
construct O
( O
HRE O
- O
Luc O
) O
and O
constitutively O
expressing O
CMV O
- O
driven O
Renilla O
luciferase O
reporter O
, O
and O
their O
ability O
to O
inhibit O
cell O
growth O
( O
GI O
( O
50 O
) O
) O
using O
the O
MTT O
assay O
. O

The O
porcine O
heart O
malate O
dehydrogenase O
( O
MDH O
) O
refolding O
assay O
revealed O
that O
compound O
1l O
inhibited O
human O
Hsp60 O
chaperone O
activity O
( O
IC O
( O
50 O
) O
: O
6 O
. O
80 O
+ O
/ O
- O
0 O
. O
25 O
mu O
M O
) O
and O
this O
inhibition O
activity O
was O
higher O
than O
that O
of O
ETB B
( O
IC O
( O
50 O
) O
: O
10 O
. O
9 O
+ O
/ O
- O
0 O
. O
63 O
mu O
M O
) O
. O

Radioreceptor O
binding O
assays O
showed O
a O
significant O
increase O
in O
alpha B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methyl I
- I
4 I
- I
isoxazole I
propionate I
and O
N O
- O
methyl O
- O
D O
- O
aspartate O
receptors O
density O
which O
was O
confirmed O
by O
immunohistochemical O
studies O
. O

Antioxidant O
properties O
of O
Neu2000 B
on O
mitochondrial O
free O
radicals O
and O
oxidative O
damage O
. O

Neu2000 B
[ O
2 B
- I
hydroxy I
- I
5 I
- I
( I
2 I
, I
3 I
, I
5 I
, I
6 I
- I
tetrafluoro I
- I
4 I
trifluoromethylbenzy I
) I
benzoic I
acid I
] O
is O
a O
dual O
- O
acting O
neuroprotective O
agent O
that O
functions O
both O
as O
a O
noncompetitive O
N O
- O
methyl O
- O
d O
- O
aspartate O
( O
NMDA O
) O
receptor O
antagonist O
and O
a O
free O
radical O
scavenger O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
scavenging O
activity O
of O
Neu2000 B
on O
various O
classes O
of O
reactive O
oxygen O
species O
and O
reactive O
nitrogen O
species O
( O
ROS O
/ O
RNS O
) O
as O
well O
as O
its O
efficacy O
for O
reducing O
free O
radicals O
and O
oxidative O
stress O
/ O
damage O
induced O
in O
spinal O
cord O
mitochondrial O
preparations O
. O

Neu2000 B
exerted O
scavenging O
activity O
against O
superoxide O
, O
nitric O
oxide O
, O
and O
hydroxyl O
radicals O
, O
and O
efficiently O
scavenged O
peroxynitrite O
. O

In O
the O
mitochondrial O
studies O
, O
Neu2000 B
markedly O
inhibited O
ROS O
/ O
RNS O
and O
hydrogen O
peroxide O
levels O
following O
antimycin B
treatment O
. O

In O
addition O
, O
Neu2000 B
effectively O
scavenged O
hydroxyl O
radicals O
generated O
by O
iron B
( I
III I
) I
- I
ascorbate I
, O
reduced O
protein O
carbonyl O
formation O
mediated O
by O
hydroxyl O
radicals O
and O
peroxynitrite O
, O
and O
prevented O
glutathione O
oxidation O
caused O
by O
tert O
- O
butyl O
hydroperoxide O
in O
isolated O
mitochondria O
. O

Interestingly O
, O
incubation O
of O
isolated O
mitochondria O
with O
Neu2000 B
followed O
by O
centrifugation O
and O
removal O
of O
the O
supernatant O
also O
resulted O
in O
a O
concentration O
- O
dependent O
decrease O
in O
lipid O
peroxidation O
. O

This O
observation O
suggests O
that O
Neu2000 B
enters O
mitochondria O
to O
target O
free O
radicals O
or O
indirectly O
affects O
mitochondrial O
function O
in O
a O
manner O
that O
promotes O
antioxidant O
activity O
. O

The O
results O
of O
the O
present O
study O
demonstrate O
that O
Neu2000 B
possesses O
potent O
in O
vitro O
antioxidant O
activity O
due O
, O
most O
likely O
, O
to O
its O
active O
phenoxy O
group O
. O

Interestingly O
, O
two O
different O
PTP O
inhibitors O
( O
namely O
, O
cyclosporin B
A I
and O
nortriptyline O
) O
prevented O
both O
ethanol O
- O
induced O
neuronal O
death O
in O
vivo O
and O
ethanol O
- O
induced O
behavioral O
modifications O
. O

The O
selective O
metabotropic O
glutamate O
2 O
/ O
3 O
receptor O
agonist O
MGS0028 B
reverses O
psychomotor O
abnormalities O
and O
recognition O
memory O
deficits O
in O
mice O
lacking O
the O
pituitary O
adenylate O
cyclase O
- O
activating O
polypeptide O
. O

In O
this O
study O
, O
we O
examined O
the O
effects O
of O
the O
selective O
metabotropic O
glutamate O
2 O
/ O
3 O
( O
mGlu2 O
/ O
3 O
) O
receptor O
agonist O
MGS0028 B
on O
behavioral O
abnormalities O
in O
mice O
lacking O
the O
pituitary O
adenylate O
cyclase O
- O
activating O
polypeptide O
( O
PACAP O
) O
, O
an O
experimental O
model O
of O
psychiatric O
disorders O
such O
as O
schizophrenia O
and O
attention O
- O
deficit O
/ O
hyperactivity O
disorder O
. O

We O
found O
that O
PACAP O
- O
deficient O
mice O
showed O
impairments O
in O
the O
novel O
object O
recognition O
test O
and O
these O
impairments O
were O
improved O
by O
MGS0028 B
( O
0 O
. O
1 O
mg O
/ O
kg O
) O
. O

Similarly O
, O
MGS0028 B
improved O
hyperactivity O
and O
jumping O
behaviors O
, O
but O
did O
not O
reverse O
increased O
immobility O
times O
in O
the O
forced O
swim O
test O
in O
PACAP O
- O
deficient O
mice O
. O

These O
results O
suggest O
that O
MGS0028 B
may O
be O
a O
potential O
, O
novel O
treatment O
for O
psychiatric O
disorders O
. O

Differential O
Effects O
of O
Crambescins O
and O
Crambescidin B
816 I
in O
Voltage O
- O
Gated O
Sodium O
, O
Potassium O
and O
Calcium O
Channels O
in O
Neurons O
. O

Crambescins B
and O
crambescidins B
are O
two O
families O
of O
guanidine B
alkaloids I
from O
the O
marine O
sponge O
Crambe O
crambe O
. O

Although O
very O
little O
information O
about O
their O
biological O
effect O
has O
been O
reported O
, O
it O
is O
known O
that O
crambescidin B
816 I
( O
Cramb816 B
) O
blocks O
calcium O
channels O
in O
a O
neuroblastoma O
X O
glioma O
cell O
line O
. O

Taking O
this O
into O
account O
, O
and O
the O
fact O
that O
ion O
channels O
are O
frequent O
targets O
for O
natural O
toxins O
, O
we O
examined O
the O
effect O
of O
Cramb816 B
and O
three O
compounds O
from O
the O
crambescin B
family O
, O
norcrambescin B
A2 I
( O
NcrambA2 B
) O
, O
crambescin B
A2 I
( O
CrambA2 B
) O
, O
and O
crambescin B
C1 I
( O
CrambC1 B
) O
, O
in O
the O
main O
voltage O
- O
dependent O
ion O
channels O
in O
neurons O
: O
sodium O
, O
potassium O
, O
and O
calcium O
channels O
. O

Electrophysiological O
recordings O
of O
voltage O
gated O
sodium O
, O
potassium O
, O
and O
calcium O
currents O
, O
in O
the O
presence O
of O
these O
guanidine B
alkaloids I
, O
were O
performed O
in O
cortical O
neurons O
from O
embryonic O
mice O
. O

Different O
effects O
were O
discovered O
: O
crambescins B
inhibited O
K O
( O
+ O
) O
currents O
with O
the O
following O
potency O
: O
NcrambA2 B
> O
CrambC1 B
> O
CrambA2 B
, O
while O
Cramb816 B
lacked O
an O
effect O
. O

Only O
CrambC1 B
and O
Cramb816 B
partially O
blocked O
Na O
( O
+ O
) O
total O
current O
. O

However O
, O
Cramb816 B
partially O
blocked O
Ca O
( O
2 O
+ O
) O
, O
while O
NcrambA2 B
did O
not O
. O

Since O
the O
blocking O
effect O
of O
Cramb816 B
on O
calcium O
currents O
has O
not O
been O
previously O
reported O
in O
detail O
, O
we O
further O
pharmacologically O
isolated O
the O
two O
main O
fractions O
of O
HVA O
Ca O
( O
2 O
+ O
) O
channels O
in O
neurons O
and O
investigated O
the O
Cramb816 B
effect O
on O
them O
. O

Here O
, O
we O
revealed O
that O
Cav1 O
or O
L O
- O
type O
calcium O
channels O
are O
the O
main O
target O
for O
Cramb816 B
. O

These O
two O
families O
of O
guanidine B
alkaloids I
clearly O
showed O
a O
structure O
- O
activity O
relationship O
with O
the O
crambescins B
acting O
on O
voltage O
- O
gated O
potassium O
channels O
, O
while O
Cramb816 B
blocks O
the O
voltage O
- O
gated O
calcium O
channel O
Cav1 O
with O
higher O
potency O
than O
nifedipine O
. O

The O
novel O
evidence O
that O
Cramb816 B
partially O
blocked O
Ca O
( O
V O
) O
and O
Na O
( O
V O
) O
channels O
in O
neurons O
suggests O
that O
this O
compound O
might O
be O
involved O
in O
decreasing O
the O
neurotransmitter O
release O
and O
synaptic O
transmission O
in O
the O
central O
nervous O
system O
. O

The O
findings O
presented O
here O
provide O
the O
first O
detailed O
approach O
on O
the O
different O
effects O
of O
crambescin B
and O
crambescidin B
compounds O
in O
voltage O
- O
gated O
sodium O
, O
potassium O
, O
and O
calcium O
channels O
in O
neurons O
and O
thus O
provide O
a O
basis O
for O
future O
studies O
. O

Protein O
synthesis O
inhibition O
and O
oxidative O
stress O
induced O
by O
cylindrospermopsin B
elicit O
apoptosis O
in O
primary O
rat O
hepatocytes O
. O

Cylindrospermopsin B
( O
CYN B
) O
is O
nowadays O
recognized O
as O
a O
widely O
distributed O
freshwater O
cyanobacterial O
toxin O
. O

Given O
that O
the O
liver O
seems O
to O
be O
the O
main O
target O
of O
cylindrospermopsin B
, O
in O
this O
work O
we O
used O
cultures O
of O
primary O
rat O
hepatocytes O
to O
study O
the O
type O
of O
cell O
death O
induced O
by O
CYN B
nanomolar O
concentrations O
. O

We O
show O
that O
cylindrospermopsin B
induces O
apoptosis O
in O
primary O
rat O
hepatocytes O
. O

Licochalcone B
A I
( O
I O
) O
, O
isolated O
from O
the O
roots O
of O
Chinese O
licorice O
, O
is O
the O
most O
promising O
antimalarial O
compound O
reported O
so O
far O
. O

In O
continuation O
of O
our O
drug O
discovery O
program O
, O
we O
isolated O
two O
similar O
chalcones O
, O
medicagenin B
( O
II O
) O
and O
munchiwarin B
( O
III O
) O
, O
from O
Crotalaria O
medicagenia O
, O
which O
exhibited O
antimalarial O
activity O
against O
Plasmodium O
falciparum O
. O

The O
neuropeptide O
oxytocin O
has O
emerged O
as O
an O
important O
anorexigen B
in O
the O
regulation O
of O
energy O
balance O
. O

Safrole B
- I
2 I
' I
, I
3 I
' I
- I
oxide I
induces O
atherosclerotic O
plaque O
vulnerability O
in O
apolipoprotein O
E O
- O
knockout O
mice O
. O

Safrole B
- I
2 I
' I
, I
3 I
' I
- I
oxide I
( O
SFO B
) O
is O
the O
major O
electrophilic O
metabolite O
of O
safrole B
( O
4 B
- I
allyl I
- I
1 I
, I
2 I
- I
methylenedioxybenzen I
) O
, O
a O
natural O
plant O
constituent O
found O
in O
essential O
oils O
of O
numerous O
edible O
herbs O
and O
spices O
and O
in O
food O
containing O
these O
herbs O
, O
such O
as O
pesto O
sauce O
, O
cola O
beverages O
and O
bologna O
sausages O
. O

The O
effects O
of O
SFO B
in O
mammalian O
systems O
, O
especially O
the O
cardiovascular O
system O
, O
are O
little O
known O
. O

In O
this O
study O
, O
we O
investigated O
SFO B
- O
induced O
atherosclerotic O
plaque O
vulnerability O
( O
possibility O
of O
rupture O
) O
in O
apolipoprotein O
E O
- O
knockout O
( O
apoE O
( O
- O
/ O
- O
) O
) O
mice O
. O

Lipid O
area O
in O
vessel O
wall O
reached O
59 O
. O
8 O
% O
in O
high O
dose O
SFO B
( O
SFO B
- O
HD O
) O
treated O
group O
, O
which O
is O
only O
31 O
. O
2 O
% O
in O
control O
group O
. O

SFO B
treatment O
changed O
the O
lesion O
composition O
to O
an O
unstable O
phenotype O
, O
increased O
the O
number O
of O
apoptotic O
cells O
in O
plaque O
and O
the O
endothelium O
in O
plaques O
was O
damaged O
after O
SFO B
treatment O
. O

Furthermore O
, O
compared O
with O
control O
groups O
, O
the O
plaque O
endothelium O
level O
of O
p75 O
( O
NTR O
) O
was O
3 O
- O
fold O
increased O
and O
the O
liver O
level O
of O
p75 O
( O
NTR O
) O
was O
17 O
. O
4 O
- O
fold O
increased O
by O
SFO B
- O
HD O
. O

Meanwhile O
, O
the O
serum O
level O
of O
KC O
( O
a O
functional O
homolog O
of O
IL O
- O
8 O
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice O
) O
in O
apoE O
( O
- O
/ O
- O
) O
mice O
was O
up O
to O
357pg O
/ O
ml O
in O
SFO B
- O
HD O
treated O
group O
. O

Thus O
, O
SFO B
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE O
( O
- O
/ O
- O
) O
mice O
through O
activating O
p75 O
( O
NTR O
) O
and O
IL O
- O
8 O
and O
cell O
apoptosis O
in O
plaque O
. O

In O
vitro O
and O
in O
vivo O
anti O
- O
inflammatory O
effects O
of O
4 B
- I
methoxy I
- I
5 I
- I
hydroxycanthin I
- I
6 I
- I
one I
, O
a O
natural O
alkaloid O
from O
Picrasma O
quassioides O
. O

In O
the O
present O
study O
, O
we O
evaluated O
the O
anti O
- O
inflammatory O
effect O
of O
4 B
- I
methoxy I
- I
5 I
- I
hydroxycanthin I
- I
6 I
- I
one I
( O
CAN B
) O
, O
a O
natural O
alkaloid O
isolated O
from O
Picrasma O
quassioides O
. O

CAN B
significantly O
inhibited O
the O
production O
of O
NO O
and O
the O
release O
of O
TNF O
- O
alpha O
induced O
by O
LPS O
in O
macrophage O
RAW O
264 O
. O
7 O
. O

Western O
blot O
showed O
that O
CAN B
can O
downregulate O
the O
expression O
of O
iNOS O
protein O
. O

After O
oral O
administration O
, O
CAN B
( O
3 O
, O
9 O
, O
and O
27 O
mg O
/ O
kg O
) O
reduced O
the O
development O
of O
carrageenan O
- O
induced O
paw O
edema O
and O
complete O
Freund O
' O
s O
adjuvant O
( O
CFA O
) O
- O
induced O
chronic O
arthritis O
in O
rats O
. O

The O
observed O
results O
indicated O
that O
pre O
- O
treatment O
with O
CAN B
might O
be O
an O
effective O
therapeutic O
intervention O
against O
inflammatory O
diseases O
including O
chronic O
arthritis O
. O

Bioavailability O
of O
stabilised O
ferrous B
gluconate I
with O
glycine O
in O
fresh O
cheese O
matrix O
: O
a O
novel O
iron O
compound O
for O
food O
fortification O
. O

This O
study O
aims O
to O
investigate O
the O
bioavailability O
of O
ferrous B
gluconate I
stabilised O
with O
glycine O
( O
FGSG O
) O
in O
a O
fresh O
cheese O
fortified O
with O
zinc O
. O

The O
iron O
bioavailability O
of O
fresh O
cheese O
fortified O
with O
either O
FGSG O
and O
with O
or O
without O
zinc O
and O
FGSG O
in O
aqueous O
solution O
and O
a O
water O
solution O
of O
ferrous B
ascorbate I
( O
reference O
dose O
) O
was O
studied O
using O
double O
radio B
iron I
( O
( B
55 I
) I
Fe I
and O
( O
59 O
) O
Fe O
) O
erythrocyte O
incorporation O
in O
15 O
male O
subjects O
. O

The O
results O
of O
the O
present O
study O
show O
that O
the O
novel O
iron O
compound O
ferrous B
gluconate I
stabilised O
with O
glycine O
in O
a O
fresh O
cheese O
matrix O
is O
a O
good O
source O
of O
iron O
and O
can O
be O
used O
in O
iron O
fortification O
programmes O
. O

Infrared O
multiple O
photon O
dissociation O
( O
IRMPD O
) O
spectroscopy O
of O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
G I
) I
Cl I
] I
( I
+ I
) I
and O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
A I
) I
Cl I
] I
( I
+ I
) I
ions O
( O
where O
A O
is O
adenine O
and O
G O
is O
guanine O
) O
has O
been O
performed O
in O
two O
spectral O
regions O
, O
950 O
- O
1900 O
and O
2900 O
- O
3700 O
cm O
( O
- O
1 O
) O
. O

Quantum O
chemical O
calculations O
at O
the O
B3LYP O
/ O
LACV3P O
/ O
6 O
- O
311G O
* O
* O
level O
yield O
the O
optimized O
geometries O
and O
IR O
spectra O
for O
the O
conceivable O
isomers O
of O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
G I
) I
Cl I
] I
( I
+ I
) I
and O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
A I
) I
Cl I
] I
( I
+ I
) I
, O
whereby O
the O
cisplatin O
residue O
is O
attached O
to O
the O
N7 O
, O
N3 O
, O
or O
carbonyl B
oxygen I
atom O
, O
( O
O6 B
) O
, O

In O
agreement O
with O
computational O
results O
, O
the O
IR O
characterization O
of O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
G I
) I
Cl I
] I
( I
+ I
) I
points O
to O
a O
covalent O
structure O
where O
Pt O
is O
bound O
to O
the O
N7 O
atom O
of O
guanine O
. O

The O
experimental O
C O
= O
O O
stretching O
feature O
of O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
G I
) I
Cl I
] I
( I
+ I
) I
at O
1718 O
cm O
( O
- O
1 O
) O
, O
remarkably O
red O
- O
shifted O
with O
respect O
to O
an O
unperturbed O
C O
= O
O O
stretching O
mode O
, O
is O
indicative O
of O
a O
lengthened O
CO O
bond O
in O
guanine O
, O
a O
signature O
that O
this O
group O
is O
involved O
in O
hydrogen O
bonding O
. O

The O
IRMPD O
spectra O
of O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
A I
) I
Cl I
] I
( I
+ I
) I
are O
consistent O
with O
the O
presence O
of O
two O
major O
isomers O
, O
PtAN3 B
and O
PtAN1 B
, O
where O
Pt O
is O
bound O
to O
the O
N3 O
and O
N1 O
positions O
of O
native O
adenine O
, O
respectively O
. O

Schizosaccharomyces O
pombe O
contains O
two O
paralogous O
proteins O
, O
Mag1 O
and O
Mag2 O
, O
related O
to O
the O
helix O
- O
hairpin O
- O
helix O
( O
HhH O
) O
superfamily O
of O
alkylpurine B
DNA O
glycosylases O
from O
yeast O
and O
bacteria O
. O

Mag1 O
excises O
N3 B
- I
and I
N7 I
- I
alkylguanines I
and O
1 B
, I
N I
( I
6 I
) I
- I
ethenoadenine I
from O
DNA O
, O
whereas O
Mag2 O
has O
been O
reported O
to O
have O
no O
detectible O
alkylpurine B
base O
excision O
activity O
despite O
high O
sequence O
and O
active O
site O
similarity O
to O
Mag1 O
. O

The O
most O
intensive O
stimulating O
DOAs O
were O
further O
investigated O
and O
compared O
with O
the O
known O
P O
- O
gp O
model O
substrates O
sertraline B
and O
verapamil O
. O

ATPase O
stimulation O
kinetics O
could O
be O
modeled O
for O
the O
entactogen O
3 B
, I
4 I
- I
methylenedioxy I
- I
alpha I
- I
ethylphenethylamine I
( O
3 B
, I
4 I
- I
BDB I
) O
, O
the O
hallucinogen O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
( O
DOI O
) O
, O
the O
abused O
alkaloid O
glaucine O
, O
the O
opioid O
- O
like O
drugs O
N B
- I
iso I
- I
propyl I
- I
1 I
, I
2 I
- I
diphenylethylamine I
( O
NPDPA B
) O
, O
and O
N O
- O
( O
1 O
- O
phenylcyclohexyl O
) O
- O

3 O
- O
ethoxypropanamine O
( O
PCEPA B
) O
, O
with O
K O
( O
m O
) O
and O
V O
( O
max O
) O
values O
within O
the O
same O
range O
as O
for O
verapamil O
or O
sertraline B
. O

The O
use O
of O
Reamer O
Irrigator O
Aspirator O
( O
RIA O
) O
autograft O
harvest O
in O
the O
treatment O
of O
critical O
- O
sized O
iliac O
wing O
defects O
in O
sheep O
: O
investigation O
of O
dexamethasone O
and O
beta B
- I
tricalcium I
phosphate I
augmentation O
. O

A O
reamer O
bone O
graft O
alone O
, O
or O
after O
short O
term O
incubation O
in O
a O
dexamethasone O
enriched O
solution O
, O
and O
a O
reamer O
graft O
collected O
using O
beta B
- I
tricalcium I
phosphate I
( O
beta B
- I
TCP I
) O
granules O
in O
the O
filter O
of O
the O
RIA O
collection O
device O
were O
compared O
to O
autologous O
iliac O
wing O
graft O
. O

Reamer O
graft O
collected O
using O
beta B
- I
TCP I
granules O
( O
29 O
. O
2 O
+ O
/ O
- O
1 O
. O
7 O
% O
) O
in O
the O
filter O
produced O
a O
significantly O
higher O
amount O
of O
bone O
in O
comparison O
to O
an O
autologous O
iliac O
wing O
graft O
evaluated O
by O
micro O
- O
CT O
. O

If O
avoidance O
of O
an O
iliac O
wing O
graft O
is O
desirable O
, O
or O
a O
reaming O
procedure O
is O
required O
, O
then O
a O
RIA O
graft O
or O
RIA O
graft O
plus O
beta B
- I
TCP I
granules O
are O
as O
good O
as O
the O
current O
gold O
standard O
for O
this O
model O
. O

Recently O
, O
an O
in O
vivo O
/ O
in O
vitro O
discrepancy O
has O
been O
described O
, O
whereby O
the O
non O
- O
genotoxic O
rat O
liver O
carcinogen O
methapyrilene B
alters O
the O
expression O
of O
the O
metabolizing O
genes O
SULT1A1 O
and O
ABAT O
, O
as O
well O
as O
the O
DNA O
damage O
response O
gene O
GADD34 O
in O
vitro O
, O
but O
not O
in O
vivo O
. O

To O
revisit O
the O
putative O
in O
vivo O
/ O
in O
vitro O
discrepancy O
, O
we O
first O
analyzed O
and O
modeled O
methapyrilene B
concentrations O
in O
the O
portal O
vein O
of O
rats O
. O

The O
relatively O
short O
half O
- O
life O
of O
2 O
. O
8 O
h O
implies O
a O
rapid O
decrease O
in O
orally O
administered O
methapyrilene B
in O
vivo O
below O
concentrations O
that O
can O
cause O
gene O
expression O
alterations O
. O

This O
corresponded O
to O
the O
time O
- O
dependent O
alteration O
levels O
of O
GADD34 O
, O
ABAT O
and O
SULT1A1 O
RNA O
in O
the O
liver O
: O
RNA O
levels O
are O
altered O
1 O
, O
6 O
and O
12 O
h O
after O
methapyrilene B
administration O
, O
but O
return O
to O
control O
levels O
after O
24 O
and O
72 O
h O
. O

In O
contrast O
, O
methapyrilene B
concentrations O
in O
the O
culture O
medium O
supernatant O
of O
primary O
rat O
hepatocyte O
cultures O
decreased O
slowly O
. O

It O
should O
also O
be O
considered O
that O
the O
earliest O
analyzed O
time O
point O
in O
the O
previous O
in O
vivo O
studies O
was O
24 O
h O
after O
methapyrilene B
administration O
. O

New O
targets O
for O
the O
antitumor O
activity O
of O
gambogic B
acid I
in O
hematologic O
malignancies O
. O

Gambogic B
acid I
( O
GA O
) O
is O
the O
main O
active O
ingredient O
of O
gamboge O
, O
a O
brownish O
to O
orange O
dry O
resin O
secreted O
from O
Garcinia O
hanburyi O
, O
a O
plant O
that O
is O
widely O
distributed O
in O
nature O
. O

Synthesis O
of O
spirolactone B
- O
type O
diterpenoid O
derivatives O
from O
kaurene B
- O
type O
oridonin B
with O
improved O
antiproliferative O
effects O
and O
their O
apoptosis O
- O
inducing O
activity O
in O
human O
hepatoma O
Bel O
- O
7402 O
cells O
. O

A O
series O
of O
novel O
spirolactone B
- O
type O
diterpenoid O
derivatives O
of O
oridonin B
( O
12a O
- O
j O
) O
were O
designed O
and O
synthesized O
. O

These O
results O
demonstrate O
that O
the O
spirolactone B
- O
type O
diterpenoid O
derivatives O
of O
oridonin B
have O
optimized O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
interesting O
apoptosis O
- O
inducing O
ability O
. O

Trichothecenes O
are O
sesquiterpenoid B
mycotoxins I
commonly O
found O
as O
contaminants O
in O
cereal O
grains O
and O
are O
a O
major O
health O
and O
food O
safety O
concern O
due O
to O
their O
toxicity O
to O
humans O
and O
farm O
animals O
. O

Principal O
component O
analysis O
indicated O
that O
a O
low O
abundance O
of O
lactate O
- O
producing O
and O
butyrate B
- O
producing O
species O
was O
associated O
with O
beta O
- O
cell O
autoimmunity O
. O

Functional O
studies O
related O
to O
the O
observed O
alterations O
in O
the O
gut O
microbiome O
are O
warranted O
because O
the O
low O
abundance O
of O
bifidobacteria O
and O
butyrate B
- O
producing O
species O
could O
adversely O
affect O
the O
intestinal O
epithelial O
barrier O
function O
and O
inflammation O
, O
whereas O
the O
apparent O
importance O
of O
the O
Bacteroides O
genus O
in O
development O
of O
type O
1 O
diabetes O
is O
insufficiently O
understood O
. O

Electrical O
stimulation O
, O
ATP O
, O
and O
insulin O
each O
increased O
fluorescent O
2 B
- I
NBD I
- I
Glucose I
( O
2 B
- I
NBDG I
) O
uptake O
in O
primary O
myotubes O
, O
but O
only O
electrical O
stimulation O
and O
ATP O
- O
dependent O
2 B
- I
NBDG I
uptake O
were O
inhibited O
by O
adenosine B
- I
phosphate I
phosphatase O
and O
by O
purinergic O
receptor O
blockade O
( O
suramin O
) O
. O

Exogenous O
ATP O
transiently O
activated O
Akt O
and O
, O
inhibiting O
phosphatidylinositol O
3 O
- O
kinase O
( O
PI3K O
) O
or O
Akt O
as O
well O
as O
dominant O
- O
negative O
Akt O
mutant O
, O
reduced O
ATP O
- O
dependent O
2 B
- I
NBDG I
uptake O
and O
Akt O
phosphorylation O
. O

ATP O
- O
dependent O
2 B
- I
NBDG I
uptake O
was O
also O
inhibited O
by O
the O
G O
protein O
beta O
gamma O
subunit O
- O
interacting O
peptide O
beta O
ark O
- O
ct O
and O
by O
the O
phosphatidylinositol O
3 O
- O
kinase O
- O
gamma O
( O
PI3K O
gamma O
) O
inhibitor O
AS605240 B
. O

ATP O
stimulated O
2 B
- I
NBDG I
uptake O
in O
normal O
and O
insulin O
- O
resistant O
adult O
muscle O
fibers O
, O
resembling O
the O
reported O
effect O
of O
exercise O
. O

While O
all O
types O
of O
tested O
TiO2 O
samples O
decrease O
cell O
viability O
in O
a O
mass O
- O
based O
concentration O
- O
and O
size O
- O
dependent O
manner O
, O
the O
polyacrylate B
- O
coated O
nano O
- O
TiO2 O
product O
was O
only O
cytotoxic O
at O
higher O
concentrations O
. O

A O
similar O
pattern O
of O
response O
was O
observed O
for O
induction O
of O
apoptosis O
/ O
necrosis O
, O
and O
no O
DNA O
damage O
was O
detected O
in O
the O
polyacrylate B
- O
coated O
nano O
- O
TiO2 O
model O
. O

A O
novel O
stimuli O
- O
synchronized O
alloy O
- O
treated O
matrix O
for O
space O
- O
defined O
gastrointestinal O
delivery O
of O
mesalamine B
in O
the O
Large O
White O
pig O
model O
. O

The O
study O
focussed O
on O
designing O
a O
Stimuli O
- O
Synchronized O
Matrix O
( O
SSM O
) O
for O
space O
- O
defined O
colonic O
delivery O
of O
the O
anti O
- O
inflammatory O
drug O
mesalamine B
. O

Formulations O
were O
optimized O
according O
to O
a O
Box O
- O
Behnken O
experimental O
design O
that O
constituted O
mesalamine B
- O
loaded O
BaSO4 B
- O
crosslinked O
chitosan O
dispersed O
within O
a O
pectin O
, O
carboxymethylcellulo O
and O
xanthan O
gum O
complex O
. O

Drug O
release O
profiles O
revealed O
distinct O
colonic O
enzyme O
responsiveness O
with O
fractions O
of O
0 O
. O
402 O
and O
0 O
. O
152 O
of O
mesalamine B
released O
in O
the O
presence O
and O
absence O
of O
enzymes O
, O
respectively O
after O
24h O
. O

This O
indicated O
polymeric O
enzyme O
cleavage O
for O
controlled O
and O
space O
- O
defined O
release O
of O
mesalamine B
. O

Discriminative O
stimulus O
effects O
of O
the O
GABAB O
receptor O
- O
positive O
modulator O
rac B
- I
BHFF I
: O
comparison O
with O
GABAB O
receptor O
agonists O
and O
drugs O
of O
abuse O
. O

To O
examine O
this O
, O
pigeons O
were O
trained O
to O
discriminate O
the O
GABA O
( O
B O
) O
receptor O
- O
positive O
modulator O
( B
R I
, I
S I
) I
- I
5 I
, I
7 I
- I
di I
- I
tert I
- I
butyl I
- I
3 I
- I
hydroxy I
- I
3 I
- I
trifluoromethyl I
- I
3H I
- I
benzofuran I
- I
2 I
- I
one I
( O
rac B
- I
BHFF I
) O
from O
its O
vehicle O
. O

The O
discriminative O
stimulus O
effects O
of O
rac B
- I
BHFF I
were O
not O
mimicked O
by O
the O
GABA O
( O
B O
) O
receptor O
agonists O
baclofen O
and O
gamma O
- O
hydroxybutyrate O
( O
GHB O
) O
, O
not O
by O
diazepam O
, O
and O
not O
by O
alcohol O
, O
cocaine O
, O
and O
nicotine O
, O
whose O
self O
- O
administration O
has O
been O
reported O
to O
be O
attenuated O
by O
GABA O
( O
B O
) O
receptor O
- O
positive O
modulators O
. O

The O
discriminative O
stimulus O
effects O
of O
rac B
- I
BHFF I
were O
not O
antagonized O
by O
the O
GABA O
( O
B O
) O
receptor O
antagonist O
3 B
- I
aminopropyl I
( I
diethoxymethyl I
) I
phosphinic I
acid I
( O
CGP35348 B
) O
but O
were O
attenuated O
by O
the O
less O
efficacious O
GABA O
( O
B O
) O
receptor O
- O
positive O
modulator O
2 B
, I
6 I
- I
di I
- I
tert I
- I
butyl I
- I
4 I
- I
( I
3 I
- I
hydroxy I
- I
2 I
, I
2 I
- I
dimethylpropyl I
) I
phenol I
( O
CGP7930 B
) O
, O
suggesting O
the O
possibility O
that O
rac O
- O

BHFF O
produces O
its O
discriminative O
stimulus O
effects O
by O
directly O
activating O
GABA B
( O
B2 O
) O
subunits O
of O
GABA O
( O
B O
) O
receptors O
. O

At O
a O
dose O
10 O
- O
fold O
lower O
than O
the O
training O
dose O
, O
rac B
- I
BHFF I
enhanced O
the O
discriminative O
stimulus O
effects O
of O
baclofen O
, O
but O
not O
of O
GHB O
. O

Finally O
, O
the O
finding O
that O
rac B
- I
BHFF I
enhanced O
effects O
of O
baclofen O
but O
not O
of O
GHB O
is O
consistent O
with O
converging O
evidence O
that O
the O
populations O
of O
GABA O
( O
B O
) O
receptors O
mediating O
the O
effects O
of O
baclofen O
and O
GHB O
are O
not O
identical O
. O

Biocompatibility O
and O
levofloxacin B
delivery O
of O
mesoporous O
materials O
. O

Finally O
, O
both O
IP O
and O
OP O
matrices O
have O
been O
loaded O
with O
levofloxacin B
to O
compare O
them O
as O
drug O
delivery O
systems O
. O

Both O
IP O
and O
OP O
matrices O
exhibit O
similar O
in O
vitro O
levofloxacin B
release O
profiles O
, O
showing O
an O
initial O
fast O
delivery O
followed O
by O
a O
sustained O
release O
during O
long O
time O
periods O
. O

Survey O
of O
recent O
literature O
related O
to O
the O
biologically O
active O
4 B
( I
3H I
) I
- I
quinazolinones I
containing O
fused O
heterocycles O
. O

The O
present O
review O
focuses O
on O
the O
synthesis O
and O
biological O
evaluation O
of O
polycyclic B
4 I
( I
3H I
) I
- I
quinazolinones I
containing O
fused O
aromatic O
or O
heteroaromatic O
rings O
. O

Most O
of O
the O
quinazolinone B
alkaloids I
belong O
to O
this O
class O
of O
molecules O
. O

The O
second O
part O
presents O
molecules O
bearing O
extra O
ring O
( O
s O
) O
fused O
to O
the O
benzo B
moiety O
of O
the O
quinazolinone B
skeleton O
. O

We O
synthesized O
copolymers O
composed O
of O
methyl B
methacrylate I
and O
2 B
- I
aminoethyl I
methacrylate I
with O
different O
protecting O
groups O
or O
ion O
- O
complexes O
on O
their O
amino O
groups O
, O
then O
dip O
- O
coated O
the O
copolymers O
onto O
a O
poly O
( O
methyl O
methacrylate O
) O
( O
PMMA O
) O
substrate O
. O

p B
- I
Toluenesulfonate I
ion O
- O
complex O
and O
tert B
- I
butoxycarbonyl I
( O
Boc B
) O
protection O
of O
amino O
groups O
were O
found O
to O
effectively O
display O
amino O
groups O
on O
the O
surface O
( O
more O
than O
70 O
pmol O
/ O
cm O
( O
2 O
) O
) O
. O

Dip O
- O
coating O
of O
the O
copolymer O
with O
Boc B
protection O
on O
various O
polymeric O
substrates O
also O
successfully O
displayed O
amino O
groups O
on O
their O
surfaces O
. O

Kinetics O
of O
the O
reaction O
of O
crystal B
violet I
with O
hydroxide O
ion O
in O
the O
critical O
solution O
of O
2 B
- I
butoxyethanol I
+ O
water O
. O

The O
kinetics O
of O
alkaline O
fading O
of O
crystal B
violet I
( O
CV O
) O
has O
been O
studied O
by O
UV O
spectrophotometry O
and O
microcalorimetry O
in O
the O
critical O
binary O
solution O
of O
2 B
- I
butoxyethanol I
+ O
water O
at O
the O
initial O
reaction O
stage O
and O
various O
temperatures O
. O

At O
least O
five O
out O
of O
the O
nine O
tested O
TKIs O
( O
erlotinib O
, O
gefitinib O
, O
nilotinib O
, O
sorafenib B
, O
vandetanib O
) O
were O
able O
to O
induce O
the O
expression O
of O
PGP O
within O
48 O
h O
in O
LS180 O
cells O
. O

Development O
of O
a O
dry O
, O
stable O
and O
inhalable O
acyl B
- I
homoserine I
- I
lactone I
- O
acylase O
powder O
formulation O
for O
the O
treatment O
of O
pulmonary O
Pseudomonas O
aeruginosa O
infections O
. O

PvdQ O
is O
an O
acyl B
- I
homoserine I
lactone I
( O
AHL B
) O
acylase O
able O
to O
degrade O
the O
signal O
molecule O
of O
P O
. O
aeruginosa O
QS O
. O

Therefore O
in O
this O
study O
we O
investigated O
the O
production O
of O
a O
PvdQ O
powder O
by O
spray O
- O
freeze O
drying O
using O
mannitol O
, O
trehalose B
and O
inulin O
as O
excipient O
. O

We O
found O
that O
the O
enzymatic O
activity O
of O
PvdQ O
is O
fully O
maintained O
during O
spray O
- O
freeze O
drying O
using O
mannitol O
, O
trehalose B
or O
inulin O
as O
excipient O
. O

However O
, O
mannitol O
was O
not O
able O
to O
stabilize O
the O
protein O
during O
storage O
, O
while O
PvdQ O
incorporated O
in O
trehalose B
or O
inulin O
was O
fully O
stabilized O
even O
during O
storage O
at O
55 O
degrees O
C O
for O
at O
least O
4 O
weeks O
. O

The O
poor O
stabilizing O
capacities O
of O
mannitol O
during O
storage O
could O
be O
related O
to O
its O
crystalline O
nature O
while O
the O
excellent O
stabilizing O
capacities O
of O
trehalose B
and O
inulin O
during O
storage O
could O
be O
related O
to O
their O
amorphous O
nature O
. O

The O
trehalose B
and O
inulin O
- O
based O
particles O
consisted O
of O
porous O
spheres O
with O
a O
volume O
average O
aerodynamical O
diameter O
of O
~ O
1 O
. O
8 O
mu O
m O
implying O
that O
they O
are O
suitable O
for O
pulmonary O
delivery O
. O

This O
is O
the O
first O
study O
in O
which O
an O
AHL B
- O
degrading O
enzyme O
is O
processed O
into O
spray O
- O
freeze O
- O
dried O
powder O
suitable O
for O
inhalation O
. O

( B
R I
) I
- I
beta I
- I
lysine I
- O
modified O
elongation O
factor O
P O
functions O
in O
translation O
elongation O
. O

Post O
- O
translational O
modification O
of O
bacterial O
elongation O
factor O
P O
( O
EF O
- O
P O
) O
with O
( B
R I
) I
- I
beta I
- I
lysine I
at O
a O
conserved O
lysine O
residue O
activates O
the O
protein O
in O
vivo O
and O
increases O
puromycin O
reactivity O
of O
the O
ribosome O
in O
vitro O
. O

The O
roles O
of O
modified O
and O
unmodified O
EF O
- O
P O
during O
different O
steps O
in O
translation O
, O
and O
how O
this O
correlates O
to O
its O
physiological O
role O
in O
the O
cell O
, O
have O
recently O
been O
linked O
to O
the O
synthesis O
of O
polyproline B
stretches O
in O
proteins O
. O

This O
was O
further O
supported O
by O
the O
inability O
of O
EF O
- O
P O
to O
enhance O
the O
rate O
of O
formation O
of O
fMet B
- I
Lys I
or O
fMet B
- I
Phe I
, O
indicating O
that O
the O
role O
of O
EF O
- O
P O
is O
not O
to O
specifically O
stimulate O
formation O
of O
the O
first O
peptide O
bond O
. O

Investigation O
of O
hydroxyl B
- I
( I
beta I
) I
- I
lysyl I
- O
EF O
- O
P O
showed O
30 O
% O
increased O
puromycin B
reactivity O
but O
no O
differences O
in O
dipeptide O
synthesis O
rates O
when O
compared O
with O
the O
beta O
- O
lysylated O
form O
. O

Biomarkers O
of O
toluene O
exposure O
in O
rats O
: O
mercapturic O
acids O
versus O
traditional O
indicators O
( O
urinary O
hippuric B
acid I
and O
o B
- I
cresol I
and O
blood O
toluene O
) O
. O

Toluene O
( O
TOL B
) O
is O
a O
neurotoxic O
, O
ototoxic O
and O
reprotoxic O
solvent O
which O
is O
metabolized O
via O
the O
glutathione O
pathway O
, O
producing O
benzylmercapturic B
, I
o I
- I
, I
m I
- I
and I
p I
- I
toluylmercapturic I
acids I
( O
MAs B
) O
. O

These O
metabolites O
could O
be O
useful O
as O
biomarkers O
of O
TOL B
exposure O
. O

The O
aims O
of O
this O
study O
were O
( O
1 O
) O
to O
provide O
data O
on O
MAs B
excretion O
in O
rat O
urine O
following O
TOL B
exposure O
by O
inhalation O
, O
( O
2 O
) O
to O
compare O
them O
to O
data O
from O
traditional O
TOL B
biomarkers O
, O
i O
. O
e O
. O
TOL B
in O
blood O
( O
Tol B
- O
B O
) O
, O
and O
urinary O
hippuric B
acid I
( O
HA O
) O
and O
o B
- I
cresol I
( O
oCre B
) O
and O
( O
3 O
) O
to O
establish O
a O
relationship O
between O
these O
different O
indicators O
and O
the O
airborne O
TOL B
concentration O
( O
Tol B
- O
A O
) O
. O

Sprague O
- O
Dawley O
rats O
were O
exposed O
to O
a O
range O
of O
TOL B
concentrations O
. O

Levels O
of O
the O
four O
MAs B
correlate O
strongly O
with O
Tol B
- O
A O
( O
comparable O
to O
the O
correlation O
with O
Tol B
- O
B O
) O
. O

MAs B
are O
thus O
clearly O
superior O
to O
oCre B
and O
HA O
as O
potential O
markers O
of O
exposure O
to O
TOL B
. O

In O
patients O
with O
ER O
+ O
tumors O
pharmacologic O
ovary O
suppression O
with O
gonadotropin B
- I
releasing I
hormone I
agonists O
in O
combination O
with O
standard O
adjuvant O
therapy O
is O
generally O
more O
effective O
than O
adjuvant O
chemotherapy O
alone O
. O

Drugs O
under O
investigation O
can O
be O
broadly O
subdivided O
into O
four O
groups O
: O
( O
1 O
) O
Agents O
that O
create O
DNA O
damage O
( O
i O
. O
e O
. O
cisplatin O
, O
cyclophosphamide O
) O
; O
( O
2 O
) O
Agents O
that O
inhibit O
poly O
( O
ADP O
- O
ribose O
) O
polymerase O
( O
PARP O
) O
; O
( O
3 O
) O
Tyrosin B
- O
kinase O
inhibitors O
and O
monoclonal O
antibodies O
; O
( O
4 O
) O
Agents O
that O
inhibit O
downstream O
signals O
. O

Structure O
- O
based O
design O
, O
synthesis O
and O
evaluation O
of O
novel O
anthra B
[ I
1 I
, I
2 I
- I
d I
] I
imidazole I
- I
6 I
, I
11 I
- I
dione I
derivatives O
as O
telomerase O
inhibitors O
and O
potential O
for O
cancer O
polypharmacology O
. O

A O
series O
of O
anthra B
[ I
1 I
, I
2 I
- I
d I
] I
imidazole I
- I
6 I
, I
11 I
- I
dione I
derivatives O
were O
synthesized O
and O
evaluated O
for O
telomerase O
inhibition O
, O
hTERT O
expression O
and O
suppression O
of O
cancer O
cell O
growth O
in O
vitro O
. O

These O
products O
exhibited O
substantial O
activity O
against O
T O
. O
cruzi O
, O
especially O
2 B
- I
( I
( I
8E I
, I
11Z I
) I
- I
heptadeca I
- I
8 I
, I
11 I
- I
dienyl I
) I
- I
3 I
- I
hydroxynaphthalene I
- I
1 I
, I
4 I
- I
dione I
( O
9 O
) O
with O
IC O
( O
50 O
) O
of O
7 O
. O
8 O
mu O
M O
. O

Synthesis O
and O
Biological O
Evaluation O
of O
[ B
1 I
, I
2 I
, I
4 I
] I
Triazolo I
[ I
3 I
, I
4 I
- I
a I
] I
phthalazine I
and O
Tetrazolo B
[ I
5 I
, I
1 I
- I
a I
] I
phthalazine I
Derivatives O
Bearing O
Substituted O
Benzylpiperazine B
Moieties O
as O
Positive O
Inotropic O
Agents O
. O

Two O
series O
of O
[ B
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
3 I
, I
4 I
- I
a I
] I
phthalazine I
and O
tetrazolo B
[ I
5 I
, I
1 I
- I
a I
] I
phthalazine I
derivatives O
bearing O
substituted O
benzylpiperazine B
moieties O
have O
been O
synthesized O
and O
evaluated O
for O
their O
positive O
inotropic O
activity O
by O
measuring O
left O
atrium O
stroke O
volume O
on O
isolated O
rabbit O
heart O
preparations O
. O

The O
majority O
of O
the O
derivatives O
exhibited O
better O
in O
vitro O
activity O
than O
the O
existing O
drug O
, O
milrinone B
, O
and O
6 B
- I
( I
( I
4 I
- I
( I
4 I
- I
methoxyphenyl I
) I
piperazin I
- I
1 I
- I
yl I
) I
methyl I
) I
tetrazolo I
[ I
5 I
, I
1 I
- I
a I
] I
phthalazine I
. O

8 O
m O
in O
particular O
was O
identified O
as O
the O
most O
potent O
with O
an O
increased O
stroke O
volume O
of O
12 O
. O
02 O
+ O
/ O
- O
0 O
. O
20 O
% O
( O
milrinone B
: O
2 O
. O
46 O
+ O
/ O
- O
0 O
. O
07 O
% O
) O
at O
a O
concentration O
of O
3 O
x O
10 O
( O
- O
5 O
) O
m O
. O

Combined O
effects O
of O
the O
herbicide O
terbuthylazine B
and O
temperature O
on O
different O
flagellates O
from O
the O
Northern O
Adriatic O
Sea O
. O

The O
triazinic O
herbicide O
terbuthylazine B
( O
TBA B
) O
is O
becoming O
an O
emergent O
contaminant O
in O
Italian O
rivers O
and O
in O
coastal O
and O
groundwater O
. O

A O
preliminary O
analysis O
of O
the O
sensitivity O
of O
marine O
flagellates O
to O
TBA B
was O
performed O
by O
monitoring O
the O
photosynthetic O
efficiency O
of O
nine O
species O
( O
belonging O
to O
the O
Dinophyceae O
or O
Raphidophyceae O
class O
) O
isolated O
from O
the O
Adriatic O
Sea O
. O

Then O
the O
response O
of O
two O
microalgae O
to O
drivers O
, O
such O
as O
temperature O
and O
terbuthylazine B
, O
applied O
in O
combination O
was O
also O
investigated O
. O

Two O
potentially O
toxic O
flagellates O
, O
Prorocentrum O
minimum O
and O
G O
. O
spinifera O
, O
were O
exposed O
, O
under O
different O
temperature O
conditions O
( O
15 O
, O
20 O
and O
25 O
degrees O
C O
) O
, O
to O
TBA B
concentrations O
that O
did O
not O
completely O
affect O
PSII O
. O

For O
both O
flagellates O
, O
effects O
of O
TBA B
on O
algal O
growth O
, O
measured O
through O
cell O
density O
and O
carbon O
analysis O
, O
as O
well O
as O
on O
the O
photosynthetic O
activity O
are O
reported O
. O

All O
parameters O
analyzed O
showed O
a O
negative O
effect O
of O
TBA B
from O
the O
exponential O
phase O
. O

TBA B
effect O
on O
algal O
growth O
was O
significantly O
enhanced O
at O
the O
optimal O
temperature O
conditions O
( O
20 O
and O
25 O
degrees O
C O
) O
, O
while O
no O
difference O
between O
control O
and O
herbicide O
treatments O
were O
detected O
for O
G O
. O
spinifera O
grown O
at O
15 O
degrees O
C O
, O
which O
represented O
a O
stress O
condition O
for O
this O
species O
. O

Chlorophyll O
- O
a O
production O
was O
increased O
only O
in O
G O
. O
spinifera O
exposed O
to O
5 O
mu O
g O
L O
( O
- O
1 O
) O
of O
TBA B
and O
the O
effect O
was O
enhanced O
with O
the O
increase O
of O
temperature O
. O

Herbicide O
- O
induced O
variations O
in O
cellular O
components O
determined O
changes O
in O
cellular O
carbon O
: O
nitrogen O
( O
C O
: O
N O
) O
and O
chlorophyll O
: O
carbon O
( O
Chl B
: O
C O
) O
ratios O
. O

The O
C O
: O
N O
ratio O
decreased O
in O
both O
species O
, O
while O
only O
G O
. O
spinifera O
showed O
an O
increase O
in O
the O
Chl B
: O
C O
ratio O
at O
all O
temperature O
conditions O
. O

In O
response O
to O
TBA B
exposure O
G O
. O
spinifera O
increased O
extracellular O
polysaccharides O
release O
at O
20 O
and O
25 O
degrees O
C O
, O
while O
no O
difference O
was O
reported O
for O
P O
. O
minimum O
. O

Nitrate O
and O
phosphate O
uptake O
significantly O
increased O
in O
the O
presence O
of O
TBA B
and O
this O
response O
was O
enhanced O
at O
25 O
degrees O
C O
, O
while O
nitrate O
uptake O
increased O
in O
G O
. O
spinifera O
only O
when O
grown O
at O
25 O
degrees O
C O
. O

In O
this O
work O
it O
is O
shown O
that O
temperature O
conditions O
can O
have O
an O
important O
role O
on O
the O
effect O
of O
terbuthylazine B
on O
algal O
growth O
and O
on O
the O
physiological O
responses O
of O
different O
species O
. O

Mode O
of O
action O
of O
human O
pharmaceuticals O
in O
fish O
: O
the O
effects O
of O
the O
5 O
- O
alpha O
- O
reductase O
inhibitor O
, O
dutasteride B
, O
on O
reproduction O
as O
a O
case O
study O
. O

Our O
research O
addressed O
the O
question O
of O
whether O
or O
not O
dutasteride B
, O
a O
pharmaceutical O
used O
to O
treat O
benign O
prostatic O
hyperplasia O
, O
may O
cause O
adverse O
effects O
in O
a O
teleost O
fish O
, O
the O
fathead O
minnow O
( O
Pimephales O
promelas O
) O
, O
by O
inhibiting O
the O
activity O
of O
both O
isoforms O
of O
5 O
alpha O
- O
reductase O
( O
5 O
alpha O
R O
) O
, O
the O
enzyme O
that O
converts O
testosterone O
into O
dihydrotestosterone O
( O
DHT O
) O
. O

Mammalian O
pharmacological O
and O
toxicological O
information O
were O
used O
to O
guide O
the O
experimental O
design O
and O
the O
selection O
of O
relevant O
endpoints O
, O
according O
to O
the O
so O
- O
called O
" O
read O
- O
across O
approach O
" O
, O
suggesting O
that O
dutasteride B
may O
affect O
male O
fertility O
and O
steroid B
hormone I
dynamics O
. O

Therefore O
, O
a O
21 O
- O
day O
reproduction O
study O
was O
conducted O
to O
determine O
the O
effects O
of O
dutasteride B
( O
10 O
, O
32 O
and O
100 O
mu O
g O
/ O
L O
) O
on O
fish O
reproduction O
. O

Exposure O
to O
dutasteride B
significantly O
reduced O
fecundity O
of O
fish O
and O
affected O
several O
aspects O
of O
reproductive O
endocrine O
functions O
in O
both O
males O
and O
females O
. O

However O
, O
none O
of O
the O
observed O
adverse O
effects O
occurred O
at O
concentrations O
of O
exposure O
lower O
than O
32 O
mu O
g O
/ O
L O
; O
this O
, O
together O
with O
the O
low O
volume O
of O
drug O
prescribed O
every O
year O
( O
10 O
. O
34 O
kg O
in O
the O
UK O
in O
2011 O
) O
, O
and O
the O
extremely O
low O
predicted O
environmental O
concentration O
( O
0 O
. O
03 O
ng O
/ O
L O
) O
, O
suggest O
that O
, O
at O
present O
, O
the O
potential O
presence O
of O
dutasteride B
in O
the O
environment O
does O
not O
represent O
a O
threat O
to O
wild O
fish O
populations O
. O

Aliquots O
of O
the O
sediment O
extracts O
were O
analyzed O
for O
4 B
- I
nonylphenols I
and O
natural O
steroidal B
estrogens I
as O
possible O
candidates O
with O
an O
estrogenic O
potential O
. O

The O
maximal O
concentrations O
of O
4 B
- I
iso I
- I
nonylphenol I
and O
estrone O
were O
115 O
mg O
/ O
kg O
dry O
weight O
and O
20 O
micro O
g O
/ O
kg O
dry O
weight O
at O
the O
sampling O
site O
Luppe O
, O
which O
showed O
in O
accordance O
the O
highest O
biological O
activity O
. O

Under O
consideration O
of O
compound O
concentration O
and O
compound O
specific O
estrogenic O
activity O
the O
4 B
- I
iso I
- I
nonylphenols I
contributed O
most O
to O
the O
observed O
estrogenic O
effect O
. O

A O
strong O
correlation O
between O
the O
measured O
estrogenic O
activity O
and O
the O
concentration O
of O
the O
sediment O
- O
associated O
4 B
- I
iso I
- I
nonylphenol I
underlines O
the O
relevance O
of O
this O
compound O
class O
as O
a O
xenoestrogen O
in O
the O
catchment O
area O
of O
the O
river O
Saale O
. O

Tritiated B
amitriptyline I
was O
added O
to O
laboratory O
microcosms O
containing O
soils O
, O
and O
the O
metabolism O
of O
the O
extractable O
( O
3 O
) O
H O
was O
monitored O
during O
incubation O
at O
30 O
degrees O
C O
. O

Nortriptyline O
( O
N B
- I
desmethyl I
amitriptyline I
) O
and O
amitriptyline B
- I
N I
- I
oxide I
were O
identified O
as O
major O
transformation O
products O
in O
all O
three O
soils O
by O
high O
performance O
liquid O
chromatography O
with O
photodiode O
array O
detector O
and O
time O
- O
of O
- O
flight O
mass O
spectrometry O
( O
HPLC O
- O
TOF O
- O
MS O
/ O
UV O
) O
. O

Hydrosoluble O
benzo B
[ I
e I
] I
pyridoindolones I
as O
potent O
inhibitors O
of O
aurora O
kinases O
. O

We O
identified O
benzo B
[ I
e I
] I
pyridoindoles I
( O
BePI B
) O
as O
powerful O
aurora O
kinase O
inhibitors O
. O

New O
BePI B
molecules O
were O
synthesized O
, O
and O
a O
structure O
- O
activity O
relationship O
study O
was O
conducted O
with O
the O
aim O
of O
improving O
the O
activity O
and O
solubility O
of O
the O
lead O
compound O
. O

Tetracyclic B
BePI I
derivatives O
are O
characterized O
by O
a O
particular O
curved O
shape O
, O
and O
the O
presence O
of O
an O
oxo O
group O
on O
the O
pyridine O
ring O
was O
found O
to O
be O
required O
for O
aurora O
kinase O
B O
inhibition O
. O

New O
hydrosoluble O
benzo B
[ I
e I
] I
pyridoindolones I
were O
subsequently O
designed O
, O
and O
their O
efficacy O
was O
tested O
by O
a O
combination O
of O
cell O
- O
cycle O
analysis O
and O
time O
- O
lapse O
experiments O
in O
live O
cells O
. O

The O
most O
active O
BePI B
derivative O
, O
13 O
b O
, O
inhibited O
the O
cell O
cycle O
, O
drove O
cells O
to O
polyploidy O
, O
and O
eventually O
induced O
apoptosis O
. O

Practical O
synthesis O
of O
( B
20S I
) I
- I
10 I
- I
( I
3 I
- I
aminopropyloxy I
) I
- I
7 I
- I
ethylcamptothecin I
, O
a O
water O
- O
soluble O
analogue O
of O
camptothecin O
. O

A O
robust O
, O
practical O
synthesis O
of O
( B
20S I
) I
- I
10 I
- I
( I
3 I
- I
aminopropyloxy I
) I
- I
7 I
- I
ethylcamptothecin I
( O
T B
- I
2513 I
, O
5 O
) O
, O
which O
is O
a O
water O
- O
soluble O
analogue O
of O
camptothecin O
, O
has O
been O
developed O
. O

The O
key O
step O
in O
this O
synthesis O
is O
a O
highly O
diastereoselective O
ethylation O
at O
the O
C20 O
position O
by O
using O
N B
- I
arylsulfonyl I
- I
( I
R I
) I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
- I
tetrahydroisoquinoli I
- I
3 I
- I
carboxylic I
acid I
ester I
as O
a O
chiral O
auxiliary O
, O
which O
affords O
the O
key O
intermediate O
ethyl O
- O
( O
S O
) O
- O
2 O
- O
acyloxy O
- O
2 O
- O
( O
6 O
- O
cyano O
- O
5 O
- O
oxo O
- O
1 O
, O
2 O
, O
3 O
, O
5 O
- O
tetrahydroindolizin O
- O
7 O
- O

Optically O
pure O
compound O
8k O
was O
obtained O
by O
a O
single O
recrystallization O
from O
acetone B
and O
its O
further O
elaboration O
through O
Friedlander O
condensation O
afforded O
compound O
5 O
. O

It O
is O
found O
that O
the O
BolA O
- O
like O
dual O
ligands O
system O
exhibits O
significantly O
enhanced O
gene O
expression O
in O
both O
HeLa O
and O
293T O
cell O
lines O
, O
as O
compared O
with O
poly B
( I
ethylenimine I
) I
PEI O
. O

New O
cyclomyrsinol B
diterpenes I
from O
Euphorbia O
aellenii O
with O
their O
immunomodulatory O
effects O
. O

( O
Euphorbiaceae O
) O
was O
investigated O
for O
its O
diterpenoidal B
constituents O
. O

This O
led O
to O
the O
isolation O
of O
two O
new O
and O
one O
known O
cyclomyrsinol B
- O
type O
diterpenes O
1 O
- O
3 O
. O

A O
class O
of O
5 B
- I
nitro I
- I
2 I
- I
furancarboxylamides I
with O
potent O
trypanocidal O
activity O
against O
Trypanosoma O
brucei O
in O
vitro O
. O

Recently O
, O
the O
World O
Health O
Organization O
approved O
the O
nifurtimox B
- O
eflornithine B
combination O
therapy O
for O
the O
treatment O
of O
human O
African O
trypanosomiasis O
, O
renewing O
interest O
in O
nitroheterocycle O
therapies O
for O
this O
and O
associated O
diseases O
. O

In O
this O
study O
, O
we O
have O
synthesized O
a O
series O
of O
novel O
5 B
- I
nitro I
- I
2 I
- I
furancarboxylamides I
that O
show O
potent O
trypanocidal O
activity O
, O
~ O
1000 O
- O
fold O
more O
potent O
than O
nifurtimox B
against O
in O
vitro O
Trypanosoma O
brucei O
with O
very O
low O
cytotoxicity O
against O
human O
HeLa O
cells O
. O

More O
importantly O
, O
the O
most O
potent O
analogue O
showed O
very O
limited O
cross O
- O
resistance O
to O
nifurtimox B
- O
resistant O
cells O
and O
vice O
versa O
. O

This O
implies O
that O
our O
novel O
, O
relatively O
easy O
to O
synthesize O
and O
therefore O
cheap O
, O
5 B
- I
nitro I
- I
2 I
- I
furancarboxylamides I
are O
targeting O
a O
different O
, O
but O
still O
essential O
, O
biochemical O
process O
to O
those O
targeted O
by O
nifurtimox B
or O
its O
metabolites O
in O
the O
parasites O
. O

Methods O
: O
A O
total O
of O
113 O
CKD O
patients O
with O
SH O
who O
were O
treated O
with O
L B
- I
thyroxine I
and O
had O
eGFR O
available O
for O
at O
least O
24 O
months O
before O
and O
after O
THRT O
were O
enrolled O
between O
January O
2005 O
and O
December O
2011 O
. O

Like O
all O
sactipeptides O
, O
SKF O
contains O
a O
thioether O
bond O
, O
which O
links O
the O
cysteine O
residue O
Cys4 B
with O
the O
alpha O
- O
carbon O
of O
the O
methionine O
residue O
Met12 B
. O

However O
, O
the O
glycosylated B
flavonoids I
showed O
relatively O
weaker O
inhibition O
which O
may O
be O
attributed O
to O
their O
hindered O
binding O
into O
the O
active O
site O
of O
AO O
by O
bulky O
sugar O
groups O
. O

Aaptamine B
derivatives O
from O
the O
Indonesian O
sponge O
Aaptos O
suberitoides O
. O

Four O
new O
aaptamine B
derivatives O
( O
1 O
- O
4 O
) O
along O
with O
aaptamine B
( O
5 O
) O
and O
three O
related O
compounds O
( O
6 O
- O
8 O
) O
were O
isolated O
from O
the O
ethanol O
extract O
of O
the O
sponge O
Aaptos O
suberitoides O
collected O
in O
Indonesia O
. O

Why O
is O
quercetin O
a O
better O
antioxidant O
than O
taxifolin B
? O

The O
stronger O
antioxidant O
capacity O
of O
the O
flavonoid O
quercetin O
( O
Q O
) O
compared O
with O
taxifolin B
( O
dihydroquercetin B
, O
T O
) O
has O
been O
the O
subject O
of O
previous O
experimental O
and O
theoretical O
studies O
. O

As O
CEs O
hydrolyze O
clinically O
used O
drugs O
, O
the O
ability O
of O
tanshinones O
and O
S O
. O
miltiorrhiza O
root O
extracts O
to O
modulate O
the O
metabolism O
of O
the O
anticancer O
prodrug O
irinotecan O
( O
CPT B
- I
11 I
) O
was O
assessed O
. O

In O
this O
paper O
, O
the O
fabrication O
, O
characterization O
, O
and O
application O
in O
oxygen O
sensing O
are O
reported O
for O
a O
novel O
multifunctional O
nanomaterial O
of O
[ O
Ru B
( I
bpy I
) I
( I
2 I
) I
phen I
- O
MMS O
] O
( O
bpy O
, O
2 B
, I
2 I
' I
- I
bipyridyl I
; O
phen B
, O
phenathrolin B
) O
which O
was O
simply O
prepared O
by O
covalently O
grafting O
the O
ruthenium B
( I
II I
) I
polypyridyl I
compounds O
into O
the O
channels O
of O
magnetic O
mesoporous O
silica O
nanocomposites O
( O
MMS O
) O
. O

THP O
- O
1 O
cells O
were O
pre O
- O
loaded O
with O
a O
ROS O
sensitive O
fluorescent O
dye O
, O
5 B
- I
( I
and I
6 I
- I
) I
- I
chloromethyl I
- I
2 I
' I
, I
7 I
' I
- I
dichlorodihydrofluor I
diacetate I
, O
acetyl B
ester I
( O
CM B
- I
H2DCFDA I
) O
, O
for O
15min O
, O
then O
incubated O
with O
test O
chemicals O
for O
30min O
. O

Differential O
anti O
- O
ischemic O
efficacy O
and O
therapeutic O
time O
window O
of O
trans B
- I
and I
cis I
- I
hinokiresinols I
: O
Stereo O
- O
specific O
antioxidant O
and O
anti O
- O
inflammatory O
activities O
. O

Cis B
- I
hinokiresinol I
, O
a O
naturally O
occurring O
phenylpropanoid O
, O
was O
previously O
reported O
to O
possess O
anti O
- O
oxidant O
, O
anti O
- O
inflammatory O
and O
estrogen O
- O
like O
activities O
. O

In O
the O
present O
study O
, O
we O
investigated O
anti O
- O
ischemic O
effects O
of O
trans B
- I
and I
cis I
- I
hinokiresinols I
using O
in O
vitro O
as O
well O
as O
in O
vivo O
experimental O
models O
. O

However O
, O
only O
trans B
- I
hinokiresinol I
significantly O
decreased O
neuronal O
injury O
in O
cultured O
cortical O
neurons O
exposed O
to O
oxygen O
- O
glucose O
deprivation O
( O
75 O
min O
) O
followed O
by O
re O
- O
oxygenation O
( O
9 O
h O
) O
. O

The O
differential O
neuroprotective O
effect O
could O
be O
due O
to O
the O
stereo O
- O
specific O
augmentation O
of O
Cu O
/ O
Zn O
- O
SOD O
activity O
by O
trans B
- I
hinokiresinol I
, O
when O
compared O
with O
cis B
- I
hinokiresinol I
. O

Similarly O
, O
in O
rats O
subjected O
to O
transient O
middle O
cerebral O
artery O
occlusion O
( O
1 O
. O
5 O
h O
) O
followed O
by O
24 O
- O
h O
reperfusion O
, O
pre O
- O
ischemic O
treatment O
with O
trans B
- I
hinokiresinol I
, O
but O
not O
with O
cis O
- O
isomer O
, O
reduced O
cerebral O
infarct O
volume O
. O

Interestingly O
, O
however O
, O
post O
- O
ischemic O
treatment O
with O
both O
hinokiresinols B
( O
2 O
and O
7 O
h O
after O
onset O
of O
ischemia O
) O
significantly O
reduced O
cerebral O
infarct O
. O

When O
administered O
after O
onset O
of O
ischemia O
, O
trans B
- I
hinokiresinol I
, O
but O
not O
its O
cis O
- O
isomer O
reduced O
nitrotyrosine B
immunoreactivity O
in O
ischemic O
regions O
. O

In O
contrast O
, O
both O
hinokiresinols B
suppressed O
neutrophil O
infiltration O
and O
IL O
- O
1 O
beta O
release O
to O
a O
similar O
extent O
. O

The O
observed O
differential O
anti O
- O
oxidant O
, O
but O
comparable O
anti O
- O
inflammatory O
, O
activities O
may O
explain O
the O
stereo O
- O
specific O
anti O
- O
ischemic O
activities O
and O
different O
therapeutic O
time O
windows O
of O
the O
hinokiresinols B
examined O
. O

More O
detailed O
delineation O
of O
the O
anti O
- O
ischemic O
mechanism O
( O
s O
) O
of O
hinokiresinols B
may O
provide O
a O
better O
strategy O
for O
development O
of O
efficacious O
regimens O
for O
cerebral O
ischemic O
stroke O
. O

Sunset B
yellow I
FCF I
, O
a O
permitted O
food O
dye O
, O
alters O
functional O
responses O
of O
splenocytes O
at O
non O
- O
cytotoxic O
dose O
. O

Sunset B
yellow I
FCF I
( O
SY O
) O
, O
a O
permitted O
food O
color O
, O
is O
extensively O
used O
in O
various O
food O
preparations O
and O
quite O
often O
exceeds O
the O
permissible O
levels O
( O
100 O
- O
200 O
mg O
/ O
kg O
) O
. O

Previous O
phytochemical O
studies O
have O
shown O
that O
the O
plants O
of O
the O
Albizia O
genus O
( O
Fabaceae O
) O
contain O
bioactive O
saponins O
, O
lignans O
, O
spermine B
alkaloids I
, O
flavonoids O
, O
glycosides B
phenols I
and O
pyridoxine O
derivatives O
. O

Remarkable O
stabilization O
of O
antiparallel O
DNA O
triplexes O
by O
strong O
stacking O
effects O
of O
consecutively O
modified O
nucleobases O
containing O
thiocarbonyl B
groups O
. O

The O
consecutive O
arrangement O
of O
2 B
' I
- I
deoxy I
- I
6 I
- I
thioguanosines I
( O
s B
( I
6 I
) I
Gs I
) O
and O
4 B
- I
thiothymidines I
( O
s B
( I
4 I
) I
Ts I
) O
in O
antiparallel O
triplex O
- O
forming O
oligonucleotides O
( O
TFOs O
) O
considerably O
stabilized O
the O
resulting O
antiparallel O
triplexes O
with O
high O
base O
recognition O
ability O
by O
the O
strong O
stacking O
effects O
of O
thiocarbonyl B
groups O
. O

Moreover O
, O
in O
comparison O
with O
unmodified O
TFOs O
, O
it O
was O
found O
that O
TFOs O
containing O
s B
( I
6 I
) I
Gs I
and O
s B
( I
4 I
) I
Ts I
could O
selectively O
bind O
to O
the O
complementary O
DNA O
duplex O
but O
not O
to O
mismatched O
DNA O
duplexes O
or O
single O
- O
stranded O
RNA O
. O

Emerging O
evidence O
suggests O
that O
the O
model O
alkylating O
agents O
methyl O
- O
and O
ethylmethanesulfonat B
and O
methylnitrosourea B
( O
MNU B
) O
and O
ethylnitrosourea B
observe O
a O
nonlinear O
dose O
- O
response O
with O
a O
no O
observed O
genotoxic O
effect O
level O
( O
NOGEL O
) O
. O

MNU B
is O
one O
of O
the O
most O
mutagenic O
simple O
alkylators O
. O

Therefore O
, O
understanding O
the O
mechanism O
of O
mutation O
induction O
, O
following O
low O
- O
dose O
MNU B
treatment O
, O
sets O
precedence O
for O
weaker O
mutagenic O
alkylating O
agents O
. O

Here O
, O
we O
tested O
MNU B
at O
10 O
- O
fold O
lower O
concentrations O
than O
a O
previous O
study O
and O
report O
a O
NOGEL O
of O
0 O
. O
0075 O
micro O
g O
/ O
ml O
( O
72 O
. O
8nM O
) O
in O
human O
lymphoblastoid O
cells O
, O
quantified O
through O
the O
hypoxanthine O
( O
guanine O
) O
phosphoribosyltransf O
assay O
( O
OECD O
476 O
) O
. O

Mechanistic O
studies O
reveal O
that O
the O
NOGEL O
is O
dependent O
upon O
repair O
of O
O B
( I
6 I
) I
- I
methylguanine I
( O
O B
( I
6 I
) I
MeG I
) O
by O
the O
suicide O
enzyme O
O B
( I
6 I
) I
MeG I
- O
DNA O
methyltransferase O
( O
MGMT O
) O
. O

Inactivation O
of O
MGMT O
sensitizes O
cells O
to O
MNU B
- O
induced O
mutagenesis O
and O
shifts O
the O
NOGEL O
to O
the O
left O
on O
the O
dose O
axis O
. O

Diets O
deficient O
in O
iodine O
were O
prepared O
by O
adding O
975 O
, O
200 O
, O
125 O
, O
25 O
, O
or O
0 O
micro O
g O
/ O
kg O
potassium B
iodate I
to O
the O
base O
casein O
diet O
to O
produce O
five O
nominal O
iodine O
levels O
ranging O
from O
ample O
( O
Diet O
1 O
: O
1000 O
mu O
g O
iodine O
/ O
kg O
chow O
, O
D1 O
) O
to O
deficient O
( O
Diet O
5 O
: O
25 O
micro O
g O
iodine O
/ O
kg O
chow O
, O
D5 O
) O
. O

Sunitinib O
( O
SUN B
) O
is O
a O
new O
multi O
- O
targeted O
oral O
tyrosine O
kinase O
inhibitor O
that O
has O
both O
anti O
- O
angiogenic O
and O
anti O
- O
tumor O
activities O
. O

However O
, O
information O
reported O
in O
the O
literature O
on O
the O
effects O
of O
SUN B
on O
the O
constitutive O
expression O
of O
cytochrome O
P450 O
1A1 O
( O
CYP1A1 O
) O
gene O
in O
cells O
from O
mammalian O
species O
remains O
unclear O
. O

Therefore O
, O
the O
main O
objectives O
of O
the O
current O
work O
were O
to O
investigate O
the O
potentiality O
of O
SUN B
to O
induce O
CYP1A1 O
gene O
expression O
in O
human O
breast O
cancer O
MCF7 O
cells O
and O
to O
explore O
the O
molecular O
mechanisms O
involved O
. O

Our O
results O
showed O
that O
SUN B
induced O
the O
CYP1A1 O
mRNA O
, O
protein O
, O
and O
activity O
levels O
in O
a O
concentration O
- O
dependent O
manner O
in O
MCF7 O
cells O
. O

The O
increase O
in O
CYP1A1 O
mRNA O
by O
SUN B
was O
completely O
blocked O
by O
the O
transcriptional O
inhibitor O
, O
actinomycin O
D O
; O
implying O
that O
SUN B
increased O
de O
novo O
RNA O
synthesis O
. O

Furthermore O
, O
the O
ability O
of O
SUN B
to O
increase O
luciferase O
reporter O
gene O
expression O
suggests O
an O
aryl O
hydrocarbon O
receptor O
( O
AhR O
) O
- O
dependent O
transcriptional O
control O
and O
excludes O
the O
possibility O
of O
any O
posttranscriptional O
mechanisms O
. O

In O
addition O
, O
blocking O
of O
AhR O
activation O
by O
resveratrol O
, O
a O
well O
- O
known O
AhR O
antagonist O
, O
prevented O
the O
SUN B
- O
induced O
CYP1A1 O
gene O
expression O
, O
further O
confirms O
the O
involvement O
of O
AhR O
. O

Interestingly O
, O
this O
was O
associated O
with O
the O
inability O
of O
SUN B
to O
directly O
bind O
to O
and O
induce O
transformation O
of O
cytosolic O
AhR O
to O
its O
DNA O
- O
binding O
form O
in O
vitro O
, O
suggesting O
that O
the O
effect O
of O
SUN B
does O
not O
involve O
direct O
binding O
to O
AhR O
. O

The O
current O
manuscript O
provides O
the O
first O
evidence O
for O
the O
ability O
of O
SUN B
to O
induce O
CYP1A1 O
gene O
expression O
in O
MCF7 O
cells O
through O
AhR O
ligand O
- O
independent O
mechanisms O
. O

Our O
search O
produced O
30 O
articles O
, O
of O
which O
23 O
were O
included O
in O
the O
review O
: O
artemisinin O
compounds O
, O
12 O
articles O
; O
lumefantrine B
, O
four O
articles O
; O
amodiaquine O
, O
five O
articles O
; O
sulfadoxine B
, O
six O
articles O
; O
pyrimethamine B
, O
one O
article O
; O
mefloquine B
, O
three O
articles O
; O
and O
piperaquine B
, O
two O
articles O
. O

Regiospecificity O
and O
stereospecificity O
of O
human O
UDP O
- O
glucuronosyltransfer O
in O
the O
glucuronidation O
of O
estriol B
, O
16 B
- I
epiestriol I
, O
17 B
- I
epiestriol I
, O
and O
13 B
- I
epiestradiol I
. O

The O
glucuronidation O
of O
estriol B
, O
16 B
- I
epiestriol I
, O
and O
17 B
- I
epiestriol I
by O
the O
human O
UDP O
- O
glucuronosyltransfer O
( O
UGTs O
) O
of O
subfamilies O
1A O
, O
2A O
, O
and O
2B O
was O
examined O
. O

UGT1A10 O
is O
highly O
active O
in O
the O
conjugation O
of O
the O
3 B
- I
OH I
in O
all O
these O
estriols B
, O
whereas O
UGT2B7 O
is O
the O
most O
active O
UGT O
toward O
one O
of O
the O
ring O
D O
hydroxyls O
, O
the O
16 B
- I
OH I
in O
estriol B
and O
16 B
- I
epiestriol I
, O
but O
the O
17 O
- O
OH O
in O
17 B
- I
epiestriol I
. O

The O
glucuronidation O
of O
the O
different O
estriols B
by O
the O
human O
liver O
and O
intestine O
microsomes O
reflects O
the O
activity O
of O
UGT1A10 O
and O
UGT2B7 O
in O
combination O
with O
the O
tissues O
' O
difference O
in O
UGT1A10 O
expression O
. O

The O
UGT1A10 O
mutant O
1A10 O
- O
F93G O
exhibited O
much O
higher O
V O
( O
max O
) O
values O
than O
UGT1A10 O
in O
estriol B
and O
17 B
- I
epiestriol I
glucuronidation O
, O
but O
a O
significantly O
lower O
value O
in O
16 B
- I
epiestriol I
glucuronidation O
. O

To O
this O
study O
on O
estriol B
glucuronidation O
we O
have O
added O
experiments O
with O
13 B
- I
epiestradiol I
, O
a O
synthetic O
estradiol O
in O
which O
the O
spatial O
arrangement O
of O
the O
methyl O
on O
C18 O
and O
the O
hydroxyl O
on O
C17 O
is O
significantly O
different O
than O
in O
other O
estrogens O
. O

In O
comparison O
with O
estradiol O
glucuronidation O
, O
the O
C13 O
configuration O
change O
decreases O
the O
turnover O
of O
UGTs O
that O
conjugate O
the O
3 B
- I
OH I
, O
but O
increases O
it O
in O
UGTs O
that O
primarily O
conjugate O
the O
17 O
- O
OH O
. O

Unexpectedly O
, O
UGT2B17 O
exhibited O
similar O
conjugation O
rates O
of O
both O
the O
17 O
- O
OH O
and O
3 B
- I
OH I
of O
13 B
- I
espiestradiol I
. O

The O
combined O
results O
reveal O
the O
strong O
preference O
of O
UGT1A10 O
for O
the O
3 B
- I
OH I
of O
physiologic O
estrogens O
and O
the O
equivalently O
strong O
preference O
of O
UGT2B7 O
and O
UGT2B17 O
for O
the O
hydroxyls O
on O
ring O
D O
of O
such O
steroid B
hormones I
. O

Induced O
expression O
of O
cytochrome O
P450 O
1A O
and O
NAD O
( O
P O
) O
H O
: O
quinone O
oxidoreductase O
determined O
at O
mRNA O
, O
protein O
, O
and O
enzyme O
activity O
levels O
in O
rats O
exposed O
to O
the O
carcinogenic O
azo O
dye O
1 B
- I
phenylazo I
- I
2 I
- I
naphthol I
( O
Sudan B
I I
) O
. O

Sudan B
I I
( O
1 B
- I
phenylazo I
- I
2 I
- I
hydroxynaphthol I
) O
is O
a O
suspected O
human O
carcinogen O
causing O
tumors O
in O
the O
livers O
and O
urinary O
bladders O
of O
rats O
, O
mice O
, O
and O
rabbits O
. O

Here O
, O
we O
investigated O
for O
the O
first O
time O
the O
influence O
of O
Sudan B
I I
exposure O
on O
the O
expression O
of O
several O
biotransformation O
enzymes O
in O
the O
livers O
, O
kidneys O
, O
and O
lungs O
of O
rats O
concomitantly O
at O
the O
mRNA O
and O
protein O
levels O
and O
assayed O
their O
enzymatic O
activities O
. O

We O
also O
studied O
its O
effect O
on O
the O
formation O
of O
Sudan B
I I
- O
derived O
DNA O
adducts O
in O
vitro O
. O

Sudan B
I I
increased O
the O
total O
amounts O
of O
cytochrome O
P450 O
( O
P450 O
) O
in O
all O
organs O
tested O
. O

Western O
blots O
using O
antibodies O
raised O
against O
various O
P450s O
, O
NADPH O
: O
P450 O
reductase O
, O
and O
NAD O
( O
P O
) O
H O
: O
quinone O
oxidoreductase O
1 O
( O
NQO1 O
) O
showed O
that O
the O
expression O
of O
P450 O
1A1 O
and O
NQO1 O
was O
induced O
in O
the O
liver O
, O
kidney O
, O
and O
lung O
of O
rats O
treated O
with O
Sudan B
I I
. O

Furthermore O
, O
9 O
. O
9 O
- O
, O
5 O
. O
9 O
- O
, O
and O
2 O
. O
8 O
- O
fold O
increases O
in O
the O
formation O
of O
Sudan B
I I
oxidative O
metabolites O
catalyzed O
by O
microsomes O
isolated O
from O
the O
liver O
, O
kidney O
, O
and O
lung O
, O
respectively O
, O
of O
rats O
treated O
with O
Sudan B
I I
were O
found O
. O

The O
relative O
amounts O
of O
P450 O
1A O
and O
NQO1 O
mRNA O
, O
measured O
by O
real O
- O
time O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
analysis O
, O
demonstrated O
that O
Sudan B
I I
induced O
the O
expression O
of O
P450 O
1A1 O
and O
NQO1 O
mRNA O
in O
the O
liver O
, O
kidney O
, O
and O
lung O
, O
and O
of O
P450 O
1A2 O
mRNA O
in O
kidney O
and O
lung O
. O

Finally O
, O
microsomes O
isolated O
from O
livers O
, O
kidneys O
, O
and O
lungs O
of O
Sudan B
I I
exposed O
rats O
more O
effectively O
catalyzed O
the O
formation O
of O
Sudan B
I I
- O
DNA O
adducts O
than O
microsomes O
from O
organs O
of O
control O
rats O
. O

Because O
P450 O
1A1 O
is O
playing O
a O
major O
role O
in O
the O
bioactivation O
of O
Sudan B
I I
in O
rat O
and O
human O
systems O
, O
its O
induction O
by O
Sudan B
I I
may O
have O
a O
profound O
effect O
on O
cancer O
risk O
by O
this O
azo O
dye O
. O

By O
studying O
the O
interaction O
of O
different O
truncated O
or O
mutated O
A O
beta O
peptides O
with O
heme O
or O
protoporphyrin B
, O
we O
further O
found O
that O
the O
porphyrin O
ring O
of O
heme O
is O
implicated O
to O
interact O
preferentially O
with O
the O
Phe O
( O
19 O
) O
residue O
, O
facilitating O
the O
binding O
of O
heme O
to O
A O
beta O
and O
disturbing O
the O
interstrand O
aromatic O
interaction O
between O
the O
Phe O
residues O
, O
which O
is O
crucial O
for O
A O
beta O
fibrillation O
. O

Compared O
to O
their O
wild O
- O
type O
littermates O
, O
Glu O
- O
CB1 O
- O
KO O
displayed O
a O
small O
decrease O
of O
CB1 O
mRNA O
amount O
, O
immunoreactivity O
and O
[ B
( I
3 I
) I
H I
] I
CP55 I
, I
940 I
binding O
. O

Surprisingly O
, O
however O
, O
saturation O
analysis O
of O
HU210 B
- O
stimulated O
[ O
( O
35 O
) O
S O
] O
GTP O
gamma O
S O
binding O
demonstrated O
that O
' O
glutamatergic O
' O
CB1 O
is O
more O
efficiently O
coupled O
to O
G O
protein O
signalling O
than O
' O
GABAergic O
' O
CB1 O
. O

Class O
III O
phosphatidylinositol O
3 O
- O
kinase O
and O
its O
catalytic O
product O
PtdIns3P B
in O
regulation O
of O
endocytic O
membrane O
traffic O
. O

Central O
in O
this O
context O
is O
class O
III O
phosphatidylinositol O
3 O
- O
kinase O
, O
an O
evolutionarily O
conserved O
enzyme O
complex O
that O
phosphorylates O
phosphatidylinositol O
into O
phosphatidylinositol B
3 I
- I
phosphate I
. O

Phosphatidylinositol B
3 I
- I
phosphate I
recruits O
specific O
effector O
proteins O
, O
most O
of O
which O
contain O
FYVE O
or O
PX O
domains O
, O
to O
promote O
endocytosis O
, O
endosome O
fusion O
, O
endosome O
motility O
and O
endosome O
maturation O
, O
as O
well O
as O
cargo O
sorting O
to O
lysosomes O
, O
the O
biosynthetic O
pathway O
or O
the O
plasma O
membrane O
. O

Here O
we O
review O
the O
functions O
of O
key O
phosphatidylinositol B
3 I
- I
phosphate I
effectors O
in O
regulation O
of O
endocytic O
membrane O
dynamics O
and O
protein O
sorting O
. O

Inhibition O
of O
HIV O
- O
1 O
replication O
by O
a O
tricyclic B
coumarin I
GUT B
- I
70 I
in O
acutely O
and O
chronically O
infected O
cells O
. O

The O
anti O
- O
HIV O
- O
1 O
activity O
of O
GUT B
- I
70 I
, O
a O
natural O
product O
derived O
from O
the O
stem O
bark O
of O
Chlophyllum O
brasiliense O
, O
was O
evaluated O
. O

GUT B
- I
70 I
inhibited O
HIV O
- O
1 O
replication O
in O
both O
acutely O
and O
chronically O
infected O
cells O
through O
suppression O
of O
NF O
- O
kappa O
B O
. O

Our O
results O
strengthen O
the O
idea O
that O
NF O
- O
kappa O
B O
pathway O
is O
one O
of O
the O
potential O
targets O
to O
control O
HIV O
- O
1 O
replication O
and O
that O
GUT B
- I
70 I
could O
serve O
as O
a O
lead O
compound O
to O
develop O
novel O
therapeutic O
agents O
against O
HIV O
- O
1 O
infection O
. O

Liposomes O
were O
made O
of O
zwitterionic O
phosphatidylcholines B
and O
experiments O
were O
performed O
at O
physiologic O
pH O
and O
at O
various O
membrane O
physical O
states O
( O
gel O
, O
ripple O
and O
fluid O
phases O
) O
. O

Cholinesterase O
and O
carboxylesterase O
inhibition O
in O
Planorbarius O
corneus O
exposed O
to O
binary O
mixtures O
of O
azinphos B
- I
methyl I
and O
chlorpyrifos O
. O

The O
present O
investigation O
was O
undertaken O
to O
explore O
the O
in O
vivo O
inhibition O
of O
the O
freshwater O
gastropod O
snail O
Planorbarius O
corneus O
cholinesterase O
( O
ChE O
) O
and O
carboxylesterases O
( O
CES O
) O
activities O
by O
the O
organophosphorus O
pesticides O
azinphos B
- I
methyl I
( O
AZM B
) O
and O
chlorpyrifos O
( O
CPF B
) O
. O

To O
this O
end O
, O
snails O
were O
exposed O
for O
48 O
h O
to O
different O
concentrations O
of O
AZM B
and O
CPF B
in O
single O
- O
chemical O
and O
binary O
- O
mixture O
studies O
, O
and O
ChE O
and O
CES O
activities O
were O
measured O
in O
the O
whole O
soft O
body O
tissues O
and O
hemolymph O
. O

ChE O
activity O
was O
measured O
with O
acetylthiocholine B
as O
substrate O
and O
CES O
activity O
was O
measured O
with O
four O
substrates O
: O
p B
- I
nitrophenyl I
acetate I
, O
p B
- I
nitrophenyl I
butyrate I
, O
1 B
- I
and I
2 I
- I
naphthyl I
acetate I
. O

Single O
- O
chemical O
experiments O
showed O
that O
CPF B
was O
a O
more O
potent O
inhibitor O
of O
ChE O
activity O
than O
AZM B
( O
350 O
and O
27 O
times O
for O
the O
whole O
soft O
tissue O
and O
hemolymph O
, O
respectively O
) O
. O

CES O
were O
15 O
times O
more O
sensitive O
than O
ChE O
when O
the O
activities O
were O
measured O
in O
the O
whole O
soft O
tissue O
of O
the O
animals O
exposed O
to O
AZM B
. O

Based O
on O
a O
default O
assumption O
of O
concentration O
addition O
, O
P O
. O
corneus O
snails O
were O
exposed O
to O
mixtures O
of O
AZM B
+ O
CPF B
designed O
to O
yield O
predicted O
soft O
tissue O
ChE O
inhibitions O
of O
31 O
% O
( O
mixture O
1 O
) O
, O
50 O
% O
( O
mixture O
2 O
) O
and O
61 O
% O
( O
mixture O
3 O
) O
. O

In O
addition O
, O
results O
obtained O
when O
the O
snails O
were O
exposed O
sequentially O
to O
the O
pesticides O
showed O
that O
the O
sequence O
AZM B
/ O
CPF B
produced O
at O
48 O
h O
a O
higher O
ChE O
inhibition O
than O
the O
sequence O
CPF B
/ O
CPF B
. O

In O
particular O
, O
the O
data O
presented O
in O
the O
present O
study O
indicate O
that O
CES O
enzymes O
would O
be O
important O
factors O
in O
determining O
the O
effects O
of O
the O
mixtures O
of O
OPs B
on O
P O
. O
corneus O
ChE O
activity O
. O

We O
explored O
BRS O
- O
3 O
expression O
in O
skeletal O
muscle O
from O
normal O
, O
obese O
or O
type O
- O
2 O
diabetic O
( O
T2D O
) O
patients O
, O
and O
the O
effect O
of O
[ O
D O
- O
Phe O
( O
6 O
) O
, O
beta B
- I
Ala I
( O
11 O
) O
, O
Phe O
( O
13 O
) O
, O
Nle O
( O
14 O
) O
] O
bombesin O
( O
6 O
- O
14 O
) O
- O
BRS O
- O
3 O
- O
agonist O
- O
peptide O
( O
BRS O
- O
3 O
- O
AP O
) O
- O
on O
glucose O
- O
related O
effects O
, O
before O
or O
after O
BRS O
- O
3 O
gene O
silencing O
. O

Mechanistically O
, O
BNF O
blocked O
light O
induction O
of O
the O
Per1 O
transcript O
in O
suprachiasmatic O
nucleus O
and O
liver O
in O
WT O
mice O
, O
and O
BNF O
blocked O
forskolin O
( O
FSK B
) O
- O
induced O
Per1 O
transcripts O
in O
Hepa O
- O
1c1c7 O
( O
c7 O
) O
cells O
. O

An O
E O
- O
box O
decoy O
did O
not O
affect O
BNF O
inhibition O
of O
FSK B
- O
induced O
Per1 O
transcripts O
in O
c7 O
cells O
. O

cAMP O
- O
response O
element O
( O
CRE O
) O
- O
dependent O
induction O
of O
Per1 O
promoter O
activity O
in O
response O
to O
FSK B
in O
combination O
with O
phorbol B
12 I
- I
tetradecanoate I
13 I
- I
acetate I
was O
suppressed O
in O
cells O
that O
expressed O
high O
levels O
of O
AhR O
( O
c7 O
) O
compared O
with O
cells O
lacking O
functional O
AhR O
activity O
( O
c12 O
) O
. O

In O
addition O
, O
the O
inhibitory O
effect O
of O
BNF O
on O
FSK B
- O
induced O
Per1 O
was O
dependent O
on O
phosphorylation O
of O
JNK O
. O

There O
were O
synthesized O
new O
types O
of O
ribbon O
type O
steroidal O
dimers O
derived O
from O
three O
types O
of O
steroidal O
skeletons O
( O
cholic O
acid O
, O
etienic B
acid I
, O
estrone O
) O
using O
Cu O
( O
I O
) O
catalyzed O
1 O
, O
3 O
- O
dipolar O
cycloaddition O
reaction O
. O

Steroid O
parts O
of O
the O
molecular O
" O
ribbons O
" O
are O
linked O
by O
heterocyclic O
moiety O
, O
namely O
by O
2 B
, I
6 I
- I
bis I
( I
( I
1H I
- I
1 I
, I
2 I
, I
3 I
- I
triazol I
- I
1 I
- I
yl I
) I
- I
methyl I
) I
pyridine I
. O

PURPOSE O
: O
Pregabalin O
( O
PRG B
) O
is O
approved O
for O
the O
treatment O
of O
neuropathic O
pain O
, O
partial O
seizures O
and O
generalised O
anxiety O
disorder O
in O
many O
countries O
and O
currently O
under O
study O
for O
other O
indications O
. O

Supported O
by O
case O
reports O
and O
the O
results O
of O
a O
limited O
number O
of O
studies O
there O
is O
an O
ongoing O
debate O
on O
the O
potential O
of O
PRG B
to O
cause O
addictive O
behaviours O
. O

However O
, O
currently O
available O
evidence O
on O
this O
issue O
is O
sparse O
, O
and O
any O
definitive O
assessment O
of O
PRG B
' O
s O
potential O
for O
abuse O
and O
dependence O
is O
not O
yet O
in O
sight O
. O

The O
aim O
of O
our O
study O
was O
to O
identify O
the O
number O
of O
cases O
of O
PRG B
abuse O
or O
dependence O
reported O
to O
the O
database O
of O
a O
German O
medical O
regulatory O
body O
and O
to O
obtain O
insights O
into O
further O
usage O
- O
specific O
parameters O
. O

METHODS O
: O
We O
conducted O
a O
query O
of O
the O
entire O
database O
of O
the O
German O
Federal O
Institute O
for O
Drugs O
and O
Medical O
Devices O
( O
BfArM O
) O
regarding O
reports O
of O
PRG B
abuse O
or O
dependence O
and O
analysed O
these O
cases O
on O
the O
basis O
of O
several O
parameters O
. O

RESULTS O
: O
A O
total O
of O
55 O
reports O
of O
PRG B
abuse O
or O
dependence O
were O
identified O
( O
mean O
age O
36 O
years O
, O
64 O
% O
of O
reports O
involved O
males O
) O
. O

Mean O
daily O
PRG B
dosage O
was O
1424 O
mg O
. O

In O
about O
one O
- O
third O
of O
the O
patients O
withdrawal O
syndromes O
subsequent O
to O
discontinuation O
of O
PRG B
were O
reported O
. O

CONCLUSIONS O
: O
Cases O
of O
PRG B
abuse O
or O
dependence O
have O
been O
reported O
to O
the O
BfArM O
since O
2008 O
, O
with O
a O
marked O
increase O
of O
such O
reports O
in O
subsequent O
years O
. O

Male O
sex O
and O
a O
history O
of O
polytoxicomania O
may O
be O
possible O
risk O
factors O
for O
the O
development O
of O
addictive O
behaviours O
related O
to O
PRG B
. O

Effects O
on O
gene O
expression O
in O
rat O
liver O
after O
administration O
of O
RXR O
agonists O
: O
UAB30 B
, O
4 B
- I
methyl I
- I
UAB30 I
, O
and O
Targretin B
( O
Bexarotene B
) O
. O

Examination O
of O
three O
retinoid O
X O
receptor O
( O
RXR O
) O
agonists O
[ O
Targretin B
( O
TRG O
) O
, O
UAB30 B
, O
and O
4 B
- I
methyl I
- I
UAB30 I
( O
4 B
- I
Me I
- I
UAB30 I
) O
] O
showed O
that O
all O
inhibited O
mammary O
cancer O
in O
rodents O
and O
two O
( O
TRG O
and O
4 B
- I
Me I
- I
UAB30 I
) O
strikingly O
increased O
serum O
triglyceride O
levels O
. O

For O
proliferator O
- O
activated O
receptor O
alpha O
/ O
RXR O
- O
activated O
genes O
, O
the O
strongest O
response O
was O
TRG O
> O
4 B
- I
Me I
- I
UAB30 I
> O
UAB30 B
. O

Many O
liver O
X O
receptor O
/ O
RXR O
- O
related O
genes O
( O
e O
. O
g O
. O
, O
Scd O
- O
1 O
and O
Srebf1 O
, O
which O
are O
associated O
with O
increased O
triglycerides O
) O
were O
highly O
expressed O
in O
TRG O
and O
4 B
- I
Me I
- I
UAB30 I
- O
but O
not O
UAB30 B
- O
treated O
livers O
. O

UAB30 B
unexpectedly O
and O
uniquely O
activated O
genes O
associated O
with O
the O
aryl O
hydrocarbon O
hydroxylase O
( O
Ah O
) O
receptor O
( O
Cyp1a1 O
, O
Cyp1a2 O
, O
Cyp1b1 O
, O
and O
Nqo1 O
) O
. O

Based O
on O
the O
Ah O
receptor O
activation O
, O
UAB30 B
was O
tested O
for O
its O
ability O
to O
prevent O
dimethylbenzanthrace B
( O
DMBA O
) O
- O
induced O
mammary O
cancers O
, O
presumably O
by O
inhibiting O
DMBA O
activation O
, O
and O
was O
highly O
effective O
. O

Gene O
expression O
changes O
were O
determined O
by O
reverse O
transcriptase O
- O
polymerase O
chain O
reaction O
in O
rat O
livers O
treated O
with O
Targretin B
for O
2 O
. O
3 O
, O
7 O
, O
and O
21 O
days O
. O

This O
is O
the O
first O
report O
indicating O
the O
antigenotoxic O
activities O
of O
MEP O
against O
several O
mutagen O
agents O
such O
as O
N B
- I
methyl I
- I
N I
' I
- I
nitro I
- I
N I
- I
nitrosoguanidine I
, O
acridin B
and O
aflatoxin O
. O

Effects O
of O
trona B
on O
the O
redox O
status O
of O
cellular O
system O
of O
male O
rats O
. O

The O
effects O
of O
trona B
( O
Kaun B
) O
, O
a O
food O
additive O
, O
on O
the O
redox O
status O
of O
the O
liver O
and O
kidney O
of O
male O
Wistar O
rats O
were O
investigated O
. O

A O
total O
of O
60 O
male O
rats O
( O
145 O
+ O
/ O
- O
2 O
. O
52 O
g O
) O
were O
grouped O
into O
four O
: O
A O
, O
B O
, O
C O
and O
D O
, O
where O
group O
A O
( O
the O
control O
) O
received O
1 O
mL O
of O
distilled O
water O
orally O
while O
those O
in O
groups O
B O
, O
C O
and O
D O
( O
test O
groups O
) O
received O
orally O
, O
same O
volume O
of O
trona B
preparation O
corresponding O
to O
100 O
, O
200 O
and O
400 O
mg O
/ O
kg O
body O
weight O
, O
respectively O
, O
for O
28 O
days O
. O

Administration O
of O
trona B
significantly O
reduced O
( O
p O
< O
0 O
. O
05 O
) O
alkaline O
phosphatase O
activity O
in O
the O
liver O
and O
kidney O
with O
corresponding O
increases O
in O
the O
serum O
enzyme O
. O

The O
activities O
of O
superoxide O
dismutase O
, O
catalase O
, O
glutathione O
peroxidase O
, O
glutathione O
reductase O
and O
the O
levels O
of O
reduced O
glutathione O
, O
vitamins B
C I
and I
E I
in O
the O
liver O
and O
kidney O
of O
the O
animals O
decreased O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
. O

In O
contrast O
, O
malondialdehyde O
and O
lipid O
hydroperoxide O
of O
trona B
- O
treated O
animals O
increased O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
in O
liver O
and O
kidney O
. O

Overall O
, O
data O
from O
this O
study O
revealed O
that O
trona B
exhibited O
its O
toxic O
effect O
by O
suppressing O
or O
depleting O
the O
antioxidant O
systems O
and O
increasing O
the O
risk O
of O
attack O
by O
oxidants O
generated O
either O
from O
its O
metabolites O
or O
from O
other O
in O
vivo O
means O
on O
the O
rat O
cellular O
system O
. O

In O
vitro O
assessment O
of O
drug O
- O
drug O
interaction O
potential O
of O
boceprevir B
associated O
with O
drug O
metabolizing O
enzymes O
and O
transporters O
. O

The O
inhibitory O
effect O
of O
boceprevir B
( O
BOC B
) O
, O
an O
inhibitor O
of O
hepatitis O
C O
virus O
nonstructural O
protein O
3 O
protease O
was O
evaluated O
in O
vitro O
against O
a O
panel O
of O
drug O
- O
metabolizing O
enzymes O
and O
transporters O
. O

BOC B
, O
a O
known O
substrate O
for O
cytochrome O
P450 O
( O
P450 O
) O
CYP3A O
and O
aldo O
- O
ketoreductases O
, O
was O
a O
reversible O
time O
- O
dependent O
inhibitor O
( O
k O
( O
inact O
) O
= O
0 O
. O
12 O
minute O
( O
- O
1 O
) O
, O
K O
( O
I O
) O
= O
6 O
. O
1 O
micro O
M O
) O
of O
CYP3A4 O
/ O
5 O
but O
not O
an O
inhibitor O
of O
other O
major O
P450s O
, O
nor O
of O
UDP O
- O
glucuronosyltransfer O
1A1 O
and O
2B7 O
. O

BOC B
showed O
weak O
to O
no O
inhibition O
of O
breast O
cancer O
resistance O
protein O
( O
BCRP O
) O
, O
P O
- O
glycoprotein O
( O
Pgp O
) O
, O
or O
multidrug O
resistance O
protein O
2 O
. O

In O
human O
hepatocytes O
, O
BOC B
inhibited O
CYP3A O
- O
mediated O
metabolism O
of O
midazolam O
, O
OATP1B O
- O
mediated O
hepatic O
uptake O
of O
pitavastatin B
, O
and O
both O
the O
uptake O
and O
metabolism O
of O
atorvastatin O
. O

The O
inhibitory O
potency O
of O
BOC B
was O
lower O
than O
known O
inhibitors O
of O
CYP3A O
( O
ketoconazole O
) O
, O
OATP1B O
( O
rifampin B
) O
, O
or O
both O
( O
telaprevir B
) O
. O

BOC B
was O
a O
substrate O
for O
Pgp O
and O
BCRP O
but O
not O
for O
OATP1B1 O
, O
OATP1B3 O
, O
OATP2B1 O
, O
organic O
cation O
transporter O
, O
or O
sodium O
/ O
taurocholate O
cotransporting O
peptide O
. O

Overall O
, O
our O
data O
suggest O
that O
BOC B
has O
the O
potential O
to O
cause O
pharmacokinetic O
interactions O
via O
inhibition O
of O
CYP3A O
and O
CYP3A O
/ O
OATP1B O
interplay O
, O
with O
the O
interaction O
magnitude O
lower O
than O
those O
observed O
with O
known O
potent O
inhibitors O
. O

Conversely O
, O
pharmacokinetic O
interactions O
of O
BOC B
, O
either O
as O
a O
perpetrator O
or O
victim O
, O
via O
other O
major O
P450s O
and O
transporters O
tested O
are O
less O
likely O
to O
be O
of O
clinical O
significance O
. O

Mathematical O
modeling O
of O
oral O
absorption O
and O
bioavailability O
of O
a O
fluoroquinolone B
after O
its O
precipitation O
in O
the O
gastrointestinal O
tract O
. O

The O
objective O
was O
to O
characterize O
the O
in O
vivo O
absorption O
and O
bioavailability O
( O
BA O
) O
of O
a O
low O
solubility O
, O
high O
permeability O
fluoroquinolone B
( O
CNV97101 B
) O
that O
precipitates O
in O
the O
gastrointestinal O
( O
GI O
) O
tract O
by O
mathematical O
modeling O
approach O
. O

Due O
to O
the O
almost O
complete O
availability O
of O
CNV97101 B
following O
IP O
administration O
, O
a O
first O
hepatic O
pass O
could O
be O
excluded O
. O

Arundinols B
A I
- I
C I
and O
arundinones B
A I
and I
B I
from O
the O
plant O
endophytic O
fungus O
Microsphaeropsis O
arundinis O
. O

Three O
new O
ent B
- I
eudesmane I
sesquiterpenoids I
, O
arundinols B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
one O
isochroman B
- I
1 I
- I
one I
, O
arundinone B
A I
( O
4 O
) O
, O
and O
a O
polyoxygenated B
benzofuran I
- I
3 I
( I
2H I
) I
- I
one I
dimer O
, O
arundinone B
B I
( O
5 O
) O
, O
were O
isolated O
from O
the O
extract O
of O
a O
plant O
endophytic O
fungus O
, O
Microsphaeropsis O
arundinis O
. O

The O
absolute O
configuration O
of O
1 O
was O
assigned O
by O
X O
- O
ray O
crystallography O
using O
Cu O
K O
alpha O
radiation O
, O
whereas O
those O
of O
the O
C O
- O
11 O
tertiary B
alcohols I
in O
2 O
and O
3 O
were O
deduced O
via O
the O
circular O
dichroism O
data O
of O
the O
in O
situ O
formed O
[ B
Rh I
( I
2 I
) I
( I
OCOCF I
( I
3 I
) I
) I
( I
4 I
) I
] I
complexes O
. O

Arundinone B
B I
( O
5 O
) O
represents O
the O
first O
dimeric O
benzofuran B
- I
3 I
( I
2H I
) I
- I
one I
, O
showing O
cytotoxicity O
against O
T24 O
and O
A549 O
cells O
. O

S O
- O
Nitrosoglutathione O
( O
GSNO B
) O
represents O
the O
newest O
addition O
to O
its O
diverse O
substrate O
spectrum O
, O
which O
includes O
a O
wide O
range O
of O
xenobiotics O
and O
endogenous O
substances O
. O

GSNO B
has O
also O
been O
shown O
to O
covalently O
modify O
and O
inhibit O
CBR1 O
. O

Of O
five O
candidate O
cysteines O
for O
modification O
by O
2 O
mM O
GSNO B
( O
positions O
26 O
, O
122 O
, O
150 O
, O
226 O
, O
227 O
) O
, O
the O
last O
four O
were O
analyzed O
using O
MALDI O
- O
TOF O
/ O
TOF O
mass O
spectrometry O
and O
then O
quantified O
using O
the O
Selected O
Reaction O
Monitoring O
Approach O
on O
hyphenated O
HPLC O
with O
a O
triple O
quadrupole O
mass O
spectrometer O
. O

The O
analysis O
confirmed O
GSNO B
concentration O
- O
dependent O
S B
- I
glutathionylation I
of O
cysteines O
at O
positions O
122 O
, O
150 O
, O
226 O
, O
227 O
which O
was O
2 O
- O
700 O
times O
higher O
compared O
to O
wild O
- O
type O
CBR1 O
( O
WT O
- O
CBR1 O
) O
. O

The O
catalytic O
properties O
of O
wild O
- O
type O
and O
enzyme O
modified O
with O
2 O
mM O
GSNO B
were O
also O
investigated O
by O
steady O
state O
kinetic O
experiments O
with O
various O
substrates O
. O

GSNO B
treatment O
of O
CBR1 O
resulted O
in O
a O
2 O
- O
5 O
- O
fold O
decrease O
in O
kcat O
with O
menadione O
, O
4 B
- I
benzoylpyridine I
, O
2 B
, I
3 I
- I
hexanedione I
, O
daunorubicin B
and O
1 B
, I
4 I
- I
naphthoquinone I
. O

In O
contrast O
, O
the O
same O
treatment O
increased O
kcat O
for O
substrates O
containing O
a O
1 B
, I
2 I
- I
diketo I
group O
in O
a O
ring O
structure O
( O
1 B
, I
2 I
- I
naphthoquinone I
, O
9 B
, I
10 I
- I
phenanthrenequinone I
, O
isatin O
) O
. O

Except O
for O
9 B
, I
10 I
- I
phenanthrenequinone I
, O
all O
changes O
in O
kcat O
were O
at O
least O
in O
part O
compensated O
for O
by O
a O
similar O
change O
in O
Km O
, O
overall O
yielding O
no O
drastic O
changes O
in O
catalytic O
efficiency O
. O

The O
findings O
indicate O
that O
GSNO B
- O
induced O
covalent O
modification O
of O
cysteine O
residues O
affects O
the O
kinetic O
mechanism O
of O
CBR1 O
both O
in O
terms O
of O
substrate O
binding O
and O
turnover O
rate O
, O
probably O
by O
covalent O
modification O
of O
Cys O
- O
226 O
and O
/ O
or O
Cys O
- O
227 O
. O

We O
investigated O
the O
influence O
of O
maternal O
airway O
exposure O
to O
nanoparticulate O
titanium O
dioxide O
( O
TiO2 O
, O
UV O
- O
Titan O
) O
and O
carbon O
black O
( O
CB O
, O
Printex90 B
) O
, O
on O
male O
reproductive O
function O
in O
the O
two O
following O
generations O
. O

Time O
- O
mated O
C57BL O
/ O
6J O
mice O
were O
exposed O
by O
inhalation O
to O
UV O
- O
Titan O
, O
or O
by O
intratracheal O
instillation O
with O
Printex90 B
. O

F2 O
offspring O
, O
whose O
fathers O
were O
prenatally O
exposed O
to O
Printex90 B
, O
showed O
lowered O
sperm O
production O
. O

SKF83959 B
is O
a O
potent O
allosteric O
modulator O
of O
sigma O
- O
1 O
receptor O
. O

SKF83959 B
( O
3 B
- I
methyl I
- I
6 I
- I
chloro I
- I
7 I
, I
8 I
- I
hydroxy I
- I
1 I
- I
[ I
3 I
- I
methylphenyl I
] I
- I
2 I
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
3 I
- I
benzazepine I
) O
, O
an O
atypical O
dopamine O
receptor O
- O
1 O
( O
D O
( O
1 O
) O
receptor O
) O
agonist O
, O
has O
shown O
many O
D O
( O
1 O
) O
receptor O
- O
independent O
effects O
, O
such O
as O
neuroprotection O
, O
blockade O
of O
Na O
( O
+ O
) O
channel O
, O
and O
promotion O
of O
spontaneous O
glutamate O
release O
, O
which O
resemble O
the O
effects O
of O

In O
the O
present O
work O
, O
we O
explored O
the O
potential O
modulation O
of O
SKF83959 B
on O
the O
sigma O
- O
1 O
receptor O
. O

The O
results O
indicated O
that O
SKF83959 B
dramatically O
promoted O
the O
binding O
of O
( B
3 I
) I
H I
( I
+ I
) I
- I
pentazocine I
( O
a O
selective O
sigma O
- O
1 O
receptor O
agonist O
) O
to O
the O
sigma O
- O
1 O
receptor O
in O
brain O
and O
liver O
tissues O
but O
produced O
no O
effect O
on O
( B
3 I
) I
H I
- I
progesterone I
binding O
( O
a O
sigma O
- O
1 O
receptor O
antagonist O
) O
. O

We O
further O
demonstrated O
that O
the O
SKF83959 B
analogs O
, O
such O
as O
SCH22390 B
[ O
( B
R I
) I
- I
( I
1 I
) I
- I
7 I
- I
chloro I
- I
8 I
- I
hydroxy I
- I
3 I
- I
methyl I
- I
1 I
- I
phenyl I
- I
2 I
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
3 I
- I
benzazepine I
hydrochloride I
] O
and O
SKF38393 B
[ O
( O
+ O
/ O
- O
) O
- O
1 O
- O
phenyl O
- O
2 O
, O
3 O
, O
4 O
, O
5 O
- O
tetrahydro O
- O
( O
1H O
) O
- O
3 O
- O
benzazepine O

Moreover O
, O
all O
three O
tested O
chemicals O
elicited O
no O
significant O
effect O
on O
( B
3 I
) I
H I
- I
1 I
, I
3 I
- I
di I
( I
2 I
- I
tolyl I
) I
- I
guanidine I
( O
( B
3 I
) I
H I
- I
DTG I
) O
binding O
to O
the O
sigma O
- O
2 O
receptor O
. O

The O
present O
data O
uncovered O
a O
new O
role O
of O
SKF83959 B
and O
its O
analogs O
on O
the O
sigma O
- O
1 O
receptor O
, O
which O
, O
in O
turn O
, O
may O
reveal O
the O
underlying O
mechanism O
for O
the O
D O
( O
1 O
) O
receptor O
- O
independent O
effect O
of O
the O
drug O
. O

Furthermore O
, O
a O
humanized O
CYP3A4 O
/ O
3A7 O
mouse O
model O
showed O
in O
vivo O
induction O
of O
CYP3A4 O
mRNA O
and O
protein O
by O
[ O
4 B
- I
chloro I
- I
6 I
- I
( I
2 I
, I
3 I
- I
xylidino I
) I
- I
2 I
- I
pyrimidinylthio I
] I
acetic I
acid I
( O
WY14 O
, O
643 O
) O
in O
liver O
but O
not O
in O
intestine O
, O
whereas O
hepatic O
occupancy O
of O
PBRs O
by O
PPAR O
alpha O
was O
ligand O
independent O
. O

Interestingly O
, O
the O
common O
phospholipid O
1 B
- I
palmitoyl I
- I
2 I
- I
oleoyl I
- I
sn I
- I
glycerol I
- I
3 I
- I
phosphocholine I
( O
16 O
: O
0 O
/ O
18 O
: O
1 O
- O
PC O
) O
, O
previously O
proposed O
to O
reflect O
nutritional O
status O
and O
shown O
to O
be O
a O
specific O
endogenous O
ligand O
of O
PPAR O
alpha O
, O
induced O
CYP3A4 O
( O
up O
to O
4 O
- O
fold O
) O
and O
other O
biotransformation O
genes O
in O
hepatocytes O
with O
similar O
selectivity O
and O
potency O
as O
WY14 O
, O
643 O
. O

Polymeric B
triamcinolone I
acetonide I
nanoparticles O
as O
a O
new O
alternative O
in O
the O
treatment O
of O
uveitis O
: O
In O
vitro O
and O
in O
vivo O
studies O
. O

Poly B
( I
d I
, I
l I
- I
lactide I
- I
co I
- I
glycolide I
) I
( O
PLGA O
) O
nanoparticles O
were O
prepared O
using O
a O
modified O
emulsification O
/ O
solvent O
diffusion O
method O
. O

Results O
indicated O
statistically O
significant O
differences O
between O
the O
effect O
of O
nanoparticles O
in O
the O
treatment O
of O
EIU O
compared O
to O
microparticles O
of O
TA O
and O
prednisolone B
acetate I
( O
PA O
) O
. O

A O
novel O
approach O
, O
called O
isothermal O
isotope O
exchange O
( O
IIE O
) O
, O
was O
applied O
to O
varying O
A O
- O
and O
B O
- O
site O
lanthanum B
manganites I
, O
ferrites B
, O
and O
cobaltites B
in O
the O
perovskite O
crystal O
structure O
in O
order O
to O
extract O
accurate O
surface O
exchange O
coefficients O
( O
k O
* O
) O
. O

Strontium B
doped I
perovskites I
exhibited O
opposite O
temperature O
dependencies O
to O
parent O
materials O
. O

Some O
perovskites B
exhibited O
an O
apparent O
negative O
activation O
energy O
for O
k O
* O
, O
the O
behavior O
of O
which O
is O
explained O
by O
a O
precursor O
- O
mediated O
mechanism O
for O
dissociative O
adsorption O
. O

In O
( O
corannulene B
) O
( O
10 O
) O
and O
( O
sumanene B
) O
( O
10 O
) O
aggregates O
, O
the O
first O
order O
hyperpolarizabilitie O
( O
beta O
( O
0 O
) O
) O
per O
molecule O
are O
enhanced O
5 O
. O
59 O
and O
6 O
. O
21 O
times O
with O
respect O
to O
a O
single O
entity O
respectively O
. O

For O
a O
larger O
buckybowl O
, O
C B
( I
36 I
) I
H I
( I
12 I
) I
, O
the O
beta O
( O
0 O
) O
value O
per O
molecule O
of O
its O
pentamer O
reaches O
191 O
. O
4 O
x O
10 O
( O
- O
30 O
) O
esu O
which O
is O
much O
higher O
than O
conventional O
dipolar O
or O
octupolar O
NLO O
chromophores O
ones O
. O

Ochratoxin O
A O
( O
OTA B
) O
is O
a O
mycotoxin O
and O
extrolite O
of O
fungi O
which O
has O
been O
reported O
in O
a O
range O
of O
foods O
. O

This O
study O
uses O
mammalian O
reporter O
gene O
assays O
( O
RGAs O
) O
with O
natural O
steroid O
receptors O
and O
the O
H295R O
steroidogenesis O
assay O
to O
assess O
the O
endocrine O
disrupting O
activity O
of O
OTA B
. O

At O
the O
receptor O
level O
, O
OTA B
( O
within O
a O
concentration O
range O
of O
0 O
. O
25 O
- O
2500 O
ng O
/ O
ml O
) O
did O
not O
induce O
an O
agonistic O
response O
in O
an O
oestrogen O
, O
androgen O
, O
progestagen B
or O
glucocorticoid O
RGA O
. O

However O
, O
while O
there O
was O
no O
significant O
cytotoxic O
effect O
observed O
in O
the O
MTT O
( O
thiazolyl B
blue I
tetrazolium I
bromide I
) O
cell O
viability O
assay O
at O
this O
concentration O
, O
there O
was O
a O
corresponding O
change O
in O
cell O
morphology O
which O
may O
be O
related O
to O
the O
resulting O
antagonistic O
effect O
. O

Insertion O
of O
ER O
alpha O
was O
blocked O
by O
the O
ER O
antagonist O
ICI O
182 O
, O
780 O
or O
with O
the O
protein O
kinase O
C O
( O
PKC O
) O
pathway O
inhibitor O
bisindolylmaleimide B
( O
BIS B
) O
. O

The O
effect O
of O
remelting O
on O
the O
physical O
properties O
of O
borotellurite B
glass O
doped O
with O
manganese O
. O

A O
systematic O
set O
of O
borotellurite B
glasses O
doped O
with O
manganese O
( B
1 I
- I
x I
) I
[ I
( I
B I
( I
2 I
) I
O I
( I
3 I
) I
) I
( I
0 I
. I
3 I
) I
( I
TeO I
( I
2 I
) I
) I
( I
0 I
. I
7 I
) I
] I
- I
xMnO I
, O
with O
x O
= O
0 O
. O
1 O
, O
0 O
. O
2 O
, O
0 O
. O
3 O
and O
0 O
. O
4 O
mol O
% O
, O
were O
successfully O
synthesized O
by O
using O
a O
conventional O
melt O
and O
quench O
- O
casting O
technique O
. O

FTIR O
spectra O
revealed O
that O
the O
addition O
of O
manganese B
oxide I
contributes O
the O
transformation O
of O
TeO B
( I
4 I
) I
trigonal O
bipyramids O
with O
bridging O
oxygen O
( O
BO O
) O
to O
TeO B
( I
3 I
) I
trigonal O
pyramids O
with O
non O
- O
bridging O
oxygen O
( O
NBO O
) O
. O

Contractions O
were O
produced O
by O
electrical O
field O
stimulation O
of O
perivascular O
nerves O
( O
EFS O
) O
, O
norepinephrine O
( O
NE O
) O
, O
adenosine O
5 O
' O
- O
triphosphate O
( O
ATP O
) O
, O
high O
K O
( O
+ O
) O
solution O
and O
by O
calcium B
chloride I
( O
CaCl O
( O
2 O
) O
) O
in O
Ca O
( O
2 O
+ O
) O
- O
free O
and O
high O
K O
( O
+ O
) O
, O
Ca O
( O
2 O
+ O
) O
- O
free O
solution O
. O

The O
EFS O
- O
evoked O
contractions O
were O
more O
sensitive O
to O
resveratrol O
and O
to O
NS1619 B
- O
selective O
openers O
of O
big O
calcium O
- O
sensitive O
( O
BK O
( O
Ca O
) O
) O
channels O
, O
than O
NE O
- O
evoked O
contractions O
. O

Resveratrol O
more O
potently O
inhibited O
CaCl O
( O
2 O
) O
than O
potassium B
chloride I
contractions O
of O
RPV O
. O

The O
antinociceptive O
effect O
of O
milnacipran O
in O
the O
monosodium B
iodoacetate I
model O
of O
osteoarthritis O
pain O
and O
its O
relation O
to O
changes O
in O
descending O
inhibition O
. O

These O
studies O
used O
monoamine O
receptor O
agents O
combined O
with O
behavioral O
studies O
and O
single O
- O
unit O
dorsal O
horn O
recordings O
to O
examine O
whether O
descending O
noradrenergic O
and O
serotonergic O
inhibitions O
are O
altered O
in O
the O
monosodium B
iodoacetate I
model O
of O
OA O
pain O
, O
and O
whether O
increasing O
these O
inhibitions O
with O
the O
serotonin O
/ O
noradrenaline O
reuptake O
inhibitor O
milnacipran O
can O
attenuate O
the O
attendant O
hypersensitivity O
. O

In O
na O
i O
ve O
animals O
and O
the O
early O
, O
but O
not O
late O
, O
phase O
of O
the O
model O
, O
spinal O
administration O
of O
the O
alpha O
( O
2 O
) O
- O
adrenoceptor O
antagonist O
atipamezole B
fully O
reversed O
this O
neuronal O
inhibition O
, O
whereas O
atipamezole B
administered O
alone O
revealed O
that O
endogenous O
noradrenergic O
inhibition O
was O
reduced O
in O
the O
late O
phase O
. O

Blocking O
spinal O
5 O
- O
hydroxytryptamine O
- O
7 O
receptors O
with O
( B
2R I
) I
- I
1 I
- I
[ I
( I
3 I
- I
hydroxyphenyl I
) I
sulfonyl I
] I
- I
2 I
- I
[ I
2 I
- I
( I
4 I
- I
methyl I
- I
1 I
- I
piperidinyl I
) I
ethyl I
] I
pyrrolidine I
hydrochloride I
suggested O
that O
the O
effects O
of O
milnacipran O
in O
the O
late O
phase O
were O
partly O
mediated O
by O
these O
receptors O
, O
and O
that O
descending O
serotonergic O
inhibition O
was O
increased O
in O
this O
phase O
. O

Effect O
of O
major O
cations O
( O
Ca O
( O
2 O
+ O
) O
, O
Mg O
( O
2 O
+ O
) O
, O
Na O
( O
+ O
) O
, O
K O
( O
+ O
) O
) O
and O
anions O
( O
SO B
42 I
- I
, O
Cl O
( O
- O
) O
, O
NO O
3 O
- O
) O
on O
Ni O
accumulation O
and O
toxicity O
in O
aquatic O
plant O
( O
Lemna O
minor O
L O
. O
) O
: O
implications O
For O
Ni O
risk O
assessment O
. O

CMT4B O
results O
from O
mutations O
in O
either O
myotubularin O
- O
related O
protein O
2 O
( O
MTMR2 O
; O
CMT4B1 O
) O
or O
MTMR13 O
( O
CMT4B2 O
) O
, O
phosphoinositide O
( O
PI O
) O
3 O
- O
phosphatases O
that O
dephosphorylate O
phosphatidylinositol B
3 I
- I
phosphate I
( O
PtdIns3P B
) O
and O
PtdIns B
( I
3 I
, I
5 I
) I
P2 I
, O
lipids O
which O
regulate O
endo O
- O
lysosomal O
membrane O
traffic O
. O

The O
analysis O
of O
medium O
polarity O
constituents O
led O
to O
the O
isolation O
of O
several O
glycosides O
, O
such O
as O
flavonoids O
, O
i O
. O
e O
. O
scutellarein O
derivatives O
; O
phenylethanoids B
, O
i O
. O
e O
. O
verbascoside O
; O
and O
iridoids O
, O
i O
. O
e O
. O
melittoside B
and O
5 B
- I
allosyloxy I
- I
aucubin I
, O
besides O
the O
diterpene O
siderol B
. O

Essential O
oils O
of O
Thymus O
leucospermus O
Hartvig O
, O
a O
Greek O
endemic O
rich O
in O
phenolic B
monoterpenes I
. O

The O
oils O
were O
particularly O
rich O
in O
phenolic B
monoterpenes I
: O
they O
had O
a O
high O
thymol O
( O
64 O
. O
7 O
- O
92 O
. O
0 O
% O
) O
or O
carvacrol O
( O
93 O
. O
4 O
% O
) O
content O
, O
whereas O
in O
one O
of O
the O
oils O
considerable O
amount O
of O
both O
compounds O
was O
found O
( O
thymol O
61 O
. O
6 O
% O
and O
carvacrol O
26 O
. O
4 O
% O
) O
. O

Tunable O
morphology O
and O
mesophase O
formation O
by O
naphthalene O
- O
containing O
poly B
( I
aryl I
ether I
) I
dendron O
- O
based O
low O
- O
molecular O
- O
weight O
fluorescent O
gels O
. O

Novel O
poly B
( I
aryl I
ether I
) I
dendron O
- O
based O
low O
- O
molecular O
- O
weight O
organogelaters O
( O
LMWG O
) O
containing O
naphthalene O
units O
at O
the O
core O
have O
been O
synthesized O
, O
and O
the O
self O
- O
assembly O
of O
the O
system O
has O
been O
examined O
in O
a O
variety O
of O
solvents O
and O
solvent O
mixtures O
. O

The O
present O
work O
unravels O
the O
subtle O
role O
of O
minute O
structural O
change O
in O
altering O
the O
properties O
of O
LMWGs O
based O
on O
poly B
( I
aryl I
ether I
) I
dendrons O
. O

Crystalline O
alpha B
- I
glucose I
is O
known O
to O
amorphize O
upon O
milling O
at O
- O
15 O
degrees O
C O
while O
it O
remains O
structurally O
invariant O
upon O
milling O
at O
room O
temperature O
. O

The O
results O
indicate O
that O
two O
different O
amorphization O
mechanisms O
occur O
upon O
milling O
: O
an O
amorphization O
at O
the O
surface O
of O
crystallites O
due O
to O
the O
mechanical O
shocks O
and O
a O
spontaneous O
amorphization O
of O
the O
crystallites O
as O
they O
reach O
a O
critical O
size O
, O
which O
is O
close O
to O
200 O
A O
in O
the O
particular O
case O
of O
alpha B
- I
glucose I
. O

Luminol B
as O
in O
situ O
light O
source O
in O
meso B
- I
tetraphenylporphyrin I
- O
mediated O
photodynamic O
therapy O
. O

In O
the O
present O
work O
, O
we O
use O
luminol B
as O
light O
source O
and O
meso B
- I
tetraphenylporphyrin I
as O
the O
photosensitizer O
. O

According O
to O
the O
results O
, O
cells O
incubated O
with O
meso B
- I
tetraphenylporphyrin I
, O
subsequently O
triggered O
by O
luminol B
, O
decreased O
significantly O
in O
assays O
including O
cell O
viability O
and O
cytotoxicity O
, O
while O
the O
other O
groups O
showed O
only O
minor O
differences O
. O

Briefly O
, O
we O
suggest O
that O
luminol B
is O
a O
promising O
light O
source O
in O
meso B
- I
tetraphenylporphyrin I
- O
mediated O
photodynamic O
therapy O
for O
its O
greater O
penetration O
depth O
and O
well O
matched O
emission O
wavelength O
. O

Moreover O
, O
identification O
of O
molecular O
markers O
as O
well O
as O
a O
better O
understanding O
of O
thyroid O
carcinogenesis O
will O
help O
develop O
innovative O
targeted O
therapies O
, O
particularly O
in O
patients O
with O
metastatic O
iodo B
- O
resistant O
thyroid O
carcinoma O
. O

Novel O
P2 O
tris B
- I
tetrahydrofuran I
group O
in O
antiviral O
compound O
1 O
( O
GRL B
- I
0519 I
) O
fills O
the O
S2 O
binding O
pocket O
of O
selected O
mutants O
of O
HIV O
- O
1 O
protease O
. O

GRL B
- I
0519 I
( O
1 O
) O
is O
a O
potent O
antiviral O
inhibitor O
of O
HIV O
- O
1 O
protease O
( O
PR O
) O
possessing O
tris B
- I
tetrahydrofuran I
( O
tris B
- I
THF I
) O
at O
P2 O
. O

The O
carbonyl O
oxygen O
of O
Gly48 O
showed O
two O
alternative O
conformations O
in O
all O
structures O
likely O
due O
to O
the O
snug O
fit O
of O
the O
large O
tris B
- I
THF I
group O
in O
the O
S2 O
subsite O
in O
agreement O
with O
high O
antiviral O
efficacy O
of O
1 O
on O
resistant O
virus O
. O

The O
method O
consists O
of O
antisolvent O
co O
- O
precipitation O
from O
an O
aqueous O
solution O
containing O
both O
an O
amino O
acid O
core O
material O
( O
e O
. O
g O
. O
D B
, I
L I
- I
valine I
) O
, O
and O
either O
bovine O
serum O
albumin O
( O
BSA O
) O
or O
lysozyme O
( O
Lys O
) O
as O
model O
proteins O
. O

The O
use O
of O
a O
polysorbate B
or O
sorbitan B
ester I
derivatives O
as O
stabilizers O
proved O
to O
be O
necessary O
to O
yield O
submicron O
particles O
. O

Synthesis O
, O
characterization O
and O
targeting O
potential O
of O
zidovudine O
loaded O
sialic O
acid O
conjugated O
- O
mannosylated B
poly I
( I
propyleneimine I
) I
dendrimers O
. O

The O
present O
investigation O
was O
aimed O
at O
exploring O
dual O
targeting O
of O
anti O
- O
HIV O
drug O
, O
zidovudine O
( O
ZDV B
) O
via O
sialic O
acid O
conjugated O
- O
mannosylated B
poly I
( I
propyleneimine I
) I
( O
PPI B
) O
dendritic O
nano O
- O
constructs O
. O

Fourth O
generation O
PPI B
dendrimers O
, O
sialic O
acid O
conjugated O
PPI B
dendrimers O
( O
SPPI O
) O
, O
mannose O
conjugated O
PPI B
dendrimers O
( O
MPPI O
) O
and O
dual O
ligand O
system O
i O
. O
e O
. O
sialic O
acid O
conjugated O
- O
mannosylated B
PPI I
dendrimers O
( O
SMPPI O
) O
were O
synthesized O
and O
characterized O
by O
FT O
- O
IR O
and O
( O
1 O
) O
H O
NMR O
spectroscopies O
and O
were O
further O
confirmed O
by O
size O
exclusion O
chromatography O
and O
differential O
scanning O
calorimetry O
. O

Various O
parameters O
like O
drug O
loading O
, O
pH O
dependent O
in O
vitro O
release O
, O
hemolytic O
toxicity O
, O
macrophage O
uptake O
and O
cytotoxicity O
concerning O
PPI B
, O
SPPI O
, O
MPPI O
and O
SMPPI O
dendrimers O
were O
evaluated O
. O

ZDV B
loaded O
SMPPI O
, O
SPPI O
and O
MPPI O
have O
shown O
reduced O
hemolytic O
toxicity O
, O
cytotoxicity O
and O
in O
vitro O
drug O
release O
at O
pH O
7 O
. O
4 O
. O

Extremely O
significant O
( O
P O
< O
0 O
. O
001 O
) O
increase O
in O
cellular O
uptake O
of O
ZDV B
by O
macrophage O
cells O
was O
observed O
in O
case O
of O
SMPPI O
as O
compared O
to O
PPI B
and O
free O
drug O
. O

The O
results O
suggested O
that O
such O
dual O
ligand O
dendritic O
system O
( O
SMPPI O
) O
hold O
potential O
to O
enhance O
biocompatibility O
and O
site O
specific O
delivery O
of O
antiretroviral O
drug O
, O
ZDV B
. O

Lamivudine B
permeability O
study O
: O
a O
comparison O
between O
PAMPA O
, O
ex O
vivo O
and O
in O
situ O
Single O
- O
Pass O
Intestinal O
Perfusion O
( O
SPIP O
) O
in O
rat O
jejunum O
. O

Our O
work O
aimed O
to O
explore O
the O
transport O
mechanism O
of O
the O
antiretroviral O
lamivudine B
( O
deoxycytidine B
nucleoside I
analogue O
) O
, O
using O
a O
three O
- O
part O
strategy O
: O
in O
vitro O
, O
an O
ex O
vivo O
and O
an O
in O
situ O
method O
, O
represented O
by O
PAMPA O
, O
rat O
jejunum O
patches O
and O
rat O
Single O
Pass O
Intestinal O
Perfusion O
( O
SPIP O
) O
, O
respectively O
. O

The O
outcomes O
of O
our O
studies O
showed O
the O
following O
predicted O
pattern O
for O
lamivudine B
effective O
jejunal O
permeability O
: O
P O
( O
eff O
) O
( O
exvivoA O
> O
B O
) O
> O
P O
( O
eff O
) O
( O
SPIP O
) O
> O
P O
( O
eff O
) O
( O
exvivo O
B O
> O
A O
) O
> O
P O
( O
eff O
) O
( O
Caco O
- O
2 O
) O
= O
~ O
P O
( O
eff O
) O
( O
MDCK O
) O
= O
~ O
P O
( O
eff O
) O
( O
PAMPA O
) O
, O
strongly O
suggesting O
that O
this O
compound O
has O
carrier O
- O
mediated O
uptake O
as O
its O
dominant O
transport O
mechanism O
. O

In O
this O
work O
, O
we O
develop O
multifunctional O
nanoparticles O
( O
NPs O
) O
for O
co O
- O
delivery O
of O
the O
conventional O
anticancer O
drug O
docetaxel O
( O
DTX B
) O
and O
the O
second O
generation O
photosensitizer O
zinc O
- O
phthalocyanine O
( O
ZnPc B
) O
as O
potential O
dual O
carrier O
system O
for O
the O
combination O
of O
chemotherapy O
and O
photodynamic O
therapy O
( O
PDT O
) O
. O

Biodegradable O
and O
amphiphilic O
block O
copolymers O
based O
on O
poly B
( I
epsilon I
- I
caprolactone I
) I
( O
PCL O
= O
B O
) O
and O
poly O
( O
ethylene O
oxide O
) O
( O
PEO O
= O
A O
) O
, O
with O
AB O
and O
ABA O
architectures O
, O
were O
assembled O
in O
" O
core O
- O
shell O
" O
NPs O
and O
loaded O
with O
both O
DTX B
and O
ZnPc B
employing O
the O
melting O
/ O
sonication O
method O
. O

Concerning O
drug O
loading O
ability O
of O
NPs O
, O
the O
entrapment O
efficiency O
was O
related O
to O
initial O
ZnPc B
/ O
DTX B
ratio O
. O

Steady O
- O
stationary O
and O
time O
- O
resolved O
emission O
fluorescence O
measurements O
pointed O
out O
the O
embedding O
of O
monomeric O
ZnPc B
in O
the O
NPs O
, O
excluding O
the O
presence O
of O
ZnPc B
self O
- O
supramolecular O
oligomers O
. O

The O
release O
of O
DTX B
was O
biphasic O
whereas O
ZnPc B
remained O
mainly O
associated O
with O
NPs O
. O

Singlet O
oxygen O
generation O
was O
observed O
when O
ZnPc B
- O
loaded O
NPs O
were O
irradiated O
at O
610nm O
within O
a O
45min O
time O
range O
, O
despite O
that O
ZnPc B
was O
not O
released O
in O
the O
medium O
. O

After O
72h O
, O
viability O
of O
cells O
treated O
with O
ZnPc B
/ O
DTX B
- O
loaded O
NPs O
strongly O
decreased O
as O
compared O
to O
NPs O
loaded O
only O
with O
DTX B
, O
thus O
showing O
a O
combined O
effect O
of O
both O
DTX B
and O
ZnPc B
. O

Superior O
antitumor O
activity O
of O
ZnPc B
/ O
DTX B
- O
loaded O
NPs O
as O
compared O
to O
DTX B
- O
loaded O
NPs O
was O
confirmed O
in O
an O
animal O
model O
of O
orthotopic O
amelanotic O
melanoma O
, O
thus O
pointing O
to O
the O
application O
of O
PEO O
- O
PCL O
NPs O
in O
the O
combined O
chemo O
- O
photodynamic O
therapy O
of O
cancer O
. O

The O
mechanism O
of O
action O
in O
vivo O
was O
elucidated O
using O
PEIs O
with O
decreased O
numbers O
of O
primary O
amine O
residues O
, O
resulting O
from O
ethylene B
carbonate I
treatment O
, O
and O
polyallylamine O
, O
a O
linear O
polyamine O
consisting O
of O
primary O
amines O
. O

This O
finding O
suggests O
that O
PEI O
combined O
with O
liposomes O
and O
with O
slightly O
decreased O
numbers O
of O
primary O
amines O
may O
be O
an O
effective O
vaginally O
administrated O
antiviral O
drug O
, O
and O
secondary B
and I
tertiary I
amine I
residues O
of O
PEI O
may O
contribute O
to O
the O
inhibitory O
efficiency O
against O
viral O
infection O
. O

In O
situ O
forming O
nimodipine B
depot O
system O
based O
on O
microparticles O
for O
the O
treatment O
of O
posthemorrhagic O
cerebral O
vasospasm O
. O

The O
present O
study O
was O
conducted O
to O
examine O
the O
feasibility O
of O
nimodipine B
- O
loaded O
PLGA O
microparticles O
suspended O
in O
Tisseel O
( O
TM O
) O
fibrin O
sealant O
as O
an O
in O
situ O
forming O
depot O
system O
. O

Depending O
on O
nimodipine B
loading O
( O
10 O
- O
40 O
% O
) O
, O
the O
particle O
diameter O
ranged O
from O
1 O
. O
9 O
+ O
/ O
- O
1 O
. O
2 O
mu O
m O
to O
2 O
. O
4 O
+ O
/ O
- O
1 O
. O
3 O
mu O
m O
. O

Thermal O
analyses O
using O
DSC O
revealed O
that O
nimodipine B
is O
dissolved O
in O
the O
PLGA O
matrix O
. O

Overall O
, O
the O
nimodipine B
in O
situ O
forming O
device O
could O
be O
a O
promising O
candidate O
for O
the O
local O
treatment O
of O
vasospasm O
after O
a O
subarachnoid O
hemorrhage O
. O

Optimization O
of O
benzyloxazoles B
as O
non O
- O
nucleoside O
inhibitors O
of O
HIV O
- O
1 O
reverse O
transcriptase O
to O
enhance O
Y181C O
potency O
. O

Methadone B
N O
- O
demethylation O
by O
the O
common O
CYP2B6 O
allelic O
variant O
CYP2B6 O
. O
6 O
. O

The O
long O
- O
acting O
opioid O
methadone B
displays O
considerable O
unexplained O
interindividual O
pharmacokinetic O
variability O
. O

Methadone B
metabolism O
clinically O
occurs O
primarily O
by O
N O
- O
demethylation O
to O
2 B
- I
ethyl I
- I
1 I
, I
5 I
- I
dimethyl I
- I
3 I
, I
3 I
- I
diphenylpyrrolidine I
( O
EDDP B
) O
, O
catalyzed O
predominantly O
by O
CYP2B6 O
. O

Retrospective O
studies O
suggest O
that O
the O
common O
allele O
variant O
CYP2B6 O
* O
6 O
may O
influence O
methadone B
plasma O
concentrations O
. O

This O
investigation O
compared O
methadone B
N O
- O
demethylation O
by O
CYP2B6 O
. O
6 O
with O
that O
by O
wild O
- O
type O
CYP2B6 O
. O
1 O
. O

Methadone B
enantiomer O
and O
racemate O
N O
- O
demethylation O
by O
recombinant O
- O
expressed O
CYP2B6 O
. O
6 O
and O
CYP2B6 O
. O
1 O
was O
determined O
. O

At O
substrate O
concentrations O
( O
0 O
. O
25 O
- O
2 O
micro O
M O
) O
approximating O
plasma O
concentrations O
occurring O
clinically O
, O
rates O
of O
methadone B
enantiomer O
N O
- O
demethylation O
by O
CYP2B6 O
. O
6 O
, O
incubated O
individually O
or O
as O
the O
racemate O
, O
were O
one O
- O
third O
to O
one O
- O
fourth O
those O
by O
CYP2B6 O
. O
1 O
. O

For O
methadone B
individual O
enantiomers O
and O
metabolism O
by O
CYP2B6 O
. O
6 O
compared O
with O
CYP2B6 O
. O
1 O
, O
Vmax O
was O
diminished O
, O
Ks O
was O
greater O
and O
the O
in O
vitro O
intrinsic O
clearance O
was O
diminished O
5 O
- O
to O
6 O
- O
fold O
. O

The O
intrinsic O
clearance O
for O
R B
- I
and I
S I
- I
EDDP I
formation O
from O
racemic B
methadone I
was O
diminished O
approximately O
6 O
- O
fold O
and O
3 O
- O
fold O
for O
R B
- I
and I
S I
- I
methadone I
, O
respectively O
. O

Both O
CYP2B6 O
. O
6 O
and O
CYP2B6 O
. O
1 O
showed O
similar O
stereoselectivity O
( O
S B
> I
R I
- I
methadone I
) O
. O

Human O
liver O
microsomes O
with O
diminished O
CYP2B6 O
content O
due O
to O
a O
CYP2B6 O
* O
6 O
allele O
had O
lower O
rates O
of O
methadone B
N O
- O
demethylation O
. O

Results O
show O
that O
methadone B
N O
- O
demethylation O
catalyzed O
by O
CYP2B6 O
. O
6 O
, O
the O
CYP2B6 O
variant O
encoded O
by O
the O
CYP2B6 O
* O
6 O
polymorphism O
, O
is O
catalytically O
deficient O
compared O
with O
wild O
- O
type O
CYP2B6 O
. O
1 O
. O

Diminished O
methadone B
N O
- O
demethylation O
by O
CYP2B6 O
. O
6 O
may O
provide O
a O
mechanistic O
explanation O
for O
clinical O
observations O
of O
altered O
methadone B
disposition O
in O
individuals O
carrying O
the O
CYP2B6 O
* O
6 O
polymorphism O
. O

Subacute O
oral O
toxicity O
of O
combinations O
of O
selected O
synthetic O
pyrethroids O
, O
piperonyl O
butoxide O
, O
and O
tetramethrin B
in O
rats O
. O

Different O
combinations O
of O
insecticides O
were O
administered O
daily O
to O
the O
experimental O
groups O
( O
group O
1 O
: O
cypermethrin O
+ O
piperonyl O
butoxide O
( O
PBO B
) O
; O
group O
2 O
: O
alphacypermethrin B
+ O
PBO B
; O
group O
3 O
: O
deltamethrin O
+ O
PBO B
; O
group O
4 O
: O
cypermethrin O
+ O
PBO B
+ O
tetramethrin B
; O
group O
5 O
: O
alphacypermethrin B
+ O
PBO B
+ O
tetramethrin B
; O
and O
group O
6 O
: O
deltamethrin O
+ O
PBO B
+ O
tetramethrin O
) O
for O
28 O
days O
. O

Red O
blood O
cells O
, O
white O
blood O
cells O
, O
and O
hemoglobin O
levels O
, O
especially O
in O
cypermethrin O
and O
alphacypermethrin B
groups O
( O
groups O
1 O
, O
2 O
, O
and O
4 O
) O
, O
were O
found O
to O
be O
higher O
than O
the O
control O
group O
( O
p O
< O
0 O
. O
05 O
) O
. O

Relative O
liver O
and O
kidney O
weights O
of O
the O
male O
animals O
increased O
in O
the O
cypermethrin O
and O
alphacypermethrin B
groups O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
polyethylenimine O
( O
PEI O
) O
derivatives O
( O
PTn O
) O
are O
prepared O
by O
treating O
PEI25k O
with O
Tris B
( I
hydroxymethyl I
) I
acrylamidomethane I
via O
the O
Michael O
addition O
. O

Aminoalkyl B
derivatives O
of O
guanidine O
diaromatic O
minor O
groove O
binders O
with O
antiprotozoal O
activity O
. O

Considering O
the O
strong O
DNA O
minor O
groove O
binding O
observed O
for O
our O
previous O
series O
of O
diaromatic O
symmetric O
and O
asymmetric O
guanidinium B
and O
2 B
- I
aminoimidazolinium I
derivatives O
, O
we O
report O
now O
the O
synthesis O
of O
new O
aminoalkyl B
derivatives O
of O
diaromatic O
guanidines O
with O
potential O
as O
DNA O
minor O
groove O
binders O
and O
antiprotozoal O
activity O
. O

The O
preparation O
of O
these O
aminoalkyl B
derivatives O
( O
12a O
- O
e O
, O
13a O
- O
e O
, O
14a O
- O
c O
, O
e O
, O
15a O
- O
e O
, O
16a O
- O
e O
) O
is O
presented O
as O
well O
as O
their O
affinity O
for O
DNA O
which O
was O
evaluated O
by O
means O
of O
DNA O
thermal O
denaturation O
experiments O
. O

Finally O
, O
the O
antiprotozoal O
activity O
of O
most O
of O
these O
aminoalkyl B
minor O
groove O
binders O
was O
evaluated O
in O
vitro O
against O
Trypanosoma O
brucei O
rhodesiense O
( O
8 O
compounds O
) O
and O
Plasmodium O
falciparum O
( O
18 O
compounds O
) O
. O

Some O
of O
the O
derivatives O
prepared O
seem O
to O
exert O
the O
antimalarial O
activity O
by O
binding O
to O
the O
DNA O
minor O
groove O
whereas O
other O
sets O
of O
compounds O
could O
exert O
this O
antimalarial O
activity O
by O
inhibiting O
the O
parasite O
dihydrofolate B
reductase O
, O
for O
example O
. O

Phenyl O
, O
propyl O
, O
and O
amyl B
moieties O
were O
used O
as O
linkers O
between O
SAK O
and O
polyethylene O
glycol O
( O
PEG O
) O
, O
respectively O
. O

Flexible O
propyl O
and O
amyl B
linkers O
lead O
to O
loose O
conformation O
. O

Optical O
probing O
of O
the O
electronic O
interaction O
between O
graphene O
and O
hexagonal O
boron B
nitride I
. O

In O
this O
report O
, O
we O
demonstrate O
that O
Raman O
spectroscopy O
can O
be O
utilized O
to O
detect O
a O
few O
percent O
decrease O
in O
the O
Fermi O
velocity O
( O
v O
( O
F O
) O
) O
of O
graphene O
caused O
by O
the O
vdW O
interaction O
with O
underlying O
hexagonal O
boron B
nitride I
( O
hBN O
) O
. O

Bioactive O
flavaglines B
and O
other O
constituents O
isolated O
from O
Aglaia O
perviridis O
. O

Eight O
new O
compounds O
, O
including O
two O
cyclopenta B
[ I
b I
] I
benzopyran I
derivatives O
( O
1 O
, O
2 O
) O
, O
two O
cyclopenta B
[ I
b I
] I
benzofuran I
derivatives O
( O
3 O
, O
4 O
) O
, O
three O
cycloartane B
triterpenoids I
( O
5 O
- O
7 O
) O
, O
and O
an O
apocarotenoid O
( O
8 O
) O
, O
together O
with O
16 O
known O
compounds O
, O
were O
isolated O
from O
the O
chloroform O
- O
soluble O
partitions O
of O
separate O
methanol O
extracts O
of O
a O
combination O
of O
the O
fruits O
, O
leaves O
, O
and O
twigs O
and O
of O
the O
roots O
of O
Aglaia O

The O
Mosher O
ester O
method O
was O
employed O
to O
determine O
the O
absolute O
configurations O
of O
5 O
- O
7 O
, O
and O
the O
absolute O
configuration O
of O
the O
9 O
, O
10 O
- O
diol O
unit O
of O
compound O
8 O
was O
established O
by O
a O
dimolybdenum B
tetraacetate I
[ O
Mo2 B
( I
AcO I
) I
4 I
] O
induced O
circular O
dichroism O
procedure O
. O

Seven O
known O
rocaglate B
derivatives O
( O
9 O
- O
15 O
) O
exhibited O
significant O
cytotoxicity O
against O
the O
HT O
- O
29 O
cell O
line O
, O
with O
rocaglaol B
( O
9 O
) O
being O
the O
most O
potent O
( O
ED50 O
0 O
. O
0007 O
mu O
M O
) O
. O

In O
addition O
, O
the O
new O
compound O
perviridicin B
B I
( O
2 O
) O
, O
three O
known O
rocaglate B
derivatives O
( O
9 O
, O
11 O
, O
12 O
) O
, O
and O
a O
known O
sesquiterpene O
, O
2 B
- I
oxaisodauc I
- I
5 I
- I
en I
- I
12 I
- I
al I
( O
17 O
) O
, O
showed O
significant O
NF O
- O
kappa O
B O
( O
p65 O
) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

A O
powerful O
aluminum O
catalyst O
for O
the O
synthesis O
of O
highly O
functional O
organic B
carbonates I
. O

An O
aluminum O
complex O
based O
on O
an O
amino B
triphenolate I
ligand O
scaffold O
shows O
unprecedented O
high O
activity O
( O
initial O
TOFs O
up O
to O
36 O
, O
000 O
h O
( O
- O
1 O
) O
) O
, O
broad O
substrate O
scope O
, O
and O
functional O
group O
tolerance O
in O
the O
formation O
of O
highly O
functional O
organic B
carbonates I
prepared O
from O
epoxides B
and O
CO O
( O
2 O
) O
. O

We O
used O
a O
sensitive O
liquid O
chromatography O
- O
mass O
spectrometry O
( O
LC O
/ O
MS O
) O
and O
LC O
/ O
MS O
/ O
MS O
method O
to O
show O
that O
L B
- I
tyrosine I
( O
Tyr O
) O
, O
an O
amino O
acid O
with O
a O
highly O
reactive O
hydroxyl O
group O
, O
readily O
reacts O
with O
cigarette O
smoke O
extract O
( O
CSE O
) O
at O
body O
temperature O
( O
37 O
degrees O
C O
) O
to O
form O
various O
Tyr O
derivatives O
. O

Among O
these O
derivatives O
were O
N B
- I
( I
3 I
- I
oxobutyl I
) I
- I
Tyr I
and O
two O
acetylated O
compounds O
, O
N B
- I
acetyl I
- I
Tyr I
and O
O B
- I
acetyl I
- I
Tyr I
, O
which O
were O
synthesized O
by O
reaction O
of O
Tyr O
with O
methyl B
vinyl I
ketone I
and O
acetic B
anhydride I
, O
respectively O
, O
at O
37 O
degrees O
C O
. O

The O
presence O
of O
methyl B
vinyl I
ketone I
and O
acetic B
anhydride I
in O
CSE O
was O
confirmed O
by O
gas O
chromatography O
- O
mass O
spectrometry O
( O
GC O
/ O
MS O
) O
. O

Schisphenlignans B
A I
- I
E I
: O
five O
new O
dibenzocyclooctadien B
lignans I
from O
Schisandra O
sphenanthera O
. O

Five O
new O
dibenzocyclooctadien B
lignans I
, O
schisphenlignans B
A I
- I
E I
( O
1 O
- O
5 O
) O
, O
together O
with O
eight O
known O
ones O
, O
were O
isolated O
from O
the O
stems O
of O
Schisandra O
sphenanthera O
. O

Tissue O
IDO O
was O
investigated O
using O
quantitative O
RT O
- O
PCR O
and O
Western O
blot O
, O
whereas O
tryptophan O
, O
kynurenine B
, O
and O
5 O
- O
hydroxytryptamine O
( O
5 O
- O
HT O
) O
concentrations O
were O
quantified O
by O
HPLC O
and O
ELISA O
. O

L O
. O
johnsonii O
feeding O
resulted O
in O
a O
17 O
% O
reduction O
in O
serum O
kynurenine B
compared O
with O
that O
in O
vehicle O
- O
fed O
controls O
, O
correlating O
with O
a O
1 O
. O
4 O
- O
fold O
elevation O
in O
5 O
- O
HT O
levels O
. O

Chemisorption O
of O
an O
appropriate O
amount O
of O
polyvinylpyrrolidone O
on O
the O
Au O
/ O
SiO O
( O
2 O
) O
catalyst O
greatly O
enhances O
the O
benzaldehyde B
selectivity O
from O
43 O
% O
to O
~ O
100 O
% O
and O
its O
yield O
from O
4 O
. O
9 O
% O
to O
7 O
. O
2 O
% O
. O

Dual O
E O
- O
and O
H O
- O
field O
control O
of O
microwave O
performance O
with O
enhanced O
ferromagnetic O
resonance O
( O
FMR O
) O
tunability O
has O
been O
demonstrated O
in O
microwave O
composites O
FeGaB B
/ O
PZN B
- I
PT I
( O
011 O
) O
. O

A O
voltage O
- O
impulse O
- O
induced O
non O
- O
volatile O
magnetization O
switching O
was O
also O
realized O
in O
this O
work O
, O
resulting O
from O
the O
hysteretic O
type O
of O
phase O
transition O
in O
PZN B
- I
PT I
( O
011 O
) O
at O
high O
electric O
fields O
. O

Derivatives O
of O
the O
azamacrocycle O
cyclam B
that O
contain O
a O
pendant O
naphthalimide O
dye O
are O
inherently O
fluorescent O
when O
zinc O
( O
II O
) O
is O
coordinated O
. O

Introducing O
a O
second O
pendant O
group O
- O
- O
biotin O
- O
- O
affords O
an O
unsymmetrical O
bis B
- I
triazole I
- O
scorpionand O
ligand O
that O
interacts O
specifically O
with O
avidin O
. O

Promiscuous O
catalysis O
of O
asymmetric O
Michael O
- O
type O
additions O
of O
linear O
aldehydes O
to O
beta B
- I
nitrostyrene I
by O
the O
proline O
- O
based O
enzyme O
4 B
- I
oxalocrotonate I
tautomerase O
. O

Exploiting O
catalytic O
promiscuity O
: O
The O
proline O
- O
based O
enzyme O
4 B
- I
oxalocrotonate I
tautomerase O
( O
4 B
- I
OT I
) O
promiscuously O
catalyzes O
asymmetric O
Michael O
- O
type O
additions O
of O
linear O
aldehydes O
- O
- O
ranging O
from O
acetaldehyde O
to O
octanal O
- O
- O
to O
trans B
- I
beta I
- I
nitrostyrene I
in O
aqueous O
solvent O
. O

The O
presence O
of O
1 O
. O
4 O
mol O
% O
of O
4 B
- I
OT I
effected O
formation O
of O
the O
anticipated O
gamma B
- I
nitroaldehydes I
in O
fair O
to O
good O
yields O
with O
dr O
values O
of O
up O
to O
93 O
: O
7 O
and O
ee O
values O
of O
up O
to O
81 O
% O
. O

Successful O
application O
of O
an O
ionic O
liquid O
carrying O
the O
fluoride O
counter O
- O
ion O
in O
biomacromolecular O
chemistry O
: O
microwave O
- O
assisted O
acylation O
of O
cellulose O
in O
the O
presence O
of O
1 B
- I
allyl I
- I
3 I
- I
methylimidazolium I
fluoride I
/ O
DMSO O
mixtures O
. O

Neat O
1 B
- I
allyl I
- I
3 I
- I
methylimidazolium I
fluoride I
( O
AlMeImF B
) O
is O
used O
as O
a O
solvent O
in O
microwave O
- O
assisted O
acylation O
of O
cellulose O
. O

A O
dramatic O
improvement O
is O
observed O
, O
when O
AlMeImF B
/ O
DMSO O
mixture O
is O
employed O
. O

The O
results O
are O
comparable O
to O
those O
obtained O
when O
pure O
1 B
- I
allyl I
- I
3 I
- I
methylimidazolium I
chloride I
is O
employed O
. O

FTIR O
spectroscopy O
shows O
that O
dissolving O
a O
carboxylic B
acid I
anhydride I
in O
IL O
- O
F O
leads O
to O
the O
formation O
of O
acyl B
fluoride I
. O

Semisynthesis O
and O
myocardial O
activity O
of O
thaliporphine B
N O
- O
homologues O
. O

The O
N O
- O
homologues O
and O
optical O
isomers O
of O
thaliporphine B
( O
5a O
) O
, O
a O
potent O
antiarrhythmic O
agent O
, O
were O
prepared O
starting O
from O
laurolitsine B
( O
1 O
) O
, O
an O
abundant O
aporphine B
present O
in O
Phoebe O
formosana O
. O

Treating O
N B
- I
propylnorglaucine I
with O
90 O
% O
H2SO4 B
yielded O
one O
additional O
product O
, O
an O
11 B
- I
sulfonyl I
- I
1 I
, I
11 I
- I
anhydroaporphine I
. O

Reaction O
of O
N B
- I
formylnorglaucine I
( O
3a O
) O
with O
90 O
% O
H2SO4 B
, O
however O
, O
yielded O
the O
9 B
- I
sulfonyl I
- I
seco I
product O
as O
a O
major O
product O
. O

Treatment O
of O
3a O
with O
98 O
% O
H2SO4 B
yielded O
pancordine O
( O
10 O
) O
, O
which O
, O
upon O
catalytic O
hydrogenation O
, O
yielded O
( B
+ I
/ I
- I
) I
- I
wilsonirine I
. O

Thaliporphine B
( O
5a O
) O
was O
demonstrated O
to O
possess O
better O
positive O
inotropic O
and O
less O
negative O
chronotropic O
effects O
than O
the O
left O
- O
hand O
optical O
isomer O
and O
showed O
the O
best O
activity O
on O
rat O
cardiac O
tissue O
among O
the O
N O
- O
homologues O
prepared O
. O

Surface O
transformations O
of O
Bioglass B
45S5 I
during O
scaffold O
synthesis O
for O
bone O
tissue O
engineering O
. O

In O
physiological O
fluid O
, O
a O
layer O
of O
hydroxycarbonate B
apatite I
, O
similar O
to O
bone O
mineral O
, O
develops O
on O
the O
surface O
of O
Bioglass B
45S5 I
. O

To O
overcome O
this O
issue O
, O
Bioglass O
is O
used O
to O
form O
a O
composite O
scaffold O
with O
poly O
( O
D O
, O
L O
- O
lactide O
) O
( O
PDLLA B
) O
, O
a O
biodegradable O
polymer O
. O

Pharmacokinetics O
, O
metabolism O
, O
and O
excretion O
of O
the O
glycogen O
synthase O
kinase O
- O
3 O
inhibitor O
LY2090314 B
in O
rats O
, O
dogs O
, O
and O
humans O
: O
a O
case O
study O
in O
rapid O
clearance O
by O
extensive O
metabolism O
with O
low O
circulating O
metabolite O
exposure O
. O

LY2090314 B
( O
3 B
- I
[ I
9 I
- I
fluoro I
- I
2 I
- I
( I
piperidin I
- I
1 I
- I
ylcarbonyl I
) I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
- I
tetrahydro I
[ I
1 I
, I
4 I
] I
diazepino I
[ I
6 I
, I
7 I
, I
1 I
- I
hi I
] I
indol I
- I
7 I
- I
yl I
] I
- I
4 I
- I
imidazo I
[ I
1 I
, I
2 I
- I
a I
] I
pyridin I
- I
3 I
- I
yl I
- I
1H I
- I
pyrrole I
- I
2 I
, I
5 I
- I
dione I
) O
is O
an O
intravenous O
glycogen O
synthase O
kinase O
- O
3 O
inhibitor O

Drug O
disposition O
was O
characterized O
after O
intravenous O
infusion O
of O
[ B
( I
14 I
) I
C I
] I
LY2090314 I
to O
rats O
and O
dogs O
, O
and O
was O
related O
to O
available O
clinical O
data O
. O

LY2090314 B
exhibited O
high O
clearance O
( O
approximating O
hepatic O
blood O
flow O
) O
and O
a O
moderate O
volume O
of O
distribution O
( O
~ O
1 O
- O
2 O
l O
/ O
kg O
) O
resulting O
in O
rapid O
elimination O
( O
half O
- O
life O
~ O
0 O
. O
4 O
, O
0 O
. O
7 O
, O
and O
1 O
. O
8 O
- O
3 O
. O
4 O
hours O
in O
rats O
, O
dogs O
, O
and O
humans O
, O
respectively O
) O
. O

LY2090314 B
was O
cleared O
by O
extensive O
metabolism O
, O
and O
the O
numerous O
metabolites O
were O
rapidly O
excreted O
into O
feces O
via O
bile O
( O
69 O
- O
97 O
% O
of O
dose O
; O
62 O
- O
93 O
% O
within O
0 O
- O
24 O
hours O
) O
; O
urinary O
recovery O
of O
drug O
- O
related O
material O
was O
low O
( O
< O
= O
3 O
% O
of O
dose O
) O
. O

Even O
in O
Mdr1a O
- O
, O
Bcrp O
- O
, O
and O
Mrp2 O
- O
knockout O
rats O
, O
LY2090314 B
metabolites O
did O
not O
appear O
in O
circulation O
, O
and O
their O
urinary O
excretion O
was O
not O
enhanced O
, O
because O
the O
hypothesized O
impaired O
biliary O
excretion O
of O
metabolites O
in O
the O
absence O
of O
these O
canalicular O
transporters O
was O
not O
observed O
. O

Canine O
metabolite O
disposition O
was O
generally O
similar O
, O
with O
the O
notable O
exception O
of O
dog O
- O
unique O
LY2090314 B
glucuronide I
. O

In O
conclusion O
, O
LY2090314 B
was O
rapidly O
cleared O
by O
extensive O
metabolism O
with O
negligible O
circulating O
metabolite O
exposures O
due O
to O
biliary O
excretion O
of O
metabolites O
into O
feces O
with O
no O
apparent O
intestinal O
reabsorption O
. O

On O
the O
basis O
of O
1D O
and O
2D O
NMR O
, O
HR O
- O
ESI O
- O
MS O
, O
and O
circular O
dichroism O
( O
CD O
) O
spectroscopic O
analysis O
, O
structures O
of O
the O
new O
compounds O
were O
elucidated O
as O
2 B
- I
( I
2 I
' I
- I
methoxy I
- I
4 I
' I
- I
hydroxy I
) I
- I
aryl I
- I
3 I
- I
methy I
- I
6 I
- I
hydroxy I
- I
benzofuran I
( O
1 O
) O
, O
( B
2S I
) I
- I
6 I
, I
7 I
- I
( I
2 I
, I
2 I
- I
dimethyldihydropyran I
) I
- I
8 I
- I
prenyl I
- I
4 I
' I
- I
hydroxyflavanone I
( O
2 O

) O
, O
and O
6 B
- I
prenyl I
- I
7 I
, I
3 I
' I
, I
4 I
' I
- I
trihydroxyflavone I
( O
3 O
) O
. O

Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK O
- O
2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
( O
sulforaphane O
, O
tert O
- O
butylhydroquinone O
, O
cinnamic B
aldehyde I
, O
and O
hydrogen O
peroxide O
) O
showed O
that O
the O
aldo O
- O
keto O
reductase O
( O
AKR O
) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O

Mitochondrial O
dysfunction O
contributes O
to O
the O
cytotoxicity O
of O
some O
3 B
, I
5 I
- I
bis I
( I
benzylidene I
) I
- I
4 I
- I
piperidone I
derivatives O
in O
colon O
HCT O
- O
116 O
cells O
. O

Effects O
of O
tris O
( O
1 O
, O
3 O
- O
dichloro O
- O
2 O
- O
propyl O
) O
phosphate O
and O
triphenyl B
phosphate I
on O
receptor O
- O
associated O
mRNA O
expression O
in O
zebrafish O
embryos O
/ O
larvae O
. O

Tris O
( O
1 O
, O
3 O
- O
dichloro O
- O
2 O
- O
propyl O
) O
phosphate O
( O
TDCPP O
) O
and O
triphenyl B
phosphate I
( O
TPP O
) O
are O
frequently O
detected O
in O
biota O
, O
including O
fish O
. O

This O
research O
aimed O
at O
evaluating O
the O
effects O
of O
cadmium O
( O
2 O
x O
10 O
( O
- O
8 O
) O
; O
10 O
( O
- O
7 O
) O
mol O
L O
( O
- O
1 O
) O
Cd O
) O
on O
lipid O
class O
and O
fatty O
acid O
composition O
of O
the O
microalga O
Chlorella O
vulgaris O
under O
varying O
phosphate O
( O
PO B
( I
4 I
) I
( I
3 I
- I
) I
) O
concentrations O
( O
6 O
. O
0 O
x O
10 O
( O
- O
7 O
) O
to O
2 O
. O
3 O
x O
10 O
( O
- O
4 O
) O
mol O
L O
( O
- O
1 O
) O
) O
. O

Under O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
and O
Cd O
stress O
, O
the O
storage O
lipid O
class O
triacylglycerol O
( O
TAG O
) O
was O
the O
most O
accumulated O
among O
the O
lipid O
classes O
. O

Fatty O
acid O
composition O
revealed O
that O
the O
degree O
of O
saturation O
increased O
with O
increasing O
Cd O
stress O
and O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
. O

Decreasing O
PO B
( I
4 I
) I
( I
3 I
- I
) I
and O
increasing O
Cd O
concentrations O
resulted O
in O
higher O
saturated B
fatty I
acid I
( O
SAFA B
) O
and O
monounsaturated B
FA I
( O
MUFA O
) O
concentrations O
. O

Total O
polyunsaturated B
FA I
( O
PUFA O
) O
and O
omega O
3 O
PUFA O
, O
and O
PUFA O
: O
SAFA B
ratios O
were O
higher O
in O
the O
control O
( O
2 O
. O
3 O
x O
10 O
( O
- O
4 O
) O
mol O
L O
( O
- O
1 O
) O
PO B
( I
4 I
) I
( I
3 I
- I
) I
) O
cells O
than O
in O
either O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
or O
Cd O
stress O
, O
or O
in O
the O
combination O
of O
both O
stresses O
. O

Contrasting O
with O
all O
the O
other O
PUFAs O
, O
18 O
: O
2n O
- O
6 O
increased O
as O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
increased O
. O

A O
significant O
positive O
relationship O
of O
PUFAs O
, O
acetone O
mobile O
polar O
lipids O
( O
AMPL O
) O
and O
phospholipids O
( O
PL O
) O
with O
phosphate O
concentration O
in O
the O
culture O
media O
was O
obtained O
, O
while O
TAG O
concentrations O
had O
a O
positive O
association O
with O
total O
MUFA O
and O
SAFA B
. O

Total O
SAFA B
, O
14 O
: O
0 O
, O
18 O
: O
1n O
- O
9 O
and O
18 O
: O
2n O
- O
6 O
were O
positively O
correlated O
with O
Cd O
and O
negatively O
with O
PO B
( I
4 I
) I
( I
3 I
- I
) I
concentrations O
. O

The O
microalga O
responded O
to O
combined O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
and O
Cd O
exposure O
by O
increasing O
its O
total O
lipid O
production O
and O
significantly O
altering O
its O
lipid O
composition O
. O

The O
FA O
18 O
: O
2n O
- O
6 O
may O
be O
considered O
a O
stress O
biomarker O
for O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
and O
Cd O
stress O
in O
C O
. O
vulgaris O
. O

Mitochondrial O
complex O
I O
couples O
electron O
transfer O
between O
matrix O
NADH O
and O
inner O
- O
membrane O
ubiquinone B
to O
the O
pumping O
of O
protons O
against O
a O
proton O
motive O
force O
. O

The O
accepted O
proton O
pumping O
stoichiometry O
was O
4 O
protons O
per O
2 O
electrons O
transferred O
( O
4H B
( I
+ I
) I
/ O
2e O
( O
- O
) O
) O
but O
it O
has O
been O
suggested O
that O
stoichiometry O
may O
be O
3H O
( O
+ O
) O
/ O
2e O
( O
- O
) O
based O
on O
the O
identification O
of O
only O
3 O
proton O
pumping O
units O
in O
the O
crystal O
structure O
and O
a O
revision O
of O
the O
previous O
experimental O
data O
. O

Measurement O
of O
proton O
pumping O
stoichiometry O
is O
challenging O
because O
, O
even O
in O
isolated O
mitochondria O
, O
it O
is O
difficult O
to O
measure O
the O
proton O
motive O
force O
while O
simultaneously O
measuring O
the O
redox O
potentials O
of O
the O
NADH O
/ O
NAD O
( O
+ O
) O
and O
ubiquinol B
/ O
ubiquinone B
pools O
. O

Here O
we O
employ O
a O
new O
method O
to O
quantify O
the O
proton O
motive O
force O
in O
living O
cells O
from O
the O
redox O
poise O
of O
the O
bc O
( O
1 O
) O
complex O
measured O
using O
multiwavelength O
cell O
spectroscopy O
and O
show O
that O
the O
correct O
stoichiometry O
for O
complex O
I O
is O
4H B
( I
+ I
) I
/ O
2e O
( O
- O
) O
in O
mouse O
and O
human O
cells O
at O
high O
and O
physiological O
proton O
motive O
force O
. O

The O
hepatoprotection O
of O
caffeic O
acid O
and O
rosmarinic O
acid O
, O
major O
compounds O
of O
Perilla O
frutescens O
, O
against O
t B
- I
BHP I
- O
induced O
oxidative O
liver O
damage O
. O

Interestingly O
, O
compared O
to O
treatment O
with O
CA O
or O
RA O
alone O
, O
a O
combination O
of O
both O
compounds O
more O
increased O
the O
endogenous O
antioxidant O
enzymes O
and O
glutathione B
( O
GSH O
) O
and O
decreased O
lipid O
peroxidation O
in O
livers O
. O

MC3T3 O
- O
E1 O
was O
cultured O
as O
mature O
osteoblasts O
and O
treated O
with O
sodium B
metasilicate I
( O
0 O
, O
1 O
, O
5 O
, O
10 O
, O
25 O
, O
50 O
, O
and O
100 O
mu O
M O
) O
as O
a O
source O
of O
Si O
. O

After O
7 O
days O
of O
treatment O
, O
5 O
and O
10 O
mu O
M O
of O
sodium B
metasilicate I
significantly O
increased O
intracellular O
alkaline O
phosphatase O
activity O
( O
p O
< O
0 O
. O
05 O
) O
when O
compared O
to O
the O
control O
. O

Additionally O
, O
all O
doses O
of O
sodium B
metasilicate I
( O
1 O
, O
5 O
, O
10 O
, O
25 O
, O
50 O
, O
and O
100 O
mu O
M O
) O
increased O
mineralized O
nodule O
formation O
at O
14 O
days O
of O
differentiation O
as O
evidenced O
by O
increased O
Alizarin B
Red I
S I
staining O
. O

In O
the O
analysis O
of O
gene O
expression O
, O
50 O
mu O
M O
of O
sodium B
metasilicate I
upregulated O
type O
I O
collagen O
( O
COL O
- O
I O
) O
compared O
to O
the O
control O
group O
. O

However O
, O
the O
increase O
of O
COL O
- O
I O
gene O
expression O
as O
a O
result O
of O
treatment O
with O
1 O
, O
10 O
, O
25 O
, O
and O
100 O
mu O
M O
of O
sodium B
metasilicate I
did O
not O
reach O
statistical O
significance O
. O

mRNA O
expression O
of O
insulin O
- O
like O
growth O
factor O
- O
I O
and O
receptor O
activator O
of O
NF O
- O
kappa O
B O
ligand O
was O
not O
significantly O
changed O
at O
any O
dose O
of O
sodium B
metasilicate I
( O
0 O
, O
1 O
, O
5 O
, O
10 O
, O
25 O
, O
50 O
, O
and O
100 O
mu O
M O
) O
. O

Herein O
, O
we O
examined O
the O
optical O
properties O
of O
three O
Si O
QDs O
with O
increasing O
sigma O
- O
pi O
conjugation O
length O
: O
octyl B
- O
, O
( B
trimethylsilyl I
) I
vinyl I
- O
, O
and O
2 B
- I
phenylvinyl I
- O
capped O
Si O
QDs O
. O

The O
PL O
photon O
energy O
obtained O
from O
as O
- O
prepared O
samples O
decreased O
by O
0 O
. O
1 O
- O
0 O
. O
3 O
eV O
, O
while O
the O
PL O
excitation O
( O
PLE O
) O
extended O
from O
360 O
nm O
( O
octyl B
- O
capped O
Si O
QDs O
) O
to O
400 O
nm O
( O
2 B
- I
phenylvinyl I
- O
capped O
Si O
QDs O
) O
. O

Hypoxia O
- O
selective O
O6 B
- I
alkylguanine I
- O
DNA O
alkyltransferase O
inhibitors O
: O
design O
, O
synthesis O
, O
and O
evaluation O
of O
6 B
- I
( I
benzyloxy I
) I
- I
2 I
- I
( I
aryldiazenyl I
) I
- I
9H I
- I
purines I
as O
prodrugs O
of O
O6 B
- I
benzylguanine I
. O

O B
( I
6 I
) I
- I
Alkylguanine I
- O
DNA O
alkyltransferase O
( O
AGT O
) O
is O
a O
DNA O
repair O
protein O
which O
removes O
alkyl O
groups O
from O
the O
O O
- O
6 O
position O
of O
guanine O
, O
thereby O
providing O
strong O
resistance O
to O
anticancer O
agents O
which O
alkylate O
this O
position O
. O

We O
investigate O
the O
effects O
of O
variation O
in O
chemical O
conditions O
( O
solvent O
composition O
, O
water O
content O
, O
polymer O
concentration O
, O
and O
added O
salt O
) O
on O
the O
morphologies O
formed O
by O
PS B
- I
b I
- I
PAA I
in O
DMF B
/ O
dioxane B
/ O
water O
mixtures O
in O
a O
two O
- O
phase O
gas O
- O
liquid O
segmented O
microfluidic O
reactor O
. O

In O
this O
study O
, O
we O
report O
thermosensitive O
hydrogels O
based O
on O
poly B
( I
ethylene I
glycol I
) I
- I
block I
- I
poly I
( I
gamma I
- I
propargyl I
- I
l I
- I
glutamate I
) I
( O
PEG B
- I
PPLG I
) O
. O

The O
presence O
of O
alkynyl B
side O
groups O
in O
the O
PEG B
- I
PPLG I
copolymers O
allowed O
convenient O
further O
functionalization O
with O
azide O
- O
modified O
bioactive O
molecules O
, O
such O
as O
biotin O
and O
galactose O
. O

We O
investigated O
the O
surface O
, O
adhesion O
, O
friction O
, O
and O
cracking O
properties O
of O
polydopamine O
( O
PDA B
) O
thin O
films O
for O
their O
effective O
transfer O
to O
functional O
devices O
and O
biocompatible O
coatings O
. O

A O
series O
of O
surface O
characterizations O
and O
mechanical O
tests O
were O
performed O
to O
reveal O
the O
static O
and O
dynamic O
properties O
of O
PDA B
films O
coated O
on O
glass O
, O
polydimethylsiloxane O
( O
PDMS O
) O
, O
and O
epoxy O
. O

We O
found O
that O
PDA B
films O
are O
highly O
hydrated O
under O
wet O
conditions O
because O
of O
their O
porous O
membrane O
- O
like O
nanostructures O
and O
hydrophilic O
functional O
groups O
. O

A O
significant O
decrease O
in O
friction O
forces O
in O
water O
was O
observed O
on O
all O
three O
material O
surfaces O
coated O
with O
PDA B
; O
thus O
, O
the O
film O
might O
serve O
as O
a O
water O
- O
based O
lubrication O
coating O
. O

We O
attributed O
the O
different O
behavior O
of O
PDA B
films O
in O
air O
and O
in O
water O
to O
its O
hydration O
effects O
. O

These O
research O
findings O
provide O
insight O
into O
the O
stability O
, O
mechanical O
, O
and O
adhesive O
properties O
of O
the O
PDA B
films O
, O
which O
are O
critical O
for O
their O
applications O
. O

Unlike O
generic O
superoleophobic O
surfaces O
, O
our O
oil O
- O
repellent O
surface O
exhibited O
strong O
repellency O
to O
the O
lateral O
flow O
of O
low O
- O
surface O
- O
tension O
liquids O
such O
as O
hexadecane O
and O
dodecane B
. O

Evaluation O
of O
Coumarin O
and O
Neoflavone B
Derivatives O
as O
HCV O
NS5B O
Polymerase O
Inhibitors O
. O

Coumarins O
and O
coumestans B
represent O
an O
important O
family O
of O
compounds O
with O
diverse O
pharmacological O
properties O
. O

We O
recently O
identified O
coumestans B
as O
novel O
inhibitors O
of O
hepatitis O
C O
virus O
NS5B O
polymerase O
and O
predicted O
their O
binding O
in O
thumb O
pocket O
- O
1 O
( O
TP O
- O
1 O
) O
of O
NS5B O
. O

As O
the O
coumarins O
are O
structurally O
related O
to O
coumestans B
by O
virtue O
of O
their O
common O
A O
- O
and O
B O
- O
rings O
, O
we O
postulated O
them O
to O
also O
exhibit O
similar O
binding O
interaction O
with O
NS5B O
and O
inhibit O
its O
polymerase O
function O
. O

We O
therefore O
investigated O
24 O
coumarin O
and O
neoflavone B
derivatives O
as O
candidate O
NS5B O
inhibitors O
and O
identified O
14 O
compounds O
inhibiting O
NS5B O
polymerase O
activity O
with O
IC50 O
values O
between O
17 O
and O
63 O
mu O
m O
. O

Of O
these O
, O
the O
newly O
synthesized O
6 B
, I
8 I
- I
diallyl I
- I
5 I
, I
7 I
- I
dihydroxycoumarin I
( O
8a O
) O
was O
produced O
in O
three O
steps O
in O
high O
chemical O
yield O
from O
floroglucinol B
and O
found O
to O
be O
the O
most O
potent O
of O
this O
series O
, O
exhibiting O
activity O
similar O
to O
the O
reference O
coumestan B
LQB B
- I
34 I
. O

Trimethylamine B
- I
N I
- I
oxide I
, O
a O
metabolite O
associated O
with O
atherosclerosis O
, O
exhibits O
complex O
genetic O
and O
dietary O
regulation O
. O

Circulating O
trimethylamine B
- I
N I
- I
oxide I
( O
TMAO B
) O
levels O
are O
strongly O
associated O
with O
atherosclerosis O
. O

We O
now O
examine O
genetic O
, O
dietary O
, O
and O
hormonal O
factors O
regulating O
TMAO B
levels O
. O

We O
demonstrate O
that O
two O
flavin O
mono O
- O
oxygenase O
family O
members O
, O
FMO1 O
and O
FMO3 O
, O
oxidize O
trimethylamine B
( O
TMA O
) O
, O
derived O
from O
gut O
flora O
metabolism O
of O
choline O
, O
to O
TMAO B
. O

FMO3 O
overexpression O
in O
mice O
significantly O
increases O
plasma O
TMAO B
levels O
while O
silencing O
FMO3 O
decreases O
TMAO B
levels O
. O

Analysis O
of O
natural O
genetic O
variation O
among O
inbred O
strains O
of O
mice O
indicates O
that O
FMO3 O
and O
TMAO B
are O
significantly O
correlated O
, O
and O
TMAO B
levels O
explain O
11 O
% O
of O
the O
variation O
in O
atherosclerosis O
. O

Identification O
of O
N B
- I
acyl I
4 I
- I
( I
5 I
- I
pyrimidine I
- I
2 I
, I
4 I
- I
dionyl I
) I
phenylalanine I
derivatives O
and O
their O
orally O
active O
prodrug O
esters O
as O
dual O
- O
acting O
alpha4 O
- O
beta1 O
and O
alpha4 O
- O
beta7 O
receptor O
antagonists O
. O

N B
- I
Acyl I
4 I
- I
( I
5 I
- I
pyrimidine I
- I
2 I
, I
4 I
- I
dionyl I
) I
phenylalanine I
derivatives O
of O
type O
4 O
were O
designed O
to O
replace O
the O
2 B
, I
6 I
- I
dichlorobenzoylamine I
portion O
of O
compound O
1 O
in O
order O
to O
identify O
novel O
compounds O
with O
improved O
potency O
against O
alpha O
4 O
- O
integrins O
. O

Investigation O
of O
a O
limited O
number O
of O
prodrug O
esters O
led O
to O
the O
discovery O
of O
the O
ethyl B
ester I
prodrug O
42 O
, O
which O
demonstrated O
good O
intestinal O
fluid O
stability O
and O
good O
permeability O
. O

Investigation O
of O
N B
- I
acyl I
4 I
- I
( I
5 I
- I
pyrimidine I
- I
2 I
, I
4 I
- I
dionyl I
) I
phenylalanine I
derivatives O
led O
to O
the O
discovery O
of O
several O
very O
potent O
dual O
- O
acting O
alpha O
4 O
- O
integrin O
antagonists O
. O

Ethyl B
ester I
prodrug O
42 O
advanced O
to O
human O
clinical O
trials O
based O
on O
the O
excellent O
intestinal O
fluid O
stability O
, O
good O
permeability O
and O
superior O
efficacy O
in O
non O
- O
human O
primates O
. O

Tricycloalternarenes B
F I
- I
H I
: O
three O
new O
mixed O
terpenoids O
produced O
by O
an O
endolichenic O
fungus O
Ulocladium O
sp O
. O
using O
OSMAC O
method O
. O

Three O
new O
mixed O
terpenoids O
, O
tricycloalternarenes B
( O
TCAs B
) O
F O
- O
H O
( O
1 O
- O
3 O
) O
, O
together O
with O
ten O
known O
tricycloalternarenes B
( O
4 O
- O
13 O
) O
, O
were O
isolated O
from O
the O
Czapek O
' O
s O
culture O
of O
an O
endophytic O
fungus O
Ulocladium O
sp O
. O

TCA B
1b O
( O
5 O
) O
showed O
weak O
activity O
against O
the O
Bacille O
Calmette O
- O
Guerin O
strain O
with O
the O
MIC O
of O
125 O
mu O
g O
/ O
mL O
. O

TCA B
9b O
( O
10 O
) O
exhibited O
strong O
cytotoxic O
activity O
against O
Hela O
cell O
line O
with O
IC50 O
of O
8 O
. O
58 O
mu O
M O
. O

Aphagrandinoids B
A I
- I
D I
, O
cycloartane B
triterpenoids I
with O
antibacterial O
activities O
from O
Aphanamixis O
grandifolia O
. O

Three O
new O
cycloartane B
triterpenoids I
, O
aphagrandinoids B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
and O
a O
new O
natural O
product O
, O
aphagrandinoid B
D I
( O
4 O
) O
, O
together O
with O
a O
known O
compound O
, O
were O
isolated O
from O
the O
leaves O
and O
twigs O
of O
Aphanamixis O
grandifolia O
. O

Aphagrandinoid B
A I
( O
1 O
) O
, O
a O
29 B
- I
nor I
- I
cycloart I
triterpenoid I
, O
features O
with O
a O
sprio O
ring O
system O
at O
the O
side O
chain O
, O
while O
aphagrandinoid B
C I
( O
3 O
) O
is O
a O
pentnortriterpenoid B
. O

E2 O
and O
its O
active O
metabolites O
, O
estrone O
and O
estriol B
have O
a O
characteristic O
phenolic O
A O
ring O
, O
unlike O
progesterone O
, O
testosterone O
, O
cortisol O
and O
aldosterone O
, O
which O
have O
an O
A O
ring O
containing O
a O
C3 O
- O
ketone O
, O
a O
Delta O
( O
4 O
) O
bond O
and O
a O
C19 O
methyl O
group O
. O

However O
, O
other O
steroids O
, O
including O
Delta B
( I
5 I
) I
- I
androstenediol I
, O
5 B
alpha I
- I
androstanediol I
and O
27 O
- O
hydroxycholesterol O
, O
which O
have O
a O
saturated O
A O
ring O
containing O
a O
3 B
beta I
- I
hydroxyl I
and O
a O
C19 O
methyl O
group O
, O
also O
mediate O
physiological O
responses O
through O
binding O
to O
estrogen O
receptor O
- O
alpha O
( O
ER O
alpha O
) O
and O
ER O
beta O
. O

Here O
, O
using O
CCI O
in O
adult O
male O
mice O
, O
we O
set O
to O
determine O
whether O
3 B
, I
5 I
, I
3 I
' I
- I
triiodothyronine I
( O
T3 O
) O
attenuates O
posttraumatic O
neurodegeneration O
and O
neuroinflammation O
in O
an O
experimental O
model O
of O
TBI O
. O

( B
- I
) I
- I
Xanthatin I
up O
- O
regulation O
of O
the O
GADD45 O
gamma O
tumor O
suppressor O
gene O
in O
MDA O
- O
MB O
- O
231 O
breast O
cancer O
cells O
: O
role O
of O
topoisomerase O
II O
alpha O
inhibition O
and O
reactive O
oxygen O
species O
. O

Previously O
, O
we O
reported O
that O
( B
- I
) I
- I
xanthatin I
, O
a O
naturally O
occurring O
xanthanolide B
present O
in O
the O
Cocklebur O
plant O
, O
exhibits O
potent O
anti O
- O
proliferative O
effects O
on O
human O
breast O
cancer O
cells O
, O
accompanied O
by O
an O
induction O
of O
the O
growth O
arrest O
and O
DNA O
damage O
- O
inducible O
gene O
45 O
gamma O
( O
GADD45 O
gamma O
) O
, O
recognized O
recently O
as O
a O
novel O
tumor O
suppressor O
gene O
. O

Topoisomerase O
II O
alpha O
( O
Topo O
II O
alpha O
) O
inhibition O
has O
been O
reported O
to O
produce O
a O
cell O
death O
response O
accompanied O
by O
an O
atypical O
DNA O
laddering O
fragmentation O
profile O
, O
similar O
to O
that O
noted O
previously O
for O
( B
- I
) I
- I
xanthatin I
. O

Therefore O
we O
hypothesized O
that O
( B
- I
) I
- I
xanthatin I
' O
s O
GADD45 O
gamma O
activation O
was O
mediated O
through O
the O
Topo O
II O
alpha O
pathway O
. O

Here O
, O
we O
identify O
that O
( B
- I
) I
- I
xanthatin I
does O
function O
as O
a O
catalytic O
inhibitor O
of O
Topo O
II O
alpha O
, O
promoting O
DNA O
damage O
. O

Mechanistically O
, O
it O
was O
determined O
that O
the O
induced O
levels O
of O
GADD45 O
gamma O
mRNA O
resulting O
from O
( B
- I
) I
- I
xanthatin I
exposures O
were O
stabilized O
by O
coordinately O
produced O
ROS O
, O
and O
that O
the O
consequent O
induction O
of O
GADD45 O
gamma O
mRNA O
, O
GADD45 O
gamma O
protein O
and O
ROS O
generation O
were O
abrogated O
by O
co O
- O
treatment O
with O
N O
- O
acetyl O
- O
l O
- O
cysteine O
. O

Taken O
together O
, O
the O
data O
support O
the O
concept O
that O
Topo O
II O
alpha O
inhibition O
by O
( B
- I
) I
- I
xanthatin I
is O
a O
trigger O
that O
stimulates O
expression O
of O
DNA O
damage O
- O
inducible O
GADD45 O
gamma O
mRNA O
and O
that O
concomitantly O
produced O
ROS O
act O
downstream O
to O
further O
enhance O
the O
GADD45 O
gamma O
mRNA O
/ O
GADD45 O
gamma O
protein O
induction O
process O
, O
resulting O
in O
breast O
cancer O
cell O
death O
. O

These O
biological O
activities O
are O
likely O
due O
to O
the O
high O
content O
of O
malvidin B
3 I
- I
O I
- I
p I
- I
coumaroyl I
- I
rutinoside I
- I
5 I
- I
O I
- I
glucoside I
and O
petunidin B
3 I
- I
O I
- I
p I
- I
coumaroyl I
- I
rutinoside I
- I
5 I
- I
O I
- I
glucoside I
. O

Asymmetric O
synthesis O
and O
anti O
- O
protozoal O
activity O
of O
the O
8 B
, I
4 I
' I
- I
oxyneolignans I
virolin B
, O
surinamensin B
and O
analogues O
. O

The O
asymmetric O
synthesis O
of O
8 B
, I
4 I
' I
- I
oxyneolignans I
( B
- I
) I
- I
virolin I
, O
( B
- I
) I
- I
surinamensin I
and O
a O
number O
of O
analogues O
has O
been O
achieved O
. O

A O
divergent O
synthesis O
was O
used O
, O
with O
all O
compounds O
being O
elaborated O
from O
a O
single O
chiral O
aldehyde O
derived O
from O
ethyl B
lactate I
. O

Bacitracin B
and O
sodium O
taurocholate O
were O
incorporated O
in O
the O
formulations O
as O
proteolytic O
enzyme O
inhibitor O
and O
absorption O
enhancer O
, O
respectively O
. O

Activity O
of O
bacitracin B
was O
also O
evaluated O
. O

In O
vitro O
release O
showed O
a O
controlled O
profile O
up O
to O
12 O
h O
and O
the O
formulation O
containing O
0 O
. O
15 O
% O
( O
w O
/ O
v O
) O
of O
bacitracin B
revealed O
a O
maximum O
biological O
activity O
of O
about O
49 O
. O
1 O
+ O
/ O
- O
4 O
. O
1 O
% O
. O

Diminutive O
effect O
on O
T O
and O
B O
- O
cell O
proliferation O
of O
non O
- O
cytotoxic O
alpha B
- I
santonin I
derived O
1 O
, O
2 O
, O
3 O
- O
triazoles O
: O
a O
report O
. O

alpha B
- I
Santonin I
derived O
new O
series O
of O
1 O
, O
2 O
, O
3 O
- O
triazoles O
synthesized O
through O
Azide O
- O
Alkyne O
Huisgen O
1 O
, O
3 O
- O
dipolar O
cycloaddition O
reaction O
between O
substituted O
aryl O
azide O
and O
a O
propargylated B
alpha I
- I
desmotrosantonin I
were O
bio O
- O
evaluated O
for O
their O
diminutive O
effect O
on O
ConA O
induced O
T O
- O
cell O
and O
LPS O
induced O
B O
- O
cell O
proliferation O
. O

Interestingly O
, O
most O
of O
the O
synthesized O
compounds O
showed O
better O
immunosuppressant O
activity O
than O
alpha B
- I
santonin I
. O

Tributyltin O
( O
TBT B
) O
is O
a O
ubiquitous O
marine O
contaminant O
due O
to O
its O
extensive O
use O
as O
a O
biocide O
, O
fungicide O
and O
antifouling O
agent O
. O

However O
, O
the O
neurotoxic O
effect O
of O
TBT B
has O
not O
been O
extensively O
studied O
, O
especially O
in O
marine O
fish O
. O

This O
study O
was O
conducted O
to O
investigate O
the O
effects O
of O
TBT B
( O
10 O
, O
100 O
and O
1000 O
ng O
/ O
L O
) O
on O
the O
predatory O
behavior O
of O
Sebastiscus O
marmoratus O
and O
to O
look O
into O
the O
mechanism O
involved O
. O

The O
results O
showed O
that O
TBT B
exposure O
depressed O
predatory O
activity O
after O
50 O
days O
exposure O
. O

Dopamine O
levels O
in O
the O
fish O
brains O
increased O
in O
a O
dose O
- O
dependent O
manner O
, O
while O
5 O
- O
hydroxytryptamine O
and O
norepinephrine O
levels O
decreased O
significantly O
in O
the O
TBT B
exposure O
group O
compared O
to O
the O
control O
. O

The O
mRNA O
levels O
of O
dopamine O
receptors O
, O
which O
have O
functions O
such O
as O
cognition O
, O
motor O
activity O
, O
motivation O
and O
reward O
, O
mood O
, O
attention O
and O
learning O
, O
were O
significantly O
down O
- O
regulated O
by O
TBT B
exposure O
. O

Although O
the O
levels O
of O
amino O
acid O
neurotransmitters O
, O
including O
glutamate O
, O
did O
not O
show O
marked O
alteration O
, O
the O
expression O
of O
the O
glutamatergic O
signaling O
pathway O
such O
as O
N O
- O
methyl O
- O
D O
- O
aspartate O
receptors O
, O
a B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methylisoxazole I
- I
4 I
- I
propionic I
acid I
receptor O
, O
calmodulin O
, O
Ca O
( O
2 O
+ O
) O
/ O
calmodulin O
- O
dependent O
protein O
kinases O
- O
II O
and O
cyclic B
adenosine I
monophosphate I
responsive O
element O
binding O
protein O
, O
was O
significantly O
reduced O
by O
TBT B
exposure O

Addition O
of O
LTCC O
opener O
BAY B
K I
8644 I
( O
10 O
( O
- O
7 O
) O
M O
) O
failed O
to O
enhance O
the O
relaxations O
. O

However O
, O
they O
were O
increased O
by O
nearly O
40 O
% O
in O
response O
to O
BAY B
K I
8644 I
( O
10 O
( O
- O
7 O
) O
M O
) O
and O
were O
inhibited O
by O
nifedipine O
( O
10 O
( O
- O
7 O
) O
M O
) O
, O
indicating O
that O
activation O
of O
the O
LTCCs O
was O
essential O
. O

Inositol B
triphosphate I
( O
InsP3 O
) O
receptor O
antagonist O
2 O
- O
APB O
( O
10 O
( O
- O
4 O
) O
M O
) O
significantly O
reduced O
, O
and O
high O
concentration O
of O
caffeine O
( O
20mM O
) O
almost O
totally O
suppressed O
the O
contractions O
. O

Occupational O
exposure O
to O
pentachlorophenol B
causing O
lymphoma O
and O
hematopoietic O
malignancy O
for O
two O
generations O
. O

OBJECTIVE O
: O
Pentachlorophenol B
( O
PCP O
) O
is O
characterized O
as O
likely O
carcinogen O
of O
lymphoma O
and O
hematopoietic O
neoplasm O
. O

SiO O
( O
2 O
) O
NPs O
( O
concentration O
range O
25 O
- O
200 O
micro O
g O
/ O
ml O
) O
induced O
dose O
- O
dependent O
cytotoxicity O
in O
both O
types O
of O
cells O
, O
which O
was O
demonstrated O
by O
cell O
viability O
( O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazoliumb I
) O
and O
lactate O
dehydrogenase O
leakage O
assays O
. O

Complex O
II O
of O
the O
mitochondrial O
respiratory O
chain O
is O
the O
key O
mediator O
of O
divalent B
manganese I
- O
induced O
hydrogen O
peroxide O
production O
in O
microglia O
. O

We O
have O
recently O
reported O
that O
divalent B
Mn I
( O
Mn O
( O
2 O
+ O
) O
) O
stimulates O
brain O
microglia O
to O
produce O
and O
release O
hydrogen O
peroxide O
( O
H2O2 O
) O
, O
and O
microglial O
- O
free O
radical O
generation O
facilitates O
Mn O
( O
2 O
+ O
) O
- O
induced O
dopaminergic O
neurotoxicity O
. O

Exposure O
to O
low O
micromolar O
concentrations O
of O
Mn O
( O
2 O
+ O
) O
, O
but O
not O
divalent B
copper I
, I
cadmium I
, I
nickel I
, I
cobalt I
, I
zinc I
, I
and I
iron I
, O
induced O
a O
significant O
production O
of O
H2O2 O
from O
rat O
microglial O
but O
not O
astroglial O
cells O
. O

Each O
recombinant O
protein O
metabolized O
AA O
and O
LA O
to O
epoxides B
and O
hydroxy O
derivatives O
. O

The O
polymer O
, O
poly B
( I
ethylene I
glycol I
) I
- I
poly I
( I
serinol I
hexamethylene I
urethane I
) I
( O
ESHU B
) O
, O
forms O
a O
physical O
gel O
when O
heated O
to O
37 O
degrees O
C O
and O
shows O
good O
cytocompatibility O
with O
ocular O
cells O
. O

ESHU B
is O
capable O
of O
sustaining O
bevacizumab O
release O
over O
17 O
weeks O
in O
vitro O
, O
and O
the O
release O
kinetics O
can O
be O
altered O
by O
changing O
the O
drug O
dose O
and O
the O
ESHU B
concentration O
. O

These O
results O
suggest O
that O
ESHU B
is O
biologically O
safe O
, O
and O
suitable O
for O
ocular O
drug O
delivery O
. O

Finally O
, O
it O
has O
also O
been O
shown O
that O
SFE O
is O
very O
selective O
towards O
some O
specific O
components O
such O
as O
manoyl B
oxide I
, O
trans B
- I
totarol I
and O
alpha B
- I
acoradiene I
. O

MMP O
inhibitors O
including O
endogenous O
tissue O
inhibitors O
( O
TIMPs O
) O
and O
pharmacological O
inhibitors O
such O
as O
zinc O
chelators O
, O
doxycycline O
, O
batimastat B
and O
marimastat B
, O
have O
been O
used O
as O
diagnostic O
and O
therapeutic O
tools O
in O
cancer O
, O
autoimmune O
and O
cardiovascular O
disease O
. O

Solphenazines B
A I
- I
F I
, O
glycosylated B
phenazines I
from O
Streptomyces O
sp O
. O
strain O
DL O
- O
93 O
. O

During O
a O
survey O
of O
actinobacteria O
known O
to O
suppress O
the O
growth O
of O
Streptomyces O
scabies O
( O
the O
causative O
agent O
of O
potato O
scab O
disease O
) O
in O
vivo O
, O
six O
new O
rhamnosylated O
alkaloids O
, O
the O
solphenazines B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
were O
isolated O
from O
a O
biological O
control O
strain O
of O
Streptomyces O
( O
DL O
- O
93 O
) O
. O

The O
known O
rhamnosyl B
analogue O
of O
paraben B
( O
9 O
) O
was O
also O
isolated O
along O
with O
a O
new O
rhamnosylated O
derivative O
of O
N B
- I
methyl I
- I
p I
- I
aminobenzoic I
acid I
( O
10 O
) O
. O

Synthesis O
and O
biological O
evaluation O
as O
microtubule O
- O
active O
agents O
of O
several O
tetrahydrofuran O
and O
spiroacetal B
derivatives O
. O

The O
stereoselective O
preparation O
of O
several O
molecules O
containing O
structural O
fragments O
of O
the O
tetrahydrofuran O
and O
spiroacetal B
type O
is O
described O
. O

Furthermore O
, O
and O
also O
in O
contrast O
to O
a O
previous O
report O
on O
closely O
related O
compounds O
, O
the O
spiroacetal B
derivatives O
do O
show O
interactions O
with O
tubulin O
, O
even O
though O
the O
precise O
mechanism O
and O
the O
binding O
site O
still O
remain O
to O
be O
established O
. O

In O
situ O
examination O
of O
the O
reductive O
desorption O
process O
for O
Au O
microelectrodes O
modified O
with O
a O
thiol O
self O
- O
assembled O
monolayer O
( O
SAM O
) O
using O
fluorescence O
microscopy O
enabled O
the O
study O
of O
the O
fate O
of O
the O
desorbed O
thiolate B
species O
. O

Once O
reductively O
desorbed O
, O
the O
thiolate B
molecules O
fluoresce O
and O
their O
direction O
and O
speed O
are O
monitored O
. O

At O
moderately O
negative O
reduction O
potentials O
, O
the O
thiolate B
species O
hemispherically O
diffuse O
away O
from O
the O
microelectrode O
. O

Also O
observed O
is O
the O
influence O
of O
a O
closely O
positioned O
counter O
electrode O
on O
the O
direction O
of O
the O
desorbed O
thiolate B
movement O
. O

Lead O
optimization O
of O
a O
pyridine B
- I
carboxamide I
series O
as O
DGAT O
- O
1 O
inhibitors O
. O

The O
structure O
- O
activity O
relationship O
studies O
of O
a O
novel O
series O
of O
carboxylic O
acid O
derivatives O
of O
pyridine B
- I
carboxamides I
as O
DGAT O
- O
1 O
inhibitors O
is O
described O
. O

Several O
scientifically O
and O
technologically O
important O
classes O
of O
disordered O
low O
- O
Z O
materials O
such O
as O
small O
and O
large O
organic O
molecules O
, O
graphitic B
powders O
, O
polymers O
and O
liquids O
are O
intentionally O
explored O
to O
certify O
the O
technique O
' O
s O
performance O
. O

Butein B
protects O
human O
dental O
pulp O
cells O
from O
hydrogen O
peroxide O
- O
induced O
oxidative O
toxicity O
via O
Nrf2 O
pathway O
- O
dependent O
heme O
oxygenase O
- O
1 O
expressions O
. O

Butein B
, O
a O
plant O
polyphenol O
, O
is O
one O
of O
the O
major O
active O
components O
of O
R O
. O
verniciflua O
. O

Here O
, O
we O
found O
that O
butein B
possesses O
cytoprotective O
effects O
on O
hydrogen O
peroxide O
( O
H2O2 O
) O
- O
induced O
dental O
cell O
death O
. O

H2O2 O
- O
induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein B
, O
and O
these O
effects O
were O
dose O
dependent O
. O

Butein B
also O
increased O
heme O
oxygenase O
- O
1 O
( O
HO O
- O
1 O
) O
protein O
expression O
and O
HO O
activity O
. O

In O
addition O
, O
butein B
- O
dependent O
HO O
- O
1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2 O
- O
induced O
cell O
death O
and O
ROS O
generation O
. O

Furthermore O
, O
butein B
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor O
- O
E2 O
- O
related O
factor O
2 O
( O
Nrf2 O
) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
( O
AREs O
) O
. O

Treatment O
of O
HDP O
cells O
with O
a O
c O
- O
Jun O
NH2 O
- O
terminal O
kinase O
( O
JNK O
) O
inhibitor O
also O
reduced O
butein B
- O
induced O
HO O
- O
1 O
expression O
, O
and O
butein B
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O

These O
results O
indicate O
that O
butein B
may O
be O
used O
to O
prevent O
functional O
dental O
cell O
death O
and O
thus O
may O
be O
useful O
as O
a O
pulpal O
disease O
agent O
. O

Ex O
vivo O
samples O
of O
human O
oral O
mucosa O
were O
exposed O
to O
Pb O
or O
BaP O
, O
and O
immunohistochemical O
staining O
was O
performed O
to O
evaluate O
active O
caspase O
- O
3 O
, O
8 B
- I
epi I
- I
prostaglandin I
F2 I
alpha I
( O
8 B
- I
epi I
- I
PGF2a I
) O
, O
and O
3 O
- O
nitrotyrosine O
( O
3 O
- O
NT O
) O
. O

8 B
- I
Epi I
- I
PGF2a I
level O
increased O
only O
after O
prolonged O
incubation O
with O
Pb O
, O
and O
this O
elevation O
was O
irrespective O
of O
BaP O
incubation O
duration O
. O

Effect O
of O
enzymatically O
modified O
isoquercitrin B
on O
preneoplastic O
liver O
cell O
lesions O
induced O
by O
thioacetamide B
promotion O
in O
a O
two O
- O
stage O
hepatocarcinogenesis O
model O
using O
rats O
. O

To O
investigate O
the O
protective O
effect O
of O
enzymatically O
modified O
isoquercitrin B
( O
EMIQ O
) O
on O
the O
hepatocarcinogenic O
process O
, O
we O
used O
a O
two O
- O
stage O
hepatocarcinogenesis O
model O
in O
N B
- I
diethylnitrosamine I
- O
initiated O
and O
thioacetamide B
( O
TAA B
) O
- O
promoted O
rats O
. O

TAA B
increased O
the O
number O
and O
area O
of O
glutathione O
S O
- O
transferase O
placental O
form O
( O
GST O
- O
P O
) O
( O
+ O
) O
liver O
cell O
foci O
and O
the O
numbers O
of O
proliferating O
and O
apoptotic O
cells O
in O
randomly O
selected O
areas O
in O
liver O
sections O
. O

TAA B
also O
increased O
the O
numbers O
of O
ED2 O
( O
+ O
) O
, O
cyclooxygenase O
- O
2 O
( O
+ O
) O
, O
and O
heme O
oxygenase O
- O
1 O
( O
+ O
) O
liver O
cells O
, O
as O
well O
as O
the O
number O
of O
CD3 O
( O
+ O
) O
lymphocytes O
. O

EMIQ O
increased O
liver O
levels O
of O
thiobarbituric O
acid O
- O
reactive O
substance O
and O
8 O
- O
hydroxydeoxyguanosin O
, O
and O
TUNEL O
( O
+ O
) O
apoptotic O
cells O
, O
death O
receptor O
5 O
( O
DR5 O
) O
( O
+ O
) O
cells O
and O
4 B
- I
hydroxy I
- I
2 I
- I
nonenal I
( O
+ O
) O
cells O
within O
GST O
- O
P O
( O
+ O
) O
foci O
. O

These O
results O
suggest O
that O
TAA B
- O
induced O
tumor O
promotion O
involves O
activation O
of O
hepatic O
macrophages O
producing O
proinflammatory O
factors O
. O

EMIQ O
may O
suppress O
the O
TAA B
- O
induced O
tumor O
- O
promoting O
activity O
by O
an O
anti O
- O
inflammatory O
mechanism O
mediated O
by O
suppressing O
the O
activation O
of O
these O
macrophages O
. O

Bioavailability O
and O
intravenous O
toxicokinetic O
parameters O
for O
Pacific O
ciguatoxin B
P O
- O
CTX B
- I
1 I
in O
rats O
. O

Ciguatoxins B
are O
sodium O
channel O
activator O
toxins O
responsible O
for O
ciguatera O
fish O
poisoning O
. O

In O
this O
study O
, O
we O
determined O
the O
toxicokinetic O
parameters O
of O
the O
Pacific O
ciguatoxin B
P O
- O
CTX B
- I
1 I
in O
rats O
after O
an O
intravenous O
( O
iv O
) O
dose O
of O
0 O
. O
13 O
ng O
P O
- O
CTX B
- I
1 I
per O
g O
of O
body O
weight O
. O

The O
ciguatoxin B
activity O
was O
assessed O
over O
time O
in O
blood O
using O
the O
sensitive O
functional O
Neuro2a O
assay O
. O

After O
exposure O
, O
the O
ciguatoxin B
activity O
exhibited O
a O
rapid O
( O
alpha O
half O
- O
life O
of O
6 O
min O
) O
and O
extensive O
distribution O
into O
tissues O
( O
apparent O
steady O
state O
volume O
of O
distribution O
of O
7 O
. O
8 O
L O
) O
. O

Ciguatoxin B
elimination O
from O
blood O
was O
slower O
with O
a O
beta O
half O
- O
life O
estimated O
at O
35 O
. O
5 O
h O
. O

The O
toxicokinetic O
parameters O
determined O
from O
this O
study O
were O
compared O
to O
data O
previously O
obtained O
after O
oral O
and O
intraperitoneal O
exposure O
of O
rats O
to O
0 O
. O
26 O
ng O
P O
- O
CTX B
- I
1 I
per O
g O
of O
body O
weight O
. O

Maximal O
bioavailability O
was O
determined O
by O
the O
area O
under O
the O
concentration O
curve O
, O
and O
was O
used O
to O
calculate O
the O
absolute O
P O
- O
CTX B
- I
1 I
bioavailabilities O
for O
oral O
and O
intraperitoneal O
routes O
of O
exposures O
of O
39 O
% O
and O
75 O
% O
, O
respectively O
. O

Huntington O
disease O
is O
a O
dominantly O
inherited O
neurodegenerative O
condition O
caused O
by O
polyglutamine B
expansion O
in O
the O
N O
terminus O
of O
the O
huntingtin O
protein O
( O
Htt O
) O
. O

Nuclear O
export O
of O
Htt O
is O
sensitive O
to O
leptomycin B
B I
and O
is O
reduced O
by O
knockdown O
of O
exportin O
1 O
. O

Determinants O
of O
regioselectivity O
and O
chemoselectivity O
in O
fosfomycin B
resistance O
protein O
FosA O
from O
QM O
/ O
MM O
calculations O
. O

FosA O
is O
a O
manganese O
- O
dependent O
enzyme O
that O
utilizes O
a O
Mn O
( O
2 O
+ O
) O
ion O
to O
catalyze O
the O
inactivation O
of O
the O
fosfomycin B
antibiotic O
by O
glutathione O
( O
GSH O
) O
addition O
. O

According O
to O
quantum O
mechanics O
/ O
molecular O
mechanics O
( O
QM O
/ O
MM O
) O
calculations O
on O
the O
full O
solvated O
protein O
, O
the O
enzyme O
- O
catalyzed O
glutathione O
addition O
reaction O
involves O
two O
major O
chemical O
steps O
that O
both O
proceed O
in O
the O
sextet O
state O
: O
proton O
transfer O
from O
the O
GSH B
thiol I
group O
to O
the O
Tyr39 B
anion O
and O
nucleophilic O
attack O
by O
the O
GSH B
thiolate I
leading O
to O
epoxide O
ring O
- O
opening O
. O

Synthesis O
and O
evaluation O
of O
antibacterial O
activity O
of O
7 B
- I
alkyloxy I
- I
4 I
, I
5 I
- I
dihydro I
- I
imidazo I
[ I
1 I
, I
2 I
- I
a I
] I
quinoline I
derivatives O
. O

In O
this O
study O
, O
a O
series O
of O
7 B
- I
alkyloxy I
- I
4 I
, I
5 I
- I
dihydro I
- I
imidazo I
[ I
1 I
, I
2 I
- I
a I
] I
quinoline I
derivatives O
was O
synthesized O
and O
tested O
for O
their O
antibacterial O
activity O
against O
various O
bacterial O
strains O
. O

Compound O
7p O
( O
7 B
- I
heptyloxy I
- I
4 I
, I
5 I
- I
dihydro I
- I
imidazo I
[ I
1 I
, I
2 I
- I
a I
] I
quinoline I
) O
was O
found O
to O
be O
the O
most O
potent O
inhibitor O
. O

Cardioprotective O
potential O
of O
N B
, I
alpha I
- I
L I
- I
rhamnopyranosyl I
vincosamide I
, O
an O
indole O
alkaloid O
, O
isolated O
from O
the O
leaves O
of O
Moringa O
oleifera O
in O
isoproterenol O
induced O
cardiotoxic O
rats O
: O
in O
vivo O
and O
in O
vitro O
studies O
. O

Hitherto O
unknown O
protective O
effect O
of O
N B
, I
alpha I
- I
L I
- I
rhamnopyranosyl I
vincosamide I
( O
VR O
) O
, O
isolated O
from O
Moringa O
oleifera O
leaves O
in O
isoproterenol O
( O
ISO O
) O
- O
induced O
cardiac O
toxicity O
was O
evaluated O
in O
rats O
. O

A O
reduction O
in O
myocardial O
necrosis O
was O
further O
evidenced O
by O
the O
tri B
- I
phenyl I
tetrazolium I
chloride I
( O
TTC B
) O
stain O
in O
isolated O
test O
drug O
pretreated O
rats O
. O

Indenoindolone B
derivatives O
as O
topoisomerase O
II O
- O
inhibiting O
anticancer O
agents O
. O

Based O
on O
known O
heterocyclic O
topoisomerase O
II O
inhibitors O
and O
anticancer O
agents O
, O
various O
indenoindolone B
derivatives O
were O
predicted O
as O
potential O
topoisomerase O
II O
- O
inhibiting O
anticancer O
agents O
. O

They O
are O
hydrazones B
, O
( B
thio I
) I
semicarbazones I
, O
and O
oximes B
of I
indenoindolones I
, O
and O
indenoindolols B
. O

These O
derivatives O
with O
suitable O
substitutions O
exhibited O
potent O
specific O
inhibition O
of O
human O
DNA O
TopoII O
alpha O
while O
not O
showing O
inhibition O
of O
topoisomerase O
I O
and O
DNA O
intercalation O
, O
despite O
the O
fact O
that O
parent O
indenoindolones B
are O
known O
poor O
/ O
moderate O
inhibitors O
of O
topoisomerase O
II O
. O

The O
potent O
topoisomerase O
II O
inhibitor O
indenoindolone B
derivatives O
exhibited O
good O
anticancer O
activities O
compared O
to O
etoposide O
and O
5 O
- O
fluorouracil O
, O
and O
relatively O
low O
toxicity O
to O
normal O
cells O
. O

These O
derivatizations O
of O
indenoindolones B
were O
found O
to O
result O
in O
enhancement O
of O
anticancer O
activities O
. O

In O
this O
study O
, O
we O
compared O
the O
effects O
of O
the O
alpha O
7 O
- O
selective O
agonist O
( O
PNU B
- I
282987 I
) O
and O
PAM O
( O
PNU O
- O
120596 O
) O
in O
a O
variety O
of O
behavioral O
tests O
in O
Sprague O
Dawley O
rats O
to O
look O
at O
their O
effects O
on O
learning O
and O
memory O
as O
well O
as O
anxiety O
. O

We O
found O
that O
neither O
PNU B
- I
282987 I
nor O
PNU O
- O
120596 O
improved O
spatial O
- O
learning O
or O
episodic O
memory O
by O
themselves O
. O

However O
when O
cognitive O
impairment O
was O
induced O
in O
the O
rats O
with O
scopolamine O
( O
1 O
mg O
/ O
kg O
) O
, O
both O
PNU O
- O
120596 O
and O
PNU B
- I
282987 I
were O
able O
to O
reverse O
this O
memory O
impairment O
and O
restore O
it O
back O
to O
normal O
levels O
. O

PNU B
- I
282987 I
on O
the O
other O
hand O
displayed O
an O
increase O
in O
anxiety O
- O
like O
behavior O
at O
a O
higher O
dose O
( O
10 O
mg O
/ O
kg O
) O
that O
was O
significantly O
reduced O
by O
the O
serotonin O
5 O
- O
HT1a O
receptor O
antagonist O
WAY B
- I
100135 I
. O

However O
the O
alpha O
7 O
receptor O
antagonist O
methyllycaconitine O
was O
unable O
to O
reverse O
these O
anxiety O
- O
like O
effects O
seen O
with O
PNU B
- I
282987 I
. O

Well O
structured O
: O
As O
a O
new O
triose B
phosphate I
isomerase O
( O
TIM O
) O
barrel O
- O
fold O
prenyl O
transferase O
, O
PcrB O
catalyzes O
the O
production O
of O
heptaprenylglyceryl B
phosphate I
from O
heptaprenyl B
diphosphate I
and O
glycerol B
- I
1 I
- I
phosphate I
. O

Associations O
between O
perfluoroalkyl B
compounds O
and O
immune O
and O
clinical O
chemistry O
parameters O
in O
highly O
exposed O
bottlenose O
dolphins O
( O
Tursiops O
truncatus O
) O
. O

Perfluoroalkyl B
compounds O
( O
PFCs O
) O
are O
ubiquitous O
, O
persistent O
chemical O
contaminants O
found O
in O
the O
environment O
, O
wildlife O
, O
and O
humans O
. O

The O
authors O
investigated O
the O
relationship O
between O
PFCs O
( O
including O
sum O
perfluorocarboxylate B
, O
sum O
perfluoroalkyl B
sulfonates I
, O
perfluorooctane O
sulfonate O
, O
perfluorooctanoic O
acid O
, O
and O
perfluorodecanoic B
acid I
) O
and O
the O
clinocopathologic O
and O
immune O
parameters O
in O
a O
highly O
exposed O
population O
( O
n O
= O
79 O
) O
of O
Atlantic O
bottlenose O
dolphins O
( O
mean O
sum O
PFCs O
= O
1970 O
ng O
/ O
ml O
; O
range O
574 O
- O
8670 O
ng O
/ O
ml O
) O
sampled O
from O
2003 O
to O
2005 O
near O
Charleston O
, O
South O
Carolina O

While O
conducting O
toxicity O
tests O
with O
nano O
titanium O
dioxide O
, O
the O
authors O
found O
that O
test O
suspensions O
were O
being O
contaminated O
with O
aluminum O
and O
titanium B
from O
tip O
erosion O
during O
direct O
sonication O
. O

Heterocycles O
as O
nonclassical O
bioisosteres O
of O
alpha B
- I
amino I
acids I
. O

Bioisosterism O
of O
alpha B
- I
amino I
acids I
is O
often O
accomplished O
by O
replacing O
the O
alpha B
- I
carboxylate I
with O
one O
of O
the O
many O
known O
carboxylic O
acid O
bioisosteres O
. O

In O
this O
Minireview O
, O
we O
summarized O
the O
reported O
heterocycles O
as O
nonclassical O
bioisosteres O
of O
alpha B
- I
amino I
acids I
, O
which O
include O
quinoxaline B
- I
2 I
, I
4 I
( I
1H I
) I
- I
dione I
, O
quinoxaline B
- I
2 I
, I
3 I
( I
1H I
) I
- I
dione I
and O
quinolin B
- I
2 I
( I
1H I
) I
- I
one I
, O
azagrevellin B
and O
azepine B
- O
derived O
structures O
. O

The O
binding O
mode O
of O
the O
crystalized O
bioisosteres O
were O
compared O
with O
those O
of O
the O
crystalized O
alpha B
- I
amino I
acids I
that O
bind O
in O
the O
same O
domain O
, O
and O
where O
no O
data O
on O
the O
crystal O
structure O
were O
available O
, O
the O
displacement O
studies O
of O
known O
orthosteric O
ligands O
were O
used O
. O

The O
reported O
bioisosteres O
share O
the O
following O
essential O
structural O
features O
for O
mimicking O
alpha B
- I
amino I
acids I
: O
an O
aromatic O
ring O
system O
joined O
to O
a O
lactam O
ring O
system O
with O
an O
acidic O
feature O
next O
to O
the O
lactam B
carbonyl I
, O
where O
this O
acidic O
feature O
together O
with O
the O
lactam B
carbonyl I
can O
mimic O
the O
alpha O
- O
carboxylate O
, O
and O
the O
lactam O
nitrogen O
together O
with O
the O
aromatic O
ring O
system O
can O
mimic O
the O
alpha B
- I
ammonium I
. O

The O
majority O
of O
these O
heterocycles O
can O
be O
prepared O
from O
three O
common O
corresponding O
starting O
materials O
: O
the O
corresponding O
anilines B
, O
isatins B
or O
anthranilic B
esters I
. O

We O
tested O
whether O
antiresorptive O
therapies O
result O
in O
higher O
fasting O
glucose O
, O
increased O
weight O
, O
or O
greater O
diabetes O
incidence O
in O
post O
- O
hoc O
analyses O
of O
three O
randomized O
, O
placebo O
- O
controlled O
trials O
in O
postmenopausal O
women O
: O
Fracture O
Intervention O
Trial O
( O
FIT O
) O
( O
N O
= O
6151 O
) O
of O
alendronate O
( O
4 O
years O
) O
, O
Health O
Outcomes O
and O
Reduced O
Incidence O
with O
Zoledronic B
Acid I
Once O
Yearly O
Pivotal O
Fracture O
Trial O
( O
HORIZON O
- O
PFT O
) O
( O
N O
= O
7113 O
) O
of O
zoledronic B
acid I
( O

Treatment O
of O
the O
silicon O
base O
and O
carbon O
nanotubes O
with O
hydrofluoric B
acid I
and O
a O
strong O
oxidizer O
( O
thionyl B
chloride I
) O
leads O
to O
a O
significant O
improvement O
in O
performance O
. O

The O
regulation O
of O
Runx2 O
by O
FGF2 O
and O
connexin43 O
requires O
the O
inositol B
polyphosphate I
/ O
protein O
kinase O
C O
delta O
cascade O
. O

In O
this O
study O
, O
we O
examined O
the O
contribution O
of O
the O
phospholipase O
C O
gamma O
1 O
/ O
inositol B
polyphosphate I
/ O
PKC O
delta O
cascade O
to O
the O
Cx43 O
- O
dependent O
transcriptional O
response O
of O
MC3T3 O
osteoblasts O
to O
FGF2 O
. O

Knockdown O
of O
expression O
and O
/ O
or O
inhibition O
of O
function O
of O
phospholipase O
C O
gamma O
1 O
, O
inositol B
polyphosphate I
multikinase O
, O
which O
generates O
InsP O
( O
4 O
) O
and O
InsP O
( O
5 O
) O
, O
and O
inositol B
hexakisphosphate I
kinase O
1 O
/ O
2 O
, O
which O
generates O
inositol B
pyrophosphates I
, O
prevented O
the O
ability O
of O
Cx43 O
to O
potentiate O
FGF2 O
- O
induced O
signaling O
through O
Runx2 O
. O

Conversely O
, O
overexpression O
of O
phospholipase O
C O
gamma O
1 O
and O
inositol B
hexakisphosphate I
kinase O
1 O
/ O
2 O
enhanced O
FGF2 O
activation O
of O
Runx2 O
and O
the O
effect O
of O
Cx43 O
overexpression O
on O
this O
response O
. O

These O
data O
reveal O
that O
FGF2 O
- O
signaling O
involves O
the O
inositol B
polyphosphate I
cascade O
, O
including O
IP6K O
, O
and O
demonstrate O
that O
IP6K O
regulates O
Runx2 O
and O
osteoblast O
gene O
expression O
. O

Additionally O
, O
these O
data O
implicate O
the O
water O
- O
soluble O
inositol B
polyphosphates I
as O
mediators O
of O
the O
Cx43 O
- O
dependent O
amplification O
of O
the O
osteoblast O
response O
to O
FGF2 O
, O
and O
suggest O
that O
these O
low O
molecular O
weight O
second O
messengers O
may O
be O
biologically O
relevant O
mediators O
of O
osteoblast O
function O
that O
are O
communicated O
by O
Cx43 O
- O
gap O
junctions O
. O

Repression O
of O
farnesyltransferase O
( O
FNTA O
) O
by O
siRNA O
and O
the O
enzyme O
inhibitor O
manumycin B
A I
caused O
elevation O
of O
ApoA O
- O
I O
secretion O
from O
hepatocytes O
and O
from O
transgenic O
mice O
expressing O
hApoA O
- O
I O
and O
cholesterol O
ester O
transfer O
protein O
transgenes O
. O

Furthermore O
, O
the O
structure O
- O
activity O
relationship O
of O
a O
bis B
( I
aryl I
) I
ether I
C O
- O
terminal O
capping O
group O
mimicking O
dipeptide O
interactions O
was O
probed O
through O
ring O
substitutions O
, O
allowing O
increased O
complementarity O
with O
the O
primary O
hydrophobic O
pocket O
. O

Four O
new O
koumine B
metabolites O
in O
rat O
liver O
microsomes O
. O

Four O
new O
metabolites O
M O
- O
1 O
[ O
1 B
, I
2 I
, I
18 I
, I
19 I
- I
tetradehydro I
- I
4 I
- I
demethyl I
- I
3 I
, I
17 I
- I
epoxy I
- I
7 I
, I
20 I
( I
2H I
, I
19H I
) I
- I
cyclovobasan I
] O
, O
M O
- O
2 O
[ O
1 B
, I
2 I
, I
4 I
, I
21 I
, I
18 I
, I
19 I
- I
hexadehydro I
- I
4 I
- I
demethyl I
- I
3 I
, I
17 I
- I
epoxy I
- I
7 I
, I
20 I
( I
2H I
, I
19H I
) I
- I
cyclovobasan I
] O
, O
M O
- O
3 O
[ O
1 O
, O
2 O
, O
18 O
, O
19 O

- O
tetradehydro O
- O
4 O
- O
demethyl O
- O
4 O
- O
formaldehyde O
- O
3 O
, O
17 O
- O
epoxy O
- O
7 O
, O
20 O
( O
2H O
, O
19H O
) O
- O
cyclovobasan O
] O
, O
and O
M O
- O
4 O
[ O
1 B
, I
2 I
, I
4 I
, I
21 I
, I
18 I
, I
19 I
- I
hexadehydro I
- I
4 I
- I
demethyl I
- I
4 I
- I
oxy I
- I
3 I
, I
17 I
- I
epoxy I
- I
7 I
, I
20 I
( I
2H I
, I
19H I
) I
- I
cyclovobasan I
] O
were O
isolated O
from O
the O
chloroform O
extract O
of O
koumine O

incubated O
with O
phenobarbital B
- O
treated O
rat O
liver O
microsomes O
. O

The O
metabolic O
pathway O
of O
koumine B
was O
proposed O
. O

The O
cytotoxic O
activities O
between O
koumine B
and O
its O
metabolites O
were O
also O
compared O
in O
the O
A549 O
cell O
line O
. O

Polymorphism O
of O
GeSbTe B
superlattice O
nanowires O
. O

Herein O
, O
we O
report O
novel O
composition O
- O
phase O
- O
tuned O
GeSbTe B
NWs O
, O
synthesized O
by O
a O
chemical O
vapor O
transport O
method O
, O
which O
guarantees O
promising O
applications O
in O
the O
field O
of O
nanoscale O
electric O
devices O
. O

As O
the O
Sb B
content O
increased O
, O
they O
showed O
a O
distinctive O
rhombohedral O
- O
cubic O
- O
rhombohedral O
phase O
evolution O
. O

Remarkable O
superlattice O
structures O
were O
identified O
for O
the O
Ge B
( I
8 I
) I
Sb I
( I
2 I
) I
Te I
( I
11 I
) I
, O
Ge B
( I
3 I
) I
Sb I
( I
2 I
) I
Te I
( I
6 I
) I
, O
Ge B
( I
3 I
) I
Sb I
( I
8 I
) I
Te I
( I
6 I
) I
, O
and O
Ge B
( I
2 I
) I
Sb I
( I
7 I
) I
Te I
( I
4 I
) I
NWs O
. O

The O
coexisting O
cubic O
- O
rhombohedral O
phase O
Ge B
( I
3 I
) I
Sb I
( I
2 I
) I
Te I
( I
6 I
) I
NWs O
exhibited O
an O
exclusively O
uniform O
superlattice O
structure O
consisting O
of O
2 O
. O
2 O
nm O
period O
slabs O
. O

The O
rhombohedral O
phase O
Ge B
( I
3 I
) I
Sb I
( I
8 I
) I
Te I
( I
6 I
) I
and O
Ge B
( I
2 I
) I
Sb I
( I
7 I
) I
Te I
( I
4 I
) I
NWs O
adopted O
an O
innovative O
structure O
; O
3Sb B
( I
2 I
) I
layers O
intercalated O
the O
Ge B
( I
3 I
) I
Sb I
( I
2 I
) I
Te I
( I
6 I
) I
and O
Ge B
( I
2 I
) I
Sb I
( I
1 I
) I
Te I
( I
4 I
) I
domains O
, O
respectively O
, O
producing O
3 O
. O
4 O
and O
2 O
. O
7 O
nm O
period O
slabs O
. O

The O
current O
- O
voltage O
measurement O
of O
the O
individual O
NW O
revealed O
that O
the O
vacancy O
layers O
of O
Ge B
( I
8 I
) I
Sb I
( I
2 I
) I
Te I
( I
11 I
) I
and O
Ge B
( I
3 I
) I
Sb I
( I
2 I
) I
Te I
( I
6 I
) I
decreased O
the O
electrical O
conductivity O
. O

A O
new O
flavonoid O
with O
6 B
- I
phenyl I
substituent O
from O
Selaginella O
uncinata O
. O

A O
new O
flavonoid O
, O
6 B
- I
( I
5 I
- I
acetyl I
- I
2 I
- I
methoxyphenyl I
) I
- I
apigenin I
( O
1 O
) O
, O
together O
with O
nine O
known O
compounds O
( O
2 O
- O
10 O
) O
, O
was O
isolated O
from O
Selaginella O
uncinata O
( O
Desv O
. O
) O
Spring O
. O

Phase O
separation O
induced O
by O
Au O
catalysts O
in O
ternary O
InGaAs B
nanowires O
. O

We O
report O
a O
novel O
phase O
separation O
phenomenon O
observed O
in O
the O
growth O
of O
ternary O
In B
( I
x I
) I
Ga I
( I
1 I
- I
x I
) I
As I
nanowires O
by O
metalorganic O
chemical O
vapor O
deposition O
. O

It O
has O
been O
found O
that O
for O
In B
( I
x I
) I
Ga I
( I
1 I
- I
x I
) I
As I
nanowires O
high O
precursor O
flow O
rates O
generate O
ternary O
In B
( I
x I
) I
Ga I
( I
1 I
- I
x I
) I
As I
cores O
with O
In O
- O
rich O
shells O
, O
while O
low O
precursor O
flow O
rates O
produce O
binary O
GaAs O
cores O
with O
ternary O
In B
( I
x I
) I
Ga I
( I
1 I
- I
x I
) I
As I
shells O
. O

Synthesis O
and O
antibacterial O
evaluation O
of O
typharin B
analog O
: O
6 B
, I
8 I
- I
dihydroxy I
- I
7 I
- I
methyl I
- I
3 I
- I
styryl I
- I
3 I
, I
4 I
- I
dihydroisocoumarin I
. O

Synthesis O
of O
the O
6 B
- I
hydroxy I
- I
7 I
- I
methyl I
analog O
of O
typharin B
( O
8 B
- I
dihydroxy I
- I
3 I
- I
styryl I
- I
3 I
, I
4 I
- I
dihydroisocoumarin I
) O
isolated O
from O
the O
rhizomes O
of O
Typha O
capensis O
has O
been O
described O
. O

Direct O
condensation O
of O
3 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
methylhomophthalic I
acid I
( O
1 O
) O
with O
cinnamoyl B
chloride I
at O
elevated O
temperature O
under O
inert O
conditions O
afforded O
6 B
, I
8 I
- I
dihydroxy I
- I
7 I
- I
methyl I
- I
3 I
- I
styrylisocoumarin I
( O
2 O
) O
. O

Hydrolysis O
of O
isocoumarin O
to O
keto B
acid I
( O
3 O
) O
followed O
by O
reduction O
and O
cyclodehydration O
of O
hydroxy B
acid I
analog O
( O
4 O
) O
afforded O
( B
+ I
/ I
- I
) I
- I
6 I
, I
8 I
- I
dimethoxy I
- I
3 I
- I
( I
4 I
- I
methoxyphenyl I
) I
- I
3 I
, I
4 I
- I
dihydroisocoumarin I
( O
5 O
) O
. O

Demethylation O
of O
the O
latter O
using O
anhydrous O
aluminum O
chloride O
/ O
ethane B
thiol I
furnished O
the O
title O
isocoumarin O
( O
6 O
) O
. O

Compounds O
( O
1 O
- O
6 O
) O
were O
screened O
for O
in O
vitro O
antibacterial O
activity O
against O
a O
representative O
panel O
of O
Gram O
- O
positive O
and O
Gram O
- O
negative O
bacteria O
using O
levofloxacin B
as O
the O
reference O
drug O
. O

The O
highest O
encapsulation O
was O
obtained O
with O
an O
organic O
phase O
consisting O
of O
acetone O
: O
dichloromethane O
( O
1 O
: O
1 O
) O
, O
polyD B
, I
L I
- I
lactide I
- I
co I
- I
glycolide I
( O
PLGA O
) O
50 O
: O
50 O
as O
polymer O
and O
an O
initial O
mass O
of O
6 O
. O
6 O
mg O
of O
methylprednisolone O
. O

Fasciospyrinadine B
, O
a O
novel O
sesquiterpene O
pyridine O
alkaloid O
from O
a O
Guangxi O
sponge O
Fasciospongia O
sp O
. O

Fasciospyrinadine B
( O
1 O
) O
, O
a O
novel O
sesquiterpene O
pyridine O
alkaloid O
with O
a O
previously O
unreported O
skeleton O
featuring O
a O
monocyclicfarnesane B
moiety O
attached O
to O
a O
3 B
- I
methylenepyridine I
residue O
, O
was O
isolated O
from O
the O
sponge O
Fasciospongia O
sp O
. O
from O
Weizhou O
Island O
, O
Guangxi O
Autonomous O
Region O
. O

Fundamental O
and O
Torsional O
Combination O
Bands O
of O
Two O
Isomers O
of O
the O
OCS B
- O
CO O
( O
2 O
) O
Complex O
in O
the O
CO O
( O
2 O
) O
nu O
( O
3 O
) O
Region O
. O

Spectra O
of O
two O
isomers O
of O
the O
weakly O
bound O
complex O
OCS B
- O
CO O
( O
2 O
) O
are O
observed O
in O
the O
region O
of O
the O
CO O
( O
2 O
) O
nu O
( O
3 O
) O
fundamental O
vibration O
( O
~ O
2349 O
cm O
( O
- O
1 O
) O
) O
, O
using O
an O
infrared O
tunable O
diode O
laser O
to O
probe O
a O
pulsed O
supersonic O
slit O
- O
jet O
expansion O
. O

For O
one O
isomer O
, O
the O
corresponding O
torsional O
combination O
band O
is O
also O
detected O
in O
the O
OCS B
nu O
( O
1 O
) O
stretching O
region O
( O
~ O
2060 O
cm O
( O
- O
1 O
) O
) O
. O

The O
resulting O
torsional O
frequencies O
are O
found O
to O
be O
18 O
. O
8 O
and O
15 O
. O
9 O
cm O
( O
- O
1 O
) O
for O
isomers O
a O
and O
b O
of O
OCS B
- O
CO O
( O
2 O
) O
, O
respectively O
. O

The O
resolution O
of O
aglinin B
A I
epimers O
and O
their O
NMR O
assignments O
. O

Aglinin B
A I
( O
1 O
) O
is O
a O
mixture O
of O
C O
( O
24 O
) O
- O
epimeric O
20S B
, I
24 I
- I
epoxy I
- I
24 I
, I
25 I
- I
dihydroxy I
- I
3 I
, I
4 I
- I
secodammar I
- I
4 I
( I
28 I
) I
- I
en I
- I
3 I
- I
oic I
acid I
and O
present O
in O
plants O
of O
the O
family O
Meliaceae O
. O

The O
two O
epimers O
of O
1 O
were O
resolved O
through O
an O
acetonide B
reaction O
, O
and O
the O
absolute O
configurations O
of O
two O
derivatives O
were O
deduced O
by O
the O
analysis O
of O
their O
( O
13 O
) O
C O
NMR O
differences O
induced O
by O
gamma O
- O
gauche O
or O
steric O
effect O
. O

Phthalazinone B
inhibitors O
of O
inosine O
- O
5 O
' O
- O
monophosphate O
dehydrogenase O
from O
Cryptosporidium O
parvum O
. O

This O
protozoan O
parasite O
relies O
on O
inosine O
5 O
' O
- O
monophosphate O
dehydrogenase O
( O
IMPDH O
) O
for O
the O
production O
of O
guanine B
nucleotides I
. O

A O
CpIMPDH O
- O
selective O
N B
- I
aryl I
- I
3 I
, I
4 I
- I
dihydro I
- I
3 I
- I
methyl I
- I
4 I
- I
oxo I
- I
1 I
- I
phthalazineacetamide I
inhibitor O
was O
previously O
identified O
in O
a O
high O
throughput O
screening O
campaign O
. O

Herein O
we O
report O
a O
structure O
- O
activity O
relationship O
study O
for O
the O
phthalazinone B
- O
based O
series O
that O
resulted O
in O
the O
discovery O
of O
benzofuranamide B
analogs O
that O
exhibit O
low O
nanomolar O
inhibition O
of O
CpIMPDH O
. O

Male O
C57BL O
/ O
6 O
mice O
( O
n O
= O
30 O
) O
were O
randomly O
divided O
into O
3 O
dietary O
groups O
consisting O
of O
either O
standard O
rodent O
chow O
( O
4 O
. O
8 O
% O
fat O
, O
20 O
% O
protein O
) O
, O
or O
a O
high O
fat O
( O
HF O
) O
diet O
( O
21 O
- O
23 O
% O
fat O
, O
19 O
% O
protein O
) O
with O
low O
GI O
( O
15 O
. O
4 O
% O
starch O
; O
HF O
- O
LG O
) O
or O
high O
GI O
( O
50 O
. O
5 O
% O
dextrose B
; O
HF O
- O
HG O
) O
ad O
libitum O
for O
10 O
weeks O
. O

Adjunctive O
aripiprazole B
therapy O
with O
escitalopram O
in O
patients O
with O
co O
- O
morbid O
major O
depressive O
disorder O
and O
alcohol O
dependence O
: O
clinical O
and O
neuroimaging O
evidence O
. O

We O
hypothesized O
that O
augmentation O
therapy O
of O
escitalopram O
with O
aripiprazole B
would O
improve O
depressive O
symptoms O
as O
well O
as O
reduce O
craving O
for O
alcohol O
and O
cue O
- O
induced O
brain O
activity O
in O
patients O
with O
co O
- O
morbid O
alcohol O
dependence O
and O
major O
depressive O
disorder O
, O
compared O
with O
treatment O
with O
escitalopram O
alone O
. O

Thirty O
- O
five O
subjects O
with O
major O
depressive O
disorder O
and O
alcohol O
dependence O
were O
recruited O
and O
randomly O
assigned O
into O
17 O
aripiprazole B
+ O
escitalopram O
and O
18 O
escitalopram O
only O
groups O
. O

During O
the O
six O
week O
treatment O
period O
, O
Beck O
Depression O
Inventory O
and O
clinical O
global O
index O
- O
severity O
( O
CGI O
- O
S O
) O
scores O
decreased O
in O
both O
the O
aripiprazole B
+ O
escitalopram O
and O
escitalopram O
only O
groups O
. O

In O
addition O
, O
following O
the O
treatment O
period O
, O
the O
Korean O
alcohol O
urge O
questionnaire O
scores O
in O
the O
aripiprazole B
+ O
escitalopram O
group O
were O
reduced O
from O
23 O
. O
3 O
+ O
/ O
- O
8 O
. O
4 O
to O
14 O
. O
3 O
+ O
/ O
- O
4 O
. O
9 O
, O
compared O
with O
those O
of O
the O
escitalopram O
group O
of O
from O
21 O
. O
6 O
+ O
/ O
- O
8 O
. O
4 O
to O
19 O
. O
3 O
+ O
/ O
- O
7 O
. O
1 O
( O
F O
= O
13 O
. O
1 O
, O
p O
< O
0 O
. O
01 O
) O
. O

The O
activity O
within O
the O
anterior O
cingulate O
was O
increased O
in O
response O
to O
the O
presentation O
of O
alcohol O
drinking O
scenes O
following O
treatment O
in O
the O
aripiprazole B
+ O
escitalopram O
group O
. O

These O
findings O
suggest O
that O
the O
effects O
of O
aripiprazole B
on O
anterior O
cingulate O
cortex O
might O
mediate O
the O
successful O
treatment O
of O
alcohol O
dependence O
in O
patients O
with O
major O
depressive O
disorder O
. O

Losmapimod B
concentration O
- O
QT O
relationship O
in O
healthy O
volunteers O
: O
meta O
- O
analysis O
of O
data O
from O
six O
clinical O
trials O
. O

PURPOSE O
: O
The O
objective O
of O
this O
work O
was O
to O
describe O
the O
losmapimod B
concentration O
- O
QT O
relationship O
using O
meta O
- O
analysis O
of O
data O
from O
clinical O
trials O
with O
healthy O
volunteers O
and O
to O
evaluate O
the O
covariates O
that O
have O
significant O
impact O
on O
the O
QT O
prolongation O
. O

METHODS O
: O
Losmapimod B
plasma O
concentration O
and O
QT O
interval O
data O
were O
collected O
from O
six O
early O
clinical O
studies O
with O
healthy O
volunteers O
. O

The O
electrocardiograms O
( O
ECGs O
) O
were O
collected O
at O
baseline O
and O
at O
a O
number O
of O
post O
- O
dose O
time O
points O
( O
losmapimod B
or O
placebo O
) O
. O

The O
population O
pharmacokinetic O
/ O
pharmacodynamic O
( O
PK O
/ O
PD O
) O
modelling O
approach O
was O
applied O
to O
investigate O
the O
relationship O
between O
losmapimod B
concentration O
and O
QT O
prolongation O
. O

RESULTS O
: O
The O
dataset O
for O
analysis O
comprised O
190 O
healthy O
adults O
who O
took O
at O
least O
one O
dose O
of O
losmapimod B
or O
placebo O
. O

Of O
the O
2 O
, O
494 O
QT O
observations O
collected O
, O
1 O
, O
532 O
observations O
had O
matched O
QT O
and O
losmapimod B
plasma O
concentration O
data O
. O

Population O
PK O
/ O
PD O
analyses O
indicated O
that O
the O
model O
with O
the O
individual O
heart O
rate O
correction O
factor O
( O
alpha O
) O
fitted O
the O
data O
better O
than O
those O
using O
fixed O
alpha O
( O
0 O
. O
33 O
for O
Fridericia O
' O
s O
correction O
or O
0 O
. O
5 O
for O
Bazett O
' O
s O
correction O
) O
and O
that O
there O
was O
no O
relationship O
between O
losmapimod B
concentration O
and O
QT O
interval O
. O

Our O
meta O
- O
analysis O
of O
healthy O
volunteer O
data O
indicated O
no O
relationship O
between O
systemic O
losmapimod B
concentration O
and O
QT O
interval O
in O
healthy O
volunteers O
. O

Ursolic O
acid O
significantly O
exerted O
cytotoxicity O
, O
increased O
the O
sub O
- O
G1 O
population O
and O
the O
number O
of O
ethidium B
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase O
( O
TdT O
) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O

Conversely O
, O
AMPK O
inhibitor O
compound B
C I
or O
GSK3 O
beta O
inhibitor O
SB216763 B
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O

Design O
, O
synthesis O
, O
in O
vitro O
MAO O
- O
B O
inhibitory O
evaluation O
, O
and O
computational O
studies O
of O
some O
6 B
- I
nitrobenzothiazole I
- O
derived O
semicarbazones B
. O

A O
series O
of O
6 B
- I
nitrobenzothiazole I
- O
derived O
semicarbazones B
were O
designed O
, O
synthesized O
, O
and O
evaluated O
as O
inhibitors O
of O
the O
rat O
brain O
MAO O
- O
B O
isoenzyme O
. O

1 B
- I
[ I
( I
4 I
- I
Chlorophenyl I
) I
( I
phenyl I
) I
methylene I
] I
- I
4 I
- I
( I
6 I
- I
nitrobenzothiazol I
- I
2 I
- I
yl I
) I
semicarbazide I
emerged O
as O
the O
lead O
MAO O
- O
B O
inhibitor O
, O
with O
top O
ranking O
in O
both O
the O
experimental O
MAO O
- O
B O
assay O
( O
IC O
( O
50 O
) O
: O
0 O
. O
004 O
+ O
/ O
- O
0 O
. O
001 O
mu O
M O
) O
and O
in O
computational O
docking O
studies O
( O
K O
( O
i O
) O
: O
1 O
. O
08 O
mu O
M O
) O
. O

Interestingly O
, O
the O
6 B
- I
nitrobenzothiazole I
moiety O
is O
stabilized O
in O
the O
substrate O
cavity O
with O
the O
aryl O
or O
diaryl O
residues O
extending O
up O
into O
the O
entrance O
cavity O
of O
the O
active O
site O
. O

According O
to O
our O
results O
, O
docking O
experiments O
could O
be O
an O
interesting O
approach O
for O
predicting O
the O
activity O
and O
binding O
interactions O
of O
this O
class O
of O
semicarbazones B
against O
MAO O
- O
B O
. O

RbgA O
, O
unlike O
many O
members O
of O
the O
Ras O
superfamily O
of O
GTPases O
, O
lacks O
a O
defined O
catalytic O
residue O
for O
carrying O
out O
guanosine B
triphosphate I
( O
GTP O
) O
hydrolysis O
. O

Abstract O
Objective O
: O
To O
design O
and O
evaluate O
a O
novel O
pressure O
sensitive O
adhesive O
( O
PSA O
) O
patch O
containing O
traditional O
Chinese O
medicine O
( O
TCM O
) O
using O
styrene B
- I
isoprene I
- I
styrene I
( O
SIS B
) O
copolymer O
. O

The O
proportions O
of O
SIS B
copolymer O
, O
tackifying O
resin O
and O
plasticizer O
were O
selected O
as O
the O
independent O
variables O
while O
tack O
force O
, O
peel O
strength O
of O
the O
patch O
and O
skin O
penetrability O
of O
methyl B
salicylate I
were O
selected O
as O
the O
dependent O
variables O
. O

Results O
: O
The O
optimized O
patch O
, O
which O
comprised O
30 O
. O
0 O
% O
SIS B
copolymer O
, O
26 O
. O
6 O
% O
tackifying O
resin O
and O
43 O
. O
4 O
% O
plasticizer O
, O
was O
superior O
to O
commercial O
patch O
in O
skin O
permeation O
, O
pharmacological O
activities O
and O
skin O
biocompatibility O
. O

Conclusion O
: O
SIS B
copolymer O
was O
a O
suitable O
substitute O
to O
natural O
rubber O
in O
producing O
patches O
containing O
TCM O
formula O
. O

Metabolism O
of O
ABT B
- I
107 I
was O
investigated O
in O
in O
vitro O
hepatic O
systems O
, O
in O
rat O
and O
monkey O
receiving O
[ B
( I
14 I
) I
C I
] I
ABT I
- I
107 I
, O
and O
in O
vivo O
plasma O
in O
rat O
, O
dog O
, O
monkey O
and O
human O
. O

In O
in O
vitro O
hepatic O
systems O
, O
ABT B
- I
107 I
was O
primarily O
cleared O
via O
oxidative O
metabolism O
, O
and O
proceeded O
via O
two O
parallel O
pathways O
. O

Pathway O
1 O
, O
ABT B
- I
107 I
was O
oxidized O
at O
the O
nitrogen O
of O
quinuclidine B
moiety O
to O
form O
M1 O
. O

ABT B
- I
107 I
was O
extensively O
metabolized O
in O
vivo O
in O
rat O
and O
monkey O
. O

Biotransformation O
of O
ABT B
- I
107 I
in O
human O
and O
monkey O
is O
markedly O
different O
from O
that O
in O
dog O
and O
rat O
, O
suggesting O
that O
monkey O
is O
an O
appropriate O
model O
for O
predicting O
human O
biotransformation O
and O
toxicology O
of O
ABT B
- I
107 I
. O

Unprecedented O
transformation O
of O
tetrathienoanthracen B
into O
pentacene B
on O
Ni B
( I
111 I
) I
. O

Our O
images O
reveal O
a O
sulfur O
abstraction O
and O
cyclization O
reaction O
that O
converts O
tetrathienoanthracen B
precursors O
into O
pentacene B
on O
the O
Ni B
( I
111 I
) I
surface O
. O

The O
macrocyclic O
peptide O
natural O
product O
CJ B
- I
15 I
, I
208 I
is O
orally O
active O
and O
prevents O
reinstatement O
of O
extinguished O
cocaine O
- O
seeking O
behavior O
. O

The O
macrocyclic B
tetrapeptide I
natural O
product O
CJ B
- I
15 I
, I
208 I
( O
cyclo B
[ I
Phe I
- I
d I
- I
Pro I
- I
Phe I
- I
Trp I
] I
) O
exhibited O
both O
dose O
- O
dependent O
antinociception O
and O
kappa O
opioid O
receptor O
( O
KOR O
) O
antagonist O
activity O
after O
oral O
administration O
. O

CJ B
- I
15 I
, I
208 I
antagonized O
a O
centrally O
administered O
KOR O
selective O
agonist O
, O
providing O
strong O
evidence O
it O
crosses O
the O
blood O
- O
brain O
barrier O
to O
reach O
KOR O
in O
the O
CNS O
. O

Orally O
administered O
CJ B
- I
15 I
, I
208 I
also O
prevented O
both O
cocaine O
- O
and O
stress O
- O
induced O
reinstatement O
of O
extinguished O
cocaine O
- O
seeking O
behavior O
in O
the O
conditioned O
place O
preference O
assay O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
. O

Thus O
, O
CJ B
- I
15 I
, I
208 I
is O
a O
promising O
lead O
compound O
with O
a O
unique O
activity O
profile O
for O
potential O
development O
, O
particularly O
as O
a O
therapeutic O
to O
prevent O
relapse O
to O
drug O
- O
seeking O
behavior O
in O
abstinent O
subjects O
. O

In O
incision O
wound O
model O
, O
wound O
granulation O
tissues O
were O
removed O
on O
8th O
post O
- O
wounding O
day O
, O
and O
the O
hydroxyproline O
, O
hexosamine B
, O
total O
protein O
, O
and O
DNA O
contents O
were O
determined O
. O

In O
STZ O
diabetic O
rats O
, O
topical O
and O
oral O
applications O
of O
embelin O
showed O
an O
increase O
in O
hydroxyproline O
, O
hexosamine B
, O
total O
protein O
, O
and O
DNA O
contents O
. O

Jatropholane B
- O
type O
diterpenes O
from O
Euphorbia O
sikkimensis O
. O

Four O
new O
jatropholane B
- O
type O
diterpenes O
( O
1 O
- O
4 O
) O
, O
named O
sikkimenoids B
A I
- I
D I
, O
were O
isolated O
from O
the O
aerial O
parts O
of O
Euphorbia O
sikkimensis O
. O

Semi O
- O
Synthetic O
Mithramycin B
SA I
Derivatives O
with O
Improved O
AntiCancer O
Activity O
. O

Mithramycin B
( O
MTM O
) O
is O
a O
potent O
anti O
- O
cancer O
agent O
that O
has O
recently O
garnered O
renewed O
attention O
. O

This O
manuscript O
describes O
the O
design O
and O
development O
of O
mithramycin B
derivatives O
through O
a O
combinational O
approach O
of O
biosynthetic O
analogue O
generation O
followed O
by O
synthetic O
manipulation O
for O
further O
derivatization O
. O

Mithramycin B
SA I
is O
a O
previously O
discovered O
analogue O
produced O
by O
the O
M7W1 O
mutant O
strain O
alongside O
the O
improved O
mithramycin B
analogues O
mithramycin B
SK I
and O
mithramycin B
SDK I
. O

Mithramycin B
SA I
shows O
decreased O
anti O
- O
cancer O
activity O
compared O
to O
mithramycin B
and O
has O
a O
shorter O
, O
two O
carbon O
aglycon O
side O
chain O
that O
is O
terminated O
in O
a O
carboxylic O
acid O
. O

The O
aglycon O
side O
chain O
is O
responsible O
for O
an O
interaction O
with O
the O
DNA O
- O
phosphate O
backbone O
as O
mithramycin B
interacts O
with O
its O
target O
DNA O
. O

This O
side O
chain O
was O
modified O
with O
a O
variety O
of O
molecules O
increasing O
the O
anti O
- O
cancer O
activity O
to O
a O
comparable O
level O
to O
mithramycin B
SK I
. O

This O
work O
shows O
the O
ability O
to O
transform O
the O
previously O
useless O
mithramycin B
SA I
into O
a O
valuable O
molecule O
and O
opens O
the O
door O
to O
further O
functionalization O
and O
semi O
- O
synthetic O
modification O
for O
the O
development O
of O
molecules O
with O
increased O
specificity O
and O
/ O
or O
drug O
formulation O
. O

Oxytocin O
( O
1 O
mu O
g O
/ O
0 O
. O
2 O
mu O
l O
) O
, O
vasotocin B
, O
an O
oxytocin O
antagonist O
( O
1 O
mu O
g O
/ O
0 O
. O
2 O
mu O
l O
) O
or O
vehicle O
was O
injected O
into O
the O
CeA O
20 O
min O
before O
the O
BVE O
. O

Vasotocin B
reduced O
sodium O
, O
urine O
output O
and O
ANP O
levels O
, O
although O
no O
changes O
were O
observed O
in O
plasma O
AVP O
and O
OT O
levels O
or O
in O
the O
expression O
of O
the O
AVP O
and O
OT O
genes O
in O
both O
hypothalamic O
nuclei O
. O

Mineralocorticoid O
receptor O
antagonists O
( O
MRAs O
) O
, O
such O
as O
spironolactone O
and O
eplerenone B
, O
prevent O
some O
of O
these O
maladaptive O
effects O
on O
the O
cardiovascular O
system O
and O
have O
proven O
to O
be O
a O
highly O
efficacious O
pharmacological O
therapy O
. O

Nitric O
oxide O
generated O
by O
the O
compound O
RuBPY B
promotes O
the O
vascular O
smooth O
cell O
membrane O
hyperpolarization O
. O

The O
cis B
- I
[ I
Ru I
( I
bpy I
) I
( I
2 I
) I
( I
py I
) I
NO I
( I
2 I
) I
] I
( I
PF I
( I
6 I
) I
) I
specie O
( O
RuBPY B
) O
has O
been O
used O
as O
nitric O
oxide O
( O
NO O
) O
delivery O
agent O
. O

This O
study O
aimed O
to O
evaluate O
the O
NO O
specie O
generated O
by O
RuBPY B
as O
compared O
to O
NO O
released O
from O
sodium O
nitroprusside O
( O
SNP O
) O
and O
to O
study O
the O
cellular O
mechanisms O
specially O
focusing O
the O
activation O
of O
soluble O
guanylyl B
- O
cyclase O
( O
sGC O
) O
, O
K O
( O
+ O
) O
channels O
and O
the O
cell O
membrane O
hyperpolarization O
, O
which O
are O
the O
main O
targets O
for O
NO O
- O
inducing O
vascular O
relaxation O
. O

NO O
generated O
by O
RuBPY B
and O
the O
vascular O
smooth O
muscle O
cell O
( O
VSMC O
) O
membrane O
potential O
were O
measured O
by O
confocal O
microscopy O
. O

NO O
released O
from O
RuBPY B
was O
higher O
than O
NO O
released O
from O
SNP O
. O

RuBPY B
released O
only O
radicalar B
NO I
( O
0 O
) O
and O
SNP O
released O
both O
NO O
( O
- O
) O
and O
NO O
( O
0 O
) O
. O

The O
concentration O
- O
effect O
curves O
for O
RuBPY B
- O
induced O
relaxation O
was O
shifted O
to O
the O
right O
by O
inhibition O
of O
sGC O
with O
ODQ O
and O
by O
the O
non O
- O
selective O
blockade O
of O
K O
( O
+ O
) O
channels O
with O
TEA O
. O

The O
simultaneous O
combination O
of O
ODQ O
and O
TEA O
abolished O
the O
vasorelaxation O
induced O
by O
RuBPY B
. O

The O
membrane O
potential O
measured O
by O
the O
sensitive O
dye O
4 B
- I
Di I
- I
ANNEPS I
demonstrated O
that O
RuBPY B
induces O
cell O
membrane O
hyperpolarization O
. O

Taken O
together O
, O
our O
results O
indicate O
that O
the O
large O
amount O
of O
NO O
( O
0 O
) O
specie O
generated O
by O
RuBPY B
induces O
vasorelaxation O
due O
to O
activation O
of O
sGC O
, O
K O
( O
+ O
) O
channels O
sensitive O
to O
TEA O
, O
and O
cell O
membrane O
hyperpolarization O
. O

These O
results O
indicate O
that O
NO O
( O
0 O
) O
generated O
from O
RuBPY B
can O
also O
directly O
activate O
the O
K O
( O
+ O
) O
channels O
in O
an O
independent O
way O
of O
sGC O
. O

Cryptotanshinone O
and O
dihydrotanshinone B
I I
exhibit O
strong O
inhibition O
towards O
human O
liver O
microsome O
( O
HLM O
) O
- O
catalyzed O
propofol O
glucuronidation O
. O

Therefore O
, O
the O
aim O
of O
the O
present O
study O
is O
to O
investigate O
the O
inhibitory O
situation O
of O
cryptotanshinone O
and O
dihydrotanshinone B
I I
towards O
UGT O
enzyme O
- O
catalyzed O
propofol O
glucuronidation O
. O

In O
vitro O
the O
human O
liver O
microsome O
( O
HLM O
) O
incubation O
system O
was O
used O
, O
and O
the O
results O
showed O
that O
cryptotanshinone O
and O
dihydrotanshinone B
I I
exhibited O
dose O
- O
dependent O
inhibition O
towards O
HLM O
- O
catalyzed O
propofol O
glucuronidation O
. O

Dixon O
plot O
and O
Lineweaver O
- O
Burk O
plot O
showed O
that O
the O
inhibition O
type O
was O
best O
fit O
to O
competitive O
inhibition O
type O
for O
both O
cryptotanshinone O
and O
dihydrotanshinone B
I I
. O

The O
second O
plot O
using O
the O
slopes O
from O
the O
Lineweaver O
- O
Burk O
plot O
versus O
the O
concentrations O
of O
cryptotanshinone O
or O
dihydrotanshinone B
I I
was O
employed O
to O
calculate O
the O
inhibition O
parameters O
( O
Ki O
) O
to O
be O
0 O
. O
4 O
and O
1 O
. O
7 O
mu O
M O
, O
respectively O
. O

Using O
the O
reported O
maximum O
plasma O
concentration O
( O
Cmax O
) O
, O
the O
altered O
in O
vivo O
exposure O
of O
propofol O
increased O
by O
10 O
% O
and O
8 O
. O
2 O
% O
for O
the O
co O
- O
administration O
of O
dihydrotanshinone B
I I
and O
cryptotanshinone O
, O
respectively O
. O

All O
these O
results O
indicated O
the O
possible O
danshen O
- O
propofol O
interaction O
due O
to O
the O
inhibition O
of O
dihydrotanshinone B
I I
and O
cryptotanshinone O
towards O
the O
glucuronidation O
reaction O
of O
propofol O
. O

Investigations O
of O
dipeptide O
structures O
containing O
pyrrolysine B
as O
N O
- O
terminal O
residues O
: O
a O
DFT O
study O
in O
gas O
and O
aqueous O
phase O
. O

A O
set O
of O
six O
dipeptides O
containing O
pyrrolysine B
invariably O
at O
their O
N O
- O
terminal O
positions O
is O
studied O
in O
gas O
and O
aqueous O
phase O
using O
a O
polarizable O
continuum O
model O
( O
PCM O
) O
. O

The O
presence O
or O
absence O
of O
three O
types O
of O
intramolecular O
H O
- O
bonds O
, O
namely O
O O
. O
. O
. O
H B
- I
N I
, O
N O
. O
. O
. O
H B
- I
N I
and O
O O
. O
. O
. O
H B
- I
C I
that O
leave O
noticeable O
signatures O
in O
the O
IR O
spectra O
, O
play O
crucial O
roles O
in O
influencing O
the O
geometry O
of O
the O
peptide O
planes O
and O
in O
determining O
the O
energetics O
of O
the O
dipeptides O
. O

Each O
was O
up O
- O
regulated O
at O
a O
different O
time O
following O
stimulation O
of O
the O
pepper O
leaves O
by O
Phytophthora O
capcisi O
and O
abiotic O
stresses O
including O
salicylic O
acid O
, O
methyl B
jasmonate I
, O
abscisic B
acid I
, O
wounding O
and O
cold O
treatment O
. O

The O
osteoblast O
cells O
( O
hFOB1 O
. O
19 O
) O
were O
cultured O
in O
a O
medium O
supplemented O
with O
different O
concentrations O
( O
50 O
, O
100 O
, O
and O
200 O
mu O
M O
) O
of O
ferric B
ammonium I
citrate I
as O
a O
donor O
of O
ferric O
ion O
. O

Reactive O
oxygen O
species O
( O
ROS O
) O
were O
detected O
by O
2 B
, I
7 I
- I
dichlorofluorescin I
diacetate I
fluorophotometry O
. O

Room O
- O
temperature O
ferromagnetism O
in O
ZnO O
- O
encapsulated O
1 O
. O
9 O
nm O
FePt3 B
nanoparticle O
- O
composite O
thin O
films O
with O
giant O
interfacial O
anisotropy O
. O

As O
synthesized O
1 O
. O
9 O
- O
nm O
FePt3 B
nanoparticles O
are O
superparamagnetic O
at O
room O
temperature O
. O

Studies O
of O
enantiomeric O
degradation O
of O
the O
triazole O
fungicide O
hexaconazole B
in O
tomato O
, O
cucumber O
, O
and O
field O
soil O
by O
chiral O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
. O

Hexaconazole B
is O
a O
chiral O
fungicide O
used O
on O
a O
variety O
of O
crops O
for O
the O
control O
of O
many O
fungal O
diseases O
. O

In O
this O
study O
, O
a O
sensitive O
and O
convenient O
chiral O
liquid O
chromatography O
coupled O
with O
tandem O
mass O
spectrometry O
( O
LC O
- O
MS O
/ O
MS O
) O
method O
was O
developed O
and O
validated O
for O
measuring O
hexaconazole B
enantiomers O
in O
tomato O
, O
cucumber O
, O
and O
soil O
. O

Then O
the O
proposed O
method O
was O
successfully O
applied O
to O
investigate O
the O
possible O
enantioselective O
degradation O
of O
rac B
- I
hexaconazole I
in O
plants O
( O
tomato O
and O
cucumber O
) O
and O
soil O
under O
field O
conditions O
. O

The O
degradation O
of O
the O
two O
enantiomers O
of O
hexaconazole B
proved O
to O
be O
enantioselective O
and O
dependent O
on O
the O
media O
: O
The O
( O
+ O
) O
- O
enantiomer O
showed O
a O
faster O
degradation O
in O
plants O
, O
while O
the O
( O
- O
) O
- O
enantiomer O
dissipated O
faster O
than O
the O
( O
+ O
) O
- O
form O
in O
field O
soil O
, O
resulting O
in O
relative O
enrichment O
of O
the O
opposite O
enantiomer O
. O

The O
results O
of O
this O
work O
demonstrate O
that O
both O
the O
environmental O
media O
and O
environmental O
conditions O
influenced O
the O
direction O
and O
rate O
of O
enantioselective O
degradation O
of O
hexaconazole B
. O

Electron O
transfer O
dissociation O
( O
ETD O
) O
: O
the O
mass O
spectrometric O
breakthrough O
essential O
for O
O B
- I
GlcNAc I
protein O
site O
assignments O
- O
a O
study O
of O
the O
O O
- O
GlcNAcylated O
protein O
host O
cell O
factor O
C1 O
. O

The O
field O
of O
intracellular O
O B
- I
GlcNAc I
( O
O O
- O
linked O
N O
- O
acetylglucosamine O
) O
signaling O
has O
especially O
advanced O
with O
the O
advent O
of O
ETD O
MS O
. O

Only O
within O
the O
last O
five O
years O
have O
proteomic O
- O
scale O
experiments O
utilizing O
ETD O
allowed O
the O
assignment O
of O
hundreds O
of O
O B
- I
GlcNAc I
sites O
within O
cells O
and O
subcellular O
structures O
. O

Our O
ability O
to O
identify O
and O
unambiguously O
assign O
the O
site O
of O
O B
- I
GlcNAc I
modifications O
using O
ETD O
is O
rapidly O
increasing O
our O
understanding O
of O
this O
regulatory O
glycosylation O
and O
its O
potential O
interaction O
with O
other O
PTMs O
. O

HCF O
- O
1 O
is O
a O
transcriptional O
coregulator O
that O
forms O
a O
stable O
complex O
with O
O B
- I
GlcNAc I
transferase O
and O
controls O
cell O
cycle O
progression O
. O

Comparison O
of O
the O
behavior O
of O
ZnPd B
near O
- O
surface O
intermetallic O
phases O
, O
unsupported O
intermetallic O
ZnPd B
and O
supported O
ZnPd B
/ O
ZnO O
catalysts O
reveals O
that O
formaldehyde O
is O
formed O
from O
methanol O
in O
parallel O
with O
CO O
( O
2 O
) O
on O
the O
former O
, O
while O
on O
unsupported O
intermetallic O
ZnPd B
and O
ZnO O
- O
supported O
ZnPd B
, O
it O
is O
efficiently O
reacted O
toward O
CO O
( O
2 O
) O
, O
thus O
, O
a O
beneficial O
role O
of O
ZnO O
in O
oxidizing O
formaldehyde O
- O
derived O
intermediates O
toward O

A O
new O
aliphatic O
enone O
, O
( B
17Z I
, I
20Z I
) I
- I
hexacosa I
- I
17 I
, I
20 I
- I
dien I
- I
9 I
- I
one I
( O
3 O
) O
, O
and O
one O
new O
bisindole B
alkaloid I
, O
gangenoid B
( O
6 O
) O
, O
together O
with O
seven O
known O
compounds O
were O
isolated O
from O
the O
roots O
and O
aerial O
parts O
of O
Desmodium O
gangeticum O
( O
family O
: O
Leguminosae O
) O
. O

High O
- O
resolution O
real O
- O
space O
mapping O
of O
Li O
- O
ion O
diffusion O
in O
the O
LiNi B
( I
1 I
/ I
3 I
) I
Co I
( I
1 I
/ I
3 I
) I
Mn I
( I
1 I
/ I
3 I
) I
O I
2 I
cathode O
within O
an O
all O
- O
solid O
- O
state O
thin O
film O
Li O
- O
ion O
battery O
has O
been O
conducted O
using O
advanced O
scanning O
probe O
microscopy O
techniques O
, O
namely O
, O
band O
excitation O
electrochemical O
strain O
microscopy O
( O
BE O
- O
ESM O
) O
and O
conductive O
atomic O
force O
microscopy O
. O

In O
addition O
, O
local O
variations O
of O
the O
electrochemical O
response O
in O
the O
LiNi B
( I
1 I
/ I
3 I
) I
Co I
( I
1 I
/ I
3 I
) I
Mn I
( I
1 I
/ I
3 I
) I
O I
2 I
thin O
film O
cathode O
at O
different O
cycling O
stages O
have O
been O
investigated O
. O

Inorganic O
polyphosphates O
are O
chains O
of O
orthophosphates B
linked O
by O
phosphoanhydride B
bonds O
that O
can O
be O
up O
to O
hundreds O
of O
orthophosphates B
in O
length O
. O

Here O
we O
demonstrate O
in O
osteoblast O
cultures O
producing O
an O
abundant O
collagenous O
matrix O
that O
normally O
show O
robust O
mineralization O
, O
that O
two O
polyphosphates O
( O
PolyP5 B
and O
PolyP65 B
, O
polyphosphates O
of O
5 O
and O
65 O
phosphate O
residues O
in O
length O
) O
are O
potent O
mineralization O
inhibitors O
. O

Twelve O
- O
day O
MC3T3 O
- O
E1 O
osteoblast O
cultures O
with O
added O
ascorbic O
acid O
( O
for O
collagen O
matrix O
assembly O
) O
and O
beta B
- I
glycerophosphate I
( O
a O
source O
of O
phosphate O
for O
mineralization O
) O
were O
treated O
with O
either O
PolyP5 B
or O
PolyP65 B
. O

This O
was O
confirmed O
by O
showing O
that O
PolyP5 B
and O
PolyP65 B
bound O
to O
synthetic O
hydroxyapatite O
in O
a O
concentration O
- O
dependent O
manner O
. O

Tissue O
- O
nonspecific O
alkaline O
phosphatase O
( O
TNAP O
, O
ALPL O
) O
efficiently O
hydrolyzed O
the O
two O
PolyPs B
as O
measured O
by O
Pi O
release O
. O

Importantly O
, O
at O
the O
concentrations O
of O
polyphosphates O
used O
in O
this O
study O
which O
inhibited O
bone O
cell O
culture O
mineralization O
, O
the O
polyphosphates O
competitively O
saturated O
TNAP O
, O
thus O
potentially O
interfering O
with O
its O
ability O
to O
hydrolyze O
mineralization O
- O
inhibiting O
pyrophosphate O
( O
PPi B
) O
and O
mineralizing O
- O
promoting O
beta B
- I
glycerophosphate I
( O
in O
cell O
culture O
) O
. O

Anti O
- O
obesity O
effects O
of O
3 B
- I
hydroxychromone I
derivative O
, O
a O
novel O
small O
- O
molecule O
inhibitor O
of O
glycogen O
synthase O
kinase O
- O
3 O
. O

Compound O
1a O
, O
a O
structure O
based O
on O
3 B
- I
hydroxychromone I
bearing O
isothiazolidine B
- I
1 I
, I
1 I
- I
dione I
, O
was O
identified O
from O
chemical O
library O
as O
a O
highly O
potent O
GSK O
- O
3 O
inhibitor O
. O

Stabilization O
of O
glycogen O
synthase O
and O
beta O
- O
catenin O
, O
which O
are O
direct O
targets O
of O
GSK O
- O
3 O
, O
by O
compound O
1a O
was O
assessed O
in O
comparison O
with O
two O
other O
GSK O
- O
3 O
inhibitors O
: O
LiCl O
and O
SB B
- I
415286 I
. O

Polyoxometalate B
- O
biomolecule O
conjugates O
: O
a O
new O
approach O
to O
create O
hybrid O
drugs O
for O
cancer O
therapeutics O
. O

Some O
polyoxometalate B
( O
POM B
) O
clusters O
have O
demonstrated O
attractive O
anticancer O
properties O
. O

At O
first O
, O
the O
POM B
cluster O
bioconjugates O
were O
created O
by O
attaching O
the O
bioactive O
ligands O
on O
an O
amine O
grafted O
POM O
via O
simple O
amidation O
reaction O
. O

The O
cytotoxicity O
study O
with O
breast O
cancer O
cells O
( O
MCF O
- O
7 O
and O
MDA O
- O
MB O
- O
231 O
) O
and O
non O
- O
cancerous O
breast O
epithelial O
cell O
( O
MCF O
- O
10A O
) O
showed O
that O
rationally O
selected O
ligands O
with O
cancer O
- O
cell O
targeting O
ability O
on O
POM B
- O
biomolecule O
conjugates O
can O
impart O
enhanced O
anti O
- O
tumor O
activity O
and O
selectivity O
, O
thus O
representing O
a O
new O
concept O
to O
develop O
novel O
POM B
- O
biomolecule O
hybrid O
drugs O
with O
the O
potential O
synergistic O
effect O
: O
increased O
bioactivity O
and O
lower O
side O
effect O
. O

Novel O
naphthoquinone B
derivatives O
: O
synthesis O
and O
activity O
against O
human O
African O
trypanosomiasis O
. O

A O
series O
of O
naphthoquinone B
derivatives O
has O
been O
synthesized O
and O
tested O
for O
its O
biological O
activity O
against O
human O
African O
trypanosomiasis O
. O

The O
use O
of O
reverse O
micellar O
medium O
not O
only O
enhanced O
the O
conversion O
rate O
, O
but O
also O
showed O
selectivity O
towards O
mono O
- O
coupled O
product O
in O
aryl B
chloride I
- O
aniline O
coupling O
reactions O
. O

Two O
derivatives O
of O
naphthoquinone B
( O
9b O
and O
9c O
) O
exhibited O
potent O
activity O
against O
Trypanosoma O
brucei O
in O
vitro O
with O
low O
cytotoxicity O
. O

3H B
- I
1 I
, I
2 I
, I
4 I
- I
Dithiazol I
- I
3 I
- I
one I
compounds O
as O
novel O
potential O
affordable O
antitubercular O
agents O
. O

Small O
molecules O
with O
oxathiazol B
- I
2 I
- I
one I
moiety O
were O
recently O
reported O
as O
potent O
inhibitors O
of O
Mycobacterium O
bovis O
var O
. O
bacilli O
Calmette O
- O
Gu O
e O
rin O
( O
BCG O
) O
, O
among O
which O
HT1171 B
was O
the O
most O
potent O
and O
selective O
proteasome O
inhibitor O
. O

Herein O
we O
synthesized O
a O
series O
of O
novel O
compounds O
by O
bioisosteric O
replacement O
of O
the O
oxathiazol B
- I
2 I
- I
one I
ring O
with O
3H B
- I
1 I
, I
2 I
, I
4 I
- I
dithiazol I
- I
3 I
- I
one I
, O
and O
also O
fifteen O
1 B
, I
3 I
, I
4 I
- I
oxathiazol I
- I
2 I
- I
one I
molecules O
in O
order O
for O
potency O
comparison O
and O
structure O
- O
activity O
relationship O
elucidation O
since O
their O
antibacterial O
effects O
on O
the O
virulent O
strains O
were O
not O
evaluated O
before O
. O

Among O
the O
tested O
compounds O
, O
3H B
- I
1 I
, I
2 I
, I
4 I
- I
dithiazol I
- I
3 I
- I
one I
compound O
4n O
was O
found O
to O
be O
the O
most O
active O
with O
a O
lowest O
MIC O
( O
90 O
) O
value O
of O
1 O
mu O
g O
/ O
mL O
. O

Compound O
4n O
displayed O
a O
lower O
inhibitory O
ratio O
than O
HT1171 B
at O
the O
concentration O
of O
100 O
mu O
M O
, O
indicating O
its O
better O
safety O
profile O
. O

Cells O
were O
exposed O
for O
24h O
to O
various O
concentrations O
( O
from O
0 O
. O
1 O
pM O
to O
1 O
mM O
) O
of O
atrazine O
( O
ATR O
) O
, O
diethylstilbestrol O
( O
DES O
) O
, O
para B
- I
nonylphenol I
( O
p B
- I
NP I
) O
, O
resveratrol O
( O
RES O
) O
and O
17 O
beta O
- O
estradiol O
( O
E2 O
) O
and O
assayed O
for O
cell O
viability O
and O
human O
beta O
- O
Chorionic O
Gonadotropin O
( O
beta O
- O
hCG O
) O
secretion O
. O

beta O
- O
hCG O
release O
was O
also O
unexpectedly O
inhibited O
by O
ATR O
, O
DES O
, O
p B
- I
NP I
and O
RES O
at O
non O
- O
toxic O
( O
pM O
- O
nM O
) O
concentrations O
. O

Electronic O
and O
EPR O
spectra O
of O
the O
species O
involved O
in O
[ B
W10O32 I
] I
4 I
- I
photocatalysis O
. O

The O
decatungstate O
anion O
[ B
W I
( I
10 I
) I
O I
( I
32 I
) I
] I
( I
4 I
- I
) I
is O
widely O
used O
as O
a O
photocatalyst O
in O
different O
transformations O
, O
during O
which O
it O
undergoes O
one O
- O
electron O
reduction O
to O
[ B
W I
( I
10 I
) I
O I
( I
32 I
) I
] I
( I
5 I
- I
) I
, O
possibly O
protonated O
; O
the O
bi O
- O
reduced O
species O
[ B
W I
( I
10 I
) I
O I
( I
32 I
) I
] I
( I
6 I
- I
) I
is O
obtained O
by O
ensuing O
disproportionation O
. O

This O
article O
reviews O
pharmacological O
, O
therapeutic O
efficacy O
and O
tolerability O
data O
relevant O
to O
the O
utilization O
of O
subcutaneous O
bortezomib O
( O
Velcade B
( O
( O
R O
) O
) O
) O
in O
the O
treatment O
of O
patients O
with O
multiple O
myeloma O
. O

Structure O
prediction O
of O
binary O
pernitride B
MN2 B
compounds O
( O
M O
= O
Ca O
, O
Sr O
, O
Ba B
, O
La O
, O
and O
Ti O
) O
. O

Metal B
- I
pernitride I
compounds O
belong O
to O
a O
class O
of O
chemical O
systems O
in O
which O
both O
the O
complex O
ions O
and O
the O
non O
- O
bonding O
electrons O
may O
play O
roles O
in O
the O
formation O
of O
their O
modified O
crystalline O
structures O
. O

To O
investigate O
this O
issue O
, O
the O
energy O
landscapes O
of O
pernitrides B
of O
metals O
with O
different O
maximum O
valence O
( O
M O
= O
Ca O
, O
Sr O
, O
Ba B
, O
La O
, O
and O
Ti O
) O
were O
globally O
explored O
on O
the O
ab O
initio O
level O
at O
standard O
and O
high O
pressures O
, O
thereby O
yielding O
possible O
( O
meta O
) O
stable O
modifications O
in O
these O
systems O
together O
with O
information O
on O
how O
the O
landscape O
changed O
as O
function O
of O
the O
valence O
of O
the O
metal O
cation O
. O

In O
particular O
, O
TiN2 B
should O
crystallize O
in O
a O
new O
structure O
type O
, O
TiN2 B
- O
I O
. O

Inhibition O
pathways O
of O
the O
potent O
organophosphate O
CBDP B
with O
cholinesterases O
revealed O
by O
X O
- O
ray O
crystallographic O
snapshots O
and O
mass O
spectrometry O
. O

Tri B
- I
o I
- I
cresyl I
- I
phosphate I
( O
TOCP B
) O
is O
a O
common O
additive O
in O
jet O
engine O
lubricants O
and O
hydraulic O
fluids O
suspected O
to O
have O
a O
role O
in O
aerotoxic O
syndrome O
in O
humans O
. O

TOCP B
is O
metabolized O
to O
cresyl B
saligenin I
phosphate I
( O
CBDP B
) O
, O
a O
potent O
irreversible O
inhibitor O
of O
butyrylcholinesteras O
( O
BChE O
) O
, O
a O
natural O
bioscavenger O
present O
in O
the O
bloodstream O
, O
and O
acetylcholinesterase O
( O
AChE O
) O
, O
the O
off O
- O
switch O
at O
cholinergic O
synapses O
. O

Also O
, O
the O
inhibition O
of O
AChE O
by O
CBDP B
is O
unexpected O
, O
from O
a O
structural O
standpoint O
, O
i O
. O
e O
. O
, O
considering O
the O
narrowness O
of O
AChE O
active O
site O
and O
the O
bulkiness O
of O
CBDP B
. O

In O
the O
following O
, O
we O
report O
on O
kinetic O
X O
- O
ray O
crystallography O
experiments O
that O
provided O
2 O
. O
7 O
- O
3 O
. O
3 O
A O
snapshots O
of O
the O
reaction O
of O
CBDP B
with O
mouse O
AChE O
and O
human O
BChE O
. O

The O
series O
of O
crystallographic O
snapshots O
reveals O
that O
AChE O
and O
BChE O
react O
with O
the O
opposite O
enantiomers O
and O
that O
an O
induced O
- O
fit O
rearrangement O
of O
Phe297 B
enlarges O
the O
active O
site O
of O
AChE O
upon O
CBDP B
binding O
. O

Mass O
spectrometry O
analysis O
of O
aging O
in O
either O
H B
( I
2 I
) I
( I
16 I
) I
O I
or O
H B
( I
2 I
) I
( I
18 I
) I
O I
furthermore O
allowed O
us O
to O
identify O
the O
inhibition O
steps O
, O
in O
which O
water O
molecules O
are O
involved O
, O
thus O
providing O
insights O
into O
the O
mechanistic O
details O
of O
inhibition O
. O

Our O
study O
thus O
shows O
that O
only O
prophylactic O
and O
symptomatic O
treatments O
are O
viable O
to O
counter O
the O
inhibition O
of O
AChE O
and O
BChE O
by O
CBDP B
. O

We O
use O
an O
electrochemical O
approach O
involving O
phenyl B
- I
diazonium I
salts I
to O
systematically O
probe O
electronic O
modification O
in O
MLG O
and O
BLG O
with O
increasing O
functionalization O
for O
the O
first O
time O
, O
obtaining O
the O
highest O
conversion O
values O
to O
date O
. O

5 B
- I
( I
( I
1 I
- I
Aroyl I
- I
1H I
- I
indol I
- I
3 I
- I
yl I
) I
methylene I
) I
- I
2 I
- I
thioxodihydropyrimid I
- I
4 I
, I
6 I
( I
1H I
, I
5H I
) I
- I
diones I
as O
potential O
anticancer O
agents O
with O
anti O
- O
inflammatory O
properties O
. O

A O
series O
of O
novel O
5 B
- I
( I
( I
1 I
- I
aroyl I
- I
1H I
- I
indol I
- I
3 I
- I
yl I
) I
methylene I
) I
- I
2 I
- I
thioxodihydropyrimid I
- I
4 I
, I
6 I
( I
1H I
, I
5H I
) I
- I
diones I
( O
3a O
- O
z O
) O
have O
been O
evaluated O
for O
in O
vitro O
cytotoxicity O
against O
a O
panel O
of O
60 O
human O
tumor O
cell O
lines O
. O

Impact O
of O
cooking O
and O
handling O
conditions O
on O
furanic B
compounds O
in O
breaded O
fish O
products O
. O

This O
study O
evaluates O
the O
influence O
of O
cooking O
and O
handling O
conditions O
on O
the O
quantity O
of O
furanic B
compounds O
( O
furan O
, O
2 B
- I
furfural I
, O
furfuryl O
alcohol O
, O
2 B
- I
pentylfuran I
, O
5 O
- O
hydroxymethylfurfura O
) O
in O
breaded O
fish O
products O
. O

Oven O
- O
baking O
and O
reheating O
in O
the O
microwave O
lead O
to O
low O
furanic B
compounds O
formation O
in O
comparison O
with O
deep O
- O
frying O
. O

The O
use O
of O
olive O
oil O
for O
deep O
- O
frying O
promoted O
higher O
levels O
of O
furanic B
compounds O
than O
sunflower O
oil O
. O

Thus O
, O
the O
generation O
of O
furanic B
compounds O
can O
be O
minimized O
by O
adjusting O
the O
cooking O
method O
and O
conditions O
, O
such O
as O
using O
an O
electric O
oven O
, O
deep O
- O
frying O
in O
sunflower O
oil O
at O
160 O
degrees O
C O
during O
4min O
, O
or O
waiting O
10min O
after O
cooking O
. O

However O
, O
these O
conditions O
that O
reduce O
furanic B
compounds O
levels O
also O
reduce O
the O
content O
of O
volatile O
compounds O
related O
to O
the O
aroma O
and O
flavour O
of O
fried O
foods O
. O

In O
this O
sense O
, O
new O
efforts O
should O
be O
done O
to O
reduce O
the O
formation O
of O
furanic B
compounds O
without O
being O
detrimental O
to O
the O
volatile O
profile O
. O

The O
endocrine O
disrupting O
chemical O
tolylfluanid B
alters O
adipocyte O
metabolism O
via O
glucocorticoid O
receptor O
activation O
. O

Previous O
studies O
have O
shown O
that O
the O
phenylsulfamide B
fungicide O
tolylfluanid B
( O
TF O
) O
augments O
glucocorticoid O
receptor O
( O
GR O
) O
- O
dependent O
luciferase O
expression O
in O
3T3 O
- O
L1 O
preadipocytes O
while O
modulating O
insulin O
action O
in O
primary O
murine O
and O
human O
adipocytes O
. O

TF O
or O
Cort O
each O
increased O
insulin O
- O
stimulated O
lipogenesis O
, O
an O
effect O
resulting O
from O
increased O
lipogenic O
gene O
expression O
and O
enhanced O
insulin O
- O
stimulated O
dephosphorylation O
of O
acetyl B
- I
coenzyme I
A I
carboxylase O
. O

The O
increase O
in O
ROS O
formation O
and O
cell O
death O
was O
assayed O
using O
the O
fluorescent O
probe O
2 B
, I
7 I
- I
dichlorofluorescin I
diacetate I
( O
DCFH O
- O
DA O
) O
and O
the O
trypan O
blue O
exclusion O
assay O
. O

Cell O
death O
was O
induced O
at O
relatively O
low O
concentrations O
by O
perfluorooctyl B
sulfonate I
( O
PFOS O
) O
, O
perfluorooctane B
sulfonylamide I
( O
PFOSA B
) O
and O
the O
fluorotelomer B
alcohol I
1H B
, I
1H I
, I
2H I
, I
2H I
- I
perfluorodecanol I
( O
FTOH B
8 I
: I
2 I
) O
with O
EC O
( O
50 O
) O
- O
values O
of O
62 O
+ O
/ O
- O
7 O
. O
6 O
, O
13 O
+ O
/ O
- O
1 O
. O
8 O
and O
15 O
+ O
/ O
- O
4 O
. O
2 O
mu O
M O
( O
mean O
+ O
/ O
- O
SD O
) O
respectively O
. O

PFOS O
, O
perfluorooctanoic O
acid O
( O
PFOA O
) O
and O
PFOSA B
induced O
a O
concentration O
dependent O
increase O
in O
ROS O
formation O
with O
EC O
( O
50 O
) O
- O
values O
of O
27 O
+ O
/ O
- O
9 O
. O
0 O
, O
25 O
+ O
/ O
- O
11 O
and O
57 O
+ O
/ O
- O
19 O
mu O
M O
respectively O
. O

Geranylgeranylaceton B
( O
GGA B
) O
is O
an O
acyclic B
polyisoprenoid I
that O
induces O
expression O
of O
heat O
shock O
protein O
( O
HSP O
) O
70 O
, O
a O
soluble O
intracellular O
chaperone O
protein O
expressed O
in O
various O
tissues O
, O
protecting O
cells O
against O
stress O
conditions O
. O

C57 O
BL O
/ O
6 O
mice O
were O
divided O
into O
four O
groups O
, O
GGA B
- O
treated O
( O
500 O
mg O
/ O
kg O
/ O
mouse O
) O
and O
UVB O
- O
exposed O
( O
400 O
mJ O
/ O
cm2 O
) O
, O
GGA B
- O
untreated O
UVB O
- O
exposed O
( O
400 O
mJ O
/ O
cm2 O
) O
, O
GGA B
- O
treated O
( O
500 O
mg O
/ O
kg O
/ O
mouse O
) O
but O
not O
exposed O
and O
naive O
controls O
. O

Irradiated O
corneal O
epithelium O
was O
significantly O
thicker O
in O
the O
eyes O
of O
mice O
treated O
with O
GGA B
compared O
with O
those O
given O
the O
vehicle O
alone O
( O
p O
< O
0 O
. O
01 O
) O
. O

Significantly O
fewer O
TUNEL O
- O
positive O
cells O
were O
observed O
in O
the O
eyes O
of O
GGA B
- O
treated O
mice O
than O
controls O
after O
irradiation O
( O
p O
< O
0 O
. O
01 O
) O
. O

Corneal O
HSP70 O
levels O
were O
significantly O
elevated O
in O
corneas O
of O
mice O
treated O
with O
GGA B
( O
p O
< O
0 O
. O
05 O
) O
. O

ROS O
signal O
was O
not O
affected O
by O
GGA B
. O

NF O
- O
kappa O
B O
activation O
was O
reduced O
but O
phospho O
- O
( O
Ser O
/ O
Ther B
) O
Akt O
substrate O
expression O
was O
increased O
in O
corneas O
after O
irradiation O
when O
treated O
with O
GGA B
. O

GGA B
- O
treatment O
induced O
HSP70 O
expression O
and O
ameliorated O
UV O
- O
induced O
corneal O
damage O
through O
the O
reduced O
NF O
- O
kappa O
B O
activation O
and O
possibly O
increased O
Akt O
phosphorilation O
. O

NMR O
crystallography O
of O
alpha B
- I
poly I
( I
L I
- I
lactide I
) I
. O

A O
complementary O
approach O
that O
combines O
NMR O
measurements O
, O
analysis O
of O
X O
- O
ray O
and O
neutron O
powder O
diffraction O
data O
and O
advanced O
quantum O
mechanical O
calculations O
was O
employed O
to O
study O
the O
alpha O
- O
polymorph O
of O
L B
- I
polylactide I
. O

The O
GIPAW O
method O
was O
used O
to O
compute O
the O
NMR O
shielding O
parameters O
for O
the O
different O
models O
, O
which O
included O
the O
alpha B
- I
PLLA I
structure O
obtained O
by O
2 O
- O
dimensional O
wide O
- O
angle O
X O
- O
ray O
diffraction O
( O
WAXD O
) O
at O
- O
150 O
degrees O
C O
( O
model O
M1 O
) O
and O
at O
25 O
degrees O
C O
( O
model O
M2 O
) O
, O
neutron O
diffraction O
( O
WAND O
) O
measurements O
( O
model O
M3 O
) O
and O
the O
fully O
optimized O
geometry O
of O
the O
PLLA O
chains O
in O
the O
unit O
cell O
with O
defined O
size O
( O
model O
M4 O
) O
. O

Photoelectron O
imaging O
experiments O
and O
detailed O
calculations O
are O
conducted O
on O
Al B
( I
n I
) I
( I
- I
) I
clusters O
( O
n O
= O
3 O
- O
6 O
) O
and O
a O
calibration O
method O
is O
developed O
for O
connecting O
experimental O
observations O
of O
photoelectron O
angular O
distributions O
to O
theoretical O
predictions O
. O

The O
highest O
occupied O
molecular O
orbitals O
of O
these O
small O
aluminum O
clusters O
are O
found O
to O
contain O
varying O
degrees O
of O
s O
- O
p O
mixing O
, O
with O
Al O
( O
3 O
) O
( O
- O
) O
containing O
the O
" O
most O
hybridized O
" O
orbital O
and O
Al B
( I
4 I
) I
( I
- I
) I
containing O
the O
" O
least O
hybridized O
" O
orbital O
. O

We O
selected O
three O
structurally O
diverse O
pharmacologically O
active O
compounds O
( O
tamoxifen O
, O
reversine B
, O
and O
FK506 O
) O
as O
model O
baits O
. O

The O
role O
of O
silver O
and O
vanadium O
release O
in O
the O
toxicity O
of O
silver B
vanadate I
nanowires O
toward O
Daphnia O
similis O
. O

Recently O
, O
a O
new O
type O
of O
silver B
vanadate I
nanowire O
decorated O
with O
silver O
nanoparticles O
( O
SVSN O
- O
LQES1 O
) O
with O
promising O
antimicrobial O
activity O
against O
different O
pathogenic O
bacteria O
was O
described O
. O

Silver B
vanadate I
nanowires O
decorated O
with O
silver O
nanoparticles O
( O
SVSN O
- O
LQES1 O
) O
are O
acutely O
toxic O
to O
D O
. O
similis O
. O

The O
essential O
oils O
consisted O
mainly O
of O
monoterpenes B
, O
alpha O
- O
pinene O
( O
27 O
. O
4 O
- O
59 O
. O
2 O
% O
) O
and O
1 B
, I
8 I
- I
cineole I
( O
6 O
. O
1 O
- O
34 O
. O
3 O
% O
) O
being O
the O
major O
components O
. O

They O
were O
also O
characterized O
by O
the O
absence O
of O
myrtenyl B
acetate I
. O

Groups O
I O
( O
78 O
% O
of O
the O
samples O
) O
and O
II O
were O
differentiated O
on O
the O
basis O
of O
the O
contents O
of O
alpha O
- O
pinene O
, O
linalool O
, O
and O
linalyl B
acetate I
. O

Subgroups O
IA O
and O
IB O
could O
be O
distinguished O
by O
their O
contents O
of O
alpha O
- O
pinene O
and O
1 B
, I
8 I
- I
cineole I
. O

Subgroups O
IIA O
and O
IIB O
differed O
substantially O
in O
their O
contents O
of O
1 B
, I
8 I
- I
cineole I
and O
limonene O
. O

All O
the O
samples O
contained O
3 B
, I
3 I
, I
5 I
, I
5 I
, I
8 I
, I
8 I
- I
hexamethyl I
- I
7 I
- I
oxabicyclo I
[ I
4 I
. I
3 I
. I
0 I
] I
non I
- I
1 I
( I
6 I
) I
- I
ene I
- I
2 I
, I
4 I
- I
dione I
( O
up O
to O
4 O
. O
9 O
% O
) O
. O

N O
- O
terminal O
sequencing O
indicated O
that O
pro O
- O
BMP O
- O
2 O
was O
cleaved O
by O
FSAP O
at O
the O
canonical O
PC O
cleavage O
site O
, O
giving O
rise O
to O
mature O
BMP O
- O
2 O
( O
Arg B
( O
282 O
) O
v O
Gln O
( O
283 O
) O
) O
, O
as O
well O
as O
in O
the O
N O
- O
terminal O
heparin O
binding O
region O
of O
mature O
BMP O
- O
2 O
, O
generating O
a O
truncated O
mature O
BMP O
- O
2 O
peptide O
( O
Arg B
( O
289 O
) O
v O
Lys O
( O
290 O
) O
) O
. O

Similarly O
, O
mature O
BMP O
- O
2 O
was O
also O
cleaved O
to O
a O
truncated O
peptide O
within O
its O
N O
- O
terminal O
region O
( O
Arg B
( O
289 O
) O
v O
Lys O
( O
290 O
) O
) O
. O

Effect O
of O
doping O
on O
the O
magnetostructural O
ordered O
phase O
of O
iron B
arsenides I
: O
a O
comparative O
study O
of O
the O
resistivity O
anisotropy O
in O
doped O
BaFe2As2 B
with O
doping O
into O
three O
different O
sites O
. O

To O
unravel O
the O
role O
of O
doping O
in O
iron O
- O
based O
superconductors O
, O
we O
investigated O
the O
in O
- O
plane O
resistivity O
of O
BaFe B
( I
2 I
) I
As I
( I
2 I
) I
doped O
at O
one O
of O
the O
three O
different O
lattice O
sites O
, O
Ba B
( I
Fe I
( I
1 I
- I
x I
) I
Co I
( I
x I
) I
) I
( I
2 I
) I
As I
( I
2 I
) I
, O
BaFe B
( I
2 I
) I
( I
As I
( I
1 I
- I
x I
) I
P I
( I
x I
) I
) I
( I
2 I
) I
, O
and O
Ba B
( I
1 I
- I
x I
) I
K I
( I
x I
) I
Fe I
( I
2 I
) I
As I
( I
2 I
) I
, O
focusing O
on O
the O
doping O
effect O
in O
the O
low O
- O
temperature O
antiferromagnetic O
/ O

Method O
: O
Twenty O
- O
one O
disintegrants O
and O
ibuprophen B
were O
characterized O
using O
SeDeM O
methodology O
. O

Efficient O
two O
- O
electron O
reduction O
of O
dioxygen O
to O
hydrogen O
peroxide O
with O
one O
- O
electron O
reductants O
with O
a O
small O
overpotential O
catalyzed O
by O
a O
cobalt B
chlorin I
complex O
. O

A O
cobalt B
chlorin I
complex O
( O
Co B
( I
II I
) I
( I
Ch I
) I
) O
efficiently O
and O
selectively O
catalyzed O
two O
- O
electron O
reduction O
of O
dioxygen O
( O
O O
( O
2 O
) O
) O
by O
one O
- O
electron O
reductants O
( O
ferrocene O
derivatives O
) O
to O
produce O
hydrogen O
peroxide O
( O
H O
( O
2 O
) O
O O
( O
2 O
) O
) O
in O
the O
presence O
of O
perchloric B
acid I
( O
HClO B
( I
4 I
) I
) O
in O
benzonitrile O
( O
PhCN B
) O
at O
298 O
K O
. O

The O
catalytic O
reactivity O
of O
Co B
( I
II I
) I
( I
Ch I
) I
was O
much O
higher O
than O
that O
of O
a O
cobalt B
porphyrin I
complex O
( O
Co B
( I
II I
) I
( I
OEP I
) I
, O
OEP B
( I
2 I
- I
) I
= O
octaethylporphyrin B
dianion O
) O
, O
which O
is O
a O
typical O
porphyrinoid O
complex O
. O

The O
two O
- O
electron O
reduction O
of O
O O
( O
2 O
) O
by O
1 B
, I
1 I
' I
- I
dibromoferrocene I
( O
Br B
( I
2 I
) I
Fc I
) O
was O
catalyzed O
by O
Co B
( I
II I
) I
( I
Ch I
) I
, O
whereas O
virtually O
no O
reduction O
of O
O O
( O
2 O
) O
occurred O
with O
Co B
( I
II I
) I
( I
OEP I
) I
. O

In O
addition O
, O
Co B
( I
II I
) I
( I
Ch I
) I
is O
more O
stable O
than O
Co B
( I
II I
) I
( I
OEP I
) I
, O
where O
the O
catalytic O
turnover O
number O
( O
TON O
) O
of O
the O
two O
- O
electron O
reduction O
of O
O O
( O
2 O
) O
catalyzed O
by O
Co B
( I
II I
) I
( I
Ch I
) I
exceeded O
30000 O
. O

The O
detailed O
kinetic O
studies O
have O
revealed O
that O
the O
rate O
- O
determining O
step O
in O
the O
catalytic O
cycle O
is O
the O
proton O
- O
coupled O
electron O
transfer O
reduction O
of O
O O
( O
2 O
) O
with O
the O
protonated O
Co B
( I
II I
) I
( I
Ch I
) I
( O
[ B
Co I
( I
II I
) I
( I
ChH I
) I
] I
( I
+ I
) I
) O
that O
is O
produced O
by O
facile O
electron O
- O
transfer O
reduction O
of O
[ B
Co I
( I
III I
) I
( I
ChH I
) I
] I
( I
2 I
+ I
) I
by O
ferrocene O
derivative O
in O
the O
presence O
of O
HClO B
( I
4 I
) I
. O

The O
one O
- O
electron O
- O
reduction O
potential O
of O
[ B
Co I
( I
III I
) I
( I
Ch I
) I
] I
( I
+ I
) I
was O
positively O
shifted O
from O
0 O
. O
37 O
V O
( O
vs O
SCE O
) O
to O
0 O
. O
48 O
V O
by O
the O
addition O
of O
HClO B
( I
4 I
) I
due O
to O
the O
protonation O
of O
[ B
Co I
( I
III I
) I
( I
Ch I
) I
] I
( I
+ I
) I
. O

Such O
a O
positive O
shift O
of O
[ B
Co I
( I
III I
) I
( I
Ch I
) I
] I
( I
+ I
) I
by O
protonation O
resulted O
in O
enhancement O
of O
the O
catalytic O
reactivity O
of O
[ B
Co I
( I
III I
) I
( I
ChH I
) I
] I
( I
2 I
+ I
) I
for O
the O
two O
- O
electron O
reduction O
of O
O O
( O
2 O
) O
with O
a O
lower O
overpotential O
as O
compared O
with O
that O
of O
[ B
Co I
( I
III I
) I
( I
OEP I
) I
] I
( I
+ I
) I
. O

Binary O
diffusion O
coefficients O
for O
mixtures O
of O
ionic O
liquids O
[ B
EMIM I
] I
[ I
N I
( I
CN I
) I
2 I
] I
, O
[ B
EMIM I
] I
[ I
NTf2 I
] I
, O
and O
[ B
HMIM I
] I
[ I
NTf2 I
] I
with O
acetone O
and O
ethanol O
by O
dynamic O
light O
scattering O
( O
DLS O
) O
. O

Mutual O
diffusivities O
for O
binary O
mixtures O
of O
the O
ionic O
liquids O
( O
ILs O
) O
[ B
EMIM I
] I
[ I
N I
( I
CN I
) I
2 I
] I
( O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
dicyanimide I
) O
, O
[ B
EMIM I
] I
[ I
NTf2 I
] I
( O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
bis I
( I
trifluoromethylsulfo I
) I
imide I
) O
, O
and O
[ B
HMIM I
] I
[ I
NTf2 I
] I
( O
1 O
- O
hexyl O
- O
3 O
- O
methylimidazolium O
bis O
( O

trifluoromethylsulfo O
) O
imide O
) O
with O
acetone B
and O
ethanol O
were O
studied O
in O
dependence O
on O
composition O
in O
the O
temperature O
range O
from O
283 O
. O
15 O
to O
323 O
. O
15 O
K O
, O
applying O
dynamic O
light O
scattering O
( O
DLS O
) O
. O

For O
the O
mixtures O
of O
[ B
EMIM I
] I
[ I
NTf2 I
] I
with O
ethanol O
, O
however O
, O
a O
minimum O
of O
the O
mutual O
diffusivities O
was O
found O
in O
the O
ethanol O
mole O
fraction O
range O
from O
0 O
. O
7 O
to O
0 O
. O
8 O
, O
which O
may O
hint O
at O
the O
vicinity O
of O
a O
critical O
demixing O
point O
. O

A O
divergent O
approach O
to O
the O
synthesis O
of O
the O
yohimbinoid B
alkaloids I
venenatine B
and O
alstovenine B
. O

The O
yohimbinoid B
alkaloids I
continue O
to O
receive O
considerable O
attention O
from O
the O
synthetic O
community O
because O
of O
their O
interesting O
chemical O
structures O
and O
varied O
biological O
activity O
. O

Herein O
, O
we O
report O
that O
a O
functionalized O
hydrindanone B
enables O
a O
divergent O
strategy O
that O
builds O
on O
existing O
precedent O
to O
address O
this O
long O
- O
standing O
challenge O
. O

Utilizing O
an O
aminonitrile B
intermediate O
, O
the O
stereochemistry O
at O
C O
( O
3 O
) O
of O
the O
yohimbinoid O
skeleton O
can O
be O
controlled O
effectively O
in O
a O
Pictet O
- O
Spengler O
reaction O
. O

We O
applied O
this O
approach O
to O
the O
first O
total O
syntheses O
of O
the O
C O
( O
3 O
) O
epimeric O
natural O
products O
venenatine B
and O
alstovenine B
. O

Some O
beta O
- O
lactam O
antibiotics O
interact O
with O
Oat3 O
, O
and O
penicillin B
G I
exhibits O
a O
strong O
dependence O
on O
Oat3 O
for O
renal O
elimination O
. O

Tissue O
accumulation O
and O
species O
- O
specific O
metabolism O
of O
technical O
pentabrominated B
diphenyl I
ether I
( O
DE B
- I
71 I
) O
in O
two O
predator O
fish O
. O

The O
tissue O
- O
specific O
accumulation O
and O
species O
- O
specific O
metabolism O
of O
polybrominated O
diphenyl O
ethers O
( O
PBDEs O
) O
in O
two O
predator O
fish O
species O
( O
redtail O
catfish O
and O
oscar O
fish O
) O
feeding O
on O
the O
same O
prey O
( O
tiger O
barb O
) O
that O
was O
exposed O
to O
technical O
pentabrominated B
diphenyl I
ether I
( O
DE B
- I
71 I
) O
in O
the O
laboratory O
were O
investigated O
. O

Several O
hydroxylated B
PBDEs I
( O
OH O
- O
PBDEs O
) O
were O
detected O
in O
serum O
samples O
from O
the O
two O
fish O
species O
, O
but O
no O
methoxylated O
PBDEs O
were O
found O
. O

This O
Full O
Paper O
addresses O
the O
electrocatalytic O
hydrogenation O
of O
glucose O
to O
sorbitol O
or O
2 B
- I
deoxysorbitol I
on O
solid O
metal O
electrodes O
in O
neutral O
media O
. O

Three O
groups O
of O
catalysts O
clearly O
show O
affinities O
toward O
: O
( O
1 O
) O
hydrogen O
formation O
[ O
on O
early O
transition B
metals I
( O
Ti O
, O
V O
, O
Cr O
, O
Mn O
, O
Zr B
, O
Nb B
, O
Mo O
, O
Hf O
, O
Ta O
, O
We B
, O
and O
Re O
) O
and O
platinum O
group O
metals O
( O
Ru O
, O
Rh O
, O
Ir O
, O
and O
Pt O
) O
] O
, O
( O
2 O
) O
sorbitol O
formation O
[ O
on O
late O
transition B
metals I
( O
Fe O
, O
Co O
, O
Ni O
, O
Cu O
, O
Pd O
, O
Au O
, O
and O
Ag O
) O
and O
Al O
( O
sp O
metal O
) O
] O
, O
and O
( O
3 O
) O
sorbitol O
and O
2 O
- O

deoxysorbitol O
formation O
[ O
on O
post O
- O
transition B
metals I
( O
In O
, O
Sn O
, O
Sb B
, O
Pb O
, O
and O
Bi B
) O
, O
as O
well O
as O
Zn O
and O
Cd O
( O
d O
metals O
) O
] O
. O

The O
mechanism O
to O
form O
2 B
- I
deoxysorbitol I
from O
glucose O
and O
/ O
or O
fructose O
is O
discussed O
according O
to O
the O
observed O
reaction O
products O
. O

Several O
new O
chemical O
entities O
are O
disclosed O
which O
act O
as O
NADPH O
oxidase O
4 O
inhibitors O
, O
and O
the O
efficacies O
of O
our O
best O
hits O
, O
in O
particular O
several O
diarylheptanoids B
and O
lignans O
, O
are O
comparable O
to O
the O
best O
available O
pharmacological O
NADPH O
oxidase O
4 O
inhibitors O
. O

The O
synthesis O
and O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
of O
amino O
acid O
- O
based O
chiral O
monomers O
, O
namely O
Boc B
- I
L I
- I
leucine I
methacryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Leu I
- I
HEMA I
, O
1a O
) O
, O
Boc B
- I
L I
- I
leucine I
acryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Leu I
- I
HEA I
, O
1b O
) O
, O
Boc B
- I
L I
- I
isoleucine I
methacryloyloxyethyl I
ester I
( O
Boc O
- O
L O
- O

Ile O
- O
HEMA O
, O
1c O
) O
, O
and O
Boc B
- I
L I
- I
isoleucine I
acryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Ile I
- I
HEA I
, O
1d O
) O
, O
are O
reported O
. O

The O
controlled O
nature O
of O
the O
polymerization O
of O
the O
said O
chiral O
monomers O
in O
N B
, I
N I
- I
dimethylformamide I
( O
DMF B
) O
at O
70 O
degrees O
C O
is O
evident O
from O
the O
formation O
of O
narrow O
polydisperse O
polymers O
, O
the O
molecular O
weight O
controlled O
by O
the O
monomer O
/ O
chain O
transfer O
agent O
( O
CTA O
) O
molar O
ratio O
and O
the O
linear O
relationship O
between O
molecular O
weight O
and O
monomer O
conversion O
. O

The O
resulting O
well O
- O
defined O
polymers O
were O
used O
as O
macro O
- O
CTAs O
to O
prepare O
corresponding O
diblock O
copolymers O
by O
RAFT O
polymerization O
of O
methyl B
( I
meth I
) I
acrylate I
monomers O
. O

Deprotection O
of O
Boc B
groups O
in O
the O
homopolymers O
and O
block O
copolymers O
under O
acidic O
conditions O
produced O
cationic O
, O
pH O
- O
responsive O
polymers O
with O
primary O
amine O
moieties O
at O
the O
side O
chains O
. O

DFT O
calculations O
show O
that O
mercaptopropionic B
acid I
( O
MPA O
) O
and O
cysteine O
( O
Cys O
) O
exhibit O
characteristic O
binding O
configurations O
on O
TiO O
( O
2 O
) O
surfaces O
. O

Biotransformation O
and O
pharmacokinetics O
of O
inositol B
hexanicotinate I
in O
rats O
. O

Inositol B
hexanicotinate I
( O
IHN B
) O
is O
an O
ester O
of O
the O
anti O
- O
hyperlipidemic O
drug O
nicotinic O
acid O
( O
NA O
) O
. O

IHN B
( O
10 O
or O
50 O
micro O
g O
/ O
mL O
) O
was O
incubated O
in O
plasma O
at O
37 O
degrees O
C O
for O
72 O
h O
. O

Kinetic O
parameters O
were O
determined O
based O
on O
the O
disappearance O
of O
IHN B
and O
the O
appearance O
of O
NA O
. O

The O
mean O
IHN B
disappearance O
and O
NA O
appearance O
half O
- O
lives O
were O
1 O
. O
07 O
and O
3 O
. O
93 O
h O
in O
human O
plasma O
, O
and O
0 O
. O
152 O
and O
2 O
. O
68 O
h O
in O
rat O
plasma O
. O

After O
single O
50 O
or O
100 O
mg O
/ O
kg O
intravenous O
dose O
of O
IHN B
to O
Sprague O
- O
Dawley O
rats O
, O
the O
drug O
showed O
statistically O
significant O
dose O
- O
dependent O
alterations O
in O
systemic O
clearance O
, O
suggesting O
a O
non O
- O
linear O
saturable O
elimination O
of O
IHN B
. O

Dose O
- O
normalized O
mean O
plasma O
levels O
of O
NA O
increased O
by O
30 O
% O
with O
increasing O
IHN B
dose O
( O
p O
< O
0 O
. O
02 O
) O
. O

The O
mean O
metabolic O
ratio O
( O
i O
. O
e O
. O
NA O
/ O
IHN B
AUC O
ratio O
) O
significantly O
increased O
with O
increasing O
IHN B
dose O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
results O
provide O
first O
indication O
of O
saturable O
elimination O
and O
rapid O
disappearance O
of O
IHN B
, O
while O
niacin B
was O
slowly O
formed O
. O

No O
significant O
difference O
was O
found O
between O
the O
groups O
with O
regard O
to O
perfluorooctane O
sulfonate O
( O
PFOS O
) O
, O
perfluorooctanoic O
acid O
( O
PFOA O
) O
, O
mono B
- I
ethylhexyl I
phthalate I
( O
MEHP O
) O
and O
di O
- O
( O
2 O
- O
ethylhexyl O
) O
phthalate O
( O
DEHP O
) O
concentrations O
. O

Among O
them O
, O
deoxynivalenol O
( O
DON O
) O
and O
zearalenone O
( O
ZEN B
) O
are O
widespread O
worldwide O
contaminants O
of O
cereal O
commodities O
and O
are O
ranked O
as O
the O
most O
important O
chronic O
dietary O
risk O
factors O
. O

This O
study O
demonstrates O
for O
the O
first O
time O
that O
DON O
and O
ZEN B
are O
effectively O
deconjugated O
by O
the O
human O
colonic O
microbiota O
, O
releasing O
their O
toxic O
aglycones O
and O
generating O
yet O
unidentified O
catabolites O
. O

Phytochemical O
investigation O
of O
the O
methanolic O
extract O
of O
Croton O
tonkinensis O
afforded O
two O
known O
kauranes B
( O
1 O
, O
2 O
) O
, O
eight O
new O
ent B
- I
kauranes I
( O
3 O
- O
10 O
) O
, O
and O
16 O
known O
ent O
- O
kaurane O
- O
type O
diterpenoids O
( O
12 O
- O
27 O
) O
. O

Among O
the O
isolated O
compounds O
, O
ent B
- I
18 I
- I
acetoxykaur I
- I
16 I
- I
en I
- I
15 I
- I
one I
( O
20 O
) O
displayed O
the O
most O
significant O
inhibition O
of O
superoxide O
anion O
generation O
and O
elastase O
release O
. O

H1152 B
promotes O
the O
degradation O
of O
polyglutamine B
- O
expanded O
ataxin O
- O
3 O
or O
ataxin O
- O
7 O
independently O
of O
its O
ROCK O
- O
inhibiting O
effect O
and O
ameliorates O
mutant O
ataxin O
- O
3 O
- O
induced O
neurodegeneration O
in O
the O
SCA3 O
transgenic O
mouse O
. O

Spinocerebellar O
ataxia O
type O
3 O
( O
SCA3 O
) O
caused O
by O
polyglutamine B
- O
expanded O
ataxin O
- O
3 O
is O
the O
most O
prevalent O
subtype O
of O
spinocerebellar O
ataxias O
. O

SCA3 O
and O
Huntington O
' O
s O
disease O
( O
HD O
) O
belong O
to O
a O
family O
of O
polyglutamine B
neurodegenerative O
diseases O
. O

Rho O
- O
kinase O
( O
ROCK O
) O
inhibitor O
Y27632 B
reduced O
brain O
level O
of O
polyglutamine B
- O
expanded O
huntingtin O
in O
HD O
transgenic O
mouse O
. O

Therefore O
, O
we O
tested O
the O
possibility O
that O
ROCK O
inhibitors O
, O
Y27632 B
, O
H1152 B
and O
GSK429286 B
, O
downregulate O
protein O
expression O
of O
polyglutamine B
- O
expanded O
ataxin O
- O
3 O
- O
Q79 O
. O

Y27632 B
or O
H1152 B
reduced O
protein O
level O
of O
HA O
- O
tagged O
ataxin O
- O
3 O
- O
Q79 O
( O
ATX O
- O
3 O
- O
Q79HA O
) O
expressed O
in O
HEK O
293 O
cells O
. O

Compared O
to O
Y27632 B
, O
H1152 B
decreased O
ATX O
- O
3 O
- O
Q79HA O
protein O
level O
with O
a O
significantly O
more O
potency O
and O
efficacy O
. O

H1152 B
also O
reduced O
protein O
level O
of O
HA O
- O
tagged O
polyglutamine B
- O
expanded O
ataxin O
- O
7 O
- O
Q52 O
( O
ATX O
- O
7 O
- O
Q52HA O
) O
, O
which O
causes O
spinocerebellar O
ataxia O
type O
7 O
( O
SCA7 O
) O
. O

H1152 B
decreased O
ATX O
- O
3 O
- O
Q79HA O
or O
ATX O
- O
7 O
- O
Q52HA O
protein O
level O
in O
vitro O
by O
augmenting O
proteasome O
activity O
and O
promoting O
ATX O
- O
3 O
- O
Q79HA O
or O
ATX O
- O
7 O
- O
Q52HA O
degradation O
. O

GSK429286 B
, O
which O
is O
structurally O
different O
from O
H1152 B
but O
equally O
inhibits O
ROCK O
, O
failed O
to O
affect O
protein O
level O
of O
ATX O
- O
3 O
- O
Q79HA O
or O
ATX O
- O
7 O
- O
Q52HA O
. O

Furthermore O
, O
shRNA O
- O
mediated O
suppression O
of O
ROCK1 O
or O
ROCK2 O
expression O
in O
293 O
cells O
did O
not O
affect O
protein O
level O
of O
ATX O
- O
3 O
- O
Q79HA O
or O
ATX O
- O
7 O
- O
Q52HA O
and O
H1152 B
reduction O
of O
ATX O
- O
3 O
- O
Q79HA O
. O

Daily O
intraperitoneal O
administration O
of O
H1152 B
significantly O
decreased O
protein O
level O
of O
ATX O
- O
3 O
- O
Q79HA O
in O
the O
cerebellum O
, O
pontine O
nuclei O
and O
spinal O
cord O
of O
SCA3 O
transgenic O
mice O
. O

H1152 B
also O
ameliorated O
pontine O
neuronal O
death O
and O
neurological O
phenotype O
of O
SCA3 O
transgenic O
mice O
. O

Our O
results O
suggest O
that O
H1152 B
might O
be O
an O
effective O
therapeutic O
agent O
for O
SCA3 O
or O
SCA7 O
. O

It O
was O
marked O
by O
significant O
accumulation O
of O
lipid O
droplets O
as O
determined O
by O
Oil B
- I
Red I
- I
O I
( O
ORO B
) O
based O
colorimetric O
assay O
, O
increased O
triacylglycerol O
( O
TAG O
) O
and O
increased O
lipid O
peroxidation O
. O

Hence O
, O
quercetin O
effectively O
reversed O
NAFLD O
symptoms O
by O
decreased O
triacyl B
glycerol I
accumulation O
, O
insulin O
resistance O
, O
inflammatory O
cytokine O
secretion O
and O
increased O
cellular O
antioxidants O
in O
OA O
induced O
hepatic O
steatosis O
in O
HepG2 O
cells O
. O

Prednisolone O
tablets O
were O
coated O
with O
a O
double O
- O
coating O
formulation O
by O
applying O
an O
inner O
layer O
composed O
of O
EUDRAGIT O
( O
R O
) O
S O
neutralised O
to O
pH O
8 O
. O
0 O
and O
a O
buffer O
salt O
( O
10 O
% O
KH B
( I
2 I
) I
PO I
( I
4 I
) I
) O
, O
which O
was O
overcoated O
with O
layer O
of O
standard O
EUDRAGIT O
( O
R O
) O
S O
organic O
solution O
. O

For O
comparison O
, O
tablets O
were O
also O
tested O
under O
the O
USP O
method O
established O
for O
modified O
release O
mesalamine B
formulations O
. O

In O
contrast O
, O
using O
the O
USP O
dissolution O
method O
, O
normally O
employed O
for O
modified O
release O
mesalamine B
products O
, O
no O
discrimination O
was O
attained O
. O

In O
the O
current O
study O
dietary O
relevant O
mixtures O
of O
isoflavones O
and O
their O
metabolites O
, O
lignans O
and O
their O
metabolites O
, O
coumestrol B
, O
and O
a O
mixture O
containing O
all O
of O
them O
, O
were O
examined O
for O
effects O
on O
adipogenesis O
in O
3T3 O
- O
L1 O
adipocytes O
, O
as O
well O
as O
tested O
for O
their O
PPAR O
gamma O
activating O
abilities O
. O

The O
results O
showed O
that O
mixtures O
of O
isoflavonoid B
parent O
compounds O
and O
metabolites O
, O
respectively O
, O
a O
mixture O
of O
lignan O
metabolites O
, O
as O
well O
as O
coumestrol B
concentration O
- O
dependently O
inhibited O
adipocyte O
differentiation O
. O

Furthermore O
, O
a O
mixture O
of O
isoflavonoid B
parent O
compounds O
, O
and O
a O
mixture O
of O
isoflavonoid B
metabolites O
were O
found O
to O
have O
PPAR O
gamma O
activating O
abilities O
. O

Previous O
work O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
( O
2 B
- I
Methyl I
- I
6 I
- I
( I
phenylethynyl I
) I
pyridine I
) O
binding O
site O
. O

However O
, O
one O
mGlu5 O
PAM O
, O
CPPHA B
( O
N B
- I
( I
4 I
- I
chloro I
- I
2 I
- I
[ I
( I
1 I
, I
3 I
- I
dioxo I
- I
1 I
, I
3 I
- I
dihydro I
- I
2H I
- I
isoindol I
- I
2 I
- I
yl I
) I
methyl I
] I
phenyl I
) I
- I
2 I
- I
hydroxybenzamide I
) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O

Using O
cell O
- O
based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA B
series O
termed O
NCFP B
( O
N B
- I
( I
4 I
- I
chloro I
- I
2 I
- I
( I
( I
4 I
- I
fluoro I
- I
1 I
, I
3 I
- I
dioxoisoindolin I
- I
2 I
- I
yl I
) I
methyl I
) I
phenyl I
) I
picolinamide I
) O
. O

NCFP B
binds O
to O
the O
CPPHA B
site O
on O
mGlu5 O
and O
potentiates O
mGlu5 O
- O
mediated O
responses O
in O
both O
recombinant O
and O
native O
systems O
. O

However O
, O
NCFP B
provides O
greater O
mGlu5 O
subtype O
selectivity O
than O
does O
CPPHA B
, O
making O
it O
more O
suitable O
for O
studies O
of O
effects O
on O
mGlu5 O
in O
CNS O
preparations O
. O

Of O
interest O
, O
NCFP B
does O
not O
potentiate O
responses O
involved O
in O
hippocampal O
synaptic O
plasticity O
( O
LTD O
/ O
LTP O
) O
, O
setting O
it O
apart O
from O
other O
previously O
characterized O
MPEP O
site O
PAMs O
. O

Previously O
we O
reported O
that O
infusion O
of O
the O
mu O
- O
opioid O
receptor O
agonist O
[ B
D I
- I
Ala2 I
, I
N I
- I
Me I
- I
Phe4 I
, I
Glycinol5 I
] I
- I
Enkephalin I
( O
DAMGO B
) O
into O
the O
mu O
- O
opioid O
receptor O
expressing O
lateral O
parabrachial O
nucleus O
increases O
feeding O
. O

We O
used O
this O
parabrachial O
circuit O
as O
a O
model O
to O
assess O
cellular O
actions O
of O
ultra O
- O
low O
doses O
of O
( O
- O
) O
- O
naloxone O
and O
( O
+ O
) O
- O
naloxone O
in O
modifying O
the O
effects O
of O
DAMGO B
. O

Our O
results O
showed O
that O
an O
ultra O
- O
low O
concentration O
of O
( O
- O
) O
- O
naloxone O
( O
0 O
. O
001 O
nM O
) O
and O
several O
concentrations O
of O
( O
+ O
) O
- O
naloxone O
( O
0 O
. O
01 O
- O
10 O
nM O
) O
enhanced O
DAMGO B
- O
stimulated O
guanosine B
- I
5 I
' I
- I
0 I
- I
( I
gamma I
- I
thio I
) I
- I
triphosphate I
incorporation O
in O
parabrachial O
sections O
in O
vitro O
. O

In O
the O
present O
study O
, O
we O
show O
that O
( O
+ O
) O
- O
naloxone O
can O
potentiate O
DAMGO B
- O
induced O
feeding O
at O
doses O
at O
which O
( O
- O
) O
- O
naloxone O
was O
an O
antagonist O
. O

In O
vitro O
stimulation O
of O
LGALS3 O
( O
- O
/ O
- O
) O
peritoneal O
macrophages O
with O
lypopolysaccharide O
( O
LPS O
) O
and O
saturated O
fatty O
acid O
palmitate B
caused O
increased O
Caspase O
- O
1 O
dependent O
IL O
- O
1 O
beta O
production O
and O
increased O
phosphorilation O
of O
NF O
kappa O
B O
p65 O
compared O
to O
WT O
cells O
. O

Transfection O
of O
LGALS3 O
( O
- O
/ O
- O
) O
macrophages O
with O
NLRP3 O
siRNA O
attenuated O
IL O
- O
1 O
beta O
production O
in O
response O
to O
palmitate B
and O
LPS O
plus O
palmitate B
. O

Prevention O
or O
restoration O
of O
these O
changes O
via O
blockade O
of O
aldosterone O
action O
in O
the O
vascular O
wall O
with O
MR O
antagonists O
( O
i O
. O
e O
. O
, O
spironolactone O
, O
eplerenone B
) O
may O
therefore O
account O
for O
the O
clinical O
benefit O
of O
these O
compounds O
in O
obese O
and O
diabetic O
patients O
with O
cardiovascular O
disease O
. O

Photocatalytic O
properties O
of O
graphdiyne B
and O
graphene O
modified O
TiO O
2 O
: O
from O
theory O
to O
experiment O
. O

The O
chemical O
structure O
and O
electronic O
properties O
of O
two O
- O
dimensional O
( O
2D O
) O
carbon O
- O
supported O
TiO O
2 O
, O
TiO B
2 I
- I
graphdiyne I
, O
and O
TiO B
2 I
- I
graphene I
composites O
have O
been O
studied O
by O
first O
- O
principles O
density O
functional O
theory O
. O

Calculation O
results O
show O
that O
TiO O
2 O
( O
001 O
) O
- O
graphdiyne B
composites O
possess O
superior O
charge O
separation O
and O
oxidation O
properties O
, O
having O
the O
longest O
lifetimes O
of O
photoexcited O
carriers O
among O
all O
of O
the O
2D O
composites O
containing O
TiO O
2 O
of O
different O
facets O
. O

Our O
experimental O
results O
further O
proved O
that O
TiO O
2 O
( O
001 O
) O
- O
graphdiyne B
composites O
could O
be O
a O
promising O
photocatalyst O
. O

For O
photocatalytic O
degradation O
of O
methylene O
blue O
, O
the O
rate O
constant O
of O
the O
TiO O
2 O
( O
001 O
) O
- O
graphdiyne B
composite O
is O
1 O
. O
63 O
+ O
/ O
- O
0 O
. O
15 O
times O
that O
of O
the O
pure O
TiO O
2 O
( O
001 O
) O
and O
1 O
. O
27 O
+ O
/ O
- O
0 O
. O
12 O
times O
that O
of O
the O
TiO O
2 O
( O
001 O
) O
- O
graphene O
composite O
. O

Abstract O
Context O
: O
Amoxicillin O
( O
AMX B
) O
and O
cefuroxime O
( O
CFX B
) O
are O
antibiotics O
used O
often O
to O
treat O
skin O
bacterial O
infections O
. O

Objectives O
: O
To O
lower O
side O
effects O
and O
increase O
therapeutic O
effectiveness O
, O
the O
percutaneous O
absorption O
and O
retention O
of O
AMX B
and O
CFX B
administered O
by O
iontophoresis O
was O
investigated O
in O
a O
rabbit O
model O
by O
measuring O
dermis O
concentrations O
via O
microdialysis O
. O

The O
cartridge O
pad O
was O
soaked O
with O
a O
solution O
of O
AMX B
in O
glycerin O
or O
of O
CFX B
in O
glycerin O
/ O
water O
( O
60 O
: O
40 O
) O
. O

Results O
: O
For O
AMX B
, O
therapeutically O
effective O
skin O
concentrations O
were O
detected O
immediately O
after O
the O
application O
of O
electrical O
current O
for O
any O
of O
the O
current O
density O
tested O
and O
remained O
above O
it O
for O
at O
least O
2 O
h O
from O
the O
end O
of O
iontophoresis O
. O

For O
CFX B
, O
skin O
concentrations O
rose O
above O
MIC O
only O
at O
the O
higher O
current O
densities O
and O
fell O
below O
the O
MIC O
by O
the O
end O
of O
the O
experiment O
. O

Conclusion O
: O
Iontophoresis O
is O
a O
promising O
method O
to O
obtain O
a O
fast O
and O
sustained O
concentration O
of O
AMX B
and O
CFX B
in O
skin O
. O

To O
realize O
the O
therapeutic O
potential O
of O
these O
cyclodepsipeptides O
, O
we O
probed O
the O
cellular O
effects O
of O
a O
novel O
and O
representative O
family O
member O
, O
symplostatin B
5 I
( O
1 O
) O
, O
which O
attenuated O
the O
downstream O
cellular O
effects O
of O
elastase O
in O
an O
epithelial O
lung O
airway O
model O
system O
, O
alleviating O
clinical O
hallmarks O
of O
chronic O
pulmonary O
diseases O
such O
as O
cell O
death O
, O
cell O
detachment O
, O
and O
inflammation O
. O

Compound O
1 O
exhibited O
activity O
comparable O
to O
the O
clinically O
approved O
elastase O
inhibitor O
sivelestat B
in O
short O
- O
term O
assays O
and O
demonstrated O
superior O
sustained O
activity O
in O
longer O
- O
term O
assays O
. O

In O
the O
dosage O
range O
of O
0 O
. O
2 O
- O
211 O
. O
2 O
, O
0 O
. O
1 O
- O
140 O
. O
2 O
, O
0 O
. O
2 O
- O
149 O
. O
9 O
mu O
m O
, O
50 O
% O
inhibiting O
concentrations O
( O
IC50 O
) O
of O
curcumin O
, O
demethoxycurcumin B
, O
and O
bisdemethoxycurcumin B
were O
26 O
. O
99 O
+ O
/ O
- O
1 O
. O
11 O
, O
19 O
. O
90 O
+ O
/ O
- O
1 O
. O
22 O
, O
and O
35 O
. O
51 O
+ O
/ O
- O
7 O
. O
29 O
mu O
m O
, O
respectively O
. O

Cleavage O
of O
DNA O
by O
proton O
- O
coupled O
electron O
transfer O
to O
a O
photoexcited O
, O
hydrated B
Ru I
( I
II I
) I
1 I
, I
10 I
- I
phenanthroline I
- I
5 I
, I
6 I
- I
dione I
complex O
. O

Visible O
light O
irradiation O
of O
a O
ruthenium O
( O
II O
) O
quinone O
- O
containing O
complex O
, O
[ B
( I
phen I
) I
( I
2 I
) I
Ru I
( I
phendione I
) I
] I
( I
2 I
+ I
) I
( O
1 O
( O
2 O
+ O
) O
) O
, O
where O
phendione B
= O
1 B
, I
10 I
- I
phenanthroline I
- I
5 I
, I
6 I
- I
dione I
, O
leads O
to O
DNA O
cleavage O
in O
an O
oxygen O
independent O
manner O
. O

A O
combination O
of O
NMR O
analyses O
, O
transient O
absorption O
spectroscopy O
, O
and O
fluorescence O
measurements O
in O
water O
and O
acetonitrile O
reveal O
that O
complex O
1 O
( O
2 O
+ O
) O
must O
be O
hydrated O
at O
the O
quinone O
functionality O
, O
giving O
[ B
( I
phen I
) I
( I
2 I
) I
Ru I
( I
phenH I
( I
2 I
) I
O I
) I
] I
( I
2 I
+ I
) I
( O
1H B
( I
2 I
) I
O I
( I
2 I
+ I
) I
, O
where O
phenH B
( I
2 I
) I
O I
= O
1 B
, I
10 I
- I
phenanthroline I
- I
6 I
- I
one I
- I
5 I
- I
diol I
) O
, O
in O
order O
to O
access O
a O
long O
- O
lived O
( O
3 O
) O

MLCT O
( O
hydrate B
) O
state O
( O
tau O
~ O
360 O
ns O
in O
H O
( O
2 O
) O
O O
) O
which O
is O
responsible O
for O
DNA O
cleavage O
. O

In O
effect O
, O
hydration O
at O
one O
of O
the O
carbonyl O
functions O
effectively O
eliminates O
the O
low O
- O
energy O
( O
3 O
) O
MLCT O
( O
SQ O
) O
state O
( O
Ru B
( I
III I
) I
phen I
- I
semiquinone I
radical O
anion O
) O
as O
the O
predominant O
nonradiative O
decay O
pathway O
. O

The O
resulting O
excited O
state O
in O
1H B
( I
2 I
) I
O I
( I
2 I
+ I
) I
* O
has O
photophysical O
properties O
similar O
to O
the O
( O
3 O
) O
MLCT O
state O
in O
[ B
Ru I
( I
phen I
) I
( I
3 I
) I
] I
( I
2 I
+ I
) I
* O
with O
the O
added O
functionality O
of O
basic O
sites O
at O
the O
ligand O
periphery O
. O

Whereas O
[ B
Ru I
( I
phen I
) I
( I
3 I
) I
] I
( I
2 I
+ I
) I
* O
does O
not O
show O
direct O
DNA O
cleavage O
, O
the O
deprotonated O
form O
of O
1H B
( I
2 I
) I
O I
( I
2 I
+ I
) I
* O
does O
via O
a O
proton O
- O
coupled O
electron O
transfer O
( O
PCET O
) O
mechanism O
where O
the O
peripheral O
basic O
oxygen O
sites O
act O
as O
the O
proton O
acceptor O
. O

In O
the O
absence O
of O
added O
salt O
, O
alternating O
adsorption O
of O
5 O
bilayers O
of O
protonated O
poly B
( I
allylamine I
) I
( O
PAH O
) O
and O
comb O
- O
like O
poly B
( I
2 I
- I
hydroxyethyl I
methacrylate I
) I
- I
graft I
- I
poly I
( I
acrylic I
acid I
) I
( O
PHEMA B
- I
g I
- I
PAA I
) O
leads O
to O
~ O
2 O
- O
fold O
thicker O
coatings O
than O
adsorption O
of O
PAH O
and O
linear O
PAA O
, O
and O
the O
difference O
in O
the O
thicknesses O
of O
the O
two O
coatings O
increases O
with O
the O
number O
of O
bilayers O
. O

Moreover O
, O
the O
( O
PAH O
/ O
PHEMA B
- I
g I
- I
PAA I
) O
n O
films O
sorb O
2 O
- O
to O
4 O
- O
fold O
more O
protein O
than O
corresponding O
films O
prepared O
with O
linear O
PAA O
, O
and O
coatings O
deposited O
at O
pH O
3 O
. O
0 O
sorb O
more O
protein O
than O
coatings O
adsorbed O
at O
pH O
5 O
. O
0 O
, O
7 O
. O
0 O
, O
or O
9 O
. O
0 O
. O

When O
deposited O
from O
0 O
. O
5 O
M O
NaCl O
at O
pH O
3 O
. O
0 O
, O
both O
( O
PAH O
/ O
PHEMA B
- I
g I
- I
PAA I
) O
5 O
and O
( O
PAH O
/ O
PAA O
) O
5 O
films O
increase O
in O
thickness O
more O
than O
400 O
% O
upon O
adsorption O
of O
lysozyme O
. O

Among O
the O
tested O
systems O
( O
barnase O
- O
barstar O
( O
BBS O
) O
, O
streptavidin B
- O
biotin O
, O
antibody O
- O
antigen O
, O
and O
protein O
A O
- O
immunoglobulin O
) O
, O
the O
BBS O
is O
notable O
due O
to O
the O
combination O
of O
its O
high O
resistance O
to O
severe O
chemical O
perturbation O
and O
unique O
advantages O
offered O
by O
genetic O
engineering O
of O
this O
entirely O
protein O
- O
based O
system O
. O

Two O
dianthramides B
( O
1 O
and O
2 O
) O
, O
three O
flavonoids O
( O
3 O
- O
5 O
) O
, O
two O
coumarins O
( O
6 O
and O
7 O
) O
and O
three O
other O
compounds O
( O
8 O
- O
10 O
) O
were O
obtained O
. O

Biosynthesis O
and O
characterization O
of O
diblock O
copolymer O
of O
p B
( I
3 I
- I
Hydroxypropionate I
) I
- I
block I
- I
p I
( I
4 I
- I
hydroxybutyrate I
) I
from O
recombinant O
Escherichia O
coli O
. O

Poly B
( I
4 I
- I
hydroxybutyrate I
) I
( O
P4HB B
) O
is O
a O
highly O
elastic O
polymer O
, O
whereas O
poly B
( I
3 I
- I
hydroxypropionate I
) I
( O
P3HP B
) O
is O
a O
polymer O
with O
enormous O
tensile O
strength O
. O

This O
study O
aimed O
to O
biosynthesize O
a O
block O
copolymer O
consisting O
of O
soft O
P4HB B
block O
with O
a O
strong O
P3HP B
block O
to O
gain O
unique O
and O
excellent O
material O
properties O
. O

A O
recombinant O
Escherichia O
coli O
strain O
that O
produces O
homopolymers O
of O
P3HP B
and O
P4HB B
was O
employed O
for O
the O
block O
copolymer O
synthesis O
. O

When O
the O
strain O
was O
grown O
in O
the O
presence O
of O
1 O
, O
4 O
- O
butanediol O
( O
BDO B
) O
as O
a O
4HB B
precursor O
, O
P4HB B
block O
was O
formed O
. O

Sequential O
supplementation O
of O
1 B
, I
3 I
- I
propanediol I
( O
PDO B
) O
as O
a O
3HP B
precursor O
allowed O
the O
strain O
to O
produce O
P3HP B
block O
. O

Thermal O
, O
NMR O
, O
fractionation O
, O
and O
mechanical O
characterizations O
confirmed O
the O
resulting O
polymer O
as O
a O
block O
copolymer O
of O
P3HP B
- I
b I
- I
P4HB I
. O

Two O
block O
copolymers O
were O
formed O
from O
this O
study O
, O
including O
the O
P3HP B
- O
b O
- O
29 O
% O
P4HB B
and O
P3HP B
- O
b O
- O
37 O
% O
P4HB B
, O
they O
showed O
superior O
properties O
over O
random O
copolymers O
P B
( I
3HP I
- I
co I
- I
4HB I
) I
. O

In O
comparison O
to O
the O
homopolymers O
P3HP B
and O
P4HB B
, O
incorporation O
of O
block O
microstructure O
resulted O
in O
the O
lowering O
of O
Tm O
, O
block O
copolymers O
were O
revealed O
with O
higher O
Young O
' O
s O
modulus O
, O
yield O
strengths O
, O
and O
tension O
strengths O
much O
better O
than O
the O
previously O
reported O
random O
copolymers O
of O
similar O
compositions O
. O

Block O
copolymerization O
of O
P3HP B
and O
P4HB B
adds O
a O
new O
vision O
on O
PHA O
polymerization O
by O
generation O
of O
new O
polymers O
with O
superior O
properties O
. O

Five O
new O
series O
of O
imidazo O
[ O
1 O
, O
2 O
- O
a O
] O
pyridines O
carrying O
biologically O
active O
pyrazoline B
( O
4a O
- O
e O
) O
, O
cyanopyridone B
( O
5a O
, O
b O
) O
, O
cyanopyridine B
( O
6a O
- O
f O
) O
, O
2 B
- I
aminopyrimidine I
( O
7a O
- O
f O
) O
and O
pyrimidine B
- I
2 I
- I
thione I
( O
8a O
- O
d O
) O
systems O
were O
designed O
and O
synthesized O
as O
prominent O
anticonvulsant O
agents O
. O

The O
target O
compounds O
were O
screened O
for O
their O
in O
vivo O
anticonvulsant O
activity O
following O
maximal O
electroshock O
( O
MES O
) O
and O
subcutaneous O
pentylene B
tetrazole I
( O
scPTZ O
) O
methods O
at O
a O
small O
test O
dose O
of O
10 O
mg O
/ O
kg O
. O

Compounds O
4b O
, O
5a O
, O
5b O
, O
6a O
, O
7e O
and O
8d O
possessing O
4 B
- I
fluorophenyl I
substituent O
at O
2nd O
position O
of O
imidazo B
[ I
1 I
, I
2 I
- I
a I
] I
pyridine I
ring O
displayed O
potent O
anticonvulsant O
activity O
without O
displaying O
any O
toxicity O
. O

Poly B
( I
styrene I
oxide I
) I
- I
poly I
( I
ethylene I
oxide I
) I
block O
copolymers O
: O
From O
" O
classical O
" O
chemotherapeutic O
nanocarriers O
to O
active O
cell O
- O
response O
inducers O
. O

Two O
poly B
( I
styrene I
oxide I
) I
- I
poly I
( I
ethylene I
oxide I
) I
( O
PSO B
- I
PEO I
) O
triblock O
copolymers O
with O
different O
chain O
lengths O
were O
analyzed O
as O
potential O
chemotherapeutic O
nanocarriers O
, O
and O
their O
ability O
to O
inhibit O
the O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
efflux O
pump O
in O
a O
multidrug O
resistant O
( O
MDR O
) O
cell O
line O
were O
measured O
in O
order O
to O
establish O
possible O
cell O
- O
responses O
induced O
by O
the O
presence O
of O
the O
copolymer O
molecules O
. O

Thus O
, O
EO33SO14EO33 O
and O
EO38SO10EO38 O
polymeric O
micelles O
were O
tested O
regarding O
doxorubicin O
( O
DOXO B
) O
entrapment O
efficiency O
( O
solubilization O
test O
) O
, O
physical O
stability O
( O
DLS O
) O
, O
cytocompatibility O
( O
fibroblasts O
) O
, O
release O
profiles O
at O
various O
pHs O
( O
in O
vitro O
tests O
) O
, O
as O
well O
as O
P O
- O
gp O
inhibition O
and O
evasion O
and O
cytotoxicity O
of O
the O
DOXO B
- O
loaded O
micelles O
in O
an O
ovarian O
MDR O
NCI O
- O
ADR O
/ O
RES O
cell O

line O
and O
in O
DOXO B
- O
sensitive O
MCF O
- O
7 O
cells O
. O

The O
copolymer O
unimers O
inhibited O
P O
- O
gp O
ATPase O
activity O
in O
a O
similar O
way O
as O
Pluronic B
P85 I
, O
favoring O
DOXO B
accumulation O
in O
the O
resistant O
cell O
line O
, O
but O
not O
in O
the O
sensitive O
cell O
line O
. O

DOXO B
loaded O
in O
the O
micelles O
accumulated O
more O
slowly O
inside O
the O
cells O
, O
but O
caused O
greater O
cytotoxicity O
than O
free O
drug O
solutions O
in O
the O
NCI O
- O
ADR O
- O
RES O
cell O
line O
, O
which O
overexpressed O
P O
- O
gp O
. O

Hence O
, O
PSO B
- I
PEO I
block O
copolymers O
offer O
interesting O
features O
as O
new O
biological O
response O
modifiers O
to O
be O
used O
in O
the O
design O
of O
efficient O
nanocarriers O
for O
cancer O
chemotherapy O
. O

After O
structure O
- O
based O
drug O
selection O
, O
SGI B
- I
1776 I
, O
ETP B
- I
45299 I
, O
and O
tryptanthrin B
were O
selected O
as O
candidates O
of O
PIM1 O
inhibitors O
that O
act O
as O
radiosensitizers O
. O

Taken O
together O
, O
our O
findings O
provided O
evidence O
that O
PIM1 O
- O
specific O
inhibitors O
, O
SGI B
- I
1776 I
, O
ETP B
- I
45299 I
, O
and O
tryptanthrin B
, O
can O
act O
as O
novel O
radiosensitizers O
to O
enhance O
the O
efficacy O
of O
radiotherapy O
by O
inhibiting O
irradiation O
- O
induced O
signaling O
pathway O
associated O
with O
radioresistance O
. O

The O
EA O
- O
7 O
/ O
8 O
- O
9 O
/ O
10 O
- O
4 O
fraction O
was O
evolved O
as O
a O
most O
potent O
fraction O
among O
all O
the O
fractions O
and O
it O
was O
identified O
as O
well O
known O
gallotannin B
compound O
1 O
, O
2 O
, O
3 O
, O
4 O
, O
6 O
penta O
- O
O O
- O
galloyl O
- O
beta O
- O
d O
- O
glucose O
( O
PGG O
) O
by O
spectral O
analysis O
. O

Single O
dose O
( O
10 O
, O
25 O
, O
50 O
and O
100mg O
/ O
kg O
) O
of O
PGG O
and O
carbenoxolone B
( O
CBX B
) O
have O
dose O
dependently O
inhibited O
the O
11 O
beta O
- O
HSD O
- O
1 O
activity O
in O
liver O
and O
adipose O
tissue O
. O

Labdane B
diterpenoids I
and O
lignans O
from O
Calocedrus O
macrolepis O
. O

Three O
new O
labdane B
diterpenoids I
, O
calomacrins B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
and O
a O
new O
diaryl B
butyrolactone I
- O
type O
lignan O
, O
calomacrol B
A I
( O
8 O
) O
, O
as O
well O
as O
four O
known O
labdane B
diterpenoids I
and O
six O
known O
lignans O
, O
were O
isolated O
from O
the O
twigs O
and O
leaves O
of O
Calocedrus O
macrolepis O
. O

Tamoxifen O
magnifies O
therapeutic O
impact O
of O
ceramide B
in O
human O
colorectal O
cancer O
cells O
independent O
of O
p53 O
. O

Ceramide B
, O
because O
of O
its O
role O
in O
orchestrating O
death O
cascades O
in O
cancer O
cells O
, O
is O
a O
versatile O
alternative O
. O

Ceramide B
can O
be O
generated O
by O
exposure O
to O
chemotherapy O
or O
ionizing O
radiation O
, O
or O
it O
can O
be O
administered O
in O
the O
form O
of O
short O
- O
chain O
analogs O
( O
C6 B
- I
ceramide I
) O
. O

Because O
intracellular O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
plays O
a O
role O
in O
catalyzing O
the O
conversion O
of O
ceramide B
to O
higher O
sphingolipids O
, O
we O
hypothesized O
that O
administration O
of O
P O
- O
gp O
antagonists O
with O
C6 B
- I
ceramide I
would O
magnify O
cell O
death O
cascades O
. O

The O
addition O
of O
either O
tamoxifen O
, O
VX B
- I
710 I
, O
verapamil O
, O
or O
cyclosporin B
A I
, O
antagonists O
of O
P O
- O
gp O
, O
enhanced O
C6 B
- I
ceramide I
cytotoxicity O
in O
all O
cell O
lines O
. O

In O
depth O
studies O
with O
C6 B
- I
ceramide I
and O
tamoxifen O
in O
LoVo O
cells O
showed O
the O
regimen O
induced O
PARP O
cleavage O
, O
caspase O
- O
dependent O
apoptosis O
, O
mitochondrial O
membrane O
permeabilization O
( O
MMP O
) O
, O
and O
cell O
cycle O
arrest O
at O
G1 O
and O
G2 O
. O

Nanoliposomal O
formulations O
of O
C6 B
- I
ceramide I
and O
tamoxifen O
were O
also O
effective O
, O
yielding O
synergistic O
cell O
kill O
. O

We O
conclude O
that O
tamoxifen O
is O
a O
favorable O
adjuvant O
for O
enhancing O
C6 B
- I
ceramide I
cytotoxicity O
in O
CRC O
, O
and O
demonstrates O
uniquely O
integrated O
effects O
. O

The O
high O
frequency O
of O
expression O
of O
P O
- O
gp O
in O
CRC O
presents O
an O
adventitious O
target O
for O
complementing O
ceramide B
- O
based O
therapies O
, O
a O
strategy O
that O
could O
hold O
promise O
for O
treatment O
of O
resistant O
disease O
. O

Involvement O
of O
Src O
and O
the O
actin O
cytoskeleton O
in O
the O
antitumorigenic O
action O
of O
adenosine B
dialdehyde I
. O

In O
this O
study O
, O
we O
examined O
the O
effects O
of O
transmethylation O
on O
tumorigenic O
responses O
and O
its O
regulatory O
mechanism O
using O
an O
upregulation O
strategy O
of O
adenosylhomocysteine O
( O
SAH B
) O
acting O
as O
a O
negative O
feedback O
inhibitor O
. O

Treatment O
with O
adenosine B
dialdehyde I
( O
AdOx B
) O
, O
an O
inhibitor O
of O
transmethylation O
- O
suppressive O
adenosylhomocysteine O
( O
SAH B
) O
hydrolase O
( O
SAHH O
) O
, O
enhanced O
the O
level O
of O
SAH B
and O
effectively O
blocked O
the O
proliferation O
, O
migration O
, O
and O
invasion O
of O
cancer O
cells O
; O
the O
treatment O
also O
induced O
the O
differentiation O
of O
C6 O
glioma O
cells O
and O
suppressed O
the O
neovascular O
genesis O
of O
eggs O
in O
a O
dose O
- O
dependent O
manner O
. O

Through O
immunoblotting O
analysis O
, O
it O
was O
found O
that O
AdOx B
was O
capable O
of O
indirectly O
diminishing O
the O
phosphorylation O
of O
oncogenic O
Src O
and O
its O
kinase O
activity O
. O

Interestingly O
, O
AdOx B
disrupted O
actin O
cytoskeleton O
structures O
, O
leading O
to O
morphological O
changes O
, O
and O
suppressed O
the O
formation O
of O
a O
signaling O
complex O
composed O
of O
Src O
and O
p85 O
/ O
PI3K O
, O
which O
is O
linked O
to O
various O
tumorigenic O
responses O
. O

In O
agreement O
with O
these O
data O
, O
the O
exogenous O
treatment O
of O
SAH B
or O
inhibition O
of O
SAHH O
by O
specific O
siRNA O
or O
another O
type O
of O
inhibitor O
, O
3 B
- I
deazaadenosine I
( O
DAZA B
) O
, O
similarly O
resulted O
in O
antitumorigenic O
responses O
, O
suppressive O
activity O
on O
Src O
, O
the O
alteration O
of O
actin O
cytoskeleton O
, O
and O
a O
change O
of O
the O
colocalization O
pattern O
between O
actin O
and O
Src O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
SAH B
/ O
SAHH O
- O
mediated O
transmethylation O
could O
be O
linked O
to O
the O
tumorigenic O
processes O
through O
cross O
- O
regulation O
between O
the O
actin O
cytoskeleton O
and O
Src O
kinase O
activity O
. O

Design O
, O
synthesis O
and O
anticancer O
properties O
of O
5 B
- I
arylbenzoxepins I
as O
conformationally O
restricted O
isocombretastatin B
A I
- I
4 I
analogs O
. O

A O
series O
of O
novel O
benzoxepins B
6 O
was O
designed O
and O
prepared O
as O
rigid O
- O
isoCA B
- I
4 I
analogs O
according O
to O
a O
convergent O
strategy O
using O
the O
coupling O
of O
N B
- I
tosylhydrazones I
with O
aryl B
iodides I
under O
palladium O
catalysis O
. O

The O
most O
potent O
compound O
6b O
, O
having O
the O
greatest O
resemblance O
to O
CA B
- I
4 I
and O
isoCA B
- I
4 I
displayed O
antiproliferative O
activity O
at O
nanomolar O
concentrations O
against O
various O
cancer O
cell O
lines O
and O
inhibited O
tubulin O
assembly O
at O
a O
micromolar O
range O
. O

In O
addition O
, O
benzoxepin B
6b O
led O
to O
the O
arrest O
of O
HCT116 O
, O
K562 O
, O
H1299 O
and O
MDA O
- O
MB231 O
cancer O
cell O
lines O
in O
the O
G2 O
/ O
M O
phase O
of O
the O
cell O
cycle O
, O
and O
strongly O
induced O
apoptosis O
at O
low O
concentrations O
. O

Docking O
studies O
demonstrated O
that O
benzoxepin B
6b O
adopt O
an O
orientation O
similar O
to O
that O
of O
isoCA B
- I
4 I
at O
the O
colchicine O
binding O
site O
on O
beta O
- O
tubulin O
. O

Cytotoxicity O
of O
lapachol B
, O
beta B
- I
lapachone I
and O
related O
synthetic O
1 O
, O
4 O
- O
naphthoquinones O
against O
oesophageal O
cancer O
cells O
. O

The O
secondary O
metabolites O
lapachol O
, O
alpha B
- I
and I
beta I
- I
lapachone I
and O
a O
series O
of O
25 O
related O
synthetic O
1 O
, O
4 O
- O
naphthoquinones O
were O
screened O
against O
the O
oesophageal O
cancer O
cell O
line O
( O
WHCO1 O
) O
. O

Cell O
death O
of O
oesophageal O
cancer O
cells O
by O
processes O
involving O
PARP O
cleavage O
caused O
by O
11a O
was O
shown O
to O
be O
associated O
with O
elevated O
c O
- O
Jun O
levels O
, O
suggesting O
a O
role O
for O
this O
pathway O
in O
the O
mechanism O
of O
action O
of O
this O
cohort O
of O
naphthoquinone B
compounds O
. O

Synthesis O
of O
an O
MIF B
- I
1 I
analogue O
containing O
enantiopure O
( B
S I
) I
- I
alpha I
- I
trifluoromethyl I
- I
proline I
and O
biological O
evaluation O
on O
nociception O
. O

The O
synthesis O
and O
the O
effect O
of O
a O
novel O
MIF B
- I
1 I
analogue O
on O
nociception O
during O
acute O
pain O
in O
rat O
model O
are O
reported O
. O

The O
synthesis O
of O
this O
enantiopure O
trifluoromethyl B
group O
containing O
tripeptide O
was O
performed O
through O
a O
peptide O
coupling O
reaction O
between O
the O
HCl O
. O

Leu B
- I
Gly I
- I
NH2 I
and O
the O
( B
S I
) I
- I
alpha I
- I
Tfm I
- I
proline I
. O

The O
analgesic O
effect O
of O
the O
CF3 B
- I
( I
MIF I
- I
1 I
) I
2 O
has O
been O
evaluated O
in O
vivo O
on O
rat O
model O
by O
paw O
pressure O
( O
PP O
) O
and O
hot O
plate O
( O
HP O
) O
tests O
and O
compared O
to O
the O
native O
peptide O
MIF B
- I
1 I
. O

Highest O
analgesic O
effect O
was O
observed O
with O
CF3 B
- I
( I
MIF I
- I
1 I
) I
2 O
only O
in O
PP O
test O
. O

In O
order O
to O
study O
the O
mechanisms O
of O
nociception O
induced O
by O
the O
studied O
peptides O
, O
the O
involvement O
of O
the O
opioid O
and O
the O
nitric B
oxideergic O
systems O
was O
investigated O
. O

The O
results O
are O
in O
favor O
of O
a O
participation O
of O
both O
system O
since O
pretreatment O
, O
20 O
min O
before O
injection O
of O
the O
CF3 B
- I
( I
MIF I
- I
1 I
) I
2 O
, O
with O
the O
non O
- O
competitive O
antagonist O
of O
opiate O
receptors O
naloxone O
, O
the O
nitric O
oxide O
synthase O
( O
NOS O
) O
inhibitor O
l B
- I
N I
( I
G I
) I
- I
nitroarginine I
ester I
( O
l O
- O
NAME O
) O
or O
the O
nitric O
oxide O
( O
NO O
) O
donor O
l O
- O
arginine O
( O
l B
- I
Arg I
) O
significantly O
decreased O
the O
pain O
perception O
in O
PP O
and O
HP O
tests O
. O

Synthesis O
, O
characterization O
, O
cytotoxicity O
and O
antimicrobial O
studies O
on O
bis B
( I
N I
- I
furfuryl I
- I
N I
- I
( I
2 I
- I
phenylethyl I
) I
dithiocarbamato I
- I
S I
, I
S I
' I
) I
zinc I
( I
II I
) I
and O
its O
nitrogen O
donor O
adducts O
. O

[ O
Zn B
( I
fpedtc I
) I
2 I
] O
( O
1 O
) O
, O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
py I
) I
] O
( O
2 O
) O
, O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
1 I
, I
10 I
- I
phen I
) I
] O
( O
3 O
) O
and O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
2 I
, I
2 I
' I
- I
bipy I
) I
] O
( O
4 O
) O
( O
where O
fpedtc B
= O
N B
- I
furfuryl I
- I
N I
- I
( I
2 I
- I
phenylethyl I
) I
dithiocarbamate I
, O
py O
= O
pyridine O
, O
1 B
, I
10 I
- I
phen I
= O

1 O
, O
10 O
- O
phenanthroline O
and O
2 B
, I
2 I
' I
- I
bipy I
= O
2 O
, O
2 O
' O
- O
bipyridine O
) O
were O
synthesized O
. O

Novel O
agmatine B
dipeptide I
inhibitors O
against O
the O
West O
Nile O
virus O
NS2B O
/ O
NS3 O
protease O
: O
A O
P3 O
and O
N O
- O
cap O
optimization O
study O
. O

This O
communication O
describes O
the O
synthesis O
and O
inhibitory O
activities O
of O
thirty O
- O
seven O
novel O
C O
- O
terminal O
agmatine B
dipeptides I
used O
as O
screening O
compounds O
to O
study O
the O
structure O
- O
activity O
relationship O
between O
active O
- O
site O
peptidomimetics O
and O
the O
West O
Nile O
virus O
( O
WNV O
) O
NS2B O
/ O
NS3 O
serine O
protease O
. O

Our O
efforts O
lead O
to O
the O
discovery O
of O
a O
novel O
agmatine B
dipeptide I
inhibitor O
( O
compound O
33 O
, O
IC50 O
2 O
. O
6 O
+ O
/ O
- O
0 O
. O
3 O
mu O
M O
) O
with O
improved O
inhibitory O
activity O
in O
comparison O
to O
the O
most O
potent O
inhibitor O
described O
in O
our O
recent O
report O
[ O
IC50 O
4 O
. O
7 O
+ O
/ O
- O
1 O
. O
2 O
mu O
M O
; O
Lim O
et O
al O
. O
, O
Eur O
. O
J O
. O
Med O
. O
Chem O
. O
46 O
( O
2011 O
) O
3130 O
- O
3134 O
] O
. O

Synthesis O
, O
pharmacological O
evaluation O
and O
QSAR O
modeling O
of O
mono O
- O
substituted O
4 B
- I
phenylpiperidines I
and O
4 B
- I
phenylpiperazines I
. O

A O
series O
of O
mono B
- I
substituted I
4 I
- I
phenylpiperidines I
and I
- I
piperazines I
have O
been O
synthesized O
and O
their O
effects O
on O
the O
dopaminergic O
system O
tested O
in O
vivo O
. O

Here O
we O
describe O
polymersomes O
able O
to O
encapsulate O
up O
to O
6 O
% O
( O
w O
/ O
w O
) O
of O
doxorubicin O
( O
DOX O
) O
together O
with O
30 O
% O
( O
w O
/ O
w O
) O
of O
superparamagnetic O
iron O
oxide O
nanoparticles O
( O
USPIO O
; O
gamma B
- I
Fe I
( I
2 I
) I
O I
( I
3 I
) I
) O
. O

Liposomal O
fasudil B
, O
a O
rho O
- O
kinase O
inhibitor O
, O
for O
prolonged O
pulmonary O
preferential O
vasodilation O
in O
pulmonary O
arterial O
hypertension O
. O

In O
this O
study O
, O
we O
tested O
the O
hypothesis O
that O
encapsulation O
of O
an O
investigational O
anti O
- O
PAH O
molecule O
fasudil B
( O
HA B
- I
1077 I
) O
, O
a O
Rho O
- O
kinase O
inhibitor O
, O
into O
liposomal O
vesicles O
results O
in O
prolonged O
vasodilation O
in O
distal O
pulmonary O
arterioles O
. O

Liposomes O
were O
prepared O
by O
hydration O
and O
extrusion O
method O
and O
fasudil B
was O
loaded O
by O
ammonium B
sulfate I
- O
induced O
transmembrane O
electrochemical O
gradient O
. O

Optimized O
formulations O
were O
tested O
for O
pulmonary O
absorption O
and O
their O
pharmacological O
efficacy O
in O
a O
monocrotaline B
( O
MCT B
) O
induced O
rat O
model O
of O
PAH O
. O

The O
entrapment O
efficiency O
of O
optimized O
liposomal O
fasudil B
formulations O
was O
between O
68 O
. O
1 O
+ O
/ O
- O
0 O
. O
8 O
% O
and O
73 O
. O
6 O
+ O
/ O
- O
2 O
. O
3 O
% O
, O
and O
the O
cumulative O
release O
at O
37 O
degrees O
C O
was O
98 O
- O
99 O
% O
over O
a O
period O
of O
5 O
days O
. O

Compared O
to O
intravenous O
( O
IV O
) O
fasudil B
, O
a O
~ O
10 O
fold O
increase O
in O
the O
terminal O
plasma O
half O
- O
life O
was O
observed O
when O
liposomal O
fasudil B
was O
administered O
as O
aerosols O
. O

The O
t1 O
/ O
2 O
of O
IV O
fasudil B
was O
0 O
. O
39 O
+ O
/ O
- O
0 O
. O
12 O
h O
. O
and O
when O
given O
as O
liposomes O
via O
pulmonary O
route O
, O
the O
t1 O
/ O
2 O
extended O
to O
4 O
. O
71 O
+ O
/ O
- O
0 O
. O
72 O
h O
. O

One O
h O
after O
intratracheal O
instillation O
of O
liposomal O
fasudil B
, O
mean O
pulmonary O
arterial O
pressure O
( O
MPAP O
) O
was O
reduced O
by O
37 O
. O
6 O
+ O
/ O
- O
5 O
. O
7 O
% O
and O
continued O
to O
decrease O
for O
about O
3 O
h O
, O
suggesting O
that O
liposomal O
formulations O
produced O
pulmonary O
preferential O
vasodilation O
in O
MCT B
induced O
PAH O
rats O
. O

Overall O
, O
this O
study O
established O
the O
proof O
- O
of O
- O
principle O
that O
aerosolized O
liposomal O
fasudil B
is O
a O
feasible O
option O
for O
a O
non O
- O
invasive O
, O
controlled O
release O
and O
pulmonary O
preferential O
treatment O
of O
PAH O
. O

Support O
for O
5 O
- O
HT2C O
receptor O
functional O
selectivity O
in O
vivo O
utilizing O
structurally O
diverse O
, O
selective O
5 O
- O
HT2C O
receptor O
ligands O
and O
the O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
elicited O
head O
- O
twitch O
response O
model O
. O

There O
are O
seemingly O
conflicting O
data O
in O
the O
literature O
regarding O
the O
role O
of O
serotonin O
( O
5 O
- O
HT O
) O
5 O
- O
HT2C O
receptors O
in O
the O
mouse O
head O
- O
twitch O
response O
( O
HTR O
) O
elicited O
by O
the O
hallucinogenic O
5 O
- O
HT2A O
/ O
2B O
/ O
2C O
receptor O
agonist O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
( O
DOI O
) O
. O

Commercially O
- O
available O
5 O
- O
HT2C O
agonists O
( O
CP B
809101 I
, O
Ro B
60 I
- I
0175 I
, O
WAY B
161503 I
, O
mCPP B
, O
and O
1 B
- I
methylpsilocin I
) O
, O
novel O
4 B
- I
phenyl I
- I
2 I
- I
N I
, I
N I
- I
dimethyl I
- I
aminotetralin I
( O
PAT B
) O
- O
type O
5 O
- O
HT2C O
agonists O
( O
with O
5 O
- O
HT2A O
/ O
2B O
antagonist O
activity O
) O
, O
and O
antagonists O
selective O
for O
5 O
- O
HT2A O
( O
M100907 B
) O
, O
5 O
- O
HT2C O
( O
SB O
- O

242084 O
) O
, O
and O
5 O
- O
HT2B O
/ O
2C O
( O
SB B
- I
206553 I
) O
receptors O
attenuated O
the O
DOI O
- O
elicited O
- O
HTR O
. O

The O
5 O
- O
HT2C O
agonists O
and O
M100907 B
decreased O
locomotion O
, O
SB B
- I
242084 I
increased O
locomotion O
, O
SB B
- I
206553 I
resulted O
in O
dose O
- O
dependent O
biphasic O
effects O
on O
locomotion O
, O
and O
the O
PATs O
did O
not O
alter O
locomotion O
. O

For O
this O
purpose O
phosphatidylcholine O
liposome O
formulations O
as O
well O
as O
d B
- I
alpha I
- I
tocopheryl I
polyethylene I
glycol I
1000 I
succinate I
( O
TPGS O
) O
micelle O
dispersions O
and O
polyvinylpyrrolidone O
( O
PVP O
) O
supersaturated O
solutions O
were O
prepared O
in O
order O
to O
increase O
the O
apparent O
solubility O
of O
HC O
. O

Effects O
of O
repeated O
exposure O
to O
MDMA O
on O
5HT1a O
autoreceptor O
function O
: O
behavioral O
and O
neurochemical O
responses O
to O
8 B
- I
OHDPAT I
. O

The O
response O
to O
the O
5 O
- O
HT1a O
agonist O
, O
8 B
- I
OHDPAT I
( O
0 O
. O
003 O
- O
0 O
. O
5 O
mg O
/ O
kg O
, O
SC O
) O
, O
was O
assessed O
using O
lower O
lip O
retraction O
( O
LLR O
) O
, O
hypoactivity O
, O
and O
5 B
- I
hydroxytryptophan I
( O
5 B
- I
HTP I
) O
accumulation O
following O
decarboxylase O
inhibition O
. O

The O
8 B
- I
OHDPAT I
produced O
a O
dose O
- O
dependent O
increase O
in O
LLR O
and O
hypoactivity O
, O
but O
these O
effects O
were O
comparable O
for O
MDMA O
and O
saline O
pretreated O
groups O
. O

MDMA O
decreased O
tissue O
levels O
of O
5 O
- O
HT O
and O
the O
accumulation O
of O
5 B
- I
HTP I
, O
but O
these O
effects O
were O
not O
reflected O
in O
the O
changes O
in O
autoreceptor O
sensitivity O
. O

After O
the O
brain O
samples O
were O
incinerated O
with O
nitric O
acid O
and O
perchloric B
acid I
, O
the O
element O
contents O
were O
determined O
by O
inductively O
coupled O
plasma O
- O
atomic O
emission O
spectrometry O
. O

Population O
pharmacokinetics O
of O
piperacillin B
/ O
tazobactam B
in O
neonates O
and O
young O
infants O
. O

OBJECTIVES O
: O
To O
develop O
population O
pharmacokinetic O
( O
PK O
) O
models O
for O
piperacillin B
/ O
tazobactam B
in O
neonates O
and O
infants O
of O
less O
than O
2 O
months O
of O
age O
in O
order O
to O
determine O
the O
appropriate O
dosing O
regimen O
and O
provide O
a O
rational O
basis O
for O
the O
development O
of O
preliminary O
dosing O
guidelines O
suitable O
for O
this O
population O
. O

A O
total O
of O
207 O
piperacillin B
and O
204 O
tazobactam B
concentration O
- O
time O
data O
sets O
from O
71 O
patients O
were O
analyzed O
using O
a O
nonlinear O
mixed O
- O
effect O
modeling O
approach O
( O
NONMEM O
VII O
) O
. O

PK O
models O
were O
developed O
for O
piperacillin B
and O
tazobactam B
. O

RESULTS O
: O
For O
neonates O
and O
young O
infants O
less O
than O
2 O
months O
of O
age O
, O
the O
median O
central O
clearance O
was O
0 O
. O
133 O
and O
0 O
. O
149 O
L O
/ O
h O
/ O
kg O
for O
piperacillin B
and O
tazobactam B
, O
respectively O
. O

Postmenstrual O
age O
( O
PMA O
) O
was O
identified O
as O
the O
most O
significant O
covariate O
on O
central O
clearance O
of O
piperacillin B
and O
tazobactam B
. O

Both O
internal O
and O
external O
evaluations O
supported O
the O
prediction O
of O
the O
final O
piperacillin B
and O
tazobactam B
PK O
models O
. O

The O
dosing O
strategy O
44 O
. O
44 O
/ O
5 O
. O
56 O
mg O
/ O
kg O
/ O
dose O
piperacillin B
/ O
tazobactam B
every O
8 O
or O
12 O
h O
evaluated O
in O
this O
study O
achieved O
the O
pharmacodynamic O
target O
( O
free O
piperacillin B
concentrations O
> O
4 O
mg O
/ O
L O
for O
more O
than O
50 O
% O
of O
the O
dosing O
interval O
) O
in O
about O
67 O
% O
of O
infants O
. O

CONCLUSIONS O
: O
Population O
PK O
models O
accurately O
described O
the O
PK O
profiles O
of O
piperacillin B
/ O
tazobactam B
in O
infants O
less O
than O
2 O
months O
of O
age O
. O

Iron B
bisterpyridine I
complexes O
are O
incorporated O
into O
a O
polymer O
network O
based O
on O
methacrylates B
, O
resulting O
in O
self O
- O
healing O
properties O
of O
these O
materials O
. O

The O
discovery O
of O
phenylbenzamide B
derivatives O
as O
Grb7 O
- O
based O
antitumor O
agents O
. O

Virtual O
screening O
strategies O
involving O
a O
shape O
- O
based O
similarity O
search O
, O
molecular O
docking O
, O
and O
2D O
- O
similarity O
searches O
complemented O
by O
experimental O
binding O
studies O
( O
Thermofluor O
and O
isothermal O
titration O
calorimetry O
) O
resulted O
in O
the O
identification O
of O
nine O
novel O
phenylbenzamide B
- O
based O
antagonists O
of O
the O
Grb7 O
SH2 O
domain O
. O

Moderate O
binding O
affinities O
were O
observed O
, O
ranging O
from O
K O
( O
d O
) O
= O
32 O
. O
3 O
mu O
M O
for O
lead O
phenylbenzamide B
NSC B
104999 I
( O
1 O
) O
to O
K O
( O
d O
) O
= O
1 O
. O
1 O
mu O
M O
for O
a O
structurally O
related O
compound O
, O
NSC B
57148 I
( O
2 O
) O
. O

Deconvolution O
of O
the O
affinity O
data O
into O
its O
components O
revealed O
differences O
in O
lead O
binding O
, O
from O
being O
entropy O
based O
( O
lead O
1 O
) O
to O
enthalpically O
driven O
( O
NSC B
100874 I
( O
3 O
) O
, O
NSC B
55158 I
( O
4 O
) O
, O
and O
compound O
2 O
) O
. O

Phosphodiesterases O
( O
PDEs O
) O
degrade O
cyclic B
nucleotides I
, O
signalling O
molecules O
that O
play O
important O
roles O
in O
synaptic O
plasticity O
and O
memory O
. O

Roles O
for O
PDE2 O
, O
4 O
, O
5 O
and O
9 O
in O
synaptic O
plasticity O
have O
so O
far O
been O
demonstrated O
and O
we O
review O
these O
studies O
here O
in O
the O
context O
of O
cyclic B
nucleotide I
signalling O
more O
generally O
. O

The O
role O
of O
other O
PDE O
families O
in O
synaptic O
plasticity O
has O
not O
yet O
been O
investigated O
, O
and O
this O
area O
promises O
to O
advance O
our O
understanding O
of O
cyclic B
nucleotide I
signalling O
in O
synaptic O
plasticity O
in O
the O
future O
. O

beta O
- O
Asarone O
( O
1 B
- I
propenyl I
- I
2 I
, I
4 I
, I
5 I
- I
methoxybenzol I
) O
is O
a O
compound O
from O
the O
traditional O
medical O
herb O
Acorus O
calamus O
Linn O
. O

Four O
new O
lanostane B
triterpenes I
, O
butyl B
lucidenate I
P I
( O
1 O
) O
, O
butyl B
lucidenate I
D I
( I
2 I
) I
( O
2 O
) O
, O
butyl B
lucidenate I
E I
( I
2 I
) I
( O
3 O
) O
and O
butyl B
lucidenate I
Q I
( O
4 O
) O
along O
with O
11 O
known O
compounds O
( O
5 O
- O
15 O
) O
were O
isolated O
from O
the O
fruiting O
bodies O
of O
Ganoderma O
lucidum O
. O

Inhibition O
of O
p O
- O
glycoprotein O
mediated O
multidrug O
resistance O
by O
stemofoline B
derivatives O
. O

We O
examined O
the O
mutidrug O
resistance O
reversing O
property O
of O
stemofoline B
derivatives O
in O
drug O
- O
resistance O
human O
cervical O
carcinoma O
( O
KB O
- O
V1 O
) O
and O
human O
leukemic O
( O
K562 O
/ O
Adr O
) O
cell O
lines O
that O
overexpress O
P O
- O
gp O
. O

Didehydrostemofoline B
and O
eleven O
of O
its O
derivatives O
were O
synthesized O
and O
the O
cytotoxicity O
and O
their O
effect O
on O
doxorubicin O
, O
vinblastine O
and O
paclitaxel O
sensitivity O
in O
drug O
resistant O
( O
KB O
- O
V1 O
and O
K562 O
/ O
Adr O
) O
and O
drug O
sensitive O
( O
KB O
- O
3 O
- O
1 O
and O
K562 O
) O
cell O
lines O
by O
a O
3 O
- O
( O
4 O
, O
5 O
- O
dimethylthiazol O
- O
2 O
- O
yl O
) O
- O
2 O
, O
5 O
- O
diphenyltetrazolium O
bromide O
( O
MTT O
) O
assay O
were O
determined O
. O

We O
found O
that O
three O
out O
of O
the O
twelve O
stemofoline B
derivatives O
including O
OH B
- I
A1 I
, O
NH B
- I
B6 I
and O
NH B
- I
D6 I
showed O
commitment O
efficiency O
to O
increase O
sensitivity O
to O
doxorubicin O
, O
vinblastine O
and O
paclitaxel O
in O
KB O
- O
V1 O
cells O
and O
increase O
sensitivity O
to O
doxorubicin O
, O
and O
paclitaxel O
in O
K562 O
/ O
Adr O
cells O
whereas O
the O
effects O
have O
not O
been O
seen O
in O
their O
parental O
sensitive O
cancer O
cell O
lines O
( O
KB O
- O
3 O
- O
1 O
and O
K562 O
) O
. O

These O
results O
indicate O
that O
stemofoline B
derivatives O
reversed O
P O
- O
gp O
- O
mediated O
multidrug O
resistance O
in O
vitro O
, O
and O
thus O
could O
be O
developed O
as O
effective O
chemosensitizers O
to O
treat O
multidrug O
- O
resistant O
cancers O
. O

We O
have O
previously O
reported O
that O
pyrroloquinoline B
quinone I
( O
PQQ B
) O
prevents O
the O
amyloid O
formation O
of O
alpha O
- O
synuclein O
, O
amyloid O
beta O
( O
1 O
- O
42 O
) O
( O
A O
beta O
( O
1 O
- O
42 O
) O
) O
, O
and O
mouse O
prion O
protein O
. O

Moreover O
, O
PQQ B
- O
modified O
alpha O
- O
synuclein O
and O
a O
proteolytic O
fragment O
of O
the O
PQQ B
- O
modified O
alpha O
- O
synuclein O
are O
able O
to O
inhibit O
the O
amyloid O
formation O
of O
alpha O
- O
synuclein O
. O

Here O
, O
we O
identified O
the O
peptide O
sequences O
that O
play O
an O
important O
role O
as O
PQQ B
- O
modified O
specific O
peptide O
inhibitors O
of O
alpha O
- O
synuclein O
. O

We O
demonstrate O
that O
the O
PQQ B
- O
modified O
alpha O
- O
Syn O
( O
36 O
- O
46 O
) O
peptide O
, O
which O
is O
a O
partial O
sequence O
of O
alpha O
- O
synuclein O
, O
prevented O
alpha O
- O
synuclein O
amyloid O
fibril O
formation O
but O
did O
not O
inhibit O
A O
beta O
( O
1 O
- O
42 O
) O
fibril O
formation O
. O

As O
the O
results O
of O
structure O
- O
activity O
relationship O
( O
SAR O
) O
study O
of O
the O
series O
, O
the O
compounds O
with O
4 B
- I
methyl I
- I
quinazoline I
- I
2 I
- I
yl I
- I
methyl I
group O
at O
N O
- O
1 O
position O
and O
2 B
- I
aminoethylaminomethy I
group O
gave O
better O
activities O
. O

Synthesis O
, O
DNA O
binding O
and O
antitumor O
evaluation O
of O
styelsamine B
and O
cystodytin B
analogues O
. O

A O
series O
of O
N O
- O
14 O
sidechain O
substituted O
analogues O
of O
styelsamine B
( O
pyrido B
[ I
4 I
, I
3 I
, I
2 I
- I
mn I
] I
acridine I
) O
and O
cystodytin B
( O
pyrido B
[ I
4 I
, I
3 I
, I
2 I
- I
mn I
] I
acridin I
- I
4 I
- I
one I
) O
alkaloids O
have O
been O
prepared O
and O
evaluated O
for O
their O
DNA O
binding O
affinity O
and O
antiproliferative O
activity O
towards O
a O
panel O
of O
human O
tumor O
cell O
lines O
. O

Overall O
it O
was O
found O
that O
styelsamine B
analogues O
were O
stronger O
DNA O
binders O
, O
with O
the O
natural O
products O
styelsamines B
B I
and I
D I
having O
particularly O
high O
affinity O
( O
K O
( O
app O
) O
5 O
. O
33 O
x O
10 O
( O
6 O
) O
and O
3 O
. O
64 O
x O
10 O
( O
6 O
) O
M O
( O
- O
1 O
) O
, O
respectively O
) O
. O

In O
comparison O
, O
the O
cystodytin B
iminoquinone I
alkaloids I
showed O
lower O
affinity O
for O
DNA O
, O
but O
were O
typically O
just O
as O
active O
as O
styelsamine B
analogues O
at O
inhibiting O
proliferation O
of O
tumor O
cells O
in O
vitro O
. O

Correlation O
was O
observed O
between O
whole O
cell O
activity O
and O
clogP O
, O
with O
the O
most O
potent O
antiproliferative O
activity O
being O
observed O
for O
3 B
- I
phenylpropanamide I
analogues O
37 O
and O
41 O
( O
NCI O
panel O
average O
GI O
( O
50 O
) O
0 O
. O
4 O
mu O
M O
and O
0 O
. O
32 O
mu O
M O
, O
respectively O
) O
with O
clogP O
~ O
4 O
. O
0 O
- O
4 O
. O
5 O
. O

A O
TK O
/ O
TD O
model O
was O
developed O
that O
simulates O
the O
effect O
on O
growth O
of O
the O
green O
algae O
Scenedesmus O
vacuolatus O
continuously O
exposed O
to O
the O
model O
chemicals O
norflurazon B
, O
triclosan O
, O
and O
N B
- I
phenyl I
- I
2 I
- I
naphthylamine I
. O

PEG O
- O
Modified O
Macroporous O
Poly O
( O
Glycidyl O
Methacrylate O
) O
and O
Poly B
( I
2 I
- I
Hydroxyethyl I
Methacrylate I
) I
Microspheres O
to O
Reduce O
Non O
- O
Specific O
Protein O
Adsorption O
. O

To O
minimize O
non O
- O
specific O
protein O
adsorption O
on O
macroporous O
poly O
( O
glycidyl O
methacrylate O
) O
and O
poly B
( I
2 I
- I
hydroxyethyl I
methacrylate I
) I
microspheres O
containing O
amino O
and O
/ O
or O
carboxyl O
groups O
, O
the O
microspheres O
are O
coated O
with O
alpha B
, I
omega I
- I
bis I
- I
carboxy I
poly I
( I
ethylene I
glycol I
) I
and O
amino O
- O
terminated O
poly B
( I
ethylene I
glycol I
- I
co I
- I
propylene I
glycol I
) I
or O
alpha O
- O
methoxy O
- O
omega O
- O
amino O

Adsorption O
of O
bovine O
serum O
albumin O
( O
BSA O
) O
, O
gamma O
- O
globulin O
, O
( B
125 I
) I
I I
- O
BSA O
, O
pepsin O
, O
and O
chymotrypsin O
on O
neat O
and O
PEGylated O
microspheres O
is O
determined O
by O
UV O
- O
VIS O
spectroscopy O
of O
supernatants O
and O
eluates O
or O
by O
measurement O
of O
radioactivity O
in O
an O
ionization O
chamber O
. O

To O
explore O
the O
acceptor O
regioselectivity O
of O
OleD O
- O
catalyzed O
glucosylation O
, O
the O
products O
of O
OleD O
- O
catalyzed O
reactions O
with O
six O
structurally O
diverse O
acceptors O
flavones O
- O
( O
daidzein O
) O
, O
isoflavones O
( O
flavopiridol B
) O
, O
stilbenes O
( O
resveratrol O
) O
, O
indole O
alkaloids O
( O
10 B
- I
hydroxycamptothecin I
) O
, O
and O
steroids O
( O
2 B
- I
methoxyestradiol I
) O
- O
were O
determined O
. O

This O
study O
highlights O
the O
first O
synthesis O
of O
flavopiridol B
and O
2 B
- I
methoxyestradiol I
glucosides I
and O
confirms O
the O
ability O
of O
OleD O
to O
glucosylate B
both O
aromatic O
and O
aliphatic O
nucleophiles O
. O

This O
was O
achieved O
by O
the O
addition O
of O
ethylene B
glycol I
diglycidyl I
ether I
( O
EGDE B
) O
into O
the O
cryogelation O
system O
. O

EGDE B
triggers O
the O
conformational O
transition O
of O
fibroin O
from O
random O
coil O
to O
beta O
- O
sheet O
structure O
and O
hence O
fibroin O
gelation O
. O

The O
mechanical O
compressive O
strength O
and O
the O
modulus O
of O
the O
scaffolds O
increase O
with O
decreasing O
pore O
diameter O
, O
that O
is O
, O
with O
decreasing O
gelation O
temperature O
or O
, O
with O
increasing O
fibroin O
or O
EGDE B
concentrations O
in O
the O
feed O
. O

We O
performed O
a O
combinatorial O
study O
to O
examine O
the O
effects O
of O
polymer O
chemistry O
and O
order O
of O
deposition O
of O
poly B
( I
beta I
- I
amino I
) I
esters I
on O
protein O
release O
kinetics O
under O
81 O
LBL O
assembly O
conditions O
. O

Epitaxial O
silicon O
dots O
self O
- O
assembled O
on O
aluminum B
nitride I
/ O
Si O
( O
111 O
) O
. O

The O
dot O
orientations O
are O
[ O
11 O
[ O
overline O
] O
0 O
] O
( O
Si O
) O
( O
or O
[ O
1 O
[ O
overline O
] O
10 O
] O
( O
Si O
) O
) O
/ O
/ O
[ O
112 O
[ O
overline O
] O
0 O
] O
( O
AlN O
) O
and O
( B
111 I
) I
( I
Si I
) I
/ O
/ O
( O
0001 O
) O
( O
AlN O
) O
, O
which O
are O
similar O
( O
or O
identical O
) O
to O
the O
orientation O
of O
AlN O
relative O
to O
the O
Si O
substrate O
. O

Safety O
of O
posaconazole B
. O

Among O
the O
commonly O
used O
triazoles O
, O
the O
recently O
released O
posaconazole B
is O
relatively O
less O
well O
investigated O
in O
terms O
of O
its O
safety O
. O

With O
expanding O
clinical O
use O
of O
posaconazole B
, O
the O
present O
review O
examines O
the O
safety O
of O
the O
drug O
and O
its O
propensity O
for O
drug O
- O
drug O
interaction O
. O

AREAS O
COVERED O
: O
This O
paper O
mainly O
discusses O
the O
safety O
profile O
of O
posaconazole B
, O
its O
adverse O
effects O
and O
drug O
- O
drug O
interaction O
. O

EXPERT O
OPINION O
: O
Posaconazole B
is O
generally O
safe O
and O
well O
tolerated O
. O

Lack O
of O
an O
intravenous O
formulation O
and O
unpredictable O
bioavailability O
of O
the O
suspension O
form O
are O
significant O
factors O
limiting O
the O
widespread O
use O
of O
posaconazole B
. O

We O
measure O
concentration O
- O
dependent O
diffusion O
rates O
for O
n O
- O
hexane O
, O
n B
- I
octane I
, O
n B
- I
decane I
, O
2 B
, I
7 I
- I
dimethyloctane I
, O
and O
cyclodecane B
, O
which O
have O
different O
carbon O
numbers O
and O
geometries O
: O
straight O
chain O
, O
branched O
chain O
, O
and O
cyclic O
. O

Micropore O
diffusion O
is O
determined O
to O
be O
the O
controlling O
mass O
transfer O
resistance O
except O
at O
low O
relative O
saturation O
for O
n B
- I
decane I
, O
where O
an O
external O
mass O
transfer O
resistance O
also O
becomes O
important O
, O
showing O
that O
the O
controlling O
mass O
transfer O
mechanism O
can O
change O
with O
system O
concentration O
. O

Design O
, O
synthesis O
, O
and O
structure O
- O
activity O
relationship O
studies O
of O
tryptanthrins B
as O
antitubercular O
agents O
. O

The O
natural O
product O
tryptanthrin B
( O
1a O
) O
represents O
a O
potential O
lead O
for O
new O
tuberculosis O
( O
TB O
) O
drugs O
since O
tryptanthrin B
and O
its O
synthetic O
analogues O
possess O
potent O
in O
vitro O
activity O
against O
Mycobacterium O
tuberculosis O
( O
Mtb O
) O
. O

Described O
herein O
are O
syntheses O
of O
new O
tryptanthrin B
analogues O
together O
with O
a O
systematic O
investigation O
of O
their O
in O
vitro O
antitubercular O
activity O
and O
ADME O
properties O
followed O
by O
pharmacokinetic O
characterization O
in O
rodents O
for O
the O
most O
promising O
compounds O
. O

Novel O
C O
- O
11 O
- O
deoxy O
( O
5b O
) O
and O
A O
- O
ring O
- O
saturated O
( O
6 O
) O
tryptanthrin B
analogues O
were O
discovered O
that O
maintained O
activity O
against O
Mtb O
and O
showed O
improved O
solubility O
compared O
to O
tryptanthrin B
as O
well O
as O
evidence O
of O
oral O
bioavailability O
in O
rodents O
. O

Although O
5b O
and O
6 O
failed O
to O
inhibit O
replication O
or O
kill O
Mtb O
in O
vivo O
, O
they O
illuminate O
a O
path O
to O
new O
structural O
variations O
of O
the O
tryptanthrin B
scaffold O
that O
may O
maximize O
the O
potential O
of O
this O
class O
of O
compounds O
against O
TB O
. O

pi O
- O
Conjugated O
nickel B
bis I
( I
dithiolene I
) I
complex O
nanosheet O
. O

A O
pi O
- O
conjugated O
nanosheet O
comprising O
planar O
nickel B
bis I
( I
dithiolene I
) I
complexes O
was O
synthesized O
by O
a O
bottom O
- O
up O
method O
. O

A O
liquid O
- O
liquid O
interfacial O
reaction O
using O
benzenehexathiol B
in O
the O
organic O
phase O
and O
nickel B
( I
II I
) I
acetate I
in O
the O
aqueous O
phase O
produced O
a O
semiconducting O
bulk O
material O
with O
a O
thickness O
of O
several O
micrometers O
. O

In O
vitro O
and O
mechanistic O
studies O
of O
an O
antiamyloidogenic O
self O
- O
assembled O
cyclic B
D I
, I
L I
- I
alpha I
- I
peptide I
architecture O
. O

Given O
the O
significant O
similarities O
between O
amyloids O
and O
the O
architecture O
of O
self O
- O
assembled O
cyclic B
D I
, I
L I
- I
alpha I
- I
peptide I
, O
we O
hypothesized O
that O
the O
latter O
may O
bind O
and O
stabilize O
a O
nontoxic O
form O
of O
A O
beta O
, O
thereby O
preventing O
its O
aggregation O
into O
toxic O
forms O
. O

By O
screening O
a O
focused O
library O
of O
six O
- O
residue O
cyclic B
D I
, I
L I
- I
alpha I
- I
peptides I
and O
optimizing O
the O
activity O
of O
a O
lead O
peptide O
, O
we O
found O
one O
cyclic B
D I
, I
L I
- I
alpha I
- I
peptide I
( O
CP B
- I
2 I
) O
that O
interacts O
strongly O
with O
A O
beta O
and O
inhibits O
its O
aggregation O
. O

In O
transmission O
electron O
microscopy O
, O
optimized O
thioflavin O
T O
and O
cell O
survival O
assays O
, O
CP B
- I
2 I
inhibits O
the O
formation O
of O
A O
beta O
aggregates O
, O
entirely O
disassembles O
preformed O
aggregated O
and O
fibrillar O
A O
beta O
, O
and O
protects O
rat O
pheochromocytoma O
PC12 O
cells O
from O
A O
beta O
toxicity O
, O
without O
inducing O
any O
toxicity O
by O
itself O
. O

Using O
various O
immunoassays O
, O
circular O
dichroism O
spectroscopy O
, O
photoinduced O
cross O
- O
linking O
of O
unmodified O
proteins O
( O
PICUP O
) O
combined O
with O
SDS O
/ O
PAGE O
, O
and O
NMR O
, O
we O
probed O
the O
mechanisms O
underlying O
CP B
- I
2 I
' O
s O
antiamyloidogenic O
activity O
. O

NMR O
spectroscopy O
indicates O
that O
CP B
- I
2 I
interacts O
with O
A O
beta O
through O
its O
self O
- O
assembled O
conformation O
and O
induces O
weak O
secondary O
structure O
in O
A O
beta O
. O

Upon O
coincubation O
, O
CP B
- I
2 I
changes O
the O
aggregation O
pathway O
of O
A O
beta O
and O
alters O
its O
oligomer O
distribution O
by O
stabilizing O
small O
oligomers O
( O
1 O
- O
3 O
mers O
) O
. O

Our O
results O
support O
studies O
suggesting O
that O
toxic O
early O
oligomeric O
states O
of O
A O
beta O
may O
be O
composed O
of O
antiparallel O
beta O
- O
peptide O
structures O
and O
that O
the O
interaction O
of O
A O
beta O
with O
CP B
- I
2 I
promotes O
formation O
of O
more O
benign O
parallel O
beta O
- O
structures O
. O

Further O
studies O
will O
show O
whether O
these O
kinds O
of O
abiotic O
cyclic B
D I
, I
L I
- I
alpha I
- I
peptides I
are O
also O
beneficial O
as O
an O
intervention O
in O
related O
in O
vivo O
models O
. O

X O
- O
ray O
absorption O
spectroscopy O
and O
energy O
storage O
of O
Ni O
- O
doped O
cobalt B
nitride I
, O
( B
Ni I
( I
0 I
. I
33 I
) I
Co I
( I
0 I
. I
67 I
) I
) I
N I
, O
prepared O
by O
a O
simple O
synthesis O
route O
. O

Metal B
nitride I
( B
Ni I
( I
0 I
. I
33 I
) I
Co I
( I
0 I
. I
67 I
) I
) I
N I
nanoparticles O
are O
prepared O
by O
nitridation O
using O
NiCo B
( I
2 I
) I
O I
( I
4 I
) I
as O
a O
precursor O
material O
by O
heating O
at O
335 O
degrees O
C O
for O
2 O
h O
in O
flowing O
NH O
( O
3 O
) O
+ O
N O
( O
2 O
) O
gas O
and O
characterized O
by O
X O
- O
ray O
diffraction O
( O
XRD O
) O
, O
field O
emission O
- O
scanning O
electron O
microscopy O
( O
FE O
- O
SEM O
) O
, O
high O
resolution O
- O
transmission O
electron O
microscopy O
( O
HR O
- O
TEM O
) O
, O
along O
with O
selective O
area O
electron O
diffraction O
( O
SAED O
) O
and O
X O

The O
( B
Ni I
( I
0 I
. I
33 I
) I
Co I
( I
0 I
. I
67 I
) I
) I
N I
showed O
a O
shift O
in O
edge O
energy O
towards O
lower O
values O
due O
to O
Ni O
- O
doping O
to O
cobalt O
site O
. O

The O
Li O
- O
storage O
behaviour O
of O
( B
Ni I
( I
0 I
. I
33 I
) I
Co I
( I
0 I
. I
67 I
) I
) I
N I
nanoparticles O
was O
evaluated O
by O
galvanostatic O
cycling O
and O
cyclic O
voltammetry O
in O
the O
cells O
with O
Li O
- O
metal O
as O
counter O
electrode O
in O
the O
voltage O
range O
of O
0 O
. O
005 O
- O
3 O
. O
0 O
V O
at O
ambient O
temperature O
. O

The O
average O
charge O
and O
discharge O
potentials O
are O
~ O
2 O
. O
03 O
and O
~ O
1 O
. O
0 O
V O
, O
respectively O
for O
the O
decomposition O
/ O
formation O
of O
Li B
( I
3 I
) I
N I
as O
determined O
by O
electroanalytical O
techniques O
. O

Data O
is O
presented O
for O
ethylammonium B
nitrate I
( O
EAN B
) O
and O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
bis I
( I
trifluoro I
- I
methylsulfonyl I
) I
imide I
( O
EMIm B
TFSI I
) O
. O

Whereas O
EAN B
is O
a O
protic O
IL O
that O
forms O
a O
nanostructured O
sponge O
phase O
in O
the O
bulk O
, O
EMIm B
TFSI I
is O
aprotic O
and O
has O
weak O
( O
or O
absent O
) O
bulk O
association O
structure O
. O

Imaging O
reveals O
EAN B
self O
assembles O
at O
the O
solid O
surface O
in O
a O
worm O
- O
like O
morphology O
, O
whereas O
EMIm B
cations O
adsorb O
in O
a O
more O
isolated O
fashion O
, O
but O
still O
in O
rows O
templated O
by O
the O
mica O
surface O
. O

To O
the O
authors O
' O
knowledge O
, O
the O
wormlike O
structures O
present O
at O
the O
EAN B
- O
mica O
interface O
are O
the O
smallest O
self O
- O
assembled O
aggregates O
ever O
imaged O
on O
a O
solid O
surface O
. O

These O
include O
trials O
of O
administering O
dichloroacetate B
( O
an O
activator O
of O
pyruvate O
dehydrogenase O
complex O
) O
, O
arginine O
or O
citrulline O
( O
precursors O
of O
nitric O
oxide O
) O
, O
coenzyme B
Q10 I
( O
CoQ10 B
; O
part O
of O
the O
electron O
transport O
chain O
and O
an O
antioxidant O
) O
, O
idebenone B
( O
a O
synthetic O
analogue O
of O
CoQ10 B
) O
, O
EPI B
- I
743 I
( O
a O
novel O
oral O
potent O
2 O
- O
electron O
redox O
cycling O
agent O
) O
, O
creatine O
( O
a O
precursor O
of O
phosphocreatine B
) O
, O
combined O
administration O
( O
of O

creatine O
, O
alpha B
- I
lipoate I
, O
and O
CoQ10 B
) O
, O
and O
exercise O
training O
( O
to O
increase O
muscle O
mitochondria O
) O
. O

One O
trial O
( O
idebenone B
treatment O
of O
Leber O
hereditary O
optic O
neuropathy O
) O
did O
not O
show O
significant O
improvement O
in O
the O
primary O
outcome O
, O
but O
there O
was O
significant O
improvement O
in O
a O
subgroup O
of O
patients O
. O

The O
pathogenicity O
of O
the O
mutation O
, O
as O
indicated O
by O
the O
structure O
- O
based O
functional O
analyses O
, O
was O
further O
confirmed O
by O
abnormal O
monolysocardiolipin B
/ O
cardiolipin O
ratio O
in O
dry O
blood O
spots O
of O
the O
patients O
as O
well O
as O
the O
occurrence O
of O
this O
mutation O
in O
another O
reported O
BTHS O
proband O
. O

As O
a O
preliminary O
electrochemical O
application O
, O
the O
obtained O
Ag O
@ O
Pt O
nanostructures O
were O
applied O
in O
the O
methanol O
oxidation O
reaction O
( O
MOR O
) O
in O
0 O
. O
5 O
M O
H B
( I
2 I
) I
SO I
( I
4 I
) I
solution O
containing O
0 O
. O
5 O
M O
methanol O
. O

The O
electrochemical O
oxygen O
reduction O
reaction O
( O
ORR O
) O
on O
a O
n O
- O
Ge O
( O
100 O
) O
surface O
in O
0 O
. O
1 O
M O
HClO4 B
was O
investigated O
in O
situ O
and O
operando O
using O
a O
combination O
of O
attenuated O
total O
reflection O
infrared O
( O
ATR O
- O
IR O
) O
spectroscopy O
and O
density O
functional O
( O
DFT O
) O
calculations O
. O

The O
vibrational O
modes O
of O
the O
detected O
intermediates O
were O
assigned O
based O
on O
DFT O
calculations O
of O
solvated O
model O
clusters O
such O
as O
Ge O
- O
bound O
superoxides B
and O
peroxides O
. O

At O
slightly O
negative O
potentials O
, O
the O
surface O
- O
bound O
peroxide O
is O
identified O
by O
an O
OOH B
bending O
mode O
as O
a O
further O
intermediate O
, O
oriented O
at O
a O
similar O
angle O
. O

Role O
of O
cytochrome O
P4502B6 O
in O
methadone B
metabolism O
and O
clearance O
. O

Methadone B
N O
- O
demethylation O
in O
vitro O
is O
catalyzed O
by O
hepatic O
cytochrome O
P4502B6 O
( O
CYP2B6 O
) O
and O
CYP3A4 O
, O
but O
clinical O
disposition O
is O
often O
attributed O
to O
CYP3A4 O
. O

This O
investigation O
tested O
the O
hypothesis O
that O
CYP2B6 O
is O
a O
prominent O
CYP O
isoform O
responsible O
for O
clinical O
methadone B
N O
- O
demethylation O
and O
clearance O
, O
using O
the O
in O
vivo O
mechanism O
- O
based O
CYP2B6 O
inhibitor O
ticlopidine B
, O
given O
orally O
for O
4 O
days O
. O

A O
preliminary O
clinical O
investigation O
with O
the O
CYP3A4 O
/ O
5 O
substrate O
probe O
alfentanil B
established O
that O
ticlopidine B
did O
not O
inhibit O
intestinal O
or O
hepatic O
CYP3A4 O
/ O
5 O
. O

Subjects O
received O
intravenous O
plus O
oral O
( O
deuterium O
- O
labeled O
) O
racemic B
methadone I
before O
and O
after O
ticlopidine B
. O

Ticlopidine B
significantly O
and O
stereoselectively O
( O
S O
> O
R O
) O
inhibited O
methadone B
N O
- O
demethylation O
, O
decreasing O
plasma O
metabolite O
/ O
methadone B
area O
under O
the O
curve O
ratios O
and O
metabolite O
formation O
clearances O
. O

Ticlopidine B
also O
significantly O
increased O
the O
dose O
- O
adjusted O
plasma O
area O
under O
the O
curve O
for O
R B
- I
and I
S I
- I
methadone I
by O
20 O
% O
and O
60 O
% O
, O
respectively O
, O
after O
both O
intravenous O
and O
oral O
dosing O
. O

CYP2B6 O
inhibition O
reduces O
methadone B
N O
- O
demethylation O
and O
clearance O
, O
and O
alters O
methadone B
concentrations O
, O
demonstrating O
an O
important O
role O
for O
CYP2B6 O
in O
clinical O
methadone B
disposition O
. O

Functional O
imaging O
with O
( B
111 I
) I
Indium I
- O
octreotide O
with O
single O
photon O
emission O
computed O
tomography O
( O
octreo O
- O
SPECT O
or O
SPECT O
/ O
CT O
) O
, O
and O
( B
18 I
) I
fluorodeoxyglucose I
positron O
emission O
tomography O
/ O
CT O
( O
FDG O
- O
PET O
/ O
CT O
) O
were O
performed O
, O
followed O
by O
anatomic O
imaging O
( O
CT O
, O
MRI O
) O
. O

Serum O
1 O
, O
25 O
- O
dihydroxyvitamin O
D O
( O
3 O
) O
( O
1 B
, I
25D I
) O
rose O
and O
exceeded O
the O
normal O
range O
. O

Sustained O
elevations O
in O
cFGF23 O
and O
1 B
, I
25D I
were O
observed O
, O
suggesting O
novel O
regulation O
of O
FGF23 O
processing O
and O
1 B
, I
25D I
generation O
. O

Using O
the O
mTOR O
inhibitor O
PP242 B
, I
we O
found O
that O
TGF O
beta O
- O
induced O
both O
early O
and O
sustained O
activation O
of O
TORC1 O
and O
TORC2 O
was O
necessary O
for O
deptor O
suppression O
. O

PP242 B
- O
induced O
reversal O
of O
deptor O
suppression O
by O
TGF O
beta O
was O
associated O
with O
a O
significant O
inhibition O
of O
TGF O
beta O
- O
stimulated O
protein O
synthesis O
and O
hypertrophy O
. O

While O
the O
cation O
exchange O
procedure O
, O
performed O
in O
solution O
phase O
approach O
, O
was O
restricted O
so O
far O
to O
chalcogenide O
based O
semiconductor O
nanocrystals O
, O
here O
ferrite B
- O
based O
nanocrystals O
were O
subjected O
to O
a O
Fe O
( O
2 O
+ O
) O
to O
Co O
( O
2 O
+ O
) O
cation O
exchange O
procedure O
. O

By O
applying O
the O
cation O
exchange O
to O
FeO B
/ O
CoFe B
( I
2 I
) I
O I
( I
4 I
) I
core O
/ O
shell O
nanocrystals O
the O
Ne O
e O
l O
temperature O
of O
the O
core O
material O
is O
increased O
and O
exchange O
- O
bias O
effects O
are O
enhanced O
so O
that O
vertical O
shifts O
of O
the O
hysteresis O
loops O
are O
obtained O
which O
are O
superior O
to O
those O
in O
any O
other O
system O
. O

Synthesis O
of O
superconducting O
nanocables O
of O
FeSe B
encapsulated O
in O
carbonaceous O
shell O
. O

The O
recent O
discovery O
of O
superconductivity O
in O
iron B
selenide I
has O
attracted O
considerable O
attention O
due O
to O
the O
simplicity O
of O
composition O
, O
unconventional O
nature O
of O
superconductivity O
, O
and O
ease O
of O
synthesis O
. O

We O
have O
synthesized O
superconducting O
FeSe B
nanowires O
with O
a O
simple O
catalyst O
- O
aided O
vapor O
transport O
reaction O
at O
800 O
degrees O
C O
in O
an O
inert O
atmosphere O
. O

The O
precursors O
were O
chosen O
to O
be O
elemental O
Se O
and O
iron B
acetylacetonate I
[ O
Fe B
( I
III I
) I
( I
C I
5 I
H I
8 I
O I
2 I
) I
3 I
] O
. O

These O
vaporized O
very O
easily O
, O
thereby O
facilitating O
transport O
, O
and O
also O
contributed O
to O
the O
formation O
of O
a O
carbonaceous O
shell O
encapsulating O
the O
FeSe B
nanowires O
. O

The O
length O
of O
FeSe B
filling O
inside O
the O
carbon O
nanofibers O
could O
be O
varied O
by O
controlling O
the O
reaction O
conditions O
while O
the O
diameter O
of O
nanowires O
was O
dependent O
on O
the O
thickness O
of O
Au B
- I
Pd I
coating O
used O
as O
a O
catalyst O
. O

Extensive O
analysis O
through O
high O
- O
resolution O
microscopy O
revealed O
that O
there O
was O
considerable O
lattice O
contraction O
of O
FeSe B
in O
the O
nanocable O
up O
to O
about O
3 O
. O
6 O
% O
along O
the O
c O
- O
direction O
leading O
to O
a O
reduced O
spacing O
between O
the O
( O
001 O
) O
lattice O
planes O
. O

Interestingly O
, O
this O
compression O
was O
more O
pronounced O
near O
the O
catalyst O
- O
FeSe B
interface O
and O
was O
reduced O
further O
along O
the O
length O
of O
the O
nanocable O
. O

The O
presence O
of O
carbon O
nanofibers O
as O
a O
shell O
around O
the O
FeSe B
protected O
the O
FeSe B
nanowires O
from O
both O
atmospheric O
O O
2 O
and O
moisture O
attack O
, O
as O
was O
evident O
from O
the O
very O
long O
ambient O
condition O
shelf O
life O
of O
these O
nanocables O
, O
and O
also O
makes O
them O
more O
stable O
under O
e O
- O
beam O
irradiation O
. O

Genistein O
, O
a O
natural O
product O
derived O
from O
soybeans O
, O
ameliorates O
polyglutamine B
- O
mediated O
motor O
neuron O
disease O
. O

Spinal O
and O
bulbar O
muscular O
atrophy O
( O
SBMA O
) O
is O
an O
inherited O
motor O
neuron O
disease O
caused O
by O
the O
expansion O
of O
a O
polyglutamine B
( O
polyQ B
) O
tract O
within O
the O
androgen O
receptor O
( O
AR O
) O
gene O
. O

High O
T O
( O
g O
) O
bio O
- O
based O
aliphatic O
polyesters B
from O
bicyclic B
D I
- I
mannitol I
. O

The O
carbohydrate O
- O
based O
diol O
2 B
, I
4 I
: I
3 I
, I
5 I
- I
di I
- I
O I
- I
methylene I
- I
d I
- I
mannitol I
( O
Manx O
) O
has O
been O
used O
to O
obtain O
aliphatic O
polyesters B
. O

Manx O
is O
a O
symmetric O
bicyclic O
compound O
consisting O
of O
two O
fused O
1 B
, I
3 I
- I
dioxane I
rings O
and O
bearing O
two O
primary O
hydroxyl O
groups O
. O

In O
terms O
of O
stiffness O
, O
it O
is O
comparable O
to O
the O
widely O
known O
isosorbide B
, O
but O
it O
affords O
the O
additional O
advantages O
of O
being O
much O
more O
reactive O
in O
polycondensation O
and O
capable O
of O
producing O
stereoregular O
polymers O
with O
fairly O
high O
molecular O
weights O
. O

A O
fully O
bio O
- O
based O
homopolyester O
( O
PManxS O
) O
has O
been O
synthesized O
by O
polycondensation O
in O
the O
melt O
from O
dimethyl B
succinate I
and O
Manx O
. O

In O
addition O
, O
random O
copolyesters O
( O
PBxManxyS O
) O
covering O
a O
broad O
range O
of O
compositions O
have O
been O
obtained O
using O
mixtures O
of O
Manx O
and O
1 O
, O
4 O
- O
butanediol O
in O
the O
reaction O
with O
dimethyl B
succinate I
. O

Tetrabenzoporphyrins B
: O
synthetic O
developments O
and O
applications O
. O

Tetrabenzoporphyrins B
have O
attracted O
considerable O
worldwide O
attention O
over O
the O
last O
few O
decades O
. O

Nowadays O
, O
tetrabenzoporphyrins B
occupy O
a O
prominent O
position O
in O
porphyrin O
chemistry O
, O
and O
this O
review O
is O
intended O
to O
cover O
the O
main O
synthetic O
methods O
and O
applications O
of O
these O
compounds O
. O

Seven O
opiate O
users O
received O
methadone B
and O
seven O
buprenorphine O
maintenance O
. O

Six O
detoxified O
subjects O
received O
naltrexone B
. O

Sucrose O
recognition O
thresholds O
and O
measurements O
of O
pleasantness O
and O
intensity O
were O
determined O
before O
and O
four O
hours O
after O
1 O
) O
a O
single O
dose O
of O
methadone B
or O
buprenorphine O
or O
2 O
) O
naltrexone B
. O

Acute O
methadone B
administration O
reduced O
salt O
thresholds O
and O
unpleasantness O
to O
control O
levels O
. O

Heracleifolinosides B
A I
- I
F I
, O
new O
triterpene B
glycosides I
from O
Cimicifuga O
heracleifolia O
, O
and O
their O
inhibitory O
activities O
against O
hypoxia O
and O
reoxygenation O
. O

Six O
new O
9 B
, I
19 I
- I
cycloartane I
triterpene I
glycosides I
, O
heracleifolinosides B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
and O
one O
new O
chromone O
, O
norkhelloside B
( O
7 O
) O
, O
were O
isolated O
from O
the O
rhizome O
of O
Cimicifuga O
heracleifolia O
, O
together O
with O
15 O
known O
compounds O
( O
8 O
- O
22 O
) O
. O

Heracleifolinoside B
B I
( O
2 O
) O
is O
effectively O
resistant O
to O
hypoxia O
and O
reoxygenation O
- O
induced O
human O
umbilical O
vein O
endothelial O
cell O
injury O
, O
with O
cell O
viabilities O
of O
61 O
. O
95 O
+ O
/ O
- O
2 O
. O
04 O
% O
, O
77 O
. O
04 O
+ O
/ O
- O
4 O
. O
44 O
% O
, O
and O
83 O
. O
65 O
+ O
/ O
- O
3 O
. O
29 O
% O
at O
concentrations O
of O
1 O
, O
10 O
, O
and O
100 O
micro O
M O
, O
respectively O
. O

Model O
for O
conformational O
relaxation O
of O
flexible O
conjugated O
polymers O
: O
application O
to O
p B
- I
phenylenevinylene I
trimers I
in O
nonpolar O
solvents O
. O

The O
model O
is O
able O
to O
account O
for O
the O
softening O
of O
solute O
- O
solvent O
interactions O
and O
its O
predictions O
are O
found O
to O
be O
in O
excellent O
agreement O
with O
the O
observed O
relaxation O
rate O
constants O
of O
a O
series O
of O
substituted O
p B
- I
phenylenevinylene I
trimers I
[ O
ChemPhysChem O
2009 O
, O
10 O
, O
448 O
- O
454 O
] O
on O
T O
, O
eta O
and O
the O
size O
of O
the O
side O
- O
chains O
. O

Progression O
in O
the O
field O
has O
taken O
a O
recent O
step O
forward O
with O
the O
approval O
of O
ruxolitinib O
( O
Jakafi B
) O
, O
a O
selective O
inhibitor O
of O
JAK1 O
/ O
2 O
and O
very O
recently O
tofacitinib B
( O
Xeljanz B
) O
, O
a O
pan O
- O
JAK O
inhibitor O
. O

EXPERT O
OPINION O
: O
JAK O
inhibitor O
therapy O
is O
entering O
a O
significant O
new O
era O
with O
the O
advent O
on O
the O
market O
of O
the O
JAK1 O
/ O
2 O
inhibitor O
ruxolitinib O
and O
the O
pan O
- O
JAK O
inhibitor O
tofacitinib B
, O
with O
unprecedented O
speed O
of O
development O
. O

Crystallization O
of O
glycine O
in O
the O
cylindrical O
nanopores O
of O
anodic O
aluminum O
oxide O
( O
AAO B
) O
revealed O
the O
formation O
of O
metastable O
beta B
- I
glycine I
in O
pores O
having O
diameters O
less O
than O
200 O
nm O
. O

Two O
- O
dimensional O
X O
- O
ray O
microdiffraction O
indicated O
that O
the O
[ O
010 O
] O
axis O
of O
the O
embedded O
beta B
- I
glycine I
nanocrystals O
coincided O
with O
the O
pore O
direction O
, O
identical O
to O
behavior O
observed O
previously O
in O
the O
cylindrical O
nanopores O
of O
polymer O
monoliths O
. O

Whereas O
the O
beta B
- I
glycine I
nanocrystals O
were O
stable O
indefinitely O
in O
ambient O
air O
and O
persisted O
upon O
heating O
, O
they O
transformed O
to O
the O
alpha O
polymorph O
upon O
standing O
at O
room O
temperature O
and O
90 O
% O
relative O
humidity O
( O
RH O
) O
. O

The O
alpha B
- I
glycine I
nanocrystals O
were O
oriented O
with O
the O
[ O
010 O
] O
axis O
nearly O
perpendicular O
to O
the O
pore O
direction O
, O
reflecting O
a O
nearly O
90 O
degrees O
rotation O
of O
the O
glycine O
molecules O
during O
the O
transition O
. O

When O
the O
beta B
- I
glycine I
nanocrystals O
were O
formed O
in O
the O
AAO B
cylinders O
in O
the O
presence O
of O
small O
amounts O
of O
racemic O
hydrophobic O
amino O
acid O
auxiliaries O
, O
which O
are O
known O
to O
bind O
selectively O
to O
the O
( O
010 O
) O
and O
( O
010 O
) O
faces O
on O
the O
fast O
- O
growing O
end O
of O
beta B
- I
glycine I
enantiomorphs O
, O
the O
beta O
- O
- O
> O
alpha O
phase O
transition O
at O
90 O
% O
RH O
was O
suppressed O
. O

In O
contrast O
, O
beta B
- I
glycine I
nanocrystals O
grown O
in O
the O
presence O
of O
an O
enantiopure O
amino O
acid O
auxiliary O
, O
which O
binds O
to O
the O
fast O
- O
growing O
end O
of O
only O
one O
of O
the O
enantiomorphs O
, O
thus O
suppressing O
its O
formation O
and O
leaving O
the O
other O
enantiomorph O
unperturbed O
, O
transformed O
into O
the O
alpha O
polymorph O
under O
the O
same O
conditions O
. O

The O
impact O
of O
functionalization O
on O
the O
stability O
, O
work O
function O
, O
and O
photoluminescence O
of O
reduced B
graphene I
oxide I
. O

Reduced B
graphene I
oxide I
( O
rGO B
) O
is O
a O
promising O
material O
for O
a O
variety O
of O
thin O
- O
film O
optoelectronic O
applications O
. O

Two O
main O
barriers O
to O
its O
widespread O
use O
are O
the O
lack O
of O
( O
1 O
) O
fabrication O
protocols O
leading O
to O
tailored O
functionalization O
of O
the O
graphene O
sheet O
with O
oxygen O
- O
containing O
chemical O
groups O
, O
and O
( O
2 O
) O
understanding O
of O
the O
impact O
of O
such O
functional O
groups O
on O
the O
stability O
and O
on O
the O
optical O
and O
electronic O
properties O
of O
rGO B
. O

We O
carry O
out O
classical O
molecular O
dynamics O
and O
density O
functional O
theory O
calculations O
on O
a O
large O
set O
of O
realistic O
rGO B
structures O
to O
decompose O
the O
effects O
of O
different O
functional O
groups O
on O
the O
stability O
, O
work O
function O
, O
and O
photoluminescence O
. O

Our O
calculations O
indicate O
the O
metastable O
nature O
of O
carbonyl O
- O
rich O
rGO B
and O
its O
favorable O
transformation O
to O
hydroxyl O
- O
rich O
rGO B
at O
room O
temperature O
via O
carbonyl O
- O
to O
- O
hydroxyl O
conversion O
reactions O
near O
carbon O
vacancies O
and O
holes O
. O

We O
demonstrate O
a O
significant O
tunability O
in O
the O
work O
function O
of O
rGO B
up O
to O
2 O
. O
5 O
eV O
by O
altering O
the O
composition O
of O
oxygen O
- O
containing O
functional O
groups O
for O
a O
fixed O
oxygen O
concentration O
, O
and O
of O
the O
photoluminescence O
emission O
by O
modulating O
the O
fraction O
of O
epoxy O
and O
carbonyl O
groups O
. O

Taken O
together O
, O
our O
results O
guide O
the O
application O
of O
tailored O
rGO B
structures O
in O
devices O
for O
optoelectronics O
and O
renewable O
energy O
. O

The O
contrasting O
activity O
of O
iodido B
versus O
chlorido B
ruthenium I
and O
osmium B
arene I
azo I
- I
and I
imino I
- I
pyridine I
anticancer O
complexes O
: O
control O
of O
cell O
selectivity O
, O
cross O
- O
resistance O
, O
p53 O
dependence O
, O
and O
apoptosis O
pathway O
. O

Organometallic O
half O
- O
sandwich O
complexes O
[ B
M I
( I
p I
- I
cymene I
) I
( I
azo I
/ I
imino I
- I
pyridine I
) I
X I
] I
( I
+ I
) I
where O
M B
= I
Ru I
( I
II I
) I
or I
Os I
( I
II I
) I
and O
X B
= I
Cl I
or I
I I
, O
exhibit O
potent O
antiproliferative O
activity O
toward O
a O
range O
of O
cancer O
cells O
. O

Not O
only O
are O
the O
iodido B
complexes O
more O
potent O
than O
the O
chlorido B
analogues O
, O
but O
they O
are O
not O
cross O
- O
resistant O
with O
the O
clinical O
platinum O
drugs O
cisplatin O
and O
oxaliplatin B
. O

The O
iodido B
complexes O
retain O
potency O
in O
p53 O
mutant O
colon O
cells O
. O

In O
general O
, O
antiproliferative O
activity O
is O
greatly O
enhanced O
by O
low O
levels O
of O
the O
glutathione O
synthase O
inhibitor O
l B
- I
buthionine I
sulfoxime I
. O

A O
nanoparticle O
synthetic O
strategy O
for O
the O
preparation O
of O
a O
new O
metastable O
Cu O
( O
I O
) O
- O
niobate B
is O
described O
, O
and O
that O
involves O
multipored O
Li B
3 I
NbO I
4 I
nanoparticles O
as O
a O
precursor O
. O

A O
hydrothermal O
reaction O
of O
HNbO B
3 I
and O
LiOH B
. I
H I
2 I
O I
in O
PEG200 B
and O
water O
at O
~ O
180 O
degrees O
C O
yields O
~ O
15 O
- O
40 O
nm O
Li B
3 I
NbO I
4 I
particles O
. O

These O
particles O
are O
subsequently O
used O
in O
a O
solvothermal O
copper O
( O
I O
) O
- O
exchange O
reaction O
with O
excess O
CuCl B
at O
150 O
degrees O
C O
. O

Heating O
these O
products O
within O
the O
used O
CuCl B
flux O
( O
mp O
= O
430 O
degrees O
C O
) O
to O
450 O
degrees O
C O
for O
30 O
min O
yields O
~ O
4 O
- O
12 O
nm O
Cu B
2 I
Nb I
8 I
O I
2 I
1 I
crystalline O
nanoparticles O
, O
and O
for O
a O
heating O
time O
of O
24 O
h O
yields O
mu O
m O
- O
sized O
, O
rod O
- O
shaped O
crystals O
. O

The O
new O
structure O
was O
characterized O
by O
single O
- O
crystal O
X O
- O
ray O
diffraction O
to O
have O
a O
condensed O
network O
consisting O
of O
NbO B
7 I
polyhedra O
and O
chains O
of O
elongated O
CuO B
4 I
tetrahedra O
. O

Electronic O
structure O
calculations O
based O
on O
density O
functional O
theory O
show O
that O
the O
bandgap O
transition O
results O
from O
the O
excitation O
of O
electrons O
at O
the O
band O
edges O
between O
filled O
Cu O
( O
I O
) O
3d O
( O
1 O
) O
0 O
- O
orbitals O
and O
empty O
Nb B
( I
V I
) I
4d O
0 O
- O
orbitals O
, O
respectively O
. O

The O
p O
- O
type O
nature O
of O
the O
Cu B
2 I
Nb I
8 I
O I
2 I
1 I
particles O
was O
confirmed O
in O
photoelectrochemical O
measurements O
on O
polycrystalline O
films O
that O
show O
a O
strong O
photocathodic O
current O
under O
visible O
- O
light O
irradiation O
in O
aqueous O
solutions O
. O

The O
polynorbornene B
- O
backbone O
- O
based O
BrBCPs O
containing O
approximately O
equal O
volume O
fractions O
of O
each O
block O
self O
- O
assembled O
into O
highly O
ordered O
lamellae O
with O
domain O
spacing O
ranging O
from O
20 O
to O
240 O
nm O
by O
varying O
molecular O
weight O
of O
the O
backbone O
in O
the O
bulk O
state O
, O
as O
revealed O
by O
small O
- O
angle O
X O
- O
ray O
scattering O
( O
SAXS O
) O
. O

Four O
new O
compounds O
, O
( B
- I
) I
- I
petrosynoic I
acids I
A I
- I
D I
( O
1 O
- O
4 O
) O
, O
and O
five O
known O
congeners O
, O
pellynols B
A I
( I
5 I
) I
, I
C I
( I
6 I
) I
, I
D I
( I
7 I
) I
, I
F I
( I
8 I
) I
, I
and I
I I
( O
9 O
) O
, O
were O
isolated O
from O
a O
Petrosia O
sp O
. O
marine O
sponge O
collected O
in O
American O
Samoa O
. O

The O
structures O
of O
the O
C31 B
- I
C33 I
polyacetylenes I
( O
1 O
- O
9 O
) O
were O
determined O
on O
the O
basis O
of O
1D O
- O
and O
2D O
- O
NMR O
analysis O
, O
mass O
spectrometry O
, O
and O
comparison O
of O
specific O
rotation O
values O
. O

Biobased O
polyesters B
with O
composition O
- O
dependent O
thermomechanical O
properties O
: O
synthesis O
and O
characterization O
of O
poly B
( I
butylene I
succinate I
- I
co I
- I
butylene I
azelate I
) I
. O

Environmentally O
friendly O
poly B
( I
butylenesuccinate I
- I
co I
- I
butyleneazelate I
) I
( O
P B
( I
BS I
- I
co I
- I
BAz I
) I
s I
) O
aliphatic B
copolyesters I
with O
composition O
- O
dependent O
thermomechanical O
properties O
were O
synthesized O
from O
succinic O
acid O
( O
SuA B
) O
, O
1 O
, O
4 O
- O
butanediol O
( O
BDO B
) O
, O
and O
dimethylazelate B
( O
DMAz B
) O
through O
a O
two O
- O
step O
polycondensation O
reaction O
. O

The O
molar O
SuA B
/ O
AzA O
ratio O
was O
varied O
from O
4 O
: O
1 O
to O
1 O
: O
4 O
, O
and O
the O
chemical O
structure O
and O
molecular O
characteristics O
of O
resulting O
( B
co I
) I
polyesters I
were O
characterized O
by O
NMR O
and O
SEC O
, O
whereas O
thermal O
properties O
and O
crystallinity O
were O
studied O
by O
differential O
scanning O
calorimetry O
( O
DSC O
) O
, O
dynamic O
mechanical O
thermal O
analyses O
( O
DMTA O
) O
, O
and O
X O
- O
ray O
diffraction O
( O
XRD O
) O
. O

A O
good O
agreement O
between O
theoretical O
and O
experimental O
SuA B
/ O
AzA O
molar O
ratios O
in O
the O
copolyesters B
was O
achieved O
, O
together O
with O
the O
recovery O
of O
semicrystalline O
random O
copolymers O
of O
uniform O
composition O
along O
the O
chains O
. O

NMR O
, O
DSC O
, O
DMTA O
, O
and O
XRD O
results O
show O
that O
depending O
on O
their O
composition O
the O
P B
( I
BS I
- I
co I
- I
BAz I
) I
copolyesters I
might O
find O
applications O
from O
elastomers O
to O
high O
- O
impact O
thermoplastics O
. O

Formulation O
, O
in O
vitro O
evaluation O
and O
study O
of O
variables O
on O
tri O
- O
layered O
gastro O
- O
retentive O
delivery O
system O
of O
diltiazem B
HCl I
. O

Objective O
: O
To O
evaluate O
the O
potential O
of O
PEO O
as O
a O
sole O
polymer O
for O
the O
controlled O
release O
and O
to O
study O
the O
effect O
of O
formulation O
variables O
on O
release O
and O
gastric O
retention O
of O
highly O
soluble O
Diltiazem B
hydrochloride I
( O
DTZ B
) O
. O

Methods O
: O
Tablets O
were O
compressed O
with O
middle O
layer O
consisting O
of O
drug O
and O
polymer O
while O
outer O
layers O
consisted O
of O
polymer O
with O
sodium B
bicarbonate I
. O

Design O
of O
formulation O
to O
obtain O
12 O
h O
, O
zero O
- O
order O
release O
and O
rapid O
floatation O
was O
done O
by O
varying O
the O
grades O
, O
quantity O
of O
PEO O
and O
sodium B
bicarbonate I
. O

With O
an O
increase O
in O
the O
amount O
of O
sodium B
bicarbonate I
, O
faster O
buoyancy O
was O
achieved O
due O
to O
the O
increased O
CO O
( O
2 O
) O
gas O
formation O
. O

Conclusion O
: O
Zero O
- O
order O
, O
controlled O
release O
profile O
with O
the O
desired O
buoyancy O
can O
be O
achieved O
by O
using O
optimum O
formula O
quantities O
of O
sodium B
bicarbonate I
and O
polymer O
. O

The O
tri O
- O
layered O
system O
shows O
promising O
delivery O
of O
DTZ B
, O
and O
possibly O
other O
water O
- O
soluble O
drugs O
. O

Currently O
, O
there O
are O
two O
NAI O
drugs O
which O
are O
licensed O
worldwide O
: O
oseltamivir B
and O
zanamivir O
, O
and O
two O
more O
drugs O
which O
have O
received O
recent O
approval O
in O
Japan O
: O
peramivir O
and O
laninamivir O
. O

They O
strongly O
exhibited O
the O
activity O
of O
NA O
in O
the O
low O
nanomolar O
range O
such O
as O
phosphonate O
congeners O
of O
zanamivir O
and O
oseltarmivir B
. O

However O
, O
these O
substituted O
phenyl B
- I
benzopyrane I
compounds O
have O
been O
reported O
to O
exert O
a O
considerable O
quenching O
effect O
, O
causing O
false O
- O
positive O
results O
in O
the O
commonly O
used O
method O
of O
enzyme O
- O
based O
NA O
inhibition O
assays O
, O
and O
thus O
, O
reliability O
of O
the O
flavonoid O
- O
based O
NAIs O
reported O
in O
the O
literature O
. O

Liver O
, O
plasma O
and O
erythrocyte O
levels O
of O
thiamine O
and O
its O
phosphate B
esters I
in O
rats O
with O
acute O
ethanol O
intoxication O
: O
a O
comparison O
of O
thiamine O
and O
benfotiamine B
administration O
. O

Thiamine O
and O
benfotiamine B
are O
vitamin B
B1 I
and O
pro B
- I
vitamin I
B1 I
substances O
, O
respectively O
. O

Vitamin B
B1 I
plays O
an O
essential O
role O
in O
energy O
metabolism O
, O
and O
its O
deficiency O
leads O
to O
neurologic O
and O
cardiovascular O
pathologies O
, O
as O
seen O
in O
alcoholics B
. O

This O
study O
presents O
new O
data O
about O
the O
effects O
of O
thiamine B
hydrochloride I
or O
benfotiamine B
treatment O
given O
to O
rats O
with O
acute O
alcohol O
intoxication O
, O
on O
the O
distribution O
of O
thiamine O
and O
its O
phosphate B
esters I
in O
liver O
, O
plasma O
and O
erythrocytes O
. O

The O
benfotiamine B
- O
treated O
group O
had O
its O
total O
plasma O
thiamine O
increased O
by O
100 O
% O
. O

In O
erythrocytes O
, O
thiamine O
levels O
were O
4 O
- O
and O
25 O
- O
fold O
higher O
in O
the O
groups O
treated O
with O
thiamine O
and O
benfotiamine B
, O
respectively O
, O
compared O
with O
the O
untreated O
groups O
. O

Thus O
, O
we O
verified O
the O
high O
bioavailability O
especially O
of O
benfotiamine B
within O
6h O
of O
ethanol O
administration O
. O

No O
marked O
change O
was O
recorded O
in O
biochemical O
parameters O
( O
plasma O
urea O
, O
creatinine O
, O
lipids O
, O
electrolytes O
, O
bilirubin O
, O
transaminases O
and O
gamma B
- I
glutamyl I
transferase O
) O
. O

The O
liver O
endogenous O
antioxidant O
enzymes O
( O
copper O
/ O
zinc O
and O
manganese B
superoxide I
dismutase O
) O
expressions O
were O
significantly O
increased O
in O
the O
rats O
receiving O
the O
highest O
dose O
of O
SODB O
( O
160USOD O
/ O
day O
) O
whatever O
the O
coating O
. O

The O
OLETF O
rats O
were O
divided O
into O
the O
following O
four O
groups O
according O
to O
diet O
for O
2months O
: O
NAFLD O
( O
chew O
) O
, O
KRG O
( O
chew O
+ O
KRG O
[ O
200mg O
/ O
kg O
/ O
day O
] O
) O
, O
urushiol O
( O
chew O
+ O
urushiol O
[ O
0 O
. O
5mg O
/ O
kg O
/ O
day O
] O
) O
, O
and O
ursodeoxycholic B
acid I
( O
UDCA B
) O
( O
chew O
+ O
UDCA B
[ O
15mg O
/ O
kg O
/ O
day O
] O
) O
groups O
. O

TNF O
alpha O
and O
Fas O
/ O
FasL O
pathways O
are O
involved O
in O
9 B
- I
Methoxycamptothecin I
- O
induced O
apoptosis O
in O
cancer O
cells O
with O
oxidative O
stress O
and O
G2 O
/ O
M O
cell O
cycle O
arrest O
. O

9 B
- I
Methoxycamptothecin I
( O
MCPT B
) O
has O
been O
recently O
reported O
to O
have O
a O
strong O
anticancer O
activity O
. O

The O
results O
showed O
that O
MCPT B
induced O
cytotoxicity O
in O
seven O
human O
cancer O
cell O
lines O
in O
a O
dose O
dependent O
manner O
after O
72h O
, O
with O
A2780 O
and O
Hela O
cell O
lines O
more O
sensitive O
, O
so O
the O
two O
cell O
lines O
were O
chosen O
to O
do O
further O
studies O
. O

MCPT B
induced O
strong O
G2 O
/ O
M O
arrest O
in O
both O
A2780 O
cells O
and O
Hela O
cells O
after O
24h O
, O
following O
by O
substantial O
sub O
- O
G1 O
arrest O
( O
indicating O
apoptosis O
) O
. O

ROS O
generation O
increased O
significantly O
in O
MCPT B
- O
induced O
apoptosis O
. O

In O
addition O
, O
MCPT B
induced O
up O
- O
regulation O
expression O
of O
most O
of O
seventeen O
genes O
in O
both O
cell O
lines O
. O

Taken O
together O
, O
MCPT B
plays O
an O
important O
role O
in O
tumor O
growth O
suppression O
by O
inducing O
apoptosis O
in O
both O
cell O
lines O
via O
extrinsic O
and O
intrinsic O
apoptotic O
pathways O
, O
and O
has O
the O
potential O
to O
be O
developed O
into O
an O
antitumor O
agent O
. O

APE1 O
/ O
Ref O
- O
1 O
prevents O
oxidative O
inactivation O
of O
ERK O
for O
G1 O
- O
to O
- O
S O
progression O
following O
lead B
acetate I
exposure O
. O

Previously O
, O
we O
have O
showed O
that O
lead B
acetate I
( O
Pb O
) O
elicits O
EGFR O
activation O
to O
initiate O
the O
SFK O
/ O
PKC O
alpha O
/ O
Ras O
/ O
Raf O
- O
1 O
/ O
MKK1 O
/ O
2 O
/ O
ERK O
signaling O
cascade O
functioning O
against O
genotoxicity O
. O

Intriguingly O
, O
the O
capability O
of O
Pb O
to O
activate O
ERK O
was O
abolished O
under O
siAPE1 O
or O
E3330 O
co O
- O
treatments O
; O
conversely O
, O
forced O
expression O
of O
APE1 O
up O
- O
regulated O
the O
ERK O
activation O
by O
Pb O
or O
serum O
in O
both O
Cys65 B
- O
redox O
activity O
dependent O
and O
independent O
manners O
. O

Synthesis O
, O
quantitative O
structure O
- O
activity O
relationship O
and O
biological O
evaluation O
of O
1 B
, I
3 I
, I
4 I
- I
oxadiazole I
derivatives O
possessing O
diphenylamine O
moiety O
as O
potential O
anticancer O
agents O
. O

Synthesis O
of O
2 B
, I
5 I
- I
disubstituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
2a O
- O
c O
) O
, O
3 B
- I
substituted I
aminomethyl I
- I
5 I
- I
substituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
- I
2 I
( I
3H I
) I
- I
thione I
( O
4a O
- O
m O
) O
and O
2 B
- I
substituted I
thio I
- I
5 I
- I
substituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
5a O
, O
b O
) O
had O
been O
described O
. O

All O
the O
synthesized O
derivatives O
were O
screened O
for O
anticancer O
activity O
against O
HT29 O
and O
MCF7 O
cancer O
cell O
lines O
using O
Sulfo B
- I
Rodamine I
B I
( O
SRB O
) O
standard O
method O
. O

Quantitative O
structure O
- O
activity O
relationship O
( O
QSAR O
) O
study O
was O
applied O
to O
find O
a O
correlation O
between O
the O
experimental O
antiproliferative O
activities O
of O
the O
newly O
synthesized O
oxadiazole B
derivatives O
with O
their O
physicochemical O
parameter O
and O
topological O
index O
. O

Flurbiprofen B
- O
loaded O
liquid O
- O
SMEDDS O
was O
dispersed O
in O
dextran O
and O
spray O
- O
dried O
. O

Furthermore O
, O
optimized O
parameters O
resulted O
a O
highly O
crystalline O
flurbiprofen B
changed O
to O
an O
amorphous O
form O
. O

Recently O
, O
we O
developed O
ATL O
cell O
- O
selective O
proliferation O
inhibitors O
based O
on O
a O
tetrahydrotetramethy B
( O
TMN B
) O
skeleton O
1 O
, O
and O
here O
we O
report O
the O
design O
and O
synthesis O
of O
silicon O
analogs O
of O
TMN B
derivatives O
. O

The O
decay O
mechanism O
was O
found O
to O
involve O
the O
loss O
of O
Ag O
( O
+ O
) O
ions O
and O
silver B
glutathionates I
. O

We O
have O
previously O
shown O
in O
a O
mouse O
model O
of O
hereditary O
iron O
overload O
that O
cytosolic O
iron O
levels O
affected O
mitochondrial O
manganese O
availability O
, O
MnSOD B
activity O
, O
and O
insulin O
secretion O
. O

We O
therefore O
sought O
to O
determine O
the O
metallation O
status O
of O
MnSOD B
in O
wild O
- O
type O
mice O
and O
whether O
altering O
that O
status O
affected O
beta O
- O
cell O
function O
. O

129 O
/ O
SvEVTac O
mice O
given O
supplemental O
manganese O
exhibited O
a O
73 O
% O
increase O
in O
hepatic O
MnSOD B
activity O
and O
increased O
metallation O
of O
MnSOD B
. O

Liver O
mitochondria O
from O
manganese O
- O
injected O
C57BL O
/ O
6J O
mice O
had O
similar O
increases O
in O
MnSOD B
activity O
( O
81 O
% O
) O
and O
metallation O
as O
were O
seen O
in O
129 O
/ O
SvEVTac O
mice O
. O

In O
conclusion O
, O
MnSOD B
metallation O
and O
activity O
can O
be O
augmented O
with O
manganese O
supplementation O
in O
normal O
mice O
on O
normal O
chow O
, O
and O
manganese O
treatment O
can O
increase O
insulin O
secretion O
to O
improve O
glucose O
tolerance O
under O
conditions O
of O
dietary O
stress O
. O

A O
simple O
and O
sensitive O
method O
for O
determination O
of O
vitamins B
D I
( I
3 I
) I
and I
K I
( I
1 I
) I
in O
rat O
plasma O
: O
application O
for O
an O
in O
vivo O
pharmacokinetic O
study O
. O

Abstract O
Purpose O
: O
To O
develop O
and O
to O
validate O
a O
simple O
but O
sensitive O
method O
for O
determination O
of O
vitamins B
D I
( I
3 I
) I
and I
K I
( I
1 I
) I
in O
rat O
plasma O
. O

Vitamin O
D O
( O
3 O
) O
and O
probucol O
were O
detected O
at O
265 O
nm O
and O
vitamin B
K I
( I
1 I
) I
at O
239 O
nm O
. O

Rats O
were O
administered O
intravenously O
by O
0 O
. O
1 O
mg O
/ O
kg O
of O
vitamin B
D I
( I
3 I
) I
or I
K I
( I
1 I
) I
and O
the O
blood O
samples O
were O
withdrawn O
pre O
- O
administration O
and O
at O
pre O
- O
determined O
time O
points O
post O
- O
administration O
. O

The O
pharmacokinetic O
parameters O
of O
vitamin O
D O
( O
3 O
) O
following O
intravenous O
administration O
were O
: O
AUC O
( O
0 O
- O
infinity O
) O
= O
11323 O
+ O
/ O
- O
1081 O
h O
x O
ng O
/ O
mL O
, O
V O
( O
d O
) O
= O
218 O
+ O
/ O
- O
80 O
mL O
/ O
kg O
, O
CL O
= O
8 O
. O
9 O
+ O
/ O
- O
0 O
. O
8 O
mL O
/ O
h O
/ O
kg O
, O
t O
( O
1 O
/ O
2 O
) O
= O
16 O
. O
8 O
+ O
/ O
- O
5 O
h O
; O
and O
of O
vitamin B
K I
( I
1 I
) I
: O
AUC O
( O
0 O
- O
infinity O
) O
= O
2495 O
+ O
/ O
- O
297 O
h O
x O
ng O
/ O
mL O
, O

Conclusion O
: O
The O
developed O
HPLC O
- O
UV O
assay O
is O
a O
simple O
and O
sensitive O
method O
for O
the O
determination O
of O
vitamins B
D I
( I
3 I
) I
and I
K I
( I
1 I
) I
in O
rat O
plasma O
. O

A O
higher O
dose O
of O
vitamin B
K I
( I
1 I
) I
should O
be O
used O
in O
future O
studies O
for O
accurate O
estimation O
of O
pharmacokinetic O
parameters O
. O

Investigation O
of O
astatine B
( I
III I
) I
hydrolyzed O
species O
: O
experiments O
and O
relativistic O
calculations O
. O

This O
work O
aims O
to O
resolve O
some O
controversies O
about O
astatine B
( I
III I
) I
hydroxide I
species O
present O
in O
oxidant O
aqueous O
solution O
. O

Batch O
- O
experiments O
using O
a O
competition O
method O
show O
the O
exchange O
of O
one O
proton O
indicating O
the O
formation O
of O
the O
AtO B
( I
OH I
) I
species O
. O

Here O
, O
we O
have O
perturbed O
vibrational O
motions O
in O
pentaerythritol B
tetranitrate I
reductase O
( O
PETNR O
) O
by O
isotopic O
substitution O
where O
all O
non O
- O
exchangeable O
atoms O
were O
replaced O
with O
the O
corresponding O
heavy O
isotope O
( O
( O
13 O
) O
C O
, O
( O
15 O
) O
N O
, O
and O
( O
2 O
) O
H O
) O
. O

Cis O
- O
trans O
isomerizations O
of O
proline O
residues O
are O
key O
to O
bradykinin B
conformations O
. O

A O
recent O
ion O
mobility O
- O
mass O
spectrometry O
( O
IM O
- O
MS O
) O
study O
of O
the O
nonapeptide O
bradykinin B
( O
BK O
, O
amino O
acid O
sequence O
Arg B
( O
1 O
) O
- O
Pro O
( O
2 O
) O
- O
Pro O
( O
3 O
) O
- O
Gly O
( O
4 O
) O
- O
Phe O
( O
5 O
) O
- O
Ser O
( O
6 O
) O
- O
Pro O
( O
7 O
) O
- O
Phe O
( O
8 O
) O
- O
Arg B
( O
9 O
) O
) O
found O
evidence O
for O
10 O
populations O
of O
conformations O
that O
depend O
upon O
the O
solution O
composition O
[ O
J O
. O
Am O
. O
Chem O
. O
Soc O
. O
2011 O
, O
133 O
, O
13810 O
] O
. O

Here O
, O
the O
role O
of O
the O
three O
proline O
residues O
( O
Pro O
( O
2 O
) O
, O
Pro O
( O
3 O
) O
, O
and O
Pro O
( O
7 O
) O
) O
in O
establishing O
these O
conformations O
is O
investigated O
using O
a O
series O
of O
seven O
analogue O
peptides O
in O
which O
combinations O
of O
alanine O
residues O
are O
substituted O
for O
prolines B
. O

BACKGROUND O
: O
The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
utility O
of O
remnant O
uptake O
on O
postoperative O
radioiodine B
scans O
as O
an O
oncologic O
indicator O
after O
thyroidectomy O
for O
differentiated O
thyroid O
cancer O
( O
DTC O
) O
. O

Synthesis O
and O
biological O
evaluation O
of O
5 B
- I
nitropyrimidine I
analogs O
with O
azabicyclic B
substituents O
as O
GPR119 O
agonists O
. O

5 B
- I
Nitropyrimidine I
analogs O
substituted O
with O
conformationally O
restricted O
azabicyclic B
amines I
and I
alcohols I
were O
prepared O
and O
evaluated O
their O
agonistic O
activity O
against O
human O
GPR119 O
. O

The O
analogs O
bearing O
endo B
- I
azabicyclic I
amines I
and I
alcohols I
( O
7 O
, O
8 O
, O
11 O
, O
and O
12 O
) O
exhibited O
full O
agonistic O
activities O
while O
the O
analogs O
with O
exo B
- I
azabicyclic I
amines I
and I
alcohols I
were O
proved O
as O
partial O
agonists O
( O
9 O
, O
10 O
, O
13 O
, O
and O
14 O
) O
regardless O
of O
their O
EC O
( O
50 O
) O
values O
. O

5 B
- I
Nitropyrimidine I
analogs O
with O
( B
2 I
- I
fluoro I
- I
4 I
- I
methylsulfonyl I
) I
phenylamino I
group O
( O
8 O
, O
10 O
, O
12 O
, O
14 O
) O
showed O
more O
potent O
GPR119 O
activation O
activities O
than O
the O
analogs O
without O
fluorine O
in O
all O
cases O
( O
7 O
, O
9 O
, O
11 O
, O
13 O
) O
. O

2 O
' O
, O
4 O
' O
- O
BNA O
/ O
LNA O
aptamers O
: O
CE O
- O
SELEX O
using O
a O
DNA O
- O
based O
library O
of O
full O
- O
length O
2 B
' I
- I
O I
, I
4 I
' I
- I
C I
- I
methylene I
- I
bridged I
/ I
linked I
bicyclic I
ribonucleotides I
. O

DNA O
- O
based O
aptamers O
that O
contain O
2 B
' I
- I
O I
, I
4 I
' I
- I
C I
- I
methylene I
- I
bridged I
/ I
linked I
bicyclic I
ribonucleotides I
( O
B O
/ O
L O
nucleotides O
) O
over O
the O
entire O
length O
were O
successfully O
obtained O
using O
a O
capillary O
electrophoresis O
systematic O
evolution O
of O
ligands O
by O
exponential O
enrichment O
( O
CE O
- O
SELEX O
) O
method O
. O

A O
novel O
class O
of O
quinoxalines B
has O
been O
discovered O
as O
antagonists O
of O
the O
IgG O
: O
FcRn O
protein O
- O
protein O
interaction O
through O
optimization O
of O
a O
hit O
derived O
from O
a O
virtual O
ligand O
- O
based O
screen O
. O

3 B
' I
- I
R I
/ I
S I
- I
Hydroxyvoacamine I
, O
a O
potent O
acetylcholinesterase O
inhibitor O
from O
Tabernaemontana O
divaricata O
. O

Guided O
by O
the O
acetylcholinesterase O
inhibiting O
activity O
, O
the O
bisindole B
alkaloid I
3 B
' I
- I
R I
/ I
S I
- I
hydroxyvoacamine I
was O
isolated O
from O
a O
stem O
extract O
of O
Tabernaemontana O
divaricata O
, O
a O
plant O
used O
in O
Thailand O
in O
traditional O
rejuvenation O
remedies O
for O
improving O
the O
memory O
. O

It O
suggested O
that O
there O
was O
12 O
. O
4 O
% O
( O
w O
/ O
w O
) O
of O
3 B
' I
- I
R I
/ I
S I
- I
hydroxyvoacamine I
in O
the O
alkaloid O
enriched O
fraction O
of O
T O
. O
divaricata O
stem O
. O

The O
alpha O
- O
subunit O
of O
tryptophan O
synthase O
( O
alpha O
TS O
) O
catalyzes O
the O
conversion O
of O
indole B
- I
3 I
- I
glycerol I
phosphate I
to O
d B
- I
glyceraldehyde I
- I
3 I
- I
phosphate I
and O
indole O
. O

Projection O
analysis O
of O
the O
chemical O
shift O
changes O
by O
site O
- O
specific O
amino O
acid O
substitutions O
and O
ligand O
titrations O
indicates O
that O
alpha O
TS O
has O
three O
important O
conformational O
states O
: O
ligand O
- O
free O
, O
glyceraldehyde B
- I
3 I
- I
phosphate I
- O
bound O
( O
like O
) O
, O
and O
the O
active O
states O
. O

In O
particular O
, O
there O
are O
long O
- O
range O
connections O
, O
only O
in O
the O
active O
state O
, O
between O
Ala47 B
, O
which O
reports O
on O
structural O
and O
dynamic O
changes O
associated O
with O
the O
general O
acid O
/ O
base O
Glu49 B
, O
and O
residues O
within O
the O
beta O
2 O
alpha O
2 O
loop O
, O
which O
contains O
the O
catalytically O
important O
Asp60 B
residue O
. O

Synthesis O
and O
biological O
evaluation O
of O
thieno B
[ I
2 I
' I
, I
3 I
' I
: I
4 I
, I
5 I
] I
pyrimido I
[ I
1 I
, I
2 I
- I
b I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazines I
and O
thieno B
[ I
2 I
, I
3 I
- I
d I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidines I
as O
anti O
- O
inflammatory O
and O
analgesic O
agents O
. O

A O
new O
series O
of O
thieno B
[ I
2 I
' I
, I
3 I
' I
: I
4 I
, I
5 I
] I
pyrimido I
[ I
1 I
, I
2 I
- I
b I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazines I
and O
thieno B
[ I
2 I
, I
3 I
- I
d I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidines I
was O
synthesized O
. O

The O
newly O
synthesized O
compounds O
were O
evaluated O
for O
their O
anti O
- O
inflammatory O
and O
analgesic O
activity O
using O
diclofenac B
Na I
as O
a O
reference O
standard O
. O

In O
general O
, O
the O
thieno B
[ I
2 I
, I
3 I
- I
d I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidine I
derivatives O
exhibited O
better O
biological O
activities O
than O
the O
thieno B
[ I
2 I
' I
, I
3 I
' I
: I
4 I
, I
5 I
] I
pyrimido I
[ I
1 I
, I
2 I
- I
b I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazines I
. O

Collectively O
, O
the O
thienotriazolopyrimi B
derivatives O
9 O
, O
13 O
and O
14a O
were O
proved O
to O
display O
distinctive O
anti O
- O
inflammatory O
activity O
at O
the O
acute O
and O
subacute O
models O
as O
well O
as O
good O
analgesic O
profile O
with O
a O
delayed O
onset O
of O
action O
. O

Molecular O
insight O
into O
the O
inhibition O
mechanism O
of O
cyrtominetin B
to O
alpha O
- O
hemolysin O
by O
molecular O
dynamics O
simulation O
. O

In O
this O
paper O
, O
experimental O
studies O
show O
that O
cyrtominetin B
( O
CTM B
) O
can O
inhibit O
the O
hemolytic O
activity O
of O
alpha O
- O
HL O
. O

To O
understand O
how O
CTM B
can O
affect O
hemolytic O
activity O
, O
molecular O
dynamics O
simulations O
were O
carried O
out O
for O
alpha O
- O
HL O
- O
CTM B
complex O
and O
these O
results O
were O
compared O
with O
the O
crystal O
structure O
of O
monomeric O
alpha O
- O
HL O
. O

With O
this O
approach O
, O
the O
analysis O
revealed O
that O
the O
inhibition O
of O
CTM B
involves O
CTM B
directly O
binding O
to O
alpha O
- O
HL O
. O

Due O
to O
the O
binding O
of O
CTM B
, O
the O
conformation O
of O
the O
critical O
" O
Loop O
" O
region O
was O
restrained O
. O

These O
findings O
indicate O
that O
CTM B
hinders O
the O
lysis O
activity O
of O
alpha O
- O
HL O
through O
a O
novel O
mechanism O
. O

The O
effects O
of O
vinclozolin O
( O
VIN B
) O
, O
an O
anti O
- O
androgenic O
fungicide O
, O
on O
quality O
, O
oxidative O
stress O
, O
DNA O
integrity O
, O
and O
ATP O
level O
of O
sterlet O
( O
Acipenser O
ruthenus O
) O
spermatozoa O
were O
investigated O
in O
vitro O
. O

Intracellular O
ATP O
content O
of O
spermatozoa O
decreased O
with O
increasing O
concentrations O
of O
VIN B
. O

The O
results O
demonstrated O
that O
VIN B
can O
induce O
reactive O
oxygen O
species O
stress O
in O
fish O
spermatozoa O
, O
which O
could O
impair O
the O
sperm O
quality O
, O
DNA O
integrity O
, O
ATP O
content O
, O
and O
the O
antioxidant O
defense O
system O
. O

Elimination O
and O
utilization O
of O
oxidized O
guanine B
nucleotides I
in O
the O
synthesis O
of O
RNA O
and O
its O
precursors O
. O

Among O
the O
various O
oxidized O
bases O
, O
8 B
- I
oxo I
- I
7 I
, I
8 I
- I
dihydroguanine I
seems O
to O
be O
the O
most O
critical O
during O
the O
transfer O
of O
genetic O
information O
because O
it O
can O
pair O
with O
both O
cytosine O
and O
adenine O
. O

During O
the O
de O
novo O
synthesis O
of O
guanine B
nucleotides I
, O
GMP B
is O
formed O
first O
, O
and O
it O
is O
converted O
to O
GDP O
by O
guanylate O
kinase O
. O

This O
enzyme O
hardly O
acts O
on O
an O
oxidized O
form O
of O
GMP B
( O
8 B
- I
oxo I
- I
GMP I
) O
formed O
by O
the O
oxidation O
of O
GMP B
or O
by O
the O
cleavage O
of O
8 B
- I
oxo I
- I
GDP I
and O
8 B
- I
oxo I
- I
GTP I
by O
MutT O
protein O
. O

Although O
the O
formation O
of O
8 B
- I
oxo I
- I
GDP I
from O
8 B
- I
oxo I
- I
GMP I
is O
thus O
prevented O
, O
8 B
- I
oxo I
- I
GDP I
itself O
may O
be O
produced O
by O
the O
oxidation O
of O
GDP O
by O
reactive O
oxygen O
species O
. O

The O
8 B
- I
oxo I
- I
GDP I
thus O
formed O
can O
be O
converted O
to O
8 B
- I
oxo I
- I
GTP I
because O
nucleoside O
- O
diphosphate O
kinase O
and O
adenylate O
kinase O
, O
both O
of O
which O
catalyze O
the O
conversion O
of O
GDP O
to O
GTP O
, O
do O
not O
discriminate O
8 B
- I
oxo I
- I
GDP I
from O
normal O
GDP O
. O

The O
8 B
- I
oxo I
- I
GTP I
produced O
in O
this O
way O
and O
by O
the O
oxidation O
of O
GTP O
can O
be O
used O
for O
RNA O
synthesis O
. O

This O
misincorporation O
is O
prevented O
by O
MutT O
protein O
, O
which O
has O
the O
potential O
to O
cleave O
8 B
- I
oxo I
- I
GTP I
as O
well O
as O
8 B
- I
oxo I
- I
GDP I
to O
8 B
- I
oxo I
- I
GMP I
. O

When O
( B
14 I
) I
C I
- I
labeled I
8 I
- I
oxo I
- I
GTP I
was O
applied O
to O
CaCl2 O
- O
permeabilized O
cells O
of O
a O
mutT O
( O
- O
) O
mutant O
strain O
, O
it O
could O
be O
incorporated O
into O
RNA O
at O
4 O
% O
of O
the O
rate O
for O
GTP O
. O

Escherichia O
coli O
cells O
appear O
to O
possess O
mechanisms O
to O
prevent O
misincorporation O
of O
8 B
- I
oxo I
- I
7 I
, I
8 I
- I
dihydroguanine I
into O
RNA O
. O

Bradykinin B
modulates O
spontaneous O
nerve O
growth O
factor O
production O
and O
stretch O
- O
induced O
ATP O
release O
in O
human O
urothelium O
. O

The O
muscle O
- O
contracting O
and O
pain O
- O
inducing O
peptide O
bradykinin B
is O
produced O
in O
various O
inflammatory O
and O
non O
- O
inflammatory O
pathologies O
associated O
with O
bladder O
overactivity O
, O
but O
the O
effect O
of O
bradykinin B
on O
human O
urothelial O
function O
has O
not O
yet O
been O
characterized O
. O

The O
human O
urothelial O
cell O
line O
UROtsa O
expresses O
mRNA O
for O
both O
B1 O
and O
B2 O
subtypes O
of O
bradykinin B
receptors O
, O
as O
determined O
by O
real O
- O
time O
PCR O
. O

Bradykinin B
concentration O
- O
dependently O
( O
pEC50 O
= O
8 O
. O
3 O
, O
Emax O
4434 O
+ O
/ O
- O
277nM O
) O
increased O
urothelial O
intracellular O
calcium O
levels O
and O
induced O
phosphorylation O
of O
the O
mitogen O
- O
activated O
protein O
kinase O
( O
MAPK O
) O
ERK1 O
/ O
2 O
. O

Activation O
of O
both O
bradykinin B
- O
induced O
signaling O
pathways O
was O
completely O
abolished O
by O
the O
B2 O
antagonist O
icatibant O
( O
1 O
mu O
M O
) O
, O
but O
not O
the O
B1 O
antagonist O
R715 O
( O
1 O
mu O
M O
) O
. O

Bradykinin B
- O
induced O
( O
100nM O
) O
B2 O
receptor O
activation O
markedly O
increased O
( O
192 O
+ O
/ O
- O
13 O
% O
of O
control O
levels O
) O
stretch O
- O
induced O
ATP O
release O
from O
UROtsa O
in O
hypotonic O
medium O
, O
the O
effect O
being O
dependent O
on O
intracellular O
calcium O
elevations O
. O

Bradykinin B
increased O
NGF O
mRNA O
expression O
and O
accelerated O
urothelial O
NGF O
release O
to O
127 O
+ O
/ O
- O
5 O
% O
in O
a O
protein O
kinase O
C O
- O
and O
ERK1 O
/ O
2 O
- O
dependent O
manner O
. O

Finally O
, O
bradykinin B
up O
- O
regulated O
mRNA O
for O
transient O
- O
receptor O
potential O
vanilloid O
( O
TRPV1 O
) O
sensory O
ion O
channel O
in O
UROtsa O
. O

In O
conclusion O
, O
we O
show O
that O
bradykinin B
represents O
a O
versatile O
modulator O
of O
human O
urothelial O
phenotype O
, O
accelerating O
stretch O
- O
induced O
ATP O
release O
, O
spontaneous O
release O
of O
NGF O
, O
as O
well O
as O
expression O
of O
sensory O
ion O
channel O
TRPV1 O
. O

Bradykinin B
- O
induced O
changes O
in O
urothelial O
sensory O
function O
might O
contribute O
to O
the O
development O
of O
bladder O
dysfunction O
. O

3 B
, I
3 I
' I
- I
Diindolymethane I
ameliorates O
adriamycin O
- O
induced O
cardiac O
fibrosis O
via O
activation O
of O
a O
BRCA1 O
- O
dependent O
anti O
- O
oxidant O
pathway O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
3 B
, I
3 I
' I
- I
diindolymethane I
( O
DIM B
) O
exhibits O
a O
significant O
anti O
- O
fibrosis O
effect O
on O
cardiac O
tissue O
in O
an O
animal O
model O
of O
adriamycin O
- O
induced O
cardiac O
fibrosis O
( O
AICF O
) O
. O

Further O
studies O
demonstrated O
that O
DIM B
is O
able O
to O
dramatically O
up O
- O
regulate O
the O
expression O
of O
breast O
cancer O
type O
1 O
susceptibility O
protein O
( O
BRCA1 O
) O
in O
cardiac O
tissue O
and O
fibroblast O
, O
which O
subsequently O
activate O
the O
transcription O
factor O
Nuclear O
factor O
( O
erythroid O
- O
derived O
2 O
) O
- O
like O
2 O
( O
Nrf2 O
) O
. O

Because O
DIM B
is O
a O
safe O
food O
additive O
that O
has O
been O
used O
for O
decades O
, O
our O
findings O
suggest O
that O
there O
is O
a O
great O
potential O
for O
this O
chemical O
to O
be O
developed O
into O
a O
clinical O
medication O
for O
the O
treatment O
of O
adriamycin O
- O
induced O
heart O
failure O
during O
cancer O
therapy O
. O

While O
most O
deaths O
from O
asphyxia O
related O
to O
buprenorphine O
( O
BUP B
) O
overdose O
have O
been O
reported O
in O
males O
, O
higher O
plasma O
concentrations O
of O
BUP B
and O
its O
toxic O
metabolite O
norbuprenorphine B
( O
NBUP B
) O
have O
been O
observed O
in O
females O
. O

We O
previously O
demonstrated O
that O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
modulation O
at O
the O
blood O
- O
brain O
barrier O
( O
BBB O
) O
contributes O
highly O
to O
BUP B
- O
related O
respiratory O
toxicity O
, O
by O
limiting O
NBUP B
entrance O
into O
the O
brain O
. O

In O
this O
work O
, O
we O
sought O
to O
investigate O
the O
role O
of O
P O
- O
gp O
- O
mediated O
transport O
at O
the O
BBB O
in O
gender O
and O
strain O
- O
related O
variability O
of O
BUP B
and O
NBUP B
- O
induced O
respiratory O
effects O
in O
mice O
. O

In O
male O
Fvb O
and O
Swiss O
mice O
, O
BUP B
was O
responsible O
for O
ceiling O
respiratory O
effects O
. O

NBUP B
- O
related O
reduction O
in O
minute O
volume O
was O
dose O
- O
dependent O
but O
more O
marked O
in O
Fvb O
( O
p O
< O
0 O
. O
01 O
at O
1mg O
/ O
kg O
NBUP B
and O
p O
< O
0 O
. O
001 O
at O
3 O
and O
9mg O
/ O
kg O
NBUP B
) O
than O
in O
Swiss O
mice O
( O
p O
< O
0 O
. O
001 O
at O
9mg O
/ O
kg O
NBUP B
) O
. O

Female O
Fvb O
mice O
were O
more O
susceptible O
to O
BUP B
than O
males O
with O
significantly O
increased O
inspiratory O
time O
( O
p O
< O
0 O
. O
05 O
) O
and O
to O
NBUP B
with O
significantly O
increased O
expiratory O
time O
( O
p O
< O
0 O
. O
01 O
) O
. O

Following O
BUP B
administration O
, O
plasma O
BUP B
concentrations O
were O
significantly O
higher O
( O
p O
< O
0 O
. O
01 O
) O
and O
plasma O
NBUP B
concentrations O
significantly O
lower O
( O
p O
< O
0 O
. O
001 O
) O
in O
Fvb O
mice O
compared O
to O
Swiss O
mice O
. O

Plasma O
BUP B
concentrations O
were O
significantly O
higher O
( O
p O
< O
0 O
. O
05 O
) O
and O
plasma O
NBUP B
concentrations O
significantly O
lower O
( O
p O
< O
0 O
. O
01 O
) O
in O
male O
compared O
to O
female O
Fvb O
mice O
. O

In O
contrast O
, O
following O
NBUP B
administration O
, O
comparable O
plasma O
NBUP B
concentrations O
were O
observed O
in O
both O
genders O
and O
strains O
. O

No O
differences O
in O
P O
- O
gp O
expression O
or O
BUP B
and O
NBUP B
transport O
across O
the O
BBB O
were O
observed O
between O
male O
and O
female O
Fvb O
mice O
as O
well O
as O
between O
Swiss O
and O
Fvb O
mice O
. O

Our O
results O
suggest O
that O
P O
- O
gp O
- O
mediated O
transport O
across O
the O
BBB O
does O
not O
play O
a O
key O
- O
role O
in O
gender O
and O
strain O
- O
related O
variability O
in O
BUP B
and O
NBUP B
- O
induced O
respiratory O
toxicity O
in O
mice O
. O

Both O
gender O
- O
and O
strain O
- O
related O
differences O
in O
respiratory O
effects O
of O
BUP B
could O
be O
attributed O
to O
BUP B
itself O
rather O
than O
to O
its O
metabolite O
, O
NBUP B
. O

Prenatal O
developmental O
toxicity O
studies O
on O
diundecyl B
and I
ditridecyl I
phthalates I
in O
Sprague O
- O
Dawley O
rats O
. O

This O
study O
evaluates O
the O
developmental O
toxicity O
of O
two O
high O
molecular O
weight O
dialkyl B
phthalate I
esters I
, O
diundecyl B
phthalate I
( O
DUDP B
) O
and O
ditridecyl B
phthalate I
( O
DTDP B
) O
. O

Sprague O
- O
Dawley O
rats O
were O
administered O
0 O
, O
0 O
. O
25 O
, O
0 O
. O
50 O
, O
or O
1g O
/ O
kg O
/ O
day O
of O
DUDP B
or O
DTDP B
, O
by O
gavage O
, O
on O
gestation O
days O
6 O
- O
20 O
. O

DUDP B
and O
DTDP B
had O
no O
adverse O
effects O
on O
maternal O
body O
weight O
and O
food O
consumption O
. O

Small O
decreases O
in O
the O
anogenital O
distance O
of O
male O
fetuses O
were O
noted O
at O
0 O
. O
5 O
and O
1g O
DUDP B
/ O
kg O
/ O
day O
. O

The O
incidence O
of O
fetuses O
with O
supernumerary O
lumbar O
ribs O
was O
significantly O
higher O
than O
control O
at O
0 O
. O
5 O
and O
1g O
DUDP B
/ O
kg O
/ O
day O
. O

Thus O
, O
DTDP B
was O
not O
developmentally O
toxic O
up O
to O
1g O
/ O
kg O
/ O
day O
and O
there O
were O
signs O
of O
DUDP B
- O
induced O
fetal O
effects O
at O
0 O
. O
5 O
and O
1g O
/ O
kg O
/ O
day O
. O

Coumarin O
anticoagulants O
, O
which O
include O
warfarin O
, O
acenocoumarol B
and O
phenprocoumon B
, O
are O
among O
the O
most O
widely O
prescribed O
drugs O
worldwide O
. O

There O
is O
now O
a O
large O
body O
of O
published O
data O
showing O
that O
genotype O
for O
certain O
common O
polymorphisms O
in O
the O
genes O
encoding O
the O
target O
vitamin B
K I
epoxide I
reductase O
( O
G O
- O
1639A O
/ O
C1173T O
) O
and O
the O
main O
metabolizing O
enzyme O
CYP2C9 O
( O
CYP2C9 O
* O
2 O
and O
* O
3 O
alleles O
) O
are O
important O
determinants O
of O
the O
individual O
coumarin O
anticoagulant O
dose O
requirement O
. O

Additional O
less O
common O
polymorphisms O
in O
these O
genes O
together O
with O
polymorphisms O
in O
other O
genes O
relevant O
to O
blood O
coagulation O
such O
as O
the O
cytochrome O
P450 O
CYP4F2 O
, O
gamma B
- I
glutamyl I
carboxylase O
, O
calumenin O
and O
cytochrome O
P450 O
oxidoreductase O
may O
also O
be O
significant O
predictors O
of O
dose O
, O
especially O
in O
ethnic O
groups O
such O
as O
Africans O
where O
there O
have O
been O
fewer O
genetic O
studies O
compared O
with O
European O
populations O
. O

Structural O
Modifications O
to O
Tetrahydropyridine B
- I
3 I
- I
carboxylate I
Esters I
en O
Route O
to O
the O
Discovery O
of O
M O
( O
5 O
) O
- O
Preferring O
Muscarinic O
Receptor O
Orthosteric O
Antagonists O
. O

We O
describe O
herein O
the O
discovery O
of O
a O
series O
of O
M O
( O
5 O
) O
- O
preferring O
orthosteric O
antagonists O
based O
on O
the O
scaffold O
of O
1 B
, I
2 I
, I
5 I
, I
6 I
- I
tetrahydropyridine I
- I
3 I
- I
carboxylic I
acid I
. O

This O
compound O
, O
although O
exhibiting O
modest O
affinity O
( O
K O
( O
i O
) O
= O
2 O
. O
24 O
mu O
M O
) O
for O
the O
[ B
( I
3 I
) I
H I
] I
N I
- I
methylscopolamine I
binding O
site O
on O
the O
M O
( O
5 O
) O
receptor O
, O
is O
potent O
( O
IC O
( O
50 O
) O
= O
0 O
. O
45 O
nM O
) O
in O
inhibiting O
oxotremorine B
- O
evoked O
[ B
( I
3 I
) I
H I
] I
DA I
release O
from O
rat O
striatal O
slices O
. O

Herein O
we O
report O
the O
near O
complete O
HN B
, O
N O
, O
CO O
, O
C O
alpha O
, O
and O
C O
beta O
chemical O
shift O
assignment O
of O
the O
P O
. O
aeruginosa O
HemO O
in O
the O
absence O
and O
presence O
of O
inhibitors O
( B
E I
) I
- I
3 I
- I
( I
4 I
- I
( I
phenylamino I
) I
phenylcarbamoyl I
) I
acrylic I
acid I
( O
3 O
) O
and O
( B
E I
) I
- I
N I
' I
- I
( I
4 I
- I
( I
dimethylamino I
) I
benzylidene I
) I
diazenecarboximidhyd I
( O
5 O
) O
. O

As O
a O
first O
step O
, O
we O
describe O
molecular O
modeling O
to O
guide O
focused O
chemical O
syntheses O
of O
conjugates O
having O
nucleoside O
( O
d4T B
) O
and O
nonnucleoside O
( O
TIBO B
) O
moieties O
tethered O
by O
a O
flexible O
polyethylene O
glycol O
( O
PEG O
) O
linker O
. O

A O
triphosphate O
of O
d4T B
- I
6PEG I
- I
TIBO I
conjugate O
was O
successfully O
synthesized O
that O
is O
recognized O
as O
a O
substrate O
by O
HIV O
- O
1 O
RT O
and O
incorporated O
into O
a O
double O
- O
stranded O
DNA O
. O

Next O
, O
we O
examined O
the O
impact O
produced O
on O
the O
same O
abilities O
by O
intra O
- O
VS O
infusion O
of O
ineffective O
doses O
of O
amphetamine O
( O
0 O
. O
3 O
mu O
g O
/ O
side O
) O
in O
association O
with O
N O
- O
methyl O
- O
D O
- O
aspartate O
( O
NMDA O
) O
( O
3 O
. O
125 O
ng O
/ O
side O
) O
or O
alpha B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methylisoxazole I
- I
4 I
- I
propionic I
acid I
( O
AMPA O
) O
( O
0 O
. O
25 O
ng O
/ O
side O
) O
receptor O
antagonist O
. O

A O
Serum O
- O
Resistant O
Low O
- O
Generation O
Polyamidoamine O
with O
PEI B
423 I
Outer O
Layer O
for O
Gene O
Delivery O
Vector O
. O

A O
new O
derivative O
of O
polyamidoamine O
and O
polyethylenimine O
, O
G2 O
. O
5 O
- O
PEI B
423 I
or O
G1 O
. O
5 O
- O
PEI B
423 I
, O
is O
prepared O
by O
an O
amidation O
reaction O
of O
PAMAM O
G2 O
. O
5 O
or O
PAMAM O
G1 O
. O
5 O
using O
PEI B
423 I
. O

The O
G2 O
. O
5 O
- O
PEI B
423 I
complexes O
display O
much O
higher O
transfection O
efficiencies O
than O
PAMAM O
G5 O
and O
Lipo O
- O
2k O
, O
and O
the O
G1 O
. O
5 O
- O
PEI B
423 I
complexes O
display O
higher O
transfection O
efficiencies O
than O
PAMAM O
G4 O
and O
PEI O
- O
25k O
. O

The O
G2 O
. O
5 O
- O
PEI B
423 I
has O
a O
great O
potential O
to O
be O
used O
as O
a O
serum O
- O
resistant O
gene O
vector O
. O

The O
population O
pharmacokinetics O
( O
PPK O
) O
of O
atorvastatin O
and O
its O
principal O
active O
metabolite O
, O
o B
- I
hydroxyatorvastatin I
, O
were O
described O
in O
6 O
- O
17 O
years O
old O
pediatric O
hypercholesterolemia O
patients O
with O
a O
2 O
- O
compartment O
model O
for O
both O
parent O
and O
metabolite O
. O

In O
this O
study O
, O
we O
assessed O
the O
effects O
of O
clopidogrel O
and O
clarithromycin O
, O
known O
CYP2B6 O
and O
CYP3A O
inhibitors O
, O
respectively O
, O
on O
the O
enantioselective O
disposition O
of O
racemic B
sibutramine I
in O
conjunction O
with O
CYP2B6 O
polymorphisms O
in O
humans O
. O

Absence O
of O
edge O
States O
in O
covalently O
bonded O
zigzag O
edges O
of O
graphene O
on O
ir B
( I
111 I
) I
. O

The O
zigzag O
edges O
of O
graphene O
on O
Ir B
( I
111 I
) I
are O
studied O
by O
ab O
initio O
simulations O
and O
low O
- O
temperature O
scanning O
tunneling O
spectroscopy O
, O
providing O
information O
about O
their O
structural O
, O
electronic O
, O
and O
magnetic O
properties O
. O

The O
studies O
reported O
here O
were O
conducted O
to O
investigate O
the O
transport O
characteristics O
of O
apixaban O
( O
1 B
- I
( I
4 I
- I
methoxyphenyl I
) I
- I
7 I
- I
oxo I
- I
6 I
- I
( I
4 I
- I
( I
2 I
- I
oxopiperidin I
- I
1 I
- I
yl I
) I
phenyl I
) I
- I
4 I
, I
5 I
, I
6 I
, I
7 I
- I
tetrahydro I
- I
1H I
- I
pyrazolo I
[ I
3 I
, I
4 I
- I
c I
] I
pyridine I
- I
3 I
- I
carboxamide I
) O
and O
to O
understand O
the O
impact O
of O
transporters O
on O
apixaban O
distribution O
and O
disposition O
. O

Apixaban O
did O
not O
inhibit O
digoxin B
transport O
in O
Caco O
- O
2 O
cells O
. O

Coincubation O
of O
a O
P O
- O
gp O
inhibitor O
( O
ketoconazole O
or O
cyclosporin B
A I
) O
and O
a O
BCRP O
inhibitor O
( O
Ko134 B
) O
provided O
more O
complete O
inhibition O
of O
apixaban O
efflux O
in O
Caco O
- O
2 O
cells O
than O
separate O
inhibition O
by O
individual O
inhibitors O
. O

The O
paramagnetic O
activity O
came O
from O
a O
Gd B
- I
DTPA I
derivative O
that O
was O
grafted O
on O
the O
silica O
surface O
. O

There O
are O
no O
data O
supporting O
an O
association O
between O
congenital O
anomalies O
in O
the O
fetus O
and O
propylthiouracil B
( O
PTU O
) O
. O

Acitretin B
affects O
bioenergetics O
of O
liver O
mitochondria O
and O
promotes O
mitochondrial O
permeability O
transition O
: O
Potential O
mechanisms O
of O
hepatotoxicity O
. O

Acitretin B
is O
a O
synthetic O
retinoid O
used O
for O
severe O
extensive O
psoriasis O
and O
it O
has O
been O
shown O
to O
be O
an O
effective O
and O
a O
safe O
therapeutic O
drug O
for O
other O
diseases O
including O
cancer O
when O
used O
in O
combination O
with O
other O
agents O
. O

However O
, O
cases O
of O
acitretin B
- O
associated O
liver O
injury O
have O
been O
documented O
, O
but O
the O
possible O
mechanisms O
of O
acitretin B
- O
associated O
hepatotoxicity O
and O
apoptosis O
are O
not O
entirely O
clarified O
. O

Acitretin B
( O
5 O
- O
20 O
mu O
M O
) O
impaired O
mitochondrial O
phosphorylation O
efficiency O
as O
demonstrated O
by O
the O
decrease O
in O
the O
state O
3 O
respiration O
and O
ATP O
levels O
, O
and O
by O
the O
increase O
in O
the O
lag O
phase O
of O
ADP O
phosphorylation O
cycle O
, O
without O
affecting O
the O
membrane O
potential O
. O

Acitretin B
induced O
Ca O
( O
2 O
+ O
) O
- O
mediated O
mitochondrial O
permeability O
transition O
( O
MPT O
) O
and O
decreased O
the O
adenine O
nucleotide O
translocase O
( O
ANT O
) O
content O
. O

Acitretin B
- O
induced O
MPT O
was O
not O
prevented O
by O
thiol O
group O
protecting O
and O
antioxidant O
agents O
, O
excluding O
the O
involvement O
of O
oxidative O
stress O
mechanisms O
. O

Therefore O
, O
our O
results O
, O
including O
the O
decrease O
in O
the O
state O
3 O
respiration O
and O
the O
increase O
in O
the O
lag O
phase O
of O
phosphorylation O
cycle O
, O
the O
ATP O
depletion O
and O
the O
induction O
of O
Ca O
( O
2 O
+ O
) O
- O
mediated O
MPT O
, O
indicate O
that O
acitretin B
- O
associated O
liver O
toxicity O
and O
apoptosis O
is O
possibly O
related O
with O
mitochondrial O
dysfunctions O
due O
to O
interactions O
with O
the O
ANT O
. O

Additionally O
, O
the O
combination O
of O
acitretin B
with O
other O
drugs O
, O
such O
as O
antiestrogens O
, O
which O
are O
able O
to O
inhibit O
the O
MPT O
, O
may O
contribute O
to O
decrease O
the O
toxicity O
induced O
by O
acitretin B
. O

An O
inorganic O
( O
sodium O
selenite O
, O
Na2SeO3 B
) O
and O
organic O
( O
selenocysteine O
, O
Cys B
- I
Se I
- I
Se I
- I
Cys I
) O
selenocompound O
have O
been O
used O
as O
Se O
sources O
. O

Previously O
, O
we O
reported O
the O
synthesis O
of O
amphiphilic O
polyvinyl O
alcohol O
and O
dextrin O
- O
based O
nanogel O
conjugates O
with O
the O
phosphorylated B
5 I
- I
FU I
nucleoside I
Floxuridine B
and O
demonstrated O
their O
enhanced O
activity O
against O
regular O
and O
drug O
- O
resistant O
cancers O
( O
T O
. O
H O
. O
Senanayake O
, O
G O
. O
Warren O
, O
S O
. O
V O
. O
Vinogradov O
, O
Novel O
anticancer O
polymeric O
conjugates O
of O
activated O
nucleoside O
analogs O
, O
Bioconjug O
. O
Chem O
. O
22 O
( O
2011 O
) O
1983 O
- O
1993 O
) O
. O

These O
conjugates O
were O
able O
to O
quickly O
release O
an O
active O
form O
of O
the O
drug O
( O
Gemcitabine B
5 I
' I
- I
mono I
- I
, I
di I
- I
and I
triphosphates I
) O
by O
specific O
enzymatic O
activities O
, O
or O
slowly O
during O
hydrolysis O
. O

In O
tumor O
xenograft O
models O
of O
several O
drug O
- O
resistant O
human O
cancers O
, O
we O
observed O
an O
efficient O
inhibition O
of O
tumor O
growth O
and O
extended O
the O
life O
- O
span O
of O
the O
animals O
by O
3 O
times O
that O
of O
the O
control O
with O
orally O
treated O
Gemcitabine O
- O
or O
Floxuridine B
- O
nanogel O
conjugates O
. O

Design O
and O
synthesis O
of O
imidazole O
and O
triazole O
derivatives O
as O
Lp O
- O
PLA O
2 O
inhibitors O
and O
the O
unexpected O
discovery O
of O
highly O
potent O
quaternary B
ammonium I
salts I
. O

New O
Lp O
- O
PLA O
( O
2 O
) O
inhibitors O
were O
synthesized O
by O
the O
bioisosteric O
replacement O
of O
the O
amide O
group O
of O
Darapladib B
with O
an O
imidazole O
or O
a O
triazole O
. O

Unfortunately O
, O
the O
inhibitory O
activities O
of O
these O
derivatives O
were O
lower O
than O
that O
of O
Darapladib B
. O

But O
interestingly O
, O
a O
series O
of O
quaternary B
ammonium I
salts I
that O
were O
isolated O
as O
by O
- O
products O
during O
this O
synthetic O
work O
were O
found O
with O
high O
potency O
. O

Of O
these O
by O
- O
products O
, O
compound O
22c O
showed O
a O
similar O
profile O
to O
Darapladib B
both O
in O
vitro O
and O
in O
vivo O
. O

Synthesis O
and O
antibacterial O
activities O
of O
new O
piperidine O
substituted O
( B
5R I
) I
- I
[ I
1 I
, I
2 I
, I
3 I
] I
triazolylmethyl I
and I
( I
5R I
) I
- I
[ I
( I
4 I
- I
F I
- I
[ I
1 I
, I
2 I
, I
3 I
] I
triazolyl I
) I
methyl I
] I
oxazolidinones I
. O

A O
novel O
series O
of O
5 B
( I
R I
) I
- I
[ I
1 I
, I
2 I
, I
3 I
] I
triazolylmethyl I
and I
( I
5R I
) I
- I
[ I
( I
4 I
- I
F I
- I
[ I
1 I
, I
2 I
, I
3 I
] I
triazolyl I
) I
methyl I
] I
oxazolidinones I
having O
various O
piperidine O
group O
were O
synthesized O
and O
evaluated O
antibacterial O
activity O
against O
clinically O
isolated O
resistant O
strains O
of O
Gram O
- O
positive O
and O
Gram O
- O
negative O
bacteria O
. O

The O
compound O
12a O
having O
exo B
- I
cyanoethylidene I
group O
in O
the O
4 O
- O
position O
of O
piperidine O
ring O
was O
found O
to O
be O
two O
to O
threefold O
more O
potent O
than O
the O
linezolid O
against O
penicillin O
- O
resistant O
Staphylococcus O
pneumonia O
and O
Staphylococcus O
agalactiae O
, O
and O
also O
exhibited O
reduced O
MAO O
- O
B O
inhibitory O
activity O
. O

The O
aim O
of O
this O
work O
was O
to O
identify O
mechanisms O
and O
potential O
biomarkers O
for O
predicting O
the O
development O
and O
progression O
of O
aflatoxin O
B1 O
( O
AFB1 B
) O
- O
induced O
acute O
hepatotoxicity O
. O

In O
this O
study O
, O
microarray O
analysis O
and O
metabolites O
profiles O
were O
used O
to O
identify O
shifts O
in O
gene O
expression O
and O
metabolite O
levels O
associated O
with O
the O
affected O
physiological O
processes O
of O
rats O
treated O
with O
AFB1 B
. O

However O
, O
gene O
expression O
analysis O
and O
metabolite O
profiles O
are O
more O
sensitive O
than O
general O
toxicity O
studies O
for O
detecting O
AFB1 B
- O
induced O
acute O
hepatotoxicity O
as O
the O
patterns O
of O
low O
- O
dose O
AFB1 B
- O
treated O
rats O
in O
these O
two O
technique O
platforms O
were O
more O
similar O
to O
the O
rats O
in O
higher O
dosage O
groups O
than O
to O
the O
control O
rats O
. O

Integrated O
analysis O
of O
the O
results O
from O
general O
toxicity O
studies O
, O
transcriptomics O
and O
metabonomics O
profiles O
suggested O
that O
p53 O
signaling O
pathway O
induced O
by O
oxidative O
damage O
was O
the O
crucial O
step O
in O
AFB1 B
- O
induced O
acute O
hepatotoxicity O
, O
whereas O
gluconeogenesis O
and O
lipid O
metabolism O
disorder O
were O
found O
to O
be O
the O
major O
metabolic O
effects O
after O
acute O
AFB1 B
exposure O
. O

The O
genes O
and O
metabolites O
significantly O
affected O
in O
common O
in O
rat O
liver O
or O
serum O
of O
three O
doses O
AFB1 B
treatments O
served O
as O
potential O
biomarkers O
for O
detecting O
AFB1 B
- O
induced O
acute O
hepatotoxicity O
. O

We O
apply O
DFTB O
in O
a O
QM O
/ O
MM O
framework O
to O
perform O
vibrational O
analysis O
of O
buried O
aspartic B
acids I
in O
bacteriorhodopsin O
and O
channelrhodopsin O
- O
2 O
. O

Preparation O
and O
evaluation O
of O
sustained O
- O
release O
doxazosin B
mesylate I
pellets O
. O

Doxazosin B
mesylate I
( O
DXM O
) O
sustained O
release O
pellets O
were O
prepared O
by O
an O
extrusion O
- O
spheronization O
and O
fluid O
- O
bed O
coating O
technique O
. O

Polymethacrylate B
derivatives O
( O
Eudragit O
( O
R O
) O
RS O
PO O
and O
RL O
PO O
) O
were O
used O
for O
coating O
agents O
, O
and O
polyethylene B
glycol I
6000 I
( O
PEG B
6000 I
) O
, O
triethyl O
citrate O
( O
TEC B
) O
and O
castor O
oil O
were O
as O
plasticizers O
. O

PEG B
6000 I
was O
an O
appropriate O
plasticizer O
for O
DXM O
pellets O
, O
and O
increasing O
the O
content O
of O
PEG B
6000 I
, O
was O
also O
slightly O
decreasing O
the O
dissolution O
rate O
. O

Nocapyrones B
H I
- I
J I
, O
3 B
, I
6 I
- I
Disubstituted I
alpha I
- I
Pyrones I
from O
the O
Marine O
Actinomycete O
Nocardiopsis O
sp O
. O

Three O
new O
3 B
, I
6 I
- I
disubstituted I
alpha I
- I
pyrones I
, O
nocapyrones B
H I
- I
J I
( O
1 O
- O
3 O
) O
, O
were O
isolated O
from O
the O
marine O
actinomycete O
Nocardiopsis O
sp O
. O

Their O
structures O
were O
assigned O
to O
be O
3 B
- I
alkylated I
6 I
- I
( I
1 I
- I
methyl I
- I
1 I
- I
propenyl I
) I
- I
2H I
- I
pyran I
- I
2 I
- I
ones I
on O
the O
basis O
of O
UV O
, O
MS O
, O
NMR O
, O
and O
high O
resolution O
( O
HR O
) O
- O
FAB O
- O
MS O
analyses O
. O

Nocapyrone B
H I
( O
1 O
) O
reduced O
the O
pro O
- O
inflammatory O
factor O
such O
as O
nitric O
oxide O
( O
NO O
) O
, O
prostaglandin O
E2 O
( O
PGE2 O
) O
and O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1 O
beta O
) O
. O

Moreover O
, O
nocapyrone B
H I
showed O
5 O
. O
82 O
% O
stronger O
inhibitory O
effect O
on O
NO O
production O
than O
chrysin O
at O
a O
concentration O
of O
10 O
micro O
m O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
BV O
- O
2 O
microglial O
cells O
. O

A O
highly O
selective O
SGLT2 O
inhibitor O
, O
tofogliflozin B
, O
and O
four O
other O
inhibitors O
with O
different O
in O
vitro O
inhibition O
potency O
to O
SGLT2 O
and O
selectivity O
toward O
SGLT2 O
, O
versus O
SGLT1 O
were O
used O
as O
test O
compounds O
, O
and O
the O
time O
courses O
for O
urinary O
glucose O
excretion O
( O
UGE O
) O
and O
the O
plasma O
glucose O
and O
compound O
concentrations O
were O
monitored O
after O
administration O
of O
the O
compounds O
. O

Among O
all O
the O
metal O
oxides O
, O
tin B
dioxide I
( O
SnO O
( O
2 O
) O
) O
is O
regarded O
as O
a O
promising O
candidate O
to O
serve O
as O
the O
anode O
material O
for O
LIBs O
due O
to O
its O
high O
theoretical O
capacity O
. O

By O
focusing O
on O
SnO O
( O
2 O
) O
, O
the O
hope O
is O
that O
such O
concepts O
and O
strategies O
can O
be O
extended O
to O
other O
potential O
metal O
oxides O
, O
such O
as O
titanium O
dioxide O
or O
iron B
oxides I
, O
thus O
shedding O
some O
light O
on O
the O
future O
development O
of O
high O
- O
performance O
metal O
- O
oxide O
based O
negative O
electrodes O
for O
LIBs O
. O

PCOS O
women O
with O
17 O
- O
hydroxyprogesterone O
( O
17OHP B
) O
basal O
values O
> O
2 O
ng O
/ O
ml O
and O
/ O
or O
post O
- O
ACTH O
> O
10 O
ng O
/ O
ml O
were O
excluded O
. O

Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl B
glucuronides I
. O

Uridine B
5 I
' I
- I
diphosphate I
- O
glucuronosyltransfer O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl B
glucuronides I
, O
but O
it O
is O
currently O
unknown O
if O
acyl B
glucuronides I
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O

Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl B
glucuronides I
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
( O
hCES1 O
) O
and O
2 O
( O
hCES2 O
) O
. O

Methods O
: O
The O
stability O
of O
six O
acyl B
glucuronides I
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
( O
100 O
mM O
potassium O
phosphate O
, O
pH O
7 O
. O
4 O
, O
37 O
degrees O
C O
) O
were O
investigated O
. O

Reversible O
inhibition O
of O
4 B
- I
nitrophenyl I
acetate I
hydrolysis O
by O
the O
acyl B
glucuronides I
was O
also O
studied O
. O

Diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
was O
used O
to O
explore O
potential O
time O
- O
dependent O
inactivation O
. O

Results O
: O
The O
chemical O
stability O
half O
- O
life O
values O
for O
CGP B
47292 I
- I
beta I
- I
d I
- I
glucuronide I
, O
diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
R I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
S I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
ibuprofen B
- I
beta I
- I
d I
- I
glucuronide I
( I
racemic I
) I
, O
clopidogrel B
- I
beta I
- I
d I
- I
glucuronide I
, O
and O
valproate O
- O
beta O
- O
d O
- O

Diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
, O
clopidogrel B
- I
beta I
- I
d I
- I
glucuronide I
, O
ibuprofen B
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
R I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
and O
( B
S I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4 O
. O
32 O
+ O
/ O
- O
0 O
. O
47 O
, O
24 O
. O
8 O
+ O
/ O
- O
4 O
. O
2 O
, O
355 O
+ O
/ O
- O
38 O
, O

Valproate B
- I
beta I
- I
d I
- I
glucuronide I
and O
CGP B
47292 I
- I
beta I
- I
d I
- I
glucuronide I
did O
not O
inhibit O
either O
hCES O
. O

Time O
- O
dependent O
inactivation O
of O
hCES1 O
by O
diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
was O
not O
observed O
. O

Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl B
glucuronides I
studied O
. O

Conclusion O
: O
Drug O
- O
drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl B
glucuronides I
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

The O
phytochemical O
study O
of O
the O
CR O
fraction O
allowed O
identifying O
the O
known O
iridoids O
secoxyloganin B
, O
sweroside O
and O
loganin B
. O

Azaspiracid B
- I
1 I
inhibits O
the O
maturation O
of O
cathepsin O
D O
in O
mammalian O
cells O
. O

Azaspiracid B
- I
1 I
( O
AZA B
- I
1 I
) O
inhibits O
endocytosis O
, O
but O
the O
consequences O
of O
this O
alteration O
on O
cellular O
processes O
are O
unknown O
. O

We O
hypothesized O
that O
the O
inhibition O
of O
endocytosis O
is O
a O
key O
step O
of O
the O
mode O
of O
action O
of O
AZA B
- I
1 I
, O
leading O
to O
perturbation O
of O
cellular O
processes O
dependent O
on O
proper O
functioning O
of O
endocytic O
machinery O
. O

We O
tested O
this O
working O
hypothesis O
by O
probing O
whether O
AZA B
- I
1 I
can O
alter O
the O
maturation O
of O
cathepsin O
D O
in O
MCF O
- O
7 O
epithelial O
cells O
, O
as O
a O
model O
system O
. O

We O
found O
that O
cell O
treatment O
with O
AZA B
- I
1 I
inhibited O
the O
conversion O
of O
52 O
kDa O
procathepsin O
D O
into O
the O
mature O
30 O
kDa O
protein O
. O

The O
effects O
induced O
by O
AZA B
- I
1 I
were O
similar O
to O
those O
elicited O
by O
chlorpromazine O
and O
other O
agents O
preventing O
proper O
maturation O
of O
lysosomal O
enzymes O
, O
indicating O
that O
the O
inhibition O
of O
endocytic O
transfer O
of O
proforms O
to O
late O
endosomes O
/ O
lysosomess O
is O
responsible O
for O
the O
effect O
induced O
by O
the O
toxin O
. O

Co O
- O
localization O
of O
cathepsin O
D O
and O
EEA O
- O
1 O
immunoreactivity O
, O
in O
turn O
, O
was O
found O
in O
cells O
exposed O
to O
AZA B
- I
1 I
, O
indicating O
that O
the O
toxin O
blocks O
protein O
maturation O
at O
the O
early O
steps O
of O
endocytosis O
, O
causing O
accumulation O
of O
procathepsin O
D O
in O
early O
endosomes O
. O

The O
molecular O
alteration O
induced O
by O
AZA B
- I
1 I
involved O
both O
secreted O
and O
intracellular O
pools O
of O
procathepsin O
D O
, O
showing O
that O
the O
toxin O
effect O
does O
not O
result O
from O
a O
general O
impairment O
of O
vesicular O
trafficking O
but O
is O
the O
outcome O
of O
a O
perturbed O
centripetal O
process O
. O

Furthermore O
, O
AZA B
- I
1 I
was O
found O
to O
inhibit O
procathepsin O
D O
maturation O
also O
in O
normal O
fibroblasts O
, O
showing O
that O
this O
molecular O
response O
is O
induced O
by O
this O
toxin O
in O
different O
cell O
types O
. O

Four O
new O
germacranes B
[ O
heyneanones B
A I
- I
D I
( O
1 O
- O
4 O
) O
] O
, O
three O
new O
guaianes B
[ O
4 B
, I
10 I
- I
epizedoarondiol I
( O
5 O
) O
, O
15 B
- I
hydroxyprocurcumenol I
( O
6 O
) O
, O
12 B
- I
hydroxycurcumenol I
( O
7 O
) O
] O
, O
and O
two O
new O
spirolactones B
[ O
curcumanolides B
C O
( O
8 O
) O
and O
D O
( O
9 O
) O
] O
were O
isolated O
from O
the O
rhizomes O
of O
Curcuma O
heyneana O
together O
with O
13 O
known O
sesquiterpenes O
and O

two O
known O
labdane B
- O
type O
diterpenes O
. O

Among O
the O
isolated O
compounds O
, O
heyneanone B
A I
( O
1 O
) O
, O
heyneanone B
C I
( O
3 O
) O
, O
4 B
, I
10 I
- I
epizedoarondiol I
( O
5 O
) O
, O
procurcumenol B
( O
16 O
) O
, O
aerugidiol B
( O
17 O
) O
, O
zerumin B
A I
( O
23 O
) O
, O
and O
( B
E I
) I
- I
15 I
, I
16 I
- I
bisnorlabda I
- I
8 I
( I
17 I
) I
, I
11 I
- I
dien I
- I
13 I
- I
one I
( O
24 O
) O
inhibited O
protein O
tyrosine O
phosphatase O
1B O
( O
PTP1B O
) O
with O
IC O
( O
50 O
) O
values O
of O
42 O

The O
amphiphilic O
diblock O
copolymer O
poly B
( I
epsilon I
- I
caprolactone I
) I
- I
b I
- I
poly I
( I
ethylene I
oxide I
) I
( O
PCL B
- I
b I
- I
PEO I
) O
was O
first O
conjugated O
with O
the O
cyclic B
( I
Arginine I
- I
Glycine I
- I
Aspartic I
acid I
- I
d I
- I
Phenylalanine I
- I
Lysine I
) I
( O
c O
( O
RGDfK O
) O
) O
and O
fluorescein B
isothiocyannate I
( O
FITC O
) O
via O
the O
functional O
terminal O
groups O
of O
hydrophilic O
block O
, O
and O
then O
assembled O
into O
micelles O
. O

The O
c O
( O
RGDfK O
) O
modified O
micelles O
assembled O
from O
PCL B
- I
b I
- I
PEO I
diblock O
copolymers O
developed O
in O
this O
study O
are O
of O
great O
potentials O
as O
nano O
- O
scaled O
drug O
delivery O
system O
for O
intravesical O
instilled O
chemotherapy O
of O
superficial O
bladder O
cancer O
. O

We O
examined O
the O
effects O
of O
PHD O
inhibiton O
by O
dimethyloxalylglycin B
on O
the O
vasomotor O
responses O
of O
isolated O
rat O
aorta O
and O
aortic O
vascular O
smooth O
muscle O
cells O
( O
VSMCs O
) O
in O
a O
model O
of O
cold O
ischemia O
/ O
warm O
reperfusion O
. O

Aortic O
segments O
underwent O
24 O
hours O
of O
cold O
ischemic O
preservation O
in O
saline O
or O
DMOG B
( O
dimethyloxalylglycin B
) O
- O
supplemented O
saline O
solution O
. O

To O
simulate O
IR O
injury O
, O
hypochlorite B
( O
NaOCl B
) O
was O
added O
during O
warm O
reperfusion O
. O

VSMCs O
were O
incubated O
in O
NaCl O
or O
DMOG B
solution O
at O
4 O
degrees O
C O
for O
24 O
hours O
after O
the O
medium O
was O
changed O
for O
a O
supplied O
standard O
medium O
at O
37 O
degrees O
C O
for O
6 O
hours O
. O

Cold O
ischemic O
preservation O
and O
NaOCl B
induced O
severe O
endothelial O
dysfunction O
, O
which O
was O
significantly O
improved O
by O
DMOG B
supplementation O
( O
maximal O
relaxation O
of O
aortic O
segments O
to O
acetylcholine O
: O
control O
95 O
% O
+ O
/ O
- O
1 O
% O
versus O
NaOCl B
44 O
% O
+ O
/ O
- O
4 O
% O
versus O
DMOG B
68 O
% O
+ O
/ O
- O
5 O
% O
) O
. O

Number O
of O
TUNEL O
- O
positive O
cell O
nuclei O
was O
significantly O
higher O
in O
the O
NaOCl B
group O
, O
and O
DMOG B
treatment O
significantly O
decreased O
apoptosis O
. O

Inducible O
heme O
- O
oxygenase O
1 O
mRNA O
expressions O
were O
significantly O
higher O
in O
the O
DMOG B
group O
. O

Pharmacological O
modulation O
of O
oxygen O
sensing O
system O
by O
DMOG B
in O
an O
in O
vitro O
model O
of O
vascular O
IR O
effectively O
preserved O
endothelial O
function O
. O

Transport O
of O
A1 O
adenosine O
receptor O
agonist O
tecadenoson B
by O
human O
and O
mouse O
nucleoside O
transporters O
: O
evidence O
for O
blood O
- O
brain O
barrier O
transport O
by O
murine O
equilibrative O
nucleoside O
transporter O
1 O
mENT1 O
. O

Tecadenoson B
is O
a O
selective O
A1 O
adenosine O
receptor O
agonist O
with O
close O
similarity O
to O
adenosine O
. O

We O
studied O
the O
binding O
and O
transmembrane O
transport O
of O
tecadenoson B
by O
recombinant O
human O
equilibrative O
nucleoside O
transporters O
( O
hENTs O
) O
hENT1 O
and O
hENT2 O
, O
and O
human O
concentrative O
nucleoside O
transporters O
( O
hCNTs O
) O
hCNT1 O
, O
hCNT2 O
, O
and O
hCNT3 O
in O
vitro O
and O
by O
mouse O
mENT1 O
in O
vivo O
. O

Binding O
affinities O
of O
the O
five O
recombinant O
human O
nucleoside O
transporters O
for O
tecadenoson B
differed O
( O
hENT1 O
> O
hCNT1 O
> O
hCNT3 O
> O
hENT2 O
> O
hCNT2 O
) O
, O
and O
tecadenoson B
was O
transported O
largely O
by O
hENT1 O
. O

Pretreatment O
of O
mice O
with O
a O
phosphorylated O
prodrug O
of O
nitrobenzylmercaptop B
riboside O
, O
an O
inhibitor O
of O
mENT1 O
, O
significantly O
decreased O
brain O
exposure O
to O
tecadenoson B
compared O
with O
that O
of O
the O
untreated O
( O
control O
) O
group O
, O
suggesting O
involvement O
of O
mENT1 O
in O
transport O
of O
tecadenoson B
across O
the O
blood O
- O
brain O
barrier O
( O
BBB O
) O
. O

In O
summary O
, O
ENT1 O
was O
shown O
to O
mediate O
the O
transport O
of O
tecadenoson B
in O
vitro O
with O
recombinant O
and O
native O
human O
protein O
and O
in O
vivo O
with O
mice O
. O

The O
micromolar O
apparent O
Km O
value O
of O
tecadenoson B
for O
transport O
by O
native O
hENT1 O
in O
cultured O
cells O
suggests O
that O
hENT1 O
will O
not O
be O
saturated O
at O
clinically O
relevant O
( O
i O
. O
e O
. O
, O
nanomolar O
) O
concentrations O
of O
tecadenoson B
, O
and O
that O
hENT1 O
- O
mediated O
passage O
across O
the O
BBB O
may O
contribute O
to O
the O
adverse O
CNS O
effects O
observed O
in O
clinical O
trials O
. O

New O
casbane B
diterpenoids I
from O
a O
South O
China O
Sea O
soft O
coral O
, O
Sinularia O
sp O
. O

Six O
new O
casbane B
diterpenoids I
, O
named O
as O
sinularcasbanes B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
along O
with O
six O
known O
analogues O
7 O
- O
12 O
, O
were O
isolated O
from O
a O
South O
China O
Sea O
soft O
coral O
, O
Sinularia O
sp O
. O

In O
this O
study O
, O
we O
compared O
their O
toxicity O
in O
vivo O
and O
in O
vitro O
based O
on O
the O
physicochemical O
properties O
of O
three O
different O
types O
of O
TiO O
( O
2 O
) O
nanowires O
, O
H B
( I
2 I
) I
Ti I
( I
3 I
) I
O I
( I
7 I
) I
nanowires O
( O
1HTO O
) O
, O
hydrothermal O
treatment O
( O
2HTO O
) O
, O
and O
calcination O
( O
3HTO O
) O
of O
1HTO O
. O

The O
effects O
of O
BMY B
- I
14802 I
against O
L B
- I
DOPA I
- O
and O
dopamine O
agonist O
- O
induced O
dyskinesia O
in O
the O
hemiparkinsonian O
rat O
. O

RATIONALE O
: O
L B
- I
DOPA I
continues O
to O
be O
the O
primary O
treatment O
for O
patients O
with O
Parkinson O
' O
s O
disease O
; O
however O
, O
the O
benefits O
of O
long O
- O
term O
treatment O
are O
often O
accompanied O
by O
debilitating O
side O
effects O
known O
as O
dyskinesias O
. O

The O
purported O
sigma O
- O
1 O
antagonist O
, O
BMY B
- I
14802 I
has O
been O
previously O
demonstrated O
to O
reduce O
L B
- I
DOPA I
induced O
dyskinesia O
in O
a O
5 O
- O
HT O
( O
1A O
) O
receptor O
dependent O
manner O
. O

OBJECTIVE O
: O
In O
the O
present O
study O
, O
we O
extend O
these O
findings O
by O
examining O
the O
anti O
- O
dyskinetic O
potential O
of O
BMY B
- I
14802 I
against O
L B
- I
DOPA I
, O
the O
D O
( O
1 O
) O
receptor O
agonist O
SKF81297 B
and O
the O
D O
( O
2 O
) O
receptor O
agonist O
, O
quinpirole O
, O
in O
the O
hemi O
- O
parkinsonian O
rat O
model O
. O

In O
addition O
, O
the O
receptor O
specificity O
of O
BMY B
- I
14802 I
' O
s O
effects O
was O
evaluated O
using O
WAY O
- O
100635 O
, O
a O
5 O
- O
HT O
( O
1A O
) O
receptor O
antagonist O
. O

RESULTS O
: O
Results O
confirmed O
the O
dose O
- O
dependent O
( O
20 O
> O
10 O
> O
5 O
mg O
/ O
kg O
) O
anti O
- O
dyskinetic O
effects O
of O
BMY B
- I
14802 I
against O
L B
- I
DOPA I
with O
preservation O
of O
anti O
- O
parkinsonian O
efficacy O
at O
10 O
mg O
/ O
kg O
. O

BMY B
- I
14802 I
at O
10 O
and O
20 O
mg O
/ O
kg O
also O
reduced O
dyskinesia O
induced O
by O
both O
D O
( O
1 O
) O
and O
D O
( O
2 O
) O
receptor O
agonists O
. O

Additionally O
, O
BMY B
- I
14802 I
' O
s O
anti O
- O
dyskinetic O
effects O
against O
L B
- I
DOPA I
, O
but O
not O
SKF81297 B
or O
quinpirole O
, O
were O
reversed O
by O
WAY O
- O
100635 O
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
. O

CONCLUSION O
: O
Collectively O
, O
these O
findings O
demonstrate O
that O
BMY B
- I
14802 I
provides O
anti O
- O
dyskinetic O
relief O
against O
L B
- I
DOPA I
and O
direct O
DA O
agonist O
in O
a O
preclinical O
model O
of O
PD O
, O
acting O
via O
multiple O
receptor O
systems O
and O
supports O
the O
utility O
of O
such O
compounds O
for O
the O
improved O
treatment O
of O
PD O
. O

Phosphodiesterase O
4 O
inhibitors O
augment O
the O
ability O
of O
formoterol B
to O
enhance O
glucocorticoid O
- O
dependent O
gene O
transcription O
in O
human O
airway O
epithelial O
cells O
: O
a O
novel O
mechanism O
for O
the O
clinical O
efficacy O
of O
roflumilast B
in O
severe O
chronic O
obstructive O
pulmonary O
disease O
. O

Post O
- O
hoc O
analysis O
of O
two O
phase O
III O
clinical O
studies O
found O
that O
the O
phosphodiesterase O
4 O
( O
PDE4 O
) O
inhibitor O
, O
roflumilast B
, O
reduced O
exacerbation O
frequency O
in O
patients O
with O
severe O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
who O
were O
taking O
inhaled O
corticosteroids O
( O
ICS O
) O
concomitantly O
, O
whereas O
patients O
not O
taking O
ICS O
derived O
no O
such O
benefit O
. O

In O
contrast O
, O
in O
two O
different O
trials O
also O
performed O
in O
patients O
with O
severe O
COPD O
, O
roflumilast B
reduced O
exacerbation O
rates O
in O
the O
absence O
of O
ICS O
, O
indicating O
that O
PDE4 O
inhibition O
alone O
is O
sufficient O
for O
therapeutic O
activity O
to O
be O
realized O
. O

Given O
that O
roflumilast B
is O
recommended O
as O
an O
" O
add O
- O
on O
" O
medication O
to O
patients O
with O
severe O
disease O
who O
will O
inevitably O
be O
taking O
a O
long O
- O
acting O
beta O
2 O
- O
adrenoceptor O
agonist O
( O
LABA O
) O
/ O
ICS O
combination O
therapy O
, O
we O
tested O
the O
hypothesis O
that O
roflumilast B
augments O
the O
ability O
of O
glucocorticoids O
to O
induce O
genes O
with O
anti O
- O
inflammatory O
activity O
. O

Using O
a O
glucocorticoid O
response O
element O
( O
GRE O
) O
luciferase O
reporter O
transfected O
into O
human O
airway O
epithelial O
cells O
[ O
both O
bronchial O
epithelium O
+ O
adenovirus O
12 O
- O
SV40 O
hybrid O
( O
BEAS O
- O
2B O
) O
cells O
and O
primary O
cultures O
] O
, O
roflumilast B
enhanced O
fluticasone O
propionate O
- O
induced O
GRE O
- O
dependent O
transcription O
. O

Roflumilast B
also O
produced O
a O
sinistral O
displacement O
of O
the O
concentration O
- O
response O
curves O
that O
described O
the O
augmentation O
of O
GRE O
- O
dependent O
transcription O
by O
the O
LABA O
formoterol B
. O

In O
BEAS O
- O
2B O
cells O
and O
primary O
airway O
epithelia O
, O
roflumilast B
interacted O
with O
formoterol B
in O
a O
positive O
cooperative O
manner O
to O
enhance O
the O
expression O
of O
several O
glucocorticoid O
- O
inducible O
genes O
that O
have O
anti O
- O
inflammatory O
potential O
. O

We O
suggest O
that O
the O
ability O
of O
roflumilast B
and O
formoterol B
to O
interact O
in O
this O
way O
supports O
the O
concept O
that O
these O
drugs O
together O
may O
impart O
clinical O
benefit O
beyond O
that O
achievable O
by O
an O
ICS O
alone O
, O
a O
PDE4 O
inhibitor O
alone O
, O
or O
an O
ICS O
/ O
LABA O
combination O
therapy O
. O

Roflumilast B
may O
, O
therefore O
, O
be O
especially O
effective O
in O
patients O
with O
severe O
COPD O
. O

The O
Au102 B
( I
pMBA I
) I
44 I
nanocluster O
becomes O
a O
superatom O
paramagnet O
after O
chemical O
oxidation O
. O

Solutions O
of O
paramagnetic O
Au102 B
( I
pMBA I
) I
44 I
heat O
in O
an O
oscillating O
magnetic O
field O
component O
of O
an O
RF O
field O
, O
but O
not O
in O
the O
electric O
component O
. O

Combined O
, O
these O
experiments O
suggest O
that O
paramagnetic O
Au102 B
( I
pMBA I
) I
44 I
heats O
through O
interactions O
of O
spin O
magnetic O
moment O
with O
an O
external O
oscillating O
magnetic O
field O
. O

A O
series O
of O
polyacenes B
shows O
the O
similar O
behavior O
of O
the O
optically O
allowed O
singlet O
excitation O
energies O
obtained O
by O
time O
- O
dependent O
spin O
- O
flip O
density O
functional O
theory O
calculations O
and O
experiments O
, O
which O
bears O
testimony O
to O
the O
singlet O
open O
- O
shell O
character O
in O
long O
polyacenes O
. O

The O
supramolecular O
host O
assembly O
[ B
Ga4L6 I
] I
( I
12 I
- I
) I
[ O
1 O
; O
L O
= O
1 B
, I
5 I
- I
bis I
( I
2 I
, I
3 I
- I
dihydroxybenzamido I
) I
naphthalene I
] O
contains O
a O
flexible O
, O
hydrophobic O
interior O
cavity O
that O
can O
encapsulate O
cationic O
guest O
molecules O
and O
catalyze O
a O
variety O
of O
chemical O
transformations O
. O

The O
Ar B
- I
CH2 I
bond O
rotational O
barrier O
for O
encapsulated O
ortho B
- I
substituted I
benzyl I
phosphonium I
guest O
molecules O
is O
sensitive O
to O
the O
size O
and O
shape O
of O
the O
host O
interior O
space O
. O

Here O
we O
examine O
how O
changes O
in O
bulk O
solvent O
( O
water O
, O
methanol O
, O
or O
DMF B
) O
or O
applied O
pressure O
( O
up O
to O
150 O
MPa O
) O
affect O
the O
rotational O
dynamics O
of O
encapsulated O
benzyl B
phosphonium I
guests O
, O
as O
a O
way O
to O
probe O
changes O
in O
host O
cavity O
size O
or O
flexibility O
. O

When O
host O
1 O
is O
dissolved O
in O
organic O
solvents O
with O
large O
solvent O
internal O
pressures O
( O
d O
U O
/ O
d O
V O
) O
T O
, O
we O
find O
that O
the O
free O
energy O
barrier O
to O
Ar B
- I
CH2 I
bond O
rotation O
increases O
by O
1 O
- O
2 O
kcal O
/ O
mol O
, O
compared O
with O
that O
in O
aqueous O
solution O
. O

ADME O
characterization O
in O
rats O
revealed O
immediate O
secretion O
of O
AZD7903 B
into O
the O
stomach O
after O
IV O
dosing O
. O

The O
distribution O
of O
AZD7903 B
and O
/ O
or O
its O
metabolites O
was O
studied O
in O
rats O
following O
a O
single O
p O
. O
o O
. O
or O
i O
. O
v O
. O
dose O
using O
quantitative O
whole O
- O
body O
autoradiography O
( O
QWBA O
) O
. O

In O
summary O
, O
the O
results O
indicate O
AZD7903 B
being O
substrate O
for O
a O
transporter O
protein O
and O
support O
the O
hypothesis O
that O
the O
differences O
in O
disposition O
between O
sexes O
are O
due O
to O
differences O
in O
metabolic O
pathways O
and O
rates O
. O

Twenty O
- O
five O
metabolites O
were O
tentatively O
identified O
for O
irgarol B
, O
terbutryn B
, O
tramadol B
, O
and O
venlafaxine O
in O
G O
. O
pulex O
( O
21 O
via O
oxidation O
and O
4 O
via O
conjugation O
reactions O
) O
and O
11 O
metabolites O
in O
D O
. O
magna O
( O
7 O
via O
oxidation O
and O
4 O
via O
conjugation O
reactions O
) O
, O
while O
no O
evidence O
of O
metabolites O
for O
clarithromycin O
and O
valsartan B
was O
found O
. O

The O
enzyme O
( O
TcCA O
) O
has O
a O
very O
high O
catalytic O
activity O
for O
the O
CO O
( O
2 O
) O
hydration O
reaction O
, O
being O
similar O
kinetically O
to O
the O
human O
( O
h O
) O
isoform O
hCA O
II O
, O
although O
it O
is O
devoid O
of O
the O
His64 B
proton O
shuttle O
. O

A O
large O
number O
of O
aromatic B
/ I
heterocyclic I
sulfonamides I
and O
some O
5 B
- I
mercapto I
- I
1 I
, I
3 I
, I
4 I
- I
thiadiazoles I
were O
investigated O
as O
TcCA O
inhibitors O
. O

The O
aromatic B
sulfonamides I
were O
weak O
inhibitors O
( O
K O
( O
I O
) O
values O
of O
192 O
nM O
to O
84 O
mu O
M O
) O
, O
whereas O
some O
heterocyclic O
compounds O
inhibited O
the O
enzyme O
with O
K O
( O
I O
) O
values O
in O
the O
range O
61 O
. O
6 O
- O
93 O
. O
6 O
nM O
. O

Toxicological O
, O
toxicokinetic O
and O
gastroprotective O
evaluation O
of O
the O
benzaldehyde B
semicarbazone I
. O

Benzaldehyde B
semicarbazone I
( O
BS O
) O
has O
presented O
positive O
results O
in O
several O
pharmacological O
models O
, O
including O
anticonvulsivant O
and O
anti O
- O
inflammatory O
models O
. O

Synthesis O
of O
Li O
- O
Mn O
- O
O O
mesocrystals O
with O
controlled O
crystal O
phases O
through O
topotactic O
transformation O
of O
MnCO B
3 I
. O

Mesocrystals O
of O
Li O
- O
Mn O
- O
O O
compounds O
, O
such O
as O
LiMn2O4 B
, O
Li2MnO3 B
, O
and O
LiMnO2 B
- O
Li2MnO3 B
, O
consisting O
of O
oriented O
nanoscale O
units O
were O
selectively O
produced O
under O
hydrothermal O
conditions O
from O
biomimetically O
prepared O
MnCO3 O
mesocrystals O
. O

Topotactic O
transformation O
through O
the O
intermediate O
phase O
of O
Mn5O8 B
inheriting O
a O
hierarchical O
structure O
of O
the O
MnCO3 O
precursor O
was O
essential O
for O
the O
formation O
of O
the O
mesocrystal O
compounds O
. O

This O
behavioral O
switch O
was O
prevented O
by O
intra O
- O
VTA O
administration O
of O
acetazolamide B
, O
an O
inhibitor O
of O
the O
bicarbonate O
ion O
- O
producing O
carbonic O
anhydrase O
enzyme O
. O

The O
competitive O
MCT O
inhibitor O
l B
- I
lactate I
was O
administered O
by O
intravenous O
infusion O
starting O
1 O
hour O
after O
GHB O
and O
GBL O
administration O
. O

Oral O
administration O
of O
l B
- I
lactate I
and O
the O
MCT O
inhibitor O
luteolin O
was O
also O
evaluated O
. O

Intravenous O
l B
- I
lactate I
, O
but O
not O
oral O
treatments O
, O
significantly O
increased O
GHB O
renal O
and O
/ O
or O
oral O
clearances O
. O

At O
the O
low O
dose O
of O
GHB O
and O
GBL O
, O
i O
. O
v O
. O
l B
- I
lactate I
increased O
GHB O
renal O
clearance O
. O

The O
lack O
of O
effect O
of O
i O
. O
v O
. O
l B
- I
lactate I
on O
renal O
clearance O
after O
a O
high O
oral O
GHB O
dose O
suggests O
possible O
effects O
of O
i O
. O
v O
. O
l B
- I
lactate I
on O
MCT O
- O
mediated O
absorption O
. O

Intravenous O
l B
- I
lactate I
also O
reduced O
mortality O
with O
the O
high O
GBL O
dose O
. O

These O
data O
indicate O
i O
. O
v O
. O
l B
- I
lactate I
represents O
a O
potential O
treatment O
strategy O
in O
oral O
overdose O
of O
GHB O
and O
GBL O
. O

GnRH B
pulse O
frequency O
- O
dependent O
stimulation O
of O
FSH O
beta O
transcription O
is O
mediated O
via O
activation O
of O
PKA O
and O
CREB O
. O

Expression O
of O
pituitary O
FSH O
and O
LH O
, O
under O
the O
control O
of O
pulsatile O
GnRH B
, O
is O
essential O
for O
fertility O
. O

cAMP O
response O
element O
- O
binding O
protein O
( O
CREB O
) O
has O
been O
implicated O
in O
the O
regulation O
of O
FSH O
beta O
gene O
expression O
, O
but O
the O
molecular O
mechanisms O
by O
which O
pulsatile O
GnRH B
regulates O
CREB O
activation O
remain O
poorly O
understood O
. O

We O
hypothesized O
that O
CREB O
is O
activated O
by O
a O
distinct O
signaling O
pathway O
in O
response O
to O
pulsatile O
GnRH B
in O
a O
frequency O
- O
dependent O
manner O
to O
dictate O
the O
FSH O
beta O
transcriptional O
response O
. O

GnRH B
stimulation O
of O
CREB O
phosphorylation O
( O
pCREB O
) O
in O
the O
gonadotrope O
- O
derived O
L O
beta O
T2 O
cell O
line O
was O
attenuated O
by O
a O
protein O
kinase O
A O
( O
PKA O
) O
inhibitor O
, O
H89 B
. O

A O
dominant O
negative O
PKA O
( O
DNPKA O
) O
reduced O
GnRH B
- O
stimulated O
pCREB O
and O
markedly O
decreased O
GnRH B
stimulation O
of O
FSH O
beta O
mRNA O
and O
FSH O
beta O
LUC O
activity O
, O
but O
had O
little O
effect O
on O
LH O
beta O
LUC O
activity O
, O
indicating O
relative O
specificity O
of O
this O
pathway O
. O

In O
perifusion O
studies O
, O
FSH O
beta O
mRNA O
levels O
and O
FSH O
beta O
LUC O
activities O
were O
increased O
by O
pulsatile O
GnRH B
, O
with O
significantly O
greater O
increases O
at O
low O
compared O
with O
high O
pulse O
frequencies O
. O

DNPKA O
markedly O
reduced O
these O
GnRH B
- O
stimulated O
FSH O
beta O
responses O
at O
both O
low O
and O
high O
pulse O
frequencies O
. O

Correlating O
with O
FSH O
beta O
activation O
, O
both O
PKA O
activity O
and O
levels O
of O
pCREB O
were O
increased O
to O
a O
greater O
extent O
by O
low O
compared O
with O
high O
GnRH B
pulse O
frequencies O
, O
and O
the O
induction O
of O
pCREB O
was O
also O
attenuated O
by O
overexpression O
of O
DNPKA O
at O
both O
low O
and O
high O
pulse O
frequencies O
. O

Taken O
together O
, O
these O
data O
indicate O
that O
a O
PKA O
- O
mediated O
signaling O
pathway O
mediates O
GnRH B
activation O
of O
CREB O
at O
low O
- O
pulse O
frequencies O
, O
playing O
a O
significant O
role O
in O
the O
decoding O
of O
the O
hypothalamic O
GnRH B
signal O
to O
result O
in O
frequency O
- O
dependent O
FSH O
beta O
activation O
. O

Pharmacokinetic O
Interactions O
between O
Monoamine O
Oxidase O
A O
Inhibitor O
Harmaline B
and O
5 B
- I
Methoxy I
- I
N I
, I
N I
- I
Dimethyltryptamine I
, O
and O
the O
Impact O
of O
CYP2D6 O
Status O
. O

5 B
- I
Methoxy I
- I
N I
, I
N I
- I
dimethyltryptamine I
( O
5 B
- I
MeO I
- I
DMT I
or O
street O
name O
" O
5 B
- I
MEO I
" O
) O
is O
a O
newer O
designer O
drug O
belonging O
to O
a O
group O
of O
naturally O
occurring O
indolealkylamines B
. O

Our O
recent O
study O
has O
demonstrated O
that O
coadministration O
of O
monoamine O
oxidase O
A O
( O
MAO O
- O
A O
) O
inhibitor O
harmaline B
( O
5 O
mg O
/ O
kg O
) O
increases O
systemic O
exposure O
to O
5 B
- I
MeO I
- I
DMT I
( O
2 O
mg O
/ O
kg O
) O
and O
active O
metabolite O
bufotenine O
. O

This O
study O
is O
aimed O
at O
delineating O
harmaline B
and O
5 B
- I
MeO I
- I
DMT I
pharmacokinetic O
( O
PK O
) O
interactions O
at O
multiple O
dose O
levels O
, O
as O
well O
as O
the O
impact O
of O
CYP2D6 O
that O
affects O
harmaline B
PK O
and O
determines O
5 B
- I
MeO I
- I
DMT I
O O
- O
demethylation O
to O
produce O
bufotenine B
. O

Our O
data O
revealed O
that O
inhibition O
of O
MAO O
- O
A O
- O
mediated O
metabolic O
elimination O
by O
harmaline B
( O
2 O
, O
5 O
, O
and O
15 O
mg O
/ O
kg O
) O
led O
to O
a O
sharp O
increase O
in O
systemic O
and O
cerebral O
exposure O
to O
5 B
- I
MeO I
- I
DMT I
( O
2 O
and O
10 O
mg O
/ O
kg O
) O
at O
all O
dose O
combinations O
. O

A O
more O
pronounced O
effect O
on O
5 B
- I
MeO I
- I
DMT I
PK O
was O
associated O
with O
greater O
exposure O
to O
harmaline B
in O
wild O
- O
type O
mice O
than O
CYP2D6 O
- O
humanized O
( O
Tg O
- O
CYP2D6 O
) O
mice O
. O

Harmaline B
( O
5 O
mg O
/ O
kg O
) O
also O
increased O
blood O
and O
brain O
bufotenine B
concentrations O
that O
were O
generally O
higher O
in O
Tg O
- O
CYP2D6 O
mice O
. O

Surprisingly O
, O
greater O
harmaline B
dose O
( O
15 O
mg O
/ O
kg O
) O
reduced O
bufotenine B
levels O
. O

The O
in O
vivo O
inhibitory O
effect O
of O
harmaline B
on O
CYP2D6 O
- O
catalyzed O
bufotenine B
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O

Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO O
- O
A O
- O
and O
CYP2D6 O
- O
catalyzed O
5 B
- I
MeO I
- I
DMT I
metabolism O
by O
harmaline B
was O
developed O
to O
describe O
blood O
harmaline B
, O
5 B
- I
MeO I
- I
DMT I
, O
and O
bufotenine B
PK O
profiles O
in O
both O
wild O
- O
type O
and O
Tg O
- O
CYP2D6 O
mouse O
models O
. O

This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline B
and O
5 B
- I
MeO I
- I
DMT I
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 O
status O
, O
and O
drive O
harmaline B
- O
5 B
- I
MeO I
- I
DMT I
pharmacodynamics O
. O

Hyperbranched O
polyesters B
( O
HPE O
) O
have O
a O
high O
efficiency O
to O
encapsulate O
bioactive O
agents O
, O
including O
drugs O
, O
genes O
, O
and O
proteins O
, O
due O
to O
their O
globe O
- O
like O
nanostructure O
. O

One O
- O
pot O
, O
exchange O
- O
free O
, O
room O
- O
temperature O
synthesis O
of O
sub O
- O
10 O
nm O
aqueous O
, O
noninteracting O
, O
and O
stable O
zwitterated B
iron I
oxide I
nanoparticles O
. O

Stable O
aqueous O
dispersions O
of O
superparamagnetic O
iron O
oxide O
nanoparticles O
were O
synthesized O
in O
one O
step O
in O
the O
presence O
of O
a O
zwitterionic B
siloxane I
as O
the O
stabilizing O
/ O
capping O
/ O
solubilizing O
ligand O
. O

The O
hydrodynamic O
diameter O
of O
the O
particles O
was O
tuned O
by O
controlling O
the O
concentration O
of O
zwitterion B
siloxane I
, O
which O
ultimately O
yielded O
monodisperse O
nanoparticles O
small O
enough O
for O
renal O
filtration O
( O
< O
6 O
nm O
diameter O
) O
. O

Tetracyclic B
diterpenoids I
with O
isomerized O
isospongian B
skeleton O
and O
labdane B
diterpenoids I
from O
the O
fruits O
of O
Amomum O
kravanh O
. O

Four O
novel O
diterpenoids O
, O
including O
three O
tetracyclic B
diterpenes I
with O
isomerized O
isospongian B
skeletons O
, O
kravanhins B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
and O
kravanhin B
D I
( O
4 O
) O
, O
and O
three O
new O
labdane B
diterpenes I
( O
5 O
- O
7 O
) O
were O
isolated O
from O
the O
fruits O
of O
Amomum O
kravanh O
. O

Compounds O
1 O
- O
4 O
had O
unprecedented O
isospongian B
diterpene I
skeletons O
with O
a O
trans O
- O
anti O
- O
cis O
fused O
tricyclic O
ring O
system O
. O

Thymidylate B
kinase O
: O
an O
old O
topic O
brings O
new O
perspectives O
. O

Thymidylate B
kinase O
( O
TMPK O
) O
is O
a O
key O
enzyme O
for O
pyrimidine O
synthesis O
that O
catalyzes O
the O
phosphorylation O
of O
thymidine O
5 O
' O
- O
monophosphate O
( O
dTMP B
) O
in O
the O
presence O
of O
ATP O
and O
Mg O
( O
2 O
+ O
) O
to O
form O
thymidine B
5 I
' I
- I
diphosphate I
( O
dTDP B
) O
, O
which O
is O
then O
converted O
to O
thymidine B
5 I
' I
- I
triphosphate I
( O
dTTP B
) O
by O
nucleoside O
- O
diphosphate O
kinase O
( O
NDK O
) O
. O

The O
growth O
strategy O
further O
permitted O
the O
controlled O
, O
in O
situ O
functionalization O
of O
the O
NCs O
with O
reactive O
groups O
( O
e O
. O
g O
. O
, O
carboxylic O
acid O
or O
amine O
) O
, O
making O
these O
nanoclusters O
compatible O
with O
common O
and O
simple O
- O
to O
- O
implement O
coupling O
strategies O
, O
such O
as O
carbodiimide B
chemistry O
. O

Gut O
microbiota O
regulates O
bile O
acid O
metabolism O
by O
reducing O
the O
levels O
of O
tauro B
- I
beta I
- I
muricholic I
acid I
, O
a O
naturally O
occurring O
FXR O
antagonist O
. O

We O
confirmed O
a O
dramatic O
reduction O
in O
muricholic B
acid I
, O
but O
not O
cholic O
acid O
, O
levels O
in O
CONV O
- O
R O
mice O
. O

Importantly O
, O
we O
identified O
tauro B
- I
conjugated I
beta I
- I
and I
alpha I
- I
muricholic I
acids I
as O
FXR O
antagonists O
. O

Among O
all O
the O
aroma O
compounds O
, O
9 O
key O
ones O
were O
identified O
in O
all O
samples O
, O
including O
ethyl B
2 I
- I
methylbutanoate I
, O
butyl B
acetate I
, O
1 O
- O
butanol O
, O
ethyl B
hexanoate I
, O
1 B
- I
hexanol I
, O
butanoic B
acid I
, O
beta B
- I
damascenone I
, O
hexanoic B
acid I
, O
and O
octanoic O
acid O
. O

Sophocarpine B
alleviates O
hepatocyte O
steatosis O
through O
activating O
AMPK O
signaling O
pathway O
. O

Sophocarpine B
, O
an O
effective O
compound O
derived O
from O
foxtail O
- O
like O
sophora O
herb O
and O
seed O
, O
has O
been O
reported O
that O
it O
can O
alleviate O
non O
- O
alcoholic O
steatohepatitis O
( O
NASH O
) O
in O
rats O
and O
affect O
adipocytokine O
synthesis O
. O

In O
the O
work O
presented O
here O
, O
primary O
hepatocytes O
were O
isolated O
from O
specific O
pathogen O
- O
free O
male O
SD O
rats O
and O
incubated O
with O
200 O
mu O
mol O
/ O
L O
oleic O
acid O
for O
24h O
to O
induce O
steatotic O
model O
, O
then O
treated O
with O
sophocarpine B
for O
72 O
h O
. O

While O
sophocarpine B
treatment O
resulted O
in O
: O
significant O
improvement O
of O
steatosis O
( O
> O
50 O
% O
decrease O
) O
, O
decrease O
of O
leptin O
expression O
( O
< O
0 O
. O
57 O
- O
fold O
) O
and O
increase O
of O
adiponectin O
expression O
( O
> O
1 O
. O
48 O
- O
fold O
) O
. O

Moreover O
, O
compared O
with O
the O
model O
group O
, O
sophocarpine B
could O
significantly O
increase O
P O
- O
AMPK O
alpha O
( O
> O
5 O
. O
82 O
- O
fold O
) O
, O
AMPK O
alpha O
( O
> O
1 O
. O
29 O
- O
fold O
) O
and O
ACC O
( O
> O
3 O
. O
27 O
- O
fold O
) O
protein O
expressions O
, O
and O
reduce O
P O
- O
ACC O
( O
< O
0 O
. O
30 O
- O
fold O
) O
and O
HNF O
- O
4 O
alpha O
( O
< O
0 O
. O
20 O
- O
fold O
) O
protein O
expression O
. O

We O
concluded O
that O
sophocarpine B
could O
alleviate O
hepatocyte O
steatosis O
and O
the O
potential O
mechanism O
might O
be O
the O
activated O
signaling O
pathway O
of O
AMPK O
. O

To O
identify O
the O
molecular O
mechanisms O
underlying O
this O
effect O
, O
we O
used O
an O
adoptive O
transfer O
approach O
in O
which O
dendritic O
cells O
( O
DCs O
) O
from O
the O
draining O
lymph O
nodes O
of O
donor O
mice O
that O
had O
been O
UVB O
- O
exposed O
and O
sensitized O
to O
2 B
, I
4 I
, I
- I
dinitrofluorobenzene I
( O
DNFB B
) O
were O
transferred O
into O
na O
i O
ve O
recipient O
mice O
. O

The O
contact O
hypersensitivity O
( O
CHS O
) O
response O
of O
the O
recipient O
mice O
to O
DNFB B
was O
then O
measured O
. O

Silymarin O
treatment O
was O
associated O
with O
rapid O
repair O
of O
UVB O
- O
induced O
cyclobutane B
pyrimidine I
dimers I
( O
CPDs B
) O
in O
DCs O
and O
silymarin O
treatment O
did O
not O
prevent O
UV O
- O
induced O
immunosuppression O
in O
XPA O
- O
deficient O
mice O
which O
are O
unable O
to O
repair O
UV O
- O
induced O
DNA O
damage O
. O

Compared O
with O
the O
decapeptide B
APP O
- O
IP O
( O
t O
& O
frac12 O
; O
= O
30 O
min O
) O
, O
APP O
- O
IP O
- O
TIMP O
- O
2 O
( O
t O
& O
frac12 O
; O
> O
> O
96 O
h O
) O
showed O
a O
much O
longer O
half O
- O
life O
in O
cultured O
tumor O
cells O
. O

All O
the O
compounds O
are O
more O
active O
and O
less O
toxic O
than O
meglumine B
antimoniate I
( O
Glucantime B
) O
. O

On O
the O
other O
hand O
, O
studies O
on O
the O
inhibitory O
effect O
of O
these O
compounds O
on O
SOD O
enzymes O
showed O
that O
while O
the O
inhibition O
of O
the O
Fe O
- O
SOD O
enzyme O
of O
the O
promastigote O
forms O
of O
the O
parasites O
is O
remarkable O
, O
the O
inhibition O
of O
human O
CuZn B
- O
SOD O
and O
Mn O
- O
SOD O
from O
Escherichia O
coli O
is O
negligible O
. O

Alcohol O
modulates O
expression O
of O
DNA O
methyltranferases O
and O
methyl B
CpG I
- O
/ O
CpG O
domain O
- O
binding O
proteins O
in O
murine O
embryonic O
fibroblasts O
. O

The O
present O
study O
was O
designed O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
( O
DNMTs O
) O
and O
various O
methyl B
CpG I
- O
binding O
proteins O
. O

In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O
( O
DNMT O
- O
1 O
, O
DNMT O
- O
3a O
, O
and O
DNMT O
- O
3b O
) O
, O
as O
well O
as O
the O
methyl B
CpG I
- O
binding O
proteins O
( O
MeCP O
- O
2 O
, O
MBD O
- O
2 O
and O
MBD O
- O
3 O
) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O

AhR O
- O
and O
NF O
- O
kappa O
B O
- O
dependent O
induction O
of O
interleukin O
- O
6 O
by O
co O
- O
exposure O
to O
the O
environmental O
contaminant O
benzanthracene B
and O
the O
cytokine O
tumor O
necrosis O
factor O
- O
alpha O
in O
human O
mammary O
MCF O
- O
7 O
cells O
. O

Co O
- O
exposure O
to O
the O
prototypical O
PAH O
benzanthracene B
( O
BZA B
) O
and O
TNF O
- O
alpha O
was O
found O
to O
markedly O
induce O
mRNA O
expression O
and O
secretion O
of O
IL O
- O
6 O
in O
human O
breast O
cancer O
cells O
MCF O
- O
7 O
, O
whereas O
exposure O
to O
either O
BZA B
or O
TNF O
- O
alpha O
alone O
was O
without O
significant O
effect O
. O

Co O
- O
treatment O
by O
BZA B
and O
TNF O
- O
alpha O
- O
containing O
conditioned O
media O
from O
human O
inflammatory O
macrophages O
similarly O
up O
- O
regulated O
IL O
- O
6 O
expression O
in O
MCF O
- O
7 O
cells O
. O

BZA B
/ O
TNF O
- O
alpha O
- O
mediated O
IL O
- O
6 O
induction O
in O
MCF O
- O
7 O
cells O
was O
counteracted O
by O
silencing O
aryl O
hydrocarbon O
receptor O
( O
AhR O
) O
, O
known O
to O
mediates O
most O
of O
PAH O
effects O
. O

Taken O
together O
, O
these O
data O
indicate O
that O
co O
- O
exposure O
to O
BZA B
/ O
TNF O
- O
alpha O
induces O
IL O
- O
6 O
expression O
by O
AhR O
- O
and O
NF O
- O
kappa O
B O
- O
dependent O
pathways O
in O
MCF O
- O
7 O
cancer O
cells O
. O

Saturable O
active O
efflux O
by O
p O
- O
glycoprotein O
and O
breast O
cancer O
resistance O
protein O
at O
the O
blood O
- O
brain O
barrier O
leads O
to O
nonlinear O
distribution O
of O
elacridar B
to O
the O
central O
nervous O
system O
. O

The O
study O
objective O
was O
to O
investigate O
factors O
that O
affect O
the O
central O
nervous O
system O
( O
CNS O
) O
distribution O
of O
elacridar B
. O

Elacridar B
inhibits O
transport O
mediated O
by O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
and O
breast O
cancer O
resistance O
protein O
( O
Bcrp O
) O
and O
has O
been O
used O
to O
study O
the O
influence O
of O
transporters O
on O
brain O
distribution O
of O
chemotherapeutics O
. O

Adequate O
distribution O
of O
elacridar B
across O
the O
blood O
- O
brain O
barrier O
( O
BBB O
) O
and O
into O
the O
brain O
parenchyma O
is O
necessary O
to O
target O
tumor O
cells O
in O
the O
brain O
that O
overexpress O
transporters O
and O
reside O
behind O
an O
intact O
BBB O
. O

We O
examined O
the O
role O
of O
P O
- O
gp O
and O
Bcrp O
on O
brain O
penetration O
of O
elacridar B
using O
Friend O
leukemia O
virus O
strain O
B O
wild O
- O
type O
, O
Mdr1a O
/ O
b O
( O
- O
/ O
- O
) O
, O
Bcrp1 O
( O
- O
/ O
- O
) O
, O
and O
Mdr1a O
/ O
b O
( O
- O
/ O
- O
) O
Bcrp1 O
( O
- O
/ O
- O
) O
mice O
. O

Initially O
, O
the O
mice O
were O
administered O
2 O
. O
5 O
mg O
/ O
kg O
of O
elacridar B
intravenously O
, O
and O
the O
plasma O
and O
brain O
concentrations O
were O
determined O
. O

The O
brain O
- O
to O
- O
plasma O
partition O
coefficient O
of O
elacridar B
in O
the O
wild O
- O
type O
mice O
was O
0 O
. O
82 O
, O
as O
compared O
with O
3 O
. O
5 O
in O
Mdr1a O
/ O
b O
( O
- O
/ O
- O
) O
mice O
, O
6 O
. O
6 O
in O
Bcrp1 O
( O
- O
/ O
- O
) O
mice O
, O
and O
15 O
in O
Mdr1a O
/ O
b O
( O
- O
/ O
- O
) O
Bcrp1 O
( O
- O
/ O
- O
) O
mice O
, O
indicating O
that O
both O
P O
- O
gp O
and O
Bcrp O
limit O
the O
brain O
distribution O
of O
elacridar B
. O

The O
four O
genotypes O
were O
then O
administered O
increasing O
doses O
of O
elacridar B
, O
and O
the O
CNS O
distribution O
of O
elacridar B
was O
determined O
. O

Overall O
, O
this O
study O
provides O
useful O
concepts O
for O
future O
applications O
of O
elacridar B
as O
an O
adjuvant O
therapy O
to O
improve O
targeting O
of O
chemotherapeutic O
agents O
to O
tumor O
cells O
in O
the O
brain O
parenchyma O
. O

The O
optimal O
coating O
- O
1 O
ALD O
cycle O
, O
which O
amounts O
to O
< O
1 O
monolayer O
of O
Co B
( I
OH I
) I
2 I
/ O
Co3O4 O
- O
resulted O
in O
significantly O
enhanced O
photoelectrochemical O
water O
oxidation O
performance O
. O

Furthermore O
, O
the O
optical O
transparency O
of O
the O
ultrathin O
Co B
( I
OH I
) I
2 I
/ O
Co3O4 O
coating O
establishes O
it O
as O
a O
particularly O
advantageous O
treatment O
for O
nanostructured O
water O
oxidation O
photoanodes O
. O

A O
detailed O
look O
at O
the O
reaction O
mechanisms O
of O
substituted O
carbenes B
with O
water O
. O

Two O
competitive O
reaction O
mechanisms O
for O
the O
gas O
- O
phase O
chemical O
transformation O
of O
singlet O
chlorocarbene B
into O
chloromethanol B
in O
the O
presence O
of O
one O
and O
two O
water O
molecules O
are O
examined O
in O
detail O
. O

Further O
, O
the O
partitioning O
in O
lipid O
bilayer O
systems O
containing O
different O
hydrophobic O
tail O
groups O
( O
DOPC O
( O
1 O
, O
2 O
- O
dioleoyl O
- O
sn O
- O
glycero O
- O
3 O
- O
phosphocholine O
) O
, O
SOPC B
( O
stearoyl B
- I
oleoylphosphatidylch I
) O
, O
DMPC O
( O
1 B
, I
2 I
- I
dimyristoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
) O
, O
and O
POPC O
( O
1 O
- O
palmitoyl O
- O
2 O
- O
oleoyl O
- O
sn O
- O

To O
determine O
the O
influence O
of O
cholesterol B
as O
an O
important O
component O
of O
cellular O
membranes O
, O
free O
energy O
profiles O
in O
the O
presence O
of O
cholesterol O
were O
calculated O
and O
shown O
to O
be O
in O
good O
agreement O
with O
experimental O
data O
. O

Quartz O
crystal O
microbalance O
with O
dissipation O
( O
QCM O
- O
D O
) O
was O
applied O
to O
investigate O
the O
adsorption O
characteristics O
of O
polyacrylamide O
- O
based O
polymers O
( O
PAMs B
) O
on O
anisotropic O
basal O
planes O
of O
kaolinite O
. O

Adsorption O
of O
an O
in O
- O
house O
synthesized O
organic O
- O
inorganic O
Al B
( I
OH I
) I
3 I
- I
PAM I
( O
Al B
- I
PAM I
) O
as O
an O
example O
of O
cationic O
hybrid O
PAM B
and O
a O
commercially O
available O
partially O
hydrolyzed O
polyacrylamide O
( O
MF1011 B
) O
as O
an O
example O
of O
anionic B
PAM I
was O
studied O
. O

Cationic B
Al I
- I
PAM I
was O
found O
to O
adsorb O
irreversibly O
and O
preferentially O
on O
tetrahedral O
silica O
basal O
planes O
of O
kaolinite O
. O

In O
contrast O
, O
anionic B
MF1011 I
adsorbed O
strongly O
on O
aluminum B
- I
hydroxy I
basal O
planes O
, O
while O
its O
adsorption O
on O
tetrahedral O
silica O
basal O
planes O
was O
weak O
and O
reversible O
. O

Adsorption O
study O
revealed O
that O
both O
electrostatic O
attraction O
and O
hydrogen O
- O
bonding O
mechanisms O
contribute O
to O
adsorption O
of O
PAMs B
on O
kaolinite O
. O

The O
adsorbed O
Al B
- I
PAM I
layer O
was O
able O
to O
release O
trapped O
water O
overtime O
and O
became O
more O
compact O
, O
while O
MF1011 B
film O
became O
more O
dissipative O
as O
backbones O
stretched O
out O
from O
kaolinite O
surface O
with O
minimal O
overlapping O
. O

Strong O
effects O
of O
cluster O
size O
and O
air O
exposure O
on O
oxygen O
reduction O
and O
carbon O
oxidation O
electrocatalysis O
by O
size O
- O
selected O
Pt B
( I
n I
) I
( O
n O
< O
= O
11 O
) O
on O
glassy O
carbon O
electrodes O
. O

Model O
Pt B
( I
n I
) I
/ O
glassy O
carbon O
electrodes O
( O
Pt B
( I
n I
) I
/ O
GCE O
) O
were O
prepared O
by O
deposition O
of O
mass O
- O
selected O
Pt B
( I
n I
) I
( I
+ I
) I
( O
n O
< O
= O
11 O
) O
on O
GCE O
substrates O
in O
ultrahigh O
vacuum O
. O

For O
other O
small O
Pt B
( I
n I
) I
on O
GCE O
, O
any O
ORR O
signal O
is O
overwhelmed O
by O
large O
oxidative O
currents O
attributed O
to O
catalysis O
of O
carbon O
oxidation O
by O
water O
. O

Exposure O
to O
SeMet O
significantly O
down O
- O
regulated O
mRNA O
abundance O
of O
protein O
tyrosine O
phosphatase O
1B O
( O
PTP O
1B O
) O
in O
muscle O
, O
and O
beta B
- I
hydroxyacyl I
coenzyme I
A I
dehydrogenase O
( O
HOAD O
) O
, O
sterol O
regulatory O
element O
binding O
protein O
1 O
( O
SREBP O
1 O
) O
and O
methionine O
adenosyltransferase O
1 O
alpha O
( O
MAT O
1A O
) O
in O
liver O
of O
adult O
zebrafish O
. O

Electron O
attachment O
to O
the O
dipeptide O
dialanine B
: O
influence O
of O
methylation O
on O
site O
selective O
dissociation O
reactions O
. O

Gas O
phase O
dissociative O
electron O
attachment O
( O
DEA O
) O
measurements O
with O
methyl B
- I
dialanine I
, O
C B
( I
7 I
) I
H I
( I
14 I
) I
N I
( I
2 I
) I
O I
( I
3 I
) I
, O
are O
performed O
in O
a O
crossed O
electron O
- O
molecular O
beam O
experiment O
at O
high O
energy O
resolution O
( O
~ O
120 O
meV O
) O
. O

Previous O
DEA O
studies O
on O
dialanine B
have O
shown O
that O
( O
M O
- O
H O
) O
( O
- O
) O
formation O
proceeds O
through O
abstraction O
of O
a O
hydrogen O
atom O
from O
the O
carboxyl O
and O
amide O
groups O
, O
contributing O
to O
two O
distinct O
resonances O
at O
0 O
. O
81 O
and O
1 O
. O
17 O
eV O
, O
respectively O
[ O
D O
. O
Gschliesser O
, O
V O
. O
Vizcaino O
, O
M O
. O
Probst O
, O
P O
. O
Scheier O
and O
S O
. O
Denifl O
, O
Chem O
. O
- O
Eur O
. O
J O
. O
, O
2012 O
, O
18 O
, O
4613 O
- O
4619 O
] O
. O

Here O
we O
show O
that O
by O
methylation O
of O
the O
carboxyl O
group O
, O
all O
( O
calculated O
) O
thresholds O
for O
H O
- O
loss O
from O
the O
different O
sites O
in O
the O
dialanine B
molecule O
are O
shifted O
up O
to O
a O
maximum O
of O
1 O
. O
4 O
eV O
. O

On O
8 O
visits O
, O
healthy O
women O
( O
n O
= O
8 O
) O
received O
intravaginal O
taggant O
( O
2 B
- I
butyl I
acetate I
, O
2 B
- I
pentyl I
acetate I
, O
isopropyl B
butyrate I
, O
or O
2 B
- I
pentyl I
butyrate I
; O
30 O
mg O
) O
formulated O
in O
hydroxyethylcellulos O
or O
tenofovir O
placebo O
gel O
. O

After O
vaginal O
administration O
, O
2 B
- I
butyl I
acetate I
, O
2 B
- I
pentyl I
acetate I
, O
and O
metabolites O
were O
observed O
in O
breath O
, O
whereas O
isopropyl B
butyrate I
, O
2 B
- I
pentyl I
butyrate I
, O
and O
metabolites O
were O
not O
. O

Pharmacokinetics O
of O
intravenous O
voriconazole B
in O
obese O
patients O
: O
implications O
of O
CYP2C19 O
homozygous O
poor O
metabolizer O
genotype O
. O

There O
is O
a O
paucity O
of O
pharmacokinetic O
studies O
describing O
weight O
- O
based O
dosing O
of O
intravenous O
voriconazole B
in O
obese O
patients O
. O

In O
this O
case O
report O
, O
we O
describe O
the O
pharmacokinetics O
of O
intravenous O
voriconazole B
in O
an O
obese O
CYP2C19 O
homozygous O
poor O
metabolizer O
and O
review O
previously O
reported O
data O
regarding O
the O
use O
of O
intravenous O
voriconazole B
in O
obese O
patients O
. O

A O
17 O
- O
year O
- O
old O
obese O
Hispanic O
male O
patient O
( O
body O
mass O
index O
35 O
kg O
/ O
m O
( O
2 O
) O
) O
received O
intravenous O
voriconazole B
for O
the O
treatment O
of O
suspected O
aspergillosis O
. O

After O
2 O
. O
5 O
days O
of O
voriconazole B
4 O
mg O
/ O
kg O
intravenously O
every O
12 O
hours O
based O
on O
adjusted O
body O
weight O
, O
the O
voriconazole B
area O
under O
the O
serum O
concentration O
- O
time O
curve O
over O
the O
course O
of O
a O
single O
( O
12 O
- O
hr O
) O
dosing O
interval O
and O
trough O
concentration O
were O
86 O
, O
100 O
ng O
. O
hr O
/ O
ml O
and O
6 O
. O
2 O
micro O
g O
/ O
ml O
, O
respectively O
. O

Six O
days O
later O
, O
the O
voriconazole B
dosage O
was O
decreased O
. O

A O
trough O
concentration O
measured O
just O
before O
the O
dosage O
reduction O
( O
after O
8 O
. O
5 O
days O
of O
voriconazole B
4 O
mg O
/ O
kg O
intravenously O
every O
12 O
hours O
based O
on O
adjusted O
body O
weight O
) O
remained O
elevated O
at O
5 O
. O
8 O
micro O
g O
/ O
ml O
. O

Voriconazole B
was O
subsequently O
discontinued O
due O
to O
QTc O
prolongation O
. O

These O
data O
and O
those O
from O
two O
recent O
publications O
suggest O
that O
voriconazole B
does O
not O
distribute O
extensively O
into O
human O
adipose O
tissue O
and O
that O
obese O
patients O
should O
be O
dosed O
on O
an O
adjusted O
body O
weight O
basis O
. O

If O
an O
obese O
patient O
dosed O
on O
total O
body O
weight O
is O
also O
a O
CYP2C19 O
poor O
metabolizer O
, O
serum O
voriconazole B
concentrations O
will O
be O
further O
elevated O
, O
potentially O
leading O
to O
drug O
- O
induced O
toxicity O
. O

Stimulating O
microbial O
growth O
through O
the O
use O
of O
acetate O
injection O
wells O
at O
the O
former O
uranium O
mill O
site O
in O
Rifle O
, O
Colorado O
, O
USA O
, O
has O
been O
shown O
to O
decrease O
dissolved O
uranium B
( I
VI I
) I
concentrations O
through O
bacterial O
reduction O
to O
immobile O
uranium B
( I
IV I
) I
. O

Downgradient O
acetate O
- O
stimulated O
water O
samples O
had O
much O
higher O
levels O
of O
arsenic O
( O
up O
to O
8 O
mu O
M O
) O
, O
and O
4 O
additional O
thioarsenic B
species O
were O
present O
under O
sulfate O
- O
reducing O
conditions O
. O

These O
thioarsenic B
species O
demonstrate O
a O
strong O
correlation O
between O
arsenic O
release O
and O
sulfide O
concentrations O
in O
groundwater O
, O
and O
their O
formation O
may O
explain O
the O
elevated O
total O
arsenic O
concentrations O
. O

Dose O
- O
response O
curves O
were O
also O
constructed O
for O
pre O
- O
incubation O
of O
vascular O
rings O
with O
N B
omega I
- I
nitro I
- I
L I
- I
arginine I
methyl I
ester I
( O
L O
- O
NAME O
) O
( O
a O
non O
- O
specific O
nitric O
oxide O
synthase O
inhibitor O
) O
, O
indomethacin O
( O
an O
unspecific O
cyclooxygenase O
inhibitor O
) O
, O
and O
1H B
- I
[ I
1 I
, I
2 I
, I
4 I
] I
oxadiazolo I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalin I
- I
1 I
- I
one I
( O
ODQ O
) O
( O
a O
guanylyl O
cyclase O

In O
vivo O
Antimalarial O
Activity O
of O
a O
Labdane B
Diterpenoid I
from O
the O
Leaves O
of O
Otostegia O
integrifolia O
Benth O
. O

Activity O
- O
guided O
fractionation O
of O
this O
extract O
which O
showed O
potent O
antiplasmodial O
activity O
resulted O
in O
the O
isolation O
of O
a O
labdane B
diterpenoid I
identified O
as O
otostegindiol B
. O

Otostegindiol B
displayed O
a O
significant O
( O
P O
< O
0 O
. O
001 O
) O
antimalarial O
activity O
at O
doses O
of O
25 O
, O
50 O
and O
100 O
mg O
/ O
kg O
with O
chemosuppression O
values O
of O
50 O
. O
13 O
, O
65 O
. O
58 O
and O
73 O
. O
16 O
% O
, O
respectively O
. O

The O
results O
of O
the O
present O
study O
indicate O
that O
otostegindiol B
is O
among O
the O
antimalarial O
principles O
in O
this O
medicinal O
plant O
, O
and O
further O
support O
claims O
for O
the O
traditional O
medicinal O
use O
of O
the O
plant O
for O
the O
treatment O
of O
malaria O
. O

Exploring O
the O
Interplay O
Between O
Ligand O
Derivatisation O
and O
Cation O
Type O
in O
the O
Assembly O
of O
Hybrid O
Polyoxometalate B
Mn O
- O
Andersons O
. O

Herein O
a O
library O
of O
hybrid O
Mn O
- O
Anderson O
polyoxometalates O
anions O
are O
presented O
: O
1 O
, O
[ B
( I
MnMo I
( I
6 I
) I
O I
( I
18 I
) I
) I
( I
( I
OCH I
( I
2 I
) I
) I
( I
3 I
) I
- I
C I
- I
( I
CH I
( I
2 I
) I
) I
( I
7 I
) I
CHCH I
( I
2 I
) I
) I
( I
2 I
) I
] I
( I
3 I
- I
) I
; O
compound O
2 O
, O
[ O
( O
MnMo O
( O
6 O
) O
O O
( O
18 O
) O
) O
( O
( O
OCH O
( O
2 O
) O
) O
( O
3 O
) O
C O
- O
NHCH O
( O
2 O
) O
C O
( O
16 O
) O
H O
( O
9 O
) O
) O
( O
2 O
) O
] O
( O
3 O
- O

) O
; O
compound O
3 O
, O
[ B
( I
MnMo I
( I
6 I
) I
O I
( I
18 I
) I
) I
( I
( I
OCH I
( I
2 I
) I
) I
( I
3 I
) I
C I
- I
( I
CH I
( I
2 I
) I
) I
( I
7 I
) I
CHCH I
( I
2 I
) I
) I
( I
1 I
) I
( I
( I
OCH I
( I
2 I
) I
) I
( I
3 I
) I
C I
- I
NHCH I
( I
2 I
) I
C I
( I
16 I
) I
H I
( I
9 I
) I
) I
( I
1 I
) I
] I
( I
3 I
- I
) I
; O
compound O
4 O
, O
[ O
( O
MnMo O
( O
6 O
) O
O O
( O
18 O
) O
) O
( O
( O
OCH O
( O
2 O
) O
) O
( O
3 O
) O
C O
- O
NHC O
( O
O O
) O
CH O
( O
2 O
) O

CHCH O
( O
2 O
) O
) O
( O
2 O
) O
] O
( O
3 O
- O
) O
and O
compounds O
5 O
- O
9 O
, O
[ B
( I
MnMo I
( I
6 I
) I
O I
( I
18 I
) I
) I
( I
( I
OCH I
( I
2 I
) I
) I
( I
3 I
) I
C I
- I
NHC I
( I
O I
) I
( I
CH I
( I
2 I
) I
) I
( I
x I
) I
CH I
( I
3 I
) I
) I
( I
2 I
) I
] I
) I
, O
where O
x O
= O
4 O
, O
10 O
, O
12 O
, O
14 O
, O
and O
18 O
respectively O
. O

The O
compounds O
resulting O
from O
the O
cation O
exchange O
of O
the O
anions O
1 O
- O
9 O
to O
give O
TBA B
( O
a O
) O
and O
DMDOA B
( O
b O
) O
salts O
, O
and O
additionally O
for O
compounds O
1 O
, O
2 O
and O
3 O
, O
tetraphenylphosphoni B
( O
PPh B
( I
4 I
) I
) O
( O
c O
) O
salts O
, O
are O
explored O
at O
the O
air O
/ O
water O
interface O
using O
scanning O
force O
microscopy O
, O
showing O
a O
range O
of O
architectures O
including O
hexagonal O
structures O
, O
nanofibers O
and O
other O
supramolecular O
forms O
. O

Additionally O
, O
on O
day O
11 O
of O
both O
study O
periods O
, O
150 O
mg O
caffeine O
( O
CYP1A2 O
) O
, O
125 O
mg O
tolbutamide O
( O
CYP2C9 O
) O
, O
20 O
mg O
omeprazole O
( O
CYP2C19 O
) O
, O
30 O
mg O
dextromethorphan B
- I
HBr I
( O
CYP2D6 O
) O
, O
and O
2 O
mg O
midazolam O
( O
CYP3A4 O
) O
were O
administered O
orally O
. O

The O
90 O
% O
CI O
for O
the O
AUC0 O
- O
t O
ratio O
of O
omeprazole O
but O
not O
for O
omeprazole O
/ O
5 B
- I
OH I
- I
omeprazole I
plasma O
ratio O
3 O
hours O
post O
- O
dose O
or O
omeprazole O
/ O
5 B
- I
OH I
- I
omeprazole I
AUC0 O
- O
t O
ratio O
( O
secondary O
CYP2C19 O
metrics O
) O
was O
above O
the O
predefined O
threshold O
of O
1 O
. O
43 O
, O
probably O
caused O
by O
the O
inherent O
high O
variability O
of O
omeprazole O
pharmacokinetics O
. O

Tacticity O
- O
induced O
changes O
in O
the O
micellization O
and O
degradation O
properties O
of O
poly B
( I
lactic I
acid I
) I
- I
block I
- I
poly I
( I
ethylene I
glycol I
) I
copolymers O
. O

Poly B
( I
lactic I
acid I
) I
- I
block I
- I
poly I
( I
ethylene I
glycol I
) I
copolymers O
( O
PLA B
- I
b I
- I
PEG I
) O
featuring O
varying O
tacticities O
( O
atactic O
, O
heterotactic O
, O
isotactic O
) O
in O
the O
PLA O
block O
were O
synthesized O
and O
investigated O
for O
their O
micellar O
stability O
, O
degradation O
, O
and O
thermal O
properties O
. O

Utilizing O
tin B
( I
II I
) I
bis I
( I
2 I
- I
ethylhexanoate I
) I
, O
aluminum B
salan I
, O
and O
aluminum B
salen I
catalysts O
, O
the O
copolymers O
were O
synthesized O
through O
the O
ring O
- O
opening O
polymerization O
of O
d O
- O
, O
l O
- O
, O
rac O
- O
, O
or O
a O
blend O
of O
l B
- I
and I
rac I
- I
lactide I
using O
monomethoxy B
- I
poly I
( I
ethylene I
glycol I
) I
as O
a O
macroinitiator O
. O

The O
copolymers O
were O
degraded O
in O
a O
methanolic O
solution O
of O
1 B
, I
5 I
, I
7 I
- I
triaza I
- I
bicyclo I
[ I
4 I
. I
4 I
. I
0 I
] I
dec I
- I
5 I
- I
ene I
and O
the O
degradation O
was O
measured O
by O
( O
1 O
) O
H O
NMR O
spectroscopic O
and O
gel O
permeation O
chromatographic O
analyses O
. O

Interestingly O
, O
while O
tin B
( I
II I
) I
bis I
( I
2 I
- I
ethylhexanoate I
) I
and O
aluminum B
salan I
- O
catalyzed O
PLA B
- I
b I
- I
PEG I
copolymers O
exhibited O
similar O
micellization O
behavior O
, O
the O
aluminum B
salen I
- O
catalyzed O
PLA B
- I
b I
- I
PEG I
exhibited O
unique O
behavior O
at O
high O
micelle O
concentration O
in O
the O
presence O
of O
the O
pyrene O
probe O
. O

AIM O
: O
The O
aim O
of O
the O
study O
is O
to O
compare O
the O
effects O
of O
metformin O
and O
insulin O
treatment O
for O
gestational O
diabetes O
mellitus O
( O
GDM O
) O
on O
vitamin O
B12 O
and O
homocysteine O
( O
Hcy B
) O
status O
. O

Fasting O
serum O
total O
vitamin O
B12 O
( O
TB12 O
) O
, O
holotranscobalamin O
( O
HoloTC O
) O
, O
a O
marker O
of O
functional O
B12 O
status O
and O
plasma O
Hcy B
concentrations O
were O
measured O
at O
20 O
- O
34 O
weeks O
( O
at O
randomization O
) O
and O
36 O
weeks O
gestation O
, O
then O
at O
6 O
- O
8 O
weeks O
postpartum O
. O

RESULTS O
: O
Circulating O
TB12 O
, O
HoloTC O
and O
Hcy B
were O
similar O
in O
both O
treatment O
groups O
at O
each O
time O
point O
. O

New O
insight O
into O
artifactual O
phenomena O
during O
in O
vitro O
toxicity O
assessment O
of O
engineered O
nanoparticles O
: O
study O
of O
TNF O
- O
alpha O
adsorption O
on O
alumina B
oxide I
nanoparticle O
. O

We O
studied O
well O
- O
characterized O
boehmite B
engineered O
NP O
[ O
aluminum B
oxide I
hydroxide I
, O
AlO O
( O
OH O
) O
] O
. O

The O
rate O
of O
TNF O
- O
alpha O
degradation O
and O
its O
adsorption O
( O
on O
boehmite B
and O
on O
the O
walls O
of O
wells O
) O
were O
determined O
in O
cell O
- O
free O
conditions O
by O
adding O
a O
known O
TNF O
- O
alpha O
concentration O
( O
1500 O
pg O
/ O
ml O
) O
under O
various O
experimental O
conditions O
. O

After O
a O
24 O
- O
h O
incubation O
, O
we O
quantified O
that O
7 O
wt O
. O
% O
of O
the O
initial O
TNF O
- O
alpha O
was O
degraded O
over O
time O
, O
6 O
wt O
. O
% O
adsorbed O
on O
the O
walls O
of O
96 O
- O
well O
plates O
, O
and O
13 O
wt O
. O
% O
adsorbed O
on O
the O
boehmite B
surface O
. O

Finally O
, O
boehmite B
NP O
were O
incubated O
with O
murine O
macrophages O
( O
RAW O
264 O
. O
7 O
cell O
line O
) O
. O

The O
release O
of O
TNF O
- O
alpha O
was O
assessed O
for O
boehmite B
NP O
and O
the O
experimental O
data O
were O
corrected O
considering O
the O
artifactual O
phenomena O
, O
which O
accounted O
for O
about O
20 O
- O
30 O
% O
of O
the O
total O
. O

H2O2 O
inhibits O
the O
[ B
( I
3 I
) I
H I
] I
carnitine I
/ O
carnitine O
antiport O
catalysed O
by O
the O
mitochondrial O
carnitine O
/ O
acylcarnitine O
transporter O
reconstituted O
in O
proteoliposomes O
. O

The O
inhibition O
was O
reversed O
by O
dithioerythritol B
, O
N O
- O
acetylcysteine O
and O
l B
- I
cysteine I
. O

DTE B
reversed O
the O
inhibition O
of O
the O
H2O2 O
sensitive O
proteins O
except O
that O
in O
the O
case O
of O
the O
mutants O
containing O
only O
C136 O
or O
C155 O
after O
long O
time O
of O
incubation O
with O
H2O2 O
. O

Carnitine O
and O
acetylcarnitine B
protected O
the O
protein O
from O
the O
inhibition O
by O
H2O2 O
. O

The O
bioaccumulation O
of O
saxitoxins B
( O
STX B
) O
in O
the O
trophic O
chain O
, O
mainly O
in O
freshwater O
, O
are O
not O
completely O
known O
. O

This O
work O
aimed O
to O
elucidate O
the O
effects O
of O
STX B
on O
Hoplias O
malabaricus O
through O
trophic O
bioassay O
. O

The O
fish O
were O
fed O
once O
every O
five O
days O
with O
Astyanax O
sp O
. O
before O
being O
subjected O
to O
an O
intraperitoneal O
inoculation O
with O
the O
lysate O
of O
Cylindrospermopsis O
raciborskii O
culture O
containing O
97 O
% O
STX B
and O
3 O
% O
by O
neosaxitoxin B
and O
gonyautoxin B
during O
20 O
days O
. O

The O
values O
of O
mean O
corpuscular O
hemoglobin O
concentration O
and O
mean O
corpuscular O
hemoglobin O
increased O
in O
the O
STX B
group O
. O

Although O
the O
STX B
effects O
are O
known O
as O
neurotoxic O
, O
this O
cyanotoxin O
caused O
liver O
biochemical O
alterations O
that O
can O
be O
considered O
ecologically O
relevant O
. O

Nitric O
acid O
data O
obtained O
in O
the O
present O
study O
were O
not O
statistically O
different O
from O
published O
data O
, O
with O
the O
exception O
of O
Mo O
, O
Sn O
, O
Sb B
, O
Tl O
and O
Th B
. O

Much O
lower O
bioavailability O
was O
observed O
for O
Al O
, O
Ba B
and O
Pb O
. O

Pyrogallol B
- O
related O
chemicals O
and O
tannins O
are O
present O
in O
dietary O
sources O
and O
individually O
produced O
strong O
activity O
: O
pyrogallol B
( O
30 O
x O
) O
, O
3 B
- I
methoxycatechol I
( O
25 O
x O
) O
, O
gallic O
acid O
( O
21 O
x O
) O
, O
and O
1 B
, I
2 I
, I
4 I
- I
benzenetriol I
( O
21 O
x O
) O
. O

Various O
substituted O
indazole O
and O
benzoxazolone B
amino O
acids O
were O
investigated O
as O
d B
- I
tyrosine I
surrogates O
in O
highly O
potent O
CGRP O
receptor O
antagonists O
. O

Compound O
3 O
, O
derived O
from O
the O
7 B
- I
methylindazole I
core O
, O
afforded O
a O
30 O
- O
fold O
increase O
in O
CGRP O
binding O
potency O
compared O
with O
its O
unsubstituted O
indazole O
analog O
1 O
. O

Formulations O
contained O
either O
microcrystalline O
cellulose O
( O
MCC O
) O
or O
dicalcium B
phosphate I
( O
DCP B
) O
as O
diluent O
, O
hydroxypropyl O
methylcellulose O
( O
HPMC O
) O
, O
lactose O
, O
and O
water O
. O

Extrudates O
were O
characterized O
for O
their O
tensile O
strength O
, O
Young O
' O
s O
modulus O
of O
elasticity O
, O
water O
absorption O
, O
gel O
forming O
capacity O
, O
and O
release O
of O
two O
model O
drugs O
, O
coumarin O
( O
COU B
) O
and O
propranolol B
hydrochloride I
( O
PRO O
) O
. O

Cohesive O
extrudates O
could O
be O
produced O
with O
both O
filling O
materials O
( O
MCC O
and O
DCP B
) O
when O
HPMC O
was O
included O
as O
a O
binder O
at O
low O
amounts O
( O
3 O
. O
3 O
- O
4 O
. O
5 O
% O
w O
/ O
w O
dry O
weight O
) O
. O

For O
DCP B
extrudates O
, O
the O
maximally O
effective O
HPMC O
amount O
was O
30 O
% O
( O
w O
/ O
w O
dry O
weight O
) O
with O
influence O
on O
both O
the O
mechanical O
properties O
and O
drug O
release O
. O

In O
this O
study O
, O
the O
stabilization O
effects O
of O
three O
polymers O
on O
four O
model O
drugs O
( O
felodipine B
, O
fenofibrate O
, O
carbamazepine O
, O
and O
celecoxib O
) O
under O
saturated O
humidity O
were O
investigated O
. O

Amongst O
the O
polymers O
tested O
in O
this O
study O
, O
EUDRAGIT B
E I
PO I
was O
found O
to O
have O
the O
greatest O
inhibitory O
effect O
on O
crystallization O
, O
whilst O
PVP O
K30 O
was O
found O
to O
have O
the O
least O
protective O
effect O
; O
presumably O
because O
of O
its O
hygroscopic O
nature O
. O

Triethylenetetramine B
prevents O
insulin O
aggregation O
and O
fragmentation O
during O
copper O
catalyzed O
oxidation O
. O

In O
this O
study O
, O
using O
recombinant O
human O
insulin O
( O
insulin O
) O
as O
a O
model O
, O
we O
investigated O
the O
ability O
of O
several O
excipients O
, O
in O
particular O
triethylenetetramine B
( O
TETA B
) O
, O
reduced O
glutathione O
( O
GSH O
) O
and O
ethylenediamine B
tetraacetic I
acid I
( O
EDTA O
) O
, O
for O
their O
ability O
to O
prevent O
protein O
oxidation O
, O
aggregation O
, O
and O
fragmentation O
. O

Among O
the O
excipients O
studied O
, O
1mM O
of O
TETA B
, O
EDTA O
, O
or O
GSH O
prevented O
insulin O
aggregation O
upon O
metal O
catalyzed O
oxidation O
( O
MCO O
) O
for O
3h O
at O
room O
temperature O
, O
based O
on O
size O
exclusion O
chromatography O
( O
SEC O
) O
. O

At O
lower O
concentration O
( O
100 O
mu O
M O
) O
, O
for O
72h O
at O
+ O
4 O
degrees O
C O
, O
TETA B
was O
the O
only O
one O
to O
inhibit O
almost O
completely O
oxidation O
- O
induced O
insulin O
aggregation O
, O
fragmentation O
, O
and O
structural O
changes O
, O
as O
indicated O
by O
SEC O
, O
nanoparticle O
tracking O
analysis O
, O
light O
obscuration O
particle O
counting O
, O
intrinsic O
/ O
extrinsic O
fluorescence O
, O
circular O
dichroism O
, O
and O
chemical O
derivatization O
. O

TETA B
also O
protected O
a O
monoclonal O
IgG1 O
against O
MCO O
- O
induced O
aggregation O
, O
suggesting O
its O
general O
applicability O
. O

In O
conclusion O
, O
TETA B
is O
a O
potential O
candidate O
excipient O
for O
inclusion O
in O
formulations O
of O
oxidation O
- O
sensitive O
proteins O
. O

Synthesis O
and O
Nrf2 O
- O
inducing O
activity O
of O
the O
isothiocyanates O
iberverin B
, O
iberin B
and O
cheirolin B
. O

However O
, O
little O
is O
known O
regarding O
the O
Nrf2 O
- O
inducing O
activities O
of O
the O
lower O
structure O
- O
related O
sulforaphane O
homologues O
, O
such O
as O
iberverin B
, O
iberin B
and O
cheirolin B
, O
which O
exhibit O
different O
sulfur O
oxidation O
states O
. O

Therefore O
, O
in O
this O
study O
we O
synthesized O
the O
isothiocyanates O
iberverin B
, O
iberin B
and O
cheirolin B
with O
a O
high O
yield O
and O
purity O
and O
determined O
their O
Nrf2 O
- O
inducing O
activity O
in O
NIH3T3 O
fibroblasts O
. O

Iberverin B
, O
iberin B
and O
cheirolin B
significantly O
induced O
Nrf2 O
nuclear O
translocation O
. O

Overall O
, O
iberverin B
, O
iberin B
and O
cheirolin B
exhibited O
a O
similar O
potency O
to O
sulforaphane O
in O
inducing O
Nrf2 O
- O
dependent O
gene O
- O
expression O
. O

Furthermore O
, O
our O
data O
suggest O
that O
the O
induction O
of O
Nrf2 O
by O
iberverin B
, O
iberin B
and O
cheirolin B
may O
have O
occurred O
via O
an O
extracellular O
signal O
- O
related O
kinase O
( O
ERK O
) O
- O
dependent O
signal O
- O
transduction O
pathway O
. O

Antofine B
- O
induced O
connexin43 O
gap O
junction O
disassembly O
in O
rat O
astrocytes O
involves O
protein O
kinase O
C O
beta O
. O

Antofine B
, O
a O
phenanthroindolizidi O
alkaloid O
derived O
from O
Cryptocaryachinensis O
and O
Ficusseptica O
in O
the O
Asclepiadaceae O
milkweed O
family O
, O
is O
cytotoxic O
for O
various O
cancer O
cell O
lines O
. O

In O
this O
study O
, O
we O
demonstrated O
that O
treatment O
of O
rat O
primary O
astrocytes O
with O
antofine B
induced O
dose O
- O
dependent O
inhibition O
of O
gap O
junction O
intercellular O
communication O
( O
GJIC O
) O
, O
as O
assessed O
by O
scrape O
- O
loading O
6 B
- I
carboxyfluorescein I
dye O
transfer O
. O

Levels O
of O
Cx43 O
protein O
were O
also O
decreased O
in O
a O
dose O
- O
and O
time O
- O
dependent O
manner O
following O
antofine B
treatment O
. O

Double O
- O
labeling O
immunofluorescence O
microscopy O
showed O
that O
antofine B
( O
10ng O
/ O
ml O
) O
induced O
endocytosis O
of O
surface O
gap O
junctions O
into O
the O
cytoplasm O
, O
where O
Cx43 O
was O
co O
- O
localized O
with O
the O
early O
endosome O
marker O
EEA1 O
. O

Inhibition O
of O
lysosomes O
or O
proteasomes O
by O
co O
- O
treatment O
with O
antofine B
and O
their O
respective O
specific O
inhibitors O
, O
NH4Cl B
or O
MG132 O
, O
partially O
inhibited O
the O
antofine O
- O
induced O
decrease O
in O
Cx43 O
protein O
levels O
, O
but O
did O
not O
inhibit O
the O
antofine O
- O
induced O
inhibition O
of O
GJIC O
. O

Co O
- O
treatment O
of O
astrocytes O
with O
antofine B
and O
the O
intracellular O
Ca O
( O
2 O
+ O
) O
chelator O
BAPTA O
- O
AM O
prevented O
downregulation O
of O
Cx43 O
and O
inhibition O
of O
GJIC O
. O

Moreover O
, O
co O
- O
treatment O
with O
antofine B
and O
a O
specific O
PKC O
beta O
inhibitor O
prevented O
endocytosis O
of O
gap O
junctions O
, O
downregulation O
of O
Cx43 O
, O
and O
inhibition O
of O
GJIC O
. O

Taken O
together O
, O
these O
findings O
indicate O
that O
antofine B
induces O
Cx43 O
gap O
junction O
disassembly O
by O
the O
PKC O
beta O
signaling O
pathway O
. O

Inhibition O
of O
GJIC O
by O
antofine B
may O
undermine O
the O
neuroprotective O
effect O
of O
astrocytes O
in O
CNS O
. O

Specifically O
, O
ritonavir O
- O
boosted O
lopinavir B
- O
and O
atazanavir B
- O
based O
regimens O
are O
preferred O
in O
pregnancy O
, O
while O
ritonavir O
- O
boosted O
darunavir O
- O
and O
saquinavir O
- O
based O
therapies O
are O
reasonable O
alternatives O
. O

11 B
- I
Oxoetiocholanolone I
and O
related O
substances O
are O
important O
metabolites O
of O
cortisol O
and O
are O
excreted O
via O
feces O
in O
ruminants O
. O

The O
antibody O
was O
raised O
in O
rabbits O
against O
11 B
- I
KT I
- I
3 I
- I
CMO I
: O
bovine O
serum O
albumin O
with O
biotinylated B
11 I
- I
KT I
as O
a O
label O
. O

Samples O
( O
0 O
. O
5 O
g O
) O
were O
extracted O
using O
80 O
% O
methanol O
and O
immunoreactive O
metabolites O
measured O
using O
the O
11 O
- O
KT O
EIA O
and O
an O
already O
established O
11 B
, I
17 I
- I
dioxoandrostane I
( O
11 B
, I
17 I
- I
DOA I
) O
EIA O
. O

Concentrations O
of O
11 B
, I
17 I
- I
DOA I
showed O
the O
same O
pattern O
, O
but O
the O
values O
were O
2 O
to O
4 O
times O
higher O
. O

From O
this O
data O
, O
the O
authors O
conclude O
that O
11 O
- O
KT O
- O
like O
substances O
, O
specifically O
C19 B
O3 I
- I
androgens I
with O
a O
17 B
beta I
- I
hydroxy I
group O
, O
were O
present O
in O
the O
feces O
. O

The O
main O
products O
obtained O
were O
desaspidinol B
, O
syringaldehyde O
, O
and O
syringol B
; O
this O
proves O
the O
efficiency O
of O
the O
depolymerization O
conditions O
applied O
. O

A O
nonionic O
inhibitor O
with O
high O
specificity O
for O
the O
UDP B
- I
Gal I
donor O
binding O
site O
of O
human O
blood O
group O
B O
galactosyltransferas O
: O
design O
, O
synthesis O
, O
and O
characterization O
. O

9 B
- I
( I
5 I
- I
O I
- I
alpha I
- I
D I
- I
galactopyranosyl I
) I
- I
D I
- I
arabinityl I
- I
1 I
, I
3 I
, I
7 I
- I
trihydropurine I
- I
2 I
, I
6 I
, I
8 I
- I
trione I
( O
1 O
) O
was O
designed O
and O
synthesized O
as O
a O
nonionic O
inhibitor O
for O
the O
donor O
binding O
site O
of O
human O
blood O
group O
B O
galactosyltransferas O
( O
GTB O
) O
. O

The O
binding O
epitope O
of O
1 O
demonstrates O
a O
high O
involvement O
of O
the O
arabinityl B
linker O
, O
whereas O
the O
galactose O
residue O
is O
only O
making O
contact O
to O
the O
protein O
via O
its O
C O
- O
2 O
site O
, O
which O
is O
very O
important O
for O
the O
discrimination O
between O
galactose O
and O
N O
- O
acetylgalactosamine O
, O
the O
substrate O
transferred O
by O
GTA O
. O

Ruthenium B
( I
II I
) I
polypyridyl I
complexes O
as O
G O
- O
quadruplex O
inducing O
and O
stabilizing O
ligands O
in O
telomeric O
DNA O
. O

Two O
ruthenium B
( I
ii I
) I
polypyridyl I
complexes O
[ B
Ru I
( I
phen I
) I
2 I
( I
4idip I
) I
] I
( I
ClO4 I
) I
2 I
( O
) O
and O
[ B
Ru I
( I
bpy I
) I
2 I
( I
4idip I
) I
] I
( I
ClO4 I
) I
2 I
( O
) O
( O
phen B
= O
1 O
, O
10 O
- O
phenanthroline O
, O
bpy O
= O
2 O
, O
2 O
' O
- O
bipyridine O
, O
4idip B
= O
4 B
- I
indoleimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
[ I
1 I
, I
10 I
] I
phenanthroline I
) O
designed O
as O
telomeric O

The O
magnetometer O
coil O
detected O
the O
HTR O
induced O
by O
the O
serotonergic O
hallucinogens O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
( O
DOI O
; O
0 O
. O
25 O
, O
0 O
. O
5 O
, O
and O
1 O
. O
0 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
lysergic B
acid I
diethylamide I
( O
LSD B
; O
0 O
. O
05 O
, O
0 O
. O
1 O
, O
0 O
. O
2 O
, O
and O
0 O
. O
4 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
with O
extremely O
high O
sensitivity O
and O
specificity O
. O

Magnetometer O
coil O
recordings O
demonstrated O
that O
the O
non O
- O
hallucinogenic O
compounds O
( O
+ O
) O
- O
amphetamine O
( O
2 O
. O
5 O
and O
5 O
. O
0 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
lisuride B
( O
0 O
. O
8 O
, O
1 O
. O
6 O
, O
and O
3 O
. O
2 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
did O
not O
induce O
the O
HTR O
. O

In O
order O
to O
determine O
a O
time O
course O
of O
Pb O
elimination O
after O
oral O
exposure O
to O
two O
different O
forms O
of O
this O
heavy O
metal O
( O
lead B
acetate I
vs O
. O
phyto O
- O
bound O
Pb O
) O
, O
a O
feeding O
study O
was O
carried O
out O
in O
experimental O
rats O
using O
the O
Pb O
phyto O
- O
hyperaccumulator O
Pistia O
stratiotes O
as O
a O
model O
diet O
. O

Considerable O
differences O
were O
revealed O
concerning O
total O
excretion O
levels O
; O
lead B
acetate I
was O
excreted O
in O
amount O
greater O
extent O
than O
those O
of O
phytobound O
Pb O
. O

Results O
of O
our O
study O
suggest O
that O
Pb O
forms O
occurring O
in O
the O
P O
. O
stratiotes O
tissues O
are O
absorbed O
through O
the O
gastrointestinal O
tract O
to O
a O
greater O
extent O
than O
Pb O
from O
lead B
acetate I
. O

Echinacea O
sanguinea O
and O
Echinacea O
pallida O
extracts O
stimulate O
glucuronidation O
and O
basolateral O
transfer O
of O
Bauer O
alkamides B
8 O
and O
10 O
and O
ketone O
24 O
and O
inhibit O
P O
- O
glycoprotein O
transporter O
in O
Caco O
- O
2 O
cells O
. O

We O
hypothesized O
that O
Bauer O
alkamides B
8 O
, O
10 O
, O
and O
11 O
and O
ketone O
24 O
were O
absorbed O
similarly O
either O
as O
pure O
compounds O
or O
from O
Echinacea O
sanguinea O
and O
Echinacea O
pallida O
ethanol O
extracts O
, O
and O
that O
these O
Echinacea O
extracts O
could O
inhibit O
the O
P O
- O
glycoprotein O
transporter O
in O
Caco O
- O
2 O
human O
intestinal O
epithelial O
cells O
. O

Using O
HPLC O
analysis O
, O
the O
permeation O
rate O
of O
Bauer O
alkamides B
by O
passive O
diffusion O
across O
Caco O
- O
2 O
cells O
corresponded O
with O
compound O
hydrophilicity O
( O
alkamide B
8 O
> O
10 O
> O
11 O
) O
, O
independent O
of O
the O
plant O
extract O
matrix O
. O

Both O
Echinacea O
ethanol O
extracts O
stimulated O
apparent O
glucuronidation O
and O
basolateral O
efflux O
of O
glucuronides O
of O
alkamides B
8 O
and O
10 O
but O
not O
alkamide B
11 O
. O

Bauer O
alkamides B
8 O
, O
10 O
, O
and O
11 O
( O
175 O
- O
230 O
micro O
M O
) O
and O
ethanol O
extracts O
of O
E O
. O
sanguinea O
( O
1 O
mg O
/ O
mL O
, O
containing O
~ O
90 O
micro O
M O
total O
alkamides B
) O
and O
E O
. O
pallida O
( O
5 O
mg O
/ O
mL O
, O
containing O
285 O
micro O
M O
total O
alkamides O
) O
decreased O
the O
efflux O
of O
the O
P O
- O
glycoprotein O
transporter O
probe O
calcein O
- O
AM O
from O
Caco O
- O
2 O
cells O
. O

These O
results O
suggest O
that O
other O
constituents O
in O
these O
Echinacea O
extracts O
facilitated O
the O
metabolism O
and O
efflux O
of O
alkamides B
and O
ketones O
, O
which O
might O
improve O
therapeutic O
benefits O
. O

Alkamides B
and O
Echinacea O
extracts O
might O
be O
useful O
in O
potentiating O
some O
chemotherapeutics O
, O
which O
are O
substrates O
for O
the O
P O
- O
glycoprotein O
transporter O
. O

To O
assess O
the O
PBDE O
concentration O
trend O
, O
and O
determine O
the O
concentrations O
of O
the O
emerging O
flame O
retardants O
Dechlorane O
Plus O
( O
DP O
) O
and O
bis B
( I
2 I
- I
ethylhexyl I
) I
- I
3 I
, I
4 I
, I
5 I
, I
6 I
- I
tetrabromophthalate I
( O
TBPH B
) O
, O
the O
authors O
measured O
the O
concentrations O
of O
8 O
PBDE O
congeners O
, O
2 O
DP O
isomers O
, O
and O
TBPH B
in O
10 O
composite O
samples O
, O
which O
were O
pooled O
from O
the O
serum O
collected O
from O
305 O
Laizhou O
Bay O
residents O
in O
October O
2011 O
. O

Brominated B
diphenyl I
ether I
- I
209 I
was O
the O
dominant O
congener O
, O
accounting O
for O
87 O
% O
of O
sum O
8 O
PBDE O
. O

Compared O
with O
a O
previous O
study O
, O
sum O
8 O
PBDE O
serum O
concentrations O
in O
the O
present O
study O
showed O
no O
change O
in O
order O
of O
magnitude O
, O
but O
the O
relative O
contribution O
of O
BDE B
- I
209 I
to O
sum O
8 O
PBDE O
was O
higher O
. O

The O
study O
also O
detected O
TBPH B
in O
the O
30 O
- O
to O
39 O
- O
yr O
- O
old O
female O
group O
, O
suggesting O
that O
TBPH B
, O
as O
an O
emerging O
HFR O
, O
requires O
further O
monitoring O
. O

Synthesis O
and O
NMR O
studies O
of O
novel O
chromone B
- I
2 I
- I
carboxamide I
derivatives O
. O

Chromones B
are O
heterocyclic O
compounds O
of O
natural O
or O
synthetic O
origin O
that O
possess O
relevant O
pharmacological O
activities O
. O

Accordingly O
, O
the O
synthesis O
and O
identification O
of O
novel O
chromone B
carboxamide I
derivatives O
with O
electron O
- O
donating O
and O
electron O
- O
withdrawing O
substituents O
in O
different O
positions O
of O
the O
exocyclic O
ring O
are O
reported O
in O
this O
work O
. O

We O
examined O
a O
number O
of O
anti O
- O
resorptive O
treatments O
to O
either O
block O
osteoclast O
activity O
, O
including O
the O
potent O
bisphosphonates O
zoledronic B
acid I
( O
ZA O
) O
and O
clodronate B
( O
CLOD B
) O
, O
which O
work O
via O
differing O
mechanisms O
, O
or O
antagonize O
osteoclastogenesis O
with O
recombinant O
OPG O
( O
HuOPG O
- O
Fc O
) O
, O
comparing O
these O
directly O
to O
an O
inhibitor O
of O
matrix O
metalloproteinase O
( O
MMP O
) O
activity O
( O
MMI270 O
) O
. O

Hard O
callus O
remodeling O
was O
, O
as O
expected O
, O
delayed O
with O
ZA O
, O
CLOD B
and O
OPG O
treatment O
at O
4 O
and O
6 O
weeks O
, O
resulting O
in O
larger O
more O
mineralized O
calluses O
at O
6 O
weeks O
. O

All O
compounds O
with O
good O
docking O
scores O
significantly O
inhibited O
FGFR4 O
kinase O
activity O
, O
some O
with O
sub O
- O
micromolar O
( O
most O
potent O
being O
V4 B
- I
015 I
with O
an O
IC O
( O
50 O
) O
of O
0 O
. O
04 O
mu O
M O
) O
. O

The O
most O
potent O
compound O
to O
date O
, O
V4 B
- I
015 I
, O
suppressed O
proliferation O
of O
MDA O
- O
MB453 O
cells O
at O
sub O
- O
micromolar O
concentrations O
, O
activated O
the O
pro O
- O
apoptotic O
caspases O
3 O
/ O
7 O
and O
inhibited O
cellular O
migration O
. O

The O
short O
- O
acting O
beta2 O
- O
agonists O
, O
including O
salbutamol B
, O
and O
fenoterol B
, O
have O
a O
rapid O
onset O
of O
action O
, O
a O
bronchodilating O
effect O
for O
3 O
- O
6 O
h O
and O
are O
used O
on O
demand O
. O

The O
longacting O
beta2 O
- O
agonists O
( O
LABAs O
) O
, O
including O
salmeterol B
and O
formoterol B
, O
have O
12 O
- O
hour O
duration O
of O
action O
and O
are O
used O
with O
a O
twice O
- O
daily O
dosing O
regimen O
for O
long O
- O
term O
COPD O
treatment O
. O

Unlike O
salmeterol B
, O
formoterol B
has O
a O
rapid O
onset O
of O
action O
. O

Indacaterol B
, O
which O
has O
been O
approved O
for O
long O
- O
term O
treatment O
of O
COPD O
in O
Europe O
and O
in O
the O
USA O
, O
has O
a O
24 O
- O
h O
duration O
of O
action O
and O
a O
once O
- O
daily O
dosing O
regimen O
. O

Newer O
ultra O
- O
LABAs O
, O
including O
olodaterol B
, O
vilanterol B
, O
milveterol B
, O
carmoterol B
, O
and O
abediterol B
, O
are O
in O
development O
. O

Combination O
with O
ICS O
( O
fluticasone B
/ O
salmeterol B
, O
budesonide O
/ O
formoterol B
, O
beclomethasone B
/ O
formoterol B
) O
appears O
to O
provide O
an O
additional O
benefit O
over O
the O
monocomponent O
therapy O
, O
although O
the O
extent O
of O
this O
benefit O
is O
variable O
and O
often O
not O
clinically O
significant O
in O
all O
the O
endpoints O
assessed O
. O

DNA O
polymerases O
replicate O
DNA O
by O
catalyzing O
the O
template O
- O
directed O
polymerization O
of O
deoxynucleoside B
triphosphate I
( O
dNTP O
) O
substrates O
onto O
the O
3 O
' O
end O
of O
a O
growing O
DNA O
primer O
strand O
. O

Synthesis O
and O
structure O
- O
activity O
relationships O
of O
indazole B
arylsulfonamides I
as O
allosteric O
CC O
- O
chemokine O
receptor O
4 O
( O
CCR4 O
) O
antagonists O
. O

A O
series O
of O
indazole B
arylsulfonamides I
were O
synthesized O
and O
examined O
as O
human O
CCR4 O
antagonists O
. O

The O
most O
potent O
N3 O
- O
substituent O
was O
5 B
- I
chlorothiophene I
- I
2 I
- I
sulfonamide I
. O

N1 O
meta O
- O
substituted O
benzyl O
groups O
possessing O
an O
alpha O
- O
amino O
- O
3 B
- I
[ I
( I
methylamino I
) I
acyl I
] I
- O
group O
were O
the O
most O
potent O
N1 O
- O
substituents O
. O

Less O
basic O
analogues O
, O
such O
as O
morpholines B
, O
had O
good O
oral O
absorption O
; O
however O
, O
they O
also O
had O
high O
clearance O
. O

The O
most O
potent O
compound O
with O
high O
absorption O
in O
two O
species O
was O
analogue O
6 O
( O
GSK2239633A B
) O
, O
which O
was O
selected O
for O
further O
development O
. O

Aryl B
sulfonamide I
antagonists O
bind O
to O
CCR4 O
at O
an O
intracellular O
allosteric O
site O
denoted O
site O
II O
. O

X O
- O
ray O
diffraction O
studies O
on O
two O
indazole B
sulfonamide I
fragments O
suggested O
the O
presence O
of O
an O
important O
intramolecular O
interaction O
in O
the O
active O
conformation O
. O

Structure O
- O
based O
discovery O
of O
pyrazolobenzothiazin B
derivatives O
as O
inhibitors O
of O
hepatitis O
C O
virus O
replication O
. O

These O
studies O
led O
to O
the O
identification O
of O
pyrazolobenzothiazin B
scaffold O
as O
a O
suitable O
template O
for O
obtaining O
novel O
anti O
- O
HCV O
agents O
targeting O
the O
NS5B O
polymerase O
. O

The O
best O
compound O
of O
this O
series O
was O
the O
meta B
- I
fluoro I
- I
N I
- I
1 I
- I
phenyl I
pyrazolobenzothiazin I
derivative O
4a O
, O
which O
exhibited O
an O
EC50 O
= O
3 O
. O
6 O
mu O
M O
, O
EC90 O
= O
25 O
. O
6 O
mu O
M O
, O
and O
CC50 O
> O
180 O
mu O
M O
in O
the O
Huh O
9 O
- O
13 O
replicon O
system O
, O
thus O
providing O
a O
good O
starting O
point O
for O
further O
hit O
evolution O
. O

In O
addition O
, O
acute O
As O
( O
III O
) O
treatment O
increased O
dihydroxyeicosatrien B
acid I
( O
DHETs B
) O
formation O
in O
the O
lung O
, O
while O
it O
did O
not O
affect O
liver O
DHETs B
formation O
and O
decreased O
kidney O
DHETs B
formation O
. O

Furthermore O
, O
As O
( O
III O
) O
increased O
20 B
- I
hydroxyeicosatetraen I
acid I
formation O
in O
the O
liver O
while O
it O
decreased O
its O
formation O
in O
the O
kidney O
. O

Protein O
recognition O
of O
the O
S23906 B
- I
1 I
- O
DNA O
adduct O
by O
nuclear O
proteins O
: O
direct O
involvement O
of O
glyceraldehyde B
- I
3 I
- I
phosphate I
dehydrogenase O
( O
GAPDH O
) O
1 O
. O

The O
benzo B
- I
b I
- I
acronycine I
derivative O
S23906 B
- I
1 I
alkylates O
guanine B
nucleobases I
in O
the O
minor O
groove O
of O
the O
DNA O
helix O
and O
presents O
an O
original O
ability O
to O
locally O
open O
the O
double O
helix O
of O
DNA O
, O
which O
appears O
to O
be O
associated O
with O
its O
cytotoxic O
activity O
. O

The O
objective O
of O
the O
present O
study O
was O
to O
identify O
proteins O
involved O
in O
the O
recognition O
and O
mechanism O
of O
action O
of O
S23906 B
- O
DNA O
adducts O
. O

We O
found O
that O
GAPDH O
( O
glyceraldehyde B
- I
3 I
- I
phosphate I
dehydrogenase O
) O
is O
a O
protein O
that O
binds O
to O
S23906 B
- O
alkylated O
single O
- O
stranded O
, O
double O
- O
stranded O
and O
telomeric O
sequences O
in O
a O
drug O
- O
dependent O
and O
DNA O
sequence O
/ O
structure O
- O
dependent O
manner O
. O

We O
used O
the O
CASTing O
( O
cyclic O
amplification O
of O
sequence O
targeting O
) O
method O
to O
identify O
GAPDH O
DNA O
- O
binding O
selectivity O
and O
then O
evaluated O
its O
binding O
to O
such O
selected O
S23906 B
- O
alkylated O
sequences O
. O

At O
the O
cellular O
level O
, O
alkylation O
of O
S23906 B
- I
1 I
results O
in O
an O
increase O
in O
the O
binding O
of O
GAPDH O
and O
its O
protein O
partner O
HMG O
( O
high O
- O
mobility O
group O
) O
B1 O
to O
the O
chromatin O
. O

Synthesis O
and O
cancer O
stem O
cell O
- O
based O
activity O
of O
substituted O
5 B
- I
morpholino I
- I
7H I
- I
thieno I
[ I
3 I
, I
2 I
- I
b I
] I
pyran I
- I
7 I
- I
ones I
designed O
as O
next O
generation O
PI3K O
inhibitors O
. O

Our O
previous O
work O
, O
built O
on O
the O
early O
pioneering O
multikinase O
inhibitor O
LY294002 O
, O
resulted O
in O
the O
only O
PI3K O
vascular O
- O
targeted O
PI3K O
inhibitor O
prodrug O
, O
SF1126 B
, O
which O
has O
now O
completed O
Phase O
I O
clinical O
trials O
. O

This O
work O
resulted O
in O
the O
discovery O
of O
the O
5 B
- I
morpholino I
- I
7H I
- I
thieno I
[ I
3 I
, I
2 I
- I
b I
] I
pyran I
- I
7 I
- I
one I
system O
as O
the O
foundation O
of O
a O
new O
compound O
class O
of O
potential O
PI3K O
inhibitors O
having O
improved O
potency O
toward O
PI3K O
. O

Injectable O
, O
in O
situ O
- O
gelling O
magnetic O
composite O
materials O
have O
been O
fabricated O
by O
using O
aldehyde O
- O
functionalized O
dextran O
to O
cross O
- O
link O
superparamagnetic O
nanoparticles O
surface O
- O
functionalized O
with O
hydrazide B
- O
functionalized O
poly O
( O
N O
- O
isopropylacrylamide O
) O
( O
pNIPAM B
) O
. O

Membrane O
fusion O
protein O
of O
hefABC O
efflux O
system O
, O
50 O
S O
ribosomal O
protein O
L33 O
, O
Hydrogenase O
expression O
protein O
/ O
formation O
of O
HypD O
, O
Cag O
pathogenecity O
island O
protein O
X O
, O
Apolipoprotein O
N B
acyl I
transferase O
, O
DNA O
methyalse O
, O
Histone O
like O
binding O
protein O
, O
Peptidoglycan O
- O
associated O
lipoprotein O
OprL O
were O
found O
to O
be O
critical O
drug O
targets O
to O
H O
. O
pylori O
. O

Profiling O
the O
structural O
determinants O
of O
heteroarylnitrile B
scaffold O
- O
based O
derivatives O
as O
falcipain O
- O
2 O
inhibitors O
by O
in O
silico O
methods O
. O

The O
combination O
of O
docking O
analysis O
and O
MD O
simulation O
shows O
that O
Gly83 B
, O
Trp43 B
and O
Ala175 O
which O
formed O
several O
H O
- O
bonds O
are O
crucial O
for O
falcipain O
- O
2 O
inhibitors O
. O

Aspulvinones B
from O
a O
mangrove O
rhizosphere O
soil O
- O
derived O
fungus O
Aspergillus O
terreus O
Gwq O
- O
48 O
with O
anti O
- O
influenza O
A O
viral O
( O
H1N1 O
) O
activity O
. O

A O
new O
butenolide B
isoaspulvinone B
E I
( O
1 O
) O
, O
together O
with O
two O
known O
butenolides B
aspulvinone B
E I
( O
2 O
) O
and O
pulvic B
acid I
( O
3 O
) O
were O
isolated O
from O
the O
marine O
- O
derived O
fungus O
, O
Aspergillus O
terreus O
Gwq O
- O
48 O
. O

Synthesis O
and O
physicochemical O
properties O
of O
new O
tripodal O
amphiphiles O
bearing O
fatty B
acids I
as O
a O
hydrophobic O
group O
. O

Saturated O
fatty O
acids O
( O
FA O
) O
were O
grafted O
using O
tyrosine O
as O
a O
spacer O
group O
to O
the O
cyclotriphosphazene B
ring O
along O
with O
equimolar O
hydrophilic O
methoxy B
poly I
( I
ethylene I
glycol I
) I
( O
MPEG O
) O
in O
cis O
- O
nongeminal O
way O
. O

Seven O
new O
cyclotriphosphazene B
amphiphiles O
were O
prepared O
from O
combinations O
of O
hydrophilic O
MPEGs B
with O
different O
molecular O
weights O
of O
350 O
, O
550 O
, O
750 O
and O
1000 O
and O
four O
different O
fatty O
acids O
of O
different O
hydrophobicity O
including O
lauric B
, I
myristic I
, I
palmitic I
and I
stearic I
acids I
. O

Electrochemical O
determination O
of O
Sudan B
I I
in O
food O
samples O
at O
graphene O
modified O
glassy O
carbon O
electrode O
based O
on O
the O
enhancement O
effect O
of O
sodium B
dodecyl I
sulphonate I
. O

This O
paper O
describes O
a O
novel O
electrochemical O
method O
for O
the O
determination O
of O
Sudan B
I I
in O
food O
samples O
based O
on O
the O
electrochemical O
catalytic O
activity O
of O
graphene O
modified O
glassy O
carbon O
electrode O
( O
GMGCE O
) O
and O
the O
enhancement O
effect O
of O
an O
anionic O
surfactant O
: O
sodium B
dodecyl I
sulphonate I
( O
SDS O
) O
. O

Using O
pH O
6 O
. O
0 O
phosphate O
buffer O
solution O
( O
PBS O
) O
as O
supporting O
electrolyte O
and O
in O
the O
presence O
of O
1 O
. O
5 O
x O
10 O
( O
- O
4 O
) O
mol O
L O
( O
- O
1 O
) O
SDS O
, O
Sudan B
I I
yielded O
a O
well O
- O
defined O
and O
sensitive O
oxidation O
peak O
at O
a O
GMGCE O
. O

The O
oxidation O
peak O
current O
of O
Sudan B
I I
remarkably O
increased O
in O
the O
presence O
of O
SDS O
. O

The O
experimental O
parameters O
, O
such O
as O
supporting O
electrolyte O
, O
concentration O
of O
SDS O
, O
and O
accumulation O
time O
, O
were O
optimised O
for O
Sudan B
I I
determination O
. O

The O
oxidation O
peak O
current O
showed O
a O
linear O
relationship O
with O
the O
concentrations O
of O
Sudan B
I I
in O
the O
range O
of O
7 O
. O
50 O
x O
10 O
( O
- O
8 O
) O
- O
7 O
. O
50 O
x O
10 O
( O
- O
6 O
) O
mol O
L O
( O
- O
1 O
) O
, O
with O
the O
detection O
limit O
of O
4 O
. O
0 O
x O
10 O
( O
- O
8 O
) O
mol O
L O
( O
- O
1 O
) O
. O

This O
new O
voltammetric O
method O
was O
successfully O
used O
to O
determine O
Sudan B
I I
in O
food O
products O
such O
as O
ketchup O
and O
chili O
sauce O
with O
satisfactory O
results O
. O

Sprague O
- O
Dawley O
rats O
were O
intraperitoneally O
given O
dimethyl B
n I
- I
nitrosamine I
( O
DMN O
) O
( O
10mg O
/ O
kg O
) O
3 O
days O
per O
week O
for O
4 O
weeks O
. O

Antioxidant O
activities O
of O
the O
synthesized O
thiol O
- O
contained O
peptides O
derived O
from O
computer O
- O
aided O
pepsin O
hydrolysis O
of O
yam O
tuber O
storage O
protein O
, O
dioscorin B
. O

Our O
previous O
report O
showed O
that O
yam O
dioscorin B
and O
its O
peptic O
hydrolysates O
exhibit O
radical O
scavenging O
activities O
; O
however O
, O
the O
functions O
of O
these O
peptic O
hydrolases O
are O
still O
under O
investigation O
. O

In O
this O
study O
, O
the O
thiol O
- O
containing O
peptides O
derived O
from O
computer O
- O
aided O
simulation O
of O
pepsin O
hydrolysis O
of O
dioscorin B
, O
namely O
, O
KTCGNGME O
( O
diotide1 O
) O
, O
PPCSE O
( O
diotide2 O
) O
, O
CDDRVIRTPLT O
( O
diotide3 O
) O
, O
KTCGY O
( O
diotide4 O
) O
, O
and O
PPCTE O
( O
diotide5 O
) O
were O
synthesized O
to O
compare O
their O
antioxidant O
activities O
with O
GSH O
and O
/ O
or O
carnosine O
by O
examining O
hydroxyl O
radical O
scavenging O
activity O
by O
electron O
spin O
resonance O

These O
results O
suggest O
that O
thiol O
- O
containing O
diotides O
derived O
from O
dioscorin B
hydrolysis O
exhibit O
antioxidant O
activities O
and O
reveal O
the O
benefits O
of O
yam O
tuber O
as O
an O
antioxidant O
- O
rich O
food O
. O

Winter O
wheat O
hull O
( O
husk O
) O
is O
a O
valuable O
source O
for O
tricin B
, O
a O
potential O
selective O
cytotoxic O
agent O
. O

The O
flavone O
, O
tricin B
( O
5 B
, I
7 I
, I
4 I
' I
- I
trihydroxy I
- I
3 I
' I
, I
5 I
' I
- I
dimethoxyflavone I
) O
has O
great O
potential O
as O
an O
anticancer O
agent O
, O
due O
to O
its O
specific O
chemopreventive O
activity O
. O

Tricin B
is O
found O
mainly O
in O
cereal O
grains O
, O
such O
as O
wheat O
, O
rice O
, O
barley O
, O
oat O
and O
maize O
. O

To O
find O
a O
reliable O
, O
rich O
source O
of O
tricin B
, O
we O
investigated O
its O
distribution O
in O
different O
parts O
of O
wheat O
( O
Triticum O
aestivum O
) O
and O
designed O
an O
efficient O
method O
for O
its O
isolation O
and O
purification O
. O

This O
concentration O
is O
one O
of O
the O
highest O
in O
any O
plant O
species O
and O
is O
considered O
as O
a O
cheap O
source O
of O
natural O
tricin B
. O

The O
purified O
wheat O
husks O
tricin B
was O
found O
to O
be O
a O
selective O
potent O
inhibitor O
of O
two O
cancer O
cell O
lines O
of O
liver O
and O
pancreas O
, O
while O
having O
no O
side O
effects O
on O
normal O
cells O
. O

This O
selective O
action O
suggests O
that O
tricin B
could O
be O
considered O
as O
a O
potential O
candidate O
for O
pre O
- O
clinical O
trials O
as O
a O
chemopreventive O
agent O
. O

In O
general O
, O
C6 O
compounds O
, O
alcohols O
, O
terpenes O
, O
phenols O
and O
C13 B
- I
norisoprenoids I
in O
Syrah O
showed O
a O
decrease O
and O
in O
Chardonnay O
an O
increase O
. O

Significantly O
( O
p O
< O
0 O
. O
05 O
) O
increased O
levels O
of O
polyphenol O
metabolites O
, O
hippuric B
acid I
and O
4 B
- I
hydroxyhippuric I
acid I
, O
and O
decreased O
creatinine O
and O
dimethylamine O
levels O
were O
the O
major O
explanations O
for O
the O
grouping O
of O
the O
postprandial O
samples O
after O
the O
different O
meals O
. O

Simultaneous O
determination O
of O
Mn2 B
+ I
and O
Fe3 B
+ I
as O
4 B
, I
4 I
' I
[ I
( I
4 I
- I
cholorophenyl I
) I
methylene I
] I
bis I
( I
3 I
- I
methyl I
- I
1 I
- I
phenyl I
- I
1H I
- I
pyrazol I
- I
5 I
- I
ol I
) I
complexes O
in O
some O
foods O
, O
vegetable O
and O
water O
samples O
by O
artificial O
neural O
networks O
. O

It O
relies O
on O
the O
complexation O
of O
analytes O
with O
recently O
synthesised O
bis O
pyrazol B
base O
ligand O
as O
4 B
, I
4 I
' I
[ I
( I
4 I
- I
cholorophenyl I
) I
methylene I
] I
bis I
( I
3 I
- I
methyl I
- I
1 I
- I
phenyl I
- I
1H I
- I
pyrazol I
- I
5 I
- I
ol I
) I
( O
CMBPP B
) O
. O

Regarding O
the O
effect O
of O
ion O
exchange O
on O
organoleptic O
characteristics O
and O
the O
quality O
of O
the O
obtained O
wines O
, O
a O
slight O
decrease O
in O
both O
anthocyanin O
and O
tannin B
contents O
was O
observed O
along O
with O
a O
small O
drop O
in O
the O
aromatic O
content O
. O

Relative O
percentages O
of O
lipid O
classes O
and O
fatty O
acids O
/ O
acyls B
composition O
of O
the O
commercial O
feeds O
and O
fish O
dorsal O
muscles O
were O
assessed O
by O
means O
of O
an O
interdisciplinary O
analytical O
approach O
. O

While O
defined O
effects O
of O
feed O
composition O
on O
fatty O
acid O
profiles O
of O
fillets O
were O
ascertained O
, O
the O
relative O
increase O
of O
fatty B
acyls I
in O
triglycerides O
and O
phospholipids O
were O
also O
estimated O
enabling O
detailed O
evaluation O
of O
TAG O
: O
PL O
ratio O
in O
adult O
offshore O
- O
farmed O
gilthead O
sea O
bream O
. O

Simple O
, O
fast O
, O
and O
efficient O
process O
for O
producing O
and O
purifying O
trehalulose B
. O

A O
new O
property O
of O
recombinant O
trehalose B
synthase O
( O
GTase O
) O
from O
Thermus O
thermophilus O
HB O
- O
8 O
( O
ATCC O
27634 O
) O
was O
found O
and O
described O
in O
this O
study O
. O

GTase O
can O
act O
on O
sucrose O
and O
catalyze O
trehalulose B
formation O
without O
isomaltose B
, O
isomaltulose B
, O
or O
isomelezitose B
, O
releasing O
small O
amounts O
of O
glucose O
and O
fructose O
as O
byproducts O
. O

Maximum O
trehalulose B
yield O
( O
approximately O
81 O
% O
) O
was O
obtained O
at O
an O
optimum O
temperature O
of O
65 O
degrees O
C O
and O
was O
independent O
of O
substrate O
concentration O
. O

A O
simple O
, O
fast O
, O
and O
efficient O
method O
of O
producing O
and O
purifying O
trehalulose B
is O
then O
described O
. O

In O
the O
first O
step O
, O
GTase O
catalyzed O
trehalulose B
formation O
using O
a O
20 O
% O
sucrose O
substrate O
. O

Miscellaneous O
sugars O
were O
then O
rapidly O
removed O
, O
while O
trehalulose B
was O
completely O
preserved O
by O
Saccharomyces O
cerevisiae O
cells O
. O

Finally O
, O
the O
cells O
were O
separated O
by O
centrifugation O
, O
and O
salt O
ions O
were O
removed O
by O
an O
ion O
- O
exchange O
resin O
, O
subsequently O
obtaining O
a O
high O
- O
purity O
trehalulose B
solution O
. O

A O
trehalulose B
recovery O
rate O
of O
over O
95 O
% O
was O
achieved O
using O
this O
process O
. O

Ascorbic O
acid O
and O
chlorogenic O
acid O
contents O
were O
determined O
by O
HPLC O
- O
DAD O
, O
total O
anthocyanin O
content O
by O
pH O
- O
differential O
spectrophotometry O
, O
glycoalkaloid B
, O
alpha B
- I
chaconine I
and O
alpha B
- I
solanine I
contents O
by O
HPLC O
- O
ESI O
/ O
MS O
/ O
MS O
. O

All O
cooking O
treatments O
reduced O
ascorbic B
and I
chlorogenic O
acid O
contents O
, O
total O
glycoalkaloids B
, O
alpha B
- I
chaconine I
and O
alpha B
- I
solanine I
with O
the O
exception O
of O
total O
anthocyanins O
. O

The O
losses O
of O
ascorbic B
and I
chlorogenic I
acids I
were O
minimised O
with O
boiling O
and O
total O
anthocyanin O
levels O
retained O
the O
highest O
. O

Boiling O
of O
peeled O
tubers O
decreased O
contents O
of O
total O
glycoalkaloids B
( O
alpha B
- I
chaconine I
and I
alpha I
- I
solanine I
) O
and O
appeared O
as O
the O
most O
favourable O
among O
the O
three O
tested O
methods O
. O

The O
rice O
samples O
were O
initially O
extracted O
with O
acetonitrile O
( O
MeCN B
) O
, O
and O
the O
targeted O
pesticides O
were O
purified O
following O
the O
dispersive O
solid O
phase O
extraction O
( O
d O
- O
SPE O
) O
cleanup O
method O
and O
detected O
by O
gas O
chromatography O
- O
tandem O
mass O
spectrometry O
( O
GC O
- O
MS O
/ O
MS O
) O
. O

The O
efficiency O
of O
citrate O
- O
buffered O
and O
unbuffered O
method O
in O
liquid O
extraction O
procedure O
was O
compared O
; O
the O
amount O
of O
primary O
secondary O
amine O
( O
PSA B
) O
was O
optimised O
. O

As O
part O
of O
a O
comprehensive O
study O
of O
the O
physiochemical O
and O
biological O
properties O
of O
phytosteryl O
phenolates O
, O
successfully O
synthesized O
chemoenzymatically O
in O
our O
lab O
, O
their O
antioxidant O
activity O
was O
evaluated O
using O
three O
different O
in O
vitro O
model O
systems O
, O
namely O
bulk O
oil O
model O
system O
, O
beta O
- O
carotene O
- O
linoleate B
model O
system O
and O
low O
- O
density O
lipoprotein O
cholesterol O
( O
LDL O
- O
C O
) O
oxidation O
assay O
. O

However O
, O
in O
beta O
- O
carotene O
- O
linoleate B
assay O
, O
an O
emulsion O
model O
system O
, O
phytosteryl O
phenolates O
showed O
enhanced O
antioxidant O
activity O
except O
phytosteryl B
ferulates I
. O

A O
nanosilver O
- O
based O
spectrophotometry O
method O
for O
sensitive O
determination O
of O
tartrazine B
in O
food O
samples O
. O

A O
new O
method O
is O
reported O
for O
sensitive O
determination O
of O
tartrazine B
in O
the O
food O
samples O
. O

The O
method O
is O
based O
on O
the O
catalytic O
effect O
of O
silver O
nanoparticle O
( O
AgNPs O
) O
on O
the O
oxidation O
reaction O
of O
tartrazine B
by O
potassium B
iodate I
in O
the O
acetate O
buffer O
medium O
. O

The O
thirty O
six O
criterion O
detection O
limit O
was O
0 O
. O
3 O
ng O
/ O
mL O
, O
and O
the O
relative O
standard O
deviation O
for O
ten O
replicate O
measurements O
of O
30 O
ng O
/ O
mL O
of O
tartrazine B
was O
0 O
. O
98 O
% O
( O
n O
= O
10 O
) O
. O

The O
method O
was O
successfully O
applied O
to O
the O
determination O
of O
tartrazine B
in O
lemon O
, O
and O
papaya O
- O
flavoured O
gelatin O
, O
candy O
, O
and O
in O
fruit O
syrup O
. O

Root O
tubers O
of O
Lactuca O
tuberosa O
as O
a O
source O
of O
antioxidant O
phenolic O
compounds O
and O
new O
furofuran B
lignans I
. O

From O
the O
root O
tubers O
of O
Lactuca O
tuberosa O
, O
a O
wild O
edible O
plant O
species O
, O
nine O
phenolic O
compounds O
were O
isolated O
, O
including O
two O
new O
furofuran B
lignan I
glucosides I
, O
named O
lactuberin B
A I
and O
lactuberin B
B I
. O

This O
is O
the O
first O
time O
that O
compounds O
belonging O
to O
the O
epi O
series O
of O
2 B
, I
6 I
- I
diaryl I
- I
3 I
, I
7 I
- I
dioxabicyclo I
[ I
3 I
. I
3 I
. I
0 I
] I
octane I
type O
furofuran B
lignans I
have O
been O
found O
in O
Lactuca O
species O
. O

Water O
- O
soluble O
apple O
peel O
polysaccharides O
( O
APP O
) O
and O
apple O
flesh O
polysaccharides O
( O
AFP O
) O
were O
isolated O
from O
Pink O
Lady O
fruits O
, O
and O
their O
in O
vitro O
antioxidant O
capacities O
were O
characterised O
by O
DPPH O
( O
) O
, O
HO B
( O
) O
, O
and O
O O
( O
2 O
) O
( O
- O
) O
systems O
, O
and O
ferric O
- O
reducing O
antioxidant O
power O
assay O
. O

The O
kinetics O
of O
degradation O
of O
chlorogenic O
acid O
( O
CG O
) O
, O
( O
- O
) O
epicatechin O
( O
EPI B
) O
, O
L O
- O
ascorbic O
acid O
( O
AA O
) O
and O
polyphenoloxidase O
( O
PPO O
) O
activity O
from O
Marie O
- O
M O
e O
nard O
apple O
in O
pH O
3 O
. O
8 O
solutions O
at O
20 O
and O
50 O
degrees O
C O
were O
investigated O
to O
provide O
information O
on O
the O
impact O
of O
the O
presence O
of O
CG O
, O
EPI B
and O
/ O
or O
AA O
on O
PPO O
thermostability O
. O

Losses O
of O
PPO O
activity O
were O
favoured O
by O
the O
presence O
of O
EPI B
in O
model O
solutions O
, O
compared O
with O
CG O
, O
due O
to O
the O
formation O
of O
o O
- O
quinones O
of O
EPI B
( O
QEPI O
) O
lowering O
PPO O
stability O
. O

Temperature O
quickened O
both O
enzymatic O
phenol O
oxidations O
before O
PPO O
deteriorated O
and O
the O
whole O
set O
of O
the O
chemical O
reactions O
, O
including O
the O
production O
of O
secondary O
oxidation O
products O
and O
CG O
or O
EPI B
regeneration O
. O

Results O
also O
confirmed O
that O
AA O
in O
excess O
induced O
a O
fast O
regeneration O
of O
CG O
and O
EPI B
from O
the O
corresponding O
o O
- O
quinones O
formed O
enzymatically O
via O
redox O
chemical O
reactions O
. O

The O
chromogenic O
array O
used O
eight O
sensing O
materials O
( O
based O
on O
aluminium O
oxide O
and O
silica O
gel O
) O
containing O
pH O
indicators O
, O
Lewis B
acids I
and O
an O
oxidation O
- O
reduction O
indicator O
. O

Piceatannol B
, O
a O
potent O
bioactive O
stilbene O
, O
as O
major O
phenolic O
component O
in O
Rhodomyrtus O
tomentosa O
. O

Piceatannol B
, O
a O
promising O
health O
- O
promoting O
stilbene O
component O
, O
was O
the O
major O
PC O
in O
the O
fruit O
with O
a O
concentration O
of O
2 O
. O
3mg O
/ O
g O
dry O
weight O
at O
full O
maturity O
stage O
. O

During O
maturation O
, O
the O
contents O
in O
piceatannol B
and O
other O
stilbenes O
, O
ellagitannins O
, O
and O
flavonols O
decreased O
while O
the O
anthocyanin O
content O
increased O
. O

Shade O
- O
grown O
sim O
fruits O
showed O
significantly O
higher O
piceatannol B
levels O
than O
sun O
- O
exposed O
fruits O
. O

The O
hypocholesterolemic O
and O
antioxidant O
activities O
of O
various O
extracts O
( O
water O
, O
methanol O
, O
ethyl O
acetate O
, O
hexane O
, O
dichloro B
- I
methane I
) O
of O
fenugreek O
seeds O
were O
investigated O
in O
cholesterol O
- O
fed O
rats O
. O

The O
phenolic O
and O
flavono B
i I
d I
contents O
were O
highest O
in O
the O
methanol O
and O
the O
ethyl O
acetate O
extracts O
. O

These O
results O
showed O
that O
the O
ethyl O
acetate O
extract O
of O
the O
fenugreek O
seeds O
had O
a O
significant O
hypocholesterolemic O
effect O
and O
antioxidant O
activity O
in O
cholesterol O
- O
fed O
rats O
, O
whether O
this O
is O
partly O
due O
to O
the O
presence O
of O
flavono B
i I
ds I
in O
the O
extract O
needs O
further O
study O
. O

The O
glucogalactan O
chains O
were O
composed O
of O
( O
1 O
- O
- O
> O
6 O
) O
- O
, O
( O
1 O
- O
- O
> O
5 O
) O
- O
and O
( O
1 O
- O
- O
> O
5 O
, O
6 O
) O
- O
linked O
beta B
- I
Galf I
, O
( O
1 O
- O
- O
> O
4 O
) O
- O
linked O
and O
non O
- O
reducing O
terminal O
beta B
- I
Glcp I
units O
, O
and O
might O
be O
attached O
to O
the O
mannan O
core O
at O
the O
O O
- O
2 O
positions O
of O
alpha B
- I
Manp I
units O
. O

Rugosin B
D I
, O
rugosin B
A I
, O
rugosin B
A I
methyl I
ester I
( O
a O
novel O
compound O
) O
, O
and O
tellimagrandin B
II I
were O
the O
main O
components O
; O
these O
4 O
ellagitannins O
exhibited O
a O
non O
- O
competitive O
type O
of O
inhibition O
, O
with O
K O
( O
i O
) O
values O
of O
approximately O
0 O
. O
35 O
- O
1 O
mu O
M O
. O

These O
K O
( O
i O
) O
values O
are O
nearly O
equal O
to O
that O
of O
histidine B
methyl I
ester I
( O
K O
( O
i O
) O
= O
0 O
. O
46 O
mu O
M O
) O
, O
an O
existing O
substrate O
analogue O
inhibitor O
. O

Procyanidin B
B3 I
spontaneously O
binds O
lysozyme O
, O
inducing O
the O
multilevel O
structural O
changes O
in O
lysozyme O
and O
the O
formation O
of O
insoluble O
complexes O
. O

Skim O
milk O
with O
low O
levels O
of O
added O
beta B
- I
mercaptoethanol I
( O
SM O
- O
ME O
) O
and O
untreated O
skim O
milk O
( O
SM O
) O
were O
heated O
and O
then O
made O
into O
acid O
gels O
. O

A O
novel O
colloidal O
gold O
- O
based O
lateral O
flow O
immunoassay O
for O
rapid O
simultaneous O
detection O
of O
cyromazine B
and O
melamine O
in O
foods O
of O
animal O
origin O
. O

A O
rapid O
and O
sensitive O
lateral O
flow O
immunoassay O
( O
LFIA O
) O
based O
on O
competitive O
format O
was O
developed O
and O
validated O
for O
simultaneous O
detection O
of O
cyromazine B
( O
CA O
) O
and O
melamine O
( O
MA O
) O
in O
foods O
of O
animal O
origin O
. O

R O
. O
hookeri O
wine O
contained O
more O
( O
p O
< O
0 O
. O
05 O
) O
Phe O
, O
Val O
, O
Ala O
, O
Gly O
, O
Pro O
, O
Asp O
, O
Asn O
, O
His O
and O
Lys O
than O
E O
. O
guineensis O
wine O
which O
contained O
more O
( O
p O
< O
0 O
. O
05 O
) O
Met O
, O
Cys O
, O
Glu O
, O
Gln O
, O
Ser O
and O
Arg B
. O

The O
E O
. O
guineensis O
and O
R O
. O
hookeri O
wines O
contained O
58 O
. O
25 O
+ O
/ O
- O
0 O
. O
56 O
% O
and O
56 O
. O
79 O
+ O
/ O
- O
0 O
. O
4 O
% O
essential O
AAs B
, O
respectively O
. O

Determination O
of O
total O
iron O
in O
food O
samples O
after O
flow O
injection O
preconcentration O
on O
polyurethane O
foam O
functionalized O
with O
N B
, I
N I
- I
bis I
( I
salicylidene I
) I
- I
1 I
, I
3 I
- I
propanediamine I
. O

Iron B
( I
III I
) I
was O
reduced O
to O
iron O
( O
II O
) O
by O
ascorbic O
acid O
and O
preconcentrated O
on O
a O
mini O
- O
column O
packed O
with O
polyurethane O
foam O
( O
PUF O
) O
functionalized O
with O
N B
, I
N I
- I
bis I
( I
salicylidene I
) I
- I
1 I
, I
3 I
- I
propanediamine I
( O
SPDA B
) O
. O

The O
retained O
Fe O
( O
II O
) O
was O
eluted O
with O
hydrochloric B
acid I
and O
subsequently O
reacted O
to O
2 B
, I
4 I
, I
6 I
- I
tri I
( I
2 I
' I
- I
pyridyl I
) I
- I
1 I
, I
3 I
, I
5 I
- I
triazine I
( O
TPTZ B
) O
then O
measured O
at O
593 O
nm O
. O

Among O
them O
, O
apigenin B
- I
glucuronide I
, O
lucenin B
- I
2 I
and O
lithospermic O
acid O
were O
tentatively O
identified O
for O
the O
first O
time O
. O

In O
unheated O
parsley O
, O
apart O
from O
the O
major O
compound O
apiin B
, O
10 O
further O
phenolics O
were O
characterised O
including O
several O
p O
- O
coumaric O
acid O
derivatives O
which O
were O
newly O
detected O
. O

Except O
for O
apiin B
, O
short O
- O
time O
steam O
- O
and O
water O
- O
blanching O
( O
1 O
min O
) O
, O
respectively O
, O
did O
not O
cause O
significant O
losses O
of O
phenolic O
compounds O
, O
and O
thus O
proved O
to O
be O
the O
most O
suitable O
measures O
to O
ensure O
polyphenol O
retention O
. O

Grape O
anthocyanin O
and O
skin O
tannin B
concentration O
increased O
as O
ripening O
progressed O
, O
while O
seed O
tannin B
declined O
. O

In O
the O
corresponding O
wines O
, O
monomeric O
anthocyanin O
and O
wine O
tannin B
concentration O
increased O
with O
harvest O
date O
, O
consistent O
with O
an O
enhanced O
extraction O
of O
skin O
- O
derived O
phenolics O
. O

In O
wines O
, O
there O
was O
an O
observed O
increase O
in O
yeast O
- O
derived O
metabolites O
, O
including O
volatile O
esters O
, O
dimethyl B
sulfide I
, O
glycerol O
and O
mannoproteins O
with O
harvest O
date O
. O

Wine O
volatiles O
which O
were O
significantly O
influenced O
by O
harvest O
date O
were O
isobutyl B
methoxypyrazine I
, O
C O
( O
6 O
) O
alcohols O
and O
hexyl B
acetate I
, O
all O
of O
which O
decreased O
as O
ripening O
progressed O
. O

To O
further O
evaluate O
the O
reliability O
of O
hydrogen O
isotopes O
of O
organic O
molecules O
, O
we O
examined O
the O
isotope O
exchangeability O
in O
fatty O
acids O
within O
phospholipid O
bilayers O
exposed O
to O
D B
( I
2 I
) I
O I
for O
12h O
. O

The O
results O
indicate O
that O
the O
isotope O
ratio O
is O
clearly O
increased O
during O
all O
examines O
( O
e O
. O
g O
. O
, O
93 O
- O
328 O
/ O
1000 O
in O
50 O
% O
D B
( I
2 I
) I
O I
) O
, O
in O
which O
its O
magnitude O
depends O
on O
type O
of O
fatty O
acids O
and O
state O
of O
bilayers O
. O

Sulforaphane O
, O
a O
naturally O
occurring O
cancer O
chemopreventive O
, O
is O
the O
hydrolysis O
product O
of O
glucoraphanin B
, O
the O
main O
glucosinolate B
in O
broccoli O
. O

Thermal O
degradation O
of O
broccoli O
glucoraphanin B
was O
investigated O
in O
addition O
to O
the O
effects O
of O
thermal O
processing O
on O
the O
formation O
of O
sulforaphane O
and O
sulforaphane B
nitrile I
. O

Limited O
thermal O
degradation O
of O
glucoraphanin B
( O
less O
than O
12 O
% O
) O
was O
observed O
when O
broccoli O
was O
placed O
in O
vacuum O
sealed O
bag O
( O
sous O
vide O
) O
and O
cooked O
in O
a O
water O
bath O
at O
100 O
degrees O
C O
for O
8 O
and O
12 O
min O
. O

Secoisolariciresinol B
, O
lariciresinol B
, O
pinoresinol B
, O
7 B
- I
hydroxymatairesinol I
, O
syringaresinol B
, O
isolariciresinol B
, O
secoisolariciresinol B
diglycoside I
, O
lariciresinol B
monoglycoside I
, O
pinoresinol B
mono I
- I
, I
di I
- I
and I
triglycoside I
, O
sesaminol B
, O
sesaminol B
triglycoside I
, O
sesamolinol B
and O
sesamolinol B
diglycoside I
were O
identified O
. O

However O
, O
p O
- O
Bad O
( O
Ser136 B
) O
and O
Bcl O
- O
2 O
were O
increased O
. O

Determination O
of O
tartrazine B
in O
beverage O
samples O
by O
stopped O
- O
flow O
analysis O
and O
three O
- O
way O
multivariate O
calibration O
of O
non O
- O
linear O
kinetic O
- O
spectrophotometric O
data O
. O

The O
performance O
of O
MCR O
- O
ALS O
was O
studied O
in O
the O
modeling O
of O
non O
- O
linear O
kinetic O
- O
spectrophotometric O
data O
acquired O
by O
a O
stopped O
- O
flow O
system O
for O
the O
quantitation O
of O
tartrazine B
in O
the O
presence O
of O
brilliant B
blue I
and I
sunset I
yellow I
FCF I
as O
possible O
interferents O
. O

MCR O
- O
ALS O
was O
the O
only O
strategy O
that O
allowed O
the O
determination O
of O
tartrazine B
in O
test O
samples O
accurately O
. O

Therefore O
, O
it O
was O
applied O
for O
the O
analysis O
of O
tartrazine B
in O
beverage O
samples O
with O
minimum O
sample O
preparation O
and O
short O
analysis O
time O
. O

Based O
on O
the O
recommended O
dietary O
allowance O
of O
iron O
, O
maximum O
germination O
rate O
and O
gamma O
- O
aminobutyric O
acid O
, O
we O
recommend O
the O
brown O
rice O
fortified O
with O
0 O
. O
25 O
g O
/ O
L O
FeSO B
( I
4 I
) I
as O
a O
suitable O
fortification O
level O
to O
use O
in O
germination O
process O
. O

Betulinic O
acid O
( O
BA O
) O
, O
a O
natural O
pentacyclic B
triterpenoid I
, O
was O
isolated O
from O
sour O
jujube O
fruits O
for O
the O
first O
time O
. O

In O
this O
study O
, O
the O
anti O
- O
proliferative O
and O
apoptosis O
mechanisms O
of O
BA B
- I
beta I
- I
CD I
on O
human O
breast O
cancer O
MCF O
- O
7 O
cells O
were O
further O
investigated O
. O

Transglycosylation O
of O
stevioside B
to O
improve O
the O
edulcorant O
quality O
by O
lower O
substitution O
using O
cornstarch O
hydrolyzate O
and O
CGTase O
. O

Stevioside B
is O
an O
abundant O
sweetener O
extracted O
from O
Stevia O
rebaudiana O
leaf O
with O
a O
bitter O
aftertaste O
. O

Enzymatic O
transglycosylation O
of O
stevioside B
is O
a O
solution O
to O
improve O
the O
edulcorant O
quality O
of O
stevioside B
, O
but O
highly O
derivatised O
stevioside B
coming O
with O
high O
conversion O
of O
stevioside B
is O
undesired O
. O

In O
this O
experiment O
, O
the O
transglycosylation O
of O
stevioside B
was O
investigated O
by O
using O
a O
commercial O
cyclodextrin O
glucanotransferase O
and O
cornstarch O
hydrolyzate O
. O

With O
controlled O
parameters O
, O
the O
product O
was O
mainly O
composed O
of O
mono B
- I
and I
di I
- I
glucosylated I
stevioside I
while O
the O
highest O
stevioside B
conversion O
reached O
77 O
. O
11 O
% O
. O

Neither O
kinetic O
nor O
thermodynamic O
factor O
stimulated O
the O
formation O
of O
high O
substituted O
steviosides B
. O

The O
simultaneous O
hydrolysis O
in O
the O
reaction O
might O
inhibit O
the O
yield O
of O
highly O
substituted O
steviosides B
. O

We O
analyzed O
the O
association O
of O
serum O
vitamin O
D O
level O
assessed O
by O
25 B
- I
hydroxyvitamin I
D I
( I
3 I
) I
{ O
25 B
( I
OH I
) I
D I
( I
3 I
) I
} O
with O
nonalcoholic O
fatty O
liver O
disease O
( O
NAFLD O
) O
in O
apparently O
healthy O
men O
. O

We O
performed O
a O
cross O
- O
sectional O
study O
of O
6 O
, O
567 O
Korean O
men O
who O
participated O
in O
a O
health O
screening O
program O
, O
evaluating O
the O
association O
of O
serum O
25 B
( I
OH I
) I
D I
( I
3 I
) I
levels O
with O
the O
risk O
of O
NAFLD O
assessed O
by O
abdominal O
ultrasonogram O
. O

Age O
, O
serum O
calcium O
, O
and O
aspartate O
aminotransferase O
levels O
showed O
weak O
but O
significant O
positive O
correlations O
with O
25 B
( I
OH I
) I
D I
( I
3 I
) I
level O
; O
total O
cholesterol O
, O
triglycerides O
, O
low O
- O
density O
lipoprotein O
cholesterol O
and O
fasting O
insulin O
level O
showed O
weak O
but O
significant O
negative O
correlations O
with O
25 B
( I
OH I
) I
D I
( I
3 I
) I
level O
. O

The O
mean O
25 B
( I
OH I
) I
D I
( I
3 I
) I
level O
was O
significantly O
lower O
in O
participants O
with O
NAFLD O
than O
in O
those O
without O
( O
38 O
. O
7 O
+ O
/ O
- O
9 O
. O
0 O
vs O
. O
39 O
. O
7 O
+ O
/ O
- O
9 O
. O
7 O
nmol O
/ O
L O
, O
p O
< O
0 O
. O
001 O
) O
. O

When O
participants O
were O
divided O
into O
tertiles O
based O
on O
mean O
25 B
( I
OH I
) I
D I
( I
3 I
) I
level O
, O
the O
proportion O
with O
NAFLD O
significantly O
increased O
as O
mean O
25 B
( I
OH I
) I
D I
( I
3 I
) I
level O
decreased O
( O
40 O
. O
0 O
, O
45 O
. O
0 O
and O
45 O
. O
9 O
% O
, O
p O
for O
linear O
trend O
< O
0 O
. O
001 O
) O
. O

Multiple O
logistic O
regression O
analyses O
with O
NAFLD O
as O
the O
dependent O
variable O
showed O
that O
the O
tertiles O
with O
lower O
25 B
( I
OH I
) I
D I
( I
3 I
) I
levels O
had O
a O
significantly O
increased O
risk O
for O
NAFLD O
compared O
with O
the O
highest O
tertile O
, O
even O
after O
adjusting O
for O
body O
mass O
index O
and O
metabolic O
syndrome O
( O
OR O
1 O
. O
247 O
and O
1 O
. O
408 O
vs O
. O
the O
highest O
tertile O
, O
p O
< O
0 O
. O
001 O
) O
. O

Thus O
, O
participants O
with O
higher O
serum O
25 B
( I
OH I
) I
D I
( I
3 I
) I
showed O
a O
significantly O
reduced O
risk O
for O
NAFLD O
compared O
with O
the O
low O
25 B
( I
OH I
) I
D I
( I
3 I
) I
groups O
, O
independent O
of O
obesity O
and O
metabolic O
syndrome O
. O

The O
G O
beta O
gamma O
- O
subunit O
inhibitor O
, O
gallein B
, O
was O
administered O
to O
C57BL O
/ O
6J O
mice O
by O
intraperitoneal O
injection O
before O
morphine O
, O
and O
data O
were O
compared O
with O
mice O
treated O
with O
vehicle O
, O
morphine O
, O
or O
gallein B
alone O
. O

Pretreatment O
with O
gallein B
produced O
a O
dose O
- O
dependent O
potentiation O
of O
morphine O
- O
mediated O
antinociception O
, O
producing O
up O
to O
a O
10 O
- O
fold O
leftward O
shift O
in O
the O
morphine O
dose O
- O
response O
curve O
and O
extending O
the O
duration O
of O
antinociception O
induced O
by O
a O
single O
dose O
of O
morphine O
. O

Gallein B
pretreatment O
also O
prevented O
acute O
antinociceptive O
tolerance O
induced O
by O
morphine O
. O

In O
contrast O
, O
the O
dose O
- O
dependent O
respiratory O
depression O
and O
hyperlocomotion O
induced O
by O
morphine O
were O
not O
potentiated O
by O
gallein B
pretreatment O
. O

Similarly O
, O
gallein B
pretreatment O
did O
not O
potentiate O
morphine O
- O
conditioned O
place O
preference O
responses O
or O
morphine O
- O
induced O
constipation O
, O
as O
measured O
as O
a O
reduction O
in O
excreta O
. O

It O
has O
been O
observed O
that O
the O
administration O
of O
hydroxypropyl O
- O
beta O
- O
cyclodextrin O
( O
HPBCD B
) O
delays O
onset O
of O
clinical O
symptoms O
and O
reduces O
accumulation O
of O
cholesterol O
and O
gangliosides B
within O
neuronal O
cells O
. O

It O
was O
assumed O
that O
HPBCD B
exerts O
its O
action O
by O
readily O
entering O
the O
CNS O
and O
directly O
interacting O
with O
neurones O
and O
other O
brain O
cells O
to O
facilitate O
removal O
of O
stored O
cholesterol O
from O
the O
late O
endosomal O
/ O
lysosomal O
compartment O
. O

We O
use O
two O
well O
established O
techniques O
for O
accurately O
measuring O
brain O
uptake O
of O
solutes O
from O
blood O
and O
show O
that O
there O
is O
no O
significant O
crossing O
of O
HPBCD B
into O
the O
brain O
. O

Neither O
study O
demonstrates O
significant O
, O
time O
- O
dependent O
uptake O
of O
HPBCD B
in O
either O
adult O
or O
neonatal O
mice O
. O

However O
, O
the O
volume O
of O
distribution O
available O
to O
HPBCD B
( O
0 O
. O
113 O
+ O
/ O
- O
0 O
. O
010 O
ml O
/ O
g O
) O
exceeds O
the O
accepted O
values O
for O
plasma O
and O
vascular O
volume O
of O
the O
brain O
. O

We O
propose O
that O
this O
indicates O
cell O
surface O
binding O
of O
HPBCD B
to O
the O
endothelium O
of O
the O
cerebral O
vasculature O
and O
may O
provide O
a O
mechanism O
for O
the O
mobilisation O
and O
clearance O
of O
cholesterol O
from O
the O
CNS O
. O

Thus O
, O
pH O
- O
sensitive O
polyvinylpyrrolidone O
- O
poly O
( O
acrylic O
acid O
) O
( O
PVP O
/ O
PAAc B
) O
nanogels O
prepared O
by O
gamma O
radiation O
- O
induced O
polymerization O
of O
acrylic O
acid O
( O
AAc B
) O
in O
an O
aqueous O
solution O
of O
polyvinylpyrrolidone O
( O
PVP O
) O
as O
a O
template O
polymer O
were O
used O
to O
encapsulate O
pilocarpine O
. O

The O
PVP O
/ O
PAAc B
nanogel O
particles O
were O
characterized O
by O
dynamic O
light O
scattering O
( O
DLS O
) O
, O
zeta O
potential O
, O
Fourier O
transform O
infrared O
spectroscopy O
( O
FTIR O
) O
, O
and O
transmission O
electron O
microscopy O
( O
TEM O
) O
, O
and O
their O
size O
can O
be O
controlled O
by O
the O
feed O
composition O
and O
concentration O
as O
well O
as O
the O
irradiation O
dose O
. O

Pilocarpine O
was O
loaded O
into O
the O
nanogel O
particles O
through O
electrostatic O
interactions O
where O
the O
AAc B
- O
rich O
nanogels O
exhibited O
the O
highest O
loading O
efficiency O
. O

The O
in O
vitro O
release O
study O
conducted O
in O
simulated O
tear O
fluid O
showed O
a O
relatively O
long O
sustained O
release O
of O
pilocarpine O
from O
the O
prepared O
PVP O
/ O
PAAc B
nanogel O
particles O
if O
compared O
with O
pilocarpine O
in O
solution O
. O

Influence O
of O
the O
bifunctional O
chelator O
on O
the O
pharmacokinetic O
properties O
of O
99mTc B
( I
CO I
) I
3 I
- O
labeled O
cyclic B
alpha I
- I
melanocyte I
stimulating I
hormone I
analog O
. O

Aiming O
at O
the O
design O
of O
specific O
melanocortin O
- O
1 O
receptor O
( O
MC1R O
) O
targeted O
imaging O
probes O
, O
we O
report O
on O
the O
effect O
of O
different O
azolyl B
- O
ring O
substitution O
patterns O
( O
carboxylate O
at O
the O
4 O
- O
position O
and O
/ O
or O
methyl O
groups O
at O
the O
3 O
, O
5 O
positions O
) O
of O
pyrazolyl B
- I
diamine I
bifunctional O
chelators O
( O
Pz O
( O
2 O
) O
- O
Pz O
( O
4 O
) O
) O
on O
the O
pharmacokinetic O
profile O
of O
the O
( O
99m O
) O
Tc O
( O
CO O
) O
3 O
- O
labeled O
lactam O
bridge O
- O
cyclized O
alpha O
- O

melanocyte O
stimulating O
hormone O
derivative O
, O
beta B
AlaNleCycMSH I
( I
hex I
) I
. O

Three O
pyrazolyl B
- I
diamine I
- O
containing O
chelators O
were O
conjugated O
to O
beta B
AlaNleCycMSHhex I
, O
with O
the O
resulting O
peptide O
conjugates O
displaying O
subnanomolar O
MC1R O
binding O
affinity O
. O

The O
introduction O
of O
a O
carboxylate O
group O
in O
the O
azolyl B
- O
ring O
leads O
to O
a O
remarkable O
reduction O
of O
the O
kidney O
( O
> O
89 O
% O
) O
and O
liver O
( O
> O
91 O
% O
) O
accumulation O
for O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- I
Pz I
( I
3 I
) I
- I
beta I
AlaNleCycMSH I
( I
hex I
) I
and O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- I
Pz I
( I
4 I
) I
- I
beta I
AlaNleCycMSH I
( I
hex I
) I
when O
compared O
to O
the O
radiopeptide O
( O
99m O
) O
Tc O
( O
CO O
) O
3 O
- O
Pz O
( O
1 O
) O

The O
good O
tumor O
uptake O
and O
favorable O
tumor O
- O
to O
- O
nontarget O
- O
organs O
ratios O
of O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- I
Pz I
( I
3 I
) I
- I
beta I
AlaNleCycMSH I
( I
hex I
) I
and O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- I
Pz I
( I
4 I
) I
- I
beta I
AlaNleCycMSH I
( I
hex I
) I
highlights O
the O
potential O
of O
both O
compounds O
as O
melanoma O
imaging O
agents O
. O

Vegfrecine B
, O
an O
Inhibitor O
of O
VEGF O
Receptor O
Tyrosine O
Kinases O
Isolated O
from O
the O
Culture O
Broth O
of O
Streptomyces O
sp O
. O

A O
new O
inhibitor O
of O
VEGF O
receptor O
tyrosine O
kinases O
, O
vegfrecine B
( O
1 O
) O
, O
was O
isolated O
from O
the O
culture O
broth O
of O
Streptomyces O
sp O
. O

Dimethylarsinic O
acid O
( O
DMAs B
( I
V I
) I
) O
, O
the O
major O
urinary O
metabolite O
of O
inorganic O
arsenic O
, O
is O
weakly O
cytotoxic O
, O
whereas O
its O
reduced O
form O
, O
dimethylarsinous O
acid O
( O
DMAs B
( I
III I
) I
) O
, O
is O
highly O
toxic O
. O

Although O
glutathione O
S O
- O
transferase O
omega O
1 O
( O
GSTO1 O
) O
and O
arsenic O
methyltransferase O
have O
been O
shown O
or O
thought O
to O
catalyze O
DMAs B
( I
V I
) I
reduction O
, O
their O
role O
in O
DMAs B
( I
V I
) I
reduction O
in O
vivo O
, O
or O
in O
cell O
extracts O
is O
uncertain O
. O

Therefore O
, O
the O
reduction O
of O
DMAs B
( I
V I
) I
to O
DMAs B
( I
III I
) I
in O
rats O
and O
in O
rat O
liver O
cytosol O
was O
studied O
to O
better O
understand O
its O
mechanism O
. O

To O
assess O
DMAs B
( I
V I
) I
reduction O
in O
rats O
, O
a O
novel O
procedure O
was O
devised O
based O
on O
following O
the O
accumulation O
of O
red O
blood O
cell O
( O
RBC O
) O
- O
bound O
dimethylarsenic B
( O
DMAs B
) O
, O
which O
represents O
DMAs B
( I
III I
) I
, O
in O
the O
blood O
of O
DMAs B
( I
V I
) I
- O
injected O
anesthetized O
rats O
. O

These O
studies O
indicated O
that O
rats O
reduced O
DMAs B
( I
V I
) I
to O
DMAs B
( I
III I
) I
to O
a O
significant O
extent O
, O
as O
in O
90 O
min O
31 O
% O
of O
the O
injected O
50 O
mu O
mol O
/ O
kg O
DMAs B
( I
V I
) I
dose O
was O
converted O
to O
DMAs B
( I
III I
) I
that O
was O
sequestered O
by O
the O
circulating O
erythrocytes O
. O

Pretreatment O
of O
rats O
with O
glutathione O
( O
GSH O
) O
depletors O
( O
phorone B
or O
BSO O
) O
delayed O
the O
elimination O
of O
DMAs B
( I
V I
) I
and O
the O
accumulation O
of O
RBC O
- O
bound O
DMAs B
, O
whereas O
the O
indirect O
methyltransferase O
inhibitor O
periodate B
- O
oxidized O
adenosine O
was O
without O
effect O
. O

Assessment O
of O
DMAs B
( I
V I
) I
- O
reducing O
activity O
of O
rat O
liver O
cytosol O
revealed O
that O
reduction O
of O
DMAs B
( I
V I
) I
required O
cytosolic O
protein O
and O
GSH O
and O
was O
inhibited O
by O
thiol O
reagents O
, O
GSSG O
and O
dehydroascorbate B
. O

Although O
thioredoxin O
reductase O
( O
TRR O
) O
inhibitors O
( O
aurothioglucose B
and O
Sb B
( I
III I
) I
) O
inhibited O
cytosolic O
DMAs B
( I
V I
) I
reduction O
, O
recombinant O
rat O
TRR O
plus O
NADPH O
, O
alone O
or O
when O
added O
to O
the O
cytosol O
, O
failed O
to O
support O
DMAs B
( I
V I
) I
reduction O
. O

In O
summary O
, O
reduction O
of O
DMAs B
( I
V I
) I
to O
the O
highly O
toxic O
DMAs B
( I
III I
) I
in O
rats O
and O
rat O
liver O
cytosol O
is O
a O
GSH O
- O
dependent O
enzymatic O
process O
, O
yet O
its O
mechanism O
remains O
uncertain O
. O

Discovery O
of O
novel O
7 B
- I
membered I
cyclic I
amide I
derivatives O
that O
inhibit O
11beta B
- I
hydroxysteroid I
dehydrogenase O
type O
1 O
. O

A O
series O
of O
novel O
5 B
- I
trans I
- I
hydroxyadamantan I
- I
2 I
- I
yl I
- I
5 I
, I
6 I
, I
7 I
, I
8 I
- I
tetrahydropyrazolo I
[ I
4 I
, I
3 I
- I
c I
] I
azepin I
- I
4 I
( I
1H I
) I
- I
ones I
that O
inhibit O
11beta B
- I
hydroxysteroid I
dehydrogenase O
type O
1 O
are O
described O
. O

We O
discovered O
these O
7 B
- I
membered I
cyclic I
amide I
derivatives O
by O
introducing O
a O
distinctive O
linker O
through O
pharmacophore O
analysis O
of O
known O
ligands O
included O
in O
X O
- O
ray O
co O
- O
crystal O
structures O
. O

Chemical O
tagging O
of O
a O
drug O
target O
using O
5 B
- I
sulfonyl I
tetrazole I
. O

Here O
we O
report O
that O
receptor O
proteins O
can O
be O
chemically O
tagged O
using O
a O
5 B
- I
sulfonyl I
tetrazole I
probe O
. O

5 B
- I
Sulfonyl I
tetrazole I
easily O
accepted O
nucleophilic O
attack O
of O
thiol O
groups O
, O
while O
5 B
- I
sulfinyl I
tetrazole I
did O
not O
. O

Cyclosporine O
A O
, O
an O
immunosuppressant O
produced O
by O
a O
microbe O
, O
was O
derivatized O
to O
possess O
5 B
- I
sulfonyl I
tetrazole I
and O
a O
tag O
group O
, O
which O
enabled O
chemical O
tagging O
of O
cyclophilin O
A O
, O
the O
cellular O
receptor O
of O
cyclosporine O
A O
. O

Cyclosporine O
A O
derivative O
possessing O
5 B
- I
sulfinyl I
tetrazole I
could O
not O
tag O
cyclophilin O
A O
. O

Inorganic O
anions O
such O
as O
cyanate B
, O
cyanide O
, O
hydrogen O
sulfide O
, O
hydrogen B
sulfite I
, O
and O
trithiocarbonate B
were O
effective O
VchCA O
inhibitors O
with O
inhibition O
constants O
in O
the O
range O
of O
33 O
- O
88 O
mu O
M O
. O

Other O
effective O
inhibitors O
were O
diethyldithiocarbama B
, O
sulfamide B
, O
sulfamate B
, O
phenylboronic B
acid I
and O
phenylarsonic B
acid I
, O
with O
KIs O
of O
7 O
- O
43 O
mu O
M O
. O

Halides B
( O
bromide O
, O
iodide O
) O
, O
bicarbonate O
and O
carbonate O
were O
much O
less O
effective O
VchCA O
inhibitors O
, O
with O
KIs O
in O
the O
range O
of O
4 O
. O
64 O
- O
28 O
. O
0mM O
. O

Synthesis O
of O
tetrazole O
analogues O
of O
phosphonohydroxamic B
acids I
: O
an O
attempt O
to O
improve O
the O
inhibitory O
activity O
against O
the O
DXR O
. O

This O
work O
is O
focused O
on O
the O
design O
of O
new O
antimicrobial O
drugs O
and O
on O
the O
development O
of O
lipophilic O
inhibitors O
of O
the O
DXR O
, O
the O
second O
enzyme O
of O
the O
MEP O
pathway O
for O
the O
biosynthesis O
of O
isoprene B
units O
in O
most O
bacteria O
, O
by O
replacing O
the O
phosphonate O
group O
of O
fosmidomycin B
derivatives O
by O
a O
tetrazoyl B
moiety O
capable O
of O
multiple O
hydrogen O
bonding O
. O

The O
N O
- O
and O
C O
- O
substituted O
tetrazole O
analogues O
of O
phosphonohydroxamate B
inhibitors O
were O
synthesized O
and O
tested O
on O
the O
DXR O
of O
Escherichia O
coli O
. O

3D O
- O
QSAR O
and O
docking O
studies O
of O
pentacycloundecylami B
at O
the O
sigma O
- O
1 O
( O
sigma O
1 O
) O
receptor O
. O

Pentacycloundecylami B
( O
PCU B
) O
derived O
compounds O
have O
been O
shown O
to O
be O
promising O
lead O
structures O
for O
the O
development O
of O
novel O
drug O
candidates O
aimed O
at O
a O
variety O
of O
neurodegenerative O
and O
psychiatric O
diseases O
. O

Here O
we O
show O
for O
the O
first O
time O
a O
3D O
quantitative O
structure O
- O
activity O
relationship O
( O
3D O
- O
QSAR O
) O
for O
a O
series O
of O
aza B
- I
PCU I
- O
derived O
compounds O
with O
activity O
at O
the O
sigma O
- O
1 O
( O
sigma O
1 O
) O
receptor O
. O

We O
also O
describe O
here O
the O
docking O
of O
the O
PCU B
- O
derived O
compounds O
into O
a O
homology O
model O
of O
the O
sigma O
- O
1 O
( O
sigma O
1 O
) O
receptor O
, O
which O
was O
developed O
to O
gain O
insight O
into O
binding O
of O
these O
cage O
compounds O
to O
the O
receptor O
. O

Based O
on O
docking O
studies O
we O
evaluated O
in O
a O
[ B
( I
3 I
) I
H I
] I
pentazocine I
binding O
assay O
an O
oxa B
- I
PCU I
, O
NGP1 B
- I
01 I
( O
IC50 O
= O
1 O
. O
78 O
mu O
M O
) O
and O
its O
phenethyl B
derivative O
( O
IC50 O
= O
1 O
. O
54 O
mu O
M O
) O
. O

Investigation O
of O
antibacterial O
mode O
of O
action O
for O
traditional O
and O
amphiphilic O
aminoglycosides B
. O

Aminoglycoside B
represents O
a O
class O
of O
versatile O
and O
broad O
spectrum O
antibacterial O
agents O
. O

In O
an O
effort O
to O
revive O
the O
antibacterial O
activity O
against O
aminoglycoside B
resistant O
bacteria O
, O
our O
laboratory O
has O
developed O
two O
new O
classes O
of O
aminoglycoside B
, O
pyranmycin B
and O
amphiphilic O
neomycin B
( O
NEOF004 B
) O
. O

The O
former O
resembles O
the O
traditional O
aminoglycoside B
, O
neomycin B
. O

The O
latter O
, O
albeit O
derived O
from O
neomycin B
, O
appears O
to O
exert O
antibacterial O
action O
via O
a O
different O
mode O
of O
action O
. O

In O
order O
to O
discern O
that O
these O
aminoglycoside B
derivatives O
have O
distinct O
antibacterial O
mode O
of O
action O
, O
RNA O
- O
binding O
affinity O
and O
fluorogenic O
dye O
were O
employed O
. O

These O
studies O
, O
together O
with O
our O
previous O
investigation O
, O
confirm O
that O
pyranmycin O
exhibit O
the O
traditional O
antibacterial O
mode O
of O
action O
of O
aminoglycosides B
by O
binding O
toward O
the O
bacterial O
rRNA O
. O

On O
the O
other O
hand O
, O
the O
amphiphilic O
neomycin B
, O
NEOF004 B
disrupts O
the O
bacterial O
cell O
wall O
. O

In O
a O
broader O
perspective O
, O
it O
verifies O
that O
structurally O
modified O
neomycin B
can O
exert O
different O
antibacterial O
mode O
of O
action O
leading O
to O
the O
revival O
of O
activity O
against O
aminoglycoside B
resistant O
bacteria O
. O

In O
order O
to O
develop O
potent O
and O
selective O
focal O
adhesion O
kinase O
( O
FAK O
) O
inhibitors O
, O
synthetic O
studies O
on O
pyrazolo B
[ I
4 I
, I
3 I
- I
c I
] I
[ I
2 I
, I
1 I
] I
benzothiazines I
targeted O
for O
the O
FAK O
allosteric O
site O
were O
carried O
out O
. O

Based O
on O
the O
X O
- O
ray O
structural O
analysis O
of O
the O
co O
- O
crystal O
of O
the O
lead O
compound O
, O
8 B
- I
( I
4 I
- I
ethylphenyl I
) I
- I
5 I
- I
methyl I
- I
1 I
, I
5 I
- I
dihydropyrazolo I
[ I
4 I
, I
3 I
- I
c I
] I
[ I
2 I
, I
1 I
] I
benzothiazine I
4 I
, I
4 I
- I
dioxide I
1 O
with O
FAK O
, O
we O
designed O
and O
prepared O
1 B
, I
5 I
- I
dimethyl I
- I
1 I
, I
5 I
- I
dihydropyrazolo I
[ I
4 I
, I
3 I
- I
c I
] I
[ I
2 I
, I
1 I
] I
benzothiazin I
derivatives O
which O
selectively O
inhibited O
kinase O
activity O
of O
FAK O
without O
affecting O
seven O

The O
optimized O
compound O
, O
N B
- I
( I
4 I
- I
tert I
- I
butylbenzyl I
) I
- I
1 I
, I
5 I
- I
dimethyl I
- I
1 I
, I
5 I
- I
dihydropyrazolo I
[ I
4 I
, I
3 I
- I
c I
] I
[ I
2 I
, I
1 I
] I
benzothiazin I
- I
8 I
- I
amine I
4 I
, I
4 I
- I
dioxide I
30 O
possessed O
significant O
FAK O
kinase O
inhibitory O
activities O
both O
in O
cell O
- O
free O
( O
IC50 O
= O
0 O
. O
64 O
mu O
M O
) O
and O
in O
cellular O
assays O
( O
IC50 O
= O
7 O
. O
1 O
mu O
M O
) O
. O

Stability O
of O
black O
cohosh O
triterpene B
glycosides I
and O
polyphenols O
: O
Potential O
clinical O
relevance O
. O

Analytical O
results O
showed O
that O
the O
major O
constituents O
, O
both O
triterpene B
glycosides I
and O
polyphenols O
, O
were O
stable O
over O
the O
3 O
- O
year O
period O
of O
testing O
. O

Metabolism O
of O
profenofos B
to O
4 B
- I
bromo I
- I
2 I
- I
chlorophenol I
, O
a O
specific O
and O
sensitive O
exposure O
biomarker O
. O

Profenofos B
is O
a O
direct O
acting O
phosphorothioate B
organophosphorus O
( O
OP O
) O
pesticide O
capable O
of O
inhibiting O
beta O
- O
esterases O
such O
as O
acetylcholinesterase O
, O
butyrylcholinesteras O
, O
and O
carboxylesterase O
. O

Profenofos B
is O
known O
to O
be O
detoxified O
to O
the O
biologically O
inactive O
metabolite O
, O
4 B
- I
bromo I
- I
2 I
- I
chlorophenol I
( O
BCP B
) O
; O
however O
, O
limited O
data O
are O
available O
regarding O
the O
use O
of O
urinary O
BCP B
as O
an O
exposure O
biomarker O
in O
humans O
. O

A O
pilot O
study O
conducted O
in O
Egyptian O
agriculture O
workers O
, O
demonstrated O
that O
urinary O
BCP B
levels O
prior O
to O
application O
( O
3 O
. O
3 O
- O
30 O
. O
0 O
mu O
g O
/ O
g O
creatinine O
) O
were O
elevated O
to O
34 O
. O
5 O
- O
3566 O
mu O
g O
/ O
g O
creatinine O
during O
the O
time O
workers O
were O
applying O
profenofos B
to O
cotton O
fields O
. O

Subsequently O
, O
the O
in O
vitro O
enzymatic O
formation O
of O
BCP B
was O
examined O
using O
pooled O
human O
liver O
microsomes O
and O
recombinant O
human O
cytochrome O
P O
- O
450s O
( O
CYPs O
) O
incubated O
with O
profenofos B
. O

Of O
the O
nine O
human O
CYPs O
studied O
, O
only O
CYPs O
3A4 O
, O
2B6 O
, O
and O
2C19 O
were O
able O
to O
metabolize O
profenofos B
to O
BCP B
. O

The O
Vmax O
for O
BCP B
formation O
was O
47 O
. O
9 O
, O
25 O
. O
1 O
, O
and O
19 O
. O
2nmol O
/ O
min O
/ O
nmol O
CYP O
for O
CYP2B6 O
, O
2C19 O
, O
and O
3A4 O
, O
respectively O
. O

Intrinsic O
clearance O
( O
Vmax O
/ O
Km O
) O
values O
of O
48 O
. O
8 O
, O
46 O
. O
9 O
, O
and O
1 O
. O
02ml O
/ O
min O
/ O
nmol O
CYP O
2C19 O
, O
2B6 O
, O
and O
3A4 O
, O
respectively O
, O
indicate O
that O
CYP2C19 O
and O
CYP2B6 O
are O
primarily O
responsible O
for O
the O
detoxification O
of O
profenofos B
. O

These O
findings O
support O
the O
use O
of O
urinary O
BCP B
as O
a O
biomarker O
of O
exposure O
to O
profenofos B
in O
humans O
and O
suggest O
polymorphisms O
in O
CYP O
2C19 O
and O
CYP O
2B6 O
as O
potential O
biomarkers O
of O
susceptibility O
. O

In O
this O
study O
, O
we O
present O
the O
signaling O
mechanisms O
of O
a O
newly O
developed O
LMW O
dihydropyridine O
agonist O
of O
the O
FSHR O
, O
Org B
214444 I
- I
0 I
. O

Org B
214444 I
- I
0 I
is O
shown O
to O
be O
a O
stereoselective O
, O
nanomolar O
potent O
FSHR O
agonist O
and O
selective O
over O
the O
structurally O
related O
LHR O
and O
TSHR O
. O

Org B
214444 I
- I
0 I
is O
an O
allosteric O
agonist O
interacting O
with O
the O
transmembrane O
region O
of O
the O
FSHR O
. O

When O
co O
- O
incubated O
with O
FSH O
, O
Org B
214444 I
- I
0 I
augments O
FSH O
' O
s O
potency O
in O
binding O
( O
6 O
. O
5 O
- O
fold O
) O
and O
adenylyl O
cyclase O
/ O
cAMP O
activation O
( O
3 O
. O
5 O
- O
fold O
) O
in O
a O
concentration O
- O
dependent O
manner O
. O

Like O
FSH O
, O
Org B
214444 I
- I
0 I
induces O
FSHR O
internalization O
and O
is O
only O
marginally O
effective O
in O
stimulating O
phospholipase O
C O
. O

Moreover O
, O
Org B
214444 I
- I
0 I
stimulates O
cAMP O
and O
estradiol O
production O
in O
human O
granulosa O
cells O
in O
culture O
and O
supports O
the O
follicular O
phase O
in O
mature O
female O
rats O
. O

We O
conclude O
that O
Org B
214444 I
- I
0 I
is O
a O
bonafide O
FSHR O
agonist O
. O

The O
principle O
of O
detection O
is O
the O
preferential O
binding O
of O
the O
oligodeoxyribonucleo O
BODIPY O
- O
TMR B
- O
5 O
' O
- O
TTCTTCTTCT O
- O
3 O
' O
to O
relaxed O
double O
- O
stranded O
plasmid O
containing O
the O
triplex O
forming O
sequence O
( O
TTC O
) O
9 O
versus O
the O
supercoiled O
plasmid O
. O

Binding O
of O
the O
oligonucleotide O
to O
the O
plasmid O
increases O
the O
fluorescence O
anisotropy O
of O
the O
BODIPY O
- O
TMR B
label O
. O

Design O
and O
synthesis O
of O
bicyclic B
pyrazinone I
and I
pyrimidinone I
amides I
as O
potent O
TF O
- O
FVIIa O
inhibitors O
. O

Bicyclic B
pyrazinone I
and I
pyrimidinone I
amides I
were O
designed O
and O
synthesized O
as O
potent O
TF O
- O
FVIIa O
inhibitors O
. O

Efficient O
synthesis O
of O
anacardic B
acid I
analogues O
and O
their O
antibacterial O
activities O
. O

Anacardic B
acid I
derivatives O
exhibit O
a O
broad O
range O
of O
biological O
activities O
. O

In O
this O
report O
, O
an O
efficient O
method O
for O
the O
synthesis O
of O
anacardic B
acid I
derivatives O
was O
explored O
, O
and O
a O
small O
set O
of O
salicylic O
acid O
variants O
synthesised O
retaining O
a O
constant O
hydrophobic O
element O
( O
a O
naphthyl O
tail O
) O
. O

The O
naphthyl O
side O
chain O
was O
introduced O
via O
Wittig O
reaction O
and O
the O
aldehyde O
installed O
using O
directed O
ortho O
- O
metalation O
reaction O
of O
the O
substituted O
o B
- I
anisic I
acids I
. O

The O
failure O
of O
ortho O
- O
metalation O
using O
unprotected O
carboxylic O
acid O
group O
compelled O
us O
to O
use O
directed O
ortho O
- O
metalation O
in O
which O
a O
tertiary B
amide I
was O
used O
as O
a O
strong O
ortho O
- O
directing O
group O
. O

In O
the O
initial O
route O
, O
tertiary B
amide I
cleavage O
during O
final O
step O
was O
challenging O
, O
but O
cleaving O
the O
tertiary B
amide I
before O
Wittig O
reaction O
was O
beneficial O
. O

The O
Wittig O
reaction O
with O
protected O
carboxylic O
group O
( O
methyl B
ester I
) O
resulted O
in O
side O
- O
products O
whereas O
using O
sodium O
salt O
resulted O
in O
higher O
yields O
. O

Although O
substitution O
on O
the O
salicylic B
head O
group O
enhanced O
antibacterial O
activities O
they O
also O
enhanced O
cytotoxicity O
. O

Substituted O
piperidinyl B
glycinyl I
2 I
- I
cyano I
- I
4 I
, I
5 I
- I
methano I
pyrrolidines I
as O
potent O
and O
stable O
dipeptidyl O
peptidase O
IV O
inhibitors O
. O

Synthesis O
and O
structure O
- O
activity O
relationship O
of O
a O
series O
of O
substituted O
piperidinyl B
glycine I
2 I
- I
cyano I
- I
4 I
, I
5 I
- I
methano I
pyrroline I
DPP O
- O
IV O
inhibitors O
are O
described O
. O

Improvement O
of O
the O
inhibitory O
activity O
and O
chemical O
stability O
of O
this O
series O
of O
compounds O
was O
respectively O
achieved O
by O
the O
introduction O
of O
bulky O
groups O
at O
the O
4 O
- O
position O
and O
1 O
- O
position O
of O
the O
piperidinyl B
glycine I
, O
leading O
to O
a O
series O
of O
potent O
and O
stable O
DPP O
- O
IV O
inhibitors O
. O

Human O
serum O
albumin O
- O
based O
design O
of O
a O
diflunisal B
prodrug O
. O

The O
cyclooxygenase O
- O
2 O
inhibitor O
, O
diflunisal B
, O
is O
used O
in O
the O
clinic O
for O
its O
anti O
- O
inflammatory O
activity O
. O

About O
99 O
% O
of O
a O
dose O
of O
diflunisal B
is O
unavailable O
for O
reaction O
with O
the O
target O
enzyme O
, O
because O
diflunisal B
strongly O
binds O
to O
human O
serum O
albumin O
( O
HSA O
) O
. O

To O
reduce O
the O
binding O
affinity O
of O
diflunisal B
to O
albumin O
, O
we O
designed O
and O
synthesized O
the O
prodrug O
acetyldiflunisal B
. O

The O
crystal O
structure O
of O
HSA O
complexed O
with O
fatty O
acid O
and O
acetyldiflunisal B
revealed O
that O
acetyldiflunisal B
binds O
to O
the O
IIA O
subdomain O
and O
that O
upon O
binding O
, O
it O
acetylates O
lysine O
199 O
. O

Mass O
spectrometry O
confirmed O
that O
acetyldiflunisal B
acetylates O
Lys199 B
. O

The O
acetylated O
albumin O
had O
twofold O
weaker O
binding O
affinity O
for O
diflunisal B
as O
demonstrated O
by O
fluorescence O
quenching O
. O

Reduced O
binding O
affinity O
means O
that O
diflunisal B
is O
more O
easily O
released O
from O
acetylated O
albumin O
into O
the O
circulation O
. O

Therefore O
, O
lower O
doses O
of O
acetyldiflunisal B
compared O
to O
diflunisal B
will O
be O
required O
. O

Taken O
together O
, O
our O
results O
not O
only O
provide O
a O
template O
for O
design O
of O
HSA O
- O
based O
prodrugs O
, O
but O
also O
pave O
the O
way O
toward O
more O
effective O
use O
of O
diflunisal B
in O
the O
clinic O
. O

Narirutin B
fraction O
from O
citrus O
peels O
attenuates O
alcoholic O
liver O
disease O
in O
mice O
. O

This O
study O
aimed O
to O
demonstrate O
protective O
activities O
of O
the O
narirutin B
fraction O
from O
peels O
of O
Citrus O
unshiu O
against O
ethanol O
- O
induced O
hepatic O
damage O
through O
an O
animal O
study O
. O

Citrus O
narirutin B
fraction O
( O
CNF O
) O
, O
contained O
75 O
% O
of O
narirutin B
, O
was O
obtained O
by O
an O
ultra O
- O
sonicated O
extraction O
and O
further O
purification O
. O

Mutagenicity O
of O
the O
cysteine O
S O
- O
conjugate O
sulfoxides B
of O
trichloroethylene B
and O
tetrachloroethylene B
in O
the O
Ames O
test O
. O

The O
nephrotoxicity O
and O
nephrocarcinogenicit O
of O
trichloroethylene B
( O
TCE B
) O
and O
tetrachloroethylene B
( O
PCE B
) O
are O
believed O
to O
be O
mediated O
primarily O
through O
the O
cysteine O
S O
- O
conjugate O
beta O
- O
lyase O
- O
dependent O
bioactivation O
of O
the O
corresponding O
cysteine O
S O
- O
conjugate O
metabolites O
S B
- I
( I
1 I
, I
2 I
- I
dichlorovinyl I
) I
- I
l I
- I
cysteine I
( O
DCVC B
) O
and O
S O
- O
( O
1 O
, O
2 O
, O
2 O
- O
trichlorovinyl O
) O
- O
l O
- O

cysteine O
( O
TCVC B
) O
, O
respectively O
. O

DCVC B
and O
TCVC B
have O
previously O
been O
demonstrated O
to O
be O
mutagenic O
by O
the O
Ames O
Salmonella O
mutagenicity O
assay O
, O
and O
reduction O
in O
mutagenicity O
was O
observed O
upon O
treatment O
with O
the O
beta O
- O
lyase O
inhibitor O
aminooxyacetic B
acid I
( O
AOAA B
) O
. O

Because O
DCVC B
and O
TCVC B
can O
also O
be O
bioactivated O
through O
sulfoxidation O
to O
yield O
the O
potent O
nephrotoxicants O
S B
- I
( I
1 I
, I
2 I
- I
dichlorovinyl I
) I
- I
l I
- I
cysteine I
sulfoxide I
( O
DCVCS B
) O
and O
S B
- I
( I
1 I
, I
2 I
, I
2 I
- I
trichlorovinyl I
) I
- I
l I
- I
cysteine I
sulfoxide I
( O
TCVCS B
) O
, O
respectively O
, O
the O
mutagenic O
potential O
of O
these O
two O
sulfoxides B
was O
investigated O
using O
the O
Ames O
Salmonella O
typhimurium O
TA100 O
mutagenicity O
assay O

The O
results O
show O
both O
DCVCS B
and O
TCVCS B
were O
mutagenic O
, O
and O
TCVCS B
exhibited O
3 O
- O
fold O
higher O
mutagenicity O
than O
DCVCS B
. O

However O
, O
DCVCS B
and O
TCVCS B
mutagenic O
activity O
was O
approximately O
700 O
- O
fold O
and O
30 O
- O
fold O
lower O
than O
DCVC B
and O
TCVC B
, O
respectively O
. O

DCVC B
and O
DCVCS B
appeared O
to O
induce O
toxicity O
in O
TA100 O
, O
as O
evidenced O
by O
increased O
microcolony O
formation O
and O
decreased O
mutant O
frequency O
above O
threshold O
concentrations O
. O

TCVC B
and O
TCVCS B
were O
not O
toxic O
in O
TA100 O
. O

The O
toxic O
effects O
of O
DCVC B
limited O
the O
sensitivity O
of O
TA100 O
to O
DCVC B
mutagenic O
effects O
and O
rendered O
it O
difficult O
to O
investigate O
the O
effects O
of O
AOAA B
on O
DCVC B
mutagenic O
activity O
. O

Collectively O
, O
these O
results O
suggest O
that O
DCVCS B
and O
TCVCS B
exerted O
a O
definite O
but O
weak O
mutagenicity O
in O
the O
TA100 O
strain O
. O

Therefore O
, O
despite O
their O
potent O
nephrotoxicity O
, O
DCVCS B
and O
TCVCS B
are O
not O
likely O
to O
play O
a O
major O
role O
in O
DCVC B
or O
TCVC B
mutagenicity O
in O
this O
strain O
. O

First O
synthesis O
and O
biological O
evaluation O
of O
indeno B
[ I
2 I
, I
1 I
- I
e I
] I
pyrazolo I
[ I
3 I
, I
4 I
- I
b I
] I
pyrazin I
- I
5 I
- I
one I
and O
related O
derivatives O
. O

The O
synthesis O
of O
indeno B
[ I
2 I
, I
1 I
- I
e I
] I
pyrazolo I
[ I
3 I
, I
4 I
- I
b I
] I
pyrazin I
- I
5 I
- I
one I
was O
achieved O
by O
intramolecular O
Friedel O
- O
Crafts O
reaction O
of O
the O
acid B
chloride I
3 B
- I
methyl I
- I
1 I
, I
6 I
- I
diphenyl I
- I
1H I
- I
pyrazolo I
[ I
3 I
, I
4 I
- I
b I
] I
pyrazine I
- I
5 I
- I
carboxylic I
acid I
chloride I
( O
4 O
) O
using O
AlCl3 O
in O
boiling O
CS2 O
. O

Compound O
4 O
proved O
to O
be O
a O
versatile O
compound O
for O
the O
synthesis O
of O
several O
Indenopyrazolopyrazi B
derivatives O
. O

At O
high O
food O
rations O
effects O
were O
only O
observed O
for O
one O
of O
the O
nano O
- O
TiO2 O
, O
P B
- I
25 I
, O
at O
high O
exposure O
levels O
( O
10 O
mg O
/ O
l O
) O
under O
both O
semi O
- O
static O
and O
particle O
re O
- O
suspension O
conditions O
, O
which O
suggest O
that O
P B
- I
25 I
effects O
were O
mediated O
by O
clogging O
the O
gut O
and O
hence O
diminishing O
food O
acquisition O
. O

By O
contrast O
, O
head O
twitches O
induced O
by O
treatment O
with O
the O
5 O
- O
HT O
( O
2A O
/ O
2C O
) O
agonist O
( B
+ I
/ I
- I
) I
- I
2 I
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodophenyl I
- I
2 I
- I
aminopropane I
( O
DOI O
) O
were O
similar O
in O
mice O
of O
all O
three O
DAT O
genotypes O
. O

The O
present O
study O
addresses O
the O
bioaccumulation O
behavior O
of O
cadmium B
selenide I
quantum O
dots O
by O
Eisenia O
andrei O
earthworms O
in O
a O
terrestrial O
environment O
. O

Results O
were O
compared O
with O
those O
from O
earthworms O
exposed O
to O
cadmium B
nitrate I
and O
selenious B
acid I
, O
as O
positive O
controls O
, O
and O
those O
exposed O
in O
untreated O
soil O
( O
negative O
control O
) O
. O

In O
contrast O
to O
pristine O
zinc O
phthalocyanine O
( O
1 O
) O
, O
zinc O
phthalocyanine O
based O
oPPV B
- O
oligomers O
( O
2 O
- O
4 O
) O
of O
different O
chain O
lengths O
interact O
tightly O
and O
reversibly O
with O
graphite O
, O
affording O
stable O
and O
finely O
dispersed O
suspensions O
of O
mono O
- O
to O
few O
- O
layer O
graphene O
- O
nanographene O
( O
NG O
) O
- O
that O
are O
photoactive O
. O

In O
NG O
/ O
2 O
, O
NG O
/ O
3 O
, O
and O
NG O
/ O
4 O
hybrids O
, O
strong O
electronic O
coupling O
between O
the O
individual O
components O
gives O
rise O
to O
charge O
transfer O
from O
the O
photoexcited O
zinc B
phthalocyanines I
to O
NG O
to O
form O
hundreds O
of O
picoseconds O
lived O
charge O
transfer O
states O
. O

Chemically O
converted O
graphene O
aerogels O
with O
ultralight O
density O
and O
high O
compressibility O
are O
prepared O
by O
diamine B
- O
mediated O
functionalization O
and O
assembly O
, O
followed O
by O
microwave O
irradiation O
. O

We O
found O
it O
rich O
in O
Aloe O
- O
emodin O
, O
a O
hydroxylanthraquinon B
with O
known O
antitumoral O
activity O
and O
in O
several O
compounds O
with O
anti O
- O
oxidant O
properties O
. O

Cytotoxic O
and O
apoptosis O
- O
inducing O
activities O
of O
steviol B
and O
isosteviol B
derivatives O
against O
human O
cancer O
cell O
lines O
. O

Seventeen O
steviol B
derivatives O
, O
i O
. O
e O
. O
, O
2 O
- O
18 O
, O
and O
19 O
isosteviol B
derivatives O
, O
i O
. O
e O
. O
, O
19 O
- O
37 O
, O
were O
prepared O
from O
a O
diterpenoid B
glycoside I
, O
stevioside B
( O
1 O
) O
. O

Upon O
evaluation O
of O
the O
cytotoxic O
activities O
of O
these O
compounds O
against O
leukemia O
( O
HL60 O
) O
, O
lung O
( O
A549 O
) O
, O
stomach O
( O
AZ521 O
) O
, O
and O
breast O
( O
SK O
- O
BR O
- O
3 O
) O
cancer O
cell O
lines O
, O
nine O
steviol B
derivatives O
, O
i O
. O
e O
. O
, O
5 O
- O
9 O
and O
11 O
- O
14 O
, O
and O
five O
isosteviol B
derivatives O
, O
i O
. O
e O
. O
, O
28 O
- O
32 O
, O
exhibited O
activities O
with O
single O
- O
digit O
micromolar O
IC O
( O
50 O
) O
values O
against O
one O
or O
more O
cell O
lines O
. O

All O
of O
these O
active O
compounds O
possess O
C O
( O
19 O
) O
- O
O B
- I
acyl I
group O
, O
and O
among O
which O
, O
ent B
- I
kaur I
- I
16 I
- I
ene I
- I
13 I
, I
19 I
- I
diol I
19 I
- I
O I
- I
4 I
' I
, I
4 I
' I
, I
4 I
' I
- I
trifluorocrotonate I
( O
14 O
) O
exhibited O
potent O
cytotoxicities O
against O
four O
cell O
lines O
with O
IC O
( O
50 O
) O
values O
in O
the O
range O
of O
1 O
. O
2 O
- O
4 O
. O
1 O
mu O
M O
. O

These O
results O
suggested O
that O
acylation O
of O
the O
19 O
- O
OH O
group O
of O
kaurane B
- O
and O
beyerane B
- O
type O
diterpenoids O
might O
be O
useful O
for O
enhancement O
of O
their O
cytotoxicities O
with O
apoptosis O
- O
inducing O
activity O
. O

The O
root O
essential O
oil O
was O
distinguished O
by O
its O
high O
content O
in O
acetylenes B
( O
matricaria B
ester I
, O
4 O
; O
74 O
. O
3 O
% O
) O
, O
while O
those O
from O
flower O
heads O
and O
leaves O
were O
dominated O
by O
oxygenated O
sesquiterpenes O
( O
61 O
. O
1 O
and O
50 O
. O
3 O
% O
, O
resp O
. O
) O
. O

The O
oils O
of O
C O
. O
sumatrensis O
from O
Tunisia O
belonged O
to O
a O
matricaria B
ester I
/ O
caryophyllene B
oxide I
chemotype O
. O

Excess O
nicotinamide O
, O
a O
form O
of O
vitamin B
B I
( I
3 I
) I
, O
is O
metabolized O
through O
two O
enzymatic O
systems O
and O
eventually O
excreted O
from O
the O
body O
. O

The O
second O
enzymatic O
system O
oxidizes O
nicotinamide O
to O
nicotinamide B
N I
- I
oxide I
. O

We O
have O
used O
human O
liver O
microsomes O
in O
combination O
with O
selective O
cytochrome O
P450 O
inhibitors O
, O
specific O
substrates O
, O
and O
antibodies O
to O
identify O
CYP2E1 O
as O
the O
main O
activity O
producing O
nicotinamide B
N I
- I
oxide I
. O

Our O
results O
suggest O
the O
potential O
use O
of O
nicotinamide B
N I
- I
oxide I
as O
a O
biomarker O
of O
CYP2E1 O
activity O
from O
urine O
or O
blood O
samples O
. O

Optical O
response O
of O
individual O
Au B
- I
Ag I
@ O
SiO O
2 O
heterodimers O
. O

The O
optical O
extinction O
response O
of O
individual O
Au B
- I
Ag I
@ O
SiO2 O
heterodimers O
whose O
individual O
morphologies O
are O
determined O
by O
transmission O
electron O
microscopy O
( O
TEM O
) O
is O
investigated O
using O
spatial O
modulation O
spectroscopy O
. O

Examples O
of O
sigma O
- O
bonds O
made O
of O
a O
single O
electron O
delocalized O
over O
two O
neighboring O
atoms O
were O
until O
recently O
found O
only O
in O
gas O
- O
phase O
cations O
such O
as O
H2 O
( O
+ O
) O
and O
Li2 B
( I
+ I
) I
and O
in O
highly O
unstable O
species O
generated O
in O
solid O
matrices O
. O

Here O
we O
report O
the O
isolation O
and O
structural O
characterization O
of O
a O
thermally O
stable O
compound O
featuring O
a O
Cu B
- I
B I
one O
- O
electron O
bond O
, O
as O
well O
as O
its O
oxidized O
( O
nonbonded O
) O
and O
reduced O
( O
two O
- O
electrons O
- O
bonded O
) O
congeners O
. O

This O
triad O
provides O
an O
excellent O
opportunity O
to O
study O
the O
degree O
of O
sigma O
- O
bonding O
in O
a O
metalloboratrane B
as O
a O
function O
of O
electron O
count O
. O

Beyond O
H O
( O
2 O
) O
S O
and O
NO O
Interplay O
: O
Hydrogen O
Sulfide O
and O
Nitroprusside B
React O
Directly O
to O
Give O
Nitroxyl O
( O
HNO B
) O
. O

A O
New O
Pharmacological O
Source O
of O
HNO B
. O

Here O
, O
we O
provide O
evidence O
that O
the O
physiological O
effects O
observed O
upon O
the O
application O
of O
sodium O
nitroprusside O
( O
SNP O
) O
and O
H O
( O
2 O
) O
S O
can O
be O
ascribed O
to O
the O
generation O
of O
nitroxyl O
( O
HNO B
) O
, O
which O
is O
a O
direct O
product O
of O
the O
reaction O
between O
SNP O
and O
H O
( O
2 O
) O
S O
, O
not O
a O
consequence O
of O
released O
NO O
subsequently O
reacting O
with O
H O
( O
2 O
) O
S O
. O

Intracellular O
HNO B
formation O
has O
been O
confirmed O
, O
and O
the O
subsequent O
release O
of O
calcitonin O
gene O
- O
related O
peptide O
from O
a O
mouse O
heart O
has O
been O
demonstrated O
. O

Unlike O
with O
other O
thiols O
, O
SNP O
reacts O
with O
H O
( O
2 O
) O
S O
in O
the O
same O
way O
as O
rhodanese O
, O
i O
. O
e O
. O
, O
the O
cyanide O
transforms O
into O
a O
thiocyanate B
. O

These O
findings O
shed O
new O
light O
on O
how O
H O
( O
2 O
) O
S O
is O
understood O
to O
interact O
with O
nitroprusside B
. O

Additionally O
, O
they O
offer O
a O
new O
and O
convenient O
pharmacological O
source O
of O
HNO B
for O
therapeutic O
purposes O
. O

Two O
new O
compounds O
, O
5 B
beta I
- I
pregnane I
- I
2 I
alpha I
, I
6 I
alpha I
, I
20 I
( I
S I
) I
- I
triol I
( O
1 O
) O
and O
8 B
- I
hydroxyl I
- I
3 I
- I
methoxyl I
- I
2 I
( I
1H I
) I
- I
quinolone I
( O
2 O
) O
, O
were O
isolated O
from O
Scolopendra O
multidens O
Newport O
. O

Soluble O
conjugated O
one O
- O
dimensional O
nanowires O
prepared O
by O
topochemical O
polymerization O
of O
a O
butadiynes B
- O
containing O
star O
- O
shaped O
molecule O
in O
the O
xerogel O
state O
. O

A O
star O
- O
shaped O
molecule O
with O
three O
butadiyne B
moieties O
attached O
to O
a O
central O
phenyl O
core O
was O
self O
- O
assembled O
via O
organogel O
formation O
in O
different O
solvents O
and O
subjected O
to O
UV O
irradiation O
in O
its O
xerogels O
form O
to O
give O
a O
soluble O
conjugated O
1D O
nanowire O
made O
of O
three O
connected O
polydiacetylene B
( O
PDA B
) O
chains O
. O

Our O
previous O
studies O
showed O
that O
overexpression O
of O
two O
mitochondrial O
anion O
transporters O
, O
the O
dicarboxylate B
( O
DIC B
, O
Slc25a10 O
) O
and O
oxoglutarate B
( O
OGC B
, O
Slc25a11 O
) O
carriers O
, O
in O
NRK O
- O
52E O
cells O
resulted O
in O
increased O
mitochondrial O
uptake O
of O
glutathione O
( O
GSH O
) O
and O
protection O
from O
chemically O
induced O
apoptosis O
. O

In O
the O
present O
study O
, O
we O
overexpressed O
DIC B
- O
and O
OGC B
- O
cDNA O
plasmids O
to O
assess O
their O
function O
in O
renal O
PT O
cells O
after O
compensatory O
renal O
hypertrophy O
. O

PT O
cells O
from O
NPX O
rats O
that O
were O
first O
preincubated O
with O
GSH O
were O
protected O
from O
cytotoxicity O
due O
to O
the O
mitochondrial O
inhibitor O
antimycin B
A I
by O
overexpression O
of O
either O
of O
the O
two O
mitochondrial O
GSH O
transporters O
. O

Screening O
of O
transition O
and O
post O
- O
transition O
metals O
to O
incorporate O
into O
copper O
oxide O
and O
copper B
bismuth I
oxide I
for O
photoelectrochemical O
hydrogen O
evolution O
. O

A O
new O
dispenser O
and O
scanner O
system O
is O
used O
to O
create O
and O
screen O
Bi B
- O
M O
- O
Cu O
oxide O
arrays O
for O
cathodic O
photoactivity O
, O
where O
M O
represents O
1 O
of O
22 O
different O
transition O
and O
post O
- O
transition O
metals O
. O

Over O
3000 O
unique O
Bi B
: O
M O
: O
Cu O
atomic O
ratios O
are O
screened O
. O

Of O
the O
22 O
metals O
tested O
, O
10 O
show O
a O
M O
- O
Cu B
oxide I
with O
higher O
photoactivity O
than O
CuO O
and O
10 O
show O
a O
Bi B
- O
M O
- O
Cu O
oxide O
with O
higher O
photoactivity O
than O
CuBi2O4 B
. O

Ag O
, O
Cd O
, O
and O
Zn O
produce O
the O
highest O
photoactivity O
Bi B
- O
M O
- O
Cu O
oxides O
with O
a O
200 O
- O
400 O
% O
improvement O
over O
CuBi2O4 B
. O

Most O
notable O
is O
a O
Bi B
- I
Ag I
- I
Cu I
oxide I
( O
Bi B
: O
Ag O
: O
Cu O
atomic O
ratio O
of O
22 O
: O
3 O
: O
11 O
) O
which O
shows O
4 O
times O
higher O
photocurrent O
than O
CuBi2O4 B
. O

A O
structural O
mapping O
of O
mutations O
causing O
succinyl B
- I
CoA I
: O
3 O
- O
ketoacid O
CoA O
transferase O
( O
SCOT O
) O
deficiency O
. O

Succinyl B
- I
CoA I
: O
3 O
- O
ketoacid O
CoA O
transferase O
( O
SCOT O
) O
deficiency O
is O
a O
rare O
inherited O
metabolic O
disorder O
of O
ketone O
metabolism O
, O
characterized O
by O
ketoacidotic O
episodes O
and O
often O
permanent O
ketosis O
. O

SCOT O
catalyzes O
the O
first O
, O
rate O
- O
limiting O
step O
of O
ketone O
body O
utilization O
in O
peripheral O
tissues O
, O
by O
transferring O
a O
CoA O
moiety O
from O
succinyl B
- I
CoA I
to O
form O
acetoacetyl B
- I
CoA I
, O
for O
entry O
into O
the O
tricarboxylic O
acid O
cycle O
for O
energy O
production O
. O

The O
amphiphilic O
character O
of O
GNSs O
allows O
the O
water O
solubility O
of O
insoluble O
hydrophobic O
cargos O
such O
as O
a O
perylene O
- O
bisimide O
derivative O
, O
[ B
60 I
] I
fullerene I
, O
or O
the O
anti O
- O
carcinogenic O
drug O
camptothecin O
( O
CPT O
) O
. O

Three O
new O
lanostanoid B
triterpenes I
from O
the O
fruiting O
bodies O
of O
Ganoderma O
tropicum O
. O

Three O
new O
lanostanoid B
triterpenes I
, O
3 B
beta I
, I
7 I
beta I
, I
15 I
beta I
- I
trihydroxy I
- I
11 I
, I
23 I
- I
dioxo I
- I
lanost I
- I
8 I
, I
16 I
- I
dien I
- I
26 I
- I
oic I
acid I
( O
1 O
) O
, O
3 B
beta I
, I
7 I
beta I
, I
15 I
beta I
- I
trihydroxy I
- I
11 I
, I
23 I
- I
dioxo I
- I
lanost I
- I
8 I
, I
16 I
- I
dien I
- I
26 I
- I
oic I
acid I
methyl I
ester I
( O
2 O
) O
, O
and O
3 O
beta O
, O
15 O
beta O
- O
dihydroxy O
- O
7 O
, O
11 O
, O
23 O
- O
trioxo O

- O
lanost O
- O
8 O
, O
16 O
- O
dien O
- O
26 O
- O
oic O
acid O
methyl O
ester O
( O
3 O
) O
were O
isolated O
from O
the O
EtOAc B
extract O
of O
the O
fruiting O
bodies O
of O
Ganoderma O
tropicum O
. O

We O
focus O
on O
one O
materials O
pair O
, O
GaP B
/ O
Si O
, O
for O
which O
we O
use O
a O
wide O
range O
of O
growth O
parameters O
. O

Reversal O
effect O
of O
rosmarinic O
acid O
on O
multidrug O
resistance O
in O
SGC7901 O
/ O
Adr B
cell O
. O

3 B
- I
( I
4 I
, I
5 I
- I
Dimethylthiazol I
) I
- I
2 I
, I
5 I
- I
diphenyl I
tetrazolium I
bromide I
( O
MTT O
) O
assay O
was O
used O
to O
investigate O
the O
reversal O
index O
of O
RA O
in O
SGC7901 O
/ O
Adr B
cell O
line O
. O

The O
intracellular O
accumulation O
of O
adriamycin O
, O
rhodamine123 O
( O
Rh123 B
) O
, O
and O
the O
expression O
of O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
were O
assayed O
by O
flow O
cytometry O
. O

The O
results O
showed O
that O
RA O
could O
reverse O
the O
MDR O
of O
SGC7901 O
/ O
Adr B
cells O
, O
increase O
the O
intracellular O
accumulation O
of O
Adr B
and O
Rh123 B
, O
and O
decrease O
the O
transcription O
of O
MDR1 O
gene O
and O
the O
expression O
of O
P O
- O
gp O
in O
SGC7901 O
/ O
Adr O
cells O
. O

Two O
new O
piperidine O
alkaloids O
, O
streptazones B
E O
( O
1 O
) O
and O
F O
( O
2 O
) O
, O
were O
isolated O
from O
Streptomyces O
sp O
. O

Synthesis O
, O
cytotoxicity O
and O
in O
vitro O
antileishmanial O
activity O
of O
naphthothiazoles B
. O

Considering O
that O
many O
lead O
leishmanicidal O
compounds O
contain O
a O
quinoidal B
scaffold O
and O
the O
thiazole O
heterocyclic O
ring O
is O
found O
in O
a O
number O
of O
antimicrobial O
drugs O
, O
we O
proposed O
a O
hybridization O
approach O
to O
generate O
a O
diverse O
set O
of O
semi O
- O
synthetic O
heterocycles O
with O
antileishmanial O
activity O
. O

The O
potent O
and O
selective O
activity O
of O
semi O
- O
synthetic O
naphthothiazoles B
against O
promastigotes O
and O
amastigotes O
reveals O
that O
the O
2 B
- I
amino I
- I
naphthothiazole I
ring O
may O
represent O
a O
scaffold O
for O
the O
design O
of O
compounds O
with O
leishmanicidal O
properties O
and O
encourage O
the O
development O
of O
drug O
formulation O
and O
new O
compounds O
for O
further O
studies O
in O
vivo O
. O

Two O
new O
drimane B
sesquiterpenoids O
, O
11 B
, I
12 I
- I
dihydroxy I
- I
15 I
- I
drimeneoic I
acid I
( O
1 O
) O
and O
3 B
alpha I
, I
11 I
, I
15 I
- I
trihydroxydrimene I
( O
2 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
basidiomycete O
Agaricus O
arvensis O
, O
together O
with O
one O
known O
compound O
3 B
beta I
, I
11 I
, I
12 I
- I
trihydroxydrimene I
( O
3 O
) O
. O

Two O
new O
sesquiterpenoids O
, O
tremulenolide B
D I
( O
1 O
) O
and O
muurolane B
- I
10 I
beta I
, I
15 I
- I
diol I
( O
2 O
) O
, O
together O
with O
four O
known O
sesquiterpenoids O
, O
tremulenediol B
A I
( O
3 O
) O
, O
2 B
beta I
- I
hydroxy I
- I
alpha I
- I
candinol I
( O
4 O
) O
, O
epicubenol B
( O
5 O
) O
, O
and O
3 B
beta I
- I
hydroxy I
- I
delta I
- I
candinol I
( O
6 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
fungus O
Ceriporia O
alachuana O
. O

Structurally O
, O
compounds O
1 O
and O
3 O
are O
tremulane B
- O
type O
sesquiterpenoids O
with O
an O
unusual O
perhydroazulene B
carbon O
skeleton O
. O

We O
have O
investigated O
the O
adsorption O
and O
organization O
at O
the O
air O
/ O
water O
interface O
of O
catanionic O
molecules O
released O
from O
a O
dispersion O
of O
solid O
- O
like O
catanionic O
vesicles O
composed O
of O
myristic O
acid O
and O
cetyl B
trimethylammonium I
chloride I
at O
the O
2 O
: O
1 O
ratio O
. O

Three O
new O
phenyl B
- I
ethanediols I
from O
the O
fruiting O
bodies O
of O
the O
mushroom O
Fomes O
fomentarius O
. O

Three O
new O
phenyl B
- I
ethanediols I
, O
( B
1R I
) I
- I
( I
3 I
- I
ethenylphenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
1 O
) O
, O
( B
1R I
) I
- I
( I
3 I
- I
formylphenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
2 O
) O
, O
and O
( B
1R I
) I
- I
( I
3 I
- I
acetophenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
3 O
) O
, O
were O
isolated O
from O
the O
fruiting O
bodies O
of O
the O
mushroom O
Fomes O
fomentarius O
, O
together O
with O
two O
related O
known O
compounds O
, O
( O
3 O
- O
ethylphenyl O

) O
- O
1 O
, O
2 O
- O
ethanediol O
( O
4 O
) O
and O
( B
4 I
- I
acetophenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
5 O
) O
. O

p53 O
- O
mediated O
autophagy O
adjustment O
is O
involved O
in O
the O
protection O
of O
silibinin B
against O
murine O
dermal O
inflammation O
and O
epidermal O
apoptosis O
induced O
by O
UVB O
irradiation O
. O

Silibinin B
protects O
dermal O
and O
epidermal O
cells O
of O
UVB O
irradiated O
skin O
against O
abnormally O
autophagy O
- O
mediated O
apoptosis O
adjustments O
. O

In O
this O
study O
, O
how O
UVB O
irradiation O
intervenes O
autophagy O
in O
dermal O
and O
epidermal O
cells O
as O
well O
as O
how O
silibinin B
protects O
UVB O
irradiated O
skin O
through O
physiological O
recovering O
of O
autophagy O
function O
in O
dermis O
and O
epidermis O
are O
focused O
and O
elucidated O
preliminarily O
. O

Silibinin B
treatment O
( O
50 O
mg O
/ O
kg O
/ O
day O
for O
4 O
days O
) O
reversed O
dermal O
and O
epidermal O
autophagy O
levels O
from O
UVB O
irradiation O
- O
induced O
improper O
autophagy O
intervention O
, O
repaired O
the O
balance O
between O
cell O
survival O
and O
death O
in O
dermis O
and O
epidermis O
, O
and O
protected O
skin O
against O
damage O
through O
mediation O
of O
p53 O
activation O
in O
dermal O
and O
epidermal O
cells O
. O

Two O
new O
coumarin B
glycosides I
from O
Chimonanthus O
nitens O
. O

Two O
new O
coumarin B
glycosides I
, O
namely O
nitensosides B
A I
- I
B I
( O
1 O
- O
2 O
) O
, O
together O
with O
six O
known O
compounds O
, O
scopolin O
( O
3 O
) O
, O
5 B
, I
6 I
, I
7 I
- I
trimethoxycoumarin I
( O
4 O
) O
, O
d B
- I
calycanthine I
( O
5 O
) O
, O
calycanthoside B
( O
6 O
) O
, O
xeroboside B
( O
7 O
) O
, O
and O
scopoletin O
( O
8 O
) O
, O
were O
isolated O
from O
Chimonanthus O
nitens O
. O

Electronic O
Spectroscopy O
and O
Electronic O
Structure O
of O
Copper B
Acetylide I
, O
CuCCH B
. O

The O
optical O
spectrum O
of O
the O
linear O
CuCCH B
molecule O
has O
been O
investigated O
for O
the O
first O
time O
, O
using O
resonant O
two O
- O
photon O
ionization O
spectroscopy O
employing O
ArF B
( O
193 O
nm O
) O
or O
F2 B
( O
157 O
nm O
) O
excimer O
radiation O
for O
photoionization O
. O

Vibrational O
assignments O
have O
provided O
the O
frequency O
of O
the O
Cu B
- I
C I
stretching O
mode O
, O
nu O
3 O
, O
in O
the O
ground O
and O
all O
three O
excited O
states O
, O
along O
with O
both O
bending O
modes O
, O
nu O
4 O
and O
nu O
5 O
, O
in O
the O
A O
( O
1 O
) O
Sigma O
( O
+ O
) O
and O
B O
( O
1 O
) O
Pi O
states O
, O
and O
the O
Cu B
- I
C I
= I
C I
bending O
mode O
, O
nu O
5 O
, O
in O
the O
ground O
state O
. O

Comparisons O
are O
made O
to O
the O
known O
electronic O
states O
of O
CuF B
, O
CuCl B
, O
CuBr B
, O
and O
CuI B
, O
and O
it O
is O
argued O
that O
like O
these O
molecules O
, O
the O
CuCCH B
molecule O
is O
essentially O
ionic O
in O
both O
the O
ground O
and O
excited O
states O
, O
with O
the O
ground O
state O
correlating O
diabatically O
to O
Cu O
( O
+ O
) O
( O
3d O
( O
10 O
) O
, O
( O
1 O
) O
S O
) O
+ O
CCH B
( I
- I
) I
( O
X O
( O
1 O
) O
Sigma O
( O
+ O
) O
) O
and O
the O
excited O
states O
correlating O
diabatically O
to O
Cu O
( O
+ O
) O
( O
3d O
( O
9 O
) O
4s O

( O
1 O
) O
, O
( O
1 O
, O
3 O
) O
D O
) O
+ O
CCH B
( I
- I
) I
( O
X O
( O
1 O
) O
Sigma O
( O
+ O
) O
) O
. O

The O
residual O
protein O
concentration O
after O
making O
contact O
with O
latex O
particles O
was O
determined O
by O
electrokinetic O
measurements O
and O
AFM O
imaging O
where O
the O
surface O
coverage O
of O
fibrinogen O
on O
mica B
was O
quantitatively O
determined O
. O

A O
solid O
solution O
series O
of O
lithium B
nickel I
metal I
oxides I
, O
Li B
[ I
Ni I
( I
1 I
- I
x I
) I
M I
( I
x I
) I
] I
O2 I
( O
with O
M O
= O
Co O
, O
Mn O
, O
and O
Al O
) O
have O
been O
investigated O
intensively O
to O
enhance O
the O
inherent O
structural O
instability O
of O
LiNiO2 B
. O

In O
an O
attempt O
to O
overcome O
these O
problems O
, O
LiNi0 B
. I
62Co0 I
. I
14Mn0 I
. I
24O2 I
cathode O
material O
with O
pillar O
layers O
in O
which O
Ni O
( O
2 O
+ O
) O
ions O
were O
resided O
in O
Li O
slabs O
near O
the O
surface O
having O
a O
thickness O
of O
~ O
10 O
nm O
was O
prepared O
using O
a O
polyvinylpyrrolidone O
( O
PVP O
) O
functionalized O
Mn O
precursor O
coating O
on O
Ni0 B
. I
7Co0 I
. I
15Mn0 I
. I
15 I
( I
OH I
) I
2 I
. O

In O
addition O
, O
the O
amount O
of O
heat O
generation O
was O
decreased O
by O
40 O
% O
, O
compared O
to O
LiNi0 B
. I
70Co0 I
. I
15Mn0 I
. I
15O2 I
. O

Chromatographic O
separation O
of O
the O
ethyl O
acetate O
soluble O
part O
of O
the O
methanolic O
extract O
from O
Seriphidium O
stenocephalum O
yielded O
three O
new O
compounds O
: O
stenocepflavone B
( O
1 O
) O
, O
stenocepflavan B
( O
2 O
) O
, O
and O
stenocephol B
( O
3 O
) O
, O
together O
with O
cirsimaritin O
( O
4 O
) O
, O
5 B
, I
7 I
, I
5 I
' I
- I
trihydroxy I
- I
3 I
' I
, I
4 I
' I
, I
6 I
- I
trimethoxyflavone I
( O
5 O
) O
, O
5 O
, O
6 O
, O
7 O
, O
5 O
' O
- O
tetrahydroxy O

- O
4 O
' O
- O
methoxyflavone O
( O
6 O
) O
, O
and O
axillaroside B
( O
7 O
) O
. O

Two O
new O
phenolic O
glycosides O
, O
linamarin B
gallate I
( O
1 O
) O
and O
walsuraside B
B I
( O
2 O
) O
, O
together O
with O
nine O
known O
compounds O
, O
catechin O
( O
3 O
) O
, O
epicatechin O
( O
4 O
) O
, O
epicatechin O
3 O
- O
O O
- O
gallate O
( O
5 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
- I
O I
- I
methyl I
) I
gallate I
( O
6 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
, I
5 I
- I
O I
- I
dimethyl I
) I
gallate I
( O
7 O
) O
, O
epicatechin O
3 O
- O
O O
- O
( O
3 O
, O
4 O
, O
5 O
- O
O O
- O
trimethyl O

) O
gallate O
( O
8 O
) O
, O
quercetin B
3 I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
9 O
) O
, O
rutin O
( O
10 O
) O
, O
and O
peltatoside B
( O
11 O
) O
, O
were O
isolated O
from O
the O
leafy O
twigs O
of O
Nigerian O
mistletoe O
Loranthus O
micranthus O
( O
Linn O
. O
) O
parasitic O
on O
Hevea O
brasiliensis O
. O

Compound O
1 O
was O
characterized O
as O
an O
unusual O
cyanogenic B
glycoside I
, O
while O
compound O
8 O
was O
isolated O
for O
the O
first O
time O
from O
a O
natural O
source O
. O

This O
is O
the O
first O
report O
of O
a O
cyanogenic B
glycoside I
from O
mistletoes O
. O

Kynurenic O
acid O
( O
KYNA O
) O
, O
one O
of O
the O
main O
product O
of O
the O
kynurenine B
pathway O
originating O
from O
tryptophan O
, O
is O
considered O
to O
be O
neuroprotective O
. O

KYNA O
- O
evoked O
neuroprotection O
disappeared O
in O
the O
presence O
of O
thiorphan B
, O
an O
inhibitor O
of O
NEP O
activity O
. O

Protein O
crystallography O
shows O
that O
this O
effect O
arises O
from O
the O
binding O
of O
the O
tweezers O
to O
a O
single O
surface O
- O
exposed O
lysine O
( O
Lys214 B
) O
of O
the O
14 O
- O
3 O
- O
3 O
protein O
in O
the O
proximity O
of O
its O
central O
channel O
, O
which O
normally O
binds O
the O
partner O
proteins O
. O

To O
determine O
whether O
dysregulation O
of O
SIRT1 O
promotes O
NADPH O
oxidase O
- O
dependent O
production O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
and O
impairs O
endothelial O
function O
we O
assessed O
the O
effects O
of O
three O
structurally O
different O
inhibitors O
of O
SIRT1 O
( O
nicotinamide O
, O
sirtinol B
, O
EX527 B
) O
in O
aorta O
segments O
isolated O
from O
young O
Wistar O
rats O
. O

Inhibition O
of O
SIRT1 O
induced O
endothelial O
dysfunction O
, O
as O
shown O
by O
the O
significantly O
reduced O
relaxation O
to O
the O
endothelium O
- O
dependent O
vasodilators O
acetylcholine O
and O
the O
calcium O
ionophore O
A23187 B
. O

A O
block O
/ O
homo O
- O
mixed O
polyplex O
micelle O
, O
comprising O
of O
cationic O
homo O
polymer O
: O
poly B
{ I
N I
' I
- I
[ I
N I
- I
( I
2 I
- I
aminoethyl I
) I
- I
2 I
- I
aminoethyl I
] I
aspartamide I
} I
P B
[ I
Asp I
( I
DET I
) I
] I
and O
block O
copolymer O
: O
polyethylene O
glycol O
( B
PEG I
) I
- I
b I
- I
P I
[ I
Asp I
( I
DET I
) I
] I
, O
has O
been O
reported O
to O
exhibit O
the O
efficient O
transgene O
expression O
in O
vivo O
by O
intratracheal O
and O
systemic O
administration O
. O

For O
evaluation O
of O
transgene O
expression O
in O
vivo O
, O
block O
/ O
homo O
polyplex O
micelles O
showed O
12 O
- O
fold O
higher O
level O
in O
luciferase O
expression O
evaluated O
by O
bioluminescence O
imaging O
system O
at O
24h O
after O
the O
i O
. O
p O
. O
administration O
compared O
with O
block O
polyplex O
micelles O
composed O
with O
only O
PEG B
- I
b I
- I
P I
[ I
Asp I
( I
DET I
) I
] I
in O
nude O
mice O
bearing O
peritoneal O
dissemination O
. O

Treating O
diabetic O
rats O
with O
dapsone B
, O
an O
agent O
known O
to O
inhibit O
neutrophil O
function O
, O
was O
associated O
with O
improved O
healing O
. O

In O
fact O
, O
the O
baseline O
proportion O
of O
hypodiploid O
cells O
and O
the O
mitochondrial O
potential O
and O
mass O
were O
higher O
in O
adults O
, O
whereas O
8 B
- I
hydroxy I
- I
2 I
' I
- I
deoxyguanosine I
( O
8 B
- I
oxo I
- I
dGuo I
) O
levels O
, O
the O
proportion O
of O
necrotic O
cells O
, O
and O
the O
extent O
of O
autophagy O
were O
higher O
early O
in O
life O
. O

Adult O
mice O
were O
more O
responsive O
to O
CS O
by O
increasing O
the O
proportion O
of O
necrotic O
cells O
and O
of O
cells O
in O
S O
/ O
G2 O
phase O
, O
whereas O
young O
mice O
maintained O
a O
high O
extent O
of O
autophagy O
, O
exhibited O
a O
greater O
increase O
of O
lipid O
peroxidation O
products O
and O
8 B
- I
oxo I
- I
dGuo I
levels O
, O
and O
had O
a O
higher O
frequency O
of O
micronucleated O
cells O
. O

Freshwater O
with O
up O
to O
120 O
mg O
/ O
L O
Ca O
( O
2 O
+ O
) O
as O
CaSO4 O
, O
250 O
mg O
/ O
L O
Mg O
( O
2 O
+ O
) O
as O
MgSO4 B
, O
or O
250 O
mg O
/ O
L O
Na O
( O
+ O
) O
as O
NaHCO3 B
did O
not O
provide O
protection O
against O
Ni O
toxicity O
. O

N O
- O
Acetylcysteine O
prevents O
doxorubucine B
- O
induced O
cardiotoxicity O
in O
rats O
. O

This O
study O
is O
designed O
to O
observe O
the O
effects O
of O
N O
- O
acetylcysteine O
( O
NAC O
) O
on O
doxorubucine B
- O
induced O
cardiac O
toxicity O
in O
rats O
both O
histologically O
and O
biochemically O
. O

The O
first O
group O
received O
only O
200 O
mg O
/ O
kg O
NAC O
intraperitoneal O
( O
i O
. O
p O
. O
) O
once O
every O
24 O
h O
for O
5 O
days O
( O
group O
1 O
) O
; O
the O
second O
group O
received O
20 O
mg O
/ O
kg O
doxorubucine B
( O
DOX O
) O
i O
. O
p O
. O
single O
dose O
plus O
NAC O
200 O
mg O
/ O
kg O
i O
. O
p O
. O
once O
every O
24 O
h O
for O
5 O
days O
( O
group O
2 O
) O
; O
the O
third O
group O
received O
DOX O
20 O
mg O
/ O
kg O
DOX O
i O
. O
p O
. O
single O
dose O
( O
group O
3 O
) O
and O
the O
fourth O
group O
, O
which O
is O
also O
the O
control O
group O
, O
received O
saline O
( O
group O
4 O
) O
. O

The O
experimental O
and O
computational O
techniques O
were O
used O
to O
study O
the O
ability O
of O
glyco O
- O
acridines B
to O
prevent O
lysozyme O
amyloid O
fibrillization O
in O
vitro O
. O

Fluorescence O
spectroscopy O
and O
atomic O
force O
microscopy O
have O
shown O
that O
glyco O
- O
acridines B
inhibit O
amyloid O
aggregation O
of O
lysozyme O
; O
the O
inhibition O
efficiency O
characterized O
by O
the O
half O
- O
maximal O
inhibition O
concentration O
IC50 O
was O
affected O
by O
the O
structure O
and O
concentration O
of O
the O
derivative O
. O

The O
most O
abundant O
components O
in O
the O
stems O
oil O
included O
carvacrol O
( O
60 O
. O
8 O
% O
) O
, O
alpha O
- O
terpineol O
( O
4 O
. O
7 O
% O
) O
and O
p B
- I
cymene I
( O
2 O
. O
4 O
% O
) O
, O
while O
carvacrol O
( O
33 O
% O
) O
, O
p B
- I
cymene I
( O
25 O
. O
3 O
% O
) O
and O
alpha O
- O
pinene O
( O
11 O
. O
6 O
% O
) O
were O
the O
main O
components O
in O
the O
leaves O
. O

Carbamate O
and O
urea O
derivatives O
are O
important O
classes O
of O
fatty O
acid O
amide O
hydrolase O
( O
FAAH O
) O
inhibitors O
that O
carbamoylate B
the O
active O
- O
site O
nucleophile O
Ser241 B
. O

The O
potential O
energy O
surfaces O
for O
decarbamoylation O
of O
FAAH O
covalent O
adducts O
, O
derived O
from O
the O
O O
- O
aryl O
carbamate O
URB597 B
and O
from O
the O
N O
- O
piperazinylurea O
JNJ1661610 B
, O
were O
calculated O
and O
compared O
to O
that O
for O
deacylation O
of O
FAAH O
acylated O
by O
the O
substrate O
oleamide B
. O

Calculations O
show O
that O
a O
carbamic B
group O
bound O
to O
Ser241 B
prevents O
efficient O
stabilization O
of O
transition O
states O
of O
hydrolysis O
, O
leading O
to O
large O
increments O
in O
the O
activation O
barrier O
. O

Moreover O
, O
the O
energy O
barrier O
for O
the O
piperazine B
carboxylate I
was O
significantly O
lower O
than O
that O
for O
the O
cyclohexyl B
carbamate I
derived O
from O
URB597 B
. O

This O
is O
consistent O
with O
experimental O
data O
showing O
slowly O
reversible O
FAAH O
inhibition O
for O
the O
N B
- I
piperazinylurea I
inhibitor O
and O
irreversible O
inhibition O
for O
URB597 B
. O

Supplementary O
techniques O
are O
fluorophore O
- O
assisted O
carbohydrate O
electrophoresis O
and O
sarcosyl B
- O
PAGE O
. O

Both O
poly B
( I
sulfobetaine I
methacrylate I
) I
( O
pSBMA B
) O
and O
poly B
( I
carboxybetaine I
methacrylate I
) I
( O
pCBMA B
) O
have O
been O
studied O
as O
matrices O
for O
the O
embedding O
of O
silver O
. O

Well O
- O
dispersed O
silver O
nanoparticles O
are O
embedded O
into O
pCBMA B
matrices O
. O

The O
obtained O
pCBMA B
- O
silver O
hybrid O
( O
CB O
- O
Ag O
) O
is O
capable O
of O
killing O
bacteria O
upon O
contact O
and O
releasing O
dead O
bacteria O
under O
wet O
conditions O
. O

Synthesis O
, O
in O
vitro O
antiplatelet O
activity O
and O
molecular O
modelling O
studies O
of O
10 B
- I
substituted I
2 I
- I
( I
1 I
- I
piperazinyl I
) I
pyrimido I
[ I
1 I
, I
2 I
- I
a I
] I
benzimidazol I
- I
4 I
( I
10H I
) I
- I
ones I
. O

The O
multistep O
preparation O
of O
the O
new O
10 B
- I
substituted I
2 I
- I
( I
1 I
- I
piperazinyl I
) I
pyrimido I
[ I
1 I
, I
2 I
- I
a I
] I
benzimidazol I
- I
4 I
( I
10H I
) I
- I
ones I
6a O
- O
o O
, O
and O
of O
the O
two O
isomers O
10 B
- I
ethyl I
- I
2 I
- I
( I
diethylamino I
) I
pyrimido I
[ I
1 I
, I
2 I
- I
a I
] I
benzimidazol I
- I
4 I
( I
10H I
) I
- I
one I
6p O
and O
10 O
- O
ethyl O
- O
4 O
- O
( O
diethylamino O
) O
pyrimido O
[ O
1 O
, O
2 O
- O
a O
] O

benzimidazol O
- O
2 O
( O
10H O
) O
- O
one O
13 O
, O
as O
well O
as O
the O
in O
vitro O
evaluation O
of O
their O
inhibitory O
activity O
on O
human O
platelet O
aggregation O
induced O
in O
platelet O
- O
rich O
plasma O
by O
ADP B
, O
collagen O
or O
the O
Ca O
( O
2 O
+ O
) O
ionophore O
A23187 B
were O
here O
described O
. O

Nine O
out O
of O
fifteen O
2 B
- I
( I
1 I
- I
piperazinyl I
) I
derivatives O
( O
6g O
- O
o O
) O
showed O
good O
inhibitory O
properties O
towards O
all O
the O
platelet O
aggregation O
agonists O
used O
. O

Synthesis O
and O
biological O
evaluation O
of O
novel O
pyranochalcone B
derivatives O
as O
a O
new O
class O
of O
microtubule O
stabilizing O
agents O
. O

Twenty O
- O
five O
novel O
pyranochalcone B
derivatives O
were O
synthesized O
and O
evaluated O
for O
their O
in O
vitro O
and O
in O
vivo O
antiproliferative O
activities O
. O

Voriconazole B
or O
posaconazole B
was O
given O
to O
the O
rats O
at O
doses O
ranging O
from O
10 O
to O
75 O
mg O
/ O
kg O
/ O
day O
via O
i O
. O
v O
. O
or O
oral O
routes O
, O
respectively O
. O

Whatever O
the O
immune O
status O
, O
the O
effective O
doses O
( O
defined O
by O
a O
doubling O
of O
the O
survival O
time O
and O
the O
absence O
of O
neurologic O
sequelae O
) O
were O
30 O
mg O
/ O
kg O
/ O
day O
for O
voriconazole B
and O
50 O
mg O
/ O
kg O
/ O
day O
for O
posaconazole B
. O

The O
effects O
of O
the O
phosphodiesterase O
type O
5 O
inhibitor O
vardenafil B
on O
cognitive O
performance O
in O
healthy O
adults O
: O
a O
behavioral O
- O
electroencephalograp O
study O
. O

Therefore O
, O
we O
examined O
whether O
the O
PDE5 O
- O
I O
vardenafil B
improves O
memory O
and O
executive O
functioning O
and O
affect O
electroencephalograp O
( O
EEG O
) O
in O
healthy O
young O
adults O
. O

Participants O
were O
selected O
out O
of O
a O
group O
of O
volunteers O
, O
based O
on O
their O
performance O
on O
a O
memory O
screening O
and O
they O
were O
orally O
treated O
with O
vardenafil B
( O
10 O
- O
20 O
mg O
or O
placebo O
) O
. O

No O
prominent O
effects O
of O
vardenafil B
on O
cognition O
were O
found O
: O
participants O
only O
made O
more O
mistakes O
on O
a O
reaction O
time O
task O
after O
20 O
mg O
vardenafil B
. O

During O
encoding O
of O
words O
, O
the O
P300 O
was O
generally O
smaller O
after O
vardenafil B
treatment O
. O

Furthermore O
, O
the O
N400 O
was O
larger O
after O
vardenafil B
10 O
mg O
than O
placebo O
treatment O
in O
a O
spatial O
memory O
task O
at O
Fz O
. O

Finally O
, O
headache O
and O
feeling O
weak O
were O
reported O
more O
after O
vardenafil B
treatment O
. O

Vardenafil B
did O
not O
affect O
cognitive O
performance O
of O
healthy O
adults O
and O
showed O
only O
some O
incidental O
effects O
on O
ERPs O
. O

Comparison O
of O
the O
anti O
- O
dopamine O
D2 O
and O
anti O
- O
serotonin O
5 O
- O
HT2A O
activities O
of O
chlorpromazine O
, O
bromperidol B
, O
haloperidol O
and O
second O
- O
generation O
antipsychotics O
parent O
compounds O
and O
metabolites O
thereof O
. O

In O
order O
to O
elucidate O
the O
differences O
between O
the O
in O
vivo O
and O
in O
vitro O
pharmacological O
characteristics O
of O
CPZ O
, O
we O
used O
a O
radioreceptor O
assay O
to O
measure O
the O
anti O
- O
D2 O
activity O
and O
the O
anti O
- O
5 O
- O
HT2A O
activity O
of O
CPZ O
and O
five O
major O
metabolites O
of O
CPZ O
, O
and O
compared O
the O
results O
to O
the O
anti O
- O
D2 O
activity O
and O
anti O
- O
5 O
- O
HT2A O
activity O
of O
risperidone O
, O
zotepine B
, O
perospirone B
, O
the O
major O
metabolites O
of O
each O
of O
these O
drugs O
, O
and O
olanzapine O
, O

bromperidol B
, O
and O
haloperidol O
. O

Monolayers O
of O
transition B
metal I
dichalcogenides I
( O
TMDCs B
) O
are O
atomically O
thin O
direct O
- O
gap O
semiconductors O
with O
potential O
applications O
in O
nanoelectronics O
, O
optoelectronics O
, O
and O
electrochemical O
sensing O
. O

Here O
we O
report O
a O
new O
method O
for O
synthesizing O
high O
optical O
quality O
monolayer O
MoS2 O
single O
crystals O
up O
to O
25 O
mu O
m O
in O
size O
on O
a O
variety O
of O
standard O
insulating O
substrates O
( O
SiO2 O
, O
sapphire B
, O
and O
glass O
) O
using O
a O
catalyst O
- O
free O
vapor O
- O
solid O
growth O
mechanism O
. O

This O
will O
allow O
greatly O
improved O
optoelectronic O
TMDC B
monolayer O
devices O
to O
be O
fabricated O
and O
studied O
routinely O
. O

2 B
- I
Arylpyrazolo I
[ I
4 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
7 I
- I
amino I
derivatives O
as O
new O
potent O
and O
selective O
human O
A3 O
Adenosine O
receptor O
antagonists O
. O

On O
the O
basis O
of O
our O
previously O
reported O
2 B
- I
arylpyrazolo I
[ I
4 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
7 I
- I
ones I
, O
a O
set O
of O
2 B
- I
arylpyrazolo I
[ I
4 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
7 I
- I
amines I
were O
designed O
as O
new O
human O
( O
h O
) O
A3 O
adenosine O
receptor O
( O
AR O
) O
antagonists O
. O

Lipophilic O
groups O
with O
different O
steric O
bulk O
were O
introduced O
at O
the O
5 O
- O
position O
of O
the O
bicyclic O
scaffold O
( O
R5 O
= O
Me O
, O
Ph O
, O
CH2Ph B
) O
, O
and O
different O
acyl O
and O
carbamoyl B
moieties O
( O
R7 O
) O
were O
appended O
on O
the O
7 B
- I
amino I
group O
, O
as O
well O
as O
a O
para B
- I
methoxy I
group O
inserted O
on O
the O
2 B
- I
phenyl I
ring O
. O

In O
fact O
, O
most O
of O
the O
7 B
- I
acylamino I
derivatives O
showed O
low O
nanomolar O
affinity O
( O
Ki O
= O
2 O
. O
5 O
- O
45 O
nM O
) O
and O
high O
selectivity O
toward O
this O
receptor O
. O

A O
few O
selected O
pyrazolo B
[ I
4 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
7 I
- I
amides I
were O
effective O
in O
counteracting O
oxaliplatin B
- O
induced O
apoptosis O
in O
rat O
astrocyte O
cell O
cultures O
, O
an O
in O
vitro O
model O
of O
neurotoxicity O
. O

ORD O
, O
ECD O
, O
and O
VCD O
Studies O
on O
Phyllostin B
, O
Scytolide B
, O
and O
Oxysporone B
. O

The O
absolute O
configuration O
( O
AC O
) O
of O
the O
bioactive O
metabolites O
phyllostin B
( O
1 O
) O
and O
scytolide B
( O
2 O
) O
, O
two O
hexahydro B
- I
1 I
, I
4 I
- I
benzodioxines I
produced O
by O
Phyllosticta O
cirsii O
, O
and O
oxysporone B
( O
3 O
) O
, O
a O
dihydrofuropyranone B
recently O
isolated O
from O
a O
strain O
of O
Diplodia O
africana O
, O
has O
been O
assigned O
by O
computational O
analysis O
of O
their O
optical O
rotatory O
dispersion O
( O
ORD O
) O
, O
electronic O
circular O
dichroism O
( O
ECD O
) O
, O
and O
vibrational O
circular O

As O
test O
material O
, O
aqueous O
nanocrystalline O
cellulose O
suspensions O
( O
aNCS O
) O
prepared O
by O
the O
H2SO4 B
route O
have O
been O
investigated O
and O
characterized O
( O
SAXS O
, O
dynamic O
light O
scattering O
, O
zeta O
potential O
) O
. O

Evaluation O
of O
difluoromethyl B
ketones I
as O
agonists O
of O
the O
gamma O
- O
aminobutyric O
acid O
type O
B O
( O
GABAB O
) O
receptor O
. O

The O
design O
, O
synthesis O
, O
biological O
evaluation O
, O
and O
in O
vivo O
studies O
of O
difluoromethyl B
ketones I
as O
GABAB O
agonists O
that O
are O
not O
structurally O
analogous O
to O
known O
GABAB O
agonists O
, O
such O
as O
baclofen O
or O
3 B
- I
aminopropyl I
phosphinic I
acid I
, O
are O
presented O
. O

The O
difluoromethyl B
ketones I
were O
assembled O
in O
three O
synthetic O
steps O
using O
a O
trifluoroacetate B
- O
release O
aldol O
reaction O
. O

Following O
evaluation O
at O
clinically O
relevant O
GABA O
receptors O
, O
we O
have O
identified O
a O
difluoromethyl B
ketone I
that O
is O
a O
potent O
GABAB O
agonist O
, O
obtained O
its O
X O
- O
ray O
structure O
, O
and O
presented O
preliminary O
in O
vivo O
data O
in O
alcohol O
- O
preferring O
mice O
. O

Structure O
- O
activity O
investigations O
determined O
that O
replacing O
the O
fluorines B
of O
the O
difluoromethyl B
ketone I
with O
hydrogens B
resulted O
in O
an O
inactive O
analogue O
. O

Resolution O
of O
the O
individual O
enantiomers O
of O
the O
difluoromethyl B
ketone I
provided O
a O
compound O
with O
full O
biological O
activity O
at O
concentrations O
less O
than O
an O
order O
of O
magnitude O
greater O
than O
the O
pharmaceutical O
, O
baclofen O
. O

In O
this O
article O
, O
we O
present O
a O
one O
- O
step O
hydrogenation O
- O
reduction O
route O
for O
the O
synthesis O
of O
Pt B
- I
Co I
nanoparticles O
( O
NPs O
) O
which O
were O
found O
to O
be O
excellent O
catalysts O
for O
aqueous O
- O
phase O
FTS O
at O
433 O
K O
. O

Coupling O
with O
atomic O
- O
resolution O
scanning O
transmission O
electron O
microscopy O
( O
STEM O
) O
and O
theoretical O
calculations O
, O
the O
outstanding O
activity O
is O
rationalized O
by O
the O
formation O
of O
Co O
overlayer O
structures O
on O
Pt O
NPs O
or O
Pt B
- I
Co I
alloy O
NPs O
. O

Cardiac O
hypertrophy O
, O
structural O
remodeling O
, O
and O
expression O
of O
the O
genes O
associated O
with O
fatty O
acid O
metabolism O
were O
examined O
in O
rats O
treated O
with O
triiodothyronine O
( O
T3 O
) O
alone O
( O
8 O
mu O
g O
/ O
100 O
g O
body O
weight O
( O
BW O
) O
, O
i O
. O
p O
. O
) O
for O
15 O
days O
or O
along O
with O
a O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
agonist O
bezafibrate B
( O
Bzf B
; O
30 O
mu O
g O
/ O
100 O
g O
BW O
, O
oral O
) O
and O
were O
found O
to O
improve O
in O
the O
Bzf B
co O
- O
treated O
condition O
. O

Ultrastructure O
of O
mitochondria O
was O
damaged O
in O
T3 O
- O
treated O
rat O
heart O
, O
which O
was O
prevented O
by O
Bzf B
co O
- O
administration O
. O

Hyperthyroidism O
- O
induced O
oxidative O
stress O
, O
reduction O
in O
cytochrome O
c O
oxidase O
activity O
, O
and O
myocardial O
ATP O
concentration O
were O
also O
significantly O
checked O
by O
Bzf B
. O

Heart O
function O
studied O
at O
different O
time O
points O
during O
the O
course O
of O
T3 O
treatment O
shows O
an O
initial O
improvement O
and O
then O
a O
gradual O
but O
progressive O
decline O
with O
time O
, O
which O
is O
prevented O
by O
Bzf B
co O
- O
treatment O
. O

The O
major O
compounds O
present O
in O
the O
extracts O
were O
: O
the O
flavonoid O
, O
phloretin B
- I
3 I
' I
, I
5 I
' I
- I
di I
- I
C I
- I
glucoside I
in O
C O
. O
subternata O
, O
the O
xanthone B
, O
mangiferin B
in O
unfermented O
C O
. O
maculata O
and O
the O
flavanone B
, O
hesperidin O
in O
fermented O
C O
. O
maculata O
. O

This O
study O
was O
designed O
to O
unravel O
the O
molecular O
mechanisms O
of O
the O
model O
obesogen O
TBT B
, O
using O
microarray O
analysis O
in O
the O
3T3 O
- O
L1 O
in O
vitro O
system O
, O
and O
to O
evaluate O
the O
use O
of O
toxicogenomics O
for O
obesogen O
screening O
. O

The O
microarray O
results O
revealed O
enrichment O
of O
Gene O
Ontology O
terms O
involved O
in O
energy O
and O
fat O
metabolism O
after O
10days O
of O
TBT B
exposure O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
study O
delivering O
an O
in O
depth O
mechanistic O
outline O
of O
the O
mode O
of O
action O
of O
TBT B
as O
an O
obesogen O
, O
combining O
effects O
on O
both O
cell O
physiological O
and O
gene O
expression O
level O
. O

In O
contrast O
, O
( O
- O
) O
- O
cannabidiol O
inhibited O
anandamide O
- O
and O
virodhamine B
- O
induced O
responses O
of O
isolated O
bronchi O
. O

A O
fatty O
acid O
amide O
hydrolase O
inhibitor O
, O
phenylmethanesulfony B
fluoride I
reversed O
the O
inhibitory O
effect O
of O
( O
- O
) O
- O
cannabidiol O
on O
anandamide O
- O
induced O
contractions O
. O

The O
objective O
of O
this O
study O
was O
to O
investigate O
protective O
effects O
of O
calcium O
channel O
blockers O
( O
CCBs O
) O
verapamil O
and O
nimodipine B
on O
nephrotoxicity O
induced O
by O
Pb B
acetate I
in O
mice O
. O

One O
hundred O
and O
twenty O
male O
mice O
were O
randomly O
divided O
into O
6 O
groups O
: O
control O
, O
Pb O
, O
low O
- O
dose O
verapamil O
, O
high O
- O
dose O
verapamil O
, O
low O
- O
dose O
nimodipine B
and O
high O
- O
dose O
nimodipine B
( O
n O
= O
20 O
per O
group O
) O
. O

Pb B
acetate I
was O
injected O
intraperitoneally O
( O
i O
. O
p O
. O
) O
at O
40 O
mg O
/ O
kg O
body O
weight O
/ O
day O
for O
10 O
days O
to O
establish O
the O
Pb O
toxicity O
model O
. O

While O
control O
mice O
received O
saline O
, O
mice O
of O
the O
treated O
groups O
simultaneously O
received O
i O
. O
p O
. O
injections O
of O
verapamil O
or O
nimodipine B
daily O
for O
10 O
days O
. O

Both O
verapamil O
and O
nimodipine B
showed O
protection O
against O
Pb O
- O
induced O
kidney O
injury O
, O
including O
alleviation O
of O
renal O
pathological O
damage O
and O
decreasing O
the O
level O
of O
Pb O
in O
kidney O
homogenate O
and O
extent O
of O
apoptosis O
in O
nephrocytes O
. O

Moreover O
, O
verapamil O
and O
nimodipine B
significantly O
down O
- O
regulated O
levels O
of O
blood O
urea O
nitrogen O
and O
creatinine O
in O
the O
serum O
. O

In O
addition O
, O
verapamil O
and O
nimodipine B
administration O
decreased O
malondialdehyde O
content O
and O
increased O
activities O
of O
super B
oxide I
dismutase O
activity O
and O
glutathione O
peroxidase O
in O
the O
kidney O
homogenate O
. O

Therefore O
, O
to O
reveal O
the O
existence O
of O
more O
permanent O
alterations O
of O
DNA O
structure O
after O
genotoxic O
stress O
, O
the O
RTG O
- O
2 O
rainbow O
trout O
cell O
line O
was O
exposed O
for O
3days O
to O
benzo O
[ O
a O
] O
pyrene O
( O
B O
[ O
a O
] O
P O
, O
0 O
. O
1 O
- O
10 O
mu O
M O
) O
and O
ethyl B
methanesulfonate I
( O
EMS O
, O
0 O
. O
1 O
- O
1mM O
) O
followed O
by O
3days O
of O
recovery O
period O
. O

Four O
extracts O
were O
spiked O
with O
different O
doses O
of O
the O
sensitizers O
citral O
, O
cinnamic B
aldehyde I
and O
isoeugenol O
. O

The O
effect O
of O
developmental O
exposure O
to O
chlorpyrifos O
( O
CPF B
) O
on O
hippocampal O
neurogenesis O
was O
examined O
in O
male O
mice O
after O
maternal O
dietary O
exposure O
to O
CPF B
at O
0 O
, O
4 O
, O
20 O
, O
or O
100ppm O
from O
gestation O
day O
10 O
to O
postnatal O
day O
( O
PND O
) O
21 O
. O

These O
results O
suggest O
that O
developmental O
CPF B
exposure O
directly O
but O
transiently O
suppresses O
maturation O
of O
late O
- O
stage O
granule O
cell O
lineages O
in O
the O
SGZ O
and O
affects O
interneuron O
populations O
in O
the O
hilus O
. O

The O
interfacial O
- O
organized O
monolayer O
water O
film O
( O
MWF O
) O
induced O
" O
two O
- O
step O
" O
aggregation O
of O
nanographene B
: O
both O
in O
stacking O
and O
sliding O
assembly O
pathways O
. O

The O
interfacial O
- O
organized O
monolayer O
water O
film O
( O
MWF O
) O
induced O
" O
two O
- O
step O
" O
aggregation O
of O
nanographene B
in O
both O
stacking O
and O
sliding O
assembly O
pathways O
was O
reported O
for O
the O
first O
time O
. O

By O
means O
of O
potential O
mean O
forces O
( O
PMFs O
) O
calculation O
, O
no O
energy O
barrier O
was O
observed O
during O
the O
sliding O
assembly O
of O
two O
graphene O
nanosheets O
, O
while O
the O
PMF O
profiles O
could O
be O
impacted O
by O
the O
contact O
forms O
of O
nanographene B
and O
the O
MWF O
within O
the O
interplate O
of O
two O
graphene O
nanosheets O
. O

We O
found O
that O
the O
compact O
, O
ordered O
structure O
and O
abundant O
H O
- O
bonds O
of O
the O
MWF O
could O
be O
taken O
as O
the O
fundamental O
aspects O
of O
the O
" O
hindering O
role O
" O
of O
interfacial O
water O
for O
the O
hydrophobic O
assembly O
of O
nanographene B
. O

The O
difficulties O
associated O
with O
the O
decision O
whether O
testicular O
toxicity O
is O
primary O
or O
secondary O
to O
hypoxia O
are O
exemplified O
by O
the O
results O
of O
inhalation O
studies O
with O
nickel B
subsulphide I
and O
gallium B
arsenide I
( O
GaAs O
) O
. O

This O
may O
first O
be O
explained O
by O
different O
effects O
on O
the O
blood O
: O
nickel B
subsulphide I
inhalation O
leads O
to O
a O
compensatory O
erythropoiesis O
that O
may O
mitigate O
pulmonary O
lack O
of O
oxygen O
uptake O
. O

Furthermore O
, O
the O
predominant O
pulmonary O
effect O
caused O
by O
GaAs O
( O
but O
not O
by O
nickel B
subsulphide I
) O
is O
alveolar O
proteinosis O
. O

Seedlings O
were O
treated O
with O
NO O
donor O
( O
0 O
. O
25 O
mM O
sodium O
nitroprusside O
, O
SNP O
) O
and O
As O
( O
0 O
. O
25 O
and O
0 O
. O
5 O
mM O
Na2HAsO4 B
. I
7H2O I
) O
separately O
and O
/ O
or O
in O
combination O
and O
grown O
for O
72 O
h O
. O

Relative O
water O
content O
( O
RWC O
) O
and O
chlorophyll O
( O
chl B
) O
content O
were O
decreased O
by O
As O
treatment O
but O
proline O
( O
Pro O
) O
content O
was O
increased O
. O

The O
monodehydroascorbate B
reductase O
( O
MDHAR O
) O
and O
catalase O
( O
CAT O
) O
activities O
were O
not O
changed O
upon O
exposure O
to O
As O
. O

The O
activities O
of O
dehydroascorbate B
reductase O
( O
DHAR O
) O
and O
glyoxalase O
I O
( O
Gly O
I O
) O
decreased O
at O
any O
levels O
of O
As O
, O
while O
glutathione O
peroxidase O
( O
GPX O
) O
and O
glyoxalase O
II O
( O
Gly O
II O
) O
activities O
decreased O
only O
upon O
0 O
. O
5 O
mM O
As O
. O

These O
inhibitory O
effects O
of O
As O
were O
markedly O
recovered O
by O
supplementation O
with O
SNP O
; O
that O
is O
, O
the O
treatment O
with O
SNP O
increased O
the O
RWC O
, O
chl B
and O
Pro O
contents O
; O
AsA O
and O
GSH O
contents O
and O
the O
GSH O
/ O
GSSG O
ratio O
as O
well O
as O
the O
activities O
of O
MDHAR O
, O
DHAR O
, O
GR O
, O
GPX O
, O
CAT O
, O
Gly O
I O
and O
Gly O
II O
in O
the O
seedlings O
subjected O
to O
As O
stress O
. O

About O
thirty O
TRPs O
have O
been O
identified O
to O
date O
and O
divided O
into O
seven O
families O
: O
TRPC O
( O
Canonical O
) O
, O
TRPV O
( O
Vanilloid B
) O
, O
TRPM O
( O
Melastatin O
) O
, O
TRPML O
( O
Mucolipin O
) O
, O
TRPP O
( O
Polycystin O
) O
, O
and O
TRPA O
( O
Ankyrin O
transmembrane O
protein O
) O
and O
TRPN O
( O
NomPClike O
) O
. O

Correlation O
between O
structural O
, O
spectroscopic O
, O
and O
reactivity O
properties O
within O
a O
series O
of O
structurally O
analogous O
metastable O
manganese B
( I
III I
) I
- I
alkylperoxo I
complexes I
. O

Manganese B
- I
peroxos I
are O
proposed O
as O
key O
intermediates O
in O
a O
number O
of O
important O
biochemical O
and O
synthetic O
transformations O
. O

Herein O
we O
report O
the O
crystallographic O
structures O
of O
a O
series O
of O
structurally O
related O
metastable O
Mn B
( I
III I
) I
- I
OOR I
compounds O
, O
and O
examine O
their O
spectroscopic O
and O
reactivity O
properties O
. O

The O
four O
reported O
Mn B
( I
III I
) I
- I
OOR I
compounds O
extend O
the O
number O
of O
known O
end O
- O
on O
Mn B
( I
III I
) I
- I
( I
eta I
( I
1 I
) I
- I
peroxos I
) I
to O
six O
. O

Strong O
correlations O
between O
structural O
( O
O B
- I
O I
and O
Mn O
. O
. O
. O
N B
( I
py I
, I
quin I
) I
distances O
) O
, O
spectroscopic O
( O
E O
( O
pi O
v O
* O
( O
O B
- I
O I
) O
- O
- O
> O
Mn O
CT O
band O
) O
, O
nu O
( O
O B
- I
O I
) O
) O
, O
and O
kinetic O
( O
Delta O
H O
( O
+ O
+ O
) O
and O
Delta O
S O
( O
+ O
+ O
) O
) O
parameters O
for O
these O
complexes O
provide O
compelling O
evidence O
for O
rate O
- O
limiting O
O B
- I
O I
bond O
cleavage O
. O

Products O
identified O
in O
the O
final O
reaction O
mixtures O
of O
Mn B
( I
III I
) I
- I
OOR I
decay O
are O
consistent O
with O
homolytic O
O B
- I
O I
bond O
scission O
. O

The O
N B
- I
heterocyclic I
amines I
and O
ligand O
backbone O
( O
Et O
vs O
Pr O
) O
are O
found O
to O
modulate O
structural O
and O
reactivity O
properties O
, O
and O
O B
- I
O I
bond O
activation O
is O
shown O
, O
both O
experimentally O
and O
theoretically O
, O
to O
track O
with O
metal O
ion O
Lewis O
acidity O
. O

The O
peroxo B
O I
- I
O I
bond O
is O
shown O
to O
gradually O
become O
more O
activated O
as O
the O
N B
- I
heterocyclic I
amines I
move O
closer O
to O
the O
metal O
ion O
causing O
a O
decrease O
in O
pi O
- O
donation O
from O
the O
peroxo O
pi O
v O
* O
( O
O B
- I
O I
) O
orbital O
. O

Phase O
discrimination O
through O
oxidant O
selection O
in O
low O
- O
temperature O
atomic O
layer O
deposition O
of O
crystalline O
iron B
oxides I
. O

Control O
over O
the O
oxidation O
state O
and O
crystalline O
phase O
of O
thin O
- O
film O
iron B
oxides I
was O
achieved O
by O
low O
- O
temperature O
atomic O
layer O
deposition O
( O
ALD O
) O
, O
utilizing O
a O
novel O
iron O
precursor O
, O
bis B
( I
2 I
, I
4 I
- I
methylpentadienyl I
) I
iron I
. O

This O
low O
- O
temperature O
( O
T O
= O
120 O
degrees O
C O
) O
route O
to O
conformal O
deposition O
of O
crystalline O
Fe3O4 O
or O
alpha B
- I
Fe2O3 I
thin O
films O
is O
determined O
by O
the O
choice O
of O
oxygen O
source O
selected O
for O
the O
second O
surface O
half O
- O
reaction O
. O

The O
approach O
employs O
ozone O
to O
produce O
fully O
oxidized O
alpha B
- I
Fe2O3 I
or O
a O
milder O
oxidant O
, O
H2O2 O
, O
to O
generate O
the O
Fe O
( O
2 O
+ O
) O
/ O
Fe O
( O
3 O
+ O
) O
spinel O
, O
Fe3O4 O
. O

We O
utilized O
this O
process O
to O
prepare O
conformal O
iron O
oxide O
thin O
films O
on O
a O
porous O
framework O
, O
for O
which O
alpha B
- I
Fe2O3 I
is O
active O
for O
photocatalytic O
water O
splitting O
. O

Studies O
on O
an O
( B
S I
) I
- I
2 I
- I
amino I
- I
3 I
- I
( I
3 I
- I
hydroxy I
- I
5 I
- I
methyl I
- I
4 I
- I
isoxazolyl I
) I
propionic I
acid I
( O
AMPA O
) O
receptor O
antagonist O
IKM B
- I
159 I
: O
asymmetric O
synthesis O
, O
neuroactivity O
, O
and O
structural O
characterization O
. O

IKM B
- I
159 I
was O
developed O
and O
identified O
as O
a O
member O
of O
a O
new O
class O
of O
heterotricyclic O
glutamate O
analogues O
that O
act O
as O
AMPA O
receptor O
- O
selective O
antagonists O
. O

However O
, O
it O
was O
not O
known O
which O
enantiomer O
of O
IKM B
- I
159 I
was O
responsible O
for O
its O
pharmacological O
activities O
. O

Here O
, O
we O
report O
in O
vivo O
and O
in O
vitro O
neuronal O
activities O
of O
both O
enantiomers O
of O
IKM B
- I
159 I
prepared O
by O
enantioselective O
asymmetric O
synthesis O
. O

By O
employment O
of O
( B
R I
) I
- I
2 I
- I
amino I
- I
2 I
- I
( I
4 I
- I
methoxyphenyl I
) I
ethanol I
as O
a O
chiral O
auxiliary O
, O
( B
2R I
) I
- I
IKM I
- I
159 I
and O
the O
( O
2S O
) O
- O
counterpart O
were O
successfully O
synthesized O
in O
0 O
. O
70 O
% O
and O
1 O
. O
5 O
% O
yields O
, O
respectively O
, O
over O
a O
total O
of O
18 O
steps O
. O

Both O
behavioral O
and O
electrophysiological O
assays O
showed O
that O
the O
biological O
activity O
observed O
for O
the O
racemic O
mixture O
was O
reproduced O
only O
with O
( B
2R I
) I
- I
IKM I
- I
159 I
, O
whereas O
the O
( O
2S O
) O
- O
counterpart O
was O
inactive O
in O
both O
assays O
. O

Racemic B
IKM I
- I
159 I
was O
crystallized O
with O
the O
ligand O
- O
binding O
domain O
of O
GluA2 O
, O
and O
the O
structure O
revealed O
a O
complex O
containing O
( B
2R I
) I
- I
IKM I
- I
159 I
at O
the O
glutamate O
binding O
site O
. O

( B
2R I
) I
- I
IKM I
- I
159 I
locks O
the O
GluA2 O
in O
an O
open O
form O
, O
consistent O
with O
a O
pharmacological O
action O
as O
competitive O
antagonist O
of O
AMPA O
receptors O
. O

A O
new O
guaianolide B
from O
Artemisia O
roxburghiana O
. O

A O
new O
member O
of O
5 B
alpha I
H I
, I
6 I
beta I
H I
, I
7 I
alpha I
H I
, I
11 I
alpha I
H I
- I
guaian I
- I
12 I
, I
6 I
alpha I
- I
olides I
, O
11 B
- I
epi I
- I
8 I
alpha I
- I
hydroxyarborescin I
, O
together O
with O
a O
mixture O
of O
( B
24R I
) I
- I
and I
( I
24S I
) I
- I
cycloart I
- I
25 I
- I
en I
- I
3b I
, I
24 I
- I
diols I
, O
palmitic O
acid O
and O
1 B
- I
octacosanol I
were O
isolated O
from O
the O
leaves O
of O
Artemisia O
roxburghiana O
Bess O
. O

Cellulose O
microspheres O
bearing O
poly B
( I
epsilon I
- I
caprolactone I
) I
grafts O
of O
different O
molecular O
weights O
were O
investigated O
to O
evaluate O
the O
effect O
of O
graft O
length O
on O
the O
interfacial O
properties O
. O

Metabolic O
Activation O
of O
Polycyclic O
Aromatic O
Hydrocarbons O
and O
Aryl B
and I
Heterocyclic I
Amines I
by O
Human O
Cytochromes O
P450 O
2A13 O
and O
2A6 O
. O

Human O
cytochrome O
P450 O
( O
P450 O
) O
2A13 O
was O
found O
to O
interact O
with O
several O
polycyclic O
aromatic O
hydrocarbons O
( O
PAHs O
) O
to O
produce O
Type O
I O
binding O
spectra O
, O
including O
acenaphthene B
, O
acenaphthylene B
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene O
, O
fluoranthene B
- I
2 I
, I
3 I
- I
diol I
, O
and O
1 B
- I
nitropyrene I
. O

P450 O
2A6 O
also O
interacted O
with O
acenaphthene B
and O
acenaphthylene B
, O
but O
not O
with O
fluoranthene O
, O
fluoranthene B
- I
2 I
, I
3 I
- I
diol I
, O
or O
1 B
- I
nitropyrene I
. O

P450 O
1B1 O
is O
well O
- O
known O
to O
oxidize O
many O
carcinogenic O
PAHs O
, O
and O
we O
found O
that O
several O
PAHs O
( O
i O
. O
e O
. O
, O
7 O
, O
12 O
- O
dimethylbenz O
[ O
a O
] O
anthracene O
, O
7 B
, I
12 I
- I
dimethylbenz I
[ I
a I
] I
anthracene I
- I
5 I
, I
6 I
- I
diol I
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene O
, O
fluoranthene B
- I
2 I
, I
3 I
- I
diol I
, O
5 B
- I
methylchrysene I
, O
benz O
[ O
a O
] O
pyrene O
- O
4 O
, O
5 O
- O

diol O
, O
benzo B
[ I
a I
] I
pyrene I
- I
7 I
, I
8 I
- I
diol I
, O
1 B
- I
nitropyrene I
, O
2 B
- I
aminoanthracene I
, O
2 B
- I
aminofluorene I
, O
and O
2 B
- I
acetylaminofluorene I
) O
interacted O
with O
P450 O
1B1 O
, O
producing O
Reverse O
Type O
I O
binding O
spectra O
. O

Metabolic O
activation O
of O
PAHs O
and O
aryl B
- I
and I
heterocyclic I
amines I
to O
genotoxic O
products O
was O
examined O
in O
Salmonella O
typhimurium O
NM2009 O
, O
and O
we O
found O
that O
P450 O
2A13 O
and O
2A6 O
( O
as O
well O
as O
P450 O
1B1 O
) O
were O
able O
to O
activate O
several O
of O
these O
procarcinogens O
. O

The O
former O
two O
enzymes O
were O
particularly O
active O
in O
catalyzing O
2 B
- I
aminofluorene I
and O
2 B
- I
aminoanthracene I
activation O
, O
and O
molecular O
docking O
simulations O
supported O
the O
results O
with O
these O
procarcinogens O
, O
in O
terms O
of O
binding O
in O
the O
active O
sites O
of O
P450 O
2A13 O
and O
2A6 O
. O

These O
results O
suggest O
that O
P450 O
2A O
enzymes O
, O
as O
well O
as O
P450 O
Family O
1 O
enzymes O
including O
P450 O
1B1 O
, O
are O
major O
enzymes O
involved O
in O
activating O
PAHs O
and O
aryl B
- I
and I
heterocyclic I
amines I
, O
as O
well O
as O
tobacco O
- O
related O
nitrosamines O
. O

Immunomodulatory O
properties O
of O
farnesoids B
: O
the O
new O
steroids O
? O

Farnesylthiosalisyli B
acid I
( O
FTS B
) O
is O
a O
potent O
non O
- O
toxic O
anticancer O
drug O
that O
targets O
oncogenic O
and O
pathologically O
activated O
Ras O
. O

The O
mechanism O
of O
action O
of O
FTS B
is O
well O
understood O
. O

Over O
the O
past O
decade O
we O
have O
extensively O
studied O
the O
effects O
of O
FTS B
in O
multiple O
animal O
models O
of O
such O
diseases O
. O

We O
were O
able O
to O
show O
potent O
anti O
- O
inflammatory O
properties O
of O
FTS B
in O
autoimmune O
disease O
models O
such O
as O
systemic O
lupus O
erythematous O
, O
antiphospholipd O
syndrome O
, O
Guillain O
- O
Barr O
e O
syndrome O
, O
multiple O
sclerosis O
, O
and O
inflammatory O
bowel O
diseases O
. O

In O
this O
review O
we O
summarize O
our O
( O
and O
others O
) O
published O
data O
, O
and O
conclude O
that O
FTS B
has O
great O
potential O
as O
a O
safe O
anti O
- O
inflammatory O
drug O
. O

Poisoning O
of O
DNA O
topoisomerase O
I O
is O
the O
mechanism O
by O
which O
camptothecins B
interfere O
with O
tumor O
growth O
. O

Although O
the O
clinical O
use O
of O
camptothecins B
has O
had O
a O
significant O
impact O
on O
cancer O
therapy O
, O
de O
novo O
or O
acquired O
clinical O
resistance O
to O
these O
drugs O
is O
common O
. O

Clinical O
resistance O
to O
camptothecins B
is O
still O
a O
poorly O
understood O
phenomenon O
, O
likely O
involving O
pharmacological O
and O
tumor O
- O
related O
factors O
. O

The O
relevance O
of O
these O
mechanisms O
to O
clinical O
drug O
resistance O
has O
not O
yet O
been O
completely O
defined O
, O
but O
their O
evaluation O
in O
clinical O
specimens O
should O
help O
to O
define O
personalized O
treatments O
including O
camptothecins B
as O
single O
agents O
or O
in O
combination O
with O
other O
cytotoxic O
and O
target O
- O
specific O
anticancer O
agents O
. O

The O
present O
review O
focuses O
on O
the O
cellular O
/ O
molecular O
aspects O
involved O
in O
resistance O
of O
tumor O
cells O
to O
camptothecins B
, O
including O
the O
potential O
role O
of O
cancer O
stem O
cells O
and O
deregulated O
miRNAs O
, O
and O
on O
the O
approaches O
proposed O
for O
overcoming O
resistance O
. O

A O
novel O
functional O
group O
, O
the O
carbonitrile B
group O
, O
was O
identified O
to O
be O
a O
key O
substituent O
in O
the O
ligand O
- O
protein O
interactions O
. O

Comprehensive O
insights O
into O
the O
structural O
and O
chemical O
changes O
in O
mixed O
- O
anion O
FeOF B
electrodes O
by O
using O
operando O
PDF O
and O
NMR O
spectroscopy O
. O

In O
- O
depth O
analysis O
of O
operando O
X O
- O
ray O
pair O
distribution O
function O
( O
PDF O
) O
data O
is O
combined O
with O
Li O
NMR O
spectroscopy O
to O
gain O
comprehensive O
insights O
into O
the O
electrochemical O
reaction O
mechanism O
of O
high O
- O
performance O
iron B
oxyfluoride I
electrodes O
. O

Guided O
by O
co O
- O
crystal O
structures O
of O
compounds O
15 O
, O
22 O
and O
30 O
, O
an O
SBDD O
approach O
led O
to O
the O
discovery O
of O
the O
6 B
- I
methyl I
pyridone I
series O
as O
a O
novel O
class O
of O
GKAs O
that O
potently O
activate O
GK O
in O
enzyme O
and O
cell O
assays O
. O

Omega B
- I
3 I
polyunsaturated I
fatty I
acids I
( O
PUFAs O
) O
are O
known O
to O
alleviate O
joint O
stiffness O
and O
pain O
in O
rheumatoid O
arthritis O
patients O
. O

Herein O
we O
discuss O
a O
novel O
class O
of O
bioactive O
lipid O
mediators O
, O
which O
are O
enzymatically O
biosynthesized O
in O
vivo O
from O
omega B
- I
3 I
eicosapentaenoic I
acid I
( O
EPA O
) O
and O
docosahexaenoic O
acid O
( O
DHA O
) O
, O
termed O
resolvins O
. O

A O
one O
- O
pot O
domino O
synthesis O
and O
discovery O
of O
highly O
functionalized O
dihydrobenzo B
[ I
b I
] I
thiophenes I
as O
AChE O
inhibitors O
. O

A O
library O
of O
novel O
5 B
- I
amino I
- I
2 I
, I
7 I
- I
diaryl I
- I
2 I
, I
3 I
- I
dihydrobenzo I
[ I
b I
] I
thiophene I
- I
4 I
, I
6 I
- I
dicarbonitriles I
have O
been O
synthesized O
regioselectively O
in O
good O
yields O
through O
the O
one O
- O
pot O
domino O
reactions O
of O
5 B
- I
aryldihydro I
- I
3 I
( I
2H I
) I
- I
thiophenones I
, O
malononitrile O
and O
aromatic O
aldehydes O
in O
the O
presence O
of O
morpholine O
. O

These O
compounds O
were O
evaluated O
for O
their O
acetylcholinesterase O
( O
AChE O
) O
inhibitory O
activity O
and O
5 B
- I
amino I
- I
2 I
, I
7 I
- I
bis I
( I
4 I
- I
methoxyphenyl I
) I
- I
2 I
, I
3 I
- I
dihydrobenzo I
[ I
b I
] I
thiophene I
- I
4 I
, I
6 I
- I
dicarbonitrile I
was O
found O
to O
be O
the O
most O
potent O
against O
AChE O
with O
IC50 O
4 O
. O
16 O
mu O
mol O
/ O
L O
. O

2 B
- I
( I
Benzothiazol I
- I
2 I
- I
yl I
) I
- I
phenyl I
- I
beta I
- I
d I
- I
galactopyranoside I
derivatives O
as O
fluorescent O
pigment O
dyeing O
substrates O
and O
their O
application O
for O
the O
assay O
of O
beta O
- O
d O
- O
galactosidase O
activities O
. O

2 B
- I
( I
Benzothiazol I
- I
2 I
- I
yl I
) I
- I
phenyl I
- I
beta I
- I
d I
- I
galactopyranoside I
derivatives O
were O
synthesized O
as O
novel O
artificial O
fluorescent O
pigment O
dyeing O
substrates O
for O
beta O
- O
d O
- O
galactosidase O
. O

Coenzyme B
Q10 I
protects O
Pc12 O
cells O
from O
cisplatin O
- O
induced O
DNA O
damage O
and O
neurotoxicity O
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
neuroprotective O
effect O
of O
a O
water O
- O
soluble O
formulation O
of O
coenzyme B
Q10 I
( O
WS O
- O
CoQ10 B
) O
in O
PC12 O
cells O
exposed O
to O
cisplatin O
, O
a O
chemotherapeutic O
agent O
with O
a O
dose O
- O
limiting O
factor O
due O
to O
neurotoxicity O
. O

In O
the O
cytokinesis O
- O
block O
micronucleus O
cytome O
assay O
( O
CBMN O
Cyt O
) O
, O
WS O
- O
CoQ10 B
( O
at O
concentrations O
of O
0 O
. O
1 O
, O
0 O
. O
5 O
and O
1 O
. O
0 O
mu O
gmL O
( O
- O
1 O
) O
) O
protected O
PC12 O
cells O
from O
cisplatin O
- O
induced O
DNA O
damage O
( O
0 O
. O
1 O
mu O
gmL O
( O
- O
1 O
) O
) O
, O
reducing O
the O
frequency O
of O
micronuclei O
( O
MNi O
) O
and O
nuclear O
buds O
( O
NBUDs O
) O
. O

WS O
- O
CoQ10 B
did O
not O
alter O
the O
mRNA O
expression O
levels O
of O
Tp53 O
( O
at O
a O
concentration O
of O
1 O
. O
0 O
mu O
gmL O
( O
- O
1 O
) O
) O
and O
exhibited O
neuroprotective O
activity O
by O
stimulating O
cisplatin O
- O
inhibited O
neurite O
outgrowth O
in O
nerve O
growth O
factor O
( O
NGF O
) O
- O
differentiated O
PC12 O
cells O
( O
at O
a O
concentration O
of O
0 O
. O
1 O
mu O
gmL O
( O
- O
1 O
) O
) O
. O

In O
conclusion O
, O
WS O
- O
CoQ10 B
protected O
the O
PC12 O
cells O
from O
cisplatin O
- O
induced O
DNA O
damage O
and O
neurotoxicity O
. O

Moreover O
, O
the O
neuroprotective O
effects O
of O
WS O
- O
CoQ10 B
suggest O
a O
possible O
application O
in O
chemotherapeutic O
protocols O
. O

Rapid O
and O
Sensitive O
Determination O
of O
Timosaponin B
AIII I
in O
Rat O
Plasma O
by O
LC O
- O
MS O
/ O
MS O
and O
Its O
Pharmacokinetic O
Application O
. O

A O
rapid O
sensitive O
and O
selective O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
( O
LC O
- O
MS O
/ O
MS O
) O
method O
was O
developed O
for O
determination O
of O
timosaponin B
AIII I
( O
TA B
- I
III I
) O
in O
rat O
plasma O
, O
using O
ginsenoside O
Re O
as O
an O
internal O
standard O
( O
IS O
) O
. O

TA B
- I
III I
and O
the O
IS O
were O
detected O
in O
MRM O
mode O
with O
a O
negative O
ionization O
electrospray O
mass O
spectrometer O
. O

The O
validated O
method O
was O
successfully O
applied O
to O
monitor O
the O
concentrations O
of O
TA B
- I
III I
in O
rat O
plasma O
after O
intragastric O
administration O
. O

The O
best O
fit O
pharmacokinetic O
model O
to O
estimate O
the O
pharmacokinetic O
parameters O
was O
a O
single O
compartment O
model O
with O
weight O
of O
1 O
/ O
x2 O
for O
oral O
administration O
groups O
of O
rats O
for O
TA B
- I
III I
. O

Daunomycin O
( O
DUN B
) O
, O
a O
chemotherapeutic O
agent O
with O
autofluorescence O
, O
was O
used O
to O
evaluate O
the O
pump O
activity O
, O
and O
OPN O
increased O
the O
drug O
pumping O
- O
out O
activity O
. O

OPN O
inhibited O
DUN B
- O
induced O
cell O
death O
, O
which O
was O
antagonized O
by O
alpha O
v O
beta O
3 O
monoclonal O
antibody O
. O

Long O
- O
term O
treatment O
with O
DUN B
further O
enhanced O
the O
expression O
of O
OPN O
. O

Knockdown O
of O
endogenous O
OPN O
potentiated O
the O
DUN B
- O
induced O
apoptosis O
of O
PC O
- O
3 O
cells O
. O

The O
animal O
studies O
also O
showed O
that O
OPN O
knockdown O
enhanced O
the O
cytotoxic O
action O
of O
DUN B
. O

Asperolide B
A I
, O
a O
marine O
- O
derived O
tetranorditerpenoid B
, O
induces O
G2 O
/ O
M O
arrest O
in O
human O
NCI O
- O
H460 O
lung O
carcinoma O
cells O
, O
is O
mediated O
by O
p53 O
- O
p21 O
stabilization O
and O
modulated O
by O
Ras O
/ O
Raf O
/ O
MEK O
/ O
ERK O
signaling O
pathway O
. O

Here O
we O
first O
demonstrate O
that O
asperolide B
A I
, O
a O
very O
recently O
reported O
marine O
- O
derived O
tetranorditerpenoid B
, O
leads O
to O
the O
inhibition O
of O
NCI O
- O
H460 O
lung O
carcinoma O
cell O
proliferation O
by O
G2 O
/ O
M O
arrest O
with O
the O
activation O
of O
the O
Ras O
/ O
Raf O
/ O
MEK O
/ O
ERK O
signaling O
and O
p53 O
- O
dependent O
p21 O
pathway O
. O

Treatment O
with O
35 O
mu O
M O
asperolide B
A I
( O
2 O
x O
IC O
( O
50 O
) O
) O
resulted O
in O
a O
significant O
increase O
in O
the O
proportion O
of O
G2 O
/ O
M O
phase O
cells O
, O
about O
a O
2 O
. O
9 O
- O
fold O
increase O
during O
48 O
h O
. O

Moreover O
, O
asperolide B
A I
significantly O
activated O
MAP O
kinases O
( O
ERK1 O
/ O
2 O
, O
JNK O
and O
p38 O
MAP O
kinase O
) O
by O
phosphorylation O
, O
and O
only O
the O
inhibition O
of O
ERK O
activation O
by O
PD98059 O
reversed O
downregulation O
of O
G2 O
/ O
M O
regulatory O
proteins O
CDC2 O
, O
and O
suppressed O
upregulation O
of O
p21 O
and O
p O
- O
p53 O
levels O
. O

Transfection O
of O
cells O
with O
dominant O
- O
negative O
Ras O
( O
RasN17 O
) O
mutant O
genes O
up O
- O
regulated O
asperolide B
A I
- O
induced O
the O
decrease O
of O
cyclin O
B1 O
and O
CDC2 O
, O
suppressed O
Raf O
, O
ERK O
activity O
and O
p53 O
- O
p21 O
expression O
, O
and O
at O
last O
, O
abolished O
G2 O
/ O
M O
arrest O
. O

This O
study O
indicates O
that O
asperolide B
A I
- O
induced O
G2 O
/ O
M O
arrest O
in O
human O
NCI O
- O
H460 O
lung O
carcinoma O
cells O
relys O
on O
the O
participation O
of O
the O
Ras O
/ O
Raf O
/ O
MEK O
/ O
ERK O
signaling O
pathway O
in O
p53 O
- O
p21 O
stabilization O
. O

An O
in O
vivo O
study O
with O
asperolide B
A I
illustrated O
a O
marked O
inhibition O
of O
tumor O
growth O
, O
and O
little O
toxcity O
compared O
to O
Cisplatin O
therapy O
. O

Overall O
, O
these O
findings O
provide O
potential O
effectiveness O
and O
a O
theoretical O
basis O
for O
the O
therapeutic O
use O
of O
asperolide B
A I
in O
the O
treatment O
of O
malignancies O
. O

Construction O
of O
monophosphoryl B
lipid I
A I
producing O
Escherichia O
coli O
mutants O
and O
comparison O
of O
immuno O
- O
stimulatory O
activities O
of O
their O
lipopolysaccharides O
. O

The O
lipid B
A I
moiety O
of O
Escherichia O
coli O
lipopolysaccharide O
is O
a O
hexaacylated B
disaccharide I
of O
glucosamine O
phosphorylated O
at O
the O
1 O
- O
and O
4 O
' O
- O
positions O
. O

The O
toxicity O
of O
lipid B
A I
depends O
on O
its O
structure O
. O

In O
this O
study O
, O
two O
E O
. O
coli O
mutants O
, O
HW001 O
and O
HW002 O
, O
were O
constructed O
by O
deleting O
or O
integrating O
key O
genes O
related O
to O
lipid B
A I
biosynthesis O
in O
the O
chromosome O
of O
E O
. O
coli O
W3110 O
. O

HW001 O
was O
constructed O
by O
deleting O
lacI O
and O
replacing O
lacZ O
with O
the O
Francisella O
novicida O
lpxE O
gene O
in O
the O
chromosome O
and O
only O
synthesizes O
monophosphoryl B
lipid I
A I
. O

HW002 O
was O
constructed O
by O
deleting O
lpxM O
in O
HW001 O
and O
synthesizes O
only O
the O
pentaacylated B
monophosphoryl I
lipid I
A I
. O

The O
structures O
of O
lipid B
A I
made O
in O
HW001 O
and O
HW002 O
were O
confirmed O
by O
thin O
layer O
chromatography O
and O
electrospray O
ionization O
mass O
spectrometry O
. O

This O
study O
provides O
a O
feasible O
way O
to O
produce O
interesting O
lipid B
A I
species O
in O
E O
. O
coli O
. O

Changes O
in O
morphometry O
and O
association O
between O
whole O
- O
body O
fatty O
acids O
and O
steroid O
hormone O
profiles O
in O
relation O
to O
bioaccumulation O
patterns O
in O
salmon O
larvae O
exposed O
to O
perfluorooctane B
sulfonic I
or I
perfluorooctane I
carboxylic I
acids I
. O

We O
observed O
changes O
in O
FA O
composition O
that O
predominantly O
involved O
increases O
in O
FA B
methyl I
esters I
( O
FAMEs B
) O
, O
mono B
- I
and I
poly I
- I
unsaturated I
FA I
( O
MUFA O
and O
PUFA O
) O
and O
a O
decrease O
in O
n O
- O
3 O
/ O
n O
- O
6 O
PUFA O
ratio O
by O
both O
PFOA O
and O
PFOS O
. O

Particularly O
, O
an O
increase O
in O
- O
pentadecenoic B
MUFA I
( O
15 O
: O
1 O
) O
, O
two O
n O
- O
3 O
PUFAs O
alpha B
- I
linolenic I
acid I
[ O
ALA O
: O
18 O
: O
3 O
n3 O
] O
and O
eicosapentaenoic O
acid O
[ O
EPA O
: O
20 O
: O
5 O
n O
- O
3 O
] O
and O
n O
- O
6 O
PUFA O
: O
arachidonic O
acid O
[ O
ARA O
: O
20 O
: O
4 O
n6 O
] O
, O
docosapentaenoic B
acid I
( O
DPA B
) O
by O
PFOA O
and O
PFOS O
were O
observed O
. O

Ferredoxin O
1 O
( O
FDX1 O
; O
adrenodoxin O
) O
is O
an O
iron O
- O
sulfur O
protein O
that O
is O
involved O
in O
various O
metabolic O
processes O
, O
including O
steroid B
hormone I
synthesis O
in O
mammalian O
tissues O
. O

Luciferase O
reporter O
assays O
showed O
that O
transcription O
of O
FDX1 O
was O
synergistically O
activated O
by O
the O
NR5A O
family O
and O
8Br B
- I
cAMP I
treatment O
through O
two O
SF O
- O
1 O
binding O
sites O
and O
a O
CRE O
- O
like O
sequence O
in O
a O
human O
ovarian O
granulosa O
cell O
line O
, O
KGN O
. O

These O
results O
indicate O
transcription O
of O
FDX1 O
is O
regulated O
by O
the O
NR5A O
family O
and O
cAMP O
signaling O
, O
and O
participates O
in O
steroid B
hormone I
production O
in O
ovarian O
granulosa O
cells O
. O

In O
addition O
, O
colocalization O
of O
acid O
sphingomyelinase O
( O
ASM O
) O
and O
ceramide B
was O
induced O
by O
OxLDL O
, O
which O
was O
blocked O
by O
statins O
. O

In O
coronary O
artery O
intima O
of O
mice O
with O
acute O
hypercholesterolemia O
, O
confocal O
microscopy O
revealed O
a O
colocalization O
of O
gp91 O
( O
phox O
) O
, O
p47 O
( O
phox O
) O
, O
ASM O
, O
or O
ceramide B
in O
MR O
clusters O
. O

Surface O
- O
enhanced O
Raman O
scattering O
spectra O
of O
adsorbates O
on O
Cu B
2 I
O I
nanospheres O
: O
charge O
- O
transfer O
and O
electromagnetic O
enhancement O
. O

Surface O
- O
enhanced O
Raman O
scattering O
( O
SERS O
) O
spectra O
of O
4 B
- I
mercaptobenzoic I
acid I
( O
4 B
- I
MBA I
) O
have O
been O
investigated O
on O
the O
surface O
of O
Cu2O O
nanospheres O
. O

The O
coupling O
between O
the O
adsorbates O
and O
the O
semiconductor O
, O
evidenced O
by O
the O
shift O
in O
absorption O
spectrum O
of O
modified O
Cu2O O
and O
the O
enhancement O
of O
non O
- O
totally O
symmetric O
modes O
of O
the O
4 B
- I
MBA I
and O
4 B
- I
mercaptopyridine I
( O
4 B
- I
MPY I
) O
molecules O
, O
were O
invoked O
to O
explain O
the O
experimental O
results O
. O

The O
inhibitory O
effects O
of O
genistin O
were O
correlated O
with O
the O
stimulation O
of O
alpha O
adrenergic O
and O
beta O
adrenergic O
receptors O
since O
these O
inhibitory O
effects O
were O
significantly O
blocked O
in O
the O
presence O
of O
phentolamine B
and O
propranolol O
respectively O
. O

The O
pharmacokinetics O
and O
pharmacodynamics O
of O
zaleplon B
delivered O
as O
a O
thermally O
generated O
aerosol O
in O
a O
single O
breath O
to O
volunteers O
. O

Pharmacokinetics O
, O
pharmacodynamics O
, O
safety O
, O
and O
tolerability O
of O
inhaled O
zaleplon B
were O
assessed O
in O
healthy O
volunteers O
. O

Forty O
participants O
received O
0 O
. O
5 O
, O
1 O
, O
2 O
, O
or O
4 O
mg O
zaleplon B
or O
placebo O
as O
a O
thermally O
generated O
aerosol O
in O
a O
randomized O
, O
double O
- O
blind O
, O
parallel O
- O
group O
, O
dose O
escalation O
study O
. O

The O
zaleplon B
AUC O
was O
dose O
proportional O
across O
doses O
, O
with O
a O
slope O
( O
90 O
% O
confidence O
interval O
) O
of O
log O
- O
AUC O
versus O
log O
- O
dose O
of O
0 O
. O
92 O
( O
0 O
. O
82 O
, O
1 O
. O
02 O
) O
. O

Zaleplon B
inhalation O
represents O
a O
safe O
, O
well O
- O
tolerated O
means O
of O
rapidly O
achieving O
effective O
plasma O
concentrations O
. O

Addition O
of O
cilostazol B
to O
conventional O
dual O
antiplatelet O
therapy O
reduces O
the O
risk O
of O
cardiac O
events O
and O
restenosis O
after O
drug O
- O
eluting O
stent O
implantation O
: O
a O
meta O
- O
analysis O
. O

This O
meta O
- O
analysis O
was O
performed O
to O
compare O
the O
risk O
of O
cardiac O
events O
and O
restenosis O
between O
triple O
antiplatelet O
therapy O
( O
TAT O
, O
addition O
of O
cilostazol B
to O
aspirin O
and O
clopidogrel O
) O
and O
conventional O
dual O
antiplatelet O
therapy O
( O
DAT O
, O
aspirin O
and O
clopidogrel O
) O
in O
drug O
- O
eluting O
stents O
( O
DES O
) O
implantation O
patients O
. O

Addition O
of O
cilostazol B
to O
DAT O
reduced O
the O
incidence O
of O
MACE O
, O
TVR O
, O
and O
TLR O
after O
DES O
implantation O
. O

Herein O
, O
we O
detail O
the O
development O
of O
robust O
H O
( O
2 O
) O
O O
( O
2 O
) O
- O
sensitive O
fluorescent O
probes O
using O
a O
boronic B
ester I
trigger O
appended O
to O
the O
fluorophore O
through O
a O
benzyl B
ether I
linkage O
. O

Mifepristone O
( O
RU B
486 I
) O
, O
a O
first O
- O
in O
- O
class O
glucocorticoid O
receptor O
antagonist O
, O
was O
approved O
by O
the O
United O
States O
Food O
and O
Drug O
Administration O
in O
2012 O
for O
use O
in O
Cushing O
' O
s O
syndrome O
to O
control O
hyperglycemia O
in O
patients O
who O
are O
not O
surgical O
candidates O
or O
have O
not O
achieved O
remission O
from O
surgery O
. O

UV O
/ O
Vis O
spectra O
of O
subporphyrazines B
and O
subphthalocyanines B
with O
aluminum O
and O
gallium O
: O
a O
time O
- O
dependent O
DFT O
study O
. O

The O
UV O
/ O
Vis O
spectra O
of O
selected O
substituted O
subporphyrazines B
( O
SubPz B
) O
and O
subphthalocyanines B
( O
SubPc B
) O
with O
aluminum O
and O
gallium O
as O
central O
atoms O
are O
analyzed O
through O
time O
- O
dependent O
DFT O
calculations O
in O
chloroform O
. O

The O
absorptions O
of O
SubPz B
( O
Al O
, O
Ga O
) O
are O
redshifted O
or O
blueshifted O
with O
respect O
to O
SubPz B
( O
B O
) O
depending O
on O
the O
nature O
of O
the O
R O
substituents O
of O
the O
molecule O
, O
whereas O
the O
absorptions O
of O
SubPc B
( O
Al O
, O
Ga O
) O
structures O
are O
redshifted O
and O
with O
smaller O
energy O
gaps O
with O
respect O
to O
SubPc B
( O
B O
) O
for O
all O
kinds O
of O
R O
substituents O
. O

We O
found O
that O
when O
isolated O
rat O
epitrochlearis O
muscle O
was O
incubated O
with O
a O
Pu O
- O
erh O
tea O
hot O
- O
water O
extract O
( O
PTE O
) O
for O
30 O
min O
, O
the O
rate O
of O
3 B
- I
O I
- I
methyl I
- I
D I
- I
glucose I
( O
3MG B
) O
transport O
increased O
in O
the O
absence O
of O
insulin O
. O

Discovery O
, O
biological O
evaluation O
, O
and O
structure O
- O
activity O
and O
- O
selectivity O
relationships O
of O
6 B
' I
- I
substituted I
( I
E I
) I
- I
2 I
- I
( I
benzofuran I
- I
3 I
( I
2H I
) I
- I
ylidene I
) I
- I
N I
- I
methylacetamides I
, O
a O
novel O
class O
of O
potent O
and O
selective O
monoamine O
oxidase O
inhibitors O
. O

Here O
, O
the O
discovery O
of O
a O
new O
class O
of O
compounds O
acting O
as O
monoamine O
oxidase O
inhibitors O
( O
MAO O
- O
Is O
) O
and O
bearing O
a O
6 B
' I
- I
substituted I
( I
E I
) I
- I
2 I
- I
( I
benzofuran I
- I
3 I
( I
2H I
) I
- I
ylidene I
) I
- I
N I
- I
alkylacetamide I
skeleton O
is O
reported O
. O

6 B
' I
- I
Sulfonyloxy I
derivatives O
exhibited O
outstanding O
affinities O
to O
MAO O
- O
A O
( O
7 O
. O
0 O
nM O
< O
IC50 O
< O
49 O
nM O
, O
much O
higher O
than O
moclobemide B
) O
and O
a O
pronounced O
MAO O
- O
A O
/ O
B O
selectivity O
. O

The O
corresponding O
6 B
' I
- I
benzyloxy I
derivatives O
showed O
potent O
MAO O
- O
B O
inhibition O
and O
inverted O
selectivity O
profile O
. O

The O
rigid O
E O
- O
geometry O
of O
the O
exocyclic O
double O
bond O
allowed O
a O
more O
efficient O
binding O
conformation O
compared O
to O
more O
flexible O
and O
less O
active O
2 B
- I
( I
1 I
- I
benzofuran I
- I
3 I
- I
yl I
) I
- I
N I
- I
methylacetamide I
isomers O
and O
4 B
- I
N I
- I
methylcarboxamidomet I
analogues O
. O

Pyranose B
ring O
flexing O
( O
puckering O
) O
in O
2 B
- I
O I
- I
sulfo I
- I
alpha I
- I
l I
- I
iduronic I
acid I
, O
which O
underlies O
heparin O
- O
mediated O
anticoagulation O
, O
was O
modulated O
by O
polymerization O
( O
chain O
position O
and O
adjacent O
residues O
) O
, O
which O
is O
supported O
by O
previous O
experiments O
. O

Furthermore O
, O
in O
coarse O
- O
grained O
simulations O
, O
inclusion O
of O
puckering O
was O
essential O
to O
predict O
macroscopic O
hydrodynamic O
properties O
of O
heparan O
sulfate O
chains O
containing O
hundreds O
of O
monosaccharaides B
. O

Definition O
of O
formulation O
design O
space O
, O
in O
vitro O
bioactivity O
and O
in O
vivo O
biodistribution O
for O
hydrophilic O
drug O
loaded O
PLGA O
/ O
PEO B
- I
PPO I
- I
PEO I
nanoparticles O
using O
OFAT O
experiments O
. O

Modified O
nanoprecipitation O
method O
was O
used O
for O
improved O
incorporation O
of O
hydrophilic O
drug O
( O
irinotecan B
hydrochloride I
) O
into O
the O
PLGA O
/ O
PEO B
- I
PPO I
- I
PEO I
blended O
and O
blended O
/ O
adsorbed O
nanoparticles O
. O

One O
factor O
at O
a O
time O
( O
OFAT O
) O
variation O
experiments O
were O
conducted O
in O
order O
to O
determine O
key O
formulation O
factors O
( O
concentration O
and O
volume O
of O
drug O
solution O
, O
evaporation O
rate O
and O
PLGA O
/ O
PEO B
- I
PPO I
- I
PEO I
ratio O
) O
influencing O
nanoparticle O
properties O
( O
particle O
size O
and O
size O
distribution O
, O
encapsulation O
efficiency O
, O
drug O
content O
, O
zeta O
potential O
, O
drug O
dissolution O
rate O
, O
as O
well O
as O
protein O
binding O
capacity O
) O
. O

The O
mean O
particle O
size O
, O
mainly O
dependent O
upon O
PLGA O
/ O
PEO B
- I
PPO I
- I
PEO I
ratio O
, O
was O
in O
the O
range O
of O
112 O
- O
125nm O
, O
with O
narrow O
unimodal O
distribution O
( O
PDI O
~ O
0 O
. O
1 O
) O
. O

Encapsulation O
efficiency O
( O
32 O
- O
63 O
% O
) O
was O
impacted O
by O
evaporation O
rate O
and O
PLGA O
/ O
PEO B
- I
PPO I
- I
PEO I
ratio O
. O

Zeta O
potential O
values O
indicated O
that O
presence O
of O
PEO B
- I
PPO I
- I
PEO I
in O
the O
formulations O
shielded O
the O
high O
surface O
negative O
charge O
of O
PLGA O
. O

PEO B
- I
PPO I
- I
PEO I
surface O
coverage O
of O
PLGA O
/ O
PEO B
- I
PPO I
- I
PEO I
blended O
as O
well O
as O
blended O
/ O
adsorbed O
nanoparticles O
depended O
upon O
amount O
of O
used O
PEO B
- I
PPO I
- I
PEO I
during O
preparation O
procedure O
and O
was O
related O
to O
the O
protein O
resistant O
characteristics O
of O
nanoparticles O
. O

Forty O
male O
albino O
Wistar O
rats O
were O
randomized O
into O
control O
( O
C O
) O
, O
sodium O
metabisulfite O
( O
Na2S2O5 B
) O
treated O
( O
S O
) O
, O
ghrelin O
treated O
( O
G O
) O
and O
, O
Na2S2O5 B
+ O
ghrelin O
treated O
( O
SG O
) O
groups O
. O

Na2S2O5 B
administration O
significantly O
elevated O
total O
oxidant O
status O
( O
TOS O
) O
levels O
while O
depleting O
total O
antioxidant O
status O
( O
TAS O
) O
levels O
in O
gastric O
mucosa O
. O

Na2S2O5 B
administration O
also O
markedly O
increased O
the O
number O
of O
apoptotic O
cells O
, O
cleaved O
caspase O
- O
3 O
and O
PAR O
expression O
( O
PARP O
activity O
indicator O
) O
and O
, O
decreased O
Ki67 O
expression O
( O
cell O
proliferation O
index O
) O
in O
gastric O
mucosal O
cells O
. O

Ghrelin O
treatment O
decreased O
the O
number O
apoptotic O
cells O
, O
cytochrome O
C O
release O
, O
PAR O
and O
, O
caspase O
- O
3 O
expressions O
while O
increasing O
Ki67 O
expression O
in O
gastric O
mucosa O
exposed O
to O
Na2S2O5 B
. O

In O
conclusion O
, O
we O
suggest O
that O
ghrelin O
treatment O
might O
ameliorate O
ingested O
- O
Na2S2O5 B
induced O
gastric O
mucosal O
injury O
stemming O
from O
apoptosis O
and O
oxidative O
stress O
in O
rats O
. O

Vitamin O
A O
or O
retinol O
is O
arguably O
the O
most O
multifunctional O
vitamin B
in O
the O
human O
body O
as O
it O
is O
essential O
from O
embryogenesis O
to O
adulthood O
. O

Synthesis O
and O
antiproliferative O
activity O
evaluation O
of O
imidazole O
- O
based O
indeno B
[ I
1 I
, I
2 I
- I
b I
] I
quinoline I
- I
9 I
, I
11 I
- I
dione I
derivatives O
. O

A O
series O
of O
new O
imidazole O
substituted O
indeno B
[ I
1 I
, I
2 I
- I
b I
] I
quinoline I
- I
9 I
, I
11 I
- I
dione I
derivatives O
were O
synthesized O
and O
evaluated O
for O
their O
antiproliferative O
effects O
on O
HeLa O
, O
LS180 O
, O
MCF O
- O
7 O
and O
Jurkat O
human O
cancer O
cell O
lines O
. O

Moreover O
; O
it O
was O
found O
that O
some O
of O
the O
tested O
compounds O
bearing O
imidazole B
- I
2 I
- I
yl I
moiety O
on O
the O
C11 O
- O
position O
of O
dihydropyridine O
ring O
exhibited O
superior O
antiproliferative O
activity O
in O
comparison O
to O
cis B
- I
platin I
especially O
in O
Jurkat O
cell O
line O
( O
compounds O
29 O
, O
31 O
, O
and O
33 O
) O
. O

The O
results O
of O
this O
study O
proposed O
that O
some O
of O
the O
imidazole O
substituted O
indeno B
[ I
1 I
, I
2 I
- I
b I
] I
quinoline I
- I
9 I
, I
11 I
- I
dione I
compounds O
may O
act O
as O
efficient O
anticancer O
agents O
in O
vitro O
, O
emphasizing O
their O
potential O
role O
as O
a O
source O
for O
rational O
design O
of O
potent O
antiproliferative O
agents O
. O

Phase O
stability O
and O
elastic O
properties O
of O
chromium B
borides I
with O
various O
stoichiometries O
. O

By O
first O
- O
principles O
calculations O
, O
we O
establish O
the O
phase O
stability O
of O
chromium B
borides I
with O
various O
stoichiometries O
. O

Moreover O
, O
the O
phases O
of O
CrB3 B
and O
CrB4 B
have O
been O
predicted O
by O
using O
a O
newly O
developed O
particle O
swarm O
optimization O
( O
PSO O
) O
algorithm O
. O

Formation O
enthalpy O
- O
pressure O
diagrams O
reveal O
that O
the O
MoB B
- O
type O
structure O
is O
more O
energetically O
favorable O
than O
the O
TiI B
- O
type O
structure O
for O
CrB B
. O

For O
CrB2 B
, O
the O
WB2 B
- O
type O
structure O
is O
preferred O
at O
zero O
pressure O
. O

The O
predicted O
new O
phase O
of O
CrB3 B
belongs O
to O
the O
hexagonal O
P O
- O
6m2 O
space O
group O
and O
it O
transforms O
into O
an O
orthorhombic O
phase O
as O
the O
pressure O
exceeds O
93 O
GPa O
. O

The O
predicted O
CrB4 B
( O
space O
group O
: O
Pnnm O
) O
phase O
is O
more O
energetically O
favorable O
than O
the O
previously O
proposed O
Immm O
structure O
. O

The O
mechanical O
and O
thermodynamic O
stabilities O
of O
predicted O
CrB3 B
and O
CrB4 B
are O
verified O
by O
the O
calculated O
elastic O
constants O
and O
formation O
enthalpies O
. O

The O
full O
phonon O
dispersion O
calculations O
confirm O
the O
dynamic O
stability O
of O
WB2 B
- O
type O
CrB2 B
and O
predicted O
CrB3 B
. O

The O
large O
shear O
moduli O
, O
large O
Young O
' O
s O
moduli O
, O
low O
Poisson O
ratios O
, O
and O
low O
bulk O
and O
shear O
modulus O
ratios O
of O
CrB4 B
< O
F8FF O
> O
PSC O
and O
CrB4 B
< O
F8FF O
> O
PSD O
indicate O
that O
they O
are O
potential O
hard O
materials O
. O

The O
equilibrium O
metal O
- O
binding O
constants O
were O
determined O
by O
dilute O
solution O
potentiometric O
titration O
of O
monofunctional O
histidine O
- O
modified O
methoxy B
- I
PEG I
and O
were O
found O
to O
be O
consistent O
with O
binding O
constants O
of O
small O
molecule O
analogs O
previously O
studied O
. O

The O
synthetic O
polymer O
- O
based O
sorbent O
Diaion B
HP20SS I
( O
cross O
- O
linked O
polystyrene O
matrix O
) O
is O
used O
as O
an O
alternative O
to O
prepare O
purified O
natural O
product O
libraries O
. O

To O
evaluate O
the O
impact O
of O
chromatographic O
media O
on O
the O
isolation O
of O
biologically O
active O
, O
yet O
chromatographically O
unstable O
natural O
products O
, O
Diaion B
HP20SS I
was O
evaluated O
side O
- O
by O
- O
side O
with O
normal O
- O
phase O
sorbents O
for O
irreversible O
binding O
of O
extract O
constituents O
and O
their O
effects O
on O
bioactivity O
. O

An O
additional O
nonpolar O
column O
wash O
of O
HP20SS B
with O
EtOAc O
retained O
considerable O
bioactivities O
of O
active O
extracts O
. O

However O
, O
HP20SS B
elution O
reduced O
significantly O
HIF O
- O
1 O
inhibitory O
activity O
of O
certain O
extracts O
( O
e O
. O
g O
. O
, O
Asimina O
triloba O
) O
. O

A O
new O
pentacyclic B
phenol I
and O
other O
constituents O
from O
the O
root O
bark O
of O
Bauhinia O
racemosa O
Lamk O
. O

Racemosolone B
( O
1 O
) O
was O
characterised O
as O
a O
pentacyclic B
phenolic I
compound O
possessing O
an O
unusual O
skeleton O
with O
a O
cycloheptane B
ring O
and O
a O
rare O
furopyran B
moiety O
. O

The O
known O
compounds O
were O
characterised O
as O
n B
- I
tetracosane I
, O
beta B
- I
sitosteryl I
stearate I
, O
eicosanoic B
acid I
, O
stigmasterol O
, O
beta O
- O
sitosterol O
, O
racemosol B
, O
octacosyl B
ferulate I
, O
de B
- I
O I
- I
methyl I
racemosol I
, O
lupeol O
and O
1 O
, O
7 O
, O
8 O
, O
12b O
- O
tetrahydro O
- O
2 O
, O
2 O
, O
4 O
- O
trimethyl O
- O
2H O
- O
benzo O
[ O
6 O
, O
7 O
] O
cyclohepta O
[ O
1 O
, O
2 O
, O
3 O
- O
de O
] O
[ O
1 O
] O

Spur O
reactions O
observed O
by O
picosecond O
pulse O
radiolysis O
in O
highly O
concentrated O
bromide B
aqueous O
solutions O
. O

The O
formation O
of O
the O
well O
- O
known O
product O
Br3 B
( I
- I
) I
, O
observed O
in O
the O
steady O
- O
state O
radiolysis O
of O
highly O
concentrated O
Br O
( O
- O
) O
aqueous O
solutions O
, O
has O
now O
been O
directly O
observed O
at O
ultrashort O
times O
corresponding O
to O
the O
relaxation O
of O
the O
spur O
. O

This O
approach O
allows O
several O
transient O
radiolytic O
species O
to O
be O
followed O
in O
parallel O
, O
particularly O
the O
solvated O
electron O
, O
BrOH B
( I
- I
* I
) I
, O
Br2 B
( I
- I
* I
) I
, O
and O
Br3 B
( I
- I
) I
. O

The O
kinetics O
measured O
within O
4 O
ns O
at O
260 O
and O
370 O
nm O
clearly O
exhibit O
that O
the O
decay O
of O
Br2 B
( I
* I
- I
) I
is O
correlated O
with O
the O
formation O
of O
Br3 B
( I
- I
) I
. O

In O
highly O
concentrated O
Br O
( O
- O
) O
solutions O
, O
the O
OH O
( O
* O
) O
radical O
is O
fully O
replaced O
by O
Br2 B
( I
* I
- I
) I
, O
and O
the O
spur O
kinetics O
of O
OH O
( O
* O
) O
radical O
in O
pure O
water O
is O
comparable O
with O
that O
of O
Br2 B
( I
- I
* I
) I
. O

Model O
calculations O
indicate O
that O
the O
main O
OH O
( O
* O
) O
radical O
combination O
product O
H2O2 O
in O
pure O
water O
has O
formation O
kinetics O
similar O
to O
that O
of O
Br3 B
( I
- I
) I
in O
6 O
M O
Br O
( O
- O
) O
solutions O
. O

Characterization O
of O
Palytoxin B
Binding O
to O
HaCaT O
Cells O
Using O
a O
Monoclonal O
Anti O
- O
Palytoxin B
Antibody O
. O

Palytoxin B
( O
PLTX B
) O
is O
the O
reference O
compound O
for O
a O
group O
of O
potent O
marine O
biotoxins O
, O
for O
which O
the O
molecular O
target O
is O
Na O
+ O
/ O
K O
+ O
- O
ATPase O
. O

Indeed O
, O
ouabain O
( O
OUA B
) O
, O
a O
potent O
blocker O
of O
the O
pump O
, O
is O
used O
to O
inhibit O
some O
PLTX B
effects O
in O
vitro O
. O

However O
, O
in O
an O
effort O
to O
explain O
incomplete O
inhibition O
of O
PLTX B
cytotoxicity O
, O
some O
studies O
suggest O
the O
possibility O
of O
two O
different O
binding O
sites O
on O
Na O
+ O
/ O
K O
+ O
- O
ATPase O
. O

Hence O
, O
this O
study O
was O
performed O
to O
characterize O
PLTX B
binding O
to O
intact O
HaCaT O
keratinocytes O
and O
to O
investigate O
the O
ability O
of O
OUA B
to O
compete O
for O
this O
binding O
. O

PLTX B
binding O
to O
HaCaT O
cells O
was O
demonstrated O
by O
immunocytochemical O
analysis O
after O
10 O
min O
exposure O
. O

An O
anti O
- O
PLTX B
monoclonal O
antibody O
- O
based O
ELISA O
showed O
that O
the O
binding O
was O
saturable O
and O
reversible O
, O
with O
a O
K O
( O
d O
) O
of O
3 O
x O
10 O
- O
10 O
M O
. O

However O
, O
kinetic O
experiments O
revealed O
that O
PLTX B
binding O
dissociation O
was O
incomplete O
, O
suggesting O
an O
additional O
, O
OUA B
- O
insensitive O
, O
PLTX B
binding O
site O
. O

Competitive O
experiments O
suggested O
that O
OUA B
acts O
as O
a O
negative O
allosteric O
modulator O
against O
high O
PLTX B
concentrations O
( O
0 O
. O
3 O
- O
1 O
. O
0 O
x O
10 O
- O
7 O
M O
) O
and O
possibly O
as O
a O
non O
- O
competitive O
antagonist O
against O
low O
PLTX B
concentrations O
( O
0 O
. O
1 O
- O
3 O
. O
0 O
x O
10 O
- O
9 O
M O
) O
. O

Antagonism O
was O
supported O
by O
PLTX B
cytotoxicity O
inhibition O
at O
OUA B
concentrations O
that O
displaced O
PLTX B
binding O
( O
1 O
x O
10 O
- O
5 O
M O
) O
. O

However O
, O
this O
inhibition O
was O
incomplete O
, O
supporting O
the O
existence O
of O
both O
OUA B
- O
sensitive O
and O
- O
insensitive O
PLTX B
binding O
sites O
. O

Strong O
fluorescence O
quenching O
was O
also O
observed O
with O
high O
redox O
potential O
metal O
ions O
such O
as O
Ag O
( O
+ O
) O
, O
Au B
( I
3 I
+ I
) I
, O
Cu O
( O
2 O
+ O
) O
and O
Hg O
( O
2 O
+ O
) O
, O
but O
not O
with O
low O
redox O
potential O
ions O
. O

This O
work O
is O
performed O
on O
the O
benchmark O
rare O
gas O
- O
hydrogen B
halide I
interaction O
( O
HCl O
- O
He O
) O
system O
. O

It O
interacts O
with O
cellular O
membrane O
of O
P O
. O
mirabilis O
and O
makes O
it O
highly O
permeable O
, O
forming O
nonspecific O
pores O
on O
plasma O
membrane O
, O
which O
in O
turn O
directs O
the O
release O
of O
260 O
nm O
absorbing O
materials O
and O
uptake O
of O
more O
crystal B
violet I
from O
the O
medium O
into O
the O
cells O
. O

Three O
new O
phenolic O
compounds O
, O
yunnanensins B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
together O
with O
fourteen O
known O
ones O
( O
4 O
- O
17 O
) O
, O
were O
isolated O
from O
the O
leaves O
and O
stems O
of O
Parakmeria O
yunnanensis O
. O

We O
have O
characterized O
the O
lysylation O
system O
of O
Plasmodium O
falciparum O
, O
and O
designed O
, O
synthesized O
, O
and O
tested O
a O
set O
of O
inhibitors O
based O
on O
the O
structure O
of O
the O
natural O
substrate O
intermediate O
: O
lysyl B
- I
adenylate I
. O

The O
human O
cytosolic O
sulfotransferase O
hSULT2A1 O
catalyzes O
the O
sulfation O
of O
a O
broad O
range O
of O
xenobiotics O
, O
as O
well O
as O
endogenous O
hydroxysteroids B
and O
bile O
acids O
. O

Three O
thiol O
oxidants O
were O
used O
as O
model O
compounds O
to O
investigate O
their O
effects O
on O
homogeneous O
preparations O
of O
hSULT2A1 O
: O
glutathione O
disulfide O
, O
5 O
, O
5 O
' O
- O
dithiobis O
( O
2 O
- O
nitrobenzoic O
acid O
) O
, O
and O
1 B
, I
1 I
' I
- I
azobis I
( I
N I
, I
N I
- I
dimethylformamide I
) O
( O
diamide B
) O
. O

The O
effects O
of O
these O
agents O
on O
the O
binding O
of O
substrates O
and O
products O
, O
liquid O
chromatography O
- O
mass O
spectrometry O
identification O
of O
the O
disulfides B
formed O
, O
and O
structural O
modeling O
of O
the O
modified O
enzyme O
were O
examined O
. O

Ypc1p O
can O
catalyze O
the O
reverse O
reaction O
, O
i O
. O
e O
. O
the O
condensation O
of O
free O
fatty O
acids O
with O
phytosphingosine O
or O
dihydrosphingosine B
and O
overexpression O
of O
YPC1 O
or O
YDC1 O
can O
provide O
enough O
ceramide B
synthesis O
as O
to O
rescue O
the O
viability O
of O
cells O
lacking O
the O
normal O
acyl O
- O
CoA O
- O
dependent O
ceramide O
synthases O
. O

To O
better O
understand O
the O
coexistence O
of O
acyl O
- O
CoA O
dependent O
ceramide B
synthases O
and O
ceramidases B
in O
the O
ER O
we O
investigated O
the O
membrane O
topology O
of O
Ypc1p O
by O
probing O
cysteine O
accessibility O
of O
natural O
and O
substituted O
cysteines O
with O
membrane O
non O
- O
permeating O
mass O
- O
tagged O
probes O
. O

The O
design O
of O
alkylated B
- I
C60 I
is O
selected O
from O
our O
recent O
research O
achievements O
, O
as O
the O
most O
attractive O
example O
of O
such O
alkylated O
- O
pi O
systems O
. O

Rapid O
method O
for O
the O
separation O
and O
recovery O
of O
endocrine O
- O
disrupting O
compound O
bisphenol B
AP I
from O
wastewater O
. O

The O
removal O
of O
bisphenol B
AP I
( O
BPAP B
) O
by O
a O
multiwalled O
carbon O
nanotube O
( O
MWCNT O
) O
was O
investigated O
. O

BPAP B
, O
representing O
typical O
scenarios O
for O
the O
BPAP B
- O
MWCNT O
interactions O
, O
was O
employed O
as O
a O
probe O
molecule O
. O

It O
was O
found O
that O
BPAP B
exhibited O
great O
adsorptive O
affinity O
to O
MWCNT O
, O
and O
the O
adsorption O
kinetics O
equilibrium O
was O
arrived O
within O
4 O
. O
0 O
min O
following O
the O
pseudo O
- O
second O
- O
order O
model O
. O

The O
hydrogen O
bond O
, O
hydrophobic O
, O
and O
pi O
- O
pi O
stacking O
interactions O
were O
dominant O
factors O
for O
the O
strong O
adsorption O
of O
BPAP B
, O
instead O
of O
the O
pH O
ionic O
strength O
and O
other O
ionic O
species O
in O
contaminated O
water O
. O

The O
MWCNT O
has O
higher O
stability O
within O
8 O
removal O
- O
regeneration O
recycles O
, O
and O
up O
to O
95 O
% O
of O
recovery O
could O
be O
obtained O
by O
eluting O
the O
adsorbed O
BPAP B
on O
MWCNT O
adsorbent O
using O
ethanol O
/ O
sodium B
hydrate I
solution O
. O

The O
results O
of O
the O
experiment O
on O
real O
samples O
verified O
the O
effectiveness O
for O
the O
recovery O
and O
removal O
of O
BPAP B
from O
wastewater O
samples O
. O

The O
photochemistry O
of O
[ B
CpRu I
( I
CO I
) I
2 I
] I
2 I
in O
P B
( I
OMe I
) I
3 I
/ O
CH2Cl2 O
solution O
has O
been O
studied O
using O
picosecond O
time O
- O
resolved O
infrared O
( O
TRIR O
) O
spectroscopy O
. O

Photolysis O
at O
400 O
nm O
leads O
to O
the O
formation O
of O
17 O
- O
electron O
CpRu B
( I
CO I
) I
2 I
( I
* I
) I
radicals O
, O
which O
react O
on O
the O
picosecond O
time O
scale O
to O
form O
19 O
- O
electron O
CpRu B
( I
CO I
) I
2P I
( I
OMe I
) I
3 I
( I
* I
) I
adducts O
. O

This O
spectral O
assignment O
is O
supported O
by O
analogous O
experiments O
on O
[ B
CpFe I
( I
CO I
) I
2 I
] I
2 I
in O
the O
same O
solvent O
, O
combined O
with O
DFT O
studies O
on O
the O
structures O
of O
the O
19 O
- O
electron O
adducts O
. O

The O
DFT O
results O
predict O
a O
bent O
CO O
ligand O
in O
CpRu B
( I
CO I
) I
2P I
( I
OMe I
) I
3 I
( I
* I
) I
, O
whereas O
approximately O
linear O
Fe B
- I
C I
- I
O I
bond O
angles O
are O
predicted O
for O
CpFe B
( I
CO I
) I
2P I
( I
OMe I
) I
3 I
( I
* I
) I
. O

TRIR O
spectra O
were O
also O
collected O
for O
[ B
CpRu I
( I
CO I
) I
2 I
] I
2 I
in O
neat O
CH2Cl2 O
, O
and O
it O
is O
interesting O
to O
note O
that O
no O
singly O
bridged O
[ B
CpRu I
( I
CO I
) I
] I
2 I
( I
mu I
- I
CO I
) I
photoproduct O
was O
observed O
to O
form O
following O
400 O
- O
or O
267 O
- O
nm O
excitation O
, O
despite O
previous O
observations O
of O
this O
species O
on O
longer O
time O
scales O
. O

Enzyme O
responsive O
hyaluronic O
Acid O
nanocapsules O
containing O
polyhexanide B
and O
their O
exposure O
to O
bacteria O
to O
prevent O
infection O
. O

Here O
, O
we O
show O
that O
novel O
hyaluronic O
acid O
( O
HA O
) O
- O
based O
nanocapsules O
containing O
the O
antimicrobial O
agent O
polyhexanide B
are O
specifically O
cleaved O
in O
the O
presence O
of O
hyaluronidase O
, O
a O
factor O
of O
pathogenicity O
and O
invasion O
for O
bacteria O
like O
Staphylococcus O
aureus O
and O
Escherichia O
coli O
. O

The O
enzyme O
triggered O
release O
of O
a O
model O
dye O
and O
the O
antimicrobial O
polyhexanide B
was O
monitored O
using O
fluorescence O
and O
UV O
spectroscopy O
. O

The O
minocycline B
hydrochloride I
( O
MH O
) O
, O
at O
higher O
doses O
, O
is O
useful O
in O
the O
treatment O
of O
neurodegenerative O
disorders O
and O
owing O
to O
its O
antioxidant O
potential O
, O
it O
may O
have O
nootropic O
effects O
. O

Discovery O
of O
7 B
- I
methoxy I
- I
6 I
- I
[ I
4 I
- I
( I
4 I
- I
methyl I
- I
1 I
, I
3 I
- I
thiazol I
- I
2 I
- I
yl I
) I
- I
1H I
- I
imidazol I
- I
5 I
- I
yl I
] I
- I
1 I
, I
3 I
- I
benzothiazole I
( O
TASP0382088 B
) O
: O
a O
potent O
and O
selective O
transforming O
growth O
factor O
- O
beta O
type O
I O
receptor O
inhibitor O
as O
a O
topical O
drug O
for O
alopecia O
. O

7 B
- I
Methoxy I
- I
6 I
- I
[ I
4 I
- I
( I
4 I
- I
methyl I
- I
1 I
, I
3 I
- I
thiazol I
- I
2 I
- I
yl I
) I
- I
1H I
- I
imidazol I
- I
5 I
- I
yl I
] I
- I
1 I
, I
3 I
- I
benzothiazole I
11 O
( O
TASP0382088 B
) O
was O
synthesized O
and O
evaluated O
as O
transforming O
growth O
factor O
- O
beta O
( O
TGF O
- O
beta O
) O
type O
I O
receptor O
( O
also O
known O
as O
activin O
receptor O
- O
like O
kinase O
5 O
or O
ALK5 O
) O
inhibitor O
. O

Increasing O
the O
proportion O
of O
magnesium B
stearate I
extended O
disintegration O
time O
. O

Discovery O
of O
aromatic O
components O
with O
excellent O
fragrance O
properties O
and O
biological O
activities O
: O
beta B
- I
ionols I
with O
antimelanogenetic O
effects O
and O
their O
asymmetric O
syntheses O
. O

Both O
enantiomers O
of O
dihydro B
- I
beta I
- I
ionol I
and O
beta B
- I
ionol I
, O
contained O
in O
the O
aromatic O
components O
of O
Osmanthus O
flower O
and O
of O
Hakuto O
peach O
, O
were O
obtained O
with O
high O
optical O
purity O
by O
lipase O
- O
catalyzed O
kinetic O
resolution O
of O
the O
racemates O
. O

The O
absolute O
configuration O
and O
the O
enantiomer O
ratios O
of O
dihydro B
- I
beta I
- I
ionol I
in O
the O
aromatic O
components O
of O
Osmanthus O
flower O
and O
of O
Hakuto O
peach O
were O
determined O
. O

The O
asymmetric O
synthesis O
of O
( B
R I
) I
- I
dihydro I
- I
beta I
- I
ionol I
, O
one O
of O
the O
most O
valuable O
raw O
materials O
for O
fragrance O
and O
flavor O
, O
was O
performed O
from O
inexpensive O
beta O
- O
ionone O
via O
lipase O
- O
catalyzed O
dynamic O
kinetic O
resolution O
followed O
by O
reduction O
. O

Three O
new O
orcinol B
- O
conjugated O
hydrolysable O
tannins O
from O
the O
leaves O
of O
Cleyera O
japonica O
. O

Three O
new O
orcinol B
( O
3 B
- I
hydroxy I
- I
5 I
- I
methylphenol I
) O
- O
conjugated O
hydrolysable O
tannins O
, O
together O
with O
two O
known O
compounds O
were O
isolated O
from O
the O
leaves O
of O
Cleyera O
japonica O
( O
CJ O
) O
, O
and O
have O
been O
tentatively O
named O
cleyeratannin B
A I
( O
1 O
) O
, O
cleyeratannin B
B I
( O
2 O
) O
and O
cleyeratannin B
C I
( O
3 O
) O
. O

To O
evaluate O
their O
anti O
- O
oxidative O
activities O
, O
1 O
, O
1 O
- O
diphenyl O
- O
2 O
- O
picrylhydrazyl O
( O
DPPH O
) O
/ O
free O
radical O
scavenging O
activity O
and O
nitroblue O
tetrazolium O
( O
NBT B
) O
/ O
superoxide O
anion O
scavenging O
activity O
were O
determined O
. O

Ceramide B
phosphoethanolamine I
biosynthesis O
in O
Drosophila O
is O
mediated O
by O
a O
unique O
ethanolamine O
phosphotransferase O
in O
the O
Golgi O
lumen O
. O

Its O
production O
involves O
the O
transfer O
of O
phosphocholine B
from O
phosphatidylcholine O
onto O
ceramide B
, O
a O
reaction O
catalyzed O
by O
SM O
synthase O
in O
the O
Golgi O
lumen O
. O

Drosophila O
lacks O
SM O
and O
instead O
synthesizes O
the O
SM O
analogue O
ceramide B
phosphoethanolamine I
( O
CPE B
) O
as O
the O
principal O
membrane O
sphingolipid O
. O

The O
corresponding O
CPE B
synthase O
shares O
mechanistic O
features O
with O
enzymes O
mediating O
phospholipid O
biosynthesis O
via O
the O
Kennedy O
pathway O
. O

Using O
a O
functional O
cloning O
strategy O
, O
we O
here O
identified O
a O
CDP B
- O
ethanolamine O
: O
ceramide B
ethanolamine O
phosphotransferase O
as O
the O
enzyme O
responsible O
for O
CPE B
production O
in O
Drosophila O
. O

CPE B
synthase O
constitutes O
a O
new O
branch O
within O
the O
CDP B
- O
alcohol O
phosphotransferase O
superfamily O
with O
homologues O
in O
Arthropoda O
( O
insects O
, O
spiders O
, O
mites O
, O
scorpions O
) O
, O
Cnidaria O
( O
Hydra O
, O
sea O
anemones O
) O
, O
and O
Mollusca O
( O
oysters O
) O
but O
not O
in O
most O
other O
animal O
phyla O
. O

The O
enzyme O
resides O
in O
the O
Golgi O
complex O
with O
its O
active O
site O
facing O
the O
lumen O
, O
contrary O
to O
the O
membrane O
topology O
of O
other O
CDP B
- O
alcohol O
phosphotransferases O
. O

Our O
findings O
open O
up O
an O
important O
new O
avenue O
to O
address O
the O
biological O
role O
of O
CPE B
, O
an O
enigmatic O
membrane O
constituent O
of O
a O
wide O
variety O
of O
invertebrate O
and O
marine O
organisms O
. O

The O
gas O
- O
phase O
reaction O
of O
methane B
sulfonic I
acid I
with O
the O
hydroxyl O
radical O
without O
and O
with O
water O
vapor O
. O

The O
gas O
phase O
reaction O
between O
methane B
sulfonic I
acid I
( O
CH3SO3H B
; O
MSA B
) O
and O
the O
hydroxyl O
radical O
( O
HO B
) O
, O
without O
and O
with O
a O
water O
molecule O
, O
was O
investigated O
with O
DFT O
- O
B3LYP O
and O
CCSD O
( O
T O
) O
- O
F12 O
methods O
. O

For O
the O
bare O
reaction O
we O
have O
found O
two O
reaction O
mechanisms O
, O
involving O
proton O
coupled O
electron O
transfer O
and O
hydrogen O
atom O
transfer O
processes O
that O
produce O
CH3SO3 B
and O
H2O O
. O

CH3SO3H B
forms O
two O
very O
stable O
complexes O
with O
water O
with O
computed O
binding O
energies O
of O
about O
10 O
kcal O
mol O
( O
- O
1 O
) O
. O

The O
presence O
of O
a O
single O
water O
molecule O
makes O
the O
reaction O
between O
CH3SO3H B
and O
HO B
much O
more O
complex O
, O
introducing O
a O
new O
reaction O
that O
consists O
in O
the O
interchange O
of O
H2O O
between O
HO B
and O
CH3SO3H B
. O

Our O
kinetic O
calculations O
show O
that O
99 O
. O
5 O
% O
of O
the O
reaction O
involves O
this O
interchange O
of O
the O
water O
molecule O
and O
, O
consequently O
, O
water O
vapor O
does O
not O
play O
any O
role O
in O
the O
oxidation O
reaction O
of O
methane B
sulfonic I
acid I
by O
the O
hydroxyl O
radical O
. O

However O
, O
the O
overwhelming O
majority O
of O
previously O
reported O
temperature O
- O
responsive O
polymers O
are O
based O
on O
poly O
( O
N O
- O
isopropylacrylamide O
) O
( O
PNIPAM B
) O
, O
despite O
the O
fact O
that O
a O
wide O
range O
of O
other O
thermoresponsive O
polymers O
have O
demonstrated O
similar O
promise O
for O
the O
preparation O
of O
adaptive O
materials O
. O

Bacteriopheophytin B
a I
in O
the O
active O
branch O
of O
the O
reaction O
center O
of O
rhodobacter O
sphaeroides O
is O
not O
disturbed O
by O
the O
protein O
matrix O
as O
shown O
by O
13C O
photo O
- O
CIDNP O
MAS O
NMR O
. O

The O
electronic O
structure O
of O
bacteriopheophytin B
a I
( O
BPhe B
a I
) O
, O
the O
primary O
electron O
acceptor O
( O
Phi O
A O
) O
in O
photosynthetic O
reaction O
centers O
( O
RCs O
) O
of O
the O
purple O
bacterium O
Rhodobacter O
sphaeroides O
, O
is O
investigated O
by O
photochemically O
induced O
dynamic O
nuclear O
polarization O
( O
photo O
- O
CIDNP O
) O
magic O
- O
angle O
spinning O
( O
MAS O
) O
NMR O
spectroscopy O
at O
atomic O
resolution O
. O

By O
comparison O
of O
these O
chemical O
shifts O
to O
those O
obtained O
from O
monomeric O
BPhe B
a I
in O
solution O
, O
it O
is O
demonstrated O
that O
Phi O
A O
in O
the O
active O
branch O
appears O
to O
be O
electronically O
close O
to O
free O
bacteriopheophytin B
. O

Highly O
enantioselective O
rhodium B
- O
catalyzed O
[ O
2 O
+ O
2 O
+ O
2 O
] O
cycloaddition O
of O
diynes B
to O
sulfonimines B
. O

A O
new O
asymmetric O
[ O
2 O
+ O
2 O
+ O
2 O
] O
cycloaddition O
of O
diynes B
to O
sulfonimines B
under O
rhodium B
catalysis O
that O
provides O
the O
corresponding O
enantioenriched O
1 B
, I
2 I
- I
dihydropyridines I
in O
good O
yields O
is O
described O
. O

Thiadiazole B
nucleus O
is O
present O
as O
a O
core O
structural O
component O
in O
an O
array O
of O
drug O
categories O
such O
as O
antimicrobial O
, O
anti O
- O
inflammatory O
, O
analgesic O
, O
antiepileptic O
, O
antiviral O
, O
antineoplastic O
, O
and O
antitubercular O
agents O
. O

The O
broad O
and O
potent O
activity O
of O
thiadiazole B
and O
their O
derivatives O
has O
established O
them O
as O
pharmacologically O
significant O
scaffolds O
. O

In O
this O
study O
, O
an O
attempt O
has O
been O
made O
with O
recent O
research O
findings O
on O
this O
nucleus O
, O
to O
review O
the O
structural O
modifications O
on O
different O
thiadiazole B
derivatives O
for O
various O
pharmacological O
activities O
. O

Trimethylamine B
N I
- I
oxide I
reductase O
( O
TorA O
) O
is O
a O
model O
bacterial O
Tat O
substrate O
and O
is O
a O
molybdenum B
cofactor O
- O
dependent O
enzyme O
. O

beta O
- O
Sheet O
Nanocrystalline O
Domains O
Formed O
from O
Phosphorylated B
Serine I
- O
Rich O
Motifs O
in O
Caddisfly O
Larval O
Silk O
: O
A O
Solid O
State O
NMR O
and O
XRD O
Study O
. O

NMR O
and O
X O
- O
ray O
results O
provide O
strong O
supporting O
evidence O
for O
a O
structural O
model O
in O
which O
phosphorylated B
serine I
repeats O
( O
pSX O
) O
4 O
complex O
with O
divalent O
cations O
Ca O
( O
2 O
+ O
) O
and O
Mg O
( O
2 O
+ O
) O
to O
form O
rigid O
nanocrystalline O
beta O
- O
sheet O
structures O
in O
caddisfly O
silk O
. O

( O
13 O
) O
C O
NMR O
data O
suggests O
that O
both O
phosphorylated B
serine I
and O
neighboring O
valine O
residues O
exist O
in O
a O
beta O
- O
sheet O
conformation O
while O
glycine O
and O
leucine O
residues O
common O
in O
GGX O
repeats O
likely O
reside O
in O
random O
coil O
conformations O
. O

Additionally O
, O
( O
31 O
) O
P O
chemical O
shift O
anisotropy O
( O
CSA O
) O
analysis O
indicates O
that O
the O
phosphates O
on O
phosphoserine B
residues O
are O
doubly O
ionized O
, O
and O
are O
charge O
- O
stabilized O
by O
divalent O
cations O
. O

Previously O
, O
we O
have O
found O
that O
BRN B
- I
103 I
, O
a O
nicotinamide O
derivative O
, O
inhibits O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
- O
mediated O
angiogenesis O
signaling O
in O
human O
endothelial O
cells O
. O

We O
found O
that O
2 B
- I
{ I
1 I
- I
[ I
1 I
- I
( I
6 I
- I
chloro I
- I
5 I
- I
fluoropyrimidin I
- I
4 I
- I
yl I
) I
ethyl I
] I
piperidin I
- I
4 I
- I
ylamino I
} I
- I
N I
- I
( I
3 I
- I
chlorophenyl I
) I
pyridine I
- I
3 I
- I
carboxamide I
( O
BRN B
- I
250 I
) O
significantly O
inhibited O
human O
umbilical O
vascular O
endothelial O
cells O
( O
HUVECs O
) O
proliferation O
, O
migration O
, O
tube O
formation O
, O
and O
microvessel O
growth O
in O
a O
concentration O
range O
of O
10 O
- O
100 O
nM O
. O

Furthermore O
, O
BRN B
- I
250 I
inhibited O
the O
VEGF O
- O
induced O
phosphorylation O
and O
intracellular O
tyrosine O
kinase O
activity O
of O
VEGF O
receptor O
2 O
( O
VEGFR2 O
) O
and O
the O
activation O
of O
its O
downstream O
AKT O
pathway O
. O

Taken O
together O
, O
these O
findings O
suggest O
that O
BRN B
- I
250 I
be O
considered O
a O
potential O
lead O
compound O
for O
cancer O
therapy O
. O

Recently O
, O
we O
reported O
the O
FDA O
- O
approved O
anthelmintic O
drug O
Niclosamide B
inhibits O
Wnt O
/ O
beta O
- O
catenin O
signaling O
by O
a O
unique O
mechanism O
, O
though O
the O
target O
responsible O
remains O
unknown O
. O

We O
found O
inhibition O
of O
Wnt O
signaling O
by O
Niclosamide B
appears O
unique O
among O
the O
structurally O
- O
related O
anthelmintic O
agents O
tested O
and O
found O
the O
potency O
and O
functional O
response O
was O
dependent O
on O
small O
changes O
in O
the O
chemical O
structure O
of O
Niclosamide B
. O

Overall O
, O
these O
findings O
support O
efforts O
to O
identify O
the O
target O
of O
Niclosamide B
inhibition O
of O
Wnt O
/ O
beta O
- O
catenin O
signaling O
and O
the O
discovery O
of O
potent O
and O
selective O
modulators O
to O
treat O
human O
disease O
. O

Jacaric B
acid I
and O
its O
octadecatrienoic B
acid I
geoisomers O
induce O
apoptosis O
selectively O
in O
cancerous O
human O
prostate O
cells O
: O
a O
mechanistic O
and O
3 O
- O
D O
structure O
- O
activity O
study O
. O

In O
this O
study O
, O
we O
determined O
the O
ability O
of O
seven O
dietary O
C B
- I
18 I
fatty I
acids I
to O
cause O
cytotoxicity O
and O
induce O
apoptosis O
in O
various O
types O
of O
human O
prostate O
cancer O
cells O
. O

These O
fatty O
acids O
included O
jacaric B
and I
punicic I
acid I
found O
in O
jacaranda O
and O
pomegranate O
seed O
oil O
, O
respectively O
, O
three O
octadecatrienoic O
geometric O
isomers O
( O
alpha B
- I
and I
beta I
- I
calendic I
and I
catalpic I
acid I
) O
and O
two O
mono B
- I
unsaturated I
C I
- I
18 I
fatty I
acids I
( O
trans B
- I
and I
cis I
- I
vaccenic I
acid I
) O
. O

Jacaric B
acid I
and O
four O
of O
its O
octadecatrienoic O
geoisomers O
selectively O
induced O
apoptosis O
in O
hormone O
- O
dependent O
( O
LNCaP O
) O
and O
- O
independent O
( O
PC O
- O
3 O
) O
human O
prostate O
cancer O
cells O
, O
whilst O
not O
affecting O
the O
viability O
of O
normal O
human O
prostate O
epithelial O
cells O
( O
RWPE O
- O
1 O
) O
. O

Jacaric B
acid I
induced O
concentration O
- O
and O
time O
- O
depedent O
LNCaP O
cell O
death O
through O
activation O
of O
intrinsic O
and O
extrinsic O
apoptotic O
pathways O
resulting O
in O
cleavage O
of O
PARP O
- O
1 O
, O
modulation O
of O
pro O
- O
and O
antiapoptotic O
Bcl O
- O
2 O
family O
of O
proteins O
and O
increased O
cleavage O
of O
caspase O
- O
3 O
, O
- O
8 O
and O
- O
9 O
. O

Jacaric B
acid I
induced O
apoptosis O
in O
PC O
- O
3 O
cells O
by O
activation O
of O
the O
intrinsic O
pathway O
only O
. O

The O
spatial O
conformation O
cis O
, O
trans O
, O
cis O
of O
jacaric B
and I
punicic I
acid I
was O
shown O
to O
play O
a O
key O
role O
in O
the O
increased O
potency O
and O
efficacy O
of O
these O
two O
fatty O
acids O
in O
comparison O
to O
the O
five O
other O
C B
- I
18 I
fatty I
acids I
tested O
. O

Three O
- O
dimensional O
conformational O
analysis O
using O
the O
PubChem O
Database O
( O
http O
: O
/ O
/ O
pubchem O
. O
ncbi O
. O
nlm O
. O
nih O
. O
gov O
) O
showed O
that O
the O
cytotoxic O
potency O
of O
the O
C B
- I
18 I
fatty I
acids I
was O
related O
to O
their O
degree O
of O
conformational O
similarity O
to O
our O
cytotoxic O
reference O
compound O
, O
punicic B
acid I
, O
based O
on O
optimized O
shape O
( O
ST O
) O
and O
feature O
( O
CT O
) O
similarity O
scores O
, O
with O
jacaric B
acid I
being O
most O
' O
biosimilar O
' O
( O
ST O
( O
ST O
- O
opt O
) O
= O
0 O
. O
81 O
; O
CT O
( O
CT O
- O
opt O
) O
= O

Synthesis O
and O
anti O
- O
acetylcholinesterase O
properties O
of O
novel O
beta B
- I
and I
gamma I
- I
substituted I
alkoxy I
organophosphonates I
. O

In O
this O
report O
, O
we O
prepared O
a O
panel O
of O
beta B
- I
substituted I
ethoxy I
and I
gamma I
- I
substituted I
propoxy I
phosphonoesters I
of O
the O
type O
p B
- I
NO I
( I
2 I
) I
PhO I
- I
P I
( I
X I
) I
( I
R I
) I
[ I
( I
O I
( I
CH I
( I
2 I
) I
) I
( I
n I
) I
Z I
] I
( O
R B
= I
Me I
, I
Et I
; I
X I
= I
O I
, I
S I
; I
n I
= I
2 I
, I
3 I
; I
Z I
= I
halogen I
, I
OTs I
) O
and O
examined O
the O
inhibition O
of O
three O
AChEs O
by O
select O
structures O
in O
the O
panel O
. O

The O
beta B
- I
fluoroethoxy I
methylphosphonate I
analog O
( O
R B
= I
Me I
, I
Z I
= I
F I
, I
n I
= I
2 I
) O
was O
the O
most O
potent O
anti O
- O
AChE O
compound O
comparable O
( O
ki O
~ O
6 O
x O
10 O
( O
6 O
) O
M O
( O
- O
1 O
) O
min O
( O
- O
1 O
) O
) O
to O
paraoxon O
against O
EEAChE O
. O

Analogs O
with O
Z B
= I
Br I
, I
I I
, I
or I
OTs I
were O
weak O
inhibitors O
of O
the O
AChEs O
, O
and O
methyl B
phosphonates I
( O
R B
= I
Me I
) O
were O
more O
potent O
than O
the O
corresponding O
ethyl B
phosphonates I
( O
R B
= I
Et I
) O
. O

As O
expected O
, O
analogs O
with O
a O
thionate B
linkage O
( O
PS O
) O
were O
poor O
inhibitors O
of O
the O
AChEs O
. O

N B
- I
Alkyldeoxynojirimyci I
derivatives O
with O
novel O
terminal O
tertiary B
amide I
substitution O
for O
treatment O
of O
bovine O
viral O
diarrhea O
virus O
( O
BVDV O
) O
, O
Dengue O
, O
and O
Tacaribe O
virus O
infections O
. O

Novel O
N B
- I
alkyldeoxynojirimyci I
( O
NADNJs B
) O
with O
two O
hydrophobic O
groups O
attached O
to O
a O
nitrogen O
linker O
on O
the O
alkyl O
chain O
were O
designed O
. O

A O
novel O
NADNJ B
containing O
a O
terminal O
tertiary B
carboxamide I
moiety O
was O
discovered O
that O
was O
a O
potent O
inhibitor O
against O
BVDV O
. O

2 B
- I
Substituted I
- I
2 I
- I
amino I
- I
6 I
- I
boronohexanoic I
acids I
as O
arginase O
inhibitors O
. O

Substitution O
at O
the O
alpha O
center O
of O
the O
known O
human O
arginase O
inhibitor O
2 B
- I
amino I
- I
6 I
- I
boronohexanoic I
acid I
( O
ABH B
) O
is O
acceptable O
in O
the O
active O
site O
pockets O
of O
both O
human O
arginase O
I O
and O
arginase O
II O
. O

In O
particular O
, O
substituents O
with O
a O
tertiary B
amine I
linked O
via O
a O
two O
carbon O
chain O
show O
improved O
inhibitory O
potency O
for O
both O
enzyme O
isoforms O
. O

This O
potency O
improvement O
can O
be O
rationalized O
by O
X O
- O
ray O
crystallography O
, O
which O
shows O
a O
water O
- O
mediated O
contact O
between O
the O
basic O
nitrogen O
and O
the O
carboxylic O
acid O
side O
chain O
of O
Asp200 B
, O
which O
is O
situated O
at O
the O
mouth O
of O
the O
active O
site O
pocket O
of O
arginase O
II O
( O
Asp181 B
in O
arginase O
I O
) O
. O

We O
believe O
that O
this O
is O
the O
first O
literature O
report O
of O
compounds O
with O
improved O
arginase O
inhibitory O
activity O
, O
relative O
to O
ABH B
, O
and O
represents O
a O
promising O
starting O
point O
for O
further O
optimization O
of O
in O
vitro O
potency O
and O
the O
identification O
of O
better O
tool O
molecules O
for O
in O
vivo O
investigations O
of O
the O
potential O
pathophysiological O
roles O
of O
arginases O
. O

In O
the O
present O
work O
, O
GSH O
( O
1 O
) O
or O
( B
R I
) I
- I
alpha I
- I
lipoic I
acid I
( O
LA O
) O
( O
2 O
) O
have O
been O
covalently O
linked O
with O
the O
NMDA O
receptor O
antagonists O
memantine O
( O
MEM B
) O
. O

Tumor O
delivery O
of O
Photofrin B
( O
R O
) O
by O
PLL B
- I
g I
- I
PEG I
for O
photodynamic O
therapy O
. O

Photofrin B
( O
R O
) O
( O
porfimer B
sodium I
) O
is O
a O
photosensitive O
reagent O
used O
for O
photodynamic O
therapy O
( O
PDT O
) O
of O
tumors O
and O
dysplasias O
. O

However O
, O
a O
photosensitive O
reaction O
is O
a O
major O
side O
effect O
of O
systemically O
delivered O
Photofrin B
. O

To O
enhance O
localization O
of O
Photofrin B
to O
tumors O
, O
we O
have O
formulated O
Photofrin B
with O
the O
tumor O
- O
localizing O
graft O
copolymer O
poly B
( I
ethylene I
glycol I
) I
- I
grafted I
poly I
( I
l I
- I
lysine I
) I
, O
PLL B
- I
g I
- I
PEG I
. O

We O
demonstrate O
that O
Photofrin B
preferentially O
interacts O
with O
PLL B
- I
g I
- I
PEG I
through O
both O
ionic O
and O
hydrophobic O
interactions O
. O

The O
serum O
competitive O
study O
showed O
that O
the O
highly O
PEG B
- I
grafted I
PLL I
is O
better O
for O
preventing O
serum O
binding O
to O
the O
Photofrin B
/ O
PLL B
- I
g I
- I
PEG I
complex O
. O

In O
tumor O
- O
bearing O
mice O
, O
formulation O
of O
Photofrin B
with O
PLL B
- I
g I
- I
PEG I
enhanced O
tumor O
localization O
of O
Photofrin B
as O
twice O
as O
Photofrin B
alone O
and O
concomitantly O
suppressed O
the O
photosensitivity O
reaction O
drastically O
. O

Examination O
of O
the O
effect O
of O
increasing O
the O
number O
of O
intra O
- O
disulfide B
amino I
functional O
groups O
on O
the O
performance O
of O
small O
molecule O
cyclic O
polyamine B
disulfide I
vectors O
. O

Recently O
, O
we O
reported O
on O
the O
ability O
of O
a O
series O
of O
small O
molecule O
, O
cyclic B
polyamine I
disulfides I
to O
condense O
and O
cage O
plasmid O
DNA O
( O
pDNA O
) O
by O
a O
process O
of O
thermodynamically O
controlled O
template O
polymerization O
, O
leading O
to O
a O
series O
of O
corresponding O
pDNA O
- O
polyplex O
nanoparticles O
able O
to O
mediate O
high O
levels O
of O
transfection O
with O
no O
associated O
cytotoxicities O
. O

The O
leading O
cyclic B
polyamine I
disulfide I
was O
shown O
to O
be O
the O
spermine B
tetra I
- I
amine I
disulfide I
( O
TetraN B
- I
3 I
, I
4 I
, I
3 I
) O
. O

Herein O
we O
report O
on O
the O
significantly O
more O
challenging O
syntheses O
of O
cyclic B
disulfides I
with O
longer O
polyamine O
motifs O
. O

Two O
new O
cyclic B
polyamine I
disulfides I
, O
based O
on O
hexa B
- I
and I
octa I
- I
amine I
inserts O
, O
were O
prepared O
and O
their O
transfection O
efficacies O
and O
cytotoxicities O
compared O
with O
our O
previously O
reported O
cyclic B
tri I
- I
and I
tetra I
- I
amine I
disulfides I
. O

The O
new O
cyclic B
hexa I
- I
and I
octa I
- I
amine I
disulfides I
prove O
more O
effective O
at O
transfection O
in O
vitro O
, O
especially O
of O
lung O
epithelial O
A549 O
cell O
line O
. O

By O
contrast O
, O
our O
original O
cyclic B
tetra I
- I
amine I
disulfide I
remains O
the O
most O
efficient O
agent O
for O
the O
transfection O
of O
lung O
epithelial O
cells O
in O
vivo O
following O
intra O
- O
nasal O
administration O
. O

Our O
data O
in O
toto O
support O
the O
concept O
of O
shorter O
cyclic B
polyamine I
disulfides I
as O
preferred O
agents O
for O
polycation O
- O
mediated O
controlled O
condensation O
and O
functional O
delivery O
of O
pDNA O
to O
lung O
epithelial O
cells O
in O
vivo O
. O

Three O
- O
month O
subchronic O
intramuscular O
toxicity O
study O
of O
rotigotine B
- O
loaded O
microspheres O
in O
SD O
rats O
. O

Rotigotine B
is O
a O
non O
- O
ergoline B
D3 O
/ O
D2 O
/ O
D1 O
dopamine O
agonist O
for O
treating O
PD O
. O

As O
a O
new O
treatment O
option O
for O
CDS O
, O
rotigotine B
- O
loaded O
microspheres O
( O
RoMS O
) O
, O
a O
long O
- O
acting O
sustained O
- O
release O
microspheres O
for O
injection O
with O
poly O
( O
lactide O
- O
co O
- O
glycolide O
) O
as O
drug O
carrier O
, O
are O
now O
being O
evaluated O
in O
clinical O
trial O
. O

The O
major O
toxicological O
effects O
were O
associated O
with O
the O
dopamine O
agonist O
- O
related O
pharmacodynamic O
properties O
of O
rotigotine B
( O
e O
. O
g O
. O
hyperactivity O
and O
stereotype O
, O
enlarged O
ovary O
, O
sporadic O
gastric O
mucous O
membrane O
lesions O
, O
decreased O
body O
weight O
, O
food O
consumption O
and O
prolactin O
, O
and O
increased O
mononuclear O
cell O
, O
neutrophil O
granulocyte O
, O
aspartate O
aminotransferase O
and O
alanine O
aminotransferase O
) O
and O
foreign O
body O
removal O
reaction O
induced O
by O
poly O
( O
lactide O
- O
co O
- O
glycolide O
) O
and O

Here O
we O
generated O
TAT O
fusion O
of O
the O
Ainp1 O
peptide O
( O
6His B
- O
TAT O
- O
Ainp1 O
) O
to O
determine O
whether O
and O
how O
the O
Ainp1 O
peptide O
suppresses O
the O
HIF O
- O
1 O
function O
. O

The O
bacterially O
expressed O
6His B
- O
TAT O
- O
Ainp1 O
was O
purified O
under O
denatured O
condition O
and O
then O
refolded O
by O
limited O
dialysis O
. O

The O
refolded O
6His B
- O
TAT O
- O
Ainp1 O
interacts O
with O
the O
helix O
- O
loop O
- O
helix O
( O
HLH O
) O
domain O
of O
ARNT O
in O
a O
similar O
fashion O
as O
the O
native O
6His B
- O
Ainp1 O
. O

6His B
- O
TAT O
- O
Ainp1 O
colocalizes O
with O
ARNT O
in O
the O
nucleus O
of O
HeLa O
and O
Hep3B O
cells O
after O
protein O
transduction O
. O

At O
2 O
mu O
M O
concentration O
, O
6His B
- O
TAT O
- O
Ainp1 O
is O
not O
cytotoxic O
in O
HeLa O
cells O
but O
suppresses O
the O
cobalt O
chloride O
- O
activated O
, O
hypoxia O
responsive O
enhancer O
- O
driven O
luciferase O
expression O
in O
a O
dose O
- O
dependent O
manner O
. O

The O
protein O
levels O
of O
HIF O
- O
1 O
alpha O
and O
ARNT O
are O
not O
altered O
in O
the O
presence O
of O
6His B
- O
TAT O
- O
Ainp1 O
. O

Toxic O
and O
genotoxic O
effects O
of O
Roundup B
on O
tadpoles O
of O
the O
Indian O
skittering O
frog O
( O
Euflictis O
cyanophlyctis O
) O
in O
the O
presence O
and O
absence O
of O
predator O
stress O
. O

We O
examined O
the O
toxic O
and O
genotoxic O
effects O
of O
Roundup B
, O
a O
commercial O
formulation O
of O
glyphosate O
, O
in O
the O
tadpoles O
of O
the O
Indian O
skittering O
frog O
( O
Euflictis O
cyanophlyctis O
) O
. O

Roundup B
at O
different O
concentrations O
( O
0 O
, O
1 O
, O
2 O
, O
3 O
, O
4 O
and O
8mg O
acid O
equivalent O
( O
ae O
) O
/ O
L O
) O
, O
tested O
in O
a O
2 O
x O
6 O
factorial O
design O
in O
the O
presence O
and O
absence O
of O
predator O
stress O
, O
induced O
concentration O
- O
dependent O
lethality O
in O
tadpoles O
. O

The O
96 O
- O
h O
LC50 O
for O
Roundup B
in O
the O
absence O
and O
presence O
of O
predator O
stress O
were O
3 O
. O
76mgae O
/ O
L O
and O
3 O
. O
39mgae O
/ O
L O
, O
respectively O
. O

The O
10 O
- O
day O
LC50 O
value O
for O
Roundup B
was O
significantly O
lower O
, O
2 O
. O
12mgae O
/ O
L O
and O
1 O
. O
91mgae O
/ O
L O
in O
the O
absence O
and O
presence O
of O
predator O
stress O
, O
respectively O
. O

Lower O
concentrations O
of O
Roundup B
( O
1 O
, O
2 O
and O
3mgae O
/ O
L O
) O
induced O
the O
formation O
of O
micronuclei O
( O
MN O
) O
in O
the O
erythrocytes O
of O
tadpoles O
at O
24 O
- O
h O
( O
F3 O
, O
56 O
= O
10 O
. O
286 O
, O
p O
< O
0 O
. O
001 O
) O
, O
48 O
- O
h O
( O
F3 O
, O
56 O
= O
48 O
. O
255 O
, O
p O
< O
0 O
. O
001 O
) O
, O
72 O
- O
h O
( O
F3 O
, O
56 O
= O
118 O
. O
933 O
, O
p O
< O
0 O
. O
001 O
) O
and O
96 O
- O
h O
( O
F3 O
, O
56 O
= O
85 O
. O
414 O
, O
p O
< O
0 O
. O
001 O
) O

Presence O
of O
predator O
stress O
apparently O
increased O
the O
toxicity O
and O
genotoxicity O
of O
Roundup B
; O
but O
these O
effects O
were O
not O
statistically O
significant O
. O

These O
findings O
suggest O
that O
Roundup B
at O
environmentally O
relevant O
concentrations O
has O
lethal O
and O
genotoxic O
impact O
on O
E O
. O
cyanophlyctis O
; O
which O
may O
have O
long O
- O
term O
fitness O
consequence O
to O
the O
species O
. O

Synthesis O
and O
biochemical O
activities O
of O
antiproliferative O
amino O
acid O
and O
phosphate O
derivatives O
of O
microtubule O
- O
disrupting O
beta B
- I
lactam I
combretastatins I
. O

The O
synthesis O
and O
biochemical O
activities O
of O
novel O
water O
- O
soluble O
beta O
- O
lactam O
analogues O
of O
combretastatin B
A I
- I
4 I
are O
described O
. O

The O
first O
series O
of O
compounds O
investigated O
, O
beta B
- I
lactam I
phosphate I
esters I
7a O
, O
8a O
and O
9a O
, O
exhibited O
potent O
antiproliferative O
activity O
and O
caused O
microtubule O
disruption O
in O
human O
breast O
carcinoma O
- O
derived O
MCF O
- O
7 O
cells O
. O

The O
second O
series O
of O
compounds O
, O
beta B
- I
lactam I
amino I
acid I
amides I
( O
including O
10k O
and O
11l O
) O
displayed O
potent O
antiproliferative O
activity O
in O
MCF O
- O
7 O
cells O
, O
disrupted O
microtubules O
in O
MCF O
- O
7 O
cells O
and O
also O
inhibited O
the O
polymerisation O
of O
tubulin O
in O
vitro O
. O

This O
indicates O
that O
the O
beta B
- I
lactam I
amides I
did O
not O
require O
metabolic O
activation O
to O
have O
antiproliferative O
effects O
, O
in O
contrast O
to O
the O
phosphate O
series O
. O

Molecular O
modelling O
studies O
indicated O
potential O
binding O
conformations O
for O
the O
beta B
- I
lactam I
amino I
acid I
amides I
10k O
and O
11l O
in O
the O
colchicine O
- O
binding O
site O
of O
tubulin O
. O

Synthesis O
, O
evaluation O
and O
absolute O
configuration O
assignment O
of O
novel O
dihydropyrimidin B
- I
2 I
- I
ones I
as O
picomolar O
sodium O
iodide O
symporter O
inhibitors O
. O

A O
small O
library O
of O
dihydropyrimidin B
- I
2 I
- I
ones I
( O
DHPMs B
) O
was O
synthesized O
and O
evaluated O
for O
their O
potency O
to O
block O
iodide O
entrapment O
in O
rat O
thyroid O
cells O
. O

Three O
DHPMs B
were O
further O
resolved O
from O
racemates O
using O
chiral O
HPLC O
and O
absolute O
configurations O
were O
assigned O
using O
circular O
dichroism O
spectroscopy O
. O

The O
extracted O
DNA O
was O
hydrolyzed O
and O
2 B
' I
- I
deoxycytidine I
and O
5 B
- I
methyl I
- I
2 I
' I
- I
deoxycytidine I
were O
determined O
by O
HPLC O
- O
UV O
. O

The O
% O
5 B
- I
methyl I
- I
2 I
' I
- I
deoxycytidine I
content O
of O
DNA O
was O
significantly O
higher O
in O
the O
brain O
compared O
to O
the O
liver O
. O

Moreover O
, O
there O
was O
no O
difference O
in O
the O
% O
5 B
- I
methyl I
- I
2 I
' I
- I
deoxycytidine I
content O
of O
DNA O
between O
the O
cocaine O
and O
the O
heroin O
treated O
animals O
. O

Rational O
design O
, O
synthesis O
and O
QSAR O
study O
of O
vasorelaxant O
active O
3 B
- I
pyridinecarbonitrile I
incorporating O
1H B
- I
benzimidazol I
- I
2 I
- I
yl I
function O
. O

A O
variety O
of O
2 B
- I
alkoxy I
- I
4 I
- I
aryl I
- I
6 I
- I
( I
1H I
- I
benzimidazol I
- I
2 I
- I
yl I
) I
- I
3 I
- I
pyridinecarbonitrile I
4a O
- O
r O
were O
prepared O
via O
either O
regioselective O
reaction O
of O
3 B
- I
aryl I
- I
1 I
- I
( I
1H I
- I
benzimidazol I
- I
2 I
- I
yl I
) I
- I
2 I
- I
propen I
- I
1 I
- I
ones I
3 O
with O
malononitrile O
or O
ylidenemalononitrile B
6 O
with O
2 B
- I
acetyl I
- I
1H I
- I
benzimidazoles I
1 O
in O

the O
presence O
of O
sodium B
alkoxide I
in O
the O
corresponding O
alcohol O
. O

All O
the O
synthesized O
compounds O
showed O
significant O
vasodilation O
properties O
using O
isolated O
thoracic O
aortic O
rings O
of O
rats O
pre O
- O
contracted O
with O
norepinephrine B
hydrochloride I
standard O
technique O
. O

Compounds O
4d O
, O
4p O
, O
4l O
, O
and O
4f O
exhibited O
remarkable O
activity O
compared O
with O
prazosin B
hydrochloride I
, O
which O
was O
used O
as O
a O
reference O
standard O
in O
the O
present O
study O
. O

Nonclassical O
antifolates O
, O
part O
3 O
: O
Synthesis O
, O
biological O
evaluation O
and O
molecular O
modeling O
study O
of O
some O
new O
2 B
- I
heteroarylthio I
- I
quinazolin I
- I
4 I
- I
ones I
. O

A O
new O
series O
of O
2 B
- I
heteroarylthio I
- I
6 I
- I
substituted I
- I
quinazolin I
- I
4 I
- I
one I
analogs O
was O
designed O
, O
synthesized O
, O
and O
evaluated O
for O
their O
in O
vitro O
DHFR O
inhibition O
, O
antimicrobial O
, O
and O
antitumor O
activities O
. O

Molecular O
modeling O
studies O
concluded O
that O
recognition O
with O
key O
amino O
acid O
Arg38 B
and O
Lys31 B
are O
essential O
for O
binding O
and O
biological O
activities O
. O

Cereal O
- O
based O
food O
products O
( O
n O
= O
174 O
) O
were O
analysed O
for O
the O
occurrence O
of O
deoxynivalenol O
, O
3 O
- O
acetyldeoxynivalenol O
, O
15 O
- O
acetyldeoxynivalenol O
, O
zearalenone O
, O
alpha B
- I
zearalenol I
, O
beta B
- I
zearalenol I
, O
T B
- I
2 I
- I
toxin I
, O
HT B
- I
2 I
- I
toxin I
, O
and O
their O
respective O
masked O
forms O
, O
including O
, O
deoxynivalenol B
- I
3 I
- I
glucoside I
, O
zearalenone B
- I
4 I
- I
glucoside I
, O
alpha O
- O

zearalenol O
- O
4 O
- O
glucoside O
, O
beta B
- I
zearalenol I
- I
4 I
- I
glucoside I
and O
zearalenone B
- I
4 I
- I
sulfate I
. O

According O
to O
a O
probabilistic O
exposure O
analysis O
, O
the O
mean O
( O
and O
P95 O
) O
mycotoxin O
intake O
for O
the O
sum O
of O
the O
deoxynivalenol O
- O
equivalents O
, O
zearalenone O
- O
equivalents O
, O
and O
the O
sum O
of O
HT B
- I
2 I
- I
and I
T I
- I
2 I
- I
toxin I
for O
all O
cereal O
- O
based O
foods O
was O
0 O
. O
1162 O
( O
0 O
. O
4047 O
, O
P95 O
) O
, O
0 O
. O
0447 O
( O
0 O
. O
1568 O
, O
P95 O
) O
and O
0 O
. O
0258 O
( O
0 O
. O
0924 O
, O
P95 O
) O
mu O
g O
kg O
( O
- O
1 O
) O
body O
weight O
day O

These O
values O
were O
below O
the O
tolerable O
daily O
intake O
( O
TDI O
) O
levels O
for O
deoxynivalenol O
, O
zearalenone O
and O
the O
sum O
of O
T B
- I
2 I
and I
HT I
- I
2 I
toxin I
( O
1 O
. O
0 O
, O
0 O
. O
25 O
and O
0 O
. O
1 O
mu O
g O
kg O
( O
- O
1 O
) O
body O
weight O
day O
( O
- O
1 O
) O
, O
respectively O
) O
. O

Two O
new O
triterpenoids O
, O
( B
24R I
/ I
S I
) I
- I
24 I
- I
hydroxy I
- I
3 I
alpha I
10 I
alpha I
- I
epoxy I
- I
9 I
- I
eip I
- I
cucurbita I
- I
25 I
- I
ene I
( O
1a O
, O
b O
) O
, O
as O
well O
as O
six O
known O
compounds O
( O
3 O
- O
8 O
) O
, O
were O
isolated O
from O
the O
extraction O
of O
Fructus O
Viticis O
Negundo O
. O

The O
suppression O
of O
hematopoiesis O
function O
in O
Balb O
/ O
c O
mice O
induced O
by O
prolonged O
exposure O
of O
microcystin B
- I
LR I
. O

Microcystins B
( O
MCs O
) O
cause O
normocytic O
anemia O
in O
patients O
in O
a O
hemodialysis O
unit O
in O
Caruaru O
, O
Brazil O
in O
1996 O
, O
but O
the O
underlying O
mechanisms O
are O
still O
unclear O
. O

In O
the O
present O
study O
, O
Balb O
/ O
c O
mice O
were O
intraperitoneally O
injected O
with O
microcystin B
- I
LR I
( O
MC B
- I
LR I
) O
at O
the O
doses O
of O
0 O
. O
5 O
, O
2 O
and O
8 O
mu O
g O
/ O
kg O
body O
weight O
( O
bw O
) O
every O
48h O
for O
30d O
. O

After O
the O
prolonged O
exposure O
of O
MC B
- I
LR I
, O
significant O
decreases O
of O
red O
blood O
cell O
count O
( O
RBC O
) O
, O
hemoglobin O
( O
Hb O
) O
and O
hematocrit O
( O
Ht O
) O
were O
observed O
in O
2 O
and O
8 O
mu O
g O
/ O
kg O
bw O
groups O
, O
but O
erythrocyte O
mean O
corpuscular O
volume O
( O
MCV O
) O
showed O
no O
significant O
changes O
. O

Significantly O
elevated O
micronucleus O
frequency O
was O
observed O
in O
bone O
marrow O
cells O
( O
BMCs O
) O
in O
all O
MC B
- I
LR I
treatments O
. O

MC B
- I
LR I
exposure O
significantly O
increased O
the O
apoptosis O
rates O
in O
all O
MC B
- I
LR I
treatments O
. O

The O
present O
study O
indicates O
prolonged O
exposure O
of O
MC B
- I
LR I
induces O
normocytic O
anemia O
, O
and O
the O
disturbed O
hematopoietic O
growth O
factors O
and O
BMCs O
apoptosis O
are O
responsible O
for O
this O
normocytic O
anemia O
. O

Platinum B
( I
II I
) I
complexes O
with O
mono B
- I
aminophosphonate I
ester I
targeting O
group O
that O
induce O
apoptosis O
through O
G1 O
cell O
- O
cycle O
arrest O
: O
Synthesis O
, O
crystal O
structure O
and O
antitumour O
activity O
. O

Six O
new O
platinum B
( I
II I
) I
complexes O
with O
mono B
- I
aminophosphonate I
ester I
were O
synthesized O
and O
characterized O
by O
elemental O
analysis O
, O
( O
1 O
) O
H O
NMR O
, O
ESI O
- O
MS O
as O
well O
as O
single O
crystal O
X O
- O
ray O
diffraction O
analysis O
. O

METHODS O
: O
Overnight O
- O
deprived O
smokers O
( O
n O
= O
24 O
) O
and O
nonsmokers O
( O
n O
= O
20 O
) O
completed O
six O
neuroimaging O
assessments O
on O
different O
days O
both O
in O
the O
absence O
of O
, O
and O
following O
, O
varenicline B
and O
/ O
or O
nicotine O
administration O
. O

Acute O
behavioural O
effects O
of O
bupropion O
and O
naltrexone B
, O
alone O
and O
in O
combination O
, O
in O
non O
- O
deprived O
male O
rats O
presented O
with O
palatable O
mash O
. O

Although O
bupropion O
and O
naltrexone B
( O
alone O
and O
in O
combination O
) O
reduce O
food O
consumption O
in O
rodents O
and O
humans O
, O
their O
effects O
on O
behaviour O
during O
feeding O
tests O
have O
not O
been O
thoroughly O
investigated O
. O

OBJECTIVES O
: O
This O
study O
aimed O
to O
assess O
the O
behavioural O
specificity O
of O
anorectic O
responses O
to O
bupropion O
, O
naltrexone B
and O
their O
combination O
. O

METHODS O
: O
Video O
analysis O
was O
employed O
to O
characterise O
the O
behavioural O
effects O
of O
acute O
systemic O
treatment O
with O
bupropion O
( O
10 O
. O
0 O
- O
40 O
. O
0 O
mg O
/ O
kg O
) O
, O
naltrexone B
( O
0 O
. O
1 O
- O
3 O
. O
0 O
mg O
/ O
kg O
) O
and O
combined O
bupropion O
( O
20 O
mg O
/ O
kg O
) O
plus O
naltrexone B
( O
0 O
. O
1 O
- O
1 O
. O
0 O
mg O
/ O
kg O
) O
in O
non O
- O
deprived O
male O
rats O
exposed O
for O
1 O
h O
to O
palatable O
mash O
. O

In O
experiment O
2 O
, O
the O
anorectic O
response O
to O
3 O
mg O
/ O
kg O
naltrexone B
was O
associated O
with O
an O
accelerated O
but O
otherwise O
normal O
BSS O
. O

In O
experiment O
3 O
, O
the O
co O
- O
administration O
of O
20 O
mg O
/ O
kg O
bupropion O
and O
naltrexone B
( O
0 O
. O
1 O
and O
1 O
. O
0 O
mg O
/ O
kg O
) O
not O
only O
produced O
an O
additive O
anorectic O
profile O
( O
including O
a O
reduced O
rate O
of O
eating O
) O
, O
but O
the O
addition O
of O
the O
opioid O
receptor O
antagonist O
also O
concurrently O
attenuated O
the O
psychomotor O
stimulant O
response O
to O
the O
atypical O
antidepressant O
. O

CONCLUSIONS O
: O
Low O
- O
dose O
co O
- O
treatment O
with O
naltrexone B
and O
bupropion O
produces O
a O
stronger O
suppression O
of O
appetite O
than O
that O
seen O
with O
either O
agent O
alone O
and O
has O
the O
additional O
advantage O
of O
reducing O
some O
of O
the O
unwanted O
effects O
of O
bupropion O
. O

One O
new O
flavonol O
, O
chlorflavonin B
A I
( O
1 O
) O
, O
four O
new O
diterpenoids O
, O
aspergiloids B
E I
- I
H I
( O
3 O
, O
5 O
- O
7 O
) O
, O
together O
with O
eight O
known O
compounds O
( O
2 O
, O
4 O
, O
8 O
- O
13 O
) O
were O
isolated O
from O
solid O
fermentation O
of O
Aspergillus O
sp O
. O

Synthesis O
of O
Isoidide B
through O
Epimerization O
of O
Isosorbide B
using O
Ruthenium O
on O
Carbon O
. O

A O
highly O
efficient O
procedure O
for O
obtaining O
resin O
- O
grade O
isoidide B
through O
catalytic O
epimerization O
of O
isosorbide B
using O
a O
ruthenium O
- O
on O
- O
carbon O
( O
Ru O
/ O
C O
) O
catalyst O
is O
reported O
. O

Epimerization O
of O
isosorbide B
in O
water O
( O
pH O
8 O
) O
at O
220 O
degrees O
C O
, O
under O
40 O
bar O
of O
hydrogen O
, O
and O
using O
a O
Ru O
/ O
C O
catalyst O
( O
5 O
% O
Ru O
) O
for O
2 O
h O
results O
in O
a O
thermodynamic O
equilibrium O
mixture O
containing O
55 O
% O
isoidide B
, O
40 O
% O
isosorbide B
, O
and O
5 O
% O
isomannide B
. O

High O
purity O
isoidide B
is O
obtained O
by O
high O
- O
vacuum O
distillation O
of O
an O
equilibrium O
mixture O
on O
a O
200 O
g O
scale O
. O

In O
this O
work O
, O
we O
found O
that O
, O
during O
storage O
or O
after O
UV O
irradiation O
, O
ThT B
is O
demethylated O
or O
oxidized O
, O
forming O
three O
derivatives O
. O

These O
three O
derivatives O
were O
purified O
by O
high O
performance O
liquid O
chromatography O
and O
characterized O
by O
mass O
and O
nuclear O
magnetic O
resonance O
spectroscopy O
and O
the O
spectroscopic O
properties O
of O
pure O
ThT B
and O
the O
derivatives O
carefully O
compared O
. O

Our O
results O
show O
that O
the O
emission O
peak O
at O
450 O
nm O
results O
from O
oxidized O
ThT B
and O
not O
from O
the O
monomeric O
form O
of O
ThT B
, O
as O
previously O
proposed O
. O

The O
partial O
conversion O
of O
ThT B
into O
oxidized O
and O
demethylated O
derivatives O
has O
an O
effect O
on O
amyloid O
detection O
using O
ThT B
assay O
. O

Irradiated O
ThT B
has O
the O
same O
lag O
time O
as O
pure O
ThT B
in O
the O
amyloidogenesis O
of O
insulin O
, O
but O
the O
intensity O
of O
the O
emitted O
fluorescence O
is O
significantly O
decreased O
. O

In O
particular O
, O
biodegradable O
nanoparticles O
formulated O
from O
poly B
( I
D I
, I
L I
- I
lactide I
- I
co I
- I
glycolide I
) I
( O
PLGA O
) O
have O
been O
extensively O
investigated O
for O
sustained O
and O
targeted O
delivery O
of O
different O
agents O
, O
including O
recombinant O
proteins O
, O
plasmid O
DNA O
, O
and O
low O
molecular O
weight O
compounds O
. O

Sub O
- O
acute O
, O
moderate O
- O
dose O
, O
but O
not O
short O
- O
term O
, O
low O
- O
dose O
dietary O
pre O
- O
exposure O
of O
mice O
to O
perfluorooctanoate B
aggravates O
concanavalin O
A O
- O
induced O
hepatitis O
. O

Exposure O
of O
mice O
to O
perfluorooctanoate B
( O
PFOA O
) O
evokes O
pronounced O
hepatomegaly O
along O
with O
significant O
alterations O
in O
both O
the O
histological O
structure O
and O
immune O
status O
of O
the O
liver O
. O

Antioxidant O
and O
Anti O
- O
inflammatory O
Meroterpenoids B
from O
the O
Brown O
Alga O
Cystoseira O
usneoides O
. O

A O
chemical O
study O
of O
the O
alga O
Cystoseira O
usneoides O
has O
led O
to O
the O
isolation O
of O
six O
new O
meroterpenoids B
, O
cystodiones B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
together O
with O
six O
known O
related O
compounds O
( O
7 O
- O
12 O
) O
. O

In O
antioxidant O
assays O
all O
of O
the O
tested O
meroterpenes B
, O
and O
in O
particular O
cystodiones B
A I
( I
1 I
) I
and I
B I
( O
2 O
) O
, O
6 B
- I
cis I
- I
amentadione I
- I
1 I
' I
- I
methyl I
ether I
( O
7 O
) O
, O
and O
amentadione B
- I
1 I
' I
- I
methyl I
ether I
( O
8 O
) O
, O
exhibited O
strong O
radical O
- O
scavenging O
activity O
. O

In O
anti O
- O
inflammatory O
assays O
, O
usneoidone B
Z I
( O
11 O
) O
and O
its O
corresponding O
6E O
isomer O
( O
12 O
) O
showed O
significant O
activity O
as O
inhibitors O
of O
the O
production O
of O
the O
proinflammatory O
cytokine O
TNF O
- O
alpha O
in O
LPS O
- O
stimulated O
THP O
- O
1 O
human O
macrophages O
. O

To O
investigate O
the O
electrical O
charge O
( O
modified O
by O
zero O
, O
one O
or O
two O
ammonium B
groups O
) O
and O
the O
molecule O
length O
( O
3 O
, O
5 O
or O
7 O
methylene O
chains O
) O
effects O
of O
bisphosphonate O
- O
type O
coatings O
, O
we O
assessed O
the O
complement O
activation O
, O
in O
vivo O
plasma O
and O
tissue O
relaxation O
time O
alterations O
of O
intravenously O
injected O
small O
iron O
oxide O
nanoparticles O
( O
< O
25nm O
) O
on O
male O
healthy O
Wistar O
rats O
. O

The O
presence O
of O
ammonium B
groups O
induces O
a O
weak O
activation O
of O
the O
complement O
whatever O
the O
size O
and O
the O
concentration O
of O
particles O
, O
whereas O
hydroxyethylenebisph B
( O
HEBP B
) O
- O
coated O
particles O
are O
poor O
complement O
activators O
only O
at O
the O
lowest O
concentration O
. O

In O
vivo O
, O
HEBP B
- O
coated O
nanoparticles O
have O
the O
greatest O
prolonged O
relaxation O
time O
effects O
, O
despite O
their O
higher O
negative O
electrical O
charge O
, O
contrary O
to O
two O
ammonium B
bearing O
coatings O
. O

No O
significant O
differences O
were O
observed O
between O
mono B
- I
ammonium I
molecular O
coatings O
. O

In O
vivo O
binding O
of O
the O
dopamine O
- O
1 O
receptor O
PET O
tracers O
[ B
( I
11 I
) I
C I
] I
NNC112 I
and O
[ B
( I
11 I
) I
C I
] I
SCH23390 I
: O
a O
comparison O
study O
in O
individuals O
with O
schizophrenia O
. O

OBJECTIVES O
: O
The O
aim O
of O
this O
investigation O
was O
to O
determine O
whether O
the O
in O
vivo O
characteristics O
of O
the O
different O
D1 O
receptor O
tracers O
used O
in O
previous O
reports O
, O
[ B
( I
11 I
) I
C I
] I
SCH23390 I
and O
[ B
( I
11 I
) I
C I
] I
NNC112 I
, O
may O
have O
contributed O
to O
these O
discrepancies O
reported O
in O
the O
literature O
. O

METHODS O
: O
Eight O
patients O
with O
schizophrenia O
and O
12 O
healthy O
control O
subjects O
were O
scanned O
with O
both O
[ B
( I
11 I
) I
C I
] I
SCH23390 I
and O
[ B
( I
11 I
) I
C I
] I
NNC112 I
. O

RESULTS O
: O
[ B
( I
11 I
) I
C I
] I
SCH23390 I
and O
[ B
( I
11 I
) I
C I
] I
NNC112 I
binding O
potentials O
in O
both O
patients O
and O
control O
subjects O
were O
compared O
and O
no O
tracer O
by O
diagnosis O
interactions O
were O
observed O
. O

CONCLUSIONS O
: O
The O
results O
of O
this O
study O
suggest O
that O
differences O
in O
the O
binding O
of O
[ B
( I
11 I
) I
C I
] I
SCH23390 I
and O
[ B
( I
11 I
) I
C I
] I
NNC112 I
observed O
in O
previous O
studies O
are O
not O
due O
to O
differences O
in O
the O
in O
vivo O
behavior O
of O
these O
tracers O
. O

( B
+ I
) I
- I
Laburnamine I
, O
a O
Natural O
Selective O
Ligand O
and O
Partial O
Agonist O
for O
the O
alpha O
4 O
beta O
2 O
Nicotinic O
Receptor O
Subtype O
. O

( B
+ I
) I
- I
Laburnamine I
( O
1 O
) O
, O
a O
rare O
alkaloid O
extracted O
from O
Laburnum O
anagyroides O
seeds O
( O
~ O
4 O
mg O
from O
1 O
kg O
) O
, O
was O
shown O
to O
bind O
with O
high O
affinity O
( O
Ki O
, O
293 O
nM O
) O
to O
the O
alpha O
4 O
beta O
2 O
nicotinic O
receptor O
subtype O
, O
which O
is O
, O
respectively O
, O
126 O
and O
136 O
times O
higher O
than O
to O
the O
alpha O
3 O
beta O
4 O
( O
Ki O
37 O
mu O
M O
) O
and O
alpha O
7 O
subtypes O
( O
Ki O
40 O
mu O
M O
) O
. O

We O
demonstrate O
that O
the O
formation O
of O
a O
supported O
lipid O
membrane O
can O
be O
quantitatively O
monitored O
from O
the O
characteristic O
fluorescence O
of O
( B
157 I
) I
Gd I
( I
3 I
+ I
) I
ions O
bound O
to O
the O
headgroup O
of O
chelator O
lipids O
. O

Moreover O
, O
we O
were O
able O
to O
localize O
the O
( B
157 I
) I
Gd I
( I
3 I
+ I
) I
ions O
along O
the O
surface O
normal O
with O
nanometer O
precision O
. O

Rhodamine O
B O
( O
Rh B
B I
) O
and O
fluorescein O
isothiocyanate O
( O
FITC O
) O
as O
model O
hydrophilic O
and O
hydrophobic O
small O
/ O
medium O
- O
size O
molecules O
, O
respectively O
, O
were O
encapsulated O
in O
poly O
lactic O
- O
co O
- O
glycolic O
acid O
( O
PLGA O
) O
nanoparticles O
( O
NPs O
) O
and O
delivered O
through O
full O
thickness O
porcine O
skin O
pretreated O
with O
MN O
array O
. O

Correlation O
between O
aflatoxin B
M1 I
content O
of O
breast O
milk O
, O
dietary O
exposure O
to O
aflatoxin O
B1 O
and O
socioeconomic O
status O
of O
lactating O
mothers O
in O
Ogun O
State O
, O
Nigeria O
. O

Aflatoxin B
M1 I
( O
AF B
M1 I
) O
, O
a O
hydroxylated O
metabolite O
of O
AF B
B1 I
, O
is O
an O
important O
toxin O
that O
can O
contaminate O
the O
milk O
of O
lactating O
mothers O
. O

A O
correlation O
study O
was O
conducted O
to O
determine O
the O
relationship O
between O
AF B
M1 I
content O
of O
breast O
milk O
, O
dietary O
exposure O
to O
AF B
B1 I
and O
socioeconomic O
status O
of O
lactating O
mothers O
in O
the O
three O
Senatorial O
districts O
of O
Ogun O
State O
, O
Nigeria O
. O

The O
level O
of O
contamination O
of O
the O
foods O
by O
AF B
B1 I
was O
low O
( O
0 O
. O
16 O
- O
0 O
. O
33 O
mu O
g O
/ O
kg O
) O
and O
differed O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
across O
the O
state O
but O
did O
not O
exceed O
the O
EU O
limit O
of O
2 O
mu O
g O
/ O
kg O
. O

The O
occurrence O
level O
of O
AF B
B1 I
was O
however O
high O
( O
93 O
. O
75 O
- O
94 O
. O
45 O
% O
) O
and O
was O
more O
pronounced O
in O
Ogun O
East O
Senatorial O
district O
( O
94 O
. O
45 O
% O
) O
. O

Eighty O
- O
two O
percent O
of O
the O
breast O
milk O
was O
contaminated O
with O
AF B
M1 I
( O
3 O
. O
49 O
- O
35ng O
/ O
l O
) O
and O
16 O
% O
exceeded O
the O
EU O
limit O
of O
25ng O
/ O
l O
while O
a O
100 O
% O
occurrence O
risk O
was O
recorded O
in O
Ogun O
Central O
Senatorial O
district O
. O

The O
socioeconomic O
status O
of O
the O
mothers O
also O
significantly O
influenced O
their O
dietary O
exposure O
and O
exposure O
risk O
of O
the O
sucklings O
to O
AF B
M1 I
. O

Cell O
cycle O
arrest O
, O
extracellular O
matrix O
changes O
and O
intrinsic O
apoptosis O
in O
human O
melanoma O
cells O
are O
induced O
by O
Boron B
Neutron O
Capture O
Therapy O
. O

In O
vitro O
drug O
release O
from O
the O
developed O
stents O
was O
carried O
in O
different O
release O
media O
, O
normal O
saline O
- O
isopropanol B
( O
NS O
- O
IP O
) O
, O
phosphate O
buffer O
( O
PB O
) O
, O
phosphate O
buffer O
saline O
( O
PBS O
) O
and O
in O
human O
plasma O
. O

Polyalkylcyanoacryla B
as O
in O
situ O
formed O
diffusion O
barriers O
in O
multimaterial O
drug O
carriers O
. O

This O
study O
proposes O
a O
multimaterial O
system O
to O
sustain O
the O
release O
by O
covering O
the O
hydrogel O
with O
a O
poly B
( I
alkyl I
- I
2 I
- I
cyanoacrylate I
) I
[ O
PACA B
] O
- O
based O
film O
, O
which O
should O
be O
formed O
by O
an O
in O
situ O
polymerization O
on O
the O
hydrogel O
surface O
initiated O
upon O
contact O
with O
water O
. O

A O
series O
of O
PACA B
- O
hydrogel O
hybrid O
systems O
with O
increasing O
PACA B
side O
chain O
hydrophobicity O
was O
prepared O
using O
physically O
crosslinked O
alginate O
films O
and O
hydrophilic O
diclofenac O
sodium O
as O
model O
hydrogel O
/ O
drug O
system O
. O

Successful O
synthesis O
of O
PACA B
at O
the O
hydrogel O
surface O
was O
confirmed O
and O
the O
PACA B
layer O
was O
identified O
to O
be O
most O
homogeneous O
for O
poly B
( I
n I
- I
butyl I
- I
2 I
- I
cyanoacrylate I
) I
on O
both O
the O
micro O
- O
and O
nanolevel O
. O

At O
the O
same O
time O
, O
the O
diclofenac O
release O
from O
the O
hybrid O
systems O
was O
substantially O
sustained O
from O
~ O
1day O
for O
unmodified O
hydrogels O
up O
to O
> O
14days O
depending O
on O
the O
type O
of O
PACA B
employed O
as O
diffusion O
barrier O
. O

Overall O
, O
in O
situ O
polymerized O
PACA B
films O
on O
hydrogels O
may O
be O
widely O
applicable O
to O
various O
hydrogel O
matrices O
, O
different O
matrix O
sizes O
as O
well O
as O
more O
complex O
shaped O
hydrogel O
carriers O
. O

The O
friction O
of O
graphene O
on O
various O
substrates O
, O
such O
as O
SiO2 O
, O
h O
- O
BN O
, O
bulk O
- O
like O
graphene O
, O
and O
mica B
, O
was O
investigated O
to O
characterize O
the O
adhesion O
level O
between O
graphene O
and O
the O
underlying O
surface O
. O

In O
addition O
, O
graphene O
deposited O
on O
mica B
, O
when O
folded O
, O
preserved O
the O
same O
corrugation O
level O
as O
before O
the O
folding O
event O
. O

Anticancer O
drugs O
directed O
against O
the O
microtubule O
, O
including O
taxanes O
and O
vinca B
alkaloids I
, O
have O
been O
the O
backbone O
of O
many O
chemotherapy O
regimes O
for O
decades O
. O

Agents O
demonstrating O
utility O
in O
Phase O
III O
clinical O
trials O
, O
including O
eribulin B
, O
ixabepilone B
, O
cabazitaxel B
and O
trastuzumab O
- O
DM1 O
will O
be O
highlighted O
, O
as O
well O
as O
novel O
agents O
currently O
in O
development O
and O
future O
directions O
for O
MTAs O
. O

Effect O
of O
stachydrine B
on O
endoplasmic O
reticulum O
stress O
- O
induced O
apoptosis O
in O
rat O
kidney O
after O
unilateral O
ureteral O
obstruction O
. O

Our O
study O
aimed O
at O
determining O
the O
effect O
of O
stachydrine B
on O
the O
PERK O
, O
CHOP O
, O
and O
caspase O
- O
3 O
in O
rat O
kidney O
with O
RIF O
. O

Rats O
were O
randomly O
divided O
into O
control O
group O
, O
model O
group O
, O
enalapril B
group O
, O
high O
stachydrine B
group O
, O
medium O
stachydrine B
group O
, O
and O
low O
stachydrine B
group O
. O

The O
expressions O
of O
PERK O
, O
CHOP O
, O
and O
caspase O
- O
3 O
in O
nephridial O
tissue O
were O
reduced O
( O
P O
< O
0 O
. O
05 O
) O
, O
tubulointerstitial O
injury O
and O
RIF O
were O
reduced O
( O
P O
< O
0 O
. O
05 O
) O
, O
and O
Scr O
and O
BUN O
were O
lower O
( O
P O
< O
0 O
. O
05 O
) O
in O
the O
high O
stachydrine B
group O
than O
those O
in O
the O
enalapril B
group O
. O

The O
expressions O
of O
PERK O
, O
CHOP O
, O
and O
caspase O
- O
3 O
were O
reduced O
in O
the O
endoplasmic O
reticulum O
stress O
- O
related O
apoptosis O
pathway O
after O
stachydrine B
treatment O
. O

Uncinataflavone B
, O
a O
new O
flavonoid O
with O
a O
methyl B
benzoate I
substituent O
from O
Selaginella O
uncinata O
. O

Uncinataflavone B
( O
1 O
) O
, O
a O
new O
flavonoid O
, O
together O
with O
four O
known O
compounds O
( O
2 O
- O
5 O
) O
, O
was O
isolated O
from O
Selaginella O
uncinata O
( O
Desv O
. O
) O
Spring O
. O

The O
structure O
of O
the O
new O
compound O
was O
determined O
as O
methyl B
3 I
- I
( I
5 I
, I
7 I
- I
dihydroxy I
- I
2 I
- I
( I
4 I
- I
hydroxyphenyl I
) I
- I
4 I
- I
oxo I
- I
4H I
- I
chromen I
- I
6 I
- I
yl I
) I
- I
4 I
- I
methoxybenzoate I
by O
means O
of O
spectroscopic O
evidence O
, O
including O
UV O
, O
IR O
, O
1D O
and O
2D O
NMR O
analyses O
as O
well O
as O
HR O
- O
ESI O
- O
MS O
. O

The O
antiviral O
effect O
of O
7 B
- I
hydroxyisoflavone I
against O
Enterovirus O
71 O
in O
vitro O
. O

In O
screening O
for O
anti O
- O
EV71 O
candidates O
, O
we O
found O
that O
7 B
- I
hydroxyisoflavone I
was O
active O
against O
EV71 O
. O

7 B
- I
Hydroxyisoflavone I
exhibited O
strong O
antiviral O
activity O
against O
three O
different O
EV71 O
strains O
. O

7 B
- I
Hydroxyisoflavone I
could O
reduce O
EV71 O
viral O
RNA O
and O
protein O
synthesis O
in O
a O
dose O
- O
dependent O
manner O
. O

Time O
course O
study O
showed O
that O
treatment O
of O
Vero O
cells O
with O
7 B
- I
hydroxyisoflavone I
at O
indicated O
times O
after O
EV71 O
inoculation O
( O
0 O
- O
6 O
h O
) O
resulted O
in O
significant O
antiviral O
activity O
. O

Results O
showed O
that O
7 B
- I
hydroxyisoflavone I
acted O
at O
an O
early O
step O
of O
EV71 O
replication O
. O

7 B
- I
Hydroxyisoflavone I
also O
exhibited O
strong O
antiviral O
activity O
against O
coxsackievirus O
B2 O
, O
B3 O
, O
and O
B6 O
. O

In O
short O
, O
7 B
- I
hydroxyisoflavone I
may O
be O
used O
as O
a O
lead O
compound O
for O
anti O
- O
EV71 O
drug O
development O
. O

Two O
new O
tri B
- I
nor I
- I
eudesmanolides I
from O
Inula O
racemosa O
. O

Two O
new O
tri B
- I
nor I
- I
eudesmane I
- O
type O
sesquiterpenoids O
were O
isolated O
from O
the O
roots O
of O
Inula O
racemosa O
, O
and O
their O
structures O
were O
elucidated O
as O
8 B
- I
oxo I
- I
tri I
- I
nor I
- I
eudesm I
- I
6 I
- I
en I
- I
5 I
alpha I
- I
ol I
( O
1 O
) O
and O
tri B
- I
nor I
- I
eudesm I
- I
5 I
- I
en I
- I
7 I
beta I
, I
8 I
beta I
- I
diol I
( O
2 O
) O
. O

A O
new O
flavanol B
from O
Cynomorium O
songaricum O
. O

A O
new O
flavanol B
, O
named O
songarin B
A I
( O
1 O
) O
, O
was O
isolated O
from O
Cynomorium O
songaricum O
Rupr O
. O

Protein O
Targets O
of O
Thioacetamide B
Metabolites O
in O
Rat O
Hepatocytes O
. O

Thioacetamide B
( O
TA O
) O
has O
long O
been O
known O
as O
a O
hepatotoxicant O
whose O
bioactivation O
requires O
S O
- O
oxidation O
to O
thioacetamide B
S I
- I
oxide I
( O
TASO B
) O
and O
then O
to O
the O
very O
reactive O
S B
, I
S I
- I
dioxide I
( O
TASO2 B
) O
. O

Isolated O
hepatocytes O
efficiently O
oxidize O
TA O
to O
TASO B
but O
experience O
little O
covalent O
binding O
or O
cytotoxicity O
because O
TA O
is O
a O
very O
potent O
inhibitor O
of O
the O
oxidation O
of O
TASO B
to O
TASO2 B
. O

However O
, O
hepatocytes O
treated O
with O
TASO B
show O
extensive O
covalent O
binding O
to O
both O
lipids O
and O
proteins O
accompanied O
by O
extensive O
cytotoxicity O
. O

In O
this O
work O
, O
we O
treated O
rat O
hepatocytes O
with O
[ B
( I
14 I
) I
C I
] I
- I
TASO I
and O
submitted O
the O
mitochondrial O
, O
microsomal O
, O
and O
cytosolic O
fractions O
to O
2DGE O
, O
which O
revealed O
a O
total O
of O
321 O
radioactive O
protein O
spots O
. O

To O
facilitate O
the O
identification O
of O
target O
proteins O
and O
adducted O
peptides O
, O
we O
also O
treated O
cells O
with O
a O
mixture O
of O
TASO B
/ O
[ B
( I
13 I
) I
C2D3 I
] I
- I
TASO I
. O

Thiobenzamide B
( O
TB O
) O
undergoes O
the O
same O
two O
- O
step O
oxidative O
bioactivation O
as O
TA O
, O
and O
it O
also O
gives O
rise O
to O
both O
amide O
and O
amidine O
adducts O
on O
protein O
lysine O
side O
chains O
but O
only O
amidine O
adducts O
to O
PE O
lipids O
. O

Despite O
their O
similarity O
in O
functional O
group O
chemical O
reactivity O
, O
only O
38 O
of O
62 O
known O
TB O
target O
proteins O
are O
found O
among O
the O
88 O
known O
targets O
of O
TASO B
. O

The O
potential O
roles O
of O
protein O
modification O
by O
TASO B
in O
triggering O
cytotoxicity O
are O
discussed O
in O
terms O
of O
enzyme O
inhibition O
, O
protein O
folding O
, O
and O
chaperone O
function O
, O
and O
the O
emerging O
role O
of O
protein O
acetylation O
in O
intracellular O
signaling O
and O
the O
regulation O
of O
biochemical O
pathways O
. O

PF B
- I
04859989 I
as O
a O
template O
for O
structure O
- O
based O
drug O
design O
: O
identification O
of O
new O
pyrazole O
series O
of O
irreversible O
KAT O
II O
inhibitors O
with O
improved O
lipophilic O
efficiency O
. O

The O
modification O
of O
the O
inhibitor O
scaffold O
of O
1 O
and O
2 O
from O
a O
dihydroquinolinone B
core O
to O
a O
tetrahydropyrazolopy B
core O
led O
to O
discovery O
of O
a O
new O
series O
of O
potent O
KAT O
II O
inhibitors O
with O
excellent O
physicochemical O
properties O
. O

Design O
, O
synthesis O
and O
antithrombotic O
evaluation O
of O
novel O
dabigatran O
prodrugs O
containing O
methyl B
ferulate I
. O

A O
novel O
series O
of O
prodrugs O
containing O
dabigatran O
and O
methyl B
( I
E I
) I
- I
3 I
- I
( I
4 I
- I
hydroxy I
- I
2 I
- I
methoxyphenyl I
) I
propenoate I
( O
methyl B
ferulate I
) O
were O
synthesized O
. O

A O
new O
series O
of O
N2 B
- I
substituted I
- I
5 I
- I
( I
p I
- I
toluenesulfonylamino I
) I
phthalimide I
analogues O
as O
alpha O
- O
glucosidase O
inhibitors O
. O

Several O
members O
of O
a O
new O
family O
of O
non O
- O
sugar O
- O
type O
alpha O
- O
glycosidase O
inhibitors O
, O
bearing O
a O
5 B
- I
( I
p I
- I
toluenesulfonylamino I
) I
phthalimide I
moiety O
and O
various O
substituent O
at O
the O
N2 O
position O
, O
were O
synthesized O
and O
their O
activities O
were O
investigated O
. O

Structure O
- O
activity O
relationship O
studies O
indicated O
that O
5 B
- I
( I
p I
- I
toluenesulfonylamino I
) I
phthalimide I
moiety O
is O
a O
favorable O
scaffold O
to O
exert O
the O
alpha O
- O
glucosidase O
inhibitory O
activity O
and O
substituents O
at O
the O
N2 O
position O
have O
considerable O
influence O
on O
the O
efficacy O
of O
the O
inhibition O
activities O
. O

Efficient O
synthesis O
and O
antimicrobial O
activity O
of O
some O
novel O
S B
- I
beta I
- I
d I
- I
glucosides I
of O
5 B
- I
aryl I
- I
1 I
, I
2 I
, I
4 I
- I
triazole I
- I
3 I
- I
thiones I
derivatives O
. O

A O
series O
of O
3 B
- I
S I
- I
beta I
- I
d I
- I
glucosides I
- I
4 I
- I
arylideneamino I
- I
5 I
- I
aryl I
- I
1 I
, I
2 I
, I
4 I
- I
triazoles I
were O
rationally O
designed O
and O
synthesized O
according O
to O
the O
principle O
of O
superposition O
of O
bioactive O
substructures O
by O
the O
combination O
of O
1 B
, I
2 I
, I
4 I
- I
triazole I
, O
Schiff O
base O
and O
glucosides B
. O

Mollugin O
treatment O
also O
significantly O
increased O
intracellular O
accumulation O
of O
the O
fluorescently O
- O
tagged O
P O
- O
gp O
substrate O
, O
rhodamine B
- I
123 I
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
miR O
- O
21 O
mediated O
resistance O
of O
the O
gastric O
cancer O
cell O
line O
SGC7901 O
to O
the O
chemotherapeutic O
agent O
cisplatin O
( O
DDP B
) O
. O

Our O
study O
found O
that O
the O
expression O
of O
miR O
- O
21 O
upregulated O
in O
the O
cisplatin O
resistant O
cell O
line O
SGC7901 O
/ O
DDP B
compared O
to O
its O
parental O
line O
SGC7901 O
. O

Inhibition O
of O
Akt O
using O
PI3K O
inhibitor O
LY B
294002 I
could O
abrogate O
miR O
- O
21 O
induced O
cell O
survival O
. O

p B
- I
Cresol I
induces O
disruption O
of O
cardiomyocyte O
adherens O
junctions O
. O

Higher O
serum O
levels O
of O
p B
- I
cresol I
in O
chronic O
kidney O
disease O
populations O
have O
been O
associated O
with O
increased O
cardiovascular O
mortality O
. O

However O
, O
studies O
on O
how O
p B
- I
cresol I
affects O
intercellular O
junctions O
between O
cardiomyocytes O
were O
limited O
. O

This O
study O
investigated O
the O
effect O
of O
p B
- I
cresol I
on O
adherens O
junction O
( O
AJ O
) O
of O
neonatal O
cultured O
cardiomyocytes O
and O
its O
underlying O
mechanism O
. O

A O
loss O
of O
N O
- O
cadherin O
and O
p120 O
- O
catenin O
( O
p120ctn O
) O
immunostaining O
from O
cell O
- O
cell O
contact O
sites O
was O
noted O
by O
p B
- I
cresol I
treatment O
. O

In O
addition O
, O
p B
- I
cresol I
disrupted O
AJs O
by O
inducing O
formation O
of O
intercellular O
gaps O
. O

Our O
previous O
study O
has O
revealed O
that O
p B
- I
cresol I
increased O
intracellular O
calcium O
levels O
and O
activated O
protein O
kinase O
C O
alpha O
( O
PKC O
alpha O
) O
by O
phosphorylation O
. O

The O
PKC O
alpha O
activation O
was O
involved O
in O
the O
p B
- I
cresol I
- O
mediated O
AJ O
disassembly O
, O
since O
pharmacological O
inhibition O
of O
PKC O
alpha O
abolished O
the O
above O
- O
mentioned O
p B
- I
cresol I
effect O
. O

SiRNA O
knockdown O
of O
PKC O
alpha O
prevented O
p B
- I
cresol I
- O
induced O
serine O
dephosphorylation O
of O
p120ctn O
and O
splitting O
of O
AJ O
. O

In O
conclusion O
, O
p B
- I
cresol I
caused O
PKC O
alpha O
- O
dependent O
AJ O
disassembly O
of O
cardiomyocytes O
, O
which O
might O
be O
related O
to O
asychronized O
contraction O
. O

Potent O
vasorelaxant O
analogs O
from O
chemical O
modification O
and O
biotransformation O
of O
isosteviol B
. O

Isosteviol B
( O
1 O
) O
has O
been O
reported O
to O
exhibit O
moderate O
vasorelaxant O
activity O
. O

In O
order O
to O
enhance O
the O
bioactivity O
of O
this O
compound O
, O
chemical O
modification O
of O
1 O
to O
the O
dihydro O
analog O
, O
ent B
- I
16 I
beta I
- I
hydroxybeyeran I
- I
19 I
- I
oic I
acid I
( O
2 O
) O
, O
was O
undertaken O
. O

Compound O
2 O
was O
then O
converted O
to O
the O
corresponding O
acetate O
derivative O
, O
ent B
- I
16 I
beta I
- I
acetoxybeyeran I
- I
19 I
- I
oic I
acid I
( O
3 O
) O
. O

The O
metabolite O
4 O
, O
ent B
- I
7 I
alpha I
- I
hydroxy I
- I
16 I
- I
ketobeyeran I
- I
19 I
- I
oic I
acid I
, O
exhibited O
the O
most O
highly O
potent O
activity O
, O
with O
EC50 O
of O
3 O
. O
46 O
nM O
, O
whereas O
the O
parent O
compound O
1 O
showed O
relatively O
low O
activity O
( O
EC50 O
57 O
. O
41 O
nM O
) O
. O

A O
novel O
insulin O
mimetic O
vanadium B
- I
flavonol I
complex O
: O
Synthesis O
, O
characterization O
and O
in O
vivo O
evaluation O
in O
STZ O
- O
induced O
rats O
. O

Since O
1985 O
, O
when O
Heyliger O
et O
al O
. O
, O
first O
demonstrated O
a O
serendipitous O
discovery O
that O
oral O
administration O
of O
0 O
. O
8 O
mg O
/ O
ml O
of O
sodium B
orthovanadate I
in O
drinking O
water O
to O
streptozotocin O
- O
induced O
diabetic O
rats O
resulted O
in O
normoglycemia O
, O
numerous O
extensive O
studies O
have O
been O
pursued O
on O
the O
anti O
- O
diabetic O
and O
insulinomimetic O
actions O
of O
vanadium O
. O

In O
order O
to O
circumvent O
the O
toxic O
effects O
of O
vanadium O
, O
we O
have O
taken O
up O
a O
combinational O
approach O
wherein O
a O
novel O
vanadium B
- I
flavonol I
complex O
was O
synthesized O
, O
characterized O
and O
its O
toxic O
as O
well O
as O
insulin O
mimetic O
potential O
was O
evaluated O
in O
STZ O
- O
induced O
experimental O
diabetes O
in O
rats O
. O

3 B
- I
Hydroxyazetidine I
carboxylic I
acids I
: O
non O
- O
proteinogenic O
amino O
acids O
for O
medicinal O
chemists O
. O

The O
formation O
from O
D O
- O
glucose O
of O
both O
enantiomers O
of O
2 B
, I
4 I
- I
dideoxy I
- I
2 I
, I
4 I
- I
iminoribonic I
acid I
is O
the O
first O
chemical O
synthesis O
of O
unprotected O
3 B
- I
hydroxyazetidine I
carboxylic I
acids I
. O

The O
long O
- O
term O
stability O
of O
3 B
- I
hydroxyazetidine I
amides I
is O
established O
at O
acidic O
and O
neutral O
pH O
and O
implies O
their O
value O
as O
non O
- O
proteinogenic O
amino O
acid O
components O
of O
peptides O
, O
providing O
medicinal O
chemists O
with O
a O
new O
class O
of O
peptide O
isosteres O
. O

The O
structure O
of O
N B
, I
3 I
- I
O I
- I
dibenzyl I
- I
2 I
, I
4 I
- I
dideoxy I
- I
2 I
, I
4 I
- I
imino I
- I
D I
- I
ribonic I
acid I
was O
established O
by O
X O
- O
ray O
crystallographic O
analysis O
. O

An O
N B
- I
methylazetidine I
amide I
derivative O
is O
a O
specific O
inhibitor O
of O
beta O
- O
hexosaminidases O
at O
the O
micromolar O
level O
, O
and O
is O
only O
the O
second O
example O
of O
potent O
inhibition O
of O
any O
glycosidase O
by O
an O
amide O
of O
a O
sugar B
amino I
acid I
related O
to O
an O
iminosugar B
. O

Hybridization O
of O
Phenylthiolate B
- O
and O
Methylthiolate B
- O
Adatom O
Species O
at O
Low O
Coverage O
on O
the O
Au O
( O
111 O
) O
Surface O
. O

Using O
scanning O
tunneling O
microscopy O
we O
observed O
reaction O
products O
of O
two O
chemisorbed O
thiolate B
species O
, O
methylthiolate B
and O
phenylthiolate B
, O
on O
the O
Au O
( O
111 O
) O
surface O
. O

Despite O
the O
apparent O
stability O
, O
organometallic O
complexes O
of O
methylthiolate B
and O
phenylthiolate B
with O
the O
gold O
- O
adatom O
( O
RS B
- I
Au I
- I
SR I
, O
with O
R O
- O
the O
hydrocarbon O
group O
) O
undergo O
a O
stoichiometric O
exchange O
reaction O
, O
forming O
hybridized O
CH3S B
- I
Au I
- I
SPh I
complexes O
. O

Complementary O
density O
functional O
theory O
calculations O
suggest O
that O
the O
reaction O
is O
most O
likely O
mediated O
by O
a O
monothiolate O
RS B
- I
Au I
complex O
bonded O
to O
the O
gold O
surface O
, O
which O
forms O
a O
trithiolate B
RS B
- I
Au I
- I
( I
SR I
) I
- I
Au I
- I
SR I
complex O
as O
a O
key O
intermediate O
. O

This O
work O
therefore O
reveals O
the O
novel O
chemical O
reactivity O
of O
the O
low O
- O
coverage O
" O
striped O
" O
phase O
of O
alkanethiols B
on O
gold O
and O
strongly O
points O
to O
the O
involvement O
of O
monoadatom O
thiolate B
intermediates O
in O
this O
reaction O
. O

Soman O
forms O
a O
stable O
, O
covalent O
bond O
with O
tyrosine O
411 O
of O
human O
albumin O
, O
with O
tyrosines B
257 O
and O
593 O
in O
human O
transferrin O
, O
and O
with O
tyrosine O
in O
many O
other O
proteins O
. O

The O
pinacolyl B
group O
of O
soman O
is O
retained O
, O
suggesting O
that O
pinacolyl B
methylphosphonate I
bound O
to O
tyrosine O
could O
generate O
specific O
antibodies O
. O

The O
soman O
- O
labeled O
tyrosines B
in O
these O
proteins O
are O
surrounded O
by O
different O
amino O
acid O
sequences O
, O
suggesting O
that O
the O
polyclonal O
recognizes O
soman O
- O
tyrosine O
independent O
of O
the O
amino O
acid O
sequence O
. O

Crystalline O
growth O
of O
rubrene B
film O
enhanced O
by O
vertical O
ordering O
in O
cadmium B
arachidate I
multilayer O
substrate O
. O

The O
growth O
of O
highly O
crystalline O
rubrene B
thin O
films O
for O
organic O
field O
effect O
transistor O
( O
OFET O
) O
application O
remains O
a O
challenge O
. O

Here O
, O
we O
report O
on O
the O
vapor O
- O
deposited O
growth O
of O
rubrene B
films O
on O
the O
substrates O
made O
of O
cadmium B
arachidate I
( O
CdA B
) O
multilayers O
deposited O
onto O
SiO2 O
/ O
Si O
( O
100 O
) O
via O
the O
Langmuir O
- O
Blodgett O
technique O
. O

The O
CdA B
films O
, O
containing O
2n O
+ O
1 O
layers O
, O
with O
integer O
n O
ranging O
from O
0 O
to O
4 O
, O
are O
surface O
- O
terminated O
identically O
by O
the O
methyl O
group O
but O
exhibit O
the O
thickness O
- O
dependent O
morphology O
. O

The O
morphology O
and O
structure O
of O
both O
CdA B
and O
rubrene B
films O
are O
characterized O
by O
X O
- O
ray O
reflectivity O
( O
XRR O
) O
, O
X O
- O
ray O
diffraction O
( O
XRD O
) O
, O
near O
- O
edge O
X O
- O
ray O
absorption O
fine O
structure O
( O
NEXAFS O
) O
spectroscopy O
, O
and O
atomic O
force O
microscopy O
( O
AFM O
) O
. O

Crystalline O
rubrene B
films O
, O
evidenced O
by O
XRD O
and O
marked O
by O
platelet O
features O
in O
AFM O
images O
, O
become O
observable O
when O
grown O
onto O
the O
CdA B
layer O
thicker O
than O
5L O
. O

XRD O
data O
show O
that O
vertical O
ordering O
, O
that O
is O
, O
ordering O
along O
surface O
normal O
, O
of O
CdA B
multilayer O
substrates O
exerts O
a O
strong O
influence O
in O
promoting O
the O
crystalline O
growth O
of O
rubrene B
films O
. O

This O
promoted O
growth O
is O
not O
due O
to O
the O
surface O
energy O
of O
CdA B
layer O
but O
derived O
from O
the O
additional O
interaction O
localized O
between O
rubrene B
and O
CdA B
island O
sidewall O
and O
presumably O
strengthened O
by O
a O
close O
dimensional O
match O
between O
the O
a O
- O
axis O
of O
rubrene B
lattice O
and O
the O
layer O
spacing O
of O
CdA B
multilayer O
. O

The O
best O
OFET O
mobility O
is O
recorded O
for O
9L O
CdA B
substrate O
and O
reaches O
6 O
. O
7 O
x O
10 O
( O
- O
2 O
) O
cm O
( O
2 O
) O
V O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
, O
presumably O
limited O
by O
the O
roughness O
of O
the O
interface O
between O
CdA B
and O
rubrene B
films O
. O

Toxoplasma O
gondii O
is O
sensitive O
to O
bulky O
pyrazolo B
[ I
3 I
, I
4 I
- I
d I
] I
pyrimidine I
( O
PP O
) O
inhibitors O
due O
to O
the O
presence O
of O
a O
Gly O
gatekeeper O
in O
the O
essential O
calcium O
dependent O
protein O
kinase O
1 O
( O
CDPK1 O
) O
. O

Here O
we O
synthesized O
a O
number O
of O
new O
derivatives O
of O
3 B
- I
methyl I
- I
benzyl I
- I
PP I
( O
3 B
- I
MB I
- I
PP I
, O
or O
1 O
) O
. O

1 B
- I
Acetyl I
- I
sinapic I
acyl I
- I
4 I
- I
( I
3 I
' I
- I
chlorine I
- I
) I
benzylpiperazine I
( O
SA9 B
) O
had O
the O
strongest O
antioxidant O
and O
anti O
- O
inflammatory O
activities O
both O
in O
vitro O
and O
in O
vivo O
. O

Thus O
, O
the O
effect O
of O
SA9 B
was O
further O
studied O
. O

SA9 B
inhibited O
tumor O
necrosis O
factor O
alpha O
- O
induced O
upregulation O
of O
adhesion O
molecules O
in O
ECs O
at O
both O
mRNA O
and O
protein O
levels O
, O
as O
well O
as O
the O
consequent O
monocyte O
adhesion O
to O
ECs O
. O

To O
study O
the O
molecular O
mechanism O
, O
results O
from O
luciferase O
assay O
, O
nuclear O
translocation O
of O
NF O
- O
kappa O
B O
, O
and O
Western O
blot O
indicated O
that O
the O
mechanism O
of O
the O
anti O
- O
inflammatory O
effects O
of O
SA9 B
might O
be O
suppression O
of O
intracellular O
generation O
of O
ROS O
and O
inhibition O
of O
NF O
- O
kappa O
B O
activation O
in O
ECs O
. O

SA9 B
is O
a O
prototype O
of O
a O
novel O
class O
of O
antioxidant O
with O
anti O
- O
inflammatory O
effects O
in O
ECs O
. O

Measurement O
of O
Transport O
Activities O
of O
3 B
beta I
- I
Hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
Acids I
in O
Bile O
Salt O
Export O
Pump O
and O
Multidrug O
Resistance O
- O
Associated O
Proteins O
Using O
LC O
- O
MS O
/ O
MS O
. O

A O
method O
has O
been O
developed O
for O
the O
measurement O
of O
transport O
activities O
in O
membrane O
vesicles O
obtained O
from O
Sf9 O
cells O
for O
3 B
beta I
- I
hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
acids I
by O
high O
- O
performance O
liquid O
chromatography O
- O
electrospray O
ionization O
- O
tandem O
mass O
spectrometry O
. O

Calibration O
curves O
for O
the O
bile O
acids O
were O
linear O
over O
the O
range O
of O
10 O
to O
2000 O
pmol O
/ O
mL O
, O
and O
the O
detection O
limit O
was O
less O
than O
1 O
pmol O
/ O
mL O
for O
3 B
beta I
- I
hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
acids I
using O
selected O
reaction O
monitoring O
analysis O
. O

The O
analytical O
method O
was O
applied O
to O
measurements O
of O
transport O
activities O
in O
membrane O
vesicles O
obtained O
from O
human O
multidrug O
resistance O
- O
associated O
protein O
2 O
- O
, O
3 O
- O
, O
and O
human O
bile O
salt O
export O
pump O
- O
expressing O
Sf9 O
cells O
for O
conjugated O
3 B
beta I
- I
hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
acids I
. O

The O
present O
study O
demonstrated O
that O
human O
multidrug O
resistance O
- O
associated O
protein O
3 O
vesicles O
accepted O
conjugated O
3 B
beta I
- I
hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
acids I
along O
with O
common O
bile O
acids O
such O
as O
glycocholic B
acid I
and O
taurolithocholic B
acid I
3 I
- I
sulfate I
. O

A O
new O
anti O
- O
inflammatory O
triterpene B
saponin I
isolated O
from O
Anabasis O
setifera O
. O

Chemical O
investigation O
of O
n O
- O
butanol O
fraction O
afforded O
alpha B
- I
amyrin I
3 I
- I
O I
- I
glucopyranoside I
( O
1 O
) O
, O
patuletin B
7 I
- I
O I
- I
glucopyranoside I
( O
2 O
) O
, O
myricitrin B
( O
3 O
) O
and O
a O
new O
oleanane B
triterpene I
saponin I
derivative O
( O
4 O
) O
, O
sophradiol O
3 O
- O
O O
- O
alpha O
- O
L O
- O
( O
1 O
) O
C4 O
- O
rhamnopyranosyl O
- O
( O
1 O
' O
' O
' O
- O
- O
> O
4 O
' O
' O
) O
- O
O O
- O
beta O
- O
D O
- O
( O
4 O
) O
C1 O
- O
galactopyranosyl O

Acute O
Myocardial O
Infarction O
During O
Regadenoson B
Myocardial O
Perfusion O
Imaging O
. O

Adenosine O
and O
dipyridamole B
are O
nonselective O
adenosine O
receptor O
agonists O
that O
have O
been O
associated O
with O
myocardial O
infarction O
( O
MI O
) O
during O
intravenous O
infusion O
. O

Regadenoson B
, O
a O
direct O
A2A O
agonist O
, O
was O
approved O
for O
use O
in O
stress O
testing O
in O
2008 O
. O

We O
describe O
a O
68 O
- O
year O
- O
old O
man O
who O
presented O
to O
our O
institution O
with O
typical O
angina O
, O
relieved O
by O
nitroglycerin B
. O

To O
further O
assess O
the O
etiology O
of O
his O
symptoms O
, O
he O
underwent O
a O
pharmacologic O
stress O
test O
with O
regadenoson B
followed O
by O
technetium B
99 I
m I
sestamibi I
. O

Six O
minutes O
after O
regadenoson B
infusion O
, O
the O
patient O
developed O
severe O
retrosternal O
chest O
pain O
accompanied O
by O
ST O
elevations O
on O
ECG O
. O

Sublingual O
nitroglycerin B
was O
administered O
that O
resolved O
both O
the O
pain O
and O
ECG O
changes O
. O

We O
conclude O
this O
case O
represents O
a O
MI O
secondary O
to O
coronary O
steal O
phenomenon O
induced O
by O
regadenoson B
infusion O
. O

Clinicians O
should O
be O
aware O
this O
adverse O
effect O
can O
occur O
despite O
the O
improved O
side O
- O
effect O
profile O
of O
regadenoson B
. O

Catalysts O
based O
on O
iron B
( I
III I
) I
, O
bismuth B
( I
III I
) I
, O
and O
gold B
( I
III I
) I
show O
higher O
conversions O
for O
S O
- O
, O
C O
- O
, O
and O
N O
- O
centered O
nucleophiles O
, O
and O
Bi B
( I
III I
) I
was O
the O
most O
efficient O
catalyst O
in O
all O
combinations O
. O

Catalysts O
based O
on O
rhenium B
( I
I I
) I
or O
rhenium B
( I
VII I
) I
, O
palladium B
( I
II I
) I
, O
and O
lanthanum B
( I
III I
) I
were O
the O
most O
efficient O
in O
performing O
the O
nucleophilic O
substitution O
on O
the O
various O
alcohols O
with O
the O
O O
- O
centered O
nucleophiles O
. O

Energies O
and O
Spin O
States O
of O
FeS B
( O
0 O
/ O
- O
) O
, O
FeS2 B
( O
0 O
/ O
- O
) O
, O
Fe2 B
S2 I
( O
0 O
/ O
- O
) O
, O
Fe3 B
S4 I
( O
0 O
/ O
- O
) O
, O
and O
Fe4 B
S4 I
( O
0 O
/ O
- O
) O
Clusters O
. O

The O
structures O
and O
energies O
of O
the O
electronic O
ground O
states O
of O
the O
FeS B
( O
0 O
/ O
- O
) O
, O
FeS2 B
( O
0 O
/ O
- O
) O
, O
Fe2 B
S2 I
( O
0 O
/ O
- O
) O
, O
Fe3 B
S4 I
( O
0 O
/ O
- O
) O
, O
and O
Fe4 B
S4 I
( O
0 O
/ O
- O
) O
neutral O
and O
anionic O
clusters O
have O
been O
computed O
systematically O
with O
nine O
computational O
methods O
in O
combination O
with O
seven O
basis O
sets O
. O

Detailed O
comparisons O
between O
the O
available O
experimental O
and O
computed O
AEA O
data O
at O
the O
B3LYP O
/ O
6 O
- O
311 O
+ O
G O
* O
level O
identified O
the O
electronic O
ground O
state O
of O
( O
5 O
) O
Delta O
for O
FeS B
, O
( O
4 O
) O
Delta O
for O
FeS B
( I
- I
) I
, O
( O
5 O
) O
B2 O
for O
FeS2 B
, O
( O
6 O
) O
A1 O
for O
FeS2 B
( I
- I
) I
, O
( O
1 O
) O
A1 O
for O
Fe2 B
S2 I
, O
( O
8 O
) O
A O
' O
for O
Fe2 B
S2 I
( I
- I
) I
, O
( O
5 O
) O
A O
' O
' O
for O
Fe3 B
S4 I
, O
( O
6 O
) O
A O
' O
' O
for O
Fe3 B
S4 I
( I
- I
) I
, O
( O

1 O
) O
A1 O
for O
Fe4 B
S4 I
, O
and O
( O
1 O
) O
A2 O
for O
Fe4 B
S4 I
( I
- I
) I
. O

In O
addition O
, O
Fe2 B
S2 I
, O
Fe3 B
S4 I
, O
Fe3 B
S4 I
( I
- I
) I
, O
Fe4 B
S4 I
, O
and O
Fe4 B
S4 I
( I
- I
) I
are O
antiferromagnetic O
at O
the O
B3LYP O
/ O
6 O
- O
311 O
+ O
G O
* O
level O
. O

Enthalpies O
of O
dilution O
of O
aqueous O
solutions O
of O
aliphatic B
6 I
, I
12 I
- I
and I
12 I
, I
12 I
- I
ionene I
bromides I
and I
fluorides I
and O
enthalpies O
of O
mixing O
with O
low O
molecular O
- O
weight O
salts O
, O
such O
as O
sodium B
fluoride I
and I
bromide I
, O
are O
determined O
. O

In O
the O
second O
part O
of O
the O
study O
, O
the O
various O
x O
, O
y O
- O
ionenes O
( O
x O
, O
y O
are O
numbers O
of O
methylene O
groups O
between O
the O
adjacent O
charges O
) O
with O
fluoride O
, O
bromide O
, O
and O
iodide O
counterions O
are O
mixed O
with O
aqueous O
sodium B
sulfate I
solution O
. O

The O
polyelectrolytes O
examined O
in O
this O
part O
of O
the O
work O
are O
3 B
, I
3 I
- I
, I
6 I
, I
9 I
- I
, I
6 I
, I
12 I
- I
, I
and I
12 I
, I
12 I
- I
ionenes I
. O

We O
show O
that O
the O
salts O
when O
ordered O
by O
heat O
effects O
produced O
by O
mixing O
of O
NaF O
and O
NaBr B
with O
3 B
, I
3 I
- I
, I
6 I
, I
9 I
- I
, I
or I
6 I
, I
12 I
- I
ionene I
fluorides I
and I
bromides I
follow O
the O
opposite O
ordering O
than O
in O
the O
case O
when O
the O
same O
alkali B
halide I
salts O
are O
mixed O
with O
more O
hydrophobic O
12 B
, I
12 I
- I
ionene I
salts O
. O

The O
results O
for O
the O
enthalpy O
of O
mixing O
of O
ionenes O
under O
study O
with O
Na2SO4 B
follow O
the O
same O
order O
as O
obtained O
for O
monovalent O
salts O
. O

We O
choose O
AOT O
/ O
Igepal B
- I
520 I
/ O
cyclohexane O
( O
Cy O
) O
mixed O
RM O
as O
a O
model O
system O
which O
exhibits O
synergistic O
water O
solubilization O
behavior O
as O
a O
function O
of O
interfacial O
stoichiometry O
. O

Dynamic O
light O
scattering O
( O
DLS O
) O
studies O
reveal O
linear O
increase O
in O
the O
droplet O
size O
and O
aggregation O
number O
of O
the O
RMs O
with O
increasing O
XIgepal O
( O
mole O
fraction O
of O
Igepal B
in O
the O
surfactant O
mixture O
) O
. O

FTIR O
study O
in O
the O
3000 O
- O
3800 O
cm O
( O
- O
1 O
) O
region O
identifies O
that O
the O
relative O
population O
of O
the O
surface O
- O
bound O
water O
molecules O
is O
higher O
in O
AOT O
RM O
compared O
to O
that O
in O
Igepal B
RM O
, O
and O
in O
mixed O
systems O
it O
also O
follows O
a O
linear O
trend O
with O
XIgepal O
. O

Water O
relaxation O
dynamics O
as O
probed O
by O
time O
- O
resolved O
fluorescence O
spectroscopy O
using O
Coumarin B
- I
500 I
also O
reveals O
an O
overall O
linear O
trend O
with O
no O
characteristic O
feature O
around O
the O
solubilization O
inflation O
point O
. O

Discovery O
of O
( B
R I
) I
- I
2 I
- I
amino I
- I
6 I
- I
borono I
- I
2 I
- I
( I
2 I
- I
( I
piperidin I
- I
1 I
- I
yl I
) I
ethyl I
) I
hexanoic I
acid I
and O
congeners O
as O
highly O
potent O
inhibitors O
of O
human O
arginases O
I O
and O
II O
for O
treatment O
of O
myocardial O
reperfusion O
injury O
. O

Recent O
efforts O
to O
identify O
treatments O
for O
myocardial O
ischemia O
reperfusion O
injury O
have O
resulted O
in O
the O
discovery O
of O
a O
novel O
series O
of O
highly O
potent O
alpha B
, I
alpha I
- I
disubstituted I
amino I
acid I
- O
based O
arginase O
inhibitors O
. O

The O
lead O
candidate O
, O
( B
R I
) I
- I
2 I
- I
amino I
- I
6 I
- I
borono I
- I
2 I
- I
( I
2 I
- I
( I
piperidin I
- I
1 I
- I
yl I
) I
ethyl I
) I
hexanoic I
acid I
, O
compound O
9 O
, O
inhibits O
human O
arginases O
I O
and O
II O
with O
IC50s O
of O
223 O
and O
509 O
nM O
, O
respectively O
, O
and O
is O
active O
in O
a O
recombinant O
cellular O
assay O
overexpressing O
human O
arginase O
I O
( O
CHO O
cells O
) O
. O

Design O
, O
Synthesis O
, O
and O
Biological O
Evaluation O
of O
a O
Series O
of O
Benzo B
[ I
de I
] I
[ I
1 I
, I
7 I
] I
naphthyridin I
- I
7 I
( I
8H I
) I
- I
ones I
Bearing O
a O
Functionalized O
Longer O
Chain O
Appendage O
as O
Novel O
PARP1 O
Inhibitors O
. O

A O
series O
of O
benzo B
[ I
de I
] I
[ I
1 I
, I
7 I
] I
naphthyridin I
- I
7 I
( I
8H I
) I
- I
ones I
possessing O
a O
functionalized O
long O
- O
chain O
appendage O
have O
been O
designed O
and O
evaluated O
as O
novel O
PARP1 O
inhibitors O
. O

The O
initial O
effort O
led O
to O
the O
first O
- O
generation O
PARP1 O
inhibitor O
26 O
bearing O
a O
terminal O
phthalazin B
- I
1 I
( I
2H I
) I
- I
one I
framework O
and O
showing O
remarkably O
high O
PARP1 O
inhibitory O
activity O
( O
0 O
. O
31 O
nM O
) O
but O
only O
moderate O
potency O
in O
the O
cell O
. O

Significant O
potentiation O
on O
the O
cytotoxicity O
of O
Temozolomide B
was O
also O
observed O
. O

Engineered O
Magnetic O
Shape O
Anisotropy O
in O
BiFeO3 B
- O
CoFe2O4 B
Self O
- O
Assembled O
Thin O
Films O
. O

We O
report O
growth O
of O
various O
phase O
architectures O
of O
self O
- O
assembled O
BiFeO3 B
- O
CoFe2O4 B
( O
BFO B
- O
CFO B
) O
thin O
films O
on O
differently O
oriented O
SrTiO3 O
( O
STO B
) O
substrates O
. O

CFO B
forms O
segregated O
square O
, O
stripe O
, O
and O
triangular O
nanopillars O
embedded O
in O
a O
coherent O
BFO B
matrix O
on O
( O
001 O
) O
- O
, O
( O
110 O
) O
- O
, O
and O
( O
111 O
) O
- O
oriented O
STO B
substrates O
, O
respectively O
. O

Nanostructures O
with O
an O
aspect O
ratio O
of O
up O
to O
5 O
: O
1 O
with O
a O
prominent O
magnetic O
anisotropy O
were O
obtained O
on O
both O
( O
001 O
) O
and O
( O
110 O
) O
STO B
along O
out O
- O
of O
- O
plane O
and O
in O
- O
plane O
directions O
. O

An O
intractable O
in O
- O
plane O
anisotropy O
was O
fixed O
in O
CFO B
on O
( O
111 O
) O
STO B
due O
to O
the O
triangular O
shape O
of O
the O
ferromagnetic O
phase O
nanopillars O
. O

We O
present O
a O
simple O
and O
straightforward O
method O
for O
the O
direct O
proton O
beam O
activation O
of O
synthetic O
or O
commercially O
available O
aluminum O
oxide O
NPs O
( O
Al2O3 O
NPs O
) O
via O
the O
( B
16 I
) I
O I
( O
p O
, O
alpha O
) O
( B
13 I
) I
N I
nuclear O
reaction O
in O
order O
to O
assess O
their O
biological O
fate O
using O
positron O
emission O
tomography O
( O
PET O
) O
. O

The O
incorporation O
of O
radioactive O
( B
13 I
) I
N I
atoms O
in O
the O
Al2O3 O
NPs O
allowed O
the O
study O
of O
the O
biodistribution O
of O
the O
metal O
oxide O
NPs O
in O
rats O
after O
intravenous O
administration O
via O
PET O
. O

Despite O
the O
short O
half O
- O
life O
of O
( B
13 I
) I
N I
( O
9 O
. O
97 O
min O
) O
, O
the O
accumulation O
of O
NPs O
in O
different O
organs O
could O
be O
measured O
during O
the O
first O
68 O
min O
after O
administration O
. O

Sonochemical O
synthesis O
and O
characterization O
of O
nano O
- O
sized O
lead B
( I
II I
) I
3D O
coordination O
polymer O
: O
Precursor O
for O
the O
synthesis O
of O
lead B
( I
II I
) I
oxybromide I
nanoparticles O
. O

Nanoparticles O
of O
a O
three O
- O
dimensional O
coordination O
polymer O
, O
[ B
Pb I
( I
L I
) I
( I
mu I
2 I
- I
Br I
) I
( I
H2O I
) I
] I
n I
( O
1 O
) O
, O
( O
L O
( O
- O
) O
= O
1H B
- I
1 I
, I
2 I
, I
4 I
- I
triazole I
- I
3 I
- I
carboxylate I
) O
, O
have O
been O
synthesized O
by O
an O
ultrasonic O
method O
and O
characterized O
by O
scanning O
electron O
microscopy O
, O
X O
- O
ray O
powder O
diffraction O
, O
IR O
spectroscopy O
and O
elemental O
analyses O
. O

Calcination O
of O
the O
compound O
1 O
at O
500 O
degrees O
C O
under O
air O
atmosphere O
yields O
Pb3O2Br2 B
nanoparticles O
. O

Melanoma O
targeting O
property O
of O
a O
Lu B
- I
177 I
- O
labeled O
lactam O
bridge O
- O
cyclized O
alpha O
- O
MSH O
peptide O
. O

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
melanoma O
targeting O
property O
of O
( B
177 I
) I
Lu I
- I
DOTA I
- I
GGNle I
- I
CycMSHhex I
in O
B16 O
/ O
F1 O
melanoma O
- O
bearing O
C57 O
mice O
. O

( B
177 I
) I
Lu I
- I
DOTA I
- I
GGNle I
- I
CycMSHhex I
exhibited O
high O
receptor O
- O
mediated O
melanoma O
uptake O
and O
fast O
urinary O
clearance O
. O

The O
tumor O
uptake O
of O
( B
177 I
) I
Lu I
- I
DOTA I
- I
GGNle I
- I
CycMSHhex I
was O
20 O
. O
25 O
+ O
/ O
- O
4 O
. O
59 O
and O
21 O
. O
63 O
+ O
/ O
- O
6 O
. O
27 O
% O
ID O
/ O
g O
at O
0 O
. O
5 O
and O
2h O
post O
- O
injection O
, O
respectively O
. O

( B
177 I
) I
Lu I
- I
DOTA I
- I
GGNle I
- I
CycMSHhex I
showed O
high O
tumor O
to O
normal O
organ O
uptake O
ratios O
except O
for O
the O
kidneys O
. O

The O
tumor O
/ O
kidney O
uptake O
ratios O
of O
( B
177 I
) I
Lu I
- I
DOTA I
- I
GGNle I
- I
CycMSHhex I
were O
2 O
. O
76 O
and O
1 O
. O
74 O
at O
2 O
and O
24h O
post O
- O
injection O
. O

The O
melanoma O
lesions O
were O
clearly O
visualized O
by O
SPECT O
/ O
CT O
using O
( B
177 I
) I
Lu I
- I
DOTA I
- I
GGNle I
- I
CycMSHhex I
as O
an O
imaging O
probe O
at O
2h O
post O
- O
injection O
. O

Overall O
, O
high O
melanoma O
uptake O
coupled O
with O
fast O
urinary O
clearance O
of O
( B
177 I
) I
Lu I
- I
DOTA I
- I
GGNle I
- I
CycMSHhex I
underscored O
its O
potential O
for O
melanoma O
treatment O
in O
the O
future O
. O

BCR O
- O
ABL O
tyrosine O
kinase O
inhibitor O
pharmacophore O
model O
derived O
from O
a O
series O
of O
phenylaminopyrimidin O
- O
based O
( O
PAP B
) O
derivatives O
. O

To O
reveal O
novel O
insights O
into O
the O
inhibition O
of O
BCR O
- O
ABL O
tyrosine O
kinase O
, O
pharmacophore O
mapping O
studies O
were O
performed O
for O
a O
series O
of O
phenylaminopyrimidin O
- O
based O
( O
PAP B
) O
derivatives O
, O
including O
imatinib O
( O
Gleevec O
) O
. O

Discovery O
of O
the O
Antibiotic O
Phosacetamycin B
via O
a O
New O
Mass O
Spectrometry O
- O
Based O
Method O
for O
Phosphonic B
Acid I
Detection O
. O

Naturally O
occurring O
phosphonates O
such O
as O
phosphinothricin B
( O
Glufosinate B
, O
a O
commercially O
used O
herbicide O
) O
and O
fosfomycin B
( O
Monurol B
, O
a O
clinically O
used O
antibiotic O
) O
have O
proved O
to O
be O
potent O
and O
useful O
biocides O
. O

Here O
, O
we O
present O
an O
efficient O
mass O
- O
spectrometric O
method O
for O
the O
selective O
detection O
of O
natural O
products O
containing O
phosphonate O
and O
phosphinate B
functional O
groups O
. O

We O
have O
used O
this O
method O
to O
identify O
a O
new O
phosphonate O
metabolite O
, O
phosacetamycin B
, O
whose O
structure O
, O
biological O
activity O
, O
and O
biosynthetic O
gene O
cluster O
are O
reported O
. O

The O
present O
study O
determined O
the O
anti O
- O
Mycobacterium O
tuberculosis O
activities O
of O
supercritical O
CO2 O
extracts O
, O
neolignans O
eupomatenoid B
- I
5 I
( O
1 O
) O
, O
conocarpan B
( O
4 O
) O
and O
eupomatenoid B
- I
3 I
( O
7 O
) O
and O
their O
derivatives O
( O
2 O
, O
3 O
, O
5 O
, O
6 O
, O
and O
8 O
) O
from O
Piper O
regnellii O
, O
as O
well O
as O
their O
cytotoxicities O
. O

In O
this O
study O
, O
prilling O
was O
evaluated O
as O
a O
technique O
for O
the O
development O
of O
multiparticulate O
dosage O
forms O
using O
the O
fatty O
acids O
, O
stearic O
acid O
, O
and O
behenic O
acid O
as O
potential O
matrix O
formers O
to O
control O
the O
release O
of O
metoprolol B
tartrate I
( O
MPT B
) O
, O
a O
highly O
water O
soluble O
drug O
. O

Solid O
state O
characterization O
indicated O
that O
the O
crystalline O
state O
of O
the O
fatty O
acids O
was O
not O
affected O
by O
thermal O
processing O
via O
prilling O
, O
while O
the O
crystallinity O
of O
MPT B
was O
decreased O
. O

During O
storage O
, O
the O
amorphous O
MPT B
fraction O
recrystallized O
in O
the O
entire O
matrix O
. O

The O
bioavailability O
of O
MPT B
, O
after O
oral O
administration O
to O
dogs O
as O
prills O
containing O
30 O
% O
and O
40 O
% O
MPT B
using O
behenic O
acid O
as O
matrix O
former O
, O
was O
not O
significantly O
different O
from O
a O
commercial O
sustained O
release O
reference O
formulation O
, O
although O
the O
40 O
% O
MPT B
prills O
showed O
a O
burst O
release O
. O

Synthesis O
and O
evaluation O
of O
3 B
- I
( I
benzylthio I
) I
- I
5 I
- I
( I
1H I
- I
indol I
- I
3 I
- I
yl I
) I
- I
1 I
, I
2 I
, I
4 I
- I
triazol I
- I
4 I
- I
amines I
as O
Bcl O
- O
2 O
inhibitory O
anticancer O
agents O
. O

A O
series O
of O
substituted O
3 B
- I
( I
benzylthio I
) I
- I
5 I
- I
( I
1H I
- I
indol I
- I
3 I
- I
yl I
) I
- I
4H I
- I
1 I
, I
2 I
, I
4 I
- I
triazol I
- I
4 I
- I
amines I
has O
been O
synthesised O
and O
tested O
in O
vitro O
as O
potential O
pro O
- O
apoptotic O
Bcl O
- O
2 O
- O
inhibitory O
anticancer O
agents O
. O

Synthesis O
of O
the O
target O
compounds O
was O
readily O
accomplished O
in O
good O
yields O
through O
a O
cyclisation O
reaction O
between O
indole B
- I
3 I
- I
carboxylic I
acid I
hydrazide I
and O
carbon O
disulfide O
under O
basic O
conditions O
, O
followed O
by O
S O
- O
benzylation O
. O

Active O
compounds O
, O
such O
as O
the O
nitrobenzyl B
analogue O
6c O
, O
were O
found O
to O
exhibit O
sub O
- O
micromolar O
IC50 O
values O
in O
Bcl O
- O
2 O
expressing O
human O
cancer O
cell O
lines O
. O

Herein O
, O
we O
develop O
a O
novel O
three O
- O
dimensional O
( O
3D O
) O
sulfur B
- I
nitrogen I
co I
- I
doped I
carbon I
foams O
( O
S O
- O
N O
- O
CF O
) O
with O
hierarchical O
pore O
structures O
, O
using O
a O
convenient O
, O
economical O
, O
and O
scalable O
method O
. O

Recently O
, O
the O
discovery O
of O
the O
aminoisoindoles B
as O
potent O
and O
selective O
inhibitors O
of O
beta O
- O
secretase O
was O
reported O
, O
including O
the O
close O
structural O
analogs O
compound O
( B
S I
) I
- I
1 I
- I
pyridin I
- I
4 I
- I
yl I
- I
4 I
- I
fluoro I
- I
1 I
- I
( I
3 I
- I
( I
pyrimidin I
- I
5 I
- I
yl I
) I
phenyl I
) I
- I
1H I
- I
isoindol I
- I
3 I
- I
amine I
[ O
( O
S O
) O
- O
25 O
] O
and O
( O
S O
) O
- O
1 O
- O
( O
2 O
- O
( O
difluoromethyl O
) O
pyridin O
- O
4 O
- O
yl O
) O
- O
4 O
- O

fluoro O
- O
1 O
- O
( O
3 O
- O
( O
pyrimidin O
- O
5 O
- O
yl O
) O
phenyl O
) O
- O
1H O
- O
isoindol O
- O
3 O
- O
amine O
hemifumarate O
( O
AZD3839 B
) O
, O
the O
latter O
being O
recently O
progressed O
to O
the O
clinic O
. O

The O
biotransformation O
of O
( O
S O
) O
- O
25 O
was O
investigated O
in O
vitro O
and O
in O
vivo O
in O
rat O
, O
rabbit O
, O
and O
human O
and O
compared O
with O
AZD3839 B
to O
further O
understand O
the O
metabolic O
fate O
of O
these O
compounds O
. O

The O
main O
proposed O
metabolic O
pathways O
in O
various O
in O
vitro O
systems O
were O
N O
- O
oxidation O
of O
the O
pyridine O
and O
/ O
or O
pyrimidine O
ring O
and O
conversion O
to O
4 B
- I
pyrimidone I
and O
pyrimidine B
- I
2 I
, I
4 I
- I
dione I
. O

Ring O
- O
contracted O
metabolites O
accounted O
for O
25 O
% O
of O
the O
total O
metabolism O
in O
the O
rat O
for O
( O
S O
) O
- O
25 O
, O
whereas O
the O
contribution O
was O
much O
smaller O
for O
AZD3839 B
. O

In O
conclusion O
, O
we O
discovered O
an O
unusual O
metabolic O
pathway O
of O
aryl B
- I
pyrimidine I
- O
containing O
compounds O
by O
a O
ring O
- O
opening O
reaction O
followed O
by O
elimination O
of O
a O
carbon O
atom O
and O
a O
ring O
closure O
to O
form O
an O
imidazole O
ring O
. O

More O
generally O
, O
we O
show O
that O
stability O
and O
electrohydrodynamics O
of O
viruses O
differ O
according O
to O
purification O
by O
( O
i O
) O
dialysis O
, O
( O
ii O
) O
isopycnic O
centrifugation O
in O
the O
cesium B
chloride I
gradient O
, O
and O
( O
iii O
) O
precipitation O
using O
polyethylene O
glycol O
( O
PEG O
) O
. O

The O
antipsychotic O
- O
like O
effects O
of O
the O
mGlu O
group O
III O
orthosteric O
agonist O
, O
LSP1 B
- I
2111 I
, O
involves O
5 O
- O
HT1A O
signalling O
. O

LSP1 B
- I
2111 I
, O
the O
group O
III O
mGlu O
receptor O
orthosteric O
agonist O
, O
with O
a O
high O
affinity O
towards O
mGlu4 O
receptors O
, O
was O
previously O
shown O
to O
exhibit O
antipsychotic O
- O
like O
action O
in O
animal O
models O
displaying O
positive O
symptoms O
of O
schizophrenia O
. O

OBJECTIVES O
: O
Here O
, O
we O
decided O
to O
investigate O
the O
possible O
role O
of O
LSP1 B
- I
2111 I
in O
models O
of O
negative O
( O
social O
interaction O
) O
and O
cognitive O
( O
NOR O
) O
symptoms O
of O
psychosis O
. O

We O
also O
investigated O
the O
involvement O
of O
5 O
- O
HT1A O
receptors O
in O
the O
LSP1 B
- I
2111 I
- O
induced O
antipsychotic O
effects O
. O

RESULTS O
: O
LSP1 B
- I
2111 I
( O
0 O
. O
5 O
, O
2 O
, O
and O
5 O
mg O
/ O
kg O
) O
dose O
- O
dependently O
inhibited O
MK O
- O
801 O
- O
induced O
deficits O
in O
social O
interaction O
and O
NOR O
tests O
. O

The O
effects O
of O
the O
drug O
were O
antagonized O
by O
5 O
- O
HT1A O
antagonist O
, O
WAY100635 B
( O
0 O
. O
1 O
mg O
/ O
kg O
) O
. O

A O
similar O
inhibition O
of O
LSP1 B
- I
2111 I
- O
induced O
effects O
was O
observed O
in O
models O
of O
positive O
symptoms O
of O
schizophrenia O
. O

Moreover O
, O
the O
concomitant O
administration O
of O
subeffective O
doses O
of O
LSP1 B
- I
2111 I
( O
0 O
. O
3 O
- O
0 O
. O
5 O
mg O
/ O
kg O
) O
with O
a O
subeffective O
dose O
of O
5 O
- O
HT1A O
agonist O
, O
( B
R I
) I
- I
( I
+ I
) I
- I
8 I
- I
Hydroxy I
- I
DPAT I
( O
0 O
. O
01 O
mg O
/ O
kg O
) O
, O
induced O
a O
clear O
antipsychotic O
- O
like O
effect O
in O
all O
of O
the O
procedures O
used O
. O

Practical O
synthesis O
of O
a O
chromene B
analog O
for O
use O
as O
a O
retinoic O
acid O
receptor O
alpha O
antagonist O
lead O
compound O
. O

Herein O
we O
report O
a O
modified O
synthesis O
of O
a O
known O
RAR O
alpha O
antagonist O
, O
2 B
- I
fluoro I
- I
4 I
- I
[ I
[ I
[ I
8 I
- I
bromo I
- I
2 I
, I
2 I
- I
dimethyl I
- I
4 I
- I
( I
4 I
- I
methylphenyl I
) I
chroman I
- I
6 I
- I
yl I
] I
carbonyl I
] I
amino I
] I
benzoic I
acid I
and O
a O
synthesis O
of O
its O
unknown O
, O
desfluoro O
analog O
, O
4 B
- I
[ I
[ I
[ I
8 I
- I
bromo I
- I
2 I
, I
2 I
- I
dimethyl I
- I
4 I
- I
( I
4 I
- I
methylphenyl I
) I
chroman I
- I
6 I
- I
yl I
] I
carbonyl I
] I
amino I
] I
benzoic I
acid I
. O

Synthesis O
of O
decacationic B
[ I
60 I
] I
fullerene I
decaiodides I
giving O
photoinduced O
production O
of O
superoxide O
radicals O
and O
effective O
PDT O
- O
mediation O
on O
antimicrobial O
photoinactivation O
. O

We O
report O
a O
novel O
class O
of O
highly O
water O
- O
soluble O
decacationic B
methano I
[ I
60 I
] I
fullerene I
decaiodides I
C60 B
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
- I
( I
I I
( I
- I
) I
) I
10 I
[ O
1 O
- O
( B
I I
( I
- I
) I
) I
10 I
] O
capable O
of O
co O
- O
producing O
singlet O
oxygen O
( O
Type O
- O
II O
) O
and O
highly O
reactive O
hydroxyl O
radicals O
, O
formed O
from O
superoxide O
radicals O
in O
Type O
- O
I O
photosensitizing O
reactions O
, O
upon O
illumination O
at O
both O
UVA O
and O
white O
light O
wavelengths O
. O

The O
O2 O
( O
- O
) O
. O
- O
production O
efficiency O
of O
1 O
- O
( B
I I
( I
- I
) I
) I
10 I
was O
confirmed O
by O
using O
an O
O2 O
( O
- O
) O
. O
- O
reactive O
bis B
( I
2 I
, I
4 I
- I
dinitrobenzenesulfon I
) I
tetrafluorofluoresce I
probe O
and O
correlated O
to O
the O
photoinduced O
electron O
- O
transfer O
event O
going O
from O
iodide O
anions O
to O
( B
3 I
) I
C60 I
* I
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
leading O
to O
C60 B
( I
- I
) I
. I
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
. O

Incorporation O
of O
a O
defined O
number O
( O
ten O
) O
of O
quaternary B
ammonium I
cationic O
charges O
per O
C60 O
in O
1 O
was O
aimed O
to O
enhance O
its O
ability O
to O
target O
pathogenic O
Gram O
- O
positive O
and O
Gram O
- O
negative O
bacterial O
cells O
. O

We O
used O
the O
well O
- O
characterized O
malonato B
[ I
60 I
] I
fullerene I
diester I
monoadduct O
C60 B
[ I
> I
M I
( I
t I
- I
Bu I
) I
2 I
] I
as O
the O
starting O
fullerene O
derivative O
to O
provide O
a O
better O
synthetic O
route O
to O
C60 B
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
via O
transesterification O
reaction O
under O
trifluoroacetic O
acid O
catalyzed O
conditions O
. O

Synthesis O
, O
antimicrobial O
, O
antiquorum O
- O
sensing O
, O
antitumor O
and O
cytotoxic O
activities O
of O
new O
series O
of O
fused O
[ B
1 I
, I
3 I
, I
4 I
] I
thiadiazoles I
. O

New O
series O
of O
[ B
1 I
, I
3 I
, I
4 I
] I
thiadiazolo I
[ I
3 I
, I
2 I
- I
a I
] I
pyrimidines I
, O
benzo B
[ I
h I
] I
[ I
1 I
, I
3 I
, I
4 I
] I
thiadiazolo I
[ I
2 I
, I
3 I
- I
b I
] I
quinazolines I
, O
benzothiadiazolotria B
, O
and O
imidazo B
[ I
2 I
, I
1 I
- I
b I
] I
[ I
1 I
, I
3 I
, I
4 I
] I
thiadiazoles I
have O
been O
synthesized O
and O
characterized O
by O
analytical O
and O
spectrometrical O
methods O
( O
IR O
, O
MS O
, O
( O
1 O
) O
H O
and O
( O
13 O
) O
C O
NMR O
) O
. O

Synthesis O
using O
microwave O
irradiation O
and O
antibacterial O
evaluation O
of O
new O
N B
, I
O I
- I
acetals I
and O
N B
, I
S I
- I
acetals I
derived O
from O
2 B
- I
amino I
- I
1 I
, I
4 I
- I
naphthoquinones I
. O

This O
paper O
describes O
a O
novel O
series O
of O
N B
, I
O I
- I
acetals I
and O
N B
, I
S I
- I
acetals I
( O
7a O
- O
o O
) O
derived O
from O
2 B
- I
amino I
- I
1 I
, I
4 I
- I
naphthoquinones I
that O
were O
synthesized O
and O
evaluated O
as O
potential O
antimicrobial O
agents O
. O

Three O
of O
our O
biologically O
active O
2 B
- I
amino I
- I
1 I
, I
4 I
- I
naphthoquinone I
N B
, I
O I
- I
acetals I
and O
N B
, I
S I
- I
acetals I
tested O
against O
hospital O
bacterial O
strains O
were O
identified O
as O
potential O
lead O
compounds O
. O

Arsenic O
speciation O
analysis O
showed O
that O
the O
less O
- O
toxic O
arsenobetaine B
( O
AsB B
) O
constituted O
80 O
. O
6 O
- O
98 O
. O
8 O
% O
of O
all O
As O
compounds O
, O
and O
dimethylarsinic O
acid O
( O
DMA B
) O
constituted O
0 O
. O
47 O
- O
3 O
. O
44 O
% O
. O

Monomethylarsonic O
acid O
( O
MMA B
) O
and O
As O
( O
V O
) O
were O
only O
detected O
in O
the O
whelk O
Drupa O
fiscella O
and O
the O
crab O
Heteropilumnus O
ciliatus O
, O
respectively O
. O

Effects O
of O
Strontium B
on O
Collagen O
Content O
and O
Expression O
of O
Related O
Genes O
in O
Rat O
Chondrocytes O
Cultured O
In O
Vitro O
. O

Strontium B
stimulates O
cartilage O
matrix O
formation O
in O
vitro O
. O

In O
this O
study O
, O
chondrocytes O
were O
isolated O
from O
rat O
articular O
cartilage O
by O
enzymatic O
digestion O
and O
cultured O
for O
24 O
- O
72 O
h O
with O
1 O
- O
5 O
mM O
strontium B
. O

We O
investigated O
the O
effects O
of O
different O
concentrations O
of O
strontium B
on O
collagen O
content O
, O
type O
II O
collagen O
, O
insulin O
- O
like O
growth O
factor O
( O
IGF O
- O
1 O
) O
and O
matrix O
metalloproteinase O
( O
MMP O
) O
- O
13 O
expression O
in O
rat O
cultured O
articular O
chondrocytes O
in O
vitro O
. O

The O
results O
showed O
that O
collagen O
content O
from O
the O
chondrocytes O
extracellular O
matrix O
increased O
with O
increasing O
strontium B
concentration O
. O

Moreover O
, O
3 O
and O
5 O
mM O
strontium B
strongly O
stimulated O
protein O
expression O
and O
mRNA O
levels O
of O
type O
II O
collagen O
and O
IGF O
- O
1 O
. O

Conversely O
, O
MMP O
- O
13 O
expression O
in O
chondrocytes O
decreased O
dose O
- O
dependently O
with O
increasing O
strontium B
concentration O
. O

These O
results O
should O
provide O
insight O
into O
the O
ability O
of O
strontium B
to O
promote O
chondrocyte O
extracellular O
matrix O
synthesis O
. O

Strontium B
could O
promote O
collagen O
synthesis O
and O
suppress O
collagen O
degradation O
via O
the O
repression O
of O
MMP O
- O
13 O
expression O
. O

1 B
- I
Hexadecyl I
- I
3 I
- I
trifluoroethylglycer I
- I
sn I
- I
2 I
- I
phosphomethanol I
( O
MJ33 B
) O
is O
a O
fluorinated O
phospholipid O
analog O
that O
inhibits O
the O
phospholipase O
A2 O
( O
PLA2 O
) O
activity O
of O
peroxiredoxin O
6 O
( O
Prdx6 O
) O
. O

In O
vitro O
, O
MJ33 B
inhibited O
agonist O
- O
stimulated O
production O
of O
ROS O
by O
the O
isolated O
perfused O
mouse O
lung O
, O
lung O
microvascular O
endothelial O
cells O
, O
and O
polymorphonuclear O
leukocytes O
. O

MJ33 B
( O
0 O
. O
02 O
- O
0 O
. O
5 O
micro O
mol O
MJ33 B
/ O
kg O
body O
weight O
) O
in O
mixed O
unilamellar O
liposomes O
was O
administered O
to O
C57BL O
/ O
6 O
mice O
by O
either O
intratracheal O
( O
i O
. O
t O
. O
) O
or O
i O
. O
v O
. O
routes O
. O

Lung O
MJ33 B
content O
, O
measured O
by O
liquid O
chromatography O
/ O
mass O
spectroscopy O
, O
showed O
uptake O
of O
67 O
- O
87 O
% O
of O
the O
injected O
dose O
for O
i O
. O
t O
. O
and O
23 O
- O
42 O
% O
for O
i O
. O
v O
. O
administration O
at O
4 O
hours O
postinjection O
. O

Both O
MJ33 B
content O
and O
PLA2 O
activity O
gradually O
returned O
to O
near O
control O
levels O
over O
the O
subsequent O
24 O
- O
72 O
hours O
. O

Mice O
treated O
with O
MJ33 B
at O
12 O
. O
5 O
- O
25 O
micro O
mol O
/ O
kg O
did O
not O
show O
changes O
( O
compared O
with O
control O
) O
in O
clinical O
symptomatology O
, O
body O
weight O
, O
hematocrit O
, O
and O
histology O
of O
lung O
, O
liver O
, O
and O
kidney O
during O
a O
30 O
- O
to O
50 O
- O
day O
observation O
period O
. O

Thus O
, O
the O
toxic O
dose O
of O
MJ33 B
was O
> O
25 O
micro O
mol O
/ O
kg O
, O
whereas O
the O
PLA2 O
inhibitory O
dose O
was O
approximately O
0 O
. O
02 O
micro O
mol O
/ O
kg O
, O
indicating O
a O
high O
margin O
of O
safety O
. O

MJ33 B
administered O
to O
mice O
prior O
to O
lung O
isolation O
markedly O
reduced O
ROS O
production O
and O
tissue O
lipid O
and O
protein O
oxidation O
during O
ischemia O
followed O
by O
reperfusion O
. O

Thus O
, O
MJ33 B
could O
be O
useful O
as O
a O
therapeutic O
agent O
to O
prevent O
ROS O
- O
mediated O
tissue O
injury O
associated O
with O
lung O
inflammation O
or O
in O
harvested O
lungs O
prior O
to O
transplantation O
. O

The O
model O
quantitatively O
captures O
literature O
data O
from O
Yannopoulos O
and O
co O
- O
workers O
for O
the O
extent O
of O
polymerization O
versus O
temperature O
for O
bulk O
sulfur O
polymerization O
and O
for O
polymerization O
in O
20 O
, O
7 O
. O
5 O
, O
and O
2 O
. O
5 O
nm O
diameter O
Gelsil B
nanopores O
, O
assuming O
that O
the O
change O
of O
entropy O
of O
nanoconfined O
chains O
scales O
with O
molecular O
size O
to O
the O
second O
power O
and O
with O
nanopore O
diameter O
to O
either O
the O
- O
3 O
. O
0 O
or O
- O
3 O
. O
8 O
power O
, O
the O
former O
of O
which O
fits O
slightly O
better O
. O

The O
fruits O
are O
an O
excellent O
source O
of O
health O
- O
related O
compounds O
, O
such O
as O
ascorbic O
acid O
( O
vitamin O
C O
) O
, O
carotenoids O
( O
provitamin O
A O
) O
, O
tocopherols O
( O
vitamin O
E O
) O
, O
flavonoids O
, O
and O
capsaicinoids B
. O

DNA O
Adducts O
in O
Aldehyde O
Dehydrogenase O
- O
Positive O
Lung O
Stem O
Cells O
of O
A O
/ O
J O
Mice O
Treated O
with O
the O
Tobacco O
Specific O
Lung O
Carcinogen O
4 B
- I
( I
Methylnitrosamino I
) I
- I
1 I
- I
( I
3 I
- I
pyridyl I
) I
- I
1 I
- I
butanone I
( O
NNK B
) O
. O

To O
investigate O
the O
presence O
of O
DNA O
modifications O
in O
these O
cells O
, O
we O
isolated O
ALDH O
- O
positive O
lung O
cells O
from O
A O
/ O
J O
mice O
exposed O
to O
the O
lung O
carcinogen O
4 B
- I
( I
methylnitrosamino I
) I
- I
1 I
- I
( I
3 I
- I
pyridyl I
) I
- I
1 I
- I
butanone I
. O

Using O
LC O
- O
NSI O
- O
HRMS O
/ O
MS O
- O
PRM O
, O
O B
( I
6 I
) I
- I
methyl I
- I
G I
, O
7 B
- I
POB I
- I
G I
, O
and O
O B
( I
2 I
) I
- I
POB I
- I
dT I
were O
positively O
identified O
in O
ALDH O
- O
positive O
cell O
DNA O
. O

Safety O
and O
efficacy O
of O
polycalcium B
for O
improving O
biomarkers O
of O
bone O
metabolism O
: O
a O
4 O
- O
week O
open O
- O
label O
clinical O
study O
. O

Polycalcium B
is O
a O
mixture O
of O
Polycan O
and O
calcium B
lactate I
- I
gluconate I
1 O
: O
9 O
( O
w O
/ O
w O
) O
with O
demonstrated O
antiosteoporosis O
activity O
in O
vitro O
and O
in O
vivo O
studies O
. O

These O
studies O
were O
a O
4 O
- O
week O
open O
- O
label O
, O
single O
- O
center O
trial O
to O
evaluate O
the O
efficacy O
of O
oral O
Polycalcium B
on O
bone O
metabolism O
and O
safety O
. O

In O
total O
, O
30 O
healthy O
women O
( O
range O
40 O
- O
60 O
years O
) O
were O
administered O
400 O
mg O
of O
Polycalcium B
for O
4 O
weeks O
. O

The O
primary O
efficacy O
parameter O
was O
urinary O
deoxypyridinoline O
( O
DPYR B
) O
levels O
, O
and O
serum O
osteocalcin O
( O
OSC O
) O
, O
bone O
- O
specific O
alkaline O
phosphatase O
( O
BALP O
) O
, O
urinary O
cross O
- O
linked O
C O
- O
telopeptide O
of O
type O
- O
1 O
collagen O
( O
CTx O
) O
, O
urinary O
cross O
- O
linked O
N O
- O
telopeptide O
of O
type O
- O
1 O
collagen O
( O
NTx O
) O
, O
calcium O
( O
Ca O
) O
, O
and O
phosphorus O
( O
P O
) O
levels O
, O
which O
were O
evaluated O
for O
comparison O
before O
and O
after O
administration O
of O

Polycalcium B
. O

After O
4 O
weeks O
of O
Polycalcium B
administration O
, O
27 O
subjects O
completed O
the O
test O
plan O
. O

Biomarkers O
of O
bone O
resorption O
: O
urinary O
DPYR B
, O
serum O
CTx O
, O
serum O
NTx O
, O
urinary O
Ca O
, O
and O
urinary O
P O
, O
at O
baseline O
after O
4 O
weeks O
of O
treatment O
were O
changed O
by O
- O
13 O
. O
40 O
% O
, O
6 O
. O
67 O
% O
, O
- O
5 O
. O
13 O
% O
, O
- O
22 O
. O
43 O
% O
, O
and O
- O
3 O
. O
04 O
% O
, O
respectively O
. O

Additionally O
, O
when O
considering O
the O
subjects O
' O
adverse O
effects O
and O
the O
results O
of O
the O
blood O
and O
urine O
tests O
over O
the O
4 O
- O
week O
trial O
period O
, O
the O
dose O
of O
400 O
mg O
Polycalcium B
showed O
efficacy O
for O
improving O
bone O
metabolism O
and O
was O
well O
tolerated O
and O
safe O
. O

Polycalcium B
was O
apparently O
safe O
and O
efficacious O
. O

Discovery O
and O
gram O
- O
scale O
synthesis O
of O
BMS B
- I
593214 I
, O
a O
potent O
, O
selective O
FVIIa O
inhibitor O
. O

A O
6 B
- I
amidinotetrahydroqui I
screening O
hit O
was O
driven O
to O
a O
structurally O
novel O
, O
potent O
, O
and O
selective O
FVIIa O
inhibitor O
through O
a O
combination O
of O
library O
synthesis O
and O
rational O
design O
. O

An O
efficient O
gram O
- O
scale O
synthesis O
of O
the O
active O
enantiomer O
BMS B
- I
593214 I
was O
developed O
, O
which O
required O
significant O
optimization O
of O
the O
key O
Povarov O
annulation O
. O

Importantly O
, O
BMS B
- I
593214 I
showed O
antithrombotic O
efficacy O
in O
a O
rabbit O
arterial O
thrombosis O
model O
. O

A O
crystal O
structure O
of O
BMS B
- I
593214 I
bound O
to O
FVIIa O
highlights O
key O
contacts O
with O
Asp O
189 O
, O
Lys O
192 O
, O
and O
the O
S2 O
pocket O
. O

We O
characterized O
the O
effects O
of O
the O
electrophilic O
arthropod O
defensive O
compound O
para B
- I
benzoquinone I
( O
pBQN B
) O
on O
the O
human O
TRPA1 O
channel O
. O

We O
found O
that O
pBQN B
activates O
TRPA1 O
starting O
at O
10 O
nM O
and O
peaking O
at O
300 O
nM O
; O
higher O
concentrations O
caused O
rapid O
activation O
followed O
by O
a O
fast O
decline O
. O

Activation O
by O
pBQN B
required O
reactivity O
with O
cysteine O
residues O
, O
but O
ones O
that O
are O
distinct O
from O
those O
previously O
reported O
to O
be O
the O
key O
targets O
of O
electrophiles O
. O

The O
current O
reduction O
we O
found O
at O
higher O
pBQN B
concentrations O
was O
a O
cysteine O
- O
dependent O
desensitization O
of O
TRPA1 O
, O
and O
did O
not O
require O
prior O
activation O
. O

The O
cysteines O
required O
for O
desensitization O
are O
not O
accessible O
to O
all O
electrophiles O
as O
iodoacetamide B
and O
internally O
applied O
2 B
- I
( I
trimethylammonium I
) I
ethyl I
methanesulfonate I
failed O
to O
cause O
desensitization O
( O
despite O
large O
activation O
) O
. O

Interestingly O
, O
following O
pBQN B
desensitization O
, O
wild O
- O
type O
TRPA1 O
had O
dramatically O
reduced O
response O
to O
the O
nonelectrophile O
agonist O
carvacrol O
, O
whereas O
the O
triple O
cysteine O
mutant O
TRPA1 O
retained O
its O
full O
response O
. O

Using O
this O
device O
we O
determine O
Km O
and O
kcat O
for O
beta O
- O
galactosidase O
and O
the O
fluorogenic O
substrate O
Resorufin B
beta I
- I
d I
- I
galactopyranoside I
( O
RBG B
) O
to O
be O
442 O
mu O
M O
and O
1070 O
s O
( O
- O
1 O
) O
, O
respectively O
. O

Pollution O
from O
xenoestrogens B
has O
been O
discovered O
in O
the O
aquatic O
environment O
of O
the O
Greater O
Pittsburgh O
Area O
and O
is O
suspected O
to O
be O
caused O
by O
the O
failing O
sewer O
system O
. O

Many O
of O
these O
compounds O
are O
suspected O
xenoestrogens B
. O

Paraben B
detection O
in O
surface O
waters O
was O
as O
follows O
: O
methyl B
paraben I
ranged O
between O
2 O
. O
2 O
to O
17 O
. O
3 O
ppt O
; O
ethyl B
paraben I
was O
not O
detectable O
; O
propyl B
paraben I
was O
detected O
at O
9 O
. O
2 O
and O
12 O
. O
0 O
ppt O
; O
butyl B
paraben I
was O
detected O
at O
0 O
. O
2 O
ppt O
. O

Estrogenic O
potential O
of O
extracts O
from O
fish O
brain O
tissue O
was O
tested O
via O
Bromodeoxyuridine O
MCF O
- O
7 O
analysis O
and O
paired O
with O
HPLC O
- O
MS O
to O
investigate O
the O
presence O
of O
xenoestrogens B
. O

Hydrogen O
sulfide O
( O
H2S B
) O
is O
a O
toxic O
gaseous O
substance O
, O
and O
accidental O
exposure O
to O
high O
concentrations O
of O
H2S B
has O
been O
reported O
to O
be O
lethal O
to O
humans O
. O

Inhaled O
and O
absorbed O
H2S B
is O
partially O
dissolved O
within O
the O
circulation O
and O
causes O
toxic O
effects O
on O
lymphocytes O
. O

However O
, O
the O
mechanisms O
involved O
in O
H2S B
toxicity O
have O
not O
been O
well O
documented O
. O

Cells O
were O
exposed O
to O
a O
H2S B
donor O
, O
sodium B
hydroxysulfide I
( O
NaHS O
) O
, O
at O
pH O
6 O
. O
0 O
, O
7 O
. O
0 O
, O
or O
8 O
. O
0 O
for O
1 O
h O
at O
37 O
degrees O
C O
in O
a O
sealed O
conical O
tube O
to O
avoid O
the O
loss O
of O
dissolved O
H2S B
gas O
. O

Chronic O
use O
of O
glyceryl B
trinitrate I
is O
limited O
by O
serious O
side O
effects O
, O
inter O
alia O
tolerance O
and O
endothelial O
dysfunction O
of O
coronary O
and O
resistance O
arteries O
. O

The O
natural O
flavonoid O
quercetin O
has O
been O
shown O
to O
counteract O
the O
development O
of O
glyceryl B
trinitrate I
tolerance O
in O
vitro O
. O

Two O
mitochondriotropic O
, O
4 B
- I
O I
- I
triphenylphosphonium I
derivatives O
of O
quercetin O
( O
QTA B
- I
3BTPI I
and O
Q B
- I
3BTPI I
) O
were O
compared O
to O
quercetin O
for O
protection O
against O
glyceryl B
trinitrate I
- O
induced O
tolerance O
and O
endothelial O
dysfunction O
of O
isolated O
rat O
aorta O
rings O
. O

Both O
QTA B
- I
3BTPI I
and O
Q B
- I
3BTPI I
significantly O
counteracted O
the O
reduced O
vascular O
responsiveness O
to O
both O
glyceryl B
trinitrate I
and O
acetylcholine O
caused O
by O
prolonged O
exposure O
of O
the O
vessel O
to O
glyceryl B
trinitrate I
itself O
, O
their O
potency O
being O
much O
greater O
than O
that O
of O
quercetin O
. O

QTA B
- I
3BTPI I
, O
however O
, O
turned O
out O
to O
cause O
endothelial O
dysfunction O
per O
se O
. O

Since O
Q B
- I
3BTPI I
antagonized O
in O
vitro O
nitrate O
tolerance O
and O
endothelial O
dysfunction O
of O
vessels O
, O
this O
encourages O
assessing O
whether O
this O
effect O
is O
displayed O
also O
in O
vivo O
during O
long O
- O
term O
glyceryl B
trinitrate I
treatment O
. O

Cytotoxic O
pentacyclic B
triterpenoids I
from O
Prinsepia O
utilis O
. O

Phytochemical O
investigation O
of O
the O
aerial O
parts O
of O
Prinsepia O
utilis O
Royle O
resulted O
in O
the O
isolation O
and O
identification O
of O
ten O
pentacyclic B
triterpenoids I
, O
including O
two O
new O
triterpenoids O
, O
2 B
alpha I
- I
O I
- I
trans I
- I
p I
- I
coumaroyl I
- I
3 I
beta I
, I
19 I
alpha I
- I
dihydroxy I
- I
urs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
1 O
) O
and O
2 O
alpha O
- O
O O
- O
cis O
- O
p O
- O
coumaroyl O
- O
3 O
beta O
, O
19 O
alpha O
- O
dihydroxy O
- O
urs O
- O
12 O
- O
en O
- O
28 O
- O

oic O
acid O
( O
2 O
) O
, O
along O
with O
eight O
known O
pentacyclic B
triterpenoids I
( O
3 O
- O
10 O
) O
. O

The O
main O
classes O
of O
phytoestrogens O
are O
flavonoids O
( O
flavonols O
, O
flavanones O
) O
, O
isoflavonoids O
( O
isoflavones O
, O
coumestans B
) O
, O
lignans O
, O
stilbenoids B
as O
well O
as O
miscellaneous O
chemical O
groups O
abundant O
in O
several O
edible O
and O
/ O
or O
medicinal O
plants O
, O
belonging O
mostly O
to O
the O
Leguminosae O
family O
. O

Structural O
Units O
Important O
for O
Activity O
of O
a O
Novel O
- O
type O
Phosphoserine B
Phosphatase O
from O
Hydrogenobacter O
thermophilus O
TK O
- O
6 O
Revealed O
by O
Crystal O
Structure O
Analysis O
. O

Novel O
- O
type O
serine O
- O
synthesizing O
enzymes O
, O
termed O
metal O
- O
independent O
phosphoserine B
phosphatases O
( O
iPSPs O
) O
, O
were O
recently O
identified O
and O
characterized O
from O
Hydrogenobacter O
thermophilus O
, O
a O
chemolithoautotrophi O
bacterium O
belonging O
to O
the O
order O
Aquificales O
. O

iPSPs O
are O
cofactor O
- O
dependent O
phosphoglycerate B
mutase O
( O
dPGM O
) O
- O
like O
phosphatases O
that O
have O
significant O
amino O
acid O
sequence O
similarity O
to O
dPGMs O
but O
lack O
phosphoglycerate B
mutase O
activity O
. O

Here O
, O
we O
determined O
the O
crystal O
structure O
of O
iPSP1 O
from O
H O
. O
thermophilus O
in O
the O
apo O
- O
form O
and O
in O
complex O
with O
its O
substrate O
l B
- I
phosphoserine I
to O
find O
structural O
units O
important O
for O
its O
phosphatase O
activity O
toward O
l B
- I
phosphoserine I
. O

N B
- I
[ I
9 I
- I
( I
ortho I
- I
Fluorobenzyl I
) I
- I
2 I
- I
Phenyl I
- I
8 I
- I
Azapurin I
- I
6 I
- I
yl I
] I
- I
Amides I
as O
Potent O
and O
Selective O
Ligands O
for O
A1 O
Adenosine O
Receptors O
. O

A O
series O
of O
N B
- I
[ I
9 I
- I
( I
ortho I
- I
fluorobenzyl I
) I
- I
2 I
- I
phenyl I
- I
8 I
- I
azapurin I
- I
6 I
- I
yl I
] I
- I
amides I
were O
synthesised O
and O
tested O
for O
their O
affinity O
toward O
A1 O
, O
A2A O
and O
A3 O
adenosine O
receptor O
subtypes O
. O

Biological O
results O
demonstrated O
that O
the O
introduction O
of O
a O
fluorine O
atom O
at O
the O
ortho O
position O
of O
the O
9 B
- I
benzyl I
group O
generally O
enhanced O
affinity O
toward O
A1 O
subtype O
and O
did O
not O
significantly O
affect O
A2A O
and O
A3 O
affinity O
. O

Very O
interesting O
is O
the O
compound O
bearing O
a O
meta B
- I
fluorophenyl I
substituent O
on O
the O
carbonyl B
carbon I
of O
the O
amide O
group O
, O
which O
shows O
significantly O
high O
A1 O
/ O
A2A O
- O
A3 O
selectivity O
. O

Compounds O
of O
this O
new O
series O
, O
together O
with O
the O
previously O
published O
analogs O
without O
the O
fluorine O
atom O
on O
the O
9 B
- I
benzyl I
group O
, O
constituted O
the O
starting O
dataset O
for O
the O
development O
of O
QSAR O
models O
. O

The O
models O
obtained O
were O
able O
to O
rationally O
describe O
the O
affinity O
trends O
resulting O
from O
biological O
testing O
, O
and O
to O
enable O
investigation O
of O
the O
role O
of O
different O
substituents O
on O
the O
8 B
- I
azapurine I
scaffold O
, O
as O
well O
as O
the O
influence O
of O
the O
newly O
introduced O
fluorine O
atom O
on O
the O
benzyl O
moiety O
. O

Furthermore O
, O
a O
molecular O
docking O
study O
was O
carried O
out O
in O
order O
to O
assess O
hypothetical O
binding O
mode O
of O
N B
- I
[ I
9 I
- I
( I
ortho I
- I
fluorobenzyl I
) I
- I
2 I
- I
phenyl I
- I
8 I
- I
azapurin I
- I
6 I
- I
yl I
] I
- I
amides I
to O
A1 O
adenosine O
receptors O
. O

Physicochemical O
Properties O
and O
Supernucleophilicity O
of O
Oxime O
- O
Functionalized O
Surfactants O
: O
Hydrolytic O
Catalysts O
toward O
Dephosphorylation O
of O
Di B
- I
and I
Triphosphate I
Esters I
. O

Aggregation O
and O
kinetic O
studies O
have O
been O
performed O
to O
understand O
the O
hydrolytic O
potencies O
of O
the O
series O
of O
oxime O
- O
functionalized O
surfactants O
, O
viz O
. O
, O
3 B
- I
hydroxyiminomethyl I
- I
1 I
- I
alkylpyridinium I
bromide I
( O
alkyl O
= O
CnH2n B
+ I
1 I
, O
n O
= O
10 O
, O
12 O
, O
14 O
, O
16 O
, O
18 O
) O
in O
the O
cleavage O
of O
phosphate B
esters I
, O
p B
- I
nitrophenyl I
diphenyl I
phosphate I
( O
PNPDPP B
) O
and O
bis B
( I
2 I
, I
4 I
- I
dinitrophenyl I
) I
phosphate I
( O

BNDPP B
) O
, O
in O
mixed O
micelles O
with O
cetylpyridinium B
bromide I
( O
CPB B
) O
. O

Micellization O
and O
surface O
properties O
of O
mixed O
micelles O
functional O
surfactants O
with O
CPB B
were O
studied O
by O
conductivity O
and O
surface O
tension O
measurements O
. O

Functionalized O
oxime O
- O
based O
surfactants O
were O
proved O
to O
be O
supernucleophiles O
to O
attack O
on O
the O
P O
= O
O O
center O
of O
tri B
- I
and I
diphosphate I
esters I
. O

Oximes O
with O
hexadecyl B
alkyl O
chain O
length O
( O
3 B
- I
C16 I
) O
showed O
maximum O
micellar O
effect O
on O
the O
rate O
constants O
toward O
PNPDPP B
. O

A O
concise O
total O
synthesis O
of O
the O
natural O
carbazole B
clauraila O
A O
. O

A O
short O
and O
efficient O
total O
synthesis O
of O
naturally O
occurring O
carbazole B
clauraila B
A I
( O
1 O
) O
is O
described O
. O

The O
approach O
is O
designed O
on O
the O
basis O
of O
the O
key O
regioselective O
Diels O
- O
Alder O
reaction O
of O
the O
properly O
substituted O
exo B
- I
2 I
- I
oxazolidinone I
diene I
3 O
with O
acrolein O
( O
4 O
) O
to O
give O
the O
corresponding O
adduct O
2 O
. O

The O
latter O
is O
converted O
to O
functionalised O
diarylamine B
8 O
, O
which O
is O
cyclised O
to O
the O
desired O
carbazole B
1 O
through O
a O
Pd O
- O
promoted O
or O
- O
catalysed O
double O
C O
- O
H O
bond O
activation O
process O
in O
a O
fairly O
good O
overall O
yield O
. O

Temperature O
- O
Dependent O
Conformations O
of O
a O
Membrane O
Supported O
Zinc B
Porphyrin I
Tweezer O
by O
2D O
Fluorescence O
Spectroscopy O
. O

We O
studied O
the O
equilibrium O
conformations O
of O
a O
zinc B
porphyrin I
tweezer O
composed O
of O
two O
carboxylphenyl B
- O
functionalized O
zinc B
tetraphenyl I
porphyrin I
subunits O
connected O
by O
a O
1 B
, I
4 I
- I
butyndiol I
spacer O
, O
which O
was O
suspended O
inside O
the O
amphiphilic O
regions O
of O
1 B
, I
2 I
- I
distearoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
( O
DSPC B
) O
liposomes O
. O

By O
combining O
phase O
- O
modulation O
two O
- O
dimensional O
fluorescence O
spectroscopy O
( O
2D O
FS O
) O
with O
linear O
absorbance O
and O
fluorimetry O
, O
we O
determined O
that O
the O
zinc B
porphyrin I
tweezer O
adopts O
a O
mixture O
of O
folded O
and O
extended O
conformations O
in O
the O
membrane O
. O

TSS O
- O
SPIONs O
were O
developed O
by O
chelation O
between O
thiolated O
chitosan O
- O
thioglycolic B
acid I
( O
chitosan O
- O
TGA B
) O
hydrogel O
and O
iron O
ions O
( O
Fe O
( O
2 O
+ O
) O
/ O
Fe O
( O
3 O
+ O
) O
) O
. O

Rules O
for O
the O
recognition O
of O
dilysine B
retrieval O
motifs O
by O
coatomer O
. O

Cytoplasmic O
dilysine B
motifs O
on O
transmembrane O
proteins O
are O
captured O
by O
coatomer O
alpha O
- O
COP O
and O
beta O
' O
- O
COP O
subunits O
and O
packaged O
into O
COPI O
- O
coated O
vesicles O
for O
Golgi O
- O
to O
- O
ER O
retrieval O
. O

Dilysine B
motif O
recognition O
involves O
lysine O
side O
- O
chain O
interactions O
with O
two O
acidic O
patches O
. O

We O
used O
Photoactivatable O
- O
Ribonucleoside B
- O
Enhanced O
Crosslinking O
and O
Immunoprecipitation O
( O
PAR O
- O
CLIP O
) O
in O
HEK293 O
cells O
and O
identified O
a O
largely O
overlapping O
set O
of O
~ O
3000 O
mRNAs O
at O
~ O
9500 O
sites O
located O
in O
the O
3 O
' O
UTR O
and O
CDS O
. O

In O
vitro O
and O
in O
vivo O
, O
LIN28 O
preferentially O
bound O
single O
- O
stranded O
RNA O
containing O
a O
uridine O
- O
rich O
element O
and O
one O
or O
more O
flanking O
guanosines B
and O
appeared O
to O
be O
able O
to O
disrupt O
base O
- O
pairing O
to O
access O
these O
elements O
when O
embedded O
in O
predicted O
secondary O
structure O
. O

Synthesis O
, O
receptor O
binding O
and O
activity O
of O
iso B
and I
azakainoids I
. O

Two O
syntheses O
for O
the O
production O
of O
an O
unsubstituted O
azakainoid B
are O
described O
. O

The O
1 O
, O
3 O
- O
dipolar O
cycloaddition O
of O
diazomethane B
with O
trans B
- I
dibenzyl I
glutaconate I
yields O
a O
1 B
- I
pyrazoline I
, O
which O
may O
be O
reduced O
directly O
to O
the O
pyrazolidine B
. O

An O
unexpected O
trans O
- O
cis O
isomerization O
is O
observed O
during O
Hg O
/ O
Al O
reduction O
of O
the O
1 B
- I
pyrazoline I
NN B
bond O
. O

Alternatively O
, O
when O
TMS B
diazomethane I
is O
used O
as O
the O
dipole O
, O
the O
resulting O
2 B
- I
pyrazoline I
obtained O
after O
desilylation O
may O
be O
reduced O
with O
NaCNBH3 B
to O
provide O
the O
trans B
azakainate I
analog O
exclusively O
. O

The O
synthesis O
of O
an O
unsubstituted O
isokainoid B
via O
Michael O
addition O
is O
also O
described O
. O

Glutamate O
receptor O
binding O
assays O
revealed O
that O
the O
azakaniod B
has O
a O
moderate O
affinity O
for O
unspecified O
glutamate O
receptors O
. O

Membrane O
depolarization O
of O
Aplysia O
neurons O
upon O
application O
of O
the O
azakainoid B
demonstrates O
that O
it O
is O
an O
ionotropic O
glutamate O
receptor O
agonist O
. O

A O
scaffold O
bearing O
eight O
terminal O
alkyne O
groups O
was O
synthesized O
from O
sucrose O
, O
and O
copies O
of O
an O
azide O
- O
terminated O
Gd B
- I
DOTA I
complex O
were O
attached O
via O
copper O
( O
I O
) O
- O
catalyzed O
azide O
- O
alkyne O
cycloaddition O
. O

Cytotoxic O
and O
Anti O
- O
Inflammatory O
Eunicellin B
- O
Based O
Diterpenoids O
from O
the O
Soft O
Coral O
Cladiella O
krempfi O
. O

Five O
new O
eunicellin B
- O
based O
diterpenoids O
, O
krempfielins B
E I
- I
I I
( O
1 O
- O
5 O
) O
and O
seven O
known O
compounds O
( O
6 O
- O
12 O
) O
were O
isolated O
from O
the O
organic O
extract O
of O
a O
Taiwanese O
soft O
coral O
Cladiella O
krempfi O
. O

New O
Azalomycin B
F I
Analogs O
from O
Mangrove O
Streptomyces O
sp O
. O

Seven O
new O
azalomycin B
F I
analogs O
( O
1 O
- O
7 O
) O
were O
isolated O
from O
the O
broth O
of O
mangrove O
Streptomyces O
sp O
. O

211726 O
, O
and O
respectively O
identified O
as O
25 B
- I
malonyl I
demalonylazalomycin I
F5a I
monoester I
( O
1 O
) O
, O
23 B
- I
valine I
demalonylazalomycin I
F5a I
ester I
( O
2 O
) O
, O
23 B
- I
( I
6 I
- I
methyl I
) I
heptanoic I
acid I
demalonylazalomycins I
F3a I
ester I
( O
3 O
) O
, O
F4a B
ester I
( O
4 O
) O
and O
F5a B
ester I
( O
5 O
) O
, O
23 B
- I
( I
9 I
- I
methyl I
) I
decanoic I
acid I
demalonylazalomycin I
F4a I
ester I
( O
6 O
) O

and O
23 B
- I
( I
10 I
- I
methyl I
) I
undecanoic I
acid I
demalony I
lazalomycin I
F4a I
ester I
( O
7 O
) O
. O

Their O
structures O
were O
established O
by O
their O
spectroscopic O
data O
and O
by O
comparing O
with O
those O
of O
azalomycins B
F3a I
, I
F4a I
and I
F5a I
. O

Sorafenib B
Hepatobiliary O
Disposition O
: O
Mechanisms O
of O
Hepatic O
Uptake O
and O
Disposition O
of O
Generated O
Metabolites O
. O

Sorafenib B
is O
an O
orally O
active O
tyrosine O
kinase O
inhibitor O
used O
in O
the O
treatment O
of O
renal O
and O
hepatocellular O
carcinoma O
. O

This O
study O
was O
designed O
to O
establish O
whether O
transport O
proteins O
are O
involved O
in O
the O
hepatic O
uptake O
of O
sorafenib B
, O
and O
to O
determine O
the O
extent O
of O
biliary O
excretion O
of O
sorafenib B
/ O
metabolites O
in O
human O
hepatocytes O
. O

[ B
( I
14 I
) I
C I
] I
Sorafenib I
( O
1 O
mu O
M O
) O
uptake O
at O
4 O
degrees O
C O
was O
~ O
61 O
- O
63 O
% O
of O
the O
uptake O
at O
37 O
degrees O
C O
, O
suggesting O
a O
high O
degree O
of O
passive O
diffusion O
. O

Hepatocyte O
uptake O
of O
[ B
( I
14 I
) I
C I
] I
sorafenib I
was O
not O
Na O
( O
+ O
) O
- O
dependent O
or O
influenced O
by O
the O
organic O
anion O
transporter O
2 O
( O
OAT2 O
) O
inhibitor O
ketoprofen O
. O

However O
, O
initial O
[ B
( I
14 I
) I
C I
] I
sorafenib I
hepatocyte O
uptake O
was O
reduced O
by O
46 O
and O
30 O
% O
compared O
to O
control O
values O
in O
the O
presence O
of O
the O
organic O
anion O
transporting O
polypeptide O
( O
OATP O
) O
inhibitor O
rifamycin B
SV I
, O
and O
the O
organic O
cation O
transporter O
( O
OCT O
) O
inhibitor O
decynium B
22 I
, O
respectively O
. O

[ B
( I
14 I
) I
C I
] I
Sorafenib I
( O
0 O
. O
5 O
to O
5 O
mu O
M O
) O
uptake O
was O
significantly O
higher O
in O
hOCT1 O
- O
transfected O
CHO O
cells O
compared O
to O
mock O
cells O
, O
and O
inhibited O
by O
the O
general O
OCT O
inhibitor O
, O
MPP O
( O
+ O
) O
. O

The O
biliary O
excretion O
index O
( O
BEI O
) O
and O
in O
vitro O
biliary O
clearance O
( O
Clbiliary O
) O
of O
sorafenib B
( O
1 O
mu O
M O
) O
in O
sandwich O
- O
cultured O
human O
hepatocytes O
were O
low O
( O
~ O
11 O
% O
and O
11 O
ml O
/ O
min O
/ O
kg O
, O
respectively O
) O
. O

Results O
suggest O
that O
sorafenib B
uptake O
in O
human O
hepatocytes O
occurs O
via O
passive O
diffusion O
, O
and O
by O
OCT1 O
and O
a O
rifamycin B
- O
sensitive O
transporter O
. O

Sorafenib B
undergoes O
modest O
biliary O
excretion O
, O
predominantly O
as O
glucuronide O
conjugate O
( O
s O
) O
. O

The O
DSSCs O
based O
on O
the O
G B
- I
TiO2 I
nanocomposites O
improved O
their O
overall O
energy O
conversion O
efficiency O
to O
7 O
. O
1 O
% O
. O

RATIONALE O
: O
Treatment O
with O
a O
carbon O
monoxide O
- O
releasing O
molecule O
( O
tricarbonyldichloror B
( I
II I
) I
dimer O
, O
CORM B
- I
2 I
) O
or O
a O
classical O
heme O
oxygenase O
1 O
inducer O
( O
cobalt B
protoporphyrin I
IX I
, O
CoPP O
) O
has O
potent O
anti O
- O
inflammatory O
effects O
, O
but O
the O
role O
played O
by O
these O
treatments O
in O
the O
antinociceptive O
effects O
of O
morphine O
during O
acute O
and O
chronic O
pain O
was O
not O
evaluated O
. O

OBJECTIVES O
: O
In O
wild O
type O
( O
WT O
) O
, O
neuronal O
( O
NOS1 O
- O
KO O
) O
, O
or O
inducible O
( O
NOS2 O
- O
KO O
) O
nitric O
oxide O
synthases O
knockout O
mice O
, O
we O
evaluated O
the O
effects O
of O
CORM B
- I
2 I
and O
CoPP O
treatments O
in O
the O
antinociceptive O
actions O
of O
morphine O
and O
their O
interaction O
with O
nitric O
oxide O
during O
acute O
, O
visceral O
, O
and O
chronic O
inflammatory O
or O
neuropathic O
pain O
. O

METHODS O
: O
Acute O
and O
visceral O
pain O
was O
assessed O
through O
formalin O
and O
acid B
acetic I
writhing O
tests O
. O

Moreover O
, O
while O
CORM B
- I
2 I
or O
CoPP O
treatments O
did O
not O
alter O
or O
reduced O
the O
antinociceptive O
effects O
of O
morphine O
during O
acute O
and O
visceral O
pain O
, O
both O
treatments O
improved O
the O
local O
antiallodynic O
and O
antihyperalgesic O
effects O
of O
morphine O
after O
chronic O
inflammatory O
or O
neuropathic O
pain O
in O
WT O
, O
but O
not O
in O
KO O
mice O
. O

CONCLUSIONS O
: O
CORM B
- I
2 I
and O
CoPP O
treatments O
improved O
the O
local O
antinociceptive O
effects O
of O
morphine O
during O
chronic O
inflammatory O
and O
neuropathic O
pain O
by O
interaction O
with O
nitric O
oxide O
synthetized O
by O
NOS1 O
and O
NOS2 O
isoforms O
. O

Paclitaxel O
is O
an O
inhibitor O
and O
its O
boron B
dipyrromethene I
derivative O
is O
a O
fluorescent O
recognition O
agent O
for O
botulinum O
neurotoxin O
subtype O
a O
. O

Embellicines B
A I
and I
B I
: O
Absolute O
Configuration O
and O
NF O
- O
kappa O
B O
Transcriptional O
Inhibitory O
Activity O
. O

Two O
new O
metabolites O
, O
embellicines B
A I
and I
B I
( O
1 O
and O
2 O
) O
, O
were O
isolated O
from O
the O
EtOAc O
extract O
of O
the O
fungus O
Embellisia O
eureka O
, O
an O
endophyte O
of O
the O
Moroccan O
plant O
Cladanthus O
arabicus O
( O
Asteraceae O
) O
. O

The O
absolute O
configuration O
of O
embellicine B
A I
( O
1 O
) O
was O
determined O
by O
TDDFT O
ECD O
calculations O
of O
solution O
conformers O
, O
whereas O
that O
of O
embellicine B
B I
( O
2 O
) O
was O
deduced O
based O
on O
ROESY O
correlations O
and O
on O
biogenetic O
considerations O
in O
comparison O
to O
1 O
. O

Both O
embellicines B
( O
1 O
and O
2 O
) O
are O
cytostatic O
, O
cytotoxic O
, O
and O
inhibit O
NF O
- O
kappa O
B O
transcriptional O
activity O
, O
indicating O
that O
inhibition O
of O
NF O
- O
kappa O
B O
may O
be O
a O
possible O
mechanism O
of O
action O
of O
these O
compounds O
. O

Embellicine B
B I
( O
2 O
) O
was O
the O
most O
active O
compound O
encountered O
in O
this O
study O
and O
acts O
at O
nanomolar O
concentrations O
without O
affecting O
tumor O
microenvironment O
. O

Tin B
- O
coated O
viral O
nanoforests O
as O
sodium O
- O
ion O
battery O
anodes O
. O

Recently O
, O
we O
identified O
1 B
- I
aminoanthracene I
as O
a O
fluorescent O
general O
anesthetic O
. O

To O
investigate O
the O
mechanism O
of O
action O
, O
a O
photoactive O
analogue O
, O
1 B
- I
azidoanthracene I
, O
was O
synthesized O
. O

Administration O
of O
1 B
- I
azidoanthracene I
to O
albino O
stage O
40 O
- O
47 O
tadpoles O
was O
found O
to O
immobilize O
animals O
upon O
near O
- O
UV O
irradiation O
of O
the O
forebrain O
region O
. O

In O
vitro O
assays O
with O
aminoanthracene B
- O
cross O
- O
linked O
tubulin O
indicated O
inhibition O
of O
microtubule O
polymerization O
, O
similar O
to O
colchicine O
. O

Stage O
40 O
- O
47 O
tadpoles O
were O
also O
incubated O
1 O
h O
with O
microtubule O
stabilizing O
agents O
, O
epothilone B
D I
or O
discodermolide B
, O
followed O
by O
dosing O
with O
1 B
- I
aminoanthracene I
. O

The O
effective O
concentration O
of O
1 B
- I
aminoanthracene I
required O
to O
immobilize O
the O
tadpoles O
was O
significantly O
increased O
in O
the O
presence O
of O
either O
microtubule O
stabilizing O
agent O
. O

Epothilone B
D I
similarly O
mitigated O
the O
effects O
of O
a O
clinical O
neurosteroid O
general O
anesthetic O
, O
allopregnanolone O
, O
believed O
to O
occupy O
the O
colchicine O
site O
in O
tubulin O
. O

Unraveling O
the O
Role O
of O
the O
Protein O
Environment O
for O
[ B
FeFe I
] I
- O
Hydrogenase O
: O
A O
New O
Application O
of O
Coarse O
- O
Graining O
. O

[ B
FeFe I
] I
- O
hydrogenases O
are O
the O
most O
effective O
of O
three O
such O
enzymes O
at O
catalyzing O
H O
( O
+ O
) O
reduction O
. O

In O
this O
study O
, O
we O
develop O
and O
apply O
a O
novel O
combination O
of O
all O
- O
atom O
molecular O
dynamics O
and O
coarse O
- O
grained O
( O
CG O
) O
analysis O
to O
characterize O
two O
important O
steps O
of O
the O
catalytic O
cycle O
of O
[ B
FeFe I
] I
- O
hydrogenase O
. O

The O
first O
is O
the O
electron O
transport O
through O
FeS B
clusters O
to O
the O
active O
site O
. O

Structural O
modifications O
of O
polymethacrylates B
: O
Impact O
on O
thermal O
behavior O
and O
release O
characteristics O
of O
glassy O
solid O
solutions O
. O

Polymethacrylates B
such O
as O
Eudragit O
( O
R O
) O
polymers O
are O
well O
established O
as O
drug O
delivery O
matrix O
. O

Here O
, O
we O
synthesize O
several O
Eudragit B
E I
PO I
( O
n B
- I
butyl I
- O
, O
dimethylaminoethyl B
- O
, O
methyl B
- I
methacrylate I
- O
terpolymer B
) O
analogues O
via O
free O
radical O
polymerization O
. O

Three O
chemical O
modifications O
increased O
the O
glass O
transition O
temperature O
of O
the O
polymer O
: O
( O
a O
) O
substitution O
of O
n B
- I
butyl I
by O
t O
- O
butyl O
groups O
, O
( O
b O
) O
reduction O
of O
the O
dimethylaminoethyl O
methacrylate O
( O
DMAEMA O
) O
content O
, O
and O
( O
c O
) O
incorporation O
of O
a O
bulky O
isobornyl B
repeating O
unit O
. O

1 B
- I
Methylimidazolium I
hydrogen I
sulfate I
catalyzed O
convenient O
synthesis O
of O
2 B
, I
5 I
- I
dimethyl I
- I
N I
- I
substituted I
pyrroles I
under O
ultrasonic O
irradiation O
. O

Ionic O
liquid O
[ B
HMIM I
] I
HSO4 I
was O
found O
to O
be O
an O
efficient O
catalyst O
for O
the O
synthesis O
of O
N B
- I
substituted I
pyrroles I
through O
the O
reaction O
of O
2 B
, I
5 I
- I
hexanedione I
with O
amines O
under O
ultrasonic O
irradiation O
at O
room O
temperature O
. O

Migrants O
determination O
and O
bioaccessibility O
study O
of O
ethyl B
lauroyl I
arginate I
( O
LAE B
) O
from O
a O
LAE B
based O
antimicrobial O
food O
packaging O
material O
. O

Ethyl B
lauroyl I
arginate I
( O
LAE B
, O
ethyl B
- I
N I
- I
dodecanoyl I
- I
L I
- I
arginate I
hydrochloride I
) O
is O
a O
strong O
antimicrobial O
agent O
that O
was O
included O
as O
an O
active O
compound O
in O
an O
antimicrobial O
food O
packaging O
material O
. O

The O
migration O
values O
found O
for O
LAE B
were O
0 O
. O
94 O
+ O
/ O
- O
0 O
. O
14 O
and O
1 O
. O
62 O
+ O
/ O
- O
0 O
. O
70 O
mu O
g O
/ O
g O
in O
ethanol O
10 O
% O
v O
/ O
v O
( O
simulant O
A O
) O
and O
in O
ethanol O
95 O
% O
v O
/ O
v O
( O
simulant O
D O
) O
, O
respectively O
, O
and O
0 O
. O
93 O
+ O
/ O
- O
0 O
. O
17 O
mu O
g O
/ O
g O
in O
chicken O
. O

Other O
migrants O
such O
as O
dipropylene B
glycol I
methyl I
ether I
or O
tributyl B
- I
o I
- I
acetylcitrate I
, O
both O
coming O
from O
the O
coating O
were O
also O
found O
, O
but O
none O
of O
them O
have O
potential O
adverse O
effects O
. O

Bioaccessibility O
studies O
showed O
that O
after O
a O
simulated O
gastrointestinal O
digestion O
, O
LAE B
was O
not O
available O
anymore O
for O
subsequent O
intestinal O
absorption O
and O
new O
toxic O
compounds O
were O
not O
formed O
. O

Stimulation O
of O
rat O
liver O
branched O
- O
chain O
alpha B
- I
keto I
acid I
dehydrogenase O
activity O
by O
low O
doses O
of O
bezafibrate B
. O

Multienzyme O
branched O
- O
chain O
alpha B
- I
ketoacid I
dehydrogenase O
complex O
( O
BCKDH O
) O
catalyzes O
the O
regulatory O
step O
of O
oxidative O
catabolism O
of O
indispensable O
branched O
- O
chain O
amino O
acids O
( O
BCAA O
) O
. O

It O
has O
been O
shown O
previously O
that O
a O
high O
dose O
of O
bezafibrate B
( O
an O
agent O
added O
to O
rat O
chow O
at O
final O
concentration O
of O
0 O
. O
5 O
% O
) O
changes O
mRNA O
levels O
of O
BCKDH O
- O
related O
enzymes O
and O
increases O
dephosphorylation O
of O
the O
complex O
leading O
to O
stimulation O
of O
liver O
BCKDH O
activity O
and O
the O
enhanced O
BCAA O
catabolism O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
determine O
an O
in O
vivo O
effect O
of O
low O
, O
clinically O
relevant O
doses O
of O
bezafibrate B
on O
BCKDH O
activity O
in O
rat O
liver O
. O

Bezafibrate B
was O
administrated O
for O
14 O
days O
by O
gastric O
gavage O
to O
Wistar O
male O
rats O
( O
fed O
low O
- O
protein O
chow O
; O
8 O
% O
protein O
) O
at O
one O
of O
the O
following O
daily O
doses O
of O
5 O
, O
10 O
and O
20mg O
/ O
kgb O
. O
wt O
. O

Initially O
bezafibrate B
caused O
a O
transient O
insignificant O
reduction O
in O
body O
weight O
, O
but O
it O
had O
no O
effect O
on O
the O
final O
body O
weight O
. O

The O
highest O
dose O
of O
bezafibrate B
induced O
hepatomegaly O
. O

In O
conclusion O
, O
these O
data O
indicate O
that O
under O
conditions O
of O
dietary O
protein O
restriction O
low O
, O
clinically O
relevant O
doses O
of O
bezafibrate B
have O
a O
similar O
adverse O
effect O
on O
rat O
liver O
BCKDH O
activity O
and O
BCAA O
degradation O
rate O
as O
the O
high O
experimental O
dose O
. O

Up O
- O
regulation O
of O
liver O
BCKDH O
activity O
by O
low O
doses O
of O
bezafibrate B
appears O
to O
result O
mainly O
from O
changes O
in O
phosphorylation O
status O
of O
the O
complex O
( O
increased O
dephosphorylation O
) O
and O
is O
not O
associated O
with O
elevations O
in O
mRNA O
levels O
of O
BCKDH O
enzymatic O
components O
. O

Amitriptyline O
, O
clomipramine B
, O
doxepin B
, O
imipramine O
, O
and O
trimipramine B
are O
demethylated O
by O
CYP2C19 O
to O
pharmacologically O
active O
metabolites O
. O

Structural O
Explanation O
for O
Allolactose B
( O
lac O
Operon O
Inducer O
) O
Synthesis O
by O
lacZ O
beta O
- O
Galactosidase O
and O
the O
Evolutionary O
Relationship O
between O
Allolactose B
Synthesis O
and O
the O
lac O
Repressor O
. O

It O
hydrolyzes O
lactose O
to O
galactose O
and O
glucose O
and O
catalyzes O
the O
intramolecular O
isomerization O
of O
lactose O
to O
allolactose B
, O
the O
lac O
operon O
inducer O
. O

We O
present O
structural O
data O
mapping O
the O
glucose O
site O
based O
on O
a O
substituted O
enzyme O
( O
G794A O
- O
beta O
- O
galactosidase O
) O
that O
traps O
allolactose B
. O

Various O
lines O
of O
evidence O
indicate O
that O
the O
glucose O
of O
the O
trapped O
allolactose B
is O
in O
the O
acceptor O
position O
. O

The O
evidence O
includes O
structures O
with O
Bis B
- I
Tris I
( I
2 I
, I
2 I
- I
bis I
( I
hydroxymethyl I
) I
- I
2 I
, I
2 I
' I
, I
2 I
' I
' I
- I
nitrilotriethanol I
) I
and O
l B
- I
ribose I
in O
the O
site O
and O
kinetic O
binding O
studies O
with O
substituted O
beta O
- O
galactosidases O
. O

Eight O
ARBs O
are O
clinically O
available O
[ O
azilsartan B
, O
candesartan O
, O
eprosartan B
, O
irbesartan B
, O
losartan O
, O
olmesartan O
, O
telmisartan O
, O
valsartan B
] O
. O

Azilsartan B
( O
in O
some O
countries O
) O
, O
candesartan O
, O
and O
olmesartan O
are O
orally O
administered O
as O
prodrugs O
, O
whereas O
the O
blocking O
action O
of O
some O
is O
mediated O
through O
active O
metabolites O
. O

The O
reactive O
uptake O
coefficients O
( O
gamma O
) O
of O
OH O
by O
levoglucosan O
, O
abietic O
acid O
, O
and O
nitroguaiacol B
serving O
as O
surrogate O
compounds O
for O
biomass O
burning O
aerosol O
have O
been O
determined O
employing O
a O
chemical O
ionisation O
mass O
spectrometer O
coupled O
to O
a O
rotating O
- O
wall O
flow O
- O
tube O
reactor O
over O
a O
wide O
range O
of O
[ O
OH O
] O
~ O
10 O
( O
7 O
) O
- O
10 O
( O
11 O
) O
molecule O
cm O
( O
- O
3 O
) O
. O

Amongst O
the O
common O
volatile O
organic O
compounds O
( O
VOCs O
) O
identified O
between O
levoglucosan O
, O
abietic O
acid O
, O
and O
nitroguaiacol B
were O
methanol O
, O
acetaldehyde O
, O
formic O
acid O
, O
and O
acetic O
acid O
. O

VOCs O
having O
the O
greatest O
enhancement O
over O
background O
were O
glucic B
acid I
from O
levoglucosan O
, O
glycolic B
acid I
from O
abietic O
acid O
, O
and O
methanol O
and O
nitric O
acid O
from O
nitroguaiacol B
. O

Reaction O
mechanisms O
leading O
to O
the O
formation O
of O
glucic B
acid I
, O
glycolic B
acid I
, O
methanol O
, O
and O
nitric O
acid O
are O
proposed O
. O

Synthesis O
, O
crystal O
structure O
and O
biological O
evaluation O
of O
a O
main O
group O
seven O
- O
coordinated O
bismuth B
( I
III I
) I
complex O
with O
2 B
- I
acetylpyridine I
N4 I
- I
phenylthiosemicarbaz I
. O

Up O
to O
now O
, O
bismuth B
( I
III I
) I
complexes O
with O
thiosemicarbazones B
have O
been O
comparatively O
rare O
. O

Here O
, O
a O
main O
group O
seven O
- O
coordinated O
bismuth B
( I
III I
) I
complex O
[ O
Bi B
( I
L I
) I
( I
NO3 I
) I
2 I
( I
CH3CH2OH I
) I
] O
( O
1 O
) O
( O
HL O
= O
2 B
- I
acetylpyridine I
N I
( I
4 I
) I
- I
phenylthiosemicarbaz I
) O
has O
been O
synthesized O
and O
characterized O
by O
elemental O
analysis O
, O
IR O
, O
( O
1 O
) O
H O
NMR O
and O
single O
- O
crystal O
X O
- O
ray O
diffraction O
studies O
. O

Identification O
and O
synthesis O
of O
N B
- I
( I
thiophen I
- I
2 I
- I
yl I
) I
benzamide I
derivatives O
as O
BRAF O
( O
V600E O
) O
inhibitors O
. O

In O
this O
study O
, O
we O
employed O
virtual O
screening O
and O
chemical O
synthesis O
to O
identify O
a O
series O
of O
N B
- I
( I
thiophen I
- I
2 I
- I
yl I
) I
benzamide I
derivatives O
as O
potent O
BRAF O
( O
V600E O
) O
inhibitors O
. O

Atmospheric O
chemistry O
of O
CF3O2 B
: O
a O
theoretical O
study O
on O
mechanisms O
and O
pathways O
of O
the O
CF3O2 B
+ O
IO B
reaction O
. O

The O
mechanisms O
and O
reaction O
pathways O
for O
the O
CF3O2 B
+ O
IO B
reaction O
have O
been O
investigated O
by O
quantum O
chemistry O
methods O
. O

On O
the O
singlet O
PES O
, O
the O
most O
important O
products O
include O
CF3OOOI B
, O
CF3OOIO B
, O
CF3OIO2 B
, O
and O
CF2O B
+ O
FIO2 B
, O
while O
other O
products O
such O
as O
CF2O B
+ O
FOIO B
, O
CF2O B
+ O
FOOI B
, O
CF3OOI B
+ O
O O
( O
( O
3 O
) O
P O
) O
, O
CF3OI B
+ O
O2 O
( O
( O
1 O
) O
Delta O
and O
( O
3 O
) O
Sigma O
) O
, O
and O
CF3O B
+ O
OIO B
are O
negligible O
due O
to O
high O
barriers O
or O
unstable O
formations O
. O

On O
the O
triplet O
PES O
, O
CF3O B
+ O
OIO B
is O
the O
dominant O
product O
with O
a O
lower O
barrier O
. O

As O
for O
FIO2 B
and O
it O
isomers O
, O
the O
most O
stable O
one O
is O
FIO2 B
. O

TDDFT O
( O
Time O
Dependent O
Density O
Functional O
Theory O
) O
calculation O
indicates O
that O
CF3OOOI B
, O
CF3OOIO B
and O
CF3OIO2 B
undergo O
photolysis O
easily O
under O
sunlight O
. O

Moreover O
, O
a O
minor O
contribution O
relative O
to O
hydrogen O
is O
found O
in O
the O
CX3O2 B
+ O
IO B
( O
X O
= O
H O
and O
F O
) O
reactions O
. O

Nicotine O
, O
varenicline B
, O
and O
cytisine B
were O
administered O
alone O
, O
in O
combination O
with O
each O
other O
, O
and O
in O
combination O
with O
mecamylamine O
and O
dihydro B
- I
beta I
- I
erythroidine I
( O
DH O
beta O
E O
) O
. O

Varenicline B
and O
cytisine B
did O
not O
fully O
substitute O
for O
nicotine O
and O
, O
as O
compared O
with O
nicotine O
, O
their O
ED50 O
values O
varied O
less O
systematically O
as O
a O
function O
of O
nicotine O
training O
dose O
. O

Varenicline B
did O
not O
antagonize O
the O
effects O
of O
nicotine O
, O
whereas O
cytisine B
produced O
a O
modest O
though O
significant O
antagonism O
of O
nicotine O
. O

CONCLUSIONS O
: O
These O
results O
suggest O
that O
differences O
in O
pharmacologic O
mechanism O
between O
nicotine O
, O
varenicline B
, O
and O
cytisine B
include O
not O
only O
differences O
in O
efficacy O
at O
a O
common O
subtype O
of O
nicotinic O
acetylcholine O
receptor O
, O
but O
also O
differential O
affinity O
and O
/ O
or O
efficacy O
at O
multiple O
receptor O
subtypes O
. O

Evaporation O
- O
Induced O
Coating O
of O
Hydrous B
Ruthenium I
Oxide I
on O
Mesoporous O
Silica O
Nanoparticles O
to O
Develop O
High O
- O
Performance O
Supercapacitors O
. O

An O
efficient O
evaporation O
- O
induced O
coating O
method O
combining O
microwave O
- O
assisted O
hydrothermal O
transformation O
and O
annealing O
is O
developed O
to O
fabricate O
an O
ideal O
electrode O
material O
from O
composites O
with O
a O
layer O
of O
hydrous B
RuO2 I
on O
mesoporous O
silica O
nanoparticles O
( O
MSNs O
) O
, O
for O
a O
high O
- O
performance O
supercapacitor O
. O

Total O
and O
RuO2 B
- O
based O
specific O
capacitances O
are O
as O
high O
as O
1125 O
and O
2000 O
F O
g O
( O
- O
1 O
) O
, O
respectively O
. O

n O
- O
Doping O
of O
solution O
- O
processible O
organic O
semiconductors O
: O
highly O
conductive O
fullerenes O
are O
demonstrated O
through O
solution O
- O
processed O
fulleropyrrolidinium B
iodide I
( O
FPI B
) O
and O
FPI B
- O
doped O
PCBM O
to O
reach O
a O
high O
conductivity O
( O
3 O
. O
2 O
S O
/ O
m O
) O
. O

The O
n O
- O
doping O
proceeds O
via O
anion O
- O
induced O
electron O
transfer O
between O
the O
iodide O
on O
FPI B
and O
the O
fullerene O
in O
the O
solid O
state O
. O

Influence O
of O
the O
Green O
Tea O
Leaf O
Extract O
on O
Neurotoxicity O
of O
Aluminium B
Chloride I
in O
Rats O
. O

Because O
green O
tea O
( O
Camellia O
sinensis O
L O
. O
) O
reportedly O
has O
health O
- O
promoting O
effects O
in O
the O
central O
nervous O
system O
, O
we O
evaluated O
the O
effects O
of O
green O
tea O
leaf O
extract O
( O
GTLE O
) O
on O
aluminium B
chloride I
( O
AlCl3 O
) O
neurotoxicity O
in O
rats O
. O

Synthesis O
and O
Structure O
- O
Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatase O
- O
Sulfatase O
Inhibitor O
4 B
- I
{ I
[ I
( I
4 I
- I
Cyanophenyl I
) I
( I
4H I
- I
1 I
, I
2 I
, I
4 I
- I
triazol I
- I
4 I
- I
yl I
) I
amino I
] I
methyl I
} I
phenyl I
sulfamate I
. O

4 B
- I
{ I
[ I
( I
4 I
- I
Cyanophenyl I
) I
( I
4H I
- I
1 I
, I
2 I
, I
4 I
- I
triazol I
- I
4 I
- I
yl I
) I
amino I
] I
methyl I
} I
phenyl I
sulfamate I
and O
its O
ortho O
- O
halogenated O
( O
F O
, O
Cl O
, O
Br O
) O
derivatives O
are O
first O
- O
generation O
dual O
aromatase O
and O
sulfatase O
inhibitors O
( O
DASIs O
) O
. O

Structure O
- O
activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen O
atom O
, O
introduction O
of O
more O
halogen O
atoms O
, O
replacement O
of O
the O
halogen O
with O
another O
group O
, O
replacement O
of O
the O
methylene O
linker O
with O
a O
difluoromethylene B
linker O
, O
replacement O
of O
the O
para B
- I
cyanophenyl I
ring O
with O
other O
ring O
structures O
, O
and O
replacement O
of O
the O
triazolyl B
group O
with O
an O
imidazolyl B
group O
. O

Ureido O
- O
derivatized O
polymers O
, O
such O
as O
poly B
( I
allylurea I
) I
( O
PU O
) O
and O
poly B
( I
L I
- I
citrulline I
) I
derivatives O
, O
exhibited O
upper O
critical O
solution O
temperature O
( O
UCST O
) O
behavior O
under O
physiological O
buffer O
conditions O
as O
we O
previously O
reported O
. O

The O
PU O
derivatives O
having O
amino O
groups O
( O
PU B
- I
Am I
) O
also O
showed O
UCST O
behavior O
. O

In O
this O
study O
, O
we O
modified O
the O
amino O
groups O
of O
the O
polymer O
with O
succinyl B
anhydride I
( O
PU B
- I
Su I
) O
or O
acetyl B
anhydride I
( O
PU B
- I
Ac I
) O
to O
determine O
the O
effects O
of O
these O
ionic O
groups O
on O
the O
UCST O
behavior O
and O
to O
control O
interactions O
between O
the O
PU O
derivatives O
and O
biocomponents O
such O
as O
proteins O
and O
cells O
. O

Succinylation O
of O
PU B
- I
Am I
resulted O
in O
a O
significant O
decrease O
in O
phase O
separation O
temperature O
( O
Tp O
) O
, O
whereas O
acetylation O
of O
PU B
- I
Am I
resulted O
in O
an O
increase O
in O
Tp O
. O

As O
expected O
, O
the O
Tp O
of O
PU B
- I
Am I
and O
PU B
- I
Su I
changed O
when O
the O
pH O
of O
the O
solution O
was O
changed O
. O

The O
Tp O
of O
PU B
- I
Am I
increased O
at O
higher O
pH O
, O
whereas O
that O
of O
PU B
- I
Su I
increased O
at O
lower O
pH O
, O
indicating O
that O
ionic O
charge O
decreases O
Tp O
of O
PU O
derivatives O
by O
increasing O
osmotic O
pressure O
and O
by O
increasing O
hydrophilicity O
of O
the O
polymer O
chains O
. O

Structural O
Rearrangement O
in O
the O
Formation O
of O
Jet O
- O
Cooled O
Complexes O
of O
Chiral O
( B
S I
) I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
- I
Tetrahydro I
- I
3 I
- I
isoquinolinemethanol I
with O
Methyl B
Lactate I
: O
Chirality O
Effect O
in O
Conformer O
Selection O
. O

The O
jet O
- O
cooled O
complexes O
between O
the O
two O
enantiomers O
of O
methyl B
lactate I
( O
ML O
) O
and O
( B
S I
) I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
- I
tetrahydro I
- I
3 I
- I
isoquinolinemethanol I
( O
THIQM B
) O
are O
studied O
by O
double O
resonance O
spectroscopy O
combined O
with O
ab O
initio O
calculations O
. O

Both O
diastereomer O
complexes O
exist O
in O
different O
isomers O
, O
involving O
either O
direct O
addition O
of O
THIQM B
on O
ML O
with O
no O
structural O
rearrangement O
of O
the O
subunits O
or O
formation O
of O
very O
stable O
structures O
involving O
multiple O
intermolecular O
hydrogen O
bonds O
and O
extensive O
deformation O
of O
the O
subunits O
. O

It O
is O
shown O
that O
the O
most O
stable O
form O
of O
the O
chromophore O
( O
THIQMI B
with O
an O
OH O
. O
. O
. O
N O
hydrogen O
bond O
) O
prefers O
to O
directly O
stick O
to O
ML O
to O
form O
the O
addition O
complex O
whereas O
the O
second O
conformer O
( O
THIQMII B
with O
NH O
. O
. O
. O
O O
hydrogen O
bond O
) O
rearranges O
to O
form O
a O
strongly O
bound O
structure O
. O

Here O
we O
use O
vibrational O
sum O
frequency O
spectroscopy O
( O
SF O
) O
to O
study O
the O
origin O
of O
the O
opposite O
Delta O
V O
signs O
of O
Langmuir O
films O
of O
CH3 B
( I
CH2 I
) I
20COCH2CH3 I
( O
ethyl B
ether I
, O
EE O
) O
and O
CH3 B
( I
CH2 I
) I
20COCH2CF3 I
( O
fluorinated B
ethyl I
ether I
, O
FEE B
) O
. O

The O
vibrational O
sum O
frequency O
spectra O
are O
recorded O
at O
the O
same O
film O
density O
of O
the O
S O
- O
phase O
of O
the O
EE O
and O
FEE B
monolayers O
and O
analyzed O
in O
the O
spectral O
regions O
of O
OH O
, O
COC B
, O
CH3 O
, O
and O
CF3 O
stretching O
vibrations O
because O
these O
functional O
groups O
could O
be O
responsible O
for O
the O
different O
dipole O
potentials O
. O

We O
compare O
the O
rearrangement O
of O
the O
pure O
water O
surface O
by O
EE O
and O
FEE B
monolayers O
and O
the O
conformations O
of O
EE O
and O
FEE B
polar O
heads O
. O

The O
results O
show O
that O
reversal O
of O
the O
Delta O
V O
sign O
caused O
by O
fluorination O
of O
the O
polar O
heads O
originates O
from O
the O
upward O
- O
oriented O
CF3 O
terminals O
of O
the O
FEE B
heads O
, O
whose O
negative O
normal O
dipole O
moment O
component O
determines O
the O
negative O
dipole O
potential O
of O
the O
FEE B
monolayer O
. O

Performances O
of O
CN O
- O
columns O
for O
the O
analysis O
of O
gamma O
- O
oryzanol O
and O
its O
p B
- I
coumarate I
and O
caffeate B
derivatives O
by O
normal O
phase O
HPLC O
and O
a O
validated O
method O
of O
quantitation O
. O

The O
analysis O
is O
performed O
on O
a O
cyanopropyl B
bonded O
column O
using O
the O
hexane O
/ O
MTBE B
gradient O
elution O
and O
UV O
detection O
at O
325 O
nm O
. O

The O
method O
allows O
: O
the O
separation O
of O
steryl B
ferulate I
, O
p B
- I
coumarate I
and O
caffeate B
esters I
, O
the O
separation O
of O
cis O
- O
from O
trans B
- I
ferulate I
isomers O
, O
the O
splitting O
of O
steroid O
moieties O
into O
saturated O
and O
unsaturated O
at O
the O
side O
chain O
. O

The O
samples O
were O
characterised O
by O
high O
content O
of O
marine O
wax O
esters O
( O
55 O
- O
67 O
mol O
% O
of O
lipid O
classes O
) O
, O
of O
docosahexaenoic B
( O
22 O
: O
6 O
n O
- O
3 O
, O
25 O
w O
% O
) O
and O
oleic O
( O
18 O
: O
1 O
n O
- O
9 O
, O
19 O
w O
% O
) O
fatty O
acids O
. O

Among O
metabolites O
, O
nutrients O
as O
taurine O
, O
nicotinamide O
and O
beta B
- I
alanine I
, O
were O
found O
. O

Theaflavins O
, O
dimeric B
catechins I
, O
inhibit O
peptide O
transport O
across O
Caco O
- O
2 O
cell O
monolayers O
via O
down O
- O
regulation O
of O
AMP O
- O
activated O
protein O
kinase O
- O
mediated O
peptide O
transporter O
PEPT1 O
. O

In O
the O
small O
intestine O
, O
peptide O
transporter O
1 O
( O
PEPT1 O
) O
plays O
a O
role O
in O
the O
transport O
of O
di B
- I
and I
tripeptides I
. O

In O
this O
study O
, O
we O
investigated O
whether O
theaflavins O
( O
TFs B
) O
affect O
the O
absorption O
of O
small O
peptides O
in O
human O
intestinal O
Caco O
- O
2 O
cells O
, O
since O
TFs B
do O
not O
penetrate O
through O
the O
cells O
and O
might O
be O
involved O
in O
intestinal O
transport O
systems O
. O

In O
transport O
experiments O
, O
the O
transport O
of O
glycyl B
- I
sarcosine I
( O
Gly B
- I
Sar I
, O
a O
model O
molecule O
for O
PEPT1 O
transport O
) O
and O
other O
dipeptides O
( O
Val B
- I
Tyr I
and O
Ile B
- I
Phe I
) O
were O
significantly O
reduced O
( O
P O
< O
0 O
. O
05 O
) O
in O
TFs B
- O
pretreated O
cells O
. O

In O
TF B
3 I
' I
- I
O I
- I
gallate I
- O
pretreated O
cells O
, O
Western O
blot O
analysis O
revealed O
attenuated O
expression O
of O
PEPT1 O
transporter O
and O
Gly B
- I
Sar I
transport O
was O
completely O
ameliorated O
by O
10 O
mu O
M O
Compound B
C I
, O
an O
AMP O
- O
activated O
protein O
kinase O
( O
AMPK O
) O
inhibitor O
. O

In O
conclusion O
, O
the O
present O
study O
demonstrated O
that O
TFs B
inhibit O
peptide O
transport O
across O
Caco O
- O
2 O
cell O
monolayers O
, O
probably O
through O
suppression O
of O
AMPK O
- O
mediated O
PEPT1 O
expression O
, O
which O
should O
be O
considered O
a O
new O
bioactivity O
of O
TFs B
in O
black O
tea O
. O

The O
formation O
of O
the O
major O
flavour O
compounds O
( O
acetaldehyde O
, O
diacetyl O
, O
acetoin O
, O
and O
2 B
- I
butanone I
) O
followed O
a O
sigmoidal O
trend O
described O
by O
the O
modified O
Gompertz O
model O
. O

In O
this O
study O
, O
gamma B
- I
glutamyl I
transpeptidase O
( O
GGT O
) O
and O
l B
- I
cysteine I
sulphoxide I
lyase O
( O
C O
- O
S O
lyase O
) O
were O
purified O
from O
the O
fruiting O
body O
of O
Lentinula O
edodes O
in O
three O
steps O
and O
then O
characterised O
. O

Optimisation O
of O
synthesis O
of O
oligosaccharides O
derived O
from O
lactulose O
( O
fructosyl B
- I
galacto I
- I
oligosaccharides I
) O
with O
beta O
- O
galactosidases O
of O
different O
origin O
. O

Batch O
synthesis O
of O
fructosyl B
- I
galacto I
- I
oligosaccharides I
from O
lactulose O
was O
performed O
with O
commercial O
beta O
- O
galactosidase O
preparations O
from O
Aspergillus O
oryzae O
, O
Kluyveromyces O
lactis O
and O
Bacillus O
circulans O
. O

Optimization O
of O
fructosyl B
- I
galacto I
- I
oligosaccharides I
synthesis O
was O
carried O
out O
using O
response O
surface O
methodology O
, O
considering O
temperature O
and O
initial O
sugar O
concentration O
as O
variables O
and O
yield O
and O
specific O
productivity O
as O
response O
parameters O
. O

Maximum O
yield O
of O
0 O
. O
41 O
g O
g O
( O
- O
1 O
) O
fructosyl B
- I
galacto I
- I
oligosaccharides I
was O
obtained O
at O
70 O
degrees O
C O
and O
60 O
% O
w O
/ O
w O
lactulose O
concentration O
, O
while O
maximum O
specific O
productivity O
of O
1 O
. O
2 O
g O
h O
( O
- O
1 O
) O
mg O
( O
- O
1 O
) O
was O
obtained O
at O
70 O
degrees O
C O
and O
40 O
% O
w O
/ O
w O
lactulose O
concentration O
. O

In O
this O
study O
, O
we O
have O
investigated O
the O
interactions O
between O
ABCG2 O
and O
56 O
naturally O
- O
occurring O
phytochemicals O
including O
phenolic O
acids O
, O
flavonoids O
, O
triterpenes O
and O
other O
common O
dietary O
phytochemicals O
, O
as O
well O
as O
two O
non O
plant O
- O
based O
compounds O
( O
hippuric B
acid I
and O
propyl O
gallate O
) O
using O
cell O
- O
and O
membrane O
- O
based O
transport O
inhibition O
assays O
. O

Of O
the O
non O
- O
flavonoid O
phytochemicals O
tested O
, O
berberine O
, O
celastrol O
, O
ellagic O
acid O
, O
limonin B
, O
oleanolic O
acid O
, O
propyl O
gallate O
, O
sinapic O
acid O
and O
ursolic O
acid O
demonstrated O
significant O
inhibition O
of O
ABCG2 O
- O
mediated O
transport O
. O

Chrysoeriol O
, O
laricitrin B
, O
myricetin B
3 I
' I
, I
4 I
' I
, I
5 I
' I
- I
trimethylether I
, O
pinocembrin O
, O
quercitrin B
, O
tamarixetin B
, O
tricetin O
and O
tricetin B
3 I
' I
, I
4 I
' I
, I
5 I
' I
- I
trimethylether I
were O
also O
identified O
as O
novel O
flavonoid O
ABCG2 O
inhibitors O
. O

Roasting O
- O
induced O
changes O
in O
arabinotriose B
, O
a O
model O
of O
coffee O
arabinogalactan O
side O
chains O
. O

Aiming O
to O
know O
more O
about O
these O
modifications O
, O
the O
structurally O
related O
alpha B
- I
( I
1 I
- I
- I
> I
5 I
) I
- I
l I
- I
arabinotriose I
was O
roasted O
at O
200 O
degrees O
C O
and O
the O
products O
obtained O
were O
identified O
by O
ESI O
- O
MS O
and O
MALDI O
- O
MS O
and O
characterised O
by O
ESI O
- O
MS O
( O
n O
) O
. O

Also O
, O
products O
resulting O
from O
dehydration O
, O
oxidation O
, O
and O
cleavage O
of O
a O
carbon O
- O
carbon O
bond O
at O
the O
reducing O
end O
of O
the O
corresponding O
non O
- O
modified O
oligosaccharide O
were O
formed O
, O
probably O
promoting O
the O
release O
of O
formaldehyde O
, O
formic O
acid O
, O
glycolaldehyde B
, O
glyoxal O
, O
acetic O
acid O
, O
glycolic B
acid I
, O
glyceraldehyde O
, O
2 B
- I
hydroxypropanedialde I
and O
lactic O
acid O
. O

Potato O
protein O
isolate O
( O
PPI O
) O
was O
phosphorylated O
with O
sodium B
trimetaphosphate I
( O
STMP B
) O
at O
ambient O
temperature O
and O
various O
reaction O
pH O
( O
5 O
. O
2 O
, O
6 O
. O
2 O
, O
8 O
. O
0 O
and O
10 O
. O
5 O
) O
to O
improve O
the O
functional O
properties O
without O
impairing O
the O
nutritional O
availability O
. O

Identification O
of O
the O
odour O
- O
active O
cyclic O
diketone O
cis B
- I
2 I
, I
6 I
- I
dimethyl I
- I
1 I
, I
4 I
- I
cyclohexanedione I
in O
roasted O
Arabica O
coffee O
brew O
. O

Gas O
chromatography O
- O
olfactometry O
( O
GC O
- O
O O
) O
and O
multidimensional O
gas O
chromatography O
- O
mass O
spectrometry O
( O
MDGC O
- O
MS O
) O
of O
the O
fraction O
which O
contained O
a O
significant O
amount O
of O
the O
target O
unknown O
compound O
revealed O
the O
cyclic O
1 O
, O
4 O
- O
diketone O
, O
cis B
- I
2 I
, I
6 I
- I
dimethyl I
- I
1 I
, I
4 I
- I
cyclohexanedione I
, O
which O
had O
a O
pungent O
odour O
, O
and O
was O
thus O
first O
identified O
in O
roasted O
coffee O
. O

Model O
experiments O
revealed O
that O
cis B
- I
2 I
, I
6 I
- I
dimethyl I
- I
1 I
, I
4 I
- I
cyclohexanedione I
was O
formed O
via O
thermal O
degradation O
of O
sugars O
, O
especially O
monosaccharides O
, O
under O
alkaline O
conditions O
. O

Further O
, O
we O
demonstrated O
that O
2 B
- I
hydroxy I
- I
3 I
- I
pentanone I
and O
1 B
- I
hydroxy I
- I
2 I
- I
propanone I
, O
thermal O
degradation O
products O
of O
monosaccharides O
, O
were O
closely O
related O
to O
the O
formation O
of O
cis B
- I
2 I
, I
6 I
- I
dimethyl I
- I
1 I
, I
4 I
- I
cyclohexanedione I
. O

Effect O
of O
dietary O
carnosic B
acid I
on O
the O
fatty O
acid O
profile O
and O
flavour O
stability O
of O
meat O
from O
fattening O
lambs O
. O

Thirty O
- O
two O
lambs O
were O
fed O
with O
barley O
straw O
supplemented O
by O
a O
concentrate O
alone O
, O
or O
a O
concentrate O
enriched O
with O
either O
vitamin O
E O
( O
VITE006 B
: O
0 O
. O
6 O
g O
kg O
( O
- O
1 O
) O
feed O
concentrate O
) O
or O
carnosic B
acid I
( O
CARN006 B
: O
0 O
. O
6 O
g O
kg O
( O
- O
1 O
) O
feed O
concentrate O
; O
or O
CARN012 B
: O
1 O
. O
2 O
g O
kg O
( O
- O
1 O
) O
feed O
concentrate O
) O
. O

Dietary O
carnosic B
acid I
did O
not O
modify O
the O
FAs O
profile O
, O
but O
had O
a O
clear O
effect O
on O
the O
production O
of O
volatile O
compounds O
, O
in O
a O
dose O
- O
dependent O
manner O
. O

These O
results O
have O
implications O
for O
the O
food O
industry O
, O
since O
dietary O
carnosic B
acid I
seems O
to O
extend O
the O
shelf O
life O
of O
lamb O
meat O
. O

Thermal O
degradation O
kinetics O
of O
the O
major O
blood O
orange O
xanthophylls O
( O
cis B
- I
violaxanthin I
, O
lutein O
, O
beta O
- O
cryptoxanthin O
, O
zeaxanthin O
and O
cis B
- I
antheraxanthin I
) O
were O
investigated O
at O
45 O
, O
60 O
, O
75 O
, O
and O
90 O
degrees O
C O
in O
real O
juice O
and O
three O
model O
systems O
formulated O
to O
evaluate O
the O
impact O
of O
xanthophyll O
form O
( O
esterified O
or O
free O
) O
and O
pH O
( O
acid O
or O
neutral O
) O
. O

In O
comparison O
, O
the O
epoxy O
carotenoids O
cis B
- I
violaxanthin I
and O
cis B
- I
antheraxanthin I
degraded O
around O
3 O
- O
fold O
faster O
in O
their O
esterified O
form O
. O

In O
their O
free O
form O
, O
cis B
- I
antheraxanthin I
degraded O
30 O
- O
fold O
faster O
while O
cis B
- I
violaxanthin I
instantaneously O
disappeared O
because O
of O
the O
isomerisation O
of O
its O
5 B
, I
6 I
- I
epoxy I
groups O
into O
5 B
, I
8 I
- I
epoxy I
. O

Synthesis O
, O
preliminary O
structure O
- O
activity O
relationships O
, O
and O
in O
vitro O
biological O
evaluation O
of O
6 B
- I
aryl I
- I
3 I
- I
amino I
- I
thieno I
[ I
2 I
, I
3 I
- I
b I
] I
pyridine I
derivatives O
as O
potential O
anti O
- O
inflammatory O
agents O
. O

In O
our O
previous O
study O
, O
a O
series O
of O
6 B
- I
aryl I
- I
3 I
- I
amino I
- I
thieno I
[ I
2 I
, I
3 I
- I
b I
] I
pyridine I
derivatives O
exhibited O
potent O
antiproliferative O
activities O
and O
an O
unique O
hepatocellular O
carcinoma O
( O
HCC O
) O
- O
specific O
anticancer O
activity O
was O
also O
observed O
. O

In O
further O
anti O
- O
inflammatory O
research O
, O
thienopyridine B
derivative O
1a O
showed O
potent O
inhibition O
of O
nitric O
oxide O
( O
NO O
) O
production O
. O

So O
a O
series O
of O
thienopyridine B
analogues O
of O
1a O
were O
synthesized O
and O
evaluated O
for O
anti O
- O
inflammatory O
activities O
. O

These O
results O
suggest O
that O
these O
6 B
- I
aryl I
- I
3 I
- I
amino I
- I
thieno I
[ I
2 I
, I
3 I
- I
b I
] I
pyridine I
derivatives O
might O
potentially O
constitute O
a O
novel O
class O
of O
anti O
- O
inflammatory O
agents O
, O
which O
require O
further O
studies O
. O

Naltrexone B
was O
injected O
subcutaneously O
( O
0 O
. O
02 O
- O
2 O
mg O
/ O
kg O
) O
or O
intrathecally O
( O
0 O
. O
07 O
mu O
g O
/ O
10 O
mu O
l O
- O
350 O
mu O
g O
/ O
10 O
mu O
l O
) O
, O
while O
selective O
mu O
- O
antagonist O
naloxonazine B
was O
administered O
intraperitoneally O
( O
5 O
mg O
/ O
kg O
) O
prior O
to O
nociceptive O
testing O
. O

The O
influence O
of O
naltrexone B
( O
2 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
on O
BTX O
- O
A O
antinociceptive O
activity O
was O
examined O
additionally O
in O
an O
experimental O
neuropathy O
induced O
by O
partial O
sciatic O
nerve O
transection O
. O

To O
investigate O
the O
effects O
of O
naltrexone B
and O
BTX O
- O
A O
on O
neuronal O
activation O
in O
spinal O
cord O
, O
c O
- O
Fos O
expression O
was O
immunohistochemicall O
examined O
in O
a O
model O
of O
formalin O
- O
induced O
pain O
. O

Antinociceptive O
effects O
of O
BTX O
- O
A O
in O
formalin O
and O
sciatic O
nerve O
transection O
- O
induced O
pain O
were O
prevented O
by O
non O
- O
selective O
opioid O
antagonist O
naltrexone B
. O

Similarly O
, O
BTX O
- O
A O
- O
induced O
pain O
reduction O
was O
abolished O
by O
low O
dose O
of O
intrathecal O
naltrexone B
and O
by O
selective O
mu O
- O
antagonist O
naloxonazine B
. O

BTX O
- O
A O
- O
induced O
decrease O
in O
dorsal O
horn O
c O
- O
Fos O
expression O
was O
prevented O
by O
naltrexone B
. O

A O
case O
study O
on O
radiolabeled B
fenofibrate I
. O

In O
the O
current O
study O
, O
four O
different O
nanosuspension O
formulations O
containing O
iodinated B
fenofibrate I
were O
prepared O
, O
physicochemically O
characterized O
and O
investigated O
concerning O
their O
in O
- O
vitro O
release O
kinetics O
from O
osmotic O
pumps O
. O

To O
assess O
the O
relation O
of O
the O
in O
- O
vitro O
release O
kinetics O
to O
the O
in O
- O
vivo O
fate O
of O
nanosuspensions O
, O
various O
[ B
( I
131 I
) I
I I
] I
iodinated I
fenofibrate I
formulations O
were O
subcutaneously O
applied O
to O
mice O
. O

The O
organ O
levels O
of O
[ B
( I
131 I
) I
I I
] I
labeled I
fenofibrate I
were O
found O
to O
be O
more O
constant O
in O
case O
of O
the O
pump O
with O
the O
higher O
viscous O
nanosuspension O
in O
contrast O
to O
the O
lower O
viscous O
counterpart O
. O

Construction O
of O
block O
copolymers O
for O
the O
coordinated O
delivery O
of O
doxorubicin O
and O
magnetite B
nanocubes O
. O

In O
this O
paper O
, O
we O
report O
the O
coordinated O
in O
vivo O
delivery O
of O
anti O
- O
cancer O
drugs O
and O
imaging O
agents O
by O
chemically O
loading O
doxorubicin O
and O
magnetite B
nanocubes O
( O
MNs O
) O
in O
the O
core O
of O
polymeric O
nanoparticles O
. O

The O
resulting O
diblock O
polymers O
consisted O
of O
one O
block O
with O
triethylene B
glycol I
brushes O
and O
another O
block O
with O
carboxylic O
acid O
groups O
to O
bind O
doxorubicin O
and O
Fe3O4 O
MNs O
. O

The O
lymphatic O
pharmacokinetics O
of O
interferon O
alpha O
2b O
( O
IFN O
, O
19kDa O
) O
and O
PEGylated O
interferon O
alpha O
2b O
( O
IFN O
- O
PEG12 B
, O
31kDa O
) O
or O
alpha O
2a O
( O
IFN O
- O
PEG40 B
, O
60kDa O
) O
was O
examined O
in O
thoracic O
lymph O
duct O
cannulated O
rats O
. O

In O
contrast O
, O
IFN O
- O
PEG12 B
was O
efficiently O
absorbed O
from O
the O
SC O
injection O
site O
( O
Fabs O
82 O
% O
) O
and O
approximately O
20 O
% O
and O
8 O
% O
of O
the O
injected O
dose O
was O
recovered O
in O
thoracic O
lymph O
over O
30h O
after O
SC O
or O
IV O
administration O
respectively O
. O

IFN O
- O
PEG40 B
, O
however O
, O
was O
incompletely O
absorbed O
from O
the O
SC O
injection O
site O
( O
Fabs O
23 O
% O
) O
and O
showed O
similar O
lymphatic O
access O
after O
SC O
administration O
to O
IFN O
- O
PEG12 B
( O
21 O
% O
) O
. O

The O
recovery O
of O
IFN O
- O
PEG40 O
in O
thoracic O
lymph O
after O
IV O
administration O
, O
however O
, O
was O
significantly O
greater O
( O
29 O
% O
) O
when O
compared O
to O
IV O
IFN O
- O
PEG12 B
. O

The O
anti O
- O
tumour O
efficacy O
of O
interferon O
against O
axillary O
metastases O
of O
a O
highly O
lymph O
- O
metastatic O
variant O
of O
human O
breast O
MDA O
- O
MB O
- O
231 O
carcinoma O
was O
significantly O
increased O
by O
SC O
administration O
of O
lymph O
- O
targeted O
IFN O
- O
PEG12 B
when O
compared O
to O
the O
administration O
of O
IFN O
on O
the O
ipsilateral O
side O
to O
the O
axillary O
metastasis O
. O

Toxicity O
of O
thienopyridines B
on O
human O
neutrophil O
granulocytes O
and O
lymphocytes O
. O

Thienopyridines B
can O
cause O
neutropenia O
and O
agranulocytosis O
. O

The O
aim O
of O
the O
current O
investigations O
was O
to O
compare O
cytotoxicity O
of O
ticlopidine B
, O
clopidogrel O
, O
clopidogrel B
carboxylate I
and O
prasugrel B
for O
human O
neutrophil O
granulocytes O
with O
the O
toxicity O
for O
lymphocytes O
and O
to O
investigate O
underlying O
mechanisms O
. O

For O
granulocytes O
, O
clopidogrel O
, O
ticlopidine B
, O
clopidogrel B
carboxylate I
and O
prasugrel B
were O
concentration O
- O
dependently O
toxic O
starting O
at O
10 O
mu O
M O
. O

Granulocytes O
metabolized O
ticlopidine B
, O
clopidogrel O
, O
clopidogrel B
carboxylate I
and O
prasugrel B
, O
and O
metabolization O
was O
inhibited O
by O
rutin O
, O
but O
not O
by O
ketoconazole O
. O

In O
conclusion O
, O
ticlopidine B
, O
clopidogrel O
, O
clopidogrel B
carboxylate I
and O
prasugrel B
are O
toxic O
for O
both O
granulocytes O
and O
lymphocytes O
. O

Six O
analogues O
of O
salpichrolides B
with O
a O
simplified O
side O
chain O
( O
6 O
- O
11 O
) O
were O
synthesized O
using O
a O
new O
methodology O
to O
obtain O
steroids O
with O
an O
aromatic O
D O
- O
ring O
. O

The O
key O
step O
was O
the O
elimination O
of O
HBr B
in O
a O
vicinal B
dibromo I
D I
- I
homosteroid I
by O
treatment O
with O
1 B
, I
4 I
- I
diazabicyclo I
[ I
2 I
. I
2 I
. I
2 I
] I
octane I
( O
DABCO B
) O
. O

In O
vitro O
, O
ex O
vivo O
and O
in O
vivo O
examination O
of O
buccal O
absorption O
of O
metoprolol B
with O
varying O
pH O
in O
TR146 O
cell O
culture O
, O
porcine O
buccal O
mucosa O
and O
G O
o O
ttingen O
minipigs O
. O

This O
work O
studied O
the O
buccal O
absorption O
of O
metoprolol B
in O
vitro O
, O
ex O
vivo O
and O
in O
vivo O
as O
a O
function O
of O
buffered O
pH O
at O
7 O
. O
4 O
, O
8 O
. O
5 O
, O
9 O
. O
0 O
and O
9 O
. O
5 O
. O

Here O
, O
we O
report O
the O
first O
crystal O
structure O
of O
KIF4 O
complexed O
with O
the O
non O
- O
hydrolyzable O
ATP O
analog O
, O
AMPPNP B
( O
adenylyl B
imidodiphosphate I
) O
, O
at O
1 O
. O
7 O
A O
resolution O
. O

The O
mechanisms O
by O
which O
oxysterols O
may O
influence O
proliferation O
are O
manifold O
: O
they O
control O
the O
transcription O
and O
the O
turnover O
of O
the O
key O
enzyme O
in O
cholesterol O
synthesis O
, O
3 B
- I
hydroxy I
- I
3 I
- I
methylglutaryl I
CoA I
reductase O
, O
by O
binding O
to O
Insig O
- O
1 O
, O
Insig O
- O
2 O
and O
liver O
X O
receptors O
. O

Ang O
II O
stimulated O
cell O
proliferation O
and O
the O
effect O
was O
antagonized O
by O
the O
KCa3 O
. O
1 O
blocker O
TRAM B
- I
34 I
and O
siRNA O
targeting O
KCa3 O
. O
1 O
. O

The O
lowest O
levels O
of O
peroxide O
value O
( O
PV O
) O
, O
thiobarbituric O
acid O
reactive O
substances O
( O
TBARs O
) O
, O
cholesterol O
oxidation O
products O
( O
COPs O
) O
and O
the O
highest O
level O
of O
polyunsaturated O
fatty O
acids O
( O
PUFAs O
) O
content O
, O
especially O
PUFA B
n I
- I
3 I
, O
were O
found O
in O
the O
untreated O
sardines O
( O
time O
zero O
) O
. O

Little O
is O
known O
in O
terms O
of O
multi O
- O
matrix O
cytochrome O
P450 O
activity O
induction O
under O
repeated O
oral O
exposure O
to O
planar O
halogenated B
and I
polycyclic I
aromatic I
hydrocarbons I
( O
PHH O
, O
PAH O
) O
. O

EROD B
activity O
, O
reflecting O
almost O
exclusively O
CYP1A1 O
and O
CYP1B1 O
activities O
, O
was O
measured O
in O
brain O
and O
liver O
microsomes O
as O
well O
as O
in O
peripheral O
blood O
lymphocytes O
( O
PBLs O
) O
. O

After O
28days O
of O
exposure O
to O
a O
6 O
mu O
g O
/ O
day O
dose O
, O
EROD B
activity O
was O
found O
to O
be O
91 O
, O
152 O
and O
94 O
- O
fold O
increased O
in O
lymphocytes O
, O
liver O
and O
brain O
, O
respectively O
, O
compared O
to O
day O
0 O
. O

Correlations O
between O
matrices O
made O
it O
possible O
to O
conclude O
that O
EROD B
activity O
in O
PBL O
should O
be O
considered O
as O
a O
sensitive O
, O
convenient O
and O
non O
- O
destructive O
approach O
for O
( O
i O
) O
evaluating O
EROD B
activity O
in O
liver O
, O
which O
was O
found O
to O
represent O
98 O
% O
of O
the O
observed O
EROD B
activities O
in O
the O
three O
tested O
matrices O
and O
( O
ii O
) O
evaluating O
oral O
exposure O
of O
homogeneous O
groups O
of O
farm O
animals O
( O
race O
, O
diet O
) O
to O
CYP O
inducing O
PAH O
and O
PHH B
. O

Novel O
chiral O
ferrocenylpyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
[ I
1 I
, I
4 I
] I
diazepin I
- I
4 I
- I
one I
derivatives O
- O
Synthesis O
, O
characterization O
and O
inhibition O
against O
lung O
cancer O
cells O
. O

A O
series O
of O
novel O
2 B
- I
ferrocenyl I
- I
7 I
- I
hydroxy I
- I
5 I
- I
phenethyl I
- I
5 I
, I
6 I
, I
7 I
, I
8 I
- I
tetrahydro I
- I
4H I
- I
pyrazolo I
[ I
1 I
, I
5 I
- I
a I
] I
[ I
1 I
, I
4 I
] I
diazepin I
- I
4 I
- I
one I
derivatives O
with O
optical O
activity O
( O
2 O
) O
was O
synthesized O
in O
the O
microwave O
- O
assisted O
condition O
and O
characterized O
by O
means O
of O
IR O
, O
( O
1 O
) O
H O
NMR O
and O
mass O
spectroscopy O
, O
and O
furthermore O
confirmed O
by O
X O
- O
ray O
analysis O
of O
a O
representative O
compound O
( O
R O
) O
- O
2a O
. O

Synthesis O
and O
evaluation O
of O
7 B
, I
8 I
- I
dehydrorutaecarpine I
derivatives O
as O
potential O
multifunctional O
agents O
for O
the O
treatment O
of O
Alzheimer O
' O
s O
disease O
. O

A O
series O
of O
7 B
, I
8 I
- I
dehydrorutaecarpine I
derivatives O
were O
synthesized O
and O
characterized O
as O
potential O
multifunctional O
agents O
for O
treatment O
of O
Alzheimer O
' O
s O
disease O
( O
AD O
) O
. O

RATIONALE O
: O
Naltrexone B
, O
a O
non O
- O
selective O
opioid O
antagonist O
, O
decreases O
the O
euphoria O
and O
positive O
subjective O
responses O
to O
alcohol O
in O
heavy O
drinkers O
. O

OBJECTIVES O
: O
To O
investigate O
the O
ability O
of O
naltrexone B
and O
beta O
- O
funaltrexamine O
, O
an O
irreversible O
mu O
- O
opioid O
specific O
antagonist O
, O
to O
inhibit O
ethanol O
- O
stimulated O
and O
morphine O
- O
stimulated O
mesolimbic O
dopamine O
release O
, O
and O
to O
determine O
whether O
opioid O
receptors O
on O
mesolimbic O
neurons O
contribute O
to O
these O
mechanisms O
. O

RESULTS O
: O
Administration O
of O
naltrexone B
( O
intravenously O
) O
and O
beta O
- O
funaltrexamine O
( O
subcutaneously O
) O
, O
as O
well O
as O
intracranial O
injection O
of O
naltrexone B
into O
the O
VTA O
did O
not O
prevent O
the O
initiation O
of O
dopamine O
release O
by O
intravenous O
ethanol O
administration O
, O
but O
prevented O
it O
from O
being O
as O
prolonged O
. O

Simultaneous O
effects O
of O
two O
fungicides O
( O
copper O
and O
dimethomorph B
) O
on O
their O
phytoremediation O
using O
Lemna O
minor O
. O

Effects O
of O
two O
fungicides O
, O
copper O
and O
dimethomorph B
( O
( B
E I
, I
Z I
) I
4 I
- I
[ I
3 I
- I
( I
4 I
- I
chlorophenyl I
) I
- I
3 I
- I
( I
3 I
- I
4dimethoxyphenyl I
) I
acryloyl I
] I
morpholine I
) O
on O
Lemna O
minor O
growth O
and O
phytoremediation O
were O
evaluated O
. O

The O
toxicity O
of O
copper O
and O
dimethomorph B
alone O
and O
in O
combination O
, O
was O
assessed O
by O
growth O
inhibition O
of O
L O
. O
minor O
cultures O
after O
96 O
and O
168 O
h O
. O

Copper O
had O
a O
severe O
impact O
on O
growth O
( O
max O
. O
inhibition O
: O
90 O
% O
at O
1 O
, O
000 O
mu O
g O
L O
( O
- O
1 O
) O
) O
while O
dimethomorph B
( O
as O
pure O
ingredient O
or O
formulated O
as O
Forum B
) O
did O
not O
( O
inhibition O
< O
45 O
% O
at O
1 O
, O
000 O
mu O
g O
L O
( O
- O
1 O
) O
) O
after O
168 O
h O
of O
treatment O
. O

When O
both O
chemicals O
were O
combined O
, O
synergism O
was O
observed O
after O
96 O
h O
of O
exposure O
to O
copper O
and O
Forum B
. O

Additivity O
was O
also O
observed O
when O
the O
pure O
active O
ingredient O
( O
dimethomorph B
) O
replaced O
Forum B
in O
the O
mixture O
of O
copper O
and O
dimethomorph B
at O
96 O
and O
168 O
h O
. O

The O
removal O
of O
copper O
increased O
with O
Forum B
concentration O
. O

After O
96 O
h O
copper O
( O
10 O
mu O
g O
L O
( O
- O
1 O
) O
initial O
concentration O
) O
elimination O
increased O
from O
36 O
. O
39 O
+ O
/ O
- O
5 O
. O
86 O
- O
60 O
. O
70 O
+ O
/ O
- O
6 O
. O
06 O
% O
when O
Forum B
concentration O
increased O
from O
0 O
to O
500 O
mu O
g O
L O
( O
- O
1 O
) O
. O

Accumulation O
of O
copper O
in O
plants O
was O
also O
increased O
by O
Forum B
but O
not O
by O
the O
active O
ingredient O
alone O
. O

Synthesis O
of O
phenyleneethynylene O
- O
doped O
poly B
( I
pphenylenebutadiynyl I
) I
s I
for O
live O
cell O
imaging O
. O

We O
developed O
a O
new O
synthetic O
approach O
to O
high O
molecular O
weight O
poly B
( I
p I
- I
phenylenebutadiynyle I
) I
s I
( O
PPBs B
) O
by O
increasing O
backbone O
flexibility O
. O

The O
high O
purity O
, O
molecular O
weight O
and O
correct O
compositions O
of O
each O
new O
polypeptide O
have O
been O
confirmed O
via O
high O
performance O
liquid O
chromatography O
( O
HPLC O
) O
, O
sodium B
dodecyl I
sulfate I
polyacrylamide I
gel I
electrophoresis O
( O
SDS O
- O
PAGE O
) O
, O
matrix O
- O
assisted O
laser O
desorption O
/ O
ionization O
mass O
spectrometry O
( O
MALDI O
- O
MS O
) O
, O
and O
amino O
acid O
analysis O
. O

Tris B
( I
hydroxymethyl I
phosphine I
) I
cross O
- O
linked O
RLP O
hydrogels O
were O
able O
to O
maintain O
their O
mechanical O
integrity O
as O
well O
as O
the O
viability O
of O
encapsulated O
primary O
human O
mesenchymal O
stem O
cells O
( O
MSCs O
) O
. O

Recently O
, O
alpha O
- O
ketoglutarate O
( O
alpha B
KG I
) O
, O
the O
carbon O
substrate O
for O
ammonia O
assimilation O
, O
has O
been O
observed O
to O
inhibit O
Escherichia O
coli O
enzyme O
I O
( O
EI O
) O
, O
the O
first O
component O
of O
the O
bacterial O
phosphotransferase O
system O
( O
PTS O
) O
, O
thereby O
providing O
a O
direct O
biochemical O
link O
between O
central O
carbon O
and O
nitrogen O
metabolism O
. O

Here O
we O
investigate O
the O
EI O
- O
alpha B
KG I
interaction O
by O
NMR O
and O
enzymatic O
assays O
. O

We O
show O
that O
alpha B
KG I
binds O
with O
a O
KD O
of O
~ O
2 O
. O
2 O
mM O
at O
the O
active O
site O
of O
EI O
, O
acting O
as O
a O
competitive O
inhibitor O
. O

We O
expect O
that O
the O
EI O
- O
alpha B
KG I
structure O
presented O
here O
will O
provide O
a O
starting O
point O
for O
structure O
- O
based O
design O
of O
EI O
mutants O
resistant O
to O
alpha B
KG I
. O

A O
comparison O
of O
the O
constituents O
in O
the O
nine O
commercial O
products O
of O
Dang O
- O
shen O
showed O
that O
compounds O
codonopyrrolidum B
A I
, I
B I
and O
codonoside B
A I
only O
exist O
in O
C O
. O
tangshen O
, O
but O
not O
in O
C O
. O
pilosula O
var O
. O
modesta O
and O
C O
. O
pilosula O
. O

A O
predominate O
compound O
, O
codonopyrrolidum B
A I
, O
can O
be O
used O
to O
distinguish O
the O
herbs O
, O
C O
. O
tangshen O
from O
C O
. O
pilosula O
var O
. O
modesta O
and O
C O
. O
pilosula O
. O

Transition O
to O
Reinforced O
State O
by O
Percolating O
Domains O
of O
Intercalated O
Brush O
- O
Modified O
Cellulose O
Nanocrystals O
and O
Poly B
( I
butadiene I
) I
in O
Cross O
- O
Linked O
Composites O
Based O
on O
Thiol B
- I
ene I
Click O
Chemistry O
. O

Composite O
films O
with O
0 O
- O
80 O
wt O
% O
of O
such O
modified O
CNCs O
( O
mCNCs O
) O
within O
a O
poly B
( I
butadiene I
) I
( O
PBD O
) O
rubber O
matrix O
were O
prepared O
via O
cross O
- O
linking O
by O
UV O
- O
light O
initiated O
thiol B
- I
ene I
click O
reaction O
. O

Biomarkers O
of O
prolonged O
exposure O
to O
microcystin B
- I
LR I
in O
mice O
. O

The O
aim O
of O
this O
work O
is O
to O
determine O
, O
based O
on O
an O
animal O
model O
of O
prolonged O
exposure O
to O
successive O
i O
. O
p O
. O
doses O
of O
25 O
mu O
g O
MC B
- I
LR I
/ O
kg O
body O
weight O
, O
several O
plasma O
parameters O
which O
could O
be O
useful O
as O
exposure O
biomarkers O
. O

We O
also O
studied O
plasma O
levels O
of O
hydroperoxides B
( O
ROOHs B
) O
, O
alpha O
- O
tocopherol O
, O
glutathione O
and O
lipid O
profile O
as O
well O
as O
superoxide O
dismutase O
( O
SOD O
) O
and O
catalase O
( O
CAT O
) O
erythrocyte O
activities O
. O

In O
addition O
, O
the O
determination O
of O
MC B
- I
LR I
levels O
in O
liver O
, O
kidney O
, O
plasma O
, O
urine O
and O
feces O
of O
treated O
mice O
was O
carried O
out O
. O

We O
found O
that O
alteration O
in O
MetHb O
, O
ROOHs B
, O
glutathione O
, O
alpha O
- O
tocopherol O
levels O
, O
SOD O
activity O
and O
plasma O
lipid O
profile O
, O
correlates O
with O
those O
expected O
if O
the O
alteration O
derived O
from O
hepatic O
damage O
. O

The O
alterated O
plasma O
paramenters O
together O
with O
MC B
- I
LR I
determination O
could O
be O
used O
as O
biomarkers O
, O
helpful O
tools O
in O
screening O
and O
epidemiological O
studies O
. O

Here O
we O
describe O
the O
LC O
- O
MS O
/ O
MS O
procedure O
enabling O
simultaneous O
determination O
of O
four O
regioisomers O
( O
8 B
- I
iso I
prostaglandin I
F2 I
alpha I
, O
8 B
- I
iso I
- I
15 I
( I
R I
) I
- I
prostaglandin I
F2 I
alpha I
, O
11 B
beta I
- I
prostaglandin I
F2 I
alpha I
, O
15 B
( I
R I
) I
- I
prostaglandin I
F2 I
alpha I
) O
in O
plasma O
samples O
collected O
from O
mice O
. O

The O
four O
plasma O
isoprostanes O
are O
determined O
by O
LC O
- O
ESI O
- O
MS O
/ O
MS O
with O
deuterated O
8 B
- I
iso I
- I
PGF2 I
alpha I
- I
d4 I
as O
an O
internal O
standard O
( O
I O
. O
S O
. O
) O
. O

The O
applicability O
of O
the O
proposed O
approach O
has O
been O
verified O
by O
the O
assessment O
of O
changes O
in O
isoprostane B
levels O
in O
plasma O
samples O
derived O
from O
mice O
exposed O
to O
tert O
- O
butyl O
hydroperoxide O
( O
TBHP B
) O
, O
a O
model O
inducer O
of O
oxidative O
stress O
, O
or O
to O
antitumor O
drug O
doxorubicin O
( O
DOX O
) O
known O
for O
potent O
stimulation O
of O
redox O
cycling O
. O

Compared O
to O
the O
control O
group O
of O
mice O
, O
both O
oxidative O
stress O
inducers O
tested O
increased O
the O
levels O
of O
three O
out O
of O
four O
isoprostanes O
in O
exposed O
animals O
; O
11 B
beta I
- I
prostaglandin I
F2 I
alpha I
being O
the O
exception O
. O

The O
greatest O
rise O
was O
observed O
in O
the O
case O
of O
15 B
( I
R I
) I
- I
prostaglandin I
F2 I
alpha I
, O
by O
about O
50 O
% O
and O
70 O
% O
in O
plasma O
samples O
derived O
from O
mice O
exposed O
to O
DOX O
and O
TBHP B
, O
respectively O
. O

An O
amphiphilic O
diblock O
copolymer O
poly B
( I
acrylamidoethylamine I
) I
90 I
- I
block I
- I
poly I
( I
dl I
- I
lactide I
) I
40 I
( O
PAEA90 B
- I
b I
- I
PDLLA40 I
) O
was O
synthesized O
, O
self O
- O
assembled O
in O
aqueous O
solution O
, O
and O
shell O
cross O
- O
linked O
using O
a O
hydrolyzable O
cross O
- O
linker O
to O
afford O
deg O
- O
cSCKs O
with O
an O
average O
core O
diameter O
of O
45 O
+ O
/ O
- O
7 O
nm O
. O

24 O
% O
of O
the O
PDLLA B
core O
into O
lactic O
acid O
within O
5 O
d O
, O
as O
opposed O
to O
only O
ca O
. O

In O
the O
present O
study O
, O
a O
reactive O
oxygen O
species O
- O
responsive O
nanocarrier O
has O
been O
successfully O
self O
- O
assembled O
from O
an O
amphiphilic O
hyperbranched O
polymer O
consisting O
of O
alternative O
hydrophobic O
selenide B
groups O
and O
hydrophilic O
phosphate O
segments O
in O
the O
dendritic O
backbone O
. O

Because O
the O
hydrophobic O
selenide B
groups O
transformed O
into O
the O
hydrophilic O
selenone B
groups O
after O
oxidation O
under O
the O
exclusive O
oxidative O
microenvironment O
within O
cancer O
cells O
, O
the O
amphiphilic O
hyperbranched O
precursors O
become O
hydrophilic O
ones O
. O

Carbonic O
anhydrase O
inhibitors O
: O
Inhibition O
of O
the O
beta O
- O
class O
enzyme O
from O
the O
pathogenic O
yeast O
Candida O
glabrata O
with O
sulfonamides O
, O
sulfamates B
and O
sulfamides B
. O

Simple O
sulfonamides O
showed O
weak O
or O
moderate O
CgNce103 O
inhibitory O
properties O
, O
whereas O
acetazolamide B
, O
and O
a O
series O
of O
4 B
- I
substituted I
ureido I
- I
benzene I
- I
sulfonamides I
, O
sulfamates B
and O
sulfamides B
showed O
effective O
CgNce103 O
inhibitory O
properties O
, O
with O
KIs O
in O
the O
range O
of O
4 O
. O
1 O
- O
115nM O
, O
being O
also O
ineffective O
as O
human O
CA O
II O
inhibitors O
. O

Population O
pharmacokinetics O
of O
intramuscular O
artesunate B
in O
african O
children O
with O
severe O
malaria O
: O
implications O
for O
a O
practical O
dosing O
regimen O
. O

Parenteral O
artesunate B
( O
ARS B
) O
is O
the O
drug O
of O
choice O
for O
the O
treatment O
of O
severe O
malaria O
. O

Pharmacokinetics O
data O
on O
intramuscular O
ARS B
are O
limited O
with O
respect O
to O
the O
main O
treatment O
group O
that O
carries O
the O
highest O
mortality O
, O
namely O
, O
critically O
ill O
children O
with O
severe O
malaria O
. O

A O
population O
pharmacokinetic O
study O
of O
ARS B
and O
dihydroartemisinin B
( O
DHA O
) O
was O
conducted O
from O
sparse O
sampling O
in O
70 O
Tanzanian O
children O
of O
ages O
6 O
months O
to O
11 O
years O
. O

All O
the O
children O
had O
been O
admitted O
with O
severe O
falciparum O
malaria O
and O
were O
treated O
with O
intramuscular O
ARS B
( O
2 O
. O
4 O
mg O
/ O
kg O
at O
0 O
, O
12 O
, O
and O
24 O
h O
) O
. O

A O
one O
- O
compartment O
disposition O
model O
accurately O
described O
first O
- O
dose O
population O
pharmacokinetics O
of O
ARS B
and O
DHA O
. O

Body O
weight O
significantly O
affected O
clearance O
and O
apparent O
volume O
of O
distribution O
( O
P O
< O
0 O
. O
001 O
) O
, O
resulting O
in O
lower O
ARS B
and O
DHA O
exposure O
levels O
in O
smaller O
children O
. O

Hop O
extract O
is O
a O
long O
used O
medicinal O
product O
and O
, O
regarding O
hormonal O
activities O
, O
in O
1999 O
a O
number O
of O
prenylflavanones B
have O
been O
identified O
as O
its O
major O
constituents O
with O
8 B
- I
prenylnaringenin I
( O
8 B
- I
PN I
) O
being O
the O
main O
active O
estrogenic O
compound O
. O

There O
have O
been O
several O
in O
vivo O
studies O
performed O
that O
demonstrate O
the O
potential O
of O
hop O
extract O
and O
the O
single O
compound O
8 B
- I
PN I
to O
alleviate O
climacteric O
symptoms O
like O
osteoporosis O
, O
vasomotoric O
complaints O
, O
and O
sexual O
motivation O
. O

Despite O
preferentially O
activating O
estrogen O
receptor O
alpha O
, O
8 B
- I
PN I
is O
only O
slightly O
uterotrophic O
, O
but O
it O
also O
elucidates O
estrogenic O
effects O
on O
the O
mammary O
gland O
. O

In O
conclusion O
, O
although O
hop O
extract O
and O
especially O
8 B
- I
PN I
are O
promising O
candidates O
as O
a O
relief O
for O
climacteric O
symptoms O
, O
data O
on O
the O
safety O
and O
efficacy O
is O
still O
scarce O
. O

Cardamonin B
Ameliorates O
Insulin O
Resistance O
Induced O
by O
High O
Insulin O
and O
High O
Glucose O
through O
the O
mTOR O
and O
Signal O
Pathway O
. O

The O
aim O
of O
this O
study O
is O
to O
investigate O
the O
effects O
of O
cardamonin B
, O
a O
potential O
inhibitor O
of O
the O
mammalian O
target O
of O
the O
rapamycin O
, O
on O
insulin O
- O
resistant O
vascular O
smooth O
muscle O
cells O
and O
the O
molecular O
mechanisms O
involved O
. O

Cardamonin B
increased O
the O
2 O
- O
deoxyglucose O
uptake O
and O
glycogen O
concentration O
, O
which O
was O
reduced O
by O
insulin O
resistance O
. O

As O
with O
rapamycin O
, O
cardamonin B
inhibited O
the O
activity O
of O
the O
mammalian O
target O
of O
rapamycin O
and O
S6 O
kinase O
1 O
, O
decreased O
the O
Ser O
636 O
/ O
639 O
phosphorylation O
of O
insulin O
receptor O
substrate O
- O
1 O
and O
increased O
the O
activation O
of O
protein O
kinase O
B O
. O

Both O
of O
them O
increased O
the O
Ser9 B
phosphorylation O
of O
glycogen O
synthesis O
kinase O
- O
3 O
beta O
and O
decreased O
the O
expression O
of O
glycogen O
synthesis O
kinase O
- O
3 O
beta O
. O

However O
, O
neither O
cardamonin B
nor O
rapamycin O
increased O
the O
expression O
of O
glucose O
transport O
4 O
which O
decreased O
in O
insulin O
- O
resistant O
vascular O
smooth O
muscle O
cells O
. O

This O
study O
suggests O
that O
cardamonin B
inhibited O
the O
activity O
of O
the O
mammalian O
target O
of O
rapamycin O
and O
eliminated O
the O
negative O
feedback O
of O
the O
mammalian O
target O
of O
rapamycin O
and O
S6 O
kinase O
1 O
on O
the O
insulin O
- O
signaling O
pathway O
. O

In O
contrast O
to O
artemisinin O
, O
deoxyartemisinin B
is O
inactive O
in O
this O
assay O
, O
demonstrating O
the O
critical O
role O
of O
the O
endoperoxide O
moiety O
of O
artemisinin O
for O
inducer O
activity O
. O

DOX B
- I
omega I
- I
3 I
FA I
group O
was O
given O
as O
omega B
- I
3 I
FAs I
at O
the O
dose O
of O
400 O
mg O
/ O
kg O
daily O
by O
intragastric O
gavage O
for O
30 O
days O
and O
received O
DOX O
at O
the O
dose O
of O
30 O
mg O
/ O
kg O
intraperitoneally O
on O
day O
28 O
. O

In O
addition O
, O
a O
significant O
decrease O
in O
MDA O
levels O
was O
observed O
in O
rats O
when O
a O
dose O
of O
omega B
- I
3 I
FAs I
was O
given O
with O
DOX O
and O
a O
significant O
increase O
was O
determined O
in O
the O
levels O
of O
GSH O
, O
SOD O
and O
GSH O
- O
Px O
activities O
in O
serum O
, O
liver O
and O
kidney O
tissues O
, O
when O
compared O
with O
DOX O
group O
. O

We O
concluded O
that O
omega B
- I
3 I
FA I
had O
favorable O
effects O
in O
rat O
liver O
and O
kidney O
tissues O
by O
preventing O
oxidative O
damage O
. O

Metabolism O
of O
Beclomethasone B
Dipropionate I
by O
Cytochrome O
P450 O
3A O
Enzymes O
. O

Inhaled O
glucocorticoids O
, O
such O
as O
beclomethasone B
dipropionate I
( O
BDP B
) O
, O
are O
the O
mainstay O
treatment O
of O
asthma O
. O

It O
is O
possible O
that O
variations O
in O
cytochrome O
P450 O
3A O
enzyme O
- O
mediated O
metabolism O
of O
BDP B
may O
contribute O
to O
this O
phenomenon O
. O

This O
hypothesis O
was O
explored O
by O
evaluating O
the O
contributions O
of O
CYP3A4 O
, O
3A5 O
, O
3A7 O
, O
and O
esterase O
enzymes O
in O
the O
metabolism O
of O
BDP B
in O
vitro O
and O
relating O
metabolism O
to O
changes O
in O
CYP3A O
enzyme O
mRNA O
expression O
via O
the O
glucocorticoid O
receptor O
in O
lung O
and O
liver O
cells O
. O

CYP3A4 O
and O
CYP3A5 O
metabolized O
BDP B
via O
hydroxylation O
( O
[ O
M4 O
] O
and O
[ O
M6 O
] O
) O
and O
dehydrogenation O
( O
[ O
M5 O
] O
) O
at O
similar O
rates O
; O
CYP3A7 O
did O
not O
metabolize O
BDP B
. O

These O
studies O
show O
that O
CYP3A4 O
and O
CYP3A5 O
metabolize O
BDP B
to O
inactive O
metabolites O
and O
suggest O
that O
differences O
in O
the O
expression O
or O
function O
of O
these O
enzymes O
in O
the O
lung O
and O
/ O
or O
liver O
could O
influence O
BDP B
disposition O
in O
humans O
. O

The O
Aryl O
Hydrocarbon O
Receptor O
( O
AhR O
) O
is O
a O
ligand O
mediated O
basic O
helix O
- O
loop O
- O
helix O
transcription O
factor O
of O
Per O
/ O
Arnt O
/ O
Sim O
family O
that O
regulates O
adaptive O
and O
toxic O
responses O
to O
variety O
of O
chemical O
pollutants O
including O
polycyclic O
aromatic O
hydrocarbons O
( O
PAH O
) O
and O
halogenated B
aromatic I
hydrocarbons I
, O
most O
notably O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo O
- O
p O
- O
dioxin O
( O
TCDD O
) O
. O

The O
amount O
of O
total O
soluble O
collagen O
was O
analyzed O
by O
Sircol B
collagen O
assay O
. O

The O
meso B
- I
tetra I
( I
2 I
, I
6 I
- I
dichloro I
- I
3 I
- I
sulfonatophenyl I
) I
porphyrinate I
of O
manganese B
( I
III I
) I
chloride I
[ B
Mn I
- I
( I
TDCPPS I
) I
Cl I
] I
biomimetic O
catalyst O
immobilized O
on O
spacer O
- O
functionalized O
kaolinite O
clay O
mineral O
was O
employed O
in O
the O
oxidative O
coupling O
reaction O
of O
a O
dissolved O
humic O
acid O
( O
HA O
) O
suprastructure O
with O
either O
chemical O
( O
H2O2 O
) O
or O
UV O
- O
light O
oxidation O
. O

Stereoselective O
Potencies O
and O
Relative O
Toxicities O
of O
gamma B
- I
Coniceine I
and O
N B
- I
Methylconiine I
Enantiomers O
. O

gamma B
- I
Coniceine I
, O
coniine B
, O
and O
N B
- I
methylconiine I
are O
toxic O
alkaloids O
present O
in O
poison O
hemlock O
( O
Conium O
maculatum O
) O
. O

We O
previously O
reported O
the O
comparison O
of O
the O
relative O
potencies O
of O
( B
+ I
) I
- I
and I
( I
- I
) I
- I
coniine I
enantiomers O
. O

In O
this O
study O
, O
we O
synthesized O
gamma B
- I
coniceine I
and O
the O
enantiomers O
of O
N B
- I
methylconiine I
and O
determined O
the O
biological O
activity O
of O
gamma B
- I
coniceine I
and O
each O
of O
the O
N B
- I
methylconiine I
enantiomers O
in O
vitro O
and O
in O
vivo O
. O

The O
relative O
potencies O
of O
these O
piperidine O
alkaloids O
on O
cells O
expressing O
human O
fetal O
muscle O
- O
type O
nicotinic O
acetylcholine O
receptors O
had O
the O
rank O
order O
of O
gamma B
- I
coniceine I
> O
( B
- I
) I
- I
N I
- I
methylconiine I
> O
( B
+ I
/ I
- I
) I
- I
N I
- I
methylconiine I
> O
( B
+ I
) I
- I
N I
- I
methylconiine I
. O

The O
relative O
lethalities O
of O
gamma B
- I
coniceine I
and O
( B
- I
) I
- I
, I
( I
+ I
/ I
- I
) I
- I
, I
and I
( I
+ I
) I
- I
N I
- I
methylconiine I
in O
vivo O
using O
a O
mouse O
bioassay O
were O
4 O
. O
4 O
, O
16 O
. O
1 O
, O
17 O
. O
8 O
, O
and O
19 O
. O
2 O
mg O
/ O
kg O
, O
respectively O
. O

The O
results O
from O
this O
study O
suggest O
gamma B
- I
coniceine I
is O
a O
more O
potent O
agonist O
than O
the O
enantiomers O
of O
N B
- I
methylconiine I
and O
that O
there O
is O
a O
stereoselective O
difference O
in O
the O
in O
vitro O
potencies O
of O
the O
enantiomers O
of O
N B
- I
methylconiine I
that O
correlates O
with O
the O
relative O
toxicities O
of O
the O
enantiomers O
in O
vivo O
. O

Herein O
we O
report O
the O
electrical O
transport O
properties O
of O
a O
series O
of O
ordered O
mesoporous O
ceria B
- I
zirconia I
( O
CexZr1 B
- I
xO2 I
, O
referred O
to O
as O
mp O
- O
CZO B
) O
thin O
films O
with O
both O
a O
cubic O
structure O
of O
( O
17 O
+ O
/ O
- O
2 O
) O
nm O
diameter O
pores O
and O
nanocrystalline O
walls O
. O

Samples O
over O
the O
whole O
range O
of O
composition O
, O
including O
bare O
CeO2 O
and O
ZrO2 B
, O
were O
fabricated O
by O
templating O
strategies O
using O
the O
large O
diblock O
copolymer O
KLE B
as O
the O
structure O
- O
directing O
agent O
. O

The O
mesoporous O
solid O
solutions O
of O
CeO2 O
- O
ZrO2 B
prepared O
in O
this O
work O
showed O
a O
higher O
stability O
against O
thermal O
ripening O
than O
both O
binary O
oxides O
, O
making O
them O
ideal O
model O
systems O
to O
study O
both O
the O
charge O
transport O
properties O
and O
the O
oxygen O
storage O
at O
elevated O
temperatures O
. O

We O
find O
that O
the O
redox O
properties O
of O
nanocrystalline O
mp O
- O
CZO B
thin O
films O
differ O
significantly O
from O
those O
of O
bulk O
CZO B
materials O
reported O
in O
the O
literature O
and O
, O
therefore O
, O
propose O
a O
defect O
chemical O
model O
of O
surface O
regions O
. O

Colocalization O
of O
the O
Ganglioside B
GM1 I
and O
Cholesterol O
Detected O
by O
Secondary O
Ion O
Mass O
Spectrometry O
. O

We O
report O
here O
the O
use O
of O
secondary O
ion O
mass O
spectrometry O
( O
SIMS O
) O
to O
image O
the O
cholesterol O
- O
dependent O
cohesive O
phase O
separation O
of O
the O
ganglioside B
GM1 I
into O
nano O
- O
and O
microscale O
assemblies O
in O
a O
canonical O
lipid O
raft O
composition O
of O
lipids O
. O

This O
assembly O
of O
domains O
was O
interrogated O
in O
a O
model O
membrane O
system O
composed O
of O
palmitoyl B
sphingomyelin I
( O
PSM B
) O
, O
cholesterol O
, O
and O
an O
unsaturated O
lipid O
( O
dioleoylphosphatidyl B
, O
DOPC O
) O
. O

Orthogonal O
isotopic O
labeling O
of O
every O
lipid O
bilayer O
component O
and O
monofluorination O
of O
GM1 B
allowed O
generation O
of O
molecule O
specific O
images O
using O
a O
NanoSIMS O
. O

Images O
of O
this O
system O
provide O
the O
first O
direct O
, O
molecule O
specific O
, O
visual O
evidence O
for O
the O
colocalization O
of O
cholesterol O
and O
GM1 B
in O
supported O
lipid O
bilayers O
and O
further O
indicate O
the O
presence O
of O
three O
compositionally O
distinct O
phases O
: O
( O
1 O
) O
the O
interdomain O
region O
; O
( O
2 O
) O
micrometer O
- O
scale O
domains O
( O
d O
> O
3 O
mu O
m O
) O
; O
( O
3 O
) O
nanometer O
- O
scale O
domains O
( O
d O
= O
100 O
nm O
to O
1 O
mu O
m O
) O
localized O
within O
the O
micrometer O
- O
scale O
domains O
and O
the O
interdomain O
region O
. O

PSM B
- O
rich O
, O
nanometer O
- O
scale O
domains O
prefer O
to O
partition O
within O
the O
more O
ordered O
, O
cholesterol O
- O
rich O
/ O
DOPC O
- O
poor O
/ O
GM1 B
- O
rich O
micrometer O
- O
scale O
phase O
, O
while O
GM1 B
- O
rich O
, O
nanometer O
- O
scale O
domains O
prefer O
to O
partition O
within O
the O
surrounding O
, O
disordered O
, O
cholesterol O
- O
poor O
/ O
PSM B
- O
rich O
/ O
DOPC O
- O
rich O
interdomain O
phase O
. O

Structure O
and O
Absolute O
Configuration O
of O
Methyl B
( I
3R I
) I
- I
Malonyl I
- I
( I
13S I
) I
- I
hydroxycheilanth I
- I
17 I
- I
en I
- I
19 I
- I
oate I
, O
a O
Sesterterpene B
Derivative O
from O
the O
Roots O
of O
Aletris O
farinosa O
. O

We O
report O
the O
isolation O
and O
structure O
elucidation O
of O
a O
new O
cheilanthane B
sesterterpene B
from O
the O
roots O
of O
Aletris O
farinosa O
that O
possesses O
an O
unusual O
malonate B
half I
- I
ester I
functional O
group O
. O

The O
structure O
of O
1 O
was O
determined O
via O
mass O
spectrometry O
and O
1D O
and O
2D O
NMR O
spectroscopy O
, O
while O
its O
absolute O
configuration O
was O
determined O
via O
X O
- O
ray O
crystallographic O
analysis O
performed O
on O
its O
methyl B
ester I
derivative O
2 O
. O

Biological O
activity O
of O
Pd B
( I
II I
) I
complexes O
with O
mono B
- I
and I
disubstituted I
pyridines I
- O
Experimental O
and O
theoretical O
studies O
. O

Due O
to O
the O
similarity O
between O
Pd O
and O
Pt O
, O
the O
complexes O
of O
palladium B
( I
II I
) I
can O
be O
considered O
as O
potential O
anticancer O
agents O
. O

Activity O
of O
six O
PdCl2 B
( I
X2Py I
) I
2 I
complexes O
( O
Py O
= O
pyridine O
, O
and O
X O
= O
CH3 O
or O
Cl O
) O
was O
measured O
by O
MTT O
test O
using O
MCF7 O
, O
CCRF O
- O
SB O
, O
PC3 O
and O
human O
B O
- O
lymphoblastoid O
cell O
lines O
. O

We O
found O
that O
the O
effect O
of O
PdCl2 B
( I
XnPy I
) I
2 I
was O
cell O
- O
specific O
and O
time O
- O
dependent O
. O

Obtained O
results O
were O
discussed O
and O
compared O
with O
the O
activation O
parameters O
calculated O
for O
the O
hydrolysis O
of O
PdCl2 B
( I
XnPy I
) I
2 I
, O
indicating O
a O
correlation O
between O
viability O
of O
MCF7 O
and O
CCRF O
- O
SB O
cells O
and O
rates O
of O
hydrolysis O
of O
the O
Pd B
( I
II I
) I
complexes O
. O

The O
Androgen O
Metabolite O
, O
5 B
alpha I
- I
Androstane I
- I
3 I
beta I
, I
17 I
beta I
- I
Diol I
( O
3 B
beta I
- I
Diol I
) O
, O
Activates O
the O
Oxytocin O
Promoter O
Through O
an O
Estrogen O
Receptor O
- O
beta O
Pathway O
. O

The O
dihydrotestosterone O
metabolite O
, O
5 B
alpha I
- I
androstane I
- I
3 I
beta I
, I
17 I
beta I
- I
diol I
( O
3 B
beta I
- I
diol I
) O
, O
binds O
and O
activates O
estrogen O
receptor O
- O
beta O
( O
ER O
- O
beta O
) O
, O
the O
predominant O
ER O
in O
the O
PVN O
. O

Therefore O
, O
we O
tested O
the O
hypothesis O
that O
3 B
beta I
- I
diol I
regulates O
OT O
expression O
through O
ER O
- O
beta O
activation O
. O

Treatment O
of O
ovariectomized O
rats O
with O
estradiol B
benzoate I
or O
3 B
beta I
- I
diol I
for O
4 O
days O
increased O
OT O
mRNA O
selectively O
in O
the O
midcaudal O
, O
but O
not O
rostral O
PVN O
compared O
with O
vehicle O
- O
treated O
controls O
. O

3 B
beta I
- I
Diol I
treatment O
also O
increased O
OT O
mRNA O
in O
the O
hypothalamic O
N38 O
cell O
line O
in O
vitro O
. O

The O
functional O
interactions O
between O
3 B
beta I
- I
diol I
and O
ER O
- O
beta O
with O
the O
human O
OT O
promoter O
were O
examined O
using O
an O
OT O
promoter O
- O
luciferase O
reporter O
construct O
( O
OT O
- O
luc O
) O
. O

In O
a O
dose O
- O
dependent O
manner O
, O
3 B
beta I
- I
diol I
treatment O
increased O
OT O
- O
luc O
activity O
when O
cells O
were O
cotransfected O
with O
ER O
- O
beta O
, O
but O
not O
ER O
- O
alpha O
. O

The O
3 B
beta I
- I
diol I
- O
induced O
OT O
- O
luc O
activity O
was O
reduced O
by O
deletion O
of O
the O
promoter O
region O
containing O
the O
composite O
hormone O
response O
element O
( O
cHRE O
) O
. O

Point O
mutations O
of O
the O
cHRE O
also O
prevented O
OT O
- O
luc O
activation O
by O
3 B
beta I
- I
diol I
. O

These O
results O
indicate O
that O
3 B
beta I
- I
diol I
induces O
OT O
promoter O
activity O
via O
ER O
- O
beta O
- O
cHRE O
interactions O
. O

Erythrocyte O
volume O
was O
estimated O
from O
forward O
scatter O
, O
phosphatidylserine O
exposure O
at O
the O
erythrocyte O
surface O
from O
annexin O
- O
V O
binding O
, O
hemolysis O
from O
hemoglobin O
release O
, O
and O
[ O
Ca O
( O
2 O
+ O
) O
] O
i O
from O
Fluo3 B
fluorescence O
. O

Ochratoxin O
A O
( O
OTA B
) O
, O
one O
of O
the O
most O
abundant O
mycotoxin O
food O
contaminants O
, O
is O
classified O
as O
" O
possibly O
carcinogenic O
to O
humans O
. O
" O
Our O
previous O
study O
showed O
that O
OTA B
could O
induce O
a O
G2 O
arrest O
in O
immortalized O
human O
gastric O
epithelium O
cells O
( O
GES O
- O
1 O
) O
. O

To O
explore O
the O
putative O
roles O
of O
oxidative O
DNA O
damage O
and O
the O
ataxia O
telangiectasia O
- O
mutated O
( O
ATM O
) O
pathways O
on O
the O
OTA B
- O
induced O
G2 O
arrest O
, O
the O
current O
study O
systematically O
evaluated O
the O
roles O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
production O
, O
DNA O
damage O
, O
and O
ATM O
- O
dependent O
pathway O
activation O
on O
the O
OTA B
- O
induced O
G2 O
phase O
arrest O
in O
GES O
- O
1 O
cells O
. O

The O
results O
showed O
that O
OTA B
exposure O
elevated O
intracellular O
ROS O
production O
, O
which O
directly O
induced O
DNA O
damage O
and O
increased O
the O
levels O
of O
8 O
- O
OHdG O
and O
DNA O
double O
- O
strand O
breaks O
( O
DSBs O
) O
. O

In O
addition O
, O
it O
was O
found O
that O
OTA B
treatment O
induced O
the O
phosphorylation O
of O
the O
ATM O
protein O
, O
as O
well O
as O
its O
downstream O
molecules O
Chk2 O
and O
p53 O
, O
in O
response O
to O
DNA O
DSBs O
. O

Inhibition O
of O
ATM O
by O
the O
pharmacological O
inhibitor O
caffeine O
or O
siRNA O
effectively O
prevented O
the O
activation O
of O
ATM O
- O
dependent O
pathways O
and O
rescued O
the O
G2 O
arrest O
elicited O
by O
OTA B
. O

Finally O
, O
pretreatment O
with O
the O
antioxidant O
N O
- O
acetyl O
- O
L O
- O
cysteine O
( O
NAC O
) O
reduced O
the O
OTA B
- O
induced O
DNA O
DSBs O
, O
ATM O
phosphorylation O
, O
and O
G2 O
arrest O
. O

In O
conclusion O
, O
the O
results O
of O
this O
study O
suggested O
that O
OTA B
- O
induced O
oxidative O
DNA O
damage O
triggered O
the O
ATM O
- O
dependent O
pathways O
, O
which O
ultimately O
elicited O
a O
G2 O
arrest O
in O
GES O
- O
1 O
cells O
. O

Primary O
mitochondrial O
disorders O
are O
clinically O
and O
genetically O
heterogeneous O
, O
caused O
by O
an O
alteration O
( O
s O
) O
in O
either O
mitochondrial O
DNA O
or O
nuclear O
DNA O
, O
and O
affect O
the O
respiratory O
chain O
' O
s O
ability O
to O
undergo O
oxidative O
phosphorylation O
, O
leading O
to O
decreased O
production O
of O
adenosine B
triphosphophate I
and O
subsequent O
energy O
failure O
. O

Methods O
: O
C57BL O
/ O
6 O
mice O
were O
fed O
a O
normal O
diet O
( O
control O
group O
) O
or O
a O
low O
iodine O
diet O
supplemented O
with O
0 O
. O
15 O
% O
propylthiouracil B
( O
PTU O
/ O
LI O
group O
) O
for O
4 O
weeks O
. O

The O
solvent O
quality O
of O
an O
aqueous O
mixture O
of O
two O
good O
solvents O
, O
urea O
and O
guanidinium B
chloride I
( O
GdmCl B
) O
, O
for O
a O
hydrophobic O
polymer O
was O
investigated O
using O
atomistic O
molecular O
dynamics O
simulations O
. O

This O
cononsolvency O
of O
the O
polymer O
in O
the O
urea O
+ O
GdmCl B
mixture O
is O
found O
to O
be O
caused O
by O
the O
preferential O
adsorption O
of O
urea O
on O
the O
polymer O
. O

We O
examined O
this O
hypothesis O
by O
using O
alginate O
and O
poly O
( O
acrylic O
acid O
) O
( O
PAA O
) O
modified O
with O
a O
controlled O
number O
of O
methacrylic B
groups O
as O
model O
inflexible O
and O
flexible O
cross O
- O
linkers O
, O
respectively O
. O

Interestingly O
, O
the O
polyacrylamide O
hydrogel O
cross O
- O
linked O
by O
the O
inflexible O
alginate O
methacrylates O
exhibited O
less O
dependency O
between O
the O
degree O
of O
swelling O
and O
the O
elastic O
modulus O
than O
the O
hydrogel O
cross O
- O
linked O
by O
flexible O
PAA O
methacrylates B
. O

Furthermore O
, O
hydrogels O
cross O
- O
linked O
with O
alginate O
methacrylates B
could O
tune O
the O
projection O
area O
of O
adhered O
cells O
by O
solely O
altering O
elastic O
moduli O
. O

In O
contrast O
, O
gels O
cross O
- O
linked O
with O
PAA O
methacrylates B
failed O
to O
modulate O
the O
cellular O
adhesion O
morphology O
due O
to O
a O
lower O
, O
and O
smaller O
, O
elastic O
modulus O
range O
to O
be O
controlled O
. O

Specifically O
, O
at O
least O
two O
alkaloids O
isolated O
from O
the O
plant O
Mitragyna O
speciosa O
, O
mitragynine O
( O
( B
E I
) I
- I
2 I
- I
[ I
( I
2S I
, I
3S I
) I
- I
3 I
- I
ethyl I
- I
8 I
- I
methoxy I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
, I
6 I
, I
7 I
, I
12 I
, I
12b I
- I
octahydroindolo I
[ I
3 I
, I
2 I
- I
h I
] I
quinolizin I
- I
2 I
- I
yl I
] I
- I
3 I
- I
methoxyprop I
- I
2 I
- I
enoic I
acid I
methyl I
ester I
; O
9 B
- I
methoxy I
coryantheidine I
; O
MG O
) O
and O

7 B
- I
hydroxymitragynine I
( O
7 B
- I
OH I
- I
MG I
) O
, O
and O
several O
synthetic O
analogues O
of O
these O
natural O
products O
display O
centrally O
mediated O
( O
supraspinal O
and O
spinal O
) O
antinociceptive O
( O
analgesic O
) O
activity O
in O
various O
pain O
models O
. O

Intestinal O
and O
hepatic O
first O
- O
pass O
extraction O
of O
the O
11 O
beta O
- O
HSD1 O
inhibitor O
AMG B
221 I
in O
rats O
with O
chronic O
vascular O
catheters O
. O

A O
catheterized O
rat O
model O
was O
used O
to O
define O
the O
intestinal O
and O
hepatic O
components O
of O
oral O
bioavailability O
for O
an O
11 O
beta O
- O
HSD1 O
inhibitor O
, O
AMG B
221 I
. O

Intestinal O
and O
hepatic O
extraction O
ratios O
of O
AMG B
221 I
obtained O
using O
a O
five O
- O
catheter O
rat O
model O
were O
0 O
. O
56 O
and O
0 O
. O
32 O
, O
respectively O
. O

Mass O
balance O
data O
and O
in O
vivo O
metabolite O
characterization O
obtained O
after O
administration O
of O
[ B
( I
14 I
) I
C I
] I
AMG I
221 I
to O
rat O
showed O
that O
AMG B
221 I
was O
completely O
absorbed O
from O
the O
gut O
lumen O
following O
an O
oral O
dose O
, O
primarily O
excreted O
in O
urine O
and O
was O
almost O
completely O
metabolized O
prior O
to O
excretion O
. O

Hepatic O
bioavailability O
( O
FH O
) O
, O
measured O
in O
two O
animals O
at O
various O
time O
points O
after O
oral O
dose O
administration O
was O
somewhat O
variable O
but O
generally O
characterized O
by O
an O
initial O
reduction O
during O
the O
absorption O
phase O
followed O
by O
an O
increase O
during O
the O
elimination O
phase O
, O
consistent O
with O
hepatic O
distribution O
of O
AMG B
221 I
. O

Synthesis O
and O
biological O
activities O
of O
some O
novel O
aminomethyl B
derivatives O
of O
4 B
- I
substituted I
- I
5 I
- I
( I
2 I
- I
thienyl I
) I
- I
2 I
, I
4 I
- I
dihydro I
- I
3H I
- I
1 I
, I
2 I
, I
4 I
- I
triazole I
- I
3 I
- I
thiones I
. O

A O
novel O
series O
of O
compounds O
were O
synthesized O
by O
cyclic O
condensation O
reaction O
of O
substituted O
isothiocyanate O
( O
2a O
- O
c O
) O
with O
2 B
- I
thiophenecarboxylic I
acid I
hydrazide I
( O
1 O
) O
in O
the O
presence O
of O
ethyl B
alcohol I
, O
to O
obtain O
intermediate O
thiosemicarbazides O
( O
3a O
- O
c O
) O
, O
which O
were O
further O
treated O
with O
sodium O
hydroxide O
in O
the O
presence O
of O
ethanol O
to O
obtain O
triazole O
derivatives O
( O
4a O
- O
c O
) O
. O

The O
latter O
were O
refluxed O
with O
substituted O
secondary B
amines I
and O
formaldehyde O
for O
6 O
- O
10 O
h O
to O
afford O
Mannich O
bases O
( O
5a O
- O
k O
) O
. O

The O
design O
, O
modeling O
, O
synthesis O
and O
biological O
activity O
evaluation O
of O
two O
hybrid O
agents O
formed O
by O
7 B
- I
oxyiminomethylcampto I
derivatives O
and O
diaminedichloro B
- I
platinum I
( I
II I
) I
complex O
are O
reported O
. O

Platinum O
- O
containing O
camptothecins B
produced O
platinum O
- O
DNA O
adducts O
and O
topoisomerase O
I O
- O
mediated O
DNA O
damage O
with O
cleavage O
pattern O
and O
persistence O
similar O
to O
SN38 B
, O
the O
active O
principle O
of O
irinotecan O
. O

The O
results O
support O
the O
interpretation O
that O
the O
diaminedichloro B
- I
platinum I
( I
II I
) I
complex O
conjugated O
via O
an O
oxyiminomethyl B
linker O
at O
the O
7 O
- O
position O
of O
the O
camptothecin O
resulted O
in O
a O
new O
class O
of O
effective O
antitumor O
compounds O
. O

Specifically O
, O
positively O
charged O
, O
1 B
, I
2 I
- I
Dioleoyl I
- I
3 I
- I
Trimethylammonium I
- I
Propane I
( O
DOTAP O
) O
- O
cholesterol O
( O
DOTAP O
: O
Chol B
) O
liposome O
- O
formulated O
protocells O
revealed O
stable O
in O
vitro O
cargo O
release O
kinetics O
and O
cellular O
interleukin O
- O
10 O
( O
IL O
- O
10 O
) O
transgene O
transfection O
. O

We O
report O
here O
that O
i O
. O
t O
. O
delivery O
of O
protocells O
, O
with O
modified O
chemistry O
supporting O
a O
surface O
coating O
of O
DOTAP O
: O
Chol B
liposomes O
and O
containing O
the O
IL O
- O
10 O
transgene O
, O
results O
in O
functional O
suppression O
of O
pain O
- O
related O
behavior O
in O
rats O
for O
extended O
periods O
. O

Chemical O
characterization O
of O
domestic O
oral O
tobacco O
products O
: O
Total O
nicotine O
, O
pH O
, O
unprotonated O
nicotine O
and O
tobacco O
- O
specific O
N B
- I
nitrosamines I
. O

In O
this O
study O
, O
we O
measured O
pH O
, O
moisture O
, O
nicotine O
( O
total O
and O
unprotonated O
) O
, O
and O
tobacco O
- O
specific O
N B
- I
nitrosamines I
( O
TSNAs O
) O
for O
other O
established O
( O
twist O
, O
loose O
leaf O
, O
plug O
, O
and O
dry O
snuff O
without O
pouch O
) O
and O
emerging O
oral O
tobacco O
products O
( O
dry O
snuff O
pouch O
, O
US O
- O
made O
snus O
, O
and O
dissolvable O
tobacco O
) O
. O

Design O
, O
synthesis O
and O
structure O
- O
activity O
relationships O
of O
3 B
, I
5 I
- I
diaryl I
- I
1H I
- I
pyrazoles I
as O
inhibitors O
of O
arylamine B
N O
- O
acetyltransferase O
. O

The O
synthesis O
and O
inhibitory O
potencies O
of O
a O
novel O
series O
of O
3 B
, I
5 I
- I
diaryl I
- I
1H I
- I
pyrazoles I
as O
specific O
inhibitors O
of O
prokaryotic O
arylamine B
N O
- O
acetyltransferase O
enzymes O
is O
described O
. O

The O
series O
is O
based O
on O
hit O
compound O
1 B
3 I
, I
5 I
- I
diaryl I
- I
1H I
- I
pyrazole I
identified O
from O
a O
high O
- O
throughout O
screen O
that O
has O
been O
carried O
out O
previously O
and O
found O
to O
inhibit O
the O
growth O
of O
Mycobacterium O
tuberculosis O
. O

Embryonic O
fibroblasts O
derived O
from O
the O
ser994 B
mutant O
mice O
were O
not O
sensitive O
to O
killing O
by O
a O
range O
of O
DNA O
damaging O
agents O
, O
but O
they O
were O
sensitive O
to O
the O
induction O
of O
sister O
chromatid O
exchanges O
induced O
by O
ultraviolet O
light O
or O
mitomycin O
C O
. O

Experimental O
evidence O
for O
surface O
freezing O
in O
supercooled O
n B
- I
alkane I
nanodroplets O
. O

Our O
recent O
experimental O
results O
suggest O
that O
highly O
supercooled O
nanodroplets O
of O
n B
- I
octane I
and O
n B
- I
nonane I
also O
surface O
freeze O
, O
and O
subsequently O
bulk O
crystallization O
occurs O
. O

Molecular O
dynamics O
simulations O
at O
the O
united O
atom O
level O
were O
used O
to O
follow O
the O
freezing O
of O
a O
supercooled O
n B
- I
octane I
drop O
and O
show O
that O
an O
ordered O
monolayer O
develops O
on O
the O
surface O
of O
the O
droplet O
almost O
immediately O
, O
and O
the O
rest O
of O
the O
droplet O
then O
freezes O
in O
a O
layer O
- O
by O
- O
layer O
manner O
. O

Au B
- I
Au I
homodimer O
and O
Au B
- I
Ag I
heterodimer O
arrays O
produced O
using O
electron O
- O
beam O
lithography O
were O
investigated O
using O
confocal O
nonlinear O
optical O
imaging O
and O
spectroscopy O
. O

Compared O
to O
the O
Au B
- I
Au I
homodimers O
, O
the O
Au B
- I
Ag I
dimers O
showed O
slightly O
broadened O
two O
- O
photon O
photoluminescence O
near O
the O
X O
symmetry O
point O
at O
the O
first O
Brillouin O
zone O
of O
Au O
, O
whilst O
that O
from O
the O
L O
symmetry O
point O
stayed O
the O
same O
. O

Additionally O
, O
weakly O
coupled O
Au B
- I
Ag I
heterodimers O
generated O
strong O
second O
harmonic O
signals O
which O
were O
invisible O
in O
the O
Au B
- I
Au I
homodimers O
. O

Pregnane O
X O
Receptor O
Mediates O
Dyslipidemia O
Induced O
by O
the O
HIV O
Protease O
Inhibitor O
Amprenavir B
in O
Mice O
. O

In O
the O
present O
study O
, O
we O
identified O
amprenavir B
, O
a O
widely O
used O
HIV O
PI O
, O
as O
a O
potent O
PXR O
- O
selective O
agonist O
. O

Computational O
docking O
studies O
combined O
with O
site O
- O
direct O
mutagenesis O
identified O
several O
key O
residues O
within O
the O
ligand O
binding O
pocket O
of O
PXR O
that O
constitute O
points O
of O
interaction O
with O
amprenavir B
. O

Amprenavir B
efficiently O
activated O
PXR O
and O
induced O
PXR O
target O
gene O
expression O
in O
vitro O
and O
in O
vivo O
. O

Short O
- O
term O
exposure O
to O
amprenavir B
significantly O
increased O
plasma O
total O
cholesterol O
and O
atherogenic O
low O
- O
density O
lipoprotein O
cholesterol O
levels O
in O
wild O
- O
type O
mice O
, O
but O
not O
in O
PXR O
- O
deficient O
mice O
. O

Amprenavir B
- O
mediated O
PXR O
activation O
stimulated O
the O
expression O
of O
several O
key O
intestinal O
genes O
involved O
in O
lipid O
homeostasis O
. O

Potent O
fibrinolysis O
inhibitor O
discovered O
by O
shape O
and O
electrostatic O
complementarity O
to O
the O
drug O
tranexamic B
Acid I
. O

One O
exception O
is O
tranexamic B
acid I
( O
TXA B
) O
, O
which O
, O
as O
a O
lysine O
mimetic O
, O
inhibits O
binding O
of O
plasminogen O
to O
fibrin O
. O

However O
, O
the O
daily O
dose O
of O
TXA B
is O
high O
due O
to O
its O
modest O
potency O
and O
pharmacokinetic O
properties O
. O

In O
this O
study O
, O
we O
report O
a O
computational O
approach O
, O
where O
the O
focus O
was O
on O
finding O
electrostatic O
potential O
similarities O
to O
TXA B
. O

Coupling O
this O
computational O
technique O
with O
a O
high O
- O
quality O
low O
- O
throughput O
screen O
identified O
5 B
- I
( I
4 I
- I
piperidyl I
) I
- I
3 I
- I
isoxazolol I
( O
4 B
- I
PIOL I
) O
as O
a O
potent O
plasminogen O
binding O
inhibitor O
with O
the O
potential O
for O
the O
treatment O
of O
various O
bleeding O
disorders O
. O

Remarkably O
, O
4 B
- I
PIOL I
was O
found O
to O
be O
more O
than O
four O
times O
as O
potent O
as O
the O
drug O
TXA B
. O

The O
integration O
of O
a O
tripeptide O
derivative O
, O
which O
is O
a O
versatile O
self O
- O
assembly O
motif O
, O
with O
a O
ruthenium B
( I
II I
) I
tris I
( I
bipyridine I
) I
complex O
affords O
the O
first O
supramolecular O
metallo O
- O
hydrogelator O
that O
not O
only O
self O
assembles O
in O
water O
to O
form O
a O
hydrogel O
but O
also O
exhibits O
gel O
- O
sol O
transition O
upon O
oxidation O
of O
the O
metal O
center O
. O

Polo O
- O
like O
kinase O
- O
2 O
( O
Plk O
- O
2 O
) O
is O
a O
potential O
therapeutic O
target O
for O
Parkinson O
' O
s O
disease O
and O
this O
Letter O
describes O
the O
SAR O
of O
a O
series O
of O
dihydropteridinone B
based O
Plk O
- O
2 O
inhibitors O
. O

Tacrine O
( O
THA B
) O
was O
the O
first O
drug O
licensed O
for O
the O
treatment O
of O
Alzheimer O
' O
s O
disease O
. O

GLPG0492 B
, O
a O
novel O
selective O
androgen O
receptor O
modulator O
, O
improves O
muscle O
performance O
in O
the O
exercised O
- O
mdx O
mouse O
model O
of O
muscular O
dystrophy O
. O

We O
focused O
on O
GLPG0492 B
, O
a O
new O
non O
- O
steroidal O
selective O
androgen O
receptor O
modulator O
that O
is O
currently O
under O
development O
for O
musculo O
- O
skeletal O
diseases O
such O
as O
sarcopenia O
and O
cachexia O
. O

GLPG0492 B
was O
tested O
in O
the O
exercised O
mdx O
mouse O
model O
of O
DMD O
in O
a O
4 O
- O
week O
trial O
at O
a O
single O
high O
dose O
( O
30mg O
/ O
kg O
, O
6 O
day O
/ O
week O
s O
. O
c O
. O
) O
, O
and O
the O
results O
were O
compared O
with O
those O
from O
the O
administration O
of O
alpha B
- I
methylprednisolone I
( O
PDN B
; O
1mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
nandrolone O
( O
NAND B
, O
5mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
. O

Similar O
to O
PDN B
and O
NAND B
, O
GLPG0492 B
significantly O
increased O
mouse O
strength O
. O

In O
acute O
exhaustion O
tests O
, O
a O
surrogate O
of O
the O
6 O
- O
min O
walking O
test O
used O
in O
DMD O
patients O
, O
GLPG0492 B
preserved O
running O
performance O
, O
whereas O
vehicle O
- O
or O
comparator O
- O
treated O
animals O
showed O
a O
significant O
increase O
in O
fatigue O
( O
30 O
- O
50 O
% O
) O
. O

In O
parallel O
, O
a O
decrease O
in O
the O
non O
- O
muscle O
area O
and O
markers O
of O
fibrosis O
was O
observed O
in O
GLPG0492 B
- O
and O
NAND B
- O
treated O
mice O
. O

These O
results O
support O
the O
interest O
of O
further O
studies O
of O
GLPG0492 B
as O
a O
potential O
treatment O
for O
DMD O
. O

Cytoprotective O
dibenzoylmethane B
derivatives O
protect O
cells O
from O
oxidative O
stress O
- O
induced O
necrotic O
cell O
death O
. O

From O
the O
cytoprotective O
compounds O
eleven O
proved O
to O
possess O
antioxidant O
activity O
( O
ABTS O
radical O
scavenger O
effect O
) O
and O
two O
were O
found O
to O
inhibit O
poly B
( I
ADP I
- I
ribosyl I
) I
ation O
( O
PARylation O
) O
, O
a O
cytotoxic O
pathway O
operating O
in O
severely O
injured O
cells O
. O

Four O
cytoprotective O
dibenzoylmethane B
( O
DBM B
) O
derivatives O
were O
investigated O
in O
more O
detail O
as O
they O
did O
not O
scavenge O
hydrogen O
peroxide O
nor O
did O
they O
inhibit O
PARylation O
. O

The O
cytoprotective O
DBMs B
suppressed O
the O
activation O
of O
Erk1 O
/ O
2 O
but O
not O
that O
of O
p38 O
. O

In O
conclusion O
we O
identified O
DBM B
analogs O
as O
a O
novel O
class O
of O
cytoprotective O
compounds O
inhibiting O
ERK1 O
/ O
2 O
kinase O
and O
protecting O
from O
necrotic O
cell O
death O
by O
a O
mechanism O
independent O
of O
poly O
( O
ADP O
- O
ribose O
) O
polymerase O
inhibition O
. O

Avermectin O
( O
AVM B
) O
is O
a O
macrocyclic O
lactone O
agent O
widely O
used O
as O
a O
nematicide O
, O
acaricide O
and O
insecticide O
in O
veterinary O
medicine O
and O
plant O
protection O
. O

To O
understand O
the O
development O
of O
AVM B
resistance O
in O
invertebrates O
, O
we O
investigated O
the O
mechanisms O
by O
which O
AVM B
affected O
P O
- O
gp O
expression O
in O
Drosophila O
S2 O
cells O
. O

We O
found O
that O
AVM B
induced O
upregulation O
of O
P O
- O
gp O
protein O
expression O
, O
increased O
P O
- O
gp O
ATPase O
activity O
and O
enhanced O
cellular O
efflux O
of O
the O
P O
- O
gp O
substrate O
rhodamine B
123 I
from O
cells O
. O

Furthermore O
, O
we O
observed O
that O
AVM B
- O
induced O
expression O
of O
P O
- O
gp O
was O
due O
to O
elevation O
of O
intracellular O
calcium O
concentration O
( O
[ O
Ca O
( O
2 O
+ O
) O
] O
i O
) O
. O

These O
results O
are O
supported O
by O
our O
observations O
that O
verapamil O
, O
a O
Ca O
( O
2 O
+ O
) O
channel O
blocker O
, O
and O
niflumic B
acid I
, O
a O
chloride O
channel O
antagonist O
, O
significantly O
attenuated O
AVM B
- O
induced O
[ O
Ca O
( O
2 O
+ O
) O
] O
i O
elevation O
, O
thereby O
reducing O
P O
- O
gp O
expression O
. O

Inhibition O
of O
P O
- O
gp O
with O
anti O
- O
P O
- O
gp O
antibody O
or O
cyclosporine O
A O
( O
a O
P O
- O
gp O
inhibitor O
) O
reduced O
the O
AVM B
- O
induced O
elevation O
of O
[ O
Ca O
( O
2 O
+ O
) O
] O
i O
, O
implying O
that O
P O
- O
gp O
and O
[ O
Ca O
( O
2 O
+ O
) O
] O
i O
regulate O
each O
other O
. O

Finally O
, O
we O
found O
that O
trifluoperazine O
, O
a O
calmodulin O
inhibitor O
, O
and O
pyrrolidine B
dithiocarbamic I
acid I
, O
an O
NF O
- O
kappa O
B O
inhibitor O
, O
attenuated O
the O
AVM B
- O
induced O
expression O
of O
P O
- O
gp O
, O
suggesting O
that O
AVM B
induces O
P O
- O
gp O
protein O
expression O
via O
the O
calmodulin O
/ O
Relish O
( O
NF O
- O
kappa O
B O
) O
signaling O
pathway O
. O

Efficient O
synthesis O
of O
new O
( B
R I
) I
- I
2 I
- I
amino I
- I
1 I
- I
butanol I
derived O
ureas B
, O
thioureas B
and O
acylthioureas B
and O
in O
vitro O
evaluation O
of O
their O
antimycobacterial O
activity O
. O

The O
synthesis O
of O
22 O
structurally O
diverse O
urea O
, O
thiourea O
and O
acylthiourea B
derivatives O
containing O
the O
( B
R I
) I
- I
2 I
- I
amino I
- I
1 I
- I
butanol I
motif O
has O
been O
performed O
. O

The O
evaluation O
of O
their O
in O
vitro O
activity O
against O
Mycobacterium O
tuberculosis O
( O
H37Rv O
and O
strain O
43 O
) O
showed O
promising O
results O
in O
the O
case O
of O
the O
acylthiourea B
derivatives O
( O
MIC O
range O
0 O
. O
36 O
- O
7 O
. O
46 O
mu O
M O
for O
H37Rv O
strain O
) O
. O

The O
objective O
of O
this O
study O
was O
to O
prepare O
and O
evaluate O
in O
situ O
forming O
gel O
systems O
designed O
by O
combination O
of O
two O
poloxamers B
( I
P407 I
and I
P188 I
) I
and O
hydroxypropylmethylc O
( O
HPMC O
) O
for O
prolonged O
release O
of O
heparin O
. O

A O
novel O
multifunctional O
Pt O
nanoparticle O
@ O
PPy B
nanofiber O
intercalated O
structure O
( O
Pt O
NP O
@ O
PPy B
NF O
) O
has O
been O
synthesized O
facilely O
in O
one O
- O
pot O
. O

Space O
- O
confined O
distribution O
of O
the O
Pt O
NPs O
was O
achieved O
within O
the O
large O
dimension O
PPy B
nanofiber O
network O
, O
which O
could O
enhance O
the O
interfacial O
electron O
transfer O
process O
as O
well O
as O
diminish O
the O
catalyst O
deformation O
. O

Enhanced O
electrocatalytic O
properties O
were O
shown O
by O
the O
Pt O
NP O
@ O
PPy B
NF O
intercalated O
structure O
, O
with O
sufficiently O
high O
enzyme O
- O
less O
glucose O
biosensitivity O
and O
a O
long O
linear O
range O
from O
1 O
- O
30 O
mM O
( O
R O
= O
0 O
. O
9995 O
) O
. O

High O
electrochemical O
cycling O
stability O
, O
chloride O
( O
Cl O
( O
- O
) O
) O
tolerance O
and O
good O
selectivity O
are O
also O
obtained O
for O
the O
Pt O
NP O
@ O
PPy B
NF O
structure O
, O
as O
the O
electrode O
showed O
no O
obvious O
response O
to O
the O
common O
interfering O
agents O
, O
such O
as O
ascorbic O
acid O
( O
AA O
) O
, O
uric O
acid O
( O
UA O
) O
, O
and O
4 B
- I
acetamidophenol I
( O
AP O
) O
. O

Furthermore O
, O
the O
Pt O
NP O
@ O
PPy B
NF O
showed O
excellent O
catalytic O
activity O
for O
the O
methanol O
oxidation O
reaction O
( O
MOR O
) O
and O
oxygen O
reduction O
reaction O
( O
ORR O
) O
, O
which O
displayed O
sufficient O
CO O
tolerance O
, O
and O
higher O
activity O
compared O
to O
the O
commercial O
Pt O
/ O
C O
catalyst O
. O

This O
intrinsically O
multifunctional O
Pt O
NP O
@ O
PPy B
NF O
with O
well O
- O
controlled O
Pt O
facets O
thus O
could O
serve O
as O
an O
advanced O
electrocatalyst O
for O
biosensing O
and O
fuel O
cell O
applications O
, O
surpassing O
the O
performance O
of O
many O
existing O
materials O
. O

FFAs O
enhanced O
the O
activation O
of O
the O
MAPKs O
in O
the O
presence O
of O
GnRH B
although O
the O
cotreatment O
did O
not O
alter O
Lhb O
induction O
, O
but O
did O
eliminate O
the O
GnRH B
induction O
of O
Fshb O
. O

Polyurethane O
elastomers O
coating O
were O
synthesised O
by O
using O
typical O
diisocyanates B
, O
polyether O
and O
polyester B
polyols I
and O
HO B
- O
tertiary O
amines O
or O
diols O
as O
a O
chain O
extenders O
. O

Obtained O
results O
were O
confronted O
with O
the O
analogous O
parameter O
values O
( O
kappa O
theor O
) O
calculated O
on O
the O
basis O
of O
process O
stoichiometry O
, O
considering O
the O
stage O
of O
the O
production O
of O
isocyanate B
prepolymers O
and O
reaction O
of O
their O
extension O
for O
polyurethanes O
. O

It O
has O
been O
found O
that O
use O
of O
2 B
, I
2 I
, I
3 I
, I
3 I
- I
tetrafluoro I
- I
1 I
, I
4 I
- I
butanediol I
as O
a O
fluorinated O
extender O
of O
prepolymer O
chains O
is O
essential O
to O
obtain O
coatings O
with O
increased O
hydrophobicity O
, O
applied O
among O
others O
as O
biomaterials O
- O
next O
to O
diphenylmethane B
diisocyanate I
and O
polyoxyethylene B
glycol I
. O

Biocomposites O
of O
pHEMA O
with O
HA O
/ O
beta B
- I
TCP I
( O
60 O
/ O
40 O
) O
for O
bone O
tissue O
engineering O
: O
Swelling O
, O
hydrolytic O
degradation O
, O
and O
in O
vitro O
behavior O
. O

We O
created O
hydrolytically O
degradable O
hydrogel O
/ O
bioceramic O
biocomposites O
, O
comprising O
poly B
( I
2 I
- I
hydroxyethyl I
methacrylate I
) I
( O
pHEMA O
) O
hydrogels O
and O
50 O
wt O
% O
biphasic O
hydroxyapatite O
/ O
beta B
- I
tricalcium I
phosphate I
( O
60 O
/ O
40 O
) O
through O
in O
situ O
polymerization O
. O

The O
hydrolytic O
degradation O
starts O
with O
hydrolysis O
of O
the O
cross O
- O
linker O
, O
N B
, I
O I
- I
dimethacryloyl I
hydroxylamine I
, O
which O
was O
synthesized O
in O
house O
. O

To O
vary O
degradability O
, O
a O
co O
- O
monomer O
, O
acrylic O
acid O
( O
AA O
) O
or O
2 B
- I
hydroxypropyl I
methacrylamide I
( O
HPMA O
) O
, O
was O
introduced O
, O
coupled O
with O
altering O
the O
concentration O
of O
the O
cross O
- O
linker O
and O
of O
the O
bioceramic O
. O

We O
conducted O
a O
literature O
search O
to O
identify O
studies O
of O
patients O
with O
ESRD O
on O
dialysis O
that O
evaluated O
the O
role O
of O
niacin B
and O
related O
compounds O
in O
decreasing O
serum O
phosphorus O
levels O
. O

We O
searched O
PubMed O
using O
the O
search O
terms O
niacin B
, O
nicotinic O
acid O
, O
niacinamide B
, O
nicotinamide O
and O
hyperphosphatemia O
. O

Multiple O
Phytoestrogens O
Inhibit O
Cell O
Growth O
and O
Confer O
Cytoprotection O
By O
Inducing O
Manganese B
Superoxide I
Dismutase O
Expression O
. O

Here O
, O
we O
show O
that O
one O
mechanism O
by O
which O
a O
number O
of O
phytoestrogens O
achieve O
their O
growth O
inhibitory O
and O
cytoprotective O
effects O
is O
via O
induction O
of O
the O
mitochondrial O
manganese B
superoxide I
dismutase O
( O
MnSOD O
) O
. O

Eight O
phytoestrogens O
, O
including O
resveratrol O
, O
coumestrol B
, O
kaempferol O
, O
genistein O
, O
daidzein O
, O
apigenin O
, O
isoliquirtigenin B
and O
glycitin B
, O
were O
tested O
for O
their O
ability O
to O
induce O
MnSOD O
expression O
in O
mouse O
C2C12 O
and O
primary O
myoblasts O
. O

Five O
of O
these O
, O
resveratrol O
, O
coumestrol B
, O
kaempferol O
, O
genistein O
and O
daidzein O
, O
significantly O
increased O
MnSOD O
expression O
, O
slowed O
proliferative O
growth O
and O
enhanced O
stress O
resistance O
( O
hydrogen O
peroxide O
LD50 O
) O
. O

When O
siRNA O
was O
used O
to O
prevent O
the O
MnSOD O
induction O
by O
genistein O
, O
coumestrol B
or O
daidzein O
, O
none O
of O
these O
compounds O
exerted O
any O
effect O
on O
proliferative O
growth O
, O
and O
only O
the O
effect O
of O
coumestrol B
on O
stress O
resistance O
persisted O
. O

The O
estrogen O
antagonist O
ICI182780 B
prevented O
the O
increased O
MnSOD O
expression O
and O
also O
the O
changes O
in O
cell O
growth O
and O
stress O
resistance O
, O
indicating O
that O
these O
effects O
are O
mediated O
by O
estrogen O
receptors O
( O
ER O
) O
. O

The O
absence O
of O
effects O
of O
resveratrol O
or O
coumestrol B
, O
but O
not O
genistein O
, O
in O
ER O
beta O
- O
null O
cells O
further O
indicated O
that O
this O
ER O
in O
particular O
is O
important O
in O
mediating O
these O
effects O
. O

The O
pre O
- O
clinical O
absorption O
, O
distribution O
, O
metabolism O
and O
excretion O
properties O
of O
IPI B
- I
926 I
, O
an O
orally O
bioavailable O
antagonist O
of O
the O
hedgehog O
signal O
transduction O
pathway O
. O

IPI B
- I
926 I
is O
a O
novel O
semisynthetic O
cyclopamine B
derivative O
that O
is O
a O
potent O
and O
selective O
Smoothened O
inhibitor O
that O
blocks O
the O
hedgehog O
signal O
transduction O
pathway O
. O

The O
in O
vivo O
clearance O
of O
IPI B
- I
926 I
is O
low O
in O
mouse O
and O
dog O
and O
moderate O
in O
monkey O
. O

IPI B
- I
926 I
is O
highly O
bound O
to O
plasma O
proteins O
and O
has O
minimal O
interaction O
with O
human O
alpha O
- O
1 O
- O
acid O
glycoprotein O
. O

IPI B
- I
926 I
is O
not O
a O
potent O
reversible O
inhibitor O
of O
CYP1A2 O
, O
2C8 O
, O
2C9 O
or O
3A4 O
( O
testosterone O
) O
. O

IPI B
- I
926 I
is O
a O
moderate O
inhibitor O
of O
CYP2C19 O
, O
2D6 O
and O
3A4 O
( O
midazolam O
) O
with O
KI O
values O
of O
19 O
, O
16 O
and O
4 O
. O
5 O
micro O
M O
, O
respectively O
. O

IPI B
- I
926 I
is O
both O
a O
substrate O
and O
inhibitor O
( O
IC50 O
= O
1 O
. O
9 O
micro O
M O
) O
of O
P O
- O
glycoprotein O
. O

In O
summary O
, O
IPI B
- I
926 I
has O
desirable O
pre O
- O
clinical O
absorption O
, O
distribution O
, O
metabolism O
and O
excretion O
properties O
. O

Thiolactone B
Sulfoxides I
as O
New O
Reactive O
Metabolites O
Acting O
as O
Bis O
- O
Electrophiles O
: O
Implication O
in O
Clopidogrel O
and O
Prasugrel B
Bioactivation O
. O

The O
antithrombotics O
of O
the O
tetrahydrothienopyri B
series O
, O
clopidogrel O
and O
prasugrel B
, O
are O
prodrugs O
that O
must O
be O
metabolized O
in O
two O
steps O
to O
become O
pharmacologically O
active O
. O

The O
first O
step O
is O
the O
formation O
of O
a O
thiolactone B
metabolite O
. O

The O
second O
step O
is O
a O
cytochrome O
P450 O
( O
P450 O
) O
- O
dependent O
oxidation O
of O
this O
thiolactone B
resulting O
in O
the O
formation O
of O
a O
sulfenic B
acid I
that O
is O
eventually O
reduced O
into O
the O
corresponding O
active O
thiol O
. O

It O
has O
been O
postulated O
that O
the O
sulfenic B
acid I
metabolite O
resulted O
from O
a O
nucleophilic O
attack O
of O
water O
on O
a O
highly O
reactive O
thiolactone B
sulfoxide I
derived O
from O
P450 O
- O
dependent O
oxidation O
of O
the O
thiolactone B
primary O
metabolite O
. O

The O
data O
described O
in O
the O
present O
article O
are O
in O
complete O
agreement O
with O
this O
proposition O
as O
they O
show O
that O
it O
was O
possible O
to O
trap O
these O
thiolactone B
sulfoxides I
by O
a O
series O
of O
nucleophiles O
such O
as O
amines O
, O
thiols O
, O
or O
cyclopentane B
- I
1 I
, I
3 I
- I
dione I
( O
CPDH B
) O
, O
an O
equivalent O
of O
dimedone B
that O
is O
used O
as O
a O
sulfenic B
acid I
trapping O
agent O
. O

One O
of O
them O
that O
resulted O
from O
the O
oxidation O
of O
2 B
- I
oxo I
- I
prasugrel I
by O
human O
liver O
microsomes O
in O
the O
presence O
of O
ethanolamine O
and O
CPDH B
was O
isolated O
and O
completely O
characterized O
by O
( O
1 O
) O
H O
and O
( O
13 O
) O
C O
NMR O
spectroscopy O
in O
addition O
to O
MS O
and O
MS O
( O
2 O
) O
spectrometry O
. O

All O
metabolites O
derived O
from O
an O
attack O
of O
H2O O
or O
an O
amine O
at O
the O
CO O
carbon O
of O
the O
intermediate O
thiolactone B
sulfoxide I
existed O
as O
a O
mixture O
of O
two O
diastereomers O
having O
a O
cis O
configuration O
of O
the O
double O
bond O
, O
whereas O
those O
formed O
in O
the O
presence O
of O
thiols O
appeared O
as O
a O
mixture O
of O
four O
diastereomers O
with O
a O
cis O
or O
trans O
configuration O
of O
the O
double O
bond O
. O

The O
results O
described O
in O
this O
article O
showed O
that O
thiolactone B
sulfoxides I
are O
formed O
as O
reactive O
metabolites O
during O
the O
metabolism O
of O
clopidogrel O
and O
prasugrel B
and O
are O
able O
to O
react O
as O
bis O
- O
electrophiles O
with O
a O
variety O
of O
nucleophiles O
. O

The O
influence O
of O
lattice O
strain O
on O
the O
oxygen O
exchange O
kinetics O
and O
diffusion O
in O
oxides O
was O
investigated O
on O
( O
100 O
) O
epitaxial O
La1 B
- I
xSrxCoO3 I
- I
delta I
( O
LSC B
) O
thin O
films O
grown O
by O
pulsed O
laser O
deposition O
. O

Planar O
tensile O
and O
compressively O
strained O
LSC B
films O
were O
obtained O
on O
single O
- O
crystalline O
SrTiO3 O
and O
LaAlO3 O
. O

( B
18 I
) I
O I
isotope O
exchange O
depth O
profiling O
with O
ToF O
- O
SIMS O
was O
employed O
to O
simultaneously O
measure O
the O
tracer O
surface O
exchange O
coefficient O
k O
* O
and O
the O
tracer O
diffusion O
coefficient O
D O
* O
in O
the O
temperature O
range O
280 O
- O
475 O
degrees O
C O
. O

The O
same O
strain O
effect O
- O
tensile O
strain O
leading O
to O
higher O
k O
* O
and O
D O
* O
- O
was O
found O
for O
different O
LSC B
compositions O
( O
x O
= O
0 O
. O
2 O
and O
x O
= O
0 O
. O
4 O
) O
and O
for O
surface O
- O
etched O
films O
. O

This O
is O
demonstrated O
in O
calculations O
for O
2 B
- I
pyridone I
and O
chlorophyll O
dimers O
. O

Molecular O
design O
, O
synthesis O
and O
biological O
evaluation O
of O
cyclic B
imides I
bearing O
benzenesulfonamide O
fragment O
as O
potential O
COX O
- O
2 O
inhibitors O
. O

A O
group O
of O
cyclic B
imides I
( O
1 O
- O
10 O
) O
was O
designed O
for O
evaluation O
as O
a O
selective O
COX O
- O
2 O
inhibitors O
and O
investigated O
in O
vivo O
for O
their O
anti O
- O
inflammatory O
activity O
. O

The O
study O
showed O
that O
the O
homosulfonamide B
fragment O
of O
8a O
inserted O
deep O
inside O
the O
2 O
degrees O
- O
pocket O
of O
the O
COX O
- O
2 O
active O
site O
, O
where O
the O
SO2NH2 B
group O
underwent O
H O
- O
bonding O
interaction O
with O
Gln O
( O
192 O
) O
( O
2 O
. O
95 O
A O
) O
, O
Phe O
( O
518 O
) O
( O
2 O
. O
82 O
A O
) O
and O
Arg B
( O
513 O
) O
( O
2 O
. O
63 O
and O
2 O
. O
73 O
A O
) O
. O

Docking O
study O
of O
the O
synthesized O
compound O
8a O
into O
the O
active O
site O
of O
COX O
- O
2 O
revealed O
a O
similar O
binding O
mode O
to O
SC B
- I
558 I
, O
a O
selective O
COX O
- O
2 O
inhibitor O
. O

Protection O
of O
glycyrrhizic B
acid I
against O
AGEs O
- O
induced O
endothelial O
dysfunction O
through O
inhibiting O
RAGE O
/ O
NF O
- O
kappa O
B O
pathway O
activation O
in O
human O
umbilical O
vein O
endothelial O
cells O
. O

Glycyrrhizic B
acid I
( O
GA O
, O
also O
known O
as O
Glycyrrhizin O
) O
, O
a O
triterpenoid B
saponin I
glycoside I
, O
is O
considered O
to O
be O
a O
bioactive O
component O
in O
Licorice O
and O
is O
beneficial O
to O
diabetic O
vascular O
complications O
. O

The O
superoxide O
dismutase O
( O
SOD O
) O
activity O
and O
malondialdehyde O
( O
MDA O
) O
level O
in O
cell O
supernatant O
were O
detected O
by O
kits O
while O
the O
intracellular O
reactive O
oxygen O
species O
( O
ROS O
) O
generation O
was O
determined O
by O
2 B
, I
7 I
- I
dichlorodihydrofluor I
diacetate I
( O
DCFH O
- O
DA O
) O
kit O
. O

The O
tested O
liposomes O
caused O
no O
or O
only O
mild O
( O
30 O
% O
) O
activation O
of O
C O
except O
for O
one O
formulation O
wherein O
the O
PEG2000 B
was O
anchored O
to O
cholesterol O
( O
CHOL B
- I
PEG2000 I
) O
. O

While O
the O
relative O
safety O
of O
weak O
C O
activator O
liposomes O
remains O
to O
be O
confirmed O
in O
vivo O
, O
the O
unique O
, O
non O
- O
charge O
and O
non O
- O
antibody O
- O
mediated O
direct O
conversion O
of O
C3 O
by O
CHOL B
- I
PEG2000 I
liposomes O
( O
although O
argues O
against O
the O
clinical O
development O
of O
these O
vesicles O
) O
opens O
new O
opportunities O
to O
understand O
liposomal O
C O
activation O
at O
the O
molecular O
level O
. O

Technological O
and O
biopharmaceutical O
optimization O
of O
nystatin B
release O
from O
a O
multiparticulate O
based O
bioadhesive O
drug O
delivery O
system O
. O

The O
polyene O
antibiotic O
nystatin B
may O
be O
an O
optimal O
choice O
for O
active O
agent O
, O
incorporated O
in O
a O
bioadhesive O
multiparticulate O
system O
. O

Using O
an O
experimental O
design O
, O
the O
micropellets O
were O
prepared O
with O
5 O
% O
nystatin B
content O
, O
taking O
the O
factors O
average O
pellet O
size O
( O
~ O
200 O
to O
~ O
800 O
mu O
m O
) O
and O
the O
amount O
of O
applied O
carbomer O
and O
hydroxyethylcellulos O
( O
0 O
- O
5 O
% O
) O
into O
consideration O
. O

Everolimus B
in O
Combination O
with O
Exemestane B
: O
A O
Review O
of O
its O
Use O
in O
the O
Treatment O
of O
Patients O
with O
Postmenopausal O
Hormone O
Receptor O
- O
Positive O
, O
HER2 O
- O
Negative O
Advanced O
Breast O
Cancer O
. O

Oral O
everolimus B
( O
Afinitor B
( O
( O
R O
) O
) O
) O
in O
combination O
with O
exemestane B
is O
indicated O
for O
the O
treatment O
of O
hormone O
receptor O
- O
positive O
, O
human O
epidermal O
growth O
factor O
receptor O
( O
HER O
) O
2 O
- O
negative O
advanced O
breast O
cancer O
in O
postmenopausal O
women O
after O
failure O
of O
treatment O
with O
letrozole B
or O
anastrozole O
( O
in O
the O
USA O
) O
or O
after O
recurrence O
of O
progression O
following O
a O
nonsteroidal O
aromatase O
inhibitor O
( O
AI O
) O
in O
women O
without O
symptomatic O
visceral O
disease O
( O
in O
the O
EU O
) O
. O

Everolimus B
, O
a O
selective O
inhibitor O
of O
mammalian O
target O
of O
rapamycin O
( O
mTOR O
) O
, O
inhibits O
the O
downstream O
signalling O
events O
of O
the O
mTOR O
pathway O
. O

This O
review O
summarizes O
the O
pharmacology O
of O
everolimus B
and O
reviews O
its O
efficacy O
and O
tolerability O
when O
administered O
in O
combination O
with O
exemestane B
in O
postmenopausal O
women O
with O
oestrogen O
receptor O
- O
positive O
, O
HER2 O
- O
negative O
advanced O
breast O
cancer O
refractory O
to O
nonsteroidal O
AIs O
. O

In O
the O
well O
- O
designed O
BOLERO O
- O
2 O
study O
, O
the O
addition O
of O
everolimus B
to O
exemestane B
was O
shown O
to O
significantly O
prolong O
progression O
- O
free O
survival O
in O
this O
patient O
population O
. O

However O
, O
treatment O
- O
emergent O
adverse O
events O
and O
treatment O
discontinuations O
occurred O
more O
frequently O
with O
combination O
therapy O
than O
with O
exemestane B
alone O
, O
suggesting O
a O
need O
for O
careful O
benefit O
/ O
risk O
assessment O
prior O
to O
initiating O
therapy O
. O

Nevertheless O
, O
current O
evidence O
suggests O
that O
everolimus B
plus O
exemestane B
combination O
therapy O
may O
be O
a O
useful O
treatment O
option O
in O
patients O
with O
postmenopausal O
hormone O
receptor O
- O
positive O
, O
HER2 O
- O
negative O
, O
advanced O
breast O
cancer O
refractory O
to O
nonsteroidal O
AIs O
. O

Lorcaserin B
: O
a O
review O
of O
its O
use O
in O
chronic O
weight O
management O
. O

Oral O
lorcaserin B
( O
BELVIQ O
( O
( O
R O
) O
) O
) O
, O
a O
selective O
serotonin O
5 O
- O
HT2C O
receptor O
agonist O
, O
is O
indicated O
in O
the O
US O
as O
an O
adjunct O
to O
diet O
and O
exercise O
in O
the O
chronic O
weight O
management O
of O
obese O
adults O
, O
or O
overweight O
adults O
with O
at O
least O
one O
weight O
- O
related O
comorbidity O
( O
e O
. O
g O
. O
dyslipidaemia O
, O
hypertension O
, O
type O
2 O
diabetes O
) O
. O

This O
article O
reviews O
the O
pharmacological O
properties O
, O
therapeutic O
efficacy O
and O
tolerability O
of O
oral O
lorcaserin B
in O
this O
patient O
population O
. O

In O
three O
large O
randomized O
, O
double O
- O
blind O
, O
multicentre O
studies O
, O
oral O
lorcaserin B
was O
more O
effective O
than O
placebo O
in O
the O
management O
of O
obese O
and O
overweight O
adults O
with O
or O
without O
type O
2 O
diabetes O
mellitus O
. O

Following O
12 O
months O
' O
therapy O
, O
significantly O
higher O
proportions O
of O
lorcaserin B
than O
placebo O
recipients O
achieved O
a O
> O
= O
5 O
and O
> O
= O
10 O
% O
reduction O
from O
baseline O
in O
their O
bodyweight O
and O
a O
significant O
between O
- O
group O
difference O
favouring O
lorcaserin B
over O
placebo O
was O
observed O
for O
the O
change O
from O
baseline O
in O
bodyweight O
. O

Moreover O
, O
among O
patients O
who O
had O
achieved O
a O
> O
= O
5 O
% O
reduction O
in O
their O
bodyweight O
after O
12 O
months O
' O
therapy O
with O
lorcaserin B
, O
a O
significantly O
higher O
proportion O
who O
received O
lorcaserin B
for O
a O
further O
12 O
months O
than O
those O
who O
switched O
to O
placebo O
maintained O
> O
= O
5 O
% O
weight O
loss O
at O
24 O
months O
. O

In O
general O
, O
oral O
lorcaserin B
was O
well O
tolerated O
in O
clinical O
studies O
, O
with O
hypoglycaemia O
and O
headache O
the O
most O
frequently O
reported O
adverse O
events O
in O
those O
with O
or O
without O
type O
2 O
diabetes O
, O
respectively O
. O

According O
to O
a O
pooled O
analysis O
, O
the O
risk O
of O
US O
- O
FDA O
- O
defined O
valvulopathy O
with O
lorcaserin B
is O
generally O
low O
and O
not O
statistically O
significantly O
different O
from O
placebo O
. O

From O
these O
and O
other O
data O
, O
the O
FDA O
has O
concluded O
that O
lorcaserin B
is O
unlikely O
to O
elevate O
the O
risk O
of O
valvulopathy O
. O

We O
tested O
associations O
of O
circulating O
vitamin O
D O
metabolite O
concentrations O
with O
subclinical O
atherosclerosis O
among O
1 O
, O
193 O
participants O
with O
type O
1 O
diabetes O
in O
the O
DCCT O
/ O
EDIC O
study O
. O
RESEARCH O
DESIGN O
AND O
METHODSWe O
measured O
plasma O
concentrations O
of O
25 O
- O
hydroxyvitamin O
D O
[ O
25 B
( I
OH I
) I
D I
] O
, O
1 O
, O
25 O
- O
dihydroxyvitamin O
D O
, O
and O
24 B
, I
25 I
- I
dihydroxyvitamin I
D I
by O
mass O
spectrometry O
at O
the O
end O
of O
the O
DCCT O
. O

Correspondingly O
, O
agonists O
of O
the O
Hedgehog O
pathway O
( O
purmorphamine B
and O
Indian O
hedgehog O
) O
in O
MC3T3 O
osteoblasts O
led O
to O
increased O
BRIL O
levels O
. O

We O
present O
evidence O
that O
residues O
required O
for O
restricted O
mobility O
mediate O
retention O
at O
the O
lateral O
membrane O
through O
interaction O
with O
ankyrin O
- O
G O
, O
while O
dileucine B
residues O
conferring O
apical O
- O
lateral O
transcytosis O
act O
through O
a O
clathrin O
- O
dependent O
process O
and O
function O
in O
an O
editing O
pathway O
. O

Clathrin O
heavy O
chain O
knockdown O
and O
dileucine B
mutation O
of O
E O
- O
cadherin O
both O
cause O
the O
same O
partial O
loss O
of O
polarity O
of O
E O
- O
cadherin O
. O

Moreover O
, O
clathrin O
knockdown O
causes O
no O
further O
change O
in O
polarity O
of O
E O
- O
cadherin O
with O
dileucine B
mutation O
, O
but O
does O
completely O
randomize O
E O
- O
cadherin O
mutants O
lacking O
ankyrin O
- O
binding O
. O

Dileucine B
mutation O
, O
but O
not O
loss O
of O
ankyrin O
- O
binding O
, O
prevented O
transcytosis O
of O
apically O
mis O
- O
sorted O
E O
- O
cadherin O
to O
the O
lateral O
membrane O
. O

Finally O
, O
neurofascin O
, O
which O
binds O
ankyrin O
but O
lacks O
dileucine B
residues O
, O
exhibited O
partial O
apical O
- O
lateral O
polarity O
that O
was O
abolished O
by O
mutation O
of O
its O
ankyrin O
- O
binding O
site O
but O
was O
not O
affected O
by O
clathrin O
knockdown O
. O

Nickel B
( I
II I
) I
Dithiocarbamate I
Complexes O
Containing O
Sulforhodamine O
B O
as O
Fluorescent O
Probes O
for O
Selective O
Detection O
of O
Nitrogen O
Dioxide O
. O

Magnetite B
Biomineralization O
in O
Magnetospirillum O
gryphiswaldense O
: O
Time O
- O
Resolved O
Magnetic O
and O
Structural O
Studies O
. O

Magnetotactic O
bacteria O
biosynthesize O
magnetite B
nanoparticles O
of O
high O
structural O
and O
chemical O
purity O
that O
allow O
them O
to O
orientate O
in O
the O
geomagnetic O
field O
. O

In O
this O
work O
we O
have O
followed O
the O
process O
of O
biomineralization O
of O
these O
magnetite B
nanoparticles O
. O

From O
the O
combination O
of O
magnetic O
and O
structural O
studies O
by O
means O
of O
Fe O
K O
- O
edge O
X O
- O
ray O
absorption O
near O
edge O
structure O
( O
XANES O
) O
and O
high O
- O
resolution O
transmission O
electron O
microscopy O
we O
have O
identified O
and O
quantified O
two O
phases O
of O
Fe O
( O
ferrihydrite O
and O
magnetite B
) O
involved O
in O
the O
biomineralization O
process O
, O
confirming O
the O
role O
of O
ferrihydrite O
as O
the O
source O
of O
Fe O
ions O
for O
magnetite B
biomineralization O
in O
M O
. O
gryphiswaldense O
. O

We O
have O
distinguished O
two O
steps O
in O
the O
biomineralization O
process O
: O
the O
first O
, O
in O
which O
Fe O
is O
accumulated O
in O
the O
form O
of O
ferrihydrite O
, O
and O
the O
second O
, O
in O
which O
the O
magnetite B
is O
rapidly O
biomineralized O
from O
ferrihydrite O
. O

In O
Vivo O
Degradation O
and O
Elimination O
of O
Injectable O
Ricinoleic B
Acid I
- O
Based O
Poly B
( I
ester I
- I
anhydride I
) I
. O

The O
in O
vivo O
degradation O
and O
elimination O
after O
subcutaneous O
implantation O
of O
injectable O
p B
( I
SA I
- I
RA I
) I
3 I
: I
7 I
copolymer O
in O
rats O
, O
followed O
by O
characterization O
of O
the O
polymer O
matrix O
composition O
during O
hydrolysis O
and O
erosion O
, O
is O
reported O
. O

( O
1 O
) O
H O
NMR O
spectral O
analysis O
was O
used O
to O
determine O
the O
structures O
and O
content O
of O
ricinoleic B
acid I
containing O
oligomeric O
chains O
present O
in O
the O
degraded O
polymer O
. O

The O
polymer O
degrades O
into O
ester O
oligomers O
of O
2 O
- O
4 O
ricinoleic B
acid I
units O
which O
further O
degrade O
to O
ricinoleic B
acid I
, O
a O
natural O
fatty O
acid O
. O

Both O
types O
of O
granules O
contain O
catechol O
oxidase O
that O
catalyzes O
oxidative O
cross O
- O
linking O
of O
L B
- I
DOPA I
. O

AIM O
: O
To O
compare O
' O
progression O
to O
insulin O
' O
for O
three O
cohorts O
on O
oral O
antidiabetic O
medication O
combinations O
: O
metformin O
/ O
sulphonylurea B
( O
Met O
/ O
SU O
) O
, O
metformin O
/ O
thiazolidinedione O
( O
Met O
/ O
TZD O
) O
and O
sulphonylurea B
/ O
thiazolidinedione O
( O
SU O
/ O
TZD O
) O
. O

The O
noncellular O
reduction O
of O
MTT B
tetrazolium I
salt I
by O
TiO2 O
nanoparticles O
and O
its O
implications O
for O
cytotoxicity O
assays O
. O

We O
report O
results O
of O
noncellular O
tests O
, O
revealing O
the O
occurrence O
of O
photocatalytic O
interactions O
between O
titanium O
dioxide O
( O
TiO2 O
, O
titania B
) O
nanoparticles O
and O
the O
MTT O
[ O
3 O
- O
( O
4 O
, O
5 O
- O
Dimethylthiazol O
- O
2 O
- O
yl O
) O
- O
2 O
, O
5 O
- O
diphenyltetrazolium O
- O
bromide O
] O
cytotoxicity O
indicator O
. O

Classical O
MTT O
assays O
have O
been O
performed O
to O
evaluate O
the O
production O
of O
formazan B
in O
DMEM O
- O
F12 O
and O
RPMI O
- O
1640 O
cell O
culture O
media O
( O
containing O
10 O
% O
fetal O
bovine O
serum O
- O
FBS O
) O
treated O
with O
Degussa O
- O
P25 B
TiO2 I
nanoparticles O
, O
in O
the O
absence O
of O
cells O
. O

The O
colorimetric O
determinations O
revealed O
the O
noncellular O
MTT O
to O
formazan B
transformation O
induced O
by O
TiO2 O
nanoparticles O
, O
under O
conditions O
commonly O
used O
for O
in O
vitro O
cytotoxicity O
testing O
of O
nanomaterials O
. O

The O
formazan B
precipitation O
was O
found O
to O
be O
proportional O
to O
the O
TiO2 O
concentration O
, O
being O
enhanced O
under O
laboratory O
daylight O
exposure O
. O

Analysis O
of O
visible O
- O
light O
- O
active O
Sn B
( I
ii I
) I
- O
TiO2 O
photocatalysts O
. O

The O
influence O
of O
Sn B
( I
ii I
) I
species O
on O
TiO2 O
is O
investigated O
. O

The O
absorption O
spectra O
of O
these O
materials O
are O
red O
- O
shifted O
by O
115 O
nm O
to O
the O
visible O
region O
of O
the O
solar O
spectrum O
compared O
with O
P25 B
TiO2 I
. O

This O
prominent O
red O
- O
shift O
is O
attributed O
to O
the O
interaction O
of O
Sn B
( I
ii I
) I
5s O
orbitals O
with O
the O
TiO2 O
decreasing O
the O
band O
gap O
of O
TiO2 O
by O
raising O
its O
valence O
band O
. O

The O
tin B
oxidation O
state O
and O
the O
materials O
electronic O
structure O
are O
evaluated O
using O
M O
o O
ssbauer O
spectroscopy O
and O
valence O
band O
X O
- O
ray O
photoelectron O
spectroscopy O
respectively O
. O

A O
pyrrolidinium B
nitrate I
protic O
ionic O
liquid O
- O
based O
electrolyte O
for O
very O
low O
- O
temperature O
electrical O
double O
- O
layer O
capacitors O
. O

This O
study O
describes O
the O
use O
of O
the O
pyrrolidinium B
nitrate I
( O
[ B
Pyrr I
] I
[ I
NO3 I
] I
) O
protic O
ionic O
liquid O
( O
PIL O
) O
in O
a O
mixture O
with O
gamma O
butyrolactone O
( O
gamma B
- I
BL I
) O
as O
an O
electrolyte O
for O
carbon O
- O
based O
supercapacitors O
with O
an O
operating O
voltage O
of O
2 O
. O
0 O
V O
and O
at O
very O
low O
temperature O
. O

The O
evolution O
of O
conductivity O
with O
the O
addition O
of O
gamma B
- I
BL I
rendered O
it O
possible O
to O
determine O
the O
optimal O
composition O
for O
electrochemical O
application O
, O
with O
a O
molar O
fraction O
of O
gamma B
- I
BL I
of O
0 O
. O
6 O
. O

At O
the O
same O
time O
, O
exceptional O
residual O
conductivity O
was O
measured O
for O
this O
composition O
at O
- O
40 O
degrees O
C O
( O
9 O
mS O
cm O
( O
- O
1 O
) O
) O
, O
thanks O
to O
the O
superionic O
character O
of O
pyrrolidinium B
nitrate I
PIL O
. O

METHODS O
: O
C57BL O
/ O
6 O
diabetic O
mice O
were O
transplanted O
with O
syngeneic O
islets O
in O
the O
liver O
and O
simultaneously O
abdominally O
implanted O
with O
a O
mini O
- O
osmotic O
pump O
delivering O
BrdU O
alone O
or O
together O
with O
an O
immunosuppressant O
( O
tacrolimus O
, O
sirolimus O
, O
everolimus B
or O
mycophenolate O
mofetil O
[ O
MMF O
] O
) O
. O

Insulinaemia O
was O
significantly O
lower O
in O
mice O
treated O
with O
everolimus B
, O
tacrolimus O
and O
sirolimus O
. O

Baseline O
cortisol O
( O
Cor0 O
) O
, O
DHEA O
- O
S O
( O
DHEA O
- O
S0 O
) O
, O
cortisol O
binding O
globulin O
( O
CBG O
) O
, O
ACTH O
, O
calculated O
free O
cortisol O
( O
by O
Coolen O
' O
s O
equation O
= O
CFC O
) O
, O
free O
cortisol O
index O
( O
FCI O
) O
, O
60 O
- O
min O
cortisol O
( O
Cor60 O
) O
, O
and O
DHEA O
- O
S O
( O
DHEA O
- O
S60 O
) O
, O
delta B
cortisol I
( O
Delta B
Cor I
) O
, O
delta B
DHEA I
- O
S O
( O
Delta B
DHEA I
- O
S O
) O
responses O

Cor60 O
, O
Delta B
Cor I
, O
and O
Delta B
DHEA I
- O
S O
were O
lower O
in O
hyperthyroidism O
. O

ACTH O
- O
stimulated O
peak O
cortisol O
, O
delta B
cortisol I
, O
and O
delta B
DHEA I
- O
S O
levels O
are O
decreased O
during O
hyperthyroidism O
, O
probably O
due O
to O
increased O
turnover O
. O

Our O
previous O
high O
- O
speed O
AFM O
studies O
showed O
that O
mutation O
of O
tryptophan O
residue O
( O
Trp40 B
; O
W40 O
) O
at O
the O
entrance O
of O
the O
catalytic O
tunnel O
drastically O
decreases O
the O
ability O
to O
degrade O
crystalline O
cellulose O
. O

Evaluation O
and O
comparison O
of O
the O
specific O
activities O
of O
the O
enzymes O
( O
WT O
, O
WTcat O
, O
W40A O
, O
and O
W40Acat O
) O
adsorbed O
on O
crystalline O
cellulose O
indicated O
that O
Trp40 B
is O
involved O
in O
recruiting O
individual O
substrate O
chains O
into O
the O
active O
site O
tunnel O
to O
initiate O
processive O
hydrolysis O
. O

A O
Novel O
Automethylation O
Reaction O
in O
the O
Aspergillus O
nidulans O
LaeA O
Protein O
Generates O
S B
- I
Methylmethionine I
. O

The O
filamentous O
fungi O
in O
the O
genus O
Aspergillus O
are O
opportunistic O
plant O
and O
animal O
pathogens O
that O
can O
adapt O
to O
their O
environment O
by O
producing O
various O
secondary O
metabolites O
including O
lovastatin B
, O
penicillin O
, O
and O
aflatoxin O
. O

In O
this O
work O
, O
we O
did O
not O
find O
a O
methyl O
- O
accepting O
substrate O
in O
A O
. O
nidulans O
with O
various O
assays O
including O
in O
vivo O
S B
- I
adenosyl I
- I
[ I
methyl I
- I
( I
3 I
) I
H I
] I
methionine I
labeling O
, O
targeted O
in O
vitro O
methylation O
experiments O
using O
putative O
protein O
substrates O
, O
or O
in O
vitro O
methylation O
assays O
using O
whole O
cell O
extracts O
grown O
under O
different O
conditions O
. O

We O
performed O
chemical O
modifications O
of O
ifenprodil O
at O
the O
benzylic O
position O
and O
on O
the O
phenol O
ring O
by O
introducing O
secondary B
amine I
or I
amide I
functions O
and O
evaluated O
alkyl O
chains O
from O
two O
to O
20 O
bonds O
either O
including O
or O
not O
including O
secondary O
amide O
functions O
as O
spacers O
. O

Despite O
effects O
of O
lesser O
amplitude O
with O
these O
probes O
relative O
to O
ifenprodil O
, O
we O
demonstrated O
that O
they O
displaced O
[ B
( I
3 I
) I
H I
] I
ifenprodil I
in O
mouse O
brain O
slices O
in O
a O
similar O
manner O
. O

By O
using O
the O
novel O
phosphorescent O
dye O
EuLH O
and O
BHQ B
- I
10 I
as O
a O
donor O
- O
acceptor O
pair O
, O
the O
FRET O
efficiency O
increases O
to O
> O
99 O
. O
5 O
% O
, O
leading O
to O
significantly O
improved O
signal O
- O
to O
- O
background O
ratio O
, O
precision O
and O
linear O
range O
. O

Synthesis O
and O
biological O
evaluation O
of O
tricyclic B
guanidine I
analogues O
of O
batzelladine B
K I
for O
antimalarial O
, O
antileishmanial O
, O
antibacterial O
, O
antifungal O
, O
and O
anti O
- O
HIV O
activities O
. O

Fifty O
analogues O
of O
batzelladine B
K I
were O
synthesized O
and O
evaluated O
for O
in O
vitro O
antimalarial O
( O
Plasmodium O
falciparum O
) O
, O
antileishmanial O
( O
Leishmania O
donovani O
) O
, O
antimicrobial O
( O
panel O
of O
bacteria O
and O
fungi O
) O
, O
antiviral O
( O
HIV O
- O
1 O
) O
activities O
. O

Analogues O
12c O
and O
14c O
having O
nonyl B
substitution O
showed O
the O
most O
potent O
antileishmanial O
activity O
with O
IC O
( O
50 O
) O
2 O
. O
39 O
and O
2 O
. O
78 O
mu O
M O
and O
IC O
( O
90 O
) O
11 O
. O
27 O
and O
12 O
. O
76 O
mu O
M O
, O
respectively O
. O

Analogue O
20l O
having O
pentyl B
and O
methyl O
substituents O
on O
tricycle O
showed O
promising O
activities O
against O
all O
pathogens O
. O

Our O
study O
demonstrated O
that O
the O
tricyclic B
guanidine I
compounds O
provide O
new O
structural O
class O
for O
broad O
spectrum O
activity O
. O

Synthesis O
and O
structure O
- O
activity O
relationship O
of O
pyripyropene B
A I
derivatives O
as O
potent O
and O
selective O
acyl O
- O
CoA O
: O
cholesterol O
acyltransferase O
2 O
( O
ACAT2 O
) O
inhibitors O
: O
Part O
2 O
. O

Synthesis O
and O
structure O
- O
activity O
relationships O
of O
7 B
- I
O I
- I
p I
- I
cyanobenzoyl I
pyripyropene I
A I
derivatives O
with O
modification O
at O
C1 O
and O
11 O
are O
described O
. O

Regioselective O
mono O
- O
deprotection O
of O
di B
- I
tert I
- I
butylsilylene I
acetal I
was O
critical O
in O
their O
synthesis O
. O

The O
extent O
of O
saturation O
and O
the O
signature O
of O
polyenic B
fatty I
acids I
varied O
according O
to O
the O
specific O
species O
of O
the O
Stichaeidae O
family O
under O
study O
. O

Evaluation O
of O
Perturbations O
in O
Serum O
Thyroid O
Hormones O
During O
Human O
Pregnancy O
Due O
to O
Dietary O
Iodide O
and O
Perchlorate B
Exposure O
Using O
a O
Biologically O
Based O
Dose O
- O
Response O
Model O
. O

The O
model O
was O
extended O
to O
describe O
perchlorate B
, O
an O
environmental O
and O
food O
contaminant O
, O
that O
competes O
with O
the O
sodium O
iodide O
symporter O
protein O
for O
thyroidal O
uptake O
of O
iodide O
. O

Using O
this O
mode O
- O
of O
- O
action O
framework O
, O
simulations O
were O
performed O
to O
determine O
the O
daily O
ingestion O
rates O
of O
perchlorate B
that O
would O
be O
associated O
with O
hypothyroxinemia O
or O
onset O
of O
hypothyroidism O
for O
varying O
iodide O
intake O
. O

Model O
simulations O
suggested O
that O
a O
maternal O
iodide O
intake O
of O
75 O
to O
250 O
micro O
g O
/ O
day O
and O
an O
environmentally O
relevant O
exposure O
of O
perchlorate B
( O
~ O
0 O
. O
1 O
micro O
g O
/ O
kg O
/ O
day O
) O
did O
not O
result O
in O
hypothyroxinemia O
or O
hypothyroidism O
. O

For O
a O
daily O
iodide O
- O
sufficient O
intake O
of O
200 O
micro O
g O
/ O
day O
, O
the O
dose O
of O
perchlorate B
required O
to O
reduce O
maternal O
fT4 O
levels O
to O
a O
hypothyroxinemic O
state O
was O
estimated O
at O
32 O
. O
2 O
micro O
g O
/ O
kg O
/ O
day O
. O

As O
iodide O
intake O
was O
lowered O
to O
75 O
micro O
g O
/ O
day O
, O
the O
model O
simulated O
daily O
perchlorate B
dose O
required O
to O
cause O
hypothyroxinemia O
was O
reduced O
by O
eightfold O
. O

Similarly O
, O
the O
perchlorate B
intake O
rates O
associated O
with O
the O
onset O
of O
subclinical O
hypothyroidism O
ranged O
from O
54 O
. O
8 O
to O
21 O
. O
5 O
micro O
g O
/ O
kg O
/ O
day O
for O
daily O
iodide O
intake O
of O
250 O
- O
75 O
micro O
g O
/ O
day O
. O

DNA O
Adduct O
Formation O
of O
2 B
- I
Amino I
- I
9H I
- I
pyrido I
[ I
2 I
, I
3 I
- I
b I
] I
indole I
and O
2 B
- I
Amino I
- I
3 I
, I
4 I
- I
dimethylimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
in O
Mouse O
Liver O
and O
Extrahepatic O
Tissues O
During O
a O
Subchronic O
Feeding O
Study O
. O

2 B
- I
Amino I
- I
9H I
- I
pyrido I
[ I
2 I
, I
3 I
- I
b I
] I
indole I
( O
A O
alpha O
C O
) O
is O
an O
abundant O
heterocyclic B
aromatic I
amine I
present O
in O
tobacco O
smoke O
. O

A O
alpha O
C O
( O
400 O
or O
800 O
ppm O
) O
and O
2 B
- I
amino I
- I
3 I
, I
4 I
- I
dimethylimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
( O
MeIQ B
) O
( O
300 O
ppm O
) O
, O
a O
liver O
and O
colon O
carcinogen O
in O
C57BL O
/ O
6 O
mice O
, O
were O
given O
in O
the O
diet O
for O
up O
to O
12 O
weeks O
. O

The O
major O
DNA O
adducts O
of O
both O
carcinogens O
were O
identified O
as O
deoxyguanosine B
- O
C8 O
adducts O
. O

The O
levels O
of O
formation O
of O
A O
alpha O
C O
- O
and O
MeIQ B
- O
DNA O
adducts O
were O
similar O
in O
liver O
and O
extrahepatic O
tissues O
when O
adjusted O
for O
dose O
. O

Recent O
developments O
in O
design O
and O
synthesis O
of O
bicyclic B
azasugars I
, O
carbasugars B
and O
related O
molecules O
as O
glycosidase O
inhibitors O
. O

Neuroprotective O
Effects O
of O
Cilostazol B
on O
Retinal O
Ganglion O
Cell O
damage O
in O
Diabetic O
Rats O
. O

We O
investigated O
the O
effects O
of O
cilostazol B
, O
which O
has O
been O
widely O
used O
to O
manage O
diabetic O
complications O
, O
on O
retinal O
ganglion O
cell O
death O
in O
diabetic O
retina O
. O

Four O
- O
week O
- O
old O
Otsuka O
Long O
- O
Evans O
Tokushima O
Fatty O
( O
OLETF O
) O
rats O
and O
Long O
- O
Evans O
Tokushima O
Otsuka O
( O
LETO O
) O
rats O
as O
matched O
nondiabetic O
controls O
were O
treated O
with O
daily O
oral O
cilostazol B
at O
30mg O
/ O
kg O
or O
0 O
. O
9 O
% O
saline O
solution O
. O

Immunofluorescence O
staining O
and O
western O
blotting O
demonstrated O
that O
cilostazol B
treatment O
reduced O
GFAP O
and O
VEGF O
expression O
in O
the O
retinas O
of O
OLETF O
rats O
. O

Terminal O
deoxynucleotidyl O
transferase O
- O
mediated O
dUTP O
nick O
- O
end O
labeling O
( O
TUNLEL O
) O
staining O
revealed O
an O
increase O
in O
the O
RGC O
layer O
in O
OLETF O
compared O
with O
LETO O
rats O
( O
P O
< O
0 O
. O
05 O
) O
, O
and O
cilostazol B
treatment O
reduced O
the O
number O
of O
TUNEL O
- O
positive O
cells O
in O
OLETF O
rats O
( O
P O
< O
0 O
. O
05 O
) O
. O

Relieving O
retinal O
ischemia O
by O
systemic O
cilostazol B
treatment O
had O
a O
noticeable O
protective O
effect O
on O
RGCs O
in O
diabetic O
rats O
. O

Cilostazol B
treatment O
may O
be O
useful O
for O
the O
management O
of O
diabetic O
retinal O
vascular O
dysfunction O
and O
neuronal O
degeneration O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
protective O
effects O
of O
taurine O
( O
Tau B
) O
on O
experimental O
acute O
pancreatitis O
( O
AP O
) O
in O
a O
rat O
model O
by O
measuring O
cytokines O
and O
oxidant O
stress O
markers O
. O
Forty O
rats O
were O
randomly O
divided O
into O
four O
groups O
: O
sham O
, O
AP O
, O
Tau B
and O
AP O
+ O
Tau O
. O

Pancreatic O
tissues O
of O
rats O
and O
blood O
samples O
were O
obtained O
. O
Tau B
treatment O
significantly O
decreased O
serum O
amylase O
activity O
( O
p O
< O
0 O
. O
001 O
) O
, O
total O
injury O
score O
( O
p O
< O
0 O
. O
001 O
) O
, O
malondialdehyde O
levels O
( O
p O
< O
0 O
. O
001 O
) O
and O
myeloperoxidase O
( O
MPO O
) O
activity O
( O
p O
< O
0 O
. O
001 O
) O
. O

There O
was O
no O
significant O
difference O
between O
the O
Tau B
and O
AP O
+ O
Tau B
groups O
in O
serum O
and O
pancreatic O
tumor O
necrosis O
factor O
- O
alpha O
, O
interleukin O
( O
IL O
) O
- O
1 O
beta O
and O
IL O
- O
6 O
levels O
( O
p O
= O
1 O
. O
000 O
) O
. O

Histopathologic O
scores O
in O
the O
AP O
+ O
Tau B
and O
Tau B
groups O
were O
significantly O
lower O
compared O
with O
the O
AP O
group O
( O
both O
p O
< O
0 O
. O
001 O
) O
. O
These O
results O
showed O
that O
Tau B
reduces O
lipid O
peroxidation O
, O
amylase O
and O
MPO O
activities O
and O
the O
concentrations O
of O
proinflammatory O
cytokines O
secondary O
to O
AP O
and O
also O
increases O
superoxide O
dismutase O
and O
glutathione O
peroxidase O
activities O
in O
rats O
with O
sodium O
taurocholate O
- O
induced O
AP O
. O

Influence O
of O
oily O
vehicles O
on O
fetal O
testis O
and O
lipid O
profile O
of O
rats O
exposed O
to O
di B
- I
butyl I
phthalate I
. O

It O
has O
been O
hypothesized O
that O
oils O
containing O
high O
levels O
of O
omega B
- I
3 I
polyunsaturated I
fatty I
acids I
, O
such O
as O
canola O
and O
fish O
oil O
, O
could O
counteract O
some O
of O
the O
adverse O
effects O
induced O
by O
phthalates O
. O

In O
the O
present O
study O
, O
the O
influence O
of O
different O
oily O
vehicles O
on O
di B
- I
butyl I
phthalate I
( O
DBP B
) O
- O
induced O
testicular O
toxicity O
and O
lipid O
profile O
was O
investigated O
. O

Pregnant O
Wistar O
rats O
were O
treated O
by O
oral O
gavage O
from O
gestation O
days O
13 O
to O
20 O
with O
DBP B
( O
500 O
mg O
/ O
kg O
/ O
day O
) O
diluted O
in O
three O
different O
vehicles O
: O
corn O
, O
canola O
or O
fish O
oil O
. O

DBP B
exposure O
lowered O
intratesticular O
testosterone O
levels O
and O
anogenital O
distance O
, O
regardless O
of O
the O
vehicle O
used O
. O

The O
percentage O
of O
seminiferous O
cords O
containing O
multinucleated O
gonocytes O
and O
cord O
diameter O
was O
increased O
in O
DBP B
- O
exposed O
groups O
, O
compared O
with O
vehicle O
controls O
, O
with O
no O
difference O
between O
the O
three O
DBP B
- O
exposed O
groups O
. O

Clustering O
of O
Leydig O
cells O
was O
seen O
in O
all O
DBP B
groups O
. O

However O
, O
content O
of O
omega B
- I
3 I
was O
diminished O
in O
DBP B
- O
treated O
groups O
. O

Overall O
, O
our O
results O
indicate O
that O
different O
oily O
vehicles O
did O
not O
alter O
fetal O
rat O
testicular O
toxicity O
induced O
by O
a O
high O
DBP B
dose O
. O

This O
study O
was O
aimed O
to O
compare O
the O
in O
vitro O
effects O
of O
3 B
- I
methyl I
- I
1 I
- I
phenyl I
- I
2 I
- I
( I
phenylseleno I
) I
oct I
- I
2 I
- I
en I
- I
1 I
- I
one I
( O
C21H2HOSe B
; O
organoselenium B
) O
and O
sodium B
selenate I
( O
inorganic O
Se O
) O
on O
adenosine O
deaminase O
( O
ADA O
) O
activity O
, O
cell O
viability O
, O
lipid O
peroxidation O
, O
scavenger O
of O
nitric O
oxide O
( O
NO O
) O
and O
nonprotein O
thiols O
( O
NP O
- O
SH O
) O
content O
in O
the O
cerebral O
cortex O

A O
decrease O
in O
ADA O
activity O
was O
observed O
when O
the O
slices O
were O
exposed O
to O
organoselenium B
at O
the O
concentrations O
of O
1 O
, O
10 O
and O
30 O
micro O
M O
. O

Comparison O
of O
the O
Relative O
Propensities O
of O
Isoamyl B
Nitrite I
and O
Sodium O
Nitrite O
to O
Ameliorate O
Acute O
Cyanide O
Poisoning O
in O
Mice O
and O
a O
Novel O
Antidotal O
Effect O
Arising O
from O
Anesthetics O
. O

Isoamyl B
nitrite I
has O
previously O
been O
considered O
acceptable O
as O
an O
inhaled O
cyanide O
antidote O
; O
therefore O
, O
the O
antidotal O
utility O
of O
this O
organic O
nitrite O
compared O
with O
sodium O
nitrite O
was O
investigated O
. O

To O
facilitate O
a O
quantitative O
comparison O
, O
doses O
of O
both O
sodium O
nitrite O
and O
isoamyl B
nitrite I
were O
given O
intraperitoneally O
in O
equimolar O
amounts O
to O
sublethally O
cyanide O
- O
challenged O
mice O
. O

Righting O
recovery O
from O
the O
knockdown O
state O
was O
clearly O
compromised O
in O
the O
isoamyl B
nitrite I
- O
treated O
animals O
, O
the O
effect O
being O
attributable O
to O
the O
toxicity O
of O
the O
isoamyl B
alchol I
produced O
during O
hydrolysis O
of O
the O
isoamyl B
nitrite I
to O
release O
nitrite O
anion O
. O

Aerosolized O
sodium O
nitrite O
has O
thus O
been O
shown O
by O
these O
experiments O
to O
have O
promise O
as O
a O
better O
alternative O
to O
organic O
nitrites B
for O
development O
as O
an O
inhaled O
cyanide O
antidote O
. O

Finally O
, O
working O
at O
slightly O
greater O
than O
LD50 O
NaCN B
doses O
, O
it O
was O
fortuitously O
discovered O
that O
( O
i O
) O
anesthesia O
leads O
to O
significantly O
prolonged O
survival O
compared O
to O
that O
of O
unanesthetized O
animals O
and O
that O
( O
ii O
) O
the O
antidotal O
activity O
of O
nitrite O
anion O
was O
completely O
abolished O
under O
anesthesia O
. O

A O
monohydroxy B
- O
tetrabrominated O
and O
a O
dihydroxy O
- O
tetrabrominated O
metabolite O
remain O
unidentified O
. O

Kinetic O
analysis O
of O
the O
rates O
of O
metabolite O
formation O
revealed O
that O
the O
major O
metabolites O
were O
5 B
- I
hydroxy I
- I
2 I
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
( O
5 B
- I
OH I
- I
BDE I
- I
47 I
) O
, O
6 B
- I
hydroxy I
- I
2 I
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
( O
6 B
- I
OH I
- I
BDE I
- I
47 I
) O
, O
and O
possibly O
the O
unidentified O
monohydroxy B
- O
tetrabrominated O
metabolite O
. O

Additional O
experiments O
involving O
the O
incubation O
of O
liver O
microsomes O
with O
individual O
monohydroxy B
- O
tetrabrominated O
metabolites O
in O
place O
of O
BDE O
- O
47 O
demonstrated O
that O
2 B
, I
4 I
- I
dibromophenol I
was O
a O
product O
of O
BDE O
- O
47 O
and O
several O
primary O
metabolites O
, O
but O
the O
dihydroxy O
- O
tetrabrominated O
metabolite O
was O
not O
formed O
by O
sequential O
hydroxylation O
of O
any O
of O
the O
monohydroxy B
- O
tetrabrominated O
metabolites O
tested O
. O

Three O
of O
them O
, O
desmethylnobiletin B
, O
pectolinarigenin B
and O
xanthomicrol B
, O
are O
a O
new O
report O
from O
this O
source O
. O

For O
two O
of O
them O
, O
viz O
. O
, O
3 B
' I
, I
4 I
' I
- I
dimethoxywogonin I
and O
4 B
' I
- I
hydroxywogonin I
, O
such O
data O
have O
not O
been O
reported O
in O
literature O
. O

Furthermore O
, O
correct O
NMR O
data O
are O
being O
provided O
for O
gardenin B
C I
as O
the O
data O
reported O
in O
literature O
were O
found O
to O
be O
incorrect O
. O

New O
triterpene B
glycoside I
and O
other O
chemical O
constituents O
from O
the O
leaves O
of O
Swartzia O
apetala O
Raddi O
var O
. O
glabra O
. O

A O
new O
triterpene B
saponin I
( O
1 O
) O
was O
isolated O
from O
a O
methanol O
extract O
of O
Swartzia O
apetala O
Raddi O
var O
. O
glabra O
, O
together O
with O
the O
flavonoids O
mauritianin B
( O
2 O
) O
, O
kaempferol O
( O
3 O
) O
and O
the O
triterpene B
saponin I
beta B
- I
D I
- I
glucopyranosyl I
3 I
beta I
- I
hydroxy I
- I
olean I
- I
12 I
- I
en I
- I
28 I
- I
oate I
( O
4 O
) O
. O

The O
analysis O
by O
HR O
- O
ESI O
- O
MS O
showed O
a O
mass O
compatible O
with O
that O
of O
triterpene B
saponin I
1 O
. O

Measurements O
of O
Rate O
Constants O
for O
the O
OH O
Reactions O
with O
Bromoform B
( O
CHBr3 O
) O
, O
CHBr2Cl B
, O
CHBrCl2 B
, O
and O
Epichlorohydrin O
( O
C3H5ClO B
) O
. O

Measurements O
of O
the O
rate O
constants O
for O
the O
gas O
phase O
reactions O
of O
OH O
radicals O
with O
bromoform B
( O
CHBr3 O
) O
and O
epichlorohydrin O
( O
C3H5ClO B
) O
were O
performed O
using O
a O
flash O
photolysis O
resonance O
- O
fluorescence O
technique O
over O
the O
temperature O
range O
230 O
- O
370 O
K O
. O

Rate O
constants O
for O
the O
reactions O
of O
OH O
with O
CHCl2Br B
and O
CHClBr2 B
were O
measured O
between O
230 O
and O
330 O
K O
. O

The O
total O
atmospheric O
lifetimes O
of O
the O
Br O
- O
containing O
methanes B
due O
to O
both O
reaction O
with O
OH O
and O
photolysis O
were O
calculated O
to O
be O
22 O
, O
50 O
, O
and O
67 O
days O
for O
CHBr3 O
, O
CHClBr2 B
, O
and O
CHCl2Br B
, O
respectively O
. O

In O
addition O
, O
major O
metabolites O
were O
identified O
and O
measurements O
of O
OH B
- I
PAHs I
( O
1 O
- O
naphthol O
, O
9 B
- I
phenantrol I
, O
9 B
- I
fluorenol I
, O
1 B
- I
pyrenol I
, O
1OH B
- I
BaP I
and O
3OH B
- I
BaP I
) O
and O
alkylphenols B
( O
4 B
- I
n I
- I
nonylphenol I
( O
4 B
- I
n I
- I
NP I
) O
and O
4 B
- I
tertoctylphenol I
( O
4 B
- I
tert I
- I
OP I
) O
) O
in O
the O
same O
fish O
bile O
extracts O
were O
taken O
by O
gas O
chromatography O
- O
mass O
spectrometry O
in O
electron O

The O
highest O
biliary O
concentrations O
of O
1 B
- I
pyrenol I
, O
9 B
- I
fluorenol I
and O
4 B
- I
n I
- I
NP I
were O
found O
in O
fish O
from O
Barcelona O
and O
from O
the O
Mar O
Menor O
coastal O
lagoon O
. O

The O
contribution O
of O
1 B
- I
pyrenol I
, O
4 B
- I
n I
- I
NP I
and O
4 B
- I
tert I
- I
OP I
to O
the O
total O
estrogenic O
potency O
measured O
in O
male O
fish O
bile O
was O
found O
to O
be O
negligible O
, O
indicating O
the O
presence O
of O
other O
estrogenic O
compounds O
in O
red O
mullet O
bile O
. O

Considerable O
amounts O
of O
ferulic B
, I
sinapinic I
and I
gallic I
acids I
, O
kaempferol O
, O
isorhamnetin O
and O
rutin O
were O
observed O
in O
the O
chemical O
ChL O
extract O
and O
were O
linked O
with O
its O
inhibitory O
effect O
on O
prostate O
cancer O
cell O
proliferation O
, O
motility O
and O
cellular O
competence O
for O
gap O
junctional O
communication O
. O

The O
effect O
of O
a O
Cimicifuga O
racemosa O
extracts O
Ze B
450 I
in O
the O
treatment O
of O
climacteric O
complaints O
- O
an O
observational O
study O
. O

METHOD O
: O
In O
this O
observational O
study O
, O
Cimicifuga O
racemosa O
( O
CR O
) O
extract O
Ze B
450 I
was O
studied O
in O
442 O
unselected O
ambulatory O
female O
outpatients O
with O
menopausal O
complaints O
under O
daily O
practice O
conditions O
. O

The O
combined O
effects O
between O
essential O
oils O
of O
cinnamon O
bark O
, O
lavender O
, O
marjoram O
, O
tea O
tree O
, O
peppermint O
and O
ampicillin O
, O
piperacillin B
, O
cefazolin B
, O
cefuroxime O
, O
carbenicillin B
, O
ceftazidime O
, O
meropenem B
, O
were O
evaluated O
by O
means O
of O
the O
checkerboard O
method O
against O
beta O
- O
lactamase O
- O
producing O
Escherichia O
coli O
. O

The O
preliminary O
results O
obtained O
highlighted O
the O
occurrence O
of O
a O
pronounced O
synergistic O
relationship O
between O
piperacillin B
/ O
cinnamon O
bark O
oil O
, O
piperacillin B
/ O
lavender O
oil O
, O
piperacillin B
/ O
peppermint O
oil O
as O
well O
as O
meropenem B
/ O
peppermint O
oil O
against O
two O
of O
the O
three O
bacteria O
under O
study O
with O
a O
FIC O
index O
in O
the O
range O
0 O
. O
26 O
- O
0 O
. O
5 O
. O

Two O
new O
tryptophan O
derivatives O
, O
N B
- I
sulfonyl I
- I
L I
- I
tryptophan I
( O
tryptorheedei B
A I
) O
( O
1 O
) O
and O
3 B
- I
( I
N I
- I
sulfonylindolyl I
) I
- I
D I
- I
lactic I
acid I
( O
tryptorheedei B
B I
) O
( O
2 O
) O
together O
with O
the O
known O
5 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
2 I
- I
hydroxyphenylacetic I
acid I
( O
3 O
) O
, O
1 B
- I
O I
- I
methylglucopyranosid I
, O
entadamide B
A I
, O
homogentisic B
acid I
and O
3 O
- O
O O

Both O
compounds O
1 O
and O
2 O
were O
found O
to O
promote O
early O
infection O
events O
in O
HIV O
, O
likely O
by O
inhibiting O
the O
enzyme O
indolamine B
2 O
, O
3 O
- O
dioxygenase O
( O
IDO O
) O
and O
preventing O
tryptophan O
depletion O
. O

IDO O
is O
also O
the O
gatekeeper O
enzyme O
for O
kynurenine B
metabolism O
, O
a O
pathway O
involved O
in O
serotonin O
and O
melatonin O
biosynthesis O
and O
the O
regulation O
of O
glutamate O
and O
dopamine O
levels O
in O
the O
brain O
. O

The O
conjugation O
of O
microcystin B
- I
RR I
by O
human O
recombinant O
GSTs O
and O
hepatic O
cytosol O
. O

Many O
cyanobacterial O
species O
can O
produce O
cyanotoxins O
, O
among O
which O
mycrocistins B
( O
MC O
) O
are O
a O
group O
of O
= O
~ O
100 O
congeners O
of O
hepatotoxic O
cyclic B
heptapeptides I
. O

MC B
- I
RR I
differs O
from O
MC B
- I
LR I
, O
the O
most O
studied O
congener O
only O
for O
one O
residue O
( O
arginine O
vs O
leucine O
) O
, O
resulting O
in O
a O
ten O
- O
fold O
difference O
in O
the O
acute O
toxicity O
in O
mice O
. O

The O
accepted O
pathway O
for O
MC O
detoxication O
is O
GSH O
conjugation O
: O
here O
the O
MC B
- I
RR I
conjugation O
with O
GSH O
catalyzed O
by O
5 O
recombinant O
human O
GSTs O
and O
human O
liver O
cytosol O
( O
HLC O
) O
has O
been O
characterized O
and O
appeared O
to O
be O
more O
efficient O
than O
MC B
- I
LR I
conjugation O
. O

However O
, O
at O
low O
MC B
- I
RR I
concentrations O
, O
representative O
of O
repeated O
oral O
exposure O
, O
and O
low O
GSH O
content O
( O
down O
to O
0 O
. O
05mM O
) O
, O
possibly O
associated O
to O
exposure O
to O
drugs O
or O
in O
patients O
affected O
by O
several O
pathologies O
, O
the O
relevance O
of O
the O
enzymatic O
reaction O
progressively O
increases O
, O
providing O
the O
predominant O
contribution O
to O
MC B
- I
RR I
detoxication O
. O

Ginsenoside O
Rg1 O
( O
Rg1 B
) O
is O
an O
active O
components O
in O
Panax O
ginseng O
, O
a O
famous O
traditional O
Chinese O
medicines O
recorded O
in O
Compendium O
of O
Materia O
Medica O
. O

Present O
study O
attempted O
to O
evaluate O
the O
potential O
mechanisms O
of O
A O
beta O
- O
mediated O
insult O
and O
the O
protective O
effects O
of O
Rg1 B
on O
human O
endothelial O
cells O
. O

Rg1 B
attenuated O
the O
A O
beta O
25 O
- O
35 O
- O
associated O
mitochondrial O
apoptotic O
events O
, O
accompanied O
by O
inhibiting O
HIF O
- O
1 O
alpha O
expression O
followed O
by O
intracellular O
reactive O
nitrogen O
species O
generation O
, O
and O
protein O
nitrotyrosination O
. O

These O
protective O
effects O
were O
abolished O
by O
glucocorticoid O
receptor O
( O
GR O
) O
antagonist O
RU486 O
or O
p O
- O
ERK O
inhibitor O
U0126 O
rather O
than O
estrogen O
receptor O
alpha O
antagonist O
ICI B
82 I
, I
780 I
. O

Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 B
protected O
against O
A O
beta O
25 O
- O
35 O
- O
induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR O
- O
dependent O
ERK O
phosphorylation O
pathways O
: O
( O
1 O
) O
down O
- O
regulating O
HIF O
- O
1 O
alpha O
initiated O
protein O
nitrotyrosination O
, O
and O
( O
2 O
) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O

These O
data O
provided O
a O
novel O
insight O
to O
the O
mechanisms O
of O
Rg1protective B
effects O
on O
A O
beta O
25 O
- O
35 O
- O
induced O
endothelial O
cells O
apoptosis O
, O
suggesting O
that O
GR O
- O
ERK O
signaling O
pathway O
might O
play O
an O
important O
role O
in O
it O
. O

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
effects O
of O
2 B
, I
4 I
- I
D I
, O
an O
herbicide O
used O
worldwide O
also O
known O
as O
endocrine O
disruptor O
, O
in O
Sertoli O
cell O
( O
SC O
) O
metabolism O
. O

Immature O
rat O
SCs O
were O
maintained O
50h O
under O
basal O
conditions O
or O
exposed O
to O
2 B
, I
4 I
- I
D I
( O
100nM O
, O
10 O
mu O
M O
and O
1mM O
) O
. O

SCs O
exposed O
to O
10 O
mu O
M O
and O
1mM O
of O
2 B
, I
4 I
- I
D I
presented O
lower O
intracellular O
glucose O
and O
lactate O
content O
. O

Exposure O
to O
10 O
mu O
M O
of O
2 B
, I
4 I
- I
D I
induced O
a O
significant O
decrease O
in O
glucose O
transporter O
- O
3 O
mRNA O
levels O
and O
phosphofructokinase O
- O
1 O
mRNA O
levels O
decreased O
in O
cells O
exposed O
to O
100nM O
and O
10 O
mu O
M O
of O
2 B
, I
4 I
- I
D I
. O

Exposure O
to O
100nM O
and O
10 O
mu O
M O
also O
induced O
a O
decrease O
in O
lactate O
dehydrogenase O
( O
LDH O
) O
mRNA O
levels O
while O
the O
LDH O
protein O
levels O
were O
only O
decreased O
in O
cells O
exposed O
to O
1mM O
of O
2 B
, I
4 I
- I
D I
. O

Exposure O
to O
2 B
, I
4 I
- I
D I
altered O
glucose O
uptake O
and O
metabolization O
in O
SCs O
, O
as O
well O
as O
lactate O
metabolism O
and O
export O
that O
may O
result O
in O
impaired O
spermatogenesis O
. O

Synthesis O
of O
some O
novel O
thieno B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidines I
as O
potential O
cytotoxic O
small O
molecules O
against O
breast O
cancer O
. O

A O
variety O
of O
novel O
thieno B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidines I
with O
different O
decorating O
functional O
groups O
were O
synthesized O
as O
a O
part O
of O
a O
study O
aiming O
to O
enrich O
the O
arsenal O
of O
chemotherapeutic O
agents O
for O
the O
treatment O
of O
cancer O
. O

The O
reported O
compounds O
herein O
are O
: O
4 B
- I
aminothienopyrimidin I
derivatives O
4a O
, O
b O
and O
their O
4 B
- I
substituted I
phenylamino I
analogues O
8a O
, O
b O
; O
4 B
- I
thienopyrimidin I
- I
4 I
- I
ones I
5a O
, O
b O
; O
N B
- I
alkyl I
thienopyrimidin I
- I
4 I
- I
ones I
6a O
- O
g O
; O
4 B
- I
chlorothienopyrimidi I
7a O
, O
b O
; O
and O
thienopyrimidoquinaz B
9a O
, O
b O
which O
are O
the O
structural O
mimics O
of O
8a O
, O
b O
. O

Carotenoid O
/ O
lipid O
hydro B
peroxide I
( O
LOOH O
) O
concentration O
was O
evaluated O
using O
two O
different O
methods O
: O
LOOH O
+ O
Fe O
( O
2 O
+ O
) O
reaction O
connected O
with O
a O
colored O
complex O
of O
ammonium B
thiocyanate I
determined O
with O
the O
help O
of O
a O
spectrophotometer O
, O
and O
LOOH O
determined O
with O
the O
help O
of O
a O
chemiluminometer O
. O

Using O
a O
combination O
of O
flow O
cytometry O
and O
microscopy O
, O
we O
found O
that O
zantrin B
Z1 I
, O
cinnamaldehyde O
, O
totarol B
, O
sanguinarine B
, O
and O
viriditoxin B
decreased O
the O
B O
. O
subtilis O
transmembrane O
potential O
or O
perturbed O
membrane O
permeability O
, O
and O
influenced O
the O
localization O
of O
the O
membrane O
- O
associated O
, O
division O
protein O
MinD O
. O

In O
vitro O
, O
lipid O
transfers O
were O
evaluated O
by O
incubation O
of O
plasma O
samples O
( O
37 O
degrees O
C O
, O
1h O
) O
with O
a O
donor O
lipid O
nanoemulsion O
labeled O
with O
3H B
- I
triglycerides I
( O
TG O
) O
and O
14C O
- O
unesterified O
cholesterol O
( O
UC O
) O
or O
with O
3H B
- I
cholesteryl I
ester I
( O
EC O
) O
and O
14C O
- O
phospholipids O
( O
PL O
) O
. O

Novel O
Pyridinone B
Derivatives O
As O
Non O
- O
Nucleoside O
Reverse O
Transcriptase O
Inhibitors O
( O
NNRTIs O
) O
with O
High O
Potency O
against O
NNRTI O
- O
Resistant O
HIV O
- O
1 O
Strains O
. O

Novel O
6 B
- I
substituted I
- I
4 I
- I
cycloalkyloxy I
- I
pyridin I
- I
2 I
( I
1H I
) I
- I
ones I
were O
synthesized O
as O
non O
- O
nucleoside O
reverse O
transcriptase O
inhibitors O
( O
NNRTIs O
) O
, O
and O
their O
biological O
activity O
was O
evaluated O
. O

Most O
of O
the O
compounds O
, O
especially O
26 O
and O
22 O
, O
bearing O
a O
3 B
- I
isopropyl I
and O
3 B
- I
iodine I
group O
, O
respectively O
, O
exhibited O
highly O
potent O
activity O
against O
wild O
- O
type O
HIV O
- O
1 O
strains O
and O
those O
resistant O
to O
reverse O
transcriptase O
inhibitors O
( O
RTIs O
) O
. O

The O
results O
suggest O
that O
these O
novel O
pyridinone B
derivatives O
have O
the O
potential O
to O
be O
further O
developed O
as O
new O
antiretroviral O
drugs O
with O
improved O
antiviral O
efficacy O
and O
drug O
resistance O
profile O
. O

Antiallodynic O
and O
Analgesic O
Effects O
of O
Maslinic B
Acid I
, O
a O
Pentacyclic B
Triterpenoid I
from O
Olea O
europaea O
. O

The O
effects O
of O
maslinic B
acid I
( O
1 O
) O
, O
a O
pentacyclic B
triterpenoid I
obtained O
from O
Olea O
europaea O
, O
were O
studied O
in O
several O
tests O
for O
nociception O
in O
mice O
. O

The O
present O
results O
demonstrate O
for O
the O
first O
time O
that O
maslinic B
acid I
induces O
antinociceptive O
and O
antiallodynic O
effects O
. O

The O
fine O
particulate O
( O
PM O
< O
2 O
. O
5 O
mu O
m O
) O
of O
wood O
smoke O
were O
the O
most O
potent O
TRPA1 O
agonists O
and O
several O
chemical O
constituents O
of O
wood O
smoke O
particulate O
, O
3 B
, I
5 I
- I
ditert I
- I
butylphenol I
, O
coniferaldehyde B
, O
formaldehyde O
, O
perinaphthenone B
, O
agathic B
acid I
, O
and O
isocupressic B
acid I
, O
were O
TRPA1 O
agonists O
. O

TRPA1 O
activation O
by O
wood O
smoke O
particles O
occurred O
through O
the O
electrophile O
/ O
oxidant O
- O
sensing O
domain O
( O
i O
. O
e O
. O
, O
C621 O
/ O
C641 O
/ O
C665 O
/ O
K710 O
) O
, O
based O
on O
the O
inhibition O
of O
cellular O
responses O
when O
the O
particles O
were O
pretreated O
with O
glutathione O
; O
a O
role O
for O
the O
menthol O
- O
binding O
site O
of O
TRPA1 O
( O
S873 O
/ O
T874 O
) O
was O
demonstrated O
for O
3 B
, I
5 I
- I
ditert I
- I
butylphenol I
. O

Effects O
of O
exposure O
to O
amitraz B
on O
noradrenaline O
, O
serotonin O
and O
dopamine O
levels O
in O
brain O
regions O
of O
30 O
and O
60 O
days O
old O
male O
rats O
. O

The O
effects O
of O
amitraz B
oral O
exposure O
( O
20 O
, O
50 O
and O
80mg O
/ O
kg O
bw O
, O
5 O
days O
) O
on O
brain O
region O
monoamine O
levels O
of O
male O
rats O
at O
30 O
and O
60 O
days O
of O
age O
were O
examined O
. O

The O
amitraz B
- O
treated O
rats O
at O
the O
oral O
doses O
of O
20 O
and O
50mg O
/ O
kg O
bw O
had O
no O
visible O
injury O
, O
i O
. O
e O
. O
, O
any O
clinical O
signs O
of O
dysfunction O
observed O
in O
any O
of O
the O
animals O
. O

However O
, O
rats O
treated O
with O
amitraz B
at O
the O
highest O
dose O
( O
80mg O
/ O
kg O
bw O
, O
5 O
days O
) O
showed O
a O
slight O
motor O
incoordination O
after O
1 O
- O
2h O
of O
treatment O
. O

After O
the O
last O
dose O
of O
amitraz B
, O
NE O
, O
DA O
and O
5 O
- O
HT O
and O
its O
metabolites O
levels O
were O
determined O
in O
the O
brain O
regions O
hypothalamus O
, O
midbrain O
, O
prefrontal O
cortex O
, O
striatum O
and O
hippocampus O
by O
HPLC O
. O

Moreover O
, O
in O
the O
brain O
regions O
studied O
, O
amitraz B
induced O
a O
statistically O
significant O
decrease O
in O
the O
metabolite O
5 O
- O
HIAA O
, O
MHPG B
, O
DOPAC O
and O
HVA O
levels O
displaying O
an O
age O
interaction O
, O
excepting O
the O
5 O
- O
HIAA O
decrease O
in O
midbrain O
and O
the O
DOPAC O
decrease O
in O
hypothalamus O
and O
striatum O
which O
were O
without O
age O
interaction O
. O

Furthermore O
, O
amitraz B
evoked O
a O
statistically O
significant O
decrease O
in O
5 O
- O
HT O
, O
NE O
and O
DA O
turnover O
in O
the O
brain O
regions O
studied O
. O

The O
present O
findings O
indicate O
that O
amitraz B
significantly O
altered O
CNS O
monoaminergic O
neurotransmitters O
in O
a O
brain O
regional O
- O
, O
dose O
- O
and O
age O
- O
related O
manner O
. O

The O
effect O
of O
plasticizer O
' O
s O
( O
PEG O
) O
molecular O
weight O
( O
MW O
) O
on O
PVP O
based O
solid O
dispersions O
( O
SDs O
) O
, O
prepared O
by O
melt O
mixing O
, O
was O
evaluated O
in O
the O
present O
study O
using O
Tibolone B
as O
a O
poorly O
water O
soluble O
model O
drug O
. O

PEGs O
with O
MW O
of O
400 O
, O
600 O
, O
and O
2000g O
/ O
mol O
were O
tested O
, O
and O
the O
effect O
of O
drug O
content O
, O
time O
and O
temperature O
of O
melt O
mixing O
on O
the O
physical O
state O
of O
Tibolone B
, O
and O
the O
dissolution O
characteristics O
from O
SDs O
was O
investigated O
. O

PVP O
blends O
with O
PEG400 B
and O
PEG600 B
were O
completely O
miscible O
, O
while O
blends O
were O
heterogeneous O
. O

Furthermore O
, O
a O
single O
Tg O
recorded O
in O
all O
samples O
, O
indicating O
that O
Tibolone B
was O
dispersed O
in O
a O
molecular O
lever O
( O
or O
in O
the O
form O
of O
nanodispersions O
) O
, O
varied O
with O
varying O
PEG O
' O
s O
molecular O
weight O
, O
melt O
mixing O
temperature O
, O
and O
drug O
content O
, O
while O
FTIR O
analysis O
indicated O
significant O
interactions O
between O
Tibolone B
and O
PVP O
/ O
PEG O
matrices O
. O

Porphyrins O
and O
chlorins B
such O
as O
Foscan O
( O
R O
) O
have O
a O
natural O
proclivity O
to O
accumulate O
in O
cancer O
cells O
. O

In O
order O
to O
improve O
on O
cellular O
selectivity O
to O
lower O
post O
- O
treatment O
photosensitivity O
bile B
acid I
porphyrin I
bioconjugates O
have O
been O
prepared O
and O
investigated O
in O
esophageal O
cancer O
cells O
. O

Synthesis O
of O
the O
conjugates O
was O
achieved O
via O
selective O
nucleophilic O
monofunctionalizatio O
of O
5 B
, I
10 I
, I
15 I
, I
20 I
- I
tetrahydroxyphenylpo I
with O
propargyl B
bromide I
followed O
by O
Cu O
( O
I O
) O
mediated O
cycloaddition O
with O
bile B
acid I
azides I
in O
good O
yields O
. O

A O
diazen B
- I
1 I
- I
ium I
- I
1 I
, I
2 I
- I
diolate I
analog O
of O
7 B
- I
azabenzobicyclo I
[ I
2 I
. I
2 I
. I
1 I
] I
heptane I
: O
Synthesis O
, O
nitric O
oxide O
and O
nitroxyl O
release O
, O
in O
vitro O
hemodynamic O
, O
and O
anti O
- O
hypertensive O
studies O
. O

1 B
- I
( I
7 I
- I
Azabenzobicyclo I
[ I
2 I
. I
2 I
. I
1 I
] I
heptane I
) I
diazen I
- I
1 I
- I
ium I
- I
1 I
, I
2 I
- I
diolate I
( O
16 O
) O
was O
designed O
with O
the O
expectation O
that O
it O
would O
act O
as O
a O
dual O
nitric O
oxide O
( O
NO O
) O
and O
nitroxyl O
( O
HNO B
) O
donor O
that O
is O
not O
carcinogenic O
or O
genotoxic O
. O

Compound O
16 O
, O
with O
a O
suitable O
half O
- O
life O
( O
17 O
. O
8min O
) O
in O
PBS O
at O
pH O
7 O
, O
released O
NO O
( O
19 O
% O
) O
and O
HNO B
( O
22 O
% O
) O
during O
a O
2h O
incubation O
in O
PBS O
at O
pH O
7 O
. O

Synthetic O
oligoureas O
of O
metaphenylenediamine B
mimic O
host O
defence O
peptides O
in O
their O
antimicrobial O
behaviour O
. O

Oligomeric O
ureas B
of O
m B
- I
phenylenediamine I
target O
anionic O
DMPG B
( O
dimyristoylphosphati B
) O
and O
possess O
promise O
as O
antimicrobial O
agents O
. O

PEG O
mediated O
synthesis O
and O
pharmacological O
evaluation O
of O
some O
fluoro B
substituted I
pyrazoline I
derivatives O
as O
antiinflammatory O
and O
analgesic O
agents O
. O

A O
new O
series O
of O
fluoro B
substituted I
pyrazoline I
derivatives O
5a O
- O
g O
and O
6a O
- O
g O
were O
synthesized O
in O
good O
to O
excellent O
yield O
from O
the O
corresponding O
pyrazole B
chalcones I
, O
4a O
- O
g O
, O
by O
using O
polyethylene B
glycol I
- I
400 I
( O
PEG O
- O
400 O
) O
as O
an O
alternative O
reaction O
medium O
. O

The O
bidentate O
metal O
binding O
amino O
acid O
bipyridylalanine B
( O
BpyAla B
) O
was O
incorporated O
into O
a O
disulfide O
linked O
cyclic O
peptide O
phage O
displayed O
library O
to O
identify O
metal O
ion O
binding O
peptides O
. O

Selection O
against O
Ni O
( O
2 O
+ O
) O
- O
nitrilotriacetic B
acid I
( O
NTA B
) O
enriched O
for O
sequences O
containing O
histidine O
and O
BpyAla B
. O

BpyAla B
predominated O
when O
selections O
were O
carried O
out O
at O
lower O
pH O
, O
consistent O
with O
the O
differential O
pKa O
' O
s O
of O
histidine O
and O
BpyAla B
. O

Two O
peptides O
containing O
BpyAla B
were O
synthesized O
and O
found O
to O
bind O
Ni O
( O
2 O
+ O
) O
with O
low O
micromolar O
dissociation O
constants O
. O

Incorporation O
of O
BpyAla B
and O
other O
metal O
binding O
amino O
acids O
into O
peptide O
and O
protein O
libraries O
should O
enable O
the O
evolution O
of O
novel O
binding O
and O
catalytic O
activities O
. O

We O
previously O
reported O
that O
the O
brief O
exposure O
of O
hippocampal O
slices O
to O
dihydroxyphenylglyci B
( O
DHPG O
) O
can O
result O
in O
a O
long O
- O
term O
depression O
( O
LTD O
) O
of O
excitatory O
synaptic O
transmission O
. O

We O
report O
that O
activation O
of O
group O
II O
mGlu O
receptors O
in O
the O
temporo O
- O
ammonic O
pathway O
( O
TAP O
) O
and O
mossy O
fibre O
pathway O
within O
the O
hippocampus O
and O
in O
the O
cortical O
input O
to O
neurons O
of O
the O
lateral O
amygdala O
induces O
an O
LTD O
that O
is O
reversed O
by O
LY341495 B
, O
a O
group O
II O
mGlu O
receptor O
antagonist O
. O

Structure O
- O
activity O
relationship O
of O
5 B
- I
chloro I
- I
2 I
- I
methyl I
- I
3 I
- I
( I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridin I
- I
4 I
- I
yl I
) I
- I
1H I
- I
indole I
analogues O
as O
5 O
- O
HT6 O
receptor O
agonists O
. O

To O
further O
investigate O
the O
structure O
- O
activity O
relationship O
( O
SAR O
) O
of O
the O
5 O
- O
hydroxytryptamine O
type O
6 O
( O
5 O
- O
HT6 O
) O
receptor O
agonist O
5 B
- I
chloro I
- I
2 I
- I
methyl I
- I
3 I
- I
( I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridin I
- I
4 I
- I
yl I
) I
- I
1H I
- I
indole I
( O
EMD386088 B
, O
6 O
) O
, O
a O
series O
of O
2 O
- O
methyl O
- O
3 O
- O
( O
1 O
, O
2 O
, O
3 O
, O
6 O
- O
tetrahydropyridin O
- O
4 O
- O
yl O
) O
- O
1H O
- O
indoles O

We O
focused O
on O
substituents O
made O
at O
the O
indole B
N O
( O
1 O
) O
- O
, O
2 O
- O
and O
5 O
- O
positions O
and O
these O
were O
found O
to O
not O
only O
influence O
the O
affinity O
at O
5 O
- O
HT6 O
receptors O
but O
also O
the O
intrinsic O
activity O
leading O
to O
antagonists O
, O
partial O
agonists O
and O
full O
agonists O
. O

In O
order O
for O
a O
compound O
to O
demonstrate O
potent O
5 O
- O
HT6 O
receptor O
agonist O
properties O
, O
the O
indole O
N O
( O
1 O
) O
should O
be O
unsubstituted O
, O
an O
alkyl O
group O
such O
as O
2 B
- I
methyl I
is O
needed O
and O
finally O
halogen O
substituents O
in O
the O
indole O
5 O
- O
position O
( O
fluoro B
, O
chloro O
or O
, O
bromo B
) O
were O
essential O
requirements O
. O

However O
, O
the O
introduction O
of O
a O
benzenesulfonyl B
group O
at O
N O
( O
1 O
) O
- O
position O
switched O
the O
full O
agonist O
6 O
to O
be O
a O
5 O
- O
HT6 O
receptor O
antagonist O
( O
30 O
) O
. O

A O
few O
compounds O
within O
the O
2 B
- I
methyl I
- I
3 I
- I
( I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridin I
- I
4 I
- I
yl I
) I
- I
1H I
- I
indoles I
were O
also O
screened O
for O
off O
- O
targets O
and O
generally O
they O
displayed O
low O
affinity O
for O
other O
5 O
- O
HT O
subtypes O
and O
serotonin O
transporter O
protein O
( O
SERT O
) O
. O

Induction O
of O
G2 O
/ O
M O
arrest O
, O
caspase O
activation O
and O
apoptosis O
by O
alpha B
- I
santonin I
derivatives O
in O
HL O
- O
60 O
cells O
. O

Sesquiterpene O
lactones O
( O
SLs B
) O
are O
natural O
products O
with O
a O
variety O
of O
biological O
activities O
. O

Previously O
, O
we O
demonstrated O
the O
cytotoxic O
effects O
of O
three O
new O
alpha B
- I
santonin I
derivatives O
on O
different O
tumor O
cell O
lines O
with O
low O
toxic O
effects O
upon O
peripheral O
human O
leukocytes O
. O

Therefore O
, O
these O
santonin B
derivatives O
are O
promising O
lead O
candidates O
for O
development O
of O
new O
cytotoxic O
agents O
. O

The O
existing O
evidence O
suggests O
that O
methyldopa B
and O
labetalol B
probably O
do O
not O
adversely O
affect O
neurobehavioral O
development O
. O

Tail O
Tip O
Proteins O
Related O
to O
Bacteriophage O
lambda O
gpL O
Coordinate O
an O
Iron B
- I
Sulfur I
Cluster O
. O

The O
C O
- O
terminal O
domain O
was O
demonstrated O
to O
coordinate O
an O
iron B
- I
sulfur I
cluster O
, O
providing O
the O
first O
example O
of O
a O
viral O
structural O
protein O
binding O
to O
this O
type O
of O
metal O
group O
. O

We O
characterized O
the O
iron B
- I
sulfur I
cluster O
using O
inductively O
coupled O
plasma O
- O
atomic O
emission O
spectroscopy O
, O
absorbance O
spectroscopy O
, O
and O
electron O
paramagnetic O
resonance O
spectroscopy O
and O
found O
that O
it O
is O
an O
oxygen O
- O
sensitive O
[ B
4Fe I
- I
4S I
] I
( I
2 I
+ I
) I
cluster O
. O

Four O
highly O
conserved O
cysteine O
residues O
were O
shown O
to O
be O
required O
for O
coordinating O
the O
iron B
- I
sulfur I
cluster O
, O
and O
substitution O
of O
any O
of O
these O
Cys O
residues O
with O
Ser O
or O
Ala O
within O
the O
context O
of O
lambda O
gpL O
abolished O
biological O
activity O
. O

These O
data O
imply O
that O
the O
intact O
iron B
- I
sulfur I
cluster O
is O
required O
for O
function O
. O

The O
presence O
of O
four O
conserved O
Cys O
residues O
in O
the O
C O
- O
terminal O
regions O
of O
very O
diverse O
gpL O
homologues O
suggest O
that O
utilization O
of O
an O
iron B
- I
sulfur I
cluster O
is O
a O
widespread O
feature O
of O
non O
- O
contractile O
tailed O
phages O
that O
infect O
Gram O
- O
negative O
bacteria O
. O

In O
addition O
, O
this O
is O
the O
first O
example O
of O
a O
viral O
structural O
protein O
that O
binds O
an O
iron B
- I
sulfur I
cluster O
. O

Oily O
nanosuspension O
for O
long O
- O
acting O
intramuscular O
delivery O
of O
curcumin B
didecanoate I
prodrug O
: O
Preparation O
, O
characterization O
and O
in O
vivo O
evaluation O
. O

The O
objective O
of O
this O
study O
was O
to O
prepare O
the O
nanocrystals O
of O
curcumin B
didecanoate I
( O
CurDD B
) O
by O
wet O
ball O
milling O
and O
to O
investigate O
the O
comparative O
pharmacokinetics O
of O
oily O
nano O
- O
and O
micro O
- O
suspensions O
after O
intramuscular O
( O
i O
. O
m O
. O
) O
administration O
to O
rats O
. O

Upon O
optimizing O
the O
wet O
ball O
milling O
parameters O
, O
CurDD B
nanocrystals O
were O
produced O
with O
median O
particle O
size O
of O
~ O
500nm O
and O
the O
freeze O
- O
dried O
nanocrystals O
were O
readily O
dispersed O
in O
peanut O
oil O
to O
form O
stable O
nanosuspensions O
. O

In O
addition O
, O
the O
nanosuspension O
provided O
significant O
higher O
plasma O
curcumin O
concentrations O
and O
brain O
CurDD B
contents O
for O
at O
least O
15days O
than O
the O
microsuspension O
, O
except O
for O
the O
initial O
times O
. O

This O
study O
demonstrates O
that O
CurDD B
nanosuspension O
may O
act O
as O
a O
long O
- O
acting O
i O
. O
m O
. O
injectable O
for O
sustained O
delivery O
of O
curcumin O
, O
potentially O
applicable O
to O
elicit O
a O
long O
- O
lasting O
antidepressant O
effect O
. O

Chloroaluminium B
phthalocyanine I
polymeric O
nanoparticles O
as O
photosensitisers O
: O
Photophysical O
and O
physicochemical O
characterisation O
, O
release O
and O
phototoxicity O
in O
vitro O
. O

Nanoparticles O
of O
poly B
( I
d I
, I
l I
- I
lactide I
- I
co I
- I
glycolide I
) I
, O
poly O
( O
d O
, O
l O
- O
lactide O
) O
and O
polyethylene B
glycol I
- I
block I
- I
poly I
( I
d I
, I
l I
- I
lactide I
) I
were O
developed O
to O
encapsulate O
chloroaluminium B
phthalocyanine I
( O
AlClPc B
) O
, O
a O
new O
hydrophobic O
photosensitiser O
used O
in O
photodynamic O
therapy O
( O
PDT O
) O
. O

The O
characteristic O
photophysical O
parameters O
were O
analysed O
: O
the O
absorption O
spectrum O
profile O
, O
fluorescence O
quantum O
yield O
and O
transient O
absorbance O
decay O
, O
with O
similar O
values O
for O
free O
and O
nanoparticles O
of O
AlClPc B
. O

The O
time O
- O
resolved O
spectroscopy O
measurements O
for O
AlClPc B
triplet O
excited O
state O
lifetimes O
indicate O
that O
encapsulation O
in O
nanocapsules O
increases O
triplet O
lifetime O
, O
which O
is O
advantageous O
for O
PDT O
efficiency O
. O

An O
in O
vitro O
phototoxic O
effect O
higher O
than O
80 O
% O
was O
observed O
in O
human O
fibroblasts O
at O
low O
laser O
light O
doses O
( O
3J O
/ O
cm O
( O
2 O
) O
) O
with O
10 O
mu O
M O
of O
AlClPc B
. O

The O
AlClPc B
loaded O
within O
polymeric O
nanocapsules O
presented O
suitable O
physical O
stability O
, O
improved O
photophysical O
properties O
, O
sustained O
released O
profile O
and O
suitable O
activity O
in O
vitro O
to O
be O
considered O
a O
promising O
formulation O
for O
PDT O
. O

Arsenic O
trioxide O
( O
As2O3 B
; O
ATO O
) O
is O
clinically O
effective O
in O
treating O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
; O
however O
, O
it O
frequently O
causes O
cardiotoxic O
effects O
. O

Finally O
, O
pretreatment O
with O
LY364947 B
, O
an O
inhibitor O
of O
TGF O
- O
beta O
signaling O
could O
apparently O
reverse O
these O
changes O
. O

Reproductive O
toxicity O
of O
phthalate O
esters O
( O
PEs B
) O
occurs O
in O
rat O
offspring O
exposed O
in O
utero O
, O
a O
phenomenon O
that O
is O
better O
studied O
in O
male O
offspring O
than O
females O
. O

The O
current O
study O
reports O
female O
reproductive O
tract O
malformations O
in O
the O
Sprague O
- O
Dawley O
rat O
similar O
to O
those O
characteristic O
of O
MRKH O
syndrome O
, O
following O
in O
utero O
exposure O
to O
a O
mixture O
of O
5 O
PEs B
. O

The O
ethylene B
bis I
- I
dithiocarbamate I
fungicide O
Mancozeb B
activates O
voltage O
- O
gated O
KCNQ2 O
potassium O
channel O
. O

Mancozeb B
( O
manganese B
/ I
zinc I
ethylene I
bis I
- I
dithiocarbamate I
) O
is O
an O
organometallic O
fungicide O
that O
has O
been O
associated O
with O
human O
neurotoxicity O
and O
neurodegeneration O
. O

In O
a O
high O
- O
throughput O
screen O
for O
modulators O
of O
KCNQ2 O
channel O
, O
a O
fundamental O
player O
modulating O
neuronal O
excitability O
, O
Mancozeb B
, O
was O
found O
to O
significantly O
potentiate O
KCNQ2 O
activity O
. O

Mancozeb B
was O
validated O
electrophysiological O
as O
a O
KCNQ2 O
activator O
with O
an O
EC50 O
value O
of O
0 O
. O
92 O
+ O
/ O
- O
0 O
. O
23 O
mu O
M O
. O

Further O
examination O
showed O
that O
manganese O
but O
not O
zinc B
ethylene I
bis I
- I
dithiocarbamate I
is O
the O
active O
component O
for O
the O
positive O
modulation O
effects O
. O

Our O
study O
suggests O
that O
potentiation O
on O
KCNQ2 O
potassium O
channels O
might O
be O
the O
possible O
mechanism O
of O
Mancozeb B
toxicity O
in O
the O
nervous O
system O
. O

Global O
and O
MGMT O
promoter O
hypomethylation O
independently O
associated O
with O
genomic O
instability O
of O
lymphocytes O
in O
subjects O
exposed O
to O
high O
- O
dose O
polycyclic B
aromatic I
hydrocarbon I
. O

We O
used O
bisulfite O
- O
PCR O
pyrosequencing O
to O
quantitate O
DNA O
methylation O
in O
long O
interspersed O
nuclear O
element O
- O
1 O
( O
LINE O
- O
1 O
) O
and O
O B
( I
6 I
) I
- I
methylguanine I
- O
DNA O
methyltransferase O
( O
MGMT O
) O
. O

In O
vitro O
study O
revealed O
that O
treatment O
of O
COE O
in O
16HBE O
cells O
resulted O
in O
higher O
production O
of O
BPDE B
- O
DNA O
adducts O
, O
LINE O
- O
1 O
hypomethylation O
, O
hypomethylation O
, O
and O
suppression O
of O
MGMT O
expression O
. O

After O
treatment O
, O
the O
levels O
of O
serum O
creatine O
kinase O
isozyme O
MB O
( O
CK O
- O
MB O
) O
, O
creatine O
kinase O
, O
creatinine O
, O
glutamate O
- O
oxalacetate B
transaminase O
( O
AST O
) O
, O
glutamate O
- O
pyruvate O
transaminase O
( O
ALT O
) O
, O
APACHE O
II O
score O
on O
the O
1st O
, O
2nd O
, O
and O
7th O
day O
in O
both O
the O
treatment O
groups O
were O
lower O
than O
that O
before O
the O
treatment O
( O
P O
< O
0 O
. O
05 O
) O
. O

The O
ameliorating O
effects O
of O
5 B
, I
7 I
- I
dihydroxy I
- I
6 I
- I
methoxy I
- I
2 I
( I
4 I
- I
phenoxyphenyl I
) I
- I
4H I
- I
chromene I
- I
4 I
- I
one I
, O
an O
oroxylin B
A I
derivative O
, O
against O
memory O
impairment O
and O
sensorimotor O
gating O
deficit O
in O
mice O
. O

We O
previously O
reported O
that O
oroxylin B
A I
, O
a O
gamma O
- O
aminobutyric O
acid O
A O
( O
GABAA O
) O
receptor O
antagonist O
, O
ameliorates O
drugs O
- O
induced O
memory O
impairments O
. O

We O
synthesized O
several O
oroxylin B
A I
derivatives O
in O
efforts O
to O
find O
a O
substance O
that O
has O
pro O
- O
cognitive O
effects O
as O
well O
as O
improves O
sensorimotor O
gating O
. O

The O
aim O
of O
the O
present O
study O
is O
to O
investigate O
the O
effect O
of O
a O
novel O
oroxylin B
A I
derivative O
, O
5 B
, I
7 I
- I
dihydroxy I
- I
6 I
- I
methoxy I
- I
2 I
( I
4 I
- I
phenoxyphenyl I
) I
- I
4H I
- I
chromene I
- I
4 I
- I
one I
( O
DMPC O
) O
, O
on O
pharmacological O
models O
of O
schizophrenia O
, O
which O
exhibit O
memory O
impairment O
and O
sensorimotor O
gating O
deficit O
. O

Progress O
in O
the O
studies O
on O
tryptanthrin B
, O
an O
alkaloid O
of O
history O
. O

Tryptanthrin B
, O
an O
indoloquinazoline B
alkaloid I
, O
was O
first O
obtained O
by O
sublimation O
of O
natural O
indigo O
and O
later O
isolated O
from O
the O
culture O
of O
fungus O
Candida O
lipolytica O
and O
a O
variety O
of O
other O
natural O
sources O
. O

Tryptanthrin B
showed O
a O
variety O
of O
intriguing O
biological O
properties O
such O
as O
antibacterial O
, O
antifungal O
, O
antiprotozoal O
, O
and O
antiparasitic O
activities O
, O
inhibitory O
activities O
against O
COX O
- O
2 O
, O
5 O
- O
LOX O
, O
NO O
synthase O
and O
PGE O
( O
2 O
) O
expression O
, O
as O
well O
as O
cytotoxic O
and O
antitumor O
activities O
. O

Present O
review O
covers O
recent O
studies O
on O
the O
natural O
sources O
, O
biological O
activities O
and O
mechanisms O
of O
their O
actions O
, O
synthesis O
, O
structure O
- O
activity O
relationship O
, O
and O
metabolism O
of O
tryptanthrin B
. O

A O
series O
of O
six O
/ O
five O
member O
( B
E I
/ I
Z I
) I
- I
Goniothalamin I
analogs O
were O
synthesized O
from O
commercially O
available O
( B
3 I
, I
4 I
- I
dihydro I
- I
2H I
- I
pyran I
- I
2 I
- I
yl I
) I
methanol I
/ O
5 B
- I
( I
hydroxymethyl I
) I
dihydrofuran I
- I
2 I
( I
3H I
) I
- I
one I
in O
three O
steps O
with O
good O
to O
moderate O
overall O
yields O
and O
their O
cytotoxicity O
against O
lymphoblastic O
leukemic O
T O
cell O
line O
( O
Jurkat O
E6 O
. O
1 O
) O
have O
been O
evaluated O
. O

Among O
the O
synthesized O
analogs O
, O
( B
Z I
) I
- I
Goniothalamin I
appeared O
to O
be O
the O
most O
active O
in O
cytotoxicity O
( O
IC50 O
= O
12 O
mu O
M O
) O
. O

Self O
- O
diffusion O
coefficient O
measurements O
were O
performed O
for O
pure O
n B
- I
alkyl I
ketone I
liquids O
using O
the O
pulsed O
field O
gradient O
NMR O
spin O
- O
echo O
technique O
. O

Ionic O
conductivities O
and O
dielectric O
constants O
of O
0 O
. O
0055 O
mol O
. O
L O
( O
- O
1 O
) O
tetrabutylammonium B
trifluoromethanesulf I
in O
2 B
- I
pentanone I
, O
2 B
- I
hexanone I
, O
2 B
- I
heptanone I
, O
2 B
- I
octanone I
, O
2 B
- I
nonanone I
, O
and O
2 B
- I
decanone I
were O
also O
measured O
. O

The O
data O
for O
the O
pure O
ketones O
and O
ketone O
- O
based O
electrolytes O
are O
compared O
with O
analogous O
data O
for O
pure O
n B
- I
alkyl I
acetates I
and O
n B
- I
alkyl I
acetate I
- O
based O
electrolytes O
. O

Synthesis O
and O
Pharmacological O
Characterization O
of O
2 B
- I
( I
Acylamino I
) I
thiophene I
Derivatives O
as O
Metabolically O
Stable O
, O
Orally O
Effective O
, O
Positive O
Allosteric O
Modulators O
of O
the O
GABAB O
Receptor O
. O

Two O
recently O
reported O
hit O
compounds O
, O
COR627 B
and O
COR628 B
, O
underpinned O
the O
development O
of O
a O
series O
of O
2 B
- I
( I
acylamino I
) I
thiophene I
derivatives O
. O

Although O
displaying O
a O
lower O
potency O
in O
vitro O
than O
the O
reference O
compound O
GS39783 B
, O
the O
new O
compounds O
6 O
, O
10 O
, O
and O
11 O
exhibited O
a O
higher O
efficacy O
in O
vivo O
: O
combination O
of O
these O
compounds O
with O
a O
per O
se O
nonsedative O
dose O
of O
baclofen O
resulted O
in O
shorter O
onset O
and O
longer O
duration O
of O
the O
loss O
of O
righting O
reflex O
in O
mice O
. O

Test O
compounds O
showed O
cytotoxic O
effects O
at O
concentrations O
comparable O
to O
or O
higher O
than O
those O
of O
GS39783 B
or O
BHF177 O
. O

Catalytic O
Asymmetric O
Synthesis O
of O
gamma B
- I
Butenolides I
by O
Direct O
Vinylogous O
Reactions O
. O

The O
gamma B
- I
butenolide I
structural O
motif O
is O
a O
prominent O
feature O
in O
many O
bioactive O
natural O
products O
and O
drugs O
. O

This O
short O
review O
summarizes O
catalytic O
asymmetric O
synthesis O
of O
gamma B
- I
butenolides I
through O
direct O
vinylogous O
reactions O
by O
metal O
complexes O
and O
organocatalysts O
. O

In O
light O
of O
building O
chiral O
gamma B
- I
tertiary I
and I
quaternary I
carbon I
centers O
of O
butenolides B
, O
three O
synthetic O
strategies O
are O
included O
: O
1 O
) O
the O
reactions O
with O
furanone O
derivatives O
as O
nucleophiles O
, O
2 O
) O
olefination O
of O
gamma B
, I
gamma I
- I
disubstituted I
butenolides I
and O
3 O
) O
the O
reactions O
by O
using O
gamma B
, I
gamma I
- I
disubstituted I
butenolides I
as O
nucleophiles O
. O

In O
this O
mini O
review O
, O
we O
summarize O
our O
recent O
studies O
on O
transition O
metal O
- O
catalyzed O
green O
and O
atom O
efficient O
transformations O
of O
P B
( I
O I
) I
- I
H I
bonds O
to O
various O
versatile O
organophosphorus O
compounds O
, O
including O
the O
highly O
regio O
- O
and O
stereoselective O
P B
( I
O I
) I
- I
H I
additions O
to O
carbon O
- O
carbon O
unsaturated O
compounds O
, O
asymmetric O
hydrophosphorylation O
reactions O
, O
and O
dehydrogenative O
coupling O
reactions O
of O
P B
( I
O I
) I
- I
H I
compounds O
with O
carbon O
- O
H O
and O
heteroatom O
- O
H O
compounds O
. O

The O
emergence O
of O
solid O
- O
phase O
and O
combinatorial O
chemistry O
has O
led O
to O
renewed O
interest O
in O
using O
organoselenium B
resins O
to O
library O
drug O
- O
like O
production O
. O

In O
this O
mini O
review O
, O
we O
summarize O
the O
construction O
of O
heterocyclic O
compounds O
libraries O
such O
as O
isoxazoles B
, O
oxadiazoles B
, O
triazoles O
, O
pyrimidines O
, O
pyrrolines B
, O
indolines B
, O
benzopyrans B
, O
furans B
etc O
. O
using O
organoselenium B
resins O
. O

Enzymatically O
catalyzed O
polycondensation O
of O
p B
- I
xylylenediamine I
and O
diethyl B
sebacate I
resulted O
in O
oligo B
( I
p I
- I
xylylene I
sebacamide I
) I
with O
high O
melting O
temperatures O
( O
223 O
- O
230 O
degrees O
C O
) O
and O
the O
enzymatic O
polycondensation O
of O
dimethyl B
terephthalate I
and O
1 B
, I
8 I
- I
diaminooctane I
leads O
to O
oligo B
( I
octamethylene I
terephthalamide I
) I
with O
two O
melting O
temperatures O
at O
186 O
and O
218 O
degrees O
C O
. O

No O
oligoamides O
, O
but O
products O
1 O
and O
2 O
, O
were O
formed O
from O
the O
enzymatic O
reaction O
of O
dimethyl B
terephthalate I
and O
p B
- I
xylylenediamine I
. O

The O
highest O
DPmax O
of O
15 O
was O
achieved O
in O
a O
one O
- O
step O
and O
two O
- O
step O
synthesis O
of O
oligo B
( I
p I
- I
xylylene I
sebacamide I
) I
catalyzed O
by O
CLEA O
cutinase O
. O

The O
aqueous O
root O
extracts O
of O
Pentanisia O
prunelloides O
combined O
( O
1 O
: O
1 O
) O
with O
Elephantorrhiza O
elephantina O
displayed O
synergistic O
interactions O
( O
Esh O
FIC O
values O
0 O
. O
31 O
- O
0 O
. O
38 O
) O
against O
Staphylococcus O
aureus O
, O
gentamycin B
- O
methicillin O
resistant O
Staphylococcus O
aureus O
, O
Staphylococcus O
epidermidis O
and O
Candida O
albicans O
. O

Fractionation O
of O
Aristea O
ecklonii O
resulted O
in O
the O
isolation O
of O
the O
known O
bioactive O
compound O
, O
plumbagin B
, O
displaying O
noteworthy O
antimicrobial O
activity O
( O
MIC O
range O
between O
2 O
. O
00 O
mu O
g O
/ O
ml O
and O
16 O
. O
00 O
mu O
g O
/ O
ml O
) O
. O

Noteworthy O
antimicrobial O
activities O
( O
MIC O
range O
between O
2 O
. O
00 O
mu O
g O
/ O
ml O
and O
16 O
. O
00 O
mu O
g O
/ O
ml O
) O
were O
observed O
for O
plumbagin B
isolated O
from O
Aristea O
ecklonii O
. O

For O
the O
first O
time O
, O
stable O
overcharge O
protection O
for O
hundreds O
of O
cycles O
was O
demonstrated O
in O
several O
cell O
chemistries O
, O
including O
LiNi1 B
/ O
3Co1 B
/ O
3Mn1 B
/ O
3O2 B
, O
LiFePO4 O
, O
and O
spinel O
Li1 B
. I
05Mn1 I
. I
95O4 I
half O
- O
cells O
. O

After O
4 O
- O
h O
incubation O
in O
supplemented O
S9 O
fraction O
, O
the O
MTX O
content O
was O
35 O
% O
lower O
and O
5 O
metabolites O
were O
identified O
: O
an O
acetoxy O
ester O
derivative O
( O
never O
described O
before O
) O
, O
two O
glutathione O
conjugates O
, O
a O
monocarboxylic O
acid O
derivative O
, O
and O
the O
naphtoquinoxaline B
, O
the O
later O
commonly O
related O
to O
MTX O
pharmacological O
effects O
. O

The O
presence O
of O
MTX O
and O
naphtoquinoxaline B
metabolite O
was O
evidenced O
in O
vivo O
in O
liver O
and O
heart O
of O
MTX O
- O
treated O
rats O
. O

The O
naphtoquinoxaline B
metabolite O
is O
described O
in O
heart O
and O
liver O
in O
vivo O
, O
highlighting O
that O
this O
metabolite O
accumulates O
in O
these O
tissues O
. O

Six O
new O
cyclic O
peptides O
, O
gypsophin B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
were O
isolated O
from O
Gypsophila O
oldhamiana O
. O

Abstract O
Objective O
: O
Lyophilized O
microparticles O
composed O
of O
budesonide O
( O
BDS B
) O
, O
hydroxypropyl O
- O
beta O
- O
cyclodextrin O
( O
HP O
- O
beta O
- O
CD O
) O
, O
and O
hydroxypropylmethylc O
( O
HPMC O
) O
or O
sodium O
carboxymethylcellulo O
( O
CMC O
- O
Na O
) O
were O
developed O
for O
intranasal O
delivery O
and O
their O
characteristics O
were O
evaluated O
. O

Results O
and O
discussion O
: O
Lyophilized O
microparticles O
exhibited O
vanishment O
of O
crystallinity O
of O
drug O
in O
XRPD O
analysis O
, O
the O
enfeeblement O
of O
carbonyl O
( O
C O
= O
O O
) O
stretching O
bands O
of O
carboxyl O
group O
in O
BDS B
in O
FT O
- O
IR O
spectra O
and O
the O
disappearance O
of O
endothermic O
peak O
of O
drug O
in O
the O
results O
of O
DSC O
study O
. O

Based O
on O
the O
results O
of O
solid O
- O
state O
studies O
, O
BDS B
was O
existed O
as O
an O
amorphous O
form O
in O
the O
lyophilized O
microparticles O
. O

Conclusion O
: O
Developed O
microparticles O
can O
efficiently O
deliver O
insoluble O
drug O
, O
such O
as O
BDS B
, O
to O
the O
nasal O
epithelium O
and O
thus O
it O
may O
improve O
therapeutic O
efficacy O
in O
the O
respiratory O
tract O
. O

Hydrogen O
sulfide O
( O
H2S B
) O
, O
known O
as O
an O
important O
cellular O
signaling O
molecule O
, O
plays O
critical O
roles O
in O
many O
physiological O
and O
/ O
or O
pathological O
processes O
. O

Modulation O
of O
H2S B
levels O
could O
have O
tremendous O
therapeutic O
value O
. O

However O
, O
the O
study O
on O
H2S B
has O
been O
hindered O
due O
to O
the O
lack O
of O
controllable O
H2S B
releasing O
agents O
that O
could O
mimic O
the O
slow O
and O
moderate O
H2S B
release O
in O
vivo O
. O

In O
this O
work O
we O
report O
the O
design O
, O
synthesis O
, O
and O
biological O
evaluation O
of O
a O
new O
class O
of O
controllable O
H2S B
donors O
. O

Their O
structures O
were O
based O
on O
a O
perthiol B
template O
, O
which O
was O
suggested O
to O
be O
involved O
in O
H2S B
biosynthesis O
. O

H2S B
release O
mechanism O
from O
these O
donors O
was O
studied O
and O
proved O
to O
be O
thiol O
- O
dependent O
. O

We O
also O
developed O
a O
series O
of O
cell O
- O
based O
assays O
to O
access O
their O
H2S B
- O
related O
activities O
. O

We O
tested O
lead O
donors O
' O
cytotoxicity O
and O
confirmed O
their O
H2S B
production O
in O
cells O
. O

Finally O
we O
demonstrated O
that O
selected O
donors O
showed O
potent O
protective O
effects O
in O
an O
in O
vivo O
murine O
model O
of O
myocardial O
ischemia O
- O
reperfusion O
injury O
, O
through O
a O
H2S B
- O
related O
mechanism O
. O

Two O
new O
hybrid O
isoprenoids O
, O
named O
indotertine B
B I
( O
2 O
) O
and O
drimentine B
H I
( O
3 O
) O
, O
along O
with O
the O
known O
analogue O
drimentine B
C I
( O
4 O
) O
, O
were O
isolated O
from O
the O
reed O
rhizosphere O
soil O
derived O
actinomycete O
Streptomyces O
sp O
. O

Indotertine B
B I
( O
2 O
) O
exists O
as O
a O
pair O
of O
rotamers O
about O
the O
N B
- I
C I
( I
O I
) I
bond O
with O
a O
2 O
: O
1 O
ratio O
and O
displays O
activities O
against O
HCT O
- O
8 O
and O
A549 O
tumor O
cell O
lines O
with O
IC50 O
values O
of O
6 O
. O
96 O
and O
4 O
. O
88 O
mu O
M O
, O
respectively O
. O

A O
Coupling O
of O
Benzamides B
and O
Donor O
/ O
Acceptor O
Diazo B
Compounds O
To O
Form O
gamma B
- I
Lactams I
via O
Rh B
( I
III I
) I
- O
Catalyzed O
C O
- O
H O
Activation O
. O

The O
coupling O
of O
O B
- I
pivaloyl I
benzhydroxamic I
acids I
with O
donor O
/ O
acceptor O
diazo B
compounds O
provides O
isoindolones B
in O
high O
yield O
. O

The O
reaction O
tolerates O
a O
broad O
range O
of O
benzhydroxamic B
acids I
and O
diazo B
compounds O
, O
including O
substituted O
2 B
, I
2 I
, I
2 I
- I
trifluorodiazoethane I
. O

Mechanistic O
experiments O
suggested O
that O
C O
- O
H O
activation O
is O
turnover O
- O
limiting O
and O
irreversible O
and O
that O
insertion O
of O
the O
diazo B
compound O
favors O
electron O
- O
deficient O
substrates O
. O

Bioavailability O
, O
metabolism O
and O
disposition O
of O
oral O
pazopanib B
in O
patients O
with O
advanced O
cancer O
. O

1 O
. O
Pazopanib B
( O
Votrient B
) O
is O
an O
oral O
tyrosine O
kinase O
inhibitor O
that O
was O
recently O
approved O
for O
the O
treatment O
of O
renal O
cell O
carcinoma O
and O
soft O
tissue O
sarcoma O
. O

2 O
. O
In O
this O
two O
- O
part O
study O
, O
we O
investigated O
the O
metabolism O
, O
disposition O
of O
[ B
( I
14 I
) I
C I
] I
pazopanib I
, O
and O
the O
oral O
bioavailability O
of O
pazopanib B
tablets O
in O
patients O
with O
advanced O
cancer O
. O

3 O
. O
In O
part O
A O
, O
three O
men O
each O
received O
a O
single O
oral O
dose O
of O
[ B
( I
14 I
) I
C I
] I
pazopanib I
in O
suspension O
( O
400 O
mg O
, O
70 O
micro O
Ci O
) O
. O

Pazopanib B
was O
the O
predominant O
drug O
- O
related O
component O
in O
circulation O
. O

Pazopanib B
was O
primarily O
excreted O
as O
the O
unchanged O
drug O
in O
faeces O
( O
67 O
% O
of O
dose O
) O
. O

4 O
. O
In O
part O
B O
, O
seven O
additional O
patients O
received O
a O
single O
intravenous O
administration O
of O
5 O
mg O
pazopanib B
( O
day O
1 O
) O
followed O
by O
oral O
administration O
of O
800 O
mg O
pazopanib B
tablet O
once O
daily O
for O
26 O
days O
( O
days O
3 O
or O
5 O
- O
28 O
) O
. O

In O
the O
three O
evaluable O
patients O
from O
part O
B O
, O
pazopanib B
had O
a O
slow O
plasma O
clearance O
and O
a O
small O
volume O
of O
distribution O
. O

The O
absolute O
oral O
bioavailability O
of O
the O
800 O
mg O
pazopanib B
tablet O
ranged O
from O
14 O
% O
to O
39 O
% O
. O

MATERIALS O
AND O
METHODS O
: O
Liver O
injury O
was O
induced O
by O
oral O
administration O
of O
30 O
% O
alcohol O
( O
10mL O
/ O
kg O
, O
twice O
per O
day O
) O
plus O
pyrazole O
( O
PRZ B
, O
30mg O
/ O
kg O
) O
with O
/ O
without O
WAC O
( O
50 O
, O
100mg O
/ O
kg O
, O
orally O
once O
per O
day O
) O
or O
silymarin O
( O
50mg O
/ O
kg O
) O
for O
10 O
days O
. O

RESULTS O
: O
Alcohol O
- O
PRZ B
treatment O
drastically O
increased O
the O
serum O
levels O
of O
aspartate O
transaminase O
( O
AST O
) O
, O
alanine O
transaminase O
( O
ALT O
) O
, O
and O
malondialdehyde O
( O
MDA O
) O
levels O
in O
serum O
and O
liver O
tissues O
while O
these O
changes O
were O
significantly O
ameliorated O
by O
WAC O
administration O
( O
p O
< O
0 O
. O
05 O
or O
0 O
. O
01 O
) O
. O

The O
prominent O
microvesicular O
steatosis O
and O
mild O
necrosis O
in O
hepatic O
histopathology O
were O
induced O
by O
alcohol O
- O
PRZ B
treatment O
, O
but O
notably O
attenuated O
by O
WAC O
administration O
. O

Moreover O
, O
the O
alcohol O
- O
PRZ B
treatment O
- O
induced O
depletions O
of O
the O
antioxidant O
components O
including O
glutathione O
content O
, O
total O
antioxidant O
capacity O
( O
TAC O
) O
, O
activities O
of O
glutathione O
peroxidase O
( O
GSH O
- O
Px O
) O
, O
reductase O
( O
GSH O
- O
Rd O
) O
, O
catalase O
, O
and O
superoxide O
dismutase O
( O
SOD O
) O
were O
significantly O
ameliorated O
by O
WAC O
administration O
( O
p O
< O
0 O
. O
05 O
, O
except O
GSH O
- O
Rd O
) O
. O

Alcohol O
- O
PRZ B
treatment O
increased O
the O
levels O
of O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
and O
transforming O
growth O
factor O
- O
beta O
( O
TGF O
- O
beta O
) O
in O
hepatic O
tissues O
. O

Novel O
quinolone O
substituted O
thiazolidin B
- I
4 I
- I
ones I
as O
anti O
- O
inflammatory O
, O
anticancer O
agents O
: O
Design O
, O
synthesis O
and O
biological O
screening O
. O

A O
library O
of O
quinolone O
substituted O
thiazolidin B
- I
4 I
- I
ones I
was O
docked O
into O
the O
active O
site O
of O
NF O
- O
kappa O
B O
and O
the O
top O
- O
ranked O
31 O
compounds O
were O
synthesized O
and O
evaluated O
for O
anti O
- O
inflammatory O
and O
anticancer O
activity O
. O

First O
, O
the O
roles O
of O
the O
amino O
acids O
cysteine O
and O
methionine O
, O
are O
discussed O
, O
followed O
by O
an O
extensive O
discussion O
of O
the O
low O
- O
molecular O
- O
weight O
tripeptide O
, O
thiol B
glutathione I
, O
which O
plays O
a O
central O
part O
in O
plant O
stress O
response O
and O
oxidative O
signalling O
and O
of O
glutathione O
- O
related O
enzymes O
, O
including O
those O
involved O
in O
the O
biosynthesis O
of O
non O
- O
protein O
thiol O
compounds O
. O

Effects O
of O
exogenous O
thiocyanate B
on O
mineral O
nutrients O
, O
antioxidative O
responses O
and O
free O
amino O
acids O
in O
rice O
seedlings O
. O

The O
effects O
of O
exogenous O
thiocyanate B
( O
SCN B
( I
- I
) I
) O
on O
amino O
acids O
composition O
, O
content O
of O
mineral O
nutrients O
and O
antioxidative O
systems O
in O
plants O
were O
investigated O
. O

Young O
rice O
seedlings O
( O
Oryza O
sativa O
L O
. O
cv O
. O
XZX O
45 O
) O
were O
grown O
in O
nutrient O
solutions O
amended O
with O
potassium B
thiocyanate I
( O
KSCN B
) O
. O

Mineral O
nutrients O
and O
free O
amino O
acids O
in O
rice O
seedlings O
were O
also O
measured O
to O
determine O
metabolic O
responses O
to O
SCN B
( I
- I
) I
exposure O
. O

SCN B
- O
induced O
toxicity O
appeared O
to O
be O
more O
sensitive O
to O
activities O
of O
POD O
in O
shoots O
and O
APX O
activities O
in O
roots O
than O
the O
others O
. O

The O
content O
of O
nutrient O
elements O
in O
rice O
seedlings O
exposed O
to O
exogenous O
SCN B
( I
- I
) I
was O
variable O
, O
while O
the O
effects O
were O
more O
evident O
at O
the O
highest O
SCN B
- O
treatment O
( O
p O
< O
0 O
. O
05 O
) O
. O

Although O
the O
change O
of O
total O
free O
amino O
acids O
in O
shoots O
of O
SCN B
- O
exposed O
seedlings O
was O
negligible O
( O
p O
> O
0 O
. O
05 O
) O
, O
responses O
of O
different O
amino O
acids O
to O
SCN B
( I
- I
) I
application O
were O
quite O
different O
. O

Among O
fifteen O
free O
amino O
acids O
detected O
, O
serine O
( O
Ser O
) O
, O
proline O
( O
Pro O
) O
, O
and O
methionine O
( O
Met O
) O
increased O
, O
while O
asparagine O
( O
Asp O
) O
decreased O
with O
an O
increase O
of O
the O
doses O
of O
SCN B
( I
- I
) I
supplied O
. O

Phyto O
- O
transport O
of O
SCN B
( I
- I
) I
was O
apparent O
and O
the O
removal O
rates O
were O
positively O
correlated O
to O
the O
doses O
, O
suggesting O
that O
phyto O
- O
assimilation O
of O
SCN B
( I
- I
) I
is O
an O
enzymatic O
process O
through O
a O
potentially O
un O
- O
identified O
degradation O
pathway O
. O

2 B
- I
Hydroxy I
- I
3 I
- I
methylanthraquinone I
from O
Hedyotis O
diffusa O
Willd O
induces O
apoptosis O
in O
human O
leukemic O
U937 O
cells O
through O
modulation O
of O
MAPK O
pathways O
. O

The O
current O
study O
determines O
the O
role O
of O
mitogen O
- O
activated O
protein O
kinases O
( O
MAPK O
) O
in O
human O
leukemic O
U937 O
cells O
apoptosis O
induced O
by O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
from O
H O
. O
diffusa O
. O

Our O
results O
showed O
that O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
decreased O
phosphorylation O
- O
ERK1 O
/ O
2 O
( O
p O
- O
ERK1 O
/ O
2 O
) O
, O
and O
increased O
p O
- O
p38MAPK O
, O
but O
did O
not O
affect O
expressions O
of O
p O
- O
JNK1 O
/ O
2 O
in O
U937 O
cells O
. O

Moreover O
, O
treatment O
of O
U937 O
cells O
with O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
resulted O
in O
activation O
of O
caspase O
- O
3 O
. O

Furthermore O
, O
PD98059 O
( O
ERK1 O
/ O
2 O
inhibitor O
) O
significantly O
enhanced O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
- O
induced O
apoptosis O
in O
U937 O
cells O
, O
whereas O
caspase O
- O
3 O
inhibitor O
or O
SB203580 O
( O
p O
- O
p38MAPK O
inhibitor O
) O
, O
decreased O
apoptosis O
in O
U937 O
cells O
. O

Taken O
together O
, O
our O
study O
for O
the O
first O
time O
suggests O
that O
2 B
- I
hydroxy I
- I
3 I
- I
methylanthraquinone I
is O
able O
to O
enhance O
apoptosis O
of O
U937 O
cells O
, O
at O
least O
in O
part O
, O
through O
activation O
of O
p O
- O
p38MAPK O
and O
downregulation O
of O
p O
- O
ERK1 O
/ O
2 O
. O

Monocarbonyl B
Curcumin I
Analogues O
: O
Heterocyclic O
Pleiotropic O
Kinase O
Inhibitors O
That O
Mediate O
Anticancer O
Properties O
. O

Eight O
new O
cycloartane B
triterpenoids I
( O
1 O
- O
8 O
) O
, O
named O
carinatins B
A I
- I
H I
, O
and O
the O
known O
compounds O
secaubryolide B
( O
9 O
) O
and O
dikamaliartane B
D I
( O
10 O
) O
were O
isolated O
from O
the O
leaves O
and O
twigs O
of O
Gardenia O
carinata O
. O

A O
high O
throughput O
assay O
for O
the O
glucuronidation O
of O
7 B
- I
hydroxy I
- I
4 I
- I
trifluoromethylcouma I
by O
recombinant O
human O
UDP O
- O
glucuronosyltransfer O
and O
liver O
microsomes O
. O

2 O
. O
We O
have O
developed O
a O
convenient O
quantitative O
multi O
- O
well O
plate O
assay O
to O
measure O
the O
glucuronidation O
rate O
of O
7 B
- I
hydroxy I
- I
4 I
- I
trifluoromethylcouma I
( O
HFC B
) O
for O
several O
UGTs O
. O

3 O
. O
We O
have O
used O
this O
method O
to O
screen O
11 O
recombinant O
human O
UGTs O
for O
HFC B
glucuronidation O
activity O
and O
studied O
the O
reaction O
kinetics O
with O
the O
most O
active O
enzymes O
. O

We O
have O
also O
examined O
the O
HFC B
glucuronidation O
activity O
of O
liver O
microsomes O
from O
human O
, O
pig O
, O
rabbit O
and O
rat O
. O

4 O
. O
At O
a O
substrate O
concentration O
of O
20 O
micro O
M O
, O
the O
most O
active O
HFC B
glucuronidation O
catalysts O
were O
UGT1A10 O
followed O
by O
UGT1A6 O
> O
UGT1A7 O
> O
UGT2A1 O
, O
whereas O
at O
300 O
micro O
M O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O

The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC B
glucuronidation O
activity O
. O

UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC B
and O
UDP O
- O
glucuronic O
acid O
than O
the O
other O
UGTs O
. O

5 O
. O
Human O
, O
pig O
and O
rabbit O
, O
but O
not O
rat O
liver O
microsomes O
, O
catalyzed O
HFC B
glucuronidation O
at O
high O
rates O
. O

6 O
. O
This O
new O
method O
is O
particularly O
suitable O
for O
fast O
activity O
screenings O
of O
UGTs O
1A6 O
, O
1A7 O
, O
1A10 O
and O
2A1 O
and O
HFC B
glucuronidation O
activity O
determination O
from O
various O
samples O
. O

Ion O
Distributions O
at O
the O
Water O
/ O
1 B
, I
2 I
- I
Dichloroethane I
Interface O
: O
Potential O
of O
Mean O
Force O
Approach O
to O
Analyzing O
X O
- O
ray O
Reflectivity O
and O
Interfacial O
Tension O
Measurements O
. O

The O
aqueous O
phase O
contains O
alkali B
- I
metal I
chlorides I
, O
including O
LiCl O
, O
NaCl O
, O
RbCl B
, O
or O
CsCl B
, O
and O
the O
organic O
phase O
is O
a O
1 B
, I
2 I
- I
dichloroethane I
solution O
of O
bis B
( I
triphenylphosphor I
anylidene I
) I
ammonium I
tetrakis I
( I
pentafluorophenyl I
) I
borate I
( O
BTPPATPFB B
) O
. O

Selected O
data O
for O
a O
subset O
of O
electric O
potential O
differences O
are O
analyzed O
to O
determine O
the O
potentials O
of O
mean O
force O
for O
Li O
( O
+ O
) O
, O
Rb O
( O
+ O
) O
, O
Cs O
( O
+ O
) O
, O
BTPPA B
( I
+ I
) I
, O
and O
TPFB B
( I
- I
) I
. O

Comparison O
of O
X O
- O
ray O
reflectivity O
data O
for O
strongly O
hydrated O
alkali B
- I
metal I
ions O
( O
Li O
( O
+ O
) O
and O
Na O
( O
+ O
) O
) O
, O
for O
which O
ion O
pairing O
to O
TPFB B
( I
- I
) I
ions O
across O
the O
interface O
is O
not O
expected O
, O
to O
data O
for O
weakly O
hydrated O
alkali B
- I
metal I
ions O
( O
Rb O
( O
+ O
) O
and O
Cs O
( O
+ O
) O
) O
indicates O
that O
the O
Gibbs O
energy O
of O
adsorption O
due O
to O
ion O
pairing O
at O
the O
interface O
must O
be O
small O
( O
< O
1 O
kBT O
per O
ion O
pair O
) O
for O
both O
the O
CsCl B
and O
RbCl B
samples O
. O

Immobilizing O
Individual O
Atoms O
beneath O
a O
Corrugated O
Single O
Layer O
of O
Boron B
Nitride I
. O

Single O
atoms O
, O
and O
in O
particular O
the O
least O
reactive O
noble B
gases I
, O
are O
difficult O
to O
immobilize O
at O
room O
temperature O
. O

Here O
we O
demonstrate O
that O
the O
boron B
nitride I
nanomesh O
, O
a O
corrugated O
single O
layer O
of O
hexagonal O
boron B
nitride I
( O
h B
- I
BN I
) O
with O
a O
3 O
. O
2 O
nm O
honeycomb O
superstructure O
formed O
on O
a O
Rh B
( I
111 I
) I
surface O
, O
can O
trap O
individual O
argon O
atoms O
at O
distinct O
subsurface O
sites O
at O
room O
temperature O
. O

A O
kinetic O
energy O
window O
for O
implantation O
is O
identified O
where O
the O
argon O
ions O
can O
penetrate O
the O
h B
- I
BN I
layer O
but O
not O
enter O
the O
Rh O
lattice O
. O

Annealing O
of O
implanted O
structures O
to O
900 O
K O
induces O
the O
formation O
of O
highly O
regular O
holes O
of O
2 O
nm O
diameter O
in O
the O
h B
- I
BN I
layer O
with O
adjacent O
flakes O
of O
the O
same O
size O
found O
on O
top O
of O
the O
layer O
. O

We O
explain O
this O
" O
can O
- O
opener O
" O
effect O
by O
the O
presence O
of O
a O
vacancy O
defect O
, O
generated O
during O
the O
penetration O
of O
the O
Ar O
ion O
through O
the O
h B
- I
BN I
lattice O
, O
and O
propagating O
along O
the O
rim O
of O
a O
nanomesh O
pore O
where O
the O
h B
- I
BN I
lattice O
is O
highly O
bent O
. O

The O
reported O
effects O
are O
also O
observed O
in O
graphene O
on O
ruthenium O
and O
for O
neon B
atoms O
. O

Effect O
of O
sugammadex B
on O
rocuronium B
induced O
changes O
in O
pancreatic O
mast O
cells O
. O

Rocuronium B
is O
known O
to O
cause O
mast O
cell O
mobilization O
, O
hypersensitivity O
, O
and O
pancreatitis O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
sugammadex B
on O
pancreatic O
changes O
due O
to O
rocuronium B
. O

A O
total O
of O
42 O
Sprague O
- O
Dawley O
male O
rats O
were O
divided O
into O
six O
equal O
groups O
to O
receive O
either O
rocuronium B
1 O
mg O
/ O
kg O
intravenously O
( O
i O
. O
v O
. O
, O
R O
group O
) O
, O
rocuronium B
1 O
mg O
/ O
kg O
+ O
sugammadex B
16 O
mg O
/ O
kg O
i O
. O
v O
. O
( O
RS16 O
group O
) O
, O
rocuronium B
1 O
mg O
/ O
kg O
+ O
sugammadex B
96 O
mg O
/ O
kg O
i O
. O
v O
. O
( O
RS96 O
group O
) O
, O
sugammadex B
16 O
mg O
/ O
kg O
( O
S16 O
) O
, O
sugammadex B
96 O
mg O
/ O
kg O
i O
. O
v O
. O
( O

Sugammadex B
was O
administered O
5s O
later O
following O
rocuronium B
. O

These O
results O
suggest O
that O
sugammadex B
may O
have O
an O
inhibitory O
effect O
on O
mobilization O
and O
morphological O
changes O
in O
pancreatic O
mast O
cells O
induced O
by O
administration O
of O
rocuronium B
and O
sugammadex B
in O
rats O
. O

Synthesis O
and O
characterization O
of O
naphthalenediimide B
- O
functionalized O
flavin O
derivatives O
. O

Two O
acceptor O
- O
acceptor O
dyads O
have O
been O
synthesized O
featuring O
a O
flavin O
moiety O
and O
a O
naphthalenediimide B
( O
NDI B
) O
unit O
. O

The O
NDI B
unit O
is O
linked O
to O
the O
flavin O
through O
a O
short O
spacer O
group O
via O
either O
the O
N O
( O
3 O
) O
or O
N O
( O
10 O
) O
positions O
of O
the O
flavin O
. O

On O
the O
Vibrational O
linear O
and O
nonlinear O
optical O
properties O
of O
compounds O
involving O
noble O
gas O
atoms O
: O
HXeOXeH B
, O
HXeOXeF B
, O
and O
FXeOXeF B
. O

HXeOXeH B
was O
used O
to O
study O
the O
effects O
of O
electron O
correlation O
, O
basis O
set O
, O
and O
geometry O
. O

Trialkylgermyl B
functionalization O
allows O
development O
of O
high O
- O
performance O
soluble O
small O
- O
molecule O
organic O
semiconductors O
with O
mobilities O
greater O
than O
5 O
cm O
( O
2 O
) O
V O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
. O

The O
Glucuronidation O
of O
R B
- I
and I
S I
- I
Lorazepam I
: O
Human O
Liver O
Microsomal O
Kinetics O
, O
UDP O
- O
Glucuronosyltransfer O
Enzyme O
Selectivity O
, O
and O
Inhibition O
by O
Drugs O
. O

The O
widely O
used O
hypnosedative O
- O
anxiolytic O
agent O
R B
, I
S I
- I
lorazepam I
is O
cleared O
predominantly O
by O
conjugation O
with O
glucuronic O
acid O
in O
humans O
, O
but O
the O
enantioselective O
glucuronidation O
of O
lorazepam O
has O
received O
little O
attention O
. O

Respective O
mean O
Km O
and O
Vmax O
values O
for O
R B
- I
and I
S I
- I
lorazepam I
by O
HLM O
were O
29 O
+ O
/ O
- O
8 O
. O
9 O
and O
36 O
+ O
/ O
- O
10 O
mu O
M O
, O
and O
7 O
. O
4 O
+ O
/ O
- O
1 O
. O
9 O
and O
10 O
+ O
/ O
- O
3 O
. O
8 O
pmol O
/ O
min O
. O
mg O
. O

Microsomal O
intrinsic O
clearances O
were O
not O
significantly O
different O
, O
suggesting O
the O
in O
vivo O
clearances O
of O
R B
- I
and I
S I
- I
lorazepam I
are O
likely O
to O
be O
similar O
. O

Both O
R B
- I
and I
S I
- I
lorazepam I
were O
glucuronidated O
by O
UGT O
2B4 O
, O
2B7 O
, O
and O
2B15 O
, O
while O
R B
- I
lorazepam I
was O
additionally O
metabolized O
by O
the O
extra O
- O
hepatic O
enzymes O
UGT O
1A7 O
and O
1A10 O
. O

Based O
on O
in O
vitro O
clearances O
and O
consideration O
of O
available O
in O
vivo O
and O
in O
vitro O
data O
, O
UGT2B15 O
is O
likely O
to O
play O
an O
important O
role O
in O
the O
glucuronidation O
of O
R B
- I
and I
S I
- I
lorazepam I
. O

In O
order O
to O
identify O
potential O
drug O
- O
drug O
interactions O
, O
codeine B
, O
fluconazole O
, O
ketamine O
, O
ketoconazole O
, O
methadone B
, O
morphine O
, O
valproic O
acid O
, O
and O
zidovudine O
were O
screened O
as O
inhibitors O
of O
R B
- I
and I
S I
- I
lorazepam I
glucuronidation O
by O
HLM O
. O

Liquid O
chromatography O
- O
mass O
spectrometry O
method O
for O
the O
quantification O
of O
posaconazole B
in O
human O
plasma O
: O
application O
to O
pharmacokinetics O
following O
single O
- O
dose O
administration O
in O
the O
fasted O
state O
and O
with O
a O
high O
- O
fat O
meal O
. O

A O
liquid O
chromatography O
/ O
tandem O
mass O
spectrometry O
( O
LC O
- O
MS O
/ O
MS O
) O
method O
was O
developed O
to O
determine O
concentrations O
of O
posaconazole B
in O
human O
plasma O
precipitated O
by O
acetonitrile O
including O
internal O
standard O
. O

Posaconazole B
- I
d4 I
was O
used O
as O
internal O
standard O
. O

The O
method O
was O
accurate O
, O
specific O
and O
sensitive O
for O
the O
analysis O
of O
posaconazole B
in O
human O
plasma O
in O
the O
concentration O
range O
of O
2 O
- O
1000 O
ng O
/ O
ml O
. O

The O
method O
facilitated O
a O
clinical O
pharmacokinetic O
study O
after O
oral O
administration O
of O
a O
single O
- O
dose O
of O
posaconazole B
suspension O
in O
the O
fasted O
state O
and O
with O
a O
high O
- O
fat O
meal O
in O
a O
two O
- O
period O
crossover O
design O
. O

Cmax O
( O
maximum O
concentration O
) O
and O
AUC O
( O
area O
under O
serum O
drug O
concentration O
) O
were O
significantly O
increased O
, O
and O
Tmax O
( O
time O
to O
maximum O
plasma O
concentration O
) O
was O
delayed O
under O
fed O
condition O
, O
which O
suggested O
that O
simultaneous O
administration O
of O
posaconazole B
with O
food O
may O
help O
to O
achieve O
higher O
plasma O
concentrations O
and O
result O
in O
better O
antifungal O
efficacy O
. O

The O
following O
surfactants O
were O
used O
in O
the O
experiments O
: O
cationic O
dodecyltrimethylammo B
bromide I
( O
DTAB B
) O
, O
anionic O
sodium O
dodecyl O
sulfate O
( O
SDS O
) O
, O
anionic O
Pantene O
shampoo O
which O
primarily O
contains O
sodium O
lauryl O
sulfate O
, O
nonionic O
tetraethylene B
glycol I
monooctyl I
ether I
( O
C8E4 B
) O
, O
and O
nonionic O
Pluronic B
( I
P I
- I
123 I
) I
surfactants O
at O
different O
concentrations O
. O

Determination O
of O
Specific O
Binding O
Interactions O
at O
l B
- I
Cystine I
Crystal O
Surfaces O
with O
Chemical O
Force O
Microscopy O
. O

The O
pathogenesis O
of O
l B
- I
cystine I
kidney O
stones O
involves O
four O
critical O
steps O
: O
nucleation O
, O
crystal O
growth O
, O
crystal O
aggregation O
, O
and O
crystal O
adhesion O
to O
cells O
. O

Although O
inhibition O
of O
crystal O
growth O
by O
l B
- I
cystine I
" O
imposters O
" O
at O
l B
- I
cystine I
crystal O
surfaces O
has O
been O
suggested O
as O
a O
plausible O
route O
for O
the O
suppression O
of O
stones O
, O
understanding O
the O
factors O
that O
govern O
crystal O
- O
crystal O
aggregation O
and O
adhesion O
of O
crystals O
to O
epithelial O
cells O
also O
is O
essential O
for O
devising O
strategies O
to O
mitigate O
l B
- I
cystine I
stone O
formation O
. O

Chemical O
force O
microscopy O
performed O
with O
atomic O
force O
microscope O
tips O
decorated O
with O
functional O
groups O
commonly O
found O
in O
urinary O
constituents O
that O
likely O
mediate O
aggregation O
and O
attachment O
( O
e O
. O
g O
. O
, O
COOH O
, O
NH2 O
, O
SH O
, O
CH3 O
, O
OH O
) O
revealed O
signatures O
that O
reflect O
differences O
in O
the O
chemical O
affinity O
of O
these O
groups O
for O
the O
( O
001 O
) O
and O
{ O
100 O
} O
faces O
of O
the O
naturally O
occurring O
hexagonal O
form O
of O
l B
- I
cystine I
single O
crystals O
and O
the O
{ O
110 O
} O
faces O
of O
the O
non O
- O
native O
tetragonal O
form O
. O

Dissolution O
enhancement O
of O
Deflazacort B
using O
hollow O
crystals O
prepared O
by O
antisolvent O
crystallization O
process O
. O

Deflazacort B
( O
DFZ B
) O
, O
a O
derivate O
of O
prednisolone O
, O
is O
a O
poorly O
soluble O
drug O
which O
has O
been O
proposed O
to O
have O
major O
advantages O
over O
other O
corticosteroids O
. O

In O
this O
study O
, O
DFZ B
was O
investigated O
in O
terms O
of O
its O
antisolvent O
crystallization O
in O
different O
solvents O
and O
under O
various O
preparation O
conditions O
( O
methanol O
/ O
water O
ratio O
, O
stirring O
and O
evaporation O
rate O
, O
etc O
. O
) O
, O
in O
order O
to O
compare O
the O
physicochemical O
properties O
between O
crystallized O
samples O
and O
raw O
materials O
available O
on O
the O
Brazilian O
market O
with O
and O
without O
micronization O
. O

Crystallization O
conditions O
were O
achieved O
which O
provided O
crystalline O
samples O
of O
hollow O
- O
shaped O
crystals O
with O
internal O
channels O
, O
which O
increased O
the O
dissolution O
rate O
of O
DFZ B
. O

A O
novel O
series O
of O
histamine O
H4 O
receptor O
antagonists O
based O
on O
the O
pyrido B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidine I
scaffold O
: O
Comparison O
of O
hERG O
binding O
and O
target O
residence O
time O
with O
PF B
- I
3893787 I
. O

In O
this O
work O
we O
describe O
the O
optimization O
of O
a O
lead O
compound O
based O
on O
the O
quinazoline O
template O
to O
give O
a O
new O
series O
of O
potent O
pyrido B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidines I
as O
histamine O
H4 O
receptor O
antagonists O
. O

The O
pyrido B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidine I
ligands O
have O
significantly O
reduced O
hERG O
binding O
compared O
to O
clinical O
stage O
compound O
PF B
- I
3893787 I
while O
showing O
good O
affinities O
at O
the O
human O
and O
rodent O
histamine O
receptors O
. O

The O
receptor O
residence O
time O
of O
several O
of O
these O
new O
compounds O
was O
determined O
for O
the O
human O
H4R O
and O
compared O
with O
JNJ7777120 B
and O
PF B
- I
3893787 I
. O

The O
pyrido B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidines I
showed O
residence O
times O
lower O
than O
JNJ7777120 B
but O
comparable O
to O
the O
residence O
time O
of O
PF B
- I
3893787 I
. O

Overall O
, O
the O
pyrido B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidines I
show O
an O
excellent O
in O
vitro O
profile O
that O
warrants O
their O
further O
investigation O
in O
relevant O
models O
of O
human O
disease O
. O

Rat O
liver O
epithelial O
cells O
( O
WB O
- O
F344 O
) O
were O
stained O
with O
the O
fluorescent O
dye O
Calcein O
AM O
( O
acetoxymethyl B
) O
and O
exposed O
to O
TPM O
from O
the O
Kentucky O
Reference O
Cigarette O
2R4F O
( O
a O
blend O
of O
Bright O
and O
Burley O
tobaccos O
) O
and O
from O
two O
single O
- O
tobacco O
cigarettes O
( O
Bright O
and O
Burley O
) O
for O
3h O
. O

Metabolites O
of O
norepinephrine O
[ O
3 B
- I
methoxy I
- I
4 I
- I
hydroxyphenylglycol I
( O
MHPG B
) O
and O
vanillylmandelic B
acid I
( O
VMA B
) O
] O
and O
dopamine O
[ O
homovanillic O
acid O
( O
HVA O
) O
] O
were O
measured O
by O
high O
- O
pressure O
liquid O
chromatography O
with O
electrochemical O
detection O
. O

RESULTS O
: O
Yohimbine O
increased O
plasma O
MHPG B
and O
VMA B
but O
not O
HVA O
. O

Yohimbine O
- O
associated O
increase O
in O
plasma O
MHPG B
correlated O
with O
increased O
impulsive O
response O
rates O
. O

Either O
the O
Li O
metal O
or O
Li O
ions O
( O
by O
the O
formation O
LixC6 B
or O
Li4 B
+ I
xTi5O12 I
) O
was O
harvested O
from O
waste O
Li O
ion O
source O
materials O
such O
as O
a O
waste O
anode O
( O
LixC6 B
) O
, O
cathode O
( O
LixFePO4 B
) O
, O
and O
electrolyte O
( O
LiPF6 B
in O
EC O
: O
DEC O
) O
by O
charging O
the O
cell O
, O
which O
then O
discharged O
with O
the O
waste O
products O
in O
the O
liquid O
cathode O
solution O
to O
produce O
electric O
energy O
. O

When O
the O
Li4Ti5O12 B
was O
used O
as O
the O
anode O
with O
the O
waste O
products O
as O
the O
cathode O
in O
the O
proposed O
battery O
system O
, O
a O
good O
cycle O
- O
life O
with O
high O
coulombic O
efficiency O
was O
observed O
. O

Storable O
sunshine O
, O
reusable O
rays O
: O
A O
solar O
rechargeable O
redox O
flow O
battery O
is O
proposed O
based O
on O
the O
photoregeneration O
of O
I3 B
( I
- I
) I
/ O
I O
( O
- O
) O
and O
[ B
Fe I
( I
C10 I
H15 I
) I
2 I
] I
( I
+ I
) I
/ O
Fe B
( I
C10 I
H15 I
) I
2 I
soluble O
redox O
couples O
, O
which O
can O
be O
regenerated O
by O
flowing O
from O
a O
discharged O
redox O
flow O
battery O
( O
RFB O
) O
into O
a O
dye O
- O
sensitized O
solar O
cell O
( O
DSSC O
) O
and O
then O
stored O
in O
tanks O
for O
subsequent O
RFB O
applications O
This O
technology O
enables O
effective O
solar O
- O
to O
- O
chemical O
energy O
conversion O
. O

Temperature O
- O
Induced O
Emission O
Enhancement O
of O
Star O
Conjugated O
Copolymers O
with O
Poly B
( I
2 I
- I
( I
dimethylamino I
) I
ethyl I
methacrylate I
) I
Coronas O
for O
Detection O
of O
Bacteria O
. O

The O
star O
copolymers O
( O
HCP O
- O
star O
- O
PDMAEMAs B
) O
with O
different O
poly B
( I
2 I
- I
( I
dimethylamino I
) I
ethyl I
methacrylate I
) I
( O
PDMAEMA O
) O
chain O
lengths O
were O
synthesized O
from O
the O
hyperbranched O
conjugated O
polymer O
( O
HCP O
) O
macroinitiator O
by O
atom O
transfer O
radical O
polymerization O
( O
ATRP O
) O
. O

Above O
the O
LCST O
, O
the O
emission O
of O
HCP O
- O
star O
- O
PDMAEMAs B
was O
enhanced O
greatly O
through O
restriction O
of O
intermolecular O
aggregation O
of O
conjugated O
polymer O
cores O
by O
the O
collapse O
of O
PDMAEMA O
arms O
. O

By O
changing O
the O
PDMAEMA O
length O
, O
the O
emission O
performance O
of O
HCP O
- O
star O
- O
PDMAEMAs B
could O
be O
readily O
adjusted O
. O

Correspondingly O
, O
this O
temperature O
- O
dependent O
emission O
enhancement O
of O
HCP O
- O
star O
- O
PDMAEMAs B
was O
successfully O
applied O
in O
the O
highly O
sensitive O
detection O
of O
bacteria O
. O

Peptide O
- O
Directed O
Preparation O
and O
X O
- O
ray O
Structural O
Study O
of O
Au O
Nanoparticles O
on O
Titanium B
Surfaces O
. O

Au O
NPs O
were O
prepared O
by O
reduction O
of O
Au B
( I
3 I
+ I
) I
compound O
onto O
HCl O
- O
refreshed O
Ti O
in O
the O
presence O
of O
thiol O
- O
functionalized O
small O
peptides O
. O

It O
was O
found O
that O
the O
use O
of O
the O
tripeptide O
glutathione O
( O
GSH O
) O
results O
in O
smaller O
NP O
size O
when O
compared O
to O
N B
- I
( I
2 I
- I
mercapto I
- I
propionyl I
) I
glycine I
( O
MPG B
) O
, O
a O
pseudodipeptide O
, O
over O
a O
wide O
range O
of O
Au O
/ O
peptide O
molar O
ratios O
( O
20 O
: O
1 O
, O
10 O
: O
1 O
, O
5 O
: O
1 O
, O
and O
2 O
: O
1 O
) O
. O

By O
varying O
the O
ligand O
concentration O
, O
the O
Au O
NP O
structure O
in O
both O
systems O
can O
be O
controlled O
, O
generating O
nanocrystals O
, O
nanoclusters O
, O
and O
Au O
- O
thiolate B
polymer O
, O
which O
is O
unique O
for O
substrate O
- O
supported O
NP O
synthesis O
. O

The O
treatments O
chosen O
for O
combination O
were O
a O
fat O
removal O
process O
( O
FRP O
) O
( O
solvent O
extraction O
using O
an O
alcohol O
- O
benzene O
mixture O
) O
, O
a O
chemical O
treatment O
( O
CT O
) O
( O
hydrolysis O
using O
1 O
% O
hydrochloric B
acid I
) O
, O
and O
an O
enzymatic O
hydrolysis O
( O
EH O
) O
. O

After O
the O
combined O
processes O
, O
pectins O
were O
extracted O
by O
isopropanol B
/ O
ethanol O
precipitation O
and O
the O
residues O
were O
analysed O
by O
HPLC O
or O
an O
elemental O
analyser O
. O

Microencapsulation O
of O
aspartame B
by O
double O
emulsion O
followed O
by O
complex O
coacervation O
to O
provide O
protection O
and O
prolong O
sweetness O
. O

The O
objective O
of O
this O
work O
was O
to O
microencapsulate O
aspartame B
by O
double O
emulsion O
followed O
by O
complex O
coacervation O
, O
aiming O
to O
protect O
it O
and O
control O
its O
release O
. O

FTIR O
confirmed O
complexation O
between O
the O
wall O
materials O
and O
the O
intact O
nature O
of O
aspartame B
. O

The O
results O
indicated O
it O
was O
possible O
to O
encapsulate O
aspartame B
with O
the O
techniques O
employed O
and O
that O
these O
protected O
the O
sweetener O
even O
at O
80 O
degrees O
C O
. O

The O
reduced O
solubility O
and O
low O
release O
rates O
indicated O
the O
enormous O
potential O
of O
the O
vehicle O
developed O
in O
controlling O
the O
release O
of O
the O
aspartame B
into O
the O
food O
, O
thus O
prolonging O
its O
sweetness O
. O

Enrichment O
of O
two O
isoflavone B
aglycones I
in O
black O
soymilk O
by O
using O
spent O
coffee O
grounds O
as O
an O
immobiliser O
for O
beta O
- O
glucosidase O
. O

beta O
- O
Glucosidase O
was O
covalently O
immobilised O
onto O
spent O
coffee O
grounds O
for O
the O
conversion O
of O
isoflavone B
glycosides I
into O
their O
aglycones O
in O
black O
soymilk O
. O

Optimum O
conditions O
were O
determined O
to O
be O
40 O
degrees O
C O
and O
pH O
6 O
using O
4 B
- I
nitrophenyl I
beta I
- I
d I
- I
glucuronide I
as O
an O
indicator O
. O

The O
kinetic O
parameters O
including O
rate O
constant O
( O
K O
) O
, O
time O
( O
tau O
50 O
) O
in O
which O
50 O
% O
of O
isoflavone O
deglycosylation O
was O
reached O
, O
and O
time O
( O
tau O
complete O
) O
required O
to O
achieve O
complete O
isoflavone O
deglycosylation O
, O
were0 O
. O
16 O
+ O
/ O
- O
0 O
. O
02min O
( O
- O
1 O
) O
, O
4 O
. O
54 O
+ O
/ O
- O
0 O
. O
32min O
, O
60min O
for O
daidzin B
and O
0 O
. O
16 O
+ O
/ O
- O
0 O
. O
02min O
( O
- O
1 O
) O
, O
2 O
. O
28 O
+ O
/ O
- O
0 O
. O
11min O
, O
60min O
for O
genistin O
, O
respectively O
. O

Antioxidant O
TLC O
assay O
- O
guided O
isolation O
on O
the O
methanol O
extract O
led O
to O
the O
isolation O
of O
a O
new O
pyranocoumarin B
, O
glabranin B
( O
1 O
) O
, O
umbelliferone O
( O
2 O
) O
, O
scopoletin O
( O
3 O
) O
and O
sesamin B
( O
4 O
) O
, O
and O
their O
structures O
were O
determined O
by O
spectroscopy O
. O

However O
, O
in O
beta O
- O
carotene O
bleaching O
assay O
, O
sesamin B
( O
4 O
) O
showed O
higher O
inhibitory O
activity O
( O
1mgml O
( O
- O
1 O
) O
, O
95 O
% O
) O
than O
glabranin B
( O
1 O
) O
( O
1mgml O
( O
- O
1 O
) O
, O
74 O
% O
) O
, O
whilst O
umbelliferone O
( O
2 O
) O
and O
scopoletin O
( O
3 O
) O
were O
slightly O
pro O
- O
oxidant O
. O

The O
crystallisation O
and O
polymorphic O
properties O
of O
three O
sunflower O
hard O
stearins B
( O
SHSs O
) O
and O
cocoa O
butter O
equivalents O
( O
CBEs O
) O
formulated O
by O
blending O
SHSs O
and O
palm O
mid O
fraction O
( O
PMF O
) O
were O
studied O
and O
compared O
with O
those O
from O
cocoa O
butter O
( O
CB O
) O
, O
to O
explore O
their O
possibilities O
as O
confectionery O
fats O
. O

This O
study O
investigated O
the O
effect O
of O
in O
vitro O
gastrointestinal O
digestion O
on O
the O
stability O
and O
composition O
of O
flavan O
- O
3 O
- O
ols O
from O
red O
grape O
skin O
and O
seed O
extracts O
( O
raw O
and O
purified O
, O
which O
are O
high O
in O
proanthocyanidins O
( O
PAs B
) O
) O
. O

The O
PAs B
were O
significantly O
degraded O
( O
up O
to O
80 O
% O
) O
during O
the O
pancreatic O
digestion O
, O
yielding O
low O
- O
molecular O
- O
weight O
compounds O
that O
diffused O
into O
the O
serum O
- O
available O
fraction O
( O
mDP O
= O
~ O
2 O
) O
. O

Hesperidin O
and O
narirutin B
were O
extracted O
from O
peels O
of O
Citrus O
unshiu O
by O
ultra O
- O
sonication O
and O
purified O
further O
. O

The O
SPME O
device O
, O
which O
was O
wetted O
with O
1 B
- I
octanol I
, O
was O
placed O
in O
a O
stirred O
apple O
samples O
to O
extract O
target O
analytes O
. O

A O
sensitive O
and O
selective O
imprinted O
solid O
phase O
extraction O
coupled O
to O
HPLC O
for O
simultaneous O
detection O
of O
trace O
quinoxaline B
- I
2 I
- I
carboxylic I
acid I
and O
methyl B
- I
3 I
- I
quinoxaline I
- I
2 I
- I
carboxylic I
acid I
in O
animal O
muscles O
. O

A O
new O
molecularly O
imprinted O
polymer O
( O
MIP O
) O
, O
selective O
for O
major O
metabolites O
of O
quinoxaline B
- I
1 I
, I
4 I
- I
dioxides I
, O
was O
prepared O
through O
bulk O
polymerisation O
using O
quinoxaline B
- I
2 I
- I
carboxylic I
acid I
( O
QCA B
) O
as O
template O
, O
diethylaminoethylmet B
as O
functional O
monomer O
and O
ethylene O
glycol O
dimethacrylate O
as O
cross O
- O
linker O
in O
tetrahydrofuran O
. O

MIP O
exhibited O
high O
affinity O
, O
fast O
kinetics O
for O
QCA B
and O
good O
selectivity O
for O
QCA B
and O
methyl B
- I
3 I
- I
quinoxaline I
- I
2 I
- I
carboxylic I
acid I
( O
MQCA B
) O
. O

MIP O
obtained O
was O
used O
as O
a O
selective O
sorbent O
for O
molecularly O
imprinted O
solid O
phase O
extraction O
( O
MISPE O
) O
coupled O
with O
HPLC O
to O
detect O
QCA B
and O
MQCA B
. O

Under O
the O
optimal O
conditions O
, O
the O
limits O
of O
detection O
( O
S O
/ O
N O
= O
3 O
) O
of O
porcine O
, O
chicken O
and O
fish O
muscles O
were O
0 O
. O
1 O
, O
0 O
. O
3 O
, O
0 O
. O
1 O
mu O
g O
/ O
kg O
for O
QCA B
and O
0 O
. O
2 O
, O
0 O
. O
3 O
, O
0 O
. O
1 O
mu O
g O
/ O
kg O
for O
MQCA B
, O
respectively O
and O
good O
recoveries O
were O
obtained O
in O
the O
range O
from O
60 O
. O
0 O
to O
119 O
. O
4 O
% O
. O

These O
results O
indicated O
the O
MISPE O
- O
HPLC O
procedure O
could O
be O
successfully O
used O
for O
the O
determination O
QCA B
and O
MQCA B
in O
animal O
muscles O
. O

Synthesis O
of O
amino O
acid O
conjugates O
of O
tetrahydrocurcumin B
and O
evaluation O
of O
their O
antibacterial O
and O
anti O
- O
mutagenic O
properties O
. O

Tetrahydrocurcumin B
( O
THC O
) O
, O
the O
hydrogenated O
and O
stable O
form O
of O
curcumin O
, O
exhibits O
physiological O
and O
pharmacological O
activities O
similar O
to O
curcumin O
. O

Various O
ursanic B
, I
oleanic I
and I
lupanic I
pentacyclic I
triterpenoids I
found O
in O
apple O
peel O
were O
studied O
for O
anti O
- O
inflammatory O
effects O
in O
vitro O
using O
T84 O
colon O
carcinoma O
cells O
. O

The O
present O
study O
confirms O
that O
triterpenoids O
present O
in O
apple O
peel O
and O
beta B
- I
damascone I
may O
be O
implicated O
in O
the O
anti O
- O
inflammatory O
properties O
of O
apple O
constituents O
, O
suggesting O
that O
these O
substances O
might O
be O
helpful O
in O
the O
treatment O
of O
IBD O
as O
nutrient O
supplements O
. O

The O
objective O
of O
this O
study O
was O
to O
determine O
antioxidant O
activities O
of O
water O
- O
soluble O
MRPs O
( O
Maillard O
reaction O
products O
) O
from O
the O
reactions O
between O
whey O
protein O
isolate O
( O
WPI O
) O
and O
xylose O
( O
X O
) O
, O
glucose O
( O
G O
) O
, O
fructose O
( O
F O
) O
, O
lactose O
( O
L O
) O
, O
maltose B
( O
M O
) O
and O
sucrose O
( O
S O
) O
at O
different O
initial O
pH O
values O
( O
3 O
, O
4 O
, O
5 O
, O
6 O
, O
7 O
, O
8 O
and O
9 O
) O
. O

Two O
major O
polyphenolics B
, O
ferulic O
acid O
and O
quercetin O
, O
were O
identified O
from O
EEAP O
by O
HPLC O
- O
DAD O
. O

Peach O
( O
Prunus O
persica O
) O
extract O
inhibits O
angiotensin B
II I
- O
induced O
signal O
transduction O
in O
vascular O
smooth O
muscle O
cells O
. O

Angiotensin B
II I
( O
Ang B
II I
) O
is O
a O
vasoactive O
hormone O
that O
has O
been O
implicated O
in O
cardiovascular O
diseases O
. O

Batsch O
, O
pulp O
extract O
on O
Ang B
II I
- O
induced O
intracellular O
Ca O
( O
2 O
+ O
) O
mobilization O
, O
reactive O
oxygen O
species O
( O
ROS O
) O
production O
and O
signal O
transduction O
events O
in O
cultured O
vascular O
smooth O
muscle O
cells O
( O
VSMCs O
) O
was O
investigated O
. O

Pretreatment O
of O
peach O
ethyl O
acetate O
extract O
inhibited O
Ang B
II I
- O
induced O
intracellular O
Ca O
( O
2 O
+ O
) O
elevation O
in O
VSMCs O
. O

Furthermore O
, O
Ang B
II I
- O
induced O
ROS O
generation O
, O
essential O
for O
signal O
transduction O
events O
, O
was O
diminished O
by O
the O
peach O
ethyl O
acetate O
extract O
. O

The O
peach O
ethyl O
acetate O
extract O
also O
attenuated O
the O
Ang B
II I
- O
induced O
phosphorylation O
of O
epidermal O
growth O
factor O
receptor O
and O
myosin O
phosphatase O
target O
subunit O
1 O
, O
both O
of O
which O
are O
associated O
with O
atherosclerosis O
and O
hypertension O
. O

These O
results O
suggest O
that O
peach O
ethyl O
acetate O
extract O
may O
have O
clinical O
potential O
for O
preventing O
cardiovascular O
diseases O
by O
interfering O
with O
Ang B
II I
- O
induced O
intracellular O
Ca O
( O
2 O
+ O
) O
elevation O
, O
the O
generation O
of O
ROS O
, O
and O
then O
blocking O
signal O
transduction O
events O
. O

The O
results O
showed O
that O
saturated O
fatty O
acids O
( O
C16 B
: I
0 I
and O
C18 B
: I
0 I
) O
were O
released O
faster O
than O
unsaturated O
fatty O
acids O
( O
C18 B
: I
1n9 I
, O
C18 B
: I
2n6 I
and O
C18 B
: I
3n3 I
) O
from O
soya O
bean O
oil O
emulsions O
; O
short O
chain O
fatty O
acids O
were O
released O
faster O
than O
long O
chain O
fatty O
acids O
from O
milk O
fat O
emulsions O
; O
long O
chain O
polyunsaturated O
fatty O
acids O
, O
such O
as O
eicosapentaenoic O
acid O
and O
docosahexaenoic O
acid O
, O
were O
released O
more O
slowly O
than O
other O
fatty O
acids O
from O
fish O
oil O
emulsions O
. O

Most O
reported O
studies O
focused O
on O
specific O
oat O
extracts O
or O
particular O
oat O
components O
, O
such O
as O
beta O
- O
glucans O
, O
tocols B
( O
vitamin O
E O
) O
, O
or O
avenanthramides B
. O

Avenanthramide B
levels O
did O
not O
correlate O
with O
the O
observed O
antioxidant O
and O
anti O
- O
inflammatory O
activities O
. O

The O
12 O
flavonoids O
identified O
were O
quercetin B
3 I
- I
O I
- I
robinobioside I
, O
quercetin B
3 I
- I
O I
- I
rutinoside I
, O
quercetin B
3 I
' I
- I
O I
- I
galactoside I
, O
quercetin O
3 O
' O
- O
O O
- O
glucoside O
, O
quercetin O
3 O
' O
- O
O O
- O
rhamnoside O
, O
quercetin B
3 I
' I
- I
O I
- I
pentosylhexoside I
, O
quercetin B
3 I
- I
O I
- I
6 I
' I
malonylglucoside I
, O
quercetin O
3 O
' O
- O
O O
- O

malonylglucoside O
, O
luteolin B
7 I
- I
O I
- I
6 I
' I
malonylglucoside I
, O
luteolin B
7 I
- I
O I
- I
malonylglucoside I
, O
myricetin B
3 I
- I
O I
- I
galactoside I
, O
and O
naringenin B
tri I
glycoside I
. O

Nine O
phenolic O
acids O
, O
protocatechuic O
acid O
, O
p O
- O
hydroxybenzoic O
acid O
, O
ferulic O
acid O
, O
chlorogenic O
acid O
, O
vanillic O
acid O
, O
caffeic O
acid O
, O
vanillin O
, O
ortho B
- I
and I
para I
- I
coumaric I
acids I
, O
were O
identified O
and O
quantified O
. O

Ethyl O
acetate O
- O
n O
- O
butanol O
- O
water O
( O
1 O
: O
2 O
: O
3 O
, O
v O
/ O
v O
/ O
v O
) O
was O
selected O
as O
the O
optimum O
solvent O
system O
to O
purify O
geniposidic B
acid I
. O

While O
three O
flavonoids O
, O
quercetin B
- I
3 I
- I
O I
- I
sambubioside I
, O
rutin O
and O
isoquercitrin B
were O
purified O
by O
petroleum O
ether O
- O
ethyl O
acetate O
- O
methanol O
- O
water O
( O
1 O
: O
5 O
: O
1 O
: O
5 O
, O
v O
/ O
v O
/ O
v O
/ O
v O
) O
. O

Cyanidin B
3 I
- I
glucoside I
, O
and O
quercetin O
and O
its O
glycosides O
were O
only O
found O
in O
the O
pulp O
powder O
, O
while O
proanthocyanidins O
were O
only O
present O
in O
the O
flour O
( O
3 O
. O
5g O
/ O
100g O
, O
mean O
degree O
of O
polymerisation O
3 O
) O
. O

Biosynthesis O
of O
highly O
enriched O
( B
13 I
) I
C I
- I
lycopene I
for O
human O
metabolic O
studies O
using O
repeated O
batch O
tomato O
cell O
culturing O
with O
( B
13 I
) I
C I
- I
glucose I
. O

Advances O
in O
tomato O
cell O
culturing O
techniques O
offer O
an O
economical O
tool O
for O
generation O
of O
highly O
- O
enriched O
( B
13 I
) I
C I
- I
lycopene I
for O
human O
bioavailability O
and O
metabolism O
studies O
. O

To O
enhance O
the O
( O
13 O
) O
C O
- O
enrichment O
and O
yields O
of O
labelled O
lycopene O
from O
the O
hp O
- O
1 O
tomato O
cell O
line O
, O
cultures O
were O
first O
grown O
in O
( B
13 I
) I
C I
- I
glucose I
media O
for O
three O
serial O
batches O
and O
produced O
increasing O
proportions O
of O
uniformly O
labelled O
lycopene O
( O
14 O
. O
3 O
+ O
/ O
- O
1 O
. O
2 O
% O
, O
39 O
. O
6 O
+ O
/ O
- O
0 O
. O
5 O
% O
, O
and O
48 O
. O
9 O
+ O
/ O
- O
1 O
. O
5 O
% O
) O
with O
consistent O
yields O
( O
from O
5 O
. O
8 O
to O
9mg O
/ O
L O
) O
. O

An O
optimised O
9 O
- O
day O
- O
long O
( O
13 O
) O
C O
- O
loading O
and O
18 O
- O
day O
- O
long O
labelling O
strategy O
developed O
based O
on O
glucose O
utilisation O
and O
lycopene O
yields O
, O
yielded O
( B
13 I
) I
C I
- I
lycopene I
with O
93 O
% O
( O
13 O
) O
C O
isotopic O
purity O
, O
and O
55 O
% O
of O
isotopomers O
were O
uniformly O
labelled O
. O

In O
this O
study O
, O
temperature O
and O
the O
presence O
of O
CO2 O
increased O
the O
release O
of O
formaldehyde O
, O
acetaldehyde O
and O
antimony B
( O
Sb B
) O
. O

However O
, O
2 B
, I
4 I
- I
di I
- I
tert I
- I
butylphenol I
, O
a O
degradation O
compound O
of O
phenolic O
antioxidants O
, O
was O
detected O
. O

In O
addition O
, O
an O
intermediary O
monomer O
, O
bis B
( I
2 I
- I
hydroxyethyl I
) I
terephthalate I
, O
was O
found O
but O
only O
in O
PET O
- O
bottled O
waters O
. O

In O
addition O
, O
gallic B
, I
vanilic I
and I
syringic I
acids I
, O
siringaldehyde B
, O
coniferaldehyde B
, O
sinapaldehyde B
, O
vanillin O
, O
5 O
- O
hydroxymethylfurfura O
and O
furfural O
were O
identified O
and O
quantified O
. O

The O
Brazilian O
woods O
, O
similar O
to O
oak O
, O
were O
jequitib O
a O
rosa O
and O
cerejeira O
, O
which O
presented O
the O
highest O
contents O
of O
some O
maturation O
- O
related O
compounds O
, O
such O
as O
vanillin O
, O
vanilic B
acid I
, O
syringaldehyde O
and O
sinapaldehyde B
. O

The O
volatile O
compounds O
of O
wines O
made O
from O
three O
grape O
varieties O
( O
Monastrell O
, O
Cabernet O
Sauvignon O
and O
Syrah O
) O
using O
three O
pre O
- O
fermentation O
techniques O
( O
grape O
freezing O
, O
dry B
- I
ice I
and O
cold O
maceration O
) O
and O
a O
control O
treatment O
were O
measured O
. O

The O
oxidation O
of O
chlorophyll O
a O
( O
chl O
a O
) O
catalysed O
by O
peroxidase O
( O
POD O
) O
from O
mesocarp O
of O
the O
olive O
fruit O
( O
Olea O
europaea O
L O
. O
, O
cv O
Hojiblanca O
) O
in O
the O
presence O
of O
H2O2 O
and O
2 B
, I
4 I
- I
dichlorophenol I
( O
2 B
, I
4 I
- I
DCP I
) O
, O
is O
characterised O
via O
the O
individualised O
quantification O
of O
the O
products O
of O
the O
enzymatic O
reaction O
using O
a O
new O
methodology O
of O
HPLC O
- O
UV O
spectrometry O
. O

This O
innovation O
has O
allowed O
the O
discovery O
that O
, O
in O
addition O
to O
13 B
( I
2 I
) I
OH I
chl I
a I
and O
15 B
( I
1 I
) I
OH I
lactone I
chl I
a I
, O
which O
are O
the O
first O
products O
of O
POD O
on O
chl O
a O
, O
the O
reaction O
process O
sequentially O
creates O
another O
series O
of O
oxidised O
chlorophyll O
derivatives O
which O
have O
not O
been O
previously O
described O
. O

Their O
origins O
have O
been O
linked O
to O
POD O
activity O
in O
the O
presence O
of O
2 B
, I
4 I
- I
DCP I
. O

Likewise O
, O
a O
study O
of O
the O
effect O
of O
the O
concentration O
of O
the O
various O
cosubstrates O
on O
the O
POD O
reaction O
rate O
demonstrated O
that O
the O
correct O
establishment O
of O
the O
relative O
concentrations O
of O
the O
same O
( O
[ O
H2O2 O
] O
/ O
[ O
2 B
, I
4 I
- I
DCP I
] O
/ O
[ O
Chl B
] O
= O
1 O
: O
3 O
: O
0 O
. O
02 O
) O
is O
crucial O
to O
explaining O
inhibition O
effects O
by O
substrates O
and O
carrying O
out O
optimum O
measurements O
. O

Among O
them O
, O
three O
isomers O
of O
feruloyl B
- I
sucrose I
were O
firmly O
identified O
and O
another O
was O
strongly O
supposed O
to O
be O
a O
sinapoyl B
- I
diglycoside I
. O

Forty O
- O
nine O
animals O
were O
divided O
into O
7 O
groups O
( O
n O
= O
7 O
) O
and O
received O
by O
oral O
gavage O
30 O
% O
glucose O
plus O
0 O
. O
55g O
/ O
kg O
body O
mass O
of O
the O
following O
WPH O
components O
: O
( O
a O
) O
control O
; O
( O
b O
) O
WPH O
; O
( O
c O
) O
l B
- I
isoleucine I
; O
( O
d O
) O
l O
- O
leucine O
; O
( O
e O
) O
l O
- O
leucine O
plus O
l B
- I
isoleucine I
; O
( O
f O
) O
l B
- I
isoleucyl I
- I
l I
- I
leucine I
dipeptide I
; O
( O
g O
) O
l B
- I
leucyl I
- I
l I
- I
isoleucine I
dipeptide I
. O

Of O
the O
WPH O
components O
tested O
, O
the O
amino O
acid O
l B
- I
isoleucine I
and O
the O
peptide O
l B
- I
leucyl I
- I
l I
- I
isoleucine I
showed O
greater O
efficiency O
in O
translocating O
GLUT O
- O
4 O
to O
the O
PM O
and O
of O
increasing O
glucose O
capture O
by O
skeletal O
muscle O
. O

In O
in O
vitro O
antioxidant O
study O
, O
the O
free O
radical O
scavenging O
effect O
of O
friedelin O
on O
2 B
, I
2 I
- I
diphenyl I
- I
picrylhydrazyl I
( O
DPPH O
) O
, O
hydroxyl O
, O
nitric O
oxide O
and O
superoxide O
radicals O
were O
evaluated O
. O

In O
in O
vivo O
antioxidant O
study O
, O
CCl4 O
induced O
oxidative O
stress O
on O
rats O
produced O
significant O
increase O
in O
serum O
glutamate O
oxaloacetate B
transaminase O
( O
SGOT O
) O
, O
serum O
glutamate O
pyruvate O
transaminase O
( O
SGPT O
) O
and O
lactate O
dehydrogenase O
( O
LDH O
) O
levels O
along O
with O
reduction O
in O
liver O
superoxide O
dismutase O
( O
SOD O
) O
, O
catalase O
( O
CAT O
) O
, O
reduced O
glutathione O
( O
GSH O
) O
and O
glutathione O
peroxidase O
( O
GPx O
) O
levels O

Major O
Se O
species O
( O
selenium B
methionine I
and O
oxidized B
selenium I
methionine I
) O
from O
dialyzate O
were O
identified O
and O
characterized O
by O
HPLC O
coupled O
to O
mass O
spectrometry O
( O
HPLC O
- O
MS O
) O
. O

Selenocystine B
was O
detected O
at O
low O
concentrations O
while O
Se O
- O
( B
Methyl I
) I
selenocysteine I
and O
inorganic O
selenium O
species O
( O
selenite B
and O
selenate O
) O
were O
not O
detected O
in O
the O
dialyzate O
. O

Similar O
bioavailability O
percentages O
was O
achieved O
for O
total O
selenium O
as O
a O
sum O
of O
selenium O
species O
( O
selenocystine B
plus O
oxidized B
selenium I
methionine I
and O
selenium B
methionine I
, O
mainly O
) O
. O

In O
this O
study O
, O
the O
inhibitory O
activities O
against O
mammalian O
DNA O
polymerases O
( O
pols O
) O
of O
16 O
major O
bioflavonoids B
were O
investigated O
. O

Myricetin O
( O
3 B
, I
3 I
' I
, I
4 I
' I
, I
5 I
, I
5 I
' I
, I
7 I
- I
hexahydroxyflavone I
) O
was O
the O
most O
potent O
inhibitor O
of O
pols O
amongst O
the O
compounds O
tested O
, O
with O
IC50 O
values O
of O
21 O
. O
3 O
- O
40 O
. O
9 O
mu O
M O
. O

The O
contents O
of O
polycyclic O
aromatic O
hydrocarbons O
( O
15 O
+ O
1 O
EU O
PAH O
) O
and O
phenolic O
substances O
( O
guaiacol B
, O
4 B
- I
methylguaiacol I
, O
syringol B
, O
eugenol O
, O
and O
trans B
- I
isoeugenol I
) O
were O
investigated O
in O
smouldering O
- O
smoked O
Frankfurters O
and O
mini O
- O
salamis O
. O

The O
results O
showed O
that O
WFI O
inhibited O
the O
mutagenicity O
of O
2 B
- I
aminoanthracene I
( O
2 B
- I
AA I
) O
, O
an O
indirect O
mutagen O
; O
and O
4 B
- I
nitroquinoline I
- I
N I
- I
oxide I
( O
4 B
- I
NQO I
) O
, O
a O
direct O
mutagen O
toward O
Salmonella O
typhimurium O
TA O
98 O
and O
TA O
100 O
. O

Within O
the O
free O
volatile O
compounds O
, O
isoamyl B
alcohols I
, O
benzaldehyde B
and O
guaiacol B
registered O
the O
largest O
increase O
above O
the O
concentration O
effect O
due O
to O
water O
loss O
; O
while O
within O
the O
bound O
volatile O
compounds O
were O
isoamyl B
alcohols I
, O
ethyl B
vanillate I
and O
benzoic O
acid O
. O

The O
effect O
of O
sodium O
alginate O
and O
calcium B
chloride I
concentration O
on O
immobilization O
was O
studied O
and O
it O
was O
found O
that O
the O
optimal O
sodium O
alginate O
and O
calcium B
chloride I
concentration O
was O
3 O
. O
0 O
% O
and O
0 O
. O
2M O
, O
respectively O
. O

The O
desferoxamine B
retarded O
beta O
- O
carotene O
degradation O
at O
pH O
4 O
. O
0 O
more O
effectively O
than O
pH O
7 O
. O
0 O
and O
more O
effectively O
in O
the O
emulsion O
with O
the O
conjugate O
than O
the O
unconjugated O
mixture O
( O
p O
< O
0 O
. O
05 O
) O
. O

For O
this O
purpose O
, O
low O
esterified O
amidated O
( O
AM O
) O
, O
low O
( O
LM O
) O
and O
high O
( O
HM O
) O
methoxylated O
citrus O
and O
apple O
pectins O
and O
a O
sugar O
beet O
pectin O
were O
added O
to O
a O
purified O
anthocyanin O
extract O
( O
ACN O
- O
E O
) O
and O
to O
an O
extract O
containing O
anthocyanins O
and O
non O
- O
anthocyanin B
phenolics I
( O
PP O
- O
E O
) O
. O

This O
was O
primarily O
due O
to O
the O
strong O
interaction O
of O
delphinidin B
glycosides I
with O
the O
citrus O
pectins O
, O
whereas O
stabilisation O
of O
cyanidin O
derivatives O
was O
less O
important O
. O

In O
the O
presence O
of O
non O
- O
anthocyanin B
phenolics I
( O
PP O
- O
E O
) O
the O
impact O
of O
the O
pectin O
source O
was O
even O
more O
pronounced O
than O
the O
effect O
of O
the O
pectin O
type O
. O

Conformational O
restriction O
approach O
to O
BACE1 O
inhibitors O
II O
: O
SAR O
study O
of O
the O
isocytosine B
derivatives O
fixed O
with O
a O
cis O
- O
cyclopropane O
ring O
. O

Discovery O
of O
ML326 B
: O
The O
first O
sub O
- O
micromolar O
, O
selective O
M5 O
PAM O
. O

This O
Letter O
describes O
the O
further O
chemical O
optimization O
of O
the O
M5 O
PAM O
MLPCN O
probes O
ML129 B
and O
ML172 B
. O

A O
multi O
- O
dimensional O
iterative O
parallel O
synthesis O
effort O
quickly O
explored O
isatin O
replacements O
and O
a O
number O
of O
southern O
heterobiaryl O
variations O
with O
no O
improvement O
over O
ML129 B
and O
ML172 B
. O

An O
HTS O
campaign O
identified O
several O
weak O
M5 O
PAMs O
( O
M5 O
EC50 O
> O
10 O
mu O
M O
) O
with O
a O
structurally O
related O
isatin O
core O
that O
possessed O
a O
southern O
phenethyl B
ether I
linkage O
. O

While O
SAR O
within O
the O
HTS O
series O
was O
very O
shallow O
and O
unable O
to O
be O
optimized O
, O
grafting O
the O
phenethyl B
ether I
linkage O
onto O
the O
ML129 B
/ O
ML172 B
cores O
led O
to O
the O
first O
sub O
- O
micromolar O
M5 O
PAM O
, O
ML326 B
( O
VU0467903 B
) O
, O
( O
human O
and O
rat O
M5 O
EC50s O
of O
409nM O
and O
500nM O
, O
respectively O
) O
with O
excellent O
mAChR O
selectivity O
( O
M1 O
- O
M4 O
EC50s O
> O
30 O
mu O
M O
) O
and O
a O
robust O
20 O
- O
fold O
leftward O
shift O
of O
the O

This O
candidate O
, O
( B
S I
) I
- I
3 I
- I
[ I
4 I
- I
( I
1 I
- I
{ I
3 I
, I
5 I
- I
dimethyl I
- I
4 I
- I
[ I
4 I
- I
( I
trifluoromethyl I
) I
- I
1H I
- I
pyrazol I
- I
1 I
- I
yl I
] I
phenoxy I
} I
butyl I
) I
benzamido I
] I
propanoic I
acid I
, O
has O
lower O
molecular O
weight O
and O
lipophilicity O
than O
historical O
glucagon O
receptor O
antagonists O
, O
resulting O
in O
excellent O
selectivity O
in O
broad O
- O
panel O
screening O
, O
lower O
cytotoxicity O
, O
and O
excellent O
overall O
in O
vivo O
safety O
in O
early O
pre O
- O
clinical O
testing O
. O

Evn B
- I
50 I
is O
a O
lignan O
compounds O
mixture O
extracted O
from O
Vitex O
negundo O
, O
a O
widely O
used O
herb O
in O
traditional O
Chinese O
medicine O
. O

This O
study O
is O
aimed O
to O
define O
the O
spectrum O
of O
cytotoxic O
activity O
of O
EVn B
- I
50 I
, O
and O
also O
to O
investigate O
mechanisms O
underlying O
the O
anticancer O
actions O
via O
assessing O
the O
influence O
on O
cell O
cycle O
using O
EVn B
- I
50 I
, O
and O
the O
lignan O
compound O
VB1 B
purified O
from O
EVn B
- I
50 I
. O

The O
cytotoxic O
effect O
of O
EVn B
- I
50 I
and O
VB1 B
was O
determined O
with O
SRB O
assay O
using O
a O
panel O
of O
cancer O
cell O
lines O
. O

Breast O
cancer O
cell O
line O
MDA O
- O
MB O
- O
435 O
and O
liver O
cancer O
cell O
line O
SMMC O
- O
7721 O
were O
selected O
for O
further O
evaluating O
the O
effect O
of O
EVn B
- I
50 I
or O
VB1 B
on O
cell O
cycle O
by O
flow O
cytometric O
analysis O
. O

Apoptosis O
exerted O
by O
EVn B
- I
50 I
or O
VB1 B
was O
measured O
by O
TUNEL O
assay O
and O
DAPI O
staining O
, O
and O
Western O
blot O
analysis O
was O
utilized O
to O
assess O
the O
influence O
on O
expression O
and O
phosphorylation O
of O
proteins O
which O
are O
closely O
related O
to O
cell O
cycle O
and O
apoptosis O
. O

EVn B
- I
50 I
possessed O
a O
broad O
spectrum O
of O
in O
vitro O
anticancer O
activity O
for O
those O
tested O
cancer O
cells O
, O
especially O
sensitive O
to O
MDA O
- O
MB O
- O
435 O
, O
SKOV O
- O
3 O
, O
BXPC O
- O
3 O
, O
SMMC O
- O
7721 O
, O
MCF O
- O
7 O
, O
HO O
- O
8910 O
, O
SGC O
- O
7901 O
, O
BEL O
- O
7402 O
, O
HCT O
- O
116 O
, O
and O
786 O
- O
O O
, O
with O
the O
respective O
IC50 O
below O
10 O
mu O
g O
/ O
ml O
. O

Treatment O
with O
EVn B
- I
50 I
or O
VB1 B
resulted O
in O
arresting O
the O
MDA O
- O
MB O
- O
435 O
and O
SMMC O
- O
7721 O
cells O
at O
G2 O
/ O
M O
phase O
, O
which O
was O
further O
supported O
by O
observations O
of O
increased O
phosphorylation O
of O
Histone O
3 O
at O
Ser10 B
, O
phosphorylation O
of O
Cdk1 O
at O
Tyr15 B
, O
expression O
of O
cyclin O
B1 O
, O
and O
decreased O
expression O
of O
Cdc25c O
. O

Moreover O
, O
we O
found O
that O
exposure O
of O
MDA O
- O
MB O
- O
435 O
cells O
to O
EVn B
- I
50 I
or O
VB1 B
caused O
obvious O
apoptosis O
of O
MDA O
- O
MB O
- O
435 O
cells O
. O

Our O
data O
show O
that O
EVn B
- I
50 I
, O
lignan O
compounds O
extracted O
from O
Vitex O
negundo O
, O
possesses O
a O
broad O
spectrum O
cytotoxic O
effect O
via O
arresting O
cancer O
cells O
at O
G2 O
/ O
M O
phase O
cell O
cycle O
and O
subsequently O
inducing O
apoptosis O
. O

2 B
- I
Hydroxychalcone I
and O
xanthohumol B
inhibit O
invasion O
of O
triple O
negative O
breast O
cancer O
cells O
. O

Here O
, O
we O
showed O
that O
treatment O
with O
chalcone O
, O
2 B
- I
hydroxychalcone I
, O
and O
xanthohumol B
for O
24h O
inhibited O
the O
growth O
of O
MDA O
- O
MB O
- O
231cells O
with O
IC50 O
values O
of O
18 O
. O
1 O
, O
4 O
. O
6 O
, O
and O
6 O
. O
7 O
mu O
M O
, O
respectively O
. O

Similarly O
, O
Chalcone O
, O
2 B
- I
hydroxychalcone I
, O
and O
xanthohumol B
also O
exerted O
cytotoxicity O
in O
another O
TNBC O
cell O
line O
, O
Hs578T O
. O

Neohesperidin B
dihydrochalcone I
, O
4 B
- I
methoxychalcone I
, O
and O
hesperidin B
methylchalcone I
did O
not O
show O
the O
cytotoxicity O
on O
the O
MDA O
- O
MB O
- O
231cells O
. O

Xanthohumol B
and O
2 B
- I
hydroxychalcone I
induced O
apoptosis O
by O
Bcl O
- O
2 O
downregulation O
. O

Importantly O
, O
2 B
- I
hydroxychalcone I
and O
xanthohumol B
exerted O
more O
potent O
inhibitory O
effects O
on O
the O
proliferation O
, O
MMP O
- O
9 O
expression O
and O
invasive O
phenotype O
of O
MDA O
- O
MB O
- O
231 O
than O
chalcone O
. O

The O
formulation O
of O
the O
extrudate O
had O
an O
AUC O
( O
0 O
- O
t O
) O
and O
Cmax O
similar O
to O
those O
of O
ITZ O
and O
also O
OH B
- I
ITZ I
compared O
with O
the O
commercial O
capsule O
( O
Sporanox B
( O
R O
) O
) O
. O

Beneficial O
effects O
of O
asiaticoside B
on O
cognitive O
deficits O
in O
senescence O
- O
accelerated O
mice O
. O

The O
effect O
of O
asiaticoside B
isolated O
from O
Hydrocotyle O
sibthorpioides O
( O
AHS O
) O
on O
the O
promotion O
of O
cognition O
in O
senescence O
- O
accelerated O
mice O
( O
SAMP O
) O
was O
evaluated O
. O

Bioreducible O
alginate O
- O
poly B
( I
ethylenimine I
) I
nanogels O
as O
an O
antigen O
- O
delivery O
system O
robustly O
enhance O
vaccine O
- O
elicited O
humoral O
and O
cellular O
immune O
responses O
. O

Cyclosporin B
A I
and O
verapamil O
, O
both O
inhibitors O
of O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
, O
significantly O
decreased O
the O
efflux O
of O
AC O
. O

In O
addition O
, O
MK B
- I
571 I
, O
an O
inhibitor O
of O
multidrug O
resistance O
- O
associated O
protein O
2 O
( O
MRP2 O
) O
, O
exhibited O
the O
same O
trend O
but O
to O
a O
lesser O
extent O
. O

Assembled O
polydimethylsiloxane O
microfluidic O
devices O
were O
modified O
with O
a O
sulfobetaine B
polymer O
through O
continuous O
" O
tip O
- O
to O
- O
tip O
" O
modification O
, O
significantly O
reducing O
blood O
clotting O
and O
extending O
device O
patency O
under O
blood O
flow O
. O

Metabolic O
response O
demonstrated O
by O
18F O
- O
FDG O
- O
PET O
/ O
CT O
in O
metastatic O
medullary O
thyroid O
carcinoma O
under O
sorafenib B
therapy O
. O

To O
evaluate O
the O
metabolic O
activity O
of O
these O
lesions O
, O
18F B
- I
fluorodeoxiglucose I
positron O
emission O
tomography O
- O
CT O
( O
FDG B
- O
PET O
/ O
CT O
) O
scan O
was O
requested O
. O

Axial O
fused O
images O
revealed O
high O
FDG B
uptake O
by O
the O
breast O
and O
thoracic O
wall O
nodules O
and O
the O
right O
hepatic O
lobe O
. O

FDG B
- O
PET O
/ O
CT O
also O
showed O
uptake O
in O
sacrum O
and O
right O
iliac O
bone O
, O
undetected O
by O
CT O
and O
bone O
scintigraphy O
. O

After O
seven O
cycles O
of O
sorafenib B
PET O
/ O
CT O
became O
negative O
. O

This O
is O
the O
first O
published O
image O
of O
the O
complete O
metabolic O
response O
of O
MTC O
to O
sorafenib B
therapy O
using O
FDG B
- O
PET O
/ O
CT O
. O

Microsomal O
epoxide O
hydrolase O
( O
mEH O
, O
EPHX1 O
) O
is O
a O
critical O
xenobiotic O
- O
metabolizing O
enzyme O
, O
catalyzing O
both O
detoxification O
and O
bioactivation O
reactions O
that O
direct O
the O
disposition O
of O
chemical O
epoxides B
, O
including O
the O
carcinogenic O
metabolites O
of O
several O
polycyclic O
aromatic O
hydrocarbons O
. O

OBJECTIVEGlutamine B
reduces O
postprandial O
glycemia O
when O
given O
before O
oral O
glucose O
. O

05 O
; O
P O
< O
0 O
. O
01 O
) O
, O
and O
phasic O
pyloric O
pressures O
( O
P O
< O
0 O
. O
05 O
; O
P O
< O
0 O
. O
05 O
) O
, O
but O
did O
not O
lower O
blood O
glucose O
( O
P O
= O
0 O
. O
077 O
; O
P O
= O
0 O
. O
5 O
) O
. O
CONCLUSIONSGlutamine B
does O
not O
lower O
glycemia O
after O
ID O
glucose O
, O
despite O
stimulating O
GLP O
- O
1 O
, O
GIP O
, O
and O
insulin O
, O
probably O
due O
to O
increased O
glucagon O
. O

OBJECTIVEMedical O
nutrition O
therapy O
based O
on O
the O
control O
of O
the O
amount O
and O
distribution O
of O
carbohydrates O
( O
CHO B
) O
is O
the O
initial O
treatment O
for O
gestational O
diabetes O
mellitus O
( O
GDM O
) O
, O
but O
there O
is O
a O
need O
for O
randomized O
controlled O
trials O
comparing O
different O
dietary O
strategies O
. O

The O
purpose O
of O
this O
study O
was O
to O
test O
the O
hypothesis O
that O
a O
low O
- O
CHO B
diet O
for O
the O
treatment O
of O
GDM O
would O
lead O
to O
a O
lower O
rate O
of O
insulin O
treatment O
with O
similar O
pregnancy O
outcomes O
compared O
with O
a O
control O
diet O
. O
RESEARCH O
DESIGN O
AND O
METHODSA O
total O
of O
152 O
women O
with O
GDM O
were O
included O
in O
this O
open O
, O
randomized O
controlled O
trial O
and O
assigned O
to O
follow O
either O
a O
diet O
with O
low O
- O
CHO B
content O
( O
40 O
% O
of O
the O
total O
diet O
energy O
content O
as O
CHO B
) O
or O
a O
control O
diet O
( O
55 O
% O
of O
the O
total O
diet O
energy O
content O
as O
CHO B
) O
. O

CHO B
intake O
was O
assessed O
by O
3 O
- O
day O
food O
records O
. O

The O
main O
pregnancy O
outcomes O
were O
also O
assessed O
. O
RESULTSThe O
rate O
of O
women O
requiring O
insulin O
was O
not O
significantly O
different O
between O
the O
treatment O
groups O
( O
low O
CHO B
54 O
. O
7 O
% O
vs O
. O
control O
54 O
. O
7 O
% O
; O
P O
= O
1 O
) O
. O

Daily O
food O
records O
confirmed O
a O
difference O
in O
the O
amount O
of O
CHO B
consumed O
between O
the O
groups O
( O
P O
= O
0 O
. O
0001 O
) O
. O

No O
differences O
were O
found O
in O
the O
obstetric O
and O
perinatal O
outcomes O
between O
the O
treatment O
groups O
. O
CONCLUSIONSTreatment O
of O
women O
with O
GDM O
using O
a O
low O
- O
CHO B
diet O
did O
not O
reduce O
the O
number O
of O
women O
needing O
insulin O
and O
produced O
similar O
pregnancy O
outcomes O
. O

In O
GDM O
, O
CHO B
amount O
( O
40 O
vs O
. O
55 O
% O
of O
calories O
) O
did O
not O
influence O
insulin O
need O
or O
pregnancy O
outcomes O
. O

LPS O
exacerbated O
the O
effects O
of O
ketoconazole O
and O
clozapine O
toxicity O
but O
not O
those O
of O
their O
non O
- O
IDILI O
- O
related O
comparators O
, O
voriconazole B
and O
olanzapine O
. O

The O
alloy O
NPs O
strongly O
absorb O
light O
and O
efficiently O
enhance O
the O
conversion O
of O
several O
reactions O
, O
including O
Suzuki O
- O
Miyaura O
cross O
coupling O
, O
oxidative O
addition O
of O
benzylamine B
, O
selective O
oxidation O
of O
aromatic B
alcohols I
to O
corresponding O
aldehydes O
and O
ketones O
, O
and O
phenol O
oxidation O
. O

Flaxseed O
- O
derived O
enterolactone B
is O
inversely O
associated O
with O
tumor O
cell O
proliferation O
in O
men O
with O
localized O
prostate O
cancer O
. O

Abstract O
Enterolactone B
and O
enterodiol B
, O
mammalian O
lignans O
derived O
from O
dietary O
sources O
such O
as O
flaxseed O
, O
sesame O
seeds O
, O
kale O
, O
broccoli O
, O
and O
apricots O
, O
may O
impede O
tumor O
proliferation O
by O
inhibiting O
activation O
of O
nuclear O
factor O
kappa O
B O
( O
NF O
kappa O
B O
) O
and O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
. O

We O
examined O
the O
associations O
between O
urinary O
enterolactone B
and O
enterodiol B
with O
prostatic O
tumor O
expression O
of O
NF O
kappa O
B O
, O
VEGF O
, O
and O
Ki67 O
among O
147 O
patients O
with O
prostate O
cancer O
who O
participated O
in O
a O
presurgical O
trial O
of O
flaxseed O
supplementation O
( O
30 O
g O
/ O
day O
) O
for O
~ O
30 O
days O
. O

Urinary O
enterolignans B
and O
tissue O
biomarkers O
were O
determined O
by O
high O
- O
performance O
liquid O
chromatography O
and O
immunohistochemistry O
, O
respectively O
. O

After O
supplementation O
, O
we O
observed O
significant O
correlations O
between O
intakes O
of O
plant O
lignan O
and O
urinary O
concentrations O
of O
total O
enterolignans B
( O
rho O
= O
0 O
. O
677 O
, O
P O
< O
. O
0001 O
) O
, O
enterolactone B
( O
rho O
= O
0 O
. O
676 O
, O
P O
< O
. O
0001 O
) O
, O
and O
enterodiol B
( O
rho O
= O
0 O
. O
628 O
, O
P O
< O
. O
0001 O
) O
. O

Importantly O
, O
we O
observed O
that O
total O
urinary O
enterolignans B
and O
enterolactone B
were O
significantly O
and O
inversely O
correlated O
with O
Ki67 O
in O
the O
tumor O
tissue O
( O
rho O
= O
- O
0 O
. O
217 O
, O
P O
= O
. O
011 O
, O
and O
rho O
= O
- O
0 O
. O
230 O
, O
P O
= O
. O
007 O
, O
respectively O
) O
, O
and O
a O
near O
- O
significant O
inverse O
association O
was O
observed O
for O
enterodiol B
( O
rho O
= O
- O
0 O
. O
159 O
, O
P O
= O
. O
064 O
) O
. O

An O
inverse O
association O
was O
observed O
between O
enterolactone B
and O
VEGF O
( O
rho O
= O
- O
0 O
. O
143 O
, O
P O
= O
. O
141 O
) O
, O
although O
this O
did O
not O
reach O
statistical O
significance O
. O

We O
did O
not O
observe O
an O
association O
between O
enterolignans B
and O
NF O
kappa O
B O
. O

In O
conclusion O
, O
flaxseed O
- O
derived O
enterolignans B
may O
hinder O
cancer O
cell O
proliferation O
via O
VEGF O
- O
associated O
pathways O
. O

Synthesis O
and O
structure O
- O
activity O
relationships O
of O
2 B
- I
amino I
- I
3 I
- I
carboxy I
- I
4 I
- I
phenylthiophenes I
as O
novel O
atypical O
protein O
kinase O
C O
inhibitors O
. O

Recent O
evidence O
suggests O
atypical O
protein O
kinase O
C O
( O
aPKC O
) O
isoforms O
are O
required O
for O
both O
TNF O
- O
and O
VEGF O
- O
induced O
breakdown O
of O
the O
blood O
- O
retinal B
barrier O
( O
BRB O
) O
and O
endothelial O
permeability O
to O
70kDa O
dextran O
or O
albumin O
. O

A O
chemical O
library O
screen O
revealed O
a O
series O
of O
novel O
small O
molecule O
phenylthiophene B
based O
inhibitors O
of O
aPKC O
isoforms O
that O
effectively O
block O
permeability O
in O
cell O
culture O
and O
in O
vivo O
. O

Our O
study O
demonstrates O
the O
key O
structural O
elements O
that O
confer O
inhibitory O
activity O
and O
highlights O
the O
requirement O
for O
electron O
- O
donating O
moieties O
off O
the O
C O
- O
4 O
aryl O
moiety O
of O
the O
2 B
- I
amino I
- I
3 I
- I
carboxy I
- I
4 I
- I
phenylthiophene I
backbone O
. O

Synthesis O
, O
cytotoxicity O
and O
topoisomerase O
II O
inhibitory O
activity O
of O
lomefloxacin B
derivatives O
. O

A O
novel O
series O
of O
amide O
derivatives O
of O
lomefloxacin B
were O
synthesized O
and O
evaluated O
for O
their O
topoisomerase O
I O
and O
II O
inhibitory O
activity O
as O
well O
as O
cytotoxicity O
against O
a O
panel O
of O
five O
human O
cancer O
cell O
lines O
. O

Tomatidine B
inhibits O
invasion O
of O
human O
lung O
adenocarcinoma O
cell O
A549 O
by O
reducing O
matrix O
metalloproteinases O
expression O
. O

Tomatidine B
is O
an O
aglycone O
of O
glycoalkaloid O
tomatine B
in O
tomato O
. O

Tomatidine B
is O
found O
to O
possess O
anti O
- O
inflammatory O
properties O
and O
may O
serve O
as O
a O
chemosensitizer O
in O
multidrug O
- O
resistant O
tumor O
cells O
. O

However O
, O
the O
effect O
of O
tomatidine B
on O
cancer O
cell O
metastasis O
remains O
unclear O
. O

This O
study O
examines O
the O
effect O
of O
tomatidine B
on O
the O
migration O
and O
invasion O
of O
human O
lung O
adenocarcinoma O
A549 O
cell O
in O
vitro O
. O

The O
data O
demonstrates O
that O
tomatidine B
does O
not O
effectively O
inhibit O
the O
viability O
of O
A549 O
cells O
. O

When O
treated O
with O
non O
- O
toxic O
doses O
of O
tomatidine B
, O
cell O
invasion O
is O
markedly O
suppressed O
by O
Boyden O
chamber O
invasion O
assay O
, O
while O
cell O
migration O
is O
not O
affected O
. O

Tomatidine B
reduces O
the O
mRNA O
level O
of O
matrix O
metalloproteinase O
- O
2 O
( O
MMP O
- O
2 O
) O
, O
MMP O
- O
9 O
and O
increases O
the O
expression O
of O
reversion O
- O
inducing O
cysteine O
- O
rich O
protein O
with O
kazal O
motifs O
( O
RECK O
) O
, O
as O
well O
as O
tissue O
inhibitor O
of O
metalloproteinase O
- O
1 O
( O
TIMP O
- O
1 O
) O
. O

The O
immunoblotting O
assays O
indicate O
that O
tomatidine B
is O
very O
effective O
in O
suppressing O
the O
phosphorylation O
of O
Akt O
and O
extracellular O
signal O
regulating O
kinase O
( O
ERK O
) O
. O

In O
addition O
, O
tomatidine B
significantly O
decreases O
the O
nuclear O
level O
of O
nuclear O
factor O
kappa O
B O
( O
NF O
- O
kappa O
B O
) O
, O
which O
suggests O
that O
tomatidine B
inhibits O
NF O
- O
kappa O
B O
activity O
. O

The O
results O
suggest O
that O
tomatidine B
inhibits O
the O
invasion O
of O
A549 O
cells O
by O
reducing O
the O
expression O
of O
MMPs O
. O

These O
findings O
demonstrate O
a O
new O
therapeutic O
potential O
for O
tomatidine B
in O
anti O
- O
metastatic O
therapy O
. O

The O
main O
components O
found O
by O
LC O
- O
MS O
analysis O
were O
quercetin B
- I
3 I
- I
O I
- I
( I
2 I
- I
rhamnosyl I
) I
rutinoside I
, O
kaempferol B
- I
3 I
- I
O I
- I
( I
2 I
- I
rhamnosyl I
) I
rutinoside I
, O
quercetin B
- I
3 I
- I
O I
- I
rutinoside I
and O
kaempferol B
- I
3 I
- I
O I
- I
rutinoside I
. O

Identification O
of O
microcystins B
in O
a O
Lake O
Victoria O
cyanobacterial O
bloom O
using O
LC O
- O
MS O
with O
thiol O
derivatization O
. O

Microcystins B
are O
cyclic B
heptapeptides I
from O
cyanobacteria O
which O
are O
responsible O
for O
poisonings O
of O
livestock O
and O
humans O
. O

Thiol O
derivatization O
of O
the O
alpha B
, I
beta I
- I
unsaturated I
amide I
present O
in O
most O
microcystins B
was O
recently O
shown O
to O
simplify O
analysis O
of O
LC O
- O
MS O
chromatograms O
of O
a O
Microcystis O
culture O
, O
making O
it O
easier O
to O
identify O
peaks O
corresponding O
to O
microcystins B
in O
complex O
mixtures O
. O

This O
method O
was O
applied O
to O
analysis O
of O
extracts O
taken O
from O
a O
natural O
cyanobacteria O
bloom O
in O
Mwanza O
Gulf O
, O
Lake O
Victoria O
, O
Tanzania O
, O
in O
2010 O
, O
revealing O
the O
presence O
of O
numerous O
putative O
microcystin B
analogues O
in O
the O
sample O
. O

Results O
were O
verified O
using O
LC O
- O
MS O
( O
2 O
) O
, O
LC O
- O
MS O
/ O
MS O
with O
precursor O
- O
ion O
scanning O
, O
and O
LC O
- O
HRMS O
, O
leading O
to O
identification O
of O
8 O
major O
and O
17 O
minor O
microcystins B
in O
the O
sample O
, O
including O
analogues O
of O
microcystin B
- I
RY I
, I
- I
RL I
and I
- I
RA I
. O

Microcystin B
- I
YR I
( I
2 I
) I
, I
- I
RR I
( I
3 I
) I
, I
and I
- I
RY I
( I
9 I
) I
were O
isolated O
from O
bloom O
material O
from O
Lake O
Victoria O
, O
and O
the O
structure O
of O
9 O
was O
confirmed O
by O
NMR O
spectroscopic O
analysis O
and O
NMR O
spectral O
comparison O
with O
2 O
and O
3 O
. O

Confirmation O
of O
the O
structure O
of O
MC B
- I
RY I
( O
9 O
) O
facilitated O
detailed O
analysis O
of O
its O
MS O
( O
2 O
) O
spectrum O
, O
thereby O
supporting O
the O
structures O
of O
related O
analogues O
tentatively O
established O
on O
the O
basis O
of O
MS O
analyses O
. O

Intra O
- O
articular O
drug O
delivery O
from O
an O
optimized O
topical O
patch O
containing O
teriflunomide O
and O
lornoxicam B
for O
rheumatoid O
arthritis O
treatment O
: O
Does O
the O
topical O
patch O
really O
enhance O
a O
local O
treatment O
? O

The O
aim O
of O
this O
work O
is O
to O
develop O
a O
compound O
transdermal O
patch O
containing O
teriflunomide O
( O
TEF B
) O
and O
lornoxicam B
( O
LOX B
) O
to O
transport O
these O
drugs O
across O
the O
skin O
with O
the O
isochronous O
permeation O
rates O
for O
RA O
therapy O
and O
investigate O
intra O
- O
articular O
delivery O
of O
TEF B
and O
LOX B
following O
transdermal O
patches O
applied O
topically O
. O

The O
salts O
of O
TEF B
and O
LOX B
with O
organic B
amines I
diethylamine B
( O
DEtA B
) O
, O
triethylamine O
( O
TEtA B
) O
, O
diethanolamine B
( O
DEA B
) O
, O
triethanolamine O
( O
TEA O
) O
and O
N B
- I
( I
2 I
' I
- I
hydroxy I
- I
ethanol I
) I
- I
piperdine I
( O
NP O
) O
were O
prepared O
to O
improve O
the O
skin O
permeation O
of O
the O
parent O
drug O
. O

After O
topical O
application O
of O
the O
optimized O
compound O
patch O
to O
only O
one O
knee O
joint O
in O
rabbit O
, O
intra O
- O
articular O
delivery O
of O
TEF B
and O
LOX B
on O
the O
application O
site O
was O
compared O
with O
that O
on O
the O
non O
- O
application O
site O
. O

The O
in O
vitro O
experiment O
results O
showed O
that O
the O
amine B
salts I
of O
TEF B
and O
LOX B
, O
especially O
TEF B
- I
TEtA I
and O
LOX B
- I
TEtA I
, O
enhanced O
the O
skin O
permeation O
of O
TEF B
and O
LOX B
from O
the O
transdermal O
patch O
system O
. O

The O
optimal O
formulation O
successfully O
displayed O
isochronous O
permeation O
rates O
for O
TEF B
and O
LOX B
across O
rabbit O
skin O
, O
and O
was O
defined O
with O
5 O
% O
of O
TEF B
- I
TEtA I
, O
10 O
% O
of O
LOX B
- I
TEtA I
and O
15 O
% O
of O
azone O
. O

The O
in O
vivo O
study O
showed O
that O
TEF B
and O
LOX B
from O
transdermal O
patches O
were O
transferred O
into O
skin O
, O
ligament O
and O
fat O
pad O
on O
the O
application O
site O
by O
direct O
diffusion O
and O
on O
the O
non O
- O
application O
site O
by O
the O
redistribution O
of O
systemic O
blood O
supply O
, O
while O
local O
absorption O
of O
TEF B
and O
LOX B
in O
synovial O
fluid O
originated O
from O
the O
systemic O
blood O
supply O
rather O
than O
direct O
diffusion O
. O

BM O
remarkably O
inhibited O
UVB O
- O
induced O
activation O
of O
inducible O
nitric O
oxide O
synthase O
( O
iNOS O
) O
and O
therefore O
generation O
of O
nitric O
oxide O
( O
NO O
) O
and O
nitrotyrosine B
, O
in O
a O
UVB O
single O
dose O
regimen O
. O

In O
multiple O
UVB O
irradiations O
, O
BM O
increased O
NO O
formation O
and O
total O
ERK O
1 O
/ O
2 O
activity O
and O
reduced O
iNOS O
activity O
and O
nitrotyrosine B
levels O
, O
inhibited O
cell O
proliferation O
, O
diminished O
p53 O
and O
caspase O
- O
3 O
immunoreactivities O
and O
increased O
the O
percentage O
of O
Bcl O
- O
2 O
positive O
cells O
. O

The O
goal O
of O
the O
current O
study O
was O
to O
characterize O
the O
degradation O
of O
1 B
, I
2 I
- I
dilinolenoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
( O
DLPC B
) O
during O
lyophilization O
and O
to O
also O
probe O
the O
influence O
of O
metal O
contaminants O
in O
promoting O
the O
observed O
degradation O
. O

Aqueous O
sugar O
formulations O
containing O
DLPC B
( O
0 O
. O
01mg O
/ O
ml O
) O
were O
lyophilized O
, O
and O
DLPC B
degradation O
was O
monitored O
using O
HPLC O
/ O
UV O
and O
GC O
/ O
MS O
methods O
. O

DLPC B
degradation O
increased O
with O
higher O
levels O
of O
ferrous O
ion O
. O

After O
lyophilization O
, O
103 O
. O
1 O
+ O
/ O
- O
1 O
. O
1 O
% O
, O
66 O
. O
9 O
+ O
/ O
- O
0 O
. O
8 O
% O
, O
and O
28 O
. O
7 O
+ O
/ O
- O
0 O
. O
7 O
% O
DLPC B
remained O
in O
the O
sucrose O
samples O
spiked O
with O
0 O
. O
0ppm O
, O
0 O
. O
2ppm O
, O
and O
1 O
. O
0ppm O
ferrous O
ion O
, O
respectively O
. O

Sugar O
concentration O
and O
buffer O
ionic O
strength O
also O
influence O
the O
extent O
of O
lipid O
degradation O
, O
and O
DLPC B
loss O
correlated O
with O
degradation O
product O
formation O
. O

We O
conclude O
that O
DLPC B
oxidation O
during O
the O
freezing O
stage O
of O
lyophilization O
dramatically O
compromises O
the O
stability O
of O
lipid O
- O
based O
formulations O
. O

Two O
novel O
ruthenium O
( O
II O
) O
complexes O
[ B
Ru I
( I
dmb I
) I
2 I
( I
addppn I
) I
] I
( I
ClO4 I
) I
2 I
( O
1 O
) O
and O
[ B
Ru I
( I
bpy I
) I
2 I
( I
addppn I
) I
] I
( I
ClO4 I
) I
2 I
( O
2 O
) O
were O
synthesized O
. O

Synthesis O
of O
novel O
1 B
, I
3 I
, I
4 I
- I
trisubstituted I
pyrazoles I
as O
anti O
- O
inflammatory O
and O
analgesic O
agents O
. O

Some O
novel O
1 B
, I
3 I
, I
4 I
- I
trisubstituted I
pyrazoles I
were O
synthesized O
and O
screened O
for O
their O
anti O
- O
inflammatory O
and O
analgesic O
activities O
as O
well O
as O
their O
ulcerogenic O
liability O
. O

They O
showed O
anti O
- O
inflammatory O
and O
analgesic O
activities O
with O
better O
GIT O
tolerance O
than O
the O
standard O
drug O
phenylbutazone B
. O

Analysis O
of O
the O
antioxidant O
properties O
of O
differently O
substituted O
2 B
- I
and I
3 I
- I
indolyl I
carbohydrazides I
and O
related O
derivatives O
. O

Herein O
, O
we O
report O
the O
antioxidant O
properties O
of O
some O
selected O
substituted O
2 B
- I
indolyl I
carbohydrazides I
( O
JL34 B
, O
JL40 B
, O
JL71 B
, O
JL87 B
, O
JL317 B
, O
JL432 B
, O
JL436 B
) O
, O
the O
substituted O
3 B
- I
indolyl I
carbohydrazide I
JL344 B
, O
3 B
- I
( I
3 I
- I
hydrazinylpropyl I
) I
- I
1H I
- I
indole I
( O
JL72 B
) O
and O
3 O
- O
( O
1H O
- O
indol O
- O
3 O
- O
yl O
) O

propanehydrazide O
( O
JL418 B
) O
, O
throughout O
the O
assessment O
of O
their O
antioxidative O
potential O
using O
different O
antioxidant O
assays O
such O
as O
DPPH O
, O
lipid O
peroxidation O
in O
the O
APPH O
, O
or O
the O
DMSO O
method O
. O

Compounds O
JL40 B
and O
JL432 B
presenting O
higher O
lipoxygenase O
inhibitory O
activity O
among O
the O
tested O
derivatives O
, O
were O
found O
to O
present O
a O
promising O
anti O
- O
inflammatory O
in O
vivo O
result O
, O
as O
well O
as O
antioxidant O
and O
LOX O
inhibitory O
profile O
. O

These O
results O
in O
combination O
to O
their O
known O
AChE O
/ O
BuChE O
inhibitory O
activities O
led O
us O
to O
propose O
these O
indolyl B
carbohydrazides I
as O
new O
multifunctional O
compounds O
against O
AD O
. O

Biological O
evaluation O
of O
bisbenzaldehydes B
against O
four O
Mycobacterium O
species O
. O

A O
series O
of O
bisbenzaldehydes B
and O
structurally O
related O
analogs O
, O
conveniently O
synthesized O
via O
microwave O
- O
assisted O
reactions O
, O
were O
evaluated O
in O
vitro O
against O
drug O
susceptible O
and O
multi O
- O
drug O
resistant O
Mycobacterium O
tuberculosis O
, O
against O
virulent O
Mycobacterium O
bovis O
, O
against O
Mycobacterium O
ulcerans O
and O
against O
two O
Mycobacterium O
avium O
subspecies O
. O

Among O
the O
33 O
substances O
that O
were O
tested O
, O
compound O
12 O
, O
i O
. O
e O
. O
4 B
, I
4 I
' I
- I
[ I
1 I
, I
12 I
- I
dodecanediyl I
( I
oxy I
) I
] I
bisbenzaldehyde I
, O
emerged O
as O
the O
most O
promising O
hit O
. O

A O
1 O
% O
( O
w O
/ O
w O
) O
chlorogenic O
acid O
or O
silver B
sulfadiazine I
ointment O
was O
applied O
topically O
once O
a O
day O
for O
15 O
days O
on O
full O
- O
thickness O
excision O
wounds O
created O
on O
rats O
. O

The O
1 O
% O
( O
w O
/ O
w O
) O
chlorogenic O
acid O
ointment O
had O
potent O
wound O
healing O
capacity O
as O
evident O
from O
the O
wound O
contraction O
on O
the O
15th O
post O
- O
surgery O
day O
, O
which O
was O
similar O
to O
that O
produced O
by O
1 O
% O
( O
w O
/ O
w O
) O
silver B
sulfadiazine I
ointment O
. O

We O
solved O
the O
crystal O
structures O
of O
tau O
55 O
- O
HPD O
and O
its O
closely O
related O
paralogue O
Huf O
and O
used O
in O
silico O
docking O
methods O
to O
identify O
phospho B
- I
serine I
and O
phospho B
- I
tyrosine I
containing O
peptides O
as O
possible O
substrates O
that O
were O
subsequently O
validated O
using O
in O
vitro O
phosphatase O
assays O
. O

Adenine O
- O
DNA O
Adducts O
Derived O
from O
the O
Highly O
Tumorigenic O
Dibenzo B
[ I
a I
, I
l I
] I
pyrene I
Are O
Resistant O
to O
Nucleotide O
Excision O
Repair O
while O
Guanine O
Adducts O
Are O
Not O
. O

Here O
we O
compared O
, O
in O
the O
same O
sequence O
context O
, O
the O
relative O
NER O
dual O
incision O
efficiencies O
elicited O
by O
two O
stereochemically O
distinct O
pairs O
of O
guanine O
( O
N O
( O
2 O
) O
- O
dG O
) O
and O
adenine O
( O
N O
( O
6 O
) O
- O
dA O
) O
DNA O
lesions O
, O
derived O
from O
enantiomeric O
genotoxic O
diol B
epoxides I
of O
the O
highly O
tumorigenic O
fjord O
region O
polycyclic O
aromatic O
hydrocarbon O
dibenzo B
[ I
a I
, I
l I
] I
pyrene I
( O
DB B
[ I
a I
, I
l I
] I
P I
) O
. O

Our O
results O
are O
consistent O
with O
the O
hypothesis O
that O
the O
high O
genotoxic O
activity O
of O
DB B
[ I
a I
, I
l I
] I
P I
is O
related O
to O
the O
formation O
of O
NER O
- O
resistant O
and O
persistent O
DB B
[ I
a I
, I
l I
] I
P I
- O
derived O
adenine O
adducts O
in O
cellular O
DNA O
. O

Reactions O
of O
Hydrocarbon B
Radicals I
and I
Biradicals I
. O

Ion O
impacts O
on O
graphene O
/ O
ir B
( I
111 I
) I
: O
interface O
channeling O
, O
vacancy O
funnels O
, O
and O
a O
nanomesh O
. O

By O
combining O
ion O
beam O
experiments O
and O
atomistic O
simulations O
we O
study O
the O
production O
of O
defects O
in O
graphene O
on O
Ir B
( I
111 I
) I
under O
grazing O
incidence O
of O
low O
energy O
Xe O
ions O
. O

We O
demonstrate O
an O
ability O
to O
tailor O
properties O
critical O
to O
zeolite O
performance O
, O
such O
as O
external O
porous O
surface O
area O
, O
crystal O
shape O
, O
and O
pore O
length O
, O
which O
can O
enhance O
sorbate B
accessibility O
to O
LTL O
pores O
, O
tune O
the O
supramolecular O
organization O
of O
guest O
- O
host O
composites O
, O
and O
minimize O
the O
diffusion O
path O
length O
, O
respectively O
. O

New O
genetic O
associations O
in O
thiopurine B
- O
related O
bone O
marrow O
toxicity O
among O
inflammatory O
bowel O
disease O
patients O
. O

Background O
: O
The O
toxicity O
related O
to O
thiopurine B
drug O
therapy O
for O
inflammatory O
bowel O
disease O
( O
IBD O
) O
varies O
widely O
among O
patients O
. O

Several O
factors O
have O
been O
implicated O
in O
determining O
this O
toxicity O
, O
mainly O
individual O
genetic O
variation O
related O
to O
formation O
of O
active O
thiopurine B
metabolites O
. O

The O
aim O
was O
to O
identify O
genes O
involved O
in O
thiopurine B
- O
related O
myelosuppression O
. O

Conclusion O
: O
We O
have O
identified O
IL6ST O
and O
FSLT5 O
as O
new O
bone O
marrow O
suppression O
susceptibility O
candidate O
genes O
after O
thiopurine B
treatment O
in O
IBD O
patients O
. O

This O
is O
the O
first O
report O
of O
variants O
associated O
with O
thiopurine B
- O
related O
myelosuppression O
that O
was O
identified O
by O
a O
genome O
- O
wide O
association O
study O
. O

The O
strength O
of O
interaction O
between O
graphene O
and O
the O
organic O
molecules O
was O
estimated O
by O
density O
functional O
theory O
( O
PBE O
, O
B97D O
, O
M06 O
- O
2X O
, O
and O
optB88 O
- O
vdW O
) O
, O
wave O
function O
theory O
( O
MP2 O
, O
SCS O
( O
MI O
) O
- O
MP2 O
, O
MP2 O
. O
5 O
, O
MP2 O
. O
X O
, O
and O
CCSD O
( O
T O
) O
) O
, O
and O
empirical O
calculations O
( O
OPLS O
- O
AA O
) O
using O
two O
graphene O
models O
: O
coronene B
and O
infinite O
graphene O
. O

A O
potent O
11 O
- O
mer O
peptide O
TSG B
- I
8 I
- I
1 I
, O
WWSYVRRWRSR O
- O
amide O
, O
was O
developed O
, O
which O
exhibited O
antimicrobial O
activity O
against O
E O
. O
coli O
and O
S O
. O
aureus O
while O
very O
little O
hemolytic O
activity O
in O
human O
erythrocytes O
was O
observed O
at O
high O
dose O
level O
. O

Pyranocycloartobilox B
A I
, O
a O
novel O
gastroprotective O
compound O
from O
Artocarpus O
obtusus O
Jarret O
, O
against O
ethanol O
- O
induced O
acute O
gastric O
ulcer O
in O
vivo O
. O

Pyranocycloartobilox B
A I
( O
PA O
) O
, O
a O
xanthone B
derived O
from O
the O
Artocarpus O
obtusus O
Jarret O
, O
belongs O
to O
the O
Moraceae O
family O
which O
is O
native O
to O
the O
tropical O
forest O
of O
Malaysia O
. O

The O
nacre O
- O
mimicking O
fibers O
are O
highly O
electrically O
conductive O
( O
~ O
350 O
S O
m O
( O
- O
1 O
) O
) O
after O
immersing O
in O
hydroiodic B
acid I
, O
enabling O
them O
to O
connect O
a O
circuit O
to O
illuminate O
an O
LED O
lamp O
. O

Walter O
on O
antioxidant O
enzyme O
activities O
such O
as O
peroxidases O
( O
PODs O
) O
, O
super B
oxide I
dismutases O
( O
SODs O
) O
and O
catalase O
( O
CAT O
) O
and O
on O
total O
protein O
contents O
( O
TPC O
) O
, O
cellular O
injury O
( O
CI O
) O
, O
and O
malondialdehyde O
( O
MDA O
) O
in O
the O
germinating O
seeds O
of O
Brassica O
napus O
L O
. O

Ultrasonic O
synthesis O
, O
characterization O
of O
beta B
- I
aminoketones I
by O
bismuth B
( I
III I
) I
triflate I
and O
determination O
of O
antigenotoxic O
properties O
. O

Direct O
- O
type O
catalytic O
Mannich O
reaction O
for O
the O
synthesis O
of O
beta B
- I
aminoketones I
from O
cyclohexanone B
, O
substituted O
aromatic B
amines I
and I
aromatic I
or I
hetero I
- I
aromatic I
aldehydes I
has O
been O
applied O
in O
water O
with O
bismuth B
triflate I
under O
ultrasound O
. O

Good O
yields O
of O
the O
expected O
beta B
- I
aminoketones I
were O
obtained O
from O
available O
substrates O
, O
at O
room O
temperature O
in O
1 O
- O
2 O
hours O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
mutagenic O
and O
antimutagenic O
potential O
of O
synthesized O
beta B
- I
aminoketones I
compounds O
using O
Ames O
/ O
Salmonella O
and O
Escherichia O
coli O
WP2 O
bacterial O
reverse O
mutation O
assay O
systems O
. O

Ameliorative O
effect O
of O
lycopene O
against O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
pdioxin I
- O
induced O
rat O
liver O
microsomal O
toxicity O
: O
An O
in O
vitro O
study O
. O

Hydrogen O
peroxide O
( O
H2O2 O
) O
production O
, O
lipid O
peroxidation O
( O
LPO O
) O
, O
protein O
carbonyl O
content O
and O
activities O
of O
uridine B
5 I
' I
- I
diphospho I
- O
glucuronyltransferas O
( O
UDPGT O
) O
and O
P450 O
were O
significantly O
increased O
. O

For O
good O
and O
intermediate O
risk O
disease O
, O
pazopanib B
, O
sunitinib O
or O
the O
combination O
of O
bevacizumab O
plus O
IFN O
are O
considered O
. O

Notably O
, O
recent O
data O
suggest O
non O
- O
inferiority O
for O
the O
efficacy O
of O
pazopanib B
compared O
to O
sunitinib O
coupled O
with O
a O
better O
toxicity O
profile O
. O

A O
novel O
VEGF O
receptor O
inhibitor O
, O
tivozanib B
, O
is O
expected O
to O
be O
approved O
based O
on O
improvement O
in O
PFS O
when O
compared O
to O
sorafenib B
in O
the O
first O
- O
line O
setting O
. O

The O
use O
of O
temsirolimus B
for O
poor O
risk O
disease O
is O
supported O
by O
a O
phase O
III O
trial O
dedicated O
to O
this O
group O
of O
patients O
. O

Following O
first O
- O
line O
VEGF O
inhibitors O
, O
second O
- O
line O
therapy O
with O
everolimus B
and O
axitinib O
have O
demonstrated O
benefits O
in O
progression O
- O
free O
survival O
( O
PFS O
) O
. O

One O
phase O
III O
trial O
comparing O
sorafenib B
and O
temsirolimus B
in O
the O
post O
- O
sunitinib O
setting O
showed O
no O
difference O
in O
PFS O
, O
the O
primary O
endpoint O
, O
but O
did O
show O
a O
superior O
overall O
survival O
for O
sorafenib B
. O

Sorafenib B
, O
pazopanib B
and O
axitinib O
have O
all O
demonstrated O
clinical O
benefit O
following O
cytokines O
. O

Finally O
, O
optimal O
therapy O
for O
non O
- O
clear O
cell O
RCC O
remains O
to O
be O
delineated O
, O
although O
sunitinib O
, O
everolimus B
and O
other O
VEGFR O
- O
TKI O
or O
mTOR O
inhibitors O
have O
all O
demonstrated O
modest O
benefit O
. O

Methods O
: O
2 B
- I
iminothiolane I
was O
covalently O
attached O
to O
a O
chitosan O
backbone O
. O

A O
preactivation O
step O
followed O
, O
mediated O
by O
6 B
, I
6 I
' I
dithionicotinamide I
, O
thiol O
groups O
were O
modified O
by O
disulfide O
bonds O
formation O
. O

Results O
: O
The O
obtained O
chitosan O
- O
thiobutylamidine B
conjugate O
displayed O
647 O
. O
4 O
+ O
/ O
- O
85 O
. O
23 O
micro O
mol O
/ O
g O
immobilized O
thiol O
groups O
. O

Chitosan O
- O
thiobutylamidine B
- O
mercaptonicotinamide B
displayed O
1 O
. O
8 O
- O
fold O
higher O
stability O
and O
1 O
. O
6 O
- O
fold O
higher O
mucoadhesive O
properties O
, O
respectively O
. O

This O
expands O
the O
number O
of O
known O
solvents O
which O
can O
support O
amphiphilic O
self O
- O
assembly O
to O
ethanol O
, O
acetone O
, O
tetrahydrofuran O
, O
N B
- I
dimethylformamide I
, O
N B
- I
cyclohexyl I
- I
2 I
- I
pyrrolidone I
, O
and O
a O
number O
of O
other O
organic O
solvents O
, O
many O
of O
which O
were O
not O
known O
to O
afford O
solvophobic O
self O
- O
assembly O
prior O
to O
this O
report O
. O

Helicity O
as O
a O
Steric O
Force O
: O
Stabilization O
and O
Helicity O
- O
Dependent O
Reversion O
of O
Colored O
o B
- I
Quinonoid I
Intermediates O
of O
Helical O
Chromenes O
. O

The O
structure O
further O
shows O
that O
diphenylvinyl B
moiety O
in O
the O
TT O
isomer O
of O
2Q O
gets O
splayed O
over O
the O
helical O
scaffold O
such O
that O
it O
is O
fraught O
with O
a O
huge O
steric O
strain O
to O
undergo O
required O
bond O
rotations O
to O
regenerate O
the O
precursor O
chromene O
. O

Aazahelical O
chromenes O
3 O
and O
4 O
with O
varying O
magnitudes O
of O
helicity O
were O
designed O
in O
pursuit O
of O
o B
- I
quinonoid I
intermediates O
with O
graded O
activation O
barriers O
. O

By O
changing O
to O
another O
polymer O
, O
poly B
( I
4 I
- I
vinylpyridine I
) I
/ O
graphene O
shows O
a O
stable O
and O
reversible O
response O
to O
pH O
, O
and O
demonstrates O
its O
potential O
for O
sensor O
application O
. O

Detection O
of O
Nitrogen O
- O
Protonated B
Nitrous I
Oxide I
( O
HNNO B
( I
+ I
) I
) O
by O
Rotational O
Spectroscopy O
. O

The O
rotational O
spectrum O
of O
nitrogen O
- O
protonated B
nitrous I
oxide I
( O
HNNO B
( I
+ I
) I
) O
, O
an O
isomer O
whose O
existence O
was O
first O
inferred O
from O
kinetic O
studies O
more O
than O
30 O
years O
ago O
, O
has O
now O
been O
detected O
by O
Fourier O
transform O
microwave O
spectroscopy O
, O
guided O
by O
new O
high O
- O
level O
coupled O
- O
cluster O
calculations O
of O
its O
molecular O
structure O
. O

The O
chi O
aa O
( O
N O
) O
values O
for O
the O
two O
isomers O
of O
protonated B
nitrous I
oxide I
are O
qualitatively O
consistent O
with O
the O
valence O
bond O
description O
of O
H B
- I
N I
= I
N I
( I
+ I
) I
= I
O I
for O
the O
electronic O
structure O
of O
the O
nitrogen O
- O
protonated O
form O
and O
N B
= I
N I
( I
+ I
) I
- I
O I
- I
H I
for O
the O
oxygen O
- O
protonated O
form O
. O

HNNO B
( I
+ I
) I
is O
found O
to O
be O
2 O
- O
4 O
times O
less O
abundant O
than O
NNOH B
( I
+ I
) I
under O
a O
range O
of O
experimental O
conditions O
, O
as O
might O
be O
expected O
because O
this O
metastable O
isomer O
is O
known O
to O
be O
only O
~ O
6 O
kcal O
mol O
( O
- O
1 O
) O
less O
stable O
than O
ground O
- O
state O
NNOH B
( I
+ I
) I
from O
kinetic O
measurements O
by O
Ferguson O
and O
co O
- O
workers O
. O

Safety O
evaluation O
of O
desloratadine B
in O
allergic O
rhinitis O
. O

Introduction O
: O
Desloratadine B
is O
a O
biologically O
active O
metabolite O
of O
second O
- O
generation O
antihistamine O
loratadine B
. O

Areas O
covered O
: O
A O
Medline O
search O
was O
conducted O
to O
identify O
preclinical O
and O
clinical O
studies O
of O
desloratadine B
. O

The O
focus O
of O
this O
review O
is O
on O
the O
safety O
profile O
of O
desloratadine B
. O

Expert O
opinion O
: O
The O
review O
of O
these O
data O
indicates O
that O
the O
safety O
profile O
of O
desloratadine B
is O
similar O
to O
other O
second O
- O
generation O
antihistamines O
. O

Desloratadine B
is O
highly O
selective O
for O
histamine O
H1 O
- O
receptors O
, O
does O
not O
cross O
the O
blood O
- O
brain O
barrier O
( O
BBB O
) O
, O
and O
has O
minimal O
adverse O
events O
( O
very O
low O
sedation O
rate O
) O
, O
with O
a O
better O
safety O
and O
tolerability O
than O
first O
- O
generation O
antihistamines O
. O

Desloratadine B
is O
safe O
and O
well O
tolerated O
without O
having O
central O
nervous O
system O
( O
CNS O
) O
or O
cardiovascular O
effects O
and O
with O
low O
drug O
interaction O
. O

Synthesis O
, O
Antidepressant O
Evaluation O
and O
Docking O
Studies O
of O
Long O
- O
Chain O
Alkylnitroquipazines B
as O
Serotonin O
Transporter O
Inhibitors O
. O

Twelve O
alkyl O
analogues O
( O
1 O
- O
12 O
) O
of O
the O
high O
- O
affinity O
serotonin O
transporter O
( O
SERT O
) O
inhibitor O
6 B
- I
nitroquipazine I
( O
6 B
- I
NQ I
) O
were O
synthesized O
and O
studied O
using O
in O
vitro O
radioligand O
competition O
binding O
assays O
to O
determine O
their O
binding O
affinity O
( O
Ki O
) O
. O

Our O
results O
showed O
that O
several O
of O
the O
6 B
- I
NQ I
analogues O
are O
high O
- O
affinity O
SERT O
inhibitors O
and O
indicated O
that O
the O
octyl B
( O
8 O
) O
, O
decyl B
( O
10 O
) O
and O
dodecyl O
( O
12 O
) O
6 B
- I
NQ I
analogues O
exhibit O
moderate O
antidepressant O
activity O
. O

Phase O
field O
simulations O
were O
conducted O
to O
investigate O
the O
effect O
of O
misfit O
strain O
on O
the O
vortex O
domain O
structure O
( O
VDS O
) O
in O
a O
BaTiO3 B
nanodot O
. O

Metabolomics O
reveals O
trichloroacetate B
as O
a O
major O
contributor O
to O
trichloroethylene B
- O
induced O
metabolic O
alterations O
in O
mouse O
urine O
and O
serum O
. O

Trichloroethylene B
( O
TCE B
) O
- O
induced O
liver O
toxicity O
and O
carcinogenesis O
is O
believed O
to O
be O
mediated O
in O
part O
by O
activation O
of O
the O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
( O
PPAR O
alpha O
) O
. O

However O
, O
the O
contribution O
of O
the O
two O
TCE B
metabolites O
, O
dichloroacetate B
( O
DCA B
) O
and O
trichloroacetate B
( O
TCA B
) O
to O
the O
toxicity O
of O
TCE B
, O
remains O
unclear O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
determine O
the O
metabolite O
profiles O
in O
serum O
and O
urine O
upon O
exposure O
of O
mice O
to O
TCE B
, O
to O
aid O
in O
determining O
the O
metabolic O
response O
to O
TCE B
exposure O
and O
the O
contribution O
of O
DCA B
and O
TCA B
to O
TCE B
toxicity O
. O

C57BL O
/ O
6 O
mice O
were O
administered O
TCE B
, O
TCA B
, O
or O
DCA B
, O
and O
urine O
and O
serum O
subjected O
to O
ultra O
- O
performance O
liquid O
chromatography O
coupled O
with O
electrospray O
ionization O
quadrupole O
time O
- O
of O
- O
flight O
mass O
spectrometry O
( O
UPLC O
- O
ESI O
- O
QTOFMS O
) O
- O
based O
global O
metabolomics O
analysis O
. O

TCE B
exposure O
resulted O
in O
a O
decrease O
in O
urine O
of O
metabolites O
involved O
in O
fatty O
acid O
metabolism O
, O
resulting O
from O
altered O
expression O
of O
PPAR O
alpha O
target O
genes O
. O

TCE B
treatment O
also O
induced O
altered O
phospholipid O
homeostasis O
in O
serum O
, O
as O
revealed O
by O
increased O
serum O
lysophosphatidylchol B
18 I
: I
0 I
and I
18 I
: I
1 I
, O
and O
phosphatidylcholine O
metabolites O
. O

TCA B
administration O
revealed O
similar O
metabolite O
profiles O
in O
urine O
and O
serum O
upon O
TCE B
exposure O
, O
which O
correlated O
with O
a O
more O
robust O
induction O
of O
PPAR O
alpha O
target O
gene O
expression O
associated O
with O
TCA B
than O
DCA B
treatment O
. O

These O
data O
show O
the O
metabolic O
response O
to O
TCE B
exposure O
and O
demonstrate O
that O
TCA B
is O
the O
major O
contributor O
to O
TCE B
- O
induced O
metabolite O
alterations O
observed O
in O
urine O
and O
serum O
. O

Different O
concentrations O
of O
sodium B
pentaborate I
pentahydrate I
( O
NaB B
) O
were O
prepared O
for O
the O
analysis O
of O
cell O
toxicity O
and O
differentiation O
evaluations O
. O

The O
NaB B
- O
treated O
group O
displayed O
the O
highest O
ALP O
activity O
and O
expression O
of O
osteo O
- O
and O
odontogenic O
- O
related O
genes O
and O
proteins O
compared O
to O
the O
other O
groups O
and O
baseline O
. O

In O
the O
current O
study O
, O
increased O
in O
vitro O
odontogenic O
and O
osteogenic O
differentiation O
capacity O
of O
hTGSCs O
by O
NaB B
application O
has O
been O
shown O
for O
the O
first O
time O
. O

The O
study O
offers O
considerable O
promise O
for O
the O
development O
of O
new O
scaffold O
systems O
combined O
with O
NaB B
in O
both O
functional O
bone O
and O
tooth O
tissue O
engineering O
. O

Attenuation O
of O
Gouty O
Arthritis O
by O
Emodinol B
in O
Monosodium B
Urate I
Crystal O
- O
Treated O
Mice O
. O

A O
series O
of O
studies O
have O
recently O
demonstrated O
that O
the O
release O
of O
interleukin O
1 O
beta O
induced O
by O
monosodium B
urate I
crystals O
is O
central O
to O
the O
experimental O
gouty O
arthritis O
. O

Emodinol B
, O
as O
a O
major O
triterpene O
compound O
in O
E O
. O
pungens O
, O
has O
been O
seldom O
reported O
to O
have O
an O
effect O
on O
gouty O
arthritis O
. O

Therefore O
, O
the O
potential O
beneficial O
effects O
and O
mechanisms O
of O
emodinol B
on O
gouty O
arthritis O
were O
investigated O
in O
this O
study O
. O

Results O
showed O
that O
it O
significantly O
ameliorated O
the O
hyperalgesia O
, O
inflammation O
, O
and O
levels O
of O
multiple O
proinflammatory O
cytokines O
in O
monosodium B
urate I
crystals O
- O
treated O
mice O
. O

These O
findings O
elucidate O
that O
emodinol B
exhibits O
a O
prominent O
effect O
on O
improving O
symptoms O
of O
acute O
gouty O
arthritis O
induced O
by O
monosodium B
urate I
crystals O
through O
inhibiting O
the O
generation O
of O
proinflammatory O
cytokines O
. O

In O
this O
study O
, O
we O
developed O
an O
original O
freeze O
- O
dried O
electrofocusing O
native O
gel O
over O
polyimide B
film O
( O
native O
- O
gel O
film O
) O
for O
scanning O
protein O
analysis O
using O
synchrotron O
radiation O
excited O
X O
- O
ray O
fluorescence O
( O
SPAX O
) O
. O

The O
lifetime O
and O
efficiency O
of O
triplet O
- O
triplet O
fluorescence O
from O
the O
excited O
state O
of O
a O
TMM B
biradical O
determined O
using O
transient O
emission O
spectroscopy O
by O
two O
- O
color O
two O
- O
laser O
flash O
photolysis O
. O

The O
single O
laser O
flash O
photolysis O
( O
FP O
) O
of O
2 B
- I
( I
4 I
- I
benzoylphenyl I
) I
- I
2 I
- I
phenyl I
- I
1 I
- I
methylenecyclopropan I
gave O
rise O
to O
a O
ground O
state O
trimethylenemethane B
( O
TMM B
) O
biradical O
with O
absorption O
bands O
at O
362 O
and O
545 O
nm O
and O
an O
excited O
state O
of O
this O
biradical O
that O
displays O
triplet O
- O
triplet O
fluorescence O
at O
580 O
nm O
. O

Profile O
hidden O
Markov O
models O
( O
HMMs O
) O
were O
used O
to O
predict O
the O
configuration O
of O
secondary B
alcohols I
and O
alpha B
- I
methyl I
branches O
of O
modular O
polyketides O
. O

Identification O
and O
Characterization O
of O
a O
Cellulose O
Binding O
Heptapeptide B
Revealed O
by O
Phage O
Display O
. O

Probing O
the O
Mechanism O
of O
TBAF B
- O
Catalyzed O
Deacylation O
of O
Cellulose O
Esters O
. O

The O
mechanism O
of O
the O
recently O
discovered O
, O
unusual O
tetrabutylammonium B
fluoride I
( O
TBAF B
) O
deacylation O
of O
cellulose O
esters O
has O
been O
investigated O
by O
methods O
including O
kinetic O
isotope O
effect O
( O
KIE O
) O
studies O
. O

Additional O
studies O
suggest O
the O
possibility O
that O
TBAF B
chelation O
by O
neighboring O
acyl O
groups O
may O
account O
for O
the O
unexpected O
regioselectivity O
at O
the O
secondary B
alcohol I
esters I
that O
is O
observed O
in O
the O
TBAF B
deacylation O
of O
cellulose O
esters O
. O

As O
of O
early O
2013 O
, O
over O
200 O
natural O
products O
are O
known O
to O
contain O
a O
nitrogen O
- O
nitrogen O
( O
N B
- I
N I
) O
bond O
. O

Finally O
, O
amphiphilic O
random O
polypeptides O
containing O
10 O
% O
and O
20 O
% O
alpha B
- I
d I
- I
mannose I
in O
addition O
to O
glucose O
containing O
a O
hydrophobic O
alkyl O
chain O
at O
its O
6 O
position O
were O
synthesized O
by O
our O
methodology O
, O
and O
these O
polymers O
were O
also O
found O
to O
assemble O
into O
spherical O
nanostructures O
. O

Treatment O
of O
these O
mice O
with O
3mg O
/ O
kg O
body O
weight O
of O
the O
model O
CAR O
activator O
1 B
, I
4 I
- I
bis I
- I
[ I
2 I
- I
( I
3 I
, I
5 I
- I
dichloropyridyloxy I
) I
] I
benzene I
( O
TCPOBOP B
) O
confirmed O
previous O
findings O
related O
to O
the O
coordinate O
regulation O
of O
drug O
metabolism O
by O
beta O
- O
catenin O
and O
CAR O
. O

The O
study O
also O
revealed O
interesting O
differences O
between O
the O
two O
mouse O
models O
: O
hepatic O
zonation O
of O
TCPOBOP B
- O
dependent O
induction O
of O
drug O
- O
metabolizing O
enzymes O
was O
restored O
in O
mice O
with O
late O
knockout O
of O
beta O
- O
catenin O
, O
and O
the O
strong O
proliferative O
response O
of O
female O
mice O
was O
exclusively O
abolished O
when O
using O
animals O
with O
a O
late O
beta O
- O
catenin O
knockout O
. O

Glutathione O
conjugation O
attenuates O
biological O
activities O
of O
6 B
- I
dehydroshogaol I
from O
ginger O
. O

6 B
- I
Dehydroshogaol I
( O
6 B
- I
DHSG I
) O
is O
a O
bioactive O
alpha O
, O
beta O
- O
unsaturated O
carbonyl O
compound O
isolated O
from O
fresh O
ginger O
with O
anti O
- O
inflammatory O
and O
phase O
II O
enzyme O
inducing O
activities O
. O

Here O
we O
describe O
the O
glutathione O
( O
GSH O
) O
- O
dependent O
metabolism O
and O
the O
effect O
of O
this O
metabolic O
transformation O
on O
the O
biological O
activities O
of O
6 B
- I
DHSG I
. O

Compared O
with O
other O
ginger O
compounds O
, O
such O
as O
6 O
- O
gingerol O
and O
6 O
- O
shogaol O
, O
6 B
- I
DHSG I
showed O
the O
most O
potent O
anti O
- O
inflammatory O
effect O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
RAW O
264 O
. O
7 O
cells O
. O

The O
biological O
activities O
of O
6 B
- I
DHSG I
were O
attenuated O
by O
sulfhydryl O
antioxidants O
such O
as O
glutathione O
( O
GSH O
) O
or O
N O
- O
acetyl O
cysteine O
( O
NAC O
) O
, O
but O
not O
ascorbic O
acid O
( O
ASC B
) O
. O

6 B
- I
DHSG I
was O
metabolised O
by O
GSH O
to O
form O
a O
GSH O
conjugate O
( O
GS B
- I
6 I
- I
DHSG I
) O
in O
RAW O
264 O
. O
7 O
cells O
, O
via O
a O
potential O
mechanism O
involving O
the O
catalytic O
activity O
of O
glutathione O
- O
S O
- O
transferase O
( O
GST O
) O
. O

GS B
- I
6 I
- I
DHSG I
showed O
reduced O
biological O
activities O
compared O
with O
6 B
- I
DHSG I
in O
multiple O
biological O
assays O
. O

Together O
, O
these O
results O
indicate O
that O
GSH O
conjugation O
attenuates O
the O
biological O
activities O
of O
6 B
- I
DHSG I
and O
other O
alpha O
, O
beta O
- O
unsaturated O
carbonyl O
compounds O
. O

Polyphenols O
in O
noni O
juice O
( O
NJ O
) O
are O
mainly O
composed O
of O
phenolic O
acids O
, O
mainly O
gentisic B
, I
p I
- I
hydroxybenoic I
, I
and I
chlorogenic I
acids I
. O

The O
addition O
of O
sodium B
sulphite I
or O
sodium O
dodecyl O
sulphate O
also O
inhibited O
precipitate O
formation O
after O
freeze O
- O
thawing O
, O
resulting O
in O
no O
fractionation O
. O

In O
this O
work O
, O
UV O
- O
activated O
visual O
oxygen O
indicator O
films O
were O
fabricated O
using O
thionine B
, O
glycerol O
, O
P25 B
TiO2 I
, O
and O
zein O
as O
a O
redox O
dye O
, O
a O
sacrificial O
electron O
donor O
, O
UV O
- O
absorbing O
semiconducting O
photocatalyst O
, O
and O
an O
encapsulation O
polymer O
, O
respectively O
. O

Impact O
of O
( O
+ O
) O
- O
catechin O
and O
gallic O
acid O
on O
sensory O
perception O
and O
volatility O
of O
isoamyl B
acetate I
, O
ethyl B
isobutyrate I
, O
ethyl B
butyrate I
and O
ethyl B
octanoate I
was O
investigated O
in O
model O
solutions O
, O
by O
means O
of O
triangle O
tests O
, O
detection O
threshold O
determination O
and O
HS O
- O
GC O
- O
MS O
analyses O
. O

Catechin O
significantly O
altered O
the O
sensory O
perception O
of O
most O
esters O
( O
ethyl B
isobutyrate I
, O
ethyl B
butyrate I
and O
ethyl B
octanoate I
) O
while O
gallic O
acid O
displayed O
no O
impact O
. O

Ethyl B
butyrate I
and O
ethyl B
octanoate I
odour O
thresholds O
doubled O
or O
tripled O
in O
the O
presence O
of O
catechin O
, O
underlining O
a O
retention O
impact O
of O
phenolic O
compounds O
in O
liquid O
matrix O
. O

The O
headspace O
analyses O
displayed O
a O
decrease O
only O
in O
ethyl B
octanoate I
volatility O
in O
presence O
of O
catechin O
, O
whereas O
no O
significant O
difference O
in O
other O
esters O
concentrations O
was O
observed O
. O

A O
simple O
and O
effective O
method O
based O
on O
magnetic O
separation O
has O
been O
developed O
for O
the O
extraction O
of O
sulfonamides O
( O
SAs B
) O
from O
egg O
samples O
using O
magnetic O
multiwalled O
carbon O
nanotubes O
( O
MMWCNTs O
) O
as O
an O
adsorbent O
. O

The O
SAs B
were O
first O
extracted O
as O
described O
above O
, O
adsorbed O
onto O
the O
MMWCNTs O
directly O
and O
finally O
analysed O
by O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
. O

The O
proposed O
method O
was O
successfully O
applied O
in O
determining O
SAs B
in O
the O
eggs O
obtained O
from O
laying O
hens O
fed O
with O
SA O
standards O
, O
and O
compared O
to O
eggs O
purchased O
from O
local O
markets O
. O

The O
results O
demonstrate O
that O
SAs B
were O
detectable O
in O
the O
incurred O
egg O
samples O
. O

Investigation O
of O
tocotrienol B
biosynthesis O
in O
rice O
( O
Oryza O
sativa O
L O
. O
) O
. O

Rice O
tocotrienol B
( O
T3 O
) O
has O
gained O
attention O
due O
to O
its O
physiological O
activities O
( O
e O
. O
g O
. O
, O
antiangiogenesis O
) O
. O

Determination O
of O
alpha B
- I
keto I
acids I
in O
pork O
meat O
and O
Iberian O
ham O
via O
tandem O
mass O
spectrometry O
. O

An O
analytical O
method O
which O
offers O
accurate O
determination O
and O
identification O
of O
eight O
alpha B
- I
keto I
acids I
( O
alpha B
- I
ketoglutaric I
acid I
, O
pyruvic B
acid I
, O
4 B
- I
hydroxyphenylpyruvic I
acid I
, O
3 B
- I
methyl I
- I
2 I
- I
oxobutyric I
acid I
, O
alpha B
- I
keto I
- I
gamma I
- I
methylthiobutyric I
acid I
, O
4 B
- I
methyl I
- I
2 I
- I
oxovaleric I
acid I
, O
3 B
- I
methyl I
- I
2 I
- I
oxovaleric I
acid I
, O
and O
phenylpyruvic B
acid I
) O
in O
pork O
meat O
and O
Iberian O
ham O
samples O
is O
reported O
. O

The O
analytical O
method O
is O
simple O
( O
although O
the O
chemical O
derivatisation O
of O
the O
alpha B
- I
keto I
acids I
with O
dansylhydrazine B
is O
required O
) O
, O
precise O
( O
< O
18 O
% O
RSD O
) O
, O
accurate O
( O
90 O
- O
110 O
% O
) O
, O
sensitive O
( O
0 O
. O
01 O
- O
0 O
. O
34mg O
/ O
kg O
of O
defatted O
and O
freeze O
- O
dried O
meat O
depending O
on O
the O
alpha B
- I
keto I
acid I
) O
and O
linear O
( O
R O
> O
0 O
. O
99 O
) O
over O
several O
orders O
of O
magnitude O
( O
until O
0 O
. O
01 O
- O
146 O
. O
1mg O
/ O
kg O
of O
defatted O
and O
freeze O
- O
dried O
meat O
depending O
on O
the O
alpha B
- I
keto I
acid I
) O
. O

Using O
this O
methodology O
, O
alpha B
- I
keto I
acids I
were O
found O
to O
be O
present O
in O
pork O
meat O
to O
a O
low O
extent O
, O
and O
their O
concentration O
increased O
when O
they O
were O
determined O
in O
Iberian O
ham O
. O

This O
is O
the O
first O
report O
of O
the O
presence O
of O
alpha B
- I
keto I
acids I
in O
both O
pork O
meats O
and O
Iberian O
hams O
. O

Prooxidative O
and O
antioxidative O
properties O
of O
beta O
- O
carotene O
in O
chlorophyll O
and O
riboflavin B
photosensitized O
oil O
- O
in O
- O
water O
emulsions O
. O

Effects O
of O
beta O
- O
carotene O
on O
the O
oxidative O
stability O
of O
chlorophyll O
or O
riboflavin B
photosensitized O
oil O
- O
in O
- O
water O
( O
O O
/ O
W O
) O
emulsions O
were O
determined O
by O
analysing O
the O
depleted O
headspace O
oxygen O
content O
, O
lipid O
hydroperoxides B
, O
fluorescence O
intensity O
, O
and O
headspace O
volatiles O
. O

However O
, O
in O
riboflavin B
photosensitized O
O O
/ O
W O
emulsions O
, O
100 O
and O
1000 O
mu O
M O
beta O
- O
carotene O
inhibited O
lipid O
oxidation O
. O

The O
development O
of O
t B
- I
2 I
- I
heptenal I
and O
1 O
- O
octen O
- O
3 O
- O
ol O
increased O
greatly O
in O
chlorophyll O
sensitised O
O O
/ O
W O
emulsions O
with O
an O
increase O
in O
beta O
- O
carotene O
concentration O
, O
implying O
that O
more O
singlet O
oxygen O
oxidation O
occurred O
due O
to O
the O
higher O
levels O
of O
remaining O
chlorophylls O
. O

However O
, O
the O
content O
of O
t B
- I
2 I
- I
heptenal I
and O
1 O
- O
octen O
- O
3 O
- O
ol O
in O
the O
riboflavin B
sensitised O
O O
/ O
W O
emulsions O
was O
not O
significantly O
correlated O
with O
the O
beta O
- O
carotene O
concentration O
, O
which O
indicates O
that O
beta O
- O
carotene O
in O
the O
lipid O
particles O
effectively O
quenched O
singlet O
oxygen O
. O

The O
oestrogenic O
and O
anti O
- O
platelet O
activities O
of O
dihydrobenzofuroisoc B
and O
homoisoflavonoids B
from O
Liriope O
platyphylla O
roots O
. O

Twenty O
- O
six O
compounds O
were O
isolated O
and O
classified O
as O
10 O
skeletons O
, O
including O
two O
unusual O
new O
dihydrobenzofuroisoc B
, O
( B
+ I
) I
- I
platyphyllarin I
A I
( I
1 I
) I
and I
B I
( O
2 O
) O
, O
one O
new O
butanoate B
, O
ethyltributanoate B
( O
3 O
) O
, O
and O
two O
new O
homoisoflavanones B
, O
( B
- I
) I
- I
liriopein I
A I
( I
4 I
) I
and I
B I
( O
5 O
) O
, O
along O
with O
21 O
known O
compounds O
, O
including O
six O
homoisoflavonoids B
, O
one O
chalcone O
, O
six O
amides O
, O
one O
lignan O
, O
one O
fatty O
acid O

derivative O
, O
one O
alkaloid O
, O
three O
benzenoids B
, O
and O
two O
steroids O
. O

Among O
the O
11 O
phenolics O
characterised O
in O
leaves O
by O
high O
- O
performance O
liquid O
chromatography O
coupled O
to O
mass O
spectrometric O
detection O
, O
several O
caffeic O
acid O
derivatives O
, O
5 B
- I
feruloylquinic I
and I
5 I
- I
p I
- I
coumaroylquinic I
acids I
were O
tentatively O
identified O
for O
the O
first O
time O
. O

In O
fruits O
, O
10 O
phenolics O
were O
detected O
, O
whereas O
rutin O
, O
a O
dicaffeic B
acid I
derivative O
and O
two O
feruloylquinic B
and I
caffeoylquinic I
acid I
isomers O
were O
newly O
detected O
. O

Synthesis O
and O
evaluation O
of O
carbamoylmethylene B
linked O
prodrugs O
of O
BMS B
- I
582949 I
, O
a O
clinical O
p38 O
alpha O
inhibitor O
. O

A O
series O
of O
carbamoylmethylene B
linked O
prodrugs O
of O
1 O
( O
BMS B
- I
582949 I
) O
, O
a O
clinical O
p38 O
alpha O
inhibitor O
, O
were O
synthesized O
and O
evaluated O
. O

Though O
the O
phosphoryloxymethyle B
carbamates I
( O
3 O
, O
4 O
, O
and O
5 O
) O
and O
alpha B
- I
aminoacyloxymethylen I
carbamates I
( O
22 O
, O
23 O
, O
and O
26 O
) O
were O
found O
unstable O
at O
neutral O
pH O
values O
, O
fumaric B
acid I
derived O
acyloxymethylene B
carbamates I
( O
2 O
, O
28 O
, O
and O
31 O
) O
were O
highly O
stable O
under O
both O
acidic O
and O
neutral O
conditions O
. O

To O
our O
knowledge O
, O
the O
unique O
type O
of O
prodrugs O
like O
2 O
, O
28 O
, O
and O
31 O
was O
not O
reported O
in O
the O
past O
and O
could O
represent O
a O
novel O
prodrug O
approach O
for O
secondary B
amides I
, O
a O
class O
of O
molecules O
frequently O
identified O
as O
drug O
candidates O
. O

Conformationally O
restricted O
homotryptamines B
. O

Part O
6 O
: O
Indole B
- I
5 I
- I
cycloalkyl I
methylamines I
as O
selective O
serotonin O
reuptake O
inhibitors O
. O

Racemic B
5 I
- I
( I
trans I
- I
2 I
- I
aminomethylcycloprop I
) I
indoles I
, O
5 B
- I
( I
trans I
- I
2 I
- I
aminomethylcyclopent I
) I
indoles I
, O
and O
5 B
- I
( I
cis I
- I
2 I
- I
aminomethylcyclopent I
) I
indoles I
were O
synthesized O
and O
evaluated O
as O
selective O
serotonin O
reuptake O
inhibitors O
. O

These O
analogs O
followed O
SAR O
trends O
similar O
to O
those O
previously O
reported O
for O
3 B
- I
cycloalkyl I
substituted I
indoles I
. O

In O
this O
study O
we O
have O
demonstrated O
the O
use O
of O
poly B
( I
lactic I
acid I
- I
co I
- I
glycolic I
acid I
) I
( O
PLGA O
) O
/ O
collagen O
biodegradable O
microparticles O
formed O
using O
water O
- O
in O
- O
oil O
- O
in O
- O
water O
( O
W O
/ O
O O
/ O
W O
) O
double O
emulsion O
method O
, O
as O
a O
neurotrophic O
factor O
delivery O
vehicle O
. O

Since O
acute O
changes O
in O
corticosterone O
levels O
can O
affect O
behavior O
, O
JZL184 O
was O
administered O
concurrently O
with O
the O
corticosterone O
synthesis O
inhibitor O
metyrapone B
, O
to O
investigate O
whether O
the O
previously O
shown O
behavioral O
effects O
of O
JZL184 O
are O
dependent O
on O
corticosterone O
. O

By O
contrast O
, O
effects O
on O
the O
" O
ethological O
" O
measures O
of O
anxiety O
( O
i O
. O
e O
. O
risk O
assessment O
) O
were O
not O
affected O
by O
metyrapone B
. O

Effect O
of O
N O
- O
acetyl O
cysteine O
( O
NAC O
) O
, O
an O
organosulfur B
compound O
from O
Allium O
plants O
, O
on O
experimentally O
induced O
hepatic O
prefibrogenic O
events O
in O
wistar O
rat O
. O

Aim O
of O
present O
study O
was O
to O
investigate O
the O
effect O
of O
NAC O
on O
experimental O
chronic O
hepatotoxicity O
models O
induced O
by O
carbon O
tetrachloride O
( O
CCl4 O
) O
and O
thioacetamide B
( O
TAA B
) O
. O

TAA B
toxicity O
was O
induced O
by O
administering O
150mg O
/ O
kg O
b O
. O

wt O
. O
of O
TAA B
i O
. O
p O
. O
, O
twice O
weekly O
for O
8 O
weeks O
. O

NAC O
treatment O
was O
started O
along O
with O
toxicants O
( O
CCl4 O
and O
TAA B
) O
for O
8 O
weeks O
and O
continued O
for O
further O
4 O
weeks O
. O

Serum O
markers O
of O
liver O
damage O
( O
AST O
, O
ALT O
, O
ALP O
and O
Bilirubin O
) O
were O
increased O
by O
CCl4 O
and O
TAA B
intoxication O
( O
p O
< O
0 O
. O
001 O
) O
, O
whereas O
co O
- O
treatment O
with O
NAC O
reversed O
such O
changes O
( O
p O
< O
0 O
. O
001 O
) O
. O

HP O
was O
enhanced O
in O
toxicant O
groups O
( O
p O
< O
0 O
. O
001 O
in O
CCl4 O
and O
TAA B
) O
, O
but O
inhibited O
by O
NAC O
( O
p O
< O
0 O
. O
001 O
) O
. O

Keeping O
in O
view O
the O
biochemical O
and O
histopathological O
studies O
, O
it O
was O
concluded O
that O
CCl4 O
and O
TAA B
are O
strong O
hepatotoxic O
agents O
that O
produce O
liver O
fibrosis O
with O
close O
proximity O
to O
human O
etiology O
( O
micronodular O
cirrhosis O
) O
and O
NAC O
has O
a O
significant O
protective O
activity O
against O
CCl4 O
and O
TAA B
. O

Studies O
on O
antioxidant O
enzymes O
showed O
that O
SA O
further O
enhanced O
the O
activities O
of O
superoxide O
dismutase O
, O
ascorbate O
peroxidase O
, O
glutathione O
reductase O
and O
glutathione O
peroxidase O
, O
and O
also O
elevated O
the O
depressed O
activities O
of O
catalase O
, O
dehydroascorbate B
reductase O
and O
glutathione O
S O
- O
transferase O
particularly O
at O
150 O
mu O
M O
Cu O
( O
2 O
+ O
) O
stress O
. O

In O
previously O
published O
articles O
, O
we O
evaluated O
the O
toxicity O
of O
four O
organophosphate O
( O
OP O
) O
pesticides O
( O
dichlorvos O
, O
dimethoate B
, O
acephate B
and O
phorate B
) O
to O
rats O
using O
metabonomic O
technology O
at O
their O
corresponding O
no O
observed O
adverse O
effect O
level O
( O
NOAEL O
) O
. O

Dimethylphosphate B
and O
dimethyldithiophosph B
exclusively O
detected O
in O
all O
treated O
groups O
can O
be O
used O
as O
early O
, O
sensitive O
biomarkers O
for O
exposure O
to O
a O
mixture O
of O
the O
OP O
pesticides O
. O

Moreover O
, O
exposure O
to O
the O
OP O
pesticides O
resulted O
in O
increased O
7 B
- I
methylguanine I
, O
ribothymidine B
, O
cholic O
acid O
, O
4 B
- I
pyridoxic I
acid I
, O
kynurenine B
and O
indoxyl B
sulfate I
levels O
, O
as O
well O
as O
decreased O
hippuric B
acid I
, O
creatinine O
, O
uric O
acid O
, O
gentisic B
acid I
, O
C18 B
- I
dihydrosphingosine I
, O
phytosphingosine O
, O
suberic B
acid I
and O
citric O
acid O
. O

Six O
compounds O
were O
isolated O
and O
identified O
from O
this O
plant O
: O
three O
phenolic O
compounds O
( O
kampferol B
, O
kampferol B
- I
3 I
- I
glucoside I
and O
kampferol B
- I
3 I
- I
galactoside I
) O
in O
addition O
to O
three O
steroidal O
compounds O
( O
1 B
- I
ethoxypentacosane I
, O
heptacosan B
- I
1 I
- I
ol I
and O
beta O
- O
sitosterol O
) O
. O

Three O
compounds O
( O
heptacosan B
- I
1 I
- I
ol I
, O
beta O
- O
sitosterol O
and O
kampferol B
- I
3 I
- I
galactoside I
) O
were O
found O
to O
be O
responsible O
for O
the O
anti O
- O
UC O
activity O
of O
E O
. O
granuleta O
extract O
. O

Decursin B
Exerts O
Anti O
- O
cancer O
Activity O
in O
MDA O
- O
MB O
- O
231 O
Breast O
Cancer O
Cells O
Via O
Inhibition O
of O
the O
Pin1 O
Activity O
and O
Enhancement O
of O
the O
Pin1 O
/ O
p53 O
Association O
. O

This O
study O
demonstrates O
that O
decursin B
, O
a O
bioactive O
compound O
from O
Angelica O
gigas O
, O
exert O
the O
anti O
- O
cancer O
effect O
against O
breast O
cancer O
cells O
via O
regulation O
of O
Pin1 O
and O
its O
related O
signaling O
molecules O
. O

We O
observed O
that O
decursin B
induced O
G1 O
arrest O
with O
decrease O
in O
cyclin O
D1 O
level O
in O
Pin1 O
- O
expressing O
breast O
cancer O
cells O
MDA O
- O
MB O
- O
231 O
, O
but O
not O
Pin1 O
- O
non O
- O
expressing O
breast O
cancer O
cells O
MDA O
- O
MB O
- O
157 O
. O

In O
addition O
, O
decursin B
significantly O
reduced O
protein O
expression O
and O
enzymatic O
activity O
of O
Pin1 O
in O
MDA O
- O
MB O
- O
231 O
cells O
. O

Further O
, O
we O
found O
that O
decursin B
treatment O
enhanced O
the O
p53 O
expression O
level O
and O
failed O
to O
down O
- O
regulate O
Pin1 O
in O
the O
cells O
transfected O
with O
p53 O
siRNA O
, O
indicating O
the O
importance O
of O
p53 O
in O
the O
decursin B
- O
mediated O
Pin1 O
inhibition O
in O
MDA O
- O
MB O
- O
231 O
cells O
. O

Decursin B
stimulated O
association O
between O
Pin1 O
to O
p53 O
. O

Moreover O
, O
decursin B
facilitated O
p53 O
transcription O
in O
MDA O
- O
MB O
- O
231 O
cells O
. O

Overall O
, O
our O
current O
study O
suggests O
the O
potential O
of O
decursin B
as O
an O
attractive O
cancer O
therapeutic O
agent O
for O
breast O
cancer O
by O
targeting O
Pin1 O
protein O
. O

Cyclooxygenase O
( O
COX O
) O
- O
2 O
- O
derived O
prostanoids B
can O
influence O
several O
processes O
that O
are O
linked O
to O
carcinogenesis O
. O

Platelet O
- O
induced O
COX O
- O
2 O
- O
dependent O
PGE2 O
synthesis O
in O
HT29 O
cells O
was O
involved O
in O
downregulation O
of O
p21 O
( O
WAF1 O
/ O
CIP1 O
) O
and O
upregulation O
of O
cyclinB1 O
, O
since O
these O
effects O
were O
prevented O
by O
rofecoxib B
( O
a O
selective O
COX O
- O
2 O
inhibitor O
) O
and O
rescued O
by O
exogenous O
PGE2 O
. O

Inhibitors O
of O
galectin O
- O
3 O
function O
( O
beta B
- I
lactose I
, O
a O
dominant O
- O
negative O
form O
of O
galectin O
- O
3 O
, O
Gal O
- O
3C O
, O
and O
anti O
- O
galectin O
- O
3 O
antibody O
M3 O
/ O
38 O
) O
or O
collagen O
receptor O
- O
mediated O
platelet O
adhesion O
( O
revacept O
, O
a O
dimeric O
collagen O
receptor O
GPVI O
- O
Fc O
) O
prevented O
aberrant O
COX O
- O
2 O
expression O
. O

Inhibition O
of O
platelet O
- O
cancer O
cell O
interaction O
by O
revacept O
was O
more O
effective O
than O
rofecoxib B
in O
preventing O
platelet O
- O
induced O
mRNA O
changes O
of O
EMT O
markers O
suggesting O
that O
direct O
cell O
- O
cell O
contact O
and O
aberrant O
COX O
- O
2 O
expression O
synergistically O
induced O
gene O
expression O
modifications O
associated O
with O
EMT O
. O

Further O
, O
we O
demonstrated O
that O
caspase O
- O
14 O
mRNA O
level O
is O
decreased O
by O
40 O
% O
in O
placental O
BeWo O
cells O
treated O
with O
forskolin O
( O
FSK B
) O
. O

A O
butterfly O
- O
shaped O
pyrene O
derivative O
of O
cholesterol O
, O
namely O
, O
N B
, I
N I
' I
- I
( I
ethane I
- I
1 I
, I
2 I
- I
diyl I
) I
- I
bis I
( I
N I
- I
( I
2 I
- I
( I
chol I
- I
amino I
) I
ethyl I
) I
pyrene I
- I
1 I
- I
sulfonamide I
) I
( O
ECPS B
) O
, O
has O
been O
designed O
and O
synthesized O
. O

Solvent O
effect O
studies O
revealed O
that O
in O
good O
solvents O
such O
as O
n O
- O
hexane O
, O
benzene O
, O
and O
1 B
, I
4 I
- I
dioxane I
, O
the O
profile O
of O
the O
fluorescence O
emission O
of O
the O
compound O
is O
characterized O
by O
pyrene O
monomer O
emission O
, O
but O
in O
poor O
solvent O
such O
as O
water O
, O
the O
emission O
is O
dominated O
by O
pyrene O
excimer O
emission O
. O

Therefore O
, O
it O
is O
assumed O
that O
ECPS B
may O
be O
used O
both O
as O
a O
polarity O
probe O
and O
a O
viscosity O
probe O
. O

Exciplex O
Formation O
in O
Blended O
Spin O
- O
Cast O
Films O
of O
Fluorene O
- O
Linked O
Dyes O
and O
Bisphthalimide B
Quenchers O
. O

Spin O
- O
cast O
films O
of O
dyes O
( O
donor O
- O
pi O
- O
donor O
, O
donor O
- O
pi O
- O
acceptor O
, O
and O
acceptor O
- O
pi O
- O
acceptor O
type O
, O
where O
the O
donor O
is O
Ph2N B
- O
, O
the O
acceptor O
is O
2 B
- I
benzothiazoyl I
, O
and O
the O
pi O
- O
linker O
is O
9 B
, I
9 I
- I
diethylfluorene I
) O
blended O
with O
nonconjugated O
bisphthalimides B
were O
prepared O
. O

Upon O
visible O
- O
light O
excitation O
of O
the O
dyes O
, O
quenching O
of O
the O
excited O
state O
occurs O
by O
exciplex O
formation O
between O
dye O
and O
bisphthalimide B
molecules O
or O
, O
in O
some O
cases O
, O
by O
excimer O
formation O
or O
aggregation O
- O
induced O
emission O
between O
two O
dye O
molecules O
. O

The O
extent O
of O
exciplex O
formation O
is O
dependent O
on O
the O
driving O
force O
, O
which O
can O
be O
calculated O
using O
the O
energy O
difference O
between O
the O
lowest O
unoccupied O
molecular O
orbitals O
( O
LUMOs O
) O
of O
the O
dyes O
and O
bisphthalimides B
. O

The O
exciplex O
emission O
energies O
can O
also O
be O
predicted O
by O
calculating O
the O
difference O
between O
the O
LUMO O
level O
of O
the O
bisphthalimide B
and O
the O
highest O
occupied O
molecular O
orbital O
( O
HOMO O
) O
of O
the O
dye O
. O

Types O
of O
damaged O
lesions O
frequently O
found O
inside O
clustered O
DNA O
damage O
sites O
include O
oxidized O
bases O
, O
abasic O
sites O
, O
nucleotide B
dimers I
, O
strand O
breaks O
or O
their O
complex O
combinations O
. O

Oligomer O
DNA O
duplexes O
( O
47bp O
) O
were O
designed O
to O
have O
two O
deoxyuridine B
in O
the O
middle O
of O
the O
sequences O
, O
three O
bases O
apart O
in O
opposite O
strands O
. O

The O
deoxyuridine B
residues O
were O
converted O
into O
abasic O
sites O
by O
treatment O
with O
UDG O
enzyme O
creating O
an O
abasic O
clustered O
damage O
site O
in O
a O
precise O
position O
in O
each O
of O
the O
single O
strand O
of O
the O
DNA O
duplex O
. O

Synthesis O
and O
antitumor O
activity O
of O
1 B
, I
3 I
, I
4 I
- I
oxadiazole I
possessing O
1 B
, I
4 I
- I
benzodioxan I
moiety O
as O
a O
novel O
class O
of O
potent O
methionine O
aminopeptidase O
type O
II O
inhibitors O
. O

A O
series O
of O
1 B
, I
3 I
, I
4 I
- I
oxadiazole I
derivatives O
containing O
1 B
, I
4 I
- I
benzodioxan I
moiety O
( O
7a O
- O
7q O
) O
have O
been O
designed O
, O
synthesized O
and O
evaluated O
for O
their O
antitumor O
activity O
. O

The O
results O
of O
apoptosis O
and O
flow O
cytometry O
( O
FCM O
) O
demonstrated O
that O
compound O
7a O
induce O
cell O
apoptosis O
by O
the O
inhibition O
of O
MetAP2 B
pathway O
. O

Molecular O
docking O
was O
performed O
to O
position O
compound O
7a O
into O
MetAP2 B
binding O
site O
in O
order O
to O
explore O
the O
potential O
target O
. O

In O
fact O
, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 O
activity O
by O
4 O
quinone O
derivatives O
( O
AA B
- I
861 I
, O
tBuBHQ B
, O
tBuBQ B
, O
and O
duroquinone B
) O
observed O
in O
3 O
different O
cellular O
models O
, O
HEK293E O
, O
T O
- O
REx O
( O
TM O
) O
, O
and O
chondrocyte O
cell O
lines O
. O

Interestingly O
, O
Nox4 O
activity O
is O
also O
stimulated O
by O
reducing O
agents O
that O
possibly O
act O
by O
reducing O
the O
disulfide O
bridge O
( O
Cys226 B
, O
Cys270 B
) O
located O
in O
the O
extracellular O
E O
- O
loop O
of O
Nox4 O
. O

Simonols B
A I
and I
B I
, O
two O
novel O
sesqui B
- I
neolignans I
from O
the O
fruits O
of O
Illicium O
simonsii O
. O

Two O
new O
sesqui B
- I
neolignans I
with O
novel O
conjugation O
way O
, O
simonol B
A I
( O
1 O
) O
, O
featuring O
a O
unique O
motif O
of O
a O
5 B
, I
5 I
- I
dihydro I
- I
pyran I
with O
a O
hemiketal B
carbon I
, O
while O
simonol B
B I
( O
2 O
) O
possessing O
two O
dihydronfuran B
rings O
in O
the O
same O
direction O
, O
were O
isolated O
from O
the O
ethanol O
extract O
of O
the O
fruits O
of O
Illicium O
simonii O
. O

Here O
we O
provide O
a O
systematic O
review O
of O
the O
existing O
literature O
and O
present O
a O
detailed O
pathway O
diagram O
that O
describes O
the O
cholesterol O
biosynthesis O
pathway O
( O
the O
mevalonate B
, O
the O
Kandutch O
- O
Russell O
and O
the O
Bloch O
pathway O
) O
and O
shunt O
pathway O
that O
leads O
to O
24 B
( I
S I
) I
, I
25 I
- I
epoxycholesterol I
synthesis O
. O

Molecular O
mechanisms O
for O
the O
anti O
- O
cancer O
effects O
of O
diallyl B
disulfide I
. O

Oil O
- O
soluble O
compounds O
such O
as O
diallyl B
sulfide I
( O
DAS B
) O
, O
diallyl B
disulfide I
( O
DADS B
) O
, O
diallyl B
trisulfide I
( O
DATS B
) O
and O
ajoene B
are O
more O
effective O
than O
water O
- O
soluble O
compounds O
in O
protection O
against O
cancer O
. O

DADS B
, O
a O
major O
organosulfur B
compound O
derived O
from O
garlic O
, O
can O
decrease O
carcinogen O
- O
induced O
cancers O
in O
experimental O
animals O
and O
inhibit O
the O
proliferation O
of O
various O
types O
of O
cancer O
cells O
. O

Thermal O
stability O
of O
oligodeoxynucleotide O
duplexes O
containing O
l B
- I
deoxynucleotide I
at O
termini O
. O

The O
effects O
of O
substituting O
l B
- I
deoxynucleotide I
for O
d B
- I
deoxynucleotide I
at O
duplex O
termini O
were O
evaluated O
and O
the O
terminal O
substitutions O
were O
found O
to O
show O
much O
less O
effects O
on O
duplex O
destabilization O
and O
to O
show O
a O
similar O
tendency O
in O
base O
pairing O
selectivity O
, O
compared O
with O
internal O
chiral O
substitutions O
. O

We O
examined O
the O
ability O
of O
ICI O
182 O
, O
780 O
( O
ICI B
) O
to O
block O
uterine O
cell O
proliferation O
via O
protein O
kinase O
b O
/ O
AKT O
pathway O
in O
the O
uterus O
of O
the O
rat O
during O
the O
estrous O
cycle O
. O

Intact O
rats O
, O
with O
regular O
estrous O
cycles O
, O
received O
a O
subcutaneous O
( O
s O
. O
c O
. O
) O
injection O
of O
either O
vehicle O
or O
ICI B
at O
08 O
: O
00h O
on O
the O
day O
of O
proestrus O
or O
at O
00 O
: O
00h O
on O
the O
day O
of O
estrus O
and O
sacrificed O
at O
13 O
: O
00h O
of O
metaestrus O
. O

Both O
ICI B
treatments O
, O
induced O
a O
significant O
decrease O
( O
p O
< O
0 O
. O
01 O
) O
in O
uterine O
estrogen O
receptor O
alpha O
( O
ER O
alpha O
) O
content O
, O
had O
no O
effect O
on O
uterine O
progesterone O
receptor O
( O
PR O
) O
protein O
expression O
and O
caused O
marked O
nuclear O
localization O
of O
cyclin O
D1 O
, O
in O
both O
luminal O
and O
glandular O
uterine O
epithelium O
, O
as O
compared O
to O
vehicle O
- O
treated O
animals O
. O

Furthermore O
, O
we O
detected O
that O
ICI B
treatment O
induced O
glycogen O
synthase O
kinase O
( O
Gsk3 O
- O
beta O
) O
Ser O
9 O
phosphorylation O
, O
which O
correlates O
with O
cyclin O
D1 O
nuclear O
localization O
. O

We O
observed O
that O
the O
administration O
of O
ICI B
at O
08 O
: O
00h O
on O
proestrus O
day O
produced O
a O
15 O
% O
inhibition O
of O
luminal O
epithelial O
cell O
proliferation O
, O
reduced O
uterine O
wet O
weight O
by O
21 O
% O
and O
caused O
reduction O
of O
Akt O
phosphorylation O
at O
Ser O
473 O
as O
compared O
to O
vehicle O
- O
treated O
animals O
, O
whereas O
ICI B
treatment O
at O
00 O
: O
00h O
on O
estrus O
day O
had O
no O
effect O
on O
these O
parameters O
. O

The O
overall O
results O
indicate O
that O
ICI B
may O
exert O
agonistic O
and O
antagonistic O
effects O
on O
uterine O
cell O
proliferation O
through O
differential O
activation O
of O
the O
Akt O
pathway O
depending O
on O
the O
administration O
period O
during O
the O
estrous O
cycle O
, O
and O
indicates O
that O
the O
mechanism O
of O
cell O
proliferation O
during O
the O
physiological O
conditions O
of O
the O
estrous O
cycle O
, O
is O
under O
a O
different O
and O
more O
complex O
regulation O
than O
in O
the O
ovariectomized O
+ O
E2 O
animal O
model O
. O

Skin O
penetration O
enhancing O
properties O
of O
the O
plant O
N B
- I
alkylamide I
spilanthol I
. O

MATERIALS O
AND O
METHODS O
: O
In O
this O
study O
, O
we O
examined O
the O
proposed O
penetration O
enhancing O
properties O
of O
spilanthol B
, O
an O
N B
- I
alkylamide I
abundantly O
present O
in O
several O
Asteraceae O
plants O
like O
Spilanthes O
acmella O
L O
. O
, O
on O
three O
model O
drugs O
( O
caffeine O
, O
testosterone O
and O
ibuprofen O
) O
. O

Moreover O
, O
as O
plants O
are O
frequently O
contaminated O
with O
toxic O
environmental O
substances O
, O
the O
mutual O
influence O
on O
the O
transdermal O
behavior O
between O
spilanthol B
and O
six O
model O
mycotoxins O
( O
aflatoxin O
B1 O
, O
ochratoxin O
A O
, O
fumonisin O
B1 O
, O
citrinin B
, O
zearalenone O
, O
T B
- I
2 I
toxin I
) O
was O
investigated O
. O

RESULTS O
: O
Spilanthol B
exhibits O
component O
and O
concentration O
dependent O
penetration O
enhancing O
effects O
. O

No O
significant O
penetration O
enhancing O
effect O
for O
ibuprofen O
has O
been O
observed O
, O
but O
with O
increasing O
spilanthol B
concentration O
( O
from O
0 O
up O
to O
1w O
/ O
V O
% O
) O
, O
the O
permeability O
of O
caffeine O
increased O
, O
resulting O
in O
an O
enhancing O
ratio O
( O
ER O
) O
of O
4 O
. O
60 O
. O

For O
testosterone O
, O
a O
maximal O
penetration O
enhancing O
concentration O
of O
0 O
. O
5 O
% O
spilanthol B
was O
found O
( O
ER O
= O
4 O
. O
13 O
) O
. O

Next O
to O
its O
beneficial O
applicability O
to O
increase O
local O
as O
well O
as O
systemic O
pharmacological O
effects O
of O
dermally O
co O
- O
administrated O
drug O
, O
this O
N B
- I
alkylamide I
negatively O
influences O
human O
health O
risk O
if O
spilanthol B
containing O
formulations O
are O
polluted O
with O
mycotoxins O
: O
the O
presence O
of O
spilanthol B
( O
0 O
. O
3w O
/ O
V O
% O
) O
induced O
a O
significant O
increase O
of O
permeability O
coefficient O
Kp O
of O
five O
investigated O
mycotoxins O
, O
with O
ER O
values O
ranging O
between O
1 O
. O
57 O
and O
6 O
. O
37 O
. O

On O
the O
other O
hand O
, O
mycotoxins O
themselves O
do O
not O
significantly O
influence O
the O
transdermal O
behavior O
of O
spilanthol B
. O

Dietary O
nimodipine B
delays O
the O
onset O
of O
methylmercury O
neurotoxicity O
in O
mice O
. O

To O
evaluate O
the O
role O
of O
calcium O
antagonism O
in O
MeHg O
toxicity O
in O
vivo O
, O
adult O
BALB O
/ O
c O
mice O
were O
exposed O
chronically O
to O
0 O
or O
15ppm O
of O
Hg O
( O
as O
MeHg O
) O
via O
drinking O
water O
and O
to O
nimodipine B
, O
a O
dihydropryidine B
, O
L O
- O
type O
Ca O
( O
2 O
+ O
) O
channel O
blocker O
with O
action O
in O
the O
CNS O
. O

Nimodipine B
was O
administered O
orally O
in O
diets O
( O
0 O
, O
20 O
, O
or O
200ppm O
, O
producing O
approximately O
0 O
, O
2 O
, O
or O
20mg O
/ O
kg O
/ O
day O
of O
nimodipine B
) O
. O

An O
incremental O
repeated O
acquisition O
( O
IRA O
) O
of O
response O
chains O
procedure O
was O
used O
to O
detect O
MeHg O
- O
induced O
deficits O
in O
learning O
or O
motoric O
function O
and O
to O
evaluate O
possible O
neuroprotection O
by O
nimodipine B
. O

MeHg O
impaired O
performance O
on O
the O
IRA O
task O
, O
and O
this O
was O
partially O
or O
completely O
blocked O
by O
dietary O
nimodipine B
, O
depending O
on O
dose O
. O

Nimodipine B
delayed O
or O
prevented O
the O
behavioral O
toxicity O
of O
MeHg O
exposure O
as O
evidenced O
by O
IRA O
performance O
; O
effects O
on O
learning O
seemed O
secondary O
to O
response O
rate O
decreases O
. O

Acute O
and O
subacute O
toxicity O
studies O
on O
triptolide B
and O
triptolide B
- O
loaded O
polymeric O
micelles O
following O
intravenous O
administration O
in O
rodents O
. O

Except O
its O
anti O
- O
tumour O
effects O
, O
triptolide B
( O
TP O
) O
also O
shows O
multiple O
pharmacological O
side O
activities O
, O
such O
as O
immune O
- O
suppressive O
and O
male O
anti O
- O
fertility O
. O

Design O
, O
synthesis O
and O
biological O
evaluation O
of O
new O
classes O
of O
thieno B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidinone I
and O
thieno B
[ I
1 I
, I
2 I
, I
3 I
] I
triazine I
as O
inhibitor O
of O
vascular O
endothelial O
growth O
factor O
receptor O
- O
2 O
( O
VEGFR O
- O
2 O
) O
. O

Driven O
by O
a O
multidisciplinary O
approach O
combination O
( O
Structure O
- O
Based O
( O
SB O
) O
Three O
- O
Dimensional O
Quantitative O
Structure O
- O
Activity O
Relationships O
( O
3 O
- O
D O
QSAR O
) O
, O
molecular O
modeling O
, O
organic O
chemistry O
and O
various O
biological O
evaluations O
) O
here O
is O
reported O
the O
disclosure O
of O
new O
thienopyrimidines B
1 O
- O
3 O
as O
inhibitors O
of O
KDR O
activity O
and O
human O
umbilical O
vein O
endothelial O
cell O
( O
HUVEC O
) O
proliferation O
. O

Meclofenamic B
acid I
blocks O
the O
gap O
junction O
communication O
between O
the O
retinal O
pigment O
epithelial O
cells O
. O

Therefore O
, O
we O
aimed O
to O
investigate O
the O
effect O
of O
meclofenamic B
acid I
( O
MFA O
) O
on O
retinal O
pigment O
epithelium O
( O
RPE O
) O
. O

Results O
: O
Analysis O
of O
Lucifer B
yellow I
( O
LY O
) O
transfer O
revealed O
that O
the O
gap O
junction O
communication O
existed O
between O
RPE O
cells O
. O

Importantly O
, O
MFA O
largely O
inhibited O
the O
gap O
junction O
conductance O
and O
induced O
the O
uncoupling O
of O
RPE O
cells O
. O
Other O
NSAIDs O
, O
like O
aspirin O
and O
flufenamic O
acid O
( O
FFA B
) O
, O
had O
the O
same O
effect O
. O

Photocytotoxicity O
of O
copper O
( O
II O
) O
complexes O
of O
curcumin O
and O
N B
- I
ferrocenylmethyl I
- I
l I
- I
amino I
acids I
. O

Copper O
( O
II O
) O
complexes O
[ B
Cu I
( I
Fc I
- I
aa I
) I
( I
cur I
) I
] I
( O
1 O
- O
3 O
) O
of O
curcumin O
( O
Hcur B
) O
and O
N B
- I
ferrocenylmethyl I
- I
l I
- I
amino I
acids I
( O
Fc B
- I
aa I
) O
, O
viz O
. O
, O
ferrocenylmethyl B
- I
l I
- I
tyrosine I
( O
Fc B
- I
TyrH I
) O
, O
ferrocenylmethyl B
- I
l I
- I
tryptophan I
( O
Fc B
- I
TrpH I
) O
and O
ferrocenylmethyl O
- O
l O
- O
methionine O

( O
Fc B
- I
MetH I
) O
, O
were O
prepared O
and O
characterized O
. O

Acetylacetonate O
( O
acac B
) O
complexes O
[ B
Cu I
( I
Fc I
- I
aa I
) I
( I
acac I
) I
] I
( O
4 O
- O
6 O
) O
were O
prepared O
and O
used O
as O
controls O
. O

Epidermal O
growth O
factor O
receptor O
- O
targeted O
NDLPs O
are O
highly O
biocompatible O
particles O
that O
provide O
cell O
- O
specific O
imaging O
, O
promote O
tumor O
retention O
of O
ND O
- O
complexes O
, O
prevent O
epirubicin B
toxicities O
and O
mediate O
regression O
of O
triple O
negative O
breast O
cancers O
. O

Alkane B
Oxidation O
by O
an O
Immobilized O
Nickel O
Complex O
Catalyst O
: O
Structural O
and O
Reactivity O
Differences O
Induced O
by O
Surface O
- O
Ligand O
Density O
on O
Mesoporous O
Silica O
. O

Immobilized O
nickel O
catalysts O
SBA O
* O
- O
L O
- O
x O
/ O
Ni O
( O
L O
= O
bis B
( I
2 I
- I
pyridylmethyl I
) I
( I
1H I
- I
1 I
, I
2 I
, I
3 I
- I
triazol I
- I
4 I
- I
ylmethyl I
) I
amine I
) O
with O
various O
ligand O
densities O
( O
L O
content O
( O
x O
) O
= O
0 O
. O
5 O
, O
1 O
, O
2 O
, O
4 O
mol O
% O
Si O
) O
have O
been O
prepared O
from O
azidopropyl B
- O
functionalized O
mesoporous O
silicas O
SBA O
- O
N3 O
- O
x O
. O

Related O
homogeneous O
ligand O
L B
( I
t I
) I
( I
Bu I
) I
and O
its O
Ni O
( O
II O
) O
complexes O
, O
[ B
Ni I
( I
L I
( I
t I
) I
( I
Bu I
) I
) I
( I
OAc I
) I
2 I
( I
H2 I
O I
) I
] I
( I
L I
( I
t I
) I
( I
Bu I
) I
/ I
Ni I
) I
and O
[ B
Ni I
( I
L I
( I
t I
) I
( I
Bu I
) I
) I
2 I
] I
BF4 I
( I
2 I
L I
( I
t I
) I
( I
Bu I
) I
/ I
Ni I
) I
, O
have O
been O
synthesized O
. O

The O
L O
/ O
Ni O
ratio O
( O
0 O
. O
9 O
- O
1 O
. O
7 O
: O
1 O
) O
in O
SBA O
* O
- O
L O
- O
x O
/ O
Ni O
suggests O
the O
formation O
of O
an O
inert O
[ O
NiL2 B
] O
site O
on O
the O
surface O
at O
higher O
ligand O
loadings O
. O

SBA O
* O
- O
L O
- O
x O
/ O
Ni O
has O
been O
applied O
to O
the O
catalytic O
oxidation O
of O
cyclohexane O
with O
m B
- I
chloroperbenzoic I
acid I
( O
mCPBA B
) O
. O

The O
catalyst O
with O
the O
lowest O
loading O
shows O
high O
activity O
in O
its O
initial O
use O
as O
the O
homogeneous O
L B
( I
t I
) I
( I
Bu I
) I
/ O
Ni O
catalyst O
, O
with O
some O
metal O
leaching O
. O

Tandem O
assays O
of O
protein O
and O
glucose O
in O
combination O
with O
mannose O
- O
functionalized O
Fe3 B
O4 I
@ O
SiO2 O
and O
Ag O
@ O
SiO2 O
tag O
particles O
have O
promising O
potential O
in O
effective O
magnetic O
separation O
and O
highly O
sensitive O
and O
selective O
SERS O
assays O
of O
biomaterials O
. O

We O
have O
employed O
in O
situ O
X O
- O
ray O
reflectivity O
( O
IXRR O
) O
to O
study O
the O
adsorption O
of O
a O
variety O
of O
proteins O
( O
lysozyme O
, O
cytochrome O
c O
, O
myoglobin O
, O
hemoglobin O
, O
serum O
albumin O
, O
and O
immunoglobulin O
G O
) O
on O
model O
hydrophilic O
( O
silicon B
oxide I
) O
and O
hydrophobic O
surfaces O
( O
octadecyltrichlorosi B
self O
- O
assembled O
monolayers O
) O
, O
evaluating O
this O
recently O
developed O
technique O
for O
its O
applicability O
in O
the O
area O
of O
biomolecular O
studies O
. O

Ligand O
Based O
Approach O
to O
L O
- O
Type O
Calcium O
Channel O
by O
Imidazo B
[ I
2 I
, I
1 I
- I
b I
] I
thiazole I
- I
1 I
, I
4 I
- I
Dihydropyridines I
: O
from O
Heart O
Activity O
to O
Brain O
Affinity O
. O

The O
synthesis O
, O
characterization O
, O
and O
functional O
in O
vitro O
assay O
in O
cardiac O
and O
smooth O
muscle O
( O
vascular O
and O
nonvascular O
) O
of O
a O
series O
of O
4 B
- I
imidazo I
[ I
2 I
, I
1 I
- I
b I
] I
thiazole I
- I
1 I
, I
4 I
- I
dihydropyridines I
are O
reported O
. O

To O
define O
the O
calcium O
blocker O
nature O
of O
the O
imidazo B
[ I
2 I
, I
1 I
- I
b I
] I
thiazole I
- I
1 I
, I
4 I
- I
DHPs I
and O
their O
selectivity O
on O
Cav1 O
. O
2 O
and O
Cav1 O
. O
3 O
isoforms O
we O
performed O
binding O
studies O
on O
guinea O
pig O
atrial O
and O
ventricular O
membranes O
, O
on O
intact O
cells O
expressing O
the O
cloned O
Cav1 O
. O
2a O
subunit O
and O
on O
rat O
brain O
cortex O
. O

All O
the O
biological O
data O
collected O
and O
reported O
herein O
allowed O
us O
to O
rationalize O
the O
structure O
- O
activity O
relationship O
of O
the O
4 B
- I
imidazo I
[ I
2 I
, I
1 I
- I
b I
] I
thiazole I
- I
1 I
, I
4 I
- I
DHPs I
and O
to O
identify O
which O
of O
these O
enhanced O
the O
activity O
at O
the O
central O
level O
. O

When O
illuminated O
with O
visible O
light O
, O
the O
free O
floating O
devices O
have O
been O
demonstrated O
to O
produce O
hydrogen O
at O
a O
stable O
rate O
for O
over O
24 O
h O
in O
corrosive O
hydroiodic B
acid I
electrolyte O
with O
light O
as O
the O
only O
input O
. O

Here O
we O
explore O
the O
hidden O
sensing O
modalities O
responsible O
for O
tailoring O
the O
gas O
detection O
ability O
of O
pristine B
graphene I
sensors O
by O
exposing O
graphene O
chemFETs O
to O
electron O
donor O
and O
acceptor O
trace O
gas O
vapors O
. O

We O
uncover O
that O
the O
sensitivity O
( O
in O
terms O
of O
modulation O
in O
electrical O
conductivity O
) O
of O
pristine B
graphene I
chemFETs O
is O
not O
necessarily O
intrinsic O
to O
graphene O
, O
but O
rather O
it O
is O
facilitated O
by O
external O
defects O
in O
the O
insulating O
substrate O
, O
which O
can O
modulate O
the O
electronic O
properties O
of O
graphene O
. O

In O
this O
paper O
, O
ultrastable O
aqueous O
foam O
stabilized O
by O
a O
kind O
of O
flexible O
connecting O
bipolar O
- O
headed O
surfactant O
alkyl B
polyoxyethylene I
sulfate I
( O
AE3S B
) O
with O
coexisting O
Mg O
( O
2 O
+ O
) O
was O
reported O
. O

Detailed O
molecular O
behaviors O
of O
AE3S B
in O
foam O
film O
with O
coexisting O
divalent O
cationic O
Ca O
( O
2 O
+ O
) O
or O
Mg O
( O
2 O
+ O
) O
were O
investigated O
by O
molecular O
dynamic O
simulation O
, O
comparing O
with O
the O
traditional O
surfactant O
sodium O
dodecyl O
sulfate O
( O
SDS O
) O
, O
to O
find O
out O
how O
the O
microcharacter O
and O
array O
behavior O
of O
molecules O
in O
the O
foam O
film O
determined O
by O
molecular O
interaction O
effect O
the O
foam O
stability O
. O

It O
was O
found O
that O
the O
ultrastable O
foam O
film O
obtained O
by O
the O
cooperation O
of O
magnesium O
ions O
and O
AE3S B
was O
driven O
from O
two O
aspects O
: O
one O
is O
the O
favorable O
arrangement O
of O
surfactant O
molecules O
, O
and O
the O
other O
is O
the O
increase O
of O
capacity O
of O
foam O
films O
for O
resolutely O
holding O
water O
molecules O
deduced O
by O
a O
dipolar O
pair O
formed O
by O
the O
flexible O
connecting O
head O
groups O
of O
AE3S B
and O
hydrated B
Mg I
( I
2 I
+ I
) I
via O
intermolecular O
coactions O
, O
both O
related O
to O
the O
presence O
of O
magnesium O
ions O
. O

Structure O
and O
Absolute O
Configuration O
of O
Fumiquinazoline B
L I
, O
an O
Alkaloid O
from O
a O
Gorgonian O
- O
Derived O
Scopulariopsis O
sp O
. O

Fumiquinazoline B
L I
( O
1 O
) O
, O
an O
alkaloid O
with O
a O
heptacyclic O
skeleton O
formed O
via O
a O
bridging O
hemiaminal O
linkage O
, O
was O
isolated O
from O
a O
gorgonian O
- O
derived O
Scopulariopsis O
sp O
. O
fungus O
. O

Fumiquinazoline B
L I
( O
1 O
) O
showed O
no O
cytotoxic O
or O
antibacterial O
activities O
. O

Identification O
of O
the O
Post O
- O
Polyketide O
Synthase O
Modification O
Enzymes O
for O
Fostriecin B
Biosynthesis O
in O
Streptomyces O
pulveraceus O
. O

Fostriecin B
( O
FST B
, O
1 O
) O
is O
a O
natural O
product O
with O
promising O
antitumor O
activity O
produced O
by O
Streptomyces O
pulveraceus O
. O

As O
a O
result O
, O
we O
determined O
that O
a O
fosK O
- O
encoded O
cytochrome O
P450 O
monooxygenase O
is O
responsible O
for O
C O
- O
18 O
hydroxylation O
, O
formation O
of O
an O
unsaturated B
lactone I
is O
dependent O
upon O
FosM O
, O
and O
the O
fosG O
gene O
product O
is O
involved O
in O
hydroxylation O
at O
C O
- O
4 O
after O
the O
action O
of O
FosM O
to O
yield O
PD B
113 I
, I
271 I
from O
FST B
. O

The O
accumulated O
analogues O
from O
the O
Delta O
fosK O
and O
Delta O
fosM O
mutant O
strains O
possessed O
a O
malonyl B
ester I
moiety O
that O
suggested O
that O
all O
the O
post O
- O
PKS O
modification O
steps O
in O
FST O
biosynthesis O
occur O
with O
the O
polyketide O
chain O
bearing O
a O
malonyl B
ester I
at O
the O
C O
- O
3 O
position O
, O
with O
formation O
of O
the O
unsaturated O
six O
- O
membered O
lactone O
as O
the O
last O
step O
in O
FST B
biosynthesis O
. O

Nocardiamides B
A I
and I
B I
, O
Two O
Cyclohexapeptides O
from O
the O
Marine O
- O
Derived O
Actinomycete O
Nocardiopsis O
sp O
. O

Two O
new O
cyclic B
hexapeptides I
, O
nocardiamides B
A O
( O
1 O
) O
and O
B O
( O
2 O
) O
, O
were O
isolated O
from O
the O
culture O
broth O
of O
marine O
- O
derived O
actinomycete O
CNX037 O
strain O
that O
was O
identified O
as O
a O
Nocardiopsis O
species O
. O

The O
planar O
structures O
of O
nocardiamides B
A O
( O
1 O
) O
and O
B O
( O
2 O
) O
were O
assigned O
on O
the O
basis O
of O
1D O
and O
2D O
NMR O
and O
HRESIMS O
spectroscopic O
analyses O
. O

The O
challenge O
of O
locating O
two O
d B
- I
and I
one I
l I
- I
valine I
residue O
in O
1 O
and O
2 O
was O
accomplished O
by O
total O
synthesis O
using O
solid O
- O
phase O
peptide O
synthetic O
methods O
. O

Potency O
switch O
between O
CHK1 O
and O
MK2 O
: O
Discovery O
of O
imidazo B
[ I
1 I
, I
2 I
- I
a I
] I
pyrazine I
- O
and O
imidazo B
[ I
1 I
, I
2 I
- I
c I
] I
pyrimidine I
- O
based O
kinase O
inhibitors O
. O

Chemistry O
has O
been O
developed O
to O
access O
both O
imidazo B
[ I
1 I
, I
2 I
- I
a I
] I
pyrazines I
and O
imidazo B
[ I
1 I
, I
2 I
- I
c I
] I
pyrimidines I
. O

The O
in O
vitro O
effect O
of O
duroquinone B
on O
functional O
competence O
, O
genomic O
integrity O
, O
and O
oxidative O
stress O
indices O
of O
sterlet O
( O
Acipenser O
ruthenus O
) O
spermatozoa O
. O

Duroquinone B
( O
derivative O
of O
1 O
, O
4 O
- O
benzoquinone O
) O
is O
a O
xenobiotic O
compound O
widespread O
in O
the O
environment O
. O

The O
effect O
of O
duroquinone B
on O
motility O
, O
DNA O
integrity O
, O
and O
oxidative O
stress O
indices O
in O
sterlet O
, O
Acispenser O
ruthenus O
, O
spermatozoa O
was O
investigated O
. O

Sterlet O
sperm O
was O
exposed O
for O
2h O
to O
duroquinone B
at O
concentrations O
of O
25 O
, O
50 O
, O
100 O
, O
and O
150 O
mu O
M O
. O

Spermatozoa O
motility O
, O
velocity O
, O
and O
ATP O
content O
were O
significantly O
decreased O
with O
exposure O
to O
duroquinone B
. O

Oxidative O
stress O
indices O
( O
lipid O
peroxidation O
and O
content O
of O
carbonyl O
proteins O
) O
and O
superoxide O
dismutase O
( O
SOD O
) O
activity O
increased O
significantly O
with O
increasing O
concentrations O
of O
duroquinone B
. O

Oxidative O
stress O
in O
sterlet O
spermatozoa O
induced O
by O
duroquinone B
was O
shown O
to O
impair O
spermatozoa O
DNA O
integrity O
, O
motility O
parameters O
, O
and O
the O
antioxidant O
defense O
system O
. O

A O
selective O
KOR O
agonist O
( O
U69593 B
, O
1 O
mu O
M O
) O
diminished O
evoked O
GABAergic O
inhibitory O
postsynaptic O
currents O
( O
IPSCs O
) O
by O
18 O
% O
( O
n O
= O
10 O
) O
in O
the O
CeA O
, O
whereas O
blockade O
of O
KORs O
with O
a O
selective O
antagonist O
( O
nor B
- I
binaltorphimine I
, O
1 O
mu O
M O
) O
augmented O
the O
baseline O
evoked O
GABAergic O
IPSCs O
by O
14 O
% O
( O
p O
< O
0 O
. O
01 O
; O
n O
= O
34 O
) O
, O
suggesting O
that O
the O
KOR O
system O
contributes O
to O
tonic O
inhibition O
of O
GABAergic O
neurotransmission O
in O
the O
CeA O
. O

The O
use O
of O
pre O
- O
treated O
material O
( O
10 O
: O
1 O
glibenclamide O
/ O
docusate B
sodium I
salt O
ratio O
spray O
- O
dried O
as O
ethanolic O
solution O
) O
resulted O
in O
a O
mean O
particle O
size O
of O
236nm O
and O
volume O
- O
based O
size O
distribution O
values O
of O
0 O
. O
131 O
mu O
m O
( O
d50 O
% O
) O
and O
0 O
. O
285 O
mu O
m O
( O
d90 O
% O
) O
. O

Reduction O
of O
the O
enniatins B
A I
, I
A1 I
, I
B I
, I
B1 I
by O
an O
in O
vitro O
degradation O
employing O
different O
strains O
of O
probiotic O
bacteria O
: O
Identification O
of O
degradation O
products O
by O
LC O
- O
MS O
- O
LIT O
. O

The O
degradation O
of O
the O
Fusarium O
mycotoxins O
ENs B
by O
9 O
bacterial O
strains O
characteristic O
of O
the O
gastrointestinal O
tract O
like O
Bb O
. O
longum O
, O
Bb O
. O
bifidum O
, O
Bb O
. O
breve O
, O
Bb O
. O
adolescentes O
, O
Lb O
. O
rhamnosus O
, O
Lb O
. O
casei O
- O
casei O
, O
S O
. O
termofilus O
, O
Lb O
. O
ruminis O
, O
Lb O
. O
casei O
and O
twenty O
two O
strains O
of O
Saccharomyces O
cerevisiae O
was O
studied O
. O

The O
fermentations O
were O
carried O
out O
in O
the O
liquid O
medium O
of O
De O
Man O
Rogosa O
Sharpe O
( O
MRS O
) O
under O
anaerobic O
conditions O
for O
Bifidobacteria O
Streptococcus O
and O
Lactobacillus O
, O
and O
in O
Potato O
Dextrose B
Broth O
( O
PDB O
) O
for O
Saccharomyces O
strains O
, O
during O
48 O
h O
. O

The O
degradation O
of O
the O
bioactive O
compounds O
ENs B
was O
also O
studied O
in O
a O
food O
system O
composed O
by O
wheat O
flour O
naturally O
contaminated O
by O
ENs B
through O
fermentation O
by O
a O
strain O
of O
Fusarium O
tricinctum O
. O

The O
determination O
of O
the O
ENs B
in O
the O
fermentation O
mediums O
was O
performed O
using O
the O
technique O
of O
the O
liquid O
chromatography O
coupled O
to O
the O
mass O
spectrometry O
detector O
in O
tandem O
( O
LC O
- O
MS O
/ O
MS O
) O
, O
whereas O
the O
identification O
of O
the O
degradation O
products O
produced O
by O
microbial O
fermentation O
was O
carried O
out O
using O
the O
technique O
of O
the O
LC O
coupled O
to O
the O
linear O
ion O
trap O
( O
LIT O
) O
. O

All O
the O
bacteria O
analyzed O
in O
this O
study O
showed O
a O
significant O
ENs B
reduction O
in O
vitro O
during O
the O
fermentation O
processes O
, O
with O
degradation O
data O
ranging O
from O
5 O
to O
the O
99 O
% O
. O

In O
the O
food O
system O
, O
the O
ENs B
degradation O
data O
evidenced O
ranged O
from O
1 O
. O
3 O
to O
49 O
. O
2 O
% O
. O

Also O
three O
ENs B
degradation O
products O
were O
identified O
. O

Changes O
in O
mRNA O
and O
protein O
expression O
in O
the O
renal O
cortex O
of O
male O
and O
female O
F344 O
rats O
treated O
with O
bromate B
. O

Bromate B
( O
BrO3 B
( I
- I
) I
) O
, O
a O
by O
- O
product O
of O
ozonation O
of O
drinking O
water O
, O
induces O
nephrotoxicity O
in O
male O
rats O
at O
much O
lower O
doses O
than O
in O
female O
rats O
. O

To O
determine O
sex O
- O
dependent O
changes O
in O
mRNA O
and O
protein O
expression O
in O
the O
renal O
cortex O
attributable O
to O
alpha O
- O
2u O
- O
globulin O
nephropathy O
, O
we O
performed O
microarray O
and O
immunohistochemical O
analyses O
in O
proximal O
renal O
tubules O
of O
male O
and O
female O
F344 O
rats O
treated O
with O
KBrO3 B
for O
28 O
days O
. O

Microarray O
analysis O
of O
male O
and O
female O
rats O
treated O
with O
BrO3 B
( I
- I
) I
at O
low O
doses O
( O
125 O
mg O
/ O
L O
KBrO3 B
) O
displayed O
marked O
sex O
- O
dependent O
changes O
in O
renal O
gene O
expression O
. O

The O
fraction O
of O
proximal O
renal O
cells O
with O
elevated O
8 B
- I
oxodeoxyguanosine I
( O
8 O
- O
OH O
- O
dG O
) O
was O
only O
increased O
at O
the O
high O
dose O
and O
did O
not O
differ O
by O
sex O
. O

Similarly O
, O
BrO3 B
( I
- I
) I
treatment O
increased O
clusterin O
and O
Kim O
- O
1 O
staining O
in O
the O
proximal O
tubules O
; O
however O
, O
staining O
for O
these O
proteins O
did O
not O
differ O
appreciably O
between O
males O
and O
females O
. O

These O
data O
demonstrate O
both O
qualitative O
and O
quantitative O
differences O
in O
the O
response O
of O
male O
versus O
female O
kidneys O
to O
BrO3 B
( I
- I
) I
- O
treatment O
. O

These O
sex O
- O
dependent O
effects O
likely O
contribute O
to O
renal O
carcinogenesis O
of O
BrO3 B
( I
- I
) I
in O
the O
male O
rat O
. O

Molecular O
Mechanisms O
of O
Silibinin B
- O
Mediated O
Cancer O
Chemoprevention O
with O
Major O
Emphasis O
on O
Prostate O
Cancer O
. O

One O
such O
nontoxic O
natural O
agent O
is O
the O
flavonoid O
silibinin B
, O
derived O
from O
the O
milk O
thistle O
plant O
( O
Silybum O
marianum O
) O
, O
which O
has O
ancient O
medicinal O
usage O
and O
potent O
antioxidant O
activity O
. O

Based O
on O
these O
properties O
, O
silibinin B
has O
been O
investigated O
in O
a O
host O
of O
cancer O
models O
where O
it O
exhibits O
broad O
- O
spectrum O
efficacy O
against O
cancer O
progression O
both O
in O
vitro O
and O
in O
vivo O
without O
noticeable O
toxicity O
. O

Specifically O
in O
prostate O
cancer O
models O
, O
silibinin B
has O
shown O
the O
ability O
to O
modulate O
cell O
signaling O
, O
proliferation O
, O
apoptosis O
, O
epithelial O
to O
mesenchymal O
transition O
, O
invasion O
, O
metastasis O
, O
and O
angiogenesis O
, O
which O
taken O
together O
provides O
strong O
support O
for O
silibinin B
as O
a O
candidate O
prostate O
cancer O
chemopreventive O
agent O
. O

In O
the O
present O
report O
, O
we O
show O
that O
Fer O
associates O
with O
the O
activated O
PDGFbeta O
receptor O
( O
PDGFRbeta O
) O
through O
multiple O
autophosphorylation O
sites O
, O
i O
. O
e O
. O
Tyr579 B
, O
Tyr581 B
, O
Tyr740 B
and O
Tyr1021 B
. O

Exposure O
to O
mercury O
among O
dental O
health O
workers O
in O
Turkey O
: O
Correlation O
with O
amalgam B
work O
and O
own O
fillings O
. O

Group O
1 O
consisted O
of O
67 O
dentists O
; O
group O
2 O
consisted O
of O
21 O
dental O
personnel O
who O
work O
with O
amalgam B
, O
and O
group O
3 O
consisted O
of O
27 O
control O
subjects O
who O
work O
in O
the O
same O
hospital O
but O
are O
non O
- O
dental O
personnel O
. O

The O
number O
of O
amalgam B
fillings O
that O
have O
been O
made O
by O
the O
dentists O
and O
the O
number O
of O
own O
fillings O
of O
the O
subjects O
were O
recorded O
. O

The O
number O
of O
amalgam B
fillings O
made O
by O
the O
dentists O
in O
the O
previous O
year O
correlated O
significantly O
with O
plasma O
Hg O
levels O
( O
r O
= O
0 O
. O
378 O
, O
p O
< O
0 O
. O
01 O
) O
. O

There O
was O
no O
significant O
correlation O
between O
the O
own O
amalgam B
fillings O
in O
the O
teeth O
of O
the O
subjects O
and O
Hg O
levels O
. O

MAO O
Inhibitory O
Activity O
of O
2 B
- I
Arylbenzofurans I
versus O
3 B
- I
Arylcoumarins I
: O
Synthesis O
, O
in O
vitro O
Study O
, O
and O
Docking O
Calculations O
. O

Several O
3 B
- I
arylcoumarin I
derivatives O
were O
previously O
described O
as O
interesting O
selective O
MAO O
- O
B O
inhibitors O
. O

Preserving O
the O
trans B
- I
stilbene I
structure O
, O
a O
series O
of O
2 B
- I
arylbenzofuran I
and O
corresponding O
3 B
- I
arylcoumarin I
derivatives O
were O
synthesized O
and O
evaluated O
as O
inhibitors O
of O
both O
MAO O
isoforms O
, O
MAO O
- O
A O
and O
MAO O
- O
B O
. O

5 B
- I
Nitro I
- I
2 I
- I
( I
4 I
- I
methoxyphenyl I
) I
benzofuran I
( O
8 O
) O
is O
the O
most O
active O
compound O
of O
the O
benzofuran O
series O
, O
presenting O
MAO O
- O
B O
selectivity O
and O
reversible O
inhibition O
( O
IC50 O
= O
140 O
nM O
) O
. O

3 B
- I
( I
4 I
' I
- I
Methoxyphenyl I
) I
- I
6 I
- I
nitrocoumarin I
( O
15 O
) O
, O
with O
the O
same O
substitution O
pattern O
as O
that O
of O
compound O
8 O
, O
was O
found O
to O
be O
the O
most O
active O
MAO O
- O
B O
inhibitor O
of O
the O
coumarin O
series O
( O
IC50 O
= O
3 O
nM O
) O
. O

However O
, O
3 B
- I
phenylcoumarin I
14 O
showed O
activity O
in O
the O
same O
range O
( O
IC50 O
= O
6 O
nM O
) O
, O
is O
reversible O
, O
and O
also O
severalfold O
more O
selective O
than O
compound O
15 O
. O

Docking O
experiments O
for O
the O
most O
active O
compounds O
into O
the O
MAO O
- O
B O
and O
MAO O
- O
A O
binding O
pockets O
highlighted O
different O
interactions O
between O
the O
derivative O
classes O
( O
2 B
- I
arylbenzofurans I
and O
3 B
- I
arylcoumarins I
) O
, O
and O
provided O
new O
information O
about O
the O
enzyme O
- O
inhibitor O
interaction O
and O
the O
potential O
therapeutic O
application O
of O
these O
scaffolds O
. O

Here O
, O
we O
investigate O
the O
self O
- O
assembly O
of O
these O
superstructures O
by O
comparing O
the O
quiescent O
and O
vortex O
- O
assisted O
aggregation O
of O
insulin O
and O
its O
individual O
A O
and O
B O
chains O
in O
the O
presence O
or O
absence O
of O
reducing O
agent O
tris B
( I
2 I
- I
carboxyethyl I
) I
phosphine I
( O
TCEP B
) O
. O

Our O
study O
shows O
that O
only O
the O
B O
chain O
in O
the O
presence O
of O
TCEP B
is O
converted O
into O
aggregates O
with O
morphology O
( O
according O
to O
atomic O
force O
microscopy O
) O
and O
optical O
activity O
( O
manifested O
as O
an O
extrinsic O
Cotton O
effect O
induced O
in O
bound O
thioflavin O
T O
) O
characteristic O
of O
amyloid O
superstructures O
that O
are O
normally O
formed O
by O
insulin O
in O
the O
absence O
of O
TCEP B
. O

Background O
: O
The O
presented O
method O
is O
able O
to O
determine O
6 O
- O
mercaptopurine O
( O
6 B
- I
MP I
) O
, O
6 B
- I
thioguanine I
, O
6 B
- I
mercaptopurine I
riboside I
and O
6 B
- I
thioguanine I
riboside I
in O
urine O
, O
and O
is O
thereby O
dedicated O
to O
control O
of O
thiopurine B
therapy O
of O
children O
with O
acute O
lymphoblastic O
leukemia O
. O

Good O
separation O
of O
the O
mentioned O
compounds O
was O
achieved O
on O
a O
C18 O
stationary O
phase O
with O
a O
sodium O
azide O
and O
sodium B
heptane I
sulfonate I
solution O
, O
acetonitrile O
and O
water O
at O
ratio O
of O
50 O
: O
1 O
: O
49 O
( O
v O
/ O
v O
/ O
v O
) O
. O

LOD O
and O
LOQ O
are O
0 O
. O
3 O
, O
0 O
. O
4 O
, O
0 O
. O
3 O
, O
0 O
. O
8 O
and O
0 O
. O
4 O
, O
0 O
. O
6 O
, O
0 O
. O
5 O
and O
0 O
. O
9 O
nmol O
/ O
ml O
of O
urine O
for O
6 B
- I
MP I
, O
6 B
- I
thioguanine I
, O
6 B
- I
mercaptopurine I
riboside I
and O
6 B
- I
thioguanine I
riboside I
, O
respectively O
. O

Intra O
- O
and O
inter O
- O
day O
recovery O
and O
RSD O
are O
close O
to O
100 O
% O
and O
less O
than O
10 O
% O
, O
respectively O
, O
for O
all O
investigated O
thiopurines B
. O

Conclusion O
: O
The O
elaborated O
method O
was O
successfully O
applied O
for O
detection O
and O
quantitation O
of O
6 B
- I
MP I
and O
its O
selected O
metabolites O
in O
patients O
' O
urine O
samples O
. O

Polyelectrolyte O
- O
Surfactant O
Complexes O
of O
Poly B
[ I
3 I
, I
5 I
- I
bis I
( I
dimethylaminomethyl I
) I
- I
4 I
- I
hydroxystyrene I
] I
- I
block I
- I
poly I
( I
ethylene I
oxide I
) I
and O
Sodium O
Dodecyl O
Sulfate O
: O
Anomalous O
Self O
- O
Assembly O
Behavior O
. O

Polyelectrolyte O
- O
surfactant O
complexes O
( O
PE O
- O
S O
) O
formed O
by O
double O
hydrophilic O
cationic O
polyelectrolyte O
poly B
[ I
3 I
, I
5 I
- I
bis I
( I
dimethylaminomethyl I
) I
- I
4 I
- I
hydroxystyrene I
] I
- I
block I
- I
poly I
( I
ethylene I
oxide I
) I
( O
NPHOS B
- I
PEO I
) O
and O
anionic O
surfactant O
sodium O
dodecyl O
sulfate O
( O
SDS O
) O
in O
acidic O
aqueous O
solutions O
were O
studied O
by O
light O
scattering O
, O
SAXS O
, O
and O
scanning O
transmission O
electron O
microcopy O
in O
the O
environmental O
mode O
( O

wet O
- O
STEM O
) O
for O
various O
stoichiometric O
ratios O
between O
the O
numbers O
of O
SDS O
anions O
and O
dimethylaminomethyl B
groups O
of O
NPHOS B
in O
the O
complex O
. O

The O
obtained O
results O
show O
that O
the O
NPHOS B
- I
PEO I
/ O
SDS O
system O
behaves O
differently O
from O
other O
systems O
of O
double O
hydrophilic O
block O
polyelectrolyte O
and O
oppositely O
charged O
ionic O
surfactant O
because O
it O
forms O
water O
- O
insoluble O
PE O
- O
S O
for O
compositions O
close O
to O
the O
zero O
net O
charge O
of O
the O
complex O
. O

This O
phase O
separation O
occurs O
, O
instead O
of O
the O
PE O
- O
S O
rearrangement O
to O
core O
- O
shell O
particles O
, O
which O
is O
hindered O
due O
to O
conformational O
rigidity O
of O
the O
NPHOS B
blocks O
. O

SAXS O
measurements O
indicate O
that O
although O
the O
NPHOS B
- I
PEO I
/ O
SDS O
system O
does O
not O
form O
the O
core O
- O
shell O
particles O
with O
the O
NPHOS B
/ O
SDS O
core O
and O
the O
PEO O
shell O
as O
other O
PE O
- O
S O
of O
double O
hydrophilic O
polyelectrolytes O
, O
the O
aggregates O
contain O
domains O
of O
closely O
packed O
surfactant O
micelles O
which O
bind O
to O
both O
NPHOS B
polyelectrolyte O
blocks O
and O
PEO O
blocks O
. O

Structure O
in O
the O
Visible O
Absorption O
Bands O
of O
Jet O
- O
Cooled O
Phenylperoxy B
Radicals O
. O

The O
visible O
absorption O
bands O
of O
the O
phenylperoxy B
radical O
in O
the O
gas O
phase O
have O
been O
investigated O
using O
cavity O
ring O
- O
down O
spectroscopy O
. O

The O
results O
provide O
a O
rationale O
for O
the O
lack O
of O
structure O
in O
room O
temperature O
spectra O
that O
have O
been O
previously O
attributed O
to O
phenylperoxy B
. O

If O
so O
, O
this O
would O
provide O
a O
more O
definitive O
signature O
for O
monitoring O
phenylperoxy B
in O
kinetic O
measurements O
. O

Micellar O
nanoparticles O
were O
assembled O
from O
amphiphilic O
diblock O
copolymers O
composed O
of O
an O
ampholytic O
core O
- O
forming O
block O
and O
a O
redesigned O
polycationic O
corona O
block O
doped O
with O
thiol O
- O
reactive O
pyridyl B
disulfide I
groups O
to O
enable O
dual O
- O
delivery O
of O
antigens O
and O
immunostimulatory O
CpG O
oligodeoxynucleotide O
( O
CpG O
ODN O
) O
adjuvants O
. O

pH O
- O
Responsive O
Aggregation O
States O
of O
Chiral O
Polymerizable O
Amphiphiles O
from O
l B
- I
Tyrosine I
and O
l B
- I
Phenyl I
Alanine I
in O
Water O
. O

Sodium O
salts O
of O
maleamic B
acid I
derivatives O
of O
lauryl B
ester I
of O
tyrosine O
( O
MTNa O
) O
and O
phenyl B
alanine I
( O
MPNa O
) O
in O
water O
exhibited O
strong O
pH O
- O
responsive O
behaviors O
of O
viscosity O
and O
specific O
conductivity O
that O
originate O
from O
the O
concentration O
and O
pH O
dependence O
of O
their O
aggregation O
states O
. O

Results O
of O
high O
- O
precision O
fitting O
of O
the O
second O
- O
harmonic O
EPR O
spectra O
of O
the O
small O
spin O
probe O
di B
- I
tert I
- I
butyl I
nitroxide I
( O
DTBN B
) O
in O
these O
aggregates O
together O
with O
viscosity O
, O
conductivity O
, O
and O
DLS O
showed O
that O
, O
at O
pH O
~ O
7 O
. O
54 O
, O
MTNa O
formed O
micelles O
and O
MPNa O
vesicles O
and O
MTNa O
exhibited O
a O
pH O
- O
induced O
micelle O
to O
vesicle O
transition O
as O
pH O
was O
lowered O
toward O
6 O
. O

The O
rate O
of O
transfer O
of O
DTBN B
between O
the O
aqueous O
phase O
and O
the O
aggregate O
was O
calculated O
from O
the O
high O
- O
field O
Lorentzian O
linewidths O
of O
the O
electron O
paramagnetic O
resonance O
( O
EPR O
) O
spectra O
. O

Discovery O
of O
aryl B
ureas I
and O
aryl B
amides I
as O
potent O
and O
selective O
histamine O
H3 O
receptor O
antagonists O
for O
the O
treatment O
of O
obesity O
( O
Part O
I O
) O
. O

A O
series O
of O
structurally O
novel O
aryl B
ureas I
was O
derived O
from O
optimization O
of O
the O
HTS O
lead O
as O
selective O
histamine O
H3 O
receptor O
( O
H3R O
) O
antagonists O
. O

Phenanthroimidazole O
- O
based O
thiobenzamide B
as O
an O
effective O
sensor O
for O
highly O
selective O
detection O
of O
mercury O
( O
II O
) O
. O

Based O
on O
highly O
selective O
and O
irreversible O
Hg O
( O
2 O
+ O
) O
- O
promoted O
desulfurization O
reaction O
, O
a O
new O
and O
simple O
phenanthroimidazole O
- O
type O
sensor O
was O
prepared O
and O
exhibited O
high O
selectivity O
towards O
Hg O
( O
2 O
+ O
) O
ion O
over O
other O
metal O
ions O
, O
accompanied O
by O
transformation O
of O
a O
weakly O
fluorescent O
thioamide B
moiety O
( O
colorless O
) O
to O
a O
highly O
fluorescent O
amide O
one O
( O
blue O
) O
, O
with O
a O
136 O
- O
fold O
increase O
in O
fluorescent O
intensity O
in O
aqueous O
solution O
with O
a O
pH O
span O
2 O
. O
57 O
- O
9 O
. O
12 O
. O

Similar O
treatment O
with O
alaproclate B
, O
a O
selective O
serotonin O
reuptake O
inhibitor O
, O
in O
contrast O
, O
produced O
temporary O
relief O
from O
the O
depressive O
symptoms O
, O
with O
the O
therapeutic O
effect O
disappearing O
soon O
after O
the O
end O
of O
the O
treatment O
. O

Current O
status O
of O
liposomal O
porphyrinoid B
photosensitizers O
. O

The O
application O
of O
liposomes O
as O
delivery O
systems O
for O
porphyrinoids B
has O
helped O
overcome O
many O
drawbacks O
of O
conventional O
photosensitizers O
and O
facilitated O
the O
development O
of O
novel O
effective O
photosensitizers O
that O
can O
be O
encapsulated O
in O
liposomes O
. O

Complexes O
of O
mono O
- O
, O
bi O
- O
( O
RB O
) O
, O
and O
tridentate O
( O
RT O
) O
receptors O
with O
a O
range O
of O
anions O
( O
Cl O
( O
- O
) O
, O
Br O
( O
- O
) O
, O
I O
( O
- O
) O
, O
NO3 O
( O
- O
) O
, O
H2PO4 B
( I
- I
) I
, O
HSO4 B
( I
- I
) I
, O
and O
tosylate B
( O
TsO B
( I
- I
) I
) O
) O
have O
been O
studied O
in O
the O
gas O
phase O
by O
both O
experimental O
and O
theoretical O
methods O
. O

Temperature O
dependent O
blackbody O
infrared O
radiative O
dissociation O
( O
BIRD O
) O
experiments O
were O
performed O
on O
complexes O
of O
C8F17I B
with O
Br O
( O
- O
) O
and O
I O
( O
- O
) O
, O
RB O
with O
I O
( O
- O
) O
, O
NO3 O
( O
- O
) O
, O
HSO4 B
( I
- I
) I
, O
H2PO4 B
( I
- I
) I
, O
and O
TsO B
( I
- I
) I
, O
and O
RT O
with O
I O
( O
- O
) O
, O
HSO4 B
( I
- I
) I
and O
TsO B
( I
- I
) I
and O
the O
observed O
Arrhenius O
parameters O
are O
reported O
here O
. O

The O
relative O
binding O
energies O
of O
ions O
were O
generally O
consistent O
with O
the O
ordering O
previously O
reported O
from O
solution O
phase O
experiments O
; O
however O
, O
the O
relatively O
strong O
binding O
of O
H2PO4 B
( I
- I
) I
to O
the O
bidentate O
receptor O
contrasted O
the O
solution O
phase O
observation O
of O
oxoanions B
having O
weaker O
interactions O
when O
compared O
to O
halides B
. O

A O
new O
potential O
nano O
- O
oncological O
therapy O
based O
on O
polyamino B
acid I
nanocapsules O
. O

Herein O
, O
we O
disclose O
a O
new O
biodegradable O
nanocarrier O
, O
polyglutamic B
acid I
( O
PGA B
) O
nanocapsules O
, O
and O
present O
the O
in O
vivo O
pharmacokinetics O
/ O
toxicity O
proof O
- O
of O
- O
concept O
for O
the O
anticancer O
drug O
plitidepsin B
. O

These O
novel O
nanocapsules O
were O
prepared O
using O
a O
modified O
solvent O
displacement O
technique O
where O
the O
polyamino B
acid I
was O
electrostatically O
deposited O
onto O
the O
lipid O
core O
. O

The O
nanocapsules O
exhibited O
an O
average O
size O
of O
200nm O
, O
a O
negative O
zeta O
potential O
and O
a O
great O
capacity O
for O
the O
encapsulation O
of O
plitidepsin B
( O
encapsulation O
efficiency O
above O
90 O
% O
) O
. O

In O
fact O
, O
the O
maximum O
tolerated O
dose O
of O
the O
nanoencapsulated O
drug O
was O
more O
than O
3 O
times O
that O
of O
the O
reference O
formulation O
( O
Cremophor B
( O
R O
) O
EL O
plitidepsin B
solution O
) O
. O

Overall O
, O
beyond O
the O
value O
of O
this O
specific O
formulation O
, O
the O
work O
reported O
here O
represents O
the O
evidence O
of O
the O
potential O
of O
polyamino B
acid I
nanocapsules O
in O
nano O
- O
oncological O
therapy O
. O

Experimental O
animals O
were O
divided O
into O
a O
control O
group O
, O
a O
sodium O
fluoride O
- O
treated O
group O
( O
NaF O
, O
50 O
mg O
/ O
L O
) O
, O
three O
sodium O
selenite O
- O
treated O
groups O
( O
Na2SeO3 B
, O
0 O
. O
375 O
, O
0 O
. O
75 O
, O
and O
1 O
. O
5 O
mg O
/ O
L O
) O
, O
and O
three O
selenium O
+ O
NaF O
- O
treated O
groups O
( O
Na2SeO3 B
, O
0 O
. O
375 O
, O
0 O
. O
75 O
, O
and O
1 O
. O
5 O
mg O
/ O
L O
; O
NaF O
, O
50 O
mg O
/ O
L O
) O
. O

The O
optimal O
dose O
of O
Na2SeO3 B
to O
protect O
against O
fluoride O
- O
induced O
renal O
cell O
apoptosis O
was O
determined O
to O
be O
1 O
. O
5 O
mg O
/ O
L O
. O

Melatonin O
and O
its O
analogue O
5 B
- I
MCA I
- I
NAT I
potentiate O
adrenergic O
receptor O
- O
mediated O
ocular O
hypotensive O
effects O
in O
rabbits O
: O
Significance O
for O
combination O
therapy O
in O
glaucoma O
. O

We O
have O
investigated O
the O
effect O
of O
melatonin O
and O
its O
analogue O
5 B
- I
methoxycarbonylamino I
- I
N I
- I
acetyltryptamine I
, O
5 B
- I
MCA I
- I
NAT I
, O
on O
beta O
2 O
/ O
alpha O
2A O
- O
adrenergic O
receptor O
mRNA O
as O
well O
as O
protein O
expression O
in O
cultured O
rabbit O
non O
- O
pigmented O
ciliary O
epithelial O
cells O
. O

In O
addition O
, O
we O
have O
studied O
the O
effect O
of O
these O
drugs O
upon O
the O
ocular O
hypotensive O
action O
of O
a O
non O
- O
selective O
beta O
- O
adrenergic O
receptor O
( O
timolol O
) O
and O
a O
selective O
alpha O
2 O
- O
adrenergic O
receptor O
agonist O
( O
brimonidine B
) O
in O
normotensive O
rabbits O
. O

IOP O
experiments O
showed O
that O
the O
administration O
of O
timolol O
in O
rabbits O
pre O
- O
treated O
with O
melatonin O
or O
5 B
- I
MCA I
- I
NAT I
evoked O
an O
additional O
IOP O
reduction O
of O
14 O
. O
02 O
+ O
/ O
- O
5 O
. O
8 O
% O
or O
16 O
. O
75 O
+ O
/ O
- O
5 O
. O
48 O
% O
( O
p O
< O
0 O
. O
01 O
) O
in O
comparison O
with O
rabbits O
treated O
with O
timolol O
alone O
for O
24 O
hours O
. O

Concerning O
brimonidine B
hypotensive O
action O
, O
an O
additional O
IOP O
reduction O
of O
29 O
. O
26 O
+ O
/ O
- O
5 O
. O
21 O
% O
or O
39 O
. O
07 O
+ O
/ O
- O
5 O
. O
81 O
% O
( O
p O
< O
0 O
. O
001 O
) O
was O
observed O
in O
rabbits O
pretreated O
with O
melatonin O
or O
5 B
- I
MCA I
- I
NAT I
when O
compared O
with O
animals O
treated O
with O
brimonidine B
alone O
for O
24 O
hours O
. O

Additionally O
, O
a O
sustained O
potentiating O
effect O
of O
a O
single O
dose O
of O
5 B
- I
MCA I
- I
NAT I
was O
seen O
in O
rabbits O
treated O
with O
brimonidine B
once O
daily O
for O
up O
four O
days O
( O
extra O
IOP O
decrease O
of O
15 O
. O
57 O
+ O
/ O
- O
5 O
. O
15 O
% O
, O
p O
< O
0 O
. O
05 O
, O
compared O
to O
brimonidine B
alone O
) O
. O

Similarly O
, O
the O
specific O
pharmacological O
FAK O
inhibitor O
PF B
- I
573 I
, I
228 I
as O
well O
as O
specific O
inhibitors O
of O
p38 O
MAPK O
and O
Src O
also O
fully O
inhibited O
collagen O
I O
- O
induced O
proliferation O
, O
whereas O
partial O
inhibition O
was O
observed O
by O
inhibition O
of O
PI3 O
- O
kinase O
and O
MEK O
. O

Charge O
- O
Transfer O
Interaction O
between O
Few O
- O
Layer O
MoS2 O
and O
Tetrathiafulvalene B
. O

Tetrathiafulvalene B
( O
TTF B
) O
interacts O
with O
thin O
, O
few O
- O
layer O
MoS2 O
material O
by O
donating O
an O
electron O
, O
resulting O
in O
the O
formation O
of O
TTF B
radical O
cation O
and O
n O
- O
type O
doping O
of O
MoS2 O
. O

Electron O
- O
withdrawing O
tetracyanoethylene B
, O
in O
contrast O
, O
does O
not O
cause O
p O
- O
type O
doping O
in O
MoS2 O
. O

Protective O
effect O
of O
wogonin B
on O
proinflammatory O
cytokine O
generation O
via O
Jak1 O
/ O
3 O
- O
STAT1 O
/ O
3 O
pathway O
in O
lipopolysaccharide O
stimulated O
BV2 O
microglial O
cells O
. O

Wogonin B
is O
a O
flavonoid O
compound O
which O
exhibits O
antioxidation O
, O
anti O
- O
inflammation O
, O
neuroprotection O
, O
and O
antitumorgenesis O
functions O
. O

However O
, O
the O
mechanism O
of O
how O
wogonin B
reduces O
proinflammatory O
cytokine O
generation O
in O
activated O
microglia O
is O
unclear O
. O

At O
present O
, O
we O
found O
wogonin B
inhibited O
lipopolysaccharide O
( O
LPS O
) O
- O
/ O
interferon O
- O
gamma O
( O
INF O
- O
gamma O
) O
- O
induced O
generation O
of O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
and O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
. O

Wogonin B
exhibited O
parallel O
inhibition O
on O
LPS O
- O
/ O
INF O
- O
gamma O
- O
induced O
expression O
of O
IL O
- O
6 O
and O
TNF O
- O
alpha O
messenger O
RNA O
at O
the O
same O
concentration O
range O
. O

LPS O
- O
/ O
INF O
- O
gamma O
- O
induced O
phosphorylation O
of O
signal O
transduction O
and O
transcription O
1 O
and O
3 O
( O
STAT1 O
/ O
3 O
) O
were O
also O
inhibited O
by O
wogonin B
. O

Although O
wogonin B
expressed O
only O
weak O
inhibitory O
effect O
on O
LPS O
- O
/ O
INF O
- O
gamma O
- O
induced O
phosphorylation O
of O
Janus O
kinase O
- O
2 O
( O
Jak O
- O
2 O
) O
and O
tyrosine O
kinase O
( O
Tyk O
) O
- O
2 O
, O
it O
significantly O
attenuated O
the O
phosphorylation O
of O
Jak O
- O
1 O
and O
Jak O
- O
3 O
. O

These O
results O
indicated O
that O
the O
blockade O
of O
IL O
- O
6 O
and O
TNF O
- O
alpha O
production O
by O
wogonin B
in O
LPS O
- O
/ O
INF O
- O
gamma O
- O
stimulated O
BV2 O
microglial O
cells O
was O
attributed O
mainly O
to O
the O
interference O
in O
Jak O
- O
1 O
/ O
- O
3 O
- O
STAT1 O
/ O
3 O
signaling O
pathway O
. O

The O
linear O
form O
of O
glucose O
forms O
a O
covalent O
bond O
to O
Lys195 B
of O
HSA O
, O
but O
not O
the O
case O
for O
fructose O
. O

Based O
on O
these O
structures O
, O
we O
propose O
a O
mechanism O
for O
glucose O
ring O
opening O
involving O
both O
residues O
Lys195 B
and O
Lys199 B
. O

The O
reactivity O
of O
bioglasses O
, O
which O
is O
related O
to O
the O
dissolution O
of O
cations O
and O
orthosilicate B
groups O
in O
the O
physiological O
fluid O
, O
strongly O
depends O
on O
the O
key O
structural O
features O
present O
at O
the O
glass O
surfaces O
. O

In O
this O
paper O
, O
the O
surface O
structures O
of O
two O
very O
different O
bioglass O
compositions O
, O
namely O
45S5 O
( O
46 O
. O
1 O
SiO2 O
, O
24 O
. O
4 O
Na2O B
, O
26 O
. O
9 O
CaO O
, O
and O
2 O
. O
6 O
P2O5 B
mol O
% O
) O
and O
77S O
( O
80 O
. O
0 O
SiO2 O
, O
16 O
. O
0 O
CaO O
, O
and O
4 O
. O
0 O
P2O5 B
mol O
% O
) O
, O
have O
been O
investigated O
by O
means O
of O
periodic O
DFT O
calculations O
based O
on O
a O
PBE O
functional O
and O
localized O
Gaussian O
basis O
set O
as O
encoded O
in O
the O
CRYSTAL O
code O
. O

Our O
calculations O
show O
that O
the O
two O
glass O
surfaces O
differ O
by O
the O
relative O
amount O
of O
key O
structural O
sites O
such O
as O
NBOs O
, O
exposed O
ions O
, O
orthosilicate B
units O
, O
and O
small O
rings O
. O

In O
this O
study O
, O
dehydration O
of O
titanium B
hydroxide I
in O
the O
cell O
wall O
is O
proposed O
as O
the O
mechanism O
that O
leads O
to O
the O
separation O
of O
neighboring O
nanotubes O
. O

These O
organoclays O
are O
produced O
via O
alkylammonium B
cation O
exchange O
with O
colloidally O
dispersed O
montmorillonite O
clay O
sheets O
followed O
by O
solvent O
casting O
. O

Matrix O
Isolation O
Spectroscopy O
and O
Nuclear O
Spin O
Conversion O
of O
NH3 O
and O
ND3 B
in O
Solid O
Parahydrogen B
. O

We O
present O
matrix O
isolation O
infrared O
absorption O
spectra O
of O
NH3 O
and O
ND3 B
trapped O
in O
solid O
parahydrogen B
( O
pH2 B
) O
at O
temperatures O
around O
1 O
. O
8 O
K O
. O

We O
used O
the O
relatively O
slow O
nuclear O
spin O
conversion O
( O
NSC O
) O
of O
NH3 O
and O
ND3 B
in O
freshly O
deposited O
pH2 B
samples O
as O
a O
tool O
to O
assign O
the O
sparse O
vibration O
- O
inversion O
- O
rotation O
( O
VIR O
) O
spectra O
of O
NH3 O
in O
the O
regions O
of O
the O
nu O
2 O
, O
nu O
4 O
, O
2 O
nu O
4 O
, O
nu O
1 O
, O
and O
nu O
3 O
bands O
and O
ND3 B
in O
the O
regions O
of O
the O
nu O
2 O
, O
nu O
4 O
, O
nu O
1 O
, O
and O
nu O
3 O
fundamentals O
. O

Detailed O
analysis O
of O
the O
nu O
2 O
bands O
of O
NH3 O
and O
ND3 B
indicates O
that O
both O
isotopomers O
are O
nearly O
free O
rotors O
; O
that O
the O
vibrational O
energy O
is O
blue O
- O
shifted O
by O
1 O
- O
2 O
% O
; O
and O
that O
the O
rotational O
constants O
and O
inversion O
tunneling O
splitting O
are O
91 O
- O
94 O
% O
and O
67 O
- O
75 O
% O
, O
respectively O
, O
of O
the O
gas O
- O
phase O
values O
. O

We O
report O
and O
assign O
a O
number O
of O
NH3 O
- O
induced O
infrared O
absorption O
features O
of O
the O
pH2 B
host O
near O
4150 O
cm O
( O
- O
1 O
) O
, O
along O
with O
a O
cooperative O
transition O
that O
involves O
simultaneous O
vibrational O
excitation O
of O
a O
pH2 B
molecule O
and O
rotation O
- O
inversion O
excitation O
of O
NH3 O
. O

The O
NSCs O
of O
NH3 O
and O
ND3 B
were O
found O
to O
follow O
first O
- O
order O
kinetics O
with O
rate O
constants O
at O
1 O
. O
8 O
K O
of O
k O
= O
1 O
. O
88 O
( O
16 O
) O
x O
10 O
( O
- O
3 O
) O
s O
( O
- O
1 O
) O
and O
k O
= O
1 O
. O
08 O
( O
8 O
) O
x O
10 O
( O
- O
3 O
) O
s O
( O
- O
1 O
) O
, O
respectively O
. O

These O
measured O
rate O
constants O
are O
compared O
to O
previous O
measurements O
for O
NH3 O
in O
an O
Ar O
matrix O
and O
with O
the O
rate O
constants O
measured O
for O
other O
dopant O
molecules O
isolated O
in O
solid O
pH2 B
. O

Physicochemical O
characterization O
of O
phyllanthin B
from O
Phyllanthus O
amarus O
Schum O
. O

Abstract O
Phyllanthin B
is O
a O
major O
bioactive O
lignan O
component O
of O
Phyllanthus O
amarus O
, O
with O
several O
known O
biological O
activities O
. O

This O
study O
dealt O
with O
the O
isolation O
and O
physicochemical O
characterization O
of O
phyllanthin B
. O

Phyllanthin B
was O
isolated O
from O
P O
. O
amarus O
leaves O
by O
column O
chromatography O
and O
purified O
by O
recrystallization O
to O
obtain O
phyllanthin B
crystals O
with O
a O
purity O
of O
more O
than O
98 O
% O
. O

UV O
, O
IR O
, O
MS O
, O
( O
1 O
) O
H O
NMR O
and O
( O
13 O
) O
C O
NMR O
spectra O
were O
employed O
to O
identify O
phyllanthin B
. O

The O
physicochemical O
properties O
of O
phyllanthin B
were O
characterized O
using O
differential O
scanning O
calorimetry O
, O
thermogravimetric O
analysis O
, O
X O
- O
ray O
diffraction O
, O
pH O
- O
solubility O
, O
ionization O
property O
and O
lipophilicity O
. O

The O
results O
indicated O
that O
phyllanthin B
crystals O
had O
the O
melting O
point O
and O
melting O
enthalpy O
range O
of O
96 O
. O
67 O
- O
97 O
. O
03 O
degrees O
C O
and O
109 O
. O
61 O
- O
116 O
. O
34 O
J O
/ O
g O
, O
respectively O
. O

Three O
kinds O
of O
phyllanthin B
crystals O
, O
recrystallized O
by O
petroleum O
ether O
, O
absolute O
ethanol O
and O
25 O
% O
ethanol O
solution O
, O
showed O
only O
one O
polymorph O
and O
no O
polymorphic O
impurity O
. O

Phyllanthin B
in O
a O
solid O
state O
was O
found O
to O
undergo O
significant O
thermal O
decomposition O
above O
200 O
degrees O
C O
. O

The O
solubility O
of O
phyllanthin B
appeared O
to O
be O
pH O
- O
independent O
of O
pH O
range O
from O
1 O
. O
07 O
to O
10 O
. O
26 O
. O

Ionization O
property O
studied O
by O
absorbance O
spectroscopy O
method O
was O
in O
agreement O
with O
the O
result O
of O
pH O
- O
solubility O
study O
, O
showing O
that O
phyllanthin B
has O
no O
pKa O
over O
a O
pH O
range O
of O
1 O
. O
12 O
- O
10 O
. O
02 O
. O

The O
log O
Pow O
value O
of O
phyllanthin B
was O
found O
to O
be O
3 O
. O
30 O
+ O
/ O
- O
0 O
. O
05 O
at O
pH O
7 O
. O
48 O
, O
suggesting O
that O
phyllanthin B
may O
have O
good O
permeability O
through O
biological O
membranes O
. O

The O
findings O
could O
be O
useful O
tools O
for O
the O
development O
of O
stable O
and O
bioavailable O
oral O
dosage O
forms O
of O
phyllanthin B
. O

Based O
on O
the O
guidance O
afforded O
by O
the O
ternary O
phase O
diagram O
of O
poly O
( O
d O
, O
l O
- O
lactic O
acid O
) O
( O
PDLLA B
) O
, O
poly O
( O
ethylene O
oxide O
) O
( O
PEO O
) O
, O
and O
genistein O
blends O
, O
certain O
selective O
compositions O
were O
electrospun O
. O

We O
obtained O
a O
uniformly O
smooth O
surface O
morphology O
in O
unmodified O
and O
genistein O
- O
modified O
PEO O
/ O
PDLLA B
fibers O
, O
documented O
by O
scanning O
electron O
microscopy O
. O

Our O
biocompatibility O
investigations O
suggest O
that O
genistein O
- O
modified O
PEO O
/ O
PDLLA B
electrospun O
mats O
exhibit O
strong O
antioxidant O
and O
anti O
- O
inflammatory O
activities O
which O
indicate O
they O
have O
potential O
applications O
for O
wound O
dressings O
. O

Compared O
with O
TOCNs O
with O
sodium O
, O
lithium O
, O
potassium O
, O
and O
cesium B
carboxylate O
groups O
, O
TOCN O
with O
free O
carboxyl O
groups O
( O
TOCN O
- O
COOH O
) O
had O
much O
high O
and O
selective O
H2 O
gas O
permeation O
performance O
. O

Thus O
, O
the O
selective O
H2 O
gas O
permeability O
for O
TOCN O
- O
COOH O
was O
probably O
due O
to O
a O
larger O
average O
size O
in O
free O
volume O
holes O
present O
between O
nanofibrils O
in O
the O
layer O
and O
film O
than O
those O
of O
other O
TOCNs O
with O
metal B
carboxylate I
groups O
. O

Antimalarial O
Activity O
of O
Axidjiferosides B
, O
New O
beta B
- I
Galactosylceramides I
from O
the O
African O
Sponge O
Axinyssa O
djiferi O
. O

A O
mixture O
containing O
new O
glycosphingolipids B
, O
named O
axidjiferoside B
- I
A I
, I
- I
B I
and I
- I
C I
, O
accounted O
for O
0 O
. O
07 O
% O
of O
sponge O
biomass O
( O
dry O
weight O
) O
and O
for O
2 O
. O
16 O
% O
of O
total O
lipids O
. O

They O
were O
identified O
as O
homologous O
beta B
- I
galactopyranosylcera I
composed O
of O
2 B
- I
amino I
- I
( I
6E I
) I
- I
octadec I
- I
6 I
- I
en I
- I
1 I
, I
3 I
, I
4 I
- I
triol I
, O
and O
the O
major O
one O
, O
axidjiferoside B
- I
A I
( O
around O
60 O
% O
) O
, O
contained O
2 B
- I
hydroxytetracosanoic I
acid I
. O

Results O
of O
this O
investigation O
showed O
that O
axidjiferosides B
are O
of O
interest O
, O
because O
they O
proved O
a O
good O
antiplasmodial O
activity O
, O
with O
only O
a O
low O
cytotoxicity O
against O
various O
human O
cell O
lines O
and O
no O
significant O
antitrypanosomal O
and O
antileishmanial O
activity O
. O

Thus O
, O
it O
seems O
that O
galactosylceramides B
with O
a O
beta O
anomeric O
configuration O
may O
be O
suitable O
in O
searching O
for O
new O
antimalarial O
drugs O
. O

The O
elucidation O
of O
the O
reaction O
mechanisms O
leading O
to O
either O
the O
desired O
production O
of O
ethene B
and O
/ O
or O
propene B
or O
undesired O
deactivation O
has O
challenged O
researchers O
for O
many O
decades O
. O

In O
this O
review O
, O
an O
overview O
of O
proposed O
reaction O
mechanisms O
for O
the O
MTO O
process O
is O
given O
, O
focusing O
on O
the O
archetypal O
MTO O
catalysts O
, O
H B
- I
ZSM I
- I
5 I
and O
H B
- I
SAPO I
- I
34 I
. O

The O
metabolism O
of O
nitrooxybutyl B
- I
esters I
of O
flurbiprofen B
and O
ferulic O
- O
acid O
, O
a O
class O
of O
organic O
nitrates O
with O
potential O
therapeutic O
implication O
in O
variety O
of O
different O
conditions O
, O
was O
investigated O
in O
comparison O
with O
glyceryl B
trinitrate I
( O
GTN B
) O
in O
human O
liver O
by O
a O
multiple O
approach O
, O
using O
a O
spontaneous O
metabolism O
- O
independent O
NO O
donor O
( O
NOC B
- I
5 I
) O
as O
a O
reference O
tool O
. O

Nitrooxybutyl B
- I
esters I
were O
rapidly O
and O
quantitatively O
metabolized O
to O
their O
respective O
parent O
compounds O
and O
the O
organic O
nitrate O
moiety O
nitrooxybutyl B
- I
alcohol I
( O
NOBA B
) O
. O

Differently O
from O
GTN B
which O
was O
rapidly O
and O
completely O
metabolized O
to O
nitrite O
, O
NOBA B
was O
slowly O
metabolized O
to O
nitrate O
. O

In O
contrast O
to O
the O
spontaneous O
NO O
donor O
NOC B
- I
5 I
, O
NOBA B
and O
GTN B
did O
not O
generate O
detectable O
NO O
and O
failed O
to O
suppress O
the O
activity O
of O
cytochromeP450 O
; O
an O
enzyme O
known O
to O
be O
inhibited O
by O
NO O
. O

The O
direct O
identification O
of O
NOBA B
following O
liver O
metabolism O
targets O
this O
compound O
as O
the O
functional O
organic O
nitrate O
metabolite O
of O
nitrooxybutyl B
- I
esters I
. O

Moreover O
the O
investigation O
of O
the O
pathways O
for O
denitration O
of O
NOBA B
and O
GTN B
suggests O
that O
organic O
nitrates O
are O
not O
primarily O
metabolized O
to O
NO O
in O
the O
liver O
but O
to O
different O
extents O
of O
nitrite O
or O
nitrate O
depending O
from O
their O
different O
chemical O
structure O
. O

Inspired O
by O
nature O
: O
Natural O
product O
isopropylstilbene B
was O
identified O
as O
an O
inhibitor O
of O
soluble O
epoxide O
hydrolase O
exhibiting O
antiproliferative O
properties O
. O

Following O
the O
natural O
product O
inspired O
design O
approach O
, O
a O
library O
of O
( B
E I
) I
- I
styryl I
- I
1H I
- I
benzo I
[ I
d I
] I
imidazoles I
was O
synthesized O
and O
evaluated O
with O
recombinant O
enzyme O
and O
on O
several O
cancer O
cell O
lines O
. O

Methamidophos B
exposure O
during O
the O
early O
postnatal O
period O
of O
mice O
: O
Immediate O
and O
late O
- O
emergent O
effects O
on O
the O
cholinergic O
and O
serotonergic O
systems O
and O
on O
behavior O
. O

Organophosphates O
( O
OPs B
) O
are O
among O
the O
most O
used O
pesticides O
. O

While O
some O
OPs B
have O
had O
their O
use O
progressively O
more O
restricted O
, O
other O
OPs B
are O
being O
used O
without O
sufficient O
investigation O
of O
their O
effects O
. O

Here O
, O
we O
investigated O
the O
immediate O
neurochemical O
and O
delayed O
neurochemical O
and O
behavioral O
actions O
of O
the O
OP O
methamidophos B
to O
verify O
whether O
there O
are O
concerns O
regarding O
exposure O
during O
early O
postnatal O
development O
. O

From O
the O
3 O
( O
rd O
) O
to O
the O
9 O
( O
th O
) O
postnatal O
day O
( O
PN O
) O
, O
Swiss O
mice O
were O
subcutaneously O
injected O
with O
methamidophos B
( O
1 O
mg O
/ O
kg O
) O
. O

At O
PN10 O
, O
the O
effects O
were O
restricted O
to O
females O
and O
to O
the O
cholinergic O
system O
: O
Methamidophos B
promoted O
increased O
choline O
transporter O
binding O
in O
the O
brainstem O
. O

Methamidophos B
elicited O
behavioral O
alterations O
suggestive O
of O
increased O
depressive O
- O
like O
behavior O
and O
impaired O
decision O
- O
making O
. O

Methamidophos B
elicited O
cholinergic O
and O
serotonergic O
alterations O
that O
depended O
on O
brain O
region O
, O
sex O
and O
age O
of O
the O
animals O
. O

Catalysis O
of O
Cope O
- O
type O
rearrangements O
of O
bis B
- I
homoallylic I
hydroxylamines I
is O
demonstrated O
using O
chiral O
thiourea O
derivatives O
. O

This O
formal O
intramolecular O
hydroamination O
reaction O
provides O
access O
to O
highly O
enantioenriched O
alpha O
- O
substituted O
pyrrolidine B
products O
and O
represents O
a O
complementary O
approach O
to O
metal O
- O
catalyzed O
methods O
. O

We O
assessed O
nociception O
, O
endocannabinoids O
and O
the O
therapeutic O
efficacy O
of O
R B
- I
flurbiprofen I
in O
young O
and O
aged O
mice O
in O
the O
spared O
nerve O
injury O
model O
of O
neuropathic O
pain O
. O

R B
- I
flurbiprofen I
was O
used O
because O
it O
is O
able O
to O
reduce O
neuropathic O
pain O
in O
young O
mice O
in O
part O
by O
increasing O
anandamide O
. O

In O
aged O
mice O
, O
R B
- I
flurbiprofen I
had O
only O
weak O
antinociceptive O
efficacy O
and O
it O
failed O
to O
restore O
normal O
anandamide O
levels O
after O
nerve O
injury O
. O

This O
may O
overwhelm O
the O
capacity O
of O
R B
- I
flurbiprofen I
to O
restore O
anandamide O
homeostasis O
and O
may O
contribute O
to O
the O
heightened O
risk O
for O
neuropathic O
pain O
at O
old O
age O
. O

This O
study O
determined O
the O
effects O
of O
MDPV O
, O
alongside O
those O
of O
the O
better O
studied O
stimulant O
d B
- I
methamphetamine I
( O
METH O
) O
, O
using O
rodent O
models O
of O
intravenous O
self O
- O
administration O
( O
IVSA O
) O
, O
thermoregulation O
and O
locomotor O
activity O
. O

Extensive O
structure O
activity O
relationship O
studies O
ultimately O
led O
to O
identification O
of O
pyrazolodiazepinone B
, O
22 O
, O
which O
was O
> O
1000 O
- O
fold O
selective O
for O
PDE2 O
over O
recombinant O
, O
full O
length O
PDEs O
1B O
, O
3A O
, O
3B O
, O
4A O
, O
4B O
, O
4C O
, O
7A O
, O
7B O
, O
8A O
, O
8B O
, O
9 O
, O
10 O
and O
11 O
. O

Recently O
, O
the O
c O
- O
Abl O
kinase O
inhibitor O
imatinib B
mesylate I
( O
imatinib O
) O
has O
become O
the O
focus O
of O
research O
as O
a O
fertoprotective O
drug O
against O
cisplatin O
. O

Surprisingly O
, O
the O
conditional O
deletion O
of O
Trp63 B
, O
but O
not O
Delta O
Np63 O
, O
in O
oocytes O
inhibited O
apoptosis O
, O
as O
well O
as O
the O
accumulation O
of O
c O
- O
Abl O
and O
TAp73 O
caused O
by O
cisplatin O
. O

Reaction O
kinetics O
of O
CO2 O
absorption O
in O
to O
phosphonium B
based O
anion O
- O
functionalized O
ionic O
liquids O
. O

The O
reaction O
kinetics O
between O
CO2 O
and O
trihexyl B
( I
tetradecyl I
) I
phosphonium I
( O
[ B
P66614 I
] I
) O
- O
based O
ionic O
liquids O
( O
ILs O
) O
with O
prolinate B
( O
[ O
Pro O
] O
) O
, O
2 B
- I
cyanopyrrolide I
( O
[ B
2 I
- I
CNpyr I
] I
) O
, O
and O
3 B
- I
( I
trifluoromethyl I
) I
pyrazolide I
( O
[ B
3 I
- I
CF3pyra I
] I
) O
anions O
are O
studied O
at O
temperatures O
from O
22 O
- O
60 O
degrees O
C O
. O

ILs O
are O
diluted O
to O
concentrations O
of O
0 O
. O
05 O
, O
0 O
. O
1 O
and O
0 O
. O
15 O
M O
with O
tetraglyme B
- O
a O
nonreactive O
, O
low O
volatility O
solvent O
with O
much O
lower O
viscosity O
than O
the O
ILs O
. O

Physical O
solubility O
of O
CO2 O
in O
the O
mixtures O
is O
calculated O
using O
correlations O
developed O
from O
CO2 O
solubility O
measurements O
in O
tetraglyme B
and O
the O
N2O B
- O
analogy O
for O
ILs O
and O
dilute O
IL O
solutions O
. O

The O
results O
indicate O
partial O
first O
order O
reaction O
kinetics O
with O
respect O
to O
IL O
with O
values O
ranging O
from O
19 O
500 O
L O
mol O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
( O
[ B
P66614 I
] I
[ I
Pro I
] I
) O
to O
3200 O
L O
mol O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
( O
[ B
P66614 I
] I
[ I
3 I
- I
CF3pyra I
] I
) O
at O
22 O
degrees O
C O
. O

The O
second O
order O
reaction O
rate O
constants O
follow O
Arrhenius O
behavior O
with O
the O
highest O
activation O
energy O
of O
43 O
kJ O
mol O
( O
- O
1 O
) O
measured O
for O
[ B
P66614 I
] I
[ I
Pro I
] I
. O

ILs O
with O
aprotic O
heterocylic O
anions O
( O
AHA O
) O
, O
on O
the O
other O
hand O
, O
show O
small O
activation O
energies O
of O
18 O
and O
11 O
kJ O
mol O
( O
- O
1 O
) O
for O
[ B
P66614 I
] I
[ I
3 I
- I
CF3pyra I
] I
and O
[ B
P66614 I
] I
[ I
2 I
- I
CNpyr I
] I
, O
respectively O
. O

Flavone B
C I
- I
glycosides I
from O
the O
flowers O
of O
Trollius O
chinensis O
and O
their O
anti O
- O
complementary O
activity O
. O

Phytochemical O
investigation O
of O
ethanol O
extract O
from O
the O
flowers O
of O
Trollius O
chinensis O
Bunge O
resulted O
in O
the O
isolation O
of O
two O
new O
flavone B
C I
- I
glycosides I
( O
1 O
- O
2 O
) O
, O
along O
with O
10 O
known O
compounds O
( O
3 O
- O
12 O
) O
. O

The O
structures O
of O
the O
new O
compounds O
were O
established O
as O
6 B
' I
' I
' I
- I
( I
3 I
- I
hydroxy I
- I
3 I
- I
methylglutaroyl I
) I
- I
2 I
' I
' I
- I
O I
- I
beta I
- I
d I
- I
galactopyranosyl I
orientin I
( O
1 O
) O
and O
6 B
' I
' I
' I
- I
( I
3 I
- I
hydroxy I
- I
3 I
- I
methylglutaroyl I
) I
- I
2 I
' I
' I
- I
O I
- I
beta I
- I
d I
- I
galactopyranosyl I
vitexin I
( O
2 O
) O
on O
the O
basis O
of O
various O
spectroscopic O
analysis O
( O
including O
different O
1D O
and O
2D O
NMR O
spectroscopies O
, O
high O
- O
resolution O

Pyranoflavones B
: O
A O
Group O
of O
Small O
- O
Molecule O
Probes O
for O
Exploring O
the O
Active O
Site O
Cavities O
of O
Cytochrome O
P450 O
Enzymes O
1A1 O
, O
1A2 O
, O
and O
1B1 O
. O

A O
highly O
selective O
P450 O
1B1 O
inhibitor O
5 B
- I
hydroxy I
- I
4 I
' I
- I
propargyloxyflavone I
( O
5H4 B
' I
FPE I
) O
was O
discovered O
. O

alpha B
- I
Naphthoflavone I
- O
like O
and O
5 B
- I
hydroxyflavone I
derivatives O
preferentially O
inhibited O
P450 O
1A2 O
, O
while O
beta O
- O
naphthoflavone O
- O
like O
flavone O
derivatives O
showed O
selective O
inhibition O
of O
P450 O
1A1 O
. O

A O
survey O
to O
determine O
the O
trans B
fatty I
acid I
content O
of O
a O
range O
of O
processed O
foods O
was O
carried O
out O
in O
response O
to O
recent O
reformulation O
work O
by O
the O
food O
industry O
to O
lower O
the O
artificial O
trans B
fatty I
acid I
content O
of O
processed O
products O
. O

Concentrations O
of O
trans B
elaidic I
acid I
( O
t9 B
- I
C18 I
: I
1 I
) O
from O
hydrogenated O
oils O
in O
all O
samples O
were O
< O
0 O
. O
2g O
/ O
100g O
food O
. O

When O
compared O
to O
other O
meat O
products O
( O
beef O
, O
mutton O
and O
chicken O
) O
it O
is O
clear O
that O
pork O
is O
a O
good O
source O
of O
B B
vitamins I
, O
especially O
vitamin B
B3 I
. O

The O
cooked O
loin O
cut O
contained O
the O
least O
vitamin B
B1 I
( O
0 O
. O
22mg O
/ O
100g O
) O
, O
B2 O
( O
0 O
. O
02mg O
/ O
100g O
) O
but O
the O
most O
vitamin B
B3 I
( O
7 O
. O
09mg O
/ O
100g O
) O
, O
of O
the O
three O
cooked O
cuts O
. O

The O
100g O
cooked O
shoulder O
, O
loin O
and O
leg O
cuts O
provide O
on O
average O
40 O
. O
11 O
% O
protein O
, O
5 O
. O
19 O
% O
magnesium O
, O
3 O
. O
37 O
% O
calcium O
, O
24 O
. O
29 O
% O
phosphorus O
, O
18 O
. O
22 O
% O
zinc O
, O
22 O
. O
33 O
% O
iron O
and O
22 O
. O
50 O
% O
vitamin B
B1 I
, O
2 O
. O
57 O
% O
vitamin B
B2 I
and O
42 O
. O
6 O
% O
vitamin B
B3 I
of O
Recommended O
Daily O
Allowances O
for O
males O
, O
age O
25 O
- O
50 O
. O

The O
content O
of O
other O
nutrients O
, O
like O
vitamins B
E I
and I
A I
, O
are O
also O
depending O
on O
the O
type O
of O
feed O
. O

Some O
bioactive O
substances O
like O
coenzyme B
Q10 I
, O
taurine O
, O
glutamine O
, O
creatine O
, O
creatinine O
, O
carnosine O
and O
anserine B
show O
a O
large O
dependence O
on O
the O
type O
of O
muscle O
. O

We O
screened O
a O
small O
collection O
of O
compounds O
and O
identified O
an O
oxygenated B
flavonoid I
derivative O
that O
inhibits O
sumoylation O
in O
vitro O
. O

Synthesis O
and O
biological O
evaluation O
of O
phosphorylated B
flavonoids I
as O
potent O
and O
selective O
inhibitors O
of O
cholesterol O
esterase O
. O

A O
series O
of O
phosphorylated B
flavonoids I
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol O
esterase O
( O
CEase O
) O
and O
acetylcholinesterase O
( O
AChE O
) O
. O

Furthermore O
, O
these O
phosphorylated B
flavonoids I
demonstrated O
good O
to O
high O
selectivity O
for O
CEase O
over O
AChE O
, O
which O
only O
showed O
micromolar O
potency O
inhibition O
of O
AChE O
. O

The O
structure O
- O
activity O
relationships O
revealed O
that O
the O
free O
hydroxyl O
group O
at O
position O
5 O
and O
phosphate O
group O
at O
position O
7 O
of O
the O
phosphorylated B
flavonoids I
are O
favorable O
to O
the O
inhibition O
of O
CEase O
. O

Like O
Artemis O
, O
Metnase O
efficiently O
trimmed O
overhangs O
terminated O
in O
3 B
' I
- I
phosphoglycolates I
( O
PGs O
) O
, O
and O
in O
some O
cases O
the O
presence O
of O
3 B
' I
- I
PG I
stimulated O
cleavage O
and O
altered O
its O
specificity O
. O

The O
nonplanar O
base O
thymine B
glycol I
in O
a O
3 O
' O
overhang O
severely O
inhibited O
cleavage O
by O
Metnase O
in O
the O
vicinity O
of O
the O
modified O
base O
, O
while O
Artemis O
was O
less O
affected O
. O

Nevertheless O
, O
thymine B
glycol I
moieties O
could O
be O
removed O
by O
Metnase O
- O
or O
Artemis O
- O
mediated O
cleavage O
at O
sites O
farther O
from O
the O
terminus O
than O
the O
lesion O
itself O
. O

In O
in O
vitro O
end O
- O
joining O
systems O
based O
on O
human O
cell O
extracts O
, O
addition O
of O
Artemis O
, O
but O
not O
Metnase O
, O
effected O
robust O
trimming O
of O
an O
unligatable O
3 B
' I
- I
PG I
overhang O
, O
resulting O
in O
a O
dramatic O
stimulation O
of O
ligase O
IV O
- O
and O
XLF O
- O
dependent O
end O
joining O
. O

Conjugates O
bearing O
the O
anticancer O
agents O
aminohexylgeldanamyc B
( O
AHGDM B
) O
, O
docetaxel O
( O
DOC B
) O
, O
or O
cisplatin O
and O
the O
GRP78 O
targeting O
peptide O
WDLAWMFRLPVG O
were O
synthesized O
and O
characterized O
. O

HSP O
targeted O
AHGDM B
and O
DOC B
conjugates O
demonstrated O
active O
binding O
comparable O
to O
native O
targeting O
peptide O
. O

HSP O
targeted O
DOC B
conjugates O
exhibited O
high O
potency O
against O
DU145 O
cells O
with O
an O
IC50 O
of O
2 O
. O
4nM O
. O

HSP O
targeted O
AHGDM B
and O
DOC B
conjugates O
demonstrated O
synergistic O
effects O
in O
combination O
with O
hyperthermia O
with O
combination O
index O
values O
of O
0 O
. O
65 O
and O
0 O
. O
45 O
respectively O
. O

Based O
on O
these O
results O
, O
HSP O
targeted O
DOC B
conjugates O
were O
selected O
for O
in O
vivo O
evaluation O
. O

Especially O
the O
regulation O
of O
the O
HPA O
axis O
seems O
to O
be O
affected O
in O
aged O
mice O
with O
a O
shift O
to O
the O
use O
of O
vasopressin B
. O

In O
the O
current O
research O
ricinoleic B
acid I
coated O
maghemite O
nanoparticles O
were O
successfully O
synthesized O
, O
characterized O
and O
incorporated O
in O
the O
polymeric O
matrix O
, O
resulting O
in O
nanosized O
magnetic O
polymeric O
particles O
. O

In O
order O
to O
develop O
new O
iodinated O
and O
fluorinated O
matched O
- O
pair O
radiotracers O
for O
Single O
- O
Photon O
Emission O
Computed O
Tomography O
( O
SPECT O
) O
/ O
Positron O
Emission O
Tomography O
( O
PET O
) O
imaging O
and O
targeted O
radionuclide O
therapy O
of O
melanoma O
, O
we O
successfully O
synthesized O
and O
radiolabelled O
with O
iodine B
- I
125 I
seven O
new O
derivatives O
, O
starting O
from O
our O
previously O
described O
lead O
structure O
3 O
. O

These O
results O
make O
compounds O
39 O
- O
42 O
suitable O
candidates O
for O
( O
i O
) O
PET O
imaging O
of O
melanoma O
after O
labelling O
with O
fluorine B
- I
18 I
and O
( O
ii O
) O
targeted O
radionuclide O
therapy O
of O
disseminated O
melanoma O
after O
labelling O
with O
iodine B
- I
131 I
. O

Triazolothiadiazoles B
and O
triazolothiadiazines B
- O
Biologically O
attractive O
scaffolds O
. O

Therefore O
, O
in O
the O
present O
perspective O
, O
the O
triazolothiadiazoles B
and O
triazolothiadiazines B
with O
broad O
spectrum O
biological O
profile O
have O
matured O
into O
indispensable O
heterocyclic O
scaffolds O
. O

The O
systemic O
effects O
of O
the O
Fusarium O
toxin O
deoxynivalenol O
( O
DON O
) O
and O
of O
bacterial O
lipopolysaccharides O
( O
LPS O
) O
were O
studied O
in O
male O
castrated O
pigs O
( O
40 O
. O
4 O
+ O
/ O
- O
3 O
. O
7kg O
) O
infused O
intravenously O
with O
either O
DON O
or O
LPS O
alone O
( O
100 O
mu O
gDON B
/ O
kg O
/ O
h O
, O
7 O
. O
5 O
mu O
g O
/ O
LPS O
/ O
kg O
/ O
h O
) O
, O
or O
together O
( O
100 O
mu O
gDON B
plus O
7 O
. O
5 O
mu O
g O
/ O
LPS O
/ O
kg O
/ O
h O
) O
. O

Furthermore O
, O
gold B
- I
thioglucose I
- O
induced O
hypothalamic O
lesions O
, O
including O
the O
VMH O
and O
the O
arcuate O
nucleus O
, O
abolished O
the O
anorexigenic O
effects O
of O
ECS O
, O
indicating O
the O
requirement O
for O
the O
activation O
of O
the O
hypothalamus O
. O

Murine O
N2A O
and O
human O
SK O
- O
N O
- O
AS O
neuroblastoma O
cells O
and O
murine O
preadipocyte O
fibroblasts O
( O
3T3 O
- O
L1 O
) O
were O
exposed O
to O
tributyltin O
( O
TBT B
) O
, O
diethylstilbestrol O
( O
DES O
) O
, O
bisphenol O
A O
( O
BPA O
) O
, O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo O
- O
[ O
p O
] O
- O
dioxin O
( O
TCDD O
) O
, O
2 O
, O
2 O
' O
, O
4 O
, O
4 O
' O
, O
5 O
, O
5 O
' O
- O

hexachlorobiphenyl O
( O
PCB B
- I
153 I
) O
, O
hexachlorobenzene B
( O
HCB B
) O
, O
hexabromocyclododeca O
( O
HBCD B
) O
, O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabrominated I
diphenyl I
ether I
( O
BDE O
- O
47 O
) O
, O
perfluorinated B
octyl I
acid I
( O
PFOA O
) O
and O
perfluorinated B
octyl I
sulfonate I
( O
PFOS O
) O
. O

A O
modest O
decrease O
in O
global O
DNA O
methylation O
was O
observed O
in O
N2A O
cells O
exposed O
to O
10 O
mu O
M O
DES O
, O
BPA O
, O
TCDD O
, O
BDE O
- O
47 O
, O
PCB B
- I
153 I
and O
1 O
mu O
M O
HCB B
, O
but O
no O
changes O
were O
found O
in O
the O
human O
SK O
- O
N O
- O
AS O
cells O
. O

Adipocyte O
differentiation O
was O
also O
enhanced O
by O
TBT B
( O
< O
= O
10nM O
) O
and O
BPA O
( O
> O
10 O
mu O
M O
) O
and O
inhibited O
by O
TCDD O
( O
< O
= O
0 O
. O
1nM O
) O
. O

The O
other O
chemicals O
showed O
either O
modest O
or O
no O
effects O
on O
adipocyte O
differentiation O
at O
the O
concentrations O
tested O
( O
PFOA O
, O
PFOS O
and O
HBCD B
at O
10 O
mu O
M O
; O
PCB B
- I
153 I
, O
3 O
. O
4 O
mu O
M O
and O
HCB B
, O
1 O
mu O
M O
) O
. O

Inhibitory O
action O
of O
salicylideneamino B
- I
2 I
- I
thiophenol I
on O
NF O
- O
kappa O
B O
signaling O
cascade O
and O
cyclooxygenase O
- O
2 O
in O
HNE B
- O
treated O
endothelial O
cells O
. O

In O
the O
present O
study O
, O
the O
anti O
- O
inflammatory O
effect O
of O
salicylideneamino B
- I
2 I
- I
thiophenol I
( O
SAL B
- I
2 I
) O
, O
a O
derivative O
of O
salicylate O
, O
on O
a O
potent O
oxidant O
4 O
- O
hydroxynonenal O
( O
HNE B
) O
- O
induced O
oxidative O
stress O
was O
investigated O
using O
rat O
prostate O
endothelial O
( O
YPEN O
- O
1 O
) O
cells O
. O

We O
focused O
on O
anti O
- O
inflammatory O
activity O
of O
SAL B
- I
2 I
which O
was O
determined O
by O
its O
ability O
to O
suppress O
COX O
- O
2 O
and O
iNOS O
gene O
expression O
through O
suppression O
of O
NF O
- O
kappa O
B O
and O
redox O
regulation O
. O

We O
found O
that O
SAL B
- I
2 I
effectively O
inhibited O
HNE B
- O
induced O
reactive O
species O
generation O
, O
while O
upregulated O
GSH O
/ O
GSSG O
ratio O
. O

Prostagrandin O
( B
PG I
) I
E2 I
production O
stimulated O
by O
arachidonic O
acid O
was O
suppressed O
by O
SAL B
- I
2 I
. O

SAL B
- I
2 I
also O
downregulated O
COX O
- O
2 O
and O
iNOS O
expression O
induced O
by O
HNE B
, O
but O
salicylate O
did O
not O
. O

We O
found O
that O
SAL B
- I
2 I
inhibited O
HNE B
- O
mediated O
IKK O
phosphorylation O
, O
I O
kappa O
B O
alpha O
degradation O
and O
nuclear O
translocation O
of O
p65 O
which O
are O
linked O
to O
NF O
- O
kappa O
B O
activation O
. O

Furthermore O
, O
SAL B
- I
2 I
inhibited O
HNE B
- O
induced O
activation O
of O
mitogen O
- O
activated O
protein O
kinases O
. O

Collectively O
, O
SAL B
- I
2 I
inhibited O
COX O
- O
2 O
and O
iNOS O
gene O
expression O
through O
suppression O
of O
NF O
- O
kappa O
B O
leading O
to O
the O
inhibition O
of O
PGE2 O
synthesis O
. O

Based O
on O
these O
data O
, O
we O
propose O
that O
with O
its O
combined O
effect O
on O
strong O
anti O
- O
oxidant O
and O
anti O
- O
inflammatory O
action O
, O
SAL B
- I
2 I
can O
be O
a O
potent O
anti O
- O
inflammatory O
agent O
for O
treatment O
of O
inflammatory O
- O
related O
diseases O
. O

As O
part O
of O
our O
ongoing O
search O
for O
natural O
sources O
of O
therapeutic O
and O
preventive O
agents O
for O
diabetic O
complications O
, O
we O
evaluated O
the O
inhibitory O
effects O
of O
components O
of O
the O
fruit O
of O
Xanthium O
strumarium O
( O
X O
. O
strumarium O
) O
on O
aldose O
reductase O
( O
AR O
) O
and O
galactitol B
formation O
in O
rat O
lenses O
with O
high O
levels O
of O
glucose O
. O

To O
identify O
the O
bioactive O
components O
of O
X O
. O
strumarium O
, O
7 O
caffeoylquinic B
acids I
and O
3 O
phenolic O
compounds O
were O
isolated O
and O
their O
chemical O
structures O
were O
elucidated O
on O
the O
basis O
of O
spectroscopic O
evidence O
and O
comparison O
with O
published O
data O
. O

From O
the O
10 O
isolated O
compounds O
, O
methyl B
- I
3 I
, I
5 I
- I
di I
- I
O I
- I
caffeoylquinate I
showed O
the O
most O
potent O
inhibition O
, O
with O
IC50 O
values O
of O
0 O
. O
30 O
and O
0 O
. O
67 O
mu O
M O
for O
rAR O
and O
rhAR O
, O
respectively O
. O

In O
the O
kinetic O
analyses O
using O
Lineweaver O
- O
Burk O
plots O
of O
1 O
/ O
velocity O
and O
1 O
/ O
substrate O
, O
methyl B
- I
3 I
, I
5 I
- I
di I
- I
O I
- I
caffeoylquinate I
showed O
competitive O
inhibition O
of O
rhAR O
. O

Furthermore O
, O
methyl B
- I
3 I
, I
5 I
- I
di I
- I
O I
- I
caffeoylquinate I
inhibited O
galactitol B
formation O
in O
the O
rat O
lens O
and O
in O
erythrocytes O
incubated O
with O
a O
high O
concentration O
of O
glucose O
, O
indicating O
that O
this O
compound O
may O
be O
effective O
in O
preventing O
diabetic O
complications O
. O

Fructose B
- I
1 I
, I
6 I
- I
bisphosphate I
ameliorates O
lipopolysaccharide O
- O
induced O
dysfunction O
of O
blood O
- O
brain O
barrier O
. O

Fructose B
- I
1 I
, I
6 I
- I
bisphosphate I
( O
FBP B
) O
, O
a O
glycolytic O
intermediate O
, O
has O
neuroprotective O
effects O
in O
various O
brain O
injury O
models O
. O

In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
FBP B
on O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
BBB O
dysfunction O
in O
in O
vitro O
BBB O
model O
comprising O
co O
- O
culture O
of O
mouse O
brain O
endothelial O
cell O
line O
, O
bEnd O
. O
3 O
and O
mouse O
primary O
astrocyte O
and O
explored O
its O
action O
mechanism O
therein O
involved O
. O

Co O
- O
administration O
of O
FBP B
alleviated O
the O
deleterious O
effects O
of O
LPS O
on O
BBB O
permeability O
and O
TEER O
in O
a O
dose O
dependent O
manner O
. O

And O
also O
FBP B
inhibited O
the O
LPS O
- O
induced O
changes O
in O
the O
distribution O
of O
endothelial O
junctional O
proteins O
, O
resulting O
in O
the O
better O
preservation O
of O
monolayer O
integrity O
. O

FBP B
suppressed O
the O
production O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
but O
did O
not O
affect O
cyclooxygenase O
- O
2 O
expression O
and O
prostaglandin O
E2 O
production O
in O
endothelial O
cells O
stimulated O
with O
LPS O
. O

Taken O
together O
, O
these O
data O
suggest O
that O
FBP B
could O
ameliorate O
LPS O
- O
induced O
BBB O
dysfunction O
through O
the O
maintenance O
of O
junctional O
integrity O
, O
which O
might O
be O
mediated O
by O
downregulation O
of O
ROS O
production O
. O

Ospemifene B
: O
first O
global O
approval O
. O

Ospemifene B
( O
Osphena B
( O
TM O
) O
) O
is O
an O
oral O
selective O
estrogen O
receptor O
modulator O
( O
SERM O
) O
, O
with O
tissue O
- O
specific O
estrogenic O
agonist O
/ O
antagonist O
effects O
. O

Ospemifene B
is O
the O
first O
non O
- O
estrogen O
treatment O
approved O
for O
moderate O
to O
severe O
dyspareunia O
in O
women O
with O
menopause O
- O
related O
vulvar O
and O
vaginal O
atrophy O
. O

This O
article O
summarizes O
the O
milestones O
in O
the O
development O
of O
ospemifene B
leading O
to O
this O
first O
approval O
for O
moderate O
to O
severe O
dyspareunia O
, O
a O
symptom O
of O
postmenopausal O
vulvar O
and O
vaginal O
atrophy O
. O

Pasireotide B
: O
A O
Review O
of O
Its O
Use O
in O
Cushing O
' O
s O
Disease O
. O

Pasireotide B
( O
Signifor B
( O
( O
R O
) O
) O
) O
is O
a O
new O
subcutaneous O
somatostatin O
analogue O
that O
acts O
via O
somatostatin O
receptors O
to O
inhibit O
the O
secretion O
of O
corticotropin O
from O
the O
pituitary O
adenoma O
in O
patients O
with O
Cushing O
' O
s O
disease O
. O

Pasireotide B
has O
a O
receptor O
binding O
profile O
that O
is O
distinct O
from O
that O
of O
other O
somatostatin O
analogues O
, O
binding O
with O
high O
affinity O
to O
somatostatin O
receptor O
subtype O
5 O
, O
which O
is O
strongly O
over O
expressed O
in O
corticotroph O
adenoma O
cells O
. O

Pasireotide B
is O
the O
first O
pituitary O
- O
directed O
agent O
to O
be O
approved O
for O
use O
in O
Cushing O
' O
s O
disease O
. O

In O
a O
phase O
III O
clinical O
trial O
in O
patients O
with O
Cushing O
' O
s O
disease O
, O
twice O
- O
daily O
pasireotide B
600 O
or O
900 O
mu O
g O
for O
6 O
months O
led O
to O
normalization O
of O
urinary O
free O
cortisol O
( O
UFC O
) O
levels O
in O
up O
to O
a O
quarter O
of O
all O
patients O
( O
primary O
endpoint O
) O
and O
significantly O
reduced O
mean O
UFC O
levels O
. O

Most O
patients O
who O
do O
not O
have O
an O
early O
response O
to O
pasireotide B
do O
not O
respond O
at O
a O
later O
time O
point O
. O

Decreases O
in O
UFC O
levels O
achieved O
during O
pasireotide B
treatment O
are O
accompanied O
by O
decreases O
in O
serum O
and O
salivary O
cortisol O
levels O
, O
as O
well O
as O
improvements O
in O
clinical O
signs O
and O
symptoms O
, O
including O
body O
weight O
, O
blood O
pressure O
and O
health O
- O
related O
quality O
- O
of O
- O
life O
. O

Pasireotide B
has O
a O
generally O
similar O
tolerability O
profile O
to O
that O
of O
other O
somatostatin O
analogues O
, O
but O
is O
associated O
with O
a O
relatively O
high O
incidence O
of O
hyperglycaemia O
, O
requiring O
the O
addition O
or O
intensification O
of O
glucose O
- O
lowering O
medication O
in O
a O
substantial O
proportion O
of O
patients O
. O

Thus O
, O
pasireotide B
, O
together O
with O
on O
- O
going O
patient O
monitoring O
, O
provides O
a O
promising O
new O
option O
for O
the O
medical O
management O
of O
Cushing O
' O
s O
disease O
. O

Bicyclic O
Derivatives O
of O
L B
- I
Idonojirimycin I
as O
Pharmacological O
Chaperones O
for O
Neuronopathic O
Forms O
of O
Gaucher O
Disease O
. O

New O
human O
beta O
- O
glucocerebrosidase O
( O
GCase O
) O
ligands O
with O
rigid O
1 B
, I
6 I
- I
anhydro I
- I
beta I
- I
L I
- I
idonojirimycin I
cores O
have O
been O
designed O
with O
the O
aid O
of O
molecular O
modeling O
. O

Proteomic O
identification O
of O
the O
candidate O
target O
proteins O
of O
15 B
- I
deoxy I
- I
delta I
( I
12 I
, I
14 I
) I
- I
prostaglandin I
J2 I
. O

15 B
- I
deoxy I
- I
delta12 I
, I
14 I
- I
prostaglandin I
J2 I
( O
15d B
- I
PGJ2 I
) O
is O
an O
endogenous O
anti O
- O
inflammatory O
lipid O
derived O
from O
PGD2 B
. O

One O
potential O
mechanism O
for O
its O
activity O
is O
the O
covalent O
modification O
of O
cellular O
proteins O
, O
via O
a O
reactive O
alpha O
, O
beta O
- O
unsaturated O
carbonyl O
group O
in O
its O
cyclopentenone B
ring O
, O
which O
in O
turn O
alters O
protein O
function O
. O

In O
order O
to O
identify O
the O
candidate O
target O
proteins O
covalently O
modified O
by O
15d B
- I
PGJ2 I
in O
human O
aortic O
endothelial O
cell O
( O
EC O
) O
, O
EC O
were O
treated O
with O
biotinylated B
- I
15d I
- I
PGJ2 I
, O
the O
modified O
proteins O
extracted O
by O
Neutravidin O
affinity O
- O
purification O
and O
the O
proteins O
identified O
by O
LTQ O
Orbitrap O
mass O
spectrometer O
. O

This O
protein O
data O
set O
highlights O
the O
potential O
for O
15d B
- I
PGJ2 I
to O
covalently O
modify O
cellular O
proteins O
and O
provides O
a O
source O
of O
data O
that O
will O
aid O
further O
studies O
on O
the O
mechanism O
of O
action O
of O
this O
endogenous O
regulator O
of O
inflammation O
. O

Emergent O
Renal O
Dysfunction O
with O
Colistin B
Pharmacotherapy O
. O

STUDY O
OBJECTIVE O
: O
To O
evaluate O
the O
association O
between O
the O
administration O
of O
intravenous O
( O
IV O
) O
colistin B
and O
the O
emergence O
of O
renal O
dysfunction O
. O

PATIENTS O
: O
A O
total O
of O
174 O
critically O
ill O
patients O
who O
received O
at O
least O
one O
dose O
of O
IV O
colistin B
between O
2004 O
and O
2007 O
. O

MEASUREMENTS O
AND O
MAIN O
RESULTS O
: O
The O
primary O
outcome O
was O
development O
of O
renal O
dysfunction O
, O
defined O
as O
an O
increase O
in O
serum O
creatinine O
of O
50 O
% O
or O
more O
during O
therapy O
or O
the O
initiation O
of O
renal O
replacement O
therapy O
( O
RRT O
) O
, O
in O
patients O
who O
received O
at O
least O
one O
dose O
of O
colistin B
and O
were O
not O
already O
on O
RRT O
. O

Of O
these O
patients O
, O
84 O
( O
48 O
% O
) O
experienced O
renal O
dysfunction O
on O
colistin B
. O

Here O
, O
a O
new O
and O
simple O
method O
based O
on O
controlled O
polymerization O
of O
2 B
- I
methacryloyloxyethyl I
phosphorylcholine I
( O
MPC B
) O
on O
the O
surface O
of O
styrene B
- I
block I
- I
( I
ethylene I
- I
co I
- I
butylene I
) I
- I
block I
- I
styrene I
( O
SEBS B
) O
is O
shown O
. O

The O
competition O
between O
polymerization O
and O
degradation O
enables O
platelet O
adhesion O
on O
SEBS B
to O
be O
switched O
on O
and O
off O
. O

Cell O
Surface O
Receptor O
Targeted O
Biomimetic O
Apatite B
Nanocrystals O
for O
Cancer O
Therapy O
. O

Because O
of O
its O
biocompatibility O
, O
high O
bioresorbability O
, O
and O
responsiveness O
to O
pH O
changes O
, O
synthetic O
biomimetic O
nanocrystalline O
apatites O
are O
used O
as O
nanocarriers O
to O
produce O
multifunctional O
nanoparticles O
, O
by O
coupling O
them O
with O
the O
chemotherapeutic O
drug O
doxorubicin O
( O
DOXO B
) O
and O
the O
DO O
- O
24 O
monoclonal O
antibody O
( O
mAb O
) O
directed O
against O
the O
Met O
/ O
Hepatocyte O
Growth O
Factor O
receptor O
( O
Met O
/ O
HGFR O
) O
, O
which O
is O
over O
- O

Moreover O
they O
discharge O
DOXO B
in O
the O
targeted O
GTL O
- O
16 O
cells O
that O
reach O
the O
nucleus O
and O
display O
cytotoxicity O
as O
assessed O
in O
an O
MTT O
assay O
. O

Two O
different O
types O
of O
ternary O
nanoparticles O
are O
prepared O
, O
differing O
for O
the O
sequence O
of O
the O
functionalization O
steps O
( O
adsorption O
of O
DOXO B
first O
and O
then O
mAb O
or O
vice O
versa O
) O
, O
and O
it O
is O
found O
that O
the O
ones O
in O
which O
mAb O
is O
adsorbed O
first O
are O
more O
efficient O
under O
all O
the O
examined O
aspects O
( O
binding O
, O
internalization O
, O
cytotoxicity O
) O
, O
possibly O
because O
of O
a O
better O
mAb O
orientation O
on O
the O
nanoparticle O
surface O
. O

Such O
ordered O
porous O
electrodes O
demonstrate O
superior O
Li O
storage O
properties O
; O
for O
example O
, O
graphene O
- O
Fe3 B
O4 I
@ O
C O
depicts O
high O
capacities O
of O
1123 O
. O
8 O
and O
505 O
mAh O
g O
( O
- O
1 O
) O
at O
current O
densities O
of O
0 O
. O
5 O
and O
10 O
A O
g O
( O
- O
1 O
) O
, O
respectively O
. O

A O
poly B
[ I
2 I
- I
( I
diethylamino I
) I
ethyl I
methacrylate I
] I
brush O
was O
grown O
on O
a O
large O
silicon O
crystal O
which O
acted O
as O
both O
a O
substrate O
for O
a O
neutron O
reflectivity O
solid O
/ O
liquid O
experiment O
but O
also O
as O
an O
FTIR O
- O
ATR O
spectroscopy O
crystal O
. O

Total O
Synthesis O
of O
the O
Marine O
Cyclic O
Depsipeptide O
Viequeamide B
A I
. O

The O
first O
total O
synthesis O
of O
viequeamide B
A I
, O
a O
natural O
cyclic O
depsipeptide O
isolated O
from O
a O
marine O
button O
cyanobacterium O
, O
was O
achieved O
with O
the O
N B
- I
Me I
- I
Val I
- I
Thr I
peptide O
bond O
as O
the O
final O
macrocyclization O
site O
. O

3 B
- I
Hydroxy I
- I
3 I
- I
methylglutaryl I
coenzyme I
A I
reductase O
inhibitors O
( O
statins O
) O
exert O
pleiotropic O
effects O
on O
the O
cardiovascular O
system O
, O
in O
part O
through O
a O
decrease O
in O
reactive O
oxygen O
species O
( O
ROS O
) O
formation O
and O
reduction O
of O
vascular O
inflammation O
. O

MATERIALS O
AND O
METHODS O
: O
Acetone O
extract O
and O
its O
sub O
- O
fractions O
of O
Acacia O
ferruginea O
stem O
bark O
were O
subjected O
to O
assess O
their O
antioxidant O
potential O
using O
various O
in O
vitro O
systems O
such O
as O
DPPH O
( O
* O
) O
, O
ABTS O
( O
* O
+ O
) O
scavenging O
, O
FRAP O
and O
phosphomolybdenum B
reduction O
activities O
. O

The O
phytochemical O
investigations O
showed O
the O
presence O
of O
cyclopeptid B
alkaloids I
, O
flavonoids O
( O
e O
. O
g O
. O
, O
( O
- O
) O
- O
epicatechin O
, O
quercetin O
, O
kaempferol O
, O
kaempferol B
- I
3 I
- I
O I
- I
beta I
- I
d I
- I
( I
6 I
' I
' I
- I
E I
- I
p I
- I
coumaryl I
) I
- I
glucopyranoside I
) I
, O
tannins O
, O
sterols O
, O
terpenes O
, O
saponins O
, O
anthraquinones O
. O

beta B
- I
estradiol I
17 I
- I
valerate I
affects O
embryonic O
development O
and O
sexual O
differentiation O
in O
Japanese O
medaka O
( O
Oryzias O
latipes O
) O
. O

beta B
- I
estradiol I
17 I
- I
valerate I
( O
EV O
) O
is O
a O
synthetic O
estrogen O
widely O
used O
in O
combination O
with O
other O
steroid B
hormones I
in O
hormone O
replacement O
therapy O
drugs O
and O
is O
detected O
in O
natural O
waters O
. O

In O
this O
study O
, O
a O
novel O
series O
of O
cycloartane B
triterpenoids I
isolated O
from O
Schisandra O
glaucescens O
Diels O
was O
found O
to O
have O
ER O
antagonistic O
effect O
, O
the O
most O
potent O
antagonist O
of O
which O
exhibited O
activity O
with O
EC50 O
value O
of O
2 O
. O
55 O
and O
4 O
. O
68 O
mu O
M O
for O
ER O
alpha O
and O
ER O
beta O
, O
respectively O
. O

Resumption O
of O
menstruation O
and O
pituitary O
response O
to O
gonadotropin B
- I
releasing I
hormone I
in O
functional O
hypothalamic O
amenorrhea O
undertaking O
estrogen O
replacement O
therapy O
. O

Aim O
: O
To O
explore O
factors O
affecting O
the O
menstrual O
resumption O
and O
to O
evaluate O
the O
pituitary O
response O
to O
gonadotropin B
- I
releasing I
hormone I
( O
GnRH B
) O
in O
FHA O
. O

All O
subjects O
were O
put O
on O
continuous O
1mg O
/ O
day O
estradiol B
valerate I
orally O
and O
followed O
up O
monthly O
. O

Gonadotropin O
response O
to O
the O
50 O
microgram O
GnRH B
challenge O
was O
tested O
every O
three O
months O
. O

Significant O
increase O
of O
serum O
luteinizing O
hormone O
( O
LH O
) O
and O
LH O
response O
to O
GnRH B
were O
noted O
after O
recovery O
. O

Low O
serum O
LH O
and O
attenuated O
LH O
response O
to O
GnRH B
were O
the O
main O
features O
of O
pituitary O
deficiency O
in O
FHA O
. O

The O
menstrual O
resumption O
in O
FHA O
was O
accompanied O
by O
the O
recovery O
of O
serum O
LH O
and O
the O
LH O
response O
to O
GnRH B
. O

A O
well O
- O
defined O
amphiphilic O
polypeptide O
, O
poly B
( I
glutamic I
acid I
) I
22 I
- I
block I
- I
poly I
( I
alanine I
) I
8 I
( O
PGlu22 B
- I
b I
- I
PAla8 I
) O
, O
which O
plays O
the O
roles O
of O
both O
soluble O
( O
functional O
) O
additive O
and O
insoluble O
( O
structural O
) O
matrix O
, O
is O
employed O
to O
mediate O
the O
mineralization O
of O
CaCO3 B
at O
the O
air O
/ O
water O
interface O
. O

X O
- O
ray O
diffraction O
( O
XRD O
) O
and O
Raman O
spectroscopy O
, O
for O
example O
, O
show O
that O
the O
polymorph O
of O
CaCO3 B
particles O
obtained O
is O
calcite B
. O

The O
observations O
from O
SEM O
and O
TEM O
suggest O
that O
PGlu22 B
- I
b I
- I
PAla8 I
initiates O
the O
amorphous O
precursor O
phase O
and O
heterogeneous O
nucleation O
of O
CaCO3 B
at O
the O
air O
/ O
water O
interface O
, O
while O
temporarily O
stabilizes O
the O
gelatinous O
precursors O
as O
a O
process O
- O
directing O
agent O
; O
nevertheless O
, O
the O
initial O
concentration O
of O
Ca O
( O
2 O
+ O
) O
controls O
the O
procedure O
of O
crystallization O
and O
the O
final O
morphology O
of O
CaCO3 B
particles O
. O

Synthesis O
of O
Atactic O
and O
Isotactic O
Poly B
( I
1 I
, I
2 I
- I
glycerol I
carbonate I
) I
s I
: O
Degradable O
Polymers O
for O
Biomedical O
and O
Pharmaceutical O
Applications O
. O

The O
synthesis O
and O
characterization O
of O
atactic O
and O
isotactic O
linear O
poly B
( I
benzyl I
1 I
, I
2 I
- I
glycerol I
carbonate I
) I
s I
are O
reported O
. O

The O
poly B
( I
benzyl I
1 I
, I
2 I
- I
glycerol I
carbonate I
) I
s I
were O
obtained O
via O
the O
ring O
- O
opening O
copolymerization O
of O
rac B
- I
/ I
( I
R I
) I
- I
benzyl I
glycidyl I
ether I
with O
CO2 O
using O
[ B
SalcyCo I
( I
III I
) I
X I
] I
complexes O
with O
high O
carbonate O
linkage O
selectivity O
and O
polymer O
/ O
cyclic O
carbonate O
selectivity O
( O
> O
99 O
% O
) O
. O

Deprotection O
of O
the O
resultant O
polymers O
afforded O
poly B
( I
1 I
, I
2 I
- I
glycerol I
carbonate I
) I
s I
with O
a O
functionalizable O
pendant O
primary O
hydroxyl O
group O
. O

Poly B
( I
1 I
, I
2 I
- I
glycerol I
carbonate I
) I
showed O
a O
remarkable O
increase O
in O
degradation O
rate O
compared O
to O
poly B
( I
1 I
, I
3 I
- I
glycerol I
carbonate I
) I
with O
a O
t1 O
/ O
2 O
= O
~ O
2 O
- O
3 O
days O
. O

Physicochemical O
characterization O
of O
nimodipine B
- O
polyethylene O
glycol O
solid O
dispersion O
systems O
. O

Abstract O
This O
study O
investigates O
the O
solid O
- O
solid O
interactions O
between O
nimodipine B
( O
NIM B
) O
and O
polyethylene O
glycol O
( O
PEG O
) O
of O
different O
mean O
molecular O
weights O
( O
PEG B
2000 I
, I
4000 I
and I
6000 I
) O
, O
in O
solid O
dispersion O
systems O
, O
applying O
differential O
scanning O
calorimetry O
( O
DSC O
) O
, O
Fourier O
- O
Transform O
infrared O
spectroscopy O
, O
powder O
X O
- O
ray O
diffraction O
( O
PXRD O
) O
, O
hot O
stage O
microscopy O
( O
HSM O
) O
and O
theoretical O
modeling O
by O
the O
Flory O
- O
Huggins O
( O
FH O
) O
solution O
theory O
. O

Studies O
on O
NIM B
' O
s O
re O
- O
crystallization O
process O
in O
the O
solid O
dispersions O
revealed O
a O
strong O
dependence O
of O
the O
crystallization O
rate O
, O
as O
well O
as O
the O
resulting O
crystal O
form O
, O
on O
the O
mean O
molecular O
weight O
and O
concentration O
of O
PEG O
: O
NIM B
crystallization O
rates O
decrease O
as O
PEG O
' O
s O
MW O
increases O
, O
while O
NIM B
mod O
II O
crystals O
predominate O
in O
dispersions O
prepared O
at O
temperatures O
above O
NIM B
' O
s O
liquidus O
and O
growth O
of O
NIM B
mod O
I O
prevailing O
in O
PEG O
- O
rich O
samples O
. O

Discovery O
of O
a O
New O
Class O
of O
Natural O
Product O
- O
Inspired O
Quinazolinone B
Hybrid O
as O
Potent O
Antileishmanial O
agents O
. O

The O
high O
potential O
of O
quinazolinone B
containing O
natural O
products O
and O
their O
derivatives O
in O
medicinal O
chemistry O
led O
us O
to O
discover O
four O
novel O
series O
of O
53 O
compounds O
of O
quinazolinone B
based O
on O
the O
concept O
of O
molecular O
hybridization O
. O

Most O
of O
the O
synthesized O
analogues O
exhibited O
potent O
leishmanicidal O
activity O
against O
intracellular O
amastigotes O
( O
IC50 O
from O
0 O
. O
65 O
+ O
/ O
- O
0 O
. O
2 O
to O
7 O
. O
76 O
+ O
/ O
- O
2 O
. O
1 O
mu O
M O
) O
as O
compared O
to O
miltefosine B
( O
IC50 O
= O
8 O
. O
4 O
+ O
/ O
- O
2 O
. O
1 O
mu O
M O
) O
and O
nontoxic O
toward O
the O
J O
- O
774A O
. O
1 O
cell O
line O
and O
Vero O
cells O
. O

New O
trifluoromethyl B
quinolone I
derivatives O
: O
Synthesis O
and O
investigation O
of O
antimicrobial O
properties O
. O

MATERIALS O
AND O
METHODS O
: O
The O
aqueous O
and O
80 O
% O
MeOH O
extracts O
, O
and O
a O
series O
of O
fractions O
and O
subfractions O
from O
the O
leaves O
, O
stem O
and O
root O
bark O
of O
Alstonia O
congensis O
were O
tested O
in O
vitro O
for O
their O
antiprotozoal O
activity O
against O
Trypanosoma O
brucei O
brucei O
, O
Trypanosoma O
cruzi O
, O
Lesihamania O
infantum O
and O
the O
chloroquine O
and O
pyrimethamine B
- O
resitant O
K1 O
strain O
of O
Plasmodium O
falciparum O
. O

The O
structural O
information O
of O
the O
first O
shell O
around O
a O
Co O
ion O
was O
expressed O
in O
terms O
of O
the O
hydration O
number O
, O
Co B
- I
O I
distance O
and O
Debye O
- O
Waller O
factor O
. O

The O
actual O
coordination O
number O
and O
the O
interatomic O
distance O
of O
Co B
- I
O I
for O
the O
dissolved O
species O
were O
remarkably O
reduced O
compared O
to O
the O
bulk O
aqueous O
solution O
indicating O
the O
dehydration O
of O
water O
molecules O
from O
Co O
ions O
and O
a O
compact O
hydrated O
structure O
in O
the O
micropore O
of O
SWNTs O
. O

Astrin B
, O
a O
protein O
associated O
with O
the O
mitotic O
spindle O
, O
was O
among O
the O
potential O
regulators O
of O
recovery O
. O

Cells O
in O
which O
astrin B
was O
depleted O
had O
decreased O
murine O
double O
minute O
2 O
( O
MDM2 O
) O
abundance O
and O
increased O
p53 O
at O
the O
later O
stages O
of O
the O
DNA O
damage O
response O
. O

Astrin B
was O
required O
for O
continued O
expression O
of O
genes O
encoding O
proteins O
that O
promote O
cell O
cycle O
progression O
in O
arrested O
cells O
. O

Cyclic B
GMP I
- O
elevating O
agents O
are O
beneficial O
in O
PAH O
, O
but O
their O
mechanism O
( O
s O
) O
of O
action O
are O
incompletely O
understood O
. O

One O
- O
Pot O
in O
Situ O
Mixed O
Film O
Formation O
by O
Azo O
Coupling O
and O
Diazonium B
Salt I
Electrografting O
. O

So O
simple O
: O
The O
in O
situ O
synthesis O
of O
an O
aryldiazonium B
salt I
and O
an O
azo B
- I
aryldiazonium I
salt I
by O
azo O
coupling O
from O
sulfanilic B
acid I
and O
aniline O
is O
reported O
. O

Biodegradable O
Polysilsesquioxane B
Nanoparticles O
as O
Efficient O
Contrast O
Agents O
for O
Magnetic O
Resonance O
Imaging O
. O

Polysilsesquioxane B
( O
PSQ B
) O
nanoparticles O
are O
crosslinked O
homopolymers O
formed O
by O
condensation O
of O
functionalized O
trialkoxysilanes B
, O
and O
provide O
an O
interesting O
platform O
for O
developing O
biologically O
and O
biomedically O
relevant O
nanomaterials O
. O

In O
this O
work O
, O
the O
design O
and O
synthesis O
of O
biodegradable O
PSQ B
particles O
with O
extremely O
high O
payloads O
of O
paramagnetic O
Gd O
( O
III O
) O
centers O
is O
explored O
, O
for O
use O
as O
efficient O
contrast O
agents O
for O
magnetic O
resonance O
imaging O
( O
MRI O
) O
. O

Two O
new O
bis B
( I
trialkoxysilyl I
) I
derivatives O
of O
Gd B
( I
III I
) I
diethylenetriamine I
pentaacetate I
( O
Gd B
- I
DTPA I
) O
containing O
disulfide O
linkages O
are O
synthesized O
and O
used O
to O
form O
biodegradable O
Gd B
- I
PSQ I
particles O
by O
base O
- O
catalyzed O
condensation O
reactions O
in O
reverse O
microemulsions O
. O

The O
Gd B
- I
PSQ I
particles O
, O
PSQ O
- O
1 O
and O
PSQ O
- O
2 O
, O
carry O
53 O
. O
8 O
wt O
% O
and O
49 O
. O
3 O
wt O
% O
of O
Gd B
- I
DTPA I
derivatives O
, O
respectively O
. O

The O
Gd B
- I
PSQ I
particles O
are O
readily O
degradable O
to O
release O
the O
constituent O
Gd O
( O
III O
) O
chelates O
in O
the O
presence O
of O
endogenous O
reducing O
agents O
such O
as O
cysteine O
and O
glutathione O
. O

The O
MR O
relaxivities O
of O
the O
Gd B
- I
PSQ I
particles O
are O
determined O
using O
a O
3T O
MR O
scanner O
, O
with O
r1 O
values O
ranging O
from O
5 O
. O
9 O
to O
17 O
. O
8 O
mMs O
( O
- O
1 O
) O
on O
a O
per O
- O
Gd O
basis O
. O

Finally O
, O
the O
high O
sensitivity O
of O
the O
Gd B
- I
PSQ I
particles O
as O
T1 O
- O
weighted O
MR O
contrast O
agents O
is O
demonstrated O
with O
in O
vitro O
MR O
imaging O
of O
human O
lung O
and O
pancreatic O
cancer O
cells O
. O

The O
enhanced O
efficiency O
of O
the O
anisamide B
- O
functionalized O
PSQ O
- O
2 O
particles O
as O
a O
contrast O
agent O
is O
corroborated O
by O
both O
confocal O
laser O
scanning O
microscopy O
imaging O
and O
ICP O
- O
MS O
analysis O
of O
Gd O
content O
in O
vitro O
. O

Diaion O
HP O
- O
2MG O
modified O
with O
2 B
- I
( I
2 I
, I
6 I
- I
dichlorobenzylidenea I
) I
benzenethiol I
as O
new O
adsorbent O
for O
solid O
phase O
extraction O
and O
flame O
atomic O
absorption O
spectrometric O
determination O
of O
metal O
ions O
. O

A O
new O
ent O
- O
kaurane O
diterpenoid B
glycoside I
from O
Isodon O
japonica O
var O
. O
glaucocalyx O
. O

A O
new O
ent O
- O
kaurane O
diterpenoid B
glycoside I
( O
1 O
) O
, O
named O
glaucocalyxin B
G I
, O
has O
been O
isolated O
from O
the O
n O
- O
butanol O
- O
soluble O
fraction O
of O
the O
dried O
whole O
plants O
of O
Isodon O
japonica O
var O
. O
glaucocalyx O
along O
with O
two O
known O
compounds O
, O
namely O
arjunglucoside B
( O
2 O
) O
and O
kaempferol B
- I
3 I
- I
O I
- I
rutinoside I
( O
3 O
) O
. O

The O
abundance O
of O
serotonin O
and O
5 O
- O
hydroxyindoleacetic O
acid O
in O
brain O
of O
Tg O
- O
2D6 O
is O
higher O
than O
in O
WT O
mice O
, O
either O
basal O
levels O
or O
after O
harmaline B
induction O
. O

Metabolomics O
of O
brain O
homogenate O
and O
cerebrospinal O
fluid O
revealed O
a O
significant O
up O
- O
regulation O
of O
L O
- O
carnitine O
, O
acetyl B
- I
L I
- I
carnitine I
, O
pantothenic B
acid I
, O
2 B
' I
- I
deoxycytidine I
diphosphate I
( O
dCDP B
) O
, O
anandamide O
, O
N B
- I
acetylglucosaminylam I
and O
a O
down O
- O
regulation O
of O
stearoyl B
- I
L I
- I
carnitine I
in O
Tg O
- O
2D6 O
mice O
compared O
with O
WT O
mice O
. O

Objective O
: O
A O
commonly O
available O
Electric O
Mosquito O
- O
Repellent O
Liquid O
pyrethroid O
insecticide O
containing O
prallethrin B
1 O
. O
6 O
% O
w O
/ O
w O
is O
widely O
used O
for O
mosquito O
control O
in O
Saudi O
Arabia O
. O

Methods O
and O
materials O
: O
Rats O
were O
exposed O
to O
prallethrin B
1 O
. O
6 O
% O
w O
/ O
w O
by O
inhalation O
for O
72 O
consecutive O
hours O
. O

Results O
: O
The O
administration O
of O
prallethrin B
1 O
. O
6 O
% O
w O
/ O
w O
created O
significant O
increased O
changes O
in O
the O
levels O
of O
total O
WBC O
, O
lymphocytes O
, O
RBC O
, O
hemoglobin O
, O
packed O
cell O
volume O
, O
platelets O
, O
mean O
corpuscular O
volume O
, O
and O
mean O
corpuscular O
hemoglobin O
in O
rats O
after O
24 O
, O
48 O
, O
and O
72 O
h O
of O
continuous O
inhalation O
; O
however O
, O
there O
was O
a O
significant O
reduction O
in O
neutrophils O
at O
transient O
reduction O
in O
the O
monocytes O
after O
24 O
and O
48 O
h O
to O
return O
to O
normal O
after O
72 O
h O
. O

Conclusions O
: O
Continuous O
inhalation O
to O
prallethrin B
1 O
. O
6 O
% O
insecticides O
poses O
toxicity O
on O
hematological O
variables O
. O

Via O
validated O
docking O
calculations O
, O
binding O
free O
energy O
calculations O
showed O
that O
the O
proposed O
compounds O
presented O
better O
binding O
affinity O
with O
DNA O
Gyrase O
B O
when O
compared O
to O
Novobiocin B
. O

The O
antioxidant O
activity O
was O
measured O
by O
employing O
the O
scavenging O
activity O
on O
DPPH O
( O
2 O
, O
2 O
- O
diphenyl O
- O
1 O
- O
picrylhydrazyl O
) O
and O
ABTS O
( O
2 B
, I
2 I
' I
- I
azinobis I
- I
3 I
- I
ethylbenzothiazoline I
- I
6 I
- I
sulfonate I
) O
radicals O
. O

Whereas O
Helianthemum O
alypoides O
, O
Helianthemum O
cinereum O
subsp O
. O
rotundifolium O
, O
Helianthemum O
hirtum O
, O
Helianthemum O
asperum O
, O
and O
Helianthemum O
marifolium O
subsp O
. O
marifolium O
were O
characterized O
by O
the O
presence O
of O
gallic O
acid O
, O
egallic B
derivatives O
and O
ellagitannins O
; O
the O
polyphenolic O
profile O
of O
Helianthemum O
apenninum O
subsp O
. O
cavanillesianum O
, O
Helianthemum O
syriacum O
and O
Helianthemum O
polygonoides O
was O
mostly O
based O
on O

Treatment O
with O
CAPE O
decreased O
protein O
abundance O
of O
Akt O
, O
Akt1 O
, O
Akt2 O
, O
Akt3 O
, O
phospho O
- O
Akt O
Ser473 B
, O
phospho O
- O
Akt O
Thr O
308 O
, O
GSK3 O
beta O
, O
FOXO1 O
, O
FOXO3a O
, O
phospho O
- O
FOXO1 O
Thr24 O
, O
phospho O
- O
FoxO3a O
Thr32 O
, O
NF O
- O
kappa O
B O
, O
phospho O
- O
NF O
- O
kappa O
B O
Ser536 O
, O
Rb O
, O
phospho O
- O
Rb O
Ser807 B
/ O

Assessment O
of O
genotoxic O
effects O
of O
flumorph B
by O
the O
comet O
assay O
in O
mice O
organs O
. O

The O
present O
study O
investigated O
the O
genotoxic O
effects O
of O
flumorph B
in O
various O
organs O
( O
brain O
, O
liver O
, O
spleen O
, O
kidney O
and O
sperm O
) O
of O
mice O
. O

The O
comet O
assay O
is O
a O
sensitive O
assay O
for O
the O
detection O
of O
genotoxicity O
caused O
by O
flumorph B
using O
mice O
as O
a O
model O
. O

Our O
data O
demonstrated O
that O
flumorph B
had O
induced O
systemic O
genotoxicity O
in O
mammals O
as O
it O
caused O
DNA O
damage O
in O
all O
tested O
vital O
organs O
, O
especially O
in O
brain O
and O
spleen O
. O

The O
halophilic O
and O
highly O
halotolerant O
bacterium O
Chromohalobacter O
salexigens O
is O
able O
to O
grow O
up O
to O
3 O
M O
NaCl O
in O
a O
minimal O
medium O
due O
to O
the O
de O
novo O
synthesis O
of O
ectoines B
. O

This O
is O
an O
osmoregulated O
pathway O
that O
burdens O
central O
metabolic O
routes O
by O
quantitatively O
drawing O
off O
TCA B
cycle O
intermediaries O
. O

Using O
[ B
1 I
- I
13C I
] I
- I
, I
[ I
2 I
- I
13C I
] I
- I
, I
[ I
6 I
- I
13C I
] I
- I
and I
[ I
U I
- I
13C6 I
] I
- I
glucose I
as O
carbon O
sources O
, O
we O
were O
able O
to O
determine O
the O
main O
central O
metabolic O
pathways O
involved O
in O
ectoines B
biosynthesis O
from O
glucose O
. O

C O
. O
salexigens O
uses O
the O
Entner O
- O
Doudoroff O
pathway O
rather O
than O
the O
standard O
glycolytic O
pathway O
for O
glucose O
catabolism O
, O
and O
anaplerotic O
activity O
is O
high O
to O
replenish O
the O
TCA B
cycle O
with O
the O
intermediaries O
withdrawn O
for O
ectoines B
biosynthesis O
. O

We O
successfully O
encapsulated O
paclitaxel O
within O
polymeric O
expansile O
nanoparticles O
( O
Pax B
- O
eNPs O
) O
at O
5 O
% O
loading O
via O
a O
miniemulsion O
polymerization O
procedure O
. O

Pax B
- O
eNPs O
were O
shown O
to O
be O
efficacious O
against O
three O
in O
vitro O
human O
breast O
adenocarcinoma O
cell O
lines O
( O
MDA O
- O
MB O
- O
231 O
, O
MCF O
- O
7 O
and O
SK O
- O
BR O
- O
3 O
) O
as O
well O
as O
cells O
isolated O
from O
the O
pleural O
effusions O
of O
two O
different O
breast O
cancer O
patients O
. O

Locked O
nucleic O
acid O
( O
LNA O
) O
is O
a O
chemical O
modification O
which O
introduces O
a O
- O
O B
- I
CH2 I
- O
linkage O
in O
the O
furanose B
sugar I
of O
nucleic O
acids O
and O
blocks O
its O
conformation O
in O
a O
particular O
state O
. O

Two O
types O
of O
modifications O
, O
namely O
, O
2 B
' I
- I
O I
, I
4 I
' I
- I
C I
- I
methylene I
- I
beta I
- I
d I
- I
ribofuranose I
( O
beta O
- O
d O
- O
LNA O
) O
and O
2 B
' I
- I
O I
, I
4 I
' I
- I
C I
- I
methylene I
- I
alpha I
- I
l I
- I
ribofuranose I
( O
alpha O
- O
l O
- O
LNA O
) O
, O
have O
been O
shown O
to O
yield O
RNA O
and O
DNA O
duplex O
- O
like O
structures O
, O
respectively O
. O

Though O
the O
alpha O
- O
LNA O
substituent O
has O
been O
proposed O
to O
mimic O
deoxyribose B
sugar O
in O
its O
conformational O
properties O
, O
the O
fully O
modified O
duplex O
was O
found O
to O
exhibit O
unique O
structural O
and O
dynamic O
properties O
with O
respect O
to O
the O
other O
three O
nucleic O
acid O
structures O
. O

A O
combination O
of O
two O
factors O
, O
namely O
, O
nature O
of O
the O
- O
O B
- I
CH2 I
- O
linkage O
in O
the O
LNAs O
vs O
their O
absence O
in O
the O
pure O
duplexes O
and O
similar O
conformations O
of O
the O
sugar O
rings O
in O
DNA O
and O
alpha O
- O
LNA O
vs O
the O
other O
two O
, O
is O
suggested O
to O
contribute O
to O
the O
stark O
differences O
among O
the O
four O
duplexes O
studied O
here O
in O
terms O
of O
their O
structural O
, O
dynamic O
, O
and O
energetic O
properties O
. O

For O
example O
, O
bortezomib O
( O
Velcade B
( O
( O
R O
) O
) O
) O
, O
the O
only O
drug O
in O
clinical O
use O
with O
boron O
as O
an O
active O
element O
, O
was O
approved O
in O
2003 O
as O
a O
proteasome O
inhibitor O
for O
the O
treatment O
of O
multiple O
myeloma O
and O
non O
- O
Hodgkin O
' O
s O
lymphoma O
. O

Boronated B
carbohydrate I
derivatives O
as O
potential O
boron O
neutron O
capture O
therapy O
reagents O
. O

Among O
the O
types O
of O
boron O
- O
containing O
molecules O
used O
as O
boron O
neutron O
capture O
therapy O
agents O
, O
boronated B
carbohydrate I
derivatives O
have O
received O
significant O
attention O
because O
of O
their O
preferential O
uptake O
by O
growing O
tumor O
cells O
. O

We O
recently O
reported O
that O
dispersing O
citrate O
- O
capped O
gold O
nanoparticles O
( O
AuNPs B
) O
in O
polymers O
such O
as O
polyethylene O
glycol O
( O
PEG O
) O
can O
achieve O
such O
a O
goal O
due O
to O
contributions O
from O
depletion O
stabilization O
. O

This O
is O
achieved O
by O
coating O
AuNPs B
with O
a O
layer O
of O
thiolated O
compound O
, O
which O
inhibits O
the O
adsorption O
of O
PEG O
and O
also O
allows O
the O
control O
of O
surface O
charge O
. O

We O
found O
that O
depletion O
stabilization O
alone O
was O
insufficient O
to O
stabilize O
AuNPs B
at O
room O
temperature O
. O

The O
size O
of O
both O
AuNPs B
and O
PEG O
was O
systematically O
varied O
and O
the O
trend O
was O
compared O
with O
theoretical O
calculations O
. O

The O
LPS O
molecule O
consists O
of O
lipid B
A I
, O
which O
anchors O
the O
LPS O
within O
the O
OM O
, O
a O
core O
polysaccharide O
region O
and O
a O
variable O
O O
- O
antigen O
polysaccharide O
chain O
. O

In O
this O
work O
we O
used O
RcLPS O
( O
consisting O
of O
lipid B
A I
plus O
the O
first O
seven O
sugars O
of O
the O
core O
polysaccharide O
) O
from O
a O
rough O
strain O
of O
E O
. O
coli O
to O
form O
stable O
monolayers O
of O
LPS O
at O
the O
air O
- O
liquid O
interface O
. O

This O
is O
in O
contrast O
to O
lipid B
A I
which O
displays O
hexagonal O
or O
, O
above O
20 O
mN O
m O
( O
- O
1 O
) O
, O
distorted O
hexagonal O
packing O
. O

Probing O
the O
Role O
of O
the O
Vancomycin O
E O
- O
Ring O
Aryl B
Chloride I
: O
Selective O
Divergent O
Synthesis O
and O
Evaluation O
of O
Alternatively O
Substituted O
E O
- O
Ring O
Analogues O
. O

The O
selective O
functionalization O
of O
a O
vancomycin O
aglycon O
derivative O
through O
direct O
conversion O
of O
the O
E O
- O
ring O
aryl B
chloride I
to O
a O
reactive O
boronic B
acid I
, O
and O
its O
use O
in O
the O
synthesis O
of O
a O
systematic O
series O
of O
vancomycin O
E O
- O
ring O
analogues O
are O
described O
. O

In O
contrast O
to O
the O
reduced O
activity O
of O
the O
unsubstituted O
E O
- O
ring O
derivatives O
, O
hydrophobic O
and O
relatively O
non O
- O
polar O
substituents O
approach O
or O
match O
the O
chloro B
substituted I
vancomycin I
and O
was O
insensitive O
to O
the O
electronic O
character O
of O
the O
substituent O
( O
e O
. O
g O
. O
Cl O
vs O
CN B
or O
OMe B
) O
, O
whereas O
highly O
polar O
substituents O
fail O
to O
provide O
the O
enhancements O
. O

Moreover O
, O
the O
active O
permethylated O
vancomycin O
aglycon O
derivatives O
examined O
exhibit O
VanB B
VRE O
antimicrobial O
activity O
at O
levels O
that O
approach O
( O
typically O
within O
2 O
- O
fold O
) O
their O
activity O
against O
sensitive O
bacteria O
. O

The O
robust O
borylation O
reaction O
also O
enabled O
the O
selective O
functionalization O
of O
a O
minimally O
protected O
vancomycin O
aglycon O
( O
N B
- I
Boc I
vancomycin O
aglycon O
) O
, O
and O
provides O
a O
direct O
method O
for O
the O
preparation O
of O
previously O
inaccessible O
analogues O
. O

Suppression O
of O
T O
beta O
R1 O
by O
the O
pharmacological O
inhibitor O
( O
SB431542 B
) O
markedly O
reduced O
VEGF O
release O
by O
HFL O
- O
1 O
in O
response O
to O
CSE O
and O
this O
effect O
was O
confirmed O
by O
T O
beta O
R1 O
siRNA O
. O

2 B
, I
3 I
, I
7 I
, I
8 I
- I
TCDD I
induces O
neurotoxicity O
and O
neuronal O
apoptosis O
in O
the O
rat O
brain O
cortex O
and O
PC12 O
cell O
line O
through O
the O
down O
- O
regulation O
of O
the O
Wnt O
/ O
beta O
- O
catenin O
signaling O
pathway O
. O

Interestingly O
the O
application O
of O
lithium B
chloride I
, O
a O
GSK O
- O
3 O
beta O
inhibitor O
, O
reversed O
the O
suppressive O
effect O
of O
TCDD O
on O
beta O
- O
catenin O
in O
PC12 O
cells O
and O
primary O
cortical O
neurons O
restoring O
cell O
viability O
and O
protecting O
cells O
from O
apoptosis O
as O
compared O
to O
untreated O
controls O
. O

AIM O
OF O
THE O
STUDY O
: O
To O
explore O
the O
effectiveness O
and O
the O
material O
basis O
of O
XXD O
in O
trinitrobenzene O
sulfonic O
acid O
( O
TNBS B
) O
- O
induced O
UC O
rats O
. O

Efficacy O
of O
XXD O
was O
positively O
related O
with O
AUC O
of O
five O
plasma O
compounds O
( O
baicalin O
, O
berberine O
, O
wogonoside B
, O
wogonin B
, O
and O
rhein B
) O
and O
concentrations O
of O
six O
colon O
tissue O
compounds O
( O
coptisine B
, O
jatrorrhizine B
, O
palmatine O
, O
berberine O
, O
baicalein O
and O
emodin O
) O
, O
respectively O
. O

Tandutinib B
( O
MLN518 B
/ O
CT53518 B
) O
targeted O
to O
stem O
- O
like O
cells O
by O
inhibiting O
the O
function O
of O
ATP O
- O
binding O
cassette O
subfamily O
G O
member O
2 O
. O

Tandutinib B
is O
a O
novel O
inhibitor O
of O
tyrosine O
kinases O
FLT3 O
, O
PDGFR O
and O
KIT O
. O

Our O
study O
was O
to O
explore O
the O
capability O
of O
tandutinib B
to O
reverse O
ABC O
transporter O
- O
mediated O
multidrug O
resistance O
. O

Tandutinib B
reversed O
ABCG2 O
- O
mediated O
drug O
resistance O
in O
ABCG2 O
- O
482 O
- O
R2 O
, O
ABCG2 O
- O
482 O
- O
G2 O
, O
ABCG2 O
- O
482 O
- O
T7 O
and O
S1 O
- O
M1 O
- O
80 O
cells O
and O
increased O
the O
accumulation O
of O
doxorubicin O
, O
rhodamine B
123 I
and O
[ B
H I
( I
3 I
) I
] I
mitoxantrone I
in O
ABCG2 O
- O
overexpressing O
cells O
. O

Importantly O
, O
tandutinib B
selectively O
sensitized O
side O
population O
cells O
to O
mitoxantrone O
. O

Taken O
together O
, O
our O
results O
advocate O
the O
potency O
of O
tandutinib B
as O
an O
ABCG2 O
modulator O
and O
stem O
- O
like O
cells O
targeted O
agent O
to O
increase O
efficiency O
of O
anticancer O
drugs O
. O

Interestingly O
, O
we O
showed O
that O
rapamycin O
shares O
all O
the O
proteasome O
targeting O
properties O
not O
only O
with O
other O
two O
- O
domain O
, O
closed O
- O
ring O
analogs O
( O
rapalogs O
) O
, O
but O
also O
with O
its O
single O
domain O
mimics O
, O
and O
with O
seco B
- I
rapamycin I
. O

Self O
- O
assembled O
monolayers O
of O
meso B
- I
5 I
, I
10 I
, I
15 I
, I
20 I
- I
tetrakis I
( I
undecyl I
) I
porphyrin I
copper I
( I
ii I
) I
on O
a O
graphite O
/ O
1 B
- I
octanoic I
acid I
interface O
have O
been O
studied O
by O
Scanning O
Tunnelling O
Microscopy O
. O

The O
sensor O
is O
a O
planar O
crystalline O
silicon O
waveguide O
, O
which O
is O
highly O
transparent O
, O
between O
lambda O
= O
1 O
. O
3 O
and O
6 O
. O
5 O
mu O
m O
, O
so O
that O
its O
operational O
spectral O
range O
covers O
most O
characteristic O
chemical O
absorption O
bands O
due O
to O
bonds O
such O
as O
C O
- O
H O
, O
N O
- O
H O
, O
O O
- O
H O
, O
C O
- O
C O
, O
N B
- I
O I
, O
C O
[ O
double O
bond O
, O
length O
as O
m O
- O
dash O
] O
O O
, O
and O
C O
[ O
triple O
bond O
, O
length O
as O
m O
- O
dash O
] O
N O
, O
as O
opposed O
to O
conventional O
UV O
, O
Vis O
, O
Near O
- O
IR O
sensors O
, O
which O
use O
weaker O
overtones O
of O
these O
fundamental O
bands O
. O

To O
extend O
light O
transmission O
beyond O
lambda O
= O
3 O
. O
7 O
mu O
m O
, O
a O
spectral O
region O
where O
a O
typical O
silicon B
dioxide I
under O
- O
clad O
is O
absorbing O
, O
we O
fabricate O
a O
unique O
air O
- O
clad O
silicon O
pedestal O
waveguide O
. O

METHODS O
: O
Adult O
gerbils O
were O
treated O
with O
MNU B
alone O
or O
associated O
with O
testosterone O
for O
3 O
or O
6 O
months O
of O
treatment O
. O

However O
, O
after O
6 O
months O
, O
there O
was O
a O
dramatic O
increase O
in O
tumor O
multiplicity O
in O
the O
VL O
, O
mainly O
in O
MNU B
- O
treated O
groups O
. O

Lesions O
clearly O
progressed O
from O
a O
premalignant O
to O
a O
malignant O
phenotype O
over O
time O
and O
tumor O
latency O
was O
decreased O
by O
MNU B
+ O
testosterone O
administration O
. O

MNU B
- O
induced O
lesions O
presented O
markers O
indicative O
of O
an O
aggressive O
phenotype O
: O
lack O
of O
basal O
cells O
, O
rupture O
of O
the O
smooth O
muscle O
cell O
layer O
, O
loss O
of O
E O
- O
cadherin O
, O
and O
high O
MGMT O
staining O
. O

The O
Effect O
of O
BCRP O
, O
MDR1 O
and O
OATP1B3 O
on O
the O
Antitumor O
Efficacy O
of O
the O
Lipophilic O
Camptothecin O
AR B
- I
67 I
In O
Vitro O
. O

AR B
- I
67 I
is O
a O
lipophilic O
camptothecin O
analogue O
, O
currently O
under O
early O
stage O
clinical O
trials O
. O

Transporters O
are O
known O
to O
have O
an O
impact O
on O
the O
disposition O
of O
camptothecins B
and O
on O
the O
response O
to O
chemotherapeutics O
in O
general O
due O
to O
their O
expression O
in O
tumor O
tissues O
. O

Therefore O
, O
the O
interplay O
between O
the O
BCRP O
, O
MDR1 O
and O
OATP1B1 O
/ O
OATP1B3 O
transporters O
and O
AR B
- I
67 I
and O
their O
impact O
on O
the O
toxicity O
profile O
of O
AR B
- I
67 I
was O
investigated O
. O

Using O
cell O
lines O
expressing O
the O
aforementioned O
transporters O
, O
we O
showed O
that O
the O
lipophilic O
AR B
- I
67 I
lactone O
form O
is O
a O
substrate O
for O
efflux O
transporters O
BCRP O
and O
MDR1 O
. O

Additionally O
, O
OATP1B1 O
and O
OATP1B3 O
facilitated O
the O
uptake O
of O
AR B
- I
67 I
carboxylate O
in O
SLCO1B1 O
and O
SLCO1B3 O
- O
transfected O
cell O
systems O
compared O
to O
the O
mock O
- O
transfected O
ones O
. O

Notably O
, O
both O
BCRPand O
MDR1 O
, O
conferred O
resistance O
to O
AR B
- I
67 I
lactone O
. O

Prompted O
by O
recent O
studies O
showing O
increased O
OATP1B3 O
expression O
in O
certain O
cancer O
types O
, O
we O
investigated O
the O
effect O
of O
OATP1B3 O
expression O
on O
cell O
viability O
after O
exposure O
to O
AR B
- I
67 I
carboxylate O
. O

In O
conclusion O
, O
BCRP O
- O
and O
MDR1 O
- O
mediated O
efflux O
of O
AR B
- I
67 I
lactone O
confers O
resistance O
to O
AR B
- I
67 I
, O
but O
OATP1B3 O
- O
mediated O
uptake O
of O
the O
AR B
- I
67 I
carboxylate O
does O
not O
sensitize O
OATP1B3 O
expressing O
tumor O
cells O
. O

Areas O
covered O
: O
An O
extensive O
literature O
search O
was O
performed O
to O
analyze O
clinical O
cases O
of O
acute O
pancreatitis O
reported O
in O
the O
literature O
or O
to O
the O
Food O
and O
Drug O
Administration O
( O
FDA O
) O
, O
in O
randomized O
clinical O
trials O
, O
and O
in O
observational O
studies O
with O
five O
DPP O
- O
4 O
inhibitors O
: O
sitagliptin O
, O
vildagliptin O
, O
saxagliptin B
, O
alogliptin O
, O
and O
linagliptin B
. O

In O
rather O
short O
- O
term O
clinical O
trials O
with O
well O
- O
selected O
diabetic O
patients O
, O
no O
increased O
risk O
of O
acute O
pancreatitis O
has O
been O
observed O
with O
any O
of O
the O
five O
commercialized O
DPP O
- O
4 O
inhibitors O
: O
sitagliptin O
, O
vildagliptin O
, O
saxagliptin B
, O
alogliptin O
, O
and O
linagliptin B
. O

Microbial O
degradation O
of O
microcystins B
. O

Hepatotoxic O
microcystins B
that O
are O
produced O
by O
freshwater O
cyanobacteria O
pose O
a O
risk O
to O
public O
health O
. O

The O
efficiencies O
of O
microcystin B
biodegradation O
pathways O
are O
documented O
in O
several O
papers O
and O
are O
compared O
here O
. O

Additionally O
, O
a O
comprehensive O
description O
of O
the O
microcystin B
enzymatic O
degradation O
scheme O
has O
been O
supplemented O
with O
a O
proposal O
for O
a O
new O
biodegradation O
pathway O
. O

We O
also O
describe O
some O
methods O
that O
are O
useful O
for O
studying O
the O
biological O
decomposition O
of O
microcystins B
, O
including O
screening O
for O
microcystin B
degraders O
and O
detecting O
microcystin B
degradation O
products O
, O
with O
an O
emphasis O
on O
mass O
spectrometric O
methodology O
. O

Insertion O
of O
CO2 O
and O
COS B
into O
Bi B
- I
C I
Bonds O
: O
Reactivity O
of O
a O
Bismuth B
NCN I
Pincer O
Complex O
of O
an O
Oxyaryl B
Dianionic O
Ligand O
, O
[ B
2 I
, I
6 I
- I
( I
Me2NCH2 I
) I
2C6H3 I
] I
Bi I
( I
C6H2tBu2O I
) I
. O

The O
reactivity O
of O
the O
unusual O
oxyaryl B
dianionic O
ligand O
, O
( B
C6H2tBu2 I
- I
3 I
, I
5 I
- I
O I
- I
4 I
) I
2 I
- O
, O
in O
the O
Bi3 B
+ I
NCN I
pincer O
complex O
Ar B
' I
Bi I
( I
C6H2tBu2 I
- I
3 I
, I
5 I
- I
O I
- I
4 I
) I
, O
1 O
, O
[ O
Ar O
' O
= O
2 B
, I
6 I
- I
( I
Me2NCH2 I
) I
2C6H3 I
] O
has O
been O
explored O
with O
small O
molecule O
substrates O
and O
electrophiles O
. O

The O
first O
insertion O
reactions O
of O
CO2 O
and O
COS B
into O
Bi B
- I
C I
bonds O
are O
observed O
with O
this O
oxyaryl B
dianionic O
ligand O
complex O
. O

These O
reactions O
generate O
new O
dianions O
that O
have O
quinoidal O
character O
similar O
to O
the O
oxyaryl B
dianionic O
ligand O
in O
1 O
. O

The O
oxyarylcarboxy B
and O
oxyarylthiocarboxy B
dianionic O
ligands O
were O
identified O
by O
X O
- O
ray O
crystallography O
in O
Ar B
' I
Bi I
[ I
O2C I
( I
C6H2tBu2 I
- I
3 I
- I
5 I
- I
O I
- I
4 I
) I
- I
kappa I
2O I
, I
O I
' I
] I
, O
2 O
and O
Ar B
' I
Bi I
[ I
OSC I
( I
C6H2tBu2 I
- I
3 I
- I
5 I
- I
O I
- I
4 I
) I
- I
kappa I
2O I
, I
S I
] I
, O
3 O
, O
respectively O
. O

Silyl B
halides I
and O
pseudohalides B
, O
R3SiX B
( O
X O
= O
Cl O
, O
CN B
, O
N3 O
; O
R O
= O
Me O
, O
Ph O
) O
, O
react O
with O
1 O
by O
attaching O
X O
to O
bismuth O
and O
R3Si B
to O
the O
oxyaryl B
oxygen O
to O
form O
Ar B
' I
Bi I
( I
X I
) I
( I
C6H2tBu2 I
- I
3 I
, I
5 I
- I
OSiR3 I
- I
4 I
) I
complexes O
, O
a O
formal O
addition O
across O
five O
bonds O
. O

These O
react O
with O
additional O
R3SiX B
to O
generate O
Ar B
' I
BiX2 I
complexes O
and O
R3SiOC6H3tBu2 B
- I
2 I
, I
6 I
. O

The O
reaction O
of O
1 O
with O
I2 B
forms O
Ar B
' I
BiI2 I
and O
the O
coupled O
quinone O
, O
3 B
, I
3 I
' I
, I
5 I
, I
5 I
' I
- I
tetra I
- I
tert I
- I
butyl I
- I
4 I
, I
4 I
' I
- I
diphenoquinone I
, O
by O
oxidative O
coupling O
. O

High O
- O
Accuracy O
Estimates O
for O
the O
Vinylidene B
- O
Acetylene O
Isomerization O
Energy O
and O
the O
Ground O
State O
Rotational O
Constants O
of O
: B
C I
= I
CH2 I
. O

Highly O
accurate O
calculations O
are O
reported O
for O
properties O
of O
vinylidene B
( O
H2C B
= I
C I
: I
) O
, O
specically O
the O
position O
of O
its O
zero O
- O
point O
vibrational O
level O
relative O
to O
that O
of O
acetylene O
and O
its O
equilibrium O
structure O
and O
ground O
state O
rotational O
constants O
. O

The O
isomerization O
energy O
of O
vinylidene B
calculated O
at O
the O
HEAT O
- O
456QP O
level O
of O
theory O
is O
45 O
. O
530 O
. O
15 O
kcal O
mol1 O
, O
in O
agreement O
with O
the O
previous O
best O
estimate O
, O
but O
associated O
with O
a O
much O
smaller O
uncertainty O
. O

In O
addition O
, O
the O
thermochemical O
calculations O
presented O
here O
also O
allow O
a O
determination O
of O
the O
: B
C I
= I
CH2 I
bond O
energy O
of O
the O
vinyl O
radical O
at O
the O
HEAT O
- O
345 O
( O
Q O
) O
level O
of O
theory O
, O
which O
is O
77 O
. O
70 O
. O
3 O
kcal O
mol1 O
. O

The O
equilibrium O
structure O
of O
vinylidene B
, O
estimated O
with O
an O
additivity O
scheme O
that O
includes O
treatment O
of O
correlation O
eects O
beyond O
CCSD O
( O
T O
) O
as O
well O
as O
relativistic O
and O
adiabatic O
( O
diagonal O
Born O
- O
Oppenheimer O
correction O
) O
contributions O
is O
rCC O
= O
1 O
. O
29820 O
. O
0003 O
A O
; O
rCH O
= O
1 O
. O
08440 O
. O
0003 O
A O
; O
and O
CCH B
= O
120 O
. O
050 O
. O
05o O
, O
with O
zero O
- O
point O
rotational O
constants O
( O
including O
vibrational O
contributions O
and O
electronic O
contributions O
to O
the O
moment O
of O
inertia O
) O
estimated O
to O
be O
A0 O
= O
9 O
. O
49250 O
. O

Using O
cross O
- O
sectional O
scanning O
tunneling O
microscope O
( O
XSTM O
) O
with O
samples O
cleaved O
in O
situ O
in O
an O
ultrahigh O
vacuum O
( O
UHV O
) O
chamber O
, O
this O
study O
demonstrates O
the O
direct O
visualization O
of O
high O
- O
resolution O
interfacial O
band O
mapping O
images O
across O
the O
film O
thickness O
in O
an O
optimized O
bulk O
heterojunction O
polymer O
solar O
cell O
consisting O
of O
nanoscale O
phase O
segregated O
blends O
of O
poly O
( O
3 O
- O
hexylthiophene O
) O
( O
P3HT O
) O
and O
[ B
6 I
, I
6 I
] I
- I
phenyl I
C61 I
butyric I
acid I
methyl I
ester I
( O
PCBM O
) O
. O

We O
were O
able O
to O
achieve O
the O
direct O
observation O
of O
the O
interfacial O
band O
alignments O
at O
the O
donor O
( O
P3HT O
) O
- O
acceptor O
( O
PCBM O
) O
interfaces O
and O
at O
the O
interfaces O
between O
the O
photoactive O
P3HT O
: O
PCBM O
blends O
and O
the O
poly O
( O
3 O
, O
4 O
- O
ethylenedioxythiophe O
) O
poly B
( I
styrenesulfonate I
) I
( O
PEDOT O
: O
PSS B
) O
anode O
modification O
layer O
with O
an O
atomic O
- O
scale O
spatial O
resolution O
. O

Hydrazides O
/ O
Hydrazones B
as O
antimicrobial O
and O
anticancer O
agents O
in O
the O
new O
millennium O
. O

Hydrazide B
/ O
hydrazone O
derivatives O
are O
of O
quite O
interest O
for O
medicinal O
chemists O
because O
of O
their O
vast O
spectrum O
of O
biological O
activity O
. O

Literature O
reports O
reveal O
that O
the O
hydrazide B
derivatives O
have O
been O
extensively O
studied O
for O
their O
biological O
profile O
during O
the O
past O
decade O
. O

The O
aim O
of O
the O
present O
work O
is O
to O
collect O
literature O
reports O
focusing O
the O
antimicrobial O
and O
anticancer O
study O
of O
different O
hydrazide B
/ O
hydrazone O
derivatives O
carried O
out O
during O
the O
past O
decade O
which O
will O
serve O
as O
a O
valuable O
source O
of O
information O
for O
the O
researchers O
working O
in O
the O
field O
of O
antimicrobial O
and O
anticancer O
research O
. O

Evaluation O
of O
Chlorpheniramine B
Maleate I
microparticles O
in O
orally O
disintegrating O
film O
and O
orally O
disintegrating O
tablet O
for O
pediatrics O
. O

Abstract O
Objective O
: O
To O
mask O
the O
bitterness O
of O
Chlorpheniramine B
Maleate I
via O
encapsulating O
drug O
into O
Eudragit B
EPO I
microparticles O
, O
and O
then O
incorporate O
these O
microparticles O
into O
orally O
disintegrating O
films O
( O
ODF O
) O
and O
orally O
disintegrating O
tablets O
( O
ODT O
) O
for O
pediatric O
uses O
. O

Methods O
: O
Spray O
drying O
of O
water O
- O
in O
- O
oil O
emulsion O
was O
utilized O
to O
encapsulate O
Chlorpheniramine B
Maleate I
into O
Eudragit B
EPO I
microparticles O
. O

Conclusion O
: O
Both O
ODF O
and O
ODT O
are O
shown O
to O
be O
suitable O
vehicles O
for O
taste O
masked O
Chlorpheniramine B
Maleate I
microparticles O
with O
potential O
for O
pediatric O
uses O
. O

The O
double O
- O
layered O
wound O
dressing O
was O
developed O
with O
PVA O
/ O
sodium B
alginate I
using O
a O
freeze O
- O
melting O
technique O
; O
one O
layer O
was O
PVA O
layer O
and O
the O
other O
was O
the O
drug O
- O
loaded O
sodium B
alginate I
layer O
. O

The O
double O
- O
layered O
wound O
dressing O
gave O
a O
similar O
gel O
fraction O
and O
Young O
' O
s O
module O
as O
single O
- O
layered O
wound O
bandages O
developed O
with O
only O
PVA O
, O
and O
a O
similar O
inflammation O
ability O
and O
WVTR O
as O
single O
- O
layered O
wound O
dressings O
developed O
with O
PVA O
and O
sodium B
alginate I
. O

Compared O
to O
the O
commercial O
product O
, O
the O
double O
- O
layered O
wound O
dressing O
comprising O
6 O
. O
7 O
% O
PVA O
, O
0 O
. O
5 O
% O
sodium B
alginate I
and O
0 O
. O
01 O
% O
AME O
significantly O
enhanced O
the O
wound O
- O
healing O
effect O
in O
the O
wound O
- O
healing O
test O
. O

Nine O
new O
triterpene O
derivatives O
, O
yunnanterpenes B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
15 B
, I
16 I
- I
seco I
- I
cimiterpenes I
A I
and I
B I
( O
7 O
, O
8 O
) O
, O
and O
cimilactone B
C I
( O
9 O
) O
, O
and O
15 O
known O
analogues O
( O
10 O
- O
24 O
) O
were O
isolated O
from O
the O
aerial O
parts O
of O
Cimicifuga O
yunnanensis O
. O

Cytotoxic O
Bisbenzylisoquinolin B
Alkaloids I
from O
Stephania O
epigaea O
. O

Six O
new O
bisbenzylisoquinolin B
alkaloids I
( O
1 O
- O
6 O
) O
and O
seven O
known O
compounds O
( O
8 O
- O
14 O
) O
were O
isolated O
from O
the O
tubers O
of O
Stephania O
epigaea O
, O
in O
addition O
to O
the O
major O
alkaloid O
, O
cepharanthine B
( O
7 O
) O
. O

Compounds O
1 O
- O
6 O
belong O
to O
the O
oxyacanthine B
type O
of O
bisbenzylisoquinolin B
alkaloids I
and O
have O
a O
rare O
methylenedioxy B
substituent O
. O

Compound O
1 O
, O
a O
dimer O
composed O
of O
benzylisoquinoline B
and O
seco B
- I
aristolactam I
units O
, O
represents O
a O
new O
type O
of O
bisbenzylisoquinolin B
alkaloid I
, O
while O
compounds O
3 O
- O
6 O
are O
bisbenzylisoquinolin B
N I
- I
oxides I
. O

Cepharanthine B
( O
7 O
) O
, O
the O
major O
component O
of O
S O
. O
epigaea O
, O
exhibited O
cytotoxicity O
against O
all O
of O
these O
cancer O
cell O
lines O
except O
ECA109 O
, O
while O
its O
known O
analogue O
, O
10 O
, O
displayed O
cytotoxicity O
against O
all O
six O
cancer O
cell O
lines O
. O

Melanogenesis O
inhibitory O
daphnane B
diterpenoids I
from O
the O
flower O
buds O
of O
Daphne O
genkwa O
. O

Two O
new O
daphnane O
- O
type O
diterpene O
esters O
, O
daphneresiniferins B
A I
( I
1 I
) I
and I
B I
( O
2 O
) O
, O
along O
with O
seven O
known O
diterpenes O
, O
yuanhuacine B
( O
3 O
) O
, O
yuanhuadine B
( O
4 O
) O
, O
yuanhuahine B
( O
5 O
) O
, O
genkwadaphnin B
( O
6 O
) O
, O
genkwanine B
A I
( O
7 O
) O
, O
genkwanine B
F I
( O
8 O
) O
, O
and O
genkwanine B
H I
( O
9 O
) O
, O
were O
isolated O
from O
the O
methanol O
extract O
of O
the O
flower O
buds O
of O
Daphne O
genkwa O

Synthesis O
of O
pyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidine I
linked O
aminobenzothiazole B
conjugates O
as O
potential O
anticancer O
agents O
. O

A O
series O
of O
pyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidine I
linked O
2 B
- I
aminobenzothizole I
conjugates O
( O
6a O
- O
t O
) O
were O
synthesized O
and O
evaluated O
for O
their O
anticancer O
activity O
against O
five O
human O
cancer O
cell O
lines O
. O

Cynomolgus O
FMO1 O
, O
FMO2 O
, O
FMO3 O
, O
and O
FMO5 O
metabolized O
benzydamine B
, O
and O
FMO1 O
/ O
FMO3 O
and O
FMO3 O
also O
metabolized O
methimazole O
and O
trimethylamine B
, O
respectively O
. O

Rates O
of O
benzydamine B
N O
- O
oxygenation O
( O
catalyzed O
by O
FMO3 O
) O
varied O
( O
approximately O
20 O
- O
fold O
) O
among O
the O
28 O
cynomolgus O
livers O
and O
were O
significantly O
correlated O
with O
FMO3 O
protein O
expression O
, O
indicating O
that O
the O
inter O
- O
animal O
variations O
in O
benzydamine B
N O
- O
oxygenation O
might O
be O
partly O
accounted O
for O
by O
the O
variable O
FMO3 O
expression O
. O

Cynomolgus O
FMO6 O
metabolized O
benzydamine B
only O
slightly O
, O
but O
minimal O
expression O
of O
FMO6 O
in O
all O
tissue O
precludes O
the O
importance O
of O
FMO6 O
in O
drug O
metabolism O
, O
unlike O
cynomolgus O
FMO1 O
, O
FMO2 O
, O
FMO3 O
, O
and O
FMO5 O
which O
were O
all O
functional O
. O

GABAA O
receptor O
modulation O
by O
piperine B
and O
a O
non O
- O
TRPV1 O
activating O
derivative O
. O

The O
action O
of O
piperine B
( O
the O
pungent O
component O
of O
pepper O
) O
and O
its O
derivative O
SCT B
- I
66 I
( B
( I
2E I
, I
4E I
) I
- I
5 I
- I
( I
1 I
, I
3 I
- I
benzodioxol I
- I
5 I
- I
yl I
) I
) I
- I
N I
, I
N I
- I
diisobutyl I
- I
2 I
, I
4 I
- I
pentadienamide I
) I
on O
different O
gamma O
- O
aminobutyric O
acid O
( O
GABA O
) O
type O
A O
( O
GABAA O
) O
receptors O
, O
transient O
- O
receptor O
- O
potential O
- O
vanilloid O
- O
1 O
( O
TRPV1 O
) O
receptors O
and O
behavioral O
effects O
were O
investigated O
. O

Modulation O
of O
GABA O
- O
induced O
chloride O
currents O
( O
IGABA O
) O
by O
piperine B
and O
SCT B
- I
66 I
and O
activation O
of O
TRPV1 O
was O
studied O
using O
the O
two O
- O
microelectrode O
- O
voltage O
- O
clamp O
technique O
and O
fast O
perfusion O
. O

Piperine B
acted O
with O
similar O
potency O
on O
all O
GABAA O
receptor O
subtypes O
( O
EC50 O
range O
: O
42 O
. O
8 O
+ O
/ O
- O
7 O
. O
6 O
mu O
M O
( O
alpha O
2 O
beta O
2 O
) O
- O
59 O
. O
6 O
+ O
/ O
- O
12 O
. O
3 O
mu O
M O
( O
alpha O
3 O
beta O
2 O
) O
) O
. O

IGABA O
modulation O
by O
piperine B
did O
not O
require O
the O
presence O
of O
a O
gamma O
2S O
- O
subunit O
, O
suggesting O
a O
binding O
site O
involving O
only O
alpha O
and O
beta O
subunits O
. O

Replacing O
the O
piperidine O
ring O
by O
a O
N B
- I
di I
- I
isobutyl I
residue O
( O
SCT B
- I
66 I
) O
prevents O
interactions O
with O
TRPV1 O
and O
simultaneously O
increases O
the O
potency O
and O
efficiency O
of O
GABAA O
receptor O
modulation O
. O

SCT B
- I
66 I
displayed O
greater O
efficacy O
on O
GABAA O
receptors O
than O
piperine B
, O
with O
different O
subunit O
- O
dependence O
. O

Both O
compounds O
induced O
anxiolytic O
, O
anticonvulsant O
effects O
and O
reduced O
locomotor O
activity O
; O
however O
, O
SCT B
- I
66 I
induced O
stronger O
anxiolysis O
without O
decreasing O
body O
temperature O
and O
without O
the O
proconvulsive O
effects O
of O
TRPV1 O
activation O
and O
thus O
may O
serve O
as O
a O
scaffold O
for O
the O
development O
of O
novel O
GABAA O
receptor O
modulators O
. O

In O
silico O
analysis O
, O
molecular O
docking O
model O
indicated O
that O
a O
tetrapyrrole B
macrocycle I
and O
two O
propionate B
chains O
within O
PPIX O
are O
necessary O
for O
the O
binding O
to O
the O
adenosine O
triphosphate O
( O
ATP O
) O
- O
binding O
pocket O
of O
HSP90 O
. O

The O
predicted O
structural O
requirement O
was O
verified O
by O
the O
differential O
inhibitory O
effects O
of O
PPIX O
analogs O
, O
or O
the O
precursor O
of O
PPIX O
, O
on O
HIF O
- O
1 O
alpha O
; O
compounds O
lacking O
either O
the O
tetrapyrrole B
macrocycle I
or O
the O
propionate B
chains O
were O
inactive O
. O

Our O
results O
show O
that O
a O
tetrapyrrole B
macrocycle I
and O
two O
attached O
propionate B
chains O
in O
PPIX O
coordinately O
interact O
with O
the O
ATP O
- O
binding O
pocket O
of O
HSP90 O
, O
offering O
structural O
information O
on O
the O
inhibitory O
effect O
of O
porphyrins O
on O
angiogenesis O
. O

Chlorpyrifos O
is O
a O
broad O
- O
spectrum O
, O
chlorinated B
organophosphate I
pesticide O
employed O
for O
pest O
control O
in O
various O
agricultural O
and O
animal O
husbandries O
. O

Acute O
and O
chronic O
exposure O
to O
CPF B
can O
elicit O
several O
adverse O
effects O
, O
including O
oxidative O
stress O
. O

We O
investigated O
neurotoxicity O
of O
CPF B
- O
treated O
mice O
, O
and O
evaluated O
the O
antioxidant O
effect O
of O
vitamin O
E O
against O
oxidative O
stress O
and O
histological O
changes O
in O
the O
livers O
and O
kidneys O
of O
CPF B
- O
treated O
mice O
. O

Kunming O
mice O
were O
divided O
randomly O
into O
five O
exposure O
groups O
of O
six O
: O
( O
A O
) O
peanut O
oil O
; O
( O
B O
) O
3mg O
/ O
kg O
CPF B
; O
( O
C O
) O
6mg O
/ O
kg O
CPF B
; O
( O
D O
) O
12mg O
/ O
kg O
CPF B
; O
( O
E O
) O
vitamin O
E O
( O
100mg O
/ O
kg O
) O
, O
3h O
after O
administration O
of O
CPF B
( O
12mg O
/ O
kg O
) O
and O
used O
as O
a O
post O
- O
treatment O
group O
. O

Oral O
administration O
of O
high O
- O
dose O
groups O
( O
12mg O
/ O
kg O
) O
CPF B
led O
to O
a O
significant O
increase O
in O
levels O
of O
reactive O
oxygen O
species O
, O
DNA O
- O
protein O
crosslinks O
, O
8 B
- I
hydroxy I
- I
2 I
- I
deoxyguanosine I
and O
malondialdehyde O
, O
decreases O
in O
acetylcholinesterase O
activity O
and O
glutathione O
level O
, O
as O
well O
as O
causing O
hepatic O
and O
renal O
histopathological O
change O
. O

Except O
for O
AChE O
activity O
levels O
, O
administration O
of O
vitamin O
E O
to O
CPF B
- O
treated O
mice O
restored O
these O
biochemical O
parameters O
to O
within O
normal O
levels O
, O
and O
resulted O
in O
overall O
improvement O
in O
damage O
to O
livers O
and O
kidneys O
. O

These O
data O
suggest O
that O
oxidative O
stress O
is O
involved O
in O
CPF B
- O
induced O
toxicity O
and O
that O
vitamin O
E O
can O
protect O
against O
the O
tissue O
damage O
induced O
by O
CPF B
. O

The O
average O
daily O
dose O
of O
calcium B
acetate I
or I
carbonate I
prescribed O
in O
the O
randomised O
controlled O
trials O
to O
control O
hyperphosphataemia O
in O
dialysis O
patients O
ranges O
between O
1 O
. O
2 O
and O
2 O
. O
3 O
g O
of O
elemental O
calcium O
. O

At O
present O
, O
there O
are O
three O
types O
of O
non O
- O
calcium O
- O
based O
phosphate O
binders O
available O
: O
sevelamer B
, O
lanthanum B
carbonate I
and O
magnesium O
salts O
. O

Sevelamer B
is O
the O
only O
non O
- O
calcium O
- O
containing O
phosphate O
binder O
that O
does O
not O
have O
potential O
for O
systemic O
accumulation O
and O
presents O
pleiotropic O
effects O
that O
may O
impact O
on O
cardiovascular O
disease O
. O

In O
contrast O
, O
lanthanum B
carbonate I
and O
magnesium O
salts O
are O
absorbed O
in O
the O
gut O
and O
their O
route O
of O
excretion O
is O
biliary O
for O
lanthanum B
and O
urinary O
for O
magnesium O
. O

Moreover O
, O
full O
adoption O
of O
sevelamer B
and O
lanthanum B
by O
government O
drug O
reimbursement O
agencies O
in O
place O
of O
calcium O
salts O
would O
lead O
to O
a O
large O
increase O
in O
health O
- O
care O
expenditure O
. O

Metoprolol B
and O
diltiazem O
ameliorate O
ziprasidone O
- O
induced O
prolonged O
corrected O
QT O
interval O
in O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
reveal O
the O
effects O
of O
metoprolol B
and O
diltiazem O
on O
ziprasidone O
drug O
- O
induced O
prolonged O
QTc O
interval O
. O

A O
total O
of O
24 O
rats O
were O
equally O
divided O
into O
the O
following O
four O
groups O
: O
the O
first O
group O
was O
used O
as O
the O
control O
and O
received O
1 O
mL O
/ O
kg O
saline O
; O
3 O
mg O
/ O
kg O
ziprasidone O
and O
saline O
were O
administered O
to O
the O
second O
group O
; O
3 O
mg O
/ O
kg O
ziprasidone O
and O
1 O
mg O
/ O
kg O
metoprolol B
were O
administered O
to O
the O
third O
group O
and O
3 O
mg O
/ O
kg O
ziprasidone O
and O
2 O
mg O
/ O
kg O
diltiazem O
were O
administered O
to O
the O
fourth O
group O
. O

The O
study O
demonstrated O
the O
effectiveness O
of O
metoprolol B
and O
diltiazem O
in O
the O
prevention O
of O
ziprasidone O
- O
induced O
elongation O
in O
the O
QTc O
interval O
. O

Both O
metoprolol B
and O
diltiazem O
may O
be O
considered O
in O
the O
prophylactic O
therapy O
of O
high O
- O
risk O
patients O
who O
are O
using O
ziprasidone O
. O

Activation O
of O
AMPK O
using O
AICAR B
resulted O
in O
STIM1 O
phosphorylation O
on O
serine O
residues O
and O
prevented O
PAR O
- O
1 O
- O
induced O
Ca2 O
+ O
entry O
. O

Further O
, O
AICAR B
pretreatment O
blocked O
PAR O
- O
1 O
- O
induced O
increase O
in O
permeability O
of O
mouse O
- O
lung O
microvessels O
. O

The O
purpose O
of O
this O
investigation O
was O
to O
design O
novel O
pentablock O
copolymers O
( O
polylatide B
- O
polycaprolactone O
- O
polyethylene O
glycol O
- O
polycaprolactone O
- O
polylatide B
) O
( O
PLA O
- O
PCL O
- O
PEG O
- O
PCL O
- O
PLA O
) O
to O
prepare O
nanoparticle O
formulations O
which O
provide O
continuous O
delivery O
of O
steroids O
over O
a O
longer O
duration O
with O
minimal O
burst O
effect O
. O

Another O
purpose O
was O
to O
evaluate O
the O
effect O
of O
poly O
( O
L O
- O
lactide O
) O
( O
PLLA O
) O
or O
poly O
( O
D O
, O
L O
- O
lactide O
) O
( O
PDLLA B
) O
incorporation O
on O
crystallinity O
of O
pentablock O
copolymers O
and O
in O
vitro O
release O
profile O
of O
triamcinolone O
acetonide O
( O
selected O
as O
model O
drug O
) O
from O
nanoparticles O
. O

Burst O
release O
of O
triamcinolone O
acetonide O
from O
nanoparticles O
was O
significantly O
minimized O
with O
incorporation O
of O
proper O
ratio O
of O
PDLLA B
in O
the O
existing O
triblock O
( O
PCL O
- O
PEG O
- O
PCL O
) O
copolymer O
. O

Bischler O
- O
Napieralski O
conditions O
were O
employed O
in O
the O
key O
step O
for O
the O
conversion O
of O
acyclic B
amides I
to O
the O
corresponding O
tetrahydroisoquinoli O
containing O
analogs O
. O

Design O
, O
synthesis O
and O
molecular O
modeling O
of O
novel O
pyrido B
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidine I
analogs O
as O
antifolates O
: O
Application O
of O
Buchwald O
- O
Hartwig O
aminations O
of O
heterocycles O
. O

A O
novel O
series O
of O
pyrido B
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidines I
as O
selective O
and O
potent O
DHFR O
inhibitors O
against O
these O
opportunistic O
infections O
are O
presented O
. O

Buchwald O
- O
Hartwig O
coupling O
reaction O
of O
substituted O
anilines O
with O
pivaloyl B
protected O
2 B
, I
4 I
- I
diamino I
- I
6 I
- I
bromo I
- I
pyrido I
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidine I
was O
successfully O
explored O
to O
synthesize O
these O
analogs O
. O

We O
present O
CCSD O
( O
T O
) O
interaction O
energies O
and O
the O
bonding O
analysis O
for O
complexes O
of O
Cu O
, O
Ag O
, O
and O
Au O
with O
the O
lone O
- O
pair O
ligands O
, O
H2O O
, O
OF2 B
, O
OMe2 B
, O
NH3 O
, O
NF3 O
, O
NMe3 B
, O
H2S B
, O
SF2 O
, O
SMe2 B
, O
PH3 B
, O
PF3 B
, O
PCl3 B
, O
PMe3 B
( O
ML O
complexes O
) O
. O

AuPH3 B
, O
AuPF3 B
and O
AuPCl3 B
( O
MPX3 O
) O
complexes O
exhibit O
particularly O
large O
relativistic O
effects O
, O
30 O
- O
46 O
kJ O
/ O
mol O
. O

For O
all O
coinage O
metals O
the O
strongest O
interactions O
are O
computed O
for O
PX3 B
ligands O
followed O
by O
SX2 B
and O
NX3 B
OX2 B
ligands O
. O

Metal B
- I
thiol I
complexes O
, O
particularly O
AuSCH3 B
, O
form O
a O
separate O
class O
. O

In O
the O
monolayer O
limit O
, O
transition B
metal I
dichalcogenides I
become O
direct O
- O
bandgap O
, O
light O
- O
emitting O
semiconductors O
. O

Physi O
- O
sorbed O
O2 O
and O
/ O
or O
H2O O
molecules O
electronically O
deplete O
n O
- O
type O
materials O
such O
as O
MoS2 O
and O
MoSe2 B
, O
which O
weakens O
electrostatic O
screening O
that O
would O
otherwise O
destabilize O
excitons O
, O
leading O
to O
the O
drastic O
enhancement O
in O
photoluminescence O
. O

In O
p O
- O
type O
materials O
such O
as O
WSe2 B
, O
the O
molecular O
physisorption O
results O
in O
the O
opposite O
effect O
. O

This O
issue O
is O
illustrated O
in O
the O
case O
of O
a O
fully O
epitaxial O
system O
: O
CoxNi1 B
- I
x I
nanowires O
in O
CeO2 O
/ O
SrTiO3 O
( O
001 O
) O
. O

The O
advantage O
brought O
by O
the O
ability O
to O
grow O
alloys O
is O
illustrated O
by O
the O
control O
of O
the O
magnetic O
anisotropy O
of O
the O
nanowires O
when O
passing O
from O
pure O
Ni O
wires O
to O
CoxNi1 B
- I
x I
alloys O
. O

The O
antiproliferative O
factor O
( O
APF O
) O
involved O
in O
interstitial O
cystitis O
is O
a O
glycosylated O
nonapeptide B
( O
TVPAAVVVA O
) O
containing O
a O
sialylated O
core O
alpha B
- I
O I
- I
disaccharide I
linked O
to O
the O
N O
- O
terminal O
threonine O
. O

We O
demonstrated O
that O
incorporation O
of O
octadecyltrimethoxys B
( O
OTMS B
) O
functionalized O
, O
spectrally O
tuned O
, O
gold O
/ O
silica O
( O
Au O
/ O
SiO2 O
) O
core O
/ O
shell O
nanospheres O
and O
nanorods O
into O
the O
active O
layer O
of O
an O
organic O
photovoltaic O
( O
OPV O
) O
device O
led O
to O
an O
in O
increase O
photo O
conversion O
efficiency O
( O
PCE O
) O
. O

Functionalization O
of O
the O
Au O
/ O
SiO2 O
core O
/ O
shell O
nanoparticles O
with O
the O
OTMS B
organic O
ligand O
was O
then O
necessary O
in O
order O
to O
transfer O
the O
Au O
/ O
SiO2 O
core O
/ O
shell O
nanoparticles O
from O
an O
ethanol O
solution O
into O
an O
OPV O
polymer O
- O
compatible O
solvent O
, O
such O
as O
dichlorobenzene B
( O
DCB B
) O
. O

The O
OTMS B
- O
functionalized O
Au O
/ O
SiO2 O
core O
/ O
shell O
nanorods O
and O
nanospheres O
were O
then O
incorporated O
into O
the O
active O
layers O
of O
two O
OPV O
polymer O
systems O
: O
a O
poly O
( O
3 O
- O
hexylthiophene O
) O
: O
[ B
6 I
, I
6 I
] I
- I
phenyl I
- I
C61 I
- I
butyric I
acid I
methyl I
ester I
( O
P3HT O
: O
PCB60M B
) O
OPV O
device O
and O
a O
poly O
[ O
2 O
, O
6 O
- O
4 O
, O
8 O
- O
di O
( O
5 O
- O
ethylhexylthienyl O
) O
benzo O
[ O
1 O
, O
2 O
- O
b O
; O
3 O
, O
4 O

- O
b O
] O
dithiophene O
- O
alt O
- O
5 O
- O
dibutyloctyl O
- O
3 O
, O
6 O
- O
bis O
( O
5 O
- O
bromothiophen O
- O
2 O
- O
yl O
) O
pyrrolo O
[ O
3 O
, O
4 O
- O
c O
] O
pyrrole O
- O
1 O
, O
4 O
- O
dione O
] O
( O
PBDTT B
- I
DPP I
: O
PC60BM B
) O
OPV O
device O
. O

For O
the O
P3HT O
: O
PC60BM B
polymer O
with O
a O
band O
edge O
of O
~ O
700 O
nm O
, O
the O
addition O
of O
the O
core O
/ O
shell O
nanorods O
with O
an O
aspect O
ratio O
( O
AR O
) O
of O
~ O
2 O
. O
5 O
( O
extinction O
peak O
~ O
670 O
nm O
) O
resulted O
in O
a O
7 O
. O
1 O
% O
improvement O
in O
PCE O
, O
while O
for O
the O
PBDTT B
- I
DPP I
: O
PC60BM B
polymer O
with O
a O
band O
edge O
~ O
860 O
nm O
, O
the O
addition O
of O
core O
/ O
shell O
nanorods O
with O
an O
AR O
of O
~ O
4 O
( O
extinction O
peak O
~ O
830 O
nm O
) O
resulted O
in O
a O
14 O
. O
4 O
% O
improvement O
in O
PCE O
. O

The O
addition O
of O
Au O
/ O
SiO2 O
core O
/ O
shell O
nanospheres O
to O
the O
P3HT O
: O
PC60BM B
- O
polymer O
resulted O
in O
a O
2 O
. O
7 O
% O
improvement O
in O
PCE O
, O
while O
their O
addition O
to O
a O
PBDTT B
- I
DPP I
: O
PC60BM B
polymer O
resulted O
in O
a O
9 O
. O
1 O
% O
improvement O
. O

Interactions O
between O
solid O
surfaces O
with O
pre O
- O
adsorbed O
poly B
( I
ethylenimine I
) I
( O
PEI O
) O
layers O
: O
effect O
of O
unadsorbed O
free O
PEI O
chains O
. O

Poly B
( I
ethylenimine I
) I
( O
PEI O
) O
polyelectrolytes O
have O
been O
widely O
used O
to O
tune O
the O
stability O
, O
rheology O
, O
or O
adhesion O
properties O
of O
colloidal O
suspensions O
due O
to O
their O
strong O
tendency O
to O
adsorb O
to O
solid O
surfaces O
. O

This O
study O
evaluated O
the O
in O
vitro O
cytotoxicity O
of O
poly B
( I
propylene I
fumarate I
) I
( O
PPF B
) O
. O

PPF B
is O
an O
aliphatic O
biodegradable O
polymer O
that O
has O
been O
well O
characterized O
for O
use O
in O
bone O
tissue O
engineering O
scaffolds O
. O

Four O
different O
cell O
types O
, O
human O
mesenchymal O
stem O
cells O
( O
hMSC O
) O
, O
fibroblasts O
( O
L929 O
) O
, O
preosteoblasts O
( O
MC3T3 O
) O
, O
and O
canine O
mesenchymal O
stem O
cells O
( O
cMSC O
) O
, O
were O
used O
to O
evaluate O
the O
cytotoxicity O
of O
PPF B
. O

These O
cell O
types O
represent O
the O
tissues O
that O
PPF B
would O
interact O
with O
in O
vivo O
as O
a O
bone O
tissue O
scaffold O
. O

The O
sol O
fraction O
of O
the O
PPF B
films O
was O
measured O
and O
then O
utilized O
to O
estimate O
cross O
- O
linking O
density O
. O

Cytotoxicity O
was O
evaluated O
using O
XTT B
assay O
and O
fluorescence O
imaging O
. O

Results O
showed O
that O
PPF B
supported O
similar O
cell O
metabolic O
activities O
of O
hMSC O
, O
L929 O
, O
MC3T3 O
, O
and O
cMSC O
compared O
to O
the O
noncytotoxic O
control O
, O
high O
- O
density O
polyethylene O
( O
HDPE O
) O
and O
were O
statistically O
different O
than O
those O
cultured O
with O
the O
cytotoxic O
control O
, O
a O
polyurethane O
film O
containing O
0 O
. O
1 O
% O
zinc B
diethyldithiocarbama I
( O
ZCF B
) O
. O

Results O
showed O
differing O
cellular O
responses O
to O
ZCF B
, O
the O
cytotoxic O
control O
. O

The O
L929 O
cells O
had O
the O
lowest O
cell O
metabolic O
activity O
levels O
after O
exposure O
to O
ZCF B
compared O
to O
the O
cell O
metabolic O
activity O
levels O
of O
the O
MC3T3 O
, O
hMSC O
, O
or O
cMSC O
cells O
. O

Qualitative O
verification O
of O
the O
results O
using O
fluorescence O
imaging O
demonstrated O
no O
change O
in O
cell O
morphology O
, O
vacuolization O
, O
or O
detachment O
when O
cultured O
with O
PPF B
compared O
to O
HDPE O
or O
blank O
media O
cultures O
. O

Overall O
, O
the O
cytotoxicity O
response O
of O
the O
cells O
to O
PPF B
was O
demonstrated O
to O
be O
similar O
to O
the O
cytotoxic O
response O
of O
cells O
to O
known O
noncytotoxic O
materials O
( O
HDPE O
) O
. O

Inducible O
nitric O
oxide O
synthase O
( O
iNOS O
) O
mRNA O
and O
protein O
levels O
at O
6h O
were O
significantly O
lower O
in O
lpr O
mice O
, O
which O
correlated O
with O
reduced O
nitrotyrosine B
staining O
. O

The O
extra O
- O
pyramidal O
symptoms O
associated O
with O
manganism B
often O
overlap O
with O
that O
seen O
in O
Parkinsonism O
suggesting O
a O
common O
link O
between O
the O
two O
disorders O
. O

Since O
wide O
deviations O
are O
observed O
in O
susceptibility O
and O
characteristics O
of O
the O
symptoms O
observed O
in O
manganism B
, O
these O
differences O
may O
be O
due O
to O
underlying O
genetic O
variability O
. O

Of O
the O
other O
Parkinson O
- O
linked O
genes O
, O
mutations O
in O
LRRK2 O
, O
an O
autosomal O
dominant O
gene O
, O
represent O
another O
likely O
candidate O
involved O
in O
the O
development O
of O
manganism B
. O

Our O
findings O
suggest O
that O
null O
mutations O
in O
LRRK2 O
which O
cause O
Parkinsonism O
potentiate O
Mn O
toxicity O
and O
increase O
susceptibility O
to O
develop O
manganism B
. O

Dendritic O
architectures O
based O
on O
bis B
- I
MPA I
: O
functional O
polymeric O
scaffolds O
for O
application O
- O
driven O
research O
. O

A O
dendritic O
family O
that O
fulfills O
these O
requirements O
is O
based O
on O
the O
2 B
, I
2 I
- I
bismethylolpropionic I
acid I
( O
bis B
- I
MPA I
) O
monomer O
. O

This O
critical O
review O
is O
the O
first O
of O
its O
kind O
to O
cover O
most O
of O
the O
research O
activities O
generated O
on O
aliphatic O
polyester O
dendritic O
architectures O
based O
on O
bis B
- I
MPA I
. O

In O
vivo O
FT O
- O
Raman O
spectroscopy O
reveals O
the O
presence O
of O
H2O2 O
, O
methionine B
sulfoxide I
, O
and O
tryptophan O
metabolites O
; O
i O
. O
e O
. O
, O
N O
- O
formylkynurenine O
and O
kynurenine B
, O
implying O
Fenton O
chemistry O
in O
the O
cascade O
( O
n O
= O
10 O
) O
. O

Matrix O
Metalloproteinase O
Inhibitors O
Based O
on O
the O
3 B
- I
Mercaptopyrrolidine I
Core O
. O

New O
series O
of O
pyrrolidine B
mercaptosulfide I
, O
2 B
- I
mercaptocyclopentane I
arylsulfonamide I
, O
and O
3 B
- I
mercapto I
- I
4 I
- I
arylsulfonamido I
pyrrolidine I
matrix O
metalloproteinase O
inhibitors O
( O
MMPIs O
) O
were O
designed O
, O
synthesized O
, O
and O
evaluated O
. O

Our O
previous O
work O
with O
the O
mercaptosulfide B
functionality O
attached O
to O
both O
cyclopentane O
and O
pyrrolidine B
frameworks O
demonstrated O
that O
the O
cis O
- O
( O
3S O
, O
4R O
) O
- O
stereochemistry O
was O
optimal O
for O
all O
of O
the O
MMPs O
tested O
. O

However O
, O
in O
our O
newest O
compounds O
an O
interesting O
shift O
of O
preference O
to O
the O
trans O
- O
form O
of O
the O
mercaptosulfonamides B
was O
observed O
with O
increased O
oxidative O
stability O
and O
biological O
compatibility O
. O

Design O
, O
Synthesis O
and O
Biological O
Evaluation O
of O
Aminoalkylindole B
Derivatives O
as O
Cannabinoid O
Receptor O
Ligands O
with O
Potential O
for O
Treatment O
of O
Alcohol O
Abuse O
. O

We O
have O
recently O
reported O
that O
a O
mono O
- O
hydroxylated O
metabolite O
of O
the O
synthetic O
aminoalkylindole B
cannabinoid O
JHW B
- I
073 I
( O
3 O
) O
exhibits O
neutral O
antagonist O
activity O
at O
CB1Rs O
and O
thus O
may O
serve O
as O
a O
promising O
lead O
for O
the O
development O
of O
novel O
alcohol O
abuse O
therapies O
. O

In O
the O
current O
study O
, O
we O
show O
that O
systematic O
modification O
of O
an O
aminoalkylindole B
scaffold O
identifies O
two O
new O
compounds O
with O
dual O
CB1R O
antagonist O
/ O
CB2R O
agonist O
activity O
. O

Collectively O
, O
these O
initial O
findings O
suggest O
that O
design O
and O
systematic O
modification O
of O
aminoalkylindoles B
such O
as O
3 O
may O
lead O
to O
development O
of O
novel O
cannabinoid O
ligands O
with O
dual O
CB1R O
antagonist O
/ O
CB2R O
agonist O
activity O
with O
potential O
for O
use O
as O
treatments O
of O
alcohol O
abuse O
. O

Milk O
- O
Derived O
Peptides O
, O
Val B
- I
Pro I
- I
Pro I
and O
Ile B
- I
Pro I
- I
Pro I
, O
Attenuate O
Atherosclerosis O
Development O
in O
Apolipoprotein O
E O
- O
Deficient O
Mice O
: O
A O
Preliminary O
Study O
. O

Abstract O
Milk O
- O
derived O
peptides O
, O
Val B
- I
Pro I
- I
Pro I
( O
VPP O
) O
and O
Ile B
- I
Pro I
- I
Pro I
( O
IPP O
) O
, O
have O
angiotensin O
I O
- O
converting O
enzyme O
inhibitory O
activities O
and O
blood O
pressure O
- O
lowering O
effects O
. O

For O
31 O
weeks O
, O
six O
- O
week O
- O
old O
male O
apoE O
( O
- O
/ O
- O
) O
mice O
received O
a O
diet O
that O
included O
one O
of O
the O
following O
: O
fermented O
milk O
containing O
both O
VPP O
and O
IPP O
; O
casein O
hydrolysate O
containing O
both O
of O
these O
peptides O
; O
synthesized O
VPP O
; O
synthesized O
IPP O
; O
enalapril B
; O
captopril O
; O
or O
control O
diet O
. O

There O
were O
no O
significant O
changes O
in O
the O
plasma O
lipid O
levels O
and O
8 B
- I
isoprostane I
, O
a O
marker O
of O
oxidative O
stress O
. O

The O
area O
ratio O
of O
intima O
to O
media O
in O
the O
aortic O
arch O
was O
significantly O
lower O
in O
the O
fermented O
milk O
, O
casein O
hydrolysate O
, O
synthesized O
VPP O
, O
enalapril B
, O
and O
captopril O
groups O
than O
in O
the O
control O
group O
. O

Highly O
Enantioselective O
Zirconium O
- O
Catalyzed O
Cyclization O
of O
Aminoalkenes B
. O

Aminoalkenes B
are O
catalytically O
cyclized O
in O
the O
presence O
of O
cyclopentadienylbis B
( I
oxazolinyl I
) I
borato I
group O
4 O
complexes O
{ B
PhB I
( I
C5H4 I
) I
( I
Ox I
( I
R I
) I
) I
2 I
} I
M I
( I
NMe2 I
) I
2 I
( O
M O
= O
Ti O
, O
Zr B
, O
Hf O
; O
Ox B
( I
R I
) I
= O
4 B
, I
4 I
- I
dimethyl I
- I
2 I
- I
oxazoline I
, O
4S B
- I
isopropyl I
- I
5 I
, I
5 I
- I
dimethyl I
- I
2 I
- I
oxazoline I
, O
4S O
- O

tert O
- O
butyl O
- O
2 O
- O
oxazoline O
) O
at O
room O
temperature O
and O
below O
, O
affording O
five O
- O
, O
six O
- O
, O
and O
seven O
- O
membered O
N B
- I
heterocyclic I
amines I
with O
enantiomeric O
excesses O
of O
> O
90 O
% O
in O
many O
cases O
and O
up O
to O
99 O
% O
. O

Secondary B
aminopentene I
cyclizations O
require O
a O
primary O
amine O
( O
1 O
- O
2 O
equiv O
vs O
catalyst O
) O
. O

Aminoalkenes B
are O
unchanged O
in O
the O
presence O
of O
a O
zirconium B
monoamido I
complex O
{ B
PhB I
( I
C5H4 I
) I
( I
Ox I
( I
4S I
- I
iPr I
, I
Me2 I
) I
) I
2 I
} I
Zr I
( I
NMe2 I
) I
Cl I
or O
a O
cyclopentadienylmono B
( I
oxazolinyl I
) I
borato I
zirconium I
diamide I
{ B
Ph2B I
( I
C5H4 I
) I
( I
Ox I
( I
4S I
- I
iPr I
, I
Me2 I
) I
) I
} I
Zr I
( I
NMe2 I
) I
2 I
. O

Asymmetric O
hydroamination O
/ O
cyclization O
of O
N B
- I
deutero I
- I
aminoalkenes I
provides O
products O
with O
higher O
optical O
purities O
than O
obtained O
with O
N B
- I
proteo I
- I
aminoalkenes I
. O

A O
six O
- O
centered O
, O
concerted O
transition O
state O
for O
C O
- O
N O
and O
C O
- O
H O
bond O
formation O
and O
N O
- O
H O
bond O
cleavage O
involving O
two O
amidoalkene B
ligands O
is O
proposed O
as O
most O
consistent O
with O
the O
current O
data O
. O

Elucidation O
of O
the O
biochemical O
basis O
for O
a O
clinical O
drug O
- O
drug O
interaction O
between O
atorvastatin O
and O
5 B
- I
( I
N I
- I
( I
4 I
- I
( I
( I
4 I
- I
ethylbenzyl I
) I
thio I
) I
phenyl I
) I
sulfamoyl I
) I
- I
2 I
- I
methyl I
benzoic I
acid I
( O
CP B
- I
778 I
875 I
) O
, O
a O
subtype O
selective O
agonist O
of O
the O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
. O

Abstract O
1 O
. O
5 B
- I
( I
N I
- I
( I
4 I
- I
( I
( I
4 I
- I
ethylbenzyl I
) I
thio I
) I
phenyl I
) I
sulfamoyl I
) I
- I
2 I
- I
methyl I
benzoic I
acid I
( O
CP B
- I
778 I
875 I
) O
, O
an O
agonist O
of O
the O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
, O
has O
been O
evaluated O
in O
the O
clinic O
to O
treat O
dyslipidemia O
and O
type O
2 O
diabetes O
mellitus O
. O

Herein O
, O
we O
investigate O
the O
effect O
of O
CP B
- I
778 I
875 I
on O
the O
pharmacokinetics O
of O
atorvastatin B
acid I
and O
its O
metabolites O
in O
humans O
. O

Group O
A O
was O
designed O
to O
estimate O
the O
effects O
of O
multiple O
doses O
of O
CP B
- I
778 I
875 I
on O
the O
single O
dose O
pharmacokinetics O
of O
atorvastatin O
. O

Subjects O
in O
group O
A O
( O
n O
= O
26 O
) O
received O
atorvastatin O
( O
40 O
mg O
) O
on O
days O
1 O
and O
9 O
and O
CP B
- I
778 I
875 I
( O
1 O
. O
0 O
mg O
QD O
) O
on O
days O
5 O
- O
12 O
. O

Group O
B O
was O
designed O
to O
examine O
the O
effects O
of O
multiple O
doses O
of O
atorvastatin O
on O
the O
single O
dose O
pharmacokinetics O
of O
CP B
- I
778 I
875 I
. O

Subjects O
in O
group O
B O
( O
n O
= O
29 O
) O
received O
CP B
- I
778 I
875 I
( O
0 O
. O
3 O
mg O
) O
on O
days O
1 O
and O
9 O
and O
atorvastatin O
( O
40 O
mg O
QD O
) O
on O
days O
5 O
- O
12 O
. O

3 O
. O
Mean O
maximum O
serum O
concentration O
( O
Cmax O
) O
and O
area O
under O
the O
curve O
of O
atorvastatin O
were O
increased O
by O
45 O
% O
and O
20 O
% O
, O
respectively O
, O
upon O
co O
- O
administration O
with O
CP B
- I
778 I
875 I
. O

Statistically O
significant O
increases O
in O
the O
systemic O
exposure O
of O
ortho B
- I
and I
para I
- I
hydroxyatorvastatin I
were O
also O
observed O
upon O
concomitant O
dosing O
with O
CP B
- I
778 I
875 I
. O

CP B
- I
778 I
875 I
pharmacokinetics O
, O
however O
, O
were O
not O
impacted O
upon O
concomitant O
dosing O
with O
atorvastatin O
. O

4 O
. O
Inhibition O
of O
organic O
anion O
transporting O
polypeptide O
1B1 O
by O
CP B
- I
778 I
875 I
( O
IC50 O
= O
2 O
. O
14 O
+ O
/ O
- O
0 O
. O
40 O
mu O
M O
) O
could O
be O
the O
dominant O
cause O
of O
the O
pharmacokinetic O
interaction O
as O
CP B
- I
778 I
875 I
did O
not O
exhibit O
significant O
inhibition O
of O
cytochrome O
P450 O
3A4 O
/ O
3A5 O
, O
multidrug O
resistant O
protein O
1 O
or O
breast O
cancer O
resistant O
protein O
, O
which O
are O
also O
involved O
in O
the O
hepatobiliary O
disposition O
of O
atorvastatin O
. O

Simultaneous O
determination O
by O
LC O
- O
MS O
/ O
MS O
of O
25 B
- I
methoxydammarane I
- I
3 I
beta I
, I
12 I
beta I
, I
20 I
- I
triol I
epimers O
and O
active O
metabolites O
in O
rat O
plasma O
after O
intravenous O
administration O
. O

The O
pharmacokinetics O
of O
the O
25 B
- I
OCH3 I
- I
PPD I
epimers O
and O
active O
metabolites O
in O
rat O
plasma O
after O
a O
single O
intravenous O
( O
i O
. O
v O
. O
) O
administration O
were O
studied O
by O
a O
rapid O
, O
selective O
and O
sensitive O
UPLC O
- O
MS O
/ O
MS O
method O
. O

The O
quantification O
was O
performed O
with O
the O
transitions O
of O
m O
/ O
z O
493 O
. O
5 O
- O
- O
> O
475 O
. O
5 O
for O
20 B
( I
R I
, I
S I
) I
- I
25 I
- I
OCH3 I
- I
PPD I
, O
m O
/ O
z O
479 O
. O
5 O
- O
- O
> O
461 O
. O
5 O
for O
20 B
( I
R I
, I
S I
) I
- I
25 I
- I
OH I
- I
PPD I
. O

The O
Lower O
Limit O
Of O
Quantitation O
( O
LLOQ O
) O
was O
20 O
. O
0 O
ng O
mL O
( O
- O
1 O
) O
for O
20 B
( I
R I
, I
S I
) I
- I
25 I
- I
OCH3 I
- I
PPD I
, O
2 O
. O
0 O
ng O
mL O
( O
- O
1 O
) O
for O
20 B
( I
R I
, I
S I
) I
- I
25 I
- I
OH I
- I
PPD I
in O
the O
plasma O
samples O
assay O
. O

The O
pharmacokinetic O
parameters O
of O
AUC O
, O
t1 O
/ O
2 O
and O
MRT O
had O
no O
difference O
between O
20 B
( I
R I
) I
- I
and I
( I
S I
) I
- I
25 I
- I
OCH3 I
- I
PPD I
, O
but O
S O
- O
epimer O
has O
a O
lower O
plasma O
clearance O
compared O
to O
the O
R O
- O
isomer O
. O

The O
active O
metabolite O
20 B
( I
S I
) I
- I
25 I
- I
OH I
- I
PPD I
showed O
significantly O
higher O
AUC O
, O
MRT O
and O
a O
longer O
half O
- O
life O
than O
that O
of O
20 B
( I
R I
) I
- I
25 I
- I
OH I
- I
PPD I
. O

These O
assay O
results O
are O
necessary O
for O
the O
evaluation O
of O
the O
pharmacokinetic O
behavior O
of O
25 B
- I
methoxydammarane I
- I
3 I
beta I
, I
12 I
beta I
, I
20 I
- I
triol I
in O
vivo O
. O

An O
investigation O
of O
the O
effect O
of O
thiamine B
pyrophosphate I
on O
cisplatin O
- O
induced O
oxidative O
stress O
and O
DNA O
damage O
in O
rat O
brain O
tissue O
compared O
with O
thiamine O
: O
Thiamine O
and O
thiamine B
pyrophosphate I
effects O
on O
cisplatin O
neurotoxicity O
. O

This O
study O
investigated O
the O
effects O
of O
thiamine B
pyrophosphate I
( O
TPP O
) O
at O
dosages O
of O
10 O
and O
20 O
mg O
/ O
kg O
on O
oxidative O
stress O
induced O
in O
rat O
brain O
tissue O
with O
cisplatin O
and O
compared O
this O
with O
thiamine O
. O

Our O
results O
showed O
that O
cisplatin O
increased O
the O
levels O
of O
oxidant O
parameters O
such O
as O
lipid O
peroxidation O
( O
thio B
barbituric I
acid I
reactive O
substance O
( O
TBARS O
) O
) O
and O
myeloperoxidase O
( O
MPO O
) O
in O
brain O
tissue O
and O
suppressed O
the O
effects O
of O
antioxidants O
such O
as O
total O
glutathione O
( O
GSH O
) O
and O
superoxide O
dismutase O
( O
SOD O
) O
. O

In O
addition O
, O
the O
level O
of O
8 B
- I
Gua I
( O
guanine O
) O
, O
a O
product O
of O
DNA O
damage O
, O
was O
1 O
. O
7 O
+ O
/ O
- O
0 O
. O
12 O
8 B
- I
hydroxyl I
guanine I
( O
8 B
- I
OH I
Gua I
) O
/ O
105 O
Gua O
in O
brain O
tissue O
in O
the O
control O
group O
receiving O
cisplatin O
, O
compared O
with O
0 O
. O
97 O
+ O
/ O
- O
0 O
. O
03 O
8 O
- O
OH O
Gua O
/ O
105 O
Gua O
in O
the O
thiamine B
pyrophosphate I
( O
20 O
mg O
/ O
kg O
) O
group O
and O
1 O
. O
55 O
+ O
/ O
- O
0 O
. O
11 O
8 B
- I
OH I
Gua I
/ O
105 O
Gua O
in O
the O

These O
results O
show O
that O
thiamine B
pyrophosphate I
significantly O
prevents O
oxidative O
damage O
induced O
by O
cisplatin O
in O
brain O
tissue O
, O
while O
the O
protective O
effect O
of O
thiamine O
is O
insignificant O
. O

The O
present O
study O
aimed O
to O
determine O
the O
acute O
toxicity O
and O
evaluate O
the O
effect O
of O
subacute O
concentrations O
of O
Ag O
- O
NPs O
( O
Nanocid B
( O
R O
) O
: O
average O
particle O
size O
of O
61 O
nm O
) O
on O
hematological O
and O
plasma O
biochemical O
indices O
of O
silver O
carp O
, O
Hypophthalmichthys O
molitrix O
, O
after O
3 O
, O
7 O
and O
14 O
days O
. O

The O
24 O
- O
, O
48 O
- O
, O
72 O
- O
and O
96 O
- O
h O
median O
lethal O
concentration O
( O
LC50 O
) O
values O
of O
Nanocid B
for O
silver O
carp O
were O
estimated O
at O
0 O
. O
810 O
, O
0 O
. O
648 O
, O
0 O
. O
383 O
and O
0 O
. O
202 O
mg O
/ O
L O
, O
respectively O
; O
20 O
% O
and O
10 O
% O
of O
the O
96 O
- O
h O
LC50 O
values O
( O
0 O
. O
04 O
and O
0 O
. O
02 O
mg O
/ O
L O
) O
were O
selected O
for O
subacute O
study O
. O

White O
blood O
cell O
( O
WBC O
) O
, O
mean O
corpuscular O
hemoglobin O
( O
MCH O
) O
, O
mean O
corpuscular O
hemoglobin O
concentration O
( O
MCHC O
) O
, O
cortisol O
and O
glucose O
levels O
in O
Nanocid B
- O
treated O
groups O
were O
significantly O
higher O
than O
the O
controlled O
group O
at O
experimental O
periods O
( O
p O
< O
0 O
. O
05 O
) O
. O

Calcium O
pathways O
such O
as O
cAMP O
modulate O
clothianidin B
action O
through O
activation O
of O
alpha O
- O
bungarotoxin O
- O
sensitive O
and O
- O
insensitive O
nicotinic O
acetylcholine O
receptors O
. O

Clothianidin B
is O
a O
neonicotinoid O
insecticide O
developed O
in O
the O
early O
2000s O
. O

Clothianidin B
was O
able O
to O
act O
as O
an O
agonist O
of O
imidacloprid O
- O
insensitive O
nAChR2 O
receptor O
and O
internal O
regulation O
of O
cAMP O
concentration O
modulated O
nAChR2 O
sensitivity O
to O
clothianidin B
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
cAMP O
modulated O
the O
agonist O
action O
of O
clothianidin B
via O
alpha O
- O
bungarotoxin O
- O
sensitive O
and O
insensitive O
receptors O
. O

Clothianidin B
- O
induced O
current O
- O
voltage O
curves O
were O
dependent O
to O
clothianidin B
concentrations O
. O

At O
10 O
mu O
M O
clothianidin B
, O
increasing O
cAMP O
concentration O
induced O
a O
linear O
current O
- O
voltage O
curve O
. O

Clothianidin B
effects O
were O
blocked O
by O
0 O
. O
5 O
mu O
M O
alpha O
- O
bungarotoxin O
suggesting O
that O
cAMP O
modulation O
occurred O
through O
alpha O
- O
bungarotoxin O
- O
sensitive O
receptors O
. O

At O
1mM O
clothianidin B
, O
cAMP O
effects O
were O
associated O
to O
alpha O
- O
bungarotoxin O
- O
insensitive O
receptors O
because O
clothianidin B
- O
induced O
currents O
were O
blocked O
by O
5 O
mu O
M O
mecamylamine O
and O
20 O
mu O
M O
d B
- I
tubocurarine I
. O

In O
addition O
, O
we O
found O
that O
application O
of O
1mM O
clothianidin B
induced O
a O
strong O
increase O
of O
intracellular O
calcium O
concentration O
. O

These O
data O
reinforced O
the O
finding O
that O
calcium O
pathways O
including O
cAMP O
modulated O
clothianidin B
action O
on O
insect O
nicotinic O
acetylcholine O
receptors O
. O

Immunoregulatory O
effects O
of O
Glycyrrhizic B
acid I
exerts O
anti O
- O
asthmatic O
effects O
via O
modulation O
of O
Th1 O
/ O
Th2 O
cytokines O
and O
enhancement O
of O
CD4 O
( O
+ O
) O
CD25 O
( O
+ O
) O
Foxp3 O
( O
+ O
) O
regulatory O
T O
cells O
in O
ovalbumin O
- O
sensitized O
mice O
. O

ETHNOPHARMACOLOGICAL O
RELEVANCE O
: O
Glycyrrhizic B
acid I
( O
GA O
) O
is O
the O
main O
bioactive O
ingredient O
of O
licorice O
( O
Glycyrrhiza O
glabra O
) O
, O
and O
has O
been O
found O
to O
be O
associated O
with O
multiple O
therapeutic O
properties O
. O

AIM O
OF O
THE O
STUDY O
: O
In O
this O
study O
, O
we O
investigated O
immunoregulatory O
effects O
of O
glycyrrhizic B
acid I
on O
anti O
- O
asthmatic O
effects O
and O
underlying O
mechanisms O
. O

These O
concepts O
are O
then O
used O
to O
analyze O
the O
electronic O
structure O
changes O
occurring O
in O
the O
reaction O
of O
C O
- O
H O
bond O
oxidation O
by O
Fe B
( I
IV I
) I
oxo I
species O
. O

The O
analysis O
reveals O
that O
the O
energy O
separation O
and O
the O
overlap O
between O
the O
electron O
donating O
orbitals O
and O
electron O
accepting O
orbitals O
of O
the O
Fe B
( I
IV I
) I
oxo I
complexes O
dictate O
the O
reaction O
stereochemistry O
, O
and O
that O
the O
manner O
in O
which O
the O
exchange O
interaction O
changes O
depends O
on O
the O
identity O
of O
these O
orbitals O
. O

The O
electronic O
reorganization O
of O
the O
Fe B
( I
IV I
) I
oxo I
species O
during O
the O
reaction O
is O
thoroughly O
analyzed O
and O
it O
is O
shown O
that O
the O
Fe B
( I
IV I
) I
oxo I
reactant O
develops O
oxyl B
radical O
character O
, O
which O
interacts O
effectively O
with O
the O
sigma O
CH O
orbital O
of O
the O
alkane B
. O

The O
theoretical O
predictions O
also O
correctly O
describe O
the O
isotopic O
effects O
in O
line O
positions O
and O
intensities O
due O
to O
the O
CH4 O
- O
- O
> O
CD4 B
substitution O
which O
is O
considered O
as O
the O
test O
for O
the O
method O
. O

The O
structure O
revealed O
a O
conformation O
intermediate O
to O
that O
of O
the O
recently O
solved O
complex O
with O
amlodipine B
and O
of O
the O
more O
compact O
complex O
with O
4 B
- I
( I
4 I
- I
chlorophenyl I
) I
imidazole I
in O
terms O
of O
the O
placement O
of O
the O
F O
- O
G O
cassette O
. O

Pyridinylquinazoline B
Selectively O
Inhibit O
Human O
Methionine O
Aminopeptidase O
- O
1 O
in O
Cells O
. O

In O
an O
effort O
to O
seek O
Co O
( O
II O
) O
- O
independent O
inhibitors O
, O
a O
novel O
structural O
class O
containing O
a O
2 B
- I
( I
pyridin I
- I
2 I
- I
yl I
) I
quinazoline I
core O
has O
been O
discovered O
. O

Indazole O
- O
based O
Potent O
and O
Cell O
- O
Active O
Mps1 O
Kinase O
Inhibitors O
: O
Rational O
Design O
from O
Pan O
- O
Kinase O
Inhibitor O
Anthrapyrazolone B
( O
SP600125 O
) O
. O

To O
design O
novel O
Mps1 O
inhibitors O
, O
we O
utilized O
the O
pan O
- O
kinase O
inhibitor O
anthrapyrazolone B
( O
4 O
, O
SP600125 O
) O
and O
its O
crystal O
structure O
bound O
to O
JNK1 O
. O

Synthesis O
and O
biological O
evaluation O
of O
( B
68 I
) I
Ga I
labeled I
bis I
- I
DOTA I
- O
3 B
, I
3 I
' I
- I
( I
benzylidene I
) I
- I
bis I
- I
( I
1H I
- I
indole I
- I
2 I
- I
carbohydrazide I
) I
as O
a O
PET O
tracer O
for O
in O
vivo O
visualization O
of O
necrosis O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
develop O
a O
( B
68 I
) I
Ga I
labeled I
bis I
- I
DOTA I
derivative O
of O
benzylidene B
- I
bis I
- I
indole I
and O
compare O
the O
in O
vivo O
stability O
and O
biodistribution O
with O
that O
of O
the O
previously O
reported O
bis B
- I
DTPA I
derivate O
for O
in O
vivo O
imaging O
of O
necrosis O
using O
PET O
. O

The O
novel O
( B
68 I
) I
Ga I
labeled O
tracer O
showed O
an O
improved O
in O
vivo O
stability O
and O
could O
therefore O
be O
used O
for O
selective O
non O
- O
invasive O
imaging O
of O
necrotic O
cell O
death O
using O
PET O
. O

We O
used O
atomic O
force O
microscopy O
( O
AFM O
) O
to O
study O
the O
dose O
- O
dependent O
change O
in O
conformational O
and O
mechanical O
properties O
of O
DNA O
treated O
with O
PT B
- I
ACRAMTU I
( B
[ I
PtCl I
( I
en I
) I
( I
ACRAMTU I
- I
S I
) I
] I
( I
NO3 I
) I
2 I
, O
( O
en O
= O
ethane B
- I
1 I
, I
2 I
- I
diamine I
, O
ACRAMTU B
= O
1 B
- I
[ I
2 I
- I
( I
acridin I
- I
9 I
- I
ylamino I
) I
ethyl I
] I
- I
1 I
, I
3 I
- I
dimethylthiourea I
. O

PT B
- I
ACRAMTU I
is O
the O
parent O
drug O
of O
a O
family O
of O
non O
- O
classical O
platinum O
- O
based O
agents O
that O
show O
potent O
activity O
in O
non O
- O
small O
cell O
lung O
cancer O
in O
vitro O
and O
in O
vivo O
. O

AFM O
images O
show O
that O
PT B
- I
ACRAMTU I
causes O
some O
DNA O
looping O
and O
aggregation O
at O
drug O
- O
to O
- O
base O
pair O
ratio O
( O
r O
b O
) O
of O
0 O
. O
1 O
and O
higher O
. O

Very O
significant O
lengthening O
of O
the O
DNA O
was O
observed O
with O
increasing O
doses O
of O
PT B
- I
ACRAMTU I
, O
and O
reached O
saturation O
at O
an O
r O
b O
of O
0 O
. O
15 O
. O

At O
r O
b O
of O
0 O
. O
1 O
, O
lengthening O
was O
0 O
. O
6 O
nm O
per O
drug O
molecule O
, O
which O
is O
more O
than O
one O
fully O
stretched O
base O
pair O
stack O
can O
accommodate O
, O
indicating O
that O
ACRAMTU B
also O
disturbs O
the O
stacking O
of O
neighboring O
base O
pair O
stacks O
. O

Analysis O
of O
the O
AFM O
images O
based O
on O
the O
worm O
- O
like O
chain O
( O
WLC O
) O
model O
showed O
that O
PT B
- I
ACRAMTU I
did O
not O
change O
the O
flexibility O
of O
( O
non O
- O
aggregated O
) O
DNA O
, O
despite O
the O
extreme O
lengthening O
. O

The O
persistence O
length O
of O
untreated O
DNA O
and O
DNA O
treated O
with O
PT B
- I
ACRAMTU I
was O
in O
the O
range O
of O
49 O
- O
65 O
nm O
. O

In O
this O
work O
we O
excite O
or O
ionize O
doped O
He O
droplets O
using O
synchrotron O
radiation O
and O
study O
the O
effect O
onto O
the O
dopant O
atoms O
depending O
on O
their O
location O
inside O
the O
droplets O
( O
rare O
gases O
) O
or O
outside O
at O
the O
droplet O
surface O
( O
alkali B
metals I
) O
. O

The O
surprising O
finding O
is O
that O
alkali B
metals I
, O
in O
contrast O
to O
the O
rare O
gases O
, O
are O
efficiently O
Penning O
ionized O
upon O
excitation O
of O
the O
( O
n O
= O
2 O
) O
- O
bands O
of O
the O
host O
droplets O
. O

Structural O
revision O
of O
methyl B
tortuoate I
D I
, O
a O
bis B
- I
cembranoid I
from O
Hainan O
Sarcophyton O
tortuosum O
and O
its O
absolute O
stereochemistry O
. O

Methyl B
tortuoate I
D I
( O
1 O
) O
, O
together O
with O
five O
other O
known O
related O
bis B
- I
cembranoids I
, O
was O
isolated O
from O
Hainan O
soft O
coral O
Sarcophyton O
tortuosum O
. O

The O
structure O
of O
methyl B
tortuoate I
D I
( O
1a O
) O
, O
firstly O
isolated O
and O
reported O
by O
Li O
et O
al O
. O
from O
the O
title O
organism O
, O
was O
corrected O
as O
1 O
by O
an O
extensive O
analysis O
of O
its O
one O
- O
dimensional O
and O
two O
- O
dimensional O
nuclear O
magnetic O
resonance O
data O
and O
by O
comparison O
with O
those O
reported O
in O
the O
literature O
. O

In O
addition O
, O
lobophytone B
K I
( O
1b O
) O
, O
recently O
isolated O
from O
Hainan O
soft O
coral O
Lobophytum O
pauciflorum O
by O
Lin O
et O
al O
. O
, O
was O
proved O
to O
be O
the O
same O
compound O
as O
1 O
and O
1a O
. O

The O
absolute O
configuration O
of O
1 O
was O
determined O
by O
comparing O
its O
electronic O
circular O
dichroism O
curve O
with O
that O
of O
co O
- O
occurring O
ximaolide B
A I
( O
2 O
) O
. O

Involvement O
of O
p O
- O
CREB O
and O
phase O
II O
detoxifying O
enzyme O
system O
in O
neuroprotection O
mediated O
by O
the O
flavonoid O
calycopterin B
isolated O
from O
Dracocephalum O
kotschyi O
. O

Herein O
, O
we O
investigated O
the O
effect O
of O
a O
natural O
neuroprotective O
flavonoid O
, O
calycopterin B
, O
on O
H2O2 O
- O
induced O
disruption O
of O
phase O
II O
detoxifying O
enzyme O
system O
and O
cAMP O
response O
element O
binding O
protein O
( O
CREB O
) O
phosphorylation O
. O

METHODS O
: O
PC12 O
cells O
were O
treated O
with O
25 O
, O
50 O
and O
100 O
mu O
M O
of O
calycopterin B
for O
3h O
, O
followed O
by O
adding O
H2O2 O
( O
150 O
mu O
M O
) O
for O
24h O
. O

The O
level O
of O
phosphorylated O
CREB O
, O
nuclear O
factor O
erythroid O
2 O
- O
related O
factor O
2 O
( O
Nrf2 O
) O
, O
glutamylcysteine B
synthetase O
( O
gamma O
- O
GCS O
) O
and O
heme O
oxygenase O
1 O
( O
HO O
- O
1 O
) O
were O
measured O
by O
western O
blot O
method O
. O

RESULT O
: O
Morphological O
analysis O
of O
protection O
induced O
by O
calycopterin B
, O
determined O
by O
comet O
assay O
, O
showed O
that O
calycopterin B
reduced O
DNA O
in O
tail O
. O

We O
found O
that O
H2O2 O
decreased O
mitochondrial O
membrane O
potential O
( O
MMP O
) O
, O
while O
, O
calycopterin B
prevented O
this O
decrease O
in O
MMP O
in O
presence O
of O
H2O2 O
. O

In O
H2O2 O
- O
treated O
cells O
, O
calycopterin B
also O
suppressed O
cytochrome O
C O
release O
to O
cytosol O
that O
is O
necessary O
for O
maintaining O
mitochondrial O
homeostasis O
in O
survived O
cells O
. O

Moreover O
, O
calycopterin B
, O
in O
presence O
of O
H2O2 O
inhibited O
the O
decrease O
caused O
by O
oxidative O
stress O
in O
stress O
- O
sensing O
transcription O
factors O
, O
CREB O
and O
Nrf2 O
, O
which O
play O
an O
important O
role O
in O
antioxidant O
capacity O
of O
the O
cell O
. O

There O
was O
also O
an O
increase O
in O
gamma O
- O
GCS O
and O
HO O
- O
1 O
levels O
in O
calycopterin B
pretreated O
cells O
. O

In O
the O
presence O
of O
H2O2 O
, O
calycopterin B
inhibited O
decrease O
in O
GSH O
level O
and O
SOD O
activity O
. O

CONCLUSION O
: O
We O
provided O
documentation O
of O
neuroprotective O
effect O
of O
a O
natural O
flavone O
, O
calycopterin B
, O
against O
H2O2 O
- O
induced O
oxidative O
stress O
in O
differentiated O
PC12 O
cells O
by O
modulating O
the O
level O
of O
CREB O
phosphorylation O
and O
Nrf2 O
pathway O
. O

Using O
E O
. O
coli O
cells O
with O
a O
special O
tRNA O
/ O
aminoacyl O
- O
tRNA O
synthetase O
pair O
, O
two O
PPAR O
alpha O
variants O
were O
prepared O
, O
in O
which O
Leu O
- O
258 O
or O
Phe O
- O
273 O
were O
site O
- O
specifically O
replaced O
by O
the O
genetically O
encoded O
photo O
- O
reactive O
amino O
acid O
para B
- I
benzoylphenylalanine I
( O
Bpa O
) O
. O

Differential O
Induction O
of O
Cytochrome O
P450 O
Isoforms O
and O
Peroxisomal O
Proliferation O
by O
Cyfluthrin B
in O
Male O
Wistar O
Rats O
. O

Cyfluthrin B
effects O
on O
in O
vivo O
drug O
metabolizing O
enzymes O
were O
evaluated O
using O
the O
oxidative O
substrate O
antipyrine B
. O

Antipyrine B
pharmacokinetics O
in O
plasma O
and O
urinary O
excretion O
of O
its O
major O
metabolites O
with O
and O
without O
cyfluthrin B
oral O
treatment O
( O
20mg O
/ O
kg O
/ O
day O
for O
6 O
days O
) O
were O
investigated O
in O
rats O
. O

Cyfluthrin B
increased O
the O
apparent O
intrinsic O
clearance O
and O
decreased O
the O
antipyrine B
half O
- O
life O
at O
beta O
phase O
. O

Cyfluthrin B
also O
increased O
the O
clearance O
of O
the O
antipyrine B
metabolites O
, O
norantipyrine B
, O
4 B
- I
hydroxyantipyrine I
and O
3 B
- I
hydroxymethylantipyr I
and O
the O
formation O
rate O
constants O
for O
each O
of O
the O
three O
metabolites O
measured O
in O
urine O
. O

These O
results O
suggest O
that O
cyfluthrin B
affects O
hepatic O
cytochrome O
P450 O
( O
CYP O
) O
system O
. O

We O
evaluated O
the O
effects O
of O
repeated O
exposure O
to O
cyfluthrin B
on O
hepatic O
and O
renal O
CYP2E O
, O
CYP1A O
and O
CYP4A O
subfamilies O
and O
peroxisomal O
proliferation O
in O
rats O
following O
oral O
administration O
( O
10 O
and O
20mg O
/ O
kg O
/ O
day O
for O
6 O
days O
) O
. O

At O
the O
highest O
dose O
, O
cyfluthrin B
increased O
renal O
and O
hepatic O
O O
- O
deethylation O
of O
ethoxyresorufin O
and O
O O
- O
demethylation O
of O
methoxyresorufin B
, O
metabolism O
mediated O
by O
the O
CYP1A O
subfamily O
. O

Liver O
and O
kidney O
were O
susceptible O
to O
cyfluthrin B
- O
dependent O
induction O
of O
12 O
- O
and O
11 O
- O
hydroxylation O
of O
lauric O
acid O
, O
suggesting O
CYP4A O
subfamily O
induction O
. O

Also O
cyfluthrin B
increased O
the O
beta O
- O
oxidation O
of O
palmitoyl O
- O
coenzyme O
A O
and O
carnitine O
acetyltransferase O
activity O
, O
supporting O
cyfluthrin B
as O
a O
peroxisome O
proliferator O
. O

In O
conclusion O
, O
the O
demonstration O
that O
cyfluthrin B
induced O
hepatic O
CYP1A O
, O
CYP4A O
subfamilies O
and O
peroxisomal O
proliferation O
raises O
the O
possibility O
of O
cyfluthrin B
could O
produce O
changes O
in O
oxidative O
stress O
. O

Indoxyl B
3 I
- I
sulfate I
stimulates O
Th17 O
differentiation O
enhancing O
phosphorylation O
of O
c O
- O
Src O
and O
STAT3 O
to O
worsen O
experimental O
autoimmune O
encephalomyelitis O
. O

In O
the O
present O
study O
, O
using O
in O
vitro O
Th17 O
differentiation O
model O
, O
we O
examined O
effects O
of O
AhR O
activation O
by O
indoxyl B
3 I
- I
sulfate I
( O
I3S B
) O
, O
a O
uremic O
toxin O
, O
on O
Th17 O
differentiation O
and O
investigated O
underlying O
mechanisms O
. O

I3S B
increased O
expression O
of O
ROR O
gamma O
t O
, O
the O
master O
transcription O
factor O
for O
Th17 O
differentiation O
, O
and O
stimulated O
Th17 O
differentiation O
, O
in O
a O
comparative O
manner O
as O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
tetrachlorodibenzo O
- O
p O
- O
dioxin O
( O
TCDD O
) O
, O
a O
prototypical O
AhR O
ligand O
. O

Activation O
of O
STAT3 O
, O
which O
is O
phosphorylated O
by O
the O
IL O
- O
6 O
signaling O
pathways O
and O
thus O
is O
necessary O
for O
Th17 O
differentiation O
, O
was O
strongly O
stimulated O
by O
I3S B
and O
TCDD O
. O

Phosphorylation O
of O
c O
- O
Src O
, O
which O
was O
shown O
to O
be O
activated O
by O
AhR O
ligands O
, O
was O
also O
increased O
by O
I3S B
and O
TCDD O
, O
and O
blocking O
of O
c O
- O
Src O
activity O
by O
4 B
- I
amino I
- I
5 I
- I
( I
4 I
- I
chlorophenyl I
) I
- I
7 I
- I
( I
t I
- I
butyl I
) I
pyrazolo I
[ I
3 I
, I
4 I
- I
d I
] I
pyrimidine I
( O
PP2 O
) O
inhibited O
phosphorylation O
of O
both O
c O
- O
Src O
and O
STAT3 O
, O
raising O
a O
possibility O
that O
stimulatory O
activities O
of O
I3S B
and O
TCDD O

Finally O
, O
we O
found O
that O
I3S B
worsened O
experimental O
autoimmune O
encephalomyelitis O
( O
EAE O
) O
, O
which O
is O
primarily O
mediated O
by O
Th17 O
cells O
, O
enhancing O
the O
frequency O
of O
IL O
- O
17 O
- O
producing O
cells O
in O
draining O
lymph O
nodes O
. O

C12 B
- O
, O
( B
C12 I
) I
2 I
- O
and O
cholesteryl B
- I
sperminex I
- O
siRNA O
were O
capable O
of O
luciferase O
knockdown O
at O
nanomolar O
concentrations O
without O
vectorization O
( O
i O
. O
e O
. O
one O
to O
two O
orders O
of O
magnitude O
more O
potent O
than O
commercially O
available O
cholesteryl B
siRNA O
) O
. O

A O
dihydrochalcone B
and O
several O
homoisoflavonoids B
from O
Polygonatum O
odoratum O
are O
activators O
of O
adenosine O
monophosphate O
- O
activated O
protein O
kinase O
. O

From O
the O
rhizomes O
of O
Polygonatum O
odoratum O
( O
Mill O
. O
) O
Druce O
, O
six O
homoisoflavonoids B
( O
1 O
- O
6 O
) O
and O
one O
dihydrochalcone B
( O
7 O
) O
were O
isolated O
, O
and O
the O
structures O
of O
polygonatones B
A I
- I
D I
( O
4 O
- O
7 O
) O
were O
elucidated O
by O
various O
spectroscopic O
analyses O
. O

Specifically O
, O
( B
3R I
) I
- I
5 I
, I
7 I
- I
dihydroxyl I
- I
6 I
- I
methyl I
- I
8 I
- I
methoxyl I
- I
3 I
- I
( I
4 I
' I
- I
hydroxylbenzyl I
) I
- I
chroman I
- I
4 I
- I
one I
( O
1 O
) O
, O
( B
3R I
) I
- I
5 I
, I
7 I
- I
dihydroxyl I
- I
6 I
, I
8 I
- I
dimethyl I
- I
3 I
- I
( I
4 I
' I
- I
hydroxylbenzyl I
) I
- I
chroman I
- I
4 I
- I
one I
( O
2 O
) O
, O
( O
3R O
) O
- O
5 O
, O
7 O
- O
dihydroxyl O
- O
6 O
- O
methyl O
- O
3 O
- O

( O
4 O
' O
- O
hydroxylbenzyl O
) O
- O
chroman O
- O
4 O
- O
one O
( O
3 O
) O
, O
and O
polygonatone B
D I
( O
7 O
) O
exhibited O
significant O
activation O
effects O
. O

Synthesis O
and O
structure O
- O
activity O
relationships O
of O
a O
novel O
and O
selective O
bone O
morphogenetic O
protein O
receptor O
( O
BMP O
) O
inhibitor O
derived O
from O
the O
pyrazolo B
[ I
1 I
. I
5 I
- I
a I
] I
pyrimidine I
scaffold O
of O
Dorsomorphin O
: O
The O
discovery O
of O
ML347 B
as O
an O
ALK2 O
versus O
ALK3 O
selective O
MLPCN O
probe O
. O

A O
structure O
- O
activity O
relationship O
of O
the O
3 O
- O
and O
6 O
- O
positions O
of O
the O
pyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidine I
scaffold O
of O
the O
known O
BMP O
inhibitors O
dorsomorphin B
, O
1 O
, O
LDN B
- I
193189 I
, O
2 O
, O
and O
DMH1 B
, O
3 O
, O
led O
to O
the O
identification O
of O
a O
potent O
and O
selective O
compound O
for O
ALK2 O
versus O
ALK3 O
. O

From O
these O
studies O
, O
a O
novel O
5 B
- I
quinoline I
molecule O
was O
identified O
and O
designated O
an O
MLPCN O
probe O
molecule O
, O
ML347 B
, O
which O
shows O
> O
300 O
- O
fold O
selectivity O
for O
ALK2 O
and O
presents O
the O
community O
with O
a O
selective O
molecular O
probe O
for O
further O
biological O
evaluation O
. O

We O
also O
describe O
in O
detail O
the O
protocol O
of O
an O
organophosphine B
- O
based O
biotin O
labeling O
of O
protein O
S O
- O
nitroso O
moieties O
. O

Mechanism O
of O
BDE209 B
- O
induced O
impaired O
glucose O
homeostasis O
based O
on O
gene O
microarray O
analysis O
of O
adult O
rat O
liver O
. O

2 B
, I
2 I
' I
, I
3 I
, I
3 I
' I
, I
4 I
, I
4 I
' I
, I
5 I
, I
5 I
' I
, I
6 I
, I
6 I
' I
- I
decabromodiphenyl I
ether I
( O
BDE209 B
) O
is O
commercially O
most O
important O
both O
in O
the O
production O
and O
in O
the O
use O
of O
polybrominated O
diphenyl O
ethers O
( O
PBDEs O
) O
. O

In O
the O
present O
study O
, O
male O
adult O
rats O
treated O
with O
BDE209 B
( O
0 O
, O
0 O
. O
05 O
, O
1 O
, O
and O
20 O
mg O
/ O
kg O
) O
for O
8 O
weeks O
were O
used O
to O
explore O
the O
effects O
of O
BDE209 B
on O
glucose O
homeostasis O
and O
possible O
mechanisms O
; O
0 O
. O
05 O
mg O
/ O
kg O
of O
BDE209 B
induced O
dose O
- O
related O
hyperglycemia O
. O

BDE209 B
induced O
1 O
, O
257 O
liver O
gene O
transcript O
changes O
, O
and O
18 O
canonical O
pathways O
were O
significantly O
enriched O
. O

Additionally O
, O
reduced O
glutathione O
and O
superoxide O
dismutase O
in O
plasma O
indicated O
that O
oxidative O
damage O
might O
partly O
contribute O
to O
BDE209 B
- O
induced O
hyperglycemia O
. O

The O
results O
of O
this O
study O
provide O
some O
new O
experimental O
evidence O
that O
the O
exposure O
to O
high O
levels O
of O
BDE209 B
may O
contribute O
to O
the O
onset O
of O
diabetes O
in O
human O
populations O
. O

This O
work O
demonstrates O
a O
novel O
multifunctional O
nanofibrous O
mat O
for O
photocatalytic O
applications O
based O
on O
TiO2 O
nanocables O
functionalized O
by O
Ag O
nanoparticles O
and O
coated O
with O
a O
thin O
( O
~ O
2 O
nm O
) O
graphitic B
shell O
. O

This O
multicomponent O
nanocable O
mat O
exhibits O
excellent O
photocatalytic O
activity O
under O
simulated O
solar O
irradiation O
for O
the O
degradation O
of O
model O
pollutants O
including O
RhB B
and O
phenol O
. O

Distinct O
role O
of O
PYK2 O
in O
mediating O
thromboxane B
generation O
downstream O
of O
both O
G12 O
/ O
13 O
and O
integrin O
alpha O
iib O
beta O
in O
platelets O
. O

We O
found O
that O
platelet O
aggregation O
and O
secretion O
in O
response O
to O
2 B
- I
MeSADP I
and O
AYPGKF O
were O
diminished O
in O
the O
presence O
of O
Pyk2 O
inhibitors O
or O
in O
Pyk2 O
- O
deficient O
platelets O
, O
suggesting O
that O
Pyk2 O
plays O
a O
positive O
regulatory O
role O
in O
platelet O
functional O
responses O
. O

It O
has O
been O
shown O
that O
ADP O
- O
, O
but O
not O
thrombin O
- O
, O
induced O
thromboxane B
( O
TxA2 B
) O
generation O
depends O
on O
integrin O
signaling O
. O

Unlike O
ADP O
, O
thrombin O
activates O
G12 O
/ O
13 O
pathways O
, O
and O
G12 O
/ O
13 O
pathways O
can O
substitute O
for O
integrin O
signaling O
for O
TxA2 B
generation O
. O

We O
found O
that O
Pyk2 O
was O
activated O
downstream O
of O
both O
G12 O
/ O
13 O
and O
integrin O
- O
mediated O
pathways O
, O
and O
both O
2 B
- I
MeSADP I
- O
and O
AYPGKF O
- O
induced O
TxA2 B
generation O
was O
significantly O
diminished O
in O
Pyk2 O
- O
deficient O
platelets O
. O

In O
addition O
, O
TxA2 B
generation O
induced O
by O
co O
- O
stimulation O
of O
Gi O
and O
Gz O
pathways O
, O
which O
is O
dependent O
on O
integrin O
signaling O
, O
was O
inhibited O
by O
blocking O
Pyk2 O
. O

Furthermore O
, O
inhibition O
of O
2 B
- I
MeSADP I
- O
induced O
TxA2 B
generation O
by O
fibrinogen O
receptor O
antagonist O
was O
not O
rescued O
by O
co O
- O
stimulation O
of O
G12 O
/ O
13 O
pathways O
in O
the O
presence O
of O
Pyk2 O
inhibitor O
. O

We O
conclude O
that O
Pyk2 O
is O
a O
common O
signaling O
effector O
downstream O
of O
both O
G12 O
/ O
13 O
and O
integrin O
alpha O
IIb O
beta O
3 O
signaling O
which O
contributes O
to O
thromboxane B
generation O
. O

For O
diethylenetriamine B
, O
triamine B
, O
or O
triethylenetetramine B
, O
tetramine B
mixed O
with O
SDS O
, O
there O
is O
monolayer O
adsorption O
at O
pH O
7 O
and O
10 O
, O
and O
multilayer O
adsorption O
at O
pH O
3 O
. O

For O
the O
slightly O
higher O
molecular O
weight O
tetraethylenepentami O
, O
pentamine B
, O
and O
pentaethylenehexamin B
, O
hexamine B
, O
the O
adsorption O
is O
in O
the O
form O
of O
a O
monolayer O
at O
pH O
3 O
and O
multilayers O
at O
pH O
7 O
and O
10 O
. O

Hence O
, O
there O
is O
a O
pH O
driven O
transition O
from O
monolayer O
to O
multilayer O
adsorption O
, O
which O
shifts O
from O
low O
pH O
to O
higher O
pH O
as O
the O
oligoamine O
molecular O
weight O
increases O
from O
tetramine B
to O
pentamine B
. O

This O
results O
from O
the O
relative O
balance O
between O
the O
electrostatic O
attraction O
between O
the O
SDS O
and O
amine B
nitrogen I
group O
which O
decreases O
as O
the O
charge O
density O
decreases O
with O
increasing O
pH O
, O
the O
ion O
- O
dipole O
interaction O
between O
the O
amine B
nitrogen I
and O
SDS B
sulfate I
group O
which O
is O
dominant O
at O
higher O
pH O
, O
and O
the O
hydrophobic O
interalkyl O
chain O
interaction O
between O
bound O
SDS O
molecules O
which O
changes O
with O
oligoamine O
molecular O
weight O
. O

Ethylene B
sulfide I
( O
ES O
) O
, O
propargyl B
carbonylimidazole I
( O
PPC B
) O
and O
azidoethyl B
carbonylimidazole I
( O
AEC B
) O
reacted O
with O
amine O
and O
/ O
or O
hydroxyl O
groups O
in O
BC O
to O
introduce O
the O
corresponding O
thiol O
, O
alkyne O
and O
azide O
groups O
on O
SS O
surfaces O
( O
SS O
- O
thiol O
, O
SS O
- O
alkyne O
and O
SS O
- O
azide O
, O
respectively O
) O
. O

Antifouling O
zwitterionic O
SS O
- O
PMPC O
surface O
was O
prepared O
by O
thiol O
- O
ene O
photopolymerization O
of O
2 B
- I
methacryloyloxyethyl I
phosphorylcholine I
( O
MPC B
) O
from O
the O
SS O
- O
thiol O
surface O
. O

Protein O
- O
resistant O
SS O
- O
PPEGMA B
and O
protein O
- O
adsorbing O
SS O
- O
PPFS B
surfaces O
were O
prepared O
by O
coupling O
of O
the O
respective O
azide O
- O
functionalized O
poly B
( I
poly I
( I
ethylene I
glycol I
) I
methyl I
ether I
methacrylate I
) I
( O
azido B
- I
PPEGMA I
) O
and O
poly B
( I
2 I
, I
3 I
, I
4 I
, I
5 I
, I
6 I
- I
pentafluorostyrene I
) I
( O
azido B
- I
PPFS I
) O
polymer O
brushes O
in O
azide O
- O
alkyne O
' O
click O
' O
reaction O
. O

Antifouling O
alkyne O
- O
functionalized O
poly B
( I
N I
- I
hydroxyethyl I
acrylamide I
) I
( O
alkynyl B
- I
PHEAA I
) O
and O
antibacterial O
alkyne O
- O
functionalized O
poly B
( I
2 I
- I
( I
methacryloyloxy I
) I
ethyl I
trimethylammonium I
chloride I
) I
( O
alkynyl B
- I
PMETA I
) O
polymer O
brushes O
were O
clicked O
on O
the O
SS O
- O
azide O
surface O
. O

The O
approach O
used O
in O
this O
paper O
allows O
the O
calculation O
of O
the O
free O
energy O
profile O
and O
enable O
us O
to O
explain O
the O
mechanism O
and O
kinetics O
of O
the O
neutral O
hydrolysis O
of O
normal O
( O
methyl B
acetate I
) O
and O
activated O
( O
methyl B
trifluoroacetate I
) O
esters O
. O

Synthesis O
of O
Hollow O
Ag B
- I
Au I
Bimetallic O
Nanoparticles O
in O
Polyelectrolyte O
Multilayers O
. O

Ag O
nanoparticles O
of O
~ O
20 O
nm O
size O
and O
rather O
uniform O
size O
distribution O
were O
synthesized O
in O
polyelectrolyte O
multilayers O
( O
PEMs O
) O
via O
an O
ion O
- O
exchange O
/ O
reduction O
process O
in O
two O
stages O
( O
seeding O
and O
growth O
) O
, O
which O
were O
used O
as O
sacrificial O
templates O
to O
fabricate O
Ag B
- I
Au I
bimetallic O
hollow O
nanoparticles O
via O
galvanic O
replacement O
reaction O
. O

The O
morphology O
and O
structure O
of O
the O
nanoparticles O
were O
characterized O
by O
transmission O
electron O
microscopy O
( O
TEM O
) O
and O
energy O
dispersive O
X O
- O
ray O
spectroscopy O
, O
which O
confirmed O
the O
formation O
of O
hollow O
Ag B
- I
Au I
bimetallic O
nanoparticles O
. O

UV O
- O
vis O
absorbance O
spectroscopy O
and O
TEM O
results O
indicated O
that O
both O
size O
and O
optical O
properties O
of O
the O
Ag O
nanoparticles O
in O
the O
PEM O
can O
be O
controlled O
by O
manipulating O
ion O
content O
in O
the O
PEM O
and O
the O
number O
of O
the O
ion O
- O
exchange O
/ O
reduction O
cycle O
, O
whereas O
that O
of O
Ag B
- I
Au I
bimetallic O
nanoparticles O
were O
dependent O
on O
size O
of O
the O
Ag O
templates O
and O
the O
replacement O
reaction O
kinetics O
. O

The O
hollow O
Ag B
- I
Au I
bimetallic O
nanoparticles O
exhibited O
a O
significant O
red O
shift O
in O
the O
surface O
plasmon O
resonance O
to O
the O
near O
- O
infrared O
region O
. O

Vibrational O
Perturbations O
of O
W B
( I
CO I
) I
6 I
Trapped O
in O
a O
Molecular O
Lattice O
Probed O
by O
Linear O
and O
Non O
Linear O
Spectroscopy O
. O

Vibrational O
dynamics O
of O
the O
T1u O
CO O
stretching O
mode O
of O
tungsten B
hexacarbonyl I
is O
explored O
when O
the O
molecule O
is O
embedded O
in O
a O
nitrogen O
matrix O
at O
low O
temperature O
. O

W B
( I
CO I
) I
6 I
is O
found O
to O
be O
trapped O
in O
two O
main O
families O
of O
sites O
differing O
by O
their O
symmetries O
( O
called O
hereafter O
Oh O
and O
D2h O
) O
. O

Experiments O
in O
solid O
krypton B
are O
performed O
to O
compare O
the O
effect O
of O
atomic O
and O
diatomic O
host O
lattices O
. O

Dephasing O
time O
in O
Kr B
does O
not O
depend O
on O
temperature O
and O
remains O
in O
the O
hundreds O
of O
picosecond O
, O
highlighting O
the O
molecular O
origin O
of O
dephasing O
process O
in O
N2 O
. O

The O
Pyrimidyn B
compounds O
: O
dual O
- O
action O
small O
molecule O
pyrimidine O
- O
based O
dynamin O
inhibitors O
. O

The O
most O
potent O
analogue O
, O
Pyrimidyn B
7 O
, O
has O
an O
IC50 O
of O
1 O
. O
1 O
mu O
M O
for O
dynamin O
I O
and O
1 O
. O
8 O
mu O
M O
for O
dynamin O
II O
, O
making O
it O
among O
the O
most O
potent O
dynamin O
inhibitors O
identified O
to O
date O
. O

We O
investigated O
the O
mechanism O
of O
action O
of O
the O
Pyrimidyn B
compounds O
in O
detail O
by O
examining O
the O
kinetics O
of O
Pyrimidyn B
7 O
inhibition O
of O
dynamin O
. O

Pyrimidyn B
6 O
and O
7 O
reversibly O
inhibit O
CME O
of O
both O
transferrin O
and O
EGF O
in O
a O
number O
of O
non O
- O
neuronal O
cell O
lines O
as O
well O
as O
inhibiting O
synaptic O
vesicle O
endocytosis O
( O
SVE O
) O
in O
nerve O
terminals O
. O

Therefore O
, O
Pyrimidyn B
compounds O
block O
endocytosis O
by O
directly O
competing O
with O
GTP O
and O
lipid O
binding O
to O
dynamin O
, O
limiting O
both O
the O
recruitment O
of O
dynamin O
to O
membranes O
and O
its O
activation O
. O

These O
findings O
substantiate O
the O
GABAergic B
system O
' O
s O
role O
in O
anxiety O
- O
related O
behaviors O
. O

Additionally O
, O
we O
did O
not O
observe O
motor O
activity O
deficits O
or O
appetite O
deficits O
following O
inhibition O
of O
GABAergic B
or O
glutamatergic O
neurotransmission O
. O

Here O
, O
we O
examined O
the O
effects O
produced O
by O
haloperidol O
, O
a O
typical O
antipsychotic O
drug O
, O
on O
the O
phosphorylation O
of O
rpS6 O
at O
Ser240 B
/ O
244 O
in O
the O
striatum O
, O
a O
brain O
region O
involved O
in O
neurodegenerative O
and O
neuropsychiatric O
disorders O
. O

Administration O
of O
haloperidol O
increased O
Ser240 B
/ O
244 O
phosphorylation O
in O
a O
subpopulation O
of O
GABA O
- O
ergic O
medium O
spiny O
neurons O
( O
MSNs O
) O
, O
which O
express O
dopamine O
D2 O
receptors O
( O
D2Rs O
) O
. O

This O
effect O
was O
prevented O
by O
rapamycin O
, O
an O
inhibitor O
of O
the O
mammalian O
target O
of O
rapamycin O
complex O
1 O
( O
mTORC1 O
) O
, O
or O
by O
PF470867 B
, O
a O
selective O
inhibitor O
of O
the O
p70 O
ribosomal O
S6 O
kinase O
1 O
( O
S6K1 O
) O
. O

We O
also O
found O
that O
the O
effect O
of O
haloperidol O
on O
Ser240 B
/ O
244 O
phosphorylation O
was O
prevented O
by O
functional O
inactivation O
of O
dopamine O
- O
and O
cAMP O
- O
regulated O
phosphoprotein O
of O
32 O
kDa O
( O
DARPP O
- O
32 O
) O
, O
an O
endogenous O
inhibitor O
of O
protein O
phosphatase O
- O
1 O
( O
PP O
- O
1 O
) O
. O

In O
line O
with O
this O
observation O
, O
incubation O
of O
striatal O
slices O
with O
okadaic B
acid I
and O
calyculin B
A I
, O
two O
inhibitors O
of O
PP O
- O
1 O
, O
increased O
Ser240 B
/ O
244 O
phosphorylation O
. O

These O
results O
show O
that O
haloperidol O
promotes O
mTORC1 O
- O
and O
S6K1 O
- O
dependent O
phosphorylation O
of O
rpS6 O
at O
Ser240 B
/ O
244 O
, O
in O
a O
subpopulation O
of O
striatal O
MSNs O
expressing O
D2Rs O
. O

They O
also O
indicate O
that O
this O
effect O
is O
exerted O
by O
suppressing O
dephosphorylation O
at O
Ser240 B
/ O
244 O
, O
through O
PKA O
- O
dependent O
activation O
of O
DARPP O
- O
32 O
and O
inhibition O
of O
PP O
- O
1 O
. O

The O
compound O
with O
the O
most O
potent O
neuroprotective O
action O
was O
N B
- I
{ I
3 I
- I
[ I
2 I
- I
( I
4 I
- I
phenyl I
- I
piperazin I
- I
1 I
- I
yl I
) I
- I
ethyl I
] I
- I
phenyl I
} I
- I
picolinamide I
( O
6b O
) O
, O
which O
reduced O
6 O
- O
OHDA O
- O
induced O
apoptotic O
death O
through O
stabilization O
of O
mitochondrial O
membrane O
and O
subsequent O
prevention O
of O
superoxide O
production O
, O
caspase O
activation O
and O
DNA O
fragmentation O
. O

The O
cytoprotective O
effect O
of O
6b O
was O
also O
observed O
in O
6 O
- O
OHDA O
- O
treated O
neuronal O
PC12 O
cells O
, O
but O
not O
in O
SH O
- O
SY5Y O
or O
PC12 O
cells O
exposed O
to O
1 B
- I
methyl I
- I
4 I
- I
phenylpyridinium I
, O
indicating O
that O
the O
observed O
neuroprotection O
was O
dependent O
on O
the O
cytotoxic O
stimulus O
. O

The O
fatty O
acid O
amide O
hydrolase O
inhibitor O
, O
URB597 B
, O
promotes O
retinal B
ganglion O
cell O
neuroprotection O
in O
a O
rat O
model O
of O
optic O
nerve O
axotomy O
. O

The O
endocannabinoid O
, O
N B
- I
arachidonoylethanola I
( O
AEA O
) O
, O
is O
degraded O
by O
the O
enzyme O
fatty O
acid O
amide O
hydrolase O
( O
FAAH O
) O
. O

This O
study O
examined O
whether O
the O
FAAH O
inhibitor O
, O
URB597 O
, O
increases O
retinal B
ganglion O
cell O
( O
RGC O
) O
survival O
following O
optic O
nerve O
axotomy O
in O
young O
and O
aged O
animals O
. O

URB597 B
alone O
, O
or O
together O
with O
either O
a O
CB1 O
or O
CB2 O
receptor O
antagonist O
, O
was O
administered O
daily O
for O
1 O
or O
2 O
weeks O
post O
- O
axotomy O
. O

Histological O
assessment O
of O
retinas O
indicated O
that O
URB597 B
increased O
RGC O
survival O
in O
young O
retina O
at O
1 O
and O
2 O
weeks O
post O
- O
axotomy O
. O

The O
CB1 O
antagonist O
, O
AM281 B
, O
but O
not O
the O
CB2 O
antagonist O
, O
AM630 B
, O
ablated O
URB597 B
- O
mediated O
RGC O
neuroprotection O
. O

CB1 O
or O
CB2 O
antagonism O
increased O
phagocytic O
microglia O
in O
URB597 B
and O
vehicle O
- O
treated O
animals O
. O

In O
aged O
animals O
, O
URB597 B
increased O
RGC O
survival O
at O
1 O
week O
, O
but O
not O
at O
2 O
weeks O
post O
- O
axotomy O
and O
had O
no O
effect O
on O
microglia O
. O

Retinal B
Iba O
- O
1 O
positive O
microglia O
were O
also O
decreased O
in O
URB597 B
- O
treated O
axotomized O
young O
animals O
and O
this O
decrease O
was O
mitigated O
by O
CB1 O
but O
not O
CB2 O
antagonism O
. O

As O
seen O
with O
phagocytotic O
microglia O
, O
the O
CB2 O
antagonist O
, O
AM630 B
, O
increased O
Iba O
- O
1 O
positive O
microglia O
in O
the O
absence O
of O
URB597 B
treatment O
. O

Measurement O
of O
retinal B
endocannabinoid O
levels O
in O
URB597 B
- O
treated O
animals O
at O
2 O
weeks O
post O
- O
axotomy O
revealed O
a O
significant O
increase O
in O
AEA O
levels O
, O
accompanied O
by O
a O
decrease O
by O
a O
decrease O
in O
the O
AEA O
metabolite O
, O
N B
- I
arachidonoylglycine I
, O
in O
young O
animals O
but O
not O
aged O
animals O
. O

These O
data O
demonstrate O
that O
URB597 B
- O
mediated O
retinal B
neuroprotective O
effects O
are O
mediated O
primarily O
through O
CB1 O
receptors O
and O
that O
URB597 B
neuroprotective O
efficacy O
declines O
with O
age O
. O

We O
found O
that O
application O
of O
Carbachol O
( O
CCh B
) O
and O
Norepinephrine O
( O
NE O
) O
both O
enhanced O
the O
spontaneous O
network O
dynamics O
by O
increasing O
( O
1 O
) O
the O
activity O
levels O
, O
( O
2 O
) O
the O
temporal O
complexity O
of O
the O
network O
activity O
, O
and O
( O
3 O
) O
the O
spatial O
complexity O
by O
decorrelating O
the O
network O
activity O
over O
a O
wide O
range O
of O
neuromodulator O
concentrations O
( O
1 O
mu O
M O
, O
10 O
mu O
M O
, O
50 O
mu O
M O
, O
and O
100 O
mu O
M O
) O
. O

Interestingly O
, O
we O
found O
that O
cholinergic O
neuromodulation O
was O
limited O
to O
the O
presence O
of O
CCh B
in O
the O
bath O
whereas O
the O
effects O
of O
NE O
, O
in O
particular O
for O
higher O
concentrations O
, O
induced O
plasticity O
that O
caused O
outlasting O
effects O
most O
prominently O
in O
the O
deep O
cortical O
layers O
. O

A O
potential O
drawback O
with O
the O
use O
of O
mannitol O
as O
a O
bulking O
agent O
is O
its O
existence O
as O
mannitol B
hemihydrate I
( O
MHH B
; O
C6H14O6 B
( I
. I
) I
0 I
. I
5H2O I
) O
in O
the O
lyophile O
. O

Once O
formed O
during O
freeze O
- O
drying O
, O
MHH B
dehydration O
may O
require O
secondary O
drying O
under O
aggressive O
conditions O
which O
can O
be O
detrimental O
to O
the O
stability O
of O
thermolabile O
components O
. O

If O
MHH B
is O
retained O
in O
the O
lyophile O
, O
the O
water O
released O
by O
MHH B
dehydration O
during O
storage O
has O
the O
potential O
to O
cause O
product O
instability O
. O

We O
systematically O
identified O
the O
conditions O
under O
which O
anhydrous O
mannitol O
and O
MHH B
crystallized O
in O
frozen O
systems O
with O
the O
goal O
of O
preventing O
MHH B
formation O
during O
freeze O
- O
drying O
. O

Based O
on O
low O
temperature O
X O
- O
ray O
diffractometry O
( O
using O
both O
laboratory O
and O
synchrotron O
sources O
) O
, O
MHH B
formation O
was O
observed O
when O
solute O
crystallization O
occurred O
at O
temperatures O
> O
= O
- O
20 O
degrees O
C O
while O
anhydrous O
mannitol O
crystallized O
at O
temperatures O
< O
= O
- O
10 O
degrees O
C O
. O

The O
transition O
temperature O
( O
anhydrate O
- O
MHH B
) O
appears O
to O
be O
~ O
- O
15 O
degrees O
C O
. O

Thus O
, O
ice O
crystallization O
followed O
by O
annealing O
at O
temperatures O
< O
= O
- O
10 O
degrees O
C O
can O
be O
an O
effective O
strategy O
to O
prevent O
MHH B
formation O
. O

Investigation O
on O
the O
interaction O
of O
the O
toxicant O
, O
gentian B
violet I
, O
with O
bovine O
hemoglobin O
. O

Gentian B
violet I
( O
GV O
) O
is O
a O
well O
- O
known O
triarylmethane B
dye O
that O
is O
used O
in O
aquacultural O
, O
industrial O
and O
medicinal O
fields O
. O

The O
C1 O
domain O
- O
targeted O
isophthalate B
derivative O
HMI O
- O
1b11 O
promotes O
neurite O
outgrowth O
and O
GAP O
- O
43 O
expression O
through O
PKC O
alpha O
activation O
in O
SH O
- O
SY5Y O
cells O
. O

Dialkyl B
5 I
- I
( I
hydroxymethyl I
) I
isophthalates I
are O
a O
novel O
group O
of O
synthetic O
C1 O
domain O
ligands O
that O
exhibit O
antiproliferative O
effect O
in O
HeLa O
cervical O
carcinoma O
cells O
. O

Here O
we O
selected O
two O
isophthalates B
, O
HMI O
- O
1a3 O
and O
HMI O
- O
1b11 O
, O
and O
characterized O
their O
effects O
in O
the O
human O
neuroblastoma O
cell O
line O
SH O
- O
SY5Y O
. O

Both O
of O
the O
active O
isophthalates B
exhibited O
significant O
antiproliferative O
and O
differentiation O
- O
inducing O
effects O
. O

Moreover O
, O
preliminary O
pharmacokinetic O
studies O
revealed O
that O
it O
showed O
improved O
oral O
absorption O
as O
compared O
to O
the O
lead O
compound O
iodiconazole B
and O
deserved O
for O
further O
evaluations O
. O

In O
addition O
, O
pretreatment O
with O
Z B
- I
Val I
- I
Ala I
- I
Asp I
- I
fluoromethylketone I
( O
Z O
- O
VAD O
- O
fmk O
) O
, O
a O
broad O
spectrum O
of O
caspase O
inhibitor O
, O
could O
not O
rescue O
apoptotic O
cells O
from O
ClpP O
toxicity O
. O

Heterologously O
expressed O
formyl B
peptide O
receptor O
2 O
( O
FPR2 O
/ O
ALX O
) O
does O
not O
respond O
to O
lipoxin B
A4 I
. O

Lipoxin B
A4 I
( O
LXA4 B
) O
has O
been O
described O
as O
an O
anti O
- O
inflammatory O
mediator O
, O
which O
exerts O
its O
effects O
through O
the O
formyl O
peptide O
receptor O
FPR2 O
, O
also O
known O
as O
ALX O
. O

However O
, O
there O
has O
been O
a O
controversy O
whether O
or O
not O
cells O
expressing O
FPR2 O
/ O
ALX O
, O
such O
as O
neutrophils O
, O
respond O
to O
LXA4 B
. O

We O
, O
therefore O
, O
systematically O
examined O
the O
ability O
of O
the O
human O
and O
murine O
forms O
of O
the O
receptor O
to O
respond O
to O
LXA4 B
. O

In O
contrast O
, O
LXA4 B
from O
different O
sources O
neither O
increased O
[ O
Ca O
( O
2 O
+ O
) O
] O
i O
and O
extracellular O
- O
signal O
- O
regulated O
kinase O
( O
ERK O
) O
phosphorylation O
, O
nor O
did O
it O
induce O
a O
decrease O
in O
cAMP O
levels O
or O
a O
translocation O
of O
beta O
- O
arrestin O
. O

Also O
, O
several O
LXA4 B
analogues O
were O
found O
to O
be O
unable O
to O
signal O
through O
FPR2 O
/ O
ALX O
. O

We O
conclude O
that O
FPR2 O
/ O
ALX O
is O
not O
activated O
by O
LXA4 B
and O
that O
the O
molecular O
mechanism O
by O
which O
LXA4 B
functions O
still O
needs O
to O
be O
identified O
. O

Design O
, O
synthesis O
and O
antiproliferative O
activity O
studies O
of O
novel O
1 B
, I
2 I
, I
3 I
- I
triazole I
- I
dithiocarbamate I
- I
urea I
hybrids O
. O

A O
series O
of O
novel O
1 B
, I
2 I
, I
3 I
- I
triazole I
- I
dithiocarbamate I
- I
urea I
hybrids O
were O
designed O
, O
synthesized O
and O
their O
antiproliferative O
activities O
against O
four O
selected O
human O
cancer O
cell O
lines O
were O
evaluated O
. O

Elucidation O
of O
the O
pharmacophore O
of O
echinocystic B
acid I
, O
a O
new O
lead O
for O
blocking O
HCV O
entry O
. O

To O
elucidate O
the O
pharmacophore O
of O
echinocystic B
acid I
( O
EA O
) O
, O
an O
oleanane O
- O
type O
triterpene O
displaying O
substantial O
inhibitory O
activity O
on O
HCV O
entry O
, O
two O
microbial O
strains O
, O
Rhizopus O
chinensis O
CICC O
3043 O
and O
Alternaria O
alternata O
AS O
3 O
. O
4578 O
, O
were O
utilized O
to O
modify O
the O
chemical O
structure O
of O
EA O
. O

Ligand O
- O
based O
design O
, O
synthesis O
, O
and O
experimental O
evaluation O
of O
novel O
benzofuroxan B
derivatives O
as O
anti O
- O
Trypanosoma O
cruzi O
agents O
. O

A O
set O
of O
substituted O
- O
[ O
N B
' I
- I
( I
benzofuroxan I
- I
5 I
- I
yl I
) I
methylene I
] I
benzohydrazides I
( O
4a O
- O
t O
) O
, O
previously O
designed O
and O
synthesized O
, O
was O
experimentally O
assayed O
against O
Trypanosoma O
cruzi O
, O
the O
etiological O
agent O
of O
Chagas O
' O
disease O
, O
one O
of O
the O
most O
neglected O
tropical O
diseases O
. O

Based O
upon O
the O
findings O
, O
six O
novel O
benzofuroxan B
derivatives O
( O
4u O
- O
z O
) O
were O
designed O
, O
synthesized O
, O
and O
in O
vitro O
assayed O
to O
perform O
the O
QSAR O
external O
prediction O
. O

N B
- I
Alkylated I
2 I
, I
3 I
, I
3 I
- I
trimethylindolenines I
and O
2 B
- I
methylbenzothiazoles I
. O

The O
synthesis O
of O
a O
variety O
of O
N B
- I
alkylated I
2 I
, I
3 I
, I
3 I
- I
trimethylindolenines I
and O
2 B
- I
methylbenzothiazoles I
is O
reported O
herein O
. O

Bioassays O
were O
set O
up O
to O
compare O
the O
efficacy O
of O
our O
range O
of O
N O
- O
alkylated O
compounds O
against O
classic O
antifungal O
agents O
; O
Amphotericin O
B O
and O
Thiabendazole B
. O

Synthesis O
and O
biological O
characterization O
of O
spiro B
[ I
2H I
- I
( I
1 I
, I
3 I
) I
- I
benzoxazine I
- I
2 I
, I
4 I
' I
- I
piperidine I
] I
based O
histone O
deacetylase O
inhibitors O
. O

Herein O
, O
we O
report O
further O
explorations O
, O
which O
resulted O
in O
the O
discovery O
of O
a O
new O
class O
of O
spiro B
[ I
2H I
- I
( I
1 I
, I
3 I
) I
- I
benzoxazine I
- I
2 I
, I
4 I
' I
- I
piperidine I
] I
derivatives O
. O

In O
addition O
, O
the O
two O
benzoxazines B
were O
found O
to O
have O
a O
minor O
affinity O
for O
the O
hERG O
potassium O
channel O
compared O
to O
their O
corresponding O
ketone O
analogues O
. O

Synthesis O
and O
in O
vitro O
anticancer O
studies O
of O
novel O
C O
- O
2 O
arylidene O
congeners O
of O
lantadenes B
. O

The O
antitumor O
pentacyclic O
triterpenoids O
, O
Lantadene B
A I
( I
1 I
) I
and I
B I
( O
2 O
) O
were O
isolated O
from O
the O
leaves O
of O
weed O
Lantana O
camara O
L O
. O

The O
Claisen O
- O
Schmidt O
reaction O
of O
22 B
beta I
- I
hydroxy I
- I
3 I
- I
oxoolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
5 O
) O
with O
requisite O
aldehydes O
afforded O
2 B
- I
arylidene I
- I
22 I
beta I
- I
hydroxy I
- I
3 I
- I
oxoolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acids I
( O
7 O
- O
16 O
) O
. O

Resulting O
from O
this O
study O
, O
a O
structurally O
novel O
class O
of O
submicromolar O
fibrinogen O
GPIIb O
/ O
IIIa O
binding O
inhibitor O
bearing O
1 B
, I
2 I
, I
4 I
- I
oxadiazol I
- I
5 I
( I
4H I
) I
- I
one I
moiety O
is O
also O
described O
. O

Synthesis O
and O
biological O
evaluation O
of O
N B
- I
( I
4 I
- I
hydroxy I
- I
3 I
- I
mercaptonaphthalen I
- I
1 I
- I
yl I
) I
amides I
as O
inhibitors O
of O
angiogenesis O
and O
tumor O
growth O
. O

A O
series O
of O
N B
- I
( I
4 I
- I
hydroxy I
- I
3 I
- I
mercaptonaphthalen I
- I
1 I
- I
yl I
) I
amides I
were O
synthesized O
and O
investigated O
for O
their O
in O
vitro O
antiangiogenic O
activity O
. O

Among O
these O
compounds O
, O
6d O
, O
which O
possesses O
an O
ortho B
- I
nitro I
group O
at O
the O
benzene O
ring O
, O
exhibited O
potent O
inhibitory O
effect O
on O
the O
proliferation O
of O
HUVECs O
, O
A549 O
, O
K562 O
, O
PC O
- O
3 O
, O
HCT116 O
, O
MDA O
- O
MB O
- O
231 O
and O
MCF O
- O
7 O
cells O
( O
IC50 O
= O
5 O
. O
34 O
, O
40 O
. O
53 O
, O
10 O
. O
81 O
, O
52 O
. O
52 O
, O
10 O
. O
19 O
, O
21 O
. O
37 O
and O
2 O
. O
81 O
mu O
M O
, O
respectively O
) O
. O

Cytotoxicity O
was O
evaluated O
with O
methyl B
thiazole I
tetrazolium I
( O
MTT O
) O
. O

RESULTS O
: O
Fractionated O
bulb O
extracts O
and O
the O
two O
isolated O
steroidal B
glycoalkaloids I
( O
1 O
) O
and O
( O
2 O
) O
induced O
NO O
production O
and O
TGF O
- O
beta O
receptor O
I O
mRNA O
expression O
in O
fibroblast O
cell O
culture O
. O

Results O
from O
the O
dermal O
fibroblast O
migration O
assay O
revealed O
that O
the O
steroidal B
glycoalkaloids I
( O
1 O
) O
and O
( O
2 O
) O
, O
and O
the O
furostanol B
saponin I
( O
3 O
) O
promoted O
fibroblast O
migration O
from O
the O
range O
of O
23 O
. O
7 O
+ O
/ O
- O
5 O
. O
7 O
to O
37 O
. O
7 O
+ O
/ O
- O
5 O
. O
1 O
% O
, O
as O
compared O
with O
the O
control O
. O

The O
neuritogenic O
and O
neuroprotective O
activities O
of O
six O
starfish O
polar O
steroids O
, O
asterosaponin B
P I
1 I
, O
( B
25S I
) I
- I
5 I
alpha I
- I
cholestane I
- I
3 I
beta I
, I
4 I
beta I
, I
6 I
alpha I
, I
7 I
alpha I
, I
8 I
, I
15 I
alpha I
, I
16 I
beta I
, I
26 I
- I
octaol I
, O
and O
( B
25S I
) I
- I
5 I
alpha I
- I
cholestane I
- I
3 I
beta I
, I
6 I
alpha I
, I
7 I
alpha I
, I
8 I
, I
15 I
alpha I
, I
16 I
beta I
, I
26 I
- I
heptaol I
( O
1 O
- O
3 O
) O
from O
the O
starfish O
Patiria O
pectinifera O
and O

distolasterosides B
D1 I
- I
D3 I
( O
4 O
- O
6 O
) O
from O
the O
starfish O
Distolasterias O
nipon O
were O
analyzed O
using O
the O
mouse O
neuroblastoma O
( O
NB O
) O
C O
- O
1300 O
cell O
line O
and O
an O
organotypic O
rat O
hippocampal O
slice O
culture O
( O
OHSC O
) O
. O

Altogether O
, O
these O
results O
suggest O
that O
neurotrophin O
- O
like O
neuritogenic O
and O
neuroprotective O
activities O
are O
most O
likely O
common O
properties O
of O
starfish O
polyhydroxysteroids B
and O
the O
related O
glycosides O
, O
although O
the O
magnitude O
of O
the O
effect O
depended O
on O
the O
particular O
compound O
structure O
. O

